<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Clin Pract</journal-id><journal-id journal-id-type="pmc-domain-id">1965</journal-id><journal-id journal-id-type="pmc-domain">ncp</journal-id><journal-id journal-id-type="publisher-id">NEURCLINPRACT</journal-id><journal-title-group><journal-title>Neurology: Clinical Practice</journal-title></journal-title-group><issn pub-type="ppub">2163-0402</issn><issn pub-type="epub">2163-0933</issn><publisher><publisher-name>American Academy of Neurology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507441</article-id><article-id pub-id-type="pmcid-ver">PMC12507441.1</article-id><article-id pub-id-type="pmcaid">12507441</article-id><article-id pub-id-type="pmcaiid">12507441</article-id><article-id pub-id-type="doi">10.1212/CPJ.0000000000200546</article-id><article-id pub-id-type="publisher-id">CPJ-2025-200123</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>26</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4703-3403</contrib-id><name name-style="western"><surname>Weber</surname><given-names initials="DM">Darren M.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-6748-6588</contrib-id><name name-style="western"><surname>Stroh</surname><given-names initials="MA">Matthew A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-5783-6513</contrib-id><name name-style="western"><surname>Taylor</surname><given-names initials="SW">Steven W.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0053-7305</contrib-id><name name-style="western"><surname>Lagier</surname><given-names initials="RJ">Robert J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-6503-9892</contrib-id><name name-style="western"><surname>Louie</surname><given-names initials="JZ">Judy Z.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-2563-6774</contrib-id><name name-style="western"><surname>Clarke</surname><given-names initials="NJ">Nigel J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5663-6476</contrib-id><name name-style="western"><surname>Vaillancourt</surname><given-names initials="DE">David E.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5212-3745</contrib-id><name name-style="western"><surname>Rayaprolu</surname><given-names initials="S">Sruti</given-names></name><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8060-6309</contrib-id><name name-style="western"><surname>Duara</surname><given-names initials="R">Ranjan</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1231-4694</contrib-id><name name-style="western"><surname>Racke</surname><given-names initials="MK">Michael K.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Quest Diagnostics Nichols Institute, San Juan Capistrano, CA;</aff><aff id="aff2"><label>2</label>Department of Applied Physiology and Kinesiology, University of Florida, Gainesville;</aff><aff id="aff3"><label>3</label>1Florida ADRC, University of Florida, Gainesville;</aff><aff id="aff4"><label>4</label>Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville;</aff><aff id="aff5"><label>5</label>J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville;</aff><aff id="aff6"><label>6</label>Department of Neurology, University of Florida, Gainesville;</aff><aff id="aff7"><label>7</label>Center for Translational Research in Neurodegenerative Disease, 1Florida ADRC, University of Florida, Gainesville; and</aff><aff id="aff8"><label>8</label>Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Mr. Weber <email>darren.m.weber@questdiagnostics.com</email></corresp><fn fn-type="other"><p>The Article Processing Charge was funded by the authors.</p></fn><fn fn-type="other"><p>Previously published in medRxiv (doi.org/10.1101/2025.02.27.25322892).</p></fn><fn fn-type="other"><p>Submitted and externally peer-reviewed. The handling editor was Associate Editor Jack W. Tsao, MD, DPhil, FAAN.</p></fn><fn fn-type="equal" id="fn1"><label>*</label><p>These authors contributed equally to this work as co-first authors.</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>6</day><month>10</month><year>2025</year></pub-date><volume>15</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">497024</issue-id><elocation-id>e200546</elocation-id><history><date date-type="received"><day>06</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CPJ-2025-200123.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="CPJ-2025-200123.pdf"/><abstract><sec><title>Background and Objectives</title><p>Plasma biomarkers provide new tools for evaluating patients with mild cognitive impairment (MCI) for Alzheimer disease (AD) pathology. Such tools are needed for anti-amyloid therapies that require efficient and accurate diagnostic evaluation to identify potential treatment candidates. This study sought to develop and evaluate the clinical performance of a multimarker combination of plasma beta-amyloid 42/40 (A&#946;42/40), ptau-217, and <italic toggle="yes">APOE</italic> genotype to predict amyloid PET positivity in a diverse cohort of patients at a memory clinic and evaluate &gt;4,000 results from &#8220;real-world&#8221; specimens submitted for high-throughput clinical testing.</p></sec><sec><title>Methods</title><p>Study participants were from the 1Florida AD Research Center. Demographics, clinical evaluations, and amyloid PET scan data were provided along with plasma specimens for model development in the intended-use cohort (MCI/AD: n = 215). A&#946;42/40 and ApoE4 proteotype (reflecting high-risk <italic toggle="yes">APOE</italic> &#603;4 alleles) were measured by mass spectrometry and ptau-217 by immunoassay. A likelihood score model was determined for each biomarker separately and in combination. Model performance was optimized using 2 cutpoints, 1 for high and 1 for low likelihood of PET positivity, to attain &#8805;90% specificity and sensitivity. These cutpoints were applied to categorize 4,326 real-world specimens and an expanded cohort stratified by cognitive status (normal cognition [NC], MCI, AD).</p></sec><sec><title>Results</title><p>For the intended-use cohort (46.0% prevalence of PET positivity), a combination of A&#946;42/40, ptau-217, and <italic toggle="yes">APOE4</italic> allele count provided the best model with a receiver operating characteristic area under the curve of 0.942 and with 2 cutpoints fixed at 91% sensitivity and 91% specificity, yielding a high cutpoint with 88% positive predictive value and 87% accuracy and a low cutpoint with 91% negative predictive value and 85% accuracy. Incorporating the <italic toggle="yes">APOE4</italic> allele count also reduced the percentage of patients with indeterminate risk from 15% to 10%. The cutpoints categorized the real-world clinical specimens as having 42% high, 51% low, and 7% indeterminate likelihood of PET positivity and differentiated between NC, MCI, and AD dementia cognitive status in the expanded cohort.</p></sec><sec><title>Discussion</title><p>Combining plasma biomarkers A&#946;42/40, ptau-217, and <italic toggle="yes">APOE4</italic> allele count is a scalable approach for evaluating patients with MCI for suspected AD pathology.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by beta-amyloid (A&#946;) plaques and neurofibrillary tangles in the brain that are associated with cognitive impairment.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Previously, PET imaging<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and CSF evaluation were the only available approaches to determine levels of A&#946; and phosphorylated tau protein<sup><xref rid="R3" ref-type="bibr">3</xref></sup> (ptau, a marker of neurofibrillary tangles) for diagnosis of AD pathology. However, these methods are perceived as invasive and/or costly. Recently approved disease-modifying monoclonal antibody treatments for AD target specific soluble aggregates of A&#946;<sup><xref rid="R4" ref-type="bibr">4,5</xref></sup> and are indicated for individuals with mild cognitive impairment (MCI) or mild AD. Eligibility for these treatments requires confirmation of amyloid pathology and <italic toggle="yes">APOE</italic> &#603;4 allele (<italic toggle="yes">APOE4</italic>) carrier status before administration. Scalable diagnostic tests that are accurate, less invasive, and affordable can fulfill this need.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p>Recent advances in blood-based biomarkers (BBMs) provide clinicians with a more cost-effective and accessible means to evaluate biomarkers such as A&#946; and ptau.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> High-throughput mass spectrometry (MS) and immunoassay platforms combined with automated sample preparation provide a scalable approach to measure large numbers of blood specimens with fast turnaround times. Recently, we developed a liquid chromatography-tandem MS (LC-MS/MS) plasma test to evaluate cerebral A&#946; pathology using the beta-amyloid 42 (A&#946;42) to beta-amyloid 40 (A&#946;40) ratio (i.e., A&#946;42/40) to predict amyloid PET status.<sup><xref rid="R8" ref-type="bibr">8,9</xref></sup> In addition, plasma tau protein phosphorylated at threonine 217 (ptau-217) is another excellent marker of AD-related neuropathology.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p><p>The Alzheimer's Association recently included A&#946;42 and ptau-217 in their guidelines as BBMs for core AD pathologies and processes.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Furthermore, combinations of plasma biomarkers can provide greater accuracy in identifying and differentiating AD dementia from other neurodegenerative disorders.<sup><xref rid="R12" ref-type="bibr">12-16</xref></sup> In addition, some studies demonstrated that inclusion of <italic toggle="yes">APOE4</italic> allele carrier status or allele count, which confers elevated risk for AD, can improve model performance when combined with the plasma A&#946;42/40 ratio and/or ptau-217<sup><xref rid="R15" ref-type="bibr">15,17</xref></sup> while others showed no statistically significant improvement.<sup><xref rid="R8" ref-type="bibr">8,14</xref></sup></p><p>For combinations of plasma biomarkers to have substantial clinical value, they should have acceptable diagnostic performance on par with currently accepted CSF tests.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> In addition, BBMs should have high test-retest reliability and scalability for high throughput to be considered useful for clinical implementation<sup><xref rid="R19" ref-type="bibr">19,20</xref></sup> as cost-effective diagnostic tests to identify potential candidates for anti-amyloid therapies.<sup><xref rid="R16" ref-type="bibr">16,21</xref></sup></p><p>In this study, our objective was to (1) develop a multibiomarker combination that achieved acceptable performance metrics while maintaining sensitivities and specificities &#8805;90% using specimens from a well-characterized cohort of patients with MCI and AD and (2) use robust high-throughput assays based on accessible cost-effective, low-resolution LC-MS/MS and immunoassay methods.<sup><xref rid="R9" ref-type="bibr">9,16</xref></sup></p><p>We note that these recommendations have been previously met using ptau-217 alone, but in a racially (97% White) and ethnically homogeneous cohort with a high prevalence (64%) of amyloid positivity,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and with a model developed using a combination of ptau-217/np-tau217 and A&#946;42/40 (94% White and 53% prevalence of amyloid positivity) on a high-resolution MS-based platform.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> In comparison, our cohort was matched for age, sex, ethnicity, and years of education across PET-negative and PET-positive groups, with a lower prevalence of PET positivity and greater ethnic diversity than in previous studies. In addition, we examined the effect of adding <italic toggle="yes">APOE</italic>4 genotype information (i.e., carrier or noncarrier vs allele count, i.e., 0, 1, or 2 alleles) to the combination of markers. Ultimately, we aimed to assess the usefulness of these tests in effectively identifying candidates for anti-amyloid therapy.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Study Design and Clinical Evaluation</title><p>This cross-sectional study included plasma specimens from 215 participants in the intended-use cohort enrolled with 1Florida Alzheimer's Disease Research Center (ADRC). All participants underwent amyloid PET imaging and cognitive testing and included 170 with MCI and 45 with AD (<xref rid="T1" ref-type="table">Table 1</xref>). Participants had a minimum of a 6<sup>th</sup>-grade reading level and spoke English and/or Spanish as their primary language. Participant ethnicity was self-reported.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline Characteristics by Amyloid PET Status</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Characteristic</td><td rowspan="1" colspan="1">Intended-use cohort [N = 215]</td><td rowspan="1" colspan="1">A&#946; PET- [N = 116]</td><td rowspan="1" colspan="1">A&#946; PET+ [N = 99]</td><td rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Demographics</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Age (y)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD) [N]</td><td rowspan="1" colspan="1">78.9 (8.4) [215]</td><td rowspan="1" colspan="1">78.6 (8.1) [116]</td><td rowspan="1" colspan="1">79.3 (8.8) [99]</td><td rowspan="1" colspan="1">0.552</td></tr><tr><td rowspan="1" colspan="1">&#8195;Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% Female [N]</td><td rowspan="1" colspan="1">56.3% [121]</td><td rowspan="1" colspan="1">53.4% [62]</td><td rowspan="1" colspan="1">59.6% [59]</td><td rowspan="1" colspan="1">0.409</td></tr><tr><td rowspan="1" colspan="1">&#8195;Ethnicity</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% Hispanic [N]</td><td rowspan="1" colspan="1">54.4% [117]</td><td rowspan="1" colspan="1">53.4% [62]</td><td rowspan="1" colspan="1">55.6% [55]</td><td rowspan="1" colspan="1">0.785</td></tr><tr><td rowspan="1" colspan="1">&#8195;Hispanic origin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Central American</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Cuban</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Dominican</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Puerto Rican</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;South American</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Missing</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Race: Hispanic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Black</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Multiracial</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;White</td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Missing</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Race: non-Hispanic</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Asian</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Black</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Multiracial</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;White</td><td rowspan="1" colspan="1">86</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Missing</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Education</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD) [N]</td><td rowspan="1" colspan="1">15.1 (3.3) [214]</td><td rowspan="1" colspan="1">15.4 (3.3) [114]</td><td rowspan="1" colspan="1">14.8 (3.2) [99]</td><td rowspan="1" colspan="1">0.192</td></tr><tr><td rowspan="1" colspan="1">Cognitive assessment</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Diagnosis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% MCI [N]</td><td rowspan="1" colspan="1">79.1% [170]</td><td rowspan="1" colspan="1">100% [116]</td><td rowspan="1" colspan="1">54.5% [54]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% AD [N]</td><td rowspan="1" colspan="1">20.9% [45]</td><td rowspan="1" colspan="1">0% [0]</td><td rowspan="1" colspan="1">45.5% [45]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;MMSE score</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;%MMSE score &#8805;25 [N]</td><td rowspan="1" colspan="1">74.7% [165]</td><td rowspan="1" colspan="1">94.0 [109]</td><td rowspan="1" colspan="1">57.7 [56]</td><td rowspan="1" colspan="1">
<italic toggle="yes">&lt; 0.001</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Median (IQR) [N]</td><td rowspan="1" colspan="1">27 (25&#8211;29) [213]</td><td rowspan="1" colspan="1">29 (27&#8211;30) [116]</td><td rowspan="1" colspan="1">25 (21&#8211;27) [97]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;CDRsb score</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% CDRsb score &gt;0 [N]</td><td rowspan="1" colspan="1">94.4% [203]</td><td rowspan="1" colspan="1">91.4% [106]</td><td rowspan="1" colspan="1">98.0% [97]</td><td rowspan="1" colspan="1">
<italic toggle="yes">0.040</italic>
</td></tr><tr><td rowspan="1" colspan="1">Plasma biomarkers</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Plasma A&#946;42/40</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD) [N]</td><td rowspan="1" colspan="1">0.157 (0.028) [215]</td><td rowspan="1" colspan="1">0.172 (0.027) [116]</td><td rowspan="1" colspan="1">0.141 (0.018) [99]</td><td rowspan="1" colspan="1">
<italic toggle="yes">&lt; 0.001</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Plasma A&#946;42 (pg/mL)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD) [N]</td><td rowspan="1" colspan="1">60.4 (18.2)</td><td rowspan="1" colspan="1">65.6 (19.2) [116]</td><td rowspan="1" colspan="1">54.4 (14.8) [99]</td><td rowspan="1" colspan="1">
<italic toggle="yes">&lt; 0.001</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;Plasma A&#946;40 (pg/mL)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Mean (SD) [N]</td><td rowspan="1" colspan="1">383.2 (87.6)</td><td rowspan="1" colspan="1">380.5 (87.5) [116]</td><td rowspan="1" colspan="1">386.3 (88.2) [99]</td><td rowspan="1" colspan="1">0.631</td></tr><tr><td rowspan="1" colspan="1">&#8195;Plasma ptau-217 (pg/mL)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;Median (IQR) [N]</td><td rowspan="1" colspan="1">0.26 (0.11&#8211;0.54) [215]</td><td rowspan="1" colspan="1">0.12 (0.06&#8211;0.25) [116]</td><td rowspan="1" colspan="1">0.51 (0.32&#8211;0.88) [99]</td><td rowspan="1" colspan="1">
<italic toggle="yes">&lt; 0.001</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;ApoE4</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% <italic toggle="yes">APOE4</italic>+ carriers [N]</td><td rowspan="1" colspan="1">38.1% [82]</td><td rowspan="1" colspan="1">21.6% [25]</td><td rowspan="1" colspan="1">57.6% [57]</td><td rowspan="1" colspan="1">
<italic toggle="yes">&lt;0.001</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% <italic toggle="yes">APOE4</italic> allele count 1 [N]</td><td rowspan="1" colspan="1">32.6% [70]</td><td rowspan="1" colspan="1">21.6% [25]</td><td rowspan="1" colspan="1">45.5% [45]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;&#8195;% <italic toggle="yes">APOE4</italic> allele count 2 [N]</td><td rowspan="1" colspan="1">5.6% [12]</td><td rowspan="1" colspan="1">0% [0]</td><td rowspan="1" colspan="1">12.1% [12]</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: A&#946; = beta-amyloid; AD = Alzheimer disease; ApoE4 = apolipoprotein E4; CDRsb = Clinical Dementia Rating Sum of Boxes; IQR = interquartile range; MMSE = Mini-Mental State Examination.</p></fn><fn><p>Not all demographic data were available for all participants; therefore, N is the number of participants with available data. <italic toggle="yes">p</italic> Values were derived from the 2-sample <italic toggle="yes">t</italic>-test or Wilcoxon rank-sum test for continuous variables and the Fisher Exact test for categorical variables in the A&#946; PET+ and A&#946; PET- subgroups. <italic toggle="yes">p</italic> Values &lt;0.05 are highlighted in italics.</p></fn></table-wrap-foot></table-wrap><p>Participants underwent an extensive neurologic and neuropsychological evaluation, including the Clinical Dementia Rating Sum of Boxes (CDRsb) Scale<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and the Mini-Mental State Examination (MMSE).<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Diagnoses of MCI and AD dementia were determined using a previously described algorithmic procedure,<sup><xref rid="R24" ref-type="bibr">24</xref></sup> which combines the neuropsychological diagnosis with the CDRsb scores.</p><p>To evaluate the diagnostic performance of the biomarkers in identifying cognitive status, we evaluated and compared additional specimens from 56 participants in the same 1Florida ADRC cohort who were assessed to have normal cognition (NC; 49 PET-negative/7 PET-positive) (eTable 1).</p><p>In addition, we performed a retrospective analysis of 4,326 consecutive plasma specimens submitted to Quest Diagnostics for plasma A&#946;42/40, ptau-217, and ApoE proteoform testing. This was a limited data set (as defined by <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hhs.gov/hipaa/for-professionals/special-topics/research/index.html" ext-link-type="uri">hhs.gov/hipaa/for-professionals/special-topics/research/index.html</ext-link>), with only information on patient age and sex available (eTable 2).</p></sec><sec id="s2-2"><title>Amyloid PET Imaging</title><p>Amyloid PET imaging was performed using [<sup>18</sup>F]florbetaben or [<sup>18</sup>F]florbetapir tracers on a Siemens 16 Biograph PET/CT scanner, as described previously.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Global amyloid status (+/-) was determined based on visual reads by 2 independently trained, experienced raters who were blinded to both diagnosis and cognitive status. When a disagreement occurred, a third experienced reader was included to form a consensus.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> All participants underwent an amyloid PET scan within 12 months of plasma collection.</p></sec><sec id="s2-3"><title>Plasma Biomarker Analysis</title><p>Blood specimens were collected by venipuncture into 10-mL tubes containing EDTA as anticoagulant and kept on ice (&lt;1 h) until centrifugation at 1,200 relative centrifuge force for 12 minutes at room temperature. Plasma aliquots (0.5 mL) were transferred into polypropylene tubes and stored at &#8722;80&#176;C until analysis. All plasma specimens were deidentified, and results were blinded during the analysis.</p><sec id="s2-3-1"><title>Plasma A&#946;42/40 Ratio and ApoE Proteoform Assays</title><p>The LC-MS/MS&#8211;based assays for the plasma A&#946;42/40 ratio and ApoE proteoforms have been described in detail elsewhere.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> All sample preparation steps were fully automated using a Hamilton Star liquid handler (Hamilton, Reno, NV). LC-MS/MS was performed using a Transcend Vanquish TLX-4 TurboFlow UPLC, with a high-throughput 4-LC column configuration, coupled to a TSQ Altis Plus Triple Quadrupole MS (both Thermo Fisher Scientific, Waltham, MA); data were analyzed using TraceFinder Clinical Research v5.1 software (Thermo Fisher Scientific).</p><p>For the A&#946;42/40 ratio, A&#946;40 and A&#946;42 were enriched by immunoprecipitation from plasma (0.5 mL), digested with Lys-C, and desalted and concentrated by solid-phase extraction. Characteristic peptides for A&#946;40 (A&#946;29&#8211;40) and A&#946;42 (A&#946;29&#8211;42) were chromatographically separated, detected, and quantified by LC-MS/MS.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><p>For ApoE proteoform determination, plasma specimens (25 &#181;L) were reduced, alkylated, and proteolytically digested with trypsin. Unique tryptic peptides to the ApoE2 and ApoE4 proteoforms, as well as shared peptides between the ApoE2 and ApoE3 proteoforms and the ApoE3 and ApoE4 proteoforms, were chromatographically separated and detected by LC-MS/MS. ApoE proteoforms were determined by the presence or absence of the unique and shared peptides and used to establish the ApoE proteotype, which has previously been shown to be 100% concordant with <italic toggle="yes">APOE</italic> genotype.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><p>Both assays were validated according to Clinical Laboratory Improvement Amendments (CLIA) guidance. For the A&#946;42/40 ratio, assay imprecision (random error) and bias (technical error) were measured previously to establish the technical robustness of the test.<sup><xref rid="R8" ref-type="bibr">8</xref>,</sup><sup><xref rid="R26" ref-type="bibr">26</xref></sup> Total error was calculated as described in the Statistical Analysis section.</p></sec><sec id="s2-3-2"><title>Plasma ptau-217 Assay</title><p>On the day of the assay, frozen calibrators, quality control (QC) samples, and plasma specimens were thawed and brought to room temperature. Plasma specimens were centrifuged to remove any debris, and plasma ptau-217 levels were quantified using the Lumipulse G ptau-217 Plasma Immunoreaction Cartridges RUO (for research use only) assay kit on a Lumipulse G System (Fujirebio Inc, Malvern, PA), which is a fully automated chemiluminescent enzyme immunoassay (CLEIA) platform.</p><p>The assay was validated according to CLIA guidance, and data were used to evaluate technical robustness.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> Interassay imprecision (random error) was determined by taking the average of 2 QC samples analyzed in duplicate over 14 nonconsecutive days. Bias (technical error) was experimentally determined by analyzing 100 previously assayed plasma specimens using a different lot of reagents. Values for ptau-217 were compared as a percentile difference calculated between the mean of the original results and retest results, as has been reported elsewhere.<sup><xref rid="R8" ref-type="bibr">8,26</xref></sup> Total error was calculated as described in Technical Robustness.</p></sec></sec><sec id="s2-4"><title>Statistical Analysis</title><sec id="s2-4-1"><title>Demographic, Clinical, and Biomarker Comparisons</title><p>Participant demographics were summarized for the full cohort and further stratified by amyloid PET status. Continuous variables were summarized as mean and SD or median and interquartile range. Categorical variables were summarized as percent and count (N). Tests for difference across PET status were assessed by the 2-sample <italic toggle="yes">t</italic>-test or Wilcoxon rank-sum test for continuous variables and the Fisher exact test for categorical variables. Significance was determined with a threshold of <italic toggle="yes">p</italic> &#8804; 0.05.</p></sec><sec id="s2-4-2"><title>Logistic Regression</title><p>Logistic regression modeling was used to assess the association between predictor variables and amyloid PET status to estimate model linear predictors. The ptau-217 variable as a predictor in the models was natural log transformed.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> The Akaike information criterion (AIC) was used to compare model fits and select the final model, with lower AIC values indicating a better balance between model complexity and fit. Amyloid PET&#8211;positivity likelihood scores on a probability scale were calculated by transforming model linear predictors using a natural exponential function. Tests for differences in the distribution of amyloid PET&#8211;positivity likelihood scores across amyloid PET status were assessed by the Wilcoxon rank-sum test. Model performances of predictors in predicting PET positivity were evaluated by ROC curve analysis. Differences between ROC curves were assessed by the method of DeLong.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Comparisons of probability/likelihood scores when stratified by amyloid PET status were conducted using a 2-tailed paired <italic toggle="yes">t</italic> test.</p><p>In addition, model performances were also evaluated by a 2-cutpoint approach, with the lower cutpoint establishing maximized sensitivity and the upper cutpoint establishing maximized specificity. PPVs and NPVs were calculated at each classification threshold using the Bayes rule, with estimated sensitivity, specificity, and prevalence as inputs. Recommended performance criteria stipulate that those patients who fall in the indeterminate zone between the 2 cutpoints represent &#8804;20% of the population.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p></sec><sec id="s2-4-3"><title>Technical Robustness</title><p>To investigate the effects of total error (assay imprecision + potential bias) for the A&#946;40, A&#946;42, and ptau-217 markers on the predictive performance of the best model, data simulations were performed. Estimates for analytical imprecision and bias were previously established for each marker (data not included). Based on these error estimates, Monte Carlo simulations were performed to generate 10,000 replicate study data sets (N = 215), with randomly assigned errors drawn from a Gaussian distribution (mean = 0, %CV = 6%) and fixed bias offsets added to each biomarker value. A&#946;42/40 ratios were generated for each paired set of perturbed amyloid markers. For each simulated data set, observations were scored using the best model (each observation retained its original <italic toggle="yes">APOE4</italic> allele count for scoring) and assigned a new predicted PET+ class (low, indeterminate, or high likelihood) based on the established classification thresholds. Predicted PET+ classes for each simulated data set were tabulated against the original (nonperturbed) data, and reclassification rates were estimated. The average (95% CI) reclassification rate due to the overall assay error was estimated as the median (2.5th percentile, 97.5th percentile) of the 10,000 simulated reclassification rates.</p><p>All data analyses were performed using R version 4.3.1 (The R Foundation for Statistical Computing).</p></sec></sec><sec sec-type="data-availability" id="s2-5"><title>Data Availability</title><p>The raw data supporting the conclusions of this article will be made available by the authors on request.</p></sec><sec id="s2-6"><title>Standard Protocol Approvals, Registrations, and Patient Consents</title><p>The studies involving humans were approved by Mount Sinai Medical Center IRB. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired as part of a previous study for which ethical approval was obtained. Written informed consent was obtained from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Demographic, Clinical, and Biomarker Comparisons</title><p>The mean age of participants in the intended-use cohort was 79 years (SD, 8 years; range 52&#8211;97), with almost 80% having MCI and the remaining having AD dementia (<xref rid="T1" ref-type="table">Table 1</xref>). Women (56%) were slightly more represented than men, and there was a slight majority (54%) of participants with Hispanic ethnicity (56% of these participants were of Cuban origin, <xref rid="T1" ref-type="table">Table 1</xref>). Most participants had a CDRsb score &gt;0 (94%) and an MMSE score &#8805;25 (nearly 75%, <xref rid="T1" ref-type="table">Table 1</xref>).</p><p>Compared with PET-negative participants, PET-positive participants had a significantly higher percentage with a CDRsb score &gt;0 (<italic toggle="yes">p</italic> = 0.040) and significantly lower median MMSE scores (<italic toggle="yes">p</italic> &lt; 0.001, <xref rid="T1" ref-type="table">Table 1</xref>). No significant differences between patient age, sex, years of education, and ethnicity were found between those who were PET-negative and PET-positive.</p><p>Compared with PET-negative participants, PET-positive participants had significantly lower mean levels of plasma A&#946;42, higher median levels of ptau-217, and a significantly lower mean A&#946;42/40 ratio (<italic toggle="yes">p</italic> &lt; 0.001 for all, <xref rid="T1" ref-type="table">Table 1</xref>). No difference in plasma A&#946;40 levels between PET-positive and PET-negative groups was observed.</p></sec><sec id="s3-2"><title>Prediction of Amyloid PET Status</title><p>As described further, the individual and multimarker predictions of amyloid PET status using either single or 2-cutpoint approaches were evaluated in terms of optimizing test performance and to meet recommended 90% sensitivity/90% specificity criteria for confirmatory testing.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> For the 2-cutpoint approach, this included keeping the percentage of patients classified as having indeterminate likelihood of PET positivity &#8804;20%.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><sec id="s3-2-1"><title>Diagnostic Performance of Individual and Combined BBMs In Predicting Amyloid PET Status Using a Single Cutpoint</title><p>Receiver operating characteristic areas under the curve (ROC-AUCs) for PET prediction using A&#946;42/40 alone (0.851, 95% CI 0.796&#8211;0.905) and ptau-217 alone (0.846, 95% CI 0.808&#8211;0.905) significantly improved (<italic toggle="yes">p</italic> &lt; 0.001) when they were combined (0.929, 95% CI 0.894&#8211;0.963) (eTable 3, <xref rid="F1" ref-type="fig">Figure 1</xref>). The AIC for the model that combined A&#946;42/40 and ptau-217 predictors was 195, lower than using A&#946;42/40 (AIC = 256) and ptau-217 (AIC = 263) alone (eTable 3). Further improvement on amyloid PET prediction was achieved when <italic toggle="yes">APOE4</italic> results were added to the model, with <italic toggle="yes">APOE4</italic> carrier status (positive/negative) yielding an AUC of 0.938 (95% CI 0.906&#8211;0.969) and <italic toggle="yes">APOE4</italic> allele count yielding an AUC of 0.942 (95% CI 0.912&#8211;0.972). However, only the AUC of the <italic toggle="yes">APOE4</italic> allele count model (AIC = 186, <italic toggle="yes">p</italic> = 0.033), and not that of the carrier status model (AIC = 189, <italic toggle="yes">p</italic> = 0.177), reached statistical significance when compared with the model without <italic toggle="yes">APOE4</italic> results added. Despite high AUCs for each combined BBM predictor, none of the models achieved &#8805;90% sensitivity/specificity when using a single cutpoint (eTable 3, <xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Model Performance of Single and Combined Biomarkers in Predicting PET Positivity Demonstrated by Receiver Operating Characteristic Curves</title><p>Receiver operating characteristic area under the curve (ROC-AUC) analysis of individual and combined biomarkers for prediction of PET status. A&#946; = beta-amyloid; <italic toggle="yes">APOE4</italic> = APOE &#949;4; AUC = area under the curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CPJ-2025-200123f1.jpg"/></fig></sec><sec id="s3-2-2"><title>Diagnostic Performance of Individual and Combined BBMs in Predicting Amyloid PET Status Using a 2-Cutpoint Method</title><p>At probability cutpoints set for &#8805;90% sensitivity and specificity, no individual biomarker met the criterion of &#8804;20% indeterminate classifications.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> A&#946;42/40 classified 34% and ptau-217 classified 42% of the intended-use population as having an indeterminate result. Combining A&#946;42/40 and ptau-217 reduced the indeterminate results to 15%, and further addition of <italic toggle="yes">APOE4</italic> allele count reduced them to 10% (<xref rid="F2" ref-type="fig">Figure 2</xref>, <xref rid="T2" ref-type="table">Table 2</xref>). The reduction represented 21 of 32 participants (66%) being reclassified in the correct direction relative to their PET status (wrong to indeterminate classification [n = 6] or indeterminate to correct classification [n = 15]). The distribution of results for the intended-use population using the A&#946;42/40+ptau-217+<italic toggle="yes">APOE4</italic> allele count model is illustrated in <xref rid="F3" ref-type="fig">Figure 3A</xref>.</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><title>Comparison of Models Using Boxplots With Dashed Lines Representing Cutoffs for Predicting Low, Indeterminate, or High Likelihood of PET Positivity Using Single and Combined Biomarkers</title><p>(A) ptau-217, (B) A&#946;42/40, (C) A&#946;42/40 + ptau-217, (D) A&#946;42/40 + ptau-217 +<italic toggle="yes">APOE4</italic> carrier status, and (E) A&#946;42/40 + ptau-217 + <italic toggle="yes">APOE4</italic> allele count. Orange dots represent individuals with MCI; blue dots represent individuals with AD. Horizontal dashed lines indicate high-likelihood and low-likelihood cutoffs. Results between these lines indicate neither a low nor a high likelihood (i.e., an indeterminate result).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CPJ-2025-200123f2.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Model Performance for Prediction of Amyloid PET Status at a Defined Sensitivity and Specificity</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Predictor: 2 cutpoint</td><td rowspan="1" colspan="1">Cutpoint</td><td rowspan="1" colspan="1">A&#946; PET+, N (%)</td><td rowspan="1" colspan="1">All, N (%)</td><td rowspan="1" colspan="1">Sensitivity (95% CI)</td><td rowspan="1" colspan="1">Specificity (95% CI)</td><td rowspan="1" colspan="1">Accuracy, % (95% CI)</td><td rowspan="1" colspan="1">AUC (95% CI)</td><td rowspan="1" colspan="1">AIC</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">ptau-217</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Low likelihood</td><td rowspan="1" colspan="1">&lt;0.2490</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">73 (34)</td><td rowspan="1" colspan="1">92% (85%&#8211;96%)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">73% (66%&#8211;78%)</td><td rowspan="1" colspan="1">0.846 (0.808&#8211;0.905)</td><td rowspan="1" colspan="1">262.7</td></tr><tr><td rowspan="1" colspan="1">&#8195;Indeterminant likelihood</td><td rowspan="1" colspan="1">0.2490 to 0.7554</td><td rowspan="1" colspan="1">49 (50)</td><td rowspan="1" colspan="1">91 (42)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High likelihood</td><td rowspan="1" colspan="1">&gt;0.7554</td><td rowspan="1" colspan="1">42 (42)</td><td rowspan="1" colspan="1">51 (24)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">92% (86%&#8211;96%)</td><td rowspan="1" colspan="1">69% (63%&#8211;75%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">A&#946;42/40</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Low likelihood</td><td rowspan="1" colspan="1">&lt;0.3925</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">95 (44)</td><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">82% (76%&#8211;86%)</td><td rowspan="1" colspan="1">0.851 (0.796&#8211;0.905)</td><td rowspan="1" colspan="1">255.6</td></tr><tr><td rowspan="1" colspan="1">&#8195;Indeterminant likelihood</td><td rowspan="1" colspan="1">0.3925 to 0.7236</td><td rowspan="1" colspan="1">53 (74)</td><td rowspan="1" colspan="1">72 (34)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High likelihood</td><td rowspan="1" colspan="1">&gt;0.7236</td><td rowspan="1" colspan="1">37 (37)</td><td rowspan="1" colspan="1">48 (22)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">66% (60%&#8211;72%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Model 1: ptau-217 + A&#946;42/40</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Low likelihood</td><td rowspan="1" colspan="1">&lt;0.3254</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">97 (45)</td><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">83% (77%&#8211;87%)</td><td rowspan="1" colspan="1">0.929&#8203; (0.894&#8211;0.963&#8203;)</td><td rowspan="1" colspan="1">194.6</td></tr><tr><td rowspan="1" colspan="1">&#8195;Indeterminant likelihood</td><td rowspan="1" colspan="1">0.3254 to 0.6460</td><td rowspan="1" colspan="1">16 (16)</td><td rowspan="1" colspan="1">33 (15)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High likelihood</td><td rowspan="1" colspan="1">&gt;0.6460</td><td rowspan="1" colspan="1">74 (75)</td><td rowspan="1" colspan="1">85 (40)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">83% (78%&#8211;88%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Model 2: ptau-217 + A&#946;42/40 + <italic toggle="yes">APOE4</italic> carrier status</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Low likelihood</td><td rowspan="1" colspan="1">&lt;0.3709</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">101 (47)</td><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">85% (79%&#8211;89%)</td><td rowspan="1" colspan="1">0.938 (0.906&#8211;0.969)</td><td rowspan="1" colspan="1">189.2</td></tr><tr><td rowspan="1" colspan="1">&#8195;Indeterminant likelihood</td><td rowspan="1" colspan="1">0.3709 to 0.5626</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">22 (10)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High likelihood</td><td rowspan="1" colspan="1">&gt;0.5626</td><td rowspan="1" colspan="1">81 (82)</td><td rowspan="1" colspan="1">92 (43)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">86% (81%&#8211;90%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Model 3: ptau-217 + A&#946;42/40 + <italic toggle="yes">APOE4</italic> allele count</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;Low likelihood</td><td rowspan="1" colspan="1">&lt;0.3714</td><td rowspan="1" colspan="1">9 (9)</td><td rowspan="1" colspan="1">101 (47)</td><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">85% (79%&#8211;89%)</td><td rowspan="1" colspan="1">0.942 (0.912&#8211;0.972)</td><td rowspan="1" colspan="1">186.6</td></tr><tr><td rowspan="1" colspan="1">&#8195;Indeterminant likelihood</td><td rowspan="1" colspan="1">0.3714 to 0.5375</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">21 (10)</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#8195;High likelihood</td><td rowspan="1" colspan="1">&gt;0.5375</td><td rowspan="1" colspan="1">82 (83)</td><td rowspan="1" colspan="1">93 (43)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td><td rowspan="1" colspan="1">87% (82%&#8211;91%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: A&#946; = beta-amyloid; ApoE4 = apolipoprotein E4; AIC = Akaike information criterion; AUC = area under the curve.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><title>Comparison of the Study Cohort With 4,000+ Real-World Clinical Specimens Using Beeswarm Plots for the Distribution of Likelihood of PET Positivity Using the Full Biomarker Model</title><p>Distribution of model results for (A) the intended-use population and (B) real-world clinical specimens. Orange dots represent individuals who are amyloid PET negative; blue dots represent those who are amyloid PET positive in panel A. Gray dots represent individuals whose amyloid PET status is unknown. Horizontal dashed lines indicate high-likelihood and low-likelihood cutoffs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CPJ-2025-200123f3.jpg"/></fig><p>The models with vs without <italic toggle="yes">APOE4</italic> allele count with the 2 cutpoints set for 91% sensitivity and 91% specificity at the study prevalence of 46% of PET positivity were compared. PPVs were 88% with <italic toggle="yes">APOE4</italic> allele count and 87% without, and NPVs were 91% for both models (<xref rid="T3" ref-type="table">Table 3</xref>). At 50% prevalence, which is the prevalence expected in an MCI population,<sup><xref rid="R29" ref-type="bibr">29</xref></sup> both the estimated PPV and NPV would reach 90% for the model with <italic toggle="yes">APOE4</italic> allele count compared with 89% for both PPV and NPV for the model without. At lower prevalence of PET positivity, such as in a primary care setting where the prevalence would be closer to 20%,<sup><xref rid="R30" ref-type="bibr">30</xref></sup> the model predictors with and without <italic toggle="yes">APOE4</italic> allele count show an estimated NPV of 97% (PPV 69% with and 66% without <italic toggle="yes">APOE4</italic> allele count). Conversely, at high prevalence of PET positivity (65%, 80%), the model predictors with and without <italic toggle="yes">APOE4</italic> allele count would have high PPV estimates (94%&#8211;97%) but lower NPVs (68%&#8211;82%, <xref rid="T3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>PPV and NPV for Each Model at Different Prevalence Rates</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Predictor</td><td colspan="2" rowspan="1">ptau-217 + A&#946;42/40</td><td colspan="2" rowspan="1">ptau-217 + A&#946;42/40 +<italic toggle="yes">APOE4</italic> allele count</td></tr><tr><td rowspan="1" colspan="1">Prevalence</td><td rowspan="1" colspan="1">PPV (95% CI)</td><td rowspan="1" colspan="1">NPV (95% CI)</td><td rowspan="1" colspan="1">PPV (95% CI)</td><td rowspan="1" colspan="1">NPV (95% CI)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">20%, as expected in a primary care setting</td><td rowspan="1" colspan="1">66% (54%&#8211;79%)</td><td rowspan="1" colspan="1">97% (95%&#8211;98%)</td><td rowspan="1" colspan="1">69% (56%&#8211;80%)</td><td rowspan="1" colspan="1">97% (95%&#8211;99%)</td></tr><tr><td rowspan="1" colspan="1">46%, observed study prevalence</td><td rowspan="1" colspan="1">87% (78%&#8211;93%)</td><td rowspan="1" colspan="1">91% (83%&#8211;95%)</td><td rowspan="1" colspan="1">88% (80%&#8211;93%)</td><td rowspan="1" colspan="1">91% (84%&#8211;95%)</td></tr><tr><td rowspan="1" colspan="1">50%, as expected in MCI population</td><td rowspan="1" colspan="1">89% (82%&#8211;94%)</td><td rowspan="1" colspan="1">89% (82%&#8211;94%)</td><td rowspan="1" colspan="1">90% (84%&#8211;94%)</td><td rowspan="1" colspan="1">90% (83%&#8211;95%)</td></tr><tr><td rowspan="1" colspan="1">65%, as expected in a general neurology setting</td><td rowspan="1" colspan="1">94% (90%&#8211;96%)</td><td rowspan="1" colspan="1">82% (72%&#8211;90%)</td><td rowspan="1" colspan="1">94% (91%&#8211;97%)</td><td rowspan="1" colspan="1">82% (73%&#8211;90%)</td></tr><tr><td rowspan="1" colspan="1">80%, as expected in a memory care setting</td><td rowspan="1" colspan="1">97% (95%&#8211;98%)</td><td rowspan="1" colspan="1">68% (54%&#8211;81%)</td><td rowspan="1" colspan="1">97% (95%&#8211;98%)</td><td rowspan="1" colspan="1">69% (55%&#8211;81%)</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3-3"><title>Stratification by Cognitive Status</title><p>Superimposing probability scores of PET positivity from the <italic toggle="yes">APOE4</italic> allele count model onto cognitive status showed significantly higher probability scores in individuals with AD compared with those with MCI and NC (<italic toggle="yes">p</italic> &lt; 0.001 for both) and significantly higher probability scores in those with MCI vs NC (<italic toggle="yes">p</italic> = 0.002, eFigure 1A).</p><p>ROC-AUCs for independent model predictors of cognitive status were 0.943 (95% CI 0.894&#8211;0.992) for NC vs AD and 0.864 (95% CI 0.817&#8211;0.911) for MCI vs AD (eFigure 1B). However, the model predictor did not perform well on ROC analysis in distinguishing NC from MCI (AUC = 0.650, 95% CI 0.568&#8211;0.740).</p></sec><sec id="s3-4"><title>Real-World Data Performance by Age</title><p>Among the 4,326 plasma specimens submitted to Quest Diagnostics for plasma A&#946;42/40, ptau-217, and ApoE proteoform testing, the mean age of individuals was 73 years (SD 10 years, age range 28&#8211;98), most (58%) were female, and 38% had 1 or 2 <italic toggle="yes">APOE4</italic> alleles (eTable 2). In total, 42% (1,822) were classified as having a high likelihood, 51% (2,204) as having a low likelihood, and 7% (300) as having an indeterminate likelihood of PET positivity (<xref rid="F3" ref-type="fig">Figure 3B</xref>).</p><p>Based on their low likelihood of PET positivity, a PET scan or CSF testing would potentially be unnecessary for the 2,204 patients (<xref rid="T4" ref-type="table">Table 4</xref>). Similarly, imaging or CSF testing may not be required for the 1,822 patients with high likelihood based on &#8805;90% sensitivity, specificity, PPV, and NPV (<xref rid="T3" ref-type="table">Table 3</xref>) and recent guidance for a projected PET positivity prevalence of 50%.<sup><xref rid="R18" ref-type="bibr">18</xref></sup></p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Proposed Linear Predictor Cutpoints for Clinical Decision Making</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">Probability of PET positivity range</td><td rowspan="1" colspan="1">Interpretation</td><td rowspan="1" colspan="1">Intended-use population, N (% of cohort)</td><td rowspan="1" colspan="1">PET positivity, N (%)</td><td rowspan="1" colspan="1">MCI, N (%)</td><td rowspan="1" colspan="1">AD, N (%)</td><td rowspan="1" colspan="1">APOE4, N (%)</td><td rowspan="1" colspan="1">Real world, N (% of cohort)</td><td rowspan="1" colspan="1">Real-world projections of PET positivity, N (%)<sup><xref rid="tblfn1" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">Follow-up evaluation and management considerations</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">&lt;0.3714</td><td rowspan="1" colspan="1">Low likelihood</td><td rowspan="1" colspan="1">101 (47.0)</td><td rowspan="1" colspan="1">9 (9.0)</td><td rowspan="1" colspan="1">101 (100)</td><td rowspan="1" colspan="1">0 (0)</td><td rowspan="1" colspan="1">16 (15.8)</td><td rowspan="1" colspan="1">2,204 (50.9)</td><td rowspan="1" colspan="1">198 (9.0)</td><td rowspan="1" colspan="1">Consider non-AD etiology</td></tr><tr><td rowspan="1" colspan="1">0.3714&#8211;0.5375</td><td rowspan="1" colspan="1">Indeterminant likelihood</td><td rowspan="1" colspan="1">21 (9.8)</td><td rowspan="1" colspan="1">8 (38.1)</td><td rowspan="1" colspan="1">18 (85.7)</td><td rowspan="1" colspan="1">3 (14.3)</td><td rowspan="1" colspan="1">10 (47.6)</td><td rowspan="1" colspan="1">300 (6.9)</td><td rowspan="1" colspan="1">114 (38.0)</td><td rowspan="1" colspan="1">Consider results within the context of full differential; refer to a neurologist</td></tr><tr><td rowspan="1" colspan="1">&gt;0.5375</td><td rowspan="1" colspan="1">High likelihood</td><td rowspan="1" colspan="1">93 (43.3)</td><td rowspan="1" colspan="1">82 (88.2)</td><td rowspan="1" colspan="1">51 (54.8)</td><td rowspan="1" colspan="1">42 (45.2)</td><td rowspan="1" colspan="1">56 (60.2)</td><td rowspan="1" colspan="1">1,822 (42.1)</td><td rowspan="1" colspan="1">1,607 (88.2)</td><td rowspan="1" colspan="1">Consider results within the context of full differential; refer to a neurologist; AD etiology likely</td></tr><tr><td rowspan="1" colspan="1">All</td><td rowspan="1" colspan="1">All</td><td rowspan="1" colspan="1">215 (100)</td><td rowspan="1" colspan="1">99 (46.0)</td><td rowspan="1" colspan="1">170 (79.1)</td><td rowspan="1" colspan="1">45 (20.9)</td><td rowspan="1" colspan="1">82 (38.1)</td><td rowspan="1" colspan="1">4,326 (100)</td><td rowspan="1" colspan="1">1,919 (44.4)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD = Alzheimer disease; ApoE4 = apolipoprotein E4 proteoform; MCI = mild cognitive impairment.</p></fn><fn id="tblfn1"><label>a</label><p>Real-world projections of PET positivity are based on percent PET positivity in the intended-use population cohort.</p></fn></table-wrap-foot></table-wrap><p>When parsed by the 3-biomarker model predictor design that uses the <italic toggle="yes">APOE4</italic> allele count, a significant difference in age between the low-likelihood and high-likelihood groups (70.3 vs 75.5, ANOVA <italic toggle="yes">p</italic> &lt; 0.001) and the low-likelihood and indeterminate-likelihood groups (70.3 vs 76.3, ANOVA <italic toggle="yes">p</italic> &lt; 0.001) was observed (eTable 2). No differences in age were seen between the indeterminate-likelihood and high-likelihood groups.</p><p>Further stratifying the results by age, we observed a significant positive relationship between increasing median age and increasing probability of PET positivity (eFigure 2). Among patients with low likelihood, the percentage who are likely PET negative decreases with age, with 90.2% of patients younger than 50 years predicted to be amyloid PET negative compared with 37.2% of those aged 90 years or older (eTable 4).</p></sec><sec id="s3-5"><title>Assay Technical Robustness and Effects of Bias and Imprecision on Likelihood Reclassification</title><p>We evaluated the effects of total error, composed of analytical bias (technical error) and imprecision (random error), on likelihood reclassification when using the model predictor with <italic toggle="yes">APOE4</italic> allele count. In this study, the measured bias was &#8722;1.1% (95% CI, &#8722;3.1% to 0.9%) for ptau-217. Previously, the measured bias was 12% for A&#946;42 and 11% for A&#946;40.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> In this study, the average measured imprecision for ptau-217, determined by taking the average of 2 QCs analyzed in duplicate over 14 nonconsecutive days, was 6%. The average imprecision for A&#946;42/40, previously measured by taking the average imprecision across 5 study samples analyzed in duplicate over 25 days, was also 6%.<sup><xref rid="R8" ref-type="bibr">8,9</xref></sup></p><p>Reclassification rates are provided in eTable 5, and visual representation of classification comparisons with and without total error applied are shown in eFigure 3. The median reclassification after applying total error across 10,000 simulations was 13.5% (9.8%&#8211;16.7%). Within these data, most reclassifications were from indeterminate to negative (3.3%, 1.4%&#8211;5.6%) and fewest were from negative to positive (0.9%, 0%&#8211;2.3%).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The need for affordable, scalable, and accessible blood-based testing for Alzheimer disease has never been more important than with the emergence of the first disease-modifying therapies. We demonstrate that the combination of plasma A&#946;42/40, ptau-217, and ApoE proteoform test results, measured using high-throughput LC-MS/MS and immunoassay methods, can predict the likelihood of amyloid pathology using an optimized model and a 2-cutpoint approach (<xref rid="T2" ref-type="table">Table 2</xref>). Automated specimen preparation and analysis allows a 96-well plate to be run in 2&#8211;8 hours, depending on the assay.</p><p>The cutpoints were optimized for detecting amyloid PET status in patients with MCI and AD, who represent the intended-use population. In addition, these optimized cutpoints are in alignment with recently published performance recommendations to minimize the number of indeterminate results to &#8804;20% while maintaining a sensitivity and specificity of &#8805;90%.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> This ensures that our test can be used to both rule in and rule out amyloid PET positivity consistent with AD pathology as the likely culprit of cognitive impairment. The model minimized the proportion of indeterminate results to &#8804;10%, thus limiting results that can be uninformative to both patients and clinicians.</p><p>The optimized model was derived from logistic regression combining A&#946;42/40, natural log-transformed ptau-217 concentrations, and <italic toggle="yes">APOE4</italic> allele count. Each component provided a statistically significant contribution to the risk score, except for the homozygous <italic toggle="yes">APOE4</italic> component. All 12 homozygous <italic toggle="yes">APOE4</italic> individuals in our cohort were PET positive, and the absence of <italic toggle="yes">APOE4</italic> homozygotes in the PET-negative group provided no statistical control.</p><p><italic toggle="yes">APOE4</italic> homozygosity has a prevalence of approximately 2% in the general population.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> We found homozygosity to be slightly higher both in our intended-use cohort and in clinical specimens (approximately 6%). However, <italic toggle="yes">APOE4</italic> homozygosity combined with PET negativity would be expected to be extremely rare. For example, a study<sup><xref rid="R32" ref-type="bibr">32</xref></sup> found that almost 99% of <italic toggle="yes">APOE4</italic> homozygotes had some Alzheimer disease neuropathologic change. The same study suggested that <italic toggle="yes">APOE4</italic> homozygosity is now being considered a genetically distinct form of Alzheimer disease.</p><p>The optimized model showed slight improvement over A&#946;42/40 combined with ptau-217 in terms of ROC-AUC and had the lowest AIC score of all models (<xref rid="T2" ref-type="table">Table 2</xref>). It is important to note that the model substantially reduced the number of participants with an indeterminate result from 15% to 10%, with approximately two-thirds of the reclassified participants having a result more predictive of their actual PET status.</p><p>The performance of combinations of biomarkers in predicting amyloid PET status has been reported by several different groups.<sup><xref rid="R14" ref-type="bibr">14-17</xref></sup> One study<sup><xref rid="R14" ref-type="bibr">14</xref></sup> reported high predictive performance for a high-resolution MS-based assay incorporating ptau-217 normalized to nonphosphorylated tau (% ptau-217, ptau-217/np-tau-217) and A&#946;42/40, optimized by a single cutpoint. The combined cohort used to develop the model in this study was less ethnically diverse than ours, although subcohort analysis indicated that their model had equivalent accuracy regardless of age, sex, race, ethnicity, or <italic toggle="yes">APOE4</italic> status.</p><p>In contrast to the study described above, the design of our study incorporated PET-positive and PET-negative participants, who were matched for age, sex, ethnicity, and years of education. While they reported on model robustness for subgroups, the prior study did not report on assay technical robustness, including the effects of technical and random error on patient classification. Our robustness analysis, which measured total error for both A&#946;42/40 and ptau-217 assays, demonstrated an overall reclassification rate of &lt;14% and just over 3% for the most risk reclassifications between 2 categories.</p><p>Other studies showing high performance using fewer biomarkers established PET positivity using quantitative centiloid (CL) values with cutoffs of &gt;25 CL or &gt;24 CL indicating PET positivity. By contrast, we established PET positivity by central visual read,<sup><xref rid="R10" ref-type="bibr">10,14,16</xref></sup> which is widely recognized as being highly accurate and the standard, with which CL quantification is compared. Studies have demonstrated a 92% agreement between visual read and CL values. However, CL values were considered supportive in only 70% of cases that were considered challenging (11% of scans, expected rate in a memory clinic setting).<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Results suggest that CL values can be supportive when added to visual read assessment but have not necessarily been shown to be superior to the highly accurate visual read approach, with the authors acknowledging that &#8220;quantification should always be done in conjunction with visual assessment to avoid misclassifications due to potential quantification errors.&#8221; In addition, the authors note the recent adoption of opinion from the Committee for Medicinal Products for Human Use (EMACDOC-17005198181200791), stating that a &#8220;threshold of greater than 30 is reflective of established amyloid pathology at the individual level with high certainty.&#8221;<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p><p>Our real-world data set was composed of 4,326 consecutively run A&#946;42/40, ptau-217, and ApoE proteoform specimens, submitted by health care providers, presumably for suspected dementia due to Alzheimer disease. As expected, we observed an increase in the likelihood of PET positivity with age, with predicted PET positivity rates ranging from 9% for individuals younger than 50 years to 55% for those aged 90 years or older (eTable 4). These results suggest that PPV/NPV could be influenced by age-dependent trends in the prevalence of amyloid PET positivity, particularly for individuals younger than 70 years.</p><p>Using our fixed cutpoints to categorize individuals into low, indeterminate, and high likelihood of amyloid PET positivity, we suggest that results may help guide physicians in clinical decision making (<xref rid="T4" ref-type="table">Table 4</xref>). Projecting the proportion of PET positivity from the intended-use population onto the 4,326 clinical specimens could potentially eliminate the need for PET or CSF testing on 2,204 individuals who are likely to have non-AD etiology, or slightly over 50% of tested individuals. Considering the cost of an amyloid PET scan in the United States (&#8764;$5,000 USD),<sup><xref rid="R34" ref-type="bibr">34</xref></sup> excluding these individuals alone may potentially save $11,020,000 (less the cost of testing) as well as eliminating travel and wait times to receive imaging services.</p><p>Key strengths of this study include its use of scalable, cost-effective plasma biomarkers in a cohort of ethnically diverse patients who are representative of the intended-use population. However, the models were developed using a cohort of participants in a memory care setting, which may not reflect the general clinical population. This concern is alleviated by similarity in the distribution between our intended-use cohort and the &#8220;real-world&#8221; clinical specimens across the 3 risk classifications (<xref rid="F3" ref-type="fig">Figure 3</xref>). Regarding ethnic diversity, although Hispanic individuals were well represented in the intended-use cohort, African Americans were less well represented, and there were no self-reported Asian Americans nor Pacific Islanders.</p><p>In addition, our study was not designed to evaluate the relevance or performance of these markers in the context of other causes of dementia, including mixed dementia with amyloid pathology or early-onset Alzheimer disease, or to address the effects of ethnically relevant genetic markers such as <italic toggle="yes">APOE4</italic> on predictive performance of the tests. Furthermore, the model will falsely identify PET-negative <italic toggle="yes">APOE4</italic> homozygote individuals as PET positives, although these individuals are expected to be extremely rare. In our expanded cohort, we found one PET-negative <italic toggle="yes">APOE4</italic> homozygote individual, but they had normal cognition, excluding them from the intended-use population on which the model was built and predictors were trained.</p><p>Notably, <italic toggle="yes">APOE4</italic> status is also leading contributor to risk of amyloid-related imaging abnormalities (ARIAs) with anti-amyloid therapies; however, <italic toggle="yes">APOE4</italic> was included solely as a predictor of amyloid status in this study, and results do not provide a quantitative measure of ARIA risk.<sup><xref rid="R35" ref-type="bibr">35</xref></sup></p><p>Another limitation is the potential for high false-positive rates that may be observed in a primary care setting (e.g., PPV 69%) with low amyloid prevalence (e.g., 20%). However, in such settings, the clinical utility of the models is better suited to rule out AD pathology, given the high NPVs (e.g., 97%) observed in these low-prevalence populations.</p><p>Finally, while the model works well for predicting PET status and differentiates individuals with different cognitive status, models for predicting cognitive status only work well for differentiating NC from AD.</p><p>Replication of these results in other ethnically and socioeconomically diverse groups will support using these biomarkers for clinical assessment of potential candidates for anti-amyloid therapies. The combination of plasma biomarkers described herein is likely to complement clinical and radiologic diagnostic evaluations to further enhance the accuracy of AD diagnosis, especially when incorporated into enhanced models. For example, combining these models with assessments of cognitive function may offer a low-cost enhancement of model performance. Combining these models with specific imaging methodology to assess diverse neurodegenerative processes may be important in selecting patients who are most likely to respond to specific therapeutic interventions.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p></sec></body><back><ack><title>Acknowledgment</title><p>The authors would like to thank Dr. Bhairavi Vajaria for her technical support generating the ptau-217 results. They would also like to thank Dr. Andrew Hellman for his assistance with reviewing the manuscript.</p></ack><sec sec-type="author-contributions"><title>Author Contributions</title><p content-type="author-contributions">D.M. Weber: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. M.A. Stroh: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. S.W. Taylor: drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data. R.J. Lagier: drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data. J.Z. Louie: analysis or interpretation of data. N.J. Clarke: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. D.E. Vaillancourt: drafting/revision of the manuscript for content, including medical writing for content. S. Rayaprolu: study concept or design. R. Duara: drafting/revision of the manuscript for content, including medical writing for content. M.K. Racke: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data.</p></sec><sec sec-type="funding"><title>Study Funding</title><p content-type="funding">Funding for this work was provided by NIH Research Grants R01NS052318 and R01NS075012 (D.E. Vaillancourt).</p></sec><sec sec-type="COI-statement"><title>Disclosure</title><p>D.M. Weber is an employee of Quest Diagnostics and holds patents for the detection of beta-amyloid by mass spectrometry as well as for the detection of apolipoprotein E proteoforms by mass spectrometry. M.A. Stroh, S.W. Taylor, R.J. Lagier, and J.Z. Louie are employees of Quest Diagnostics. N.J. Clarke is an employee of Quest Diagnostics and holds patents for the detection of beta-amyloid by mass spectrometry as well as for the detection of apolipoprotein E proteoforms by mass spectrometry. D.E. Vaillancourt, S. Rayaprolu, and R. Duara report no disclosures relevant to the manuscript. M.K. Racke is an employee of Quest Diagnostics. Full disclosure form information provided by the authors is available with the full text of this article at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000200546" ext-link-type="uri">Neurology.org/cp</ext-link>.<boxed-text id="B1" position="float" orientation="portrait"><sec><title>TAKE-HOME POINTS</title><p><list list-type="simple"><list-item><p>&#8594; The approval of disease-modifying therapies for Alzheimer disease ushers in the need for accessible, affordable, and accurate blood-based testing for Alzheimer pathology.</p></list-item><list-item><p>&#8594; Models implementing multiple analytes have demonstrated high performance in identifying patients with brain amyloid pathology.</p></list-item><list-item><p>&#8594; We developed high-throughput, robust, multiple-analyte assays and models aimed at predicting the likelihood of amyloid PET positivity.</p></list-item><list-item><p>&#8594; We report 2 models with excellent performance in alignment with current recommendations for blood-based testing.</p></list-item><list-item><p>&#8594; A&#946;42/40 + ptau-217 + <italic toggle="yes">APOE4</italic> allele count provided the best prediction for amyloid PET positivity when sensitivity and specificity were both fixed at 91%.</p></list-item></list></p></sec></boxed-text></p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Amieva</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Alzheimer disease</article-title>. <source>Nat Rev Dis Primers</source>. <year>2021</year>;<volume>7</volume>(<issue>1</issue>):<fpage>33</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chapleau</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iaccarino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Soleimani-Meigooni</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Rabinovici</surname><given-names>GD</given-names></string-name></person-group>. <article-title>The role of amyloid PET in imaging neurodegenerative disorders: a review</article-title>. <source>J Nucl Med</source>. <year>2022</year>;<volume>63</volume>(<issue>suppl 1</issue>):<fpage>13S</fpage>-<lpage>19S</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.121.263195</pub-id><pub-id pub-id-type="pmid">35649652</pub-id><pub-id pub-id-type="pmcid">PMC9165727</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Arias</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>11</issue>):<fpage>1505</fpage>-<lpage>1521</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2018.07.220</pub-id><pub-id pub-id-type="pmid">30316776</pub-id><pub-id pub-id-type="pmcid">PMC10013957</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Sabbagh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name></person-group>. <article-title>Lecanemab in early Alzheimer's disease. Reply</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>388</volume>(<issue>17</issue>):<fpage>1631</fpage>-<lpage>1632</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMc2301380</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sims</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>CD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>330</volume>(<issue>6</issue>):<fpage>512</fpage>-<lpage>527</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mattke</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wallick</surname><given-names>C</given-names></string-name></person-group>. <article-title>Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis</article-title>. <source>Alzheimers Res Ther</source>. <year>2023</year>;<volume>15</volume>(<issue>1</issue>):<fpage>128</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-023-01272-z</pub-id><pub-id pub-id-type="pmid">37481563</pub-id><pub-id pub-id-type="pmcid">PMC10362635</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Canestaro</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Monane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Braunstein</surname><given-names>JB</given-names></string-name></person-group>. <article-title>Use of a blood biomarker test improves economic utility in the evaluation of older patients presenting with cognitive impairment</article-title>. <source>Popul Health Manag</source>. <year>2024</year>;<volume>27</volume>(<issue>3</issue>):<fpage>174</fpage>-<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1089/pop.2023.0309</pub-id><pub-id pub-id-type="pmid">38546435</pub-id><pub-id pub-id-type="pmcid">PMC11304753</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weber</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Lagier</surname><given-names>RJ</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clinical utility of plasma A&#946;42/40 ratio by LC-MS/MS in Alzheimer's disease assessment</article-title>. <source>Front Neurol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1364658</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2024.1364658</pub-id><pub-id pub-id-type="pmid">38595851</pub-id><pub-id pub-id-type="pmcid">PMC11003272</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weber</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Goldman</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Racke</surname><given-names>MK</given-names></string-name></person-group>. <article-title>New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment</article-title>. <source>J Investig Med</source>. <year>2024</year>;<volume>72</volume>(<issue>5</issue>):<fpage>465</fpage>-<lpage>474</lpage>. doi:<pub-id pub-id-type="doi">10.1177/10815589241246537</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title>. <source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>(<issue>3</issue>):<fpage>255</fpage>-<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5143</fpage>-<lpage>5169</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The accuracy and robustness of plasma biomarker models for amyloid PET positivity</article-title>. <source>Alzheimers Res Ther</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>26</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-021-00942-0</pub-id><pub-id pub-id-type="pmid">35130933</pub-id><pub-id pub-id-type="pmcid">PMC8819863</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cullen</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>An accurate fully automated panel of plasma biomarkers for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1204</fpage>-<lpage>1215</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12751</pub-id><pub-id pub-id-type="pmid">35950735</pub-id><pub-id pub-id-type="pmcid">PMC9918613</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meyer</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Kirmess</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Eastwood</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A&#946;42/40 ratio to identify presence of brain amyloid</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>5</issue>):<fpage>3179</fpage>-<lpage>3192</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13764</pub-id><pub-id pub-id-type="pmid">38491912</pub-id><pub-id pub-id-type="pmcid">PMC11095426</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kirmess</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>MR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>4</issue>):<fpage>e228392</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.8392</pub-id><pub-id pub-id-type="pmid">35446396</pub-id><pub-id pub-id-type="pmcid">PMC9024390</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Figdore</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Griswold</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bornhorst</surname><given-names>JA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>9</issue>):<fpage>6506</fpage>-<lpage>6516</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14140</pub-id><pub-id pub-id-type="pmid">39030981</pub-id><pub-id pub-id-type="pmcid">PMC11497693</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>West</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kirmess</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>MR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A blood-based diagnostic test incorporating plasma A&#946;42/40 ratio, ApoE proteotype, and age accurately identifies&#160;brain amyloid status: findings from a multi cohort validity analysis</article-title>. <source>Mol Neurodegener</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>30</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13024-021-00451-6</pub-id><pub-id pub-id-type="pmid">33933117</pub-id><pub-id pub-id-type="pmcid">PMC8088704</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Galasko</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Acceptable performance of blood biomarker tests of amyloid pathology&#8212;recommendations from the Global CEO Initiative on Alzheimer's Disease</article-title>. <source>Nat Rev Neurol</source>. <year>2024</year>;<volume>20</volume>(<issue>7</issue>):<fpage>426</fpage>-<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41582-024-00977-5</pub-id><pub-id pub-id-type="pmid">38866966</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Edelmayer</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Boxer</surname><given-names>AL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>2669</fpage>-<lpage>2686</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12756</pub-id><pub-id pub-id-type="pmid">35908251</pub-id><pub-id pub-id-type="pmcid">PMC10087669</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Blood-based biomarkers for Alzheimer's disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>66</fpage>-<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(21)00361-6</pub-id><pub-id pub-id-type="pmid">34838239</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsoy</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>VandeVrede</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>3</issue>):<fpage>2089</fpage>-<lpage>2101</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13686</pub-id><pub-id pub-id-type="pmid">38224278</pub-id><pub-id pub-id-type="pmcid">PMC10942726</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name></person-group>. <article-title>The Clinical Dementia Rating (CDR): current version and scoring rules</article-title>. <source>Neurology</source>. <year>1993</year>;<volume>43</volume>(<issue>11</issue>):<fpage>2412</fpage>-<lpage>2414</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.43.11.2412-a</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Folstein</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Folstein</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>PR</given-names></string-name></person-group>. <article-title>&#8220;Mini-mental state&#8221;. A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source>. <year>1975</year>;<volume>12</volume>(<issue>3</issue>):<fpage>189</fpage>-<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duara</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Loewenstein</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Greig</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2010</year>;<volume>18</volume>(<issue>4</issue>):<fpage>363</fpage>-<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1097/jgp.0b013e3181c534a0</pub-id><pub-id pub-id-type="pmid">20306566</pub-id><pub-id pub-id-type="pmcid">PMC2844658</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duara</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Loewenstein</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Lizarraga</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity</article-title>. <source>Neuroimage Clin</source>. <year>2019</year>;<volume>22</volume>:<fpage>101800</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nicl.2019.101800</pub-id><pub-id pub-id-type="pmid">30991618</pub-id><pub-id pub-id-type="pmcid">PMC6447735</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rabe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bittner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Jethwa</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clinical performance and robustness evaluation of plasma amyloid-&#946;<sub>42/40</sub> prescreening</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>4</issue>):<fpage>1393</fpage>-<lpage>1402</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12801</pub-id><pub-id pub-id-type="pmid">36150024</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases</article-title>. <source>Nat Aging</source>. <year>2023</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1079</fpage>-<lpage>1090</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43587-023-00471-5</pub-id><pub-id pub-id-type="pmid">37653254</pub-id><pub-id pub-id-type="pmcid">PMC10501903</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeLong</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>DeLong</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Clarke-Pearson</surname><given-names>DL</given-names></string-name></person-group>. <article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title>. <source>Biometrics</source>. <year>1988</year>;<volume>44</volume>(<issue>3</issue>):<fpage>837</fpage>-<lpage>845</lpage>. doi:<pub-id pub-id-type="doi">10.2307/2531595</pub-id><pub-id pub-id-type="pmid">3203132</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jansen</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Janssen</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Tijms</surname><given-names>BM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>3</issue>):<fpage>228</fpage>-<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2021.5216</pub-id><pub-id pub-id-type="pmid">35099509</pub-id><pub-id pub-id-type="pmcid">PMC12138908</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Aakre</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kremers</surname><given-names>WK</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting</article-title>. <source>JAMA Neurol</source>. <year>2018</year>;<volume>75</volume>(<issue>8</issue>):<fpage>970</fpage>-<lpage>979</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2018.0629</pub-id><pub-id pub-id-type="pmid">29710225</pub-id><pub-id pub-id-type="pmcid">PMC6142936</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>R&#233;gy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dugravot</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sabia</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The role of dementia in the association between APOE4 and all-cause mortality: pooled analyses of two population-based cohort studies</article-title>. <source>Lancet Healthy Longev</source>. <year>2024</year>;<volume>5</volume>(<issue>6</issue>):<fpage>e422</fpage>-<lpage>e430</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-7568(24)00066-7</pub-id><pub-id pub-id-type="pmid">38824957</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fortea</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pegueroles</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alcolea</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>(<issue>5</issue>):<fpage>1284</fpage>-<lpage>1291</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-024-02931-w</pub-id><pub-id pub-id-type="pmid">38710950</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Collij</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Bischof</surname><given-names>GN</given-names></string-name>, <string-name name-style="western"><surname>Altomare</surname><given-names>D</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD diagnostic and patient management study</article-title>. <source>J Nucl Med</source>. <year>2025</year>;<volume>66</volume>(<issue>1</issue>):<fpage>110</fpage>-<lpage>116</lpage>. doi:<pub-id pub-id-type="doi">10.2967/jnumed.124.268119</pub-id><pub-id pub-id-type="pmid">39542700</pub-id><pub-id pub-id-type="pmcid">PMC11705786</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pierce</surname><given-names>C</given-names></string-name></person-group>. <article-title>PrecivityAD for diagnosis of alzheimer disease</article-title>. <source>Am Fam Physician</source>. <year>2022</year>;<volume>105</volume>(<issue>1</issue>):<fpage>79</fpage>-<lpage>81</lpage>.<pub-id pub-id-type="pmid">35029942</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Withington</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>RS</given-names></string-name></person-group>. <article-title>Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease</article-title>. <source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>862369</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2022.862369</pub-id><pub-id pub-id-type="pmid">35401412</pub-id><pub-id pub-id-type="pmcid">PMC8985815</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>DeSimone</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>WE</given-names></string-name>, <string-name name-style="western"><surname>Loewenstein</surname><given-names>DA</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Diffusion MRI relates to plasma A&#946;42/40 in PET negative participants without dementia</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>4</issue>):<fpage>2830</fpage>-<lpage>2842</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13693</pub-id><pub-id pub-id-type="pmid">38441274</pub-id><pub-id pub-id-type="pmcid">PMC11032550</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id><journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id><journal-id journal-id-type="pmc-domain-id">1472</journal-id><journal-id journal-id-type="pmc-domain">neurother</journal-id><journal-title-group><journal-title>Neurotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">1933-7213</issn><issn pub-type="epub">1878-7479</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491809</article-id><article-id pub-id-type="pmcid-ver">PMC12491809.1</article-id><article-id pub-id-type="pmcaid">12491809</article-id><article-id pub-id-type="pmcaiid">12491809</article-id><article-id pub-id-type="pmid">40413074</article-id><article-id pub-id-type="doi">10.1016/j.neurot.2025.e00615</article-id><article-id pub-id-type="pii">S1878-7479(25)00093-5</article-id><article-id pub-id-type="publisher-id">e00615</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Qi</surname><given-names initials="L">Liqin</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Kang</surname><given-names initials="H">Huimin</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Zeng</surname><given-names initials="F">Feihui</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Zhan</surname><given-names initials="M">Menglan</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Huang</surname><given-names initials="C">Cuihua</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Huang</surname><given-names initials="Q">Qintao</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Lin</surname><given-names initials="L">Lijing</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>He</surname><given-names initials="G">Guanlian</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xiaoying</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Liu</surname><given-names initials="X">Xiaohong</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Liu</surname><given-names initials="L">Libin</given-names></name><email>libinliu@fjmu.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Endocrinology, Fujian Institute of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China</aff><aff id="aff2"><label>b</label>Department of Pediatrics, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>libinliu@fjmu.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0010">These authors make equal contribution to this research</p></fn></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">498231</issue-id><elocation-id>e00615</elocation-id><history><date date-type="received"><day>9</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>3</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Diabetes-associated cognitive decline (DACD), characterized by cognitive impairment, is a serious complication of diabetes mellitus (DM). Research has shown that semaglutide, a novel glucagon-like peptide-1 receptor agonist, has neurotrophic and neuroprotective properties. However, a comprehensive understanding of the specific effects and underlying mechanisms of semaglutide treatment in patients with DACD remains lacking. In this study, we evaluated the potential of semaglutide to alleviate DACD in mice with DM. Eight-week-old mice fed a high-fat diet with streptozotocin-induced DM were subcutaneously injected with semaglutide (30 &#8203;nmol/kg qd) for 12 weeks. Semaglutide administration significantly alleviated cognitive impairment, inhibited hippocampal neuron loss, improved the hippocampal synaptic ultrastructure, and effectively mitigated neuroinflammation. Furthermore, semaglutide treatment increased the relative abundances of <italic toggle="yes">g_Alistipes, g_norank_f_Eubacterium_coprostanoligenes, g_Bacteroides,</italic> and <italic toggle="yes">g_Parabacteroides</italic>, while decreasing the relative abundances of <italic toggle="yes">g_ faecalibaculum, g_Colodertribacter, g_GCA-900066575, g_Erysipelatoclostridium,</italic> and <italic toggle="yes">g_norank_f_Lachnospiraceae</italic>. Semaglutide also induced alterations in fecal and serum metabolites, as well as transcriptomic changes in brain tissue, with significant common enrichment in neuroactive ligand-receptor interactions. Furthermore, strong correlations were observed among semaglutide-affected genes, metabolites, and microbiota, as assessed by correlation analysis and integrative modeling. In conclusion, these findings suggest a correlation between the protective effects of semaglutide against DACD and the microbiota-gut-brain axis.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Semaglutide</kwd><kwd>Cognitive impairment</kwd><kwd>Gut microbiota</kwd><kwd>Neuroactive ligand-receptor interactions</kwd><kwd>Metabolome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">The global population affected by diabetes mellitus (DM) is estimated to be approximately 500 million, leading to significant challenges for society, the economy, and families [<xref rid="bib1" ref-type="bibr">1</xref>]. Diabetes-associated cognitive decline (DACD) is a serious complication of DM characterized by cognitive impairment, memory deficits, and neuronal loss [<xref rid="bib2" ref-type="bibr">2</xref>]. The mechanisms underlying DACD include brain insulin resistance, hyperglycemia, hypoglycemia, oxidative stress, cerebral microvascular dysfunction, neuroinflammation, and microbiota dysbiosis [<xref rid="bib3" ref-type="bibr">3</xref>]. Although understanding these potential mechanisms can aid in developing treatment strategies for DACD, there is still no effective strategy to halt its progression.</p><p id="p0015">The &#8220;gut-brain&#8221; axis is a multiple biological communication system that facilitates bidirectional interactions between the gut microbiota and the brain [<xref rid="bib4" ref-type="bibr">4</xref>]. It plays a pivotal role in maintaining both the gut microenvironment and central nervous system, making it a key area of research related to neurological disorders. The three primary methods of bidirectional communication include neuronal pathways, impact on metabolism, and immune system modulation [<xref rid="bib5" ref-type="bibr">5</xref>]. Increasing evidence suggests that the gut microbiota may mediate the development and progression of neurodegenerative disorders, including Parkinson's disease (PD) [<xref rid="bib6" ref-type="bibr">6</xref>], Alzheimer's disease (AD) [<xref rid="bib7" ref-type="bibr">7</xref>], and DACD [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. Clinical studies have shown that patients with diabetes often exhibit intestinal mucosal injury and microbial dysbiosis [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>]. These findings indicate that correcting the intestinal microenvironment disorders caused by DM may be crucial for treating DACD. Therefore, targeting the &#8220;microbiota-gut-brain axis (MGBA)&#8221; has become an important research focus for developing potential therapeutic strategies for DACD.</p><p id="p0020">Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), treats type 2 DM [<xref rid="bib13" ref-type="bibr">13</xref>]. Emerging evidence suggests that semaglutide exerts neuroprotective effects [<xref rid="bib14" ref-type="bibr">14</xref>]. Semaglutide has been shown to reduce cognitive impairment induced by a high-fat diet (HFD) in obese mice by increasing the phosphorylation of proteins related to neuronal development and synaptic plasticity [<xref rid="bib15" ref-type="bibr">15</xref>]. In addition, semaglutide enhanced the cognitive abilities of rats with type 2 diabetes-related depression, protected synaptic plasticity, and reduced neuroinflammation [<xref rid="bib16" ref-type="bibr">16</xref>]. Our previous study revealed that liraglutide, another GLP-1RA, increased the support provided by astrocytes to neurons via promoting aerobic glycolysis and decreased p-tau levels by inhibiting glycogen synthase kinase-3&#946; (GSK-3&#946;) [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Moreover, regarding the gut microbiota, semaglutide has been shown to alleviate gut microbiota dysbiosis associated with non-alcoholic fatty liver disease and restore the abundance of <italic toggle="yes">Akkermansia, Faecalibaculum, Allobaculum, Lachnospiraceae</italic> and <italic toggle="yes">Bacteroides</italic> in obese mice [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. However, the mechanisms through which semaglutide modulates MGBA and improves DACD pathology remain unclear.</p><p id="p0025">In this study, we investigated the effects and underlying mechanisms of semaglutide treatment on cognitive function in HFD-fed, streptozotocin (STZ)-induced DM mice. We evaluated pathological changes and neuroinflammation in the brain following semaglutide treatment. The mechanisms through which semaglutide regulates DACD were explored using a combination of the microbiome, fecal metabolome, blood metabolome, and brain transcriptomic analyses. This study provides new insights for the prevention and treatment of DACD.</p></sec><sec id="sec2"><title>Material and Methods</title><sec id="sec2.1"><title>Animals</title><p id="p0030">Eight-week-old male C57BL/6 mice were purchased from Beijing Huafukang Biotechnology Co., Ltd. [Animal certificate number: SCXK (Jing) 2019-0008]. All animals were housed in a pathogen-free facility (ICV system, Tecniplast, Italy) and maintained in a stable environment with a temperature of 23 &#8203;&#177; &#8203;1 &#8203;&#176;C, 50&#8211;60 &#8203;% humidity, and a 12 &#8203;h light/dark cycle with free access to food and clean tap water.</p><p id="p0035">The animals underwent a 1-week adaptive feeding period before the experiment. Mice were then randomly divided into four groups: normal control (NC), normal control with semaglutide (SE), diabetes mellitus (DM), and diabetes mellitus with semaglutide (DM_SE). Each group consisted of 12 mice. Mice in the DM and DM_SE groups were fed HFD (60 &#8203;% fat) (TP23400, TROPHIC Animal Feed High-Tech Co. LTD, China) in the 2nd &#8722;27th weeks to induced DM, while those in the NC and SE groups were fed a normal control diet. In the 14th-15th weeks, mice in the DM and DM_SE groups received intraperitoneal injections of STZ at 40 &#8203;mg/kg for 5 consecutive days, while mice in the NC and SE groups received an equal dose of physiological saline. Blood samples were collected from the tail tip for random blood glucose testing on days 3, 5, and 7 after the final injection of STZ.A blood glucose level &#8805;16.7 &#8203;mmol/L on at least two occasions confirmed successful induction of the diabetes model. Afterward, in the 16th-27th weeks, all animals in the SE and DM_SE groups received subcutaneous injections of semaglutide (30 &#8203;nmol/kg, qd) for 12 weeks, while animals in the NC and DM groups received vehicle injections. The semaglutide dose was gradually increased over the first 6 days (0.6, 1.2, 2.4, 4.8, 12, 30 &#8203;nmol/kg) to mitigate temporary discomfort induced by GLP-1RA treatment [<xref rid="bib21" ref-type="bibr">21</xref>]. The final dose was maintained for the remainder of the treatment [<xref rid="bib22" ref-type="bibr">22</xref>].</p><p id="p0040">Body weight was monitored weekly throughout the experiment. Random blood glucose levels from the tail vein and food intake were measured weekly following the initiation of semaglutide treatment. Food intake was calculated as the mean daily consumption per mouse. The experimental groups and treatment protocols are illustrated in <xref rid="fig1" ref-type="fig">Fig. 1</xref>A. All animal procedures were complied with ARRIVE guidelines and approved by the Institutional Animal Care and Use Committee of Fujian Medical University (IACUC FJMU). [Approval Number: IACUC FJMU 2022-0807].<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Semaglutide treatment improved learning and memory impairments in DM mice. (A) Timeline of the study and experimental design. (B) Body weight of each group (n &#8203;= &#8203;10&#8211;12 mice per group). (C) Food intake. (D) Caloric intake. (E) Random blood glucose levels across weeks. (F) Fasting blood glucose levels. (G) Serum TG concentration (H) Serum LDL-C concentration (n &#8203;= &#8203;6&#8211;8 mice per group). (I) Escape latency during the 5-day training trial in the Morris water maze test. (J) Number of platform crossings. (K) Time spent in the target quadrant. (L) Swimming speed in the spatial exploration test. (M) Representative swimming tracks of mice during the acquisition trial phase on day 5 and probe trials (n &#8203;= &#8203;10&#8211;12 mice per group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data are presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.2"><title>Morris water maze (MWM)</title><p id="p0045">The learning and memory abilities of the mice were assessed using the MWM test, as described in our previous study [<xref rid="bib18" ref-type="bibr">18</xref>]. Briefly, all mice underwent four trials per day with at least 10-min intervals for 5 consecutive days during the acquisition phase. Mice were allowed 60 &#8203;s to find the submerged platform. If a mouse failed to locate the platform within 60 &#8203;s, it was placed on the platform for 10 &#8203;s. The escape latency was defined as the time required to find the platform within 60 &#8203;s. Escape latency and average swimming speed were recorded for each trial. On day 6, a &#8220;probe trial&#8221; was conducted with the submerged platform removed. The mice were allowed to swim freely for 60 &#8203;s, and the number of crossings over the target quadrant and time spent in the target quadrant were recorded.</p></sec><sec id="sec2.3"><title>Sample collection</title><p id="p0050">The mice were anesthetized with 2 &#8203;% pentobarbital sodium (50 &#8203;mg/kg, intraperitoneally). Blood samples were collected by enucleating the eyeball, centrifuged at 3000 r/min for 10 &#8203;min at 4 &#8203;&#176;C, and stored at &#8722;80 &#8203;&#176;C. The skulls were then removed, and the brains were rapidly placed on ice. Four brains from each group were split in half; the left hemispheres were fixed in 4 &#8203;% paraformaldehyde, and the right hippocampus was dissected and fixed using fixative (G1102, Servicebio, China) for transmission electron microscopy (TEM). The remaining cerebral cortex and hippocampus were dissected on ice. The brain samples were snap-frozen in liquid nitrogen and stored at &#8722;80 &#8203;&#176;C for further analysis, including metabolomic analysis and enzyme-linked immunosorbent assay (ELISA).</p></sec><sec id="sec2.4"><title>Biochemical analyses</title><p id="p0055">Fasting glucose, serum triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels were detected using commercial kits (RXWB0458-96 Ruixinbio, Quanzhou, China), TG Content assay kits (RXWB0011-96 Ruixinbio, Quanzhou, China), and LDL-C Content assay kits (RXWB0792-96 Ruixinbio, Quanzhou, China), respectively, according to the manufacturer's instructions.</p></sec><sec id="sec2.5"><title>Histology and immunofluorescence</title><p id="p0060">Paraffin-embedded tissues were sectioned into 5 &#8203;&#956;m-thick slices. After dewaxing and dehydration, the sections were stained with a Nissl staining solution. Subsequently, cells were differentiated using 95 &#8203;% alcohol, dehydrated with anhydrous alcohol, permeabilized with xylene, and sealed with a neutral resin. Images of the Nissl staining were observed under a microscope (Eclipse 50i, Nikon, Japan).</p><p id="p0065">Double immunofluorescence staining was performed on the brain slices. Non-specific binding was blocked using 5 &#8203;% bovine serum albumin (BSA, B2064, Sigma) for 20 &#8203;min at room temperature (RT) before incubation at 4 &#8203;&#176;C overnight with primary antibodies (anti-GFAP, 1:400, ab68428, Abcam, USA; anti-Iba-1, 1:200, ab178847, USA). After washing with phosphate-buffered saline (PBS), the slices were incubated with a secondary antibody (1:200, ab150077, Abcam) for 30 &#8203;min at 37 &#8203;&#176;C. The slices were then incubated with try-594 tyramine conversion reagent for 20 &#8203;min at RT. Subsequently, for double staining, antigen retrieval and incubation were repeated, and the sections were further incubated with try-488 tyramine conversion reagent for 20 &#8203;min at RT. Nuclei were counterstained with 4&#8242;,6-diamidino-2-phenylindole (DAPI) (P0131, Beyotime Biotechnology, Jiangsu, China). Immunofluorescent signal images were acquired using a digital slide scanner (3DHISTECH; PANNORAMIC SCAN II, Budapest, Hungary). Fluorescence signals were observed by ImageJ software (NIH, Bethesda, MD, USA).</p></sec><sec id="sec2.6"><title>Transmission electron microscope (TEM)</title><p id="p0070">The CA1 region of the right hippocampus was cut into 1 &#8203;mm<sup>3</sup> cubes, which were fixed by immersion in 2.5 &#8203;% buffered glutaraldehyde at 4 &#8203;&#176;C. After washing with 0.1 &#8203;M PBS (pH 7.4), the specimen was postfixed with 1 &#8203;% osmic acid at RT 2 &#8203;h in the dark, and then in a 1 &#8203;% osmium tetroxide solution. Grades of ethanol and acetone were used for dehydration. Subsequently, the specimen was resin-penetrated and embedded using acetone and EMBed 812. The resin blocks were cut into 70 &#8203;nm thick sections using an ultramicrotome (Leica UC7, Leica, Germany). The slices were stained with 2 &#8203;% uranyl acetate and 2.6 &#8203;% lead citrate. The sections were observed using a TEM (HT7800, Hitachi, Japan).</p></sec><sec id="sec2.7"><title>Gut microbiota analysis</title><p id="p0075">Before sacrificing the mice, fresh fecal samples were collected, snap-frozen in liquid nitrogen, and then stored at &#8722;80 &#8203;&#176;C. Total genomic DNA was extracted using a PF Mag-Bind Stool DNA Kit (M9636-02) (Omega Bio-Tek, Norcross, GA, USA) according to the manufacturer's instructions. After determining the DNA concentration and integrity, the 16S rRNA gene, comprising hypervariable regions V3&#8211;V4, was amplified using a pair of primes (338F: 5&#8242;-ACTCCTACGGGAGGCAGCAG-3&#8217;; 806R: 5&#8242;-GGACTACHVGGGTWTCTAAT-3&#8242;) to enrich the target fragment for each fecal sample. The PCR products were sequenced using the Illumina PE300 platform (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. FastP and FLASH software were used to filter and merge raw sequencing data. High-quality sequences were denoised using the DADA2 plugin in the Qiime2 pipeline (version 2020.2). DADA2-denoised sequences are known as amplicon sequence variants (ASVs). Species taxonomic analysis of the ASVs was performed using the na&#239;ve Bayes classifier in Qiime2.</p></sec><sec id="sec2.8"><title>Metabolomics analysis</title><p id="p0080">Metabolomic profiling analysis was performed using blood and fecal samples, as previously described [<xref rid="bib23" ref-type="bibr">23</xref>]. Briefly, blood samples were mixed with a 4-fold volume of extraction solution (acetonitrile: methanol &#8203;= &#8203;1:1), subjected to low-temperature ultrasonic extraction, and the supernatant was analyzed after centrifugation. For fecal samples, 400 &#8203;&#956;L of extraction solution (methanol: water &#8203;= &#8203;4:1) was added to 50 &#8203;g of fecal material, ground, extracted with low-temperature ultrasound, and centrifuged and the supernatant was collected for analysis. The LC-MS/MS analysis was performed on a Thermo UHPLC-Q Exactive HF-X system equipped with an ACQUITY HSS T3 column (100 &#8203;mm &#8203;&#215; &#8203;2.1 &#8203;mm i.d., 1.8 &#8203;&#956;m; Waters, USA). The raw data generated were converted into a common format using Progenesis QI software (Waters, Milford, USA) through baseline removal, smoothing and peak values, and alignment. Metabolites were identified by searching databases, including the HMDB (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hmdb.ca/" id="intref0010">http://www.hmdb.ca/</ext-link>) and Metlin (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://metlin.scripps.edu/" id="intref0015">https://metlin.scripps.edu/</ext-link>). Principal component analysis (PCA) and orthogonal least partial squares discriminant analysis (OPLS-DA) were conducted using the R package &#8220;ropls&#8221; (Version 1.6.2). The Kyoto Encyclopedia of Genes and Genomes database (KEGG, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/" id="intref0020">http://www.genome.jp/kegg/</ext-link>) was used for the enrichment analysis of differential metabolites.</p></sec><sec id="sec2.9"><title>Transcriptomic analysis</title><p id="p0085">Total RNA was extracted from the cerebral cortex using TRIzol Reagent (T01-500, Yuhua Biomedical Technology Co., Ltd., Majorbio, Shanghai, China) following the manufacturer's protocol. RNA concentration and purity were quantified using a Nanodrop-2000 system (Thermo Scientific, Waltham, MA, USA). RNA purification, library preparation, and transcriptome sequencing were performed by Shanghai Bio-Pharm Biotechnology Co. Ltd. (Majorbio, Shanghai, China). Briefly, 1 &#8203;&#956;g of total RNA was used for library construction with the Illumina&#174; Stranded mRNA Prep Ligation Kit (20040534, Illumina, San Diego, CA, USA), according to the manufacturer's protocol. After quality assessment using Qubit 4.0, paired-end reads were generated using the NovaSeq Xplus sequencer platform (Illumina, San Diego, CA, USA). Raw data were trimmed and quality controlled via fastp using default parameters [<xref rid="bib24" ref-type="bibr">24</xref>]. Subsequently, the clean reads were separately aligned to the reference genome of mice using HISAT2 software [<xref rid="bib25" ref-type="bibr">25</xref>]. The mapped reads of each sample were analyzed using StringTie [<xref rid="bib26" ref-type="bibr">26</xref>]. The DESeq2 software was used to perform differential analysis of gene expression between samples [<xref rid="bib27" ref-type="bibr">27</xref>]. Genes with p &#8203;&lt; &#8203;0.05 and an absolute value of log2 fold change (|log2FC|) &#8203;&gt; &#8203;1.2 were considered significantly differentially expressed genes (DEGs). GO functional enrichment and KEGG pathway analyses were performed to further analyze the DEGs.</p></sec><sec id="sec2.10"><title>Statistical analysis</title><p id="p0090">Data are presented as mean &#8203;&#177; &#8203;standard deviation (SD). Statistical analyses were performed using GraphPad Prism 9.4.0 (GraphPad Software, California, USA). Two-way analysis of variance, followed by Tukey's post-hoc multiple comparison test, was applied for the data analysis. Statistical significance was set at <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Effect of semaglutide on STZ-induced diabetes in mice</title><p id="p0095">The grouping and treatment of the mice are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>A. As shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>B, the body weight of mice in the DM group and the DM-SE group significantly increased (16.36 &#8203;&#177; &#8203;2.87 &#8203;g, 15.35 &#8203;&#177; &#8203;3.17 &#8203;g, respectively) after induction with HFD. However, after 12 weeks of treatment with semaglutide, the weight loss in the DM-SE group (5.55 &#8203;&#177; &#8203;2.97 &#8203;g) was significantly greater than that of the DM group (2.78 &#8203;&#177; &#8203;1.51 &#8203;g) (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001). The body weight of the SE group decreased (4.39 &#8203;&#177; &#8203;2.05 &#8203;g), while the NC group showed a slight increase in body weight (1.02 &#8203;&#177; &#8203;0.73 &#8203;g). In terms of food intake, the initial intervention with semaglutide reduced the amount of food intake in mice, but there was no significant difference in food intake between the groups after 12 weeks of intervention (<xref rid="fig1" ref-type="fig">Fig. 1</xref>C, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05). Similar results were observed for caloric intake (<xref rid="fig1" ref-type="fig">Fig. 1</xref>D, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05). Semaglutide significantly reduced blood glucose levels of diabetic mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) but had no significant effect on NC mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05). <xref rid="fig1" ref-type="fig">Fig. 1</xref>F shows the fasting blood glucose levels of mice after semaglutide intervention. Blood glucose levels in the DM group were significantly higher than those in the NC group (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). After semaglutide treatment, blood glucose levels significantly decreased (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). The levels of triglycerides (TG) and low-density lipoprotein cholesterol (LDL) in the mouse serum increased in the DM group (<xref rid="fig1" ref-type="fig">Fig. 1</xref>G, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01; <xref rid="fig1" ref-type="fig">Fig. 1</xref>H, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001). Semaglutide intervention significantly reduced TG levels in DM mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>G, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01); however, there was no significant difference in LDL levels (<xref rid="fig1" ref-type="fig">Fig. 1</xref>H, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05).</p></sec><sec id="sec3.2"><title>Semaglutide improves cognitive performance of DM mice</title><p id="p0100">To evaluate the effects of semaglutide on memory in DM mice, we used the MWM to assess spatial learning and memory. As shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>I, compared to the control group, the average escape latency in the hidden platform test of HFD- and STZ-induced DM mice was significantly increased (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001). In addition, the average escape latency of the DM_SE group was partly preserved compared with that of DM mice (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001). As expected, semaglutide did not affect escape latencies in the search for hidden platforms in normal mice. In the probe trial, with the platform removed, the number of platform crossings varied significantly among the four groups. Mice in the DM group had fewer platform crossings over the area where the platform was previously located (<xref rid="fig1" ref-type="fig">Fig. 1</xref>J, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01) than mice in the NC group. After semaglutide treatment, the number of platform crossings increased (<xref rid="fig1" ref-type="fig">Fig. 1</xref>J, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). We calculated the time spent in the target quadrant during the probe trial and found that the DM group mice spent less time than the NC group mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>K, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001), while the DM-SE group mice spent more time in the target quadrant than the DM group mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>K, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). The data indicated that semaglutide partially preserved the cognitive impairment induced by HFD and STZ. The swimming speed data among the four groups were not significantly different (<xref rid="fig1" ref-type="fig">Fig. 1</xref>L, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05), indicating no significant difference in motor abilities among the groups. Typical swimming trajectories for each group of mice in the acquisition and probe trials are shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>M.</p></sec><sec id="sec3.3"><title>Semaglutide alleviates pathological changes of the hippocampus in DM mice</title><p id="p0105">The number of hippocampal neurons in the CA1 and CA3 regions was significantly lower in the DM group than in the NC group (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A&#8211;C), whereas no significant differences were observed in the CA4 and DG subregions of the DM groups (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D&#8211;E, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05). Semaglutide treatment significantly prevented the loss of hippocampal neurons in the CA1 and CA3 subregions in DM mice compared to that in the NC group (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B&#8211;C, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). However, the number of hippocampal neurons in the CA4 and DG subregions did not increase after semaglutide treatment in DM mice (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D&#8211;E, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05, <italic toggle="yes">p</italic> &#8203;&gt; &#8203;0.05).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Effect of semaglutide treatment on neurons and synapsis in the hippocampus. (A) Representative graphs of Nissl staining in the hippocampus (n &#8203;= &#8203;4 per group). (B&#8211;E) Number of neurons in CA1 region (B), CA3 region (C), CA4 region (D), and DG region (E). (F) Ultrastructure of chemical synapses in hippocampal CA1 region (n &#8203;= &#8203;3 per group). (G) Thickness of postsynaptic density (PSD)(H) Width of the synaptic cleft. White arrow: synapse. Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0110">Transmission electron microscopy was used to observe the ultrastructure of synapses in the CA1 region of each group of mice. <xref rid="fig2" ref-type="fig">Fig. 2</xref>F shows typical synaptic structures in each group. The white arrows indicate the synapses. In the NC and SE groups, the presynaptic and postsynaptic membranes were intact and consecutive. The postsynaptic membrane had many dense (PSD) substances, and synaptic vesicles contained abundant neurotransmitters. The synaptic cleft was narrow and parallel to the postsynaptic membrane. However, in the DM group, as shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>F, the synaptic structure was altered, with a partial fracture of the presynaptic and postsynaptic membranes, significant reduction in PSD, and widening of the synaptic cleft. These changes in the chemical synapses of DM mice suggest decreased cognitive memory. In the DM_SE group, the synaptic structure was partially restored, with evenly distributed vesicles, more regular presynaptic and postsynaptic membranes, slightly thickened PSD, and a narrower synaptic cleft compared to the DM group. <xref rid="fig2" ref-type="fig">Fig. 2</xref>G and H show the statistical analysis of PSD thickness and synaptic cleft width, respectively. As expected, the PSD thickness of the DM mice decreased (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001), and the synaptic cleft width increased (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001). Semaglutide treatment partially reversed these trends (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01 and <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001, respectively). These results suggest that semaglutide protects the structure of chemical synapses in the CA1 region of mice.</p><p id="p0115">In addition, immunofluorescence of GFAP and Iba-1 was used to investigate the activation of astrocytes and microglia. As shown in <xref rid="fig3" ref-type="fig">Fig. 3</xref>A and B, heightened GFAP and Iba-1 were observed in the hippocampus and cortex of the DM group compared to the NC and SE groups. However, the increase in the number of GFAP and Iba-1 positive cells was substantially reduced in the semaglutide-treated mice in both the hippocampus and cortex (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C&#8211;F). These results suggest that semaglutide effectively attenuates neuroinflammation in DM mice.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Effect of semaglutide treatment on neuroinflammation. (A) Immunofluorescent images of GFAP (green)/Iba-1 (red) colocalization in the hippocampus. (B) Immunofluorescent images of GFAP (green)/Iba-1 (red) colocalization in the cortex. (n &#8203;= &#8203;3/group). (C&#8211;D) Number of GFAP/Iba-1 positive cells in the hippocampus. (E&#8211;F) Number of GFAP/Iba-1 positive cells in the cortex. (n &#8203;= &#8203;3/group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.4"><title>The effect of semaglutide treatment on gut microbiota composition</title><p id="p0120">Next, we investigated whether semaglutide altered the composition of the gut microbiota. Fecal samples were collected, and the composition of the gut microbiota was analyzed by 16S rRNA pyrosequencing. The obtained sequences had a mean length of 415 base pairs and were classified as 4518 ASVs. A total of 178 ASVs were shared among all samples, while over 84 &#8203;% of the ASVs were unique to the different groups of mice. This indicates that only 3.9 &#8203;% of the observed ASVs were unaffected by drug treatment or diabetes modeling, suggesting significant differences among the four groups (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). The &#945;-diversity and &#946;-diversity analysis revealed significant differences in microbial abundance among the groups. The &#945;-diversity and &#946;-diversity of DM group mice were significantly reduced (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B and C), while the &#946;-diversity of DM-SE group mice increased compared to that of DM group mice (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C), indicating that SE treatment can improve the gut microbiota composition in DM mice. The PcoA analysis further confirmed significant alterations in gut microbiota composition across the different groups (<italic toggle="yes">R</italic> &#8203;= &#8203;0.9742, <italic toggle="yes">p</italic> &#8203;= &#8203;0.001) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D). <xref rid="fig4" ref-type="fig">Fig. 4</xref>E shows the microbial composition at the family level, while <xref rid="fig4" ref-type="fig">Fig. 4</xref>F shows the dominant species at the genus level in each group of mice. LEfSe and linear discriminant analysis (LDA) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>H) were used to identify specific taxa (from domain to genus level) that were significantly altered among the groups.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Semaglutide treatment modified the composition of gut microbiota in DM mice. (A) Venn diagrams of unique ASV in different groups. (B) &#945;-diversity analysis. (C) &#946;-diversity differences analysis. (D) PCoA analysis at the ASV level. (E) Relative abundance (%) at the family level in each group. (F) Main microbial composition of each group at the family level. (G) Clustering tree of LEfSe comparison from the domain to the genus level. (H) LDA analysis. (I) Relative abundance of representative gut microbiota at genus level. (J&#8211;K) Correlation analysis between gut microbiota and weight, RBG (J), and behavioral function (K), in impaired mice. (L) COG function classification. (n &#8203;= &#8203;8/group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data are presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0125">At the genus level, the relative abundances of <italic toggle="yes">g_Alistipes</italic>, <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes_group,</italic> and <italic toggle="yes">g_Parabacteroides</italic> significantly decreased in DM mice, but semaglutide treatment reversed this trend. Semaglutide also significantly decreased the relative abundances of <italic toggle="yes">g_faecalibaculum</italic>, <italic toggle="yes">g_Colodertribacter</italic>, <italic toggle="yes">g_GCA-900066575</italic>, <italic toggle="yes">g_Erysipelatoclostridium</italic>, <italic toggle="yes">g_norank_f_Lachnospiraceae</italic> in DM mice (<xref rid="fig4" ref-type="fig">Fig. 4</xref>I). These results suggest that semaglutide intervention can significantly restore gut microbiota disruption caused by DM.</p><p id="p0130">Furthermore, the identified semaglutide-related genera were correlated with cognition, obesity-associated weight, and random blood glucose (RBG) levels using Spearman analyses (<xref rid="fig4" ref-type="fig">Fig. 4</xref>J and K). As shown in <xref rid="fig4" ref-type="fig">Fig. 4</xref>J, <italic toggle="yes">Prevotellaceae_NK3B31_group</italic>, <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes_group</italic>, <italic toggle="yes">Clostridium_sensu_strito_1</italic>, <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Coriobacteriaceae_UGC-002</italic>, and <italic toggle="yes">Eubacterium_xyanophilum_group</italic> were associated with weight, whereas <italic toggle="yes">norank_f_Muribaculaceae</italic>, <italic toggle="yes">Prevotellaceae_NK3B31_group</italic>, <italic toggle="yes">Faecalibaculum</italic>, <italic toggle="yes">Prevotellaeae_UCG-001</italic>, <italic toggle="yes">Colidextribacter</italic>, <italic toggle="yes">Blautia</italic>, <italic toggle="yes">Coriobacteriaceae_UGC-002</italic>, and <italic toggle="yes">Eubacterium_xyanophilum_group</italic> were correlated with RBG. In addition, <italic toggle="yes">norank_f_Muribaculaceae</italic>, <italic toggle="yes">Prevotellaceae_NK3B31_group</italic>, <italic toggle="yes">Prevotellaeae_UCG-001</italic>, <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes_group</italic>, <italic toggle="yes">Ruminococcus</italic> positively correlated with cognitive ability, while <italic toggle="yes">Faecalibaculum</italic>, <italic toggle="yes">Colidextribacter</italic>, <italic toggle="yes">Coriobacteriaceae_UGC-002</italic>, <italic toggle="yes">Akkermansia</italic>, <italic toggle="yes">GCA-900066575</italic> were negatively associated with cognitive abilities (<xref rid="fig4" ref-type="fig">Fig. 4</xref>K). Thus, the beneficial effects of semaglutide on cognitive function may be associated with the maintenance of gut microbiota homeostasis.</p><p id="p0135">As shown in <xref rid="fig4" ref-type="fig">Fig. 4</xref>L, COG functional classification analysis revealed the presence of gut bacteria in the four groups of fecal samples. The biological processes involved in the gut microbiota of the DM_SE group were more similar to those of the NC group than to those of the DM group.</p></sec><sec id="sec3.5"><title>The effects of semaglutide treatment on fecal metabolic profiles</title><p id="p0140">After observing the changes in the gut microbiota, we explored whether there were changes in fecal metabolites. The fecal metabolites in the four groups were analyzed using UHPLC-MS/MS, identifying a total of 4547 metabolites, including 2692 positive metabolites and 1855 negative metabolites. Of these, 1958 metabolites were annotated in the KEGG database (43 &#8203;%). PCA was used to assess the overall metabolic differences between the groups of samples. As shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>A, the metabolites in the four groups were clearly distinguished, with the first principal component accounting for 50.7 &#8203;% of the total metabolites. To better differentiate between regional groups and improve the effectiveness and parsing ability of the model, we used OPLS-DA. As shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>B&#8211;D, the comparisons between DM vs. NC, DM_SE vs. DM, and SE vs. NC revealed significant separation, with high <italic toggle="yes">R</italic><sup><italic toggle="yes">2</italic></sup><italic toggle="yes">Y</italic> and <italic toggle="yes">Q</italic><sup><italic toggle="yes">2</italic></sup> values verifying the reliability of the model. Venn analysis was used to further identify differential metabolites, applying the screening criteria of <italic toggle="yes">p-</italic>value &lt;0.05, VIP scores &gt;1, and FC &#8203;&gt; &#8203;1. The number of differential metabolites in the comparisons of DM vs. NC, DM_SE vs. DM, and SE vs. NC was 1998, 1258, and 1432, respectively (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E). VIP score analysis further identified differential metabolites, focusing on those with VIP values greater than 2. As shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>F&#8211;H, the top 40 differential metabolites are listed. In the NC and DM groups, typical metabolites include <italic toggle="yes">N</italic>-Docosahexaenoyl Glutamine (VIP &#8203;= &#8203;2.45), Gamma-Glutaminyl-4-hydroxybenzene (VIP &#8203;= &#8203;2.41), Ser-Tyr (VIP &#8203;= &#8203;2.40). In the DM_SE group compared to DM, key differential metabolites include Glucose pyruvate (VIP &#8203;= &#8203;3.03), Minoxidil Glucuronide (VIP &#8203;= &#8203;3.47), Dihydrozeatin-7-<italic toggle="yes">N</italic>-glucoside (VIP &#8203;= &#8203;3.66), Homo-L-arginine (VIP &#8203;= &#8203;3.82). Between SE and NC, differential metabolites include 16-Hydroxy-10-oxohexadecanoic acid (VIP &#8203;= &#8203;3.54), D-Glucosamine 6-phosphate (VIP &#8203;= &#8203;2.80) and Asparaginylhydroxyproline (VIP &#8203;= &#8203;3.87).<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Semaglutide treatment regulated differential microbial metabolites in feces. (A) PCA analysis of feces. OPLS-DA of feces between NC and DM groups (B), DM and DM_SE groups (C). NC and SE groups (D). (E) Venn analysis. VIP scores analysis of NC and DM (F), DM and DM_SE (G), NC and SE groups (H). (I) Selected potential metabolites biomarkers. (J) Bubble diagram of enriched KEGG pathways. (n &#8203;= &#8203;7&#8211;8/group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data are presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0145">According to OPLS-DA and VIP scores analysis, potential biomarkers including Glutamyllysine, <italic toggle="yes">N</italic>-alpha-Acetyl-L-citrulline, 3-Hydroxy-N6,N6,N6-trimethyl-L-lysine, Galactaric acid, 5&#8242;-Thymidylic acid, Glucose pyruvate, (Z,Z)-3,6-Dodecadien-1-ol, Glycyrrhetinic acid, Capsidiol, Emodin were significantly decreased in DM mice compared to NC (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05). These trends were reversed by semaglutide treatment in DM_SE (<xref rid="fig5" ref-type="fig">Fig. 5</xref>J). The abundance of Homo-L-arginine, Dihydrozeatin-7-<italic toggle="yes">N</italic>-glucoside Minoxidil Glucuronide increased in the DM group, but decreased after semaglutide treatment (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05).</p><p id="p0150">Differential metabolites were subjected to enrichment analyses using the Kyoto Encyclopedia of Genes and Genomes database. As shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>I, common pathways co-enriched in the DM vs NC, DM_SE vs DM, and SE vs NC comparisons include Steroid hormone biosynthesis (map00140), Tryptophan metabolism (map00380), Linoleic acid metabolism (map00591), Sphingolipid signaling pathway (map 04071), Neuroactive ligand-receptor interaction (map 04080), Arachidonic acid metabolism(map 00590), and Phenylpropanoid biosynthesis (map 00940).</p></sec><sec id="sec3.6"><title>The effects of semaglutide treatment on blood metabolic profiles</title><p id="p0155">Blood metabolic variations in the comparisons of DM vs. NC, DM_SE vs. DM, and SE vs. NC were obtained using UHPLC-MS/MS. A total of 3116 metabolites were identified. PCA was performed to gain a preliminary understanding of the overall metabolic differences among each group and the degree of variation among samples within each group. PCA analysis showed significant differences among all groups (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). OPLS-DA was then used to further explore potential biomarkers following semaglutide treatment. The corresponding <italic toggle="yes">R</italic><sup><italic toggle="yes">2</italic></sup><italic toggle="yes">Y</italic> values were 0.998, 0.995, and 0.999, respectively, and the corresponding <italic toggle="yes">Q</italic><sup><italic toggle="yes">2</italic></sup> values were 0.92, 0.848, and 0.774, respectively, in the comparisons of DM vs. NC, DM_SE vs. DM, and SE vs. NC, respectively, indicating the reliability of the proposed models (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B&#8211;D). We used a <italic toggle="yes">p</italic>-value &lt;0.05, VIP score &gt;1, and FC &#8203;&gt; &#8203;1 as the conditions for screening differential metabolites for the Venn analysis. As shown in <xref rid="fig6" ref-type="fig">Figs. 6</xref>E, 1666 differential metabolites were detected between the NC and DM groups. Relative to DM and NC, 1482 and 1335 differential metabolites were obtained in the DM_SE and DM_SE groups, respectively. Based on the above results, we conducted a cluster analysis using the top 40 differential metabolites with VIP scores greater than 2 (<xref rid="fig6" ref-type="fig">Fig. 6</xref>F&#8211;H). More than 100 differential metabolites had VIP scores &gt;2.0 in the DM group relative to NC, in DM_SE mice relative to DM mice, and in SE mice relative to NC mice. The typical differential metabolites in VIP scores analysis in DM included histidylproline (VIP &#8203;= &#8203;3.15), 2,3-Dihydroxybenzenesulfonic acid (VIP &#8203;= &#8203;3.37), hydroquinone (VIP &#8203;= &#8203;3.51), and dopamine (VIP &#8203;= &#8203;3.03) when compared to NC. The typical differential metabolites in VIP scores analysis in DM_SE included 4-Hydroxybutyric acid (VIP &#8203;= &#8203;3.86), N -Formylmethionine (VIP &#8203;= &#8203;3.37), Sulfallate (VIP &#8203;= &#8203;3.44), histidylproline (VIP &#8203;= &#8203;2.79) when compared to DM. The typical differential metabolites in VIP scores analysis in SE included Oxoadipic acid (VIP &#8203;= &#8203;4.36), Acetyl citrate (VIP &#8203;= &#8203;4.65), and p-Cresol sulfate (VIP &#8203;= &#8203;4.38) when compared to NC.<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Semaglutide treatment regulated differential microbial metabolites in serum. (A) PCA analysis in serum. OPLS-DA in serum between NC and DM groups (B), DM and DM_SE groups (C), NC and SE groups (D). (E) Venn analysis. VIP score analysis of NC and DM (F), DM and DM_SE (G), NC and SE groups (H). (I) Selected potential metabolites biomarkers. (J) Bubble diagram of enriched KEGG pathways. (n &#8203;= &#8203;6&#8211;10/group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. Data presented as mean &#8203;&#177; &#8203;SD. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0160">According to OPLS-DA and VIP score analysis, potential biomarkers, such as desthiobiotin, diacetyl, histidylproline, <italic toggle="yes">N</italic>-Formylmethionine, oxalic acid, propyl alcohol, 4-Hydroxybutyric acid, sulfate, and TG, were significantly increased in DM mice relative to NC, and these trends were reversed by semaglutide treatment in DM_SE (<xref rid="fig6" ref-type="fig">Fig. 6</xref>J). The abundance of ser-gln-leu-lys decreased in the DM group, and semaglutide treatment increased their abundance (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001).</p><p id="p0165">Similarly, the differential metabolites between the groups were used for enrichment analysis in the KEGG database. As shown in <xref rid="fig6" ref-type="fig">Fig. 6</xref>I, the differential metabolites between the NC and DM groups were mainly enriched in ABC transporters (map 02010), bile secretion (map 04976), neuroactive ligand-receptor interactions (map 04080), and central carbon metabolism in cancer (map 05230). For the comparison of DM_SE and DM, pathways mainly involved in sphingolipid metabolism (map 00600), the sphingolipid signaling pathway (map 04071), the cAMP signaling pathway (map 04024), and neuroactive ligand-receptor interaction (map 04080). In the comparison of SE and NC, regulated metabolites were mainly enriched in choline metabolism in cancer (map 05231), bile secretion (map 04976), and neuroactive ligand-receptor interaction (map 04080). These differential metabolites in the blood were co-enriched in the same pathways, such as bile secretion, neuroactive ligand-receptor interaction, and biosynthesis of cofactors.</p></sec><sec id="sec3.7"><title>The effects of semaglutide treatment on the cerebral transcriptome</title><p id="p0170">RNA-Seq analysis was performed on cerebral samples from the NC, SE, DM, and DM_SE groups. A total of 46.35&#8211;75.55 million clean reads were detected for each sample after quality control. Venn analysis identified 2012 DEGs in the DM group compared to the NC group (<xref rid="fig7" ref-type="fig">Fig. 7</xref>A), with 550 genes upregulated and 1462 downregulated (<xref rid="fig7" ref-type="fig">Fig. 7</xref>D). Relative to the DM group, 929 DEGs were detected in the DM_SE group, including 536 upregulated and 393 downregulated genes (<xref rid="fig7" ref-type="fig">Fig. 7</xref>E). Semaglutide also induced 832 DEGs in the SE group relative to those in the NC group (<xref rid="fig7" ref-type="fig">Fig. 7</xref>F). GO enrichment analysis revealed that the significant DEGs that were primarily enriched in processes related to innervation, ligand-gate anion channel activity, integral components of synaptic vesicle membranes, myelination, transport vesicle membranes, intrinsic components of postsynaptic density membranes, and visual learning (<xref rid="fig7" ref-type="fig">Fig. 7</xref>B). Reactome annotation analysis of the DEGs revealed that they were mainly enriched in signal transduction, metabolism, gene expression (transcription), and vesicle-mediated transport (<xref rid="fig7" ref-type="fig">Fig. 7</xref>C).<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Effect of semaglutide on brain transcriptome. (A) Venn analysis. (B) GO enrichment analysis of DEGs. (C) Reactome annotations analysis. (D&#8211;F) Volcano plots of significant DEGs for DM vs. NC (D), DM_SE vs. DM (E), and SE vs. NC (F). Red dots indicate upregulated genes; blue dots indicate downregulated genes. (G) Bubble diagram of KEGG enrichment analysis. (H&#8211;I) Circle diagram of KEGG enrichment analysis for DM vs. NC (H), DM_SE vs. DM (I), and SE vs. NC (J). (n &#8203;= &#8203;4/group). Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group.</p></caption><alt-text id="alttext0045">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0175">Enrichment analysis of the DEGs between each group was conducted using the KEGG database (<xref rid="fig7" ref-type="fig">Fig. 7</xref>G). The most abundant DEGs were identified in the DM vs. NC comparison, with neuroactive ligand-receptor interactions, the synaptic vesicle cycle, nicotine addiction, and insulin secretion as the main biological processes (<xref rid="fig7" ref-type="fig">Fig. 7</xref>H). In the DM_SE vs. DM comparison, enriched pathways included neuroactive ligand-receptor interactions, GABAergic synapses, transcriptional misregulation in cancer, and the cAMP signaling pathway (<xref rid="fig7" ref-type="fig">Fig. 7</xref>I). In the SE group compared to the NC group, the DEGs were mainly enriched in glutamatergic synapses, pathways of neurodegeneration associated with multiple diseases, and neuroactive ligand-receptor interactions (<xref rid="fig7" ref-type="fig">Fig. 7</xref>J). Notably, neuroactive ligand-receptor interaction processes were enriched in all three comparisons, indicating that semaglutide treatment significantly influenced these interactions in both DM and NC mice. In the neuroactive ligand-receptor interaction pathway, the DEGs in the DM group were mostly downregulated compared to those in the NC group, whereas the DEGs in the DM_SE group were mostly upregulated compared to those in the DM group. This suggests that semaglutide improves cognitive function in DM mice by reversing the dysregulation of the neuroactive ligand-receptor interaction pathway.</p></sec><sec id="sec3.8"><title>Correlation analysis</title><p id="p0180">In-depth analyses were conducted by integrating DEGs (|log2FC|&#8805;1.2 and <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) and differential metabolites (VIP &#8805;1 and <italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) from blood and fecal metabolic profiles. As shown in <xref rid="fig8" ref-type="fig">Fig. 8</xref>A, eight common KEGG enrichment pathways (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) were identified between the blood metabolic profiles and DEGs in the cerebral transcriptome. <xref rid="fig8" ref-type="fig">Fig. 8</xref>B highlights these common pathways, such as the neuroactive ligand-receptor, synaptic vesicle cycle, and cAMP signaling pathways. In addition, four common KEGG pathways (<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05) were identified between the fecal metabolic profiles and DEGs in the cerebral transcriptome (<xref rid="fig8" ref-type="fig">Fig. 8</xref>C), including the neuroactive ligand-receptor, cAMP signaling pathway, cocaine addiction, and serotonergic synapses (<xref rid="fig8" ref-type="fig">Fig. 8</xref>D). <xref rid="fig8" ref-type="fig">Fig. 8</xref>E shows the common pathways between the blood and fecal metabolic profiles.<fig id="fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Integration of correlation analysis for metabolites, microbes and genes. (A) Venn diagram of common significant KEGG enrichment pathways for blood metabolic profiles and DEGs. (B) Specific common significant KEGG enrichment pathways for blood metabolic profiles and DEGs. (C) Venn diagram of common significant KEGG enrichment pathways for feces metabolic profiles and DEGs. (D) Specific common significant KEGG enrichment pathways for blood metabolic profiles and DEGs. (E) Bubble diagram of KEGG enrichment analysis for blood and fecal metabolic profiles. (F) Heat map of DEGs involved in neuroactive ligand-receptor interaction. (G) Heat map of differential serum metabolites involved in neuroactive ligand-receptor interaction. (H) Heat map of differential fecal metabolites involved in neuroactive ligand-receptor interaction. (I) Spearman correlation analyses of DEGs and differential serum metabolites involved in neuroactive ligand-receptor interaction. (J) Spearman correlation analyses of DEGs and differential fecal metabolites involved in neuroactive ligand-receptor interaction. (K) Spearman correlation analysis of gut microbiota and DEGs involved in neuroactive ligand-receptor interaction. (L) Spearman correlation analysis of gut microbiota and differential serum metabolites involved in neuroactive ligand-receptor interaction. (M) Spearman correlation analysis of gut microbiota and differential fecal metabolites involved in neuroactive ligand-receptor interaction. Red indicates a positive correlation; blue indicates a negative correlation. Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group. &#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &#8203;&lt; &#8203;0.0001.</p></caption><alt-text id="alttext0050">Fig. 8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p><p id="p0185">Furthermore, considering the blood metabolome, fecal metabolome, and transcriptome, semaglutide is speculated to alleviate cognitive impairment in DM mice by modulating the neuroactive ligand-receptor pathway. To further verify this observation, the key DEGs and metabolites (blood and feces) enriched in the neuroactive ligand-receptor pathway were analyzed and presented using heat maps (<xref rid="fig8" ref-type="fig">Fig. 8</xref>F&#8211;H). As shown in <xref rid="fig8" ref-type="fig">Fig. 8</xref>F&#8211;H, the clustering of the four groups differed significantly. To further investigate the role of the gut microbiota in cognitive function, we conducted a correlation analysis between DEGs or differential metabolites in the neuroactive ligand-receptor pathway and the gut microbiota. As shown in <xref rid="fig8" ref-type="fig">Figs. 8</xref>I, 73 significant DEGs&#8211;microbiota correlation pairs were detected, with 35 pairs being significantly positively correlated and 38 pairs being negatively correlated. In the analysis of blood metabolites and microbiota, 26 correlation pairs were identified, with 11 positive and 15 negative correlations (<xref rid="fig8" ref-type="fig">Fig. 8</xref>J). In total, 160 significant correlation pairs were detected in the analysis of fecal metabolites and microbiota (<xref rid="fig8" ref-type="fig">Fig. 8</xref>K). These results indicate that the gut microbiota is closely related to the genes and metabolites enriched in the neuroactive ligand-receptor pathway.</p></sec><sec id="sec3.9"><title>Integrated multi-OMICs analysis on semaglutide treatment</title><p id="p0190">After identifying the different omics signatures that were upregulated or downregulated in key signaling pathways of semaglutide-treated DM mice, we evaluated the interaction between gene expression in the cortex (<xref rid="fig7" ref-type="fig">Fig. 7</xref>), gut microbiota (<xref rid="fig4" ref-type="fig">Fig. 4</xref>), and microbial metabolites (<xref rid="fig5" ref-type="fig">Fig. 5</xref>, <xref rid="fig6" ref-type="fig">Fig. 6</xref>), in relation to the impact of semaglutide treatment on cognitive impairment in DM mice (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). By integrating the gene-microbiota and metabolite-microbiota correlation pairs, candidate genes (n &#8203;= &#8203;21), metabolites (n &#8203;= &#8203;10), and genera (n &#8203;= &#8203;10) were identified as key predictors from each omics dataset. The latent component method (DIABLO) was used for multi-OMIC data integration analysis to identify biomarkers. The predictors were highly correlated and contributed to the significant separation between the DM and DM_SE groups (<xref rid="fig9" ref-type="fig">Fig. 9</xref>A). Network correlation analysis revealed a close correlation between different types of signatures (<xref rid="fig9" ref-type="fig">Fig. 9</xref>B). A correlation greater than 0.6 between different types of signatures is shown in <xref rid="fig9" ref-type="fig">Fig. 9</xref>C. Based on betweenness centrality, the expression or abundance of N_Acetyl_1_ aspartylglutamic acid, <italic toggle="yes">Galr1</italic>, <italic toggle="yes">Glra1,</italic> and <italic toggle="yes">g_Erysipelatoclostridium</italic> may play key roles in the network. Compared to DM mice, the <italic toggle="yes">Grin2d</italic>, <italic toggle="yes">g_parabacteroides</italic>, <italic toggle="yes">Ghr</italic>, <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes_group</italic>, <italic toggle="yes">Edn3</italic>, <italic toggle="yes">Glra1</italic>, <italic toggle="yes">Galr1</italic>, N_Acetyl_1_aspartylgutamic_acid were significantly increased, while the expression or abundance of g_Erysipelatoclostridium, g_norank_f_Lachnospiraceae, X1_9Z_octadecenyl_2_acetyl_sn_glycero_3_phosphocholine, L_Glutamic_acid, g_Faecalibaculum, Sphinganine_1_phosphate and Sphingosine_1_phosphate were significantly decreased (<xref rid="fig9" ref-type="fig">Fig. 9</xref>D).<fig id="fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Integrated multi-OMICs analysis of semaglutide treatment. (A) Diagnostic plot Samples were colored by grouping. The ellipse represents a 95 &#8203;% confidence level ellipse plot. The number in the bottom left corner represents the correlation coefficient between the first principal component of each dataset. (B) Correlation Network Analysis showed correlations between selected signatures. The yellow, blue, and orange dots represent genes, metabolites, and microbes, respectively. The node size represents the magnitude of the central coefficient value, which is positively correlated. The thickness of the line indicates the magnitude of the correlation coefficient, with yellow indicating positive correlation and blue indicating negative correlation (C) The Circos plot shows positive (negative) correlations with a correlation cut-off (r &#8203;= &#8203;0.6), denoted by red (blue) lines, between selected signatures. (D) The clustered heatmap of selected signatures from each omics dataset. Rows represent samples, and columns represent features. Abbreviations: NC: normal control group; SE: normal control with semaglutide group; DM: Diabetes mellitus group; DM_SE: Diabetes mellitus with semaglutide group.</p></caption><alt-text id="alttext0055">Fig. 9</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr9.jpg"/></fig></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0195">In this study, we provided evidence demonstrating the beneficial effects of semaglutide treatment in alleviating cognitive dysfunction. Semaglutide treatment ameliorated gut dysbiosis in STZ-induced diabetic mice. Furthermore, we observed that semaglutide significantly altered the neuroactive ligand-receptor interaction pathway in plasma metabolic profiles, fecal metabolic profiles, and the cerebral transcriptome. These findings suggest the potential of semaglutide therapy as a probiotic intervention for diabetes-related cognitive impairment.</p><p id="p0200">Semaglutide (C<sub>187</sub>H<sub>291</sub>N<sub>45</sub>O<sub>59</sub>) is a long-acting GLP-1 receptor agonist with 94 &#8203;% sequence homology to native GLP-1 [<xref rid="bib28" ref-type="bibr">28</xref>]. Compared to native GLP-1, semaglutide has a similar ability to activate the GLP-1 receptor, but its half-life is longer due to its resistance to dipeptidyl peptidase IV [<xref rid="bib29" ref-type="bibr">29</xref>]. Recently, the effects of semaglutide on the central nervous system have received widespread attention, and it has become increasingly clear that semaglutide exerts neuroprotective effects. However, the underlying molecular mechanism remains unclear. Previous studies have shown that semaglutide ameliorates cognitive and glucose metabolism dysfunction in AD mice [<xref rid="bib30" ref-type="bibr">30</xref>], reduces inflammation and apoptosis, and stabilizes neurogenesis in a stroke model [<xref rid="bib31" ref-type="bibr">31</xref>]. GLP-1 receptors are present in the brain, including the cerebral cortex and hippocampus, and semaglutide can interact with these receptors [<xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>]. Therefore, we explored the neuroprotective effects of semaglutide and investigated the metabolomic, transcriptomic, and microbiological mechanisms involved using a mouse model of diabetes. In the MWM tests, semaglutide reversed STZ-induced impairment of spatial learning and memory. Furthermore, subsequent evaluation revealed that the subcutaneous injection of semaglutide significantly hindered the loss of hippocampal neurons in the CA1 and CA3 regions of DM mice, which are key factors in hippocampal-dependent cognitive function. Similarly, TEM revealed that damage to synapses, including an increase in synaptic width and a decrease in PSD thickness, was alleviated by semaglutide. Synaptic plasticity is widely believed to be crucial for biological processes in learning and memory. Consistent with our results, STZ-induced diabetic mice have cognitive impairment [<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib36" ref-type="bibr">36</xref>]. In addition, semaglutide increases the number of hippocampal neurons in the CA1 and CA3 subregions in a rat stroke model [<xref rid="bib31" ref-type="bibr">31</xref>]. Furthermore, DM mice show markedly activated astrocytes and microglia in the hippocampus and cortex. Interestingly, this effect was significantly inhibited by semaglutide treatment. These observations suggest that semaglutide substantially ameliorates cognitive impairment in mice with DM.</p><p id="p0205">The gut microbiota regulates the host brain function and cognitive behavior. Disruptions in gut microbes also contribute to the pathogenesis of neurodegenerative diseases [<xref rid="bib37" ref-type="bibr">37</xref>]. The results of this study indicate that DACD mice exhibit a significant gut microbial disorder. Interestingly, this effect was partially reversed with semaglutide treatment. We found that semaglutide treatment prevented a significant decrease in the abundance of <italic toggle="yes">g_Alistipes</italic> in DM mice. <italic toggle="yes">Alistipes</italic> play an important role in maintaining intestinal integrity and cognitive function [<xref rid="bib38" ref-type="bibr">38</xref>]. The abundance of <italic toggle="yes">Alistipes</italic> decreases significantly at the order, family, and genus levels in cognitively impaired mice [<xref rid="bib39" ref-type="bibr">39</xref>]. A previous study showed that leucine restriction (LR) improved HFD-induced cognitive impairment and increased the abundance of <italic toggle="yes">Alistipes,</italic> which can produce short-chain fatty acid (SCFA) [<xref rid="bib40" ref-type="bibr">40</xref>]. In addition, Dendrobium officinale polysaccharide treatment was shown to alleviate AD-related cognitive decline and reshape the perturbation of gut microbe, including upregulating the abundance of <italic toggle="yes">Alistipes</italic> [<xref rid="bib41" ref-type="bibr">41</xref>]. Furthermore, Stefano et al. reported that insulin degludec/liraglutide (another GLP-1 analog) alters the gut microbiome of older patients with type 2 diabetes, and an increased abundance of <italic toggle="yes">Alistipes</italic> was directly associated with cognitive function [<xref rid="bib42" ref-type="bibr">42</xref>].</p><p id="p0210">Moreover, LEfSe analysis revealed that semaglutide treatment increased the relative abundance of <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes, g_Bacteroides, and g_Parabacteroides</italic>. Supplementation with Mexican functional foods has been reported to improve cognitive behavior and increase the abundance of <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes</italic> which are involved in multiple beneficial metabolic effects [<xref rid="bib43" ref-type="bibr">43</xref>]. <italic toggle="yes">Eubacterium_coprostanoligenes</italic> may also enhance the integrity of the intestinal mucus barrier by promoting mucin secretion [<xref rid="bib44" ref-type="bibr">44</xref>] and mediate dyslipidemia through sphingosine [<xref rid="bib45" ref-type="bibr">45</xref>]. In our study, we found a positive correlation between <italic toggle="yes">g_norank_f_Eubacterium_coprostanoligenes</italic> and cognitive function. <italic toggle="yes">Bacteroides</italic>, a SCFA-producing bacterium, has potent immunomodulatory and anti-inflammatory effects [<xref rid="bib46" ref-type="bibr">46</xref>]. A previous study showed that <italic toggle="yes">Bacteroides</italic> is decreased in patients with AD [<xref rid="bib47" ref-type="bibr">47</xref>]. It has also been reported that <italic toggle="yes">Bacteroides</italic> was related to infant composite cognition [<xref rid="bib48" ref-type="bibr">48</xref>] and is positively associated with subsequent neurodevelopment in male infants [<xref rid="bib49" ref-type="bibr">49</xref>]. A recent study showed that <italic toggle="yes">Parabacteroides</italic> is positively correlated with cognitive function [<xref rid="bib50" ref-type="bibr">50</xref>]. <italic toggle="yes">Parabacteroides</italic> can regulate propanoic, citramalic, and acetic acids, significantly improving cognitive abilities [<xref rid="bib51" ref-type="bibr">51</xref>]<italic toggle="yes">.</italic> Interestingly, fecal <italic toggle="yes">Alistipes</italic>, <italic toggle="yes">Parabacteroides</italic>, and <italic toggle="yes">Bacteroides</italic> were significantly enriched in centenarians compared to younger controls, indicating that these may be potential markers of successful aging [<xref rid="bib52" ref-type="bibr">52</xref>].</p><p id="p0215">Additionally, we found that <italic toggle="yes">g__Faecalibaculum</italic>, <italic toggle="yes">g__unclassified_f__Lachnospiraceae</italic>, <italic toggle="yes">g__Coriobacteriaceae_UCG-002</italic>, <italic toggle="yes">g__Colidextribacter</italic>, <italic toggle="yes">g__GCA-900066575</italic>, <italic toggle="yes">g__Erysipelatoclostridium</italic>, <italic toggle="yes">g__norank_f__Lachnospiraceae</italic> were significantly increased in DM mice, and semaglutide treatment partly reversed these changes. This suggests that semaglutide helps maintain a stable gut microbiota. A high-sugar diet can promote the growth of <italic toggle="yes">g_Faecalibaculum</italic>, which can replace normal gut bacteria and cause an imbalance in the gut microbiota [<xref rid="bib53" ref-type="bibr">53</xref>]. It has been shown that <italic toggle="yes">Lachnospiraceae</italic> is associated with the odds of amyloid positivity and p-tau status [<xref rid="bib54" ref-type="bibr">54</xref>]. Previous studies have demonstrated that <italic toggle="yes">g__Coriobacteriaceae_UCG-002</italic> is a harmful bacterium correlated with abnormal metabolism and inflammation [<xref rid="bib55" ref-type="bibr">55</xref>,<xref rid="bib56" ref-type="bibr">56</xref>]. Additionally, <italic toggle="yes">g__Colidextribacter</italic> has been reported to be positively associated with pro-inflammatory factors and negatively correlated with the activities of antioxidant enzymes, with a significant increase observed in HFD-treated mice [<xref rid="bib57" ref-type="bibr">57</xref>,<xref rid="bib58" ref-type="bibr">58</xref>]. Moreover, <italic toggle="yes">Erysipelatoclostridium</italic> has also been identified as a harmful bacterium [<xref rid="bib35" ref-type="bibr">35</xref>], and as a hub gene of AD, it is associated with AD via interactions mediated by fecal deoxycholic acid [<xref rid="bib59" ref-type="bibr">59</xref>].</p><p id="p0220">Furthermore, correlation and multi-OMIC analyses revealed strong links between microbial metabolites and semaglutide-induced alterations in the microbiome profile, and cortex neuroactive ligand receptor-related gene expression. These findings suggest a correlation between the beneficial effect of semaglutide on DACD and the gut-metabolism-brain axis. In this study, we observed that semaglutide altered the expression of neuroactive ligand receptor-related genes, including <italic toggle="yes">Grin2d, Ghr, End3, Glra1, and Galr1</italic>. The <italic toggle="yes">Grin2d</italic> gene, which encodes the GluN2D subunit of the glutamate receptor <italic toggle="yes">N</italic>-methyl-D-aspartate (NMDA), plays a central role in learning, memory, neuronal development, and postsynaptic signaling [<xref rid="bib60" ref-type="bibr">60</xref>,<xref rid="bib61" ref-type="bibr">61</xref>]. In a genome-wide association study of Alzheimer's disease, it was found that the expression of the brain messenger glutamate receptor <italic toggle="yes">Grin2d</italic> was reduced, potentially leading to impaired synaptic function, which is crucial for communication between nerve cells in the brain [<xref rid="bib62" ref-type="bibr">62</xref>]. <italic toggle="yes">Ghr</italic> (growth gene) encodes a transmembrane GH receptor that modulates synaptic function, glutamatergic neurotransmission, and neural plasticity in the hippocampus, promoting cognition and memory [<xref rid="bib63" ref-type="bibr">[63]</xref>, <xref rid="bib64" ref-type="bibr">[64]</xref>, <xref rid="bib65" ref-type="bibr">[65]</xref>]. <italic toggle="yes">End3</italic> encodes a member of the (ET) protein family. Endothelin is an endothelial-derived vasoactive peptide involved in various biological processes. Research has shown that ET-3 has anti-inflammatory effects, such as attenuating platelet-activating factor (PAF)-induced inflammation [<xref rid="bib66" ref-type="bibr">66</xref>,<xref rid="bib67" ref-type="bibr">67</xref>]. In our study, we found that semaglutide increased the expression of <italic toggle="yes">End3</italic>, suggesting that semaglutide has an anti-inflammatory effect associated with PAF. <italic toggle="yes">Glra1</italic> encodes a subunit of the inhibitory glycine receptor, mediating fast synaptic inhibition in the central nervous system [<xref rid="bib68" ref-type="bibr">68</xref>]. Galr1 (Galanin receptor 1) is encoded by the <italic toggle="yes">Galr1</italic> gene. Upon binding to Galr1, galanin regulates insulin secretion [<xref rid="bib69" ref-type="bibr">69</xref>], promotes growth hormone release [<xref rid="bib70" ref-type="bibr">70</xref>], and affects cognitive performance [<xref rid="bib71" ref-type="bibr">71</xref>]. In our study, we found that semaglutide promoted the expression of <italic toggle="yes">Galr1</italic>, indicating that the regulatory effects of semaglutide on cognitive function may be multifaceted.</p><p id="p0225">Metabolomic analysis showed that semaglutide treatment increased the level of <italic toggle="yes">N</italic>-acetyl aspartyl glutamic acid (NAAG) and decreased the levels of L-glutamate, 2-acetyl-1-(9Z-octadecenyl)-sn-glycero-3-phosphocholine, sphingosine-1-phosphate (S1P), and sphinganine-1-phosphate (SA1P). NAAG primarily functions by activating presynaptic metabotropic glutamate (mGlu) receptors, inhibiting the release of neurotransmitters, including glutamate, and reducing the excitatory neurotoxicity of glutamate [<xref rid="bib72" ref-type="bibr">72</xref>]. In AD, NAAG levels in the most severely affected brain regions are significantly lower than those in healthy individuals [<xref rid="bib73" ref-type="bibr">73</xref>]. Interestingly, some studies suggest that increasing endogenous NAAG or activating the NAAG ligand mGlu3 is a promising strategy for treating neurodegenerative diseases [<xref rid="bib74" ref-type="bibr">74</xref>,<xref rid="bib75" ref-type="bibr">75</xref>]. Furthermore, semaglutide decreased glutamate levels. Glutamate is the main excitatory neurotransmitter in the central nervous system [<xref rid="bib76" ref-type="bibr">76</xref>,<xref rid="bib77" ref-type="bibr">77</xref>]. However, when synaptic glutamate concentrations increase excessively, they can induce excitotoxic cell death through NMDA receptor-mediated increases in intracellular Ca2<sup>+</sup>concentrations. Studies have shown that increased glutamate release within synaptic gaps and subsequent activation of glutamate receptors collectively mediate amyloid-beta protein-induced neurotoxicity [<xref rid="bib78" ref-type="bibr">78</xref>]. In our study, we found that semaglutide intervention partially reversed the increase in glutamate and decrease in NAAG content in DM mice, suggesting that the glutamate circulatory system may play an important role in the cognitive improvement of semaglutide. 2-acetyl-1-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is an intermediate in ether lipid metabolism, also known as PAF. PAF induces neurotoxicity [<xref rid="bib79" ref-type="bibr">79</xref>] and may be involved in dementia [<xref rid="bib80" ref-type="bibr">80</xref>]. Neurotoxic concentrations of glutamate can increase PAF content in the primary neuronal culture medium of the rat cerebral cortex [<xref rid="bib81" ref-type="bibr">81</xref>]. In addition, PAF is an important pro-inflammatory mediator, which may be one mechanism through which it mediates neurotoxicity [<xref rid="bib82" ref-type="bibr">82</xref>]. When inflammation intensifies, elevated PAF levels promote glutamate excitotoxicity and induce neurodegenerative changes [<xref rid="bib81" ref-type="bibr">81</xref>]. These findings suggest that PAF amplifies the neuroinflammatory cascade associated with neurodegeneration and may be a potential biomarker of inflammation and neurodegeneration [<xref rid="bib83" ref-type="bibr">83</xref>]. Sphingosine-1-phosphate (S1P) and Sphinganine-1-phosphate (SA1P) are both phosphate sphingolipids. The homeostasis of neural sphingolipids plays an important role in preventing synaptic loss, cell death, and neurodegenerative diseases [<xref rid="bib84" ref-type="bibr">84</xref>]. Research has found that S1P can induce mitochondrial dysfunction, activate various inflammasomes, and increase the IL-1&#946; formation [<xref rid="bib85" ref-type="bibr">85</xref>]. Interestingly, research suggests that there are metabolic disorders of SA1P and S1P in both the brain and plasma in AD and confirms that SA1P and S1P in plasma and brain have great potential as biomarkers for AD [<xref rid="bib86" ref-type="bibr">86</xref>,<xref rid="bib87" ref-type="bibr">87</xref>]. In the present study, we found that semaglutide intervention improved sphingolipid metabolism disorders in DM mice, which may be one of the mechanisms through which GLP-1 improves cognitive impairment in DM mice.</p><p id="p0230">In this study, we observed that semaglutide can maintain the homeostasis of gut microbiota and improve the cognitive ability of DM mice. Nevertheless, we cannot conclude that the gut microbiome plays a causative role in cognitive function. Moreover, we cannot conclude that the gut microbiome is the only factor mediating semaglutide improvement of cognitive abilities. A study showed that semaglutide can promote glucose metabolism through the SIRT1 pathway, thereby improving cognitive ability in AD mice [<xref rid="bib30" ref-type="bibr">30</xref>]. Moreover, another study reported that semaglutide can improve autophagy flux, reduce oxidative stress, alleviate mitochondrial dysfunction, reduce inflammation, promote cellular neurogenesis, and activate dopamine synaptic pathways [<xref rid="bib88" ref-type="bibr">88</xref>]. Therefore, it is worth noting that the improvement of cognitive function by semaglutide may involve multiple factors; however, in DM mice with cognitive impairment induced by HFD combined with STZ, gut microbiota is intricately involved in semaglutide enhancing cognitive function.</p><p id="p0235">In conclusion, we identified a novel and compelling link between gut microbiota and cognitive function in DM mice treated with semaglutide. Specifically, Semaglutide treatment modulated gut microbiota composition and structure, altered microbial metabolites, regulated the expression of genes related to neuroactive ligand receptors, alleviated astrocyte activation and neuroinflammation, protected the chemical synapse structure, and improved cognitive function in DM mice. These findings suggest that semaglutide or similar stable GLP-1 analogs may be promising therapies to prevent the degenerative processes observed in cognitive impairment diseases such as DACD.</p></sec><sec id="sec5"><title>Author contributions</title><p id="p0240">Liqin Qi and Huimin Kang:Conceptualization, Funding acquisition and wrote the original draft. Feihui Zeng and Menglan Zhan: Methodology and Software. Cuihua Huang: Data curation. Qintao Huang and Lijing Lin: Supervision. Guanlian He: Writing, review, and editing. Xiaoying Liu and Xiaohong Liu: Resources. Libin Liu: Project administration.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of Competing Interest</title><p id="p0245">The authors have declared no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Saeedi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petersohn</surname><given-names>I.</given-names></name><name name-style="western"><surname>Salpea</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malanda</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karuranga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Unwin</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas</article-title><source>Diabetes Res Clin Pract</source><volume>157</volume><year>2019</year><object-id pub-id-type="publisher-id">107843</object-id><comment>9<sup>th</sup> edition</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>von Strauss</surname><given-names>E.</given-names></name></person-group><article-title>Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention</article-title><source>Dialogues Clin Neurosci</source><volume>11</volume><issue>2</issue><year>2009</year><fpage>111</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">19585947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.31887/DCNS.2009.11.2/cqiu</pub-id><pub-id pub-id-type="pmcid">PMC3181909</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Type 2 diabetes mellitus-associated cognitive dysfunction: advances in potential mechanisms and therapies</article-title><source>Neurosci Biobehav Rev</source><volume>137</volume><year>2022</year><object-id pub-id-type="publisher-id">104642</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2022.104642</pub-id><pub-id pub-id-type="pmid">35367221</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Polysaccharide extracted from Sarcandra glabra residue attenuate cognitive impairment by regulating gut microbiota in diabetic mice</article-title><source>Int J Biol Macromol</source><volume>270</volume><issue>Pt 1</issue><year>2024</year><object-id pub-id-type="publisher-id">132121</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2024.132121</pub-id><pub-id pub-id-type="pmid">38719002</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Morais</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>H.L.</given-names><suffix>4th</suffix></name><name name-style="western"><surname>Mazmanian</surname><given-names>S.K.</given-names></name></person-group><article-title>The gut microbiota-brain axis in behaviour and brain disorders</article-title><source>Nat Rev Microbiol</source><volume>19</volume><issue>4</issue><year>2021</year><fpage>241</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">33093662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-00460-0</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Liou</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease</article-title><source>Neurology</source><volume>98</volume><issue>8</issue><year>2022</year><fpage>e848</fpage><lpage>e858</lpage><pub-id pub-id-type="pmid">34996879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000013225</pub-id><pub-id pub-id-type="pmcid">PMC8883514</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Bulgart</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Neczypor</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Wold</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mackos</surname><given-names>A.R.</given-names></name></person-group><article-title>Microbial involvement in Alzheimer disease development and progression</article-title><source>Mol Neurodegener</source><volume>15</volume><issue>1</issue><year>2020</year><fpage>42</fpage><pub-id pub-id-type="pmid">32709243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00378-4</pub-id><pub-id pub-id-type="pmcid">PMC7382139</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment</article-title><source>Nat Commun</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>855</fpage><pub-id pub-id-type="pmid">32071312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-14676-4</pub-id><pub-id pub-id-type="pmcid">PMC7029019</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice</article-title><source>Microbiome</source><volume>9</volume><issue>1</issue><year>2021</year><fpage>145</fpage><pub-id pub-id-type="pmid">34172092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-021-01088-9</pub-id><pub-id pub-id-type="pmcid">PMC8235853</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A metagenome-wide association study of gut microbiota in type 2 diabetes</article-title><source>Nature</source><volume>490</volume><issue>7418</issue><year>2012</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nature11450</pub-id><pub-id pub-id-type="pmid">23023125</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Rosell-D&#237;az</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petit-Gay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Molas-Prat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallardo-Nuell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rami&#243;-Torrent&#224;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garre-Olmo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men</article-title><source>Metabolism</source><volume>157</volume><year>2024</year><object-id pub-id-type="publisher-id">155941</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2024.155941</pub-id><pub-id pub-id-type="pmid">38871078</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name></person-group><article-title>The impact of microbiota-gut-brain Axis on diabetic cognition impairment</article-title><source>Front Aging Neurosci</source><volume>9</volume><year>2017</year><fpage>106</fpage><comment>Published 2017 Apr 27</comment><pub-id pub-id-type="pmid">28496408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2017.00106</pub-id><pub-id pub-id-type="pmcid">PMC5406474</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Smits</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Van Raalte</surname><given-names>D.H.</given-names></name></person-group><source>Saf Semaglutide</source><volume>12</volume><year>2021 Nov 10</year><object-id pub-id-type="publisher-id">786732</object-id><pub-id pub-id-type="doi">10.3389/fendo.2021.786732</pub-id><comment>Front Endocrinol (Lausanne). 2021;12:645563</comment></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#237;a-Casares</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Gonz&#225;lez</surname><given-names>G.</given-names></name><name name-style="western"><surname>de la Cruz-Cosme</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garz&#243;n-Maldonado</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>de Rojas-Leal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Effects of GLP-1 receptor agonists on neurological complications of diabetes</article-title><source>Rev Endocr Metab Disord</source><volume>24</volume><issue>4</issue><year>2023</year><fpage>655</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">37231200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11154-023-09807-3</pub-id><pub-id pub-id-type="pmcid">PMC10404567</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ban</surname><given-names>J.</given-names></name><etal/></person-group><source>Front Pharmacol</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">975830</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2023.975830</pub-id><pub-id pub-id-type="pmcid">PMC10063902</pub-id><pub-id pub-id-type="pmid">37007007</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>de Paiva</surname><given-names>I.H.R.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>J.R.B.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>C.A.</given-names></name></person-group><article-title>Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain Axis</article-title><source>J Neuroimmune Pharmacol</source><volume>19</volume><issue>1</issue><year>2024</year><fpage>36</fpage><pub-id pub-id-type="pmid">39042202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-024-10142-w</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease</article-title><source>Mol Metab</source><volume>47</volume><year>2021</year><object-id pub-id-type="publisher-id">101180</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2021.101180</pub-id><pub-id pub-id-type="pmcid">PMC7905479</pub-id><pub-id pub-id-type="pmid">33556642</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3&#946; pathway in an amyloid &#946; protein induced alzheimer disease mouse model</article-title><source>Eur J Pharmacol</source><volume>783</volume><year>2016</year><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">27131827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2016.04.052</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Semaglutide alters gut microbiota and improves NAFLD in db/db mice</article-title><source>Biochem Biophys Res Commun</source><volume>710</volume><year>2024</year><object-id pub-id-type="publisher-id">149882</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.149882</pub-id><pub-id pub-id-type="pmid">38583231</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet</article-title><source>Eur J Pharmacol</source><volume>969</volume><year>2024</year><object-id pub-id-type="publisher-id">176440</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2024.176440</pub-id><pub-id pub-id-type="pmid">38402930</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Kanoski</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Fortin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>De Jonghe</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M.R.</given-names></name></person-group><article-title>The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide</article-title><source>Neuropharmacology</source><volume>62</volume><issue>5-6</issue><year>2012</year><fpage>1916</fpage><lpage>1927</lpage><pub-id pub-id-type="pmid">22227019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2011.12.022</pub-id><pub-id pub-id-type="pmcid">PMC4183930</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>M&#248;llerh&#248;j</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Veidal</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Thrane</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Or&#243;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>C.G.</given-names></name><etal/></person-group><article-title>Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH</article-title><source>Clin Transl Sci</source><volume>15</volume><issue>5</issue><year>2022</year><fpage>1167</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">35143711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.13235</pub-id><pub-id pub-id-type="pmcid">PMC9099137</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Untargeted metabonomic analysis of a cerebral stroke model in rats: a study based on UPLC-MS/MS</article-title><source>Front Neurosci</source><volume>17</volume><year>2023</year><object-id pub-id-type="publisher-id">1084813</object-id><comment>Published 2023 Aug 8</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2023.1084813</pub-id><pub-id pub-id-type="pmcid">PMC10442664</pub-id><pub-id pub-id-type="pmid">37614341</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name></person-group><article-title>fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title><source>Bioinformatics</source><volume>34</volume><issue>17</issue><year>2018</year><fpage>i884</fpage><lpage>i890</lpage><pub-id pub-id-type="pmid">30423086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bty560</pub-id><pub-id pub-id-type="pmcid">PMC6129281</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langmead</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>S.L.</given-names></name></person-group><article-title>HISAT: a fast spliced aligner with low memory requirements</article-title><source>Nat Methods</source><volume>12</volume><issue>4</issue><year>2015</year><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">25751142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.3317</pub-id><pub-id pub-id-type="pmcid">PMC4655817</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Ibelli</surname><given-names>A.M.G.</given-names></name><name name-style="western"><surname>Cant&#227;o</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Peixoto</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Ledur</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Long non-coding RNAs differentially expressed in swine fetuses</article-title><source>Animals (Basel)</source><volume>14</volume><issue>13</issue><year>2024 Jun 27</year><fpage>1897</fpage><pub-id pub-id-type="pmid">38998009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ani14131897</pub-id><pub-id pub-id-type="pmcid">PMC11240794</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><volume>15</volume><issue>12</issue><year>2014</year><fpage>550</fpage><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name></person-group><article-title>The discovery and development of liraglutide and semaglutide</article-title><source>Front Endocrinol</source><volume>10</volume><year>2019</year><fpage>155</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2019.00155</pub-id><pub-id pub-id-type="pmcid">PMC6474072</pub-id><pub-id pub-id-type="pmid">31031702</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sch&#228;ffer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pettersson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Spetzler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kofoed</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide</article-title><source>J Med Chem</source><volume>58</volume><issue>18</issue><year>2015</year><fpage>7370</fpage><lpage>7380</lpage><pub-id pub-id-type="pmid">26308095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.5b00726</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway</article-title><source>Neuropharmacology</source><volume>240</volume><year>2023</year><object-id pub-id-type="publisher-id">109716</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2023.109716</pub-id><pub-id pub-id-type="pmid">37730113</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke</article-title><source>Neuropharmacology</source><volume>158</volume><year>2019</year><object-id pub-id-type="publisher-id">107748</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2019.107748</pub-id><pub-id pub-id-type="pmid">31465784</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Gabery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ahnfelt-R&#248;nne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alanentalo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baquero</surname><given-names>A.F.</given-names></name><etal/></person-group><article-title>Semaglutide lowers body weight in rodents via distributed neural pathways</article-title><source>JCI Insight</source><volume>5</volume><issue>6</issue><year>2020</year><object-id pub-id-type="publisher-id">e133429</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.133429</pub-id><pub-id pub-id-type="pmcid">PMC7213778</pub-id><pub-id pub-id-type="pmid">32213703</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Harasta</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Power</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>von Jonquieres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Karl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Drucker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Housley</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior</article-title><source>Neuropsychopharmacology</source><volume>40</volume><issue>8</issue><year>2015</year><fpage>1969</fpage><lpage>1978</lpage><pub-id pub-id-type="pmid">25669605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/npp.2015.47</pub-id><pub-id pub-id-type="pmcid">PMC4839521</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>H&#246;lscher</surname><given-names>C.</given-names></name></person-group><article-title>Semaglutide is neuroprotective and reduces &#945;-synuclein levels in the chronic MPTP mouse model of Parkinson's disease</article-title><source>J Parkinsons Dis</source><volume>9</volume><issue>1</issue><year>2019</year><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">30741689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JPD-181503</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Biessels</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramakers</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Spruijt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Erkelens</surname><given-names>D.W.</given-names></name><etal/></person-group><article-title>Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats</article-title><source>Diabetes</source><volume>45</volume><issue>9</issue><year>1996</year><fpage>1259</fpage><lpage>1266</lpage><pub-id pub-id-type="pmid">8772732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.45.9.1259</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>An</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.E.</given-names></name><etal/></person-group><article-title>Long-lasting exendin-4 fusion protein improves memory deficits in high-fat diet/streptozotocin-induced diabetic mice</article-title><source>Pharmaceutics</source><volume>12</volume><issue>2</issue><year>2020</year><fpage>159</fpage><pub-id pub-id-type="pmid">32079069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics12020159</pub-id><pub-id pub-id-type="pmcid">PMC7076426</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F.</given-names></name></person-group><article-title>Alzheimer's disease and gut microbiota</article-title><source>Sci China Life Sci</source><volume>59</volume><issue>10</issue><year>2016</year><fpage>1006</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">27566465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-016-5083-9</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name></person-group><article-title>Live and pasteurized Akkermansia muciniphila ameliorates diabetic cognitive impairment by modulating gut microbiota and metabolites in db/db mice</article-title><source>Exp Neurol</source><volume>378</volume><year>2024</year><object-id pub-id-type="publisher-id">114823</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2024.114823</pub-id><pub-id pub-id-type="pmid">38782351</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Changes in intestinal microflora and its metabolites underlie the cognitive impairment in preterm rats</article-title><source>Front Cell Infect Microbiol</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">945851</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2022.945851</pub-id><pub-id pub-id-type="pmcid">PMC9437323</pub-id><pub-id pub-id-type="pmid">36061856</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Leucine-restricted diet ameliorates obesity-linked cognitive deficits: involvement of the microbiota-gut-brain Axis</article-title><source>J Agric Food Chem</source><volume>71</volume><issue>24</issue><year>2023</year><fpage>9404</fpage><lpage>9418</lpage><pub-id pub-id-type="pmid">37306277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jafc.3c01524</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Dendrobium officinale polysaccharide attenuates cognitive impairment in circadian rhythm disruption mice model by modulating gut microbiota</article-title><source>Int J Biol Macromol</source><volume>217</volume><year>2022</year><fpage>677</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">35853505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.07.090</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Rizza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pietrucci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Menghini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teofani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piciucchi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Impact of insulin degludec/liraglutide fixed combination on the gut microbiomes of elderly patients with type 2 diabetes: results from a subanalysis of a small non-randomised single arm study</article-title><source>Aging Dis</source><volume>14</volume><issue>2</issue><year>2023</year><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">37008061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2023.0118</pub-id><pub-id pub-id-type="pmcid">PMC10017153</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Rosas-Campos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meza-Rios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodriguez-Sanabria</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>la Rosa-Bibiano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corona-Cervantes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mena</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dietary supplementation with Mexican foods, Opuntia ficus indica, Theobroma cacao, and Acheta domesticus: improving obesogenic and microbiota features in obese mice</article-title><source>Front Nutr</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">987222</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2022.987222</pub-id><pub-id pub-id-type="pmcid">PMC9755723</pub-id><pub-id pub-id-type="pmid">36532548</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Eubacterium coprostanoligenes alleviates chemotherapy-induced intestinal mucositis by enhancing intestinal mucus barrier</article-title><source>Acta Pharm Sin B</source><volume>14</volume><issue>4</issue><year>2024</year><fpage>1677</fpage><lpage>1692</lpage><pub-id pub-id-type="pmid">38572095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.12.015</pub-id><pub-id pub-id-type="pmcid">PMC10985029</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Fecal g. Streptococcus and g. Eubacterium_coprostanoligenes_group combined with sphingosine to modulate the serum dyslipidemia in high-fat diet mice</article-title><source>Clin Nutr</source><volume>40</volume><issue>6</issue><year>2021</year><fpage>4234</fpage><lpage>4245</lpage><pub-id pub-id-type="pmid">33608131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2021.01.031</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Howitt</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Panikov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Michaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gallini</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bohlooly-Y</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis</article-title><source>Science</source><volume>341</volume><issue>6145</issue><year>2013</year><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">23828891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1241165</pub-id><pub-id pub-id-type="pmcid">PMC3807819</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Z.</given-names></name></person-group><article-title>Gut microbiome features of Chinese patients newly diagnosed with alzheimer's disease or mild cognitive impairment</article-title><source>J Alzheimers Dis</source><volume>80</volume><issue>1</issue><year>2021</year><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">33523001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-201040</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Cerd&#243;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ruiz-Rodr&#237;guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acu&#241;a</surname><given-names>I.</given-names></name><name name-style="western"><surname>Torres-Esp&#237;nola</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Mench&#233;n-M&#225;rquez</surname><given-names>S.</given-names></name><name name-style="western"><surname>G&#225;miz</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Infant gut microbiota contributes to cognitive performance in mice</article-title><source>Cell Host Microbe</source><volume>31</volume><issue>12</issue><year>2023</year><fpage>1974</fpage><lpage>1988.e4</lpage><pub-id pub-id-type="pmid">38052208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2023.11.004</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Tamana</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tun</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Konya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chari</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Field</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Guttman</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Bacteroides-dominant gut microbiome of late infancy is associated with enhanced neurodevelopment</article-title><source>Gut Microbes</source><volume>13</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2021.1930875</pub-id><pub-id pub-id-type="pmcid">PMC8210878</pub-id><pub-id pub-id-type="pmid">34132157</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Analysis of intestinal flora and cognitive function in maintenance hemodialysis patients using combined 16S ribosome DNA and shotgun metagenome sequencing</article-title><source>Aging Clin Exp Res</source><volume>36</volume><issue>1</issue><year>2024</year><fpage>28</fpage><pub-id pub-id-type="pmid">38334873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-023-02645-y</pub-id><pub-id pub-id-type="pmcid">PMC10857965</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Bi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Integrated analyses of microbiomics and metabolomics explore the effect of gut microbiota transplantation on diabetes-associated cognitive decline in zucker diabetic fatty rats</article-title><source>Front Aging Neurosci</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">913002</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.913002</pub-id><pub-id pub-id-type="pmcid">PMC9204715</pub-id><pub-id pub-id-type="pmid">35721013</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Atarashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Plichta</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasajima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians</article-title><source>Nature</source><volume>599</volume><issue>7885</issue><year>2021</year><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">34325466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03832-5</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Kawano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bilate</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Tanoue</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome</article-title><source>Cell</source><volume>185</volume><issue>19</issue><year>2022</year><fpage>3501</fpage><lpage>3519.e20</lpage><pub-id pub-id-type="pmid">36041436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.08.005</pub-id><pub-id pub-id-type="pmcid">PMC9556172</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Verhaar</surname><given-names>B.J.H.</given-names></name><name name-style="western"><surname>Hendriksen</surname><given-names>H.M.A.</given-names></name><name name-style="western"><surname>de Leeuw</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Doorduijn</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>van Leeuwenstijn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Gut microbiota composition is related to AD pathology</article-title><source>Front Immunol</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">794519</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.794519</pub-id><pub-id pub-id-type="pmcid">PMC8843078</pub-id><pub-id pub-id-type="pmid">35173707</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schroyen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>Depletion of gut microbiota inhibits hepatic lipid accumulation in high-fat diet-fed mice</article-title><source>Int J Mol Sci</source><volume>23</volume><issue>16</issue><year>2022</year><fpage>9350</fpage><pub-id pub-id-type="pmid">36012616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23169350</pub-id><pub-id pub-id-type="pmcid">PMC9408850</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Apple polyphenol extract ameliorates sugary-diet-induced depression-like behaviors in male C57BL/6 mice by inhibiting the inflammation of the gut-brain axis</article-title><source>Food Funct</source><volume>15</volume><issue>6</issue><year>2024</year><fpage>2939</fpage><lpage>2959</lpage><pub-id pub-id-type="pmid">38406886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3fo04606k</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>J.</given-names></name></person-group><article-title>Resveratrol-loaded selenium/chitosan nano-flowers alleviate glucolipid metabolism disorder-associated cognitive impairment in Alzheimer's disease</article-title><source>Int J Biol Macromol</source><volume>239</volume><year>2023</year><object-id pub-id-type="publisher-id">124316</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2023.124316</pub-id><pub-id pub-id-type="pmid">37004937</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name></person-group><article-title>Oyster (Crassostrea gigas) polysaccharide ameliorates obesity in association with modulation of lipid metabolism and gut microbiota in high-fat diet fed mice</article-title><source>Int J Biol Macromol</source><volume>216</volume><year>2022</year><fpage>916</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">35868410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.07.100</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Gut microbiota-driven metabolic alterations reveal gut-brain communication in Alzheimer's disease model mice</article-title><source>Gut Microbes</source><volume>16</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">2302310</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19490976.2024.2302310</pub-id><pub-id pub-id-type="pmcid">PMC10807476</pub-id><pub-id pub-id-type="pmid">38261437</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Camp</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name></person-group><article-title>GRIN2D/GluN2D NMDA receptor: unique features and its contribution to pediatric developmental and epileptic encephalopathy</article-title><source>Eur J Paediatr Neurol</source><volume>24</volume><year>2020</year><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">31918992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpn.2019.12.007</pub-id><pub-id pub-id-type="pmcid">PMC7035963</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Hildebrand</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pitcher</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Harding</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Beggs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salter</surname><given-names>M.W.</given-names></name></person-group><article-title>GluN2B and GluN2D NMDARs dominate synaptic responses in the adult spinal cord</article-title><source>Sci Rep</source><volume>4</volume><year>2014</year><fpage>4094</fpage><pub-id pub-id-type="pmid">24522697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep04094</pub-id><pub-id pub-id-type="pmcid">PMC3923208</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ohlei</surname><given-names>O.</given-names></name><name name-style="western"><surname>K&#252;&#231;&#252;kali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bos</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Timsina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning</article-title><source>Genome Med</source><volume>15</volume><issue>1</issue><year>2023</year><fpage>79</fpage><pub-id pub-id-type="pmid">37794492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-023-01233-z</pub-id><pub-id pub-id-type="pmcid">PMC10548686</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Donato</surname><given-names>J Jr</given-names></name><name name-style="western"><surname>Kopchick</surname><given-names>J.J.</given-names></name></person-group><article-title>New findings on brain actions of growth hormone and potential clinical implications</article-title><source>Rev Endocr Metab Disord</source><volume>25</volume><issue>3</issue><year>2024</year><fpage>541</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">38060062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11154-023-09861-x</pub-id><pub-id pub-id-type="pmcid">PMC11156798</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Mahmoud</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Grover</surname><given-names>L.M.</given-names></name></person-group><article-title>Growth hormone enhances excitatory synaptic transmission in area CA1 of rat hippocampus</article-title><source>J Neurophysiol</source><volume>95</volume><issue>5</issue><year>2006</year><fpage>2962</fpage><lpage>2974</lpage><pub-id pub-id-type="pmid">16481459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00947.2005</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Q.J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Growth hormone promotes myelin repair after chronic hypoxia via triggering pericyte-dependent angiogenesis</article-title><source>Neuron</source><volume>112</volume><issue>13</issue><year>2024 Jul 3</year><fpage>2177</fpage><lpage>2196.e6</lpage><pub-id pub-id-type="pmid">38653248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2024.03.026</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebina</surname><given-names>K.</given-names></name></person-group><article-title>Common mechanism in endothelin-3 and PAF receptor function for anti-inflammatory responses</article-title><source>Eur J Pharmacol</source><volume>718</volume><issue>1-3</issue><year>2013</year><fpage>30</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">24055926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2013.09.025</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebina</surname><given-names>K.</given-names></name></person-group><article-title>Endothelin-3 at low concentrations attenuates inflammatory responses via the endothelin B2 receptor</article-title><source>Inflamm Res</source><volume>62</volume><issue>4</issue><year>2013</year><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">23370722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00011-013-0594-3</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Salceda</surname><given-names>R.</given-names></name></person-group><article-title>Glycine neurotransmission: its role in development</article-title><source>Front Neurosci</source><volume>16</volume><year>2022 Sep 16</year><object-id pub-id-type="publisher-id">947563</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.947563</pub-id><pub-id pub-id-type="pmcid">PMC9525178</pub-id><pub-id pub-id-type="pmid">36188468</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Verchere</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name></person-group><article-title>Effect of galanin on endocrine secretions from the isolated perfused rat stomach and pancreas</article-title><source>Eur J Pharmacol</source><volume>145</volume><issue>1</issue><year>1988</year><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">2450759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0014-2999(88)90347-0</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Bauer</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Venetikou</surname><given-names>M.</given-names></name><name name-style="western"><surname>MacKay</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Burrin</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>S.R.</given-names></name></person-group><article-title>Growth hormone release in man induced by galanin, a new hypothalamic peptide</article-title><source>Lancet</source><volume>2</volume><issue>8500</issue><year>1986</year><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">2425204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(86)92490-6</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Wrenn</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Kinney</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Saavedra</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor</article-title><source>Eur J Neurosci</source><volume>19</volume><issue>5</issue><year>2004</year><fpage>1384</fpage><lpage>1396</lpage><pub-id pub-id-type="pmid">15016096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2004.03214.x</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Neale</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Olszewski</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Gehl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wroblewska</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bzdega</surname><given-names>T.</given-names></name></person-group><article-title>The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia</article-title><source>Trends Pharmacol Sci</source><volume>26</volume><issue>9</issue><year>2005</year><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">16055199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2005.07.004</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Jaarsma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veenma-van der Duin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Korf</surname><given-names>J.</given-names></name></person-group><article-title>N-acetylaspartate and N-acetylaspartylglutamate levels in Alzheimer's disease post-mortem brain tissue</article-title><source>J Neurol Sci</source><volume>127</volume><issue>2</issue><year>1994</year><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">7707082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-510x(94)90077-9</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Bukke</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Archana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Wawrzyniak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balawender</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The dual role of glutamatergic neurotransmission in alzheimer's disease: from pathophysiology to pharmacotherapy</article-title><source>Int J Mol Sci</source><volume>21</volume><issue>20</issue><year>2020</year><fpage>7452</fpage><pub-id pub-id-type="pmid">33050345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21207452</pub-id><pub-id pub-id-type="pmcid">PMC7589203</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Morland</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nordengen</surname><given-names>K.</given-names></name></person-group><article-title>N-Acetyl-Aspartyl-Glutamate in brain health and disease</article-title><source>Int J Mol Sci</source><volume>23</volume><issue>3</issue><year>2022</year><fpage>1268</fpage><pub-id pub-id-type="pmid">35163193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23031268</pub-id><pub-id pub-id-type="pmcid">PMC8836185</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pocernich</surname><given-names>C.B.</given-names></name></person-group><article-title>The glutamatergic system and Alzheimer's disease: therapeutic implications</article-title><source>CNS Drugs</source><volume>17</volume><issue>9</issue><year>2003</year><fpage>641</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">12828500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00023210-200317090-00004</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>P.T.</given-names></name></person-group><article-title>Glutamatergic systems in Alzheimer's disease</article-title><source>Int J Geriatr Psychiatry</source><volume>18</volume><issue>Suppl 1</issue><year>2003</year><fpage>S15</fpage><lpage>S21</lpage><pub-id pub-id-type="pmid">12973746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.934</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Z.H.</given-names></name></person-group><article-title>Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases</article-title><source>Acta Pharmacol Sin</source><volume>30</volume><issue>4</issue><year>2009</year><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">19343058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/aps.2009.24</pub-id><pub-id pub-id-type="pmcid">PMC4002277</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Zi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>MacIsaac</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gras</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>Y.C.</given-names></name><etal/></person-group><article-title>Identification of neurotoxic compounds in cyanobacteria exudate mixtures</article-title><source>Sci Total Environ</source><volume>857</volume><issue>Pt 2</issue><year>2023</year><object-id pub-id-type="publisher-id">159257</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2022.159257</pub-id><pub-id pub-id-type="pmid">36208737</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Hershkowitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adunsky</surname><given-names>A.</given-names></name></person-group><article-title>Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients</article-title><source>Neurobiol Aging</source><volume>17</volume><issue>6</issue><year>1996</year><fpage>865</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">9363797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0197-4580(96)00073-5</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Frisardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Seripa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Farooqui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Farooqui</surname><given-names>A.A.</given-names></name></person-group><article-title>Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology</article-title><source>Prog Lipid Res</source><volume>50</volume><issue>4</issue><year>2011</year><fpage>313</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">21703303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plipres.2011.06.001</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.X.</given-names></name></person-group><article-title>Involvement of the NMDA receptor/nitric oxide signal pathway in platelet-activating factor-induced neurotoxicity</article-title><source>Neuroreport</source><volume>15</volume><issue>2</issue><year>2004</year><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">15076749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001756-200402090-00010</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Mazereeuw</surname><given-names>G.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Swardfager</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration</article-title><source>Neurosci Biobehav Rev</source><volume>37</volume><issue>8</issue><year>2013</year><fpage>1611</fpage><lpage>1621</lpage><pub-id pub-id-type="pmid">23800745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2013.06.010</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Alessenko</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Albi</surname><given-names>E.</given-names></name></person-group><article-title>Exploring sphingolipid implications in neurodegeneration</article-title><source>Front Neurol</source><volume>11</volume><year>2020</year><fpage>437</fpage><comment>Published 2020 May 21</comment><pub-id pub-id-type="pmid">32528400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.00437</pub-id><pub-id pub-id-type="pmcid">PMC7254877</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Squillace</surname><given-names>S.</given-names></name><name name-style="western"><surname>Niehoff</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cuzzocrea</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment</article-title><source>J Clin Investig</source><volume>132</volume><issue>17</issue><year>2022</year><object-id pub-id-type="publisher-id">e157738</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI157738</pub-id><pub-id pub-id-type="pmcid">PMC9433103</pub-id><pub-id pub-id-type="pmid">36047496</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Studies on diagnostic biomarkers and therapeutic mechanism of Alzheimer's disease through metabolomics and hippocampal proteomics</article-title><source>Eur J Pharm Sci</source><volume>105</volume><year>2017</year><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">28495476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2017.05.003</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment</article-title><source>Alzheimers Res Ther</source><volume>12</volume><issue>1</issue><year>2020</year><fpage>122</fpage><pub-id pub-id-type="pmid">32998767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00694-3</pub-id><pub-id pub-id-type="pmcid">PMC7528375</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Tipa</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Balan</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Georgescu</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ignat</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Vacaroiu</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Georgescu</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>A systematic review of semaglutide's influence on cognitive function in preclinical animal models and cell-line studies</article-title><source>Int J Mol Sci</source><volume>25</volume><issue>9</issue><year>2024</year><fpage>4972</fpage><pub-id pub-id-type="pmid">38732190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25094972</pub-id><pub-id pub-id-type="pmcid">PMC11084700</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0250">This work was supported by Excellent Young Scholars Cultivation Project of <funding-source id="gs1">Fujian Medical University Union Hospital</funding-source> (No. <award-id award-type="grant" rid="gs1">2022XH036</award-id>), the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (No. <award-id award-type="grant" rid="gs2">81800712</award-id>) and Joint Funds for the <funding-source id="gs3">innovation of science and Technology, Fujian province</funding-source> (<award-id award-type="grant" rid="gs3">2023Y9125</award-id>).</p></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="methods-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med</journal-id><journal-id journal-id-type="pmc-domain-id">3997</journal-id><journal-id journal-id-type="pmc-domain">annmed</journal-id><journal-title-group><journal-title>Annals of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0785-3890</issn><issn pub-type="epub">1365-2060</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12490389</article-id><article-id pub-id-type="pmcid-ver">PMC12490389.1</article-id><article-id pub-id-type="pmcaid">12490389</article-id><article-id pub-id-type="pmcaiid">12490389</article-id><article-id pub-id-type="pmid">41031551</article-id><article-id pub-id-type="doi">10.1080/07853890.2025.2566397</article-id><article-id pub-id-type="publisher-id">2566397</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Method</subject></subj-group><subj-group subj-group-type="heading"><subject>Geriatrics</subject></subj-group></article-categories><title-group><article-title>Preoperative electroacupuncture for prevention of postoperative delirium in older adults undergoing total knee arthroplasty: protocol for a multicenter randomized controlled trial</article-title><alt-title alt-title-type="left-running-head">Y. Zhuo et al.</alt-title><alt-title alt-title-type="right-running-head">Electroacupuncture for Delirium in Older People Post-Tka</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-1312-5367</contrib-id><name name-style="western"><surname>Zhuo</surname><given-names initials="Y">Yifen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AF0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-7538-8684</contrib-id><name name-style="western"><surname>Yang</surname><given-names initials="J">Jialin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AF0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-2444-2299</contrib-id><name name-style="western"><surname>Shi</surname><given-names initials="X">Xuezhen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AF0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="AUFN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1315-508X</contrib-id><name name-style="western"><surname>Lin</surname><given-names initials="H">Huifen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><xref rid="AF0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5388-5971</contrib-id><name name-style="western"><surname>Liao</surname><given-names initials="X">Xincheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="AF0005" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8488-8876</contrib-id><name name-style="western"><surname>Yao</surname><given-names initials="Y">Yusheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AF0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-5642-155X</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="L">Lei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AF0006" ref-type="aff">
<sup>f</sup>
</xref><xref rid="AN0002" ref-type="corresp"/></contrib><aff id="AF0001"><label><sup>a</sup></label><institution>Department of Anesthesiology, Xiamen Haicang Hospital</institution>, <city>Xiamen</city>, <country>China</country></aff><aff id="AF0002"><label><sup>b</sup></label><institution>Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital</institution>, <city>Fuzhou</city>, <country>China</country></aff><aff id="AF0003"><label><sup>c</sup></label><institution>Department of Anesthesiology, General Hospital of Taining County</institution>, <city>Taining</city>, <country>China</country></aff><aff id="AF0004"><label><sup>d</sup></label><institution>Department of Anesthesiology, Sanming First Hospital Affiliated to Fujian Medical University</institution>, <city>Sanming</city>, <country>China</country></aff><aff id="AF0005"><label><sup>e</sup></label><institution>Department of Anesthesiology, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine</institution>, <city>Fuzhou</city>, <country>China</country></aff><aff id="AF0006"><label><sup>f</sup></label><institution>Department of Anesthesiology, People&#8217;s Hospital Affiliated to Fujian University of Traditional Chinese Medicine</institution>, <city>Fuzhou</city>, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>*</label><p>These authors contributed equally to this work.</p></fn><corresp id="AN0001">CONTACT Yusheng Yao <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:fjslyys@fjmu.edu.cn">fjslyys@fjmu.edu.cn</email><institution>Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital</institution>, <addr-line>134 Dongjie</addr-line>, <city>Fuzhou</city><postal-code>365001</postal-code>, <country>China</country></corresp><corresp id="AN0002">Lei Chen <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:chenlei@fjtcm.edu.cn">chenlei@fjtcm.edu.cn</email><institution>Department of Anesthesiology, People&#8217;s Hospital Affiliated to Fujian University of Traditional Chinese Medicine</institution>, <addr-line>602 Bayiqi Road</addr-line>, <city>Fuzhou</city><postal-code>350004</postal-code>, <country>China</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>57</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">476479</issue-id><elocation-id>2566397</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 10:25:15.040"><day>03</day><month>10</month><year>2025</year></date></event><event event-type="received"><date><day>4</day><month>9</month><year>2024</year></date></event><event event-type="revised"><date><day>11</day><month>9</month><year>2025</year></date></event><event event-type="accepted"><date><day>12</day><month>9</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>29</day><month>9</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>29</day><month>9</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IANN_57_2566397.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="IANN_57_2566397.pdf"/><abstract><title>Abstract</title><sec><title>Introduction</title><p>Postoperative delirium is a common and serious complication following total knee arthroplasty in older adults, leading to increased mortality, prolonged hospitalization, and cognitive decline. Although electroacupuncture has shown promise in improving cognitive function, its efficacy in preventing postoperative delirium following arthroplasty remains unknown. This study investigates whether preoperative electroacupuncture prevents postoperative delirium in older adults undergoing total knee arthroplasty.</p></sec><sec><title>Methods and analysis</title><p>This multicenter, randomized, double-blind, sham-controlled trial will enroll 1460 participants aged 65&#8211;90&#8201;years scheduled for elective total knee arthroplasty. Participants will be randomly assigned (1:1) to receive either active electroacupuncture (at GV24 and bilateral GB13 acupoints, 1&#8201;mA for 30&#8201;min before anesthesia induction; <italic toggle="yes">n</italic>&#8201;=&#8201;730) or sham electroacupuncture (<italic toggle="yes">n</italic>&#8201;=&#8201;730). The primary outcome is delirium incidence within 72&#8201;h after surgery, assessed using the Confusion Assessment Method. Secondary outcomes include delirium severity and subtypes, cognitive function, anxiety, depression, sleep quality, pain scores, cumulative morphine consumption, recovery quality, length of hospital stay, and adverse events.</p></sec><sec><title>Ethics and dissemination</title><p>The protocol was approved by the Institutional Review Board of Fujian Provincial Hospital (K2023-02-004/02). All participating centers obtained ethics committee approval before enrollment. Written informed consent will be obtained from all participants. Results will be published in peer-reviewed journals, regardless of the outcome.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Electroacupuncture</kwd><kwd>postoperative delirium</kwd><kwd>total knee arthroplasty</kwd><kwd>older adults</kwd><kwd>randomized controlled trial</kwd><kwd>perioperative neurocognitive disorders</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Scientific Research Project from Fujian University of Traditional Chinese Medicine</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution>Natural Science Foundation of Fujian Province</institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003392</institution-id></institution-wrap></funding-source><award-id>2025J01071</award-id></award-group><award-group><funding-source><institution-wrap><institution>Joint Funds for the Innovation of Science and Technology, Fujian Province</institution></institution-wrap></funding-source></award-group><funding-statement>This study is supported by the Science and Technology Program of Haicang District of Xiamen (350205Z20232004), Natural Science Foundation of Xiamen (3502Z202374068), Scientific Research Project from Fujian University of Traditional Chinese Medicine (XB2024002), Natural Science Foundation of Fujian Province (2025J01071), and Joint Funds for the Innovation of Science and Technology, Fujian Province (2023Y9275). The funders had no role in study design, data collection, analysis, or manuscript preparation.</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="12"/><word-count count="5748"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><title>Introduction</title><sec disp-level="2" id="S0001-S2001"><title>Background</title><p>Total knee arthroplasty (TKA) remains the definitive treatment for end-stage knee osteoarthritis, with over 1.6 million procedures performed in the United States between 2012 and 2022 [<xref rid="CIT0001" ref-type="bibr">1</xref>]. As the global population ages, the demand for TKA is projected to increase substantially, yet older patients face significant perioperative risks [<xref rid="CIT0002" ref-type="bibr">2</xref>].</p><p>Postoperative delirium (POD) stands out as a particularly serious complication. This acute neuropsychiatric syndrome involves fluctuating attention and consciousness within seven days after surgery [<xref rid="CIT0003" ref-type="bibr">3</xref>]. While delirium affects 15&#8211;25% of older patients after major elective surgery and exceeds 50% in high-risk procedures [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref>], arthroplasty patients show variable rates: 6&#8211;17% following hip replacement versus 8&#8211;24% following TKA, with incidence doubling in patients over 75&#8201;years [<xref rid="CIT0006" ref-type="bibr">6</xref>]. POD carries significant implications: immediate risks include a 2-fold increased mortality and 3&#8211;5&#8201;day prolonged hospitalization, while long-term consequences include a 2.3-fold increased risk of cognitive decline [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>Current prevention strategies face significant limitations. The American Society of Anesthesiologists&#8217; Perioperative Brain Health Initiative recommends non-pharmacological strategies as first-line delirium prevention [<xref rid="CIT0008" ref-type="bibr">8</xref>]. Although multicomponent interventions effectively reduce delirium by 30&#8211;40%, their complexity and resource requirements limit practical implementation [<xref rid="CIT0009" ref-type="bibr">9</xref>]. These barriers have prompted exploration of complementary approaches, particularly electroacupuncture, which combines traditional acupuncture with controlled electrical stimulation to reduce neuroinflammation and enhance cerebral perfusion [<xref rid="CIT0010" ref-type="bibr">10</xref>].</p><p>Evidence for electroacupuncture in TKA-related delirium prevention remains limited. A recent meta-analysis examining electroacupuncture in arthroplasty found promising results but included only three studies with inconsistent delirium assessment methods [<xref rid="CIT0011" ref-type="bibr">11</xref>]. A systematic review demonstrated that transcutaneous electrical acupoint stimulation reduced delirium in mixed surgical populations but lacked TKA-specific data [<xref rid="CIT0012" ref-type="bibr">12</xref>]. Consequently, high-quality evidence for electroacupuncture&#8217;s effectiveness in preventing delirium specifically in older TKA patients is still lacking.</p></sec><sec disp-level="2" id="S0001-S2002"><title>Objective</title><p>This study determines whether electroacupuncture, added to standard non-pharmacological care, reduces delirium incidence in older patients undergoing TKA. We hypothesize that electroacupuncture will provide additional benefit beyond current best practices for this vulnerable population.</p></sec></sec><sec disp-level="1" id="S0002"><title>Patients and methods</title><sec disp-level="2" id="S0002-S2001"><title>Setting and design</title><p>This multicenter, prospective, randomized, double-blinded, parallel-group, sham-controlled trial will be conducted at four hospitals in Fujian Province, China: Fujian Provincial Hospital (primary center), Sanming First Hospital, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, and People&#8217;s Hospital Affiliated to Fujian University of Traditional Chinese Medicine. The study is scheduled to run from September 2024 to August 2026 and adheres to the principles outlined in the Declaration of Helsinki. <xref rid="t0001" ref-type="table">Table 1</xref> presents the study timeline, and <xref rid="F0001" ref-type="fig">Figure 1</xref> shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram. This protocol adheres to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines [<xref rid="CIT0013" ref-type="bibr">13</xref>].</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Consolidated Standards of reporting trials (CONSORT) flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" position="float" orientation="portrait" xlink:href="IANN_A_2566397_F0001_C.jpg"/></fig><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Study timeline and assessment schedule.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th colspan="13" align="left" rowspan="1">Study period<hr/></th></tr><tr><th rowspan="3" align="left" colspan="1">Timepoint</th><th colspan="2" align="center" rowspan="1">Enrollment<hr/></th><th align="center" colspan="1" rowspan="1">Randomization/Allocation</th><th colspan="9" align="center" rowspan="1">Post-allocation<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">Day &#8722;1</th><th colspan="3" align="center" rowspan="1">Day 0<hr/></th><th align="center" colspan="1" rowspan="1">Day 1</th><th align="center" colspan="1" rowspan="1">Day 2</th><th align="center" colspan="1" rowspan="1">Day 3</th><th rowspan="2" align="center" colspan="1">Discharge</th><th align="center" colspan="1" rowspan="1">1 m</th><th align="center" colspan="1" rowspan="1">3 m</th><th align="center" colspan="1" rowspan="1">6 m</th><th align="center" colspan="1" rowspan="1">12 m</th></tr><tr><th align="center" colspan="1" rowspan="1">Screening/Consent</th><th align="center" colspan="1" rowspan="1">Morning (Baseline)</th><th align="center" colspan="1" rowspan="1">Intervention (30&#8201;min pre-anesthesia)</th><th align="center" colspan="1" rowspan="1">Intraoperative</th><th colspan="3" align="center" rowspan="1">Postoperative</th><th colspan="4" align="center" rowspan="1">Follow-up</th></tr></thead><tbody valign="top"><tr><td colspan="13" align="left" rowspan="1">Enrolment</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;MMSE</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Eligibility screening</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Informed consent</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Demographic data &#8195;collection</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td colspan="13" align="left" rowspan="1">Interventions</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Allocation</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Active &#8195;electroacupuncture</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sham &#8195;electroacupuncture</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Blinding assessment &#8195;(post-intervention)</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td colspan="13" align="left" rowspan="1">Assessments</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CAM</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">2X</td><td align="char" char="." colspan="1" rowspan="1">2X</td><td align="char" char="." colspan="1" rowspan="1">2X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;DRS-R-98 &#8195;(If delirium present)</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;RASS &#8195;(If delirium present)</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AMTS</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="left" colspan="1" rowspan="1">X</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HADS</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;RCSQ</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;NRS</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cumulative morphine &#8195;consumption</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;In-hospital antipsychotic&#8195;/sedative use</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;QoR-15</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;LOS</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Adverse events &#8195;monitoring</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">X</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Abbreviations: AMTS, Abbreviated Mental Test Score; CAM, Confusion Assessment Method; DRS-R-98, Delirium Rating Scale-Revised-98; HADS, Hospital Anxiety and Depression Scale; LOS, length of stay; MMSE, Mini-Mental State Examination; NRS, Numerical Rating Scale; QoR-15, 15-item Quality of Recovery questionnaire; RASS, Richmond Agitation-Sedation Scale; RCSQ, Richards-Campbell Sleep Questionnaire.</p></fn><fn id="TF2"><p>Notes: CAM assessment performed at both Day &#8722;1 screening and Day 0 morning to exclude pre-existing delirium; Formal enrollment and randomization occur after negative Day 0 morning CAM; 2X indicates twice-daily assessments (09:00&#8211;11:00 and 18:00&#8211;20:00) on postoperative days 1&#8211;3; DRS-R-98 and RASS administered only when CAM positive; NRS assessed at 1, 3, 6, 12, 24, 36, 48, 60, 72&#8201;h postoperatively; HADS and RCSQ assessed at Day 0 baseline then daily for 3 postoperative days; Cumulative morphine consumption calculated at 72&#8201;h; Adverse events monitored from intervention through discharge CAM assessment at Day &#8722;1 and Day 0 morning confirms absence of pre-existing delirium; positive.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0002-S2002"><title>Participants</title><p>We will enroll patients aged 65&#8211;90&#8201;years undergoing elective unilateral total knee arthroplasty under general anesthesia. Eligible participants must have American Society of Anesthesiologists (ASA) physical status class II or III, indicating mild to moderate systemic disease.</p><p>Exclusion criteria include: cognitive impairment (Mini-Mental State Examination [MMSE] score &lt;24); implanted electrical devices; infection at acupuncture sites; severe bleeding disorders; communication barriers (inability to communicate in Mandarin or severe audiovisual impairments); alcohol or substance use disorder; current sedative, antidepressant, or glucocorticoid use; acupuncture exposure within six months; and any condition deemed unsafe by the research team.</p><p>Designated researchers will screen patients scheduled for total knee arthroplasty. Initial screening occurs one day before surgery (Friday for Monday surgeries) during preoperative evaluation and includes MMSE assessment to evaluate baseline cognitive function, with scores below 24 resulting in immediate exclusion. Following MMSE screening, the first Confusion Assessment Method (CAM) evaluation is conducted to detect any pre-existing delirium, with CAM-positive patients excluded immediately. Researchers will explain study objectives, methods, benefits, risks, and adverse event procedures to eligible patients who pass both MMSE and CAM screening. Written informed consent will be obtained from patients or legal representatives. On the surgery morning, eligibility is reconfirmed with a second CAM assessment. Only patients with negative CAM at both timepoints proceed to randomization, ensuring all enrolled participants meet criteria at intervention.</p></sec><sec disp-level="2" id="S0002-S2003"><title>Randomisation and blinding</title><p>Enrolled patients will undergo 1:1 randomization to active or sham electroacupuncture using block randomization (size 4) stratified by center. An independent statistician generates the allocation sequence using R version 4.0.5 (&#8216;blockrand&#8217; package). Allocations remain concealed in sequentially numbered, opaque envelopes until enrollment confirmation. Unblinded researchers prepare equipment according to the allocation.</p><p>Participants, surgeons, and outcome assessors remain blinded; acupuncturists cannot be blinded due to the intervention&#8217;s nature. Identical-appearing devices ensure participant blinding. Sham electroacupuncture uses retractable placebo needles without electrical output, simulating insertion without penetration [<xref rid="CIT0014" ref-type="bibr">14</xref>]. Blinding success is assessed by asking participants which treatment they believe they received.</p></sec><sec disp-level="2" id="S0002-S2004"><title>Electroacupuncture administration</title><p>We selected Shenting (GV24) and bilateral Benshen (GB13) acupoints, which are associated with cognitive function in Traditional Chinese Medicine and have been shown to reduce cognitive impairment in prior studies [<xref rid="CIT0015" ref-type="bibr">15</xref>]. GV24 is located 0.5 cun (&#8776;10&#8201;mm) above the anterior hairline midpoint, with GB13 positioned 3 cun (&#8776;60&#8201;mm) lateral to GV24 (<xref rid="F0002" ref-type="fig">Figure 2</xref>), following WHO standardized locations [<xref rid="CIT0016" ref-type="bibr">16</xref>]. Equipment included disposable acupuncture needles (0.30&#8201;mm &#215; 75&#8201;mm), non-penetrating needles (0.30&#8201;mm &#215; 25&#8201;mm) for sham treatment, and SDZ-V electroacupuncture devices (Hwato, China). All participants received 30-minute treatment sessions before anesthesia induction.</p><fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>Location of acupoints for patients receiving active electroacupuncture and sham electroacupuncture.</p><p>Notes: Frontal view showing acupuncture point locations. Active electroacupuncture points (orange) at bilateral GB13 (Benshen) and GV24 (Shenting). Sham electroacupuncture points (blue) positioned 20&#8201;mm lateral to GV24 and 20&#8201;mm posterior to bilateral GB13. GB13 = Gallbladder 13; GV24 = Governing Vessel 24.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" position="float" orientation="portrait" xlink:href="IANN_A_2566397_F0002_C.jpg"/></fig><p>For active treatment, certified acupuncturists inserted needles 20&#8211;24&#8201;mm into the subgaleal layer at oblique angles, then manually manipulated them to elicit de qi (sensations of fullness, numbness, or soreness). Electrodes delivered alternating stimulation (2/15&#8201;Hz, 1&#8201;mA), producing mild skin movement without pain. Sham treatment targeted non-acupoints 20&#8201;mm above GV24 and 20&#8201;mm lateral to GB13, placing them in different dermatomes to prevent location-specific effects [<xref rid="CIT0017" ref-type="bibr">17</xref>]. The sham protocol used non-penetrating needles without manipulation, de qi sensation, or electrical stimulation.</p></sec><sec disp-level="2" id="S0002-S2005"><title>Standard anesthetic management</title><p>All patients will receive standardized anesthetic care with continuous monitoring throughout surgery. The protocol includes: pre-oxygenation (100% oxygen, 3&#8201;min); induction with propofol 1.5&#8211;2.0&#8201;mg/kg, sufentanil 0.3&#8201;&#956;g/kg, and rocuronium 0.6&#8201;mg/kg; laryngeal mask airway insertion; and maintenance with sevoflurane 1.5% and remifentanil 0.05&#8211;0.2&#8201;&#956;g/kg/min. Hemodynamics will be maintained within 20% of baseline with a bispectral index between 40 and 60. Additional rocuronium 0.15&#8201;mg/kg maintains muscle relaxation as needed. At surgery completion, sugammadex reverses neuromuscular blockade before airway removal. Immediate postoperative analgesia includes wound infiltration (20&#8201;mL 0.5% ropivacaine), intravenous flurbiprofen axetil (50&#8201;mg initially, then every 6&#8201;h for 72&#8201;h), and patient-controlled morphine (2.0&#8201;mg bolus, 10-minute lockout) for pain exceeding 3/10.</p></sec><sec disp-level="2" id="S0002-S2006"><title>Postoperative care</title><p>After achieving recovery criteria (Aldrete score &#8805;9), patients will be transferred to orthopedic wards with 1:4 nurse ratios (during days) and 1:6 (at nights). Monitoring includes: 24-hour oximetry, vital signs every 4&#8201;h (for 48&#8201;h) then every 8&#8201;h, and daily wound checks. Analgesia continues for 72&#8201;h: scheduled flurbiprofen (50&#8201;mg every 6&#8201;h), patient-controlled morphine for breakthrough pain, ice therapy (20&#8201;min every 2&#8201;h while awake), and transition to oral celecoxib (200&#8201;mg twice daily) from day 3. Pain assessment occurs every 4&#8201;h.</p><p>Structured mobilization begins immediately: Day 0&#8212;bed exercises; Day 1&#8212;bedside sitting, passive motion (0&#8211;40&#176;), assisted walking; Day 2&#8212;50-meter ambulation, active flexion to 60&#176;; Day 3+ &#8211; independent walking, progressive flexion targeting 90&#176;. Physical therapy occurs twice daily (30-minute sessions). Patients will be discharged when meeting criteria: independent 100-meter ambulation, 90&#176; knee flexion, controlled pain (score &lt;4), absence of complications, and confirmed home support.</p></sec><sec disp-level="2" id="S0002-S2007"><title>Delirium prevention protocol</title><p>Both groups will receive identical evidence-based prevention measures: orientation boards displaying date and care teams; physiotherapy-assisted mobilization from postoperative day one; family visitation (08:00&#8211;20:00) with reorientation participation; immediate access to sensory aids with functionality checks; clustered nighttime care with quiet protocols after 21:00; and optimized analgesia for pain scores &gt;3. These evidence-based interventions represent current best practice, allowing assessment of electroacupuncture&#8217;s additional benefit beyond standard care.</p></sec><sec disp-level="2" id="S0002-S2008"><title>Outcomes and assessments</title><p>The primary outcome is the incidence of POD within 72&#8201;h after surgery, assessed using the CAM, a diagnostic tool specifically designed to identify delirium [<xref rid="CIT0018" ref-type="bibr">18</xref>]. This differs from the MMSE used during initial screening, which evaluates baseline cognitive function for eligibility determination rather than acute confusional states. Baseline CAM assessments occur at screening (day &#8722;1) and surgery morning (day 0) to detect any pre-existing delirium, not to assess general cognition. CAM-positive patients are excluded and referred for clinical care. The Day 0 morning CAM serves as the definitive baseline, confirming the absence of pre-existing delirium immediately before intervention. CAM diagnoses delirium when criteria 1 (acute onset/fluctuation) and 2 (inattention) are present, plus either criterion 3 (disorganized thinking) or 4 (altered consciousness). Postoperative assessments will occur 2&#8201;h post-surgery, then twice daily (09:00&#8211;11:00, 18:00&#8211;20:00) for three days. Blinded assessors will perform all evaluations. This schedule balances comprehensive detection with feasibility, capturing the period when 90% of POD cases manifest.</p><p>Secondary outcomes comprise delirium severity measured using the Delirium Rating Scale-Revised-98 (DRS-R-98) [<xref rid="CIT0019" ref-type="bibr">19</xref>]; delirium subtypes classified by the Richmond Agitation-Sedation Scale (RASS) [<xref rid="CIT0020" ref-type="bibr">20</xref>]; cognitive function assessed longitudinally using the Abbreviated Mental Test Score (AMTS) at baseline, 1, 3, 6, and 12&#8201;months, which provides a brief cognitive screening tool suitable for repeated assessments distinct from the initial MMSE screening [<xref rid="CIT0021" ref-type="bibr">21</xref>]; anxiety and depression measured with the Hospital Anxiety and Depression Scale (HADS) assessed preoperatively and daily for 72&#8201;h [<xref rid="CIT0022" ref-type="bibr">22</xref>]; pain intensity evaluated using the Numeric Rating Scale (NRS) at 1, 3, 6, 12, 24, 36, 48, 60, and 72&#8201;h post-surgery; cumulative morphine consumption over 72&#8201;h; antipsychotic and sedative medication use including drug type, dose, and duration; recovery quality measured by the Quality of Recovery-15 (QoR-15) questionnaire assessed at discharge and daily for 72&#8201;h [<xref rid="CIT0023" ref-type="bibr">23</xref>]; and sleep quality evaluated using the Richards-Campbell Sleep Questionnaire (RCSQ) assessed preoperatively and daily for 72&#8201;h [<xref rid="CIT0024" ref-type="bibr">24</xref>]. Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) standards.</p></sec><sec disp-level="2" id="S0002-S2009"><title>Monitoring</title><p>The Institutional Review Board appoints monitors for quarterly verification, who recommend trial continuation or termination based on safety and adherence. Quality control ensures multicenter consistency. Personnel undergo standardized training with certification: CAM assessors achieve kappa &gt;0.80 through video cases; acupuncturists demonstrate proficiency <italic toggle="yes">via</italic> practical examination. Monthly calibration meetings maintain assessment consistency. The electronic case report form (eCRF) system provides real-time monitoring with automated validations, triggering 48&#8201;h resolution queries. Quarterly visits include 20% source verification and protocol assessment; sites exceeding 5% error rates receive additional support. Discrepancies will be resolved within two weeks.</p><p>Safety monitoring employs dual surveillance: structured assessment for electroacupuncture events (ecchymosis, dizziness, hematoma, needle pain) and daily record review for all events. Adverse events (AEs) will be coded (MedDRA), graded (CTCAE v5.0), and assessed for causality. Serious AEs will be reported within 24&#8201;h. The principal investigator will determine intervention-relatedness with independent monitoring. For participants with serious AEs, follow-up is modified to minimize burden while maintaining oversight. Assessments may be adapted (telephone replacing visits) or deferred, documented as missing data, not violations. All AEs will be followed to resolution.</p><p>One-year follow-up includes all participants. Lost participants will not be replaced. To minimize attrition, multiple contact methods will be used; reminder calls precede assessments. Participants may withdraw without justification; reasons will be documented when possible to assess bias.</p></sec><sec disp-level="2" id="S0002-S2010"><title>Sample size calculation</title><p>Sample size was calculated using PASS software version 15.0 (NCSS LLC, Kaysville, UT, USA). Based on 23.9% postoperative delirium incidence in older surgical patients [<xref rid="CIT0025" ref-type="bibr">25</xref>], 660 participants per group provide 90% power to detect a 30% relative reduction (from 23.9% to 16.8%) with <italic toggle="yes">&#945;</italic>&#8201;=&#8201;0.05 (two-sided). Accounting for 10% attrition, we will enroll 730 participants per group (1460 total). Recognizing that TKA-specific studies report lower incidence (14&#8211;16%) [<xref rid="CIT0006" ref-type="bibr">6</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>], our protocol includes adaptive sample size re-estimation at the planned interim analysis to maintain statistical power if the observed incidence falls below 20% [<xref rid="CIT0027" ref-type="bibr">27</xref>].</p></sec><sec disp-level="2" id="S0002-S2011"><title>Data collection, management, and analysis</title><p>Trained assessors blinded to group allocation will collect all study data, including baseline characteristics, primary and secondary outcomes, and adverse events. Statistical analysis will follow intention-to-treat principles using SPSS version 26.0 (IBM SPSS Inc., Chicago, IL, USA). After normality assessment <italic toggle="yes">via</italic> Shapiro-Wilk tests and Q-Q plots, continuous variables will be reported as mean&#8201;&#177;&#8201;SD (normal) or median (IQR) (non-normal), with group comparisons using Student&#8217;s t-test or Mann-Whitney U test accordingly. Categorical variables will be expressed as n (%) and compared using <italic toggle="yes">&#967;</italic><sup>2</sup> or Fisher&#8217;s exact tests. POD incidence will be analyzed using Kaplan-Meier curves with log-rank testing, reporting relative risks and 95% confidence intervals. Statistical significance is set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 (two-tailed).</p><p>Secondary outcomes will be analyzed using generalized linear mixed models accounting for repeated measures and relevant covariates. Missing data will be handled through multiple imputation with sensitivity analyses evaluating robustness under different assumptions. Post-hoc subgroup analyses will explore effect modification across six predefined categories: age (65&#8211;74 vs. &#8805;75&#8201;years), baseline cognition (MMSE 24&#8211;26 vs. 27&#8211;30), comorbidity burden (Charlson Comorbidity Index &#8804;2 vs. &gt;2), frailty status (Clinical Frailty Scale), surgery duration (&lt;90 vs. &#8805;90&#8201;min), and preoperative anxiety (HADS-<italic toggle="yes">A</italic>&#8201;&lt;&#8201;8 vs. &#8805;8). Treatment-by-subgroup interactions will be tested using regression models with interaction p-values &lt;0.10 indicating potential differential effects. Forest plots will visualize subgroup-specific treatment effects.</p><p>An interim analysis at 50% enrollment will evaluate safety and efficacy using predetermined stopping boundaries for futility or harm. The Data Safety Monitoring Board will review results and recommend trial continuation, modification, or termination based on pre-specified criteria.</p></sec><sec disp-level="2" id="S0002-S2012"><title>Ethics and confidentiality</title><p>The Institutional Review Board of Fujian Provincial Hospital approved the study protocol (K2023-02-004/02). The trial is registered at ClinicalTrials.gov (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06564506">NCT06564506</ext-link>). Written informed consent will be obtained from all participants before study initiation. Each participant will receive a unique identification code for data linkage and eCRF generation. Personal data will remain confidential, requiring explicit authorization from the principal investigator, Yusheng Yao (ORCID: 0000-0001-8488-8876), for disclosure. Study documents will be retained for 10&#8201;years post-completion.</p></sec><sec disp-level="2" id="S0002-S2013"><title>Patient and public involvement</title><p>No patient or public involvement occurred in the design or implementation of this study.</p></sec><sec disp-level="2" id="S0002-S2014"><title>Protocol amendments</title><p>Protocol modifications affecting study conduct will be reported to the Institutional Review Board of Fujian Provincial Hospital by the principal investigator, Yusheng Yao (ORCID: 0000-0001-8488-8876), who retains final decision-making authority for all amendments.</p></sec><sec disp-level="2" id="S0002-S2015"><title>Dissemination plan</title><p>Study results will be published in peer-reviewed journals regardless of outcome and presented at scientific conferences. Findings will be shared with participating institutions. The principal investigator, Yusheng Yao (ORCID: 0000-0001-8488-8876), oversees dissemination activities.</p></sec></sec><sec sec-type="discussion" disp-level="1" id="S0003"><title>Discussion</title><p>Postoperative delirium, the most common surgical complication in older people, manifests as an acute, fluctuating state of confusion, inattention, and altered consciousness within seven days post-surgery [<xref rid="CIT0028" ref-type="bibr">28</xref>]. This heterogeneous syndrome confers increased mortality, prolonged hospitalization, and long-term cognitive deterioration [<xref rid="CIT0029" ref-type="bibr">29</xref>]. Incidence in patients &#8805;65&#8201;years undergoing orthopedic procedures ranges from 12 to 51% [<xref rid="CIT0030" ref-type="bibr">30</xref>].</p><p>Total knee arthroplasty provides an optimal model for delirium prevention research due to converging risk factors and rehabilitation demands. TKA uniquely combines multiple delirium precipitants: tourniquet-induced ischemia-reperfusion injury (up to 90&#8201;min), bone cement embolization with hemodynamic instability, and severe postoperative pain requiring high-dose opioids [<xref rid="CIT0031" ref-type="bibr">31</xref>]. Unlike hip arthroplasty, TKA requires immediate intensive knee mobilization to prevent arthrofibrosis&#8212;precisely when delirium risk peaks. Delirium-related mobilization delays increase complications by 35% and extend hospitalization 3&#8211;5&#8201;days, directly compromising surgical outcomes [<xref rid="CIT0032" ref-type="bibr">32</xref>]. This convergence of elevated delirium risk with mandatory early rehabilitation makes TKA ideal for testing preventive interventions with measurable functional impact.</p><p>Acupuncture-based interventions demonstrate established perioperative benefits, including pain reduction, nausea relief, and decreased opioid consumption [<xref rid="CIT0033" ref-type="bibr">33</xref>,<xref rid="CIT0034" ref-type="bibr">34</xref>]. Beyond these conventional applications, emerging evidence suggests specific efficacy in preventing postoperative delirium. Clinical studies indicate that acupuncture techniques represent safe and effective non-pharmacological strategies for delirium prevention [<xref rid="CIT0035" ref-type="bibr">35</xref>]. These benefits are especially important for older adults, who face heightened delirium risk from age-related declines in cognitive reserve [<xref rid="CIT0036" ref-type="bibr">36</xref>]. Proposed mechanisms include reduced neuroinflammation and neuronal injury, decreased blood-brain barrier permeability, and enhanced cerebral perfusion and metabolism [<xref rid="CIT0037" ref-type="bibr">37</xref>]. Among available modalities, electroacupuncture emerges as particularly promising due to its standardizable parameters and consistent therapeutic delivery.</p><p>Critically, electroacupuncture is tested as an adjunctive intervention to standard non-pharmacological delirium prevention, not a replacement. Both groups receive identical prevention protocols comprising orientation strategies, early mobilization, family involvement, and sensory optimization [<xref rid="CIT0038" ref-type="bibr">38</xref>]. This design isolates electroacupuncture&#8217;s incremental benefit beyond current best practices, which reduce delirium from 20 to 14%&#8212;a 30% relative reduction&#8212;in orthopedic populations [<xref rid="CIT0039" ref-type="bibr">39</xref>,<xref rid="CIT0040" ref-type="bibr">40</xref>]. Unlike multicomponent interventions requiring sustained staffing over multiple days, electroacupuncture provides a pragmatic single-session treatment readily integrated into surgical workflows while targeting distinct neuroinflammatory pathways.</p><p>Sham acupoints were carefully selected and validated to maintain blinding integrity. Positioned 20&#8201;mm from true acupoints in different dermatomes, these locations minimize neurological overlap. Preliminary studies confirmed no measurable physiological responses, including absent brain activation patterns on functional imaging and no autonomic changes. The retractable needle design prevents skin penetration while maintaining visual similarity to active treatment, and absence of electrical stimulation eliminates the therapeutic component. This protocol provides methodologically rigorous control while preserving participant blinding and ethical standards.</p><p>Optimal electroacupuncture parameters&#8212;including acupoint selection, frequency, intensity, and timing&#8212;remain incompletely defined. In Traditional Chinese Medicine, the scalp points GV24 (Shenting) and bilateral GB13 (Benshen) are linked to cognitive function [<xref rid="CIT0041" ref-type="bibr">41</xref>]. This combination, termed &#8216;Acupuncture at 3-points for intelligence&#8217;, effectively treats cognitive impairment in neurodegenerative conditions including Alzheimer&#8217;s disease [<xref rid="CIT0042" ref-type="bibr">42</xref>]. Given these established cognitive benefits, we hypothesize that preoperative electroacupuncture at GV24 and bilateral GB13 will reduce postoperative delirium incidence in older people undergoing TKA.</p><p>We selected electroacupuncture parameters of alternating 2/15&#8201;Hz (dense-disperse waves) at 1&#8201;mA intensity, consistent with standard clinical practice for perioperative adjuvant treatments [<xref rid="CIT0043" ref-type="bibr">43</xref>]. This wave pattern alternates between sparse and dense stimulation, potentially reducing tolerance while enhancing metabolism, blood circulation, and anti-inflammatory effects. Intensity was determined by observed skin trembling and participant comfort, as sensory and tolerance thresholds for scalp acupoints range from 0.2 to 2.5&#8201;mA [<xref rid="CIT0044" ref-type="bibr">44</xref>]. Our selected intensity of 1&#8201;mA produces minimal skin trembling at the acupoint without eliciting pain, ensuring patient comfort and safety.</p><p>Timing of electroacupuncture administration is critical for this study. While electroacupuncture can be delivered preoperatively, intraoperatively, or both, we selected a preoperative approach. Participants receive electroacupuncture for 30&#8201;min, beginning 30&#8201;min before anesthesia induction. This timing was chosen for three reasons: first, it ensures patients receive the full therapeutic effect without anesthetic interference; second, it modulates the autonomic nervous system before surgical stress; and third, it enables treatment during the conscious state, which enhances both efficacy and safety [<xref rid="CIT0045" ref-type="bibr">45</xref>]. This design allows clear assessment of electroacupuncture&#8217;s independent effect on postoperative outcomes. While this timing aligns with established perioperative acupuncture protocols, optimal timing remains to be definitively established through further research.</p><p>This multicenter, randomized, double-blind, sham-controlled trial provides robust methodological rigor through standardized training with inter-rater reliability testing (kappa &gt; 0.80), multimodal analgesia protocols, and comprehensive blinding procedures. Our sample size of 1460 participants, calculated based on 23.9% anticipated POD incidence, provides 90% power to detect clinically meaningful differences. The protocol incorporates adaptive sample size re-estimation at interim analysis to maintain statistical power if observed incidence falls below 20%, ensuring robust conclusions regardless of baseline event rates.</p><p>Several limitations merit consideration. First, blinding challenges exist despite identical-appearing devices. The de qi sensation unique to active electroacupuncture and potential recognition by patients with remote acupuncture experience (beyond our six-month exclusion window) may compromise masking. We address this through formal blinding verification and planned sensitivity analyses stratified by blinding success. Second, our strict eligibility criteria limit generalizability. Excluding patients on psychotropic medications eliminates approximately 30% of typical TKA candidates, while restricting enrollment to ASA II&#8211;III excludes those at highest delirium risk. Using general anesthesia rather than neuraxial techniques diverges from enhanced recovery protocols, and requirements for trained acupuncturists further restrict implementation feasibility. Third, temporal and mechanistic constraints affect interpretation. The 72-hour monitoring period, while capturing peak delirium incidence and aligning with major trials, may miss delayed cases. Twice-daily assessment may underestimate true incidence compared to continuous monitoring. Without biomarkers, we cannot elucidate whether benefits derive from reduced neuroinflammation, improved perfusion, or other mechanisms. Despite these constraints, this trial provides essential efficacy data. Competing risks from mortality and attrition will be addressed through intention-to-treat and sensitivity analyses, with pre-specified subgroup analyses exploring treatment effects across age, cognition, comorbidity, frailty, surgery duration, and anxiety phenotypes.</p><p>This study aims to investigate the effects of electroacupuncture on postoperative delirium in older adults undergoing TKA. Our findings will establish whether electroacupuncture warrants inclusion in multimodal delirium prevention protocols for older TKA patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge the contributions of all study participants and their families, as well as the healthcare professionals involved in this trial. We thank the investigators, anesthesiologists, and support staff at participating institutions for their dedication and expertise.</p></ack><sec disp-level="1" id="S0007"><title>Patient consent for publication</title><p>Not applicable.</p></sec><sec disp-level="1" id="S0008"><title>Trial registration</title><p>ClinicalTrials.gov; Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06564506">NCT06564506</ext-link>.</p></sec><sec disp-level="1" id="S0009"><title>Administrative information</title><p>This manuscript is based on protocol version 4.0_2024.06.10. Trial sponsor: Yusheng Yao.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0005"><title>Disclosure statement</title><p>The authors report no conflicts of interest in this work.</p></sec><sec sec-type="data-availability" disp-level="1" id="S0006"><title>Data availability statement</title><p>Individual participant data, study protocol, statistical analysis plan, and clinical study report will be available upon reasonable request from the principal investigator (Yusheng Yao, ORCID: 0000-0001-8488-8876) after publication.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Rates of total joint replacement in the United States: future projections to 2020-2040 using the National Inpatient Sample</article-title>. <source>J Rheumatol</source>. <year>2019</year>;<volume>46</volume>(<issue>9</issue>):<fpage>1134</fpage>&#8211;<lpage>1140</lpage>. doi: <pub-id pub-id-type="doi">10.3899/jrheum.170990</pub-id>.<pub-id pub-id-type="pmid">30988126</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>George</surname><given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sloan</surname><given-names>FA.</given-names></string-name></person-group><article-title>The effects of total knee arthroplasty on physical functioning and health among the under age 65 population</article-title>. <source>Value Health</source>. <year>2014</year>;<volume>17</volume>(<issue>5</issue>):<fpage>605</fpage>&#8211;<lpage>610</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jval.2014.04.004</pub-id>.<pub-id pub-id-type="pmid">25128054</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marcantonio</surname><given-names>ER.</given-names></string-name></person-group><article-title>Delirium in hospitalized older adults</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>15</issue>):<fpage>1456</fpage>&#8211;<lpage>1466</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMcp1605501</pub-id>.<pub-id pub-id-type="pmid">29020579</pub-id><pub-id pub-id-type="pmcid">PMC5706782</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marcantonio</surname><given-names>ER.</given-names></string-name></person-group><article-title>Postoperative delirium: a 76-year-old woman with delirium following surgery</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>308</volume>(<issue>1</issue>):<fpage>73</fpage>&#8211;<lpage>81</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2012.6857</pub-id>.<pub-id pub-id-type="pmid">22669559</pub-id><pub-id pub-id-type="pmcid">PMC3604975</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inouye</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Westendorp</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Saczynski</surname><given-names>JS.</given-names></string-name></person-group><article-title>Delirium in elderly people</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>383</volume>(<issue>9920</issue>):<fpage>911</fpage>&#8211;<lpage>922</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60688-1</pub-id>.<pub-id pub-id-type="pmid">23992774</pub-id><pub-id pub-id-type="pmcid">PMC4120864</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weinstein</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Poultsides</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Baaklini</surname><given-names>LR</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Postoperative delirium in total knee and hip arthroplasty patients: a study of perioperative modifiable risk factors</article-title>. <source>Br J Anaesth</source>. <year>2018</year>;<volume>120</volume>(<issue>5</issue>):<fpage>999</fpage>&#8211;<lpage>1008</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bja.2017.12.046</pub-id>.<pub-id pub-id-type="pmid">29661417</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldberg</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Association of delirium with long-term cognitive decline: a meta-analysis</article-title>. <source>JAMA Neurol</source>. <year>2020</year>;<volume>77</volume>(<issue>11</issue>):<fpage>1373</fpage>&#8211;<lpage>1381</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2273</pub-id>.<pub-id pub-id-type="pmid">32658246</pub-id><pub-id pub-id-type="pmcid">PMC7358977</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peden</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Deiner</surname><given-names>SG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team</article-title>. <source>Br J Anaesth</source>. <year>2021</year>;<volume>126</volume>(<issue>2</issue>):<fpage>423</fpage>&#8211;<lpage>432</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bja.2020.10.037</pub-id>.<pub-id pub-id-type="pmid">33413977</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hshieh</surname><given-names>TT</given-names></string-name>, <string-name name-style="western"><surname>Yue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effectiveness of multicomponent non-pharmacological delirium interventions: a meta-analysis</article-title>. <source>JAMA Intern Med</source>. <year>2015</year>;<volume>175</volume>(<issue>4</issue>):<fpage>512</fpage>&#8211;<lpage>520</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamainternmed.2014.7779</pub-id>.<pub-id pub-id-type="pmid">25643002</pub-id><pub-id pub-id-type="pmcid">PMC4388802</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Mechanisms of acupuncture-electroacupuncture on neuropathic pain</article-title>. <source>Anesthesiology</source>. <year>2014</year>;<volume>120</volume>(<issue>2</issue>):<fpage>482</fpage>&#8211;<lpage>503</lpage>. doi: <pub-id pub-id-type="doi">10.1097/ALN</pub-id>.0000000000000101<pub-id pub-id-type="pmid">24322588</pub-id><pub-id pub-id-type="pmcid">PMC3947586</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Electroacupuncture for the prevention of postoperative cognitive dysfunction among older adults undergoing hip and knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Front Med (Lausanne)</source>. <year>2021</year>;<volume>8</volume>:<fpage>778474</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2021.778474</pub-id>.<pub-id pub-id-type="pmid">35059414</pub-id><pub-id pub-id-type="pmcid">PMC8764307</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Transcutaneous electrical acupoint stimulation for the prevention of perioperative neurocognitive disorders in geriatric patients: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Medicine (Baltimore)</source>. <year>2022</year>;<volume>101</volume>(<issue>50</issue>):<fpage>e32329</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000032329</pub-id>.<pub-id pub-id-type="pmid">36550918</pub-id><pub-id pub-id-type="pmcid">PMC9771360</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Tetzlaff</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>158</volume>(<issue>3</issue>):<fpage>200</fpage>&#8211;<lpage>207</lpage>. doi: <pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id>.<pub-id pub-id-type="pmid">23295957</pub-id><pub-id pub-id-type="pmcid">PMC5114123</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Streitberger</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kleinhenz</surname><given-names>J.</given-names></string-name></person-group><article-title>Introducing a placebo needle into acupuncture research</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>352</volume>(<issue>9125</issue>):<fpage>364</fpage>&#8211;<lpage>365</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(97)10471-8</pub-id>.<pub-id pub-id-type="pmid">9717924</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Acupuncture for patients with mild to moderate Alzheimer&#8217;s disease: a randomized controlled trial</article-title>. <source>BMC Complement Altern Med</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>556</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12906-017-2064-x</pub-id>.<pub-id pub-id-type="pmid">29284465</pub-id><pub-id pub-id-type="pmcid">PMC5747102</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lim</surname><given-names>S.</given-names></string-name></person-group><article-title>WHO standard acupuncture point locations</article-title>. <source>Evid Based Complement Alternat Med</source>. <year>2010</year>;<volume>7</volume>(<issue>2</issue>):<fpage>167</fpage>&#8211;<lpage>168</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ecam/nep006</pub-id>.<pub-id pub-id-type="pmid">19204011</pub-id><pub-id pub-id-type="pmcid">PMC2862941</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ots</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kandirian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Szilagyi</surname><given-names>I</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The selection of dermatomes for sham (placebo) acupuncture points is relevant for the outcome of acupuncture studies: a systematic review of sham (placebo)-controlled randomized acupuncture trials</article-title>. <source>Acupunct Med</source>. <year>2020</year>;<volume>38</volume>(<issue>4</issue>):<fpage>211</fpage>&#8211;<lpage>226</lpage>. doi: <pub-id pub-id-type="doi">10.1177/0964528419889636</pub-id>.<pub-id pub-id-type="pmid">32026725</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Marcantonio</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Ngo</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>M</given-names></string-name>, <etal>et al.</etal></person-group><article-title>3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study</article-title>. <source>Ann Intern Med</source>. <year>2014</year>;<volume>161</volume>(<issue>8</issue>):<fpage>554</fpage>&#8211;<lpage>561</lpage>. doi: <pub-id pub-id-type="doi">10.7326/M14-0865</pub-id>.<pub-id pub-id-type="pmid">25329203</pub-id><pub-id pub-id-type="pmcid">PMC4319978</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Lai</surname><given-names>YC</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Chinese version of the Delirium Rating Scale-Revised-98: reliability and validity</article-title>. <source>Compr Psychiatry</source>. <year>2009</year>;<volume>50</volume>(<issue>1</issue>):<fpage>81</fpage>&#8211;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.comppsych.2008.05.011</pub-id><pub-id pub-id-type="pmid">19059519</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ely</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Truman</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shintani</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS)</article-title>. <source>JAMA</source>. <year>2003</year>;<volume>289</volume>(<issue>22</issue>):<fpage>2983</fpage>&#8211;<lpage>2991</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.289.22.2983</pub-id>.<pub-id pub-id-type="pmid">12799407</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lindsay</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Moppett</surname><given-names>IK.</given-names></string-name></person-group><article-title>Interchangeability of AMT4 and AMTS in a hip fracture population</article-title>. <source>Anaesthesia</source>. <year>2019</year>;<volume>74</volume>(<issue>11</issue>):<fpage>1477</fpage>&#8211;<lpage>1478</lpage>. doi: <pub-id pub-id-type="doi">10.1111/anae.14803</pub-id>.<pub-id pub-id-type="pmid">31592546</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cassiani-Miranda</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Scoppetta</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Cabanzo-Arenas</surname><given-names>DF.</given-names></string-name></person-group><article-title>Validity of the Hospital Anxiety and Depression Scale (HADS) in primary care patients in Colombia</article-title>. <source>Gen Hosp Psychiatry</source>. <year>2022</year>;<volume>74</volume>:<fpage>102</fpage>&#8211;<lpage>109</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.genhosppsych.2021.01.014</pub-id>.<pub-id pub-id-type="pmid">33750606</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Myles</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Shulman</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>J</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Measurement of quality of recovery after surgery using the 15-item quality of recovery scale: a systematic review and meta-analysis</article-title>. <source>Br J Anaesth</source>. <year>2022</year>;<volume>128</volume>(<issue>6</issue>):<fpage>1029</fpage>&#8211;<lpage>1039</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bja.2022.03.009</pub-id>.<pub-id pub-id-type="pmid">35430086</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tonna</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Dalton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Presson</surname><given-names>AP</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The effect of a quality improvement intervention on sleep and delirium in critically Ill patients in a surgical ICU</article-title>. <source>Chest</source>. <year>2021</year>;<volume>160</volume>(<issue>3</issue>):<fpage>899</fpage>&#8211;<lpage>908</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chest.2021.03.030</pub-id>.<pub-id pub-id-type="pmid">33773988</pub-id><pub-id pub-id-type="pmcid">PMC8448998</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gleason</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Schmitt</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Kosar</surname><given-names>CM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effect of delirium and other major complications on outcomes after elective surgery in older adults</article-title>. <source>JAMA Surg</source>. <year>2015</year>;<volume>150</volume>(<issue>12</issue>):<fpage>1134</fpage>&#8211;<lpage>1140</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamasurg.2015.2606</pub-id>.<pub-id pub-id-type="pmid">26352694</pub-id><pub-id pub-id-type="pmcid">PMC4684425</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Incidence and risk factors of postoperative delirium following total knee arthroplasty: a retrospective nationwide inpatient sample database study</article-title>. <source>Knee</source>. <year>2022</year>;<volume>35</volume>:<fpage>61</fpage>&#8211;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.knee.2022.02.006</pub-id>.<pub-id pub-id-type="pmid">35220134</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mehta</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Pocock</surname><given-names>SJ.</given-names></string-name></person-group><article-title>Adaptive increase in sample size when interim results are promising: a practical guide with examples</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>(<issue>28</issue>):<fpage>3267</fpage>&#8211;<lpage>3284</lpage>. doi: <pub-id pub-id-type="doi">10.1002/sim.4102</pub-id>.<pub-id pub-id-type="pmid">22105690</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vacas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Canales</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Deiner</surname><given-names>SG</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Perioperative brain health in the older adult: a patient safety imperative</article-title>. <source>Anesth Analg</source>. <year>2022</year>;<volume>135</volume>(<issue>2</issue>):<fpage>316</fpage>&#8211;<lpage>328</lpage>. doi: <pub-id pub-id-type="doi">10.1213/ANE</pub-id>.0000000000006090<pub-id pub-id-type="pmid">35584550</pub-id><pub-id pub-id-type="pmcid">PMC9288500</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Potter</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Prendergast</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>JG.</given-names></string-name></person-group><article-title>From traditional typing to intelligent insights: a narrative review of directions toward targeted therapies in delirium</article-title>. <source>Crit Care Med</source>. <year>2024</year>;<volume>52</volume>(<issue>8</issue>):<fpage>1285</fpage>&#8211;<lpage>1294</lpage>. doi: <pub-id pub-id-type="doi">10.1097/CCM.0000000000006362</pub-id>.<pub-id pub-id-type="pmid">39007569</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>ZC</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>HD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Risk factors of postoperative delirium in the knee and hip replacement patients: a systematic review and meta-analysis</article-title>. <source>J Orthop Surg Res</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>76</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13018-020-02127-1</pub-id>.<pub-id pub-id-type="pmid">33482875</pub-id><pub-id pub-id-type="pmcid">PMC7821501</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leurcharusmee</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sawaddiruk</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Punjasawadwong</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The possible pathophysiological outcomes and mechanisms of tourniquet-induced ischemia-reperfusion injury during total knee arthroplasty</article-title>. <source>Oxid Med Cell Longev</source>. <year>2018</year>;<volume>2018</volume>(<issue>1</issue>):<fpage>8087598</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2018/8087598</pub-id>.<pub-id pub-id-type="pmid">30524661</pub-id><pub-id pub-id-type="pmcid">PMC6247434</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bellelli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mazzola</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Morandi</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Duration of postoperative delirium is an independent predictor of 6-month mortality in older adults after hip fracture</article-title>. <source>J Am Geriatr Soc</source>. <year>2014</year>;<volume>62</volume>(<issue>7</issue>):<fpage>1335</fpage>&#8211;<lpage>1340</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jgs.12885</pub-id>.<pub-id pub-id-type="pmid">24890941</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Yeh</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>FP</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: a randomized placebo-controlled trial</article-title>. <source>J Integr Med</source>. <year>2022</year>;<volume>20</volume>(<issue>4</issue>):<fpage>321</fpage>&#8211;<lpage>328</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.joim.2022.04.002</pub-id>.<pub-id pub-id-type="pmid">35459599</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Miao</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Transcutaneous electrical acupoint stimulation for preventing postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized controlled trials</article-title>. <source>Int J Surg</source>. <year>2020</year>;<volume>73</volume>:<fpage>57</fpage>&#8211;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijsu</pub-id>.2019.10.036<pub-id pub-id-type="pmid">31704425</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joo</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>JW</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Acupuncture for postoperative delirium (POD): a systematic review and meta-analysis protocol</article-title>. <source>Medicine (Baltimore)</source>. <year>2021</year>;<volume>100</volume>(<issue>3</issue>):<fpage>e23822</fpage>. doi: <pub-id pub-id-type="doi">10.1097/MD.0000000000023822</pub-id>.<pub-id pub-id-type="pmid">33545947</pub-id><pub-id pub-id-type="pmcid">PMC7837831</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bugiani</surname><given-names>O.</given-names></string-name></person-group><article-title>Why is delirium more frequent in the elderly?</article-title><source>Neurol Sci</source>. <year>2021</year>;<volume>42</volume>(<issue>8</issue>):<fpage>3491</fpage>&#8211;<lpage>3503</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10072-021-05339-3</pub-id>.<pub-id pub-id-type="pmid">34031797</pub-id><pub-id pub-id-type="pmcid">PMC8143064</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname><given-names>KY</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Transcutaneous electrical acupoint stimulation for the prevention of postoperative delirium in elderly surgical patients: a systematic review and meta-analysis</article-title>. <source>Front Aging Neurosci</source>. <year>2023</year>;<volume>15</volume>:<fpage>1046754</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2023.1046754</pub-id>.<pub-id pub-id-type="pmid">36798530</pub-id><pub-id pub-id-type="pmcid">PMC9928205</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inouye</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Bogardus</surname><given-names>ST</given-names>, <suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>DI</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The hospital elder life program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program</article-title>. <source>J Am Geriatr Soc</source>. <year>2000</year>;<volume>48</volume>:<fpage>1697</fpage>&#8211;<lpage>1706</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1532-5415</pub-id>.2000.tb03885. x<pub-id pub-id-type="pmid">11129764</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oh</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Fong</surname><given-names>TG</given-names></string-name>, <string-name name-style="western"><surname>Hshieh</surname><given-names>TT</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Delirium in older persons: advances in diagnosis and treatment</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>318</volume>(<issue>12</issue>):<fpage>1161</fpage>&#8211;<lpage>1174</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2017.12067</pub-id>.<pub-id pub-id-type="pmid">28973626</pub-id><pub-id pub-id-type="pmcid">PMC5717753</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Siddiqi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Clegg</surname><given-names>A</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Interventions for preventing delirium in hospitalized non-ICU patients</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2016</year>;<volume>3</volume>(<issue>3</issue>):<fpage>CD005563</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD005563.pub3</pub-id>.<pub-id pub-id-type="pmid">26967259</pub-id><pub-id pub-id-type="pmcid">PMC10431752</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Acupuncture ameliorated behavioral abnormalities in the autism rat model via pathways for hippocampal serotonin</article-title>. <source>Neuropsychiatr Dis Treat</source>. <year>2023</year>;<volume>19</volume>:<fpage>951</fpage>&#8211;<lpage>972</lpage>. doi: <pub-id pub-id-type="doi">10.2147/NDT.S406942</pub-id>.<pub-id pub-id-type="pmid">37096024</pub-id><pub-id pub-id-type="pmcid">PMC10122481</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Electroacupuncture ameliorates beta-amyloid pathology and cognitive impairment in Alzheimer disease via a novel mechanism involving activation of TFEB (transcription factor EB)</article-title>. <source>Autophagy</source>. <year>2021</year>;<volume>17</volume>(<issue>11</issue>):<fpage>3833</fpage>&#8211;<lpage>3847</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15548627.2021.1886720</pub-id>.<pub-id pub-id-type="pmid">33622188</pub-id><pub-id pub-id-type="pmcid">PMC8632298</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jianjun</surname><given-names>X</given-names></string-name>, <collab>Chinese Society of Integrative Anesthesiology, Gansu Provincial Society of Integrative Anesthesiology</collab>, <etal>et al.</etal></person-group><article-title>Clinical practice guidelines for acupoint stimulation as an adjuvant treatment of postoperative pain (2021)</article-title>. <source>Chin J Anesthesiol</source>. <year>2021</year>;<volume>41</volume>:<fpage>1159</fpage>&#8211;<lpage>1165</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.cn131073.20211009.01002</pub-id>.</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cui</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Electroacupuncture and transcutaneous electrical nerve stimulation induced sensations in Bell&#8217;s palsy patients: a quantitative current intensity analysis</article-title>. <source>Front Neurosci</source>. <year>2021</year>;<volume>15</volume>:<fpage>692088</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2021.692088</pub-id>.<pub-id pub-id-type="pmid">34305521</pub-id><pub-id pub-id-type="pmcid">PMC8299110</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>JL</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Acupuncture for stroke rehabilitation</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2016</year>;<volume>2016</volume>(<issue>8</issue>):<fpage>CD004131</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD004131.pub3</pub-id>.<pub-id pub-id-type="pmid">27562656</pub-id><pub-id pub-id-type="pmcid">PMC6464684</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Neurosci</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Neurosci</journal-id><journal-id journal-id-type="pmc-domain-id">639</journal-id><journal-id journal-id-type="pmc-domain">frontcellneuro</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id><journal-title-group><journal-title>Frontiers in Cellular Neuroscience</journal-title></journal-title-group><issn pub-type="epub">1662-5102</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488627</article-id><article-id pub-id-type="pmcid-ver">PMC12488627.1</article-id><article-id pub-id-type="pmcaid">12488627</article-id><article-id pub-id-type="pmcaiid">12488627</article-id><article-id pub-id-type="pmid">41048372</article-id><article-id pub-id-type="doi">10.3389/fncel.2025.1636185</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Spatiotemporal crosstalk among mitochondrial dynamics, NLRP3 inflammasome activation, and histone lactylation drives <italic toggle="yes">&#945;</italic>-synuclein pathology in prodromal Parkinson&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lv</surname><given-names initials="P">Peizhu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3057567"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shiping</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/3146505"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2616672"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="Y">Yan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2882651"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shun</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yulin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role></contrib></contrib-group><aff id="aff1"><label>1</label><institution>The Second Clinical Medical College, Heilongjiang University of Traditional Chinese Medicine</institution>, <city>Harbin</city>, <country country="cn">China</country></aff><aff id="aff2"><label>2</label><institution>Institute of Acupuncture and Moxibustion, Heilongjiang Academy of Traditional Chinese Medicine</institution>, <city>Harbin</city>, <country country="cn">China</country></aff><author-notes><corresp id="c001"><label>*</label>Correspondence: Shun Wang, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:hljwang@aliyun.com">hljwang@aliyun.com</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-09-18"><day>18</day><month>9</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>19</volume><issue-id pub-id-type="pmc-issue-id">481747</issue-id><elocation-id>1636185</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Lv, Chen, Liu, Zhang, Bai, Wang and Wang.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lv, Chen, Liu, Zhang, Bai, Wang and Wang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-09-18">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fncel-19-1636185.pdf"/><abstract><p>This article conducts a systematic search of literature in the fields of neuroscience, cell biology, immunometabolism, etc. from 1990 to 2025, with PubMed/WebofScience as the core database. Experimental and clinical studies covering the core mechanisms of the preprophase of PD (mitochondrial imbalance &#8594; NLRP3 activation &#8594; lactation modification &#8594; <italic toggle="yes">&#945;</italic> -SYN pathology) were included, and non-interaction mechanisms and clinical-phase studies were excluded. The pathological interaction network of mitochondrial dynamic imbalance, lysosomes - mitochondrial interaction disorder and neuroinflammation in Parkinson&#8217;s disease (PD) was explained. Construct a three-dimensional pathological network of &#8220;energy-inflammation-protein homeostasis&#8221; to provide a theoretical basis for early intervention. The imbalance of mitochondrial fission/fusion leads to the accumulation of fragmented mitochondria, triggering energy metabolism disorders and oxidative stress; abnormal aggregation of <italic toggle="yes">&#945;</italic>-synuclein (&#945;-syn) disrupts mitochondrial-endoplasmic reticulum membrane (MAM) calcium signaling, upregulates Miro protein to inhibit mitochondrial autophagy clearance, forming a vicious cycle of neuronal damage. Defects in the PINK1/Parkin pathway and LRRK2 mutations interfere with the turnover of mitochondrial fission complexes, causing mtDNA leakage, activating the NLRP3 inflammasome, and driving neuroinflammatory cascades. Additionally, lysosomal dysfunction caused by GBA1 mutations exacerbates mitochondrial quality control defects through Rab7 activity imbalance. Abnormal lactate metabolism may influence inflammasome activity through epigenetic regulation, but its role in PD needs further validation. Based on the above mechanisms, a diagnostic strategy for the prodromal phase integrating dynamic monitoring of mitochondrial fragmentation index, lysosomal function markers, and inflammatory factors is proposed, along with new intervention directions targeting Drp1, NLRP3, and the lysosome-mitochondria interface.</p></abstract><kwd-group><kwd>Parkinson&#8217;s disease</kwd><kwd>prodromal phase</kwd><kwd>mitochondrial dynamics</kwd><kwd>NLRP3 inflammasome</kwd><kwd>lactylation modification</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the National Natural Science Foundation of China.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="119"/><page-count count="13"/><word-count count="11230"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cellular Neuropathology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>Introduction</title><p>The prodromal phase of Parkinson&#8217;s disease (PD) constitutes a preclinical stage exceeding 20&#8239;years (Braak stages I&#8211;III), characterized by cell-type-specific pathology (e.g., glutamatergic neurons in the olfactory bulb, cholinergic neurons in the dorsal motor nucleus of the vagus) and temporospatial progression (brainstem-to-cortex spread per Braak staging) (<xref rid="ref5" ref-type="bibr">Braak et al., 2003</xref>; <xref rid="ref47" ref-type="bibr">Kulkarni et al., 2022</xref>). During early disease (Braak I&#8211;II), <italic toggle="yes">&#945;</italic>-synuclein (&#945;-syn) preferentially accumulates in the olfactory bulb (glutamatergic neurons) and dorsal motor nucleus (cholinergic neurons), disrupting N-type calcium channels (Cav2.2) to induce calcium dyshomeostasis and mitochondrial oxidative stress. This manifests clinically as olfactory dysfunction (impaired synaptic transmission) and autonomic disturbances (vagal nucleus dysfunction) (<xref rid="ref5" ref-type="bibr">Braak et al., 2003</xref>; <xref rid="ref24" ref-type="bibr">Dryanovski et al., 2013</xref>). By Braak stage III, dopaminergic neurons in the substantia nigra are affected, where microglial activation and TNF-<italic toggle="yes">&#945;</italic> release amplify <italic toggle="yes">&#946;</italic>-band oscillations (15&#8211;35&#8239;Hz) in the basal ganglia, driving pre-motor symptoms (<xref rid="ref7" ref-type="bibr">Brown et al., 2001</xref>). Mid-prodromally (Braak II&#8211;III), microglia shift from a P2Y12<sup>+</sup> phagocytic state to a CD16<sup>+</sup> pro-inflammatory phenotype, propagating <italic toggle="yes">&#945;</italic>-syn via tunneling nanotubes to exacerbate synaptic toxicity (<xref rid="ref81" ref-type="bibr">Scheiblich et al., 2021</xref>). In late prodromal stages (Braak IV), &#945;-syn impairs astrocytic glutamate transporter GLT-1, inducing excitotoxicity and activating the NF-&#954;B pathway to release pro-inflammatory factors (e.g., IL-6), which synergize with microglia to disrupt the blood&#8211;brain barrier (<xref rid="ref32" ref-type="bibr">Gonz&#225;lez-Rodr&#237;guez et al., 2021</xref>).</p><p>Despite advances in understanding genetic (e.g., SNCA, LRRK2mutations) and environmental (e.g., MPTP, pesticides) risk factors, motor symptom onset marks irreversible neuronal loss, underscoring the urgency to delineate prodromal mechanisms for early intervention (<xref rid="ref32" ref-type="bibr">Gonz&#225;lez-Rodr&#237;guez et al., 2021</xref>). Previous studies have narrowly focused on isolated pathways&#8212;mitochondrial dysfunction, neuroinflammation, or protein aggregation&#8212;overlooking their cross-scale network interactions. This work bridges this gap by proposing a unified &#8220;Energy-Inflammation-Proteostasis Tripartite Model,&#8221; integrating mitochondrial dynamics, lysosomal-mitochondrial metabolic crosstalk, and epigenetic regulation. We elucidate molecular couplings&#8212;e.g., Drp1-dependent hyperfission, PINK1/Parkin pathway defects, and NLRP3 inflammasome activation (where LRRK2 enhances inflammation via JNK/NF-&#954;B signaling)&#8212;that drive <italic toggle="yes">&#945;</italic>-syn propagation and metabolic decompensation. Our three-tiered framework (molecular interactions, interorganelle metabolic reprogramming, clinical translation) advances novel diagnostic strategies targeting mtDNA damage indices and dynamic IL-1&#946; monitoring, offering transformative avenues for prodromal diagnosis and disease-modifying therapies (see <xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>This figure demonstrates the mechanism of mitochondrial dynamic imbalance in the prodromal stage of Parkinson&#8217;s disease, including abnormal division/fusion (dysregulation of Drp1 and Mfn1/2), energy metabolism disorders caused by the accumulation of fragmented mitochondria, and the pathological vicious cycle of &#945; -synuclein. This figure was created using the software BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-19-1636185-g001.jpg"><alt-text content-type="machine-generated">Cycle diagram showing mitochondrial dynamic imbalance. Starts with mitochondrial damage, progresses to neuroinflammation, leading to neuronal death, then alpha-synuclein aggregates, and circles back to mitochondrial damage. Labeled as a vicious cycle.</alt-text></graphic></fig><sec id="sec2"><label>1.1</label><title>Mitochondrial dynamics imbalance and its pathological association with PD</title><p>The dynamic balance of mitochondrial morphology is maintained by the cooperative action of fusion proteins (Mfn1/2 regulating the outer membrane, OPA1 regulating the inner membrane) and fission proteins (Drp1 and its receptor complexes). Imbalance between the two leads to defects in mitochondrial autophagy and the accumulation of dysfunctional mitochondria (<xref rid="ref12" ref-type="bibr">Chan, 2020</xref>; <xref rid="ref15" ref-type="bibr">Chen et al., 2023</xref>; <xref rid="ref73" ref-type="bibr">Quintana-Cabrera and Scorrano, 2023</xref>). Additionally, mitochondrial transport relies on the microtubule network and associated motor protein complexes, which, in conjunction with dynein, regulate the positioning of mitochondria in neuronal axons, with Mfn2 participating in this process through physical binding to the Miro-Milton complex (<xref rid="ref12" ref-type="bibr">Chan, 2020</xref>; <xref rid="ref29" ref-type="bibr">Gao et al., 2017</xref>). In the pathological process of PD, mitochondrial dynamics abnormalities manifest as excessive fission and fusion defects, leading to mitochondrial network fragmentation, energy metabolism disorders, and imbalances in reactive oxygen species (ROS) and calcium homeostasis (<xref rid="ref87" ref-type="bibr">Subramaniam and Chesselet, 2013</xref>; <xref rid="ref74" ref-type="bibr">Rani and Mondal, 2020</xref>). A study published in the Journal of Neurochemistry in 1990 first confirmed that the activity of mitochondrial complex I in the substantia nigra of PD patients was significantly reduced compared to healthy controls (decreased by 30%, <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.05), while the activity of complexes II-III was unaffected (<xref rid="ref80" ref-type="bibr">Schapira et al., 1990</xref>) Correspondingly, an animal model experiment showed that a single injection of 40&#8239;mg/kg MPTP in mice of different ages resulted in age-related declines in complex I function, antioxidant capacity, and increased MAO-B activity, the latter accelerating the conversion of MPTP to toxic metabolite MPP+, suggesting that MPTP-induced oxidative stress and complex I inhibition are potential driving factors of early PD pathology (<xref rid="ref2" ref-type="bibr">Ali et al., 1994</xref>). To adapt to this functional defect, the density of mitochondria and the expression of complex I/IV proteins in surviving axons increase compensatorily (<xref rid="ref75" ref-type="bibr">Reeve et al., 2018</xref>). However, the forced enhancement of mitochondrial respiratory chain activity during compensation induces the accumulation of mitochondrial-derived oxidative damage, ultimately triggering or exacerbating neuroinflammatory responses, leading to the collapse of compensatory repair. Pathogenic <italic toggle="yes">&#945;</italic>-syn mutations (e.g., A30P) significantly reduce its localization in MAM by disrupting its interaction with MAM lipid rafts, leading to decreased physical connections between ER and mitochondria (lower Mander coefficient) and impaired calcium signaling mediated by MAM (<xref rid="ref34" ref-type="bibr">Guardia-Laguarta et al., 2014</xref>; <xref rid="ref42" ref-type="bibr">Jiao et al., 2025</xref>); this subsequently leads to reduced mitochondrial calcium uptake and energy metabolism disorders (<xref rid="ref8" ref-type="bibr">Cal&#236; et al., 2012</xref>; <xref rid="ref23" ref-type="bibr">Devi et al., 2008</xref>). Notably, this fragmentation is not driven by the classical fission pathway mediated by DRP1 but is associated with abnormal cleavage of OPA1 protein, suggesting that <italic toggle="yes">&#945;</italic>-syn may indirectly affect morphology by regulating mitochondrial fusion-related proteins (<xref rid="ref25" ref-type="bibr">Duvezin-Caubet et al., 2006</xref>; <xref rid="ref34" ref-type="bibr">Guardia-Laguarta et al., 2014</xref>). Furthermore, the reduced presence of mutant <italic toggle="yes">&#945;</italic>-syn in MAM may promote its abnormal accumulation in the mitochondrial membrane, directly interfering with mitochondrial membrane potential and exacerbating oxidative stress by inhibiting complex I activity (<xref rid="ref23" ref-type="bibr">Devi et al., 2008</xref>), thus forming a vicious cycle of calcium imbalance, energy metabolism disorders, and oxidative damage.</p><p>Abnormal accumulation of &#945;-synuclein delays mitochondrial autophagy by upregulating Miro protein levels. Specifically, the clearance rate of damaged mitochondria on the surface of Miro decreases, leading to delayed mitochondrial transport and ultimately resulting in the accumulation of abnormal mitochondria within neurons (<xref rid="ref82" ref-type="bibr">Shaltouki et al., 2018</xref>). Miro&#8217;s abnormal accumulation on the surface of damaged mitochondria causes the motor protein complex (kinesin/Miro/milton) to continuously bind, leading to excessive transport of mitochondria to the distal axon and their retention (<xref rid="ref50" ref-type="bibr">Lee and Lu, 2014</xref>). Retained mitochondria produce ROS due to electron transport chain dysfunction, and local oxidative stress exacerbates synaptic damage and mtDNA leakage (<xref rid="ref93" ref-type="bibr">Verma et al., 2023</xref>). Notably, in PD patients, mutations in PINK1 prevent the phosphorylation of Miro at the Ser156 site, leading to the obstruction of Parkin-dependent ubiquitin degradation (<xref rid="ref84" ref-type="bibr">Shlevkov et al., 2016</xref>; <xref rid="ref68" ref-type="bibr">Narendra et al., 2012</xref>). The absence of Parkin directly blocks mitochondrial autophagy, resulting in the accumulation of abnormal mitochondria in neuronal cell bodies and axons, ultimately leading to selective death of dopaminergic neurons (<xref rid="ref57" ref-type="bibr">Liu et al., 2012</xref>; <xref rid="ref97" ref-type="bibr">Wang et al., 2011a</xref>,<xref rid="ref98" ref-type="bibr">b</xref>). Accordingly, it can be reasonably inferred that retained damaged mitochondria release DAMPs, such as mtDNA and ROS, activating the NLRP3 inflammasome in microglia and triggering the IL-1&#946;/IL-18 cascade, forming a vicious cycle of &#8220;protein abnormal aggregation-mitochondrial damage-neuroinflammation-neuronal death.&#8221;</p></sec><sec id="sec3"><label>1.2</label><title>Upstream events related to mitochondrial dynamics imbalance in PD</title><p>Studies have shown that Drp1-dependent fission is a key upstream event in the pathology of PD (<xref rid="ref112" ref-type="bibr">Zhang D. et al., 2019</xref>; <xref rid="ref110" ref-type="bibr">Zhang Q. et al., 2019</xref>). MPP&#8239;+&#8239;induces energy metabolism disorders by inhibiting mitochondrial complex I, activating Drp1-mediated excessive mitochondrial fission, leading to mitochondrial fragmentation (<xref rid="ref78" ref-type="bibr">Santos et al., 2015</xref>; <xref rid="ref19" ref-type="bibr">Chuang et al., 2016</xref>). The ROS produced by fragmented mitochondria and abnormal calcium signaling further positively feedback to enhance Drp1 activity, forming a vicious cycle that ultimately leads to the death of dopaminergic neurons. Inhibiting Drp1 can block fragmentation, almost completely rescuing MPP&#8239;+&#8239;-induced ROS generation, loss of mitochondrial membrane potential, and cell death (<xref rid="ref78" ref-type="bibr">Santos et al., 2015</xref>; <xref rid="ref104" ref-type="bibr">Yang et al., 2021</xref>; <xref rid="ref97" ref-type="bibr">Wang et al., 2011a</xref>,<xref rid="ref98" ref-type="bibr">b</xref>). Based on the above mechanisms, targeting the inhibition of Drp1 activity or regulating its mitochondrial translocation may effectively delay the degeneration of dopaminergic neurons in the prodromal phase of Parkinson&#8217;s disease by blocking the vicious cycle of mitochondrial fragmentation-ROS-calcium imbalance, providing a new strategy for early neuroprotection (see <xref rid="fig2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>This figure describes the upstream event mechanism of mitochondrial dynamic imbalance, focusing on how DRP1-dependent hyperdivision, defects in the PINK1/Parkin pathway, and LRRK2 mutations induce excessive mitochondrial division, mtDNA leakage, and NLRP3 inflammasome activation, driving the molecular cascade of neuronal damage. This figure was created using the software BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-19-1636185-g002.jpg"><alt-text content-type="machine-generated">Diagram illustrating the pathway of cellular events triggered by LRRK2 G2019S mutation and PINK1/Parkin deficiency leading to mitochondrial dysfunction. It includes ROS overproduction, calcium dysregulation, mitochondrial DNA leak, NLRP3 inflammasome assembly, and the release of inflammatory cytokines IL-1&#946; and IL-18. This results in inflammatory amplification and formation of &#945;-synuclein aggregates, associated with DJ-1 deficiency and MPP+ exposure.</alt-text></graphic></fig><p>For example, mutations in the Parkin and PINK1 genes lead to early-onset Parkinson&#8217;s disease, with mechanisms involving defects in the PINK1/Parkin pathway that cause abnormal mitochondrial quality control. When the E3 ubiquitin ligase activity of Parkin is impaired, the abnormal ubiquitination of Mfn1/2 hinders mitochondrial fission and autophagosome formation, resulting in decreased mitochondrial clearance capacity (<xref rid="ref31" ref-type="bibr">Gegg et al., 2010</xref>). In PINK1 knockout rat models, dopaminergic neurons in the substantia nigra exhibit impaired mitochondrial respiratory function and elevated oxidative stress levels, confirming that mitochondrial homeostasis imbalance is associated with PD pathology (<xref rid="ref94" ref-type="bibr">Wang et al., 2023</xref>). Defects in the PINK1/Parkin pathway can induce the leakage of mitochondrial DNA (mtDNA) into the cytoplasm, activating the cGAS-STING pathway as a damage-associated molecular pattern (DAMP), which in turn triggers NLRP3 inflammasome assembly and promotes the release of pro-inflammatory factors such as IL-1&#946; and IL-18 (<xref rid="ref94" ref-type="bibr">Wang et al., 2023</xref>; <xref rid="ref67" ref-type="bibr">Mouton-Liger et al., 2018</xref>). The absence of Parkin weakens the negative feedback regulation of NF-&#954;B signaling by downregulating the anti-inflammatory protein A20, further amplifying NLRP3 inflammasome activity (<xref rid="ref67" ref-type="bibr">Mouton-Liger et al., 2018</xref>). Meanwhile, PINK1 deficiency exacerbates the loss of mitochondrial membrane potential and calcium homeostasis imbalance, activating inflammatory responses in microglia and macrophages, leading to a chronic neuroinflammatory microenvironment (<xref rid="ref94" ref-type="bibr">Wang et al., 2023</xref>). The continuous release of pro-inflammatory factors such as IL-1&#946; and TNF-&#945; synergizes with mitochondrial dysfunction, resulting in oxidative stress, energy metabolism exhaustion, and abnormal aggregation of &#945;-synuclein in dopaminergic neurons, ultimately triggering neuronal apoptosis and degeneration of the nigrostriatal pathway (<xref rid="ref94" ref-type="bibr">Wang et al., 2023</xref>). The LRRK2 G2019S mutation causes excessive mitochondrial fission by enhancing the phosphorylation of Drp1 at the Thr595 site, accompanied by increased levels of reactive oxygen species (ROS) and mtDNA damage (<xref rid="ref86" ref-type="bibr">Su and Qi, 2013</xref>). This damage is manifested as a reduction in mtDNA copy number and its cytoplasmic leakage, directly activating the NLRP3 inflammasome (<xref rid="ref70" ref-type="bibr">Pena et al., 2024</xref>). <xref rid="ref37" ref-type="bibr">He et al. (2023)</xref> confirmed that the LRRK2 G2019S mutation enhances NLRP3 activation in astrocytes through the NF-&#954;B pathway, promoting the release of IL-1&#946; and TNF-&#945;, a mechanism validated in mouse models and lymphoblasts derived from patients, with LRRK2 kinase activity inhibition significantly reducing inflammasome activity. <xref rid="ref119" ref-type="bibr">Zhu et al. (2013)</xref> further revealed that LRRK2 G2019S enhances ULK1-dependent mitophagy by activating the JNK signaling pathway, exacerbating mitochondrial clearance abnormalities and neuronal damage. These studies suggest that defects in the PINK1/Parkin pathway and LRRK2 mutations accelerate the pathological process of PD through mitochondrial stress-related inflammatory signaling, and early intervention during the prodromal phase could target the inhibition of NLRP3 or enhance the expression of the anti-inflammatory protein A20 to delay neuronal loss (<xref rid="ref94" ref-type="bibr">Wang et al., 2023</xref>; <xref rid="ref67" ref-type="bibr">Mouton-Liger et al., 2018</xref>). Notably, the mtDNA damage caused by the LRRK2 G2019S mutation due to abnormal kinase activity exhibits significant dynamic reversibility. Treatment with EB-42168 or MLi-2 for 2&#8239;h to acutely inhibit G2019S LRRK2 kinase activity can rapidly restore mtDNA damage to normal levels, while the damage phenotype reappears within 2&#8239;h after the withdrawal of the inhibitor (<xref rid="ref70" ref-type="bibr">Pena et al., 2024</xref>). This suggests that mitochondrial dysfunction during the prodromal phase may be in a &#8220;metabolic imbalance&#8221; state rather than structural damage, and this dynamic balance of damage-repair characteristics provides a critical time window for early intervention based on kinase activity monitoring. Dynamic monitoring of mtDNA damage indices and inflammatory factors may construct a combination of prodromal-specific biomarkers, while the combined application of gene editing technology for targeted mtDNA repair and selective kinase inhibitors may achieve precise regulation from molecular mechanisms to clinical phenotypes. Additionally, using induced pluripotent stem cells to construct patient-specific brain organoid models will provide a new platform for optimizing personalized treatment plans.</p><p>Recent studies indicate that DJ-1 is a key downstream mediator of PINK1/parkin-dependent mitophagy (<xref rid="ref92" ref-type="bibr">Thomas et al., 2011</xref>; <xref rid="ref61" ref-type="bibr">McCoy and Cookson, 2011</xref>). In fibroblasts and induced dopaminergic neurons from PARK7 mutation patients, the absence of DJ-1 leads to the failure of the autophagy receptor optineurin to be recruited to depolarized mitochondria, directly hindering the clearance of damaged mitochondria and causing the accumulation of mitochondrial fragments (<xref rid="ref40" ref-type="bibr">Imberechts and Vandenberghe, 2023</xref>). Experiments confirm that the mitochondrial localization of DJ-1 depends on the PINK1/parkin pathway, and artificially targeting DJ-1 to the outer mitochondrial membrane can bypass upstream defects to directly restore optineurin recruitment (<xref rid="ref39" ref-type="bibr">Imberechts et al., 2022</xref>). These findings indicate that DJ-1 plays a critical role in maintaining mitochondrial quality control, and its deficiency, by blocking downstream steps of autophagy, contributes to the degenerative changes in dopaminergic neurons in conjunction with PINK1/parkin mutations, representing a common pathological mechanism of autosomal recessive PD (see <xref rid="fig3" ref-type="fig">Figure 3</xref>).</p><fig position="float" id="fig3" orientation="portrait"><label>Figure 3</label><caption><p>This figure clarifies the pathological interaction mechanism between the mitochondrial-lysosomal interaction disorder and the NLRP3 inflammasome, including lysosomal membrane permeation (CTSB leakage), mtDNA release, and the cascade amplification of inflammatory factors (such as IL-1&#946;), forming a positive feedback loop of &#945; -synuclein diffusion and neuroinflammation. This figure was created using the software BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-19-1636185-g003.jpg"><alt-text content-type="machine-generated">Pathway diagram illustrating how GBA1 mutation and CTSB deficiency lead to neuronal death. Lysosomal dysfunction causes membrane permeabilization, cathepsin B leak, and alpha-synuclein aggregates. This triggers mitochondrial dysfunction, increased reactive oxygen species, and DNA leakage. These events activate caspase-1 and microglial cells, further aggravating inflammation through IL-1&#946; and IL-18, ultimately causing neuronal death.</alt-text></graphic></fig></sec><sec id="sec4"><label>1.3</label><title>Pathological interaction between mitochondrial dynamic imbalance and NLRP3 inflammasome</title><p>The NLRP3 inflammasome, as a core regulatory component of innate immunity, is closely related to the neuroinflammatory process and loss of dopaminergic neurons in PD. This complex is composed of the NLRP3 receptor protein, the adaptor protein ASC, and the precursor caspase-1 (<xref rid="ref48" ref-type="bibr">Lamkanfi and Dixit, 2014</xref>), which triggers polymer assembly and activates caspase-1 by sensing danger signals such as intracellular potassium efflux and mitochondrial reactive oxygen species (ROS) bursts (<xref rid="ref28" ref-type="bibr">Fu and Wu, 2023</xref>; <xref rid="ref111" ref-type="bibr">Zhang et al., 2023</xref>), subsequently cleaving pro-IL-1&#946; and pro-IL-18 to generate mature inflammatory factors while inducing pyroptosis (<xref rid="ref90" ref-type="bibr">Swanson et al., 2019</xref>). Co-culture experiments show that NLRP3-activated microglia significantly increase the death of dopaminergic neurons (SH-SY5Y and MN9D cells) (<xref rid="ref49" ref-type="bibr">Lee et al., 2019</xref>).</p><p>In PD patients, mitochondrial ROS serve as the initial signal promoting NLRP3 activation (<xref rid="ref65" ref-type="bibr">Mishra et al., 2021</xref>), and Parkin can directly regulate NLRP3 stability. The absence of Parkin leads to the accumulation of NLRP3 protein in microglia, enhancing caspase-1 activation and IL-1&#946; secretion, ultimately resulting in the loss of dopaminergic neurons in the substantia nigra (<xref rid="ref101" ref-type="bibr">Yan et al., 2023</xref>). Specifically, mitochondrial autophagy impairment hinder s the clearance of damaged mitochondria, and the released ROS and mtDNA activate neuroinflammation through dual mechanisms (<xref rid="ref56" ref-type="bibr">Lin and Beal, 2006</xref>; <xref rid="ref107" ref-type="bibr">Yu et al., 2025</xref>): on one hand, excessive ROS production due to mitochondrial dysfunction directly promotes NLRP3 inflammasome assembly (<xref rid="ref79" ref-type="bibr">Sarkar et al., 2017</xref>; <xref rid="ref117" ref-type="bibr">Zhou et al., 2011</xref>); on the other hand, the released mtDNA from damaged mitochondria synergizes with ROS, further activating the NLRP3 inflammasome by enhancing mitochondrial membrane potential depolarization and lysosomal rupture, driving caspase-1-dependent maturation and secretion of IL-1&#946; (<xref rid="ref83" ref-type="bibr">Shao et al., 2021</xref>; <xref rid="ref41" ref-type="bibr">Javed et al., 2020</xref>; <xref rid="ref38" ref-type="bibr">Holley and Schroder, 2020</xref>). Additionally, recent studies indicate that LPS-induced metabolic reprogramming enhances glycolysis and succinate accumulation in the TCA cycle, increasing mitochondrial membrane potential (&#916;&#968;m) by reducing F1F0-ATP synthase-dependent proton backflow, while succinate oxidation maintains the pool of reduced CoQ, collectively driving complex I reverse electron transport (RET)-dependent mtROS bursts that regulate NLRP3 inflammasome activation and IL-1&#946; release (<xref rid="ref9" ref-type="bibr">Casey et al., 2025</xref>). Furthermore, studies have shown that the oxidized sterol metabolite 27-hydroxycholesterol (27-OHC) triggers a cascade of damage by inducing lysosomal membrane permeabilization (LMP): the destruction of lysosomal membrane integrity leads to abnormal leakage of cathepsin B (CTSB), which activates the NLRP3 inflammasome and drives the cleavage of the pyroptosis execution protein GSDMD in a caspase-1-dependent manner, directly causing neuronal inflammatory death (<xref rid="ref17" ref-type="bibr">Chen et al., 2019</xref>); on the other hand, the abnormal localization of CTSB further exacerbates lysosomal dysfunction, forming a vicious cycle. It is noteworthy that the functional defects of CTSB have a multiple amplification effect&#8212;recent studies reveal that CTSB gene knockout or inhibition leads to a triad effect of decreased lysosomal degradation capacity: reduced GCase activity (synergistic effect with GBA1 mutations), autophagic flow blockage, and compensatory increase in lysosomal generation but decreased degradation capacity. This lysosomal collapse state significantly enhances the pathological aggregation of phosphorylated <italic toggle="yes">&#945;</italic>-synuclein (pSyn-S129) induced by &#945;-synuclein preformed fibrils (PFF), directly leading to &#945;-synuclein aggregation, exacerbating the pathological progression of PD, and potentially initiating an irreversible neurodegenerative process during the prodromal phase of PD (<xref rid="ref44" ref-type="bibr">Jones-Tabah et al., 2024</xref>; <xref rid="ref66" ref-type="bibr">Moors et al., 2024</xref>).</p><p>The underlying mechanisms of this pathological network are closely related to mitochondrial-lysosomal interaction disorders. GBA1 mutations lead to decreased <italic toggle="yes">&#946;</italic>-glucocerebrosidase (GCase) activity, triggering the accumulation of glucosylceramide (GlcCer), which degrades TBC1D15 through the ubiquitin-proteasome pathway, ultimately hindering Rab7-GTP hydrolysis, prolonging mitochondrial-lysosomal (M/L) contact time, and inhibiting Drp1-mediated fission and PINK1-Parkin pathway-dependent autophagy initiation (<xref rid="ref45" ref-type="bibr">Kim et al., 2021</xref>; <xref rid="ref100" ref-type="bibr">Xie et al., 2025</xref>), forming a dual defect in mitochondrial quality control. Additionally, Parkin mutations significantly reduce M/L contact frequency by decreasing Rab7 activity (dependent on its E3 ubiquitin ligase function), leading to a deficiency of essential amino acids for mitochondria, such as isoleucine and valine, while causing amino acid accumulation in the lysosomal lumen. This not only impairs mitochondrial oxidative phosphorylation function but also further weakens lysosomal clearance capacity by inhibiting the maturation of lysosomal enzymes such as cathepsin D (<xref rid="ref71" ref-type="bibr">Peng et al., 2020</xref>). This interaction disorder creates a chain reaction of &#8220;quality control failure-metabolic disorder&#8221; in a spatiotemporal dimension: GBA1/Parkin mutations lead to abnormal contact time/frequency, while CTSB defects disrupt metabolic terminal clearance capacity, intertwining <italic toggle="yes">&#945;</italic>-synuclein aggregation and the release of inflammatory factors. The IL-1&#946; released after NLRP3 activation exacerbates &#945;-synuclein aggregation and oxidative stress by activating the P38/STAT1 pathway, while IL-6 secreted by neurons enhances the secretion of pro-inflammatory factors from microglia through the JAK2/STAT3 signaling pathway, forming a cascading amplification effect of &#8220;inflammatory factors-protein aggregation&#8221; (<xref rid="ref51" ref-type="bibr">Lee et al., 2023</xref>; <xref rid="ref14" ref-type="bibr">Chen et al., 2021</xref>).</p><p>It is noteworthy that the characteristic pathological product of PD&#8212;fibrillated <italic toggle="yes">&#945;</italic>-synuclein aggregates&#8212;can also act as an endogenous danger signal to activate the NLRP3 inflammasome: studies have confirmed that microglia phagocytose &#945;-synuclein fibrils derived from Lewy bodies, releasing cathepsin B through lysosomal membrane rupture, accompanied by a large generation of ROS, which synergistically activates the NLRP3-caspase-1 axis, driving the maturation and release of IL-1&#946; (<xref rid="ref108" ref-type="bibr">Yu et al., 2024</xref>; <xref rid="ref54" ref-type="bibr">Li G. et al., 2024</xref>; <xref rid="ref53" ref-type="bibr">Li M. M. et al., 2024</xref>; <xref rid="ref20" ref-type="bibr">Codolo et al., 2013</xref>; <xref rid="ref60" ref-type="bibr">Martinon et al., 2002</xref>). The released IL-1&#946; further recruits and activates surrounding glial cells, forming a chronic neuroinflammatory microenvironment that exacerbates mitochondrial dysfunction in dopaminergic neurons (<xref rid="ref36" ref-type="bibr">Halle et al., 2008</xref>). Abnormally aggregated fibrillar &#945;-synuclein drives the inflammatory response through dual mechanisms: on the one hand, by activating Toll-like receptor 2 (TLR2) and TLR3, it synergistically enhances the nuclear factor &#954;B (NF-&#954;B) signaling pathway and upregulates the gene expression of TNF-<italic toggle="yes">&#945;</italic> and IL-1&#946; (<xref rid="ref95" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="ref22" ref-type="bibr">Daniele et al., 2015</xref>), and on the other hand, it relies on lysosomal rupture, reactive oxygen species generation, and cathepsin B release to promote the maturation and secretion of IL-1&#946; by triggering the NLRP3 inflammasome, thereby amplifying neuroinflammation (<xref rid="ref26" ref-type="bibr">Fan et al., 2020</xref>). This forms a positive feedback loop of &#8220;<italic toggle="yes">&#945;</italic>-synuclein deposition-inflammation amplification-neuronal death&#8221; (<xref rid="ref20" ref-type="bibr">Codolo et al., 2013</xref>). Genetic evidence further supports this mechanism: &#945;Syn-induced neuroinflammation and motor dysfunction are significantly alleviated in NLRP3 gene knockout mice (<xref rid="ref33" ref-type="bibr">Gordon et al., 2018</xref>). In summary, the activation mechanism of the NLRP3 inflammasome and its role in PD provide important clues for understanding the pathological mechanisms of this disease, while also laying the foundation for developing new therapeutic strategies. Future research needs to further explore the regulatory mechanisms of the NLRP3 inflammasome and its potential applications in PD treatment.</p><p>Based on existing research evidence, during the prodromal phase of PD, the interplay between mitochondrial-lysosomal interaction disorders and neuroinflammation creates a unique diagnostic and intervention window. The ROS and mtDNA release caused by mitochondrial autophagy defects can be detected through the following pathways: elevated mtDNA fragments in cerebrospinal fluid, abnormal mitochondrial membrane potential (&#916;&#968;m), and activation markers of the NLRP3 inflammasome such as caspase-1 cleavage products and IL-1&#946; levels. Lysosomal function assessment should focus on CTSB activity detection, lysosomal membrane stability markers, and GCase activity evaluation (especially for GBA1 mutation carriers). Notably, the oligomer levels of phosphorylated <italic toggle="yes">&#945;</italic>-synuclein (pSyn-S129) combined with metabolomics analysis may reveal the interaction between &#8220;metabolic reprogramming-&#945;-syn pathology, &#8220;providing dynamic evidence for risk assessment of the transition from prodromal to clinical stages. Additionally, methods to detect NLRP3 ubiquitination levels in peripheral blood mononuclear cells, such as immunoprecipitation-mass spectrometry combined techniques, can be developed to assess Parkin functional status, providing warning markers for the prodromal phase of PD. It is emphasized that the sensitivity and specificity of this method still need clinical cohort validation, and interference from other E3 ubiquitin ligases must be excluded.</p><p>Intervention strategies should be based on the spatiotemporal characteristics of the pathological network: at the metabolic level, drugs that inhibit reverse electron transfer (RET) of complex I block glycolysis-enhanced mtROS bursts (<xref rid="ref9" ref-type="bibr">Casey et al., 2025</xref>); supplementing essential mitochondrial amino acids such as isoleucine and valine to alleviate metabolic compartmentalization imbalance caused by Parkin mutations. To address lysosomal-mitochondrial interaction disorders, targeting the dynamic balance of Rab7 activity to restore the synergy of mitochondrial fission and autophagy (<xref rid="ref43" ref-type="bibr">Jimenez-Orgaz et al., 2018</xref>; <xref rid="ref55" ref-type="bibr">Liang et al., 2023</xref>); CTSB activators or lysosomal membrane stabilizers to restore lysosomal degradation capacity (<xref rid="ref72" ref-type="bibr">Prieto Huarcaya et al., 2022</xref>), blocking the &#8220;seed effect&#8221; of <italic toggle="yes">&#945;</italic>-syn pathological aggregation. At the level of inflammation regulation, combining NLRP3 inhibitors with necroptosis pathway blockers simultaneously inhibits IL-1&#946; secretion and neuronal inflammatory death (<xref rid="ref91" ref-type="bibr">Tantra et al., 2024</xref>; <xref rid="ref116" ref-type="bibr">Zhou et al., 2024</xref>); microglia-specific JAK2/STAT3 pathway inhibitors cut off IL-6-mediated inflammation spread (<xref rid="ref86" ref-type="bibr">Su and Qi, 2013</xref>). For genetically susceptible populations, integrating enzyme replacement therapy with personalized metabolic interventions is necessary to break the &#8220;mutation-metabolism-inflammation&#8221; vicious cycle. The core of this multidimensional intervention system lies in the early identification of the pathological critical point of &#8220;mitochondrial autophagy defects-lysosomal collapse-inflammation cascade, &#8220;through spatiotemporally specific drugs, such as nanocarriers targeting mitochondrial-lysosomal contact regions, to reshape cellular homeostasis before irreversible neurodegeneration, providing a new paradigm for disease-modifying treatment in the prodromal phase of PD.</p></sec><sec id="sec5"><label>1.4</label><title>The catalytic role of lactylation modification</title><p>Lactylation modification is a newly discovered epigenetic regulatory mechanism that dynamically regulates protein function through the covalent binding of lactyl groups to lysine residues, becoming a core hub connecting metabolic abnormalities and neurodegenerative diseases (see <xref rid="fig4" ref-type="fig">Figure 4</xref>).</p><fig position="float" id="fig4" orientation="portrait"><label>Figure 4</label><caption><p>This figure demonstrates the catalytic mechanism of lactic acid modification, which affects mitochondrial function, autophagy deficiency and NLRP3 inflammatory response through metabolic reprogramming (such as enhanced glycolysis) and epigenetic regulation (histone H3K9la modification), connecting the spatiotemporal dynamics of abnormal energy metabolism and neurodegeneration. This figure was created using the software BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fncel-19-1636185-g004.jpg"><alt-text content-type="machine-generated">Illustration showing the process of histone lactylation. It begins with the attachment of a lactyllysine (La) to a histone, impacting DNA. This leads to two outcomes: NLRP3 inflammasome activation and mitochondrial RNA leakage, marked by reactive oxygen species (ROS) in mitochondria. Both contribute to mitophagy and neuroinflammation. Arrows indicate the sequence and impact of events.</alt-text></graphic></fig><p>Lactylation is involved in physiological processes such as energy metabolism and inflammatory responses. In non-tumor diseases like atherosclerosis and Alzheimer&#8217;s disease, lactylation exacerbates pathological damage by regulating inflammation, fibrosis, and cellular senescence (<xref rid="ref114" ref-type="bibr">Zhao et al., 2025</xref>; <xref rid="ref112" ref-type="bibr">Zhang D. et al., 2019</xref>; <xref rid="ref110" ref-type="bibr">Zhang Q. et al., 2019</xref>; <xref rid="ref6" ref-type="bibr">Brand et al., 2016</xref>). As mentioned earlier, in the pathological process of PD, the abnormal aggregation of &#945;-synuclein has been confirmed to disrupt the integrity of the mitochondria-associated endoplasmic reticulum membrane (MAM), leading to impaired function of mitochondrial complex I and accumulation of reactive oxygen species (ROS) (<xref rid="ref34" ref-type="bibr">Guardia-Laguarta et al., 2014</xref>). Studies on MPTP-induced Parkinson&#8217;s disease models indicate that its toxic metabolite MPP&#8239;+&#8239;significantly reduces ATP synthesis efficiency by inhibiting mitochondrial complex I (<xref rid="ref2" ref-type="bibr">Ali et al., 1994</xref>), prompting cells to activate glycolytic pathways to increase lactate production. This phenomenon shares similar metabolic characteristics with the Warburg effect observed in the tumor microenvironment (<xref rid="ref11" ref-type="bibr">Certo et al., 2021</xref>). Lactate can inhibit OXPHOS activity through lactylation modification of mitochondrial metabolic enzymes mediated by AARS2, such as PDHA1 K336, forming a negative feedback loop to limit excessive ROS generation (<xref rid="ref59" ref-type="bibr">Mao et al., 2024</xref>). When this regulatory mechanism is disrupted (e.g., AARS2 deficiency), excessive OXPHOS activity leads to ROS accumulation, potentially triggering mitochondrial oxidative damage and ultimately resulting in the accumulation of dysfunctional mitochondria (<xref rid="ref63" ref-type="bibr">Mi et al., 2023</xref>). The role of histone lactylation modification in neurological diseases has some experimental support. Research through proteomic analysis has found widespread protein lactylation modifications in mouse brain tissue, and neuronal excitation can significantly increase lactate levels and histone lactylation levels (<xref rid="ref35" ref-type="bibr">Hagihara et al., 2021</xref>; <xref rid="ref46" ref-type="bibr">Kuang et al., 2025</xref>; <xref rid="ref89" ref-type="bibr">Sun et al., 2025</xref>) (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Summary of lactylation biology.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Lactation modification site</th><th align="left" valign="top" rowspan="1" colspan="1">Detection methods</th><th align="left" valign="top" rowspan="1" colspan="1">Functional mechanisms</th><th align="left" valign="top" rowspan="1" colspan="1">Results</th><th align="left" valign="top" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mitochondrial complex I proteins</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitochondrial protein IP-MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactylation inhibits complex I function, aggravating mitochondrial dysfunction and oxidative stress</td><td align="left" valign="middle" rowspan="1" colspan="1">Parkinson&#8217;s disease(PD)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref32" ref-type="bibr">Gonz&#225;lez-Rodr&#237;guez et al. (2021)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#945;-tubulin K40</td><td align="left" valign="middle" rowspan="1" colspan="1">IP-MS, lactylation-specific antibody WB</td><td align="left" valign="middle" rowspan="1" colspan="1">HDAC6-catalyzed lactylation enhances microtubule dynamics; alters axonal stability balance, enhances plasticity; impairs dopaminergic neuronal transport function</td><td align="left" valign="middle" rowspan="1" colspan="1">Neurodegenerative diseases (PD/AD, etc.)</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref88" ref-type="bibr">Sun et al. (2024)</xref> and <xref rid="ref32" ref-type="bibr">Gonz&#225;lez-Rodr&#237;guez et al. (2021)</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H4K12</td><td align="left" valign="middle" rowspan="1" colspan="1">CUT&amp;Tag + qChIP; Immunofluorescence staining; Western Blotting</td><td align="left" valign="middle" rowspan="1" colspan="1">Activates the &#8220;glycolysis-H4K12la-PKM2&#8221; positive feedback loop, exacerbating microglial dysfunction</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimer&#8217;s disease (AD)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref69" ref-type="bibr">Pan et al. (2022)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLRP3-K245</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactylation antibody + co-precipitation</td><td align="left" valign="middle" rowspan="1" colspan="1">LDHA promotes cardiomyocyte pyroptosis</td><td align="left" valign="middle" rowspan="1" colspan="1">Myocardial ischemia&#8211;reperfusion injury</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref27" ref-type="bibr">Fang et al. (2024)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Histone H1</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunohistochemistry (IHC)</td><td align="left" valign="middle" rowspan="1" colspan="1">Increased neuronal excitability drives Kla in the prefrontal cortex, associated with anxiety-like behavior</td><td align="left" valign="middle" rowspan="1" colspan="1">Social defeat stress (anxiety model)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref35" ref-type="bibr">Hagihara et al. (2021)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H4K5</td><td align="left" valign="middle" rowspan="1" colspan="1">ChIP-qPCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Macrophage phenotypic transition disorder, increased release of pro-inflammatory factors (TNF-&#945;, IL-6), aggravates vascular inflammation</td><td align="left" valign="middle" rowspan="1" colspan="1">Atherosclerosis (AS)</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref103" ref-type="bibr">Yang H. et al. (2022)</xref> and <xref rid="ref102" ref-type="bibr">Yang K. et al. (2022)</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLC25A4-K245, SLC25A5-K96</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactylation antibody + co-precipitation</td><td align="left" valign="middle" rowspan="1" colspan="1">Interfere with the calcium signaling pathway, induce mitochondrial Ca<sup>2+</sup> overload and neuronal apoptosis</td><td align="left" valign="middle" rowspan="1" colspan="1">Cerebral ischemia&#8211;reperfusion injury (CIRI)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref105" ref-type="bibr">Yao et al. (2023)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HMGB1</td><td align="left" valign="middle" rowspan="1" colspan="1">ELISA, cellular confocal imaging</td><td align="left" valign="middle" rowspan="1" colspan="1">Disrupts vascular endothelial barrier</td><td align="left" valign="middle" rowspan="1" colspan="1">Sepsis</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref103" ref-type="bibr">Yang H. et al. (2022)</xref> and <xref rid="ref102" ref-type="bibr">Yang K. et al. (2022)</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APOC2-K70</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunoprecipitation-mass spectrometry (IP-MS)</td><td align="left" valign="middle" rowspan="1" colspan="1">Induces tumor metastasis and resistance to immunotherapy</td><td align="left" valign="middle" rowspan="2" colspan="1">Non-small cell lung cancer (NSCLC)</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref13" ref-type="bibr">Chen B. et al. (2024)</xref>; <xref rid="ref16" ref-type="bibr">Chen J. et al. (2024)</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H3K18</td><td align="left" valign="middle" rowspan="1" colspan="1">ChIP-seq&#12289;WB</td><td align="left" valign="middle" rowspan="1" colspan="1">Activates POM121/MYC/PD-L1 pathway to promote immune escape</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref113" ref-type="bibr">Zhang et al. (2024)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#946;-catenin</td><td align="left" valign="middle" rowspan="1" colspan="1">Immunofluorescence, Co-IP</td><td align="left" valign="middle" rowspan="1" colspan="1">Activates Wnt signaling pathway to promote proliferation</td><td align="left" valign="middle" rowspan="2" colspan="1">Colorectal cancer (CRC)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref64" ref-type="bibr">Miao et al. (2023)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSUN2-K356</td><td align="left" valign="middle" rowspan="1" colspan="1">Lactylation antibody + MS validation</td><td align="left" valign="middle" rowspan="1" colspan="1">Promotes tumor progression</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref13" ref-type="bibr">Chen B. et al. (2024)</xref>; <xref rid="ref16" ref-type="bibr">Chen J. et al. (2024)</xref></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H3K9, H3K56</td><td align="left" valign="middle" rowspan="1" colspan="1">Histone modification profile analysis</td><td align="left" valign="middle" rowspan="1" colspan="1">Upregulates ESM1 to enhance malignant phenotype</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatocellular carcinoma (HCC)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref115" ref-type="bibr">Zhao et al. (2024)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H3K18</td><td align="left" valign="middle" rowspan="1" colspan="1">CUT&amp;Tag Anti-H3K18la antibody WB</td><td align="left" valign="middle" rowspan="1" colspan="1">Activate neuroendocrine genes such as Mycn and Ascl1</td><td align="left" valign="middle" rowspan="1" colspan="1">Neuroendocrine prostate cancer (NEPC)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<xref rid="ref96" ref-type="bibr">Wang et al. (2024)</xref>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">XRCC1-K247</td><td align="left" valign="middle" rowspan="1" colspan="1">Anti-XRCC1 lac-K247 antibody Immunoprecipitation mass spectrometry (IP-MS)</td><td align="left" valign="middle" rowspan="1" colspan="1">Induces therapy resistance</td><td align="left" valign="middle" rowspan="1" colspan="1">Glioblastoma (GBM)</td><td align="left" valign="middle" rowspan="1" colspan="1"><xref rid="ref54" ref-type="bibr">Li G. et al. (2024)</xref>; <xref rid="ref53" ref-type="bibr">Li M. M. et al. (2024)</xref></td></tr></tbody></table></table-wrap><p>In summary, the abnormal accumulation of lactate may exacerbate neuroinflammation through a tripartite attack:</p><list list-type="order"><list-item><p>By remodeling the promoter regions of glycolysis-related genes through histone lactylation modification, a positive feedback loop is formed involving glycolytic hyperactivity, histone lactylation modification, and transcription of glycolytic genes. <xref rid="ref69" ref-type="bibr">Pan et al. (2022)</xref> found that in an Alzheimer&#8217;s disease model, lactate accumulation due to glycolytic hyperactivity in microglia induces histone H4K12 lactylation modification, activating the transcription of glycolytic genes such as PKM2, further strengthening glycolytic metabolism and forming a self-sustaining vicious cycle, impairing phagocytic function and promoting pro-inflammatory phenotypes, ultimately leading to microglial dysfunction and exacerbated neuroinflammation. Although there is currently a lack of direct research data targeting PD, if lactate levels in the brain increase due to mitochondrial dysfunction or metabolic abnormalities, it may similarly lead to impaired phagocytic function in microglia, enhancing the pro-inflammatory phenotype and resulting in the release of pro-inflammatory factors such as TNF-<italic toggle="yes">&#945;</italic> and IL-1&#946;, exacerbating dopaminergic neuronal damage.</p></list-item><list-item><p>Inhibition of PINK1/Parkin pathway-mediated mitophagy leads to the accumulation of damaged mitochondria and the release of ROS, mtDNA, and other DAMPs. Some studies have found that lactylation modification regulates Parkin-mediated mitochondrial quality control by targeting mitochondrial metabolic enzyme PCK2, where lactate activates KAT8 to catalyze lactylation modification at the Lys100 site of PCK2, significantly enhancing its kinase activity. Activated PCK2 competitively inhibits the ubiquitination degradation of the rate-limiting enzyme (OXSM) for mitochondrial fatty acid synthesis by Parkin, leading to increased stability of OXSM protein, which drives abnormal enhancement of mitochondrial fatty acid synthesis and oxidative phosphorylation. This metabolic reprogramming process triggers mitochondrial membrane potential depolarization and ROS overload (<xref rid="ref109" ref-type="bibr">Yuan et al., 2025</xref>). Based on the above mechanisms, it can be reasonably speculated that in PD, abnormal lactate metabolism may inhibit PINK1/Parkin pathway-mediated mitophagy through similar pathways: lactylation modification may target interacting proteins of PINK1 or Parkin, obstructing the ubiquitination marking and autophagosome encapsulation of damaged mitochondria; defects in mitophagy lead to the accumulation of depolarized mitochondria, leaking large amounts of ROS through the electron transport chain, and releasing damage-associated molecular patterns (DAMPs) such as mtDNA and ATP, activating the NLRP3 inflammasome in microglia; additionally, mitochondrial DAMPs may upregulate the expression of pro-inflammatory factors (such as IL-1&#946; and IL-18) through epigenetic regulation (e.g., histone H3K18la) in conjunction with lactylation modification, synergistically amplifying the neuroinflammatory response. These mechanisms may be related to the pathological spread of <italic toggle="yes">&#945;</italic>-synuclein and the loss of dopaminergic neurons during the prodromal phase of PD, but need to be validated in PD models and the role of specific lactylation targets.</p></list-item><list-item><p>Lactylation modification promotes the activation of the NLRP3 inflammasome and the expression of inflammatory factors through epigenetic regulatory mechanisms (<xref rid="ref106" ref-type="bibr">You et al., 2024</xref>; <xref rid="ref99" ref-type="bibr">Wang et al., 2025</xref>; <xref rid="ref27" ref-type="bibr">Fang et al., 2024</xref>). Recent research by Ge et al. directly confirmed through chromatin immunoprecipitation (ChIP) experiments that the enrichment of H3K9la at the NLRP3/ASC promoter is positively correlated with gene expression, revealing that lactate produced by macrophages under LPS stimulation enhances the accessibility of the NLRP3 and ASC promoters through H3K9la modification, promoting inflammasome assembly and the maturation and release of IL-1&#946;, forming a pro-inflammatory microenvironment (<xref rid="ref30" ref-type="bibr">Ge et al., 2025</xref>). This provides direct evidence for the epigenetic regulatory role of lactylation modification. Accordingly, it can be reasonably speculated that during the course of PD, a similar lactylation-NLRP3 regulatory axis may exacerbate neuroinflammation. The characteristic aggregation of <italic toggle="yes">&#945;</italic>-synuclein in PD can activate the NLRP3 inflammasome in microglia, while the abnormal increase in lactate levels in the brain may enhance the inflammatory response of microglia by promoting H3K9la modification. This mechanism may explain the elevated levels of IL-1&#946; in the cerebrospinal fluid of PD patients and provide a theoretical basis for neuroprotective strategies targeting lactylation modification. Future research needs to verify the spatiotemporal association between lactate metabolism and NLRP3 activation in the microenvironment of midbrain dopaminergic neurons, as well as the regulatory effects of lactate dehydrogenase inhibitors on neuroinflammation.</p></list-item></list><p>Lactylation is a key link between metabolism and epigenetic regulation. Some studies have found that lactyl-CoA is a donor for lactylation, and its modification is catalyzed by CBP (CREBBP) or p300 (EP300). CBP/p300 acts as the writer enzyme for lactylation modification, catalyzing the lactylation of histone lysines through its acetyltransferase structural domain (<xref rid="ref112" ref-type="bibr">Zhang D. et al., 2019</xref>; <xref rid="ref110" ref-type="bibr">Zhang Q. et al., 2019</xref>; <xref rid="ref21" ref-type="bibr">Dai et al., 2022</xref>). Histone deacetylases HDAC1-3 have the activity to remove H3K18la and act as &#8220;eraser enzymes&#8221; for lactylation, inhibiting the transcriptional activity of related genes by hydrolyzing lactylation modifications (<xref rid="ref21" ref-type="bibr">Dai et al., 2022</xref>). Therefore, targeting the regulation of the activity of writer or eraser enzymes may balance the levels of lactylation in the brain, potentially providing a direction for neuroprotection during the prodromal phase of PD, but further experimental validation is needed. The discovery of lactylation modification provides a new perspective for PD treatment: as a triple regulatory node of metabolism, epigenetics, and inflammation, it can explain the co-occurrence of energy metabolism abnormalities and neuroinflammation in PD, and lay a theoretical foundation for developing multidimensional intervention strategies targeting both the NLRP3 inflammasome and mitophagy. Future studies should precisely analyze the spatiotemporal dynamics of lactylation modification and its interaction mechanisms with <italic toggle="yes">&#945;</italic>-synuclein pathology in PD models using single-cell metabolic imaging combined with CUT&amp;Tag technology.</p></sec></sec><sec sec-type="discussion" id="sec6"><label>2</label><title>Discussion</title><p>Mitochondrial dynamic imbalance is a core hub in the pathological process of PD, where network fragmentation, energy metabolism disorders, and calcium homeostasis imbalance together constitute early driving factors for neurodegeneration (<xref rid="ref10" ref-type="bibr">Celardo et al., 2014</xref>; <xref rid="ref77" ref-type="bibr">Rocha et al., 2018</xref>). The abnormal aggregation of &#945;-synuclein not only exacerbates the energy metabolism crisis by disrupting calcium signaling in mitochondria-associated membranes (MAM) (<xref rid="ref58" ref-type="bibr">Mao et al., 2022</xref>; <xref rid="ref85" ref-type="bibr">Sironi et al., 2020</xref>) but also hinders the autophagic clearance of damaged mitochondria by upregulating Miro protein levels (<xref rid="ref82" ref-type="bibr">Shaltouki et al., 2018</xref>), ultimately leading to a vicious cycle of abnormal mitochondrial accumulation and oxidative damage within neurons. In this process, although the compensatory increase in mitochondrial density temporarily maintains energy supply, it accelerates oxidative stress and neuroinflammation due to the overload of respiratory chain activity, suggesting that early diagnosis should focus on the dynamic monitoring of mitochondrial network morphology and the precise definition of metabolic compensation thresholds. For example, combining the mitochondrial fragmentation index in the substantia nigra with cerebrospinal fluid mitochondrial complex I activity detection can identify the critical point of transition from the compensatory phase to the decompensatory phase; quantitative analysis of MAM connection proteins may reveal early associations between <italic toggle="yes">&#945;</italic>-syn pathology and mitochondrial calcium imbalance, providing spatiotemporal specific targets for intervention strategies.</p><p>In-depth exploration of upstream events of mitochondrial dynamic imbalance reveals that excessive activation of Drp1-dependent fission is not only a pathological core induced by neurotoxins like MPTP but is also closely related to the collapse of mitochondrial quality control networks caused by gene mutations such as VPS35 and PINK1/Parkin. The lysosomal degradation barrier mediated by mitochondrial-derived vesicles (MDVs) leads to abnormal turnover of Drp1, causing excessive assembly of fission complexes and exacerbating mitochondrial fragmentation; mtDNA leakage caused by defects in the PINK1/Parkin pathway promotes NLRP3 inflammasome assembly through the activation of the cGAS-STING pathway, tightly coupling mitochondrial damage with neuroinflammation. These findings suggest that interventions during the preclinical phase need to balance precise molecular-level regulation with systemic-level network repair: on one hand, in-depth studies on the locking of Drp1 conformations or the regulation of Rab7 activity to restore the spatiotemporal coordination of mitochondrial fission-autophagy; on the other hand, targeting the protection of mtDNA integrity or inhibiting excessive activation of the NLRP3 inflammasome may block the cascade reaction of &#8220;mitochondrial damage-inflammation amplification&#8221; (<xref rid="ref52" ref-type="bibr">Li et al., 2020</xref>). Notably, DJ-1, as a downstream hub of the PINK1/Parkin pathway, may provide a common therapeutic window across mutation types for autosomal recessive PD through functional replacement strategies, such as mitochondrial-targeted optineurin recruitment-enhancing peptides.</p><p>The interaction barrier between mitochondria and lysosomes, along with the pathological interaction of the NLRP3 inflammasome, further expands the intervention dimensions during the preclinical phase of PD. The leakage of CTSB caused by lysosomal membrane permeabilization (LMP) not only directly activates NLRP3 (<xref rid="ref62" ref-type="bibr">Meng et al., 2023</xref>), but also accelerates pathological protein aggregation by inhibiting <italic toggle="yes">&#945;</italic>-synuclein clearance (<xref rid="ref3" ref-type="bibr">Bellomo et al., 2020</xref>). In this context, spatiotemporally specific intervention strategies, such as targeting lysosomal membrane stability (e.g., TRPML1 activators) combined with mTORC1 inhibitors, may restore lysosomal degradation function and inhibit oxidative stress driven by the glycolysis-mitochondrial ROS axis (<xref rid="ref4" ref-type="bibr">Bonam et al., 2019</xref>). Furthermore, the mechanism by which &#945;-syn aggregates activate microglia through the TLR2/NLRP3 dual pathway suggests that immune modulation targeting pathological protein conformations, such as neutralizing antibodies against &#945;-syn oligomers, in combination with inflammatory pathway blockade, may effectively interrupt the self-reinforcing loop of &#8220;protein aggregation-inflammation diffusion&#8221; during the preclinical phase.</p><p>The interaction barrier between mitochondria and lysosomes, along with the pathological interaction of the NLRP3 inflammasome, constitutes a core driving network for the progression of Parkinson&#8217;s disease (<xref rid="ref79" ref-type="bibr">Sarkar et al., 2017</xref>; <xref rid="ref1" ref-type="bibr">Abdelaziz, 2025</xref>). Genetic defects disrupt mitochondrial-lysosomal contact dynamics, bi-directionally disturbing quality control mechanisms: on one hand, the inhibition of mitochondrial fission protein Drp1 function leads to the accumulation of fragmented mitochondria, while impaired autophagic flow promotes mtDNA leakage and ROS bursts; on the other hand, lysosomal enzyme maturation defects weaken the clearance capacity of &#945;-synuclein aggregates, creating a &#8220;seed effect&#8221; of abnormal protein deposition. This dual collapse of metabolism and degradation activates the NLRP3 inflammasome through spatial coupling mechanisms: leaked mtDNA triggers inflammasome assembly via the cGAS-STING pathway, while cathepsin B released from lysosomal membrane permeabilization directly cleaves NLRP3, and &#945;-synuclein fibers drive IL-1&#946; maturation through the TLR2/NLRP3 dual signaling axis, ultimately forming a cascade amplification loop of &#8220;mitochondrial damage-lysosomal collapse-inflammation storm.&#8221; Targeting this pathological network, early diagnosis should establish a multi-dimensional biomarker system: integrating dynamic monitoring of cerebrospinal fluid mtDNA fragment quantification, lysosomal membrane stability indicators, and NLRP3 activation markers, along with &#945;-synuclein oligomer detection and metabolomic feature analysis, can accurately identify the critical point of &#8220;compensation-decompensation&#8221; transition. Intervention strategies should focus on spatiotemporally specific regulation, restoring mitochondrial-lysosomal contact rhythms, and rationally developing and utilizing targeted Drp1 inhibitors and CTSB activators, while simultaneously inhibiting reverse electron transfer in complex I to reduce mtROS production, effectively restoring the interaction mechanisms between mitochondria and lysosomes and preventing further inflammation spread.</p><p>The discovery of lactylation modifications injects a triple regulatory perspective of metabolism-epigenetics-inflammation into the pathological mechanism of PD. The accumulation of lactate caused by mitochondrial dysfunction not only inhibits the transcription of autophagy genes through histone lactylation modifications, leading to the collapse of quality control networks, but also enhances the chromatin accessibility of the NLRP3 promoter, amplifying neuroinflammation. Targeting this mechanism, early diagnosis during the preclinical phase of PD can develop molecular imaging technologies based on dynamic lactate metabolism combined with cerebrospinal fluid lactylation modification marker detection, while integrating assessments of mitochondrial autophagic flow and NLRP3 activation indicators to construct a multi-dimensional early warning system. Intervention strategies should focus on the synergistic regulation of metabolism and epigenetics: designing blood&#8211;brain barrier penetrating nanocarriers loaded with LDHA inhibitors and KAT8 antagonists to target and block the cascade effects of lactylation modifications (<xref rid="ref18" ref-type="bibr">Cheng et al., 2024</xref>); developing spatiotemporally specific gene editing tools to selectively clear lactylation modifications at pro-inflammatory gene loci; and combining targeting mitochondrial homeostasis with the use of NLRP3 inhibitors to break the vicious cycle of &#8220;metabolic compensation-inflammation amplification&#8221;(<xref rid="ref76" ref-type="bibr">Ren et al., 2024</xref>; <xref rid="ref118" ref-type="bibr">Zhu et al., 2025</xref>). These intervention measures need to be validated for their neuroprotective effects in organoid models and gene-edited animals, ultimately achieving a transition from &#8220;pathological blockade&#8221; to &#8220;homeostatic remodeling, &#8220;providing a new paradigm for precision medicine in the preclinical phase of PD.</p><p>In summary, the pathological network during the preclinical phase of PD exhibits characteristics of multi-level, cross-scale interactions, from mitochondrial fragmentation to epigenetic reprogramming of lactylation modifications, from lysosomal collapse to NLRP3 inflammation storms. Each mechanistic node is not isolated but forms a tightly coupled vicious cycle through energy metabolism imbalance and neuroinflammation diffusion. Early diagnosis needs to break through the limitations of single biomarkers and establish a multi-dimensional assessment system integrating morphological compensation markers, metabolic-epigenetic correlation profiles, and interface interaction dynamics parameters; while intervention strategies should focus on the &#8220;fragile nodes&#8221; of the pathological network, achieving the remodeling of quality control networks and reversal of inflammatory microenvironments through spatiotemporally specific drugs and gene-metabolism combined regulation within the compensation threshold. Future research needs to validate the synergistic effects of these strategies in PD preclinical animal models and explore the dynamic associations between cerebrospinal fluid exosomal markers and imaging genomics, thereby opening up new paradigms for pre-diagnosis of motor symptoms and disease-modifying therapies.</p></sec></body><back><fn-group><fn id="fn0001" fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/627215/overview" ext-link-type="uri">Junhui Wang</ext-link>, University of Toronto, Canada</p></fn><fn id="fn0002" fn-type="reviewed-by"><p>Reviewed by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2741325/overview" ext-link-type="uri">Marla Tipping</ext-link>, Providence College, United States; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1824655/overview" ext-link-type="uri">Slawomir Jakiela</ext-link>, Warsaw University of Life Sciences, Poland</p></fn></fn-group><sec sec-type="author-contributions" id="sec7"><title>Author contributions</title><p>PL: Writing &#8211; original draft. XC: Writing &#8211; original draft. SL: Writing &#8211; original draft. YZ: Writing &#8211; original draft. YB: Writing &#8211; review &amp; editing. SW: Writing &#8211; review &amp; editing. YW: Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="sec9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec10"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="sec11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names>A. M.</given-names></name></person-group> (<year>2025</year>). <article-title>Alpha-Synuclein drives NURR1 and NLRP3 Inflammasome dysregulation in Parkinson's disease: from pathogenesis to potential therapeutic strategies</article-title>. <source>Int. Immunopharmacol.</source><volume>156</volume>:<fpage>114692</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2025.114692</pub-id>, PMID: <pub-id pub-id-type="pmid">40267723</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>David</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Newport</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Cadet</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Slikker</surname><given-names>W.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1994</year>). <article-title>MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels</article-title>. <source>Synapse</source><volume>18</volume>, <fpage>27</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1002/syn.890180105</pub-id>, PMID: <pub-id pub-id-type="pmid">7825121</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellomo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paciotti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gatticchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parnetti</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>The vicious cycle between &#945;-synuclein aggregation and autophagic-lysosomal dysfunction</article-title>. <source>Mov. Disord.</source><volume>35</volume>, <fpage>34</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.27895</pub-id>, PMID: <pub-id pub-id-type="pmid">31729779</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Lysosomes as a therapeutic target</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>18</volume>, <fpage>923</fpage>&#8211;<lpage>948</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41573-019-0036-1</pub-id>, PMID: <pub-id pub-id-type="pmid">31477883</pub-id><pub-id pub-id-type="pmcid">PMC7097195</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Del Tredici</surname><given-names>K.</given-names></name><name name-style="western"><surname>R&#252;b</surname><given-names>U.</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Jansen Steur</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Braak</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Staging of brain pathology related to sporadic Parkinson's disease</article-title>. <source>Neurobiol. Aging</source><volume>24</volume>, <fpage>197</fpage>&#8211;<lpage>211</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0197-4580(02)00065-9</pub-id>, PMID: <pub-id pub-id-type="pmid">12498954</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koehl</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Kolitzus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schoenhammer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>LDHA-associated lactic acid production blunts tumor Immunosurveillance by T and NK cells</article-title>. <source>Cell Metab.</source><volume>24</volume>, <fpage>657</fpage>&#8211;<lpage>671</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.011</pub-id>, PMID: <pub-id pub-id-type="pmid">27641098</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oliviero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mazzone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Insola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tonali</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Lazzaro</surname><given-names>V.</given-names></name></person-group> (<year>2001</year>). <article-title>Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease</article-title>. <source>J. Neurosci.</source><volume>21</volume>, <fpage>1033</fpage>&#8211;<lpage>1038</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-03-01033.2001</pub-id>, PMID: <pub-id pub-id-type="pmid">11157088</pub-id><pub-id pub-id-type="pmcid">PMC6762327</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cal&#236;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ottolini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Negro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brini</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>&#945;-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions</article-title>. <source>J. Biol. Chem.</source><volume>287</volume>, <fpage>17914</fpage>&#8211;<lpage>17929</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M111.302794</pub-id>, PMID: <pub-id pub-id-type="pmid">22453917</pub-id><pub-id pub-id-type="pmcid">PMC3365710</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Prag</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>E.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Pro-inflammatory macrophages produce mitochondria-derived superoxide by reverse electron transport at complex I that regulates IL-1&#946; release during NLRP3 inflammasome activation</article-title>. <source>Nat. Metab.</source><volume>7</volume>, <fpage>493</fpage>&#8211;<lpage>507</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s42255-025-01224-x</pub-id>, PMID: <pub-id pub-id-type="pmid">39972217</pub-id><pub-id pub-id-type="pmcid">PMC11946910</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Celardo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Unravelling mitochondrial pathways to Parkinson's disease</article-title>. <source>Br. J. Pharmacol.</source><volume>171</volume>, <fpage>1943</fpage>&#8211;<lpage>1957</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bph.12433</pub-id>, PMID: <pub-id pub-id-type="pmid">24117181</pub-id><pub-id pub-id-type="pmcid">PMC3976614</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Certo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Pucino</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Mauro</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Lactate modulation of immune responses in inflammatory versus tumour microenvironments</article-title>. <source>Nat. Rev. Immunol.</source><volume>21</volume>, <fpage>151</fpage>&#8211;<lpage>161</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-020-0406-2</pub-id>, PMID: <pub-id pub-id-type="pmid">32839570</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>D. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondrial dynamics and its involvement in disease</article-title>. <source>Annu. Rev. Pathol.</source><volume>15</volume>, <fpage>235</fpage>&#8211;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012419-032711</pub-id>, PMID: <pub-id pub-id-type="pmid">31585519</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Metabolic recoding of NSUN2-mediated m5C modification promotes the progression of colorectal cancer via the NSUN2/YBX1/m5C-ENO1 positive feedback loop</article-title>. <source>Adv. Sci.</source><volume>11</volume>:<fpage>e2309840</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202309840</pub-id>, PMID: <pub-id pub-id-type="pmid">38769664</pub-id><pub-id pub-id-type="pmcid">PMC11267267</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y. R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K. H.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Pathomechanism characterization and potential therapeutics identification for Parkinson's disease targeting Neuroinflammation</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>:<fpage>1062</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22031062</pub-id>, PMID: <pub-id pub-id-type="pmid">33494411</pub-id><pub-id pub-id-type="pmcid">PMC7865530</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Mitochondrial dynamics in health and disease: mechanisms and potential targets</article-title>. <source>Signal Transduct. Target. Ther.</source><volume>8</volume>:<fpage>333</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-023-01547-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37669960</pub-id><pub-id pub-id-type="pmcid">PMC10480456</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis</article-title>. <source>Adv. Sci.</source><volume>11</volume>:<fpage>e2406333</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202406333</pub-id>, PMID: <pub-id pub-id-type="pmid">38981044</pub-id><pub-id pub-id-type="pmcid">PMC11481198</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>27-hydroxycholesterol contributes to lysosomal membrane Permeabilization-mediated Pyroptosis in co-cultured SH-SY5Y cells and C6 cells</article-title>. <source>Front. Mol. Neurosci.</source><volume>12</volume>:<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2019.00014</pub-id>, PMID: <pub-id pub-id-type="pmid">30881285</pub-id><pub-id pub-id-type="pmcid">PMC6405519</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z. S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>W. N.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Intrathecal lactate dehydrogenase a inhibitors FX11 and oxamate alleviate chronic constriction injury-induced nociceptive sensitization through neuroinflammation and angiogenesis</article-title>. <source>J. Headache Pain</source><volume>25</volume>:<fpage>207</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s10194-024-01916-x</pub-id>, PMID: <pub-id pub-id-type="pmid">39587478</pub-id><pub-id pub-id-type="pmcid">PMC11590346</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chuang</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>I. L.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J. W.</given-names></name></person-group> (<year>2016</year>). <article-title>Melatonin prevents the dynamin-related protein 1-dependent mitochondrial fission and oxidative insult in the cortical neurons after 1-methyl-4-phenylpyridinium treatment</article-title>. <source>J. Pineal Res.</source><volume>61</volume>, <fpage>230</fpage>&#8211;<lpage>240</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jpi.12343</pub-id>, PMID: <pub-id pub-id-type="pmid">27159033</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Codolo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plotegher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pozzobon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brucale</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tessari</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bubacco</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Triggering of inflammasome by aggregated &#945;-synuclein, an inflammatory response in synucleinopathies</article-title>. <source>PLoS One</source><volume>8</volume>:<fpage>e55375</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0055375</pub-id>, PMID: <pub-id pub-id-type="pmid">23383169</pub-id><pub-id pub-id-type="pmcid">PMC3561263</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z. Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Dynamic profiling and functional interpretation of histone lysine crotonylation and lactylation during neural development</article-title>. <source>Development</source><volume>149</volume>:<fpage>dev200049</fpage>. doi: <pub-id pub-id-type="doi">10.1242/dev.200049</pub-id>, PMID: <pub-id pub-id-type="pmid">35735108</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniele</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>B&#233;raud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maguire-Zeiss</surname><given-names>K. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Activation of MyD88-dependent TLR1/2 signaling by misfolded &#945;-synuclein, a protein linked to neurodegenerative disorders</article-title>. <source>Sci. Signal.</source><volume>8</volume>:<fpage>ra45</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scisignal.2005965</pub-id>, PMID: <pub-id pub-id-type="pmid">25969543</pub-id><pub-id pub-id-type="pmcid">PMC4601639</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Raghavendran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Avadhani</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Anandatheerthavarada</surname><given-names>H. K.</given-names></name></person-group> (<year>2008</year>). <article-title>Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain</article-title>. <source>J. Biol. Chem.</source><volume>283</volume>, <fpage>9089</fpage>&#8211;<lpage>9100</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M710012200</pub-id>, PMID: <pub-id pub-id-type="pmid">18245082</pub-id><pub-id pub-id-type="pmcid">PMC2431021</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dryanovski</surname><given-names>D. I.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Galteri</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Volpicelli-Daley</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V. M. Y.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Calcium entry and &#945;-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons</article-title>. <source>J. Neurosci.</source><volume>33</volume>, <fpage>10154</fpage>&#8211;<lpage>10164</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5311-12.2013</pub-id>, PMID: <pub-id pub-id-type="pmid">23761910</pub-id><pub-id pub-id-type="pmcid">PMC3682382</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duvezin-Caubet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jagasia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wagener</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trifunovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Proteolytic processing of OPA1 links mitochondrial dysfunction to alterations in mitochondrial morphology</article-title>. <source>J. Biol. Chem.</source><volume>281</volume>, <fpage>37972</fpage>&#8211;<lpage>37979</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M606059200</pub-id>, PMID: <pub-id pub-id-type="pmid">17003040</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Systemic activation of NLRP3 inflammasome and plasma &#945;-synuclein levels are correlated with motor severity and progression in Parkinson's disease</article-title>. <source>J. Neuroinflammation</source><volume>17</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-019-1670-6</pub-id>, PMID: <pub-id pub-id-type="pmid">31915018</pub-id><pub-id pub-id-type="pmcid">PMC6950934</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>LDHA exacerbates myocardial ischemia-reperfusion injury through inducing NLRP3 lactylation</article-title>. <source>BMC Cardiovasc. Disord.</source><volume>24</volume>:<fpage>651</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12872-024-04251-w</pub-id>, PMID: <pub-id pub-id-type="pmid">39548367</pub-id><pub-id pub-id-type="pmcid">PMC11568565</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>Structural mechanisms of NLRP3 Inflammasome assembly and activation</article-title>. <source>Annu. Rev. Immunol.</source><volume>41</volume>, <fpage>301</fpage>&#8211;<lpage>316</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-immunol-081022-021207</pub-id>, PMID: <pub-id pub-id-type="pmid">36750315</pub-id><pub-id pub-id-type="pmcid">PMC10159982</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Su</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>). <article-title>Abnormalities of mitochondrial dynamics in neurodegenerative diseases</article-title>. <source>Antioxidants</source><volume>6</volume>:<fpage>25</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antiox6020025</pub-id>, PMID: <pub-id pub-id-type="pmid">28379197</pub-id><pub-id pub-id-type="pmcid">PMC5488005</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Ultraviolet-treated riboflavin alleviates atopic dermatitis by inhibiting NLRP3 inflammasome activation and M1 macrophage polarization via histone lactylation</article-title>. <source>Biochem. Pharmacol.</source><volume>236</volume>:<fpage>116879</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2025.116879</pub-id>, PMID: <pub-id pub-id-type="pmid">40118287</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gegg</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schapira</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Taanman</surname><given-names>J. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy [published correction appears in hum Mol genet. 2013 Apr 15; 22(8): 1697]</article-title>. <source>Hum. Mol. Genet.</source><volume>19</volume>, <fpage>4861</fpage>&#8211;<lpage>4870</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddq419</pub-id>, PMID: <pub-id pub-id-type="pmid">20871098</pub-id><pub-id pub-id-type="pmcid">PMC3583518</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Rodr&#237;guez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zampese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Ilijic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Disruption of mitochondrial complex I induces progressive parkinsonism</article-title>. <source>Nature</source><volume>599</volume>, <fpage>650</fpage>&#8211;<lpage>656</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-021-04059-0</pub-id>, PMID: <pub-id pub-id-type="pmid">34732887</pub-id><pub-id pub-id-type="pmcid">PMC9189968</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Albornoz</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Inflammasome inhibition prevents &#945;-synuclein pathology and dopaminergic neurodegeneration in mice</article-title>. <source>Sci. Transl. Med.</source><volume>10</volume>:<fpage>eaah 4066</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aah4066</pub-id>, PMID: <pub-id pub-id-type="pmid">30381407</pub-id><pub-id pub-id-type="pmcid">PMC6483075</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guardia-Laguarta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Area-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>R&#252;b</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Magran&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>&#945;-Synuclein is localized to mitochondria-associated ER membranes</article-title>. <source>J. Neurosci.</source><volume>34</volume>, <fpage>249</fpage>&#8211;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2507-13.2014</pub-id>, PMID: <pub-id pub-id-type="pmid">24381286</pub-id><pub-id pub-id-type="pmcid">PMC3866487</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagihara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shoji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Otabi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Namihira</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Protein lactylation induced by neural excitation</article-title>. <source>Cell Rep.</source><volume>37</volume>:<fpage>109820</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109820</pub-id>, PMID: <pub-id pub-id-type="pmid">34644564</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornung</surname><given-names>V.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Reinheckel</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>The NALP3 inflammasome is involved in the innate immune response to amyloid-beta</article-title>. <source>Nat. Immunol.</source><volume>9</volume>, <fpage>857</fpage>&#8211;<lpage>865</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ni.1636</pub-id>, PMID: <pub-id pub-id-type="pmid">18604209</pub-id><pub-id pub-id-type="pmcid">PMC3101478</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y. T.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric &#945;-synuclein through NF-&#954;B pathway</article-title>. <source>iScience</source><volume>26</volume>:<fpage>108130</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.isci.2023.108130</pub-id>, PMID: <pub-id pub-id-type="pmid">37876795</pub-id><pub-id pub-id-type="pmcid">PMC10590863</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holley</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>The rOX-stars of inflammation: links between the inflammasome and mitochondrial meltdown</article-title>. <source>Clin. Transl. Immunol.</source><volume>9</volume>:<fpage>e01109</fpage>. doi: <pub-id pub-id-type="doi">10.1002/cti2.1109</pub-id>, PMID: <pub-id pub-id-type="pmid">32055400</pub-id><pub-id pub-id-type="pmcid">PMC7008497</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imberechts</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kinnart</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>F.</given-names></name><name name-style="western"><surname>Terbeek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manders</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wierda</surname><given-names>K.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy</article-title>. <source>Brain</source><volume>145</volume>, <fpage>4368</fpage>&#8211;<lpage>4384</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awac313</pub-id>, PMID: <pub-id pub-id-type="pmid">36039535</pub-id><pub-id pub-id-type="pmcid">PMC9762950</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imberechts</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vandenberghe</surname><given-names>W.</given-names></name></person-group> (<year>2023</year>). <article-title>Defects in PINK-PRKN-PARK7/DJ-1-dependent mitophagy and autosomal recessive Parkinson disease</article-title>. <source>Autophagy</source><volume>19</volume>, <fpage>1872</fpage>&#8211;<lpage>1873</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15548627.2022.2139129</pub-id>, PMID: <pub-id pub-id-type="pmid">36282786</pub-id><pub-id pub-id-type="pmcid">PMC10262757</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thangavel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Selvakumar</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Dubova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M. E.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease</article-title>. <source>Int. Immunopharmacol.</source><volume>83</volume>:<fpage>106441</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106441</pub-id>, PMID: <pub-id pub-id-type="pmid">32259702</pub-id><pub-id pub-id-type="pmcid">PMC7255416</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2025</year>). <article-title>Serine-129 phosphorylated &#945;-synuclein drives mitochondrial dysfunction and calcium dysregulation in Parkinson's disease model</article-title>. <source>Front. Aging Neurosci.</source><volume>17</volume>:<fpage>1538166</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnagi.2025.1538166</pub-id>, PMID: <pub-id pub-id-type="pmid">40230488</pub-id><pub-id pub-id-type="pmcid">PMC11994663</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jimenez-Orgaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kvainickas</surname><given-names>A.</given-names></name><name name-style="western"><surname>N&#228;gele</surname><given-names>H.</given-names></name><name name-style="western"><surname>Denner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eimer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dengjel</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Control of RAB7 activity and localization through the retromer-TBC1D5 complex enables RAB7-dependent mitophagy</article-title>. <source>EMBO J.</source><volume>37</volume>, <fpage>235</fpage>&#8211;<lpage>254</lpage>. doi: <pub-id pub-id-type="doi">10.15252/embj.201797128</pub-id>, PMID: <pub-id pub-id-type="pmid">29158324</pub-id><pub-id pub-id-type="pmcid">PMC5770787</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones-Tabah</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karpilovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Senkevich</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deyab</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pietrantonio</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The Parkinson's disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons [published correction appears in Mol Neurodegener. 2024 18;19(1):94. doi: 10.1186/s13024-024-00791-z]</article-title>. <source>Mol. Neurodegener.</source><volume>19</volume>:<fpage>88</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-024-00779-9</pub-id>, PMID: <pub-id pub-id-type="pmid">39587654</pub-id><pub-id pub-id-type="pmcid">PMC11587650</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krainc</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease</article-title>. <source>Nat. Commun.</source><volume>12</volume>:<fpage>1807</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-22113-3</pub-id>, PMID: <pub-id pub-id-type="pmid">33753743</pub-id><pub-id pub-id-type="pmcid">PMC7985376</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name></person-group> (<year>2025</year>). <article-title>The lactate metabolism and protein lactylation in epilepsy</article-title>. <source>Front. Cell. Neurosci.</source><volume>18</volume>:<fpage>1464169</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2024.1464169</pub-id>, PMID: <pub-id pub-id-type="pmid">39876842</pub-id><pub-id pub-id-type="pmcid">PMC11772370</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Brundin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wesson</surname><given-names>D. W.</given-names></name></person-group> (<year>2022</year>). <article-title>Linking &#945;-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease</article-title>. <source>Brain Commun.</source><volume>4</volume>:<fpage>fcac165</fpage>. doi: <pub-id pub-id-type="doi">10.1093/braincomms/fcac165</pub-id>, PMID: <pub-id pub-id-type="pmid">35822101</pub-id><pub-id pub-id-type="pmcid">PMC9272065</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamkanfi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>V. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Mechanisms and functions of inflammasomes</article-title>. <source>Cell</source><volume>157</volume>, <fpage>1013</fpage>&#8211;<lpage>1022</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2014.04.007</pub-id>, PMID: <pub-id pub-id-type="pmid">24855941</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration</article-title>. <source>Cell Death Differ.</source><volume>26</volume>, <fpage>213</fpage>&#8211;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41418-018-0124-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29786072</pub-id><pub-id pub-id-type="pmcid">PMC6329843</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>The myriad roles of Miro in the nervous system: axonal transport of mitochondria and beyond</article-title>. <source>Front. Cell. Neurosci.</source><volume>8</volume>:<fpage>330</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2014.00330</pub-id><pub-id pub-id-type="pmid">25389385</pub-id><pub-id pub-id-type="pmcid">PMC4211407</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I. Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>IL-6/JAK2/STAT3 axis mediates neuropathic pain by regulating astrocyte and microglia activation after spinal cord injury</article-title>. <source>Exp. Neurol.</source><volume>370</volume>:<fpage>114576</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.expneurol.2023.114576</pub-id>, PMID: <pub-id pub-id-type="pmid">37863306</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mastaglia</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>S. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era</article-title>. <source>Med. Res. Rev.</source><volume>40</volume>, <fpage>2650</fpage>&#8211;<lpage>2681</lpage>. doi: <pub-id pub-id-type="doi">10.1002/med.21718</pub-id>, PMID: <pub-id pub-id-type="pmid">32767426</pub-id><pub-id pub-id-type="pmcid">PMC7589267</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X. F.</given-names></name></person-group> (<year>2024</year>). <article-title>LncRNA KCNQ1OT1 promotes NLRP3 inflammasome activation in Parkinson's disease by regulating pri-mi R-186/mature miR-186/NLRP3 axis</article-title>. <source>Biochim. Biophys. Acta Mol. basis Dis.</source><volume>1870</volume>:<fpage>167454</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbadis.2024.167454</pub-id>, PMID: <pub-id pub-id-type="pmid">39122224</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Glycometabolic reprogramming-induced XRCC1 lactylation confers therapeutic resistance in ALDH1A3-overexpressing glioblastoma</article-title>. <source>Cell Metab.</source><volume>36</volume>, <fpage>1696</fpage>&#8211;<lpage>1710.e10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2024.07.011</pub-id>, PMID: <pub-id pub-id-type="pmid">39111285</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Najor</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Quiles</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Mitochondria are secreted in extracellular vesicles when lysosomal function is impaired</article-title>. <source>Nat. Commun.</source><volume>14</volume>:<fpage>5031</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-023-40680-5</pub-id>, PMID: <pub-id pub-id-type="pmid">37596294</pub-id><pub-id pub-id-type="pmcid">PMC10439183</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Beal</surname><given-names>M. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title>. <source>Nature</source><volume>443</volume>, <fpage>787</fpage>&#8211;<lpage>795</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature05292</pub-id>, PMID: <pub-id pub-id-type="pmid">17051205</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Silverio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alapatt</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria</article-title>. <source>PLoS Genet.</source><volume>8</volume>:<fpage>e1002537</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1002537</pub-id>, PMID: <pub-id pub-id-type="pmid">22396657</pub-id><pub-id pub-id-type="pmcid">PMC3291531</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Potential role of mitochondria-associated endoplasmic reticulum membrane proteins in diseases</article-title>. <source>Biochem. Pharmacol.</source><volume>199</volume>:<fpage>115011</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2022.115011</pub-id>, PMID: <pub-id pub-id-type="pmid">35314166</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Hypoxia induces mitochondrial protein lactylation to limit oxidative phosphorylation</article-title>. <source>Cell Res.</source><volume>34</volume>, <fpage>13</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41422-023-00864-6</pub-id>, PMID: <pub-id pub-id-type="pmid">38163844</pub-id><pub-id pub-id-type="pmcid">PMC10770133</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro IL-beta</article-title>. <source>Mol. Cell</source><volume>10</volume>, <fpage>417</fpage>&#8211;<lpage>426</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1097-2765(02)00599-3</pub-id>, PMID: <pub-id pub-id-type="pmid">12191486</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCoy</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Cookson</surname><given-names>M. R.</given-names></name></person-group> (<year>2011</year>). <article-title>DJ-1 regulation of mitochondrial function and autophagy through oxidative stress</article-title>. <source>Autophagy</source><volume>7</volume>, <fpage>531</fpage>&#8211;<lpage>532</lpage>. doi: <pub-id pub-id-type="doi">10.4161/auto.7.5.14684</pub-id>, PMID: <pub-id pub-id-type="pmid">21317550</pub-id><pub-id pub-id-type="pmcid">PMC3127213</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Apigenin alleviated high-fat-diet-induced hepatic Pyroptosis by Mitophagy-ROS-CTSB-NLRP3 pathway in mice and AML12 cells</article-title>. <source>J. Agric. Food Chem.</source><volume>71</volume>, <fpage>7032</fpage>&#8211;<lpage>7045</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jafc.2c07581</pub-id>, PMID: <pub-id pub-id-type="pmid">37141464</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vitali</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Raikes</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration</article-title>. <source>Nat. Metab.</source><volume>5</volume>, <fpage>445</fpage>&#8211;<lpage>465</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s42255-023-00756-4</pub-id>, PMID: <pub-id pub-id-type="pmid">36959514</pub-id><pub-id pub-id-type="pmcid">PMC10202034</pub-id></mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group> (<year>2023</year>). <article-title>Hypoxia induced &#946;-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway</article-title>. <source>Exp. Cell Res.</source><volume>422</volume>:<fpage>113439</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113439</pub-id>, PMID: <pub-id pub-id-type="pmid">36464122</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Mahapatra</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Behera</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhol</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Panigrahi</surname><given-names>D. P.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Mitochondrial dysfunction as a driver of NLRP3 inflammasome activation and its modulation through mitophagy for potential therapeutics</article-title>. <source>Int. J. Biochem. Cell Biol.</source><volume>136</volume>:<fpage>106013</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biocel.2021.106013</pub-id>, PMID: <pub-id pub-id-type="pmid">34022434</pub-id></mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moors</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Morella</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Bertran-Cobo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geut</surname><given-names>H.</given-names></name><name name-style="western"><surname>Udayar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Timmermans-Huisman</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases</article-title>. <source>Acta Neuropathol.</source><volume>147</volume>:<fpage>67</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-024-02707-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38581586</pub-id><pub-id pub-id-type="pmcid">PMC10998821</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouton-Liger</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rosazza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sepulveda-Diaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ieang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hassoun</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Claire</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop</article-title>. <source>Glia</source><volume>66</volume>, <fpage>1736</fpage>&#8211;<lpage>1751</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.23337</pub-id>, PMID: <pub-id pub-id-type="pmid">29665074</pub-id><pub-id pub-id-type="pmcid">PMC6190839</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narendra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Youle</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondrial quality control mediated by PINK1 and parkin: links to parkinsonism</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source><volume>4</volume>:<fpage>a011338</fpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a011338</pub-id>, PMID: <pub-id pub-id-type="pmid">23125018</pub-id><pub-id pub-id-type="pmcid">PMC3536340</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease</article-title>. <source>Cell Metab.</source><volume>34</volume>, <fpage>634</fpage>&#8211;<lpage>648.e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2022.02.013</pub-id>, PMID: <pub-id pub-id-type="pmid">35303422</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pena</surname><given-names>N.</given-names></name><name name-style="western"><surname>Richbourg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gonzalez-Hunt</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wren</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barlow</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage</article-title>. <source>NPJ Parkinsons Dis.</source><volume>10</volume>:<fpage>49</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41531-024-00660-y</pub-id>, PMID: <pub-id pub-id-type="pmid">38429321</pub-id><pub-id pub-id-type="pmcid">PMC10907374</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Krainc</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondria-lysosome contacts regulate mitochondrial Ca2+ dynamics via lysosomal TRPML1</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>117</volume>, <fpage>19266</fpage>&#8211;<lpage>19275</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2003236117</pub-id>, PMID: <pub-id pub-id-type="pmid">32703809</pub-id><pub-id pub-id-type="pmcid">PMC7430993</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prieto Huarcaya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drobny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>A. R. A.</given-names></name><name name-style="western"><surname>di Spiezio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dobert</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Balta</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Recombinant pro-CTSD (cathepsin D) enhances SNCA/&#945;-Synuclein degradation in &#945;-Synucleinopathy models</article-title>. <source>Autophagy</source><volume>18</volume>, <fpage>1127</fpage>&#8211;<lpage>1151</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15548627.2022.2045534</pub-id>, PMID: <pub-id pub-id-type="pmid">35287553</pub-id><pub-id pub-id-type="pmcid">PMC9196656</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintana-Cabrera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scorrano</surname><given-names>L.</given-names></name></person-group> (<year>2023</year>). <article-title>Determinants and outcomes of mitochondrial dynamics</article-title>. <source>Mol. Cell</source><volume>83</volume>, <fpage>857</fpage>&#8211;<lpage>876</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2023.02.012</pub-id>, PMID: <pub-id pub-id-type="pmid">36889315</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>A. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Emerging concepts of mitochondrial dysfunction in Parkinson's disease progression: pathogenic and therapeutic implications</article-title>. <source>Mitochondrion</source><volume>50</volume>, <fpage>25</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mito.2019.09.010</pub-id>, PMID: <pub-id pub-id-type="pmid">31654753</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeve</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Grady</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Cosgrave</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Bennison</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hepplewhite</surname><given-names>P. D.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis.</source><volume>4</volume>:<fpage>9</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41531-018-0044-6</pub-id>, PMID: <pub-id pub-id-type="pmid">29872690</pub-id><pub-id pub-id-type="pmcid">PMC5979968</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren&#233;</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>G.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Kaixinsan regulates neuronal mitochondrial homeostasis to improve the cognitive function of Alzheimer's disease by activating CaMKK&#946;-AMPK-PGC-1&#945; signaling axis</article-title>. <source>Phytomedicine</source><volume>135</volume>:<fpage>156170</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phymed.2024.156170</pub-id>, PMID: <pub-id pub-id-type="pmid">39520951</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rocha</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>De Miranda</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>L. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease</article-title>. <source>Neurobiol. Dis.</source><volume>109</volume>, <fpage>249</fpage>&#8211;<lpage>257</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2017.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">28400134</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Esteves</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Janu&#225;rio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>The impact of mitochondrial fusion and fission modulation in sporadic Parkinson's disease</article-title>. <source>Mol. Neurobiol.</source><volume>52</volume>, <fpage>573</fpage>&#8211;<lpage>586</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-014-8893-4</pub-id>, PMID: <pub-id pub-id-type="pmid">25218511</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malovic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harishchandra</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Ghaisas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Panicker</surname><given-names>N.</given-names></name><name name-style="western"><surname>Charli</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis.</source><volume>3</volume>:<fpage>30</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41531-017-0032-2</pub-id>, PMID: <pub-id pub-id-type="pmid">29057315</pub-id><pub-id pub-id-type="pmcid">PMC5645400</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schapira</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Dexter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Jenner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>C. D.</given-names></name></person-group> (<year>1990</year>). <article-title>Mitochondrial complex I deficiency in Parkinson's disease</article-title>. <source>J. Neurochem.</source><volume>54</volume>, <fpage>823</fpage>&#8211;<lpage>827</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb02325.x</pub-id>, PMID: <pub-id pub-id-type="pmid">2154550</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheiblich</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dansokho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mercan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Bousset</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wischhof</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes</article-title>. <source>Cell</source><volume>184</volume>, <fpage>5089</fpage>&#8211;<lpage>5106.e21</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2021.09.007</pub-id>, PMID: <pub-id pub-id-type="pmid">34555357</pub-id><pub-id pub-id-type="pmcid">PMC8527836</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaltouki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2018</year>). <article-title>Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models</article-title>. <source>Acta Neuropathol.</source><volume>136</volume>, <fpage>607</fpage>&#8211;<lpage>620</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00401-018-1873-4</pub-id>, PMID: <pub-id pub-id-type="pmid">29923074</pub-id><pub-id pub-id-type="pmcid">PMC6123262</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q. L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Divanillyl sulfone suppresses NLRP3 inflammasome activation via inducing mitophagy to ameliorate chronic neuropathic pain in mice</article-title>. <source>J. Neuroinflammation</source><volume>18</volume>:<fpage>142</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-021-02178-z</pub-id>, PMID: <pub-id pub-id-type="pmid">34162415</pub-id><pub-id pub-id-type="pmcid">PMC8223331</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shlevkov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schapansky</surname><given-names>J.</given-names></name><name name-style="western"><surname>LaVoie</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>T. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Miro phosphorylation sites regulate parkin recruitment and mitochondrial motility</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>113</volume>, <fpage>E6097</fpage>&#8211;<lpage>E6106</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1612283113</pub-id>, PMID: <pub-id pub-id-type="pmid">27679849</pub-id><pub-id pub-id-type="pmcid">PMC5068282</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sironi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Restelli</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Tolnay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neutzner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Dysregulated Interorganellar crosstalk of mitochondria in the pathogenesis of Parkinson's disease</article-title>. <source>Cells</source><volume>9</volume>:<fpage>233</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells9010233</pub-id>, PMID: <pub-id pub-id-type="pmid">31963435</pub-id><pub-id pub-id-type="pmcid">PMC7016713</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y. C.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name></person-group> (<year>2013</year>). <article-title>Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation</article-title>. <source>Hum. Mol. Genet.</source><volume>22</volume>, <fpage>4545</fpage>&#8211;<lpage>4561</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddt301</pub-id>, PMID: <pub-id pub-id-type="pmid">23813973</pub-id></mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramaniam</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Chesselet</surname><given-names>M. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Mitochondrial dysfunction and oxidative stress in Parkinson's disease</article-title>. <source>Prog. Neurobiol.</source><volume>106-107</volume>, <fpage>17</fpage>&#8211;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">23643800</pub-id><pub-id pub-id-type="pmcid">PMC3742021</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed &#945;-tubulin lactylation</article-title>. <source>Nat. Commun.</source><volume>15</volume>:<fpage>8377</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-024-52729-0</pub-id><pub-id pub-id-type="pmid">39333081</pub-id><pub-id pub-id-type="pmcid">PMC11437170</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>MeCP2 Lactylation protects against ischemic brain injury by transcriptionally regulating neuronal apoptosis</article-title>. <source>Adv. Sci.</source><volume>12</volume>:<fpage>2415309</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202415309</pub-id><pub-id pub-id-type="pmcid">PMC12140320</pub-id><pub-id pub-id-type="pmid">40271828</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>K. V.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J. P.</given-names></name></person-group> (<year>2019</year>). <article-title>The NLRP3 inflammasome: molecular activation and regulation to therapeutics</article-title>. <source>Nat. Rev. Immunol.</source><volume>19</volume>, <fpage>477</fpage>&#8211;<lpage>489</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41577-019-0165-0</pub-id>, PMID: <pub-id pub-id-type="pmid">31036962</pub-id><pub-id pub-id-type="pmcid">PMC7807242</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tantra</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rahaman</surname><given-names>T. A. A.</given-names></name><name name-style="western"><surname>Nandini</surname></name><name name-style="western"><surname>Chaudhary</surname><given-names>S.</given-names></name></person-group> (<year>2024</year>). <article-title>Therapeutic role of NLRP3 inflammasome inhibitors against Alzheimer's disease</article-title>. <source>Bioorg. Chem.</source><volume>153</volume>:<fpage>107912</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bioorg.2024.107912</pub-id>, PMID: <pub-id pub-id-type="pmid">39504636</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Blackinton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beilina</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Brug</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sandebring</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy</article-title>. <source>Hum. Mol. Genet.</source><volume>20</volume>, <fpage>40</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddq430</pub-id>, PMID: <pub-id pub-id-type="pmid">20940149</pub-id><pub-id pub-id-type="pmcid">PMC3000675</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gangwar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Understanding the neuronal synapse and challenges associated with the mitochondrial dysfunction in mild cognitive impairment and Alzheimer's disease</article-title>. <source>Mitochondrion</source><volume>73</volume>, <fpage>19</fpage>&#8211;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mito.2023.09.003</pub-id>, PMID: <pub-id pub-id-type="pmid">37708950</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miu</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W. Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Outlook of PINK1/parkin signaling in molecular etiology of Parkinson's disease, with insights into Pink1 knockout models</article-title>. <source>Zool. Res.</source><volume>44</volume>, <fpage>559</fpage>&#8211;<lpage>576</lpage>. doi: <pub-id pub-id-type="doi">10.24272/j.issn.2095-8137.2022.406</pub-id>, PMID: <pub-id pub-id-type="pmid">37161651</pub-id><pub-id pub-id-type="pmcid">PMC10236303</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Walston</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>S. X.</given-names></name></person-group> (<year>2019</year>). <article-title>Interferon-&#947; potentiates &#945;-Synuclein-induced neurotoxicity linked to toll-like receptors 2 and 3 and tumor necrosis factor-&#945; in murine astrocytes</article-title>. <source>Mol. Neurobiol.</source><volume>56</volume>, <fpage>7664</fpage>&#8211;<lpage>7679</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-019-1567-5</pub-id>, PMID: <pub-id pub-id-type="pmid">31098954</pub-id><pub-id pub-id-type="pmcid">PMC7404632</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer</article-title>. <source>Cell Death Differ.</source><volume>31</volume>, <fpage>779</fpage>&#8211;<lpage>791</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41418-024-01295-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38654072</pub-id><pub-id pub-id-type="pmcid">PMC11164927</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Castellani</surname><given-names>R. J.</given-names></name><etal/></person-group>. (<year>2011a</year>). <article-title>DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease</article-title>. <source>Aging Cell</source><volume>10</volume>, <fpage>807</fpage>&#8211;<lpage>823</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1474-9726.2011.00721.x</pub-id>, PMID: <pub-id pub-id-type="pmid">21615675</pub-id><pub-id pub-id-type="pmcid">PMC3173562</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ashrafi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schlehe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>D.</given-names></name><etal/></person-group>. (<year>2011b</year>). <article-title>PINK1 and parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility</article-title>. <source>Cell</source><volume>147</volume>, <fpage>893</fpage>&#8211;<lpage>906</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2011.10.018</pub-id>, PMID: <pub-id pub-id-type="pmid">22078885</pub-id><pub-id pub-id-type="pmcid">PMC3261796</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>H4K12 lactylation-regulated NLRP3 is involved in cigarette smoke-accelerated Alzheimer-like pathology through mTOR-regulated autophagy and activation of microglia</article-title>. <source>J. Hazard. Mater.</source><volume>488</volume>:<fpage>137310</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhazmat.2025.137310</pub-id>, PMID: <pub-id pub-id-type="pmid">39862777</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Han</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Novel strategies targeting mitochondria-lysosome contact sites for the treatment of neurological diseases</article-title>. <source>Front. Mol. Neurosci.</source><volume>17</volume>:<fpage>1527013</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2024.1527013</pub-id>, PMID: <pub-id pub-id-type="pmid">39877141</pub-id><pub-id pub-id-type="pmcid">PMC11772484</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>Y. Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z. H.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>N. J.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease</article-title>. <source>Aging Cell</source><volume>22</volume>:<fpage>e13834</fpage>. doi: <pub-id pub-id-type="doi">10.1111/acel.13834</pub-id>, PMID: <pub-id pub-id-type="pmid">37029500</pub-id><pub-id pub-id-type="pmcid">PMC10265164</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis</article-title>. <source>Cell Death Differ.</source><volume>29</volume>, <fpage>133</fpage>&#8211;<lpage>146</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41418-021-00841-9</pub-id>, PMID: <pub-id pub-id-type="pmid">34363018</pub-id><pub-id pub-id-type="pmcid">PMC8738735</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Diverse epigenetic regulations of macrophages in atherosclerosis</article-title>. <source>Front. Cardiovasc. Med.</source><volume>9</volume>:<fpage>868788</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcvm.2022.868788</pub-id>, PMID: <pub-id pub-id-type="pmid">35425818</pub-id><pub-id pub-id-type="pmcid">PMC9001883</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Squamosamide derivative FLZ diminishes aberrant mitochondrial fission by inhibiting dynamin-related protein 1</article-title>. <source>Front. Pharmacol.</source><volume>12</volume>:<fpage>588003</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2021.588003</pub-id>, PMID: <pub-id pub-id-type="pmid">33815098</pub-id><pub-id pub-id-type="pmcid">PMC8017221</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bade</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Global-scale profiling of differential expressed lysine-Lactylated proteins in the cerebral endothelium of cerebral ischemia-reperfusion injury rats</article-title>. <source>Cell. Mol. Neurobiol.</source><volume>43</volume>, <fpage>1989</fpage>&#8211;<lpage>2004</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10571-022-01277-6</pub-id>, PMID: <pub-id pub-id-type="pmid">36030297</pub-id><pub-id pub-id-type="pmcid">PMC11412193</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Glycolytic reprogramming governs crystalline silica-induced pyroptosis and inflammation through promoting lactylation modification</article-title>. <source>Ecotoxicol. Environ. Saf.</source><volume>283</volume>:<fpage>116952</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ecoenv.2024.116952</pub-id>, PMID: <pub-id pub-id-type="pmid">39217895</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Mitochondrial DAMPs: key mediators in neuroinflammation and neurodegenerative disease pathogenesis</article-title>. <source>Neuropharmacology</source><volume>264</volume>:<fpage>110217</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2024.110217</pub-id>, PMID: <pub-id pub-id-type="pmid">39557152</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Role of NLRP3 in Parkinson's disease: specific activation especially in dopaminergic neurons</article-title>. <source>Heliyon</source><volume>10</volume>:<fpage>e28838</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e28838</pub-id>, PMID: <pub-id pub-id-type="pmid">38596076</pub-id><pub-id pub-id-type="pmcid">PMC11002585</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>The lactate-primed KAT8&#8211;PCK2 Axis exacerbates hepatic Ferroptosis during ischemia/reperfusion injury by reprogramming OXSM-dependent mitochondrial fatty acid synthesis</article-title>. <source>Adv. Sci.</source><volume>12</volume>:<fpage>e2414141</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202414141</pub-id>, PMID: <pub-id pub-id-type="pmid">39853940</pub-id><pub-id pub-id-type="pmcid">PMC11923996</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp 1-mediated aberrant mitochondrial fission in Parkinson's disease</article-title>. <source>Exp. Mol. Med.</source><volume>51</volume>, <fpage>1</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s12276-019-0318-z</pub-id>, PMID: <pub-id pub-id-type="pmid">31578315</pub-id><pub-id pub-id-type="pmcid">PMC6802738</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S. Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>NLRP3 Inflammasome: a key contributor to the inflammation formation</article-title>. <source>Food Chem. Toxicol.</source><volume>174</volume>:<fpage>113683</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.fct.2023.113683</pub-id>, PMID: <pub-id pub-id-type="pmid">36809826</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Metabolic regulation of gene expression by histone lactylation</article-title>. <source>Nature</source><volume>574</volume>, <fpage>575</fpage>&#8211;<lpage>580</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-019-1678-1</pub-id>, PMID: <pub-id pub-id-type="pmid">31645732</pub-id><pub-id pub-id-type="pmcid">PMC6818755</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>H3K18 Lactylation potentiates immune escape of non-small cell lung cancer</article-title>. <source>Cancer Res.</source><volume>84</volume>, <fpage>3589</fpage>&#8211;<lpage>3601</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-23-3513</pub-id>, PMID: <pub-id pub-id-type="pmid">39137401</pub-id></mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name></person-group> (<year>2025</year>). <article-title>Lactylation in health and disease: physiological or pathological?</article-title><source>Theranostics</source><volume>15</volume>, <fpage>1787</fpage>&#8211;<lpage>1821</lpage>. <comment>Published 2025 Jan 2</comment>. doi: <pub-id pub-id-type="doi">10.7150/thno.105353</pub-id>, PMID: <pub-id pub-id-type="pmid">39897556</pub-id><pub-id pub-id-type="pmcid">PMC11780532</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group> (<year>2024</year>). <article-title>Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell-specific molecule 1 expression</article-title>. <source>Mol. Carcinog.</source><volume>63</volume>, <fpage>2078</fpage>&#8211;<lpage>2089</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mc.23794</pub-id>, PMID: <pub-id pub-id-type="pmid">39016629</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Necroptosis inhibitors: mechanisms of action and therapeutic potential</article-title>. <source>Apoptosis</source><volume>29</volume>, <fpage>22</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10495-023-01905-6</pub-id>, PMID: <pub-id pub-id-type="pmid">38001341</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yazdi</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Menu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tschopp</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>A role for mitochondria in NLRP3 inflammasome activation [published correction appears in nature. 2011 7; 475 (7354): 122]</article-title>. <source>Nature</source><volume>469</volume>, <fpage>221</fpage>&#8211;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature09663</pub-id>, PMID: <pub-id pub-id-type="pmid">21124315</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>R. X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>R. X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Inactivation of NLRP3 inflammasome by dephosphorylation at serine 658 alleviates glial inflammation in the mouse model of Parkinson's disease</article-title>. <source>Mol. Neurodegener.</source><volume>20</volume>:<fpage>27</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-025-00818-z</pub-id>, PMID: <pub-id pub-id-type="pmid">40038816</pub-id><pub-id pub-id-type="pmcid">PMC11881452</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name></person-group> (<year>2013</year>). <article-title>ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression</article-title>. <source>Protein Cell</source><volume>4</volume>, <fpage>711</fpage>&#8211;<lpage>721</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s13238-013-3910-3</pub-id>, PMID: <pub-id pub-id-type="pmid">27023913</pub-id><pub-id pub-id-type="pmcid">PMC4875534</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-id journal-id-type="pmc-domain-id">2814</journal-id><journal-id journal-id-type="pmc-domain">apsb</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491689</article-id><article-id pub-id-type="pmcid-ver">PMC12491689.1</article-id><article-id pub-id-type="pmcaid">12491689</article-id><article-id pub-id-type="pmcaiid">12491689</article-id><article-id pub-id-type="pmid">41049735</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2025.04.026</article-id><article-id pub-id-type="pii">S2211-3835(25)00288-6</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Artificial intelligence in drug development for delirium and Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Ai</surname><given-names initials="R">Ruixue</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Xiao</surname><given-names initials="X">Xianglu</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Deng</surname><given-names initials="S">Shenglong</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">&#8224;</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Yang</surname><given-names initials="N">Nan</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Xing</surname><given-names initials="X">Xiaodan</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Watne</surname><given-names initials="LO">Leiv Otto</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Selb&#230;k</surname><given-names initials="G">Geir</given-names></name><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff8" ref-type="aff">h</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Wedatilake</surname><given-names initials="Y">Yehani</given-names></name><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Xie</surname><given-names initials="C">Chenglong</given-names></name><xref rid="aff10" ref-type="aff">j</xref><xref rid="aff11" ref-type="aff">k</xref><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Rubinsztein</surname><given-names initials="DC">David C.</given-names></name><xref rid="aff13" ref-type="aff">m</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Palmer</surname><given-names initials="JE">Jennifer E.</given-names></name><xref rid="aff13" ref-type="aff">m</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Neerland</surname><given-names initials="BE">Bj&#248;rn Erik</given-names></name><xref rid="aff9" ref-type="aff">i</xref><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Chen</surname><given-names initials="H">Hongming</given-names></name><xref rid="aff16" ref-type="aff">p</xref><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Niu</surname><given-names initials="Z">Zhangming</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Yang</surname><given-names initials="G">Guang</given-names></name><email>g.yang@imperial.ac.uk</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff18" ref-type="aff">r</xref><xref rid="aff19" ref-type="aff">s</xref><xref rid="aff20" ref-type="aff">t</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Fang</surname><given-names initials="EF">Evandro Fei</given-names></name><email>e.f.fang@medisin.uio.no</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff21" ref-type="aff">u</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, L&#248;renskog 1478, Norway</aff><aff id="aff2"><label>b</label>Bioengineering Department and Imperial-X, Imperial College London, London W12 7SL, UK</aff><aff id="aff3"><label>c</label>Mindrank AI Ltd., Hangzhou 310018, China</aff><aff id="aff4"><label>d</label>AI Research Center, MindRank Technologies Ltd., London M11 2WJ, UK</aff><aff id="aff5"><label>e</label>Department of Geriatric Medicine, Akershus University Hospital, L&#248;renskog 1478, Norway</aff><aff id="aff6"><label>f</label>Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo 1478, Norway</aff><aff id="aff7"><label>g</label>Norwegian National Centre for Ageing and Health, Vestfold Hospital Trust, T&#248;nsberg 3103, Norway</aff><aff id="aff8"><label>h</label>Institute of Clinical Medicine, University of Oslo, Oslo 1478, Norway</aff><aff id="aff9"><label>i</label>Department of Geriatric Medicine, Oslo University Hospital, Oslo 0450, Norway</aff><aff id="aff10"><label>j</label>Department of Neurology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China</aff><aff id="aff11"><label>k</label>Key Laboratory of Alzheimer&#8217;s Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou 325035, China</aff><aff id="aff12"><label>l</label>Department of Geriatrics, Geriatric Medical Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China</aff><aff id="aff13"><label>m</label>Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK</aff><aff id="aff14"><label>n</label>UK Dementia Research Institute, Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge CB2 0XY, UK</aff><aff id="aff15"><label>o</label>Oslo Delirium Research Group, Department of Geriatric Medicine, Oslo University Hospital, Oslo 0450, Norway</aff><aff id="aff16"><label>p</label>Guangzhou National Laboratory, Guangzhou 510005, China</aff><aff id="aff17"><label>q</label>School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511495, China</aff><aff id="aff18"><label>r</label>National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK</aff><aff id="aff19"><label>s</label>Cardiovascular Research Centre, Royal Brompton Hospital, London SW3 6NP, UK</aff><aff id="aff20"><label>t</label>School of Biomedical Engineering &amp; Imaging Sciences, King&#8217;s College London, London WC2R 2LS, UK</aff><aff id="aff21"><label>u</label>The Norwegian Centre on Healthy Ageing (NO-Age) and the Norwegian National Anti-Alzheimer&#8217;s (NO-AD) Networks, Oslo 1478, Norway</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>g.yang@imperial.ac.uk</email><email>e.f.fang@medisin.uio.no</email></corresp><fn id="fn1"><label>&#8224;</label><p id="ntpara0020">These authors make equal contributions to this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>4</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498229</issue-id><fpage>4386</fpage><lpage>4410</lpage><history><date date-type="received"><day>25</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Delirium is a common cause and complication of hospitalization in the elderly and is associated with higher risk of future dementia and progression of existing dementia, of which 70% is Alzheimer&#8217;s disease (AD). AD and delirium, which are known to be aggravated by one another, represent significant societal challenges, especially in light of the absence of effective treatments. The intricate biological mechanisms have led to numerous clinical trial setbacks and likely contribute to the limited efficacy of existing therapeutics. Artificial intelligence (AI) presents a promising avenue for overcoming these hurdles by deploying algorithms to uncover hidden patterns across diverse data types. This review explores the pivotal role of AI in revolutionizing drug discovery for AD and delirium from target identification to the development of small molecule and protein-based therapies. Recent advances in deep learning, particularly in accurate protein structure prediction, are facilitating novel approaches to drug design and expediting the discovery pipeline for biological and small molecule therapeutics. This review concludes with an appraisal of current achievements and limitations, and touches on prospects for the use of AI in advancing drug discovery in AD and delirium, emphasizing its transformative potential in addressing these two and possibly other neurodegenerative conditions.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>The right applications of different artificial intelligence (AI) technologies could facilitate the development of early biomarkers and drug candidates against two common brain diseases, delirium and Alzheimer.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Delirium</kwd><kwd>Neurodegeneration</kwd><kwd>Artificial intelligence</kwd><kwd>Drug discovery</kwd><kwd>Deep learning</kwd><kwd>Target identification</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Delirium and dementia are two common, currently incurable, brain diseases which likely aggravate one another<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>. Delirium is an acute condition characterized by a disturbance in attention and awareness, with primary features that include an unpredictable course and perceptual abnormalities<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>. Risk factors include a range of stressors, such as alcohol use, infection, depression, malnutrition, medications and environment changes, as well as conditions such as hip fracture and severe COVID-19<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>. These stressors are often experienced by older individuals with frailty, chronic comorbidities, and other underlying heath conditions<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>. Diagnosis requires at least one additional cognitive impairment, such as deficits in memory, orientation, language, visuospatial ability, or perception to distinguish it from other forms of acute confusion<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>. Patients with delirium usually experience fluctuations in mental status throughout the day, which is a cardinal feature rather than evidence for ruling out other conditions<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>. To diagnose delirium, the disturbances cannot be explained by other neurocognitive disorders alone, and there must be clear evidence that the disturbances are caused by a medical condition, trauma, surgery, drug intoxication or withdrawal<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref>. Commonly triggered by hospitalization or illness, delirium is associated with poor short- and long-term outcomes, for example, functional and cognitive decline, prolonged hospital stay, more severe hospital-associated complications, increased readmission rates, and increased mortality<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>. Although delirium occurs in 29%&#8211;65% of hospitalized people<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>, the diagnosis is frequently missed. The consequences of underdiagnosis extend beyond individual health outcomes to impose a substantial economic burden. In the US, the national burden of delirium was estimated to be $143 billion to $152 billion<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref>. In a 2019 meta- analysis, the health-care costs for delirium were estimated to range between $806 and $24,509 USD per hospitalised patient<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>.</p><p id="p0015">Dementia is a gradual, long-term decline in cognitive abilities, affecting memory, language, orientation, and the capacity to carry out everyday activities<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>. Alzheimer&#8217;s disease (AD) is the most prevalent type of dementia, responsible for up to 70% of cases<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref>. Typical AD is characterized by significant episodic memory impairment, along with gradual cognitive and functional decline, including diminished word-finding ability, spatial cognition, and executive functions<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>. Two key pathological hallmarks of AD are amyloid beta (A<italic toggle="yes">&#946;</italic>) plaques and p-Tau formulated neurofibrillary tangles in the brain, which disrupt normal neuronal functions<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>; other pathological features and contributing factors include inflammation, cell senescence, compromised mitophagy/autophagy, and accumulation of damaged mitochondria, among others<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>. It is estimated that 50 million people currently have dementia, and this number is projected to triple by 2050<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref>. Associated costs are expected to rise from US $ 1 trillion in 2018 to estimated US $ 2 trillion by 2023<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref>.</p><p id="p0020">Delirium and dementia have a complicated inter-relationship, with individuals experiencing delirium being at a greater risk of developing dementia<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>. Moreover, delirium is associated with accelerated long-term cognitive decline<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, with AD serving as a classic example of this progression<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref>. Dementia and cognitive impairment are also risk factors for developing delirium<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref>. Compared to individuals with dementia who do not develop delirium, individuals with both dementia and delirium often face extended hospital stays, more severe cognitive and functional decline, and a higher risk of institutionalization and mortality<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref>. AD pathology might affect delirium risk through neuro-inflammation and gene&#8211;protein interactions<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref>.</p><p id="p0025">Drug development is typically a lengthy, costly, complex, and uncertain process<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>. In 2022, bringing a new drug to market was estimated to cost US $1784 million and use more than 13.5 years to develop<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>. Even after this lengthy, expensive process, only 5% of drugs are finally approved by the US Food and Drug Administration<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>. New candidate drugs for use in AD treatment, such as nicotinamide adenine dinucleotide oxidized form precursor, urolithin A, and two molecules kaempferol and rhapontigenin identified by artificial intelligence (AI) have been reported<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>; the clinical efficacy of these molecules is either under testing or still needs to be tested<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. The development of drugs for use in the central nervous system presents unique challenges including incomplete understanding of underlying mechanisms, limited predictive validity of current animal models (biological perspective), difficulty in designing drugs that can cross the blood&#8211;brain barrier (BBB) (chemical perspective), and patient heterogeneity, along with a lack of biomarkers for delirium to confirm engagement of potential targets (clinical perspective)<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>. While AD has some well-defined biomarkers (CSF, amyloid PET, tau-PET), the tissues they are located in are not easily accessible<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>; however, this may change with the discovery of blood-based biomarkers. The FDA recently approved lecanemab for AD, an IgG1 monoclonal antibody. While lecanemab has a modest effect on cognitive decline (coupled with substantial risk of serious side-effects), most clinical studies on other drugs have shown poor efficacy or serious adverse reactions in the majority of clinical AD and delirium candidates<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>. For delirium, evidence-based guidelines do not currently recommend the routine use of any drug to treat the condition<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref>. However, expert opinion supports a role for medication in some situations, for example, where there is intractable patient distress or if the patient&#8217;s or others' safety is compromised<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref>. Given the relationship between delirium and AD, it may also be possible to explore the prevention of AD through the management of delirium<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>.</p><p id="p0030">Recent advancements in AI, including machine learning (ML) and deep learning (DL) techniques, have shown potential for accelerating drug discovery and improving success rates<xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>. The strength of AI modeling lies in its ability to learn from extensive historical datasets, extract critical features from multi-omics data, and simultaneously consider multiple parameters for drug design<xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>. These approaches aim to deepen our understanding of the biological mechanisms underlying AD and delirium, enable the development of drugs with enhanced affinity and PK (pharmacokinetic) profiles, ultimately improving clinical outcomes for these conditions<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref>.</p><p id="p0035">In addition, AI is a rapidly developing field and the, recent success of protein structure prediction models, such as AlphaFold<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>, has paved the way for more rational drug design not only for small molecules but also for protein-based therapeutics<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>. In this review, we will focus on recent advancements in applying AI to the design of small molecules and protein therapeutics for delirium and AD, specifically reviewing AI technologies used for target identification, drug design, and optimization.</p></sec><sec id="sec2"><label>2</label><title>Advances in AI modeling for drug discovery: Data representation, modeling techniques, and applications</title><p id="p0040">Recently, AI has advanced rapidly, from the development of large language models like GPT-4 to groundbreaking developments like AlphaFold in protein structure prediction<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref>. The core focus is on algorithms that leverage high-performance computing resources to analyze large amounts of complex data<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>. Although this review covers a wide range of AI models, they all follow a similar structure that includes data input representation, a main modeling architecture, and the application of different prediction performances for various purposes (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>A general workflow on the application of artificial intelligence (AI) Modeling in drug discoveries for delirium and Alzheimer&#8217;s disease. Based on data availability and the modelling objectives, various sources, including omics data, structures of small molecules and proteins, and experimental and clinical results, can be used as inputs for AI models. These raw data are transformed into matrices and vectors using different data representation techniques to capture essential features. AI models, such as machine learning, graph neural networks, attention mechanisms, and generative models, are then used to reveal hidden patterns from these representations. Depending on the specific applications, different functions and training methods are applied to accomplish tasks such as target hypothesis generation, hit screening, molecule design, lead optimization, or assisting in clinical studies. Figure was generated using BioRender and Flaticon software.</p></caption><alt-text id="alttext0015">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0045">Data input representation is the process of transforming raw data such as molecular structures, proteins sequences, or biological annotations, which cannot be directly understood by machines, into the matrices and vectors that form machine-learnable data using various computational methods<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. Features and descriptors are used to compute specific properties of the data, creating meaningful numeric representations<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. For small molecules, descriptors, fingerprints, and SMILES (Simplified Molecular Input Line Entry System, a line notation that encodes molecular structures as computer-friendly text strings) have been developed to encode molecular structures into vectors, capturing the presence and arrangements of atomic substructures, as well as features such as the number of hydrogen donors, acceptors, and molecular weights<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref>. In addition to 1D textual representation, 2D graph-based representations have been developed to capture information about neighboring atoms using graph structures<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref>. This includes vectors generated by neural networks such as Message Passing Neural Networks (MPNN)<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> and Graph Convolutional Networks (GCNs)<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>. These methods utilize trainable parameters to effectively model the properties of small molecules<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>. Furthermore, 3D AI-based molecular representation methods, including voxel-based, point cloud, and graph-based 3D approaches, capture spatial and structural information by leveraging techniques like 3D convolutional networks, geometric DL, and rotationally invariant models<xref rid="bib67" ref-type="bibr">67</xref>, <xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>.</p><p id="p0050">Building upon the foundational concepts of 1D, 2D, and 3D representations, more advanced techniques have emerged to better capture specialized biological data types, such as AlphaFold 3 and ESM3 (Evolutionary Scale Modeling) in protein representation<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. AlphaFold 3 leverages Multiple Sequence Alignment to represent evolutionary information, Pair Representation to capture pairwise distances and relationships between amino acid residues, and 3D coordinates for protein sequence embedding<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. ESM3 represents proteins using large-scale language models trained on protein sequences to learn their underlying biological information. It treats amino acid sequences as a form of &#8216;language&#8217; and uses transformer-based architectures to capture relationships between amino acids, learning patterns related to protein structure and function<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>. Different data types require different forms of representation; effective data representation is able to capture essential features, enabling AI models to perform more accurately and efficiently.</p><p id="p0055">Various modeling techniques can be applied to different applications based on the data representation. As shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, modeling approaches such as Graph Neural Networks (GNNs; including GCNs and MPNN), Recurrent Neural Networks (RNNs), Convolutional Neural Networks, Transformers, and traditional ML models can be applied to general-purpose molecular and protein modeling for tasks such as classification and regression<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref>. Additionally, generative models like Variational Autoencoders (VAEs)<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> and Generative Adversarial Networks (GAN)<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref>are used for designing new molecular structures and optimizing their properties. Some approaches, such as transformers, involve complex calculations with large parameters, making them more suitable for large datasets<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref>. In contrast, methods like Random Forest (RF) are less computationally intensive and can perform well on smaller datasets with simpler representations<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref>. There is no single best model; rather, the most suitable model depends on the specific data type and the application. In this review, we do not aim to compare different modeling approaches. Instead, we will focus on reviewing their applications in AD and delirium drug discovery.</p></sec><sec id="sec3"><label>3</label><title>Data resources for delirium and AD discovery</title><p id="p0060">The research community benefits from several disease specialized databases that include multi-omics data for AD and delirium. These databases often encompass genomics, epigenomics, transcriptomics, proteomics, metabolomics, and imaging data, providing comprehensive insights into disease mechanisms, pathological progression, and potential therapeutic targets (<xref rid="tbl1" ref-type="table">Table 1</xref>). There are also compounds, proteins, affinity database like protein structural databases (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., Protein Data Bank<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref>, Repository of 3D structures of biological molecules<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref>), structure comparison tools<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>, protein&#8211;protein interaction databases (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., Pan Immune Repertoire Database: Validated protein interactions with interface regions<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref>), genetic databases (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., scRNA-seq datasets<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref>), and the human reference genome browser<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>. These resources are invaluable in understanding the molecular mechanisms underlying drug interactions and support the development of therapeutic strategies for AD and delirium<xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>. Furthermore, they facilitate discovery of biomarkers for predicting disease onset, tracking disease progression and assessing drug efficacy in clinical trials<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>A summary of selected databases for delirium and AD.</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Database</th><th colspan="1" rowspan="1">Description</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">ADNI</td><td colspan="1" rowspan="1">A major resource for imaging and biomarker data for AD research.</td><td colspan="1" rowspan="1"><xref rid="bib88" ref-type="bibr">88</xref></td></tr><tr><td colspan="1" rowspan="1">NIAGADS</td><td colspan="1" rowspan="1">Providing genetic data for Alzheimer&#8217;s research.</td><td colspan="1" rowspan="1"><xref rid="bib89" ref-type="bibr">89</xref></td></tr><tr><td colspan="1" rowspan="1">AD knowledge portal</td><td colspan="1" rowspan="1">A platform providing access to data, analyses, and tools for AD research.</td><td colspan="1" rowspan="1"><xref rid="bib90" ref-type="bibr">90</xref></td></tr><tr><td colspan="1" rowspan="1">AIZGPS</td><td colspan="1" rowspan="1">A resource for genomics and related research data on AD.</td><td colspan="1" rowspan="1"><xref rid="bib91" ref-type="bibr">91</xref></td></tr><tr><td colspan="1" rowspan="1">TACA</td><td colspan="1" rowspan="1">Focusing on clinical and translational research data for AD.</td><td colspan="1" rowspan="1"><xref rid="bib92" ref-type="bibr">92</xref></td></tr><tr><td colspan="1" rowspan="1">HUNT</td><td colspan="1" rowspan="1">HUNT databank of the Tr&#248;ndelag Health Study, a Norwegian population-based health study that collects extensive health and genetic data for research on delirium and AD prevention and public health.</td><td colspan="1" rowspan="1"><xref rid="bib93" ref-type="bibr">93</xref></td></tr><tr><td colspan="1" rowspan="1">UK biobank</td><td colspan="1" rowspan="1">The UK biobank is a large-scale biomedical database in the United Kingdom that provides genetic, lifestyle, and health information from 500,000 participants including delirium and AD patients to support medical research.</td><td colspan="1" rowspan="1"><xref rid="bib94" ref-type="bibr">94</xref></td></tr><tr><td colspan="1" rowspan="1">RosMap</td><td colspan="1" rowspan="1">The ROS/MAP cohort is a longitudinal study of aging and AD that provides deeply phenotyped clinical, cognitive, neuropathological, and multi-omics data, enabling investigation into the biological mechanisms underlying cognitive decline and dementia.</td><td colspan="1" rowspan="1"><xref rid="bib95" ref-type="bibr">95</xref></td></tr></tbody></table><table-wrap-foot><fn><p>AD: Alzheimer&#8217;s disease; ADNI: AD Neuroimaging Initiative; AIZGPS: the Alzheimer&#8217;s Integrated Genetics Program; NIAGADS: National Institute on Aging Genetics of AD Data Storage Site; RosMap: the Religious Orders Study and Memory and Aging Project; TACA: the Translational and Clinical Research AD database.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4"><label>4</label><title>AI applications in drug discovery</title><p id="p0065">Due to the current state of research and diagnostic challenges, there is a significantly larger focus on AD compared to delirium within the field of AI-driven drug discovery, resulting in many AI applications focusing exclusively on case studies related to AD. However, given the connections between AD and delirium, as well as the broad applicability of AI methodologies, research advances in AI for AD can readily be adapted to delirium studies<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>. This cross-applicability provides a valuable foundation for extending AI-driven insights and techniques from AD research to delirium, ultimately benefiting both fields.</p><sec id="sec4.1"><label>4.1</label><title>Target identification for AD and delirium</title><p id="p0070">The standard approach to drug discovery aims to design drug molecules&#8211;such as small molecules, peptides, antibodies, or newer modalities like short RNAs or cell therapies&#8211;that reverse disease progression by modulating the activity and/or degradation of disease-associated biological targets<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>. The process of selecting a suitable target based on available evidence is known as target identification and prioritization<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>97</sup></xref>. This crucial step aims to ensure that the modulation of the target provides a therapeutic benefit while maintaining an acceptable safety margin<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>97</sup></xref>. Following target identification, the selected target&#8217;s role in the disease is validated through <italic toggle="yes">in vivo</italic> studies using disease models, and eventually through clinical trials<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>97</sup></xref>. The identification of drug targets significantly influences the overall success of drug development, guiding the progression from preclinical studies to market<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref>.</p><p id="p0075">In the context of AD, classical targets include A<italic toggle="yes">&#946;</italic>, tau protein, and cholinergic neurotransmission pathways. The <italic toggle="yes">&#946;</italic>-amyloid hypothesis has been central to AD drug discovery, with numerous therapies aimed at reducing the generation of amyloid plaques and removal of existing plaques, while tau-targeting approaches seek to prevent tau aggregation and neurofibrillary tangle formation<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref>. Additionally, drugs targeting the glutamatergic system and cholinergic deficits, such as acetylcholinesterase (AChE) inhibitors, have been widely used in symptomatic treatment of AD<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref>. However, despite decades of research, many therapies targeting these classical pathways have shown limited clinical success, highlighting the need for new strategies (<xref rid="tbl2" ref-type="table">Table 2</xref>)<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>. Emerging AI-assisted approaches have uncovered novel targets, such as EPHX2, PLCG2, ABCA7, SORL1, BACE1, and INPP5D, offering deeper insight into AD pathology beyond merely identifying new therapeutic candidates<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref>.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>A summary on the status of drug candidates against AD (a selected non-exhaustive list).</p></caption><alt-text id="alttext0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Drug name</th><th colspan="1" rowspan="1">Company</th><th colspan="1" rowspan="1">Target pathway</th><th colspan="1" rowspan="1">Mechanism</th><th colspan="1" rowspan="1">Approval status</th><th colspan="1" rowspan="1">Efficacy in patients</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Tacrine</td><td colspan="1" rowspan="1">Pfizer</td><td colspan="1" rowspan="1">Cholinergic system</td><td colspan="1" rowspan="1">Acetylcholinesterase inhibitor</td><td colspan="1" rowspan="1">Approved (withdrawn)</td><td colspan="1" rowspan="1">Moderate symptomatic relief; withdrawn due to safety concerns</td></tr><tr><td colspan="1" rowspan="1">Donepezil</td><td colspan="1" rowspan="1">Eisai, Pfizer</td><td colspan="1" rowspan="1">Cholinergic system</td><td colspan="1" rowspan="1">Acetylcholinesterase inhibitor</td><td colspan="1" rowspan="1">Approved</td><td colspan="1" rowspan="1">Moderate symptomatic relief</td></tr><tr><td colspan="1" rowspan="1">Rivastigmine</td><td colspan="1" rowspan="1">Novartis</td><td colspan="1" rowspan="1">Cholinergic system</td><td colspan="1" rowspan="1">Acetylcholinesterase and butyrylcholinesterase inhibitor</td><td colspan="1" rowspan="1">Approved</td><td colspan="1" rowspan="1">Moderate symptomatic relief</td></tr><tr><td colspan="1" rowspan="1">Galantamine</td><td colspan="1" rowspan="1">Janssen</td><td colspan="1" rowspan="1">Cholinergic system</td><td colspan="1" rowspan="1">Acetylcholinesterase inhibitor and nicotinic receptor modulator</td><td colspan="1" rowspan="1">Approved</td><td colspan="1" rowspan="1">Moderate symptomatic relief</td></tr><tr><td colspan="1" rowspan="1">Memantine</td><td colspan="1" rowspan="1">Merz pharmaceuticals</td><td colspan="1" rowspan="1">Glutamatergic system</td><td colspan="1" rowspan="1">NMDA receptor antagonist</td><td colspan="1" rowspan="1">Approved</td><td colspan="1" rowspan="1">Moderate symptomatic relief</td></tr><tr><td rowspan="2" colspan="1">Aducanumab</td><td rowspan="2" colspan="1">Biogen, Eisai</td><td rowspan="2" colspan="1">Amyloid beta</td><td rowspan="2" colspan="1">Monoclonal antibody targeting amyloid protofibrils</td><td colspan="1" rowspan="1">Approved (2021)</td><td rowspan="2" colspan="1">Controversial, limited efficacy</td></tr><tr><td colspan="1" rowspan="1">Discontinued (2024)</td></tr><tr><td colspan="1" rowspan="1">Lecanemab</td><td colspan="1" rowspan="1">Biogen, Eisai</td><td colspan="1" rowspan="1">Amyloid beta</td><td colspan="1" rowspan="1">Monoclonal antibody targeting amyloid protofibrils</td><td colspan="1" rowspan="1">Approved</td><td colspan="1" rowspan="1">Slows disease progression</td></tr><tr><td colspan="1" rowspan="1">Donanemab</td><td colspan="1" rowspan="1">Eli Lilly</td><td colspan="1" rowspan="1">Amyloid beta</td><td colspan="1" rowspan="1">Monoclonal antibody targeting amyloid protofibrils</td><td colspan="1" rowspan="1">Approved (2024)</td><td colspan="1" rowspan="1">Slows disease progression</td></tr><tr><td colspan="1" rowspan="1">Verubecestat</td><td colspan="1" rowspan="1">Merck</td><td colspan="1" rowspan="1">APP</td><td colspan="1" rowspan="1">BACE1 inhibitor</td><td colspan="1" rowspan="1">Discontinued (phase III trials)</td><td colspan="1" rowspan="1">No significant clinical benefit, potential for worsening cognition.</td></tr><tr><td colspan="1" rowspan="1">Semagacestat</td><td colspan="1" rowspan="1">Eli Lilly</td><td colspan="1" rowspan="1">APP</td><td colspan="1" rowspan="1">Secretase inhibitor</td><td colspan="1" rowspan="1">Discontinued (phase III trials)</td><td colspan="1" rowspan="1">Worsening of cognitive function, increased risk of skin cancer (basal cell carcinoma). No clinical benefit.</td></tr><tr><td colspan="1" rowspan="1">Zagotenemab</td><td colspan="1" rowspan="1">Eli Lilly</td><td colspan="1" rowspan="1">Tau</td><td colspan="1" rowspan="1">Monoclonal antibody targeting tau</td><td colspan="1" rowspan="1">Discontinued (2021)</td><td colspan="1" rowspan="1">Failed to show efficacy</td></tr><tr><td colspan="1" rowspan="1">Tilavonemab</td><td colspan="1" rowspan="1">AbbVie</td><td colspan="1" rowspan="1">Tau</td><td colspan="1" rowspan="1">Monoclonal antibody targeting tau</td><td colspan="1" rowspan="1">Discontinued (2019)</td><td colspan="1" rowspan="1">Failed to show efficacy</td></tr><tr><td colspan="1" rowspan="1">Semorinemab</td><td colspan="1" rowspan="1">Genentech, AC immune</td><td colspan="1" rowspan="1">Tau</td><td colspan="1" rowspan="1">Monoclonal antibody targeting tau</td><td colspan="1" rowspan="1">Failed phase II (2021)</td><td colspan="1" rowspan="1">Limited efficacy in secondary analyses</td></tr><tr><td colspan="1" rowspan="1">Sargramostim</td><td colspan="1" rowspan="1">Partner therapeutics</td><td colspan="1" rowspan="1">Neuroinflammation</td><td colspan="1" rowspan="1">Granulocyte-macrophage colony-stimulating factor (GM-CSF)</td><td colspan="1" rowspan="1">Phase II (2021)</td><td colspan="1" rowspan="1">Under investigation</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Various academic institutions</td><td colspan="1" rowspan="1">Neuroinflammation</td><td colspan="1" rowspan="1">Anti-inflammatory antibiotic</td><td colspan="1" rowspan="1">Inconclusive</td><td colspan="1" rowspan="1">Inconclusive results</td></tr><tr><td colspan="1" rowspan="1">Pioglitazone</td><td colspan="1" rowspan="1">Takeda</td><td colspan="1" rowspan="1">Neuroinflammation</td><td colspan="1" rowspan="1">Anti-inflammatory effects</td><td colspan="1" rowspan="1">Failed phase III</td><td colspan="1" rowspan="1">Failed to show efficacy</td></tr><tr><td colspan="1" rowspan="1">Intranasal insulin</td><td colspan="1" rowspan="1">Various institutions</td><td colspan="1" rowspan="1">Metabolic</td><td colspan="1" rowspan="1">Modulates brain glucose metabolism</td><td colspan="1" rowspan="1">Mixed results</td><td colspan="1" rowspan="1">Mixed results</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">Generic</td><td colspan="1" rowspan="1">Metabolic</td><td colspan="1" rowspan="1">AMPK activator with neuroprotective effects</td><td colspan="1" rowspan="1">Under investigation</td><td colspan="1" rowspan="1">Under investigation</td></tr><tr><td colspan="1" rowspan="1">Blarcamesine (anavex2-73)</td><td colspan="1" rowspan="1">Anavex life sciences</td><td colspan="1" rowspan="1">Metabolic</td><td colspan="1" rowspan="1">Sigma-1 receptor agonist modulating synaptic function</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1">Potential neuroprotection, under trial</td></tr><tr><td colspan="1" rowspan="1">Tideglusib</td><td colspan="1" rowspan="1">Zeltia, AMBAR</td><td colspan="1" rowspan="1">Metabolic</td><td colspan="1" rowspan="1">GSK-3 inhibitor for neuroprotection</td><td colspan="1" rowspan="1">Failed phase II</td><td colspan="1" rowspan="1">Failed to show efficacy</td></tr><tr><td colspan="1" rowspan="1">Idalopirdine</td><td colspan="1" rowspan="1">Axovant sciences</td><td colspan="1" rowspan="1">5-HT6 receptor</td><td colspan="1" rowspan="1">5-HT6 receptor antagonist</td><td colspan="1" rowspan="1">Discontinued (phase III trials)</td><td colspan="1" rowspan="1">No significant clinical benefit</td></tr><tr><td colspan="1" rowspan="1">VG-3927</td><td colspan="1" rowspan="1">Vigil neuroscience</td><td colspan="1" rowspan="1">TREM2 signaling</td><td colspan="1" rowspan="1">TREM2 agonist (small molecule)</td><td colspan="1" rowspan="1">Phase II trials</td><td colspan="1" rowspan="1">Early data shows promise, including a reduction in TREM2 levels. Further trials are ongoing to determine clinical efficacy</td></tr></tbody></table></table-wrap></p><p id="p0080">Modern biology is becoming increasingly data-intensive, encompassing human genetic information from large populations, transcriptomic, proteomic and metabolomics analyses of both healthy and diseased individuals, as well as high-content imaging of clinical material<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib100" ref-type="bibr"><sup>100</sup></xref>. This presents new opportunities to identify novel drug targets, moving beyond classical hypotheses and toward a systems biology approach that incorporates multiple disease mechanisms. However, more effective techniques to handle large-scale multidimensional biological data are required. AI models, including ML and DL, can process and analyze large-scale biological datasets such as genomics, proteomics, and transcriptomics<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>97</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref>. Unlike traditional methods that rely heavily on predefined hypotheses, AI can uncover novel patterns in high-dimensional data, revealing previously unknown molecular drivers of AD pathology, such as PLCG1<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib102" ref-type="bibr"><sup>102</sup></xref>. These technologies have proven highly effective at identifying molecular targets that traditional methods may overlook, offering a mechanistic understanding of disease pathways and new avenues for therapeutic intervention (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>A schematic flow showing how artificial intelligence (AI) can be used for drug target discovery in Alzheimer&#8217;s disease (AD) and delirium covering data acquisition to drug target identification and assessment. AI models are employed to process large-scale biological datasets such as genomics, transcriptomics, metabolomics, proteomics, and imaging data. Machine learning models (such as Support Vector Machines/SVM, Random Forest/RF), deep learning models (like graph convolutional networks/GCN, Graph Neural Networks/GNNs, RNNs/Recurrent Neural Networks, and Long Short-Term Memory/LSTMs), AlphaFold, and Knowledge Graph can be used jointly in understanding disease progression, prioritizing druggable targets, and predicting disease-driving genes. Figure was generated using BioRender and Flaticon software. The brain image was generated using ChatGPT-4o.</p></caption><alt-text id="alttext0020">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0085">AD is a progressive condition that requires dynamic analysis of time-series multi-omics data, adding additional challenges to understanding the mechanisms underlying these diseases. Delirium can worsen the progression of AD<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref>. DL techniques, particularly RNNs and Long Short-Term Memory models, have proven instrumental in understanding disease progression in neurodegenerative disease due to their ability to process sequential information<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>. These models are particularly adept at analyzing time-series data from multi-omics sources, such as genomics, transcriptomics, and epigenetics, to identify key genetic mutations linked to the onset and progression of AD<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref>. AI-driven models have revealed previously underexplored targets like SORL1 and EPHX2<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref>, which play a role in lipid metabolism and endosomal trafficking in AD.</p><p id="p0090">AI has also facilitated advancements in the prediction of disease driver genes. ML algorithms such as Support Vector Machines and RF have been applied to predict disease-associated genes by analyzing genetic and multi-omics data, aiding in the prioritization of potential therapeutic targets<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib105" ref-type="bibr"><sup>105</sup></xref>. By integrating genetic risk factors with molecular pathway analysis, AI not only identifies candidate genes but also reconstructs disease-associated networks, providing deeper insights into disease progression and possible therapeutic leverage points<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref>. For instance, INPP5D<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref>, a gene associated with immune regulation, was identified through AI-assisted multi-omics analysis as a potential key player in AD (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). This approach has proven effective in AD research, where novel genes and pathways implicated in disease progression have been identified<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib105" ref-type="bibr"><sup>105</sup></xref>.</p><p id="p0095">Furthermore, AI has demonstrated significant potential in analyzing complex data such as multi-omics. The integration of multi-omics data&#8212;combining genomic, transcriptomic, proteomic, and metabolomic datasets&#8212;has become a critical component of AI-driven target identification<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref><sup>,</sup><xref rid="bib106" ref-type="bibr">106</xref>, <xref rid="bib107" ref-type="bibr">107</xref>, <xref rid="bib108" ref-type="bibr">108</xref>. By reconstructing disease networks and functional relationships between genes, AI provides a mechanistic understanding of AD that extends beyond target discovery to elucidate disease etiology. This holistic approach offers a comprehensive view of AD pathology, enabling researchers to identify and prioritize new drug targets. AI models have also been used to uncover previously overlooked genetic contributions to AD<xref rid="bib106" ref-type="bibr">106</xref>, <xref rid="bib107" ref-type="bibr">107</xref>, <xref rid="bib108" ref-type="bibr">108</xref>. For example, the AI tool DeepSEA<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref> predicted the functional effects of non-coding variants in the <italic toggle="yes">INPP5D</italic> gene, revealing novel variants associated with an increased risk of late-onset AD<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref>. In addition, network-based methods have proven to be highly effective in generating new hypotheses for potential targets in neurodegenerative diseases by leveraging multi-omics data<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref><sup>,</sup><xref rid="bib108" ref-type="bibr"><sup>108</sup></xref>. For example, a network DL approach was used to analyze RNA sequencing data, protein&#8211;protein interaction (PPI) networks, and gene networks to identify specific microglial subtypes involved in human AD brains<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref>. A knowledge graph generated through text mining of literature that integrates gene, disease, and compound information can also be used to generate hypotheses for druggable targets in AD<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref>.</p><p id="p0100">In addition to genetic data, AI has demonstrated success in generating hypotheses for other omics data, such as disease-associated microRNAs, which regulate gene expression and are involved in AD pathogenesis<xref rid="bib109" ref-type="bibr">109</xref>, <xref rid="bib110" ref-type="bibr">110</xref>, <xref rid="bib111" ref-type="bibr">111</xref>. Neural network models, such as NNMDA, have identified novel miRNA-disease associations, contributing to the discovery of new therapeutic targets for disease<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref>. AI-based tools have also been applied to predict alternative splicing events, which play a critical role in gene expression regulation and protein diversity. Tools like AVISPA and DeepChem<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref> have enabled more accurate predictions of alternative splicing, aiding in the discovery of new therapeutic opportunities in AD<xref rid="bib109" ref-type="bibr"><sup>109</sup></xref><sup>,</sup><xref rid="bib110" ref-type="bibr"><sup>110</sup></xref>.</p><p id="p0105">Moreover, protein structure prediction models like AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>, developed by DeepMind, have demonstrated the potential to accelerate biological research by offering a fast and effective option for modeling protein structures<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. Compared with experiments such as protein crystallography or cryo-EM tomography, which require months to years to determine structures<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref>, this package can predict structures within minutes<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. Beyond drug target identification, AI-powered structural biology allows researchers to explore PPI and novel binding sites, further refining our understanding of AD pathogenesis. This has led to better characterization of targetable structures in protein such as ABCA7<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref>, which has been implicated in lipid transport and insoluble amyloid level in AD<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref>. In addition, the recent development of AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> provides new approaches to modeling more complex interactions between proteins and small molecules, nucleic acids, and other proteins<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. This presents new opportunities for modeling more complex biological mechanisms using predictive models.</p><p id="p0110">Additionally, AI has transformed the druggability assessment of AD-related targets<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref><sup>,</sup><xref rid="bib116" ref-type="bibr"><sup>116</sup></xref>. AI models, such as the RF-based SCREEN tool, assess the druggability of proteins by evaluating the geometric and structural features of binding sites. These advancements help prioritize targets with the highest therapeutic potential<xref rid="bib116" ref-type="bibr"><sup>116</sup></xref>. AI-based optimization frameworks, particularly those based on reinforcement learning (RL), have also facilitated multi-objective optimization, balancing critical parameters like target potency, selectivity, and permeability<xref rid="bib115" ref-type="bibr"><sup>115</sup></xref>.</p><p id="p0115">In summary, AI extends beyond the simple identification of new therapeutic targets by enabling a more profound understanding of AD pathology through the integration of multi-omics, disease progression modeling, and neural network and biological network-based analyses. Unlike conventional methods that focus primarily on known pathways such A<italic toggle="yes">&#946;</italic> and tau, AI-driven approaches uncover novel targets, including EPHX2, PLCG2, ABCA7, SORL1, and INPP5D<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref> (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). These discoveries refine disease mechanisms and enhance druggability assessment. This shift from a single-target paradigm to a systems biology approach represents a transformative advancement in AD research, accelerating the development of effective treatments<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref>.</p></sec><sec id="sec4.2"><label>4.2</label><title>Small molecule drug design and optimization</title><p id="p0120">Small molecule drugs, defined as low molecular weight organic compounds, have dominated the pharmaceutical industry for nearly a century due to advantages such as oral administration, the ability to cross cell membranes to reach intracellular targets, and flexible design options to engage biological targets through various modes of action<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. Five small-molecule drugs, including tacrine, donepezil, rivastigmine, galantamine, and memantine, which inhibit AChE or act as antagonists to <italic toggle="yes">N</italic>-methyl-<sc>d</sc>-aspartate receptors to alleviate AD and delirium symptoms, were approved in the 1990s and 2000s<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>.</p><p id="p0125">Small molecule drug discovery involves identifying or designing molecules with high selectivity and potency to effectively modulate target proteins by inhibiting, activating or degrading them<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. Suitable candidate compounds must undergo further optimization to improve pharmacodynamic and pharmacokinetic (PK) properties, mitigate toxicity, and maintain efficacy<xref rid="bib118" ref-type="bibr"><sup>118</sup></xref>. Studies have demonstrated that AI can potentially significantly speed up this process for AD and delirium<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> drug discovery. This section will review various applications, including virtual screening (VS), <italic toggle="yes">de novo</italic> drug design, drug repurposing, compound&#8211;target interaction prediction, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) optimizations (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <xref rid="tbl3" ref-type="table">Table 3</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>A summary of the broad applications of AI in the development of small molecule- and protein (<italic toggle="yes">e</italic>.<italic toggle="yes">g</italic>., antibody)-based drug candidates for delirium and AD. Many current AI models in drug design aim to enhance pharmacodynamics and pharmacokinetics while reducing toxicity risks. AI-driven approaches such as drug design, virtual screening, and drug repurposing, along with predictive models for molecular properties, are employed to achieve this goal. These methods enable the automatic selection of drug candidates with desirable characteristics based on predicted results, aiding the development of small molecule and protein-based therapeutics for these conditions. ADMET: Absorption Distribution Metabolism Excretion and Toxicity; CPI: compound&#8211;protein interaction; DC<sub>50</sub>: half-maximal drug concentration; EC<sub>50</sub>: half-maximal effective concentration; IC<sub>50</sub>: half-maximal inhibitory concentration; PPI: protein&#8211;protein interaction; VS: virtual screening. Figure was generated using BioRender and Flaticon software.</p></caption><alt-text id="alttext0025">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>A summary of different AI models in the designing and optimizing of small molecule drug candidates for delirium and AD.</p></caption><alt-text id="alttext0040">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Model</th><th colspan="1" rowspan="1">Target</th><th colspan="1" rowspan="1">Approach description</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">VS</td></tr><tr><td colspan="1" rowspan="1">Pretrained representation model for LBVS</td><td colspan="1" rowspan="1">Mitophagy inducers</td><td colspan="1" rowspan="1">LBVS workflow that utilized a pretraining process to learn a molecular representation model from a library of 19.9 million compounds</td><td colspan="1" rowspan="1">Two inducers validated in animal models</td><td colspan="1" rowspan="1"><xref rid="bib42" ref-type="bibr">42</xref></td></tr><tr><td colspan="1" rowspan="1">Multiple ML</td><td colspan="1" rowspan="1"><italic toggle="yes">&#946;</italic>-Amyloid</td><td colspan="1" rowspan="1">A molecular property filter based on charge, molecular weight, and log<italic toggle="yes">P</italic>, alongside ML models using simple chemical descriptors and 3D field points in forge software for shape and surface properties.</td><td colspan="1" rowspan="1">Five compounds validated in molecular-level experiments</td><td colspan="1" rowspan="1"><xref rid="bib119" ref-type="bibr">119</xref></td></tr><tr><td colspan="1" rowspan="1">ML</td><td colspan="1" rowspan="1">Dual 5-HT6/5-HT2A receptor</td><td colspan="1" rowspan="1">The process included 2D fingerprint screening, ADMET filtering, 3D pharmacophore screening, and flexible docking, resulting in the selection of 92 compounds for <italic toggle="yes">in vitro</italic> binding affinity evaluation.</td><td colspan="1" rowspan="1">Fourteen compounds validated in molecular-level experiments</td><td colspan="1" rowspan="1"><xref rid="bib120" ref-type="bibr">120</xref></td></tr><tr><td colspan="1" rowspan="1">VirtualFlow</td><td colspan="1" rowspan="1">KEAP1</td><td colspan="1" rowspan="1">A highly automated and versatile open-source platform with perfect scaling behavior for screening ultra-large libraries</td><td colspan="1" rowspan="1">One compound validated in molecular-level experiments</td><td colspan="1" rowspan="1"><xref rid="bib121" ref-type="bibr">121</xref></td></tr><tr><td colspan="5" rowspan="1"><italic toggle="yes">De novo</italic> drug design</td></tr><tr><td colspan="1" rowspan="1">Wasserstein GAN</td><td colspan="1" rowspan="1">BACE1</td><td colspan="1" rowspan="1">The framework utilizes a Wasserstein GAN with gradient penalty, which can generate new molecular structures using the generator and evaluate their bioactivity and BBB permeability using the discriminator.</td><td colspan="1" rowspan="1">Generation of over 1,000,000 new molecules with favorable properties.</td><td colspan="1" rowspan="1"><xref rid="bib122" ref-type="bibr">122</xref></td></tr><tr><td colspan="1" rowspan="1">RationaleRL</td><td colspan="1" rowspan="1">JNK3; GSK3<italic toggle="yes">&#946;</italic></td><td colspan="1" rowspan="1">The generative model constructs molecules as combinations of multiple rationale completions, fine-tuning the mixture to maintain the desired properties.</td><td colspan="1" rowspan="1">Generate new molecules with favorable properties.</td><td colspan="1" rowspan="1"><xref rid="bib123" ref-type="bibr">123</xref></td></tr><tr><td colspan="5" rowspan="1">Drug repurposing</td></tr><tr><td colspan="1" rowspan="1">NETTAG</td><td colspan="1" rowspan="1">Multipletargets</td><td colspan="1" rowspan="1">A topology-based DL framework integrates multi-omics data with the human PPI network to predict drug repurposing candidates.</td><td colspan="1" rowspan="1">Four drugs supported by literature evidence</td><td colspan="1" rowspan="1"><xref rid="bib124" ref-type="bibr">124</xref></td></tr><tr><td colspan="1" rowspan="1">Network-based, multimodal approach</td><td colspan="1" rowspan="1">Multipletargets</td><td colspan="1" rowspan="1">A network-based, multimodal approach for drug discovery informed by single-cell/nucleus genomics.</td><td colspan="1" rowspan="1">Fluticasone and mometasone have been identified as potential treatments for AD</td><td colspan="1" rowspan="1"><xref rid="bib125" ref-type="bibr">125</xref></td></tr><tr><td colspan="1" rowspan="1">DRIAD</td><td colspan="1" rowspan="1">Multipletargets</td><td colspan="1" rowspan="1">A machine learning framework that quantifies potential associations between Alzheimer&#8217;s disease severity, measured by braak stage, and molecular mechanisms represented in gene lists.</td><td colspan="1" rowspan="1">Network that supports AD-related drug discovery</td><td colspan="1" rowspan="1"><xref rid="bib126" ref-type="bibr">126</xref></td></tr><tr><td colspan="1" rowspan="1">AI-DrugNet</td><td colspan="1" rowspan="1">Multipletargets</td><td colspan="1" rowspan="1">Integrated drug and target features, with drug&#8211;target pairs as nodes and their associations as edges in the AD network, including drug&#8211;drug, target&#8211;target, and drug&#8211;target relationships.</td><td colspan="1" rowspan="1">Network that supports AD-related drug discovery</td><td colspan="1" rowspan="1"><xref rid="bib127" ref-type="bibr">127</xref></td></tr><tr><td colspan="5" rowspan="1">Compound target interactions prediction</td></tr><tr><td colspan="1" rowspan="1">QSAR ML models</td><td colspan="1" rowspan="1">AChE</td><td colspan="1" rowspan="1">An ensemble learning model combining CatBoost and XGBoost, based on QSAR</td><td colspan="1" rowspan="1">Four drugs (phenserine, physostigmine, velnacrine, ipidacrine) supported by literature evidence</td><td colspan="1" rowspan="1"><xref rid="bib128" ref-type="bibr">128</xref></td></tr><tr><td colspan="1" rowspan="1">3D-QSAR deep neural network</td><td colspan="1" rowspan="1">BACE1</td><td colspan="1" rowspan="1">A deep neural network model integrating both structure-based and ligand-based features.</td><td colspan="1" rowspan="1">Fifth place in BACE prediction in the D3R grand challenge 4.</td><td colspan="1" rowspan="1"><xref rid="bib129" ref-type="bibr">129</xref></td></tr><tr><td colspan="1" rowspan="1">3D-QSAR deep neural network</td><td colspan="1" rowspan="1">BACE1</td><td colspan="1" rowspan="1">The descriptor space includes binary molecular fingerprints, 1D and 2D descriptors, and advanced 3D molecular fields requiring aligned chemical scaffolds in a unified space.</td><td colspan="1" rowspan="1">Qualitative classification achieved &#8764;70% accuracy, while quantitative IC<sub>50</sub> predictions had an RMSE of &#8764;1 log.</td><td colspan="1" rowspan="1"><xref rid="bib130" ref-type="bibr">130</xref></td></tr><tr><td colspan="1" rowspan="1">3D-QSAR</td><td colspan="1" rowspan="1">AChE</td><td colspan="1" rowspan="1">3D-QSAR modeling was conducted for inhibitory activity using a 3D-fingerprint descriptor to encode protein-ligand interactions.</td><td colspan="1" rowspan="1">External validation results demonstrated strong performance with <italic toggle="yes">n</italic> = 26, <italic toggle="yes">R</italic><sup>2</sup> = 0.89, and an MAE of 0.38 log units.</td><td colspan="1" rowspan="1"><xref rid="bib131" ref-type="bibr">131</xref></td></tr><tr><td colspan="1" rowspan="1">MathDL</td><td colspan="1" rowspan="1">BACE1</td><td colspan="1" rowspan="1">Advanced mathematics encodes high-dimensional interactions into low-dimensional representations, integrated with GANs for pose prediction and CNNs for energy evaluation.</td><td colspan="1" rowspan="1">Top place in BACE prediction in the D3R grand challenge 4 phase I.</td><td colspan="1" rowspan="1"><xref rid="bib132" ref-type="bibr">132</xref></td></tr><tr><td colspan="1" rowspan="1">Bipartite graph neural network</td><td colspan="1" rowspan="1">BACE1</td><td colspan="1" rowspan="1">A bipartite graph neural network combined with transfer learning was used for affinity prediction.</td><td colspan="1" rowspan="1">Top 9% results in BACE prediction in the D3R grand challenge 4 phase II.</td><td colspan="1" rowspan="1"><xref rid="bib133" ref-type="bibr">133</xref></td></tr><tr><td colspan="5" rowspan="1">ADMET optimization</td></tr><tr><td colspan="1" rowspan="1">LightBBB</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">A ML model utilizing the light gradient boosting machine algorithm was developed for BBB prediction.</td><td colspan="1" rowspan="1">The model achieved an overall accuracy of 89%, an AUC of 0.93, a specificity of 0.77, and a sensitivity of 0.93.</td><td colspan="1" rowspan="1"><xref rid="bib189" ref-type="bibr">189</xref></td></tr><tr><td colspan="1" rowspan="1">Deep-B3</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Molecular descriptors, fingerprints, molecular graphs, and SMILES text notation were used for BBB prediction.</td><td colspan="1" rowspan="1">Deep-B3 (raw) achieved 95% sensitivity (SN), 41% specificity (SP), 0.41 MCC, 0.66 accuracy (ACC), and 0.80 AUC.</td><td colspan="1" rowspan="1"><xref rid="bib191" ref-type="bibr">191</xref></td></tr></tbody></table><table-wrap-foot><fn><p>ADMET: absorption, distribution, metabolism, excretion, and toxicity; BBB: blood&#8211;brain barrier; DL: deep learning; DRIAD: Drug Repurposing in Alzheimer&#8217;s Disease; GANs: generative adversarial networks; LBVS: ligand-based virtual screening; ML: machine learning; NETTAG: Network Topology-Based Deep Learning for Drug Discovery; PPI: protein&#8211;protein interaction; QSAR: quantitative structure&#8211;activity relationship; SMILES: simplified molecular input line entry system; VS: virtual screening.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec4.2.1"><label>4.2.1</label><title>VS</title><p id="p0130">The initial step in small molecule drug design is to find compounds with a high potential to bind to a drug target, known as &#8220;hits&#8221;. Good hits are important for drug discovery as they serve as the starting points for developing potent and selective drug candidates<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref>. There are multiple successful case studies demonstrating the effective application of virtual screening (VS) in selecting promising compounds across various diseases<xref rid="bib137" ref-type="bibr">137</xref>, <xref rid="bib138" ref-type="bibr">138</xref>, <xref rid="bib139" ref-type="bibr">139</xref>, <xref rid="bib140" ref-type="bibr">140</xref>, <xref rid="bib141" ref-type="bibr">141</xref>.</p><p id="p0135">VS is an effective and widely adopted computational approach for hit discovery. It follows a step by step filtering procedure, including different criteria such as molecule size, ligand similarity, and predicted physicochemical and PK properties in order to select suitable compounds from a large compound library<xref rid="bib142" ref-type="bibr"><sup>142</sup></xref>. There are two main approaches: ligand-based VS (LBVS), which relies on known active compounds to find similar molecules, and structure-based VS structure-based VS (SBVS), which uses the 3D structure of the target protein. VS helps prioritize compounds for experimental validation and has been shown to be effective across multiple studies for discovering hits for AD<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref><sup>,</sup><xref rid="bib120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="bib143" ref-type="bibr">143</xref>, <xref rid="bib144" ref-type="bibr">144</xref>, <xref rid="bib145" ref-type="bibr">145</xref>, <xref rid="bib146" ref-type="bibr">146</xref>.</p><p id="p0140">For LBVS, researchers focus on generating molecular representation matrices that encode the structural and functional characteristics of molecules based on DL or rule-based approaches<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib119" ref-type="bibr"><sup>119</sup></xref><sup>,</sup><xref rid="bib120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="bib143" ref-type="bibr"><sup>143</sup></xref><sup>,</sup><xref rid="bib145" ref-type="bibr"><sup>145</sup></xref><sup>,</sup><xref rid="bib146" ref-type="bibr"><sup>146</sup></xref>. For instance, a workflow was developed using vector representations of molecular structures, pharmacophore fingerprinting, and conformer fingerprinting, along with a pre-training process, to train a molecule representation model from a library of 19.9 million compounds for LBVS<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. This molecular representation helped identify two potent mitophagy inducers, kaempferol and rhapontigenin<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>, from a natural compound library for AD treatment. Subsequent testing in nematode and rodent models of AD demonstrated that these molecules significantly enhanced the survival and functionality of glutamatergic and cholinergic neurons<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. Additionally, they were shown to reduce amyloid-<italic toggle="yes">&#946;</italic> and tau pathologies and improve memory in the animal models<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. LBVS approaches have been extensively explored for targets in AD, as shown in <xref rid="tbl4" ref-type="table">Table 4</xref>. These studies cover various targets, such as GSK3B, amyloid-beta peptide, 5-HT receptors, and BACE1. A range of methods, including ML, pharmacophore-based deep neural networks, and hybrid approaches, have been applied, demonstrating the broad applicability of LBVS in AD research<xref rid="bib119" ref-type="bibr"><sup>119</sup></xref><sup>,</sup><xref rid="bib120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="bib143" ref-type="bibr"><sup>143</sup></xref><sup>,</sup><xref rid="bib145" ref-type="bibr"><sup>145</sup></xref><sup>,</sup><xref rid="bib146" ref-type="bibr"><sup>146</sup></xref>.<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>A summary of applications of AI in protein-based therapeutics for delirium and AD.</p></caption><alt-text id="alttext0045">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Model</th><th colspan="1" rowspan="1">Target</th><th colspan="1" rowspan="1">Approach description</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">Structure prediction</td></tr><tr><td colspan="1" rowspan="1">AlphaFold2</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Based on DL and MSAs to predict 3D protein folding.</td><td colspan="1" rowspan="1">First place in CASP14, with over 85% GDT_TS backbone accuracy for complex protein structures.</td><td colspan="1" rowspan="1"><xref rid="bib60" ref-type="bibr">60</xref></td></tr><tr><td colspan="1" rowspan="1">EquiFold</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">SE (3)-equivariant all-atom protein structure prediction model for faster and more accurate antibody prediction.</td><td colspan="1" rowspan="1">Achieves similar or better backbone atom RMSD for antibody prediction compared to AlphaFold-Multimer and IgFold, while being significantly faster.</td><td colspan="1" rowspan="1"><xref rid="bib147" ref-type="bibr">147</xref></td></tr><tr><td colspan="1" rowspan="1">DeepH3</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Employs DL to predict antibody H3 loop structures, critical for antigen binding.</td><td colspan="1" rowspan="1">DeepH3 reduced the average RMSD by 32.1% (1.4 &#197;) compared to Rosetta on the Rosetta antibody benchmark dataset.</td><td colspan="1" rowspan="1"><xref rid="bib148" ref-type="bibr">148</xref></td></tr><tr><td colspan="1" rowspan="1">ABLooper</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Utilizes ML and knowledge-based methods to model antibody CDR loops.</td><td colspan="1" rowspan="1">On the Rosetta antibody benchmark, ABlooper achieves an average CDR-H3 RMSD of 2.49 &#197;, which improves to 2.05 &#197; for its top 75% most confident predictions.</td><td colspan="1" rowspan="1"><xref rid="bib149" ref-type="bibr">149</xref></td></tr><tr><td colspan="1" rowspan="1">RoseTTAFold all-Atom</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">A unified approach for structure prediction and design of assemblies involving proteins, nucleic acids, small molecules, metals, and chemical modifications.</td><td colspan="1" rowspan="1">The most accurate predictions in the CAMEO blind ligand-docking challenge were achieved for proteins with low sequence homology (BLAST <italic toggle="yes">e</italic>-value &gt;1) and ligands with low similarity (Tanimoto similarity &lt;0.5).</td><td colspan="1" rowspan="1"><xref rid="bib150" ref-type="bibr">150</xref></td></tr><tr><td colspan="1" rowspan="1">AlphaFold3</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Enables the prediction of joint structures for complexes, encompassing proteins, nucleic acids, small molecules, ions, and modified residues.</td><td colspan="1" rowspan="1">Achieves best performance in predicting structures of various complexes through time-series splitting.</td><td colspan="1" rowspan="1"><xref rid="bib59" ref-type="bibr">59</xref></td></tr><tr><td colspan="5" rowspan="1">Binding site prediction</td></tr><tr><td colspan="1" rowspan="1">ProB-site</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">The model generates three feature sets per amino acid from protein sequences, processes them with sub-CNNs, and classifies the combined features using fully connected layers.</td><td colspan="1" rowspan="1">ProB-site achieved 0.799 accuracy and 0.844 ARROC on the benchmark dataset, and on test_315, it yielded an MCC of 0.351 and AUPRC of 0.446.</td><td colspan="1" rowspan="1"><xref rid="bib151" ref-type="bibr">151</xref></td></tr><tr><td colspan="1" rowspan="1">EquiBind</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">The SE (3)-equivariant geometric deep learning model enables direct prediction of a ligand&#8217;s bound pose and orientation as well as receptor binding sites.</td><td colspan="1" rowspan="1">Improves over the baselines for predictions in the &gt;4 &#197; regime for blind self-docking, while outperforming baselines in all metrics except the 25th percentile and the fraction of predictions with RMSD below 2 &#197; for blind re-docking.</td><td colspan="1" rowspan="1"><xref rid="bib152" ref-type="bibr">152</xref></td></tr><tr><td colspan="1" rowspan="1">TANKBind</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">TANKBind is a trigonometry-aware neural network for binding prediction, using trigonometric constraints and segmenting the protein into functional blocks to target binding sites.</td><td colspan="1" rowspan="1">Compared to baselines, this model increases the fraction of predictions with ligand RMSD below 5 &#197; by 16% in re-docking, 22% in self-docking, and 42% in the more challenging new-protein setting.</td><td colspan="1" rowspan="1"><xref rid="bib153" ref-type="bibr">153</xref></td></tr><tr><td colspan="1" rowspan="1">EpiCluster</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Clustering-based approach for identifying common epitopes across multiple antigens.</td><td colspan="1" rowspan="1">EpiCluster outperforms previous methods, achieving an AUC of 0.89 and an MCC of 0.49 on the epitope3D benchmark set.</td><td colspan="1" rowspan="1"><xref rid="bib154" ref-type="bibr">154</xref></td></tr><tr><td colspan="1" rowspan="1">EpiDope</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">DL-based approach to predict peptide sequences that can serve as epitopes.</td><td colspan="1" rowspan="1">EpiDope, with an area under the receiver operating characteristic curve of 0.67 &#177; 0.07, outperforms all current linear B-cell epitope prediction tools.</td><td colspan="1" rowspan="1"><xref rid="bib155" ref-type="bibr">155</xref></td></tr><tr><td colspan="1" rowspan="1">BepFAMN</td><td colspan="1" rowspan="1">Delirium AD</td><td colspan="1" rowspan="1">Uses ML to predict linear B-cell epitopes from protein sequences.</td><td colspan="1" rowspan="1">The performance on the testing dataset demonstrates notable improvements, achieving an accuracy of 78.27%, sensitivity of 81.87%, specificity of 74.75%, and an AUC of 0.7831.</td><td colspan="1" rowspan="1"><xref rid="bib156" ref-type="bibr">156</xref></td></tr><tr><td colspan="5" rowspan="1"><italic toggle="yes">De novo</italic> protein design</td></tr><tr><td colspan="1" rowspan="1">FoldIt, Rosetta, ProteinMPNN, AlphaFold 2</td><td colspan="1" rowspan="1">Amyloid</td><td colspan="1" rowspan="1">FoldIt-designed proteins were enhanced with strands and helices. Rosetta optimized sequences, followed by interface redesign to improve affinity. ProteinMPNN refined surface residues, and AlphaFold2 validated designs for testing.</td><td colspan="1" rowspan="1">Nanomolar affinities to target peptides <italic toggle="yes">in vitro</italic> and in cells.</td><td colspan="1" rowspan="1"><xref rid="bib157" ref-type="bibr">157</xref></td></tr><tr><td colspan="1" rowspan="1">Rosetta, RosettaRemodel, FastDesign, MotifGraft docking</td><td colspan="1" rowspan="1">Amyloid</td><td colspan="1" rowspan="1">Designed a library of miniproteins with an <italic toggle="yes">&#945;</italic>-helix and 2&#8211;3 <italic toggle="yes">&#946;</italic>-strands using Rosetta, optimized with RosettaRemodel and FastDesign. MotifGraft docking generated 1 million sequences ranked by binding energy, with stable designs confirmed by MD and validated <italic toggle="yes">via</italic> CD spectroscopy and denaturation studies.</td><td colspan="1" rowspan="1">ThT kinetics assays confirmed the inhibitors block primary amyloid aggregation, while biosensor cell assays showed they also inhibit secondary seeding, with varying effects between tau and <italic toggle="yes">&#945;</italic>Syn inhibitors due to differences in aggregation pathways.</td><td colspan="1" rowspan="1"><xref rid="bib158" ref-type="bibr">158</xref></td></tr><tr><td colspan="1" rowspan="1">Fine-tuned Rfdiffusion, RoseTTAFold2, ProteinMPNN</td><td colspan="1" rowspan="1">IL-7R<italic toggle="yes">&#945;</italic></td><td colspan="1" rowspan="1">Fine-tuned RFdiffusion and RoseTTAFold2 on antibody structures before <italic toggle="yes">de novo</italic> antibody design. CDR loops were designed with ProteinMPNN and refined using the fine-tuned RoseTTAFold2.</td><td colspan="1" rowspan="1">Nanomolar binding affinity of the antibodies was confirmed.</td><td colspan="1" rowspan="1"><xref rid="bib159" ref-type="bibr">159</xref></td></tr><tr><td colspan="1" rowspan="1">Rosetta, AlphaFold 2, MD</td><td colspan="1" rowspan="1">Tau</td><td colspan="1" rowspan="1">The tau oligomer-selective epitope 343KLDFK347 and designed a <italic toggle="yes">&#946;</italic>-helical scaffold with multiple copies of the tau fragment (amino acids 339&#8211;354).</td><td colspan="1" rowspan="1">In SPR experiments, the <italic toggle="yes">&#946;</italic>-helical scaffold bound tau epitope antibodies, indicating a tau oligomer-like conformation.</td><td colspan="1" rowspan="1"><xref rid="bib160" ref-type="bibr">160</xref></td></tr><tr><td colspan="5" rowspan="1">Protein optimization</td></tr><tr><td colspan="1" rowspan="1">RF Classifier</td><td colspan="1" rowspan="1">IL-17A</td><td colspan="1" rowspan="1">Their &#8220;re-epitoping&#8221; strategy identifies antibodies with initial complementarity to a desired epitope. Using analyses of epitopes and paratopes, they predicted amino acid substitutions to enhance binding, generating small antibody libraries selected <italic toggle="yes">via</italic> ML.</td><td colspan="1" rowspan="1">X-ray crystallography confirmed that the designed antibody binds to the targeted epitope, and cell-based assays verified its functionality.</td><td colspan="1" rowspan="1"><xref rid="bib161" ref-type="bibr">161</xref></td></tr></tbody></table><table-wrap-foot><fn><p>AUC: Area Under the ROC Curve; AUPRC: Area Under the Precision-Recall Curve; ARROC: Area under the Robust Receiver Operating Characteristic curve; BLAST: Basic Local Alignment Search Tool; CAMEO: Continuous Automated Model Evaluation; CASP14: Critical Assessment of protein Structure Prediction, Round 14; CDR: Complementarity-Determining Region; CDR-H3: The third hypervariable region of the heavy chain CDR; CNNs: Convolutional Neural Networks; DL: Deep Learning; GDT_TS: Global Distance Test - Total Score; IL-17A: Interleukin-17A; IL-7R<italic toggle="yes">&#945;</italic>: Interleukin-7 Receptor Alpha chain; ML: Machine Learning; MCC: Matthews Correlation Coefficient; MSAs: Multiple Sequence Alignments; ProteinMPNN: Protein Message Passing Neural Network; RMSD: Root Mean Square Deviation; SE(3)-equivariant: Special Euclidean Group in 3D equivariance; SPR: Surface Plasmon Resonance.</p></fn></table-wrap-foot></table-wrap></p><p id="p0145">Docking and molecular simulation are traditional and widely used methods in SBVS for drug discovery<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref><sup>,</sup><xref rid="bib162" ref-type="bibr">162</xref>, <xref rid="bib163" ref-type="bibr">163</xref>, <xref rid="bib164" ref-type="bibr">164</xref>. The main limitation of these approaches is the high computational cost, especially when screening large compound databases, and the need for accurate protein structures, which limits the accuracy of the screening outcomes. For instance, VirtualFlow<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref>, a highly automated and versatile open-source platform, has a perfect scaling behavior for screening ultra-large libraries. Based on VirtualFlow, they identified a nanomolar affinity inhibitor for KEAP1, a target for AD and delirium, from a library of 1.4 billion make-on-demand compounds<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref>. Despite the successful discovery of hit compounds, it takes around 15 h using 160,000 CPUs to dock 1 billion compounds<xref rid="bib121" ref-type="bibr"><sup>121</sup></xref>.</p><p id="p0150">Recent developments in DL-based docking methods have demonstrated relatively faster speeds and better accuracy compared to traditional docking methods<xref rid="bib144" ref-type="bibr"><sup>144</sup></xref>. A Deep Docking platform has been introduced that speeds up the process by up to 100 times and significantly improves the identification of promising drug candidates compared to conventional computational methods<xref rid="bib144" ref-type="bibr"><sup>144</sup></xref>. The core of these DL-based docking methods are Compound Target Interactions (CTI)<xref rid="bib165" ref-type="bibr"><sup>165</sup></xref> prediction methods, which will be explained in detail later. Currently, there are limited studies focused on AD drug discovery using DL-based docking for SBVS, making this an interesting area that warrants further research.</p></sec><sec id="sec4.2.2"><label>4.2.2</label><title>De novo drug design</title><p id="p0155"><italic toggle="yes">De novo</italic> drug design is another method that utilizes generative models to design hits or carry out lead optimization based on specific demands<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref><sup>,</sup><xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr">166</xref>, <xref rid="bib167" ref-type="bibr">167</xref>, <xref rid="bib168" ref-type="bibr">168</xref>, <xref rid="bib169" ref-type="bibr">169</xref>, <xref rid="bib170" ref-type="bibr">170</xref>, <xref rid="bib171" ref-type="bibr">171</xref>, <xref rid="bib172" ref-type="bibr">172</xref>, <xref rid="bib173" ref-type="bibr">173</xref>, <xref rid="bib174" ref-type="bibr">174</xref>, <xref rid="bib175" ref-type="bibr">175</xref>, <xref rid="bib176" ref-type="bibr">176</xref>, <xref rid="bib177" ref-type="bibr">177</xref>. The generative models learn from the molecules within the training dataset, extract representative features and representations, and eventually generate new molecular structures with a high potential for better drug profiles in terms of bioactivity and other properties<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr"><sup>166</sup></xref><sup>,</sup><xref rid="bib167" ref-type="bibr"><sup>167</sup></xref>. Compared with VS, <italic toggle="yes">de novo</italic> design can generate novel molecular structures and optimize the molecules with desirable properties. However, VS identifies in-stock compounds instead of novel structures, which minimizes the time and cost for compound synthesis. As an example, a recent study used generative AI to design a small-molecule TNIK inhibitor; in a randomized, double-blind, placebo-controlled phase I clinical trial, the new compound demonstrated safety and PK profiles comparable to existing treatments, showcasing the capabilities of the generative AI-driven drug discovery pipeline<xref rid="bib168" ref-type="bibr"><sup>168</sup></xref>.</p><p id="p0160">A wide range of DL models, including GAN<xref rid="bib171" ref-type="bibr"><sup>171</sup></xref><sup>,</sup><xref rid="bib172" ref-type="bibr"><sup>172</sup></xref>, VAEs<xref rid="bib169" ref-type="bibr"><sup>169</sup></xref><sup>,</sup><xref rid="bib170" ref-type="bibr"><sup>170</sup></xref>, RL<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib173" ref-type="bibr"><sup>173</sup></xref>, RNNs<xref rid="bib174" ref-type="bibr"><sup>174</sup></xref>, GNNs<xref rid="bib175" ref-type="bibr"><sup>175</sup></xref>, transformers<xref rid="bib177" ref-type="bibr"><sup>177</sup></xref>, and diffusion models, such as RoseTTAFold All-Atom<xref rid="bib150" ref-type="bibr"><sup>150</sup></xref><sup>,</sup><xref rid="bib176" ref-type="bibr"><sup>176</sup></xref>, have been developed for <italic toggle="yes">de novo</italic> drug design. The main differences among these models lie in their molecular representation approaches, generation methods, and validation techniques. The applications of these models have also increased from molecule generation based on reference molecules to Scaffold Hopping, or drug optimization and design of 3D ligands within the protein pocket directly<xref rid="bib176" ref-type="bibr"><sup>176</sup></xref><sup>,</sup><xref rid="bib177" ref-type="bibr"><sup>177</sup></xref>.</p><p id="p0165">A generative framework was proposed for designing inhibitors for BACE1, an enzyme implicated in Alzheimer&#8217;s disease that has proven challenging to target effectively, with multiple existing clinical trial failures due to insufficient brain penetration and off-target effects<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>. Potential candidates need to demonstrate both good bioactivity for inhibiting BACE1 and good permeability through the BBB<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>. This framework utilizes a Wasserstein GAN with Gradient Penalty, which can generate new molecular structures using the generator and evaluate their bioactivity and BBB permeability using the discriminator<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>. This approach resulted in the generation of more than 1,000,000 new candidate inhibitors for BACE1 with optimal bioactivity and BBB properties<xref rid="bib122" ref-type="bibr"><sup>122</sup></xref>.</p><p id="p0170">Graph generative models were proposed to generate hits for JNK3 and GSK3B using substructures called molecular rationales, identified based on their contribution to properties of interest<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>. These models expand molecular fragments&#8212;referred to as &#8216;rationales&#8217; in this context (key structural elements contributing to specific properties or biological activities)&#8212;into complete molecules. They compose these molecules as mixtures of multiple rational completions and are fine-tuned to maintain the desired properties<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref>. This generative approach shows significant improvements in the accuracy, diversity, and novelty of generated compounds compared to state-of-the-art baselines in various drug design tasks<xref rid="bib174" ref-type="bibr"><sup>174</sup></xref>.</p><p id="p0175">However, most <italic toggle="yes">de novo</italic> design work relies on <italic toggle="yes">in silico</italic> methods instead of wet lab experiments to validate the outcomes<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref><sup>,</sup><xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr">166</xref>, <xref rid="bib167" ref-type="bibr">167</xref>, <xref rid="bib168" ref-type="bibr">168</xref>, <xref rid="bib169" ref-type="bibr">169</xref>, <xref rid="bib170" ref-type="bibr">170</xref>, <xref rid="bib171" ref-type="bibr">171</xref>, <xref rid="bib172" ref-type="bibr">172</xref>, <xref rid="bib173" ref-type="bibr">173</xref>, <xref rid="bib174" ref-type="bibr">174</xref>, <xref rid="bib175" ref-type="bibr">175</xref>, <xref rid="bib176" ref-type="bibr">176</xref>, <xref rid="bib177" ref-type="bibr">177</xref>. This is mainly because novel structures are difficult to synthesize. This limitation prevents proper assessment of the results in real-world scenarios for different DL approaches, thereby constraining the advancement of these models for AD and delirium drug discovery.</p></sec><sec id="sec4.2.3"><label>4.2.3</label><title>Drug repurposing</title><p id="p0180">Drug repurposing, also known as drug repositioning, is a strategy in the biopharmaceutical industry that involves finding new therapeutic uses for existing drugs<xref rid="bib178" ref-type="bibr"><sup>178</sup></xref>. While the development of new drugs is typically costly and time-consuming, repurposing existing drugs not only accelerates the process but also benefits from previously-known safety profiles<xref rid="bib179" ref-type="bibr"><sup>179</sup></xref>. Effective therapies have been identified for many diseases through drug repurposing, including cancer and Parkinson&#8217;s disease, demonstrating the effectiveness of this approach for drug discovery<xref rid="bib180" ref-type="bibr"><sup>180</sup></xref><sup>,</sup><xref rid="bib181" ref-type="bibr"><sup>181</sup></xref>. The Ballard et al.<xref rid="bib182" ref-type="bibr"><sup>182</sup></xref> study serves as an example of how a literature review combined with the Delphi consensus process can be employed to identify potential repurposed agents for AD. For example, memantine, initially developed as an anti-diabetic agent, has been repurposed for AD<xref rid="bib183" ref-type="bibr"><sup>183</sup></xref>.</p><p id="p0185">There are also multiple studies leveraging DL approaches for drug repurposing in AD<xref rid="bib124" ref-type="bibr">124</xref>, <xref rid="bib125" ref-type="bibr">125</xref>, <xref rid="bib126" ref-type="bibr">126</xref>, <xref rid="bib127" ref-type="bibr">127</xref><sup>,</sup><xref rid="bib178" ref-type="bibr"><sup>178</sup></xref><sup>,</sup><xref rid="bib182" ref-type="bibr"><sup>182</sup></xref><sup>,</sup><xref rid="bib184" ref-type="bibr"><sup>184</sup></xref><sup>,</sup><xref rid="bib185" ref-type="bibr"><sup>185</sup></xref>. Compared to traditional drug repurposing methods, which rely on human efforts to review literature and vote on results, DL provides a more effective approach. It can integrate structured biological contexts, such as pathways and networks, as well as analyze large-scale multi-omics datasets. By identifying potential targets, and recommending drugs based on drug-target network predictions<xref rid="bib184" ref-type="bibr"><sup>184</sup></xref>, DL facilitates more effective drug repurposing by providing a comprehensive analysis of the diseases, leading to better identification of potential drug candidates<xref rid="bib182" ref-type="bibr"><sup>182</sup></xref><sup>,</sup><xref rid="bib186" ref-type="bibr"><sup>186</sup></xref>.</p><p id="p0190">As an example, a network topology-based DL framework (NETTAG)<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref> has been presented, which integrates diverse molecular quantitative trait loci (QTLs) datasets, such as expression-QTL and histone-QTL, with the human PPI networks<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref>. This approach identified over 150 AD-risk genes and numerous druggable targets, highlighting the framework&#8217;s potential in uncovering disease mechanisms and advancing therapeutic development<xref rid="bib185" ref-type="bibr"><sup>185</sup></xref>. By leveraging network-based predictions and retrospective case&#8211;control analyses involving 10 million individuals, NETTAG identified four drugs (ibuprofen, gemfibrozil, cholecalciferol, and ceftriaxone) as being associated with a reduced risk of AD incidence. This work underscores the power of using DL to analyze various data sources to drive drug repurposing efforts<xref rid="bib124" ref-type="bibr"><sup>124</sup></xref>.</p><p id="p0195">Similarly, as mentioned, different studies have utilized various types of multi-omics data, such as genomics, transcriptomics, epigenetics, and drug-target networks, to identify potential drugs for AD<xref rid="bib125" ref-type="bibr">125</xref>, <xref rid="bib126" ref-type="bibr">126</xref>, <xref rid="bib127" ref-type="bibr">127</xref>. These studies demonstrate the ability of DL to analyze complex datasets and generate drug repurposing results.</p></sec><sec id="sec4.2.4"><label>4.2.4</label><title>Compound-Target Interaction prediction</title><p id="p0200">Compound-Target Interaction (CTI) prediction, also known as affinity or drug-target interaction prediction, involves forecasting the biochemical interaction between a compound and a specific biological target, usually a protein<xref rid="bib165" ref-type="bibr"><sup>165</sup></xref>. The compound binds to the target at a specific site, and the strength of this interaction, determined by factors such as hydrogen bonding, hydrophobic interactions, and van der Waals forces, is referred to as affinity. Accurate CTI predictions help identify compounds that can modulate target protein activity, leading to therapeutic effects<xref rid="bib187" ref-type="bibr"><sup>187</sup></xref>. CTI prediction can serve as <italic toggle="yes">in silico</italic> assessment metrics for VS and <italic toggle="yes">de novo</italic> design, enabling the identification and optimization of compounds with better affinity for drug targets, ultimately improving the pharmacodynamics of drugs<xref rid="bib188" ref-type="bibr"><sup>188</sup></xref>.</p><p id="p0205">ML approaches have been developed for predicting CTIs<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>, <xref rid="bib192" ref-type="bibr">192</xref>, <xref rid="bib193" ref-type="bibr">193</xref>. Quantitative structure&#8211;activity relationship (QSAR) models, which predict compound properties from molecular structure, are widely used in CTI prediction for AD<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>, <xref rid="bib192" ref-type="bibr">192</xref>, <xref rid="bib193" ref-type="bibr">193</xref>. These models leverage molecular descriptors (numerical values for properties like hydrophobicity, electronic distribution, hydrogen bonding, and geometry) and apply statistical or ML techniques to predict how structural changes affect CTIs<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib189" ref-type="bibr"><sup>189</sup></xref>. QSAR-based methods have been widely applied to develop CTI prediction models for various targets, including AChE, KEAP1, BACE1, and butyrylcholinesterase inhibitors, using techniques like ensemble learning and artificial neural networks, as shown in <xref rid="tbl4" ref-type="table">Table 4</xref>
<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>, <xref rid="bib192" ref-type="bibr">192</xref>. Other studies have demonstrated that QSAR modeling can predict the CTIs of compounds against multiple different targets<xref rid="bib191" ref-type="bibr"><sup>191</sup></xref><sup>,</sup><xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>. These studies underscore the wide application of QSAR modeling for CTI prediction in AD drug discovery.</p><p id="p0210">However, these QSAR models rely solely on two-dimensional molecular descriptors without accounting for the three-dimensional spatial arrangement of the compound interacting with proteins<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>, <xref rid="bib192" ref-type="bibr">192</xref>, <xref rid="bib193" ref-type="bibr">193</xref>. This limitation results in a lack of robustness and generalizability in the prediction outcomes. To address this, some research integrates 3D-based descriptors, generated by docking programs, into the modeling process to incorporate three-dimensional information<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib194" ref-type="bibr"><sup>194</sup></xref>. Researchers incorporate 3D information generated by Open Babel, Smina, 3D field-based descriptors, and molecular docking to improve prediction accuracy. This enhances prediction performance and has led to good results in competitions such as the Drug Design Data Resource Grand Challenge 4<xref rid="bib129" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib194" ref-type="bibr"><sup>194</sup></xref>. However, these 3D QSAR models also have a major drawback: inaccurate docking results can lead to inaccuracies in the 3D-based descriptors, resulting in false predictions<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib193" ref-type="bibr"><sup>193</sup></xref>.</p><p id="p0215">Recent advances in DL models for predicting CTIs based on protein and compound representations provide alternative techniques with higher accuracy compared to docking and QSAR models<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib195" ref-type="bibr"><sup>195</sup></xref>. AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>, for example, uses multiple sequence alignments to identify residue pairs that co-mutate, indicating that these pairs are likely in proximity in 3D space<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. It then employs a graph-based representation to link these residue pairs and predict a probable 3D structure, like AlphaFold 2<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>. Additionally, AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> includes a diffusion model that utilizes &#8216;noised&#8217; atomic coordinates, which is beneficial for proteins with limited Multiple Sequence Alignment coverage, such as antibodies and novel proteins. It achieves significantly higher accuracy in predicting protein-ligand binding conformations (measured by more structures with less than 2 &#197;ngstr&#246;ms deviation from experimental structures) compared to the best traditional docking program, Vina, when evaluated on PoseBusters, a standard benchmark dataset designed to assess the quality of molecular docking predictions<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. Specifically, AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> shows a 37.9% higher percentage for PoseBusters V1 (89.2% <italic toggle="yes">vs</italic>. 52.3%) and a 33.5% higher percentage for PoseBusters V2 (93.2% <italic toggle="yes">vs</italic>. 59.7%)<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref>. Other DL models, such as TransformerCPI, have been developed to improve the prediction accuracy of CTIs<xref rid="bib195" ref-type="bibr"><sup>195</sup></xref>.</p><p id="p0220">Researchers are also exploring similar methods for AD-related drug discovery<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib133" ref-type="bibr"><sup>133</sup></xref>. For instance, MathDL<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref> uses techniques such as differential geometry and algebraic topology to encode complex interactions into low-dimensional representations, excelling in pose prediction for BACE1 ligands, achieving the top position in pose prediction for BACE1 ligands in Stage 1a<xref rid="bib132" ref-type="bibr"><sup>132</sup></xref>. Another approach combines a bipartite GNNs with transfer learning&#8212;an algorithm that applies knowledge gained from one problem to help solve related problems&#8212;creating representations of both drug molecules and protein binding sites. This method outperformed the leading competitor by 9% when predicting interactions with the BACE1 target<xref rid="bib133" ref-type="bibr"><sup>133</sup></xref>. These studies highlight the potential of DL to predict compound&#8211;target interactions directly from protein and compound inputs.</p></sec><sec id="sec4.2.5"><label>4.2.5</label><title>ADMET optimization</title><p id="p0225">Optimization of Absorption, Distribution, Metabolism, and Excretion-Toxcitity (ADMET) properties is critical in drug discovery as it affects a drug&#8217;s efficacy, safety, and clinical success<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref>. Early assessment and optimization of these PK properties help reduce late-stage failures and associated costs<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref>. Computational approaches offer a fast, cost&#8211;effective way to focus on candidates with better ADMET potential, thereby minimizing the need for labor-intensive wet-lab experiments<xref rid="bib197" ref-type="bibr"><sup>197</sup></xref>. These computational ADMET prediction and optimization methods enable rapid screening, predictive modeling, integration with experimental data, and iterative optimization of lead compounds, ultimately enhancing the efficiency and success rate of drug development.</p><p id="p0230">ADMET prediction has evolved significantly, but started with rule-based methods based on expert summarization. For instance, Lipinski&#8217;s Rule of Five<xref rid="bib198" ref-type="bibr"><sup>198</sup></xref>, formulated by Christopher A. Lipinski in 1997, is a set of guidelines for evaluating the drug-likeness of a compound, particularly its potential as an orally active drug in humans<xref rid="bib199" ref-type="bibr"><sup>199</sup></xref>. Another widely used expert system is Derek for Toxicity<xref rid="bib200" ref-type="bibr"><sup>200</sup></xref>, which predicts potential toxicological endpoints based on structural alerts&#8212;specific chemical substructures or patterns associated with known toxic effects<xref rid="bib200" ref-type="bibr"><sup>200</sup></xref><sup>,</sup><xref rid="bib201" ref-type="bibr"><sup>201</sup></xref>. By analyzing the structural features of a compound, Derek can provide early warning signs of potential toxicity, aiding researchers in the drug development process and helping to prioritize safer compounds for further testing<xref rid="bib201" ref-type="bibr"><sup>201</sup></xref>. However, rule-based methods for ADMET prediction are limited by their static nature, often excluding promising compounds and including toxic ones due to their inability to cover the complex and diverse chemical space.</p><p id="p0235">Recent developments in QSAR-based approaches and DL models provide improved methods for automatically learning complex patterns from large datasets, leading to more accurate predictions of ADMET properties<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref><sup>,</sup><xref rid="bib202" ref-type="bibr">202</xref>, <xref rid="bib203" ref-type="bibr">203</xref>, <xref rid="bib204" ref-type="bibr">204</xref>, <xref rid="bib205" ref-type="bibr">205</xref>, <xref rid="bib206" ref-type="bibr">206</xref>, <xref rid="bib207" ref-type="bibr">207</xref>. These advanced models can analyze vast amounts of data to uncover intricate relationships between molecular structures and their PK and toxicological profiles. Similar to CTIs, ADMET prediction can also leverage ML algorithms to analyze descriptors, as seen in 2D QSAR models<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref>. For DL approaches, various methods have been developed for ADMET prediction, such as MPNN<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib202" ref-type="bibr"><sup>202</sup></xref>, GNNs<xref rid="bib203" ref-type="bibr">203</xref>, <xref rid="bib204" ref-type="bibr">204</xref>, <xref rid="bib205" ref-type="bibr">205</xref>, and graph transformers<xref rid="bib186" ref-type="bibr"><sup>186</sup></xref><sup>,</sup><xref rid="bib206" ref-type="bibr"><sup>206</sup></xref><sup>,</sup><xref rid="bib207" ref-type="bibr"><sup>207</sup></xref>.</p><p id="p0240">Additionally, there are multiple online platforms for ADMET prediction based on DL approaches<xref rid="bib208" ref-type="bibr">208</xref>, <xref rid="bib209" ref-type="bibr">209</xref>, <xref rid="bib210" ref-type="bibr">210</xref>, <xref rid="bib211" ref-type="bibr">211</xref>, <xref rid="bib212" ref-type="bibr">212</xref>, <xref rid="bib213" ref-type="bibr">213</xref>. ADMETLab 3.0<xref rid="bib208" ref-type="bibr"><sup>208</sup></xref> is a web server that employs a multi-task Directed MPNN architecture, enabling the prediction of over 119 ADMET endpoints<xref rid="bib208" ref-type="bibr"><sup>208</sup></xref>. Similarly, platforms such as ADMET-boost, admetSAR 2.0, SwissADME FAF-Drugs4, vNN-ADMET, and pkCSM provide accessible online tools for <italic toggle="yes">in silico</italic> ADMET prediction, streamlining the drug discovery process by offering rapid and reliable computational assessments<xref rid="bib209" ref-type="bibr">209</xref>, <xref rid="bib210" ref-type="bibr">210</xref>, <xref rid="bib211" ref-type="bibr">211</xref>, <xref rid="bib212" ref-type="bibr">212</xref>, <xref rid="bib213" ref-type="bibr">213</xref>.</p><p id="p0245">For AD and delirium drug discovery, effective drugs need to cross the BBB to reach their targets in the central nervous system<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref>. To properly assess the BBB permeability of a compound, a dataset of 7162 compounds with BBB permeability data was constructed using information compiled from the literature<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref>. Authors then trained a ML model based on the Light Gradient Boosting Machine algorithm (a decision-tree based algorithm that efficiently handles large datasets and delivers fast and accurate predictions)<xref rid="bib214" ref-type="bibr"><sup>214</sup></xref> and achieved an overall accuracy of 89% for predicting BBB permeability<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref>. Similarly, another DL-based multi-model framework, Deep-B3, which includes molecular descriptors and fingerprints, molecular graphs, and SMILES text notation as feature inputs has been developed to predict BBB permeability<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref>. The online web server for Deep-B3 is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cbcb.cdutcm.edu.cn/deepb3/" id="intref0010">http://cbcb.cdutcm.edu.cn/deepb3/</ext-link> for free access<xref rid="bib135" ref-type="bibr"><sup>135</sup></xref>. Many other DL-based approaches to predict BBB permeability exist, including RNNs<xref rid="bib215" ref-type="bibr"><sup>215</sup></xref>, GCNs<xref rid="bib216" ref-type="bibr"><sup>216</sup></xref>, and attentive GNNs<xref rid="bib215" ref-type="bibr"><sup>215</sup></xref>.</p><p id="p0250">In addition, drug dosing and administration can be optimized using AI for delirium and AD. For instance, RL has been applied to identify the best dosing for dexmedetomidine in delirium patients, optimizing clinical outcomes to prevent delirium in intensive care unit patients<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref><sup>,</sup><xref rid="bib218" ref-type="bibr"><sup>218</sup></xref>.</p></sec></sec><sec id="sec4.3"><label>4.3</label><title>Protein-based therapeutics</title><p id="p0255">Protein-based therapeutics encompass categories such as protein or peptides (short chains of amino acids used for signaling or as hormones), antibodies (immune proteins designed to target specific antigens), and other therapeutic proteins such as enzymes and cytokines that modulate biological processes<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref>. Protein-based therapeutics have shown promising results in clinical trials for AD treatment, slowing disease progression and improving cognitive function<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref><sup>,</sup><xref rid="bib220" ref-type="bibr"><sup>220</sup></xref>.</p><p id="p0260">Recently, the US FDA approved lecanemab<xref rid="bib221" ref-type="bibr"><sup>221</sup></xref>, an IgG1 monoclonal antibody, for AD treatment. An 18-month, multicentre, double-blind Phase III clinical trial demonstrated that lecanemab reduced amyloid markers in early AD and led to a small but significant deceleration of cognitive and functional decline compared to placebo, although it was associated with severe adverse events<xref rid="bib222" ref-type="bibr"><sup>222</sup></xref>. Additionally, other antibodies like donanemab and remternetug have shown promising results in Phase III trials for reducing amyloid markers<xref rid="bib223" ref-type="bibr"><sup>223</sup></xref>, with donanemab approved by the FDA on July 2, 2024<xref rid="bib224" ref-type="bibr"><sup>224</sup></xref>.</p><p id="p0265">The discovery of protein-based therapeutics such as antibodies has traditionally relied on experimental methods such as directed evolution<xref rid="bib225" ref-type="bibr"><sup>225</sup></xref> and animal immunization<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref><sup>,</sup><xref rid="bib225" ref-type="bibr"><sup>225</sup></xref>. However, these approaches are time-consuming, labor-intensive, and face challenges in targeting epitopes and scaling antibody production<xref rid="bib226" ref-type="bibr"><sup>226</sup></xref>. Recent developments in various AI predictive modeling approaches, such as AlphaFold for structure prediction<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>, ProteinMPNN for protein sequence design<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref>, and ESM3 as a generative foundation model<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref>, offer alternative methods by applying computational and AI-based techniques to protein design with desirable functions<xref rid="bib228" ref-type="bibr"><sup>228</sup></xref><sup>,</sup><xref rid="bib229" ref-type="bibr"><sup>229</sup></xref>. This section will focus on discussing the applications of AI in the development of protein-based therapeutics for AD and delirium (<xref rid="tbl4" ref-type="table">Table 4</xref>).</p><sec id="sec4.3.1"><label>4.3.1</label><title>Structure and binding site prediction</title><p id="p0270">Understanding a protein&#8217;s structure is crucial for rational protein design, as even minor mutations in its sequence can lead to structural changes that significantly affect various characteristics of the drug, such as binding affinity, specificity, and stability<xref rid="bib220" ref-type="bibr"><sup>220</sup></xref>. However, determining accurate protein structures is a lengthy and costly process, posing one of the major obstacles to rational drug design for protein-based therapeutics<xref rid="bib230" ref-type="bibr"><sup>230</sup></xref>. Traditionally, protein structures have been predicted computationally through physics-based modeling techniques like molecular dynamics (MD) simulations<xref rid="bib231" ref-type="bibr"><sup>231</sup></xref>, homology-based modeling<xref rid="bib232" ref-type="bibr"><sup>232</sup></xref>, or hybrid approaches such as MODELLER<xref rid="bib233" ref-type="bibr"><sup>233</sup></xref>. However, these methods rely on known structural information, are computationally intensive, and have limitations in their scoring functions<xref rid="bib234" ref-type="bibr"><sup>234</sup></xref>.</p><p id="p0275">AlphaFold 2, a ML-based model released in 2020, represents a significant breakthrough in protein structure prediction<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref>. It won first place in the 14th Critical Assessment of Structure Prediction&#8212;a global community-wide experiment to evaluate the state of the art in protein structure prediction&#8212;achieving high backbone accuracy (with GDT_TS values exceeding 85%) even for complex protein structures<xref rid="bib235" ref-type="bibr"><sup>235</sup></xref>. Additionally, DL models such as EquiFold<xref rid="bib217" ref-type="bibr"><sup>217</sup></xref>, DeepH3<xref rid="bib148" ref-type="bibr"><sup>148</sup></xref>, and ABLooper<xref rid="bib149" ref-type="bibr"><sup>149</sup></xref> have been developed to predict specific protein structures like antibodies, addressing challenges such as the diverse conformations of antibody complementarity-determining regions, which can result in low prediction accuracy. Recently, DL approaches like RoseTTAFold All-Atom<xref rid="bib150" ref-type="bibr"><sup>150</sup></xref> and AlphaFold 3<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> have extended prediction capabilities for joint structures of complexes, including proteins, nucleic acids, small molecules, ions, and modified residues. This broadens the application of these models in biological studies and drug design.</p><p id="p0280">In addition to protein structure prediction, identifying potential protein binding sites is vital for drug design and optimization<xref rid="bib151" ref-type="bibr">151</xref>, <xref rid="bib152" ref-type="bibr">152</xref>, <xref rid="bib153" ref-type="bibr">153</xref>, <xref rid="bib154" ref-type="bibr">154</xref>, <xref rid="bib155" ref-type="bibr">155</xref>, <xref rid="bib156" ref-type="bibr">156</xref><sup>,</sup><xref rid="bib236" ref-type="bibr"><sup>236</sup></xref>. Several computational methods have been developed to predict and analyze these binding sites. Tools like ProB-Site<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref>, EquiBind<xref rid="bib152" ref-type="bibr"><sup>152</sup></xref>, DiffDock<xref rid="bib236" ref-type="bibr"><sup>236</sup></xref> and TANKBind<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref> are designed to predict and examine the protein binding sites critical for drug interaction. For more specialized tasks such as epitope and paratope prediction in antibodies, methods like EpiCluster<xref rid="bib154" ref-type="bibr"><sup>154</sup></xref>, EpiDope<xref rid="bib155" ref-type="bibr"><sup>155</sup></xref>, and BepFAMN<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref> have been developed to provide specific insights, enhancing the precision of antibody design. These tools help address the complexities involved in predicting binding interactions, ultimately improving the efficacy of therapeutic interventions.</p><p id="p0285">Overall, recent developments in DL modeling allow for more accurate predictions of protein structure based on sequence data. This has become an important procedure for protein-based therapeutic discovery. Additionally, the representation component of structure prediction models has been used for developing protein design models. Despite the fact that errors may occur with complex proteins and flexible regions, these structure prediction approaches are becoming increasingly important and are widely applied in modern protein therapeutic discovery<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref>.</p></sec><sec id="sec4.3.2"><label>4.3.2</label><title>De novo protein design</title><p id="p0290">Protein <italic toggle="yes">de novo</italic> design refers to the process of creating new protein structures and sequences entirely from scratch, without using templates from existing natural proteins<xref rid="bib238" ref-type="bibr"><sup>238</sup></xref>. The goal is to engineer proteins with specific structures and functions that don&#8217;t naturally exist. For example, Rosetta Design<xref rid="bib239" ref-type="bibr"><sup>239</sup></xref> is a well-known suite of computational tools for protein design. It uses an energy minimization approach to predict and optimize protein structures, with algorithms for tasks such as sequence redesign, protein docking, and <italic toggle="yes">de novo</italic> design. However, these traditional methods are often limited because they rely on modifying existing proteins, which constrains their application<xref rid="bib237" ref-type="bibr"><sup>237</sup></xref><sup>,</sup><xref rid="bib238" ref-type="bibr"><sup>238</sup></xref>.</p><p id="p0295">Recently, several generative AI methods for <italic toggle="yes">de novo</italic> protein design have emerged, such as ProteinMPNN<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref> and Rosetta Diffusion<xref rid="bib240" ref-type="bibr"><sup>240</sup></xref>. These advanced computational approaches use DL models, including diffusion models, language models, and VAEs, to directly generate protein structures without needing specific templates<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref><sup>,</sup><xref rid="bib240" ref-type="bibr"><sup>240</sup></xref>. By leveraging vast amounts of protein structure and sequence data through pretraining, these generative models are able to create entirely new sequences or structures<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref><sup>,</sup><xref rid="bib240" ref-type="bibr"><sup>240</sup></xref>.</p><p id="p0300"><italic toggle="yes">De novo</italic>-designed scaffolds with deep peptide-binding clefts were used to prevent amyloid fibril formation by targeting amyloidogenic sequences like A<italic toggle="yes">&#946;</italic>42, tau, and serum amyloid A1<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>. Researchers leveraged the peptides&#8217; tendency to form <italic toggle="yes">&#946;</italic>-strands, designing scaffolds with a central <italic toggle="yes">&#946;</italic>-strand and <italic toggle="yes">&#945;</italic>-helices. Using Rosetta<xref rid="bib241" ref-type="bibr"><sup>241</sup></xref> for sequence optimization and AlphaFold2<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> for validation, they refined the binders for high affinity through hydrophobic interactions<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>. The binders inhibited A<italic toggle="yes">&#946;</italic>42 fibril formation <italic toggle="yes">in vitro</italic> and in cells, showing nanomolar affinities comparable to antibodies like aducanumab, and blocked secondary nucleation sites, offering tools for studying amyloid species<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref>.</p><p id="p0305">Inhibitors were designed to prevent amyloid fibril growth by capping their ends<xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>. Using Rosetta, authors created a library of miniproteins (35&#8211;48 amino acids) with <italic toggle="yes">&#945;</italic>-helices and <italic toggle="yes">&#946;</italic>-strands, optimized for binding energy and stability<xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>. Docking <italic toggle="yes">via</italic> the MotifGraft protocol and MD identified stable designs, which were validated through circular dichroism spectroscopy and denaturation studies<xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>. Thioflavin T kinetics assays confirmed that the inhibitors block amyloid aggregation, and biosensor assays showed inhibition of secondary seeding, with distinct effects for tau and <italic toggle="yes">&#945;</italic>Syn due to differences in their aggregation pathways<xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>.</p><p id="p0310"><italic toggle="yes">De novo</italic>-designed VHH antibodies, variable domains of heavy chain-only antibodies, also known as nanobodies (small, single-domain antibody fragments), targeting specific epitopes were developed using a fine-tuned RF diffusion network<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. RFdiffusion and RoseTTAFold2 were fine-tuned on antibody structures, designing complementarity-determining regions loops witSh ProteinMPNN and refining them further with RoseTTAFold2<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. Using a humanized VHH framework, researchers created antibodies targeting interleukin-7 receptor alpha, a potential target for AD<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>. The designed antibodies showed nanomolar-level binding affinity, highlighting the potential of <italic toggle="yes">de novo</italic> antibody design for treating these conditions<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref>.</p><p id="p0315"><italic toggle="yes">De novo</italic> design weas applied to develop a novel cyclic peptide that resembles toxic tau aggregates, providing an improved platform for evaluating potential therapeutic antibodies in Alzheimer&#8217;s disease research<xref rid="bib242" ref-type="bibr"><sup>242</sup></xref>. Authors incorporated multiple copies of the tau fragment (339&#8211;354) into a <italic toggle="yes">&#946;</italic>-helical scaffold<xref rid="bib242" ref-type="bibr"><sup>242</sup></xref>. Surface plasmon resonance experiments showed the scaffold effectively bound tau-specific antibodies, closely mimicking the conformation of toxic tau oligomers<xref rid="bib242" ref-type="bibr"><sup>242</sup></xref>. The scaffold&#8217;s ability to mimic oligomer conformation suggests it could serve as an effective immunogen and supports the use of <italic toggle="yes">de novo</italic> protein design for both drug development and <italic toggle="yes">in vitro</italic> assay creation for screening<xref rid="bib242" ref-type="bibr"><sup>242</sup></xref>.</p><p id="p0320">Overall, while the development of <italic toggle="yes">de novo</italic> protein design using generative models is still relatively new, there is already substantial research highlighting their potential in protein drug discovery. Future studies may explore combining generative protein design models with MD simulations, docking, and other computational methods to further accelerate protein drug design for conditions such as AD and delirium.</p></sec><sec id="sec4.3.3"><label>4.3.3</label><title>Protein optimization</title><p id="p0325">As mentioned earlier, the discovery of protein-based therapeutics, particularly antibodies, has traditionally relied on animal immunization<xref rid="bib219" ref-type="bibr"><sup>219</sup></xref>. Consequently, various computational approaches have been developed to further optimize natural proteins by improving factors such as binding specificity and affinity, reducing immunogenicity, preventing aggregation, increasing bioavailability, decreasing molecular weight, solubility, aggregation propensity, and extending half-life<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref><sup>,</sup><xref rid="bib158" ref-type="bibr"><sup>158</sup></xref><sup>,</sup><xref rid="bib243" ref-type="bibr">243</xref>, <xref rid="bib244" ref-type="bibr">244</xref>, <xref rid="bib245" ref-type="bibr">245</xref>, <xref rid="bib246" ref-type="bibr">246</xref>. These protein properties are important for the clinical success of protein drugs. For example, antibody therapeutics can aggregate, which may result in precipitation and a reduced shelf life before administration<xref rid="bib247" ref-type="bibr"><sup>247</sup></xref>. Additionally, aggregation within the body can increase the drug&#8217;s immunogenicity, potentially triggering unwanted immune responses<xref rid="bib248" ref-type="bibr"><sup>248</sup></xref>. As a result, different data modeling approaches have been established to predict these properties and enable better selection of protein candidates with the most optimal properties.</p><p id="p0330">An antibody for interleukin-17 receptor alpha, a potential target for AD, was optimized to enhance selectivity and affinity<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref> using a &#8220;re-epitoping&#8221; strategy. This strategy is a sophisticated approach to antibody engineering that begins with identifying antibodies possessing initial complementarity&#8212;such as similar shape or charge&#8212;to a desired epitope, even if their original binding target is unrelated<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>. By utilizing knowledge-driven and physicochemical analyses of thousands of epitopes and paratopes, amino acid substitutions were strategically predicted to enhance complementarity<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>. Small libraries of antibody variants were subsequently created and screened <italic toggle="yes">in silico</italic> for binding affinity to the novel target protein, guided by a ML algorithm<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>. The structural accuracy of the designed antibody binding to the targeted epitope was confirmed through X-ray crystallography, while cell-based assays validated its functional efficacy<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref>.</p><p id="p0335">There are various methods to enhance the drug-likeness of protein-based therapeutics, such as reducing immunogenicity, preventing aggregation, lowering viscosity, and extending the protein&#8217;s half-life <xref rid="bib157" ref-type="bibr">157</xref>, <xref rid="bib158" ref-type="bibr">158</xref>, <xref rid="bib159" ref-type="bibr">159</xref><sup>,</sup><xref rid="bib249" ref-type="bibr">249</xref>, <xref rid="bib250" ref-type="bibr">250</xref>, <xref rid="bib251" ref-type="bibr">251</xref>, <xref rid="bib252" ref-type="bibr">252</xref>, <xref rid="bib253" ref-type="bibr">253</xref>. For instance, tools like ProteinMPNN<xref rid="bib227" ref-type="bibr"><sup>227</sup></xref> can assist in refining surface residues for crystallization and humanization, helping reduce immunogenicity<xref rid="bib157" ref-type="bibr"><sup>157</sup></xref><sup>,</sup><xref rid="bib158" ref-type="bibr"><sup>158</sup></xref>. Additionally, solubility and aggregation prediction tools like Camsol<xref rid="bib249" ref-type="bibr"><sup>249</sup></xref>, SOLart<xref rid="bib250" ref-type="bibr"><sup>250</sup></xref>, and AGGRESCAN 3D<xref rid="bib251" ref-type="bibr"><sup>251</sup></xref>, as well as humanization tools such as Hu-mAb<xref rid="bib252" ref-type="bibr"><sup>252</sup></xref>, and BioPhi<xref rid="bib253" ref-type="bibr"><sup>253</sup></xref>, provide valuable insights into optimizing protein properties. However, the application of these models for improving protein drug properties related to AD and delirium remains limited, necessitating further studies.</p></sec></sec><sec id="sec4.4"><label>4.4</label><title>Biomarker discovery and disease diagnosis</title><p id="p0340">Biomarkers are used to evaluate disease risk, confirm diagnoses, or predict progression as measurable indicators of biological processes, disease activity, or treatment responses<xref rid="bib254" ref-type="bibr"><sup>254</sup></xref>. Research in dementia and delirium has explored a wide range of biomarkers across various biological domains, including genetics, gene expression, proteins, metabolism, neuroimaging, electrophysiology, gut microbiota, sleep patterns, gait, and digital measures<xref rid="bib255" ref-type="bibr">255</xref>, <xref rid="bib256" ref-type="bibr">256</xref>, <xref rid="bib257" ref-type="bibr">257</xref>, <xref rid="bib258" ref-type="bibr">258</xref>, <xref rid="bib259" ref-type="bibr">259</xref>, <xref rid="bib260" ref-type="bibr">260</xref>, <xref rid="bib261" ref-type="bibr">261</xref>, <xref rid="bib262" ref-type="bibr">262</xref>, <xref rid="bib263" ref-type="bibr">263</xref>, <xref rid="bib264" ref-type="bibr">264</xref>.</p><p id="p0345">Metabolomic biomarkers have been shown to enhance the understanding of postoperative delirium pathogenesis<xref rid="bib264" ref-type="bibr"><sup>264</sup></xref>. By applying ML algorithms such as XGBoost (eXtreme Gradient Boosting)<xref rid="bib265" ref-type="bibr"><sup>265</sup></xref> and denoising autoencoders<xref rid="bib266" ref-type="bibr"><sup>266</sup></xref><sup>,</sup><xref rid="bib267" ref-type="bibr"><sup>267</sup></xref>, researchers successfully identified potential primary and secondary markers from serum samples, highlighting the potential of ML in discovering delirium biomarkers<xref rid="bib264" ref-type="bibr"><sup>264</sup></xref>.</p><p id="p0350">Neuroimaging biomarkers, such as MRI or PET scans, can reveal structural or functional changes in the brain, while protein-based biomarkers in blood or cerebrospinal fluid can detect abnormal levels of amyloid or tau associated with neurodegenerative conditions<xref rid="bib259" ref-type="bibr"><sup>259</sup></xref><sup>,</sup><xref rid="bib262" ref-type="bibr"><sup>262</sup></xref><sup>,</sup><xref rid="bib263" ref-type="bibr"><sup>263</sup></xref>. Digital tools, including wearable devices, mobile apps, and sensors, provide continuous, real-world monitoring, capturing biomarkers related to movement, sleep, heart rate variability, and cognitive function<xref rid="bib260" ref-type="bibr"><sup>260</sup></xref><sup>,</sup><xref rid="bib268" ref-type="bibr"><sup>268</sup></xref>. ML models can then integrate this diverse information, identifying patterns within complex datasets and predicting disease outcomes or treatment responses with greater precision, an area where traditional statistical analysis methods often face challenges<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref>. Furthermore, AI can facilitate biomarker discovery by enabling the molecular subtyping of dementia and potentially uncovering relationships between complex conditions such as delirium and AD<xref rid="bib269" ref-type="bibr">269</xref>, <xref rid="bib270" ref-type="bibr">270</xref>, <xref rid="bib271" ref-type="bibr">271</xref>.</p><p id="p0355">Researchers have developed effective data representation approaches for these different data modalities, allowing for the identification of hidden relationships between biomarkers and diseases. In addition, AI models such as RNNs are well-suited for analyzing time-series data, providing an effective method for studying disease progression<xref rid="bib272" ref-type="bibr"><sup>272</sup></xref><sup>,</sup><xref rid="bib273" ref-type="bibr"><sup>273</sup></xref>.</p><p id="p0360">However, challenges remain regarding the availability of high-quality patient data, particularly related to data heterogeneity, patient data security, and trust in AI. Data collected from various sources, such as neuroimaging, digital tools, and molecular assays, can differ significantly in format, scale, and quality, creating challenges for harmonization and integration<xref rid="bib274" ref-type="bibr"><sup>274</sup></xref>. Additionally, ensuring patient data security and privacy is crucial, as sensitive health information must be protected to comply with ethical standards and regulations. Furthermore, building trust in AI models used for biomarker discovery and disease prediction requires transparency in how these models process data, make decisions, and address biases. Addressing these factors is key to advancing AI-driven research in dementia and delirium while maintaining the ethical use of patient data<xref rid="bib275" ref-type="bibr"><sup>275</sup></xref>.</p></sec></sec><sec id="sec5"><label>5</label><title>Discussion</title><p id="p0365">Delirium and AD share common challenges in drug discovery. Biologically, our understanding of their mechanisms remains incomplete, and reliable animal models, especially for delirium, are lacking<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>. Chemically, designing drugs that effectively bind to their targets and cross the BBB is difficult<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref><sup>,</sup><xref rid="bib135" ref-type="bibr"><sup>135</sup></xref><sup>,</sup><xref rid="bib196" ref-type="bibr"><sup>196</sup></xref><sup>,</sup><xref rid="bib215" ref-type="bibr"><sup>215</sup></xref><sup>,</sup><xref rid="bib216" ref-type="bibr"><sup>216</sup></xref>. Clinically, patient heterogeneity and a lack of robust biomarkers complicate confirmation of target engagement and treatment efficacy<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref>. While AD research has benefited from established biomarkers<xref rid="bib276" ref-type="bibr"><sup>276</sup></xref>, delirium remains in need of similar advancements. Despite the significant progress in AI-driven drug discovery for AD, these approaches have not been extended to research into delirium where they could be useful given the shared challenges.</p><p id="p0370">AI holds promise for addressing these challenges by enhancing target identification, compound screening, and drug repurposing. For instance, AI-assisted multi-omics analysis can uncover novel targets in both conditions<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref><sup>,</sup><xref rid="bib97" ref-type="bibr"><sup>97</sup></xref><sup>,</sup><xref rid="bib264" ref-type="bibr"><sup>264</sup></xref>, and models trained on BBB permeability data can help identify candidate compounds that reach the brain<xref rid="bib134" ref-type="bibr"><sup>134</sup></xref><sup>,</sup><xref rid="bib135" ref-type="bibr"><sup>135</sup></xref><sup>,</sup><xref rid="bib196" ref-type="bibr"><sup>196</sup></xref><sup>,</sup><xref rid="bib215" ref-type="bibr"><sup>215</sup></xref><sup>,</sup><xref rid="bib216" ref-type="bibr"><sup>216</sup></xref>. In addition, deep neural network-based AI methods can enable drug repurposing studies exploring shared potential drug candidates between delirium and AD, informed by a deeper understanding of these diseases&#8217; connections<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref><sup>,</sup><xref rid="bib132" ref-type="bibr">132</xref>, <xref rid="bib133" ref-type="bibr">133</xref>, <xref rid="bib134" ref-type="bibr">134</xref>, <xref rid="bib135" ref-type="bibr">135</xref>, <xref rid="bib136" ref-type="bibr">136</xref>, <xref rid="bib137" ref-type="bibr">137</xref>. These tools, along with other ML and computational approaches, can accelerate the discovery and optimization of therapeutics for these complex neurodegenerative disorders. However, several key barriers remain.</p><sec id="sec5.1"><label>5.1</label><title>Data limitations and quality</title><p id="p0375">Despite concerted efforts to establish large AD and general drug discovery databases, high-quality data that allow the development of more accurate predictive models are still missing<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref>. High-quality data refers to information that is accurate, complete, and systematically collected, minimizing errors such as missing data, misdiagnoses, and inconsistencies in assessment methods. This issue is even more pronounced in delirium research, where collecting high-quality, standardized data from patients experiencing delirium is inherently difficult<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>. In population-based cohorts<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>, reliable baseline dementia status data can be obtained, but delirium status is often extracted from hospital records, which may lead to a high number of false negatives. A recent Norwegian study found a ninefold increase in identified delirium cases when all case notes were thoroughly reviewed compared to discharge records alone<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>. Conversely, studies including acutely admitted patients<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> benefit from bedside assessments ensuring high-quality delirium data, but dementia status before inclusion must rely on hospital records, information from relatives, and care home documentation, sources that are known to underreport cases. For instance, in Norway, only 30% of dementia patients have a formal diagnosis<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref>. Only recently have studies emerged that incorporate both high-quality baseline dementia assessments and robust delirium data from bedside evaluations<xref rid="bib277" ref-type="bibr"><sup>277</sup></xref><sup>,</sup><xref rid="bib278" ref-type="bibr"><sup>278</sup></xref>.</p><p id="p0380">Moreover, the datasets are relatively small in scale and often require further cleaning and standardization. For instance, binding affinity experimental data for AD-related targets are typically limited to a few thousand entries, which constrains the ability to achieve high accuracy in binding prediction models using DL approaches<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib133" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib190" ref-type="bibr"><sup>190</sup></xref>. As another example, many predictive models for BBB permeability are built using the BBBP dataset from the public MoleculeNet repository<xref rid="bib279" ref-type="bibr"><sup>279</sup></xref>. However, this public dataset includes records sourced from various public data sources, which often contain errors, such as contradictory results for the same compounds, as well as inaccuracies in SMILES strings and molecular properties like chirality. These errors introduce noise and inconsistencies into the predictive models, negatively impacting their accuracy and reliability for predicting BBB permeability, which is critical for AD and delirium drug design.</p></sec><sec id="sec5.2"><label>5.2</label><title>Disease heterogeneity and dynamic nature</title><p id="p0385">Both AD and delirium are highly heterogeneous<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, which challenges the development of AI models that generalize across diverse patient populations. For instance, models trained on mixed subtypes, such as hypoactive and hyperactive delirium, may overlook the distinct features of each, limiting their utility for targeted therapy development. Similarly, AD presents with diverse phenotypes and variable disease progression, particularly in younger patients. In addition, delirium&#8217;s onset may be rapid, and symptoms may change dramatically over short periods<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>. This makes data collection and modeling extremely challenging. Traditional AI models often assume static data, but delirium requires approaches that can handle temporal dynamics and rapid changes.</p></sec><sec id="sec5.3"><label>5.3</label><title>Gaps in experimental validation</title><p id="p0390">In addition, a major limitation in current AI drug discovery studies for AD and delirium is the lack of direct validation in relevant animal models, as studies often rely on affinity experiments or <italic toggle="yes">in silico</italic> simulations rather than complex <italic toggle="yes">in vivo</italic> experiments that provide more clinically translatable results<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib119" ref-type="bibr"><sup>119</sup></xref><sup>,</sup><xref rid="bib120" ref-type="bibr"><sup>120</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref><sup>,</sup><xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib143" ref-type="bibr">143</xref>, <xref rid="bib144" ref-type="bibr">144</xref>, <xref rid="bib145" ref-type="bibr">145</xref>, <xref rid="bib146" ref-type="bibr">146</xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref><sup>,</sup><xref rid="bib166" ref-type="bibr">166</xref>, <xref rid="bib167" ref-type="bibr">167</xref>, <xref rid="bib168" ref-type="bibr">168</xref>, <xref rid="bib169" ref-type="bibr">169</xref>, <xref rid="bib170" ref-type="bibr">170</xref>, <xref rid="bib171" ref-type="bibr">171</xref>, <xref rid="bib172" ref-type="bibr">172</xref>, <xref rid="bib173" ref-type="bibr">173</xref>, <xref rid="bib174" ref-type="bibr">174</xref>, <xref rid="bib175" ref-type="bibr">175</xref>, <xref rid="bib176" ref-type="bibr">176</xref>, <xref rid="bib177" ref-type="bibr">177</xref><sup>,</sup><xref rid="bib189" ref-type="bibr">189</xref>, <xref rid="bib190" ref-type="bibr">190</xref>, <xref rid="bib191" ref-type="bibr">191</xref>, <xref rid="bib192" ref-type="bibr">192</xref>, <xref rid="bib193" ref-type="bibr">193</xref>. This challenge arises because existing animal models only partially mimic the complex pathology and heterogeneity of human AD and delirium, limiting their effectiveness in capturing the full scope of these diseases<xref rid="bib280" ref-type="bibr"><sup>280</sup></xref><sup>,</sup><xref rid="bib281" ref-type="bibr"><sup>281</sup></xref>. Additionally, the high costs and lengthy timelines of clinical trials further hinder comprehensive validation efforts<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>. As a result, bridging this gap requires a collaborative effort among AI experts, clinical researchers, and organizations to develop improved methods for preclinical validation that better reflect human disease, as well as AI-driven strategies for optimizing clinical trial design, identifying more sensitive outcome measures, and even predicting individual patient responses to treatment.</p></sec><sec id="sec5.4"><label>5.4</label><title>Leveraging emerging AI tools</title><p id="p0395">The breakthroughs in the AI field can be actively explored further to tackle the afore-mentioned challenges. For instance, the recent development of large language models enables more effective data cleaning approaches, improving the quality and quantity of data related to delirium and AD, though this raises significant privacy concerns and regulatory challenges under data protection frameworks like GDPR<xref rid="bib282" ref-type="bibr"><sup>282</sup></xref>. New ADMET-related datasets, such as PharmaBench<xref rid="bib196" ref-type="bibr"><sup>196</sup></xref>, have utilized large language models for data cleaning, demonstrating the potential of applying these AI advancements to enhance drug discovery efforts. This showcases the possibility of leveraging recent AI breakthroughs to address data-related issues and accelerate progress in the drug discovery field.</p><p id="p0400">The field of AI has grown rapidly, allowing researchers to better understand the features learned by AI models<xref rid="bib275" ref-type="bibr"><sup>275</sup></xref><sup>,</sup><xref rid="bib283" ref-type="bibr"><sup>283</sup></xref>. This should be encouraged in the context of delirium and AD research to provide deeper insights into model predictions and enhance trust in AI-driven findings. Moreover, AI can be integrated with other computational approaches, such as physics-based methods<xref rid="bib284" ref-type="bibr"><sup>284</sup></xref><sup>,</sup><xref rid="bib285" ref-type="bibr"><sup>285</sup></xref> to further enhance accuracy and efficiency in drug discovery. These combined approaches could lead to more powerful predictive models and innovative solutions for complex neurodegenerative diseases.</p></sec><sec id="sec5.5"><label>5.5</label><title>Combination therapy and synergistic design</title><p id="p0405">In addition, given the limitations of monotherapies in treating the complex and multifaceted nature of AD and delirium, combination therapies, guided by AI, represent a promising avenue for future research. ML models, particularly network-based approaches and those trained on large datasets of drug&#8211;drug interactions, molecular pathways, and clinical outcomes, can predict synergistic drug combinations<xref rid="bib186" ref-type="bibr"><sup>186</sup></xref><sup>,</sup><xref rid="bib286" ref-type="bibr"><sup>286</sup></xref><sup>,</sup><xref rid="bib287" ref-type="bibr"><sup>287</sup></xref>. These models can also help optimize dosing regimens to maximize therapeutic effects while minimizing adverse reactions<xref rid="bib286" ref-type="bibr"><sup>286</sup></xref><sup>,</sup><xref rid="bib287" ref-type="bibr"><sup>287</sup></xref>. For example, while not discovered through AI, the combination therapy involving memantine and cholinesterase inhibitors for dementia highlights the potential benefits of multi-drug approaches in AD<xref rid="bib288" ref-type="bibr"><sup>288</sup></xref>. By leveraging AI&#8217;s ability to analyze complex datasets and predict drug interactions, researchers can accelerate the discovery of effective combination therapies for both AD and delirium, addressing a critical need in the treatment of these devastating conditions.</p></sec><sec id="sec5.6"><label>5.6</label><title>Real-world applications and progress</title><p id="p0410">Recent advances<xref rid="bib289" ref-type="bibr"><sup>289</sup></xref> in AI-driven drug discovery have led to significant milestones in clinical trials. Since 2015, 75 AI-discovered molecules have entered clinical trials, with 67 still ongoing as of 2023<xref rid="bib289" ref-type="bibr"><sup>289</sup></xref>. These molecules have demonstrated impressive success rates, with 80%&#8211;90% advancing through Phase I and approximately 40% progressing to Phase II. Notably, failures in Phase I were predominantly due to factors such as insufficient funding, strategic shifts in company priorities, or changes in the competitive landscape, rather than deficiencies in meeting the scientific evaluation criteria. Much of this early success can be attributed to a focus on well-validated biological targets. By targeting pathways and mechanisms already known to be involved in disease, researchers minimize the risk of failure due to unexpected biological effects<xref rid="bib289" ref-type="bibr"><sup>289</sup></xref>. At the same time, the statistics of AI-discovered molecules that have not gone through the clinical stage cannot be accurately calculated due to limited data<xref rid="bib290" ref-type="bibr"><sup>290</sup></xref>. In the realm of Alzheimer&#8217;s research, Exscientia&#8217;s development of DSP-0038, a dual-targeted 5-HT1A agonist and 5-HT2A antagonist designed to tackle AD psychosis, provides a concrete example of AI&#8217;s application<xref rid="bib291" ref-type="bibr"><sup>291</sup></xref>.</p></sec><sec id="sec5.7"><label>5.7</label><title>The path forward: interdisciplinary collaboration</title><p id="p0415">The successful applications of AI in drug discovery for AD and delirium require close collaborations between experts from multiple disciplines, including molecular neuroscience, neurology, pharmacology, bioinformatics, computer science, and others. While AI can efficiently analyze complex biological data and predict potential drug candidates<xref rid="bib292" ref-type="bibr"><sup>292</sup></xref><sup>,</sup><xref rid="bib293" ref-type="bibr"><sup>293</sup></xref>, its effectiveness depends on domain knowledge to ensure biological relevance and clinical feasibility<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref><sup>,</sup><xref rid="bib294" ref-type="bibr"><sup>294</sup></xref>. Interdisciplinary teams can address AI&#8217;s limitations by refining model interpretability, improving data quality through curated biomedical datasets<xref rid="bib295" ref-type="bibr"><sup>295</sup></xref>, and integrating experimental validation with computational predictions<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>. Strengthening collaboration across these fields will be essential for successfully translating AI-driven discoveries into clinically viable therapeutics.</p><p id="p0420">Overall, with the advancement of modeling approaches, the growing availability of data, and improvements in hardware, AI is expected to become increasingly applicable and significantly enhance the drug discovery process for delirium and AD.</p></sec></sec><sec id="sec6"><label>6</label><title>Conclusions</title><p id="p0425">In summary, AI has already demonstrated its transformative potential in drug discovery for delirium and AD, ranging from identifying novel therapeutic targets to optimizing drug design. While challenges remain in data quality and model interpretability, ongoing advancements in AI methodologies, data cleaning techniques, and hardware capabilities promise to further accelerate the drug discovery process. As AI continues to evolve, it is expected to significantly contribute to the development of more effective therapies for these two brain diseases, as well as other complex neurodegenerative conditions.</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0430">Ruixue Ai and Xianglu Xiao contributed to Conceptualization. Ruixue Ai, Xianglu Xiao, and Shenlong Deng contributed to Writing (original draft). All authors contributed to writing (Review &amp; Editing). Guang Yang and Evandro Fei Fang contributed to supervision, project administration, and funding acquisition.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflicts of interest</title><p id="p0435">Evandro Fei Fang is a co-owner of Fang-S Consultation AS (Organization number 931,410,717) and NO-Age AS (Organization number 933 219 127); he has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO, and MTAs with GeneHarbor (Hong Kong, China) Biotechnologies Limited and Hong Kong Longevity Science Laboratory (Hong Kong, China); he is a consultant to MindRank AI (China), NYO3 (Norway), AgeLab (Vitality Nordic AS, Norway), and Hong Kong Longevity Science Laboratory (Hong Kong, China). Geir Selb&#230;k has received honoraria for giving lectures to Eisai and Eli-Lilly and participated in advisory boards for Eisai, Roche and Eli-Lilly concerning disease-modifying treatments of Alzheimer&#8217;s disease. David C. Rubinsztein is a consultant for Aladdin Healthcare Technologies Ltd., Mindrank AI, Nido Biosciences, Retro Biosciences, Drishti Discoveries, Carlyle Investment Management LLC, Alexion Pharma International Operations Limited, and PAQ Therapeutics.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Mosharaf</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahumud</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Mollah</surname><given-names>M.N.H.</given-names></name></person-group><article-title>Common molecular and pathophysiological underpinnings of delirium and Alzheimer&#8217;s disease: molecular signatures and therapeutic indications</article-title><source>BMC Geriatr</source><volume>24</volume><year>2024</year><fpage>716</fpage><pub-id pub-id-type="pmid">39210294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-024-05289-3</pub-id><pub-id pub-id-type="pmcid">PMC11363673</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Mart</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shehabi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>MacLullich</surname><given-names>A.M.J.</given-names></name><etal/></person-group><article-title>Delirium</article-title><source>Nat Rev Dis Primers</source><volume>6</volume><year>2020</year><fpage>90</fpage><pub-id pub-id-type="pmid">33184265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-020-00223-4</pub-id><pub-id pub-id-type="pmcid">PMC9012267</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>L.</given-names></name></person-group><article-title>Delirium in elderly people: a review</article-title><source>Front Neurol</source><volume>3</volume><year>2012</year><fpage>101</fpage><pub-id pub-id-type="pmid">22723791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2012.00101</pub-id><pub-id pub-id-type="pmcid">PMC3377955</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Ormseth</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>LaHue</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Oldham</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Josephson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Whitaker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>V.C.</given-names></name></person-group><article-title>Predisposing and precipitating factors associated with delirium: a systematic review</article-title><source>JAMA Netw Open</source><volume>6</volume><year>2023</year><object-id pub-id-type="publisher-id">e2249950</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.49950</pub-id><pub-id pub-id-type="pmcid">PMC9856673</pub-id><pub-id pub-id-type="pmid">36607634</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.Y.</given-names></name></person-group><article-title>Risk factors, preventive interventions, overlapping symptoms, and clinical measures of delirium in elderly patients</article-title><source>World J Psychiatr</source><volume>13</volume><year>2023</year><fpage>973</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">38186721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5498/wjp.v13.i12.973</pub-id><pub-id pub-id-type="pmcid">PMC10768493</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Kukreja</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>U.</given-names></name><name name-style="western"><surname>Popp</surname><given-names>J.</given-names></name></person-group><article-title>Delirium in the elderly: current problems with increasing geriatric age</article-title><source>Indian J Med Res</source><volume>142</volume><year>2015</year><fpage>655</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">26831414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0971-5916.174546</pub-id><pub-id pub-id-type="pmcid">PMC4774062</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Needham</surname><given-names>E.</given-names></name></person-group><article-title>Diagnosis of delirium: a practical approach</article-title><source>Pract Neurol</source><volume>23</volume><year>2023</year><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">36581459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/pn-2022-003373</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>S.K.</given-names></name></person-group><article-title>The inter-relationship between delirium and dementia: the importance of delirium prevention</article-title><source>Nat Rev Neurol</source><volume>18</volume><year>2022</year><fpage>579</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">36028563</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00698-7</pub-id><pub-id pub-id-type="pmcid">PMC9415264</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Tieges</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>MacLullich</surname><given-names>A.M.J.</given-names></name></person-group><article-title>The neuropsychology of delirium: advancing the science of delirium assessment</article-title><source>Int J Geriatr Psychiatr</source><volume>33</volume><year>2018</year><fpage>1501</fpage><lpage>1511</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4711</pub-id><pub-id pub-id-type="pmcid">PMC6704364</pub-id><pub-id pub-id-type="pmid">28393426</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Al Huraizi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Al-Maqbali</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Al Farsi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Al Zeedy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Al-Saadi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Al-Hamadani</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Delirium and its association with short- and long-term health outcomes in medically admitted patients: a prospective study</article-title><source>J Clin Med</source><volume>12</volume><year>2023</year><fpage>5346</fpage><pub-id pub-id-type="pmid">37629388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12165346</pub-id><pub-id pub-id-type="pmcid">PMC10455146</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Titlestad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Haugarvoll</surname><given-names>K.</given-names></name><name name-style="western"><surname>Solvang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Norekval</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Skogseth</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Andreassen</surname><given-names>O.A.</given-names></name><etal/></person-group><article-title>Delirium is frequently underdiagnosed among older hospitalised patients despite available information in hospital medical records</article-title><source>Age Ageing</source><volume>53</volume><year>2024</year><fpage>afae006</fpage><pub-id pub-id-type="pmid">38342753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ageing/afae006</pub-id><pub-id pub-id-type="pmcid">PMC10859244</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Leslie</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>S.K.</given-names></name></person-group><article-title>The importance of delirium: economic and societal costs</article-title><source>J Am Geriatr Soc</source><volume>59</volume><issue>Suppl 2</issue><year>2011</year><fpage>S241</fpage><lpage>S243</lpage><pub-id pub-id-type="pmid">22091567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.2011.03671.x</pub-id><pub-id pub-id-type="pmcid">PMC3415302</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Kinchin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Agar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trepel</surname><given-names>D.</given-names></name></person-group><article-title>The economic cost of delirium: a systematic review and quality assessment</article-title><source>Alzheimer&#8217;s Dement</source><volume>17</volume><year>2021</year><fpage>1026</fpage><lpage>1041</lpage><pub-id pub-id-type="pmid">33480183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12262</pub-id></element-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="other" id="sref14">Organization WH. Dementia. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/dementia" id="intref0015">https://www.who.int/news-room/fact-sheets/detail/dementia</ext-link>.</mixed-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ribaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mukadam</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Dementia prevention in memory clinics: recommendations from the European task force for brain health services</article-title><source>Lancet Reg Health Eur</source><volume>26</volume><year>2023</year><object-id pub-id-type="publisher-id">100576</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2022.100576</pub-id><pub-id pub-id-type="pmcid">PMC9989648</pub-id><pub-id pub-id-type="pmid">36895446</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>DeTure</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name></person-group><article-title>The neuropathological diagnosis of Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>14</volume><year>2019</year><fpage>32</fpage><pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="book" id="sref17"><source>2020 Alzheimer&#8217;s disease facts and figures. Alzheimer&#8217;s Dement</source><year>2020</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1002/alz.12068</pub-id><pub-id pub-id-type="pmid">32157811</pub-id></element-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="other" id="sref18">Organization WH. Dementia: a public health priority. Organization, World Health. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://iris.who.int/handle/10665/75263" id="intref0020">https://iris.who.int/handle/10665/75263</ext-link>.</mixed-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Karantzoulis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galvin</surname><given-names>J.E.</given-names></name></person-group><article-title>Distinguishing Alzheimer&#8217;s disease from other major forms of dementia</article-title><source>Expert Rev Neurother</source><volume>11</volume><year>2011</year><fpage>1579</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">22014137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/ern.11.155</pub-id><pub-id pub-id-type="pmcid">PMC3225285</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Lopez</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Kuller</surname><given-names>L.H.</given-names></name></person-group><article-title>Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer&#8217;s disease and other dementias</article-title><source>Handb Clin Neurol</source><volume>167</volume><year>2019</year><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">31753130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-804766-8.00009-1</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>K.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease drug development pipeline: 2019</article-title><source>Alzheimer&#8217;s Dement</source><volume>5</volume><year>2019</year><fpage>272</fpage><lpage>293</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.05.008</pub-id><pub-id pub-id-type="pmcid">PMC6617248</pub-id><pub-id pub-id-type="pmid">31334330</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Lautrup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>E.F.</given-names></name></person-group><article-title>NAD<sup>+</sup> in brain aging and neurodegenerative disorders</article-title><source>Cell Metab</source><volume>30</volume><year>2019</year><fpage>630</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">31577933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2019.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6787556</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Grammatikakis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gottimukkala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Senolytic therapy alleviates Abeta-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer&#8217;s disease model</article-title><source>Nat Neurosci</source><volume>22</volume><year>2019</year><fpage>719</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">30936558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-019-0372-9</pub-id><pub-id pub-id-type="pmcid">PMC6605052</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Palikaras</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adriaanse</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer&#8217;s disease</article-title><source>Nat Neurosci</source><volume>22</volume><year>2019</year><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">30742114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0332-9</pub-id><pub-id pub-id-type="pmcid">PMC6693625</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Kerr</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Adriaanse</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Greig</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Mattson</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cader</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Bohr</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>Mitophagy and Alzheimer&#8217;s disease: cellular and molecular mechanisms</article-title><source>Trends Neurosci</source><volume>40</volume><year>2017</year><fpage>151</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">28190529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2017.01.002</pub-id><pub-id pub-id-type="pmcid">PMC5341618</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><collab>Collaborators GBDDF</collab></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Growdon</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Albuquerque</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>S.K.</given-names></name></person-group><article-title>The interface between delirium and dementia in elderly adults</article-title><source>Lancet Neurol</source><volume>14</volume><year>2015</year><fpage>823</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">26139023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(15)00101-5</pub-id><pub-id pub-id-type="pmcid">PMC4535349</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.H.J.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>B.C.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Recurrent delirium over 12 months predicts dementia: results of the Delirium and Cognitive Impact in Dementia (DECIDE) study</article-title><source>Age Ageing</source><volume>50</volume><year>2021</year><fpage>914</fpage><lpage>920</lpage><pub-id pub-id-type="pmid">33320945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ageing/afaa244</pub-id><pub-id pub-id-type="pmcid">PMC8099011</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Leighton</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Herron</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deligianni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cavanagh</surname><given-names>J.</given-names></name></person-group><article-title>Delirium and the risk of developing dementia: a cohort study of 12 949 patients</article-title><source>J Neurol Neurosurg Psychiatr</source><volume>93</volume><year>2022</year><fpage>822</fpage><lpage>827</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-328903</pub-id><pub-id pub-id-type="pmcid">PMC9304115</pub-id><pub-id pub-id-type="pmid">35606105</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Gjini</surname><given-names>K.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Her</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Delirium is associated with loss of feedback cortical connectivity</article-title><source>Alzheimer&#8217;s Dement</source><volume>20</volume><year>2024</year><fpage>511</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">37695013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13471</pub-id><pub-id pub-id-type="pmcid">PMC10840828</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Pandharipande</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Girard</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Morandi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pun</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Long-term cognitive impairment after critical illness</article-title><source>N Engl J Med</source><volume>369</volume><year>2013</year><fpage>1306</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">24088092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1301372</pub-id><pub-id pub-id-type="pmcid">PMC3922401</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Gross</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Habtemariam</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Tommet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Quach</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Delirium and long-term cognitive trajectory among persons with dementia</article-title><source>Arch Intern Med</source><volume>172</volume><year>2012</year><fpage>1324</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">23403619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinternmed.2012.3203</pub-id><pub-id pub-id-type="pmcid">PMC3740440</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Muniz-Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keage</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ince</surname><given-names>P.G.</given-names></name><etal/></person-group><article-title>Association of delirium with cognitive decline in late life: a neuropathologic study of 3 population-based cohort studies</article-title><source>JAMA Psychiatry</source><volume>74</volume><year>2017</year><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">28114436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2016.3423</pub-id><pub-id pub-id-type="pmcid">PMC6037291</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Muniz Terrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Keage</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahkonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oinas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>F.E.</given-names></name><etal/></person-group><article-title>Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study</article-title><source>Brain</source><volume>135</volume><year>2012</year><fpage>2809</fpage><lpage>2816</lpage><pub-id pub-id-type="pmid">22879644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aws190</pub-id><pub-id pub-id-type="pmcid">PMC3437024</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Q.Y.C.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Klainin-Yobas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haugan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.V.</given-names></name></person-group><article-title>Prevalence, risk factors, and impact of delirium on hospitalized older adults with dementia: a systematic review and meta-analysis</article-title><source>J Am Med Dir Assoc</source><volume>23</volume><year>2022</year><fpage>23</fpage><lpage>32.e27</lpage><pub-id pub-id-type="pmid">34648761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jamda.2021.09.008</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Idland</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Wyller</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Stoen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eri</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Frihagen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Raeder</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Preclinical Amyloid-beta and axonal degeneration pathology in delirium</article-title><source>J Alzheimers Dis</source><volume>55</volume><year>2017</year><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">27662296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160461</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name></person-group><article-title>Why 90% of clinical drug development fails and how to improve it?.</article-title><source>Acta Pharm Sin B</source><volume>12</volume><year>2022</year><fpage>3049</fpage><lpage>3062</lpage><pub-id pub-id-type="pmid">35865092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.02.002</pub-id><pub-id pub-id-type="pmcid">PMC9293739</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Mohs</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Greig</surname><given-names>N.H.</given-names></name></person-group><article-title>Drug discovery and development: role of basic biological research</article-title><source>Alzheimer&#8217;s Dement</source><volume>3</volume><year>2017</year><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2017.10.005</pub-id><pub-id pub-id-type="pmcid">PMC5725284</pub-id><pub-id pub-id-type="pmid">29255791</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mytelka</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Dunwiddie</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Persinger</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Munos</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Lindborg</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>How to improve R&amp;D productivity: the pharmaceutical industry&#8217;s grand challenge</article-title><source>Nat Rev Drug Discov</source><volume>9</volume><year>2010</year><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">20168317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3078</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="other" id="sref40"><person-group person-group-type="author"><collab>FTLOScience</collab></person-group><article-title>The process and costs of drug development</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ftloscience.com/process-costs-drug-development/" id="intref0025">https://ftloscience.com/process-costs-drug-development/</ext-link><year>2022</year></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Reiten</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Wilvang</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>E.F.</given-names></name></person-group><article-title>Preclinical and clinical evidence of NAD<sup>+</sup> precursors in health, disease, and ageing</article-title><source>Mech Ageing Dev</source><volume>199</volume><year>2021</year><object-id pub-id-type="publisher-id">111567</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mad.2021.111567</pub-id><pub-id pub-id-type="pmid">34517020</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lautrup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Amelioration of Alzheimer&#8217;s disease pathology by mitophagy inducers identified <italic toggle="yes">via</italic> machine learning and a cross-species workflow</article-title><source>Nat Biomed Eng</source><volume>6</volume><year>2022</year><fpage>76</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">34992270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-021-00819-5</pub-id><pub-id pub-id-type="pmcid">PMC8782726</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Danon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Reekie</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kassiou</surname><given-names>M.</given-names></name></person-group><article-title>Challenges and opportunities in central nervous system drug discovery</article-title><source>Trends Chem</source><volume>1</volume><year>2019</year><fpage>612</fpage><lpage>624</lpage></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="book" id="sref44"><part-title>Drug development challenges</part-title><source>Forum on neuroscience and nervous system disorders, editors. Improving and accelerating therapeutic development for nervous system disorders: workshop summary</source><year>2014</year><publisher-name>National Academies Press (US)</publisher-name><publisher-loc>Washington (DC)</publisher-loc><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK195047/" id="intref0030">https://www.ncbi.nlm.nih.gov/books/NBK195047/</ext-link><pub-id pub-id-type="pmid">24354031</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suarez-Calvet</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Acceptable performance of blood biomarker tests of amyloid pathology&#8212;recommendations from the Global CEO Initiative on Alzheimer&#8217;s Disease</article-title><source>Nat Rev Neurol</source><volume>20</volume><year>2024</year><fpage>426</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">38866966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00977-5</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.Q.</given-names></name><etal/></person-group><article-title>Current and future therapeutic strategies for Alzheimer&#8217;s disease: an overview of drug development bottlenecks</article-title><source>Front Aging Neurosci</source><volume>15</volume><year>2023</year><object-id pub-id-type="publisher-id">1206572</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1206572</pub-id><pub-id pub-id-type="pmcid">PMC10438465</pub-id><pub-id pub-id-type="pmid">37600514</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Tomlinson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Schnitker</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>P.A.</given-names></name></person-group><article-title>Exploring antipsychotic use for delirium management in adults in hospital, sub-acute rehabilitation and aged care settings: a systematic literature review</article-title><source>Drugs Aging</source><volume>41</volume><year>2024</year><fpage>455</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">38856874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40266-024-01122-z</pub-id><pub-id pub-id-type="pmcid">PMC11193698</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Faeder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hedayati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Israel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moschenross</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Preventing and treating delirium in clinical settings for older adults</article-title><source>Ther Adv Psychopharmacol</source><volume>13</volume><year>2023</year><object-id pub-id-type="publisher-id">20451253231198462</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/20451253231198462</pub-id><pub-id pub-id-type="pmcid">PMC10493062</pub-id><pub-id pub-id-type="pmid">37701890</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="other" id="sref49"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group><article-title>Delirium: prevention, diagnosis and management in hospital and long-term care</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK553009/" id="intref0035">https://www.ncbi.nlm.nih.gov/books/NBK553009/</ext-link><pub-id pub-id-type="pmid">31971702</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Zhavoronkov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mamoshina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vanhaelen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Scheibye-Knudsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moskalev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A.</given-names></name></person-group><article-title>Artificial intelligence for aging and longevity research: recent advances and perspectives</article-title><source>Ageing Res Rev</source><volume>49</volume><year>2019</year><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">30472217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2018.11.003</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Vamathevan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>D.</given-names></name><name name-style="western"><surname>Czodrowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dunham</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ferran</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Applications of machine learning in drug discovery and development</article-title><source>Nat Rev Drug Discov</source><volume>18</volume><year>2019</year><fpage>463</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">30976107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-019-0024-5</pub-id><pub-id pub-id-type="pmcid">PMC6552674</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Engkvist</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Olivecrona</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blaschke</surname><given-names>T.</given-names></name></person-group><article-title>The rise of deep learning in drug discovery</article-title><source>Drug Discov Today</source><volume>23</volume><year>2018</year><fpage>1241</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">29366762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2018.01.039</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sanap</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalyane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kalia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tekade</surname><given-names>R.K.</given-names></name></person-group><article-title>Artificial intelligence in drug discovery and development</article-title><source>Drug Discov Today</source><volume>26</volume><year>2021</year><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">33099022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2020.10.010</pub-id><pub-id pub-id-type="pmcid">PMC7577280</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name></person-group><article-title>Artificial intelligence for drug discovery: resources, methods, and applications</article-title><source>Mol Ther Nucleic Acids</source><volume>31</volume><year>2023</year><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">36923950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2023.02.019</pub-id><pub-id pub-id-type="pmcid">PMC10009646</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Bengio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Courville</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>P.</given-names></name></person-group><article-title>Representation learning: a review and new perspectives</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><volume>35</volume><year>2013</year><fpage>1798</fpage><lpage>1828</lpage><pub-id pub-id-type="pmid">23787338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TPAMI.2013.50</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Zhavoronkov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ivanenkov</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veselov</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Aladinskiy</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Aladinskaya</surname><given-names>A.V.</given-names></name><etal/></person-group><article-title>Deep learning enables rapid identification of potent DDR1 kinase inhibitors</article-title><source>Nat Biotechnol</source><volume>37</volume><year>2019</year><fpage>1038</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">31477924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-019-0224-x</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>LeCun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hinton</surname><given-names>G.</given-names></name></person-group><article-title>Deep learning</article-title><source>Nature</source><volume>521</volume><year>2015</year><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">26017442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14539</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Blanco-Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cabezon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seco-Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Conde-Torres</surname><given-names>D.</given-names></name><name name-style="western"><surname>Antelo-Riveiro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pineiro</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The role of AI in drug discovery: challenges, opportunities, and strategies</article-title><source>Pharmaceuticals</source><volume>16</volume><year>2023</year><fpage>891</fpage><pub-id pub-id-type="pmid">37375838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16060891</pub-id><pub-id pub-id-type="pmcid">PMC10302890</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Abramson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dunger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pritzel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Accurate structure prediction of biomolecular interactions with AlphaFold 3</article-title><source>Nature</source><volume>630</volume><year>2024</year><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">38718835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-07487-w</pub-id><pub-id pub-id-type="pmcid">PMC11168924</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Jumper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pritzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><name name-style="western"><surname>Figurnov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ronneberger</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><year>2021</year><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">34265844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmcid">PMC8371605</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="book" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Achiam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>L.</given-names></name><name name-style="western"><surname>Akkaya</surname><given-names>I.</given-names></name><etal/><collab>OpenAI</collab></person-group><part-title>GPT-4 technical report</part-title><year>2023/03/15</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2303.08774</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Theodore Armand</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Nfor</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.C.</given-names></name></person-group><article-title>Applications of artificial intelligence, machine learning, and deep learning in nutrition: a systematic review</article-title><source>Nutrients</source><volume>16</volume><year>2024</year><fpage>1073</fpage><pub-id pub-id-type="pmid">38613106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu16071073</pub-id><pub-id pub-id-type="pmcid">PMC11013624</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Boulougouri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vandergheynst</surname><given-names>P.</given-names></name><name name-style="western"><surname>Probst</surname><given-names>D.</given-names></name></person-group><article-title>Molecular set representation learning</article-title><source>Nat Mach Intell</source><volume>6</volume><year>2024</year><fpage>754</fpage><lpage>763</lpage></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>M.</given-names></name></person-group><article-title>Extended-connectivity fingerprints</article-title><source>J Chem Inf Model</source><volume>50</volume><year>2010</year><fpage>742</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">20426451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ci100050t</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="book" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Gilmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schoenholz</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Vinyals</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>G.E.</given-names></name></person-group><part-title>Neural message passing for quantum chemistry</part-title><year>2017/04/04</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1704.01212</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="book" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Kipf</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Welling</surname><given-names>M.</given-names></name></person-group><part-title>Semi-supervised classification with graph convolutional networks</part-title><year>2016</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1609.02907</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><etal/></person-group><article-title>RotNet: a rotationally invariant graph neural network for quantum mechanical calculations</article-title><source>Small Methods</source><volume>8</volume><year>2024</year><object-id pub-id-type="publisher-id">e2300534</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202300534</pub-id><pub-id pub-id-type="pmid">37727096</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Kuzminykh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Polykovskiy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kadurin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhebrak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baskov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nikolenko</surname><given-names>S.</given-names></name><etal/></person-group><article-title>3D molecular representations based on the wave transform for convolutional neural networks</article-title><source>Mol Pharm</source><volume>15</volume><year>2018</year><fpage>4378</fpage><lpage>4385</lpage><pub-id pub-id-type="pmid">29473756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.7b01134</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="book" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>C.E.</given-names></name></person-group><part-title>EGformer: equirectangular geometry-biased transformer for 360 depth estimation</part-title><year>2023/04/16</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2304.07803</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Akin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sofroniew</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Oktay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Simulating 500 million years of evolution with a language model</article-title><source>bioRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.07.01.600583</pub-id><pub-id pub-id-type="pmid">39818825</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Frishcosy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huzumi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Methodology-centered review of molecular modeling, simulation, and prediction of SARS-CoV-2</article-title><source>Chem Rev</source><volume>122</volume><year>2022</year><fpage>11287</fpage><lpage>11368</lpage><pub-id pub-id-type="pmid">35594413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.1c00965</pub-id><pub-id pub-id-type="pmcid">PMC9159519</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Doersch</surname><given-names>C.</given-names></name></person-group><article-title>Tutorial on variational autoencoders</article-title><source>ArXiv</source><year>2016</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1606.05908</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pouget-Abadie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Warde-Farley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ozair</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Generative adversarial networks</article-title><source>Commun ACM</source><volume>63</volume><year>2020</year><fpage>139</fpage><lpage>144</lpage></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Attention is all you need: utilizing attention in AI-enabled drug discovery</article-title><source>Brief Bioinform</source><volume>25</volume><year>2023</year><object-id pub-id-type="publisher-id">bbad467</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbad467</pub-id><pub-id pub-id-type="pmcid">PMC10772984</pub-id><pub-id pub-id-type="pmid">38189543</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Nayarisseri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tanwar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madhavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thakur</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Artificial intelligence, big data and machine learning approaches in precision medicine &amp; drug discovery</article-title><source>Curr Drug Targets</source><volume>22</volume><year>2021</year><fpage>631</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">33397265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389450122999210104205732</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Westbrook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gilliland</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Weissig</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The protein data bank</article-title><source>Nucleic Acids Res</source><volume>28</volume><year>2000</year><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/28.1.235</pub-id><pub-id pub-id-type="pmcid">PMC102472</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Embick</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Maeng</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Juskiewicz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cerulli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crean</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Wittink</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Demonstrated health care cost savings for women: findings from a community health worker intervention designed to address depression and unmet social needs</article-title><source>Arch Womens Ment Health</source><volume>24</volume><year>2021</year><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">32548774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00737-020-01045-9</pub-id><pub-id pub-id-type="pmcid">PMC9305631</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Bittrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Segura</surname><given-names>J.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Burley</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>Y.</given-names></name></person-group><article-title>RCSB protein Data bank: exploring protein 3D similarities <italic toggle="yes">via</italic> comprehensive structural alignments</article-title><source>Bioinformatics</source><volume>40</volume><year>2024</year><fpage>btae370</fpage><pub-id pub-id-type="pmid">38870521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btae370</pub-id><pub-id pub-id-type="pmcid">PMC11212067</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.</given-names></name><etal/></person-group><article-title>PIRD: pan immune repertoire database</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><fpage>897</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">31373607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz614</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="other" id="sref80"><person-group person-group-type="author"><collab>Hemberg Group</collab></person-group><article-title>Public scRNA-seq datasets</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/hemberg-lab/scRNA.seq.datasets" id="intref0040">https://github.com/hemberg-lab/scRNA.seq.datasets</ext-link></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="other" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Risso</surname><given-names>D.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>C.</given-names></name></person-group><article-title>scRNAseq: collection of public single-cell RNA-seq datasets</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://bioconductor.org/packages/scRNAseq" id="intref0045">https://bioconductor.org/packages/scRNAseq</ext-link><year>2024</year></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Benet-Pages</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clawson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Diekhans</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The UCSC Genome Browser database: 2025 update</article-title><source>Nucleic Acids Res</source><volume>53</volume><year>2025</year><fpage>D1243</fpage><lpage>D1249</lpage><pub-id pub-id-type="pmid">39460617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae974</pub-id><pub-id pub-id-type="pmcid">PMC11701590</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Villa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavitrano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Combi</surname><given-names>R.</given-names></name></person-group><article-title>Molecular and imaging biomarkers in Alzheimer&#8217;s disease: a focus on recent insights</article-title><source>J Pers Med</source><volume>10</volume><year>2020</year><fpage>61</fpage><pub-id pub-id-type="pmid">32664352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm10030061</pub-id><pub-id pub-id-type="pmcid">PMC7565667</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yulug</surname><given-names>B.</given-names></name><name name-style="western"><surname>Altay</surname><given-names>O.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hanoglu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Multi-omics analysis reveals the key factors involved in the severity of the Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>16</volume><year>2024</year><fpage>213</fpage><pub-id pub-id-type="pmid">39358810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01578-6</pub-id><pub-id pub-id-type="pmcid">PMC11448018</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>La Cognata</surname><given-names>V.</given-names></name><name name-style="western"><surname>Morello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cavallaro</surname><given-names>S.</given-names></name></person-group><article-title>Omics data and their integrative analysis to support stratified medicine in neurodegenerative diseases</article-title><source>Int J Mol Sci</source><volume>22</volume><year>2021</year><fpage>4820</fpage><pub-id pub-id-type="pmid">34062930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22094820</pub-id><pub-id pub-id-type="pmcid">PMC8125201</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Leyden</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Elsworth</surname><given-names>B.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>Smith G.</given-names></name><etal/></person-group><article-title>Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation</article-title><source>PLoS Biol</source><volume>20</volume><year>2022</year><object-id pub-id-type="publisher-id">e3001547</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pbio.3001547</pub-id><pub-id pub-id-type="pmcid">PMC8906647</pub-id><pub-id pub-id-type="pmid">35213538</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matelska</surname><given-names>D.</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burren</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Disease prediction with multi-omics and biomarkers empowers case-control genetic discoveries in the UK Biobank</article-title><source>Nat Genet</source><volume>56</volume><year>2024</year><fpage>1821</fpage><lpage>1831</lpage><pub-id pub-id-type="pmid">39261665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-024-01898-1</pub-id><pub-id pub-id-type="pmcid">PMC11390475</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Gamst</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease neuroimaging initiative (ADNI): clinical characterization</article-title><source>Neurology</source><volume>74</volume><year>2010</year><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Greenfest-Allen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valladares</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kuksa</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Gangadharan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Cifello</surname><given-names>J.</given-names></name><etal/></person-group><article-title>NIAGADS Alzheimer&#8217;s GenomicsDB: a resource for exploring Alzheimer&#8217;s disease genetic and genomic knowledge</article-title><source>Alzheimer&#8217;s Dement</source><volume>20</volume><year>2024</year><fpage>1123</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">37881831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13509</pub-id><pub-id pub-id-type="pmcid">PMC10916966</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Leanza</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Poehlman</surname><given-names>W.L.</given-names></name><etal/></person-group><article-title>The AD Knowledge Portal: a repository for multi-omic data on Alzheimer&#8217;s disease and aging</article-title><source>Curr Protoc Hum Genet</source><volume>108</volume><year>2020</year><object-id pub-id-type="publisher-id">e105</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cphg.105</pub-id><pub-id pub-id-type="pmcid">PMC7587039</pub-id><pub-id pub-id-type="pmid">33085189</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer&#8217;s drug discovery</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>24</fpage><pub-id pub-id-type="pmid">33441136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-020-00760-w</pub-id><pub-id pub-id-type="pmcid">PMC7804907</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>The Alzheimer&#8217;s Cell Atlas (TACA): a single-cell molecular map for translational therapeutics accelerator in Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement</source><volume>8</volume><year>2022</year><object-id pub-id-type="publisher-id">e12350</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12350</pub-id><pub-id pub-id-type="pmcid">PMC9558163</pub-id><pub-id pub-id-type="pmid">36254161</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Brumpton</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Surakka</surname><given-names>I.</given-names></name><name name-style="western"><surname>Skogholt</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Loset</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>L.G.</given-names></name><etal/></person-group><article-title>The HUNT study: a population-based cohort for genetic research</article-title><source>Cell Genom</source><volume>2</volume><year>2022</year><object-id pub-id-type="publisher-id">100193</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xgen.2022.100193</pub-id><pub-id pub-id-type="pmcid">PMC9903730</pub-id><pub-id pub-id-type="pmid">36777998</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Bycroft</surname><given-names>C.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petkova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Band</surname><given-names>G.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The UK Biobank resource with deep phenotyping and genomic data</article-title><source>Nature</source><volume>562</volume><year>2018</year><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">30305743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmcid">PMC6786975</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Gonzalez</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Garcia-Kroepfly</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Perez-Fuentes</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Garcia-Reyes</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Solis-Roldan</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Alba-Gonzalez</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>The ROSMAP project: aging and neurodegenerative diseases through omic sciences</article-title><source>Front Neuroinf</source><volume>18</volume><year>2024</year><object-id pub-id-type="publisher-id">1443865</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fninf.2024.1443865</pub-id><pub-id pub-id-type="pmcid">PMC11439699</pub-id><pub-id pub-id-type="pmid">39351424</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Emmerich</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Gamboa</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>M.C.J.</given-names></name><name name-style="western"><surname>Bonin-Andresen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arbach</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schendel</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Improving target assessment in biomedical research: the GOT-IT recommendations</article-title><source>Nat Rev Drug Discov</source><volume>20</volume><year>2021</year><fpage>64</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">33199880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0087-3</pub-id><pub-id pub-id-type="pmcid">PMC7667479</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Pun</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Ozerov</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Zhavoronkov</surname><given-names>A.</given-names></name></person-group><article-title>AI-powered therapeutic target discovery</article-title><source>Trends Pharmacol Sci</source><volume>44</volume><year>2023</year><fpage>561</fpage><lpage>572</lpage><pub-id pub-id-type="pmid">37479540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2023.06.010</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Loera-Valencia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cedazo-Minguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kenigsberg</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Page</surname><given-names>G.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Giusti</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Current and emerging avenues for Alzheimer&#8217;s disease drug targets</article-title><source>J Intern Med</source><volume>286</volume><year>2019</year><fpage>398</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">31286586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.12959</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>Artificial intelligence for drug discovery and development in Alzheimer&#8217;s disease</article-title><source>Curr Opin Struct Biol</source><volume>85</volume><year>2024</year><object-id pub-id-type="publisher-id">102776</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sbi.2024.102776</pub-id><pub-id pub-id-type="pmid">38335558</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Awan</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Naz</surname><given-names>A.</given-names></name><name name-style="western"><surname>deAndres-Galiana</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cernea</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Innovations in genomics and big data analytics for personalized medicine and health care: a review</article-title><source>Int J Mol Sci</source><volume>23</volume><year>2022</year><fpage>4645</fpage><pub-id pub-id-type="pmid">35563034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23094645</pub-id><pub-id pub-id-type="pmcid">PMC9104788</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>T.M.</given-names></name></person-group><article-title>Machine learning: trends, perspectives, and prospects</article-title><source>Science</source><volume>349</volume><year>2015</year><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">26185243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaa8415</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#246;lkopf</surname><given-names>B.</given-names></name><name name-style="western"><surname>Locatello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Kalchbrenner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Toward causal representation learning</article-title><source>Proc IEEE</source><volume>109</volume><year>2021</year><fpage>612</fpage><lpage>634</lpage></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Krogseth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watne</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Juliebo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Skovlund</surname><given-names>E.</given-names></name><name name-style="western"><surname>Engedal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frihagen</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Delirium is a risk factor for further cognitive decline in cognitively impaired hip fracture patients</article-title><source>Arch Gerontol Geriatr</source><volume>64</volume><year>2016</year><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26952375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archger.2015.12.004</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Ensemble of deep convolutional neural networks based multi-modality images for Alzheimer&#8217;s disease diagnosis</article-title><source>IET Image Process</source><volume>14</volume><year>2020</year><fpage>318</fpage><lpage>326</lpage></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name></person-group><article-title>The application of artificial intelligence in the genetic study of Alzheimer&#8217;s disease</article-title><source>Aging Dis</source><volume>11</volume><year>2020</year><fpage>1567</fpage><lpage>1584</lpage><pub-id pub-id-type="pmid">33269107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2020.0312</pub-id><pub-id pub-id-type="pmcid">PMC7673858</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pieper</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Leverenz</surname><given-names>J.B.</given-names></name></person-group><article-title>Discovery of disease-associated, tau, and inflammatory microglial subpopulations and molecular drivers in Alzheimer&#8217;s disease using network-based deep learning integration of human brain single-cell RNA-sequencing data</article-title><source>Alzheimer&#8217;s Dement</source><volume>19</volume><year>2023</year><fpage>2</fpage></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>E.F.</given-names></name><etal/></person-group><article-title>PharmKG: a dedicated knowledge graph benchmark for bomedical data mining</article-title><source>Brief Bioinform</source><volume>22</volume><year>2021</year><object-id pub-id-type="publisher-id">bbaa344</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbaa344</pub-id><pub-id pub-id-type="pmid">33341877</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Troyanskaya</surname><given-names>O.G.</given-names></name></person-group><article-title>Predicting effects of noncoding variants with deep learning-based sequence model</article-title><source>Nat Methods</source><volume>12</volume><year>2015</year><fpage>931</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">26301843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.3547</pub-id><pub-id pub-id-type="pmcid">PMC4768299</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>B.J.</given-names></name></person-group><article-title>Deep learning of the tissue-regulated splicing code</article-title><source>Bioinformatics</source><volume>30</volume><year>2014</year><fpage>i121</fpage><lpage>i129</lpage><pub-id pub-id-type="pmid">24931975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu277</pub-id><pub-id pub-id-type="pmcid">PMC4058935</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Barash</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Vaquero-Garcia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonzalez-Vallinas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>AVISPA: a web tool for the prediction and analysis of alternative splicing</article-title><source>Genome Biol</source><volume>14</volume><year>2013</year><object-id pub-id-type="publisher-id">R114</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2013-14-10-r114</pub-id><pub-id pub-id-type="pmcid">PMC4014802</pub-id><pub-id pub-id-type="pmid">24156756</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Q.</given-names></name></person-group><article-title>Prediction of potential disease-associated micrornas by using neural networks</article-title><source>Mol Ther Nucleic Acids</source><volume>16</volume><year>2019</year><fpage>566</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">31077936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.04.010</pub-id><pub-id pub-id-type="pmcid">PMC6510966</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="book" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Ramsundar</surname><given-names>B.</given-names></name></person-group><part-title>Molecular machine learning with DeepChem</part-title><year>2018</year><publisher-name>Stanford University</publisher-name><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dl.acm.org/doi/book/10.5555/AAI28115197" id="intref0050">https://dl.acm.org/doi/book/10.5555/AAI28115197</ext-link></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Sarah</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ikechukwu</surname><given-names>A.</given-names></name></person-group><article-title>Exploring the complexity of protein structure determination through X-ray diffraction</article-title><source>J Plant Sci Phytopathol</source><volume>7</volume><year>2023</year><fpage>124</fpage><lpage>132</lpage></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Steinberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stefansson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Johannsdottir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ingason</surname><given-names>A.</given-names></name><name name-style="western"><surname>Helgason</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Loss-of-function variants in ABCA7 confer risk of Alzheimer&#8217;s disease</article-title><source>Nat Genet</source><volume>47</volume><year>2015</year><fpage>445</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">25807283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3246</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Lambrinidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tsantili-Kakoulidou</surname><given-names>A.</given-names></name></person-group><article-title>Challenges with multi-objective QSAR in drug discovery</article-title><source>Expet Opin Drug Discov</source><volume>13</volume><year>2018</year><fpage>851</fpage><lpage>859</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2018.1496079</pub-id><pub-id pub-id-type="pmid">29996683</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Di Palma</surname><given-names>F.</given-names></name><name name-style="western"><surname>Abate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Decherchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>A.</given-names></name></person-group><article-title>Ligandability and druggability assessment <italic toggle="yes">via</italic> machine learning</article-title><source>WIREs Comput Mol Sci</source><volume>13</volume><year>2023</year><object-id pub-id-type="publisher-id">e1676</object-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="other" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Tenenbaum</surname><given-names>J.B.</given-names></name><collab>Building Machines that Learn and Think Like People</collab></person-group><article-title>Adaptive agents and multi-agent systems</article-title><comment>Available from:</comment><pub-id pub-id-type="doi">10.48550/arXiv.1604.00289</pub-id><year>2018</year></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Southey</surname><given-names>M.W.Y.</given-names></name><name name-style="western"><surname>Brunavs</surname><given-names>M.</given-names></name></person-group><article-title>Introduction to small molecule drug discovery and preclinical development</article-title><source>Front Drug Discov</source><volume>3</volume><year>2023</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.3389/fddsv.2023.1314077</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Chisholm</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>C.A.</given-names></name></person-group><article-title>Discovery of high-affinity amyloid ligands using a ligand-based virtual screening pipeline</article-title><source>J Am Chem Soc</source><volume>145</volume><year>2023</year><fpage>15936</fpage><lpage>15950</lpage><pub-id pub-id-type="pmid">37439212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.3c03749</pub-id><pub-id pub-id-type="pmcid">PMC10375536</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Staron</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurczab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Warszycki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Satala</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bugno</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Virtual screening-driven discovery of dual 5-HT<sub>6</sub>/5-HT<sub>2A</sub> receptor ligands with pro-cognitive properties</article-title><source>Eur J Med Chem</source><volume>185</volume><year>2020</year><object-id pub-id-type="publisher-id">111857</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2019.111857</pub-id><pub-id pub-id-type="pmid">31734022</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Gorgulla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boeszoermenyi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Coote</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Padmanabha Das</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>An open-source drug discovery platform enables ultra-large virtual screens</article-title><source>Nature</source><volume>580</volume><year>2020</year><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">32152607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2117-z</pub-id><pub-id pub-id-type="pmcid">PMC8352709</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kementzidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Papadopoulos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aktas</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name></person-group><article-title>An AI-driven framework for discovery of BACE1 inhibitors for Alzheimer&#8217;s disease</article-title><source>bioRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.05.15.594361</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="book" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barzilay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><part-title>Multi-objective molecule generation using interpretable substructures</part-title><year>2020/02/08</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2002.03244</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer&#8217;s disease</article-title><source>Cell Rep</source><volume>41</volume><year>2022</year><object-id pub-id-type="publisher-id">111717</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2022.111717</pub-id><pub-id pub-id-type="pmcid">PMC9837836</pub-id><pub-id pub-id-type="pmid">36450252</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bekris</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer&#8217;s disease</article-title><source>Genome Res</source><volume>31</volume><year>2021</year><fpage>1900</fpage><lpage>1912</lpage><pub-id pub-id-type="pmid">33627474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.272484.120</pub-id><pub-id pub-id-type="pmcid">PMC8494225</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hug</surname><given-names>C.</given-names></name><name name-style="western"><surname>Todorov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moret</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boswell</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Machine learning identifies candidates for drug repurposing in Alzheimer&#8217;s disease</article-title><source>Nat Commun</source><volume>12</volume><year>2021</year><fpage>1033</fpage><pub-id pub-id-type="pmid">33589615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-21330-0</pub-id><pub-id pub-id-type="pmcid">PMC7884393</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coban Akdemir</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>AI-DrugNet: a network-based deep learning model for drug repurposing and combination therapy in neurological disorders</article-title><source>Comput Struct Biotechnol J</source><volume>21</volume><year>2023</year><fpage>1533</fpage><lpage>1542</lpage><pub-id pub-id-type="pmid">36879885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.csbj.2023.02.004</pub-id><pub-id pub-id-type="pmcid">PMC9984442</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="book" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name></person-group><part-title>AChEI-EL: prediction of acetylcholinesterase inhibitors based on ensemble learning model</part-title><source>IEEE conference publication, IEEE xplore. 2022 7th international conference on big data analytics (ICBDA)</source><year>2022</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1109/ICBDA55095.2022.9760329</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>H.L.</given-names></name></person-group><article-title>Deep neural network affinity model for BACE inhibitors in D3R Grand Challenge 4</article-title><source>J Comput Aided Mol Des</source><volume>34</volume><year>2020</year><fpage>201</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">31916049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10822-019-00275-z</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ramsundar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pande</surname><given-names>V.</given-names></name><name name-style="western"><surname>Denny</surname><given-names>R.A.</given-names></name></person-group><article-title>Computational modeling of <italic toggle="yes">&#946;</italic>-secretase 1 (BACE-1) inhibitors using ligand based approaches</article-title><source>J Chem Inf Model</source><volume>56</volume><year>2016</year><fpage>1936</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">27689393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.6b00290</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barron</surname><given-names>M.G.</given-names></name></person-group><article-title>Development of 3D-QSAR model for acetylcholinesterase inhibitors using a combination of fingerprint, molecular docking, and structure-based pharmacophore approaches</article-title><source>Toxicol Sci</source><volume>148</volume><year>2015</year><fpage>60</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26202430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/toxsci/kfv160</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>G.W.</given-names></name></person-group><article-title>MathDL: mathematical deep learning for D3R Grand Challenge 4</article-title><source>J Comput Aided Mol Des</source><volume>34</volume><year>2020</year><fpage>131</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">31734815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10822-019-00237-5</pub-id><pub-id pub-id-type="pmcid">PMC7376411</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.O.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Affinity prediction using deep learning based on SMILES input for D3R grand challenge 4</article-title><source>J Comput Aided Mol Des</source><volume>36</volume><year>2022</year><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">35314897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10822-022-00448-3</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Shaker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>LightBBB: computational prediction model of blood-brain-barrier penetration based on LightGBM</article-title><source>Bioinformatics</source><volume>37</volume><year>2021</year><fpage>1135</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">33112379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btaa918</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name></person-group><article-title>A merged molecular representation deep learning method for blood-brain barrier permeability prediction</article-title><source>Brief Bioinform</source><volume>23</volume><year>2022</year><object-id pub-id-type="publisher-id">bbac357</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbac357</pub-id><pub-id pub-id-type="pmid">36002937</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalindjian</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>K.L.</given-names></name></person-group><article-title>Principles of early drug discovery</article-title><source>Br J Pharmacol</source><volume>162</volume><year>2011</year><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">21091654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1476-5381.2010.01127.x</pub-id><pub-id pub-id-type="pmcid">PMC3058157</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Raza</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Farwa</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ishaque</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al-Sehemi</surname><given-names>A.G.</given-names></name></person-group><article-title>Designing of thiazolidinones against chicken pox, monkey pox, and hepatitis viruses: a computational approach</article-title><source>Comput Biol Chem</source><volume>103</volume><year>2023</year><object-id pub-id-type="publisher-id">107827</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiolchem.2023.107827</pub-id><pub-id pub-id-type="pmcid">PMC9922439</pub-id><pub-id pub-id-type="pmid">36805155</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Mun</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Sing</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Karunakaran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ravichandran</surname><given-names>V.</given-names></name></person-group><article-title>Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of coumarin based compounds targeting proteins involved in development of COVID-19</article-title><source>Saudi J Biol Sci</source><volume>29</volume><year>2022</year><object-id pub-id-type="publisher-id">103458</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sjbs.2022.103458</pub-id><pub-id pub-id-type="pmcid">PMC9512525</pub-id><pub-id pub-id-type="pmid">36187455</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Mohseni</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Nasri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Davari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mirzaie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moradzadegan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Identification of novel inhibitor against endonuclease subunit of Influenza pH1N1 polymerase: a combined molecular docking, molecular dynamics, MMPBSA, QMMM and ADME studies to combat influenza A viruses</article-title><source>Comput Biol Chem</source><volume>77</volume><year>2018</year><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">30396155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiolchem.2018.08.005</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baweja</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Asati</surname><given-names>V.</given-names></name></person-group><article-title>Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: design, synthesis and <italic toggle="yes">in vivo</italic> studies</article-title><source>Eur J Med Chem</source><volume>261</volume><year>2023</year><object-id pub-id-type="publisher-id">115826</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115826</pub-id><pub-id pub-id-type="pmid">37793328</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Channa Basappa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hamse Kameshwar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kumara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Achutha</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Neratur Krishnappagowda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kariyappa</surname><given-names>A.K.</given-names></name></person-group><article-title>Design and synthesis of coumarin-triazole hybrids: biocompatible anti-diabetic agents, <italic toggle="yes">in silico</italic> molecular docking and ADME screening</article-title><source>Heliyon</source><volume>6</volume><year>2020</year><object-id pub-id-type="publisher-id">e05290</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2020.e05290</pub-id><pub-id pub-id-type="pmcid">PMC7575805</pub-id><pub-id pub-id-type="pmid">33102875</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Lavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Giovanni</surname><given-names>C.</given-names></name></person-group><article-title>Virtual screening strategies in drug discovery: a critical review</article-title><source>Curr Med Chem</source><volume>20</volume><year>2013</year><fpage>2839</fpage><lpage>2860</lpage><pub-id pub-id-type="pmid">23651302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/09298673113209990001</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Palakurti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>R.</given-names></name></person-group><article-title>Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of beta-secretase</article-title><source>Comput Biol Chem</source><volume>68</volume><year>2017</year><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">28288354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiolchem.2017.03.001</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Gentile</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yaacoub</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Gleave</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ton</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ban</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking</article-title><source>Nat Protoc</source><volume>17</volume><year>2022</year><fpage>672</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">35121854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-021-00659-2</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Galati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Stefano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Granchi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gado</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Identification of new GSK3beta inhibitors through a consensus machine learning-based virtual screening</article-title><source>Int J Mol Sci</source><volume>24</volume><year>2023</year><object-id pub-id-type="publisher-id">17233</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242417233</pub-id><pub-id pub-id-type="pmcid">PMC10743990</pub-id><pub-id pub-id-type="pmid">38139062</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>Deep learning and random forest approach for finding the optimal traditional Chinese medicine formula for treatment of Alzheimer&#8217;s disease</article-title><source>J Chem Inf Model</source><volume>59</volume><year>2019</year><fpage>1605</fpage><lpage>1623</lpage><pub-id pub-id-type="pmid">30888812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.9b00041</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Yadollahpour</surname><given-names>P.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Leaver-Fay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ra</surname><given-names>S.</given-names></name><etal/></person-group><article-title>EquiFold: protein structure prediction with a novel coarse-grained structure representation</article-title><source>bioRxiv</source><year>2022</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2022.10.07.511322</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Ruffolo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Sulam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.J.</given-names></name></person-group><article-title>Geometric potentials from deep learning improve prediction of CDR H3 loop structures</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><fpage>i268</fpage><lpage>i275</lpage><pub-id pub-id-type="pmid">32657412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btaa457</pub-id><pub-id pub-id-type="pmcid">PMC7355305</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Abanades</surname><given-names>B.</given-names></name><name name-style="western"><surname>Georges</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bujotzek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation</article-title><source>Bioinformatics</source><volume>38</volume><year>2022</year><fpage>1877</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">35099535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btac016</pub-id><pub-id pub-id-type="pmcid">PMC8963302</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahern</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sturmfels</surname><given-names>P.</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalvet</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Generalized biomolecular modeling and design with RoseTTAFold All-Atom</article-title><source>Science</source><volume>384</volume><year>2024</year><object-id pub-id-type="publisher-id">eadl2528</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adl2528</pub-id><pub-id pub-id-type="pmid">38452047</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Tayara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>K.T.</given-names></name></person-group><article-title>ProB-Site: protein binding site prediction using local features</article-title><source>Cells</source><volume>11</volume><year>2022</year><fpage>2117</fpage><pub-id pub-id-type="pmid">35805201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells11132117</pub-id><pub-id pub-id-type="pmcid">PMC9266162</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name></person-group><article-title>EQUIBIND: a geometric deep learning-based protein&#8211;ligand binding prediction method</article-title><source>Drug Discov Ther</source><volume>17</volume><year>2023</year><fpage>363</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">37766553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5582/ddt.2023.01063</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name></person-group><article-title>TANKBind: trigonometry-aware neural networks for drug&#8211;protein binding structure prediction</article-title><source>bioRxiv</source><year>2022-06-06</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2022.06.06.495043</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="book" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name></person-group><part-title>EpiCluster: end-to-end deep learning model for B cell epitope prediction designed to capture epitope clustering property</part-title><year>2023</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.21203/rs.3.rs-2709196/v1</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Collatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mock</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sachse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marz</surname><given-names>M.</given-names></name></person-group><article-title>EpiDope: a deep neural network for linear B-cell epitope prediction</article-title><source>Bioinformatics</source><volume>37</volume><year>2021</year><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">32915967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btaa773</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>La Marca</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>R.D.S.</given-names></name><name name-style="western"><surname>Lotufo</surname><given-names>A.D.P.</given-names></name><name name-style="western"><surname>Bartholomeu</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Minussi</surname><given-names>C.R.</given-names></name></person-group><article-title>BepFAMN: a method for linear B-cell epitope predictions based on fuzzy-ARTMAP artificial neural network</article-title><source>Sensors</source><volume>22</volume><year>2022</year><fpage>4027</fpage><pub-id pub-id-type="pmid">35684648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s22114027</pub-id><pub-id pub-id-type="pmcid">PMC9185646</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Sahtoe</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Andrzejewska</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Han</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Rennella</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Meisl</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Design of amyloidogenic peptide traps</article-title><source>Nat Chem Biol</source><volume>20</volume><year>2024</year><fpage>981</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">38503834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41589-024-01578-5</pub-id><pub-id pub-id-type="pmcid">PMC11288891</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Griner</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bowler</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Abskharon</surname><given-names>R.</given-names></name><etal/></person-group><article-title><italic toggle="yes">De novo</italic> designed protein inhibitors of amyloid aggregation and seeding</article-title><source>Proc Natl Acad Sci U S A</source><volume>119</volume><year>2022</year><object-id pub-id-type="publisher-id">e2206240119</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2206240119</pub-id><pub-id pub-id-type="pmcid">PMC9407671</pub-id><pub-id pub-id-type="pmid">35969734</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ragotte</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Borst</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>See</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Weidle</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Atomically accurate <italic toggle="yes">de novo</italic> design of antibodies with RFdiffusion</article-title><source>bioRxiv</source><year>2025</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.03.14.585103</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Aina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>S.C.C.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S.S.</given-names></name></person-group><article-title><italic toggle="yes">De novo</italic> design of a <italic toggle="yes">&#946;</italic>-helix Tau protein scaffold: an oligomer-selective vaccine immunogen candidate for Alzheimer&#8217;s disease</article-title><source>ACS Chem Neurosci</source><volume>14</volume><year>2023</year><fpage>2603</fpage><lpage>2617</lpage><pub-id pub-id-type="pmid">37458595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.3c00007</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Nimrod</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fischman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keyes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leiderman</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Computational design of epitope-specific functional antibodies</article-title><source>Cell Rep</source><volume>25</volume><year>2018</year><comment>2121&#8211;31.e5</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2018.10.081</pub-id><pub-id pub-id-type="pmid">30463010</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Integrating machine learning-based virtual screening with multiple protein structures and bio-assay evaluation for discovery of novel GSK3beta inhibitors</article-title><source>Front Pharmacol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">566058</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.566058</pub-id><pub-id pub-id-type="pmcid">PMC7517831</pub-id><pub-id pub-id-type="pmid">33041806</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name></person-group><article-title>Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis</article-title><source>J Biomol Struct Dyn</source><volume>34</volume><year>2016</year><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">25707809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2015.1022603</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.W.</given-names></name></person-group><article-title>Structure-based virtual screening for the inhibition and clearance of amyloidosis by small molecules as pharmacological chaperones</article-title><source>Europ J Med Chem Rep</source><volume>9</volume><year>2023</year><object-id pub-id-type="publisher-id">100107</object-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Souza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prema</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Balaji</surname><given-names>S.</given-names></name></person-group><article-title>Machine learning models for drug-target interactions: current knowledge and future directions</article-title><source>Drug Discov Today</source><volume>25</volume><year>2020</year><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">32171918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2020.03.003</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Generative models for <italic toggle="yes">de novo</italic> drug design</article-title><source>J Med Chem</source><volume>64</volume><year>2021</year><fpage>14011</fpage><lpage>14027</lpage><pub-id pub-id-type="pmid">34533311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00927</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Meyers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>N.</given-names></name></person-group><article-title><italic toggle="yes">De novo</italic> molecular design and generative models</article-title><source>Drug Discov Today</source><volume>26</volume><year>2021</year><fpage>2707</fpage><lpage>2715</lpage><pub-id pub-id-type="pmid">34082136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2021.05.019</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuppe</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models</article-title><source>Nat Biotechnol</source><volume>43</volume><year>2025</year><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">38459338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-024-02143-0</pub-id><pub-id pub-id-type="pmcid">PMC11738990</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Bombarelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Duvenaud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hernandez-Lobato</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sanchez-Lengeling</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sheberla</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Automatic chemical design using a data-driven continuous representation of molecules</article-title><source>ACS Cent Sci</source><volume>4</volume><year>2018</year><fpage>268</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">29532027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.7b00572</pub-id><pub-id pub-id-type="pmcid">PMC5833007</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="book" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Barzilay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaakkola</surname><given-names>T.</given-names></name></person-group><part-title>Junction tree variational autoencoder for molecular graph generation</part-title><year>2018</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1802.04364</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="book" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>De Cao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kipf</surname><given-names>T.</given-names></name></person-group><part-title>MolGAN: an implicit generative model for small molecular graphs</part-title><year>2018/05/30</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1805.11973</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Prykhodko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Kotsias</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Arus-Pous</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bjerrum</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Engkvist</surname><given-names>O.</given-names></name><etal/></person-group><article-title>A <italic toggle="yes">de novo</italic> molecular generation method using latent vector based generative adversarial network</article-title><source>J Cheminf</source><volume>11</volume><year>2019</year><fpage>74</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13321-019-0397-9</pub-id><pub-id pub-id-type="pmcid">PMC6892210</pub-id><pub-id pub-id-type="pmid">33430938</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tibo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janet</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Voronov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mervin</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Reinvent 4: modern AI-driven generative molecule design</article-title><source>J Cheminf</source><volume>16</volume><year>2024</year><fpage>20</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13321-024-00812-5</pub-id><pub-id pub-id-type="pmcid">PMC10882833</pub-id><pub-id pub-id-type="pmid">38383444</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Multi-objective <italic toggle="yes">de novo</italic> drug design with conditional graph generative model</article-title><source>J Cheminf</source><volume>10</volume><year>2018</year><fpage>33</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13321-018-0287-6</pub-id><pub-id pub-id-type="pmcid">PMC6057868</pub-id><pub-id pub-id-type="pmid">30043127</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="book" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Simm</surname><given-names>G.N.C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Lobato</surname><given-names>J.M.</given-names></name></person-group><part-title>A generative model for molecular distance geometry</part-title><year>2019</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.1909.11459</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="book" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group><part-title>DecompDiff: diffusion models with decomposed priors for structure-based drug design</part-title><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2403.07902</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>SyntaLinker: automatic fragment linking with deep conditional transformer neural networks</article-title><source>Chem Sci</source><volume>11</volume><year>2020</year><fpage>8312</fpage><lpage>8322</lpage><pub-id pub-id-type="pmid">34123096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0sc03126g</pub-id><pub-id pub-id-type="pmcid">PMC8163338</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chandak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Havaldar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leskovec</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A foundation model for clinician-centered drug repurposing</article-title><source>Nat Med</source><volume>30</volume><year>2024</year><fpage>3601</fpage><lpage>3613</lpage><pub-id pub-id-type="pmid">39322717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03233-x</pub-id><pub-id pub-id-type="pmcid">PMC11645266</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grabowska</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Leveraging generative AI to prioritize drug repurposing candidates: validating identified candidates for Alzheimer&#8217;s disease in real-world clinical datasets</article-title><source>medRxiv</source><year>2023</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2023.07.07.23292388</pub-id><pub-id pub-id-type="pmcid">PMC10897392</pub-id><pub-id pub-id-type="pmid">38409350</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Medicine</surname><given-names>Stewart AK.</given-names></name></person-group><article-title>How thalidomide works against cancer</article-title><source>Science</source><volume>343</volume><year>2014</year><fpage>256</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">24436409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1249543</pub-id><pub-id pub-id-type="pmcid">PMC4084783</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Hubsher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name></person-group><article-title>Amantadine: the journey from fighting flu to treating Parkinson disease</article-title><source>Neurology</source><volume>78</volume><year>2012</year><fpage>1096</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">22474298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31824e8f0d</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Ballard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aarsland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>R.</given-names></name><name name-style="western"><surname>Molinuevo</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Drug repositioning and repurposing for Alzheimer disease</article-title><source>Nat Rev Neurol</source><volume>16</volume><year>2020</year><fpage>661</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">32939050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-020-0397-4</pub-id><pub-id pub-id-type="pmcid">PMC8291993</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Karimi</surname><given-names>Tari P.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Collingridge</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G.</given-names></name></person-group><article-title>Memantine: updating a rare success story in pro-cognitive therapeutics</article-title><source>Neuropharmacology</source><volume>244</volume><year>2024</year><object-id pub-id-type="publisher-id">109737</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropharm.2023.109737</pub-id><pub-id pub-id-type="pmid">37832633</pub-id></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>14</volume><year>2022</year><fpage>7</fpage><pub-id pub-id-type="pmid">35012639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00951-z</pub-id><pub-id pub-id-type="pmcid">PMC8751379</pub-id></element-citation></ref><ref id="bib185"><label>185</label><mixed-citation publication-type="other" id="oref1">Xu J, Hou Y, Zhou Y, Hu M, Cheng F. A network-based deep learning framework catalyzes GWAS and multi-omics findings to biology and drug repurposing for Alzheimer's disease. <italic toggle="yes">bioRxiv</italic> 2021. Available from: <pub-id pub-id-type="doi">10.1101/2021.10.20.465087</pub-id>.</mixed-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Battaglia</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Hamrick</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Bapst</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sanchez-Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zambaldi</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Malinowski</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Relational inductive biases, deep learning, and graph networks</article-title><source>ArXiv</source><year>2018</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2408.03943</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>B.X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yiu</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Compound-protein interaction prediction by deep learning: databases, descriptors and models</article-title><source>Drug Discov Today</source><volume>27</volume><year>2022</year><fpage>1350</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">35248748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2022.02.023</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Abdollahi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaub</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Barroso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laubach</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hutwelker</surname><given-names>W.</given-names></name><name name-style="western"><surname>Panzer</surname><given-names>U.</given-names></name><etal/></person-group><article-title>A comprehensive comparison of deep learning-based compound-target interaction prediction models to unveil guiding design principles</article-title><source>J Cheminf</source><volume>16</volume><year>2024</year><fpage>118</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13321-024-00913-1</pub-id><pub-id pub-id-type="pmcid">PMC11520803</pub-id><pub-id pub-id-type="pmid">39468635</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Sandhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>P.</given-names></name></person-group><article-title>Machine learning-based modeling to predict inhibitors of acetylcholinesterase</article-title><source>Mol Divers</source><volume>26</volume><year>2022</year><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">33891263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11030-021-10223-5</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Mukerjee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Al-Khafaji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suhail Wadi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Recognizing novel drugs against Keap1 in Alzheimer&#8217;s disease using machine learning grounded computational studies</article-title><source>Front Mol Neurosci</source><volume>15</volume><year>2022</year><object-id pub-id-type="publisher-id">1036552</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2022.1036552</pub-id><pub-id pub-id-type="pmcid">PMC9764216</pub-id><pub-id pub-id-type="pmid">36561895</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>AlzhCPI: a knowledge base for predicting chemical-protein interactions towards Alzheimer&#8217;s disease</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><object-id pub-id-type="publisher-id">e0178347</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0178347</pub-id><pub-id pub-id-type="pmcid">PMC5460905</pub-id><pub-id pub-id-type="pmid">28542505</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Dhamodharan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>C.G.</given-names></name></person-group><article-title>Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer&#8217;s disease</article-title><source>Mol Divers</source><volume>26</volume><year>2022</year><fpage>1501</fpage><lpage>1517</lpage><pub-id pub-id-type="pmid">34327619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11030-021-10282-8</pub-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>K.</given-names></name></person-group><article-title>Multi-target QSAR modeling for the identification of novel inhibitors against Alzheimer&#8217;s disease</article-title><source>Chemometr Intell Lab Syst</source><volume>233</volume><year>2023</year><object-id pub-id-type="publisher-id">104734</object-id></element-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ramsundar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pande</surname><given-names>V.</given-names></name><name name-style="western"><surname>Denny</surname><given-names>R.A.</given-names></name></person-group><article-title>Computational modeling of beta-secretase 1 (BACE-1) inhibitors using ligand based approaches</article-title><source>J Chem Inf Model</source><volume>56</volume><year>2016</year><fpage>1936</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">27689393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.6b00290</pub-id></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>TransformerCPI: improving compound-protein interaction prediction by sequence-based deep learning with self-attention mechanism and label reversal experiments</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><fpage>4406</fpage><lpage>4414</lpage><pub-id pub-id-type="pmid">32428219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btaa524</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>PharmaBench: enhancing ADMET benchmarks with large language models</article-title><source>Sci Data</source><volume>11</volume><year>2024</year><fpage>985</fpage><pub-id pub-id-type="pmid">39256394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41597-024-03793-0</pub-id><pub-id pub-id-type="pmcid">PMC11387650</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Dulsat</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#243;pez-Nieto</surname><given-names>B.</given-names></name><name name-style="western"><surname>Estrada-Tejedor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borrell</surname><given-names>J.I.</given-names></name></person-group><article-title>Evaluation of free online ADMET tools for academic or small biotech environments</article-title><source>Molecules</source><volume>28</volume><year>2023</year><fpage>776</fpage><pub-id pub-id-type="pmid">36677832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28020776</pub-id><pub-id pub-id-type="pmcid">PMC9864198</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Benet</surname><given-names>L.Z.</given-names></name><name name-style="western"><surname>Hosey</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ursu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Oprea</surname><given-names>T.I.</given-names></name></person-group><article-title>BDDCS, the rule of 5 and drugability</article-title><source>Adv Drug Deliv Rev</source><volume>101</volume><year>2016</year><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">27182629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2016.05.007</pub-id><pub-id pub-id-type="pmcid">PMC4910824</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Gimenez</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ferrarini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.P.</given-names></name></person-group><article-title>Evaluation of blockbuster drugs under the rule-of-five</article-title><source>Pharmazie</source><volume>65</volume><year>2010</year><fpage>148</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">20225662</pub-id></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>C.A.</given-names></name></person-group><article-title>Prediction of rodent carcinogenicity using the DEREK system for 30 chemicals currently being tested by the National Toxicology Program. The DEREK Collaborative Group</article-title><source>Environ Health Perspect</source><volume>104</volume><issue>Suppl 5</issue><year>1996</year><fpage>1065</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">8933056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.96104s51065</pub-id><pub-id pub-id-type="pmcid">PMC1469697</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Cariello</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Britt</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Wedd</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Burlinson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gombar</surname><given-names>V.</given-names></name></person-group><article-title>Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Deductive estimate of risk from existing knowledge. Toxicity prediction by komputer assisted technology</article-title><source>Mutagenesis</source><volume>17</volume><year>2002</year><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">12110629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mutage/17.4.321</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="book" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><part-title>Learning attributed graph representations with communicative message passing transformer</part-title><year>2021/07/19</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2107.08773</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name></person-group><article-title>Double-head transformer neural network for molecular property prediction</article-title><source>J Cheminf</source><volume>15</volume><year>2023</year><fpage>27</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13321-023-00700-4</pub-id><pub-id pub-id-type="pmcid">PMC9951429</pub-id><pub-id pub-id-type="pmid">36823530</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>An effective self-supervised framework for learning expressive molecular global representations to drug discovery</article-title><source>Brief Bioinform</source><volume>22</volume><year>2021</year><fpage>bbab109</fpage><pub-id pub-id-type="pmid">33940598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab109</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>FP-GNN: a versatile deep learning architecture for enhanced molecular property prediction</article-title><source>Brief Bioinform</source><volume>23</volume><year>2022</year><object-id pub-id-type="publisher-id">bbac408</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbac408</pub-id><pub-id pub-id-type="pmid">36124766</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="book" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><etal/></person-group><part-title>Uni-Mol: a universal 3D molecular representation learning framework. ChemRxiv</part-title><year>2022</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.26434/chemrxiv-2022-jjm0j</pub-id></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="book" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><part-title>One transformer can understand both 2D &amp; 3D molecular data. arXiv</part-title><year>2022</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.48550/arXiv.2210.01765</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support</article-title><source>Nucleic Acids Res</source><volume>52</volume><year>2024</year><fpage>W422</fpage><lpage>W431</lpage><pub-id pub-id-type="pmid">38572755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae236</pub-id><pub-id pub-id-type="pmcid">PMC11223840</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties</article-title><source>Bioinformatics</source><volume>35</volume><year>2019</year><fpage>1067</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">30165565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bty707</pub-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ketkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>P.</given-names></name></person-group><article-title>ADMETboost: a web server for accurate ADMET prediction</article-title><source>J Mol Model</source><volume>28</volume><year>2022</year><fpage>408</fpage><pub-id pub-id-type="pmid">36454321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00894-022-05373-8</pub-id><pub-id pub-id-type="pmcid">PMC9903341</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Schyman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wallqvist</surname><given-names>A.</given-names></name></person-group><article-title>vNN web server for ADMET predictions</article-title><source>Front Pharmacol</source><volume>8</volume><year>2017</year><fpage>889</fpage><pub-id pub-id-type="pmid">29255418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2017.00889</pub-id><pub-id pub-id-type="pmcid">PMC5722789</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Blundell</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ascher</surname><given-names>D.B.</given-names></name></person-group><article-title>pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures</article-title><source>J Med Chem</source><volume>58</volume><year>2015</year><fpage>4066</fpage><lpage>4072</lpage><pub-id pub-id-type="pmid">25860834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.5b00104</pub-id><pub-id pub-id-type="pmcid">PMC4434528</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Lagorce</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bouslama</surname><given-names>L.</given-names></name><name name-style="western"><surname>Becot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miteva</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Villoutreix</surname><given-names>B.O.</given-names></name></person-group><article-title>FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery</article-title><source>Bioinformatics</source><volume>33</volume><year>2017</year><fpage>3658</fpage><lpage>3660</lpage><pub-id pub-id-type="pmid">28961788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btx491</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>J.H.</given-names></name></person-group><article-title>Greedy function approximation: a gradient boosting machine</article-title><source>Ann Stat</source><year>2001</year><fpage>1189</fpage><lpage>1232</lpage></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Alsenan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Turaiki</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hafez</surname><given-names>A.</given-names></name></person-group><article-title>A Recurrent Neural Network model to predict blood&#8211;brain barrier permeability</article-title><source>Comput Biol Chem</source><volume>89</volume><year>2020</year><object-id pub-id-type="publisher-id">107377</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiolchem.2020.107377</pub-id><pub-id pub-id-type="pmid">33010784</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name></person-group><article-title>Relational graph convolutional networks for predicting blood&#8211;brain barrier penetration of drug molecules</article-title><source>Bioinformatics</source><volume>38</volume><year>2022</year><fpage>2826</fpage><lpage>2831</lpage><pub-id pub-id-type="pmid">35561199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btac211</pub-id><pub-id pub-id-type="pmcid">PMC9113341</pub-id></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hyeon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>H.G.</given-names></name><etal/></person-group><article-title>Reinforcement learning model for optimizing dexmedetomidine dosing to prevent delirium in critically ill patients</article-title><source>NPJ Digit Med</source><volume>7</volume><year>2024</year><fpage>325</fpage><pub-id pub-id-type="pmid">39557970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-024-01335-x</pub-id><pub-id pub-id-type="pmcid">PMC11574043</pub-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Sutton</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Barto</surname><given-names>A.G.</given-names></name></person-group><article-title>Reinforcement learning: an introduction</article-title><source>IEEE Trans Neural Network</source><volume>9</volume><year>1998</year><fpage>1054</fpage></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mir</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name></person-group><article-title>Therapeutic proteins: developments, progress, challenges, and future perspectives</article-title><source>3 Biotech</source><volume>14</volume><year>2024</year><fpage>112</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13205-024-03958-z</pub-id><pub-id pub-id-type="pmcid">PMC10948735</pub-id><pub-id pub-id-type="pmid">38510462</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Ebrahimi</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Samanta</surname><given-names>D.</given-names></name></person-group><article-title>Engineering protein-based therapeutics through structural and chemical design</article-title><source>Nat Commun</source><volume>14</volume><year>2023</year><fpage>2411</fpage><pub-id pub-id-type="pmid">37105998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-38039-x</pub-id><pub-id pub-id-type="pmcid">PMC10132957</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="other" id="sref221"><person-group person-group-type="author"><collab>U.S. Food &amp; Drug Administration</collab></person-group><article-title>FDA grants accelerated approval for Alzheimer&#8217;s disease treatment</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment" id="intref0060">https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment</ext-link><year>2023</year></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>388</volume><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Maheshwari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Mahmood</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wasim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Navigating the dementia landscape: biomarkers and emerging therapies</article-title><source>Ageing Res Rev</source><volume>94</volume><year>2024</year><object-id pub-id-type="publisher-id">102193</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102193</pub-id><pub-id pub-id-type="pmid">38215913</pub-id></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="other" id="sref224"><person-group person-group-type="author"><collab>Company ELa</collab></person-group><article-title>Lilly&#8217;s Kisunla&#8482; (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer&#8217;s disease</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early#:%7E:text=Symptoms/may/include/swelling/of,or/after/a/Kisunla/infusion.%26text=Tell/your/healthcare/provider/right,your/unborn/or/breastfeedi" id="intref0065">https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early#:&#8764;:text=Symptoms/may/include/swelling/of,or/after/a/Kisunla/infusion.&amp;text=Tell/your/healthcare/provider/right,your/unborn/or/breastfeeding/baby</ext-link><year>2024</year></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Development of therapeutic antibodies for the treatment of diseases</article-title><source>J Biomed Sci</source><volume>27</volume><year>2020</year><fpage>1</fpage><pub-id pub-id-type="pmid">31894001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12929-019-0592-z</pub-id><pub-id pub-id-type="pmcid">PMC6939334</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Kandari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R.</given-names></name></person-group><article-title>Antibody engineering and its therapeutic applications</article-title><source>Int Rev Immunol</source><volume>42</volume><year>2023</year><fpage>156</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">34355613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08830185.2021.1960986</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Dauparas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anishchenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ragotte</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Milles</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Robust deep learning-based protein sequence design using ProteinMPNN</article-title><source>Science</source><volume>378</volume><year>2022</year><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">36108050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.add2187</pub-id><pub-id pub-id-type="pmcid">PMC9997061</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>McFee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Abdin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.M.</given-names></name></person-group><article-title>Computational and artificial intelligence-based methods for antibody development</article-title><source>Trends Pharmacol Sci</source><volume>44</volume><year>2023</year><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">36669976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2022.12.005</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Silver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maddison</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Guez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sifre</surname><given-names>L.</given-names></name><name name-style="western"><surname>van den Driessche</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Mastering the game of Go with deep neural networks and tree search</article-title><source>Nature</source><volume>529</volume><year>2016</year><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">26819042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature16961</pub-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name></person-group><article-title>AlphaFold2 and its applications in the fields of biology and medicine</article-title><source>Signal Transduct Target Ther</source><volume>8</volume><year>2023</year><fpage>115</fpage><pub-id pub-id-type="pmid">36918529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01381-z</pub-id><pub-id pub-id-type="pmcid">PMC10011802</pub-id></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Shirai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sarmiento</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>High-resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations</article-title><source>Proteins</source><volume>82</volume><year>2014</year><fpage>1624</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">24756852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prot.24591</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Sircar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>J.J.</given-names></name></person-group><article-title>RosettaAntibody: antibody variable region homology modeling server</article-title><source>Nucleic Acids Res</source><volume>37</volume><year>2009</year><fpage>W474</fpage><lpage>W479</lpage><pub-id pub-id-type="pmid">19458157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkp387</pub-id><pub-id pub-id-type="pmcid">PMC2703951</pub-id></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Webb</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sali</surname><given-names>A.</given-names></name></person-group><article-title>Comparative protein structure modeling using MODELLER</article-title><source>Curr Protoc Bioinform</source><volume>54</volume><year>2016</year><comment>5.6.1&#8211;5.6.37</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpbi.3</pub-id><pub-id pub-id-type="pmcid">PMC5031415</pub-id><pub-id pub-id-type="pmid">27322406</pub-id></element-citation></ref><ref id="bib234"><label>234</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Guedes</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>F.S.S.</given-names></name><name name-style="western"><surname>Dardenne</surname><given-names>L.E.</given-names></name></person-group><article-title>Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges</article-title><source>Front Pharmacol</source><volume>9</volume><year>2018</year><fpage>1089</fpage><pub-id pub-id-type="pmid">30319422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.01089</pub-id><pub-id pub-id-type="pmcid">PMC6165880</pub-id></element-citation></ref><ref id="bib235"><label>235</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>Jumper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pritzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Green</surname><given-names>T.</given-names></name><name name-style="western"><surname>Figurnov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ronneberger</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Applying and improving AlphaFold at CASP14</article-title><source>Proteins</source><volume>89</volume><year>2021</year><fpage>1711</fpage><lpage>1721</lpage><pub-id pub-id-type="pmid">34599769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prot.26257</pub-id><pub-id pub-id-type="pmcid">PMC9299164</pub-id></element-citation></ref><ref id="bib236"><label>236</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Fortela</surname><given-names>D.L.B.</given-names></name><name name-style="western"><surname>Mikolajczyk</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Carnes</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>W.</given-names></name><name name-style="western"><surname>Revellame</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Predicting molecular docking of per- and polyfluoroalkyl substances to blood protein using generative artificial intelligence algorithm DiffDock</article-title><source>Biotechniques</source><volume>76</volume><year>2024</year><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">37947020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2144/btn-2023-0070</pub-id></element-citation></ref><ref id="bib237"><label>237</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Korendovych</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>DeGrado</surname><given-names>W.F.</given-names></name></person-group><article-title><italic toggle="yes">De novo</italic> protein design, a retrospective</article-title><source>Q Rev Biophys</source><volume>53</volume><year>2020</year><fpage>e3</fpage><pub-id pub-id-type="pmid">32041676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033583519000131</pub-id><pub-id pub-id-type="pmcid">PMC7243446</pub-id></element-citation></ref><ref id="bib238"><label>238</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kortemme</surname><given-names>T.</given-names></name></person-group><article-title>Recent advances in <italic toggle="yes">de novo</italic> protein design: Principles, methods, and applications</article-title><source>J Biol Chem</source><volume>296</volume><year>2021</year><object-id pub-id-type="publisher-id">100558</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbc.2021.100558</pub-id><pub-id pub-id-type="pmcid">PMC8065224</pub-id><pub-id pub-id-type="pmid">33744284</pub-id></element-citation></ref><ref id="bib239"><label>239</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Leman</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Weitzner</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Adolf-Bryfogle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alford</surname><given-names>R.F.</given-names></name><etal/></person-group><article-title>Macromolecular modeling and design in Rosetta: recent methods and frameworks</article-title><source>Nat Methods</source><volume>17</volume><year>2020</year><fpage>665</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">32483333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-020-0848-2</pub-id><pub-id pub-id-type="pmcid">PMC7603796</pub-id></element-citation></ref><ref id="bib240"><label>240</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Juergens</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Trippe</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Yim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eisenach</surname><given-names>H.E.</given-names></name><etal/></person-group><article-title><italic toggle="yes">De novo</italic> design of protein structure and function with RFdiffusion</article-title><source>Nature</source><volume>620</volume><year>2023</year><fpage>1089</fpage><lpage>1100</lpage><pub-id pub-id-type="pmid">37433327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06415-8</pub-id><pub-id pub-id-type="pmcid">PMC10468394</pub-id></element-citation></ref><ref id="bib241"><label>241</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>Fleishman</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Leaver-Fay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corn</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Strauch</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Khare</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>N.</given-names></name><etal/></person-group><article-title>RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e20161</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0020161</pub-id><pub-id pub-id-type="pmcid">PMC3123292</pub-id><pub-id pub-id-type="pmid">21731610</pub-id></element-citation></ref><ref id="bib242"><label>242</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Aina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>S.C.C.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Plotkin</surname><given-names>S.S.</given-names></name></person-group><article-title><italic toggle="yes">De novo</italic> design of a beta-helix tau protein scaffold: an oligomer-selective vaccine immunogen candidate for Alzheimer&#8217;s disease</article-title><source>ACS Chem Neurosci</source><volume>14</volume><year>2023</year><fpage>2603</fpage><lpage>2617</lpage><pub-id pub-id-type="pmid">37458595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.3c00007</pub-id></element-citation></ref><ref id="bib243"><label>243</label><element-citation publication-type="journal" id="sref243"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Herbstman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>A powerful and flexible weighted distance-based method incorporating interactions between DNA methylation and environmental factors on health outcomes</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">31504174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz630</pub-id><pub-id pub-id-type="pmcid">PMC7523680</pub-id></element-citation></ref><ref id="bib244"><label>244</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>Razmara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bayat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shirian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shabankare</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mohamadnia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mortazavi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Application of a collagen scaffold saturated with platelet-rich plasma in prevention of bisphosphonate-related osteonecrosis of the jaw in the rat animal model</article-title><source>Heliyon</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">e06930</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.heliyon.2021.e06930</pub-id><pub-id pub-id-type="pmcid">PMC8111602</pub-id><pub-id pub-id-type="pmid">34007929</pub-id></element-citation></ref><ref id="bib245"><label>245</label><element-citation publication-type="journal" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>Joel</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Sulaimon</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Idris</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Adigun</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Adisa</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ademoye</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Descriptor-free QSAR: effectiveness in screening for putative inhibitors of FGFR1</article-title><source>J Biomol Struct Dyn</source><volume>41</volume><year>2023</year><fpage>2016</fpage><lpage>2032</lpage><pub-id pub-id-type="pmid">35073829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2022.2026248</pub-id></element-citation></ref><ref id="bib246"><label>246</label><element-citation publication-type="journal" id="sref246"><person-group person-group-type="author"><name name-style="western"><surname>Jendele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krivak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Skoda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoksza</surname><given-names>D.</given-names></name></person-group><article-title>PrankWeb: a web server for ligand binding site prediction and visualization</article-title><source>Nucleic Acids Res</source><volume>47</volume><year>2019</year><fpage>W345</fpage><lpage>W349</lpage><pub-id pub-id-type="pmid">31114880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkz424</pub-id><pub-id pub-id-type="pmcid">PMC6602436</pub-id></element-citation></ref><ref id="bib247"><label>247</label><element-citation publication-type="journal" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Sreenivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schoneich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rathore</surname><given-names>A.S.</given-names></name></person-group><article-title>Aggregation of therapeutic monoclonal antibodies due to thermal and air/liquid interfacial agitation stress: occurrence, stability assessment strategies, aggregation mechanism, influencing factors, and ways to enhance stability</article-title><source>Int J Pharm</source><volume>666</volume><year>2024</year><object-id pub-id-type="publisher-id">124735</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2024.124735</pub-id><pub-id pub-id-type="pmid">39326478</pub-id></element-citation></ref><ref id="bib248"><label>248</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Lundahl</surname><given-names>M.L.E.</given-names></name><name name-style="western"><surname>Fogli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colavita</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Scanlan</surname><given-names>E.M.</given-names></name></person-group><article-title>Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies</article-title><source>RSC Chem Biol</source><volume>2</volume><year>2021</year><fpage>1004</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">34458822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d1cb00067e</pub-id><pub-id pub-id-type="pmcid">PMC8341748</pub-id></element-citation></ref><ref id="bib249"><label>249</label><element-citation publication-type="journal" id="sref249"><person-group person-group-type="author"><name name-style="western"><surname>Sormanni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vendruscolo</surname><given-names>M.</given-names></name></person-group><article-title>Protein solubility predictions using the camsol method in the study of protein homeostasis</article-title><source>Cold Spring Harbor Perspect Biol</source><volume>11</volume><year>2019</year><object-id pub-id-type="publisher-id">a033845</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a033845</pub-id><pub-id pub-id-type="pmcid">PMC6886446</pub-id><pub-id pub-id-type="pmid">30833455</pub-id></element-citation></ref><ref id="bib250"><label>250</label><element-citation publication-type="journal" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kwasigroch</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rooman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pucci</surname><given-names>F.</given-names></name></person-group><article-title>SOLart: a structure-based method to predict protein solubility and aggregation</article-title><source>Bioinformatics</source><volume>36</volume><year>2020</year><fpage>1445</fpage><lpage>1452</lpage><pub-id pub-id-type="pmid">31603466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btz773</pub-id></element-citation></ref><ref id="bib251"><label>251</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Kuriata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pujols</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurcinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kmiecik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>S.</given-names></name></person-group><article-title>Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility</article-title><source>Nucleic Acids Res</source><volume>47</volume><year>2019</year><fpage>W300</fpage><lpage>W307</lpage><pub-id pub-id-type="pmid">31049593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkz321</pub-id><pub-id pub-id-type="pmcid">PMC6602499</pub-id></element-citation></ref><ref id="bib252"><label>252</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hummer</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>Humanization of antibodies using a machine learning approach on large-scale repertoire data</article-title><source>Bioinformatics</source><volume>37</volume><year>2021</year><fpage>4041</fpage><lpage>4047</lpage><pub-id pub-id-type="pmid">34110413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btab434</pub-id><pub-id pub-id-type="pmcid">PMC8760955</pub-id></element-citation></ref><ref id="bib253"><label>253</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Prihoda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maamary</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waight</surname><given-names>A.</given-names></name><name name-style="western"><surname>Juan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fayadat-Dilman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Svozil</surname><given-names>D.</given-names></name><etal/></person-group><article-title>BioPhi: a platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning</article-title><source>MAbs</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">2020203</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/19420862.2021.2020203</pub-id><pub-id pub-id-type="pmcid">PMC8837241</pub-id><pub-id pub-id-type="pmid">35133949</pub-id></element-citation></ref><ref id="bib254"><label>254</label><element-citation publication-type="book" id="sref254"><person-group person-group-type="editor"><name name-style="western"><surname>Carini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>M.</given-names></name><name name-style="western"><surname>As</surname><given-names>van Gool</given-names></name><name name-style="western"><surname>Carini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fidock</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Gool</surname><given-names>A.</given-names></name></person-group><source>Handbook of biomarkers and precision medicine</source><edition>1st ed.</edition><year>2019</year><publisher-name>Chapman and Hall/CRC</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bib255"><label>255</label><element-citation publication-type="journal" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Soleimani Zakeri</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Pashazadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>MotieGhader</surname><given-names>H.</given-names></name></person-group><article-title>Gene biomarker discovery at different stages of Alzheimer using gene co-expression network approach</article-title><source>Sci Rep</source><volume>10</volume><year>2020</year><object-id pub-id-type="publisher-id">12210</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-69249-8</pub-id><pub-id pub-id-type="pmcid">PMC7376049</pub-id><pub-id pub-id-type="pmid">32699331</pub-id></element-citation></ref><ref id="bib256"><label>256</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Saji</surname><given-names>N.</given-names></name><name name-style="western"><surname>Murotani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hisada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kunihiro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuduki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Relationship between dementia and gut microbiome-associated metabolites: a cross-sectional study in Japan</article-title><source>Sci Rep</source><volume>10</volume><year>2020</year><fpage>8088</fpage><pub-id pub-id-type="pmid">32424166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-020-65196-6</pub-id><pub-id pub-id-type="pmcid">PMC7235213</pub-id></element-citation></ref><ref id="bib257"><label>257</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Pedrero-Prieto</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Garcia-Carpintero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frontinan-Rubio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Llanos-Gonzalez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aguilera Garcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alcain</surname><given-names>F.J.</given-names></name><etal/></person-group><article-title>A comprehensive systematic review of CSF proteins and peptides that define Alzheimer&#8217;s disease</article-title><source>Clin Proteom</source><volume>17</volume><year>2020</year><fpage>21</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12014-020-09276-9</pub-id><pub-id pub-id-type="pmcid">PMC7273668</pub-id><pub-id pub-id-type="pmid">32518535</pub-id></element-citation></ref><ref id="bib258"><label>258</label><element-citation publication-type="journal" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>Meghdadi</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Stevanovic</surname><given-names>Karic M.</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rupp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Resting state EEG biomarkers of cognitive decline associated with Alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>PLoS One</source><volume>16</volume><year>2021</year><object-id pub-id-type="publisher-id">e0244180</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0244180</pub-id><pub-id pub-id-type="pmcid">PMC7864432</pub-id><pub-id pub-id-type="pmid">33544703</pub-id></element-citation></ref><ref id="bib259"><label>259</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>Marquez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yassa</surname><given-names>M.A.</given-names></name></person-group><article-title>Neuroimaging biomarkers for Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>14</volume><year>2019</year><fpage>21</fpage><pub-id pub-id-type="pmid">31174557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0325-5</pub-id><pub-id pub-id-type="pmcid">PMC6555939</pub-id></element-citation></ref><ref id="bib260"><label>260</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Mander</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>M.P.</given-names></name></person-group><article-title>Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer&#8217;s disease?.</article-title><source>Trends Neurosci</source><volume>39</volume><year>2016</year><fpage>552</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">27325209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2016.05.002</pub-id><pub-id pub-id-type="pmcid">PMC4967375</pub-id></element-citation></ref><ref id="bib261"><label>261</label><element-citation publication-type="journal" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>H.C.</given-names></name></person-group><article-title>A metabolomic approach to identifying biomarkers in blood of Alzheimer&#8217;s disease</article-title><source>Ann Clin Transl Neurol</source><volume>6</volume><year>2019</year><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">30911577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.726</pub-id><pub-id pub-id-type="pmcid">PMC6414491</pub-id></element-citation></ref><ref id="bib262"><label>262</label><element-citation publication-type="journal" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Grenier-Boley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bis</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Damotte</surname><given-names>V.</given-names></name><name name-style="western"><surname>Naj</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing</article-title><source>Nat Genet</source><volume>51</volume><year>2019</year><fpage>414</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></element-citation></ref><ref id="bib263"><label>263</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>A.J.</given-names></name></person-group><article-title>The role of biomarkers and imaging in the clinical diagnosis of dementia</article-title><source>Age Ageing</source><volume>47</volume><year>2018</year><fpage>641</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">29432519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ageing/afy004</pub-id></element-citation></ref><ref id="bib264"><label>264</label><element-citation publication-type="journal" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>Ivanisenko</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Rogachev</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Makarova</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Basov</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Gaisler</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Kuzmicheva</surname><given-names>I.N.</given-names></name><etal/></person-group><article-title>AI-assisted identification of primary and secondary metabolomic markers for postoperative delirium</article-title><source>Int J Mol Sci</source><volume>25</volume><year>2024</year><fpage>11847</fpage><pub-id pub-id-type="pmid">39519398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms252111847</pub-id><pub-id pub-id-type="pmcid">PMC11546914</pub-id></element-citation></ref><ref id="bib265"><label>265</label><element-citation publication-type="book" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guestrin</surname><given-names>C.</given-names></name></person-group><part-title>XGBoost</part-title><source>Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining</source><year>2016</year><publisher-name>Association for Computing Machinery</publisher-name><publisher-loc>San Francisco, California, USA</publisher-loc><comment>Available from: </comment><pub-id pub-id-type="doi">10.1145/2939672.2939785</pub-id></element-citation></ref><ref id="bib266"><label>266</label><element-citation publication-type="book" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Sakurada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yairi</surname><given-names>T.</given-names></name></person-group><part-title>Anomaly detection using autoencoders with nonlinear dimensionality reduction</part-title><source>Proceedings of the MLSDA 2014 2nd workshop on machine learning for sensory data analysis</source><year>2014</year><publisher-name>Association for Computing Machinery</publisher-name><publisher-loc>Gold Coast, Australia QLD, Australia</publisher-loc><comment>Available from: </comment><pub-id pub-id-type="doi">10.1145/2689746.2689747</pub-id><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dl.acm.org/doi/10.1145/2689746.2689747" id="intref0070">https://dl.acm.org/doi/10.1145/2689746.2689747</ext-link></element-citation></ref><ref id="bib267"><label>267</label><element-citation publication-type="journal" id="sref267"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lajoie</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Manzagol</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bottou</surname><given-names>L.</given-names></name></person-group><article-title>Stacked denoising autoencoders: learning useful representations in a deep network with a local denoising criterion</article-title><source>J Mach Learn Res</source><volume>11</volume><year>2010</year><fpage>3371</fpage><lpage>3408</lpage></element-citation></ref><ref id="bib268"><label>268</label><element-citation publication-type="journal" id="sref268"><person-group person-group-type="author"><name name-style="western"><surname>Kourtis</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Regele</surname><given-names>O.B.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>G.B.</given-names></name></person-group><article-title>Digital biomarkers for Alzheimer&#8217;s disease: the mobile/wearable devices opportunity</article-title><source>NPJ Digit Med</source><volume>2</volume><year>2019</year><fpage>9</fpage><pub-id pub-id-type="pmid">31119198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-019-0084-2</pub-id><pub-id pub-id-type="pmcid">PMC6526279</pub-id></element-citation></ref><ref id="bib269"><label>269</label><element-citation publication-type="journal" id="sref269"><person-group person-group-type="author"><name name-style="western"><surname>Pencina</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>RB Sr</given-names></name><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>R.B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Vasan</surname><given-names>R.S.</given-names></name></person-group><article-title>Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond</article-title><source>Stat Med</source><volume>27</volume><year>2008</year><fpage>157</fpage><lpage>172</lpage><comment>discussion 207-12</comment><pub-id pub-id-type="pmid">17569110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.2929</pub-id></element-citation></ref><ref id="bib270"><label>270</label><element-citation publication-type="journal" id="sref270"><person-group person-group-type="author"><name name-style="western"><surname>Myszczynska</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Ojamies</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Lacoste</surname><given-names>A.M.B.</given-names></name><name name-style="western"><surname>Neil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saffari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mead</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Applications of machine learning to diagnosis and treatment of neurodegenerative diseases</article-title><source>Nat Rev Neurol</source><volume>16</volume><year>2020</year><fpage>440</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">32669685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-020-0377-8</pub-id></element-citation></ref><ref id="bib271"><label>271</label><element-citation publication-type="journal" id="sref271"><person-group person-group-type="author"><name name-style="western"><surname>Mirzaei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adeli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Adeli</surname><given-names>H.</given-names></name></person-group><article-title>Imaging and machine learning techniques for diagnosis of Alzheimer&#8217;s disease</article-title><source>Rev Neurosci</source><volume>27</volume><year>2016</year><fpage>857</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">27518905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/revneuro-2016-0029</pub-id></element-citation></ref><ref id="bib272"><label>272</label><element-citation publication-type="journal" id="sref272"><person-group person-group-type="author"><name name-style="western"><surname>Narasimhan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gopalan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sikkandar</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Alassaf</surname><given-names>A.</given-names></name><name name-style="western"><surname>AlMohimeed</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alhussaini</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Employing deep-learning approach for the early detection of mild cognitive impairment transitions through the analysis of digital biomarkers</article-title><source>Sensors</source><volume>23</volume><year>2023</year><fpage>8867</fpage><pub-id pub-id-type="pmid">37960568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/s23218867</pub-id><pub-id pub-id-type="pmcid">PMC10647614</pub-id></element-citation></ref><ref id="bib273"><label>273</label><element-citation publication-type="journal" id="sref273"><person-group person-group-type="author"><name name-style="western"><surname>Archetti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ingala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Venkatraghavan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wottschel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bellio</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer&#8217;s disease</article-title><source>Neuroimage Clin</source><volume>24</volume><year>2019</year><object-id pub-id-type="publisher-id">101954</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.101954</pub-id><pub-id pub-id-type="pmcid">PMC6675943</pub-id><pub-id pub-id-type="pmid">31362149</pub-id></element-citation></ref><ref id="bib274"><label>274</label><element-citation publication-type="journal" id="sref274"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ser</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schonlieb</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Data harmonisation for information fusion in digital healthcare: a state-of-the-art systematic review, meta-analysis and future research directions</article-title><source>Inf Fusion</source><volume>82</volume><year>2022</year><fpage>99</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">35664012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.inffus.2022.01.001</pub-id><pub-id pub-id-type="pmcid">PMC8878813</pub-id></element-citation></ref><ref id="bib275"><label>275</label><element-citation publication-type="journal" id="sref275"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name></person-group><article-title>Unbox the black-box for the medical explainable AI <italic toggle="yes">via</italic> multi-modal and multi-centre data fusion: a mini-review, two showcases and beyond</article-title><source>Inf Fusion</source><volume>77</volume><year>2022</year><fpage>29</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">34980946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.inffus.2021.07.016</pub-id><pub-id pub-id-type="pmcid">PMC8459787</pub-id></element-citation></ref><ref id="bib276"><label>276</label><element-citation publication-type="journal" id="sref276"><person-group person-group-type="author"><name name-style="western"><surname>Hawksworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gevaert</surname><given-names>K.</given-names></name></person-group><article-title>A new generation of AD biomarkers: 2019 to 2021</article-title><source>Ageing Res Rev</source><volume>79</volume><year>2022</year><object-id pub-id-type="publisher-id">101654</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2022.101654</pub-id><pub-id pub-id-type="pmid">35636691</pub-id></element-citation></ref><ref id="bib277"><label>277</label><element-citation publication-type="journal" id="sref277"><person-group person-group-type="author"><name name-style="western"><surname>Krogseth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watne</surname><given-names>L.O.</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Delirium, neurofilament light chain, and progressive cognitive impairment: analysis of a prospective Norwegian population-based cohort</article-title><source>Lancet Healthy Longev</source><volume>4</volume><year>2023</year><fpage>e399</fpage><lpage>e408</lpage><pub-id pub-id-type="pmid">37459878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(23)00098-3</pub-id></element-citation></ref><ref id="bib278"><label>278</label><element-citation publication-type="journal" id="sref278"><person-group person-group-type="author"><name name-style="western"><surname>Tsui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Searle</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hornby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goslett</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The effect of baseline cognition and delirium on long-term cognitive impairment and mortality: a prospective population-based study</article-title><source>Lancet Healthy Longev</source><volume>3</volume><year>2022</year><fpage>e232</fpage><lpage>e241</lpage><pub-id pub-id-type="pmid">35382093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-7568(22)00013-7</pub-id><pub-id pub-id-type="pmcid">PMC7612581</pub-id></element-citation></ref><ref id="bib279"><label>279</label><element-citation publication-type="journal" id="sref279"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ramsundar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geniesse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pappu</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>MoleculeNet: a benchmark for molecular machine learning</article-title><source>Chem Sci</source><volume>9</volume><year>2018</year><fpage>513</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">29629118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7sc02664a</pub-id><pub-id pub-id-type="pmcid">PMC5868307</pub-id></element-citation></ref><ref id="bib280"><label>280</label><element-citation publication-type="journal" id="sref280"><person-group person-group-type="author"><name name-style="western"><surname>De Felice</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>D.P.</given-names></name></person-group><article-title>Opportunities and challenges in developing relevant animal models for Alzheimer&#8217;s disease</article-title><source>Ageing Res Rev</source><volume>26</volume><year>2016</year><fpage>112</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">26829469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2016.01.006</pub-id></element-citation></ref><ref id="bib281"><label>281</label><element-citation publication-type="journal" id="sref281"><person-group person-group-type="author"><name name-style="western"><surname>Vasunilashorn</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lunardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Crosby</surname><given-names>G.</given-names></name><name name-style="western"><surname>Acker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Preclinical and translational models for delirium: recommendations for future research from the NIDUS delirium network</article-title><source>Alzheimer&#8217;s Dement</source><volume>19</volume><year>2023</year><fpage>2150</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">36799408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12941</pub-id><pub-id pub-id-type="pmcid">PMC10576242</pub-id></element-citation></ref><ref id="bib282"><label>282</label><element-citation publication-type="other" id="sref282"><person-group person-group-type="author"><name name-style="western"><surname>Sartor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lagioia</surname><given-names>F.</given-names></name></person-group><article-title>The impact of the general data protection regulation (GDPR) on artificial intelligence</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.europarl.europa.eu/RegData/etudes/STUD/2020/641530/EPRS_STU(2020)641530_EN.pdf" id="intref0075">https://www.europarl.europa.eu/RegData/etudes/STUD/2020/641530/EPRS_STU(2020)641530_EN.pdf</ext-link></element-citation></ref><ref id="bib283"><label>283</label><element-citation publication-type="journal" id="sref283"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>How good are current pocket-based 3D generative models?: the benchmark set and evaluation of protein pocket-based 3D molecular generative models</article-title><source>J Chem Inf Model</source><volume>64</volume><year>2024</year><fpage>9260</fpage><lpage>9275</lpage><pub-id pub-id-type="pmid">39629985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.4c01598</pub-id></element-citation></ref><ref id="bib284"><label>284</label><element-citation publication-type="journal" id="sref284"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Pre-training of equivariant graph matching networks with conformation flexibility for drug binding</article-title><source>Adv Sci</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">e2203796</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202203796</pub-id><pub-id pub-id-type="pmcid">PMC9685463</pub-id><pub-id pub-id-type="pmid">36202759</pub-id></element-citation></ref><ref id="bib285"><label>285</label><element-citation publication-type="journal" id="sref285"><person-group person-group-type="author"><name name-style="western"><surname>Pyrkov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aliper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bezrukov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Polykovskiy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kamya</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Quantum computing for near-term applications in generative chemistry and drug discovery</article-title><source>Drug Discov Today</source><volume>28</volume><year>2023</year><object-id pub-id-type="publisher-id">103675</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2023.103675</pub-id><pub-id pub-id-type="pmid">37331692</pub-id></element-citation></ref><ref id="bib286"><label>286</label><element-citation publication-type="journal" id="sref286"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>DrugComboRanker: drug combination discovery based on target network analysis</article-title><source>Bioinformatics</source><volume>30</volume><year>2014</year><fpage>i228</fpage><lpage>i236</lpage><pub-id pub-id-type="pmid">24931988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btu278</pub-id><pub-id pub-id-type="pmcid">PMC4058933</pub-id></element-citation></ref><ref id="bib287"><label>287</label><element-citation publication-type="journal" id="sref287"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Network-based prediction of anti-cancer drug combinations</article-title><source>Front Pharmacol</source><volume>15</volume><year>2024</year><object-id pub-id-type="publisher-id">1418902</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1418902</pub-id><pub-id pub-id-type="pmcid">PMC11357946</pub-id><pub-id pub-id-type="pmid">39211773</pub-id></element-citation></ref><ref id="bib288"><label>288</label><element-citation publication-type="journal" id="sref288"><person-group person-group-type="author"><name name-style="western"><surname>McShane</surname><given-names>R.</given-names></name><name name-style="western"><surname>Westby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.</given-names></name><name name-style="western"><surname>Minakaran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>L.</given-names></name><name name-style="western"><surname>Farrimond</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Memantine for dementia</article-title><source>Cochrane Database Syst Rev</source><volume>3</volume><year>2019</year><object-id pub-id-type="publisher-id">CD003154</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD003154.pub6</pub-id><pub-id pub-id-type="pmcid">PMC6425228</pub-id><pub-id pub-id-type="pmid">30891742</pub-id></element-citation></ref><ref id="bib289"><label>289</label><element-citation publication-type="journal" id="sref289"><person-group person-group-type="author"><name name-style="western"><surname>Kp</surname><given-names>Jayatunga M.</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jayanth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>C.</given-names></name></person-group><article-title>How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons</article-title><source>Drug Discov Today</source><volume>29</volume><year>2024</year><object-id pub-id-type="publisher-id">104009</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2024.104009</pub-id><pub-id pub-id-type="pmid">38692505</pub-id></element-citation></ref><ref id="bib290"><label>290</label><element-citation publication-type="journal" id="sref290"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>L.</given-names></name></person-group><article-title>Artificial intelligence in small molecule drug discovery from 2018 to 2023: does it really work?.</article-title><source>Bioorg Chem</source><volume>141</volume><year>2023</year><object-id pub-id-type="publisher-id">106894</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2023.106894</pub-id><pub-id pub-id-type="pmid">37776682</pub-id></element-citation></ref><ref id="bib291"><label>291</label><element-citation publication-type="other" id="sref291"><person-group person-group-type="author"><collab>Profiles of Major Products under Development</collab></person-group><article-title>Sumitomo Pharma</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline_profile.html" id="intref0080">https://www.sumitomo-pharma.com/rd/pipeline_new-medicine/pipeline_profile.html</ext-link></element-citation></ref><ref id="bib292"><label>292</label><element-citation publication-type="journal" id="sref292"><person-group person-group-type="author"><name name-style="western"><surname>Mullowney</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>N.</given-names></name><name name-style="western"><surname>van der Hooft</surname><given-names>J.J.J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>N.I.</given-names></name><etal/></person-group><article-title>Artificial intelligence for natural product drug discovery</article-title><source>Nat Rev Drug Discov</source><volume>22</volume><year>2023</year><fpage>895</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">37697042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-023-00774-7</pub-id></element-citation></ref><ref id="bib293"><label>293</label><element-citation publication-type="journal" id="sref293"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Artificial intelligence in drug development</article-title><source>Nat Med</source><volume>31</volume><year>2025</year><fpage>45</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">39833407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03434-4</pub-id></element-citation></ref><ref id="bib294"><label>294</label><element-citation publication-type="journal" id="sref294"><person-group person-group-type="author"><name name-style="western"><surname>Elemento</surname><given-names>O.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tourassi</surname><given-names>G.</given-names></name></person-group><article-title>Artificial intelligence in cancer research, diagnosis and therapy</article-title><source>Nat Rev Cancer</source><volume>21</volume><year>2021</year><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">34535775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00399-1</pub-id></element-citation></ref><ref id="bib295"><label>295</label><element-citation publication-type="journal" id="sref295"><person-group person-group-type="author"><name name-style="western"><surname>Albahri</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Duhaim</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fadhel</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alnoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baqer</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Alzubaidi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A systematic review of trustworthy and explainable artificial intelligence in healthcare: assessment of quality, bias risk, and data fusion</article-title><source>Inform Fusion</source><volume>96</volume><year>2023</year><fpage>156</fpage><lpage>191</lpage></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0440">This project is supported by the <funding-source id="gs33">Wellcome Leap&#8217;s Dynamic Resilience Program</funding-source> (jointly funded by Temasek Trust) to Evandro Fei Fang (#<award-id award-type="grant" rid="gs33">104617</award-id>). Evandro Fei Fang is also supported by <funding-source id="gs20">Cure Alzheimer&#8217;s Fund</funding-source> (#<award-id award-type="grant" rid="gs20">282952</award-id>; #<award-id award-type="grant" rid="gs20">284930</award-id>), <funding-source id="gs22">HELSE S&#216;R-&#216;ST</funding-source> (#<award-id award-type="grant" rid="gs22">2020001</award-id>, #<award-id award-type="grant" rid="gs22">2021021</award-id>, #<award-id award-type="grant" rid="gs22">2023093</award-id>), the <funding-source id="gs23">Research Council of Norway</funding-source> (#<award-id award-type="grant" rid="gs23">262175</award-id>, #<award-id award-type="grant" rid="gs23">334361</award-id>), <funding-source id="gs27">Molecule AG/VITADAO</funding-source> (#<award-id award-type="grant" rid="gs27">282942</award-id>), <funding-source id="gs6">NordForsk</funding-source> Foundation (#<award-id award-type="grant" rid="gs6">119986</award-id>), the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (#<award-id award-type="grant" rid="gs7">81971327</award-id>), <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012446</institution-id><institution>Akershus University Hospital</institution></institution-wrap></funding-source> (#<award-id award-type="grant" rid="gs8">269901</award-id>, #<award-id award-type="grant" rid="gs8">261973</award-id>, #<award-id award-type="grant" rid="gs8">262960</award-id>), the <funding-source id="gs29">Civitan Norges Forskningsfond for Alzheimers sykdom</funding-source> (#<award-id award-type="grant" rid="gs29">281931</award-id>), the <funding-source id="gs31">Czech Republic&#8211;Norway KAPPA programme</funding-source> (with Martin Vyhn&#225;lek, #<award-id award-type="grant" rid="gs31">TO01000215</award-id>), the <funding-source id="gs32">Rosa sl&#248;yfe/Norwegian Cancer Society &amp; Norwegian Breast Cancer Society</funding-source> (#<award-id award-type="grant" rid="gs32">207819</award-id>), and <funding-source id="gs34">HORIZON-TMA-MSCA-DN</funding-source> (#<award-id award-type="grant" rid="gs34">101073251</award-id>, with Riekelt Houtkooper). Guang Yang was supported in part by the <funding-source id="gs35">ERC IMI</funding-source> (<award-id award-type="grant" rid="gs35">101005122</award-id>), the <funding-source id="gs36">H2020</funding-source> (<award-id award-type="grant" rid="gs36">952172</award-id>), the <funding-source id="gs13">MRC</funding-source> (<award-id award-type="grant" rid="gs13">MC/PC/21013</award-id>), the <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000288</institution-id><institution>Royal Society</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs15">IEC&#8726;NSFC&#8726;211235</award-id>), the NVIDIA Academic Hardware Grant Program, the SABER project supported by <funding-source id="gs16">Boehringer Ingelheim</funding-source> Ltd., <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013342</institution-id><institution>NIHR Imperial Biomedical Research Centre</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs17">RDA01</award-id>), <funding-source id="gs18"><institution-wrap><institution-id institution-id-type="doi">10.13039/100028897</institution-id><institution>Wellcome Leap</institution></institution-wrap></funding-source> Dynamic Resilience, <funding-source id="gs19"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014013</institution-id><institution>UKRI</institution></institution-wrap></funding-source> guarantee funding for Horizon Europe MSCA Postdoctoral Fellowships (<award-id award-type="grant" rid="gs19">EP/Z002206/1</award-id>), <funding-source id="gs37">UKRI MRC Research Grant</funding-source>, <funding-source id="gs24"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016934</institution-id><institution>TFS</institution></institution-wrap></funding-source> Research Grants (<award-id award-type="grant" rid="gs24">MR/U506710/1</award-id>), and the <funding-source id="gs25"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014013</institution-id><institution>UKRI</institution></institution-wrap></funding-source> Future Leaders Fellowship (<award-id award-type="grant" rid="gs25">MR/V023799/1</award-id>). David C. Rubinsztein is funded from <funding-source id="gs26"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100017510</institution-id><institution>UK Dementia Research Institute</institution></institution-wrap></funding-source> through UK DRI Ltd. (principally funded by the <funding-source id="gs28"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source>) and Parkinson&#8217;s UK (David C. Rubinsztein). This research was also supported by the <funding-source id="gs30"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100018956</institution-id><institution>NIHR Cambridge Biomedical Research Centre</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs30">NIHR203312</award-id>). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We are also grateful to the Cambridge Trust, the Rutherford Foundation, and the Royal Society Te Ap&#257;rangi (to Jennifer E. Palmer). Hongming Chen acknowledges funding from the <funding-source id="gs38">Guangzhou Basic and Applied Basic Research Project</funding-source> (<award-id award-type="grant" rid="gs38">202201011795</award-id>) and the <funding-source id="gs39">Pearl River Recruitment Program of Talents</funding-source> (No. <award-id award-type="grant" rid="gs39">2021CX020227</award-id>). Xianglu Xiao acknowledges funding from the <funding-source id="gs40">EPSRC Doctoral Training Programme</funding-source>. Ruixue Aia, Xianglu Xiao, Nan Yang, Xiaodan Xing, Leiv Otto Watne, Geir Selb&#230;k, Yehani Wedatilake, David C. Rubinsztein, Zhangming Niu, Guang Yang, Evandro Fei Fang are supported by <funding-source id="gs41">Wellome Leap&#8217;s Dynamic Resilience Program</funding-source> (jointly funded by Temasek Trust).</p></ack><fn-group><fn id="d36e1003"><p id="ntpara0010">This article is part of a special issue entitled: AI, computational and systems biology-guided translational research in Alzheimer's disease published in Acta Pharmaceutica Sinica B.</p></fn><fn id="d36e1006"><p id="ntpara0015">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" id="e45799240" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Anal Chem</journal-id><journal-id journal-id-type="iso-abbrev">Anal Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">ac</journal-id><journal-title-group><journal-title>Analytical Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0003-2700</issn><issn pub-type="epub">1520-6882</issn><self-uri>pubs.acs.org/ac</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489885</article-id><article-id pub-id-type="pmcid-ver">PMC12489885.1</article-id><article-id pub-id-type="pmcaid">12489885</article-id><article-id pub-id-type="pmcaiid">12489885</article-id><article-id pub-id-type="pmid">40954136</article-id><article-id pub-id-type="doi">10.1021/acs.analchem.5c03630</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>ICP-MS for
Multiplexed Protein Determination in Extracellular
Vesicles from APP/PS1 Mice Blood Serum&#8211;Application to a Zn
Supplementation Pilot Study</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e19-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7711520</contrib-id><name name-style="western"><surname>Mart&#237;nez-Garc&#237;a</surname><given-names initials="J">Jaime</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1309206</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2592-1442</contrib-id><name name-style="western"><surname>Fern&#225;ndez</surname><given-names initials="B">Beatriz</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7711527</contrib-id><name name-style="western"><surname>Artime</surname><given-names initials="E">Enol</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7711530</contrib-id><name name-style="western"><surname>&#193;lvarez</surname><given-names initials="L">Lidia</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><name name-style="western"><surname>Gonz&#225;lez-Iglesias</surname><given-names initials="H">H&#233;ctor</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4018798</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3880-9385</contrib-id><name name-style="western"><surname>Clases</surname><given-names initials="D">David</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">347186</contrib-id><name name-style="western"><surname>Pereiro</surname><given-names initials="R">Rosario</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Physical and Analytical Chemistry</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">16763</institution-id><institution>University
of Oviedo</institution></institution-wrap>, <addr-line>Julian Claver&#237;a 8</addr-line>, <postal-code>33006</postal-code>
<city>Oviedo</city>, <country country="ES">Spain</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">585603</institution-id><institution>Fundaci&#243;n
de Investigaci&#243;n Oftalmol&#243;gica (FIO)</institution></institution-wrap>, <addr-line>Avda. Dres. Fern&#225;ndez-Vega,
34</addr-line>, <postal-code>33012</postal-code>
<city>Oviedo</city>, <country country="ES">Spain</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Dairy
Research Institute of Asturias</institution>, <institution>Spanish
National Research Council (IPLA-CSIC)</institution>, <addr-line>C. Francisco Pintado Fe, 26</addr-line>, <postal-code>33011</postal-code>
<city>Oviedo</city>, <country country="ES">Spain</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">NanoMicroLab,
Analytical Chemistry, Institute of Chemistry</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">27267</institution-id><institution>University of Graz</institution></institution-wrap>, <addr-line>Universit&#228;tsplatz 1</addr-line>, <postal-code>8010</postal-code>
<city>Graz</city>, <country country="AT">Austria</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label><email>fernandezbeatriz@uniovi.es</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>30</day><month>9</month><year>2025</year></pub-date><volume>97</volume><issue>38</issue><issue-id pub-id-type="pmc-issue-id">498181</issue-id><fpage>20928</fpage><lpage>20936</lpage><history><date date-type="received"><day>17</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>8</month><year>2025</year></date><date date-type="online"><day>15</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 00:25:14.440"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-09-15"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-09-15">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac5c03630.pdf"/><abstract><p>Neurodegenerative diseases represent a significant challenge
due
to their complex etiology, late diagnosis, and lack of effective treatments.
Extracellular vesicles (EVs) have emerged as promising carriers of
disease biomarkers, especially proteins, but their low abundance in
biological fluids complicates their detection. Here, we present a
novel strategy for the multiplexed quantitative determination of EV-associated
proteins in blood serum from APP/PS1 transgenic mice, a model of Alzheimer&#8217;s
disease. The method combines inductively coupled plasma&#8211;time-of-flight
mass spectrometry (ICP-ToFMS) with competitive immunoassays using
metal nanocluster-labeled (AuNCs, PtNCs, IrNCs) antibodies targeting
Alpha-Actinin 1 (ACTN), Galectin-3-binding protein (LG3BP), and Moesin
(MSN). EVs were isolated using an optimized ultracentrifugation protocol
to reduce the level of serum protein contamination. Proteomic screening
identified target proteins with a known relevance to neurodegeneration,
and the developed assay achieved detection limits in the low femtomolar
range. The approach was applied to a pilot study on Zn supplementation
in 16-month-old APP/PS1 mice, revealing sex-dependent and genotype-specific
differences in protein expression but sex-independent patterns in
regulatory mechanisms (especially for MSN and LG3BP). Among the studied
markers, MSN levels showed statistically significant differences with
Zn treatment in male homozygous mice. This work demonstrates the potential
of ICP-MS for sensitive and multiplexed biomarker quantification in
EVs, supporting its use in neurodegenerative research and supplementation
studies.</p></abstract><abstract abstract-type="graphical"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ac5c03630_0006.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="tgr1" specific-use="not-for-print" position="float" orientation="portrait" xlink:href="ac5c03630_0005.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Gobierno del Principado de Asturias</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100011941</institution-id></institution-wrap></funding-source><award-id>BP21-041</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Gobierno del Principado de Asturias</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/100011941</institution-id></institution-wrap></funding-source><award-id>IDE/2024/000694</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>European Commission</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000780</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2022-137319OB-C21</award-id></award-group></funding-group><funding-group><award-group id="fnd-5"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2022-137319OB-C22</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ac5c03630</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ac5c03630</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-no-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>3eeddbc0fcc70c1ab54bfe6b1e98231e8a8e1c6c1eabc060a5c5238df4d4861b</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Neurodegeneration involves physiological
processes in the central nervous system (CNS) that lead to diseases
affecting a large portion of the aging population.<xref rid="ref1" ref-type="bibr"/> Degeneration is primarily caused by the accumulation of
extracellular deposits that damage neurons and glial cells, disrupt
communication with the bloodstream, and ultimately lead to cell death.<xref rid="ref2" ref-type="bibr"/> Current therapies for neurodegenerative diseases
are not fully effective, and early diagnostic methods remain inefficient.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref4" ref-type="bibr"/>
</named-content> Moreover, while Alzheimer&#8217;s and Parkinson&#8217;s diseases
are the most extensively studied, less common disorders like Huntington&#8217;s
disease and amyotrophic lateral sclerosis also contribute to diagnostic
challenges due to overlapping symptoms.<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>
</named-content> These aspects
highlight the urgent need to identify disease pathways and reliable
biomarkers. However, given the extremely limited access to human CNS
samples, dedicated studies to study cause-effect are complicated and
limit targeted development of intervention studies.<xref rid="ref7" ref-type="bibr"/> Consequently, systemic body fluids like blood serum, as
well as specific animal models (such as the widely used APP/PS1 mouse
model for Alzheimer&#8217;s disease), are often employed in the early
stages of biomarker research.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content>
</p><p>In recent years,
extracellular vesicles (EVs) have gained considerable
attention regarding their potential role as biomarkers for a range
of pathological conditions and for treatment options.<xref rid="ref10" ref-type="bibr"/> EVs are nanometer-sized particles that carry proteins,
nucleic acids, and metabolites, which can be found in any biological
liquid. Proteins are relevant targets due to their role in metabolic
processes and can be targeted in immunochemical approaches. However,
protein levels within EVs are low and, in addition, isolating EVs
from blood-derived samples is usually subjected to contamination by
abundant serum proteins, leading to samples that contain unwanted
proteins that may introduce artifacts.<xref rid="ref11" ref-type="bibr"/> Given the limited blood volume in most common models and the low
protein concentration in EVs, highly sensitive analytical methods
are required to identify possible target biomarkers. In this context,
inductively coupled plasma-mass spectrometry (ICP-MS) has emerged
as a selective and sensitive technique for the quantitative analysis
of proteins using metal-labeled immunoprobes in biological samples.<xref rid="ref12" ref-type="bibr"/> Moreover, time-of-flight (ToF) MS enables the
simultaneous detection of multiple analytes within a sample.<xref rid="ref13" ref-type="bibr"/> Nevertheless, reports on the use of ICP-MS for
EV analysis remain scarce to date. The literature describes the use
of DNA sequences and antibodies labeled with lanthanides or with gold
nanoparticles as recognition probes.<named-content content-type="bibref-group">
<xref rid="ref14" ref-type="bibr"/>&#8722;<xref rid="ref15" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref16" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref17" ref-type="bibr"/>
</named-content> Recently, Zhang et al.<xref rid="ref18" ref-type="bibr"/> reported an aptamer-proximity-ligation activated
rolling circle amplification method for the sensitive detection of
EVs by single particle ICP-MS. This approach allowed the identification
of external protein biomarkers expressed on individual EVs and the
differentiation of EVs derived from tumor and normal cells.</p><p>Metal nanoclusters (MNCs), constituted of a few hundred atoms,
have demonstrated a strong amplification effect enabling the detection
of biomolecules at extremely low concentrations in individual cells.<xref rid="ref19" ref-type="bibr"/> However, so far, their potential has not yet
been explored for more challenging analysis of EVs. In this work,
we present a straightforward strategy for the simultaneous determination
of three proteins within EVs previously purified from serum samples
of the neurodegeneration mouse model APP/PS1 using inductively coupled
plasma&#8211;time-of-flight mass spectrometry (ICP-ToFMS) in combination
with multiplexed competitive immunoassays based on MNC-labeled immunoprobes.
The target proteins were selected through proteomic studies using
liquid chromatography (LC)-MS/MS. In particular, AuNCs, PtNCs, and
IrNCs were employed to label specific antibodies to Alpha-Actinin
1 (ACTN), Galectin-3-binding protein (LG3BP), and Moesin (MSN), respectively.
These three proteins are closely associated with cytoskeletal dynamics
and the early stages of protein aggregation, making them potentially
relevant biomarkers in the context of Alzheimer&#8217;s disease.
The selected proteins are located either partially (MSN) or entirely
(LG3BP, ACTN) within the lumen of EVs and, therefore, a lysis protocol
was implemented prior to the immunoassay to expose the EV content
to MNC-labeled antibodies. The developed method was applied to the
quantitative determination of targeted proteins in a pilot study of
16 month old APP/PS1 mice supplemented with zinc.</p><sec id="sec2"><title>Experimental Section</title><sec id="sec2.1"><title>APP/PS1 Mouse Model: Mouse Strains, Breeding, Husbandry, and
Zn Supplementation</title><p>APP/PS1 double transgenic mice B6.Cg-Tg&#173;(APPswe,PSEN1dE9)&#173;85Dbo/&#173;Mmjax
(initially obtained from The Jackson Laboratory, JAX stock #34832)
were used in the present study.<xref rid="ref20" ref-type="bibr"/> APP/PS1
mice express a chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe)
and a mutant human presenilin 1 (PS1-dE9), both mutations associated
with early onset Alzheimer&#8217;s disease. As a result of this mutation,
hemizygous transgenic mice (+/&#8211;, +/&#8722;) begin to develop
beta-amyloid deposits in the brain by 6 to 7 months of age. This makes
the APP/PS1 mouse a well-established and suitable <italic toggle="yes">in vivo</italic> model for Alzheimer&#8217;s disease research.</p><p>Mice were maintained
on a 12 h light&#8211;dark cycle, where humidity and temperature
were controlled, with food and water available <italic toggle="yes">ad libitum</italic>. All experimental procedures followed ARRIVE (Animal Research: Reporting
of In Vivo Experiments) guidelines<xref rid="ref21" ref-type="bibr"/> and
were carried out in accordance with the European Communities Council
Directive (2010/63/UE) on the protection of animals used for scientific
purposes and the Spanish regulations on the protection of animals
used for research. The study was approved by the Animal Research Ethics
Committee of the University of Oviedo in accordance with Royal Decree
53/2013 and authorized by the Ministry of Rural Environment and Territorial
Cohesion of the Government of the Principality of Asturias (PROAE
25/2021).</p><p>To investigate the potential neuroprotective effects
of Zn, supplementation
was carried out in the animal model by adding ZnSO<sub>4</sub> monohydrate,
99% purity (ref 389802500, Thermo Scientific Chemicals), to drinking
tap water to a final concentration of 30 mg L<sup>&#8211;1</sup> Zn.
This supplementation protocol was designed based on previous works
demonstrating the beneficial role of Zn in neurodegenerative processes.<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#8722;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr"/>
</named-content> Supplemented water was fed to APP/PS1 mice from 1-month-old until
their sacrifice at 16 months. Age- and sex-matched untreated APP/PS1
mice were fed tap water. In this work, the following simplified nomenclature
was adopted: +/+ for homozygous (+/+,+/+) individuals and +/&#8211;
for heterozygous (+/&#8211;,+/&#8722;) individuals. Zn supplementation
was indicated as w/o (without Zn) or w/w (with Zn). Each study group
consisted of five animals, except for the +/&#8211; w/o Zn group,
with only three mice due to limited availability.</p></sec><sec id="sec2.2"><title>Instrumentation</title><p>Ultracentrifugation steps for EV isolation
were performed using an Optima L-90K ultracentrifuge (Beckman Coulter,
Inc.). Total protein determination was conducted via spectrophotometric
measurements by using a Multiskan SkyHigh spectrophotometer (Thermo
Fisher Scientific, Inc.). For the characterization of MNCs, fluorometric
measurements were conducted with a PerkinElmer LS-50B luminescence
spectrophotometer (PerkinElmer, Inc.). Proteomic analysis was performed
using a Evosep One liquid chromatography (LC) system (Evosep) coupled
to a ZenoTOF 7600 series quadrupole (Q)-ToF spectrometer (Sciex).
ICP-MS measurements were carried out using two different instruments:
(1) A 7900 series ICP-QMS (Agilent Technologies) equipped with a conventional
Meinhard nebulizer (300 &#956;L min<sup>&#8211;1</sup>) and a double
pass spray chamber for MNC characterization and (2) A Vitesse ICP-ToFMS
(Nu Instruments) for the multiplexed detection of target proteins
in EVs purified from serum samples of the animal model. <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> depicts the ICP-MS operating
conditions for both ICP-QMS and ICP-ToFMS instruments.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>ICP-QMS Operating Conditions for the
Characterization of MNC Synthesis Used as Labels for the Immunoprobes
and ICP-ToFMS Operating Conditions for the Analysis of Ir, Pt, and
Au as Detection Labels in the Multiplexed Immunoassay Designed in
This Work</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">ICP-QMS</th><th align="center" colspan="1" rowspan="1">ICP-ToFMS</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Acquisition mode</td><td align="left" colspan="1" rowspan="1">Spectrum</td><td align="left" colspan="1" rowspan="1">Spectrum</td></tr><tr><td align="left" colspan="1" rowspan="1">RF power</td><td align="left" colspan="1" rowspan="1">1550&#160;W</td><td align="left" colspan="1" rowspan="1">1350&#160;W</td></tr><tr><td align="left" colspan="1" rowspan="1">Auxiliary
gas</td><td align="left" colspan="1" rowspan="1">0.9&#160;L&#160;min<sup>&#8211;1</sup>
</td><td align="left" colspan="1" rowspan="1">2&#160;L&#160;min<sup>&#8211;1</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Plasma
gas</td><td align="left" colspan="1" rowspan="1">15&#160;L&#160;min<sup>&#8211;1</sup>
</td><td align="left" colspan="1" rowspan="1">13&#160;L&#160;min<sup>&#8211;1</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Nebulizer
gas flow</td><td align="left" colspan="1" rowspan="1">1.07&#160;L&#160;min<sup>&#8211;1</sup>
</td><td align="left" colspan="1" rowspan="1">1.18&#160;L&#160;min<sup>&#8211;1</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Make
up gas flow</td><td align="left" colspan="1" rowspan="1">0.10&#160;L&#160;min<sup>1</sup>
</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Collision gas (He) flow</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">12&#160;mL&#160;min<sup>&#8211;1</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Reaction gas
(H<sub>2</sub>) flow</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">10&#160;mL&#160;min<sup>&#8211;1</sup>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Integration time</td><td align="left" colspan="1" rowspan="1">100&#160;ms</td><td align="left" colspan="1" rowspan="1">100&#160;ms</td></tr><tr><td align="left" colspan="1" rowspan="1">Isotopes</td><td align="left" colspan="1" rowspan="1">
<sup>105</sup>Pd&#160;(IS),&#160;<sup>193</sup>Ir,&#160;<sup>195</sup>Pt,&#160;<sup>197</sup>Au</td><td align="left" colspan="1" rowspan="1">
<sup>185</sup>Re&#160;(IS),&#160;<sup>193</sup>Ir,&#160;<sup>195</sup>Pt,&#160;<sup>197</sup>Au</td></tr></tbody></table></table-wrap></sec><sec id="sec3"><title>Experimental Methods</title><sec id="sec3.1"><title>Serum Sample Extraction</title><p>Blood was collected from anesthetized
APP/PS1 mice by exsanguination through cardiac puncture at 16 months
of age. After the blood sample coagulated (1 h at 37 &#176;C followed
by 6 h at 4 &#176;C), the serum was separated by centrifugation at
2000 rpm for 5 min at 4 &#176;C and then stored at &#8722;80 &#176;C
until further use.</p></sec><sec id="sec3.2"><title>Synthesis and Characterization of MNCs and MNC-Labeled Immunoprobes</title><p>Three different MNCs stabilized with lipoate ligands were synthesized
following protocols previously reported for IrNCs, PtNCs, and AuNCs.<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>&#8722;<xref rid="ref26" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref27" ref-type="bibr"/>
</named-content> Details related to the experimental procedures for the synthesis
and characterization of MNCs are collected in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Supporting Information (SI)</ext-link>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S1</ext-link> collects spectra obtained in the fluorometric characterization of
IrNCs, PtNCs, and AuNCs. The MNCs were previously characterized by
high-resolution transmission electron microscopy, which yielded spherical
shapes and average diameters of 1.9 nm for IrNCs,<xref rid="ref23" ref-type="bibr"/> 1.5 for PtNCs,<xref rid="ref24" ref-type="bibr"/> and 2.7 nm<xref rid="ref25" ref-type="bibr"/> for AuNCs. The synthesis of the MNC-labeled
immunoprobes was carried out using protocols that had also been previously
optimized<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>&#8722;<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr"/>
</named-content> and are summarized in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>. ICP-QMS operating conditions for MNC characterization are listed
in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>.</p></sec><sec id="sec3.3"><title>Proteomic Analysis of EVs by Molecular Mass Spectrometry</title><p>For proteomic analysis, EVs from the four animal cohorts under study
were purified from mouse blood serum initially based on a previous
protocol.<xref rid="ref28" ref-type="bibr"/> Briefly, serum was diluted
1:15 with cold 1&#215; PBS, and larger particles (such as cell fragments
and microvesicles) were removed by centrifugation at 40,000<italic toggle="yes">g</italic> for 2 h. The supernatant was then subjected to ultracentrifugation
at 100,000<italic toggle="yes">g</italic> for 2 h, followed by a final washing
of the EV pellet with 1&#215; PBS at 100,000<italic toggle="yes">g</italic> for
2 h. All centrifugation steps were performed at 4 &#176;C. In the
present study, the isolation protocol was optimized compared to the
previous version to minimize the contribution of serum proteins to
the final measurements by incorporating additional washing steps for
the EV pellet (details of the optimization procedures, along with
a summary of the experimental results, are provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>, including Table S1). The effectiveness of
these studies was assessed based on the number of proteins identified
during proteomic characterization for which commercial mouse serum
was employed. The pellet obtained from the isolation was frozen directly
at &#8722;20 &#176;C without resuspension until further use.</p><p>The preparation of samples for proteomic analysis by LC-MS/MS began
by dissolving the proteins in the EV pellet in 40 &#956;L of a 0.2%
RapiGest SF solution in 50 mM ammonium bicarbonate. For such a purpose,
the solution was sonicated in 90 s cycles with 30 s pauses between
cycles on ice to avoid overheating until complete dissolution of the
protein pellet. Next, the total protein content was measured with
the Qubit kit to determine the appropriate reagent amounts for the
subsequent protocol stages. Once the protein content was determined,
the following steps were carried out (amounts of reagents expressed
for 50 &#956;g of protein in 40 &#956;L of RapiGest SF solution):
(1) Addition of 4.4 &#956;L of 50 mM dithiothreitol in 50 mM ammonium
bicarbonate followed by incubation at 60 &#176;C for 30 min; (2) Addition
of 5.3 &#956;L of 100 mM iodoacetamide in 50 mM ammonium bicarbonate
followed by incubation at room temperature (RT) for 30 min, protected
from light; (3) Adjustment of the pH of the solution to be within
the range of 8&#8211;8.5; (4) Addition of 11.6 &#956;L of a trypsin
solution in 50 mM ammonium bicarbonate ensuring a final trypsin concentration
40 times lower than the total protein content and incubation at 37
&#176;C for 2 h; and (5) Addition of 11.6 &#956;L of the same trypsin
solution followed by incubation at 37 &#176;C for 15 h.</p><p>After
protein digestion, the solution was prepared for LC-MS/MS
analysis. To adjust the pH to 2, 2.13 &#956;L of a 10% trifluoroacetic
solution was added, and the mixture was incubated at 37 &#176;C for
1 h. The solution was then centrifuged at 20,000<italic toggle="yes">g</italic> for 10 min, and the supernatant was transferred to a new vial, where
2.25 &#956;L of acetonitrile was added. The solution was centrifuged
again at 20,000<italic toggle="yes">g</italic> for 3 min, followed by centrifugation
at 20,000<italic toggle="yes">g</italic> for 10 min. Finally, the resulting solution
was adjusted with water to achieve a final protein concentration of
500 &#956;g mL<sup>&#8211;1</sup> and subjected to further analysis.</p></sec><sec id="sec3.4"><title>Competitive Immunoassay for Protein Detection in EVs</title><p>The quantitative analysis of proteins of interest in purified EVs
was performed using multiplexed competitive immunoassays with MNC-labeled
immunoprobes. The protein standards (ACTN, LG3BP, and MSN) used for
coating and the antimouse-protein antibodies (Anti-m-ACTN, Anti-m-LG3BP,
and Anti-m-MSN) were maintained at the same working concentrations
across all the experiments: 26 and 20 nM, respectively. These concentrations
were chosen based on previous experience with this type of immunoassay
format.<xref rid="ref29" ref-type="bibr"/> The immunoassays were carried
out as follows: (1) Coating step: each well was coated with 100 &#956;L
of a 26 nM protein solution and incubated at 37 &#176;C for 2 h in
a microplate thermomixer; (2) Blocking step: a 1% BSA solution in
1&#215; PBS (200 &#956;L per well) was added and incubated at 37
&#176;C for 2 h; (3) Washing steps: three washes with 1&#215; PBS
containing 0.1% Tween-20 were performed to remove excess blocking
solution; and (4) The competitive immunoassay step was carried out.
First, protein standard solutions were prepared with concentrations
from 1 nM to 10<sup>&#8211;8</sup> nM through serial dilutions from
a 100 nM stock solution. Then, both standard solutions and EV samples
(prediluted appropriately) were mixed with a 1:2 molar ratio with
the MNC-labeled immunoprobe solutions (Anti-m-ACTN:AuNCs, Anti-m-LG3BP:PtNCs,
and Anti-m-MSN:IrNCs) to achieve a final Ab concentration of 20 nM.
The mixture was stirred at RT for 15 min in a thermomixer. Then, the
prepared solutions were loaded into the coated microplate wells, and
the immunoassay was performed at 37 &#176;C for 2 h in a plate thermomixer.
Five final washes with 1&#215; PBS containing 0.1% Tween-20 were performed,
and the well contents were collected with 50 &#956;L of concentrated
nitric acid and incubated for 30 min, followed by digestion in an
ultrasound bath for another 30 min.</p><p>It is important to note
that the three target proteins (ACTN, LG3BP, and MSN) are located
within the EV lumen. Therefore, a prior lysis step was required to
expose EV content to the MNC-labeled immunoprobes. This step was optimized
by evaluating different concentrations of Triton X-100 (TX100) before
a competitive immunoassay. A final concentration of 0.1% TX100 was
added to both the protein standards and EVs samples, followed by incubation
at 37 &#176;C for 15 min prior to the competitive step. To assess
potential nonspecific interactions, a negative control was included
under the same competitive immunoassay conditions. In this control,
a goat antihuman immunoglobulin E antibody (specific to a protein
from a different species and unrelated to the targets under study)
was used as the detection antibody for each of the proteins and associated
MNC labels tested.</p></sec><sec id="sec3.5"><title>Determination of Target Proteins in EVs by ICP-MS</title><p>The
target proteins were quantified by measuring with ICP-MS the levels
of the metals in the MNC-labeled immunoprobes (IrNCs, PtNCs, AuNCs)
that interacted with the coated protein in the wells after the competitive
step of the immunoassay. Thus, the more element detected in the well,
the less protein there is in the analyzed samples. This quantification
is performed in a similar way to other calibrations, by substituting
the analytical signal (amount of element in the well) in the equation
of the response curve and obtaining a concentration of protein in
the sample (as long as the sample concentration is in the linear region
of the curve). Thus, external calibrations were performed using Ir,
Pt, and Au standards (with metal concentrations up to 10 &#956;g
L<sup>&#8211;1</sup> and containing 5 &#956;g L<sup>&#8211;1</sup> of Re as internal standard, IS). Specific ICP-ToFMS measurement
conditions are listed in <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>. To reduce the acidity of the solution and ensure metal levels
within the external calibration range, the digested well contents
were diluted 1:100 with deionized ultrapure water before ICP-MS analysis.</p></sec><sec id="sec3.6"><title>Data Normalization</title><p>For normalization of ACTN, LG3BP,
and MSN concentration values, three data normalization strategies
were studied in the present work. The first method was the use of
the serum volume of the studied samples, determined after blood centrifugation
by weighing. Another method of normalization was the total protein
content of the EVs purified from serum determined with a commercial
BCA kit.</p><p>We also proposed a normalization of the concentration
of the target protein levels in the samples with a concentration of
CD81, an EV marker protein. CD81 levels were determined with an independent
competitive immunoassay, following identical experimental conditions
to those explained in <xref rid="sec3.4" ref-type="sec">&#8220;Competitive Immunoassay
for Protein Detection in EVs&#8221;</xref>, using anti-m-CD81:AuNCs
as detection immunoprobe and not performing EV lysis, as CD81 is a
protein located exclusively on EV membranes.</p></sec><sec id="sec3.7"><title>Statistical Analysis in Molecular and Elemental MS Measurements</title><p>For protein identification in proteomic analysis by LC-MS/MS, MSFragger,
FragPipe, and ProteomeDiscoverer software were used. Statistical analysis
of the data obtained from the different study groups by ICP-MS was
performed using Origin Pro (OriginLab Corporation). Each study group
included five biological replicates, except for the heterozygous Zn-supplemented
individuals (+/&#8211; w/o Zn), for which only three biological replicates
were available. Considering the low number of individuals per sample
group, differences in protein levels between groups were evaluated
using Kruskal&#8211;Wallis ANOVA. Multiple comparisons were adjusted
using the Bonferroni correction.</p></sec></sec></sec><sec id="sec4"><title>Results and Discussion</title><sec id="sec4.1"><title>Proteomic Analysis of EVs Purified from APP/PS1 Blood Serum</title><p>EVs of serum pools of male mice for each of the four cohorts under
study of the APP/PS1 model were isolated following an optimized protocol
with three-washing steps (the detailed optimization process of EV
isolation is collected in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>). <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref> depicts a summary
of the obtained proteomes, represented as a Venn diagram (a detailed
list of identified proteins can be found in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_001.zip" ext-link-type="uri">SI</ext-link> as an independent .xlsx file named <italic toggle="yes">Identified proteins_APP-PS1_16-month-male_4
groups_1 replicate</italic>). A similar number of proteins were identified
in the four groups (385, 597, 475, and 594 proteins identified in
the +/+ w/o Zn, +/+ w Zn, +/&#8211; w/o Zn, and +/&#8211; w Zn groups,
respectively), with a slightly lower number of proteins identified
in the +/+ w/o Zn group. As expected, the identity of serum proteins
was similar to that previously observed in commercial mouse serum.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Venn diagram
showing LC-MS/MS proteomic data of EVs from serum
of male APP/PS1 mice (+/+ and +/&#8211;, with or without Zn supplementation).
One replicate of serum pools per each group, all individuals being
16-month-old male mice, were analyzed. A detailed list of identified
proteins in each sample is provided in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_001.zip" ext-link-type="uri">SI</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr1" position="float" orientation="portrait" xlink:href="ac5c03630_0001.jpg"/></fig><p>To identify target proteins relevant to neurodegeneration,
the
proteins present in the four proteomes were analyzed in detail. For
this purpose, the &#8220;Top 100 Extracellular Vesicle Markers&#8221;
from Vesiclepedia (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://microvesicles.org/">http://microvesicles.org/</uri>, a bibliographic tool that compiles the most frequently reported
proteins in EVs based on scientific publications) were evaluated.
41 EV markers from this list were identified among 311 common proteins
in our animal model. Subsequently, a protein screening (according
to the unique and total peptide values obtained in the analysis) was
carried out within each group and compared with the proteome of commercial
serum EVs to identify proteins showing the greatest variation between
the different study groups. It is important to note that these analyses
are not quantitative, as protein abundances (based, in this case,
on the total and unique peptides registered) depend on the sample
and experimental pretreatment. Only proteins showing substantial differences
in abundance between groups were selected, with abundances normalized
to the total number of proteins identified in each study group.</p><p>Finally, a bibliographic review was conducted to assess the relevance
of the proteins that showed the greatest variation in the context
of neurodegeneration. Based on this analysis, the following proteins
were selected as targets for the development of the multiplex immunoassay
for protein determination by ICP-MS: ACTN, LG3BP, and MSN. These three
proteins participate in cytoskeleton dynamics and cell adhesion, closely
linked to the onset of neurodegeneration. ACTN protein is intimately
related to neurodegeneration onset because it tends to bind to other
proteins and form aggregates, thus compromising the actin skeleton
stability and cell integrity.<xref rid="ref30" ref-type="bibr"/> In the
case of LG3BP, the relationship of this protein with the metabolism
of beta-amyloid peptide has been previously reported; elevated levels
of LG3BP have been found in different samples of interest in neurodegeneration
situation, so we could expect a deregulation of this protein in EVs
of our working samples.<named-content content-type="bibref-group">
<xref rid="ref31" ref-type="bibr"/>&#8722;<xref rid="ref32" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref33" ref-type="bibr"/>
</named-content> MSN participates in the binding
of the cell actin cytoskeleton to the membrane, regulating the shape
of the local areas of the cell cortex. In the context of Alzheimer&#8217;s
disease and neurodegeneration, it has been observed that this protein
is related to the stabilization of the actin cytoskeleton mediated
by Tau protein, and the consequent stabilization of neurodegenerative
processes.<xref rid="ref34" ref-type="bibr"/>
</p></sec><sec id="sec4.2"><title>Optimization of the Multiplexed Immunoassay for the Detection
of the Target Proteins in EVs by ICP-MS</title><p>The next step was
the development of a competitive immunoassay for the simultaneous
quantitative analysis of ACTN, LG3BP, and MSN in EVs from the mouse
model by ICP-ToFMS. Based on the identification carried out in the
proteomic study for the EVs of the mouse model and considering the
average signal amplification provided by the MNCs labels (1760 for
IrNCs, 1264 for PtNCs, and 466 for AuNCs<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>,<xref rid="ref35" ref-type="bibr"/>
</named-content>), the following protein-MNC associations
were established: IrNCs for MSN, PtNCs for LG3BP, and AuNCs for ACTN
detection. As can be seen in Figure S2 in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>, the simultaneous detection of the three proteins by ICP-MS,
under the operating conditions detailed in the <xref rid="sec2" ref-type="sec">Experimental
Section</xref>, resulted in response curves with the expected fits
(sigmoidal curves with negative slopes). The response curves for the
target proteins yielded limits of detection (LoDs), determined considering
standard deviations of each concentration tested,<xref rid="ref36" ref-type="bibr"/> in the low femtomolar range.</p><p>To determine the levels
of the target proteins in the EV samples, a prior lysis step is required
to expose the EV lumen, as ACTN and LG3BP are exclusively present
within the lumen, while MSN is present in both the EV membrane and
lumen. For this purpose, TX100, a surfactant widely used for cells
lysis and previously reported to be effective for EVs,<xref rid="ref37" ref-type="bibr"/> was chosen. To evaluate the effectiveness of
TX100 lysis, the levels of the target proteins in an EV sample from
the animal model were determined by ICP-MS, comparing four final TX100
concentrations: 0.001%, 0.01%, 0.1%, and 1% (v/v). The results (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) showed that increasing
TX100 concentration up to 0.1% led to higher detected levels of ACTN,
LG3BP, and MSN in EV samples together with a better reproducibility
between replicates, while no significant changes were observed between
0.1% and 1% TX100. All tests were performed on the same sample to
avoid biological variability, and the immunoassay response curves
were carried out in the absence of TX100 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S2</ext-link>).</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Concentration of Target Proteins (ACTN,
LG3BP, and MSN) Found in EVs Purified from Blood Serum of the APP/PS1
Animal Model (16-Month-Old Heterozygous Male Nonsupplemented with
Zn) Determined by ICP-MS Using the MNC-Labeled Immunoprobe Methodology
and Comparing Four TX100 Concentrations for EV Lysis<xref rid="tbl2-fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="center" char="." colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" rowspan="1">[Protein]
(pM)<hr/></th></tr><tr><th align="center" char="." colspan="1" rowspan="1">TX100 (%,&#160;v/v)</th><th align="center" colspan="1" rowspan="1">ACTN</th><th align="center" colspan="1" rowspan="1">LG3BP</th><th align="center" char="." colspan="1" rowspan="1">MSN</th></tr></thead><tbody><tr><td align="char" char="." colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">&lt;LoD</td><td align="left" colspan="1" rowspan="1">&lt;LoD</td><td align="char" char="." colspan="1" rowspan="1">4&#160;&#177;&#160;1</td></tr><tr><td align="char" char="." colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">2&#160;&#177;&#160;1</td><td align="left" colspan="1" rowspan="1">3&#160;&#177;&#160;1</td><td align="center" char="." colspan="1" rowspan="1">8.6&#160;&#177;&#160;0.9</td></tr><tr><td align="char" char="." colspan="1" rowspan="1">0.1</td><td align="left" colspan="1" rowspan="1">7.4&#160;&#177;&#160;0.5</td><td align="left" colspan="1" rowspan="1">50&#160;&#177;&#160;4</td><td align="char" char="." colspan="1" rowspan="1">15&#160;&#177;&#160;1</td></tr><tr><td align="char" char="." colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7.3&#160;&#177;&#160;0.9</td><td align="left" colspan="1" rowspan="1">50&#160;&#177;&#160;6</td><td align="char" char="." colspan="1" rowspan="1">15&#160;&#177;&#160;3</td></tr></tbody></table><table-wrap-foot><fn id="tbl2-fn1"><label>a</label><p>LoD stands for limit of detection,
and standard deviations correspond to the measurements of three instrumental
replicates per sample.</p></fn></table-wrap-foot></table-wrap><p>Once the optimal TX100 concentration was selected
for EV lysis,
a detailed study was performed to assess the effect of TX100 on immunogenic
reaction. To this end, two independent immunoassays were performed
for each protein studied: one in which standards were incubated with
0.1% TX100 for 15 min (&#8220;immunoassay with TX100&#8221;) and
another identical immunoassay in which this step was omitted (&#8220;immunoassay
without TX100&#8221;). As an example, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref> shows the response curves for LG3BP detection
using the Anti-m-LG3BP:PtNCs immunoprobe (response curves for ACTN
and MSN, obtained using, respectively, Anti-m-ACTNP:AuNCs and Anti-m-MSN:IrNCs
immunoprobes, are shown in Figure S3 of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>). The results indicate that TX100 had a slight effect on the response
curves for LG3BP and MSN (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S3A</ext-link>, respectively)
and a negligible effect for ACTN (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S3B</ext-link>). In all three cases, the levels of Ir, Pt, and Au detected by ICP-MS
were slightly lower in the immunoassay with TX100 compared to the
one without it. However, LoDs obtained were significantly lower for
the three proteins when TX100 was used (37, 13, and 79 fM for MSN,
LG3BP, and ACTN, respectively) compared to the immunoassay without
TX100 (48, 20, and 130 fM for MSN, LG3BP, and ACTN, respectively).
The methods demonstrated acceptable reproducibility with relative
standard deviations (RSD) below 5% across triplicate measurements
(<italic toggle="yes">n</italic> = 3) for each protein concentration tested.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Comparative
response curves obtained by ICP-MS for the competitive
immunoassay for LG3BP detection using the Anti-m-LG3BP:PtNCs immunoprobe.
The effect of Triton X100 (TX100) was evaluated; the dashed curve
with triangles represents the response curve with TX100, whereas the
dashed curve with dots represents the response curve without TX100.
Error bars indicate the standard deviation of the mean signal from
three independent measurements.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr2" position="float" orientation="portrait" xlink:href="ac5c03630_0002.jpg"/></fig><p>To confirm these results, a model sample (LG3BP,
MSN, and ACTN
protein standards with a known concentration of 1 pM) was analyzed
using immunoassays performed with and without TX100 (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S3</ext-link>). As shown in the results presented in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref> &#8211; Section A, the concentrations
of LG3BP, MSN, and ACTN in the sample reached the expected values
in all cases, with a relative error below 10%. Thus, it can be concluded
that TX100 matching calibration for both standards and samples allows
for accurate protein determination using the proposed methodology.
However, when the study was conducted using non-TX100 matched calibrations
(i.e., a sample treated with TX100 analyzed using the immunoassay
without TX100 or a sample without TX100 analyzed using the immunoassay
with TX100, as shown in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref> &#8211; Section B), the measured protein concentrations
deviated significantly from the expected values. This discrepancy
was particularly notable for the sample treated with TX100 when the
calibration was performed without TX100, yielding ACTN, LG3BP, and
MSN concentrations of 1.4 &#177; 0.1, 4.1 &#177; 0.5, and 5.7 &#177;
0.5 pM, respectively. These results confirmed that 0.1% TX100 is necessary
in both standards and EV samples to ensure an optimal assay performance.
Finally, once the immunoassay conditions were optimized, the negative
control experiments performed for each target protein showed negligible
nonspecific interactions between the antibodies and either the EVs
or the well surfaces. The resulting Ir, Pt, and Au signals were comparable
to those obtained at the highest protein concentration calibration
points, where no free (unbound) antibody remained in the well, thus
supporting the specificity of the method. Nonspecific interactions
coming from unconjugated reagents are not considered, assuming that
three washing steps of the immunoprobe synthesized would remove any
unconjugated reagent&#8217;s excess.<xref rid="ref38" ref-type="bibr"/>
</p><table-wrap position="float" id="tbl3" orientation="portrait"><label>3</label><caption><title>Protein Concentrations Determined
by ICP-MS in a Model Sample (1 pM ACTN, LG3BP, and MSN Prepared from
Protein Standards) Using the Competitive Immunoassay with MNC-Labeled
Immunoprobes with and without Triton X-100<xref rid="tbl3-fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th colspan="4" align="center" rowspan="1">Section&#160;A</th></tr><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" char="." colspan="1" rowspan="1">ACTN</th><th align="center" char="." colspan="1" rowspan="1">LG3BP</th><th align="center" char="." colspan="1" rowspan="1">MSN</th></tr></thead><tbody><tr><td colspan="4" align="center" rowspan="1">Immunoassay
with TX100 (Standards and Sample)</td></tr><tr><td align="left" colspan="1" rowspan="1">[Protein] (pM)</td><td align="char" char="." colspan="1" rowspan="1">1.08&#160;&#177;&#160;0.06</td><td align="char" char="." colspan="1" rowspan="1">1.1&#160;&#177;&#160;0.1</td><td align="char" char="." colspan="1" rowspan="1">1.02&#160;&#177;&#160;0.08</td></tr><tr><td colspan="4" align="center" rowspan="1">Immunoassay without TX100 (Standards and Sample)</td></tr><tr><td align="left" colspan="1" rowspan="1">[Protein] (pM)</td><td align="char" char="." colspan="1" rowspan="1">1.0&#160;&#177;&#160;0.1</td><td align="char" char="." colspan="1" rowspan="1">1.05&#160;&#177;&#160;0.09</td><td align="char" char="." colspan="1" rowspan="1">1.04&#160;&#177;&#160;0.08</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th colspan="4" align="center" rowspan="1">Section&#160;B</th></tr><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" char="." colspan="1" rowspan="1">ACTN</th><th align="center" char="." colspan="1" rowspan="1">LG3BP</th><th align="center" char="." colspan="1" rowspan="1">MSN</th></tr></thead><tbody><tr><td colspan="4" align="center" rowspan="1">Immunoassay
without TX100 Sample with TX100</td></tr><tr><td align="left" colspan="1" rowspan="1">[Protein] (pM)</td><td align="char" char="." colspan="1" rowspan="1">1.4&#160;&#177;&#160;0.1</td><td align="char" char="." colspan="1" rowspan="1">4.1&#160;&#177;&#160;0.5</td><td align="char" char="." colspan="1" rowspan="1">5.7&#160;&#177;&#160;0.5</td></tr><tr><td colspan="4" align="center" rowspan="1">Immunoassay with TX100 Sample without TX100</td></tr><tr><td align="left" colspan="1" rowspan="1">[Protein] (pM)</td><td align="char" char="." colspan="1" rowspan="1">0.8&#160;&#177;&#160;0.1</td><td align="char" char="." colspan="1" rowspan="1">0.34&#160;&#177;&#160;0.03</td><td align="char" char="." colspan="1" rowspan="1">0.20&#160;&#177;&#160;0.02</td></tr></tbody></table><table-wrap-foot><fn id="tbl3-fn1"><label>a</label><p>Section A: Matched calibrations;
Section B: Non-matched calibrations. Standard deviations correspond
to the measurements of three instrumental replicates per sample.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4.3"><title>Determination of the Three Target Proteins in Serum EVs Isolated
from APP/PS1 Mice by ICP-MS</title><p>Once the protocol was optimized
for protein detection in EVs by a multiplexed competitive immunoassay
using MNC-labeled immunoprobes and ICP-ToFMS, the analysis of the
three target proteins (ACTN, LG3BP, and MSN) in EVs from the mouse
model was attempted across the four cohorts described in the <xref rid="sec2" ref-type="sec">Experimental Section</xref>, including both male and female
specimens to assess gender influence. EV isolation was carried out
in an interleaved manner, alternating samples from different groups
and sexes, to minimize operational biases. Each study group included
five samples, except for heterozygous males and females supplemented
with Zn, where only three individuals were available. In all cases,
three replicates were analyzed for each sample.</p><p>For normalization
purposes, three strategies were evaluated: (1) serum volume as the
reference method, (2) levels of the membrane EV marker CD81, determined
by an independent competitive immunoassay using a AuNC-labeled immunoprobe
(Anti-m-CD81:AuNCs) and ICP-MS detection, and (3) total protein levels
in the EV samples, determined by the BCA assay. As a preliminary treatment
of the results obtained, sex was not considered as a variable, so
that males and females in each of the study cohorts were treated as
a single group. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S4</ext-link> shows box plots
for the determination of ACTN, LG3BP, and MSN in all mice analyzed.
As shown in the box plots, when data for male and female mice were
analyzed together, a high interindividual variability was observed;
overall, the high data dispersion hindered the identification of an
optimal normalization approach. In addition to the inherent biological
heterogeneity of living systems, sex-based variability could affect
the results. Therefore, we concluded that analyzing male and female
data separately may help reduce variability and allow for a better
evaluation of the normalization strategies.</p><p>When the data is
segregated by sex, the trends observed allow one
to draw firmer conclusions. <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> shows comparative box plots for the determination
of ACTN, LG3BP, and MSN in all male mice analyzed (data for female
mice, with the same <italic toggle="yes">y</italic>-axis scale, are provided in
the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>, Figure S5). A similar trend was
observed in our experiments when comparing protein concentrations
normalized by the initial serum volume (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> &#8211; Panel A) with those normalized
using the CD81 levels (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> &#8211; Panel B). However, this trend was less consistent
when normalization was performed using total protein content (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref> &#8211; Panel C),
and this may be attributed to the uncontrolled coprecipitation of
serum proteins when purifying EVs. A similar pattern was observed
in female mice (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S5</ext-link>). Consequently,
the total protein content was discarded as a suitable normalization
method.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Box plots showing the normalized protein mass in EVs purified from
the blood serum of male mice determined by ICP-MS for ACTN (1), LG3BP
(2), and MSN (3) across four cohorts: +/+ without Zn (in yellow),
+/+ with Zn (in orange), +/&#8211; without Zn (in purple), and +/&#8211;
with Zn (in blue). Three normalization strategies were applied: (A)
Serum volume, (B) CD81 levels, and (C) Total protein content. Data
included the analysis of five individuals per group, except for heterozygous
males supplemented with Zn (+/&#8211; w Zn), where only three individuals
were available.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gr3" position="float" orientation="portrait" xlink:href="ac5c03630_0003.jpg"/></fig><p>Next, the normalized average values of ACTN, LG3BP,
and MSN (ng
protein per mL of serum) for males and females across the different
cohorts were evaluated (data available in Table S2, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">SI</ext-link>). In most cases, a clear differentiation was observed between
males and females, with females generally showing lower values, especially
for LG3BP and MSN. These differences could be attributed to sex-related
dissimilarities in phenotypic expression,<xref rid="ref39" ref-type="bibr"/> prompting the decision to additionally analyze data from both sexes
separately. The trends observed for each protein are discussed in
detail below.</p><p>Regarding ACTN levels in male mice (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A1), an increase in both levels
and variability
was observed in the +/&#8211; group with respect to the +/+ group
when they were not supplemented with Zn. Conversely, in Zn-supplemented
groups, ACTN levels decreased compared to their nonsupplemented counterparts,
reaching similar values in both +/+ and +/&#8211; groups. This may
indicate that Zn supplementation may stabilize ACTN levels regardless
of disease progression. Regarding ACTN levels in female mice (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S5A1</ext-link>), no significant differences were
observed between the +/+ and +/&#8211; groups in general. Zn supplementation
reduced variability in the homozygous group but had no conclusive
effect in the heterozygous group. This could be attributed to lower
effectiveness of Zn supplementation in heterozygous females, resulting
in greater data dispersion. However, no statistically significant
differences (<italic toggle="yes">p</italic> &gt; 0.05) were recorded between any
of the study cohorts for both males and females.</p><p>The trends
observed for LG3BP in male mice (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A2) are inconclusive. Lower levels were observed
in the +/&#8211; nonsupplemented group compared to the corresponding
+/+ group. However, Zn supplementation had opposite effects in both
groups: while it decreased LG3BP levels in the homozygous group, it
increased them in the heterozygous group. In fact, LG3BP levels in
the +/+ Zn-supplemented group were comparable to those in the +/&#8211;
nonsupplemented group. When comparing these results with those obtained
for females (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S5A2</ext-link>), similar trends
were observed, particularly the high variability in the heterozygous
Zn-supplemented group (as previously noted for ACTN). These findings
do not allow us to draw relevant conclusions, suggesting that LG3BP
may not be a suitable biomarker for neurodegeneration in EVs. Note
that, even though differences were registered in LG3BP levels between
the study cohorts, no statistically significant differences (<italic toggle="yes">p</italic> &gt; 0.05) were recorded for both male and female mice.
Finally,
regarding the MSN data for males (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A3), lower levels were detected in the nonsupplemented
heterozygous group compared to the homozygous group, although without
a statistically significant difference (<italic toggle="yes">p</italic> &gt; 0.05).
In the homozygous groups, values decreased with Zn supplementation
(statistically significant with <italic toggle="yes">p</italic> = 0.01835, Kruskal&#8211;Wallis
ANOVA with Dunn&#8217;s test), and this trend was also observed in
the heterozygous group, though less clearly and without statistical
difference (<italic toggle="yes">p</italic> &gt; 0.05), due to the high dispersity
recorded in the +/&#8211; w group. For females (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">Figure S5A3</ext-link>), the trend observed in males was repeated but
in a subtler way and without statistical difference (<italic toggle="yes">p</italic> &gt; 0.05).</p></sec></sec><sec id="sec5"><title>Conclusions</title><p>This study presents a multiplexed strategy
for the quantification
of three proteins in EVs (ACTN, LG3BP, MSN) using ICP-ToFMS and MNC-labeled
immunoprobes, addressing a key challenge in EV analysis. The levels
of CD81 in the isolated samples allow us to reflect EV presence, and
in addition, it could act as a better alternative rather than total
protein content for normalization purposes. However, it must be taken
into account that CD81 concentrations can be affected by EV size and
supplementation, thus restricting its applicability.</p><p>Implementation
of single-EV strategies could address population-level
variability and significantly enhance biomarker research. To this
end, future experiments will focus on single-vesicle analysis to enable
the characterization of individual EVs, thereby overcoming the averaging
effects inherent to bulk measurements.</p><p>Despite the small number
of animals per cohort and the fact that
Zn intake was not individually controlled, preliminary results suggest
that the effects of Zn supplementation and genotype may be reflected
in ACTN and MSN levels, with MSN showing significant differences in
specific conditions. Furthermore, although absolute protein levels
were found to be different between sexes, similar trends for LG3BP
and MSN were observed across study groups in both males and females,
indicating a likely sex-independent regulation mechanism linked to
neurodegeneration and the Zn effect for these two proteins specifically.
However, these results are preliminary, as we stated before, and a
proper statistical study with more individuals per group should be
carried out for firmer conclusions.</p><p>Finally, this method offers
a powerful alternative for EV relative
protein assessment, enabling highly multiplexed protein analysis with
good sensitivity. These advantages position ICP-ToFMS coupled with
MNC-labeled immunoassays as a powerful tool for research in neurodegeneration
and other clinically related topics.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ac5c03630_si_001.zip" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ac5c03630_si_002.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e964-autogenerated"><p>This work
was financially supported through the coordinated
project PID2022-137319OB (-C21 and -C22) funded by MCIN/AEI/10.13039/501100011033/FEDER,
European Union (EU), and Project IDE/2024/000694 of the Government
of the Principality of Asturias and FEDER Program of the EU through
SEKUENS Agency. J.M.-G. acknowledges the &#8220;<italic toggle="yes">Severo Ochoa</italic>&#8221; Program Grant with ref. BP21-041 (Principality of Asturias,
Spain). Additionally, authors acknowledge the technical support provided
by Servicios Cient&#237;fico-T&#233;cnicos of the University of
Oviedo &#8211; Mass Spectrometry unit and the Proteomic unit of the
Instituto Sanitario del Principado de Asturias (ISPA). Additionally,
the authors would like to acknowledge the website <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinformatics.psb.ugent.be/webtools/Venn/">https://bioinformatics.psb.ugent.be/webtools/Venn/</uri>, a free online tool provided by Ghent University for constructing
Venn diagrams, which was used to create <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref> of this manuscript.</p></ack><notes id="notes-2" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/10.1021/acs.analchem.5c03630?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.analchem.5c03630</ext-link>.<list list-type="simple" id="silist"><list-item><p>Detailed list of identified proteins in each replicate
of the protocols studied (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_001.zip" ext-link-type="uri">ZIP</ext-link>)</p></list-item><list-item><p>List of reagents along with detailed protocols
for the
synthesis and characterization of MNCs and MNCs-labeled immunoprobes
(Ab:MNCs); information on the optimization of EV purification for
protein selection via LC-MS/MS as well as the resulting proteomes
for all samples; response curves for the three MNC-labeled immunoprobes
used in the multiplexed competitive immunoassay (targeting MSN, LG3BP,
and ACTN), accompanied by comparative immunoassay responses with and
without TX100; box plots showing the protein mass in EVs purified
from the blood serum of all mice (both, male and female), as well
as from female mice only, across the four cohorts; comparative table
summarizing the average protein mass values normalized to serum volume
for male and female mice (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.analchem.5c03630/suppl_file/ac5c03630_si_002.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-1" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Van
Schependom</surname><given-names>J.</given-names></name><name name-style="western"><surname>D&#8217;haeseleer</surname><given-names>M.</given-names></name><article-title>Advances in Neurodegenerative Diseases</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>1709</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12051709</pub-id><pub-id pub-id-type="pmid">36902495</pub-id><pub-id pub-id-type="pmcid">PMC10002914</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Ross</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>M. A.</given-names></name><article-title>Protein Aggregation and Neurodegenerative Disease</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>S10</fpage><lpage>S17</lpage><pub-id pub-id-type="doi">10.1038/nm1066</pub-id><pub-id pub-id-type="pmid">15272267</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Ayeni</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Aldossary</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Ayejoto</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Gbadegesin</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Alshehri</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Alfassam</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Afewerky</surname><given-names>H. K.</given-names></name><name name-style="western"><surname>Almughem</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Tawfik</surname><given-names>E. A.</given-names></name><article-title>Neurodegenerative Diseases: Implications
of Environmental and Climatic Influences on Neurotransmitters and
Neuronal Hormones Activities</article-title><source>Int. J. Environ.
Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>12495</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph191912495</pub-id><pub-id pub-id-type="pmid">36231792</pub-id><pub-id pub-id-type="pmcid">PMC9564880</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Hansson</surname><given-names>O.</given-names></name><article-title>Biomarkers
for Neurodegenerative Diseases</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01382-x</pub-id><pub-id pub-id-type="pmid">34083813</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Breijyeh</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R.</given-names></name><article-title>Comprehensive Review
on Alzheimer&#8217;s Disease:
Causes and Treatment</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>5789</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Dugger</surname><given-names>B. N.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D. W.</given-names></name><article-title>Pathology of Neurodegenerative
Diseases</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2017</year><volume>9</volume><elocation-id>a028035</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028035</pub-id><pub-id pub-id-type="pmid">28062563</pub-id><pub-id pub-id-type="pmcid">PMC5495060</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Mukherjee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>S. K.</given-names></name><article-title>Role of Animal Models in Biomedical
Research: a review</article-title><source>Lab. Anim. Res.</source><year>2022</year><volume>38</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.1186/s42826-022-00128-1</pub-id><pub-id pub-id-type="pmid">35778730</pub-id><pub-id pub-id-type="pmcid">PMC9247923</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Lok</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><article-title>Characterization
of APP/PS1Mouse
Model of Alzheimer&#8217;s Disease in Senescence Accelerated Background</article-title><source>Neurosci. Lett.</source><year>2013</year><volume>557</volume><fpage>84</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.10.051</pub-id><pub-id pub-id-type="pmid">24176881</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Hosseinpour
Mashkani</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>D. P</given-names></name><name name-style="western"><surname>Westerhausen</surname><given-names>M. T</given-names></name><name name-style="western"><surname>Adlard</surname><given-names>P. A</given-names></name><name name-style="western"><surname>Golzan</surname><given-names>S M.</given-names></name><article-title>Alterations in Zinc, Copper, and
Iron Levels in the Retina and Brain of Alzheimer&#8217;s Disease
Patients and the APP/PS1Mouse Model</article-title><source>Metallomics</source><year>2024</year><volume>16</volume><elocation-id>mfae053</elocation-id><pub-id pub-id-type="doi">10.1093/mtomcs/mfae053</pub-id><pub-id pub-id-type="pmid">39520546</pub-id><pub-id pub-id-type="pmcid">PMC11630249</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Doyle</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M. Z.</given-names></name><article-title>Overview of Extracellular
Vesicles, their Origin, Composition,
Purpose, and Methods for Exosome Isolation and Analysis</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>727</elocation-id><pub-id pub-id-type="doi">10.3390/cells8070727</pub-id><pub-id pub-id-type="pmid">31311206</pub-id><pub-id pub-id-type="pmcid">PMC6678302</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Yakubovich</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Polischouk</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Evtushenko</surname><given-names>V. I.</given-names></name><article-title>Principles and Problems of Exosome
Isolation from Biological Fluids</article-title><source>Biochem. (Mosc.)
Suppl. Ser. A Membr. Cell Biol.</source><year>2022</year><volume>16</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1134/S1990747822030096</pub-id><pub-id pub-id-type="pmcid">PMC9202659</pub-id><pub-id pub-id-type="pmid">35730027</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Clases</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gonz&#225;lez de Vega</surname><given-names>R.</given-names></name><article-title>Facets of ICP-MS and
their Potential
in the Medical Sciences&#58872;Part 2: Nanomedicine, Immunochemistry,
Mass cytometry, and Bioassays</article-title><source>Anal. Bioanal.
Chem.</source><year>2022</year><volume>414</volume><fpage>7363</fpage><lpage>7386</lpage><pub-id pub-id-type="doi">10.1007/s00216-022-04260-8</pub-id><pub-id pub-id-type="pmid">36042038</pub-id><pub-id pub-id-type="pmcid">PMC9427439</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Chang</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W. Y.</given-names></name><article-title>ICP-MS-based methodology in metallomics:
Towards Single Particle Analysis, Single Cell Analysis, and Spatial
Metallomics</article-title><source>At. Spectrosc.</source><year>2022</year><volume>43</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.46770/AS.2022.108</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Zhang</surname><given-names>X. W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M. X.</given-names></name><name name-style="western"><surname>He</surname><given-names>M. Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. H.</given-names></name><article-title>Integral Multielement
Signals by DNA-programmed UCNP-AuNP
Nanosatellite Assemblies for Utrasensitive ICP-MS Detection of Exosomal
Proteins and Cancer Identification</article-title><source>Anal. Chem.</source><year>2021</year><volume>93</volume><fpage>6437</fpage><lpage>6445</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c00152</pub-id><pub-id pub-id-type="pmid">33844518</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><article-title>ICP-MS and Photothermal Dual-readout
Assay for Ultrasensitive and Point-of-care Detection of Pancreatic
Cancer Exosomes</article-title><source>Anal. Chem.</source><year>2021</year><volume>93</volume><fpage>11540</fpage><lpage>11546</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.1c02004</pub-id><pub-id pub-id-type="pmid">34369746</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><article-title>Sensitive Detection
of Exosomes by Gold Nanoparticles Labeling Inductively Coupled Plasma
Mass Spectrometry Based on Cholesterol Recognition and Rolling Circle
Amplification</article-title><source>Anal. Chim. Acta</source><year>2022</year><volume>1212</volume><elocation-id>339938</elocation-id><pub-id pub-id-type="doi">10.1016/j.aca.2022.339938</pub-id><pub-id pub-id-type="pmid">35623789</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><article-title>Selective Detection
of Exosomes by Elemental Labeling ICP-MS Based
on Cholesterol-EpCAM Aptamer Proximity Ligation Mediated MNAzyme Assembly</article-title><source>Sens. Actuators B Chem.</source><year>2024</year><volume>416</volume><elocation-id>136013</elocation-id><pub-id pub-id-type="doi">10.1016/j.snb.2024.136013</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Zhang</surname><given-names>X. W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>G. X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. H.</given-names></name><article-title>Ultrasensitive
and
Wash-free Detection of Tumor Extracellular Vesicles by Aptamer-proximity-ligation-activated
Rolling Circle Amplification Coupled to Single Particle ICP-MS</article-title><source>Anal. Chem.</source><year>2024</year><volume>96</volume><fpage>10800</fpage><lpage>10808</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.4c02066</pub-id><pub-id pub-id-type="pmid">38904228</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Lores-Padin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Menero-Valdes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><article-title>Nanoparticles as Labels
of Specific-recognition Reactions for the Determination of Biomolecules
by Inductively Coupled Plasma-Mass Spectrometry</article-title><source>Anal. Chim. Acta</source><year>2020</year><volume>1128</volume><fpage>251</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2020.07.008</pub-id><pub-id pub-id-type="pmid">32825909</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Jankowsky</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Fadale</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Borchelt</surname><given-names>D. R.</given-names></name><article-title>Mutant
Presenilin
Specifically Elevate the Levels of the 42 Residue Beta-amyloid Peptide <italic toggle="yes">in vivo</italic>: Evidence for Augmentation of a 42-specific Gamma
Secretase</article-title><source>Hum. Mol. Genet.</source><year>2004</year><volume>13</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh019</pub-id><pub-id pub-id-type="pmid">14645205</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Kilkenny</surname><given-names>C.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cuthill</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Emerson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>D. G.</given-names></name><collab>NC3Rs Reporting Guidelines
Working Group</collab><article-title>Animal Research:
Reporting <italic toggle="yes">in vivo</italic> Experiments: The ARRIVE Guidelines</article-title><source>Br. J.
Pharmacol.</source><year>2010</year><volume>160</volume><fpage>1577</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00872.x</pub-id><pub-id pub-id-type="pmid">20649561</pub-id><pub-id pub-id-type="pmcid">PMC2936830</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><collab>The
Age-Related Eye Disease Study Group</collab><article-title>The Age-Related Eye Disease Study (AREDS): Design Implications
AREDS Report No. 1</article-title><source>Control. Clin. Trials</source><year>1999</year><volume>20</volume><fpage>573</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1016/S0197-2456(99)00031-8</pub-id><pub-id pub-id-type="pmid">10588299</pub-id><pub-id pub-id-type="pmcid">PMC1473211</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Chew</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Clemons</surname><given-names>T.</given-names></name><name name-style="western"><surname>SanGiovanni</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Danis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Domalpally</surname><given-names>A.</given-names></name><name name-style="western"><surname>McBee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sperduto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>F. L.</given-names></name><article-title>The Age-Related
Eye Disease Study 2 (AREDS2): Study Design and Baseline Characteristics
(AREDS2 Report Number 1)</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><fpage>2282</fpage><lpage>2289</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2012.05.027</pub-id><pub-id pub-id-type="pmid">22840421</pub-id><pub-id pub-id-type="pmcid">PMC3485447</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Aranaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alvarez-Barrios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costas-Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gonzalez-Iglesias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vanhaecke</surname><given-names>F.</given-names></name><article-title>Study of the
Protective Role of Zn in Cultured Retinal Pigment Epithelial Cells
Subjected to Pro-Inflammatory Conditions Using Transcriptomics and
Mass Spectrometry</article-title><source>Microchem. J.</source><year>2022</year><volume>183</volume><elocation-id>108033</elocation-id><pub-id pub-id-type="doi">10.1016/j.microc.2022.108033</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Menero-Valdes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lores-Padin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonzalez-Iglesias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><article-title>Iridium Nanoclusters
as High Sensitive-tunable Elemental
Labels for Immunoassays: Determination of IgE and APOE in Aqueous
Humor by Inductively Coupled Plasma-Mass Spectrometry</article-title><source>Talanta</source><year>2022</year><volume>244</volume><elocation-id>123424</elocation-id><pub-id pub-id-type="doi">10.1016/j.talanta.2022.123424</pub-id><pub-id pub-id-type="pmid">35378356</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Lores-Padin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cruz-Alonso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez-Iglesias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><article-title>Bimodal determination of Immunoglobulin
E by Fluorimetry
and ICP-MS by Using Platinum Nanoclusters as a Label in an Immunoassay</article-title><source>Microchim. Acta</source><year>2019</year><volume>186</volume><elocation-id>705</elocation-id><pub-id pub-id-type="doi">10.1007/s00604-019-3868-9</pub-id><pub-id pub-id-type="pmid">31630258</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Cruz-Alonso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gonzalez-Iglesias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Traub</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jakubowski</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><article-title>Bioimaging of Metallothioneins
in Ocular Tissue Sections by LA-ICP-MS using Bioconjugated Gold Nanoclusters
as Specific Tags</article-title><source>Microchim. Acta</source><year>2018</year><volume>185</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1007/s00604-017-2597-1</pub-id><pub-id pub-id-type="pmid">29594525</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Malys</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Aigner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Schachner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Kain</surname><given-names>R.</given-names></name><article-title>Isolation of Small
Extracellular
Vesicles from Human Sera</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>4653</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094653</pub-id><pub-id pub-id-type="pmid">33925027</pub-id><pub-id pub-id-type="pmcid">PMC8124960</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Alonso</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Trapiella-Alfonso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J. M. C.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanz-Medel</surname><given-names>A.</given-names></name><article-title>Functionalized
Gold Nanoclusters as Fluorescent Labels for Immunoassays: Application
to Human Serum Immunoglobulin E Determination</article-title><source>Biosens. Bioelectron.</source><year>2016</year><volume>77</volume><fpage>1055</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/j.bios.2015.08.011</pub-id><pub-id pub-id-type="pmid">26547433</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Pelucchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stringhi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marcello</surname><given-names>E.</given-names></name><article-title>Dendritic Spines in
Alzheimer&#8217;s
Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>908</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21030908</pub-id><pub-id pub-id-type="pmid">32019166</pub-id><pub-id pub-id-type="pmcid">PMC7036943</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Seki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanagawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kowa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yahata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Toda</surname><given-names>T.</given-names></name><article-title>Galectin 3&#8211;binding
Protein Suppresses Amyloid Production by Modulating Cleavage of Amyloid
Precursor Protein</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>3678</fpage><lpage>3691</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008703</pub-id><pub-id pub-id-type="pmid">31996371</pub-id><pub-id pub-id-type="pmcid">PMC7076203</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Boza-Serrano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vrillon</surname><given-names>a.</given-names></name><name name-style="western"><surname>Minta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Paulus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camprub&#237;-Ferrer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Antonell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wennstr&#246;m</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gouras</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dumurgier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cognat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Molina-Porcel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Balasa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Victoria</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#225;nchez-Valle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paquet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Venero</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Deieborg</surname><given-names>T.</given-names></name><article-title>Galectin-3
is Elevated in CSF and is Associated with A&#946; Deposits and Tau
Aggregates in Brain Tissue in Alzheimer&#8217;s Disease</article-title><source>Acta Neuropathol.</source><year>2022</year><volume>144</volume><fpage>843</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1007/s00401-022-02469-6</pub-id><pub-id pub-id-type="pmid">35895141</pub-id><pub-id pub-id-type="pmcid">PMC9547798</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Garc&#237;a-Revilla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boza-Serrano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Espinosa-Oliva</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Deierborg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Pablos</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Burguillos</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Venero</surname><given-names>J. L.</given-names></name><article-title>Galectin-3, a Rising Star in Modulating Microglia Activation
Under Conditions of Neurodegeneration</article-title><source>Cell
Death Dis.</source><year>2022</year><volume>13</volume><elocation-id>628</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-022-05058-3</pub-id><pub-id pub-id-type="pmid">35859075</pub-id><pub-id pub-id-type="pmcid">PMC9300700</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Beckmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gamez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Mange</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bieniek</surname><given-names>K. F.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>B.</given-names></name><article-title>Moesin is an Effector
of Tau-induced Actin Overstabilization, Cell Cycle Activation, and
Neurotoxicity in Alzheimer&#8217;s Disease</article-title><source>iScience</source><year>2023</year><volume>26</volume><elocation-id>106152</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2023.106152</pub-id><pub-id pub-id-type="pmid">36879821</pub-id><pub-id pub-id-type="pmcid">PMC9984563</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Lores-Padin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mavrakis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez-Iglesias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pergantis</surname><given-names>S. A.</given-names></name><article-title>Gold Nanoclusters as Elemental Label
for the Sequential Quantification of Apolipoprotein E and Metallothionein
2A in Individual Human Cells of the Retinal Pigment Epithelium Using
Single Cell-ICP-MS</article-title><source>Anal. Chim. Acta</source><year>2022</year><volume>1203</volume><elocation-id>339701</elocation-id><pub-id pub-id-type="doi">10.1016/j.aca.2022.339701</pub-id><pub-id pub-id-type="pmid">35361429</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Quinn</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Semenova</surname><given-names>V. A.</given-names></name><name name-style="western"><surname>Elie</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Romero-Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stamey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Steward-Clark</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Mothershed</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pruckler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Helsel</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Holder</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Kellum</surname><given-names>M.</given-names></name><name name-style="western"><surname>Messmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Besser</surname><given-names>L.</given-names></name><name name-style="western"><surname>Plikaytis</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Dull</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sejvar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schuchat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lingappa</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bronsdon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlone</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Bajani-Ari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>B. A.</given-names></name><article-title>Specific, Sensitive,
and Quantitative Enzyme-linked Immunosorbent Assay for Human Immunoglobulin
G Antibodies to Anthrax Toxin Protective Antigen</article-title><source>Emerg. Infect. Dis.</source><year>2002</year><volume>8</volume><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.3201/eid0810.020380</pub-id><pub-id pub-id-type="pmid">12396924</pub-id><pub-id pub-id-type="pmcid">PMC2730307</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Gray</surname><given-names>W. D.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Searles</surname><given-names>C. D.</given-names></name><article-title>An Accurate, Precise Method for General
Labeling of Extracellular Vesicles</article-title><source>Methods</source><year>2015</year><volume>2</volume><fpage>360</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.mex.2015.08.002</pub-id><pub-id pub-id-type="pmcid">PMC4589801</pub-id><pub-id pub-id-type="pmid">26543819</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Mart&#237;nez-Garc&#237;a</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pereiro</surname><given-names>R.</given-names></name><article-title>Quantification of CD81 in Mouse Serum-derived
Extracellular Vesicles via Inductively Coupled Plasma &#8211; Mass
Spectrometry Using Gold-Based Labels</article-title><source>Talanta</source><year>2026</year><volume>297</volume><elocation-id>128609</elocation-id><pub-id pub-id-type="doi">10.1016/j.talanta.2025.128609</pub-id><pub-id pub-id-type="pmid">40716298</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Bianco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antonacci</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>M.</given-names></name><article-title>Sex and Gender Differenecs in Neurodegenerative
Diseases: Challenges for Therapeutic Opportunities</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>6354</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24076354</pub-id><pub-id pub-id-type="pmid">37047320</pub-id><pub-id pub-id-type="pmcid">PMC10093984</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Digit Med</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Digit Med</journal-id><journal-id journal-id-type="pmc-domain-id">3605</journal-id><journal-id journal-id-type="pmc-domain">npjdigitmed</journal-id><journal-title-group><journal-title>NPJ Digital Medicine</journal-title></journal-title-group><issn pub-type="epub">2398-6352</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12488890</article-id><article-id pub-id-type="pmcid-ver">PMC12488890.1</article-id><article-id pub-id-type="pmcaid">12488890</article-id><article-id pub-id-type="pmcaiid">12488890</article-id><article-id pub-id-type="pmid">41034564</article-id><article-id pub-id-type="doi">10.1038/s41746-025-02004-3</article-id><article-id pub-id-type="publisher-id">2004</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Large language models forecast patient health trajectories enabling digital twins</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Makarov</surname><given-names initials="N">Nikita</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Bordukova</surname><given-names initials="M">Maria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quengdaeng</surname><given-names initials="P">Papichaya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garger</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rodriguez-Esteban</surname><given-names initials="R">Raul</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Schmich</surname><given-names initials="F">Fabian</given-names></name><address><email>fabian.schmich@roche.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Menden</surname><given-names initials="MP">Michael P.</given-names></name><address><email>michael.menden@unimelb.edu.au</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00sh68184</institution-id><institution-id institution-id-type="GRID">grid.424277.0</institution-id><institution>Roche Innovation Center Munich (RICM), </institution></institution-wrap>Penzberg, Germany </aff><aff id="Aff2"><label>2</label>Computational Health Center, Helmholtz Munich, Munich, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05591te55</institution-id><institution-id institution-id-type="GRID">grid.5252.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 973X</institution-id><institution>Department of Biology, </institution><institution>Ludwig Maximilian University of Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02kkvpp62</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 2966</institution-id><institution>TUM School of Computation, Information and Technology, </institution><institution>Technical University of Munich, </institution></institution-wrap>Munich, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00by1q217</institution-id><institution-id institution-id-type="GRID">grid.417570.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0374 1269</institution-id><institution>Roche Innovation Center Basel (RICB), </institution></institution-wrap>Basel, Switzerland </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ej9dk98</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution>Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, </institution><institution>The University of Melbourne, </institution></institution-wrap>Melbourne, VIC Australia </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">478273</issue-id><elocation-id>588</elocation-id><history><date date-type="received"><day>5</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 00:25:14.440"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41746_2025_Article_2004.pdf"/><abstract id="Abs1"><p id="Par1">Generative artificial intelligence is revolutionizing digital twin development, enabling virtual patient representations that predict health trajectories, with large language models (LLMs) showcasing untapped clinical forecasting potential. We developed the Digital Twin&#8212;Generative Pretrained Transformer (DT-GPT), extending LLM-based forecasting solutions to clinical trajectory prediction. DT-GPT leverages electronic health records without requiring data imputation or normalization and overcomes real-world data challenges such as missingness, noise, and limited sample sizes. Benchmarking on non-small cell lung cancer, intensive care unit, and Alzheimer&#8217;s disease datasets, DT-GPT outperformed state-of-the-art machine learning models, reducing the scaled mean absolute error by 3.4%, 1.3% and 1.8%, respectively. It maintained distributions and cross-correlations of clinical variables, and demonstrated explainability through a human-interpretable interface. Additionally, DT-GPT&#8217;s ability to perform zero-shot forecasting highlights potential advantages of LLMs as clinical forecasting platforms, proposing a path towards digital twin applications in clinical trials, treatment selection, and adverse event mitigation.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Computational biology and bioinformatics</kwd><kwd>Computational models</kwd><kwd>Data processing</kwd><kwd>Machine learning</kwd><kwd>Predictive medicine</kwd><kwd>Biomarkers</kwd><kwd>Outcomes research</kwd></kwd-group><funding-group><award-group><funding-source><institution>F. Hoffmann-La Roche AG</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>European Union's Horizon 2020 Research and Innovation Programme</institution></funding-source><award-id>950293 - COMBAT-RES</award-id><award-id>950293 - COMBAT-RES</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Clinical forecasting involves predicting patient-specific health outcomes and clinical events over time, which is essential for patient monitoring, treatment selection, and drug development<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. An emerging approach to support such forecasting is the use of digital twins<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. These are virtual representations of patients that generate detailed, multivariable predictions of future health states by leveraging longitudinal medical history<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. When initialized with individual patient characteristics, digital twins can simulate real-time personalized responses to medical interventions or treatments<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">Digital twins offer a comprehensive framework for patient modeling by integrating diverse data streams, which can include history of medical examinations, diagnoses and treatments, deep molecular profiling, lifestyle and environmental factors, as well as general biomedical knowledge<sup><xref ref-type="bibr" rid="CR6">6</xref>&#8211;<xref ref-type="bibr" rid="CR8">8</xref></sup>. They provide a holistic reflection of an individual&#8217;s status within the broader context of the patient population, accounting for the interplay of disease dynamics and medical interventions<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. By bridging the gap between population-level evidence and individual-level insights, the application of digital twins is poised to revolutionize healthcare in areas such as precision and personalized medicine, predictive analytics, virtual testing, continuous monitoring, and enhanced decision support<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par4">Generative artificial intelligence (AI) holds promise for creating digital twins due to its potential to produce synthetic yet realistic data, but this area of application is still in its infancy<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Generative AI methods for predicting patient trajectories include recurrent neural networks, transformers and stable diffusion<sup><xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref></sup>. These often fall short in terms of handling missing data, interpretability and performance. These challenges can be partially addressed by causal machine learning<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, but these algorithms face limitations related to small datasets or being confined to simulations<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par5">Recent breakthroughs in generative AI have been achieved with foundation models, which are pre-trained AI models adaptable to various specific tasks involving different types of data. Most foundation models for patient forecasting focus on single-point predictions rather than comprehensive longitudinal patient trajectories, which are needed for clinical decision-making<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Recently, clinically focused, LLM-inspired methods have been proposed<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, however, with their evaluation focus still being on single-point predictions rather than longitudinal trajectories, and without using the knowledge of pretrained LLMs. Less explored for this purpose remain text-focused Large Language Models (LLMs), which have demonstrated forecasting capabilities<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>, including some approaches showing the ability of zero-shot forecasting, i.e., forecasting without any prior specific training in the task, thus highlighting their remarkable generalizability<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par6">LLM-based forecasting has made great progress in general forecasting. However, some common methods, such as LSTPrompt<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, LLMTime<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, Time-LLM<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, and GPT4TS<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, make assumptions which may not necessarily hold in clinical trajectory forecasting. One example is channel independence, whereby, for multivariate time series, channel-independent models process each time series separately, without modeling interactions and inter-time series dependencies. This approach may not be optimal in the clinical setting, in which we often observe correlated time series, putatively driven by causal biological links, highlighting the need to process all aspects of a patient simultaneously.</p><p id="Par7">We propose the creation of digital twins based on LLMs that leverage data from electronic health records (EHRs) from real world data (RWD) and observational studies. EHRs are a key source of training data for machine learning models in healthcare, as they record patient characteristics such as demographics, diagnoses, and lab results over time<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. However, they pose specific challenges such as data heterogeneity, rare events, sparsity, and quality issues<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. There have been developments in machine learning to overcome these challenges, especially for data sparsity, usually by adapting the model&#8217;s architecture, resulting in increased model complexity and the introduction of further assumptions on the data<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par8">We hypothesize that LLMs will empower the next generation of digital twins in healthcare. Here, we introduce the Digital Twin - Generative Pretrained Transformer (DT-GPT) model (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), which<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>The LLM-based DT-GPT framework enables forecasting patient trajectories, identifying key variables, and zero-shot predictions.</title><p>Here exemplified, <bold>a</bold> sparse patient timeline, which <bold>b</bold> DT-GPT utilizes for generating longitudinal clinical variable forecasts, e.g., <bold>c</bold> neutrophil and <bold>d</bold> hemoglobin blood levels. DT-GPT can <bold>e</bold> chat and respond to inquiries about important variables, as well as (<bold>f</bold>) perform zero-shot forecasting on clinical variables previously not used during training.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e413" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig1_HTML.jpg"/></fig></p><p id="Par9">enables: (i) forecasting of clinical variable trajectories, (ii) zero-shot predictions of clinical variables not previously trained on, and (iii) preliminary interpretability utilizing chatbot functionalities. DT-GPT is an extension of previous LLM-based forecasting solutions, based on fine-tuning LLMs on clinical data using a straightforward data encoding scheme. The method is designed to solve clinically specific issues, be model-agnostic and to be applied to any text-focused LLM without any further architectural changes.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><p id="Par10">We analyzed the performance of DT-GPT by forecasting various clinical values on diverse datasets, including on a short-term scale (next 24&#8201;h) for Intensive Care Unit (ICU) patients, a medium-term scale (up to 13 weeks) for non-small cell lung cancer (NSCLC) patients, as well as a long-term Alzheimer&#8217;s Disease dataset (next 24 months). The ICU dataset is based on Medical Information Mart for Intensive Care IV (MIMIC-IV)<sup><xref ref-type="bibr" rid="CR25">25</xref></sup> with 35,131 patients, whilst the NSCLC dataset is based on the the nationwide Flatiron Health EHR-derived de-identified database, containing 16,496 NSCLC patients (&#8220;Methods&#8221;; Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>&#8211;<xref rid="MOESM1" ref-type="media">4</xref>; Supplementary Note <xref rid="MOESM1" ref-type="media">1</xref>). The Alzheimer&#8217;s disease dataset is derived from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) dataset, containing 1,140 patients (Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM1" ref-type="media">5</xref>; Supplementary Note <xref rid="MOESM1" ref-type="media">1</xref>). The datasets complement the analysis to understand how the model works on short-, medium- and long-term scales, as well as on different amounts of patients available for training. All details on task setup, data preprocessing, model training, and evaluation are provided in the &#8220;Methods&#8221; section.</p><sec id="Sec3"><title>DT-GPT achieved state-of-the-art forecasting performance</title><p id="Par11">DT-GPT achieved the lowest overall scaled mean absolute error (MAE) across benchmark tasks in comparison with state-of-the-art models (Table <xref rid="Tab1" ref-type="table">1</xref>), with the z-score scaling allowing comparison and aggregation across variables (&#8220;Methods&#8221;). In the NSCLC dataset, we predicted six laboratory values weekly for up to 13 weeks post-therapy initiation, leveraging all pre-treatment data to model patient trajectories under treatment. For the ICU task, we forecasted the next 24&#8201;h by predicting respiratory rate, magnesium and oxygen saturation based on the previous 24&#8201;h history, enabling real-time monitoring and timely intervention. In the Alzheimer&#8217;s dataset, we forecasted Mini Mental State Examination (MMSE)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, Clinical Dementia Rating sum of boxes (CDR-SB)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and Alzheimer&#8217;s Disease Assessment Scale (ADAS11)<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> cognitive scores, over the next 24 months at 6 month intervals using baselines measurements. All comparisons were performed on unseen patients.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Benchmark of clinical variable forecasting across three datasets</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Scaled mean absolute error</th><th rowspan="2" colspan="1">Model</th><th colspan="6" rowspan="1">Non-small cell lung cancer (NSCLC)</th><th colspan="3" rowspan="1">Intensive care unit</th><th colspan="3" rowspan="1">Alzheimer&#8217;s disease</th></tr><tr><th colspan="1" rowspan="1">Hemoglobin</th><th colspan="1" rowspan="1">Leukocytes</th><th colspan="1" rowspan="1">Lymphocytes/ Leukocytes</th><th colspan="1" rowspan="1">Lymphocytes</th><th colspan="1" rowspan="1">Neutrophils</th><th colspan="1" rowspan="1">Lactate Dehydrogenase</th><th colspan="1" rowspan="1">Magnesium</th><th colspan="1" rowspan="1">Resp. Rate</th><th colspan="1" rowspan="1">Oxygen Saturation</th><th colspan="1" rowspan="1">MMSE</th><th colspan="1" rowspan="1">CDR-SB</th><th colspan="1" rowspan="1">ADAS11</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Channel-Independent Input</td><td colspan="1" rowspan="1">Copy Forward</td><td colspan="1" rowspan="1">0.698</td><td colspan="1" rowspan="1">0.969</td><td colspan="1" rowspan="1">0.731</td><td colspan="1" rowspan="1">0.569</td><td colspan="1" rowspan="1">0.974</td><td colspan="1" rowspan="1">0.433</td><td colspan="1" rowspan="1">0.681</td><td colspan="1" rowspan="1">0.769</td><td colspan="1" rowspan="1">0.746</td><td colspan="1" rowspan="1">0.654</td><td colspan="1" rowspan="1">0.539</td><td colspan="1" rowspan="1">0.519</td></tr><tr><td colspan="1" rowspan="1">PatchTST</td><td colspan="1" rowspan="1">0.684</td><td colspan="1" rowspan="1">0.968</td><td colspan="1" rowspan="1">0.719</td><td colspan="1" rowspan="1">0.560</td><td colspan="1" rowspan="1">0.959</td><td colspan="1" rowspan="1">0.447</td><td colspan="1" rowspan="1">0.671</td><td colspan="1" rowspan="1">0.635</td><td colspan="1" rowspan="1">0.646</td><td colspan="1" rowspan="1">0.654</td><td colspan="1" rowspan="1">0.540</td><td colspan="1" rowspan="1">0.506</td></tr><tr><td colspan="1" rowspan="1">Time-LLM</td><td colspan="1" rowspan="1">0.665</td><td colspan="1" rowspan="1">0.894</td><td colspan="1" rowspan="1">0.684</td><td colspan="1" rowspan="1">0.544</td><td colspan="1" rowspan="1">0.878</td><td colspan="1" rowspan="1">0.443</td><td colspan="1" rowspan="1">0.664</td><td colspan="1" rowspan="1">0.655</td><td colspan="1" rowspan="1">0.665</td><td colspan="1" rowspan="1">0.654</td><td colspan="1" rowspan="1">0.540</td><td colspan="1" rowspan="1">0.506</td></tr><tr><td colspan="1" rowspan="1">LLMTime</td><td colspan="1" rowspan="1">0.736</td><td colspan="1" rowspan="1">0.923</td><td colspan="1" rowspan="1">0.725</td><td colspan="1" rowspan="1">0.601</td><td colspan="1" rowspan="1">0.900</td><td colspan="1" rowspan="1">0.437</td><td colspan="1" rowspan="1">0.759</td><td colspan="1" rowspan="1">0.686</td><td colspan="1" rowspan="1">0.688</td><td colspan="1" rowspan="1">0.654</td><td colspan="1" rowspan="1">0.539</td><td colspan="1" rowspan="1">0.503</td></tr><tr><td rowspan="11" colspan="1">Channel-Dependent Input</td><td colspan="1" rowspan="1">BioMistral-7B</td><td colspan="1" rowspan="1">0.984</td><td colspan="1" rowspan="1">1.097</td><td colspan="1" rowspan="1">0.756</td><td colspan="1" rowspan="1">0.997</td><td colspan="1" rowspan="1">1.953</td><td colspan="1" rowspan="1">0.600</td><td colspan="1" rowspan="1">0.790</td><td colspan="1" rowspan="1">0.770</td><td colspan="1" rowspan="1">0.945</td><td colspan="1" rowspan="1">2.064</td><td colspan="1" rowspan="1">0.883</td><td colspan="1" rowspan="1">0.728</td></tr><tr><td colspan="1" rowspan="1">Qwen3-32B</td><td colspan="1" rowspan="1">0.670</td><td colspan="1" rowspan="1">0.942</td><td colspan="1" rowspan="1">0.736</td><td colspan="1" rowspan="1">0.573</td><td colspan="1" rowspan="1">0.937</td><td colspan="1" rowspan="1">0.453</td><td colspan="1" rowspan="1">0.709</td><td colspan="1" rowspan="1">0.720</td><td colspan="1" rowspan="1">0.791</td><td colspan="1" rowspan="1">0.686</td><td colspan="1" rowspan="1">0.546</td><td colspan="1" rowspan="1">0.555</td></tr><tr><td colspan="1" rowspan="1">TCN</td><td colspan="1" rowspan="1">0.660</td><td colspan="1" rowspan="1">0.857</td><td colspan="1" rowspan="1">0.752</td><td colspan="1" rowspan="1">0.606</td><td colspan="1" rowspan="1">0.832</td><td colspan="1" rowspan="1">0.731</td><td colspan="1" rowspan="1">0.612</td><td colspan="1" rowspan="1">0.713</td><td colspan="1" rowspan="1">0.726</td><td colspan="1" rowspan="1"><italic toggle="yes">Not Applicable</italic></td><td colspan="1" rowspan="1">
<italic toggle="yes">Not Applicable</italic></td><td colspan="1" rowspan="1">
<italic toggle="yes">Not Applicable</italic></td></tr><tr><td colspan="1" rowspan="1">Linear Regression</td><td colspan="1" rowspan="1">0.486</td><td colspan="1" rowspan="1">0.782</td><td colspan="1" rowspan="1">0.668</td><td colspan="1" rowspan="1">0.506</td><td colspan="1" rowspan="1">0.778</td><td colspan="1" rowspan="1">0.475</td><td colspan="1" rowspan="1">0.606</td><td colspan="1" rowspan="1">0.680</td><td colspan="1" rowspan="1">0.681</td><td colspan="1" rowspan="1">0.551</td><td colspan="1" rowspan="1">0.449</td><td colspan="1" rowspan="1"><bold>0.457</bold></td></tr><tr><td colspan="1" rowspan="1">RNN</td><td colspan="1" rowspan="1">0.529</td><td colspan="1" rowspan="1">0.806</td><td colspan="1" rowspan="1">0.671</td><td colspan="1" rowspan="1">0.511</td><td colspan="1" rowspan="1">0.801</td><td colspan="1" rowspan="1">0.433</td><td colspan="1" rowspan="1">0.597</td><td colspan="1" rowspan="1">0.647</td><td colspan="1" rowspan="1">0.674</td><td colspan="1" rowspan="1">0.545</td><td colspan="1" rowspan="1">0.463</td><td colspan="1" rowspan="1">0.465</td></tr><tr><td colspan="1" rowspan="1">Transformer</td><td colspan="1" rowspan="1">0.496</td><td colspan="1" rowspan="1">0.749</td><td colspan="1" rowspan="1">0.683</td><td colspan="1" rowspan="1">0.503</td><td colspan="1" rowspan="1">0.741</td><td colspan="1" rowspan="1">0.514</td><td colspan="1" rowspan="1">0.537</td><td colspan="1" rowspan="1">0.644</td><td colspan="1" rowspan="1">0.651</td><td colspan="1" rowspan="1">0.553</td><td colspan="1" rowspan="1">0.485</td><td colspan="1" rowspan="1">0.481</td></tr><tr><td colspan="1" rowspan="1">LSTM</td><td colspan="1" rowspan="1">0.526</td><td colspan="1" rowspan="1">0.781</td><td colspan="1" rowspan="1">0.665</td><td colspan="1" rowspan="1">0.495</td><td colspan="1" rowspan="1">0.764</td><td colspan="1" rowspan="1">0.441</td><td colspan="1" rowspan="1">0.567</td><td colspan="1" rowspan="1">0.643</td><td colspan="1" rowspan="1">0.642</td><td colspan="1" rowspan="1">0.545</td><td colspan="1" rowspan="1">0.468</td><td colspan="1" rowspan="1">0.475</td></tr><tr><td colspan="1" rowspan="1">Temporal Fusion Transformer</td><td colspan="1" rowspan="1">0.469</td><td colspan="1" rowspan="1">0.719</td><td colspan="1" rowspan="1">0.651</td><td colspan="1" rowspan="1">0.463</td><td colspan="1" rowspan="1">0.717</td><td colspan="1" rowspan="1">0.480</td><td colspan="1" rowspan="1">0.537</td><td colspan="1" rowspan="1">0.635</td><td colspan="1" rowspan="1">0.644</td><td colspan="1" rowspan="1"><bold>0.520</bold></td><td colspan="1" rowspan="1">0.451</td><td colspan="1" rowspan="1">0.466</td></tr><tr><td colspan="1" rowspan="1">TiDE</td><td colspan="1" rowspan="1">0.464</td><td colspan="1" rowspan="1">0.737</td><td colspan="1" rowspan="1">0.655</td><td colspan="1" rowspan="1">0.465</td><td colspan="1" rowspan="1">0.740</td><td colspan="1" rowspan="1">0.453</td><td colspan="1" rowspan="1">0.534</td><td colspan="1" rowspan="1">0.635</td><td colspan="1" rowspan="1">0.652</td><td colspan="1" rowspan="1">0.578</td><td colspan="1" rowspan="1">0.498</td><td colspan="1" rowspan="1">0.506</td></tr><tr><td colspan="1" rowspan="1">LightGBM</td><td colspan="1" rowspan="1">0.453</td><td colspan="1" rowspan="1">0.727</td><td colspan="1" rowspan="1">0.644</td><td colspan="1" rowspan="1">0.456</td><td colspan="1" rowspan="1">0.734</td><td colspan="1" rowspan="1">0.425</td><td colspan="1" rowspan="1">0.520</td><td colspan="1" rowspan="1"><bold>0.634</bold></td><td colspan="1" rowspan="1">0.644</td><td colspan="1" rowspan="1">0.540</td><td colspan="1" rowspan="1">0.455</td><td colspan="1" rowspan="1">0.462</td></tr><tr><td colspan="1" rowspan="1"><bold>DT-GPT (ours)</bold></td><td colspan="1" rowspan="1"><bold>0.439</bold></td><td colspan="1" rowspan="1"><bold>0.687</bold></td><td colspan="1" rowspan="1"><bold>0.643</bold></td><td colspan="1" rowspan="1"><bold>0.434</bold></td><td colspan="1" rowspan="1"><bold>0.701</bold></td><td colspan="1" rowspan="1"><bold>0.418</bold></td><td colspan="1" rowspan="1"><bold>0.505</bold></td><td colspan="1" rowspan="1">0.636</td><td colspan="1" rowspan="1"><bold>0.635</bold></td><td colspan="1" rowspan="1">0.535</td><td colspan="1" rowspan="1"><bold>0.417</bold></td><td colspan="1" rowspan="1">0.458</td></tr></tbody></table><table-wrap-foot><p>DT-GPT outperformed the baselines in the majority of cases of the non-small cell lung cancer (NSCLC), intensive-care unit (ICU), and Alzheimer&#8217;s disease dataset. All errors refer to mean absolute error (MAE; lower is better) scaled by standard deviation.</p></table-wrap-foot></table-wrap></p><p id="Par12">We compared DT-GPT to 14 multi-step, multivariate baselines, ranging from a na&#239;ve model that copies over the last observed value to state-of-the-art forecasting models. These included linear regression model, time series LightGBM model, Temporal Fusion Transformer (TFT), Temporal Convolutional Network (TCN), Recurrent Neural Network (RNN), Long Short-Term Memory (LSTM), Transformer, and Time-series Dense Encoder (TiDE) model<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. The na&#239;ve model ensured that models with better performance capture nonstationary time series, whilst advanced models were chosen for their ability to handle future variables and achieving state-of-the-art performance in both medical and standard time series forecasting<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. To understand the contribution of fine-tuning, we also run the general, state-of-the-art LLM Qwen3-32B and the biomedical LLM BioMistral-7B<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. Note that DT-GPT is a fine-tuned 7-billion-parameter model based on BioMistral, whilst Qwen3 is a significantly larger model at 32 billion parameters. Additionally, we benchmarked advanced time-series LLM-based methods, i.e. Time-LLM and LLMTime<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>, as well as a patch based model PatchTST<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, all of which are channel-independent models, which process each input time series separately.</p><p id="Par13">On the NSCLC dataset, DT-GPT achieved an average scaled MAE of 0.55&#8201;&#177;&#8201;0.04, whilst LightGBM, the second best model, achieved an average scaled MAE of 0.57&#8201;&#177;&#8201;0.05, showing a relative improvement of 3.4% (Table <xref rid="Tab1" ref-type="table">1</xref>), On the ICU dataset, DT-GPT achieved an average scaled MAE of 0.59&#8201;&#177;&#8201;0.03, whilst the second best model, LightGBM, performed at 0.60&#8201;&#177;&#8201;0.03, equivalent to a 1.3% improvement (Table <xref rid="Tab1" ref-type="table">1</xref>). On the Alzheimer&#8217;s disease dataset, DT-GPT achieved an average scaled MAE of 0.47&#8201;&#177;&#8201;0.03, with Temporal Fusion Transformer being the second best model with 0.48&#8201;&#177;&#8201;0.02, representing a relative improvement of 1.8%. We note that the scaled MAE is normalized by standard deviation, with DT-GPT consistently achieving absolute MAE (Supplementary Tables <xref rid="MOESM1" ref-type="media">6</xref>&#8211;<xref rid="MOESM1" ref-type="media">17</xref>) that is lower than the standard deviation, indicating that forecasting errors are smaller than the natural variability present in the data. DT-GPT is shown to be the best performer out of 14 models across all datasets, and achieving statistical significance over the second-best performing model on the NSCLC (<italic toggle="yes">p</italic> value&#8201;&lt;&#8201;9.6162&#8201;&#215;&#8201;10<sup>&#8722;17</sup>) and ICU (p-value&#8201;&lt;&#8201;0.00043) datasets (Supplementary Note <xref rid="MOESM1" ref-type="media">2</xref>; Supplementary Tables <xref rid="MOESM1" ref-type="media">18</xref>&#8211;<xref rid="MOESM1" ref-type="media">19</xref>; Supplementary Figs. <xref rid="MOESM1" ref-type="media">1</xref>&#8211;<xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par14">Channel-independent models, such as LLMTime, Time-LLM and PatchTST, perform worse with respect to scaled MAE on variables that are more sparse and correlate less with other time series. Inversely, we see that the channel-independent models perform relatively better on respiratory rate and oxygen saturation, which have generally more dense measurements and are less correlated to time series such as treatment, in comparison, for example, to neutrophils in NSCLC.</p><p id="Par15">The LLMs without fine-tuning performed significantly worse than DT-GPT, often incorrectly hallucinating results. DT-GPT outperformed BioMistral by 47.9%, 29.1% and 61.1%, and outperformed the larger Qwen3-32B model by 22.9%, 19.9% and 21.1% on NSCLC, ICU and Alzheimer&#8217;s disease datasets, respectively.</p><p id="Par16">To comprehensively evaluate DT-GPT, we assessed a range of metrics, including derived classification metrics (&#8220;Methods&#8221;). DT-GPT consistently performed well across various metrics, capturing trajectory trends effectively (Supplementary Tables <xref rid="MOESM1" ref-type="media">6</xref>&#8211;<xref rid="MOESM1" ref-type="media">17</xref>). For forecasting, we compared scaled MAE, absolute MAE, mean absolute scaled error (MASE), symmetric mean absolute percentage error (SMAPE), and Spearman Correlation (&#8220;Methods&#8221;). For classification, we evaluated the area under the receiver operating characteristic curve (AUC) of clinically low/high predictions and overall trends (Supplementary Tables <xref rid="MOESM1" ref-type="media">6</xref>&#8211;<xref rid="MOESM1" ref-type="media">11</xref>). These metrics collectively offer insights into different aspects of model performance (Supplementary Note <xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par17">DT-GPT shows strong potential in capturing clinically relevant lab trends but has limitations in predicting specific critical events. For example, DT-GPT struggled with forecasting critically low hemoglobin levels (&#8201;&lt;&#8201;7.5&#8201;g/dL; ROC AUC&#8201;=&#8201;0.506), likely due to their low prevalence (1.2%; Methods; Supplementary Tables <xref rid="MOESM1" ref-type="media">6</xref>&#8211;<xref rid="MOESM1" ref-type="media">11</xref>; Supplementary Note <xref rid="MOESM1" ref-type="media">2</xref>). Similarly, prediction of high leukocyte counts (&#8201;&gt;&#8201;11.0&#8201;&#215;&#8201;10&#8313;/L) was modest (ROC AUC&#8201;=&#8201;0.578) and fell below the copy-forward baseline (ROC AUC&#8201;=&#8201;0.616).</p><p id="Par18">Notably, DT-GPT demonstrated robust predictive performance across several routine yet clinically informative laboratory parameters. This includes detection of mild anemia (hemoglobin below reference; ROC AUC&#8201;=&#8201;0.793) and elevated LDH (lactate dehydrogenase; &gt;222&#8201;U/L; ROC AUC&#8201;=&#8201;0.793), a marker of NSCLC progression<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. It also captured three-week trends in hemoglobin (increasing/decreasing; ROC</p><p id="Par19">AUCs&#8201;=&#8201;0.704/0.638) and rising leukocytes, lymphocytes, and neutrophils suggestive of inflammation (ROC AUCs&#8201;=&#8201;0.65&#8211;0.68)<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par20">DT-GPT forecasts preserved inter-variable relationships. The correlations between the variables forecasted by DT-GPT aligned with the correlations between the variables in the test datasets with an R<sup>2</sup> of 0.98 and 0.99, whilst those of LightGBM achieved an R<sup>2</sup> of 0.97 and 0.99 (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3</xref>) on the NSCLC and ICU datasets, respectively. Additionally, DT-GPT outperformed LightGBM in the majority of timepoints in both datasets, demonstrating that the improvement was consistent across time (Fig. <xref rid="Fig2" ref-type="fig">2a, b</xref>). For Alzheimer&#8217;s disease, both DT-GPT and the second best model TFT achieved an R<sup>2</sup> of 0.99.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>DT-GPT achieves state-of-the-art performance for clinical trajectory forecasting.</title><p><bold>a</bold> The long-term non-small cell lung cancer (NSCLC) and <bold>b</bold> the short-term intensive-care unit (ICU) dataset, with the x-axis showing relative time points and the y-axis the corresponding scaled mean absolute error (MAE), comparing with the second best forecasting model LightGBM. The scaling is done by the standard deviation, allowing comparison across variables with different value ranges and calculating a final performance score by averaging across the variables. Here exemplified, DT-GPT forecasts of neutrophil counts in patients with (<bold>c</bold>) low and <bold>d</bold> high error, for all weeks where the ground truth exists. <bold>e</bold> Histogram of MAE distribution for all predicted neutrophil counts.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1136" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig2_HTML.jpg"/></fig></p><p id="Par21">DT-GPT can be further improved by utilising alternative trajectory aggregation methods. To inspect both low and high MAE predictions from DT-GPT, we visualized two sample individual-patient forecasts for the variable neutrophils (Fig. <xref rid="Fig2" ref-type="fig">2c, d</xref>) picked from the low and high end of performance distribution (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>).</p><p id="Par22">It is important to note that the final prediction was derived by averaging 30 generated trajectories and that, even in poor performing cases, individual non-averaged forecasted trajectories sometimes succeeded in capturing aspects of the true trajectory.</p><p id="Par23">To assess the impact of trajectory aggregation, we calculated the error given an optimal aggregation. To this end, we selected the individual trajectories with the lowest scaled MAE and recalculated the hypothetical scaled MAE on the NSCLC dataset, achieving a 26% improvement in error to 0.40&#8201;&#177;&#8201;0.02, without any further model training, noting that this is a theoretical lower bound. Finally, we observed that in the distribution of scaled MAE for neutrophils across all patients, most of the errors were right-skewed, indicating that high errors came from a small number of patients with likely uncommon trajectories (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>).</p><p id="Par24">DT-GPT preserves the overall distribution of target variables&#8212;a property that, while not sufficient, is arguably necessary for clinically meaningful forecasting. To assess this, we computed the Kolmogorov&#8211;Smirnov (KS) statistic across all target variables in the NSCLC cohort, comparing predicted and true distributions (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). DT-GPT exhibited the lowest median KS score among all models,<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>DT-GPT resembles the distribution of the original data.</title><p><bold>a</bold> The distribution of DT-GPT forecasted values is the closest to the ground truth distribution according to the absolute Kolmogorov-Smirnov distance. This can also be observed from the distribution histograms associated with (<bold>b</bold>) the ground truth, <bold>c</bold> DT-GPT, <bold>d</bold> LLMTime, and <bold>e</bold> LightGBM. While LightGBM has the lowest scaled MAE after DT-GPT, LLM-based methods such as LLMTime more accurately resemble ground-truth data distribution. Lymph./Leuk. lymphocytes/leukocytes).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1180" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig3_HTML.jpg"/></fig></p><p id="Par25">indicating the best distributional alignment. Notably, several recent baselines, including TiDE, TCN, and TFT, struggled with the distribution modeling. We also visualized the distributions of the ground truth (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>) and DT-GPT predictions (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>), alongside LLMTime which had the second lowest mean score on the Kolomogorov-Smirnov statistic (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>), and LightGBM which was the best performing baseline with respect to scaled MAE (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>).</p></sec><sec id="Sec4"><title>DT-GPT is robust to common RWD challenges</title><p id="Par26">DT-GPT is flexible and robust to common practical data challenges, exhibiting desired properties in a variety of ablation studies, here exemplified on the average performance on all six clinical variables of the NSCLC dataset. First, DT-GPT performance was competitive with baselines after training with data corresponding to 5000 patients and it further improved with the number of patients in the training dataset (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>; Table <xref rid="Tab1" ref-type="table">1</xref>), and consistent in further subsampling ablation studies (Supplementary Table <xref rid="MOESM1" ref-type="media">20</xref>). Additionally, DT-GPT could handle increased input missingness, with performance degradation only showing after more than 20% of the input was randomly masked, on top of the 94.4% initial missingness of the NSCLC dataset (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). Thirdly, DT-GPT was stable to misspellings in the input, only significantly degrading in performance after 25 misspellings per patient sample (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>). We note that misspellings cannot be handled by most established machine learning methods and either require completely dropping or manual curation of the data.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>DT-GPT is robust to common RWD issues in the long-term NSCLC dataset.</title><p><bold>a</bold> Mean absolute error (MAE) according to the number of patients in the training set. Assessing impact on MAE based on (<bold>b</bold>) added missingness, on top of the baseline 94.4% missingness of the NSCLC dataset, and <bold>c</bold> injected misspellings in the input.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1231" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>DT-GPT enables prediction insights and zero-shot forecasting</title><p id="Par27">DT-GPT retains its conversational capability post-fine-tuning for the forecasting task, facilitating user interaction and enabling the inquiries into the reasoning behind predictions. For each patient sample, 10 predicted trajectories were generated, accompanied by a set of explanatory variables elucidating these predictions (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). We extracted explanatory variables from 25,575 out of 27,730 chatbot responses. The most influential variables were therapy, ECOG status and leukocyte count (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>; Supplementary Table <xref rid="MOESM1" ref-type="media">21</xref>; Supplementary Figs. <xref rid="MOESM1" ref-type="media">4</xref>&#8211;<xref rid="MOESM1" ref-type="media">9</xref>; Supplementary Note <xref rid="MOESM1" ref-type="media">3</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>DT-GPT preserves its conversational ability after the fine-tuning, allowing inquiring into prediction rationale and zero-shot forecasting.</title><p><bold>a</bold> Example of a chatbot interaction providing explanations for predictions. <bold>b</bold> Five most important variables for predicting all variables derived from forecasting test patient samples with 10 predicted trajectories each. <bold>c</bold> The most important variable, therapy, influences predicted hemoglobin trajectories, with (<bold>d</bold>) the corresponding ground truth. Here, the lines show average trajectories and the error bars correspond to the standard error. <bold>e</bold> The second most important variable, ECOG, influences predicted hemoglobin trajectories, and <bold>f</bold> showing the corresponding ground truth. Lines represent average trajectories and the error bars correspond to the standard error. <bold>g</bold> Example of a chatbot interaction for forecasting a variable not previously trained on. <bold>h</bold> We train 69 separate LightGBM models on other variables, whilst the single DT-GPT model receives no further training, resulting in DT-GPT outperforming LightGBM models on 13 out of 69 non-target variables. <bold>i</bold> DT-GPT is superior for variables more biologically related to the target variables used during fine tuning, with the respective LOINC codes depicted in parentheses. ECOG Eastern Cooperative Oncology Group performance status scale, LDH lactate dehydrogenase, ALT alanine aminotransferase).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1290" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig5_HTML.jpg"/></fig></p><p id="Par28">Therapy emerged as a key determinant of hemoglobin dynamics, aligning with existing literature<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. Patients receiving immunotherapy and targeted therapy generally exhibited higher hemoglobin levels over time compared to those undergoing chemotherapy or combination therapies (i.e., chemotherapy and immunotherapy), where hemoglobin levels tended to decline due to the chemotherapy-induced bone marrow suppression (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>; Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p><p id="Par29">ECOG status also played a significant role in shaping hemoglobin trajectories. The last recorded ECOG value in a patient&#8217;s medical history was predictive of future hemoglobin levels (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>), with lower ECOG values&#8212;indicative of fewer performance restrictions&#8212;correlating with higher hemoglobin levels over time, consistent with prior research<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Additionally, age has been widely recognized as an important prognostic factor<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Notably, these findings are also reflected in the original data, reinforcing the validity of DT-GPT&#8217;s predictions (Supplementary Fig. <xref rid="MOESM1" ref-type="media">9</xref>).</p><p id="Par30">DT-GPT enables zero-shot forecasting of non-target clinical variables, expanding its applicability beyond fine-tuned predictions. It can forecast 69 non-target clinical variables that are recorded in patient medical histories but were not explicitly included during model fine tuning. In our experiments, we forecasted each non-target variable separately (Fig. <xref rid="Fig5" ref-type="fig">5e</xref>) and extracted 81,004 trajectories from 81,918 forecasting results.</p><p id="Par31">To benchmark DT-GPT&#8217;s zero-shot performance, we compared it against a traditional machine learning approach. We extensively trained 69 LightGBM models, each using data from over 13,000 patients for individual target variables, and compared their performance to a single DT-GPT model that received no such additional training (i.e., zero-shot setting) and therefore was at a disadvantage. LightGBM was therefore anticipated to perform better than the zero-shot DT-GPT model.</p><p id="Par32">Surprisingly, zero-shot DT-GPT outperformed LightGBM on 13 out of 69 non-target variables (Fig. <xref rid="Fig5" ref-type="fig">5f</xref>. The variables with improved performance can be described as closely related to the target variables (Fig. <xref rid="Fig5" ref-type="fig">5g</xref>). For instance, <italic toggle="yes">segmented neutrophils</italic>, <italic toggle="yes">band form neutrophils</italic> and <italic toggle="yes">neutrophils by automated count</italic> have different LOINC codes from the trained variable (30451-9, 26507-4, 751-8, respectively), but these measurements were functionally related to the target variable <italic toggle="yes">neutrophils</italic> (LOINC 26499-4). A table containing scaled MAE values for DT-GPT and the LightGBM baseline is provided in Supplementary Table <xref rid="MOESM1" ref-type="media">22</xref>.</p><p id="Par33">We identified that DT-GPT performs better in zero-shot predictions for variables highly correlated with the fine-tuned targets. Specifically, 11 of 13 non-target variables for which DT-GPT demonstrates equal or superior performance compared to LightGBM, exhibit a strong Spearman correlation coefficient (&#8201;|&#8201;&#961;&#8201;|&#8201;&gt;&#8201;0.7) with at least one fine-tuned target variable (Supplementary Fig. <xref rid="MOESM1" ref-type="media">10</xref>). For the remaining well-performing zero-shot targets without strong correlations, feature importance analysis and relevant literature suggest that DT-GPT may capture clinically meaningful relationships, such as the ferritin-to-hemoglobin ratio and components of the Albumin-Bilirubin (ALBI) score in NSCLC patients (Supplementary Fig. <xref rid="MOESM1" ref-type="media">11</xref>; Supplementary Table <xref rid="MOESM1" ref-type="media">23</xref>)<sup><xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par34">Our main finding is that a simple yet effective method allows training LLMs on EHRs and study data to generate detailed patient trajectories that preserve inter-variable correlations. This method achieves state-of-the-art performance in clinical forecasting, while closely reproducing the distribution of original data and outperforming baselines in predicting clinically meaningful events in the trajectory. This highlights the potential of using LLMs as a digital twin platform that can mimic individual patients, with applications such as treatment selection and clinical trial support.</p><p id="Par35">Building on past LLM research in general forecasting, DT-GPT outperforms existing baselines<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup> in NSCLC, ICU and Alzheimer&#8217; s disease datasets. These findings align with recent LLM forecasting developments, demonstrating that clinically-specific adjustments enable accurate predictions<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Further analysis of several existing LLM forecasting approaches reveals that channel dependent modeling is a crucial aspect for patient trajectories, with DT-GPT showing that even a simple approach here can be highly effective. Notably, fine-tuning remains necessary for optimal performance, as demonstrated by the lower accuracy of non-fine-tuned LLMs, even when benchmarked against significantly larger models. Additionally, DT-GPT&#8217;s generative nature allows for multiple trajectory simulations per patient, offering insights into possible patient scenarios, cohort simulations, and uncertainty estimates. Finally, while all models were optimized for the forecasting task only, DT-GPT consistently outperformed baselines in classification tasks in detecting clinically relevant events by achieving best or second-best performance.</p><p id="Par36">The positive performance of LLMs for patient forecasting may stem from parallels between natural language and biomedical data, such as non-random missingness. For example, a doctor might skip measuring blood pressure if a patient appears healthy, indicating information by omission. Natural language implicitly handles such ambiguity; unspoken words can still convey meaning or none at all. Recent advancements suggest that LLMs can capture these complex relationships<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>.</p><p id="Par37">DT-GPT addresses EHR challenges including noise, sparsity, and lack of data normalization<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Unlike most established machine learning models that require data normalization and imputation, DT-GPT operates without these requirements. Here, we demonstrated its robustness to sparsity, misspellings, and noisy medical data often encountered in real-world datasets. Moreover, EHR data often contain mixed data encodings; for instance, drug information may vary in encoding, such as the dosage used or noted only as &#8220;administered&#8221;, both of which DT-GPT handles without additional preprocessing. Overall, DT-GPT simplifies and streamlines data preparation, thus enabling faster deployment across diverse datasets.</p><p id="Par38">DT-GPT can be inquired about the rationale of predictions, which increases the interpretability of the model. This capability helps bridge the gap between medical expert and model, enabling the exploration of prediction rationales and alternative patient scenarios efficiently. We believe that this advancement could enhance human-computer interaction with AI predictions and may positively affect clinical practices in the near future.</p><p id="Par39">DT-GPT enables zero-shot predictions, demonstrating its ability to forecast variables not explicitly included in its fine-tuning phase by learning their dynamics and adapting to novel tasks. Remarkably, zero-shot DT-GPT outperforms a supervised, fully-trained machine learning model on a subset of clinical variables, highlighting the pioneering potential of LLM-based approaches in RWD forecasting.</p><p id="Par40">Applying the preliminary interpretability approach also on the zero shot variables, we hypothesize that the model is potentially able to capture latent clinical knowledge, such as the importance of the ferritin-to-hemoglobin ratio and parts of the Albumin-Bilirubin (ALBI) score, both which are emerging prognostic biomarkers in NSCLC<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. It is important to note that the underlying BioMistral 7B model was trained on a vast amount of biomedical databases and publications. Therefore, these are preliminary hypotheses that require extensive investigation and validation from clinical experts.</p><p id="Par41">DT-GPT shows promise for clinical trajectory forecasting, with strong performance on standard metrics (e.g., MAE) and robust modeling of temporal dependencies. It effectively detects moderate abnormalities such as anemia, tracks inflammation-related trends, and predicts progression markers such as elevated LDH. However, performance declines for specific acute events&#8212;e.g., severe hemoglobin drops or high leukocyte counts&#8212;highlighting the challenge of forecasting low-prevalence, high-variance outcomes. Future improvements will require methods that enhance sensitivity to high-risk events, such as tailored loss functions, anomaly detection, and integration of unstructured clinical data.</p><p id="Par42">A challenge of LLM-based models is the restricted number of simultaneously forecasted variables. The current constraint on the number of forecasted variables is due to the limited sequence length of both input and output of the LLMs used in fine-tuning. Advances in extending the context length will enable modeling of additional patient variables, such as by using larger, more advanced models such as Qwen3-32B as the base model. Furthermore, we anticipate that transitioning from zero-shot to few-shot learning, where the model receives further training on a small subset of data, would enable a wider span of forecasted variables and extend DT-GPT&#8217;s applicability to broader clinical challenges.</p><p id="Par43">Future work can also take inspiration from developments in LLM-based forecasting. Specifically, ideas such as patching and prompt-as-a-prefix from Time-LLM<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, as well as normalization and generation of continuous likelihoods from LLMTime<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, can be adapted for clinical use, further improving forecasting performance. Additionally, even though DT-GPT was able to capture the clinically relevant events better than other models, performance can still be improved to increase clinical relevance, therefore we consider the optimization of the classification performance to be an important direction of future work. Related to this, future research should also focus on developing disease-specific forecasting metrics that correlate well with clinical utility.</p><p id="Par44">Another established shortcoming of LLM-based models is their tendency to hallucinate, as well as recreating the biases from the underlying data. In our case, the hallucination could be reflected in explainability results not necessarily providing true answers. This is a critical aspect for the medical domain, and we believe that a human-in-the-loop setup will be required, together with advanced training of clinicians on the use of LLM outputs. Regarding model biases, it is well established that models recreate the biases from the underlying data, which is especially pronounced in minority populations<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. To overcome the bias issues, methodological work, training of users, as well as the gathering of large scale, diverse clinical datasets, is needed.</p><p id="Par45">Finally, we observe that high error predictions often occur due to the high variance between the multiple generated trajectories of each patient sample, with the mean aggregation into the final prediction not capturing key dynamics. It is thus an open challenge to develop improved aggregation methods, for example by using a second LLM as an arbiter or by having a human expert select the most realistic trajectory.</p><p id="Par46">In conclusion, DT-GPT highlights the utility of using LLMs as a digital twin forecasting platform, enabling state-of-the-art and stable predictions, exploratory interpretability via a natural-language interface, and forecasting of patient variables not used in fine-tuning. Whilst further advancements are needed for wide-scale deployment, DT-GPT exhibits digital twin behaviors, potentially reproducing many aspects of the patients it represents, and surpassing traditional AI methods optimized for individual variables. We believe that through further method development and extensive validation, patient-level digital twins will impact clinical trials by supporting biomarker exploration, trial design, and interim analysis. Additionally, future digital twins will assist doctors in treatment selection and patient monitoring. Overall, we envision LLM-powered digital twins becoming integral to healthcare systems.</p></sec><sec id="Sec7"><title>Methods</title><p id="Par47">DT-GPT is a method that employs pre-trained LLMs fine-tuned on clinical data (Fig. <xref rid="Fig6" ref-type="fig">6a</xref>). Notably, this method is agnostic regarding the underlying LLM and can be applied without architectural changes to any general-purpose or specialized text-focused LLM. We trained and evaluated DT-GPT for forecasting patients&#8217; laboratory values across three independent datasets, i.e., non-small cell lung cancer (NSCLC), intensive care unit (ICU), and Alzheimer&#8217;s disease patients.<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>The DT-GPT framework transforms EHRs into text and subsequently fine-tunes an LLM on this data.</title><p><bold>a</bold> Overview of the pipeline: datasets are split and encoded into input/output text based on landmark timepoints, then used to fine-tune an LLM, here BioMistral. The model output is evaluated for trajectory forecasting whilst zero-shot predictions and variable importances are explored via a chat interface. <bold>b</bold> Sample size, visit frequency, and sparsity of the Alzheimer&#8217;s disease (AD), non-small cell lung cancer (NSCLC), intensive care unit (ICU) datasets. <bold>c</bold> Input and <bold>d</bold> output encoded examples, emphasizing the chronological encoding of observations.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1474" position="float" orientation="portrait" xlink:href="41746_2025_2004_Fig6_HTML.jpg"/></fig></p><sec id="Sec8"><title>NSCLC dataset</title><p id="Par48">For the US-based NSCLC dataset, we used the nationwide Flatiron Health EHR-derived de-identified database. The data are de-identified and subject to obligations to prevent re-identification and protect patient confidentiality. The Flatiron Health database is a longitudinal database, comprising de-identified patient-level structured and unstructured data, curated via technology-enabled abstraction<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. During the study period, the de-identified data originated from approximately 280 cancer clinics (&#8201;~&#8201;800 sites of care).</p><p id="Par49">The study included 16,496 patients diagnosed with NSCLC from 01 January 1991 to 06 July 2023. The majority of patients in the database originate from community oncology settings; relative community/academic proportions may vary depending on the study cohort. Patients with a birth year of 1938 or earlier may have an adjusted birth year in Flatiron Health datasets due to patient de-identification requirements. To harmonize the data, we aggregated all values in a week based on the last observed value.</p><p id="Par50">We focused on the 50 most common diagnoses and 80 most common laboratory measurements, complemented by the Eastern Cooperative Oncology Group (ECOG) score, metastases, vitals, drug administrations, response, and mortality variables totaling 773,607 patient-days across 320 variables.</p><p id="Par51">For every NSCLC patient, we divided their trajectory into input and output segments based on the start date of each line of therapy to create each patient sample. All variables up to the start date were considered input data. The objective was to predict the weekly values up to 13 weeks after the start date of the following variables and their respective LOINC codes: hemoglobin (718-7), leukocytes (26464-8), lymphocytes/leukocytes (26478-8), lymphocytes (26474-7), neutrophils (26499-4) and lactate dehydrogenase (2532-0). These variables were selected due to their frequent measurement and relevance in reflecting key characteristics of NSCLC treatment response (Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">2</xref>).</p></sec><sec id="Sec9"><title>ICU dataset</title><p id="Par52">To demonstrate the generalizability of DT-GPT, we analyzed ICU trajectories from the publicly-accessible Medical Information Mart for Intensive Care IV (MIMIC-IV) dataset<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. We employed an established processing pipeline, resulting in 300 input variables across 1,686,288 time points from 35,131 patients<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>.</p><p id="Par53">Here, the objective was to predict a patient&#8217;s future hourly lab variables given their first 24&#8201;h in the ICU. Specifically, the patient history was considered as the first 24&#8201;h for all variables, and the task was to forecast the future 24 hourly values for the following variables: O2 saturation pulse oximetry, respiratory rate and magnesium. These variables were selected due to having the highest temporal variability, thus making the forecasting task more challenging, and the fact that at least 50% of patients had at least one measurement for each, highlighting their widespread clinical usage (Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">3</xref>, <xref rid="MOESM1" ref-type="media">4</xref>). These criteria not only increased the forecasting challenge, but also ensured wide representation across the patient population.</p></sec><sec id="Sec10"><title>Alzheimer&#8217;s disease dataset</title><p id="Par54">To further demonstrate the generalizability of DT-GPT, we ran DT-GPT and the baseline models on the Alzheimer&#8217;s disease dataset, based on the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://adni.loni.usc.edu">adni.loni.usc.edu</ext-link>). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer&#8217;s disease (AD).</p><p id="Par55">We preprocessed the dataset, including 1140 patients. The task was to predict the 24 month trajectory of three cognitive variables, given the baseline measurements of the patients. Specifically, the variables were Mini Mental State Examination (MMSE), Clinical Dementia Rating sum of boxes (CDR-SB) and Alzheimer&#8217;s Disease Assessment Scale (ADAS11), which are key indicators of cognitive decline commonly measured in Alzheimer&#8217;s disease patients (Supplementary Tables <xref rid="MOESM1" ref-type="media">1</xref>, <xref rid="MOESM1" ref-type="media">5</xref>).</p></sec><sec id="Sec11"><title>Data splitting and filtering</title><p id="Par56">The NSCLC and ICU datasets were split at the patient level into 80% training, 10% validation, and 10% test set. The splitting was performed randomly for the ICU dataset, whilst stratified by group stage, smoking status, number of observations per visit and number of visits with drug administrations to ensure a balanced evaluation. The Alzheimer&#8217;s disease dataset was randomly split into 80% training and 20% test, selected due to the small sample size, with all hyperparameters determined via a further splitting on the training set. Thus, each set comprised disjoint sets of patients to avoid data leakage. The test sets were solely used for final evaluation and to assess the model&#8217;s generalizability (Fig. <xref rid="Fig6" ref-type="fig">6b</xref>).</p><p id="Par57">We applied a two-step outlier filtering procedure on all datasets: all target values below or above three standard deviations were filtered out first, then we calculated new standard deviation values on the filtered dataset and clipped target values below and above those values. This approach ensured that the noise present in the data was removed, while some of the outliers were replaced with reasonable low or high values to maintain the biological signal. The data for all of the baselines excluding DT-GPT were then also standardized using z-scores.</p></sec><sec id="Sec12"><title>Encoding</title><p id="Par58">We encoded patient trajectories by using templates that converted medical histories based on EHRs into a text format compatible with LLMs, as proposed by Xue et al.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and Liu et al.<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup> (Fig. <xref rid="Fig6" ref-type="fig">6c, d</xref>; Supplementary Note <xref rid="MOESM1" ref-type="media">4</xref>). The input template is structured into four components: (1) patient history, (2) demographic data, (3) forecast dates and (4) prompt. The patient history contains a chronological description of patient visits, requiring no data imputation for missing variables. The output trajectories were also encoded using templates, containing only the relevant output variables for the forecasted time points. We utilized a manually developed template for input encoding and JSON-format encoding for the output (Supplementary Fig. <xref rid="MOESM1" ref-type="media">12</xref>).</p></sec><sec id="Sec13"><title>LLMs and fine-tuning</title><p id="Par59">We utilized the biomedical LLM BioMistral 7B DARE, since it is provided with an open source license and based on a recognized LLM<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Furthermore, BioMistral is instruction tuned and through its biomedical specialization incorporates compressed representations of vast amounts of biomedical knowledge. We further fine tuned this LLM using the standard cross entropy loss, masked so that the gradient was only computed on the output text. We performed 30 predictions for each patient sample during evaluation, then took the mean for each time point as the final prediction<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. All hyperparameters of DT-GPT used fine-tuning (Supplementary Note <xref rid="MOESM1" ref-type="media">5</xref>) and are compared to baseline models (Supplementary Note <xref rid="MOESM1" ref-type="media">6</xref>).</p></sec><sec id="Sec14"><title>Handling of missing and noise data</title><p id="Par60">We investigated the ability of DT-GPT as a LLM-based model to handle missing data and misspelling in the input prompts. For the missing data study, we randomly masked between 0 and 80% of data, in addition to the already missing data in a dataset. Evaluation of the effect of missingness was performed on a randomly sampled 200 patients from the test set, which can potentially lead to higher variance in the results, but allowed for a more extensive exploration.</p><p id="Par61">For the noise study, we introduce a misspelling algorithm. This algorithm randomly performs either perturbation, insertion, deletion, or replacement, using all ASCII letters &amp; digits, applied to the entire input text. This includes dates, variable names, values, baseline information, and prompts. One operation is considered one misspelling.</p><p id="Par62">For the evaluation of the effects of RWD missingness and noise we randomly sampled 200 patients of the test set, which can potentially lead to higher variance in the results, but allowed for a more extensive exploration.</p></sec><sec id="Sec15"><title>Chatbot and zero-shot learning</title><p id="Par63">We employed the DT-GPT model to run a chatbot based on patient histories for prediction explanation and zero-shot forecasting. For this, first we used DT-GPT to generate forecasting results from patient history and, consecutively, added a task-specific prompt surrounded by the respective instruction-indication tokens to the DT-GPT chat history for receiving a response. For prediction explanation, the prompt asked for the most important variables influencing the predicted trajectory. For zero-shot forecasting, the prompt specified the output format and days to predict new clinical variables that were not subject to optimization during training. Example prompts and chatbot interactions for both tasks are provided in Supplementary Note <xref rid="MOESM1" ref-type="media">7</xref> and Fig. <xref rid="Fig5" ref-type="fig">5a, e</xref>.</p></sec><sec id="Sec16"><title>Forecasting evaluation</title><p id="Par64">Forecasting metrics, i.e. Eqs. (<xref rid="Equ1" ref-type="disp-formula">1</xref>)&#8211;(<xref rid="Equ5" ref-type="disp-formula">5</xref>), are designed to quantify the disparity between predicted and observed numeric values, providing an objective measure of the model&#8217;s predictive accuracy (Supplementary Note <xref rid="MOESM1" ref-type="media">8</xref>). Let <inline-formula id="IEq1"><alternatives><tex-math id="d33e1622">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{v}_{t}}^{(i)}$$\end{document}</tex-math><mml:math id="d33e1627"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq1.gif"/></alternatives></inline-formula> be an observed (non-missing) value of clinical variable <inline-formula id="IEq2"><alternatives><tex-math id="d33e1641">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="d33e1646"><mml:mi>v</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq2.gif"/></alternatives></inline-formula> for a subject <inline-formula id="IEq3"><alternatives><tex-math id="d33e1651">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1656"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq3.gif"/></alternatives></inline-formula>, <inline-formula id="IEq4"><alternatives><tex-math id="d33e1660">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i=1,\cdots ,n$$\end{document}</tex-math><mml:math id="d33e1665"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#8943;</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq4.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq5"><alternatives><tex-math id="d33e1676">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$n$$\end{document}</tex-math><mml:math id="d33e1681"><mml:mi>n</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq5.gif"/></alternatives></inline-formula> is the total number of subjects, and time step <inline-formula id="IEq6"><alternatives><tex-math id="d33e1685">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="d33e1690"><mml:mi>t</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq6.gif"/></alternatives></inline-formula>, <inline-formula id="IEq7"><alternatives><tex-math id="d33e1694">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t=1,\cdots ,{T}_{i}$$\end{document}</tex-math><mml:math id="d33e1699"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>&#8943;</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq7.gif"/></alternatives></inline-formula>, where <inline-formula id="IEq8"><alternatives><tex-math id="d33e1714">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{i}$$\end{document}</tex-math><mml:math id="d33e1719"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq8.gif"/></alternatives></inline-formula> is the total number of time steps for the subject <inline-formula id="IEq9"><alternatives><tex-math id="d33e1728">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$i$$\end{document}</tex-math><mml:math id="d33e1733"><mml:mi>i</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq3.gif"/></alternatives></inline-formula>. Let baseline value <inline-formula id="IEq10"><alternatives><tex-math id="d33e1737">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{0}^{(i)}$$\end{document}</tex-math><mml:math id="d33e1742"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq10.gif"/></alternatives></inline-formula> be the baseline value at time step <inline-formula id="IEq11"><alternatives><tex-math id="d33e1754">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${t}_{0}$$\end{document}</tex-math><mml:math id="d33e1759"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq11.gif"/></alternatives></inline-formula>, <inline-formula id="IEq12"><alternatives><tex-math id="d33e1767">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t=0$$\end{document}</tex-math><mml:math id="d33e1772"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq12.gif"/></alternatives></inline-formula>. We denote predicted values as <inline-formula id="IEq13"><alternatives><tex-math id="d33e1779">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\hat{v}}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e1784"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mo>&#710;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq13.gif"/></alternatives></inline-formula>. The forecasting metrics used are mean absolute error (MAE), scaled MAE, mean absolute scaled error (MASE), symmetric mean absolute percentage error (SMAPE) and Spearman correlation coefficient defined as follows:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="d33e1799">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${MAE}=\frac{1}{n}\mathop{\sum }\limits_{i=1}^{n}\frac{1}{{T}_{i}}\mathop{\sum }\limits_{t=1}^{{T}_{i}}|{v}_{t}^{(i)}-{\hat{v}}_{t}^{(i)}|$$\end{document}</tex-math><mml:math id="d33e1805"><mml:mrow><mml:mi mathvariant="italic">MAE</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:munderover><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mi>|</mml:mi><mml:msubsup><mml:mi>v</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>&#710;</mml:mo></mml:mover><mml:mi>t</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mi>|</mml:mi></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ1.gif"/></alternatives></disp-formula><disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="d33e1855">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${scaled\; MAE}=\frac{{MAE}}{\sigma }$$\end{document}</tex-math><mml:math id="d33e1861"><mml:mrow><mml:mi mathvariant="italic">scaled MAE</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="italic">MAE</mml:mi><mml:mi>&#963;</mml:mi></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ2.gif"/></alternatives></disp-formula>where <inline-formula id="IEq14"><alternatives><tex-math id="d33e1872">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\sigma$$\end{document}</tex-math><mml:math id="d33e1877"><mml:mi>&#963;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq14.gif"/></alternatives></inline-formula> is the standard deviation of the clinical variable after outlier filtering;<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="d33e1881">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${MASE}=\frac{{MAE}}{\,\frac{1}{n}{\sum }_{i=1}^{n}\frac{1}{{T}_{i}}{\sum }_{t=1}^{{T}_{i}}|{v}_{t}^{(i)}-{v}_{0}^{(i)}|}$$\end{document}</tex-math><mml:math id="d33e1887"><mml:mrow><mml:mi mathvariant="italic">MASE</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mi mathvariant="italic">MAE</mml:mi><mml:mrow><mml:mspace width="1em"/><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mi>|</mml:mi><mml:msubsup><mml:mi>v</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mn>0</mml:mn><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mi>|</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ3.gif"/></alternatives></disp-formula><disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="d33e1939">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${SMAPE}=\frac{200}{n}\mathop{\sum }\limits_{i=1}^{n}\frac{1}{{T}_{i}}\mathop{\sum }\limits_{t=1}^{{T}_{i}}\frac{{|{{v}_{t}}^{(i)}\,-{{\,\hat{v}}_{t}}^{(i)}|}}{|{v}_{t}^{(i)}|+|{\hat{v}}_{t}^{(i)}|}{\mathbb{1}_{\{|v_t^{(i)}| + |\hat{v}_t^{(i)}| \neq 0\}}}$$\end{document}</tex-math><mml:math id="d33e1945"><mml:mrow><mml:mi>S</mml:mi><mml:mi>M</mml:mi><mml:mi>A</mml:mi><mml:mi>P</mml:mi><mml:mi>E</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>200</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:mfrac><mml:munderover accent="false" accentunder="false"><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:munderover accent="false" accentunder="false"><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mfrac><mml:mrow><mml:mo>&#8739;</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mspace width="0.25em"/><mml:mo>&#8722;</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mspace width="0.25em"/><mml:mover accent="true"><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>^</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:mo>&#8739;</mml:mo></mml:mrow><mml:mrow><mml:mo>&#8739;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&#8739;</mml:mo><mml:mo>+</mml:mo><mml:mo>&#8739;</mml:mo><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>^</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&#8739;</mml:mo></mml:mrow></mml:mfrac><mml:mi mathvariant="double-struck">1</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo>&#8739;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&#8739;</mml:mo><mml:mo>+</mml:mo><mml:mo>&#8739;</mml:mo><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mo>^</mml:mo></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msubsup><mml:mo>&#8739;</mml:mo><mml:mo>&#8800;</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ4.gif"/></alternatives></disp-formula>where <inline-formula id="IEq15"><alternatives><tex-math id="d33e2102">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\mathbb{1}}$$\end{document}</tex-math><mml:math id="d33e2107"><mml:mn mathvariant="double-struck">1</mml:mn></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq15.gif"/></alternatives></inline-formula> is the indicator function to avoid division by 0;<disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="d33e2112">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$Spearman\,\rho =\frac{{\sum }_{i=1}^{n}\,\frac{1}{{T}_{i}}{\sum }_{t=1}^{{T}_{i}}\,(R[{v}_{t}^{(i)}]-\underline{R[v]})(R[{\widehat{v}}_{t}^{(i)}]-\underline{R[\widehat{v}]})}{\sqrt{{\sum }_{i=1}^{n}\,\frac{1}{{T}_{i}}{\sum }_{t=1}^{{T}_{i}}{(R[{v}_{t}^{(i)}]-\underline{R[v]})^{2}}\,{\sum }_{i=1}^{n}\frac{1}{{T}_{i}}\,{\sum }_{t=1}^{{T}_{i}}\,(R[{\widehat{v}}_{t}^{(i)}]-\underline{R[\widehat{v}]})^{2}}}$$\end{document}</tex-math><mml:math id="d33e2118"><mml:mrow><mml:mi>S</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>&#961;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mspace width="thinmathspace"/><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mspace width="thinmathspace"/><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>]</mml:mo><mml:mo>&#8722;</mml:mo><mml:munder><mml:mrow><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:mi>v</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>_</mml:mo></mml:munder><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mrow><mml:mover><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>]</mml:mo><mml:mo>&#8722;</mml:mo><mml:munder><mml:mrow><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:mrow><mml:mover><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>_</mml:mo></mml:munder><mml:mo>)</mml:mo></mml:mrow><mml:msqrt><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mspace width="thinmathspace"/><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mrow><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>]</mml:mo><mml:mo>&#8722;</mml:mo><mml:munder><mml:mrow><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:mi>v</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>_</mml:mo></mml:munder><mml:msup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mspace width="thinmathspace"/><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mspace width="thinmathspace"/><mml:msubsup><mml:mrow><mml:mo>&#8721;</mml:mo></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msubsup><mml:mspace width="thinmathspace"/><mml:mo>(</mml:mo><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mrow><mml:mover><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>]</mml:mo><mml:mo>&#8722;</mml:mo><mml:munder><mml:mrow><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:mrow><mml:mover><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>_</mml:mo></mml:munder><mml:msup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:msqrt></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ5.gif"/></alternatives></disp-formula>where <inline-formula id="IEq16"><alternatives><tex-math id="d33e2342">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$R[.]$$\end{document}</tex-math><mml:math id="d33e2347"><mml:mrow><mml:mi>R</mml:mi><mml:mo>[</mml:mo><mml:mo>.</mml:mo><mml:mo>]</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq16.gif"/></alternatives></inline-formula> is a rank function, ordering values from lowest to the highest, whereby, for the data points with the same value, their average rank is assigned, and <inline-formula id="IEq17"><alternatives><tex-math id="d33e2355">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\underline{R[v]}=\frac{1}{n}{\sum }_{i=1}^{n}\,\frac{1}{{T}_{i}}{\sum }_{t=1}^{{T}_{i}}\,R[{v}_{t}^{(i)}]$$\end{document}</tex-math><mml:math id="d33e2360"><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mi>v</mml:mi><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mspace width="0.25em"/><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mspace width="0.25em"/><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq17.gif"/></alternatives></inline-formula> and <inline-formula id="IEq18"><alternatives><tex-math id="d33e2417">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\underline{R[\widehat{v}]}=\frac{1}{n}\,{\sum }_{i=1}^{n}\,\frac{1}{{T}_{i}}\,{\sum }_{t=1}^{{T}_{i}}\,R[{\widehat{v}}_{t}^{(i)}]$$\end{document}</tex-math><mml:math id="d33e2422"><mml:mrow><mml:munder accentunder="true"><mml:mrow><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">_</mml:mo></mml:munder><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:mspace width="0.25em"/><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:mspace width="0.25em"/><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mfrac><mml:mspace width="0.25em"/><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:mspace width="0.25em"/><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>t</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq18.gif"/></alternatives></inline-formula> are the mean ranks of actual and predicted values, respectively.</p><p id="Par65">We chose scaled MAE, i.e., Eq. (<xref rid="Equ2" ref-type="disp-formula">2</xref>), as our primary metric as it allows comparison across all variables, and hence can be used to benchmark different models on all datasets.</p><sec id="Sec17"><title>Classification evaluation</title><p id="Par66">Classification metrics assess the model&#8217;s clinical utility to capture events, such as abrupt changes in clinical variables indicative of acute conditions (e.g., sudden drops or increases) or prolonged trends in variable changes that are characteristic of a chronic condition (e.g., gradual increases or decreases over extended periods). Below, we provide detailed definitions of the metrics employed in our evaluation. An interpretation of introduced metrics is provided in Supplementary Note <xref rid="MOESM1" ref-type="media">8</xref>.</p><p id="Par67">First, we assess the model&#8217;s ability to detect values outside the normal range of clinical variables. Let <inline-formula id="IEq19"><alternatives><tex-math id="d33e2500">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$[{v}_{\min \,},\,{v}_{\max }]$$\end{document}</tex-math><mml:math id="d33e2505"><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>min</mml:mi><mml:mspace width="0.25em"/></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq19.gif"/></alternatives></inline-formula> be the reference interval for the clinical variable <inline-formula id="IEq20"><alternatives><tex-math id="d33e2524">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$v$$\end{document}</tex-math><mml:math id="d33e2529"><mml:mi>v</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq2.gif"/></alternatives></inline-formula>. We label the observed variable value <inline-formula id="IEq21"><alternatives><tex-math id="d33e2533">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2538"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq21.gif"/></alternatives></inline-formula> as &#8220;low&#8221; if <inline-formula id="IEq22"><alternatives><tex-math id="d33e2550">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)} &lt; {v}_{\min }$$\end{document}</tex-math><mml:math id="d33e2555"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>min</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq22.gif"/></alternatives></inline-formula>, as &#8220;high&#8221; if <inline-formula id="IEq23"><alternatives><tex-math id="d33e2574">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)} &gt; {v}_{\max }$$\end{document}</tex-math><mml:math id="d33e2579"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq23.gif"/></alternatives></inline-formula> and as &#8220;normal&#8221; if <inline-formula id="IEq24"><alternatives><tex-math id="d33e2599">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{\min } &lt; {v}_{t}^{(i)} &lt; {v}_{\max }$$\end{document}</tex-math><mml:math id="d33e2604"><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>min</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq24.gif"/></alternatives></inline-formula>. We define <inline-formula id="IEq25"><alternatives><tex-math id="d33e2629">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2634"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq21.gif"/></alternatives></inline-formula> as &#8220;not low&#8221; if it is &#8220;normal&#8221; or &#8220;high&#8221;, as &#8220;not high&#8221; if it is &#8220;normal&#8221; or &#8220;low&#8221;, and as &#8220;not normal&#8221; if it is &#8220;low&#8221; or &#8220;high&#8221;. Analogously, we label each predicted variable value <inline-formula id="IEq26"><alternatives><tex-math id="d33e2646">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\hat{v}}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2651"><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mo>&#710;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq13.gif"/></alternatives></inline-formula>. With this, we are in the classification task settings.</p><p id="Par68">For the binary classification tasks &#8220;low&#8221; versus &#8220;not low&#8221;, &#8220;high&#8221; versus &#8220;not high&#8221;, and &#8220;normal&#8221; versus &#8220;not normal&#8221;, we calculate area under the receiver operating characteristic curve (AUC ROC) and denote it as <inline-formula id="IEq27"><alternatives><tex-math id="d33e2668">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{low}}$$\end{document}</tex-math><mml:math id="d33e2673"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq27.gif"/></alternatives></inline-formula>, <inline-formula id="IEq28"><alternatives><tex-math id="d33e2685">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{high}}$$\end{document}</tex-math><mml:math id="d33e2690"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">high</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq28.gif"/></alternatives></inline-formula> and <inline-formula id="IEq29"><alternatives><tex-math id="d33e2702">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{normal}}$$\end{document}</tex-math><mml:math id="d33e2707"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">normal</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq29.gif"/></alternatives></inline-formula>, respectively. For the multiclass classification task &#8220;low&#8221; versus &#8220;normal&#8221; versus &#8220;high&#8221;, we calculate weighted AUC ROC, denoted by AUC weighted (Eq. (<xref rid="Equ6" ref-type="disp-formula">6</xref>)), that is given by<disp-formula id="Equ6"><label>6</label><alternatives><tex-math id="d33e2722">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{AUC}_{\text{weighted}} = \frac{(\text{AUC}_{\text{low}} \times \#\text{low}) + (\text{AUC}_{\text{normal}} \times \#\text{normal}) + (\text{AUC}_{\text{high}} \times \#\text{high})}{\#\text{low} + \#\text{normal} + \#\text{high}}$$\end{document}</tex-math><mml:math id="d33e2728"><mml:mrow><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mtext>weighted</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mtext>low</mml:mtext></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>low</mml:mtext><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mtext>normal</mml:mtext></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>normal</mml:mtext><mml:mo>)</mml:mo><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mtext>AUC</mml:mtext><mml:mrow><mml:mtext>high</mml:mtext></mml:mrow></mml:msub><mml:mo>&#215;</mml:mo><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>high</mml:mtext><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>low</mml:mtext><mml:mo>+</mml:mo><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>normal</mml:mtext><mml:mo>+</mml:mo><mml:mi mathvariant="normal">#</mml:mi><mml:mtext>high</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41746_2025_2004_Article_Equ6.gif"/></alternatives></disp-formula>where <inline-formula id="IEq30"><alternatives><tex-math id="d33e2785">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\#low}$$\end{document}</tex-math><mml:math id="d33e2790"><mml:mi mathvariant="italic">#low</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq30.gif"/></alternatives></inline-formula>, <inline-formula id="IEq31"><alternatives><tex-math id="d33e2795">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\#normal}$$\end{document}</tex-math><mml:math id="d33e2800"><mml:mi mathvariant="italic">#normal</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq31.gif"/></alternatives></inline-formula> and <inline-formula id="IEq32"><alternatives><tex-math id="d33e2805">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\#high}$$\end{document}</tex-math><mml:math id="d33e2810"><mml:mi mathvariant="italic">#high</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq32.gif"/></alternatives></inline-formula>, correspond to the number of observed variables values <inline-formula id="IEq33"><alternatives><tex-math id="d33e2815">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{v}_{t}}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2820"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq1.gif"/></alternatives></inline-formula> labeled as &#8220;low&#8221;, &#8220;normal&#8221; and &#8220;high&#8221; respectively. Weighted aggregation accounts for the class imbalance, whereby most of the variable values fall within the reference range and are labeled as &#8220;normal&#8221;.</p><p id="Par69">We evaluated the model&#8217;s trend forecasting performance by analyzing its predicted value trajectories over a specified time interval <inline-formula id="IEq34"><alternatives><tex-math id="d33e2836">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$s$$\end{document}</tex-math><mml:math id="d33e2841"><mml:mi>s</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq34.gif"/></alternatives></inline-formula>. Within these forecasts, a predicted value <inline-formula id="IEq35"><alternatives><tex-math id="d33e2845">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2850"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq21.gif"/></alternatives></inline-formula> was classified as &#8216;decreasing trend&#8217; if <inline-formula id="IEq36"><alternatives><tex-math id="d33e2862">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t+1}^{(i)} &lt; {v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2867"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq36.gif"/></alternatives></inline-formula> or as an &#8216;increasing trend&#8217; if <inline-formula id="IEq37"><alternatives><tex-math id="d33e2892">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t+1}^{(i)} &gt; {v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2897"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq37.gif"/></alternatives></inline-formula>. For a trend to be classified at time <inline-formula id="IEq38"><alternatives><tex-math id="d33e2922">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$t$$\end{document}</tex-math><mml:math id="d33e2927"><mml:mi>t</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq6.gif"/></alternatives></inline-formula>, the direction of change between consecutive predicted values had to be consistent throughout the entire preceding lookback window. Specifically, <inline-formula id="IEq39"><alternatives><tex-math id="d33e2932">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{t}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2937"><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq21.gif"/></alternatives></inline-formula> was classified as &#8216;decreasing trend&#8217; only if <inline-formula id="IEq40"><alternatives><tex-math id="d33e2949">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{k+1}^{(i)} &lt; {v}_{k}^{(i)}$$\end{document}</tex-math><mml:math id="d33e2954"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq40.gif"/></alternatives></inline-formula> for all time steps <inline-formula id="IEq41"><alternatives><tex-math id="d33e2979">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k$$\end{document}</tex-math><mml:math id="d33e2984"><mml:mi>k</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq41.gif"/></alternatives></inline-formula> within the interval <inline-formula id="IEq42"><alternatives><tex-math id="d33e2988">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$[{time}(t)-s,{time}(t)]$$\end{document}</tex-math><mml:math id="d33e2993"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="italic">time</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&#8722;</mml:mo><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">time</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>]</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq42.gif"/></alternatives></inline-formula>, and &#8216;increasing trend&#8217; only if <inline-formula id="IEq43"><alternatives><tex-math id="d33e3013">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{k+1}^{(i)} &gt; {v}_{k}^{(i)}$$\end{document}</tex-math><mml:math id="d33e3018"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq43.gif"/></alternatives></inline-formula> for all <inline-formula id="IEq44"><alternatives><tex-math id="d33e3043">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$k$$\end{document}</tex-math><mml:math id="d33e3048"><mml:mi>k</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq41.gif"/></alternatives></inline-formula> in that same interval. Here, <inline-formula id="IEq45"><alternatives><tex-math id="d33e3053">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${time}(t)$$\end{document}</tex-math><mml:math id="d33e3058"><mml:mrow><mml:mi mathvariant="italic">time</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq45.gif"/></alternatives></inline-formula> represents the time since the last input measurement. Ground truth trends were derived similarly from observed data. We then assessed the model&#8217;s classification of these trends in its forecasts using two binary classification tasks: &#8216;decreasing&#8217; versus &#8216;not decreasing&#8217;, and &#8216;increasing&#8217; versus &#8216;not increasing&#8217;. Performance was quantified by calculating the area under the receiver operating characteristic curve (AUC) based on the forecasted values, yielding <inline-formula id="IEq46"><alternatives><tex-math id="d33e3067">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{trend}\downarrow }$$\end{document}</tex-math><mml:math id="d33e3072"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">trend</mml:mi><mml:mo>&#8595;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq46.gif"/></alternatives></inline-formula> and <inline-formula id="IEq47"><alternatives><tex-math id="d33e3085">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{trend}\uparrow }$$\end{document}</tex-math><mml:math id="d33e3090"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">trend</mml:mi><mml:mo>&#8593;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq47.gif"/></alternatives></inline-formula>. Forecasted values were excluded from this analysis if <inline-formula id="IEq48"><alternatives><tex-math id="d33e3103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${time}(t) &lt; s$$\end{document}</tex-math><mml:math id="d33e3108"><mml:mrow><mml:mi mathvariant="italic">time</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq48.gif"/></alternatives></inline-formula> to ensure a complete lookback window was available. We provide an example and illustration in Supplementary Fig. <xref rid="MOESM1" ref-type="media">13</xref>.</p><p id="Par70">We performed the classification evaluation only on the NSCLC data. For this, we used parameters for the reference ranges <inline-formula id="IEq49"><alternatives><tex-math id="d33e3124">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$[{v}_{\min },\,{v}_{\max }]$$\end{document}</tex-math><mml:math id="d33e3129"><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>min</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>max</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq49.gif"/></alternatives></inline-formula> as found in the literature. For hemoglobin [g/dL], we set [14, 18] and [12, 16] for male and female patients<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, respectively. We set [4.5, 11.0] for leukocytes [10<sup>9</sup>/L]<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, [20, 40] for leukocytes/lymphocytes [%]<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, [1.0, 4.0] for lymphocytes [10<sup>9</sup>/L]<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, [1.8, 7.5] for neutrophils [10<sup>9</sup>/L]<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> and [122, 222] for lactate dehydrogenase [U/L]<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par71">We further address the model ability to detect a significant drop in hemoglobin associated with a bleeding by calculating <inline-formula id="IEq50"><alternatives><tex-math id="d33e3180">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${AU}{C}_{{low}}$$\end{document}</tex-math><mml:math id="d33e3185"><mml:mrow><mml:mi mathvariant="italic">AU</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">low</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq27.gif"/></alternatives></inline-formula> with <inline-formula id="IEq51"><alternatives><tex-math id="d33e3197">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${v}_{\min }$$\end{document}</tex-math><mml:math id="d33e3202"><mml:msub><mml:mrow><mml:mi>v</mml:mi></mml:mrow><mml:mrow><mml:mi>min</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq51.gif"/></alternatives></inline-formula>&#8201;=&#8201;7.5. As for the trend detection, we consider time intervals of 3 weeks and set <inline-formula id="IEq52"><alternatives><tex-math id="d33e3210">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$s=21$$\end{document}</tex-math><mml:math id="d33e3215"><mml:mrow><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>21</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_Article_IEq52.gif"/></alternatives></inline-formula> days for all NSCLC variables. This time period is clinically relevant to capture the increasing or decreasing dynamics of a clinical variable.</p></sec></sec></sec><sec id="Sec18" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41746_2025_2004_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Nikita Makarov, Maria Bordukova.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41746-025-02004-3.</p></sec><ack><title>Acknowledgements</title><p>We would like to thank Anton Kraxner for providing crucial insights into NSCLC, as well as Ginte Kutkaite, Hugo Loureiro, Franziska Braun, Rudolf Kinder, Venus So, Guy Amster and Will Shapiro for their valuable input and discussions. This study was funded by F. Hoffmann-La Roche and the European Union's Horizon 2020 Research and Innovation Programme (Grant agreement No. 950293&#8211;COMBAT-RES). The funder played no role in study design, data collection, analysis and interpretation of data, or the writing of this manuscript. Data collection and sharing for the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19AG024904). The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National In-Institutes of Health (FNIH) including generous contributions from the following: AbbVie, Alzheimer&#8217;s Association; Alzheimer&#8217;s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>N.M., M.B. and P.Q. performed data processing. N.M. and M.B. performed model implementation. N.M., M.B. and D.G. performed model evaluation. R.R.-E., F.S. and M.P.M. supervised, designed and directed the project. N.M and M.B. drafted the manuscript. N.M., M.B., D.G., R.R.-E., F.S. and M.P.M. substantially revised this manuscript. All authors have read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The Flatiron Health data that support the findings of this study were originated by and are the property of Flatiron Health, Inc., which has restrictions prohibiting the authors from making the data set publicly available. Requests for data sharing by license or by permission for the specific purpose of replicating results in this manuscript can be submitted to PublicationsDataAccess@flatiron.com. The Medical Information Mart for Intensive Care IV (MIMIC-IV) is available online upon request under <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://physionet.org/content/mimiciv">https://physionet.org/content/mimiciv</ext-link>. The Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) dataset is available online upon request under <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/data-samples/adni-data/">https://adni.loni.usc.edu/data-samples/adni-data/</ext-link>.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The code is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/MendenLab/DT-GPT">https://github.com/MendenLab/DT-GPT</ext-link>, including all package and Python versions, as well as license information. Specific parameters used to generate and analyze the datasets presented in this manuscript are detailed in the repository&#8217;s README file and relevant configuration files.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par72">N.M., M.B., R.R.E. and F.S. are all employees of F. Hoffmann-La Roche. M.P.M. collaborates and is financially supported by GSK, F. Hoffmann-La Roche, and AstraZeneca. M.P.M. is supported by the European Union&#8217;s Horizon 2020 Research and Innovation Programme (Grant agreement No. 950293&#8212;COMBAT-RES). N.M., M.B., R.R.E., F.S. and M.P.M. are authors of an in-force patent entitled &#8220;Forecasting of subject-related attributes using generative machine-learning model&#8221; (patent publication number 2025/021719, patent application number EP2024070632) owned by F. Hoffmann-La Roche and Helmholtz Zentrum Munich. The patent covers application of large language models such as DT-GPT for forecasting of clinical trajectories of patients during a clinical trial. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schachter</surname><given-names>AD</given-names></name><name name-style="western"><surname>Ramoni</surname><given-names>MF</given-names></name></person-group><article-title>Clinical forecasting in drug development</article-title><source>Nat. Rev. Drug Discov.</source><year>2007</year><volume>6</volume><fpage>107</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/nrd2246</pub-id><pub-id pub-id-type="pmid">17342862</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Schachter, A. D. &amp; Ramoni, M. F. Clinical forecasting in drug development. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>6</bold>, 107&#8211;108 (2007.<pub-id pub-id-type="pmid">17342862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2246</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>A</given-names></name><etal/></person-group><article-title>A digital twins machine learning model for forecasting disease progression in stroke patients</article-title><source>Appl. Sci.</source><year>2021</year><volume>11</volume><fpage>5576</fpage><pub-id pub-id-type="doi">10.3390/app11125576</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Allen, A. et al. A digital twins machine learning model for forecasting disease progression in stroke patients. <italic toggle="yes">Appl. Sci.</italic><bold>11</bold>, 5576 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boulos</surname><given-names>MNK</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name></person-group><article-title>Digital twins: From personalised medicine to precision public health</article-title><source>J. Pers. Med.</source><year>2021</year><volume>11</volume><fpage>745</fpage><pub-id pub-id-type="doi">10.3390/jpm11080745</pub-id><pub-id pub-id-type="pmid">34442389</pub-id><pub-id pub-id-type="pmcid">PMC8401029</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Boulos, M. N. K. &amp; Zhang, P. Digital twins: From personalised medicine to precision public health. <italic toggle="yes">J. Pers. Med.</italic><bold>11</bold>, 745 (2021).<pub-id pub-id-type="pmid">34442389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11080745</pub-id><pub-id pub-id-type="pmcid">PMC8401029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bordukova</surname><given-names>M</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>N</given-names></name><name name-style="western"><surname>Rodriguez-Esteban</surname><given-names>R</given-names></name><name name-style="western"><surname>Schmich</surname><given-names>F</given-names></name><name name-style="western"><surname>Menden</surname><given-names>MP</given-names></name></person-group><article-title>Generative artificial intelligence empowers digital twins in drug discovery and clinical trials</article-title><source>Expert Opin. Drug Discov.</source><year>2024</year><volume>19</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1080/17460441.2023.2273839</pub-id><pub-id pub-id-type="pmid">37887266</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. &amp; Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. <italic toggle="yes">Expert Opin. Drug Discov.</italic><bold>19</bold>, 33&#8211;42 (2024).<pub-id pub-id-type="pmid">37887266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2023.2273839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coorey</surname><given-names>G</given-names></name><etal/></person-group><article-title>The health digital twin to tackle cardiovascular disease&#8212;a review of an emerging interdisciplinary field</article-title><source>npj Digit. Med.</source><year>2022</year><volume>5</volume><fpage>126</fpage><pub-id pub-id-type="doi">10.1038/s41746-022-00640-7</pub-id><pub-id pub-id-type="pmid">36028526</pub-id><pub-id pub-id-type="pmcid">PMC9418270</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Coorey, G. et al. The health digital twin to tackle cardiovascular disease&#8212;a review of an emerging interdisciplinary field. <italic toggle="yes">npj Digit. Med.</italic><bold>5</bold>, 126 (2022).<pub-id pub-id-type="pmid">36028526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00640-7</pub-id><pub-id pub-id-type="pmcid">PMC9418270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>KP</given-names></name><name name-style="western"><surname>Raza</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kvedar</surname><given-names>JC</given-names></name></person-group><article-title>Health digital twins as tools for precision medicine: Considerations for computation, implementation, and regulation. npj Digit</article-title><source>Med</source><year>2022</year><volume>5</volume><fpage>150</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00694-7</pub-id><pub-id pub-id-type="pmcid">PMC9500019</pub-id><pub-id pub-id-type="pmid">36138125</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Venkatesh, K. P., Raza, M. M. &amp; Kvedar, J. C. Health digital twins as tools for precision medicine: Considerations for computation, implementation, and regulation. npj Digit. <italic toggle="yes">Med</italic><bold>5</bold>, 150 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00694-7</pub-id><pub-id pub-id-type="pmcid">PMC9500019</pub-id><pub-id pub-id-type="pmid">36138125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bordukova</surname><given-names>M</given-names></name><etal/></person-group><article-title>Generative AI and digital twins: shaping a paradigm shift from precision to truly personalized medicine</article-title><source>Expert Opin. Drug Discov.</source><year>2025</year><volume>20</volume><fpage>821</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1080/17460441.2025.2507376</pub-id><pub-id pub-id-type="pmid">40375366</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bordukova, M. et al. Generative AI and digital twins: shaping a paradigm shift from precision to truly personalized medicine. <italic toggle="yes">Expert Opin. Drug Discov.</italic><bold>20</bold>, 821&#8211;826 (2025).<pub-id pub-id-type="pmid">40375366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17460441.2025.2507376</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moingeon</surname><given-names>P</given-names></name><name name-style="western"><surname>Chenel</surname><given-names>M</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>C</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>E</given-names></name><name name-style="western"><surname>Guedj</surname><given-names>M</given-names></name></person-group><article-title>Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>103605</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103605</pub-id><pub-id pub-id-type="pmid">37146963</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Moingeon, P., Chenel, M., Rousseau, C., Voisin, E. &amp; Guedj, M. Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials. <italic toggle="yes">Drug Discov. Today</italic><bold>28</bold>, 103605 (2023).<pub-id pub-id-type="pmid">37146963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2023.103605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predicting Alzheimer&#8217;s disease progression using deep recurrent neural networks</article-title><source>NeuroImage</source><year>2020</year><volume>222</volume><fpage>117203</fpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117203</pub-id><pub-id pub-id-type="pmid">32763427</pub-id><pub-id pub-id-type="pmcid">PMC7797176</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Nguyen, M. et al. Predicting Alzheimer&#8217;s disease progression using deep recurrent neural networks. <italic toggle="yes">NeuroImage</italic><bold>222</bold>, 117203 (2020).<pub-id pub-id-type="pmid">32763427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2020.117203</pub-id><pub-id pub-id-type="pmcid">PMC7797176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Jung, W., Mulyadi, A. W. &amp; Suk, H. I. Unified Modeling of Imputation, Forecasting, and Prediction for AD Progression. in <italic toggle="yes">Lecture Notes in Computer Science</italic> 168&#8211;176 (2019).</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Wu, F. et al. Forecasting Treatment Outcomes Over Time Using Alternating Deep Sequential Models. <italic toggle="yes">IEEE Transactions on Biomedical Engineering</italic><bold>PP</bold>, 1&#8211;10 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TBME.2023.3331298</pub-id><pub-id pub-id-type="pmcid">PMC11246606</pub-id><pub-id pub-id-type="pmid">37943640</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Phetrittikun, R. et al. Temporal Fusion Transformer for forecasting vital sign trajectories in intensive care patients. in <italic toggle="yes">2021 13th Biomed Eng Int Conf (BMEiCON)</italic> 1&#8211;5 (2021).</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>P</given-names></name><etal/></person-group><article-title>A transformer-based diffusion probabilistic model for heart rate and blood pressure forecasting in Intensive Care Unit</article-title><source>Comput. Methods Prog. Biomed.</source><year>2024</year><volume>246</volume><fpage>108060</fpage><pub-id pub-id-type="doi">10.1016/j.cmpb.2024.108060</pub-id><pub-id pub-id-type="pmcid">PMC10940190</pub-id><pub-id pub-id-type="pmid">38350189</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Chang, P. et al. A transformer-based diffusion probabilistic model for heart rate and blood pressure forecasting in Intensive Care Unit. <italic toggle="yes">Comput. Methods Prog. Biomed.</italic><bold>246</bold>, 108060 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmpb.2024.108060</pub-id><pub-id pub-id-type="pmcid">PMC10940190</pub-id><pub-id pub-id-type="pmid">38350189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Melnychuk, V., Frauen, D. &amp; Feuerriegel, S. Causal Transformer for Estimating Counterfactual Outcomes. in <italic toggle="yes">International Conference on Machine Learning</italic> 15293&#8211;15293 (2022).</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaddour</surname><given-names>J</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>A</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Kusner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Silva</surname><given-names>R</given-names></name></person-group><article-title>Causal machine learning: A survey and open problems.</article-title><source>Foundations and Trendsr in Optimization</source><year>2025</year><volume>9</volume><fpage>1</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1561/2400000052</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kaddour, J., Lynch, A., Liu, Q., Kusner, M. J. &amp; Silva, R. Causal machine learning: A survey and open problems. <italic toggle="yes">Foundations and Trendsr in Optimization</italic><bold>9</bold>, 1&#8211;247 (2025).</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wornow</surname><given-names>M</given-names></name><etal/></person-group><article-title>The shaky foundations of large language models and foundation models for electronic health records</article-title><source>npj Digital Med.</source><year>2023</year><volume>6</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1038/s41746-023-00879-8</pub-id><pub-id pub-id-type="pmcid">PMC10387101</pub-id><pub-id pub-id-type="pmid">37516790</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wornow, M. et al. The shaky foundations of large language models and foundation models for electronic health records. <italic toggle="yes">npj Digital Med.</italic><bold>6</bold>, 135 (2023).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-023-00879-8</pub-id><pub-id pub-id-type="pmcid">PMC10387101</pub-id><pub-id pub-id-type="pmid">37516790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renc</surname><given-names>P</given-names></name><etal/></person-group><article-title>Zero shot health trajectory prediction using transformer. npj Digit</article-title><source>Med</source><year>2024</year><volume>7</volume><fpage>256</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-024-01235-0</pub-id><pub-id pub-id-type="pmcid">PMC11412988</pub-id><pub-id pub-id-type="pmid">39300208</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Renc, P. et al. Zero shot health trajectory prediction using transformer. npj Digit. <italic toggle="yes">Med</italic><bold>7</bold>, 256 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-024-01235-0</pub-id><pub-id pub-id-type="pmcid">PMC11412988</pub-id><pub-id pub-id-type="pmid">39300208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Liang, Y. et al. Foundation Models for Time Series Analysis: A Tutorial and Survey. in <italic toggle="yes">Proceedings of the 30th ACM SIGKDD conference on knowledge discovery and data mining</italic> (2024).</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Xue, H. &amp; Salim, F. D. PromptCast: A New Prompt-based Learning Paradigm for Time Series Forecasting. <italic toggle="yes">IEEE Transactions on Knowledge and Data Engineering</italic> (2023).</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Liu, H., Zhao, Z., Wang, J., Kamarthi, H. &amp; Prakash, B. B. LSTPrompt: Large Language Models as Zero-Shot Time Series Forecasters by Long-Short-Term Prompting. in <italic toggle="yes">Association for Computational Linguistics Findings 2024</italic> (2024).</mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Gruver, N., Finzi, M., Qiu, S. &amp; Wilson, A. G. Large Language Models Are Zero-Shot Time Series Forecasters. in <italic toggle="yes">Advances in Neural Information Processing Systems</italic> (2023).</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Jin, M. et al. Time-LLM: Time Series Forecasting by Reprogramming Large Language Models. in <italic toggle="yes">International Conference on Learning Representations</italic> (2024). 10.48550/arxiv.2310.01728.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Zhou, T., Niu, P., Wang, X., Sun, L. &amp; Jin, R. One Fits All:Power General Time Series Analysis by Pretrained LM. arXiv (2023) 10.48550/arxiv.2302.11939.</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loureiro</surname><given-names>H</given-names></name><etal/></person-group><article-title>Correlation between early trends of a prognostic biomarker and overall survival in non&#8211;small-cell lung cancer clinical trials</article-title><source>JCO Clin. Cancer Inform.</source><year>2023</year><volume>7</volume><fpage>e2300062</fpage><pub-id pub-id-type="doi">10.1200/CCI.23.00062</pub-id><pub-id pub-id-type="pmid">37922432</pub-id><pub-id pub-id-type="pmcid">PMC10730042</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Loureiro, H. et al. Correlation between early trends of a prognostic biomarker and overall survival in non&#8211;small-cell lung cancer clinical trials. <italic toggle="yes">JCO Clin. Cancer Inform.</italic><bold>7</bold>, e2300062 (2023).<pub-id pub-id-type="pmid">37922432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/CCI.23.00062</pub-id><pub-id pub-id-type="pmcid">PMC10730042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>AE</given-names></name><etal/></person-group><article-title>MIMIC-IV, a freely accessible electronic health record dataset</article-title><source>Sci. Data</source><year>2023</year><volume>10</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/s41597-022-01899-x</pub-id><pub-id pub-id-type="pmid">36596836</pub-id><pub-id pub-id-type="pmcid">PMC9810617</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Johnson, A. E. et al. MIMIC-IV, a freely accessible electronic health record dataset. <italic toggle="yes">Sci. Data</italic><bold>10</bold>, 1 (2023).<pub-id pub-id-type="pmid">36596836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41597-022-01899-x</pub-id><pub-id pub-id-type="pmcid">PMC9810617</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tombaugh</surname><given-names>TN</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>NJ</given-names></name></person-group><article-title>The mini-mental state examination: A comprehensive review</article-title><source>J. Am. Geriatr. Soc.</source><year>1992</year><volume>40</volume><fpage>922</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1992.tb01992.x</pub-id><pub-id pub-id-type="pmid">1512391</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Tombaugh, T. N. &amp; McIntyre, N. J. The mini-mental state examination: A comprehensive review. <italic toggle="yes">J. Am. Geriatr. Soc.</italic><bold>40</bold>, 922&#8211;935 (1992).<pub-id pub-id-type="pmid">1512391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1992.tb01992.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Bryant</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer&#8217;s coordinating center database</article-title><source>Arch. Neurol.</source><year>2010</year><volume>67</volume><fpage>746</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2010.115</pub-id><pub-id pub-id-type="pmid">20558394</pub-id><pub-id pub-id-type="pmcid">PMC2888493</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">O&#8217;Bryant, S. E. et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer&#8217;s coordinating center database. <italic toggle="yes">Arch. Neurol.</italic><bold>67</bold>, 746&#8211;749 (2010).<pub-id pub-id-type="pmid">20558394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2010.115</pub-id><pub-id pub-id-type="pmcid">PMC2888493</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kueper</surname><given-names>JK</given-names></name><name name-style="western"><surname>Speechley</surname><given-names>M</given-names></name><name name-style="western"><surname>Montero-Odasso</surname><given-names>M</given-names></name></person-group><article-title>The Alzheimeras disease assessment scale-cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. a narrative review</article-title><source>Journal of Alzheimeras Disease</source><year>2018</year><volume>63</volume><fpage>423</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.3233/JAD-170991</pub-id><pub-id pub-id-type="pmcid">PMC5929311</pub-id><pub-id pub-id-type="pmid">29660938</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kueper, J. K., Speechley, M. &amp; Montero-Odasso, M. The Alzheimeras disease assessment scale-cognitive subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. a narrative review. <italic toggle="yes">Journal of Alzheimeras Disease</italic><bold>63</bold>, 423&#8211;444 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170991</pub-id><pub-id pub-id-type="pmcid">PMC5929311</pub-id><pub-id pub-id-type="pmid">29660938</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>B</given-names></name><name name-style="western"><surname>Ar&#305;k</surname><given-names>S</given-names></name><name name-style="western"><surname>Loeff</surname><given-names>N</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>T</given-names></name></person-group><article-title>Temporal Fusion Transformers for interpretable multi-horizon time series forecasting</article-title><source>Int. J. Forecast.</source><year>2021</year><volume>37</volume><fpage>1748</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1016/j.ijforecast.2021.03.012</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Lim, B., Ar&#305;k, S., Loeff, N. &amp; Pfister, T. Temporal Fusion Transformers for interpretable multi-horizon time series forecasting. <italic toggle="yes">Int. J. Forecast.</italic><bold>37</bold>, 1748&#8211;1764 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Das, A. et al. Long-term Forecasting with TiDE: Time-series Dense Encoder. <italic toggle="yes">Transactions on Machine Learning Research</italic> (2023).</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nespoli</surname><given-names>L</given-names></name><name name-style="western"><surname>Medici</surname><given-names>V</given-names></name></person-group><article-title>Multivariate Boosted Trees and Applications to Forecasting and Control</article-title><source>J. Mach. Learn. Res.</source><year>2022</year><volume>23</volume><fpage>1</fpage><lpage>47</lpage></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nespoli, L. &amp; Medici, V. Multivariate Boosted Trees and Applications to Forecasting and Control. <italic toggle="yes">J. Mach. Learn. Res.</italic><bold>23</bold>, 1&#8211;47 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Ke, G., Meng, Q., Finley, T., Wang, T., Chen, W., Ma, W., Ye, Q. &amp; Liu, T. Y. Lightgbm: A highly efficient gradient boosting decision tree. In <italic toggle="yes">Advances in neural information processing systems.</italic> 30 (2017).</mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Labrak, Y. et al. BioMistral: A collection of open-source pretrained large language models for medical domains. arXiv (2024).</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Qwen3 technical report</article-title><source>arXiv</source><year>2025</year><pub-id pub-id-type="doi">10.48550/arxiv.2505.09388</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yang, A. et al. Qwen3 technical report. <italic toggle="yes">arXiv</italic>10.48550/arxiv.2505.09388 (2025).41019226
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Nie, Y., Nguyen, N. H., Sinthong, P. &amp; Kalagnanam, J. A Time Series is Worth 64 Words: Long-term Forecasting with Transformers. in International Conference on Learning Representations (2023).</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Farhana, A. &amp; Lappin, S. L. <italic toggle="yes">Biochemistry, Lactate Dehydrogenase</italic>. (2023).<pub-id pub-id-type="pmid">32491468</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margraf</surname><given-names>A</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Zarbock</surname><given-names>A</given-names></name></person-group><article-title>Neutrophils in acute inflammation: current concepts and translational implications</article-title><source>Blood</source><year>2022</year><volume>139</volume><fpage>2130</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1182/blood.2021012295</pub-id><pub-id pub-id-type="pmid">34624098</pub-id><pub-id pub-id-type="pmcid">PMC9728535</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Margraf, A., Lowell, C. A. &amp; Zarbock, A. Neutrophils in acute inflammation: current concepts and translational implications. <italic toggle="yes">Blood</italic><bold>139</bold>, 2130&#8211;2144 (2022).<pub-id pub-id-type="pmid">34624098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2021012295</pub-id><pub-id pub-id-type="pmcid">PMC9728535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Groopman</surname><given-names>JE</given-names></name><name name-style="western"><surname>Itri</surname><given-names>LM</given-names></name></person-group><article-title>Chemotherapy-induced anemia in adults: incidence and treatment</article-title><source>J. Natl. Cancer Inst.</source><year>1999</year><volume>91</volume><fpage>1616</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.19.1616</pub-id><pub-id pub-id-type="pmid">10511589</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Groopman, J. E. &amp; Itri, L. M. Chemotherapy-induced anemia in adults: incidence and treatment. <italic toggle="yes">J. Natl. Cancer Inst.</italic><bold>91</bold>, 1616&#8211;1634 (1999).<pub-id pub-id-type="pmid">10511589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/91.19.1616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Razeq</surname><given-names>H</given-names></name><name name-style="western"><surname>Hashem</surname><given-names>H</given-names></name></person-group><article-title>Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>2020</year><volume>145</volume><fpage>102837</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.102837</pub-id><pub-id pub-id-type="pmid">31830663</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Abdel-Razeq, H. &amp; Hashem, H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. <italic toggle="yes">Crit. Rev. Oncol. Hematol.</italic><bold>145</bold>, 102837 (2020).<pub-id pub-id-type="pmid">31830663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2019.102837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Probin</surname><given-names>V</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name></person-group><article-title>Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy</article-title><source>Curr. Cancer Ther. Rev.</source><year>2006</year><volume>2</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.2174/157339406777934717</pub-id><pub-id pub-id-type="pmid">19936034</pub-id><pub-id pub-id-type="pmcid">PMC2779029</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Wang, Y., Probin, V. &amp; Zhou, D. Cancer therapy-induced residual bone marrow injury: Mechanisms of induction and implication for therapy. <italic toggle="yes">Curr. Cancer Ther. Rev.</italic><bold>2</bold>, 271&#8211;279 (2006).<pub-id pub-id-type="pmid">19936034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157339406777934717</pub-id><pub-id pub-id-type="pmcid">PMC2779029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cella</surname><given-names>D</given-names></name></person-group><article-title>The functional assessment of cancer therapy-anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue</article-title><source>Semin. Hematol.</source><year>1997</year><volume>34</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9253779</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cella, D. The functional assessment of cancer therapy-anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. <italic toggle="yes">Semin. Hematol.</italic><bold>34</bold>, 13&#8211;19 (1997).<pub-id pub-id-type="pmid">9253779</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pathak</surname><given-names>N</given-names></name><etal/></person-group><article-title>Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): A phase 2 study</article-title><source>J. Cancer Res. Clin. Oncol.</source><year>2023</year><volume>149</volume><fpage>6399</fpage><lpage>6409</lpage><pub-id pub-id-type="doi">10.1007/s00432-023-04617-1</pub-id><pub-id pub-id-type="pmid">36759393</pub-id><pub-id pub-id-type="pmcid">PMC11797346</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Pathak, N. et al. Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): A phase 2 study. <italic toggle="yes">J. Cancer Res. Clin. Oncol.</italic><bold>149</bold>, 6399&#8211;6409 (2023).<pub-id pub-id-type="pmid">36759393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00432-023-04617-1</pub-id><pub-id pub-id-type="pmcid">PMC11797346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tas</surname><given-names>F</given-names></name><name name-style="western"><surname>Ciftci</surname><given-names>R</given-names></name><name name-style="western"><surname>Kilic</surname><given-names>L</given-names></name><name name-style="western"><surname>Karabulut</surname><given-names>S</given-names></name></person-group><article-title>Age is a prognostic factor affecting survival in lung cancer patients</article-title><source>Oncol. Lett.</source><year>2013</year><volume>6</volume><fpage>1507</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.3892/ol.2013.1566</pub-id><pub-id pub-id-type="pmid">24179550</pub-id><pub-id pub-id-type="pmcid">PMC3813578</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Tas, F., Ciftci, R., Kilic, L. &amp; Karabulut, S. Age is a prognostic factor affecting survival in lung cancer patients. <italic toggle="yes">Oncol. Lett.</italic><bold>6</bold>, 1507&#8211;1513 (2013).<pub-id pub-id-type="pmid">24179550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2013.1566</pub-id><pub-id pub-id-type="pmcid">PMC3813578</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>H</given-names></name><name name-style="western"><surname>Shim</surname><given-names>B</given-names></name></person-group><article-title>Prognostic value of ferritin-to-hemoglobin ratio in patients with advanced non-small-cell lung cancer</article-title><source>J. Cancer</source><year>2019</year><volume>10</volume><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.7150/jca.26853</pub-id><pub-id pub-id-type="pmid">31205527</pub-id><pub-id pub-id-type="pmcid">PMC6548010</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lee, S., Jeon, H. &amp; Shim, B. Prognostic value of ferritin-to-hemoglobin ratio in patients with advanced non-small-cell lung cancer. <italic toggle="yes">J. Cancer</italic><bold>10</bold>, 1717&#8211;1725 (2019).<pub-id pub-id-type="pmid">31205527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/jca.26853</pub-id><pub-id pub-id-type="pmcid">PMC6548010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsukane</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>15057</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-94336-9</pub-id><pub-id pub-id-type="pmid">34301991</pub-id><pub-id pub-id-type="pmcid">PMC8302741</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Matsukane, R. et al. Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. <italic toggle="yes">Sci. Rep.</italic><bold>11</bold>, 15057 (2021).<pub-id pub-id-type="pmid">34301991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-94336-9</pub-id><pub-id pub-id-type="pmcid">PMC8302741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>M</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Hara</surname><given-names>M</given-names></name><name name-style="western"><surname>Ayabe</surname><given-names>T</given-names></name><name name-style="western"><surname>Onitsuka</surname><given-names>T</given-names></name></person-group><article-title>Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients</article-title><source>Anticancer Res</source><year>2008</year><volume>28</volume><fpage>1947</fpage><lpage>1950</lpage><pub-id pub-id-type="pmid">18630486</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Tomita, M., Shimizu, T., Hara, M., Ayabe, T. &amp; Onitsuka, T. Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients. <italic toggle="yes">Anticancer Res</italic><bold>28</bold>, 1947&#8211;1950 (2008).<pub-id pub-id-type="pmid">18630486</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Sravanthi, S. L. et al. PUB: A Pragmatics Understanding Benchmark for Assessing LLMs&#8217; Pragmatics Capabilities. in <italic toggle="yes">Findings of the Association for Computational Linguistics: ACL 2024</italic> (2024).</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>JL</given-names></name><name name-style="western"><surname>Choma</surname><given-names>MA</given-names></name><name name-style="western"><surname>Onofrey</surname><given-names>JA</given-names></name></person-group><article-title>Bias in medical AI: Implications for clinical decision-making</article-title><source>PLOS Digit. Heal.</source><year>2024</year><volume>3</volume><fpage>e0000651</fpage><pub-id pub-id-type="doi">10.1371/journal.pdig.0000651</pub-id><pub-id pub-id-type="pmcid">PMC11542778</pub-id><pub-id pub-id-type="pmid">39509461</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Cross, J. L., Choma, M. A. &amp; Onofrey, J. A. Bias in medical AI: Implications for clinical decision-making. <italic toggle="yes">PLOS Digit. Heal.</italic><bold>3</bold>, e0000651 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pdig.0000651</pub-id><pub-id pub-id-type="pmcid">PMC11542778</pub-id><pub-id pub-id-type="pmid">39509461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Ma, X., Long, L., Moon, S., Adamson, B. &amp; Baxi, S. Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR. <italic toggle="yes">medRxiv</italic><bold>2020</bold>, (2023).</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Birnbaum, B. et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. <italic toggle="yes">arXiv preprint arXiv:2007.XXXX</italic> (2020).</mixed-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Gupta, M. et al. An Extensive Data Processing Pipeline for MIMIC-IV. in <italic toggle="yes">Proceedings of Machine Learning Research</italic> 311&#8211;325 (2022).<pub-id pub-id-type="pmcid">PMC9854277</pub-id><pub-id pub-id-type="pmid">36686986</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Wang, X. et al. Self-Consistency Improves Chain of Thought Reasoning in Language Models. in <italic toggle="yes">The Eleventh International Conference on Learning Representations</italic> (2022).</mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Billett, H. H., Walker, H. K., 1, W. D. H. &amp; Hurst, J. W. Hemoglobin and Hematocrit. in <italic toggle="yes">Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd Edition</italic> (1990).<pub-id pub-id-type="pmid">21250045</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riley</surname><given-names>LK</given-names></name><name name-style="western"><surname>Rupert</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of patients with leukocytosis</article-title><source>Am. Fam. physician</source><year>2015</year><volume>92</volume><fpage>1004</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">26760415</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Riley, L. K. &amp; Rupert, J. Evaluation of patients with leukocytosis. <italic toggle="yes">Am. Fam. physician</italic><bold>92</bold>, 1004&#8211;1011 (2015).<pub-id pub-id-type="pmid">26760415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Haematology reference ranges. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gloshospitals.nhs.uk/our-services/services-we-offer/pathology/haematology/haematology-reference-ranges/">https://www.gloshospitals.nhs.uk/our-services/services-we-offer/pathology/haematology/haematology-reference-ranges/</ext-link> (2024).</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurobiol Stress</journal-id><journal-id journal-id-type="iso-abbrev">Neurobiol Stress</journal-id><journal-id journal-id-type="pmc-domain-id">2903</journal-id><journal-id journal-id-type="pmc-domain">nstr</journal-id><journal-title-group><journal-title>Neurobiology of Stress</journal-title></journal-title-group><issn pub-type="epub">2352-2895</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489926</article-id><article-id pub-id-type="pmcid-ver">PMC12489926.1</article-id><article-id pub-id-type="pmcaid">12489926</article-id><article-id pub-id-type="pmcaiid">12489926</article-id><article-id pub-id-type="pmid">41050105</article-id><article-id pub-id-type="doi">10.1016/j.ynstr.2025.100762</article-id><article-id pub-id-type="pii">S2352-2895(25)00056-6</article-id><article-id pub-id-type="publisher-id">100762</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review article</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">FKBP5/</italic>FKBP51-mediated signaling pathways in neuropsychiatric diseases: Insights for biomarker development and targeted therapies</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yinglong</given-names></name></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Lian</surname><given-names initials="J">Jiahe</given-names></name></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Fu</surname><given-names initials="Y">Youli</given-names></name></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shishan</given-names></name></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yongxin</given-names></name></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Zhang</surname><given-names initials="R">Rui</given-names></name><email>zhangrui@sdsmu.edu.cn</email><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Han</surname><given-names initials="H">Huirong</given-names></name><email>hrhan@sdsmu.edu.cn</email><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff1">Laboratory of Anesthesia and Critical Care Medicine in Colleges and Universities of Shandong Province, School of Anesthesiology, Shandong Second Medical University, Weifang, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>zhangrui@sdsmu.edu.cn</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. <email>hrhan@sdsmu.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><volume>39</volume><issue-id pub-id-type="pmc-issue-id">497702</issue-id><elocation-id>100762</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The FK506-binding protein 5 gene encodes FKBP51, a molecular chaperone linked to the pathogenesis of neuropsychiatric diseases. Recent evidence shows that FKBP51 modulates activity of the HPA axis and GR-mediated feedback via dynamic interactions with GR, thereby influencing stress adaptation, inflammatory responses, and neuronal survival. This review systematically analyzes the mechanisms by which <italic toggle="yes">FKBP5</italic> (and its encoded FKBP51) contributes to neuropsychiatric diseases and identifies shared pathways across these conditions. We further highlight key factors mediating disease variability and susceptibility: sex-, region-, and cell type-specific expression patterns of <italic toggle="yes">FKBP5</italic>/FKBP51, their temporal dynamics, genetic variants, epigenetic regulation, and gene&#8211;environment interactions. Additionally, we propose a &#8220;biphasic stress-response model&#8221; to conceptualize the temporal dynamics of <italic toggle="yes">FKBP5</italic>/FKBP51 expression during disease progression. Finally, we explore the translational potential of targeting FKBP51 signaling, and outline pharmacological strategies to modulate chaperone-dependent protein folding and stress pathways as novel therapeutic interventions.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">Deciphered the <italic toggle="yes">FKBP5</italic> gene.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Deciphering the mechanism of action of <italic toggle="yes">FKBP5</italic> in neuropsychiatric diseases.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020"><italic toggle="yes">FKBP5</italic>-related drugs were synthesized.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd><italic toggle="yes">FKBP5/</italic>FKBP51</kwd><kwd>Neuropsychiatric diseases</kwd><kwd>Depression</kwd><kwd>Anxiety disorder</kwd><kwd>PTSD</kwd><kwd>AD</kwd><kwd>PD</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><sec id="sec1.1"><label>1.1</label><title>Overview of psychiatric disorders</title><p id="p0030">The World Health Organization (WHO) reports an increasing global prevalence of psychiatric disorders, including depression, anxiety disorders, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD) (<xref rid="bib180" ref-type="bibr">Wittchen et al., 2011</xref>). Beyond compromising individual mental health, these disorders exert a significant economic and social toll on families and society (<xref rid="bib112" ref-type="bibr">Ormel et al., 1994</xref>). Their etiology involves complex interactions among genetic, environmental, and psychological determinants (<xref rid="bib135" ref-type="bibr">Schiele et al., 2020</xref>). Genetic studies demonstrate significant familial clustering for many psychiatric disorders, underscoring the importance of genetic predisposition in their pathogenesis (<xref rid="bib11" ref-type="bibr">Ballard et al., 2019</xref>; <xref rid="bib106" ref-type="bibr">Miller et al., 2019</xref>; <xref rid="bib123" ref-type="bibr">Quick et al., 2022</xref>). Environmental factors, including early life experiences, social support, and stressful life events, significantly influence the onset of these disorders (<xref rid="bib78" ref-type="bibr">Kong et al., 2020</xref>; <xref rid="bib124" ref-type="bibr">Quinn et al., 2017</xref>; <xref rid="bib176" ref-type="bibr">Whittle et al., 2024</xref>). Cabanis et al. identify childhood trauma as a significant risk factor for depressive and anxiety disorders in adulthood (<xref rid="bib23" ref-type="bibr">Cabanis et al., 2021</xref>). Understanding the fundamental mechanisms of these disorders facilitates early prevention, optimizes treatment, slows disease progression, and enhances quality of life for patients and families.</p></sec><sec id="sec1.2"><label>1.2</label><title>Overview of neurodegenerative diseases</title><p id="p0035">The central nervous system (CNS) regulates core physiological functions&#8212;including motor control, sensory processing, cognition, and emotional regulation&#8212;making its maintenance critical to health. Global population aging and changing environmental/lifestyle factors are driving a continuous increase in the prevalence of CNS diseases, constituting a major public health challenge (<xref rid="bib180" ref-type="bibr">Wittchen et al., 2011</xref>). These diseases encompass a heterogeneous spectrum spanning diseases of genetic, infectious, degenerative, vascular, or neoplastic origin, notably including Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and multiple sclerosis (MS) (<xref rid="bib180" ref-type="bibr">Wittchen et al., 2011</xref>). Given the CNS's structural complexity and multifaceted roles, such diseases often cause severe complications and significantly reduce patients' quality of life. Early diagnosis and personalized treatments are therefore essential to slow disease progression and improve outcomes.</p></sec><sec id="sec1.3"><label>1.3</label><title>Introduction to the basic concepts and functions of FKBP51</title><p id="p0040">The <italic toggle="yes">FKBP5</italic> gene encodes FKBP51, a 51-kDa immunophilin protein. This protein belongs to the FK506-binding protein (FKBP) family and participates in critical biological functions including immunomodulation, protein folding, and intracellular translocation (<xref rid="bib100" ref-type="bibr">Mendonca et al., 2021</xref>). FKBP51 comprises three structural domains: (1) an N-terminal FK506-binding domain (FK1), (2) a catalytically inactive FK506-like binding domain (FK2), and (3) a C-terminal domain with three tandem tetratricopeptide repeats (TPRs) mediating protein-protein interactions (<xref rid="bib139" ref-type="bibr">Sinars et al., 2003</xref>). FKBP51 localizes to both the cytoplasm and nucleus, where it dynamically assembles with heat shock protein 90 (Hsp90) into a chaperone complex that allosterically regulates the glucocorticoid receptor (GR) (<xref rid="bib110" ref-type="bibr">Noddings et al., 2023</xref>; <xref rid="bib165" ref-type="bibr">Verkhivker, 2022</xref>; <xref rid="bib166" ref-type="bibr">Vermeer et al., 2003</xref>). FKBP51 attenuates GR activity by impairing glucocorticoid (GC) binding affinity, which compromises hormone-dependent GR nuclear translocation (<xref rid="bib181" ref-type="bibr">Wochnik et al., 2005</xref>). Under stress or elevated GC levels, GC binding to the GR triggers dissociation of the GR-Hsp90 complex and co-chaperone exchange&#8212;replacing FKBP51 with FKBP52. This exchange facilitates GR nuclear translocation and target gene activation, which upregulates FKBP51 expression. Elevated FKBP51 then stabilizes the GR-Hsp90 complex by competitively inhibiting FKBP52 binding, thereby establishing a negative feedback loop that enhances cellular GC resistance as an adaptive stress response (<xref rid="bib102" ref-type="bibr">Menke et al., 2012</xref>; <xref rid="bib132" ref-type="bibr">Scharf et al., 2011</xref>)(<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Co-chaperone Exchange Mediates GR Activation and FKBP51-Driven Feedback</p><p>GC binding during stress induces GR dissociation from the Hsp90 complex and FKBP52-FKBP51 co-chaperone exchange. This enables GR nuclear translocation and transcriptional activation, upregulating FKBP51 expression. Elevated FKBP51 competitively stabilizes cytosolic GR-Hsp90 complexes, terminating activation cycles via negative feedback.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0045">Beyond its role in GR signaling, FKBP51 engages multiple functional interactors: (1) the small molecule rapamycin; (2) kinase regulators including AKT and GSK-3&#946;; (3) steroid hormone receptors (progesterone receptor (PR), androgen receptor (AR)); (4) IKK&#945;; and (5) PH domain- or leucine-rich repeat-containing proteins such as the phosphatase PHLPP (<xref rid="bib20" ref-type="bibr">Bouwmeester et al., 2004</xref>; <xref rid="bib47" ref-type="bibr">Gassen et al., 2016</xref>; <xref rid="bib88" ref-type="bibr">Li et al., 2011</xref>). Via these interactions, FKBP51 allosterically modulates protein complex assembly and subcellular localization, thereby orchestrating key processes including stress adaptation, metabolic signaling, and immune regulation (<xref rid="bib7" ref-type="bibr">Baischew et al., 2024</xref>; <xref rid="bib67" ref-type="bibr">Jagtap et al., 2019</xref>) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Structural Domains of FKBP51 with Domain-Resolved Protein and Drug Interactors</p><p>AKT&#160;=&#160;protein kinase B, a serine/threonine protein kinase also known as PKB; CBD&#160;=&#160;cannabidiol; FK = FKBP-type structural domain; GSK-3&#946;&#160;=&#160;glycogen synthase kinase-3&#946;, a serine/threonine protein kinase; IKK&#945;&#160;=&#160;I&#954;B kinase &#945; subunit; PHLPP = PH domain and leucine-rich repeat sequence protein phosphatase; SR&#160;=&#160;steroid hormone receptor; SAFit1&#160;=&#160;selective inhibitor; SAFit2&#160;=&#160;selective inhibitor; TPR&#160;=&#160;tetratricopeptide repeat.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0050">Research on neuropsychiatric diseases now prioritizes intracellular signaling and stress response pathways. Within these, FKBP51 critically regulates neural processes by orchestrating stress adaptation, fine-tuning immune responses, and governing apoptotic pathways (<xref rid="bib56" ref-type="bibr">Hartmann et al., 2024</xref>; <xref rid="bib111" ref-type="bibr">Nold et al., 2022</xref>; <xref rid="bib117" ref-type="bibr">Park, J. M. et al., 2021</xref>; <xref rid="bib160" ref-type="bibr">Tufano et al., 2021</xref>; <xref rid="bib199" ref-type="bibr">Zannas, 2023</xref>). Elevated FKBP51 expression is mechanistically linked to psychiatric disorder pathogenesis (<xref rid="bib31" ref-type="bibr">Criado-Marrero et al., 2019</xref>; <xref rid="bib51" ref-type="bibr">Grossmann et al., 2024</xref>) and exacerbates disease progression (<xref rid="bib94" ref-type="bibr">Matosin et al., 2023</xref>). It also drives neurodegenerative processes by disrupting proteostasis, as evidenced in tauopathies (<xref rid="bib113" ref-type="bibr">Oroz et al., 2018</xref>). A mechanistic dissection of FKBP51 in CNS diseases illuminates disease pathogenesis and reveals actionable therapeutic targets. This review synthesizes structural and functional evidence for FKBP51's dual roles in psychiatric and neurodegenerative conditions, critically evaluating its targetability. By integrating recent advances, we delineate molecular drivers of neuropsychiatric disease and identify tractable strategies for intervention.</p></sec></sec><sec id="sec2"><label>2</label><title>Link between FKBP51 and psychiatric disorders</title><sec id="sec2.1"><label>2.1</label><title>The relationship between FKBP51 and depression</title><p id="p0055">Depression is characterized by core psychopathological features including persistent depressed mood and anhedonia (the loss of pleasure or interest) (<xref rid="bib2" ref-type="bibr">American Psychiatric Association, 2022</xref>). According to WHO statistics, approximately 3.8&#160;% of the global population (equivalent to &#8764;280 million individuals) is affected by depression. Among adults, the prevalence is approximately 5&#160;%, with rates of 4&#160;% in males and 6&#160;% in females (<xref rid="bib183" ref-type="bibr">World Health Organization, 2023a</xref>). In China, an estimated 95 million people are affected by depression. Approximately 280,000 suicides occur annually, with 40&#160;% of victims being diagnosed with this disorder. Notably, 30.28&#160;% of depression patients in China are under 18 years of age, indicating a trend toward younger onset (<xref rid="bib64" ref-type="bibr">Huang et al., 2019</xref>). Given this disease burden, elucidating the pathogenesis of depression while optimizing diagnostic and therapeutic strategies has become a global research priority.</p><p id="p0060">Depression involves complex interactions among social, psychological, and biological factors (<xref rid="bib1" ref-type="bibr">Alexopoulos, 2005</xref>; <xref rid="bib2" ref-type="bibr">American Psychiatric Association, 2022</xref>). Individuals experiencing adverse life events (e.g., unemployment, bereavement, or trauma) are at significantly elevated risk for depression (<xref rid="bib95" ref-type="bibr">Matosin et al., 2018</xref>; <xref rid="bib97" ref-type="bibr">Mazure et al., 2000</xref>; <xref rid="bib119" ref-type="bibr">Patton et al., 2003</xref>). Depression propagates a self-reinforcing cycle by inducing hypothalamic-pituitary-adrenal (HPA) axis dysregulation and functional disability, which collectively exacerbate core pathology (<xref rid="bib60" ref-type="bibr">Holsboer, 2001</xref>; <xref rid="bib77" ref-type="bibr">Knorr et al., 2010</xref>; <xref rid="bib115" ref-type="bibr">Pariante and Miller, 2001</xref>; <xref rid="bib143" ref-type="bibr">Stetler and Miller, 2011</xref>). FKBP51, a stress-inducible regulator of GR signaling, impairs GR-mediated negative feedback during stress. This results in sustained HPA axis activation&#8212;a mechanistically defined pathway increasingly implicated in depression pathogenesis (<xref rid="bib58" ref-type="bibr">Hausl et al., 2021</xref>).</p><p id="p0065">Post-mortem analyses demonstrate elevated <italic toggle="yes">FKBP5</italic> transcription in bipolar disorder and major depression. Sinclair et al. identified increased prefrontal <italic toggle="yes">FKBP5</italic> mRNA in bipolar patients versus controls via RNA-Seq/qPCR (<xref rid="bib140" ref-type="bibr">Sinclair et al., 2013</xref>). This finding extends to depression and schizophrenia in a larger cohort, where cortical <italic toggle="yes">FKBP5</italic> expression was significantly upregulated (<xref rid="bib94" ref-type="bibr">Matosin et al., 2023</xref>). Antidepressant response dynamically modulates <italic toggle="yes">FKBP5</italic> mRNA and FKBP51 protein levels: responders exhibit decreased peripheral expression after 6 weeks, whereas non-responders maintain elevated levels (<xref rid="bib66" ref-type="bibr">Ising et al., 2019</xref>). In contrast, chronically medicated depressed patients show suppressed <italic toggle="yes">FKBP5</italic> expression versus controls (<xref rid="bib61" ref-type="bibr">Hori et al., 2024</xref>), suggesting antidepressant exposure may confound biomarker interpretation. Transgenic <italic toggle="yes">FKBP5</italic> overexpression in mice precipitates depression-like behaviors, establishing causal involvement in depressive phenotypes (<xref rid="bib33" ref-type="bibr">Criado-Marrero et al., 2020</xref>). The above study confirmed a positive correlation between <italic toggle="yes">FKBP5</italic> expression and depressive-like behavior in both brain tissue and whole blood.</p><p id="p0070">Compared with established findings, Mengelkoch et al. report reduced <italic toggle="yes">FKBP5</italic> levels in high-risk versus low-risk adolescent females (<xref rid="bib101" ref-type="bibr">Mengelkoch et al., 2025</xref>)&#8212;a reversal of the positive correlation between <italic toggle="yes">FKBP5</italic> expression and depression severity observed in diagnosed patients. This apparent contradiction reflects fundamental methodological distinctions: prior conclusions derive from confirmed depression cohorts, whereas Mengelkoch's data address preclinical risk stratification in undiagnosed populations. Additionally, Mengelkoch et al. exclusively studied adolescent females&#8212;a sex-specific cohort distinct from previous investigations employing mixed-sex cohorts. Prospective studies linking <italic toggle="yes">FKBP5</italic> dynamics to depression risk remain scarce. Most evidence derives from retrospective analyses correlating peripheral blood <italic toggle="yes">FKBP5</italic> mRNA levels with childhood adversity in diagnosed patients. Key findings from these retrospective investigations include: In major depressive disorder (MDD) patients carrying the rs1360780&#160;T allele (genotypes TT or TC), higher childhood adversity scores correlate with lower methylation levels of <italic toggle="yes">FKBP5</italic> intron 7 (<xref rid="bib159" ref-type="bibr">Tozzi et al., 2018</xref>). Given the established inverse correlation between <italic toggle="yes">FKBP5</italic> methylation and expression (<xref rid="bib17" ref-type="bibr">Blair et al., 2013</xref>), childhood adversity-induced demethylation mechanistically drives <italic toggle="yes">FKBP5</italic> upregulation&#8212;a pathogenic pathway mediating MDD development. This mechanism is consistently replicated across independent cohorts (<xref rid="bib76" ref-type="bibr">Klengel et al., 2013</xref>; <xref rid="bib99" ref-type="bibr">Mendonca et al., 2023</xref>; <xref rid="bib148" ref-type="bibr">Sun et al., 2025</xref>; <xref rid="bib161" ref-type="bibr">Tyrka et al., 2015</xref>; <xref rid="bib177" ref-type="bibr">Wiechmann et al., 2019</xref>). Depression emerges from multifactorial gene-environment interplay, necessitating integrated analysis of genetic susceptibility and environmental exposures. Distinct environmental stressors&#8212;particularly during neurodevelopmentally sensitive periods&#8212;elicit divergent pathophysiological trajectories. This principle is exemplified in the discussed studies: Mengelkoch et al. specifically model chronic exposure to maternal depression in adolescent females, capturing a high-risk developmental milieu (<xref rid="bib101" ref-type="bibr">Mengelkoch et al., 2025</xref>). Notably, childhood adversity in depression cohorts was assessed using the Childhood Trauma Questionnaire (CTQ), a multidimensional instrument that quantifies five domains of abuse and neglect (<xref rid="bib103" ref-type="bibr">Menke et al., 2018</xref>; <xref rid="bib148" ref-type="bibr">Sun et al., 2025</xref>). Methodologically, this approach differs fundamentally from Mengelkoch et al.&#8217;s focus on discrete exposure to maternal depression. We argue that such measurement heterogeneity&#8212;comprehensive survey versus targeted stressor assessment&#8212;underlies the observed discrepancies in <italic toggle="yes">FKBP5</italic> expression, highlighting the need to investigate adversity-specific epigenetic mechanisms.</p><p id="p0075">Notably, the prevalence of depression exhibits statistically significant sex differences, with a higher incidence in women than in men (<xref rid="bib121" ref-type="bibr">Potter and Yoon, 2023</xref>; <xref rid="bib146" ref-type="bibr">Sun et al., 2021</xref>; <xref rid="bib208" ref-type="bibr">Zhou et al., 2023</xref>). Further exploration of underlying mechanisms reveals sex-specific differences in FKBP51 expression. Chronic mild stress (CMS) increased hippocampal FKBP51 expression in both sexes, with a non-significant trend toward higher upregulation in males. Moreover, venlafaxine normalized FKBP51 levels in stressed male rats but failed to exert a therapeutic effect in females, thereby indicating sexually dimorphic pharmacodynamics of antidepressants (<xref rid="bib190" ref-type="bibr">Xing et al., 2013</xref>). Under basal conditions, hippocampal <italic toggle="yes">FKBP5</italic> expression showed no sex differences. However, acute stress superimposed on chronic stress paradigms revealed sexually divergent <italic toggle="yes">FKBP5</italic> dynamics: females exhibited prolonged <italic toggle="yes">FKBP5</italic> upregulation, exacerbating HPA axis dysregulation and depression susceptibility. Conversely, males displayed rapid <italic toggle="yes">FKBP5</italic> normalization with concomitant increases in GR co-activators (e.g., <italic toggle="yes">SRC-1</italic>), indicating enhanced adaptive capacity (<xref rid="bib19" ref-type="bibr">Bourke et al., 2013</xref>). Female mice show greater sensitivity to <italic toggle="yes">FKBP5</italic>-early life adversity (ELA) interactions, characterized by prolonged HPA axis dysregulation, exacerbated depression-like behaviors, and impaired GR feedback mechanisms. Conversely, male mice exhibit blunted molecular and neuroendocrine responses to equivalent stress exposure (<xref rid="bib111" ref-type="bibr">Nold et al., 2022</xref>). Collectively, these data demonstrate sex-divergent <italic toggle="yes">FKBP5</italic> expression as a molecular correlate of differential depression prevalence. While this dysregulation contributes to elevated female susceptibility, comprehensive pathomechanistic models must integrate epigenetic (e.g., <italic toggle="yes">FKBP5</italic> intron 7 methylation) and single nucleotide polymorphisms (SNPs) that gate stress-responsive <italic toggle="yes">FKBP5</italic> transcription.</p><p id="p0080">The rs1360780 (C/T) polymorphism, located in intron 2 of <italic toggle="yes">FKBP5</italic>, upregulates <italic toggle="yes">FKBP5</italic> expression (<xref rid="bib14" ref-type="bibr">Binder, 2009</xref>). Studies have demonstrated that the rs1360780 polymorphism of the <italic toggle="yes">FKBP5</italic> gene is linked to cognitive susceptibility factors (dysfunctional attitudes) in depression by affecting HPA axis function (<xref rid="bib149" ref-type="bibr">Suzuki et al., 2014</xref>). The rs1360780&#160;T allele in <italic toggle="yes">F5</italic> demonstrates dose-dependent clinical effects: homozygous (TT) depressed patients exhibit enhanced antidepressant response but higher recurrence rates versus CT/CC carriers (<xref rid="bib16" ref-type="bibr">Binder et al., 2004</xref>). This risk allele interacts with childhood trauma, as evidenced by Appel et al.: physically abused TT individuals showed more severe adult depression and 2.8-fold higher MDD prevalence (<xref rid="bib4" ref-type="bibr">Appel et al., 2011</xref>). Subsequent work confirmed depression associations for multiple <italic toggle="yes">FKBP5</italic> SNPs (rs1360780, rs9470080, rs4713916, rs9296158, rs9394309) (<xref rid="bib151" ref-type="bibr">Szczepankiewicz et al., 2014</xref>), collectively establishing <italic toggle="yes">FKBP5</italic> as a genetically modulated susceptibility node (<xref rid="bib84" ref-type="bibr">Lekman et al., 2008</xref>). Additionally, studies have found that the interaction between the <italic toggle="yes">FKBP5</italic> rs1360780&#160;T allele and childhood abuse induces structural and functional abnormalities in brain regions involved in emotional processing (e.g., the insula and inferior frontal gyrus) in depressed patients (<xref rid="bib158" ref-type="bibr">Tozzi et al., 2016</xref>). These abnormalities elevate susceptibility to depression. Polymorphisms in the <italic toggle="yes">FKBP5</italic> gene, particularly the rs1360780&#160;T allele, are significantly associated with depression onset and development. This supports the gene-cognition-environment interaction model of depression pathogenesis, in which genetic variants modulate depression risk via their effects on cognitive vulnerability.</p><p id="p0085"><italic toggle="yes">FKBP5</italic>, a key GR regulator, shows positive correlation between its expression levels and depressive-like behaviors. Polymorphisms in this gene&#8212;particularly the rs1360780&#160;T allele&#8212;interact with childhood adversity, epigenetically upregulating <italic toggle="yes">FKBP5</italic> expression through mechanisms like dysregulated methylation. <italic toggle="yes">FKBP5</italic>-mediated pathology exhibits marked sexual dimorphism. Females demonstrate heightened sensitivity to <italic toggle="yes">FKBP5</italic>-adversity interactions, resulting in persistent HPA axis dysfunction. In contrast, males typically exhibit rapid functional recovery. This differential response likely contributes to the higher depression prevalence in females. Antidepressants dynamically modulate <italic toggle="yes">FKBP5</italic> expression, with expression changes reflecting treatment response. Significant <italic toggle="yes">FKBP5</italic> downregulation occurs in treatment-responsive patients, suggesting its utility as a predictive biomarker for both depression risk and therapeutic efficacy. Collectively, <italic toggle="yes">FKBP5</italic> functions as a central molecular mediator in gene-environment interactions governing depression susceptibility, sexual dimorphism, and treatment response, representing a pivotal target for mechanistic research and targeted interventions.</p></sec><sec id="sec2.2"><label>2.2</label><title>Advances in the study of FKBP51 and anxiety disorders</title><p id="p0090">In 2019, anxiety disorders affected approximately 301 million people globally (4&#160;% of the world's population), ranking among the most prevalent psychiatric disorders (<xref rid="bib184" ref-type="bibr">World Health Organization, 2023b</xref>). Anxiety disorders involve persistent excessive worry disproportionate to actual threats, often significantly impairing daily functioning and quality of life in severe cases (<xref rid="bib2" ref-type="bibr">American Psychiatric Association, 2022</xref>). This diagnostic category includes generalized anxiety disorder (GAD), panic disorder, specific phobias, and childhood-onset conditions like separation anxiety disorder and selective mutism (<xref rid="bib145" ref-type="bibr">Strohle et al., 2018</xref>). Despite distinct clinical presentations, all anxiety disorders share uncontrollable excessive worry. Their multifactorial etiology encompasses genetic, biochemical, psychological, and environmental determinants. Understanding these mechanisms is essential for developing effective treatments to improve patient well-being.</p><p id="p0095">HPA axis dysfunction, a primary stress-response system, is a well-established hallmark of anxiety disorders (<xref rid="bib38" ref-type="bibr">Fang et al., 2023</xref>; <xref rid="bib126" ref-type="bibr">Rieder et al., 2017</xref>). The <italic toggle="yes">FKBP5</italic> gene has been shown to modulate stress sensitivity, increasing susceptibility to anxiety disorders&#8212;particularly following trauma, which impairs HPA axis regulation and exacerbates susceptibility to anxiety symptoms (<xref rid="bib21" ref-type="bibr">Buchmann et al., 2014</xref>; <xref rid="bib125" ref-type="bibr">Richter et al., 2021</xref>).</p><p id="p0100">In the mouse bed nucleus of the stria terminalis (BNST), deacetylase sirtuin 1 (SIRT1)-mediated deacetylation impairs FKBP51 activity, facilitating its dissociation from the GR. This attenuates FKBP51-mediated inhibition of GR, enhances GR-dependent repression of corticotropin-releasing factor (CRF) transcription, and thereby alleviates chronic stress-induced anxiety behaviors via CRF downregulation (<xref rid="bib63" ref-type="bibr">Hu et al., 2023</xref>). Stress upregulates cellular retinoic acid binding protein 1 (Crabp1) expression, which drives FKBP51 accumulation and subsequent GR inhibition; this impairs HPA axis negative feedback and consequently exacerbates anxiety. Targeting this pathway (e.g., via reducing Crabp1/FKBP51 levels) alleviates anxiety symptoms (<xref rid="bib90" ref-type="bibr">Lin et al., 2021</xref>). Additionally, FKBP51 overexpression in the basolateral amygdala (BLA) promotes anxiety-like behavior, whereas FKBP51 antagonists (e.g., Ligand2, SAFit2) produce anxiolysis by attenuating FKBP51-mediated inhibition of GR (<xref rid="bib57" ref-type="bibr">Hartmann et al., 2015</xref>). Apelin-13 ameliorates anxiety by enhancing GR activity and reducing FKBP51 expression (<xref rid="bib3" ref-type="bibr">Aminyavari et al., 2019</xref>). FKBP51 overexpression synergizes with early-life stress (ELS) to exacerbate anxiety-like behavior by impairing dorsal hippocampal AKT signaling and GR-mediated negative feedback, with heightened female sensitivity to this interaction (<xref rid="bib31" ref-type="bibr">Criado-Marrero et al., 2019</xref>). Attwood et al. identified a novel amygdalar FKBP51-anxiety pathway: stress-induced, neuroprotease-dependent EphB2 cleavage promotes its dissociation from NMDAR NR1 subunits, thereby enhancing NMDAR currents, stimulating FKBP51 expression, and driving anxiety behaviors (<xref rid="bib5" ref-type="bibr">Attwood et al., 2011</xref>)(<xref rid="fig3" ref-type="fig">Fig. 3</xref>). Collectively, these studies demonstrate that FKBP51 critically regulates anxiety: elevated expression promotes symptoms whereas reduced expression alleviates anxiety.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>FKBP51 Signaling in Anxiety Pathophysiology</p><p>A: SIRT1 Antagonizes Stress Anxiety via FKBP51/GR/CRF Axis. By deacetylating FKBP51, SIRT1 promotes FKBP51 dissociation from GR, enhancing GR repression of CRF transcription and reducing CRF levels, ultimately reversing chronic stress-induced anxiety-like behavior.</p><p>B: Crabp1-ko/SAFit2/Apelin-13 &#8594;FKBP51&#8595; &#8594; Reduced FKBP51 Inhibition of GR &#8594; Enhanced GR Feedback &#8594; Cortisol&#8595; &#8594; Anxiety&#8595;. Interventions decrease FKBP51 expression. Lower FKBP51 levels reduce inhibition of GR signaling, enhancing GR feedback inhibition, lowering cortisol, and ultimately reducing anxiety-like behaviors.</p><p>C: Stress &#8594; Amygdalar EphB2 Cleavage &#8594; EphB2/NR1 Dissociation &amp; Turnover &#8594; &#8593; NMDA Currents &#8594; &#8593; FKBP51 &#8594; &#8593; Anxiety. Neuroprotease cleaves EphB2 under stress, dissociating it from NR1 and promoting its turnover. This enhances NMDA currents, induces FKBP51, and elevates anxiety-like behaviors.</p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0105">Interestingly, FKBP51 overexpression in the BLA induces pronounced anxiety-like behavior; in contrast, its overexpression in the central amygdala (CeA) induces only mild anxiety-like phenotypes, while overexpression in the dorsal hippocampus (dHc) has no significant effect on anxiety-like behavior (<xref rid="bib57" ref-type="bibr">Hartmann et al., 2015</xref>). Thus, FKBP51 regulates anxiety in a brain region-specific manner, consistent with other findings. In the oval bed nucleus of the stria terminalis (ovBNST), FKBP51 overexpression produced mild anxiolytic effects while knockout increased anxiety, highlighting region-specific functional roles in anxiety circuitry (<xref rid="bib37" ref-type="bibr">Engelhardt et al., 2021</xref>). FKBP51 shows region-specific expression and diverse roles in anxiety regulation, reflecting varied neuroanatomical contributions to anxiety disorders. This neuroanatomical heterogeneity highlights anxiety's multifactorial etiology, which arises from gene-brain-environment interactions.</p><p id="p0110">FKBP51 knockout regulates anxiety-like behavior in a sex- and cell type-specific manner. In female mice, glutamatergic neuron knockout (<italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">Nex</italic></sup>) increases anxiety-like behavior, whereas GABAergic neuron knockout (<italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">Dlx</italic></sup>) produces an anxiolytic phenotype. In male mice, however, phenotypes diverge from anxiety: <italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">Nex</italic></sup> impairs aversive spatial context memory, while <italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">Dlx</italic></sup> enhances this memory (<xref rid="bib163" ref-type="bibr">van Doeselaar et al., 2023</xref>). Anxiety disorder research prominently features sex differences. ELS induces anxiolysis in female mice, an effect abolished by <italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">Nex</italic></sup>, indicating FKBP51 in these neurons is required for ELS-induced anxiolysis. Conversely, ELS and FKBP51 deficiency exert minimal effects on anxiety-like behavior in males, demonstrating sex-specific mechanisms (<xref rid="bib162" ref-type="bibr">van Doeselaar et al., 2025</xref>). Female FKBP51-overexpressing (rTg<italic toggle="yes">FKBP5</italic>) mice exhibited exacerbated anxiety-like behavior following ELS, recapitulating the higher female prevalence of clinical anxiety disorders (<xref rid="bib31" ref-type="bibr">Criado-Marrero et al., 2019</xref>). The apparent contradictions between (van Doeselaar et al.) and (Criado-Marrero et al.) arise from differing interactions between FKBP51 expression (normal vs. overexpressed) and ELS intensity (moderate vs. excessive). This indicates FKBP51's dual dose- and context-dependent function, highlighting the need for context-specific analyses. Research confirms that distinct environmental stimuli differentially affect FKBP51-mediated signaling pathways. In inflammation-induced anxiety, FKBP51 mediates anti-anxiety resilience by activating hippocampal GR signaling and upregulating the &#947;-amino butyric acid (GABA) synthase Glutamic acid decarboxylase 65 (GAD65) to enhance inhibitory neurotransmission. Conversely, in GC-induced anxiety, FKBP51 deficiency alleviates anxiety (<xref rid="bib44" ref-type="bibr">Gan et al., 2022</xref>). <italic toggle="yes">FKBP5</italic> polymorphisms contribute to the onset of anxiety disorders through interactions with environmental factors: individuals with minor alleles are more sensitive to mild-to-moderate adverse life events and have an increased risk of developing it; however, the impact of severe adverse events is independent of the <italic toggle="yes">FKBP5</italic> genotype (<xref rid="bib134" ref-type="bibr">Scheuer et al., 2016</xref>). <italic toggle="yes">FKBP5</italic>-deficient mice exhibit baseline anxiety behavior comparable to that of wild-type controls. However, following acute stress exposure, they exhibit enhanced active coping strategies (e.g., increased swimming in the forced swim test) (<xref rid="bib156" ref-type="bibr">Touma et al., 2011</xref>). This is consistent with Engelhardt et al.: acute stress-induced upregulation of <italic toggle="yes">FKBP5</italic> in the ovBNST mediates an adaptive stress response, thereby transiently reducing anxiety (<xref rid="bib37" ref-type="bibr">Engelhardt et al., 2021</xref>). The aforementioned research appears to contain two seemingly contradictory elements, but such contradictions are apparent. We propose a &#8220;biphasic stress-response model&#8221;: Phase 1 (Acute): Transient FKBP51 elevation and HPA axis activation result in adaptive anxiolysis. Phase 2 (Chronic): Sustained HPA hyperactivity causes neuroendocrine dysregulation, contributing to anxiety and depression (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). Critically, FKBP51, whether elevated or reduced, disrupts HPA homeostasis, establishing a pathological baseline that, if sustained, inevitably progresses to psychiatric disorders.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Schematic diagram of the &#8220;biphasic stress-response model&#8221;.</p></caption><alt-text id="alttext0025">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0115">FKBP51 regulates anxiety through brain region (BLA, CeA, dHc, ovBNST)-, sex-, and cell type-specific mechanisms. Its context-dependent functions are dynamically shaped by environmental variables&#8212;including ELS intensity/type, inflammation, and GC exposure&#8212;while <italic toggle="yes">FKBP5</italic> polymorphisms modulate anxiety disorder susceptibility via gene-environment interactions. Our proposed &#8220;biphasic stress-response model&#8221; integrates these observations, partially explaining FKBP51's paradoxical roles. Furthermore, this stress model can be extended to other psychiatric disorders such as depression and PTSD, thus positioning FKBP51 as a key molecular hub in stress-related disorders, with its multifunctional effects reflecting the gene-brain-environment etiology of anxiety pathologies.</p></sec><sec id="sec2.3"><label>2.3</label><title>Association of FKBP51 with PTSD</title><p id="p0120">PTSD is a severe psychiatric condition triggered by severe trauma. Core symptoms include: traumatic re-experiencing (e.g., flashbacks, nightmares), persistent avoidance of trauma reminders, negative affect (e.g., fear, anger, shame), and hyperarousal (<xref rid="bib105" ref-type="bibr">Miao et al., 2018</xref>). PTSD risk increases with the severity and duration of traumatic stress, accounting for its higher prevalence in trauma-exposed occupations (e.g., combat veterans, first responders) (<xref rid="bib109" ref-type="bibr">Nemeroff et al., 2006</xref>). Identifying these risk factors facilitates targeted interventions in high-risk populations.</p><p id="p0125">PTSD involves complex biological and psychosocial mechanisms. Traumatic experiences alter psychological and physiological functions through pathways such as dysregulation of the HPA axis, which is a central neuroendocrine feature of the pathogenesis of PTSD (<xref rid="bib35" ref-type="bibr">de Kloet et al., 2005</xref>; <xref rid="bib92" ref-type="bibr">Lupien et al., 2009</xref>). Chronic stress induces persistent activation of the HPA axis, dysregulating the cortisol release and contributing to psychiatric disorders. As a key regulator of the HPA axis, <italic toggle="yes">FKBP5</italic> critically modulates stress pathology, including that of PTSD (<xref rid="bib42" ref-type="bibr">Fries et al., 2017</xref>; <xref rid="bib95" ref-type="bibr">Matosin et al., 2018</xref>; <xref rid="bib188" ref-type="bibr">Xiao et al., 2023</xref>; <xref rid="bib192" ref-type="bibr">Yehuda, 2002</xref>).</p><p id="p0130">Recent studies using spatial transcriptomics show widespread <italic toggle="yes">FKBP5</italic> overexpression in the dorsolateral prefrontal cortex (dlPFC) of PTSD patients, with significantly higher expression specifically in endothelial cells (ENDs) and oligodendrocytes (OLGs) (<xref rid="bib65" ref-type="bibr">Hwang et al., 2025</xref>). This finding aligns with post-mortem evidence of <italic toggle="yes">FKBP5</italic> transcript upregulation in the PFC of PTSD patients (<xref rid="bib34" ref-type="bibr">Daskalakis et al., 2024</xref>; <xref rid="bib48" ref-type="bibr">Girgenti et al., 2021</xref>). <italic toggle="yes">FKBP5</italic> mRNA is elevated in the medial orbitofrontal cortex (BA11) of PTSD patients and may drive pathological processes through altered dendritic spine morphology, characterized by reduced mushroom spines and increased short, thick spines (<xref rid="bib194" ref-type="bibr">Young et al., 2015</xref>). Investigators characterized alterations in peripheral immune cells in whole blood from PTSD patients. Notably, <italic toggle="yes">FKBP5</italic> is consistently upregulated across these cells, including CD4<sup>+</sup>T, CD8<sup>+</sup>T, B cells, and monocytes (<xref rid="bib80" ref-type="bibr">Kuan et al., 2019</xref>). Naive rats show higher basal FKBP51 expression in the prelimbic cortex (PL) than in the infralimbic cortex (IL). Fear conditioning selectively upregulates FKBP51 in the IL but not the PL, indicating region-specific functions of FKBP51 in fear regulation (<xref rid="bib32" ref-type="bibr">Criado-Marrero et al., 2017</xref>). Other studies support this view, including Torrisi et al., who found <italic toggle="yes">FKBP5</italic> expression was significantly upregulated in the medial prefrontal cortex (mPFC) of PTSD-susceptible mice but downregulated in the amygdala, hippocampus, and hypothalamus of PTSD-resistant mice (<xref rid="bib155" ref-type="bibr">Torrisi et al., 2021</xref>). Hippocampal <italic toggle="yes">FKBP5</italic> mRNA expression was significantly decreased in rats after single prolonged stress (SPS), a validated PTSD model (<xref rid="bib89" ref-type="bibr">Lin et al., 2022</xref>; <xref rid="bib171" ref-type="bibr">Wang et al., 2024</xref>). SPS suppressed <italic toggle="yes">FKBP5</italic> mRNA in the paraventricular nucleus (PVN) but not in the BNST. Urocortin 3 (Ucn3), a CRHR2 agonist, rescued <italic toggle="yes">FKBP5</italic> expression in the PVN while increasing its levels in the BNST (<xref rid="bib153" ref-type="bibr">Tillinger et al., 2024</xref>). <italic toggle="yes">FKBP5</italic> exhibits region-specific dysregulation in PTSD pathogenesis, with divergent regulation in cortical regions (especially the PFC) versus limbic structures (amygdala, hippocampus, hypothalamus).</p><p id="p0135">PTSD patients are stratified into HPA axis response subtypes: hypocortisolemic &#8220;non-responders&#8221; exhibit blunted cortisol/ACTH responses and dissociative symptoms, driven by <italic toggle="yes">FKBP5</italic> downregulation (<xref rid="bib198" ref-type="bibr">Zaba et al., 2015</xref>). This subtype accounts for cross-study heterogeneity in HPA responses and represents a distinct pathophysiological entity. Variations in subgroup proportions among PTSD samples across studies may underlie these conflicting findings. For example, among 324 World Trade Center rescue workers, <italic toggle="yes">FKBP5</italic> expression was upregulated in those with current PTSD, regardless of genotype (<xref rid="bib79" ref-type="bibr">Kuan et al., 2017</xref>). Transcriptomic analysis of whole blood from 35 Caucasian World Trade Center attack survivors showed significantly reduced <italic toggle="yes">FKBP5</italic> expression in those with PTSD (<xref rid="bib193" ref-type="bibr">Yehuda et al., 2009</xref>). Discrepant findings across studies may stem from methodological differences, including variations in PTSD subtypes and sample characteristics. Yehuda et al.&#8217;s study was limited by a focus on Caucasian participants alone and small sample size.</p><p id="p0140">Pre-onset alterations in whole-blood <italic toggle="yes">FKBP5</italic> levels are predictive biomarkers for PTSD risk. Adult survivors of childhood exposure to suicide bombings had significantly lower <italic toggle="yes">FKBP5</italic> expression than healthy controls. Expression levels were graded: lowest in trauma-exposed individuals with PTSD, intermediate in trauma-exposed without PTSD, and highest in non-exposed controls (<xref rid="bib50" ref-type="bibr">Goltser-Dubner et al., 2023</xref>). In a prospective cohort of 448 combat-deployed male soldiers, lower pre-deployment <italic toggle="yes">FKBP5</italic> mRNA expression independently predicted subsequent PTSD symptom onset (<xref rid="bib164" ref-type="bibr">van Zuiden et al., 2012</xref>). Furthermore, increased <italic toggle="yes">FKBP5</italic> expression strongly predicts PTSD symptom improvement (<xref rid="bib86" ref-type="bibr">Levy-Gigi et al., 2013</xref>). <italic toggle="yes">FKBP5</italic> expression exhibits temporal dynamics in PTSD progression. In the SPS rat model, anxiety symptoms worsened over time (17.5&#160;% with severe anxiety at 1 week; 57.1&#160;% at 2 weeks) (<xref rid="bib137" ref-type="bibr">Serova et al., 2019</xref>). Over the same period, hypothalamic <italic toggle="yes">FKBP5</italic> mRNA showed biphasic regulation&#8212;an initial increase followed by a decrease&#8212;supporting its potential as a molecular marker for the acute-to-chronic PTSD transition and reinforcing the &#8220;biphasic stress-response model&#8221;&#12290;</p><p id="p0145"><italic toggle="yes">FKBP5</italic> gene polymorphisms are strongly associated with PTSD susceptibility, indicating that genetic variation influences stress response (<xref rid="bib172" ref-type="bibr">Watkins et al., 2016</xref>). These variants alter <italic toggle="yes">FKBP5</italic> expression and function. Specific risk alleles&#8212;including rs1360780T, rs3800373C, and rs9470080T&#8212;interact with early-life trauma to increase vulnerability to PTSD and depression (<xref rid="bib15" ref-type="bibr">Binder et al., 2008</xref>; <xref rid="bib168" ref-type="bibr">Wang et al., 2018</xref>). Specifically, Binder et al. found four <italic toggle="yes">FKBP5</italic> SNPs (rs9296158, rs3800373, rs1360780, rs9470080) moderate childhood abuse's effect on adult PTSD symptoms, without directly determining overall symptom severity. Gene-environment interactions further modulate risk: childhood maltreatment and alcohol dependence potentiate PTSD susceptibility in carriers of <italic toggle="yes">FKBP5</italic> variants (e.g., rs9470080) across ethnic groups (<xref rid="bib189" ref-type="bibr">Xie et al., 2010</xref>). Concurrently, neuroimaging studies associate <italic toggle="yes">FKBP5</italic> risk variants with structural brain alterations in PTSD. Carriers of the rs1360780&#160;T allele exhibit reduced fractional anisotropy in the left posterior cingulate (PC), indicating impaired white matter integrity (<xref rid="bib39" ref-type="bibr">Fani et al., 2012</xref>, <xref rid="bib40" ref-type="bibr">2014</xref>). Altered hippocampal-anterior cingulate connectivity is also associated with <italic toggle="yes">FKBP5</italic> variation (<xref rid="bib41" ref-type="bibr">Fani et al., 2016</xref>). Furthermore, rs3800373-AA and rs1360780-CC genotypes correlate with reduced left hippocampal volume and depression severity in PTSD patients (<xref rid="bib197" ref-type="bibr">Yun et al., 2022</xref>). Elucidating how <italic toggle="yes">FKBP5</italic> polymorphisms interact with environmental factors to drive PTSD etiology and progression remains critical.</p><p id="p0150">Yang et al. found that <italic toggle="yes">FKBP5</italic> methylation levels in whole blood were significantly associated with PTSD symptom severity. Among patients undergoing prolonged exposure therapy, treatment responders showed a progressive decrease in <italic toggle="yes">FKBP5</italic> methylation, whereas non-responders exhibited no significant changes (<xref rid="bib191" ref-type="bibr">Yang et al., 2021</xref>). Conversely, <italic toggle="yes">FKBP5</italic> methylation was elevated in treatment responders after meditation therapy (<xref rid="bib83" ref-type="bibr">Lee et al., 2024</xref>). This divergence may reflect distinct intervention mechanisms: meditation promotes <italic toggle="yes">FKBP5</italic> hypermethylation, thereby attenuating excessive stress responses, whereas exposure therapy facilitates HPA axis adaptation via demethylation, achieved through direct retrieval of traumatic memories. PTSD treatment choices have specific molecular consequences beyond symptom relief, involving unique signaling mechanisms and potential long-term outcomes requiring further investigation.</p><p id="p0155">MicroRNAs (miRNAs), as epigenetic regulators, modulate the pathogenesis of PTSD by targeting <italic toggle="yes">FKBP5</italic> (<xref rid="bib54" ref-type="bibr">Gupta et al., 2021</xref>). Kang et al. identified <italic toggle="yes">FKBP5</italic>-targeting miRNAs via integrated analyses of <italic toggle="yes">FKBP5</italic><sup><italic toggle="yes">&#8722;/&#8722;</italic></sup> mouse models and human PTSD cohorts. Their expression levels correlated with serum biomarker profiles, molecular alterations, and behavioral phenotypes in PTSD (<xref rid="bib72" ref-type="bibr">Kang et al., 2020</xref>). Park et al. found <italic toggle="yes">FKBP5</italic> deficiency dysregulated 41 miRNAs in the mPFC of restraint-stressed mice, with miR-690 most notably upregulated. MiR-690 overexpression rescued stress-induced behavioral deficits (<xref rid="bib118" ref-type="bibr">Park, J. et al., 2021</xref>). MiR-511 directly binds to the 3&#8242;-UTR of <italic toggle="yes">FKBP5</italic> to suppress its expression. In PTSD models, upregulation of miR-511 may partially restore GR function by repressing <italic toggle="yes">FKBP5</italic>, thereby attenuating HPA axis overactivation; failure of this compensatory mechanism may exacerbate symptomatology (<xref rid="bib206" ref-type="bibr">Zheng et al., 2016</xref>). Collectively, these findings indicate that miRNAs modulate PTSD pathogenesis and remission by regulating <italic toggle="yes">FKBP5</italic> expression.</p><p id="p0160">The above content systematically elucidates the central role of <italic toggle="yes">FKBP5</italic> in PTSD, encompassing its region-specific dysregulation and its association with PTSD pathophysiology. Proposed PTSD subtypes based on HPA-axis reactivity (&#8220;non-responders&#8221; vs. &#8220;responders&#8221;) may account for previously conflicting findings across studies. Additionally, <italic toggle="yes">FKBP5</italic> represents a promising biomarker for predicting PTSD risk and evaluating prognosis, while its gene&#8211;environment interactions modulate disease susceptibility. These findings offer multidimensional insights into PTSD's molecular mechanisms and potential therapeutic targets. Finally, the temporal and functional dynamics of <italic toggle="yes">FKBP5</italic> further validate our previously proposed &#8220;biphasic stress-response model&#8221;.</p></sec></sec><sec id="sec3"><label>3</label><title>Role of FKBP51 in neurodegenerative diseases</title><sec id="sec3.1"><label>3.1</label><title>Relationship between FKBP51 and AD</title><p id="p0165">AD, a complex neurodegenerative disorder, imposes significant burdens on patients, families, and society. It is characterized by progressive memory loss, cognitive impairment, and personality changes (<xref rid="bib133" ref-type="bibr">Scheltens et al., 2021</xref>). Globally, &#8764;55 million people lived with dementia in 2019, projected to rise to 139 million by 2050 (<xref rid="bib29" ref-type="bibr">Collaborators, 2022</xref>). With accelerating global aging, AD has become a critical public health challenge, underscoring the need to elucidate its pathological mechanisms and identify novel therapeutic targets.</p><p id="p0170">AD pathogenesis is defined by two core pathological hallmarks: amyloid-&#946; (A&#946;) plaque accumulation and tau hyperphosphorylation (<xref rid="bib73" ref-type="bibr">Karran and De Strooper, 2022</xref>). A&#946; peptides, cleaved from amyloid precursor protein (APP), aggregate into plaques that induce synaptic toxicity, disrupt neuronal communication, and ultimately cause cognitive impairment (<xref rid="bib136" ref-type="bibr">Selkoe and Hardy, 2016</xref>). Normally, tau stabilizes microtubules and regulates their dynamics (<xref rid="bib71" ref-type="bibr">Kadavath et al., 2015</xref>); in AD, however, hyperphosphorylated tau forms neurofibrillary tangles, promoting neuronal dysfunction and death (<xref rid="bib142" ref-type="bibr">Spillantini and Goedert, 2013</xref>). Interactions between A&#946; and tau pathologies exacerbate neuroinflammation, synaptic loss, and widespread neurodegeneration. Beyond these protein aggregates, AD pathogenesis involves complex genetic, environmental, and biological factors.</p><p id="p0175">Beyond its established role in stress response regulation, FKBP51 directly contributes to AD progression (<xref rid="bib27" ref-type="bibr">Cao and Konsolaki, 2011</xref>; <xref rid="bib130" ref-type="bibr">Salminen et al., 2011</xref>). In AD, FKBP51 drives neuroinflammation via aberrant secretory autophagy (SA), promoting IL-1&#946; release, NLRP3 inflammasome activation, and Gasdermin D-mediated neurotoxicity&#8212;collectively contributing to cognitive decline (<xref rid="bib8" ref-type="bibr">Bajaj et al., 2024</xref>). Reduced spindle and kinetochore associated complex subunit 2 (SKA2) expression facilitates this pathway by relieving FKBP51 inhibition (<xref rid="bib56" ref-type="bibr">Hartmann et al., 2024</xref>). Jinwal et al. showed that FKBP51 stabilizes microtubules via interaction with tau (<xref rid="bib70" ref-type="bibr">Jinwal et al., 2010</xref>). Blair et al. further demonstrated that FKBP51, in a chaperone complex with Hsp90, binds tau and inhibits its proteasomal degradation. This stabilization promotes oligomeric tau accumulation, enhancing its neurotoxicity (<xref rid="bib17" ref-type="bibr">Blair et al., 2013</xref>). Research demonstrates that FKBP51 expression increases with age in the brain, is further elevated in AD patients, and correlates directly with disease severity (<xref rid="bib17" ref-type="bibr">Blair et al., 2013</xref>; <xref rid="bib70" ref-type="bibr">Jinwal et al., 2010</xref>; <xref rid="bib94" ref-type="bibr">Matosin et al., 2023</xref>; <xref rid="bib175" ref-type="bibr">Wen et al., 2025</xref>). The above findings suggest that AD is characterized by age-dependent onset. In microglia, <italic toggle="yes">FKBP5</italic> shows a female-biased expression pattern&#8212;one that is retained in AD. Notably, the female-biased expression of <italic toggle="yes">FKBP5</italic> is concentrated in microglia rather than neurons or astrocytes, supporting microglial <italic toggle="yes">FKBP5</italic> as a critical contributor to AD pathogenesis and a potential mediator of the increased AD risk in women (<xref rid="bib175" ref-type="bibr">Wen et al., 2025</xref>). These findings establish FKBP51's complex role in AD progression, with implications in both neuroinflammatory and neurodegenerative pathways. Targeting FKBP51 and its associated pathways thus represents a promising therapeutic strategy to mitigate disease progression (<xref rid="fig5" ref-type="fig">Fig. 5</xref>).<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>FKBP51-Mediated Pathways in Alzheimer's Pathogenesis</p><p>A: Regulation of SA by FKBP51 and SKA2. The SA pathway involves TRIM16/SEC22B-mediated cargo (e.g., IL-1&#946;) delivery to LC3B&#160;+&#160;autophagosomes. SEC22B (R-SNARE) then drives fusion with the plasma membrane by assembling with Q-SNAREs SNAP23/29 (Qbc) and STX3/4 (Qa), enabling extracellular cargo release. FKBP51 facilitates SA by promoting TRIM16-SEC22B complex stability and SNARE complex assembly, enhancing fusion efficiency (positive regulator). Conversely, SKA2 suppresses SA by inhibiting SNARE complex formation during fusion, acting as a gatekeeper (negative regulator).</p><p>B: FKBP51/HSP90 Complex Drives Pathogenic Tau Processing. Tau binding by the FKBP51/HSP90 complex orders tau and inhibits 20S proteasomal degradation, resulting in the accumulation of neurotoxic tau oligomers.</p></caption><alt-text id="alttext0030">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0180">Impaired A&#946; clearance, rather than overproduction, is a major driver of AD pathogenesis (<xref rid="bib96" ref-type="bibr">Mawuenyega et al., 2010</xref>), supporting enhanced clearance as a promising therapeutic strategy (<xref rid="bib69" ref-type="bibr">Jin et al., 2017</xref>; <xref rid="bib136" ref-type="bibr">Selkoe and Hardy, 2016</xref>). Autophagy, a key cellular clearance pathway, is suppressed in AD via upregulated mammalian target of rapamycin (mTOR) signaling (<xref rid="bib24" ref-type="bibr">Caccamo et al., 2010</xref>; <xref rid="bib104" ref-type="bibr">Menzies et al., 2015</xref>). This impairment is critical: disrupting core autophagy proteins such as Beclin 1 exacerbates A&#946; accumulation (<xref rid="bib120" ref-type="bibr">Pickford et al., 2008</xref>; <xref rid="bib150" ref-type="bibr">Swaminathan et al., 2016</xref>), while activating regulators such as transcription factor EB (TFEB) reduces it (<xref rid="bib186" ref-type="bibr">Xiao et al., 2015</xref>; <xref rid="bib204" ref-type="bibr">Zhang and Zhao, 2015</xref>). Given this central role of autophagic dysfunction, recent evidence links FKBP51 to autophagy regulation (<xref rid="bib6" ref-type="bibr">Bailus et al., 2021</xref>), positioning it as a potential therapeutic target. We thus hypothesize a novel mechanism in AD: FKBP51 impedes A&#946; clearance by disrupting autophagy, making this pathway a promising therapeutic target.</p><p id="p0185">AD is characterized by marked mitochondrial dysfunction and cerebral glucose hypometabolism, which often precede clinical symptoms (<xref rid="bib12" ref-type="bibr">Bano et al., 2023</xref>; <xref rid="bib85" ref-type="bibr">Levin et al., 2021</xref>). These metabolic defects cause bioenergetic deficits in neurons, reducing ATP production, impairing synaptic function, and thereby driving cognitive decline (<xref rid="bib93" ref-type="bibr">Massaro et al., 2025</xref>). Mitochondrial dysfunction further promotes A&#946; production and tau hyperphosphorylation (<xref rid="bib209" ref-type="bibr">Zhou et al., 2018</xref>), which subsequently disrupt glial function&#8212;characterized by reduced astrocytic glucose metabolism (<xref rid="bib107" ref-type="bibr">Minhas et al., 2024</xref>; <xref rid="bib212" ref-type="bibr">Zysk et al., 2023</xref>), impaired microglial phagocytosis (<xref rid="bib98" ref-type="bibr">McIntosh et al., 2019</xref>), and increased neuroinflammation (<xref rid="bib26" ref-type="bibr">Calsolaro and Edison, 2016</xref>; <xref rid="bib114" ref-type="bibr">Pan et al., 2022</xref>)&#8212;thus perpetuating a self-reinforcing cycle of disease progression. Under basal conditions, FKBP51 localizes to mitochondria via the import machinery, where its TPR domain mediates interactions with Hsp90 (<xref rid="bib154" ref-type="bibr">Toneatto et al., 2013</xref>). FKBP51 deficiency enhances mitochondrial function: by regulating fatty acid &#946;-oxidation and amino acid metabolism, it modulates bioenergetics and homeostasis, thereby acting as a critical regulatory factor (<xref rid="bib178" ref-type="bibr">Williams et al., 2023</xref>). FKBP51 correlates with age and AD severity and suppresses mitochondrial function. These findings suggest that FKBP51 inhibition could therapeutically rescue mitochondrial dysfunction and ameliorate AD pathogenesis, supporting its potential as a drug target. Moreover, FKBP51 compromises hippocampal synaptic function and plasticity via a GR-dependent pathway, directly mediating cognitive deficits in AD (<xref rid="bib171" ref-type="bibr">Wang et al., 2024</xref>; <xref rid="bib203" ref-type="bibr">Zhang et al., 2022</xref>). Given this, FKBP51 overexpression is a central pathogenic driver of AD, and targeting FKBP51 emerges as a compelling therapeutic strategy to rescue cognitive function.</p><p id="p0190">These findings identify FKBP51 as a key driver of AD pathology, including neuroinflammation, neurodegeneration, and metabolic dysfunction. Thus, targeting FKBP51 is a promising strategy to slow AD progression.</p></sec><sec id="sec3.2"><label>3.2</label><title>A study of FKBP51 in relation to PD</title><p id="p0195">PD, a neurodegenerative disorder, is characterized by core motor symptoms: resting tremor, rigidity, bradykinesia, and postural instability (<xref rid="bib68" ref-type="bibr">Jankovic, 2008</xref>). With global aging, its prevalence is projected to double from 6.2 million cases in 2015 to 12.9 million by 2040, substantially increasing disease burden (<xref rid="bib52" ref-type="bibr">Guerreiro et al., 2018</xref>). Beyond motor impairments, PD involves debilitating non-motor symptoms&#8212;including cognitive decline, mood disorders, and autonomic dysfunction (e.g., gastrointestinal and cardiac dysregulation)&#8212;that severely compromise quality of life and are critical targets for comprehensive management (<xref rid="bib68" ref-type="bibr">Jankovic, 2008</xref>).</p><p id="p0200">The central pathology of PD involves progressive degeneration of dopaminergic (DA) neurons in the nigrostriatal pathway, causing dopamine depletion and motor dysfunction (<xref rid="bib22" ref-type="bibr">Burch and Sheerin, 2005</xref>). A key neuropathological hallmark is Lewy body formation&#8212;primarily composed of &#945;-synuclein aggregates&#8212;intimately associated with neuronal death (<xref rid="bib25" ref-type="bibr">Calo et al., 2016</xref>; <xref rid="bib157" ref-type="bibr">Tozzi et al., 2021</xref>). While PD's exact etiology remains incompletely understood, genetic predisposition, environmental factors, oxidative stress, mitochondrial dysfunction, and neuroinflammation are implicated as potential contributors (<xref rid="bib108" ref-type="bibr">Morris et al., 2024</xref>).</p><p id="p0205">Loss-of-function mutations in putative protein kinase 1 (PINK1) are linked to PD pathogenesis (<xref rid="bib59" ref-type="bibr">Hernandez et al., 2016</xref>). In PINK1 deficiency, FKBP51 overexpression exacerbates 1-methyl-4-phenylpyridine (MPP+)-induced neuronal death, while its knockdown is protective&#8212;directly implicating FKBP51 in PINK1-related toxicity (<xref rid="bib18" ref-type="bibr">Boonying et al., 2019</xref>). Mechanistically, PINK1 phosphorylates FKBP51 to attenuate the AKT-PHLPP interaction, activating pro-survival AKT signaling. FKBP51 phosphorylation may thus be pivotal to PD pathogenesis via the PINK1-FKBP51 axis.</p><p id="p0210">Recent PD-focused studies have observed that FKBP51 is significantly upregulated during aging and in the PD brain, particularly in microglia and DA neurons. Its upregulation correlates with disease progression, supporting its role as a potential biomarker. FKBP51 serves as a central node in PD pathogenesis by linking protein aggregation and neuroinflammation: binding of FKBP51 to Hsp90 impairs &#945;-synuclein clearance while activating pro-inflammatory microglia. Notably, the inhibitor SAFit2 counteracts both processes: it reduces proteotoxicity and neuroinflammation, thereby protecting DA neurons and restoring motor function (<xref rid="bib45" ref-type="bibr">Garcia-Gomara et al., 2025</xref>). In AD, FKBP51 functions similarly: it binds Hsp90 to impair tau clearance and enhance inflammation. This underscores FKBP51's broad therapeutic potential across neurodegenerative diseases and implies that progress in AD research may directly inform understanding of PD.</p><p id="p0215">Studying FKBP51 in PD has the potential to clarify PD's disease mechanisms, uncover novel biomarkers and therapeutic targets, and thereby facilitate early clinical intervention.</p></sec></sec><sec id="sec4"><label>4</label><title>Potential mechanisms of FKBP51 in neuropsychiatric diseases</title><p id="p0220">Reactive gliosis and chronic neuroinflammation represent key hallmarks of neurodegenerative diseases, including AD and PD (<xref rid="bib185" ref-type="bibr">Wyss-Coray and Rogers, 2012</xref>). As Woo et al. noted, inflammatory conditions in the CNS induce neurotoxicity via ionic imbalance, excitotoxicity, oxidative stress, and neuroimmune crosstalk&#8212;factors that collectively drive mitochondrial dysfunction and epigenetic dysregulation (<xref rid="bib182" ref-type="bibr">Woo et al., 2024</xref>). Neuroinflammation is closely associated with psychiatric disorders. Longitudinal studies show that elevated childhood interleukin-6 (IL-6) levels dose-dependently raise the risk of depression and psychosis in adolescence (<xref rid="bib75" ref-type="bibr">Khandaker et al., 2014</xref>), whereas recurrent depressive episodes predict higher C-reactive protein (CRP) levels (<xref rid="bib30" ref-type="bibr">Copeland et al., 2012</xref>). Meta-analyses confirm elevated pro-inflammatory cytokines (e.g., IL-6, tumor necrosis factor-&#945; (TNF-&#945;), IL-1&#946;) and acute-phase proteins in MDD (<xref rid="bib36" ref-type="bibr">Dowlati et al., 2010</xref>; <xref rid="bib62" ref-type="bibr">Howren et al., 2009</xref>; <xref rid="bib91" ref-type="bibr">Liu et al., 2012</xref>) and anxiety disorders (<xref rid="bib28" ref-type="bibr">Chan et al., 2023</xref>; <xref rid="bib49" ref-type="bibr">Goldsmith et al., 2023</xref>).</p><p id="p0225">As resident immune cells of the CNS, microglia regulate neurodevelopment, synaptic function, and neural circuitry by releasing cytokines (e.g., interleukins) and key inflammatory mediators such as TNF (<xref rid="bib131" ref-type="bibr">Salter and Stevens, 2017</xref>). The observed upregulation of FKBP51 in PD microglia highlights its cell-type-specific role (<xref rid="bib45" ref-type="bibr">Garcia-Gomara et al., 2025</xref>). Exploring whether this specificity extends to other neuropsychiatric diseases represents a key future research direction.</p><p id="p0230">FKBP51 mediates inflammatory regulation by modulating nuclear factor &#954;B (NF-&#954;B) signaling and promoting IKK complex (e.g., IKK&#945;/&#946;/&#947;) assembly, thereby increasing pro-inflammatory cytokine production (<xref rid="bib20" ref-type="bibr">Bouwmeester et al., 2004</xref>; <xref rid="bib127" ref-type="bibr">Romano et al., 2004</xref>, <xref rid="bib128" ref-type="bibr">2015</xref>; <xref rid="bib200" ref-type="bibr">Zannas et al., 2019</xref>)(<xref rid="fig6" ref-type="fig">Fig. 6</xref>). Concurrently, FKBP51 impairs GR function by decreasing GR's ligand affinity and nuclear translocation efficiency, which in turn disrupts the HPA axis-mediated negative feedback regulation of inflammation (<xref rid="bib138" ref-type="bibr">Silverman and Sternberg, 2012</xref>; <xref rid="bib201" ref-type="bibr">Zannas et al., 2016</xref>). This dual action indicates FKBP5 may enhance susceptibility to inflammatory and stress-associated pathologies (<xref rid="bib144" ref-type="bibr">Storer et al., 2011</xref>).<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>FKBP51 Regulation of NF-&#954;B Signaling</p><p>FKBP51 Drives NF-&#954;B Activation via IKK&#945;/I&#954;B&#945;. Stimuli like radiation or inflammation engage FKBP51 to modulate IKK&#945;. Activated IKK&#945; phosphorylates I&#954;B&#945;, targeting it for degradation. I&#954;B&#945; degradation liberates NF-&#954;B, allowing nuclear entry and transcriptional activation of pro-inflammatory genes, thereby promoting inflammation.</p></caption><alt-text id="alttext0035">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0235">FKBP51 drives a pro-inflammatory state characterized by elevated IL-6, TNF-&#945;, and IL-1&#946; via a dual mechanism: NF-&#954;B activation and GR feedback disruption. This sustained neuroinflammation is a key pathogenic driver of both neurodegenerative and psychiatric diseases. The upregulation of FKBP51 in PD microglia provides direct support for this model; extending this mechanism to AD and psychiatric disorders remains a critical future research goal.</p><p id="p0240">FKBP51 inhibits GSK-3&#946; via two mechanisms: direct binding dependent on its FK1 domain, and coordinated recruitment of regulatory partners (e.g., cyclin-dependent kinase 5 (CDK5), protein phosphatase 2A (PP2A)) to enhance GSK-3&#946; suppression (<xref rid="bib47" ref-type="bibr">Gassen et al., 2016</xref>). In AD, GSK-3&#946; promotes pathogenesis by inducing tau hyperphosphorylation and disrupting APP processing to increase A&#946; aggregation (<xref rid="bib13" ref-type="bibr">Beurel et al., 2015</xref>; <xref rid="bib82" ref-type="bibr">Lauretti et al., 2020</xref>). Furthermore, GSK-3&#946;&#8242;s clinical relevance is supported by studies: probiotics target the AKT/GSK-3&#946; pathway to ameliorate AD pathology (<xref rid="bib122" ref-type="bibr">Qian et al., 2024</xref>), while loss of microglial spleen tyrosine kinase (SYK) signaling accelerates plaque formation via disruption of the PI3K-AKT-GSK-3&#946;-mTOR axis (<xref rid="bib169" ref-type="bibr">Wang et al., 2022</xref>). Although FKBP51 inhibits GSK-3&#946; activity, both proteins are upregulated in AD. This contradiction suggests that more potent, multi-dimensional pathological mechanisms prevail in the AD-specific context&#8212;highlighting a critical focus for future research.</p><p id="p0245">Although the precise mechanisms of GSK-3&#946; in depression, anxiety, and PTSD remain unclear, empirical studies show that modulating GSK-3&#946; signaling&#8212;via pharmacological or microRNA-based approaches&#8212;alleviates disease symptoms (<xref rid="bib81" ref-type="bibr">Latapy et al., 2012</xref>; <xref rid="bib152" ref-type="bibr">Thornton et al., 2018</xref>; <xref rid="bib171" ref-type="bibr">Wang et al., 2024</xref>; <xref rid="bib179" ref-type="bibr">Williams and Harwood, 2000</xref>; <xref rid="bib195" ref-type="bibr">Yu et al., 2021</xref>; <xref rid="bib207" ref-type="bibr">Zheng et al., 2024</xref>). FKBP51, a key endogenous inhibitor of GSK-3&#946;, mitigates core pathological features and retards disease progression in neuropsychiatric diseases, thereby serving as a critical hub connecting pathogenic mechanisms to therapeutic modalities. To facilitate the development of novel treatments, future research must: (1) decipher the regulatory circuitry of the &#8220;upstream signal &#8594; FKBP51 &#8594; GSK-3&#946;&#8221; axis; (2) delineate cell type- and disease-specific functions of FKBP51- GSK-3&#946;; and (3) characterize its role in microglia-mediated neuroimmune crosstalk.</p><p id="p0250">FKBP51 is critical for autophagy regulation, an intracellular degradation pathway that sustains cellular homeostasis (<xref rid="bib104" ref-type="bibr">Menzies et al., 2015</xref>). Research demonstrates that FKBP51 regulates AKT1/BECN1 phosphorylation and activates autophagy by assembling into the &#8220;FKBP51-AKT1-PHLPP-BECN1&#8221; complex&#8212;a mechanism critical for antidepressant action across cellular, animal, and human models (<xref rid="bib46" ref-type="bibr">Gassen et al., 2015</xref>). FKBP51 uses its TPR domain as a scaffold to bind, stabilize, and orchestrate assembly of the VPS34 complex, thereby activating autophagy initiation (<xref rid="bib116" ref-type="bibr">Park et al., 2025</xref>). Furthermore, in the mediobasal hypothalamus, FKBP51 integrates metabolic stress signals via scaffolding AMP-activated protein kinase (AMPK)-activating and mechanistic target of rapamycin kinase complex 1 (MTORC1)-inhibiting complexes to regulate autophagy. Notably, FKBP51 and autophagy display a biphasic, inverted U-shaped association: moderate FKBP51 levels promote autophagic flux and metabolic homeostasis, FKBP51 deficiency impairs autophagy, and paradoxically, its overexpression suppresses central but enhances peripheral autophagy (<xref rid="bib9" ref-type="bibr">Bajaj et al., 2022</xref>). In Huntington's disease models, <italic toggle="yes">FKBP5</italic> knockdown or inhibition enhances autophagic flux via an unc-51 like autophagy activating kinase 1 (ULK1)-mediated mechanism that is independent of mTOR (<xref rid="bib6" ref-type="bibr">Bailus et al., 2021</xref>). In cerebral ischemia and reperfusion (I/R) injury, FKBP51 drives pathogenic autophagy by upregulating its expression: this inhibits AKT/FOXO3 phosphorylation, activates autophagic pathways, and exacerbates neuronal damage (<xref rid="bib196" ref-type="bibr">Yu et al., 2020</xref>). In demyelinating diseases, FKBP51 acts as a critical switch linking pathological stimuli to mitophagy activation via PPAR-&#947; inhibition and PINK1-Parkin disinhibition. This pathway eliminates damaged mitochondria, mitigates secondary damage, and promotes remyelination by optimizing the regenerative microenvironment (<xref rid="bib147" ref-type="bibr">Sun et al., 2023</xref>). Autophagy serves as both a pathogenic mechanism and therapeutic target in neuropsychiatric diseases (<xref rid="bib53" ref-type="bibr">Gulbins et al., 2018</xref>; <xref rid="bib167" ref-type="bibr">Wang et al., 2021</xref>; <xref rid="bib187" ref-type="bibr">Xiao et al., 2018</xref>; <xref rid="bib211" ref-type="bibr">Zhu et al., 2023</xref>); thus, elucidating the FKBP51-autophagy axis is critical for the development of novel therapies (<xref rid="fig7" ref-type="fig">Fig. 7</xref>).<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>FKBP51 Modulates Autophagic Pathways</p><p>A: FKBP51 Scaffolds AKT1-PHLPP to Activate Autophagy. In antidepressant contexts, FKBP51 acts as a scaffold facilitating PHLPP-AKT1 interaction. This enhances AKT1 dephosphorylation/inactivation, reducing Beclin1 phosphorylation. Consequently, autophagy initiation and autophagosome formation are amplified.</p><p>B: FKBP51 Amplifies PINK1/Parkin-Mediated Mitophagy. Copper stress elevates FKBP5, suppressing PPAR-&#947;. This drives PINK1 accumulation on damaged mitochondria, triggering Parkin-mediated ubiquitination. Enhanced FKBP5 promotes autophagosome formation and flux, facilitating clearance of dysfunctional mitochondria.</p></caption><alt-text id="alttext0040">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0255">As a complex modulator of autophagy, FKBP51 exerts distinct, region-specific functions across different pathological models. Given this nuance, its effects require case-by-case analysis. Future studies should prioritize mechanistic dissection of FKBP51 in individual disease states to facilitate precise therapeutic targeting.</p></sec><sec id="sec5"><label>5</label><title>FKBP51-related drugs</title><p id="p0260">Multiple FKBP51-targeting compounds exhibit therapeutic potential. The potent, selective FKBP51 inhibitors SAFit1 and SAFit2 have therapeutic potential (<xref rid="bib43" ref-type="bibr">Gaali et al., 2015</xref>); notably, SAFit2 alleviates neuropathic pain and neuroinflammation via FKBP51 inhibition (<xref rid="bib174" ref-type="bibr">Wedel et al., 2022</xref>, <xref rid="bib173" ref-type="bibr">2023</xref>). Rapamycin enhances autophagy through binding to FKBP51, which is enabled by the FKBP51's structural homology with FKBP12 (<xref rid="bib139" ref-type="bibr">Sinars et al., 2003</xref>). Additional FKBP5/FKBP51 antagonists include benztropine, which disrupts FKBP51&#8211; GR/Hsp90 complex formation (<xref rid="bib129" ref-type="bibr">Sabbagh et al., 2018</xref>); fluoxetine, which reverses stress-induced FKBP51 upregulation and depressive behaviors (<xref rid="bib210" ref-type="bibr">Zhu et al., 2025</xref>); and CBD, which directly binds to FKBP51 to inhibit IKK&#8211;NF-&#954;B signaling and downstream inflammation (<xref rid="bib170" ref-type="bibr">Wang et al., 2023</xref>). Other candidates targeting FKBP51-related pathways include vitamin D (<xref rid="bib74" ref-type="bibr">Kassi et al., 2016</xref>), JQ1 (a BET protein inhibitor) (<xref rid="bib202" ref-type="bibr">Zeng et al., 2023</xref>), galiellalactone (a selective STAT3 inhibitor) (<xref rid="bib55" ref-type="bibr">Handle et al., 2018</xref>), mifepristone and the selective GR antagonist CORT125134 (<xref rid="bib10" ref-type="bibr">Bali et al., 2016</xref>).</p><p id="p0265">Traditional Chinese medicine (TCM) research, particularly in its clinical efficacy and mechanisms, has received increasing attention in recent years. By targeting FKBP51, the active components of Xiaoyao San (e.g., baicalin A, paeoniflorin) inhibit FKBP51 expression and its interaction with IKK&#945;/&#946;, thereby suppressing overactivation of the NF-&#954;B pathway. This cascade restores the immune T helper 17 (Th17)/regulatory T (Treg) cell balance, which in turn ameliorates chronic stress-induced depression-like behaviors and neurological impairment (<xref rid="bib205" ref-type="bibr">Zhang et al., 2025</xref>). Animal and cell experiments confirm that ginsenosides restore the HPA axis negative feedback by downregulating FKBP51 and alleviating its suppression of GR nuclear translocation, ultimately ameliorating chronic stress-induced depressive symptoms (<xref rid="bib87" ref-type="bibr">Li et al., 2024</xref>). Song et al. evaluated the therapeutic effect of an essential oil blend (bergamot, peppermint, rose) in a CMS-induced depression model. For inhalation aromatherapy, depressive symptom amelioration relied on a silent information regulator1 (Sirt1)-mediated pathway rather than direct FKBP51 inhibition: increased Sirt1 expression suppressed FKBP51 activity, which subsequently restored GR function and attenuated NF-&#954;B-driven inflammation (<xref rid="bib141" ref-type="bibr">Song et al., 2025</xref>). Although TCM has been shown to ameliorate depressive disorders by targeting FKBP51, its role in other neuropsychiatric conditions remains unaddressed. Given the shared mechanistic pathways (e.g., GR dysfunction, NF-&#954;B signaling) among depression, anxiety, and PTSD, FKBP51-targeted TCM strategies could have wider translational utility. Expanding this line of research would therefore establish a mechanistic rationale for repurposing TCM interventions in these related disorders.</p><p id="p0270">FKBP51 is integral to the pathophysiology of stress-related neuropsychiatric diseases, functioning as a core regulator of GR signaling to integrate neuroendocrine, inflammatory, and neurotransmitter responses to stress. Its expression is co-modulated by genetic variants and environmental stressors, and this gene&#8211;environment interplay determines individual disease risk. Given its centrality, FKBP51 holds dual value: a potential biomarker for stress-related pathology and a viable therapeutic target. Pharmacological inhibition of FKBP51, for instance, may alleviate symptoms and improve prognosis in affected individuals. To advance translational progress, further research into FKBP51's mechanisms&#8212;particularly how gene&#8211;environment interactions modulate its function&#8212;is essential for developing targeted, personalized treatments. In short, deeper insights into FKBP51 could drive the development of novel therapies, enhancing clinical care and quality of life for patients with stress-related disorders.</p></sec><sec id="sec6"><label>6</label><title>Conclusion</title><p id="p0275"><italic toggle="yes">FKBP5</italic>/FKBP51, core regulators of the GR signaling pathway, are critical to the pathophysiology of multiple neuropsychiatric diseases. They thus represent promising biomarkers for neuropsychiatric disease assessment and viable therapeutic targets. Notably, FKBP51 exhibits distinct sex differences, brain region/cell type specificity, and temporal specificity during disease progression-key drivers of conflicting findings in current research. To resolve this, individual disease cases should be analyzed separately, or additional studies conducted to establish a consistent understanding. Finally, we propose a &#8220;biphasic stress-response model&#8221; that effectively captures the dynamic changes in <italic toggle="yes">FKBP5</italic>/FKBP51 levels throughout neuropsychiatric disease progression.</p></sec><sec id="sec8"><title>CRediT authorship contribution statement</title><p id="p0285"><bold>Yinglong Liu:</bold> Writing &#8211; original draft, Resources, Methodology, Funding acquisition, Conceptualization. <bold>Jiahe Lian:</bold> Visualization. <bold>Youli Fu:</bold> Visualization. <bold>Shishan Wang:</bold> Writing &#8211; review &amp; editing. <bold>Yongxin Liu:</bold> Writing &#8211; review &amp; editing. <bold>Rui Zhang:</bold> Supervision, Project administration, Conceptualization. <bold>Huirong Han:</bold> Supervision, Project administration.</p></sec><sec id="sec9"><title>Ethics approval and consent to participate</title><p id="p0290">Not applicable.</p></sec><sec id="sec10"><title>Consent for publication</title><p id="p0295">Not applicable.</p></sec><sec sec-type="data-availability" id="sec11"><title>Availability of data and materials</title><p id="p0300">Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></sec><sec id="sec12"><title>Declaration of generative AI and AI-assisted technologies in the writing process</title><p id="p0305">During the preparation of this work, the authors utilized DeepSeek, an AI-powered language model, solely to assist with readability enhancement and language polishing. This assistance was limited to simplifying complex sentences, correcting grammatical errors, refining syntax, and ensuring terminological consistency&#8212;without altering the core scientific content or conclusions of the work. After using this tool, the authors reviewed and edited the content as needed. The authors take full responsibility for the final content of the article.</p></sec><sec id="sec13"><title>Funding</title><p id="p0310">This review article was supported by the <funding-source id="gs13"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014718</institution-id><institution>Innovative Research Group Project of the National Natural Science Foundation of China</institution></institution-wrap></funding-source> (No.<award-id award-type="grant" rid="gs13">82371291</award-id>).</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0315">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Alexopoulos</surname><given-names>G.S.</given-names></name></person-group><article-title>Depression in the elderly</article-title><source>Lancet</source><volume>365</volume><issue>9475</issue><year>2005</year><fpage>1961</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66665-2</pub-id><pub-id pub-id-type="pmid">15936426</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="book" id="sref2"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><part-title>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision</part-title><year>2022</year><publisher-name>American Psychiatric Association</publisher-name><publisher-loc>Washington, DC</publisher-loc></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Aminyavari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zahmatkesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khodagholi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanati</surname><given-names>M.</given-names></name></person-group><article-title>Anxiolytic impact of Apelin-13 in a rat model of Alzheimer's disease: involvement of glucocorticoid receptor and FKBP5</article-title><source>Peptides</source><volume>118</volume><year>2019</year><object-id pub-id-type="publisher-id">170102</object-id><pub-id pub-id-type="doi">10.1016/j.peptides.2019.170102</pub-id><pub-id pub-id-type="pmid">31199948</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwahn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mahler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fenske</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stender</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barnow</surname><given-names>S.</given-names></name><name name-style="western"><surname>John</surname><given-names>U.</given-names></name><name name-style="western"><surname>Teumer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Biffar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nauck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volzke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Freyberger</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Grabe</surname><given-names>H.J.</given-names></name></person-group><article-title>Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population</article-title><source>Neuropsychopharmacology</source><volume>36</volume><issue>10</issue><year>2011</year><fpage>1982</fpage><lpage>1991</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.81</pub-id><pub-id pub-id-type="pmid">21654733</pub-id><pub-id pub-id-type="pmcid">PMC3158316</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Attwood</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Bourgognon</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mucha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schiavon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Skrzypiec</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Young</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Shiosaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Korostynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Piechota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Przewlocki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>R.</given-names></name></person-group><article-title>Neuropsin cleaves EphB2 in the amygdala to control anxiety</article-title><source>Nature</source><volume>473</volume><issue>7347</issue><year>2011</year><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature09938</pub-id><pub-id pub-id-type="pmid">21508957</pub-id><pub-id pub-id-type="pmcid">PMC3145099</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Bailus</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Scheeler</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Simons</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tshilenge</surname><given-names>K.</given-names></name><name name-style="western"><surname>Creus-Muncunill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naphade</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lopez-Ramirez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lakshika Madushani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moroz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loureiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ellerby</surname><given-names>L.M.</given-names></name></person-group><article-title>Modulating FKBP5/FKBP51 and autophagy lowers HTT (huntingtin) levels</article-title><source>Autophagy</source><volume>17</volume><issue>12</issue><year>2021</year><fpage>4119</fpage><lpage>4140</lpage><pub-id pub-id-type="doi">10.1080/15548627.2021.1904489</pub-id><pub-id pub-id-type="pmid">34024231</pub-id><pub-id pub-id-type="pmcid">PMC8726715</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Baischew</surname><given-names>A.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Taubert</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name></person-group><article-title>Structural and biochemical insights into FKBP51 as a Hsp90 co-chaperone</article-title><source>J. Cell. Biochem.</source><volume>125</volume><issue>12</issue><year>2024</year><object-id pub-id-type="publisher-id">e30384</object-id><pub-id pub-id-type="doi">10.1002/jcb.30384</pub-id><pub-id pub-id-type="pmcid">PMC11649850</pub-id><pub-id pub-id-type="pmid">36791213</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dillmann</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Sokn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name></person-group><article-title>SKArred 2 death: neuroinflammatory breakdown of the hippocampus</article-title><source>Autophagy</source><volume>20</volume><issue>11</issue><year>2024</year><fpage>2581</fpage><lpage>2583</lpage><pub-id pub-id-type="doi">10.1080/15548627.2024.2373675</pub-id><pub-id pub-id-type="pmid">38934263</pub-id><pub-id pub-id-type="pmcid">PMC11572194</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hausl</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name></person-group><article-title>FKBP5/FKBP51 on weight watch: central FKBP5 links regulatory WIPI protein networks to autophagy and metabolic control</article-title><source>Autophagy</source><volume>18</volume><issue>11</issue><year>2022</year><fpage>2756</fpage><lpage>2758</lpage><pub-id pub-id-type="doi">10.1080/15548627.2022.2063006</pub-id><pub-id pub-id-type="pmid">35438043</pub-id><pub-id pub-id-type="pmcid">PMC9629130</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Bali</surname><given-names>U.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Unitt</surname><given-names>J.</given-names></name></person-group><article-title>FKBP5 mRNA expression is a biomarker for GR antagonism</article-title><source>J. Clin. Endocrinol. Metab.</source><volume>101</volume><issue>11</issue><year>2016</year><fpage>4305</fpage><lpage>4312</lpage><pub-id pub-id-type="doi">10.1210/jc.2016-1624</pub-id><pub-id pub-id-type="pmid">27459525</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Ballard</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vandeleur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castelao</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zarate</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Preisig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merikangas</surname><given-names>K.R.</given-names></name></person-group><article-title>Familial aggregation and coaggregation of suicide attempts and comorbid mental disorders in adults</article-title><source>JAMA Psychiatry</source><volume>76</volume><issue>8</issue><year>2019</year><fpage>826</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.0248</pub-id><pub-id pub-id-type="pmid">30916728</pub-id><pub-id pub-id-type="pmcid">PMC6583867</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Bano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ehninger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bagetta</surname><given-names>G.</given-names></name></person-group><article-title>Decoding metabolic signatures in Alzheimer's disease: a mitochondrial perspective</article-title><source>Cell Death Discov.</source><volume>9</volume><issue>1</issue><year>2023</year><fpage>432</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01732-3</pub-id><pub-id pub-id-type="pmid">38040687</pub-id><pub-id pub-id-type="pmcid">PMC10692234</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Beurel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grieco</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Jope</surname><given-names>R.S.</given-names></name></person-group><article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title><source>Pharmacol. Ther.</source><volume>148</volume><year>2015</year><fpage>114</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.016</pub-id><pub-id pub-id-type="pmid">25435019</pub-id><pub-id pub-id-type="pmcid">PMC4340754</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders</article-title><source>Psychoneuroendocrinology</source><volume>34</volume><issue>Suppl. 1</issue><year>2009</year><fpage>S186</fpage><lpage>S195</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2009.05.021</pub-id><pub-id pub-id-type="pmid">19560279</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Deveau</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Heim</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Cubells</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults</article-title><source>JAMA</source><volume>299</volume><issue>11</issue><year>2008</year><fpage>1291</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1001/jama.299.11.1291</pub-id><pub-id pub-id-type="pmid">18349090</pub-id><pub-id pub-id-type="pmcid">PMC2441757</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Salyakina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lichtner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wochnik</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Putz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Papiol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lucae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nickel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kunzel</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>B.</given-names></name><name name-style="western"><surname>Majer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pfennig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Modell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baghai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deiml</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zill</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bondy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rupprecht</surname><given-names>R.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kohnlein</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dabitz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bruckl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lohmussaar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strom</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Bettecken</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meitinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name></person-group><article-title>Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment</article-title><source>Nat. Genet.</source><volume>36</volume><issue>12</issue><year>2004</year><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1038/ng1479</pub-id><pub-id pub-id-type="pmid">15565110</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Nordhues</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Scaglione</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>O'Leary</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Breydo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cotman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Muschol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Klengel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Kayed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Golde</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Berchtold</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name></person-group><article-title>Accelerated neurodegeneration through chaperone-mediated oligomerization of tau</article-title><source>J. Clin. Investig.</source><volume>123</volume><issue>10</issue><year>2013</year><fpage>4158</fpage><lpage>4169</lpage><pub-id pub-id-type="doi">10.1172/JCI69003</pub-id><pub-id pub-id-type="pmid">23999428</pub-id><pub-id pub-id-type="pmcid">PMC3784538</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Boonying</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joselin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Safarpour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iyirhiaro</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>Y.R.</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Slack</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Figeys</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.S.</given-names></name></person-group><article-title>Pink1 regulates FKBP5 interaction with AKT/PHLPP and protects neurons from neurotoxin stress induced by MPP</article-title><source>J. Neurochem.</source><volume>150</volume><issue>3</issue><year>2019</year><fpage>312</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1111/jnc.14683</pub-id><pub-id pub-id-type="pmid">30734931</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Bourke</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Raees</surname><given-names>M.Q.</given-names></name><name name-style="western"><surname>Malviya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bradburn</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Neigh</surname><given-names>G.N.</given-names></name></person-group><article-title>Glucocorticoid sensitizers Bag1 and Ppid are regulated by adolescent stress in a sex-dependent manner</article-title><source>Psychoneuroendocrinology</source><volume>38</volume><issue>1</issue><year>2013</year><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.05.001</pub-id><pub-id pub-id-type="pmid">22647578</pub-id><pub-id pub-id-type="pmcid">PMC3443296</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Bouwmeester</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bauch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruffner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Angrand</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Bergamini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Croughton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cruciat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eberhard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gagneur</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghidelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hopf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huhse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mangano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Michon</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Schirle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schlegl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Drewes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gavin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Joberty</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neubauer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuster</surname><given-names>B.</given-names></name><name name-style="western"><surname>Superti-Furga</surname><given-names>G.</given-names></name></person-group><article-title>A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway</article-title><source>Nat. Cell Biol.</source><volume>6</volume><issue>2</issue><year>2004</year><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/ncb1086</pub-id><pub-id pub-id-type="pmid">14743216</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Buchmann</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Holz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boecker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blomeyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rietschel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>G.</given-names></name><name name-style="western"><surname>Banaschewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brandeis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>U.S.</given-names></name><name name-style="western"><surname>Laucht</surname><given-names>M.</given-names></name></person-group><article-title>Moderating role of FKBP5 genotype in the impact of childhood adversity on cortisol stress response during adulthood</article-title><source>Eur. Neuropsychopharmacol.</source><volume>24</volume><issue>6</issue><year>2014</year><fpage>837</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2013.12.001</pub-id><pub-id pub-id-type="pmid">24411633</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Burch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheerin</surname><given-names>F.</given-names></name></person-group><article-title>Parkinson's disease</article-title><source>Lancet</source><volume>365</volume><issue>9459</issue><year>2005</year><fpage>622</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)17915-X</pub-id><pub-id pub-id-type="pmid">15708109</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Cabanis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Outadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>F.</given-names></name></person-group><article-title>Early childhood trauma, substance use and complex concurrent disorders among adolescents</article-title><source>Curr. Opin. Psychiatr.</source><volume>34</volume><issue>4</issue><year>2021</year><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1097/YCO.0000000000000718</pub-id><pub-id pub-id-type="pmid">33993169</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Caccamo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majumder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oddo</surname><given-names>S.</given-names></name></person-group><article-title>Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments</article-title><source>J. Biol. Chem.</source><volume>285</volume><issue>17</issue><year>2010</year><fpage>13107</fpage><lpage>13120</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.100420</pub-id><pub-id pub-id-type="pmid">20178983</pub-id><pub-id pub-id-type="pmcid">PMC2857107</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Calo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wegrzynowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santivanez-Perez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grazia</surname><given-names>S.M.</given-names></name></person-group><article-title>Synaptic failure and alpha-synuclein</article-title><source>Mov. Disord.</source><volume>31</volume><issue>2</issue><year>2016</year><fpage>169</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1002/mds.26479</pub-id><pub-id pub-id-type="pmid">26790375</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Calsolaro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Edison</surname><given-names>P.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer's disease: current evidence and future directions</article-title><source>Alzheimer's Dement.</source><volume>12</volume><issue>6</issue><year>2016</year><fpage>719</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.02.010</pub-id><pub-id pub-id-type="pmid">27179961</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Konsolaki</surname><given-names>M.</given-names></name></person-group><article-title>FKBP immunophilins and Alzheimer's disease: a chaperoned affair</article-title><source>J. Biosci.</source><volume>36</volume><issue>3</issue><year>2011</year><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1007/s12038-011-9080-7</pub-id><pub-id pub-id-type="pmid">21799260</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Poller</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Swirski</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>S.J.</given-names></name></person-group><article-title>Central regulation of stress-evoked peripheral immune responses</article-title><source>Nat. Rev. Neurosci.</source><volume>24</volume><issue>10</issue><year>2023</year><fpage>591</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/s41583-023-00729-2</pub-id><pub-id pub-id-type="pmid">37626176</pub-id><pub-id pub-id-type="pmcid">PMC10848316</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Collaborators</surname><given-names>G.D.F.</given-names></name></person-group><article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global burden of disease study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><issue>2</issue><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Copeland</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Worthman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Angold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>E.J.</given-names></name></person-group><article-title>Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis</article-title><source>Biol. Psychiatry</source><volume>71</volume><issue>1</issue><year>2012</year><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.09.023</pub-id><pub-id pub-id-type="pmid">22047718</pub-id><pub-id pub-id-type="pmcid">PMC3586231</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Criado-Marrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gebru</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name></person-group><article-title>Early life stress and high FKBP5 interact to increase anxiety-like symptoms through altered AKT signaling in the Dorsal Hippocampus</article-title><source>Int. J. Mol. Sci.</source><volume>20</volume><issue>11</issue><year>2019</year><pub-id pub-id-type="doi">10.3390/ijms20112738</pub-id><pub-id pub-id-type="pmcid">PMC6600369</pub-id><pub-id pub-id-type="pmid">31167373</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Criado-Marrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morales Silva</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Velazquez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Soler-Cedeno</surname><given-names>O.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>J.T.</given-names></name></person-group><article-title>Dynamic expression of FKBP5 in the medial prefrontal cortex regulates resiliency to conditioned fear</article-title><source>Learn. Mem.</source><volume>24</volume><issue>4</issue><year>2017</year><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1101/lm.043000.116</pub-id><pub-id pub-id-type="pmid">28298552</pub-id><pub-id pub-id-type="pmcid">PMC5362697</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Criado-Marrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Penny</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gulick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name></person-group><article-title>FKBP5 and early life stress affect the hippocampus by an age-dependent mechanism</article-title><source>Brain Behav. Immun. Health</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">100143</object-id><pub-id pub-id-type="doi">10.1016/j.bbih.2020.100143</pub-id><pub-id pub-id-type="pmcid">PMC8474669</pub-id><pub-id pub-id-type="pmid">34589890</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Daskalakis</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Iatrou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chatzinakos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jajoo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snijders</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>D.</given-names></name><name name-style="western"><surname>DiPietro</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Tsatsani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pernia</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Soliva-Estruch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arasappan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bharadwaj</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Collado-Torres</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wuchty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Dammer</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Deep-Soboslay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Eagles</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Huuki</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Logue</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Lugenbuhl</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Maihofer</surname><given-names>A.X.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Nievergelt</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Pertea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sendi</surname><given-names>M.S.E.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tooke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Zeier</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Berretta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Champagne</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seyfried</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kleinman</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>Systems biology dissection of PTSD and MDD across brain regions, cell types, and blood</article-title><source>Science</source><volume>384</volume><issue>6698</issue><year>2024</year><fpage>eadh3707</fpage><pub-id pub-id-type="doi">10.1126/science.adh3707</pub-id><pub-id pub-id-type="pmid">38781393</pub-id><pub-id pub-id-type="pmcid">PMC11203158</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>de Kloet</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Joels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name></person-group><article-title>Stress and the brain: from adaptation to disease</article-title><source>Nat. Rev. Neurosci.</source><volume>6</volume><issue>6</issue><year>2005</year><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/nrn1683</pub-id><pub-id pub-id-type="pmid">15891777</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Dowlati</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swardfager</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sham</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reim</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Lanctot</surname><given-names>K.L.</given-names></name></person-group><article-title>A meta-analysis of cytokines in major depression</article-title><source>Biol. Psychiatry</source><volume>67</volume><issue>5</issue><year>2010</year><fpage>446</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2009.09.033</pub-id><pub-id pub-id-type="pmid">20015486</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Engelhardt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Elkhateib</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bordes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brix</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>van Doeselaar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hausl</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Schraut</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name></person-group><article-title>FKBP51 in the oval bed nucleus of the Stria terminalis regulates anxiety-like behavior</article-title><source>eNeuro</source><volume>8</volume><issue>6</issue><year>2021</year><pub-id pub-id-type="doi">10.1523/ENEURO.0425-21.2021</pub-id><pub-id pub-id-type="pmcid">PMC8687485</pub-id><pub-id pub-id-type="pmid">34872938</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Di</surname><given-names>Q.</given-names></name></person-group><article-title>Heat exposure intervention, anxiety level, and multi-omic profiles: a randomized crossover study</article-title><source>Environ. Int.</source><volume>181</volume><year>2023</year><object-id pub-id-type="publisher-id">108247</object-id><pub-id pub-id-type="doi">10.1016/j.envint.2023.108247</pub-id><pub-id pub-id-type="pmid">37871510</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Fani</surname><given-names>N.</given-names></name><name name-style="western"><surname>King</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Glover</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ely</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gutman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>White matter integrity in highly traumatized adults with and without post-traumatic stress disorder</article-title><source>Neuropsychopharmacology</source><volume>37</volume><issue>12</issue><year>2012</year><fpage>2740</fpage><lpage>2746</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.146</pub-id><pub-id pub-id-type="pmid">22871912</pub-id><pub-id pub-id-type="pmcid">PMC3473340</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Fani</surname><given-names>N.</given-names></name><name name-style="western"><surname>King</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Reiser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>FKBP5 genotype and structural integrity of the posterior cingulum</article-title><source>Neuropsychopharmacology</source><volume>39</volume><issue>5</issue><year>2014</year><fpage>1206</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.322</pub-id><pub-id pub-id-type="pmid">24253961</pub-id><pub-id pub-id-type="pmcid">PMC3957115</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Fani</surname><given-names>N.</given-names></name><name name-style="western"><surname>King</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brewster</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name></person-group><article-title>Structural and functional connectivity in posttraumatic stress disorder: associations with FKBP5</article-title><source>Depress. Anxiety</source><volume>33</volume><issue>4</issue><year>2016</year><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1002/da.22483</pub-id><pub-id pub-id-type="pmid">27038411</pub-id><pub-id pub-id-type="pmcid">PMC4983452</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Fries</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name></person-group><article-title>The FKBP51 glucocorticoid receptor co-chaperone: Regulation, function, and implications in health and disease</article-title><source>Int. J. Mol. Sci.</source><volume>18</volume><issue>12</issue><year>2017</year><pub-id pub-id-type="doi">10.3390/ijms18122614</pub-id><pub-id pub-id-type="pmcid">PMC5751217</pub-id><pub-id pub-id-type="pmid">29206196</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Gaali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuboni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kozany</surname><given-names>C.</given-names></name><name name-style="western"><surname>Balsevich</surname><given-names>G.</given-names></name><name name-style="western"><surname>Namendorf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez-Vizarra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sippel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zannas</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Draenert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Ruhter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Touma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bracher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name></person-group><article-title>Selective inhibitors of the FK506-binding protein 51 by induced fit</article-title><source>Nat. Chem. Biol.</source><volume>11</volume><issue>1</issue><year>2015</year><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1699</pub-id><pub-id pub-id-type="pmid">25436518</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Jeng</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.H.</given-names></name></person-group><article-title>FKBP51 mediates resilience to inflammation-induced anxiety through regulation of glutamic acid decarboxylase 65 expression in mouse hippocampus</article-title><source>J. Neuroinflammation</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>152</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02517-8</pub-id><pub-id pub-id-type="pmid">35705957</pub-id><pub-id pub-id-type="pmcid">PMC9198626</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Gomara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Legarra-Marcos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Serena</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rojas-de-Miguel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Espelosin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcilla</surname><given-names>I.</given-names></name><name name-style="western"><surname>Perez-Mediavilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luquin</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Lanciego</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Burrell</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cuadrado-Tejedor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia-Osta</surname><given-names>A.</given-names></name></person-group><article-title>FKBP51 inhibition ameliorates neurodegeneration and motor dysfunction in the neuromelanin-SNCA mouse model of Parkinson's disease</article-title><source>Mol. Ther.</source><volume>33</volume><issue>3</issue><year>2025</year><fpage>895</fpage><lpage>916</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2025.01.049</pub-id><pub-id pub-id-type="pmid">39905728</pub-id><pub-id pub-id-type="pmcid">PMC11897814</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name></person-group><article-title>FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action</article-title><source>Autophagy</source><volume>11</volume><issue>3</issue><year>2015</year><fpage>578</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1080/15548627.2015.1017224</pub-id><pub-id pub-id-type="pmid">25714272</pub-id><pub-id pub-id-type="pmcid">PMC4502647</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zannas</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kretzschmar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zschocke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maccarrone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zellner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kollmannsberger</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kloiber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turck</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lucae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chrousos</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name></person-group><article-title>FKBP51 inhibits GSK3beta and augments the effects of distinct psychotropic medications</article-title><source>Mol. Psychiatr.</source><volume>21</volume><issue>2</issue><year>2016</year><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/mp.2015.38</pub-id><pub-id pub-id-type="pmid">25849320</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Girgenti</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Gelernter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duman</surname><given-names>R.S.</given-names></name></person-group><article-title>Transcriptomic organization of the human brain in post-traumatic stress disorder</article-title><source>Nat. Neurosci.</source><volume>24</volume><issue>1</issue><year>2021</year><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-00748-7</pub-id><pub-id pub-id-type="pmid">33349712</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Goldsmith</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Bekhbat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Felger</surname><given-names>J.C.</given-names></name></person-group><article-title>Inflammation-related functional and structural dysconnectivity as a pathway to psychopathology</article-title><source>Biol. Psychiatry</source><volume>93</volume><issue>5</issue><year>2023</year><fpage>405</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2022.11.003</pub-id><pub-id pub-id-type="pmid">36725140</pub-id><pub-id pub-id-type="pmcid">PMC9895884</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Goltser-Dubner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shalev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benarroch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Canetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kalla</surname><given-names>C.</given-names></name><name name-style="western"><surname>Masarwa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pevzner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Saloner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lavon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lotan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galili-Weisstub</surname><given-names>E.</given-names></name><name name-style="western"><surname>Segman</surname><given-names>R.</given-names></name></person-group><article-title>Decreased mononuclear cell NR3C1 SKA2 and FKPB5 expression levels among adult survivors of suicide bombing terror attacks in childhood are associated with the development of PTSD</article-title><source>Mol. Psychiatr.</source><volume>28</volume><issue>9</issue><year>2023</year><fpage>3851</fpage><lpage>3855</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02278-7</pub-id><pub-id pub-id-type="pmid">37845495</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Grossmann</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Weihs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wiechmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rex-Haffner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volzke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Volker</surname><given-names>U.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Teumer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Homuth</surname><given-names>G.</given-names></name><name name-style="western"><surname>Klinger-Konig</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grabe</surname><given-names>H.J.</given-names></name></person-group><article-title>Methylation patterns of the FKBP5 gene in association with childhood maltreatment and depressive disorders</article-title><source>Int. J. Mol. Sci.</source><volume>25</volume><issue>3</issue><year>2024</year><pub-id pub-id-type="doi">10.3390/ijms25031485</pub-id><pub-id pub-id-type="pmcid">PMC10855893</pub-id><pub-id pub-id-type="pmid">38338761</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Guerreiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Kun-Rodrigues</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Orme</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eicher</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Parkkinen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Darwent</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heckman</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Troncoso</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pletnikova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ansorge</surname><given-names>O.</given-names></name><name name-style="western"><surname>Clarimon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lleo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morenas-Rodriguez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>L.</given-names></name><name name-style="western"><surname>Honig</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Marder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lemstra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rogaeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>St</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Londos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>I.</given-names></name><name name-style="western"><surname>Braae</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Troakes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Al-Sarraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Holton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Compta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Van Deerlin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Santana</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pastor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diez-Fairen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tienari</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Myllykangas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oinas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Revesz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Ferman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Escott-Price</surname><given-names>V.</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pickering-Brown</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Halliday</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Bras</surname><given-names>J.</given-names></name></person-group><article-title>Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study</article-title><source>Lancet Neurol.</source><volume>17</volume><issue>1</issue><year>2018</year><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30400-3</pub-id><pub-id pub-id-type="pmid">29263008</pub-id><pub-id pub-id-type="pmcid">PMC5805394</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Gulbins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wilker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Soddemann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boldrin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Kleuser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kornhuber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gulbins</surname><given-names>E.</given-names></name></person-group><article-title>Antidepressants act by inducing autophagy controlled by sphingomyelin-ceramide</article-title><source>Mol. Psychiatr.</source><volume>23</volume><issue>12</issue><year>2018</year><fpage>2324</fpage><lpage>2346</lpage><pub-id pub-id-type="doi">10.1038/s41380-018-0090-9</pub-id><pub-id pub-id-type="pmcid">PMC6294742</pub-id><pub-id pub-id-type="pmid">30038230</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guleria</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>Y.Z.</given-names></name></person-group><article-title>MicroRNAs as biomarker and novel therapeutic target for posttraumatic stress disorder in Veterans</article-title><source>Psychiatry Res.</source><volume>305</volume><year>2021</year><object-id pub-id-type="publisher-id">114252</object-id><pub-id pub-id-type="doi">10.1016/j.psychres.2021.114252</pub-id><pub-id pub-id-type="pmcid">PMC8857765</pub-id><pub-id pub-id-type="pmid">34739954</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Handle</surname><given-names>F.</given-names></name><name name-style="western"><surname>Puhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lorito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hoefer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guggenberger</surname><given-names>F.</given-names></name><name name-style="western"><surname>Santer</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>van Weerden</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Claessens</surname><given-names>F.</given-names></name><name name-style="western"><surname>Erb</surname><given-names>H.</given-names></name><name name-style="western"><surname>Culig</surname><given-names>Z.</given-names></name></person-group><article-title>The STAT3 inhibitor galiellalactone reduces IL6-Mediated AR activity in benign and malignant prostate models</article-title><source>Mol. Cancer Therapeut.</source><volume>17</volume><issue>12</issue><year>2018</year><fpage>2722</fpage><lpage>2731</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0508</pub-id><pub-id pub-id-type="pmid">30254184</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klengel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gellner</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Junglas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anderzhanova</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Missig</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rexrode</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trussell</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.X.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Mackert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lardenoije</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dedic</surname><given-names>N.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Prochnicki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rhomberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Payton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>V.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carlezon</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Murgatroyd</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berretta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klengel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pantazopoulos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name></person-group><article-title>SKA2 regulated hyperactive secretory autophagy drives neuroinflammation-induced neurodegeneration</article-title><source>Nat. Commun.</source><volume>15</volume><issue>1</issue><year>2024</year><fpage>2635</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46953-x</pub-id><pub-id pub-id-type="pmid">38528004</pub-id><pub-id pub-id-type="pmcid">PMC10963788</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Gaali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirschner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kozany</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ruhter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dedic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hausl</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Hoeijmakers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Westerholz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Namendorf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name></person-group><article-title>Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties</article-title><source>J. Neurosci.</source><volume>35</volume><issue>24</issue><year>2015</year><fpage>9007</fpage><lpage>9016</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4024-14.2015</pub-id><pub-id pub-id-type="pmid">26085626</pub-id><pub-id pub-id-type="pmcid">PMC6605153</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Hausl</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Brix</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menegaz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brivio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stoffel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goss</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Reul</surname><given-names>J.M.H.M.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name></person-group><article-title>The co-chaperone Fkbp5 shapes the acute stress response in the paraventricular nucleus of the hypothalamus of male mice</article-title><source>Mol. Psychiatr.</source><volume>26</volume><issue>7</issue><year>2021</year><fpage>3060</fpage><lpage>3076</lpage><pub-id pub-id-type="doi">10.1038/s41380-021-01044-x</pub-id><pub-id pub-id-type="pmcid">PMC8505251</pub-id><pub-id pub-id-type="pmid">33649453</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>X.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>A.B.</given-names></name></person-group><article-title>Genetics in Parkinson disease: mendelian versus Non-Mendelian inheritance</article-title><source>J. Neurochem.</source><volume>139</volume><issue>Suppl. 1</issue><year>2016</year><fpage>59</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/jnc.13593</pub-id><comment>(Suppl 1)</comment><pub-id pub-id-type="pmid">27090875</pub-id><pub-id pub-id-type="pmcid">PMC5155439</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name></person-group><article-title>Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy</article-title><source>J. Affect. Disord.</source><volume>62</volume><issue>1&#8211;2</issue><year>2001</year><fpage>77</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/s0165-0327(00)00352-9</pub-id><pub-id pub-id-type="pmid">11172875</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Hori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>I.</given-names></name><name name-style="western"><surname>Matsuo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kunugi</surname><given-names>H.</given-names></name></person-group><article-title>Blood mRNA expression levels of glucocorticoid receptors and FKBP5 are associated with depressive disorder and altered HPA axis</article-title><source>J. Affect. Disord.</source><volume>349</volume><year>2024</year><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2024.01.080</pub-id><pub-id pub-id-type="pmid">38199409</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Howren</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lamkin</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Suls</surname><given-names>J.</given-names></name></person-group><article-title>Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis</article-title><source>Psychosom. Med.</source><volume>71</volume><issue>2</issue><year>2009</year><fpage>171</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1097/PSY.0b013e3181907c1b</pub-id><pub-id pub-id-type="pmid">19188531</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Swaab</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.N.</given-names></name></person-group><article-title>SIRT1 in the BNST modulates chronic stress-induced anxiety of male mice via FKBP5 and corticotropin-releasing factor signaling</article-title><source>Mol. Psychiatr.</source><volume>28</volume><issue>12</issue><year>2023</year><fpage>5101</fpage><lpage>5117</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02144-6</pub-id><pub-id pub-id-type="pmid">37386058</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Prevalence of mental disorders in China: a cross-sectional epidemiological study</article-title><source>Lancet Psychiatry</source><volume>6</volume><issue>3</issue><year>2019</year><fpage>211</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(18)30511-X</pub-id><pub-id pub-id-type="pmid">30792114</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Skarica</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coudriet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Terwilliger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sliby</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Deans</surname><given-names>P.J.M.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Levey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Glausier</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gelernter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holtzheimer</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gerstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sestan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brennand</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Young</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Che</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Girgenti</surname><given-names>M.J.</given-names></name></person-group><article-title>Single-cell transcriptomic and chromatin dynamics of the human brain in PTSD</article-title><source>Nature</source><volume>643</volume><issue>8072</issue><year>2025</year><fpage>744</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1038/s41586-025-09083-y</pub-id><pub-id pub-id-type="pmid">40533550</pub-id><pub-id pub-id-type="pmcid">PMC12267058</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maccarrone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bruckl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scheuer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hennings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turck</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucae</surname><given-names>S.</given-names></name></person-group><article-title>FKBP5 gene expression predicts antidepressant treatment outcome in depression</article-title><source>Int. J. Mol. Sci.</source><volume>20</volume><issue>3</issue><year>2019</year><pub-id pub-id-type="doi">10.3390/ijms20030485</pub-id><pub-id pub-id-type="pmcid">PMC6387218</pub-id><pub-id pub-id-type="pmid">30678080</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Jagtap</surname><given-names>P.K.A.</given-names></name><name name-style="western"><surname>Asami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sippel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaila</surname><given-names>V.R.I.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sattler</surname><given-names>M.</given-names></name></person-group><article-title>Selective inhibitors of FKBP51 employ conformational selection of dynamic invisible states</article-title><source>Angew Chem. Int. Ed. Engl.</source><volume>58</volume><issue>28</issue><year>2019</year><fpage>9429</fpage><lpage>9433</lpage><pub-id pub-id-type="doi">10.1002/anie.201902994</pub-id><pub-id pub-id-type="pmid">31100184</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Jankovic</surname><given-names>J.</given-names></name></person-group><article-title>Parkinson's disease: clinical features and diagnosis</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>79</volume><issue>4</issue><year>2008</year><fpage>368</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.131045</pub-id><pub-id pub-id-type="pmid">18344392</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.J.</given-names></name></person-group><article-title>Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model</article-title><source>Acta Neuropathol.</source><volume>134</volume><issue>2</issue><year>2017</year><fpage>207</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1007/s00401-017-1721-y</pub-id><pub-id pub-id-type="pmid">28477083</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Jinwal</surname><given-names>U.K.</given-names></name><name name-style="western"><surname>Koren</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Borysov</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Abisambra</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Shults</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>O'Leary</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Buchner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name></person-group><article-title>The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules</article-title><source>J. Neurosci.</source><volume>30</volume><issue>2</issue><year>2010</year><fpage>591</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4815-09.2010</pub-id><pub-id pub-id-type="pmid">20071522</pub-id><pub-id pub-id-type="pmcid">PMC2830818</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Kadavath</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jaremko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jaremko</surname><given-names>L.</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zweckstetter</surname><given-names>M.</given-names></name></person-group><article-title>Folding of the tau protein on microtubules</article-title><source>Angew Chem. Int. Ed. Engl.</source><volume>54</volume><issue>35</issue><year>2015</year><fpage>10347</fpage><lpage>10351</lpage><pub-id pub-id-type="doi">10.1002/anie.201501714</pub-id><pub-id pub-id-type="pmid">26094605</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Namgung</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lyoo</surname><given-names>I.K.</given-names></name></person-group><article-title>FKBP5-associated miRNA signature as a putative biomarker for PTSD in recently traumatized individuals</article-title><source>Sci. Rep.</source><volume>10</volume><issue>1</issue><year>2020</year><fpage>3353</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-60334-6</pub-id><pub-id pub-id-type="pmid">32098997</pub-id><pub-id pub-id-type="pmcid">PMC7042218</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Karran</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name></person-group><article-title>The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics</article-title><source>Nat. Rev. Drug Discov.</source><volume>21</volume><issue>4</issue><year>2022</year><fpage>306</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1038/s41573-022-00391-w</pub-id><pub-id pub-id-type="pmid">35177833</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Kassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nasiri-Ansari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spilioti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kalotychou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Apostolou</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Moutsatsou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Papavassiliou</surname><given-names>A.G.</given-names></name></person-group><article-title>Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells</article-title><source>Cell. Mol. Life Sci.</source><volume>73</volume><issue>22</issue><year>2016</year><fpage>4341</fpage><lpage>4354</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2281-3</pub-id><pub-id pub-id-type="pmid">27220430</pub-id><pub-id pub-id-type="pmcid">PMC11108367</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Khandaker</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Zammit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>P.B.</given-names></name></person-group><article-title>Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study</article-title><source>JAMA Psychiatry</source><volume>71</volume><issue>10</issue><year>2014</year><fpage>1121</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.1332</pub-id><pub-id pub-id-type="pmid">25133871</pub-id><pub-id pub-id-type="pmcid">PMC4561502</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Klengel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Anacker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rex-Haffner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pariante</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>T.W.W.</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Mayberg</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Heim</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions</article-title><source>Nat. Neurosci.</source><volume>16</volume><issue>1</issue><year>2013</year><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nn.3275</pub-id><pub-id pub-id-type="pmid">23201972</pub-id><pub-id pub-id-type="pmcid">PMC4136922</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Knorr</surname><given-names>U.</given-names></name><name name-style="western"><surname>Vinberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kessing</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J.</given-names></name></person-group><article-title>Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis</article-title><source>Psychoneuroendocrinology</source><volume>35</volume><issue>9</issue><year>2010</year><fpage>1275</fpage><lpage>1286</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2010.04.001</pub-id><pub-id pub-id-type="pmid">20447770</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brismar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gissler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lavebratt</surname><given-names>C.</given-names></name></person-group><article-title>Associations of different types of maternal diabetes and body mass index with offspring psychiatric disorders</article-title><source>JAMA Netw. Open</source><volume>3</volume><issue>2</issue><year>2020</year><object-id pub-id-type="publisher-id">e1920787</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20787</pub-id><pub-id pub-id-type="pmid">32031649</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Kuan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Waszczuk</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kotov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clouston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Cortes Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bromet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luft</surname><given-names>B.J.</given-names></name></person-group><article-title>Gene expression associated with PTSD in world trade center responders: an RNA sequencing study</article-title><source>Transl. Psychiatry</source><volume>7</volume><issue>12</issue><year>2017</year><fpage>1297</fpage><pub-id pub-id-type="doi">10.1038/s41398-017-0050-1</pub-id><pub-id pub-id-type="pmid">29249826</pub-id><pub-id pub-id-type="pmcid">PMC5802695</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Kuan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Clouston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kotov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Waszczuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bromet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luft</surname><given-names>B.J.</given-names></name></person-group><article-title>Cell type-specific gene expression patterns associated with posttraumatic stress disorder in world trade center responders</article-title><source>Transl. Psychiatry</source><volume>9</volume><issue>1</issue><year>2019</year><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/s41398-018-0355-8</pub-id><pub-id pub-id-type="pmid">30664621</pub-id><pub-id pub-id-type="pmcid">PMC6341096</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Latapy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rioux</surname><given-names>V.</given-names></name><name name-style="western"><surname>Guitton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Beaulieu</surname><given-names>J.M.</given-names></name></person-group><article-title>Selective deletion of forebrain glycogen synthase kinase 3beta reveals a central role in serotonin-sensitive anxiety and social behaviour</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><volume>367</volume><issue>1601</issue><year>2012</year><fpage>2460</fpage><lpage>2474</lpage><pub-id pub-id-type="doi">10.1098/rstb.2012.0094</pub-id><pub-id pub-id-type="pmid">22826345</pub-id><pub-id pub-id-type="pmcid">PMC3405679</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Lauretti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dincer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pratico</surname><given-names>D.</given-names></name></person-group><article-title>Glycogen synthase kinase-3 signaling in Alzheimer's disease</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><volume>1867</volume><issue>5</issue><year>2020</year><object-id pub-id-type="publisher-id">118664</object-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2020.118664</pub-id><pub-id pub-id-type="pmcid">PMC7047718</pub-id><pub-id pub-id-type="pmid">32006534</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thuras</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Erbes</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Polusny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>J.R.</given-names></name></person-group><article-title>Serotonin transporter (SLC6A4) and FK506-Binding protein 5 (FKBP5) genotype and methylation relationships with response to meditation in veterans with PTSD</article-title><source>Mol. Neurobiol.</source><volume>61</volume><issue>11</issue><year>2024</year><fpage>9608</fpage><lpage>9622</lpage><pub-id pub-id-type="doi">10.1007/s12035-024-04096-6</pub-id><pub-id pub-id-type="pmid">38671329</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Lekman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laje</surname><given-names>G.</given-names></name><name name-style="western"><surname>Charney</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Sorant</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Lipsky</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Manji</surname><given-names>H.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>S.</given-names></name></person-group><article-title>The FKBP5-gene in depression and treatment response--an association study in the sequenced treatment Alternatives to relieve depression (STAR&#8727;D) cohort</article-title><source>Biol. Psychiatry</source><volume>63</volume><issue>12</issue><year>2008</year><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.10.026</pub-id><pub-id pub-id-type="pmid">18191112</pub-id><pub-id pub-id-type="pmcid">PMC2587308</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dyrba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buchert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Teipel</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Grothe</surname><given-names>M.J.</given-names></name></person-group><article-title>Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration</article-title><source>Alzheimers Res. Ther.</source><volume>13</volume><issue>1</issue><year>2021</year><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00785-9</pub-id><pub-id pub-id-type="pmid">33608059</pub-id><pub-id pub-id-type="pmcid">PMC7896407</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Levy-Gigi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kelemen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Keri</surname><given-names>S.</given-names></name></person-group><article-title>Association among clinical response, hippocampal volume, and FKBP5 gene expression in individuals with posttraumatic stress disorder receiving cognitive behavioral therapy</article-title><source>Biol. Psychiatry</source><volume>74</volume><issue>11</issue><year>2013</year><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.017</pub-id><pub-id pub-id-type="pmid">23856297</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name></person-group><article-title>Ginsenosides modulate hypothalamic-pituitary-adrenal function by inhibiting FKBP51 on glucocorticoid receptor to ameliorate depression in mice exposed to chronic unpredictable mild stress</article-title><source>Phytother Res.</source><volume>38</volume><issue>10</issue><year>2024</year><fpage>5016</fpage><lpage>5029</lpage><pub-id pub-id-type="doi">10.1002/ptr.8075</pub-id><pub-id pub-id-type="pmid">39278841</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>The role of FKBP5 in cancer aetiology and chemoresistance</article-title><source>Br. J. Cancer</source><volume>104</volume><issue>1</issue><year>2011</year><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6606014</pub-id><pub-id pub-id-type="pmid">21119664</pub-id><pub-id pub-id-type="pmcid">PMC3039800</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Effects of RU486 in treatment of traumatic stress-induced glucocorticoid dysregulation and fear-related abnormalities: early versus late intervention</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><issue>10</issue><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23105494</pub-id><pub-id pub-id-type="pmcid">PMC9141845</pub-id><pub-id pub-id-type="pmid">35628305</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Lerdall</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Nhieu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.N.</given-names></name></person-group><article-title>Crabp1 modulates HPA axis homeostasis and anxiety-like behaviors by altering FKBP5 expression</article-title><source>Int. J. Mol. Sci.</source><volume>22</volume><issue>22</issue><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms222212240</pub-id><pub-id pub-id-type="pmcid">PMC8619219</pub-id><pub-id pub-id-type="pmid">34830120</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Mak</surname><given-names>A.</given-names></name></person-group><article-title>Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression</article-title><source>J. Affect. Disord.</source><volume>139</volume><issue>3</issue><year>2012</year><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2011.08.003</pub-id><pub-id pub-id-type="pmid">21872339</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Lupien</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McEwen</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Gunnar</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Heim</surname><given-names>C.</given-names></name></person-group><article-title>Effects of stress throughout the lifespan on the brain, behaviour and cognition</article-title><source>Nat. Rev. Neurosci.</source><volume>10</volume><issue>6</issue><year>2009</year><fpage>434</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/nrn2639</pub-id><pub-id pub-id-type="pmid">19401723</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Massaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baudo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name></person-group><article-title>Nuclear respiratory factor-1 (NRF1) induction drives mitochondrial biogenesis and attenuates amyloid beta-induced mitochondrial dysfunction and neurotoxicity</article-title><source>Neurotherapeutics</source><volume>22</volume><issue>2</issue><year>2025</year><object-id pub-id-type="publisher-id">e00513</object-id><pub-id pub-id-type="doi">10.1016/j.neurot.2024.e00513</pub-id><pub-id pub-id-type="pmcid">PMC12014405</pub-id><pub-id pub-id-type="pmid">39730291</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Matosin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arloth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Czamara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Edmond</surname><given-names>K.Z.</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frohlich</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curry</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Worf</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rehawi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Halldorsdottir</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cruceanu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gagliardi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerstner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kodel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murek</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ziller</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Scarr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Arzberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Falkai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kleinmann</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Mechawar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>B.</given-names></name><name name-style="western"><surname>Turecki</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hyde</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Associations of psychiatric disease and ageing with FKBP5 expression converge on superficial layer neurons of the neocortex</article-title><source>Acta Neuropathol.</source><volume>145</volume><issue>4</issue><year>2023</year><fpage>439</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/s00401-023-02541-9</pub-id><pub-id pub-id-type="pmid">36729133</pub-id><pub-id pub-id-type="pmcid">PMC10020280</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Matosin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Halldorsdottir</surname><given-names>T.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: the FKBP5 model</article-title><source>Biol. Psychiatry</source><volume>83</volume><issue>10</issue><year>2018</year><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2018.01.021</pub-id><pub-id pub-id-type="pmid">29573791</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Mawuenyega</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Sigurdson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ovod</surname><given-names>V.</given-names></name><name name-style="western"><surname>Munsell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kasten</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Yarasheski</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name></person-group><article-title>Decreased clearance of CNS beta-amyloid in Alzheimer's disease</article-title><source>Science</source><volume>330</volume><issue>6012</issue><year>2010</year><fpage>1774</fpage><pub-id pub-id-type="doi">10.1126/science.1197623</pub-id><pub-id pub-id-type="pmid">21148344</pub-id><pub-id pub-id-type="pmcid">PMC3073454</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Mazure</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Maciejewski</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>S.C.</given-names></name></person-group><article-title>Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response</article-title><source>Am. J. Psychiatr.</source><volume>157</volume><issue>6</issue><year>2000</year><fpage>896</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.157.6.896</pub-id><pub-id pub-id-type="pmid">10831468</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>McIntosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mela</surname><given-names>V.</given-names></name><name name-style="western"><surname>Harty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Minogue</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kerskens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name></person-group><article-title>Iron accumulation in microglia triggers a cascade of events that leads to altered metabolism and compromised function in APP/PS1 mice</article-title><source>Brain Pathol.</source><volume>29</volume><issue>5</issue><year>2019</year><fpage>606</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1111/bpa.12704</pub-id><pub-id pub-id-type="pmid">30661261</pub-id><pub-id pub-id-type="pmcid">PMC8028264</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Mendonca</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mangiavacchi</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Loureiro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Martin-Santos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gloria</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>W.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanashiro</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hallak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crippa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rios</surname><given-names>A.</given-names></name></person-group><article-title>DNA methylation in regulatory elements of the FKBP5 and NR3C1 gene in mother-child binomials with depression</article-title><source>J. Affect. Disord.</source><volume>331</volume><year>2023</year><fpage>287</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2023.03.031</pub-id><pub-id pub-id-type="pmid">36933666</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Mendonca</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mangiavacchi</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Rios</surname><given-names>A.</given-names></name></person-group><article-title>Regulatory functions of FKBP5 intronic regions associated with psychiatric disorders</article-title><source>J. Psychiatr. Res.</source><volume>143</volume><year>2021</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2021.08.014</pub-id><pub-id pub-id-type="pmid">34433110</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Mengelkoch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alley</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Slavich</surname><given-names>G.M.</given-names></name></person-group><article-title>Transcriptional evidence of HPA axis dysregulation in adolescent females: unique contributions of chronic early-life stressor exposure and maternal depression history</article-title><source>J. Affect. Disord.</source><volume>371</volume><year>2025</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2024.11.024</pub-id><pub-id pub-id-type="pmid">39532234</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Menke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arloth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Putz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klengel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gonik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rex-Haffner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rubel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients</article-title><source>Neuropsychopharmacology</source><volume>37</volume><issue>6</issue><year>2012</year><fpage>1455</fpage><lpage>1464</lpage><pub-id pub-id-type="doi">10.1038/npp.2011.331</pub-id><pub-id pub-id-type="pmid">22237309</pub-id><pub-id pub-id-type="pmcid">PMC3327850</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Menke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lehrieder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fietz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leistner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wurst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stonawski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lechner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deckert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domschke</surname><given-names>K.</given-names></name></person-group><article-title>Childhood trauma dependent anxious depression sensitizes HPA axis function</article-title><source>Psychoneuroendocrinology</source><volume>98</volume><year>2018</year><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2018.07.025</pub-id><pub-id pub-id-type="pmid">30086534</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Menzies</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rubinsztein</surname><given-names>D.C.</given-names></name></person-group><article-title>Compromised autophagy and neurodegenerative diseases</article-title><source>Nat. Rev. Neurosci.</source><volume>16</volume><issue>6</issue><year>2015</year><fpage>345</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/nrn3961</pub-id><pub-id pub-id-type="pmid">25991442</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.J.</given-names></name></person-group><article-title>Posttraumatic stress disorder: from diagnosis to prevention</article-title><source>Mil. Med. Res.</source><volume>5</volume><issue>1</issue><year>2018</year><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/s40779-018-0179-0</pub-id><pub-id pub-id-type="pmid">30261912</pub-id><pub-id pub-id-type="pmcid">PMC6161419</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Musser</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Nigg</surname><given-names>J.T.</given-names></name></person-group><article-title>Sibling recurrence risk and cross-aggregation of attention-Deficit/Hyperactivity disorder and autism spectrum disorder</article-title><source>JAMA Pediatr.</source><volume>173</volume><issue>2</issue><year>2019</year><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1001/jamapediatrics.2018.4076</pub-id><pub-id pub-id-type="pmid">30535156</pub-id><pub-id pub-id-type="pmcid">PMC6439602</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Minhas</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Latif-Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durairaj</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mhatre</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Uenaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crapser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Conley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ennerfelt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Ay</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Matrongolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Newmeyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ullian</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Wernig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rabinowitz</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Suematsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>McReynolds</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Gage</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>K.I.</given-names></name></person-group><article-title>Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies</article-title><source>Science</source><volume>385</volume><issue>6711</issue><year>2024</year><object-id pub-id-type="publisher-id">eabm6131</object-id><pub-id pub-id-type="doi">10.1126/science.abm6131</pub-id><pub-id pub-id-type="pmcid">PMC12313320</pub-id><pub-id pub-id-type="pmid">39172838</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Spillantini</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sue</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Williams-Gray</surname><given-names>C.H.</given-names></name></person-group><article-title>The pathogenesis of Parkinson's disease</article-title><source>Lancet</source><volume>403</volume><year>2024</year><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01478-2</pub-id><comment>10423</comment><pub-id pub-id-type="pmid">38245249</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Bremner</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Foa</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Mayberg</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>North</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.B.</given-names></name></person-group><article-title>Posttraumatic stress disorder: a state-of-the-science review</article-title><source>J. Psychiatr. Res.</source><volume>40</volume><issue>1</issue><year>2006</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2005.07.005</pub-id><pub-id pub-id-type="pmid">16242154</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Noddings</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Agard</surname><given-names>D.A.</given-names></name></person-group><article-title>Cryo-EM reveals how Hsp90 and FKBP immunophilins co-regulate the glucocorticoid receptor</article-title><source>Nat. Struct. Mol. Biol.</source><volume>30</volume><issue>12</issue><year>2023</year><fpage>1867</fpage><lpage>1877</lpage><pub-id pub-id-type="doi">10.1038/s41594-023-01128-y</pub-id><pub-id pub-id-type="pmid">37945740</pub-id><pub-id pub-id-type="pmcid">PMC10716051</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Nold</surname><given-names>V.</given-names></name><name name-style="western"><surname>Portenhauser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Blasius</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>I.</given-names></name><name name-style="western"><surname>Koros</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peleh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hengerer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kolassa</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Slezak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allers</surname><given-names>K.A.</given-names></name></person-group><article-title>Impact of Fkbp5 x early life adversity x sex in humanised mice on multidimensional stress responses and circadian rhythmicity</article-title><source>Mol. Psychiatr.</source><volume>27</volume><issue>8</issue><year>2022</year><fpage>3544</fpage><lpage>3555</lpage><pub-id pub-id-type="doi">10.1038/s41380-022-01549-z</pub-id><pub-id pub-id-type="pmcid">PMC9708571</pub-id><pub-id pub-id-type="pmid">35449298</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Ormel</surname><given-names>J.</given-names></name><name name-style="western"><surname>VonKorff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ustun</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Pini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Korten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oldehinkel</surname><given-names>T.</given-names></name></person-group><article-title>Common mental disorders and disability across cultures. Results from the WHO collaborative study on psychological problems in general health care</article-title><source>JAMA</source><volume>272</volume><issue>22</issue><year>1994</year><fpage>1741</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1001/jama.272.22.1741</pub-id><pub-id pub-id-type="pmid">7966922</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Oroz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Wysoczanski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perez-Lara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hofele</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Urlaub</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Zweckstetter</surname><given-names>M.</given-names></name></person-group><article-title>Structure and pro-toxic mechanism of the human Hsp90/PPIase/Tau complex</article-title><source>Nat. Commun.</source><volume>9</volume><issue>1</issue><year>2018</year><fpage>4532</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06880-0</pub-id><pub-id pub-id-type="pmid">30382094</pub-id><pub-id pub-id-type="pmcid">PMC6208366</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name></person-group><article-title>Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease</article-title><source>Cell Metab.</source><volume>34</volume><issue>4</issue><year>2022</year><fpage>634</fpage><lpage>648.e6</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2022.02.013</pub-id><pub-id pub-id-type="pmid">35303422</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Pariante</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment</article-title><source>Biol. Psychiatry</source><volume>49</volume><issue>5</issue><year>2001</year><fpage>391</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/s0006-3223(00)01088-x</pub-id><pub-id pub-id-type="pmid">11274650</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blackstone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name></person-group><article-title>A depression-associated protein FKBP5 functions in autophagy initiation through scaffolding the VPS34 complex</article-title><source>Mol. Neurobiol.</source><year>2025</year><pub-id pub-id-type="doi">10.1007/s12035-025-04897-3</pub-id><pub-id pub-id-type="pmid">40175715</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bera</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gurbani</surname><given-names>D.</given-names></name><name name-style="western"><surname>von Hoyningen-Huene</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sakurada</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pruett-Miller</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Westover</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>M.B.</given-names></name></person-group><article-title>The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51</article-title><source>PLoS Biol.</source><volume>19</volume><issue>6</issue><year>2021</year><object-id pub-id-type="publisher-id">e3001281</object-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001281</pub-id><pub-id pub-id-type="pmcid">PMC8202955</pub-id><pub-id pub-id-type="pmid">34077419</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.J.</given-names></name></person-group><article-title>Regulation of behavioral response to stress by microRNA-690</article-title><source>Mol. Brain</source><volume>14</volume><issue>1</issue><year>2021</year><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s13041-021-00728-3</pub-id><pub-id pub-id-type="pmid">33422095</pub-id><pub-id pub-id-type="pmcid">PMC7797085</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Posterino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlin</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Bowes</surname><given-names>G.</given-names></name></person-group><article-title>Life events and early onset depression: cause or consequence?</article-title><source>Psychol. Med.</source><volume>33</volume><issue>7</issue><year>2003</year><fpage>1203</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.1017/s0033291703008626</pub-id><pub-id pub-id-type="pmid">14580075</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Pickford</surname><given-names>F.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Britschgi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Small</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rockenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name></person-group><article-title>The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice</article-title><source>J. Clin. Investig.</source><volume>118</volume><issue>6</issue><year>2008</year><fpage>2190</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1172/JCI33585</pub-id><pub-id pub-id-type="pmid">18497889</pub-id><pub-id pub-id-type="pmcid">PMC2391284</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.L.</given-names></name></person-group><article-title>Interpersonal factors, peer relationship stressors, and gender differences in adolescent depression</article-title><source>Curr. Psychiatry Rep.</source><volume>25</volume><issue>11</issue><year>2023</year><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1007/s11920-023-01465-1</pub-id><pub-id pub-id-type="pmid">37773480</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name></person-group><article-title>Multi-strain probiotics ameliorate alzheimer's-like cognitive impairment and pathological changes through the AKT/GSK-3beta pathway in senescence-accelerated mouse prone 8 mice</article-title><source>Brain Behav. Immun.</source><volume>119</volume><year>2024</year><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2024.03.031</pub-id><pub-id pub-id-type="pmid">38548184</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Quick</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Conway</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Swendsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stapp</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Merikangas</surname><given-names>K.R.</given-names></name></person-group><article-title>Comorbidity and coaggregation of major depressive disorder and bipolar disorder and cannabis use disorder in a controlled family Study</article-title><source>JAMA Psychiatry</source><volume>79</volume><issue>7</issue><year>2022</year><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.1338</pub-id><pub-id pub-id-type="pmid">35648395</pub-id><pub-id pub-id-type="pmcid">PMC9161121</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Rickert</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Weibull</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lichtenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Almqvist</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Iliadou</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>D'Onofrio</surname><given-names>B.M.</given-names></name></person-group><article-title>Association between maternal smoking during pregnancy and severe mental illness in offspring</article-title><source>JAMA Psychiatry</source><volume>74</volume><issue>6</issue><year>2017</year><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2017.0456</pub-id><pub-id pub-id-type="pmid">28467540</pub-id><pub-id pub-id-type="pmcid">PMC5539841</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Richter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Bayati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paraskevopoulou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>O.</given-names></name></person-group><article-title>Interaction of FKBP5 variant rs3800373 and city living alters the neural stress response in the anterior cingulate cortex</article-title><source>Stress</source><volume>24</volume><issue>4</issue><year>2021</year><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1080/10253890.2020.1855420</pub-id><pub-id pub-id-type="pmid">33541187</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Rieder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Alderman</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>S.C.</given-names></name></person-group><article-title>Microbes and mental health: a review</article-title><source>Brain Behav. Immun.</source><volume>66</volume><year>2017</year><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.016</pub-id><pub-id pub-id-type="pmid">28131791</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Avellino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bisogni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Venuta</surname><given-names>S.</given-names></name></person-group><article-title>Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells</article-title><source>Eur. J. Cancer</source><volume>40</volume><issue>18</issue><year>2004</year><fpage>2829</fpage><lpage>2836</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2004.08.017</pub-id><pub-id pub-id-type="pmid">15571967</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Romano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>M.</given-names></name><name name-style="western"><surname>D'Angelillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Masullo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.C.</given-names></name></person-group><article-title>FKBP51 employs both scaffold and isomerase functions to promote NF-kappaB activation in melanoma</article-title><source>Nucleic Acids Res.</source><volume>43</volume><issue>14</issue><year>2015</year><fpage>6983</fpage><lpage>6993</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv615</pub-id><pub-id pub-id-type="pmid">26101251</pub-id><pub-id pub-id-type="pmcid">PMC4538817</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Sabbagh</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cordova</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Criado-Marrero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Nordhues</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Darling</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Martinez-Licha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rutz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buchner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leahy</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Koren</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name></person-group><article-title>Targeting the FKBP51/GR/Hsp90 complex to identify functionally relevant treatments for depression and PTSD</article-title><source>ACS Chem. Biol.</source><volume>13</volume><issue>8</issue><year>2018</year><fpage>2288</fpage><lpage>2299</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b00454</pub-id><pub-id pub-id-type="pmid">29893552</pub-id><pub-id pub-id-type="pmcid">PMC6126901</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ojala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaarniranta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hiltunen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H.</given-names></name></person-group><article-title>Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease</article-title><source>Prog. Neurobiol.</source><volume>93</volume><issue>1</issue><year>2011</year><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.10.006</pub-id><pub-id pub-id-type="pmid">21056617</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Salter</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>B.</given-names></name></person-group><article-title>Microglia emerge as central players in brain disease</article-title><source>Nat. Med.</source><volume>23</volume><issue>9</issue><year>2017</year><fpage>1018</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1038/nm.4397</pub-id><pub-id pub-id-type="pmid">28886007</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Scharf</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Liebl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.B.</given-names></name></person-group><article-title>Expression and regulation of the Fkbp5 gene in the adult mouse brain</article-title><source>PLoS One</source><volume>6</volume><issue>2</issue><year>2011</year><object-id pub-id-type="publisher-id">e16883</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0016883</pub-id><pub-id pub-id-type="pmcid">PMC3036725</pub-id><pub-id pub-id-type="pmid">21347384</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chetelat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W.M.</given-names></name></person-group><article-title>Alzheimer's disease</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id><comment>10284</comment><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Scheuer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>von Klitzing</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A.M.</given-names></name></person-group><article-title>FKBP5 polymorphisms moderate the influence of adverse life events on the risk of anxiety and depressive disorders in preschool children</article-title><source>J. Psychiatr. Res.</source><volume>72</volume><year>2016</year><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2015.10.009</pub-id><pub-id pub-id-type="pmid">26521051</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Schiele</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Domschke</surname><given-names>K.</given-names></name></person-group><article-title>The applied implications of epigenetics in anxiety, affective and stress-related disorders - a review and synthesis on psychosocial stress, psychotherapy and prevention</article-title><source>Clin. Psychol. Rev.</source><volume>77</volume><year>2020</year><object-id pub-id-type="publisher-id">101830</object-id><pub-id pub-id-type="doi">10.1016/j.cpr.2020.101830</pub-id><pub-id pub-id-type="pmid">32163803</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer's disease at 25 years</article-title><source>EMBO Mol. Med.</source><volume>8</volume><issue>6</issue><year>2016</year><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Serova</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Nwokafor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>B.A.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sabban</surname><given-names>E.L.</given-names></name></person-group><article-title>Single prolonged stress PTSD model triggers progressive severity of anxiety, altered gene expression in locus coeruleus and hypothalamus and effected sensitivity to NPY</article-title><source>Eur. Neuropsychopharmacol.</source><volume>29</volume><issue>4</issue><year>2019</year><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2019.02.010</pub-id><pub-id pub-id-type="pmid">30878321</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Silverman</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Sternberg</surname><given-names>E.M.</given-names></name></person-group><article-title>Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>1261</volume><year>2012</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06633.x</pub-id><pub-id pub-id-type="pmid">22823394</pub-id><pub-id pub-id-type="pmcid">PMC3572859</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Sinars</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Cheung-Flynn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rimerman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Scammell</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Clardy</surname><given-names>J.</given-names></name></person-group><article-title>Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>100</volume><issue>3</issue><year>2003</year><fpage>868</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1073/pnas.0231020100</pub-id><pub-id pub-id-type="pmid">12538866</pub-id><pub-id pub-id-type="pmcid">PMC298693</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Sinclair</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fillman</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Weickert</surname><given-names>C.S.</given-names></name></person-group><article-title>Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness</article-title><source>Sci. Rep.</source><volume>3</volume><year>2013</year><fpage>3539</fpage><pub-id pub-id-type="doi">10.1038/srep03539</pub-id><pub-id pub-id-type="pmid">24345775</pub-id><pub-id pub-id-type="pmcid">PMC3866598</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name></person-group><article-title>Potential roles of inhalation aromatherapy on stress-induced depression by inhibiting inflammation in the peripheral olfactory system</article-title><source>Neurochem. Int.</source><volume>186</volume><year>2025</year><object-id pub-id-type="publisher-id">105967</object-id><pub-id pub-id-type="doi">10.1016/j.neuint.2025.105967</pub-id><pub-id pub-id-type="pmid">40158533</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Spillantini</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goedert</surname><given-names>M.</given-names></name></person-group><article-title>Tau pathology and neurodegeneration</article-title><source>Lancet Neurol.</source><volume>12</volume><issue>6</issue><year>2013</year><fpage>609</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70090-5</pub-id><pub-id pub-id-type="pmid">23684085</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Stetler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G.E.</given-names></name></person-group><article-title>Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research</article-title><source>Psychosom. Med.</source><volume>73</volume><issue>2</issue><year>2011</year><fpage>114</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1097/PSY.0b013e31820ad12b</pub-id><pub-id pub-id-type="pmid">21257974</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Storer</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Galigniana</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.B.</given-names></name></person-group><article-title>FKBP51 and FKBP52 in signaling and disease</article-title><source>Trends Endocrinol. Metabol.</source><volume>22</volume><issue>12</issue><year>2011</year><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2011.08.001</pub-id><pub-id pub-id-type="pmcid">PMC3229651</pub-id><pub-id pub-id-type="pmid">21889356</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Strohle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gensichen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domschke</surname><given-names>K.</given-names></name></person-group><article-title>The diagnosis and treatment of anxiety disorders</article-title><source>Dtsch. Arztebl. Int.</source><volume>155</volume><issue>37</issue><year>2018</year><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.3238/arztebl.2018.0611</pub-id><pub-id pub-id-type="pmid">30282583</pub-id><pub-id pub-id-type="pmcid">PMC6206399</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Psycho-social factors associated with high depressive symptomatology in female adolescents and gender difference in adolescent depression: an epidemiological survey in China's Hubei Province</article-title><source>BMC Psychiatry</source><volume>21</volume><issue>1</issue><year>2021</year><fpage>168</fpage><pub-id pub-id-type="doi">10.1186/s12888-021-03165-7</pub-id><pub-id pub-id-type="pmid">33771118</pub-id><pub-id pub-id-type="pmcid">PMC7995784</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name></person-group><article-title>FKBP5 activates mitophagy by ablating PPAR-gamma to shape a benign remyelination environment</article-title><source>Cell Death Dis.</source><volume>14</volume><issue>11</issue><year>2023</year><fpage>736</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-06260-7</pub-id><pub-id pub-id-type="pmid">37952053</pub-id><pub-id pub-id-type="pmcid">PMC10640650</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name></person-group><article-title>Methylome-wide association study of adolescent depressive episode with psychotic symptoms and childhood trauma</article-title><source>J. Affect. Disord.</source><volume>370</volume><year>2025</year><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2024.10.029</pub-id><pub-id pub-id-type="pmid">39442698</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sadahiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Enokido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Otani</surname><given-names>K.</given-names></name></person-group><article-title>Relationship of the FKBP5 C/T polymorphism with dysfunctional attitudes predisposing to depression</article-title><source>Compr. Psychiatry</source><volume>55</volume><issue>6</issue><year>2014</year><fpage>1422</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1016/j.comppsych.2014.04.019</pub-id><pub-id pub-id-type="pmid">24889341</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Swaminathan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Plowey</surname><given-names>E.D.</given-names></name></person-group><article-title>BECN1/Beclin 1 sorts cell-surface APP/amyloid beta precursor protein for lysosomal degradation</article-title><source>Autophagy</source><volume>12</volume><issue>12</issue><year>2016</year><fpage>2404</fpage><lpage>2419</lpage><pub-id pub-id-type="doi">10.1080/15548627.2016.1234561</pub-id><pub-id pub-id-type="pmid">27715386</pub-id><pub-id pub-id-type="pmcid">PMC5173276</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Szczepankiewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leszczynska-Rodziewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Narozna</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rajewska-Rager</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilkosc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zaremba</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maciukiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Twarowska-Hauser</surname><given-names>J.</given-names></name></person-group><article-title>FKBP5 polymorphism is associated with major depression but not with bipolar disorder</article-title><source>J. Affect. Disord.</source><volume>164</volume><year>2014</year><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2014.04.002</pub-id><pub-id pub-id-type="pmid">24856550</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Thornton</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hare</surname><given-names>B.</given-names></name><name name-style="western"><surname>Colie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pendlebury</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Nebreda</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Falls</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Rincon</surname><given-names>M.</given-names></name></person-group><article-title>Failure to inactivate nuclear GSK3beta by Ser(389)-Phosphorylation leads to focal neuronal death and prolonged fear response</article-title><source>Neuropsychopharmacology</source><volume>43</volume><issue>2</issue><year>2018</year><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/npp.2017.187</pub-id><pub-id pub-id-type="pmid">28832021</pub-id><pub-id pub-id-type="pmcid">PMC5729567</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Tillinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zvozilova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mach</surname><given-names>M.</given-names></name><name name-style="western"><surname>Horvathova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dziewiczova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Osacka</surname><given-names>J.</given-names></name></person-group><article-title>Single intranasal administration of Ucn3 affects the development of PTSD symptoms in an animal model</article-title><source>Int. J. Mol. Sci.</source><volume>25</volume><issue>22</issue><year>2024</year><pub-id pub-id-type="doi">10.3390/ijms252211908</pub-id><pub-id pub-id-type="pmcid">PMC11594197</pub-id><pub-id pub-id-type="pmid">39595978</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Toneatto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charo</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Susperreguy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Galigniana</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Piwien-Pilipuk</surname><given-names>G.</given-names></name></person-group><article-title>Dynamic mitochondrial-nuclear redistribution of the immunophilin FKBP51 is regulated by the PKA signaling pathway to control gene expression during adipocyte differentiation</article-title><source>J. Cell Sci.</source><volume>126</volume><issue>Pt 23</issue><year>2013</year><fpage>5357</fpage><lpage>5368</lpage><pub-id pub-id-type="doi">10.1242/jcs.125799</pub-id><pub-id pub-id-type="pmid">24101724</pub-id><pub-id pub-id-type="pmcid">PMC3843136</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Torrisi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lavanco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Gulisano</surname><given-names>W.</given-names></name><name name-style="western"><surname>Laudani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geraci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barbagallo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Caraci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bucolo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ragusa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papaleo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campolongo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Puzzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drago</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salomone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leggio</surname><given-names>G.M.</given-names></name></person-group><article-title>A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice</article-title><source>Neurobiol. Stress</source><volume>14</volume><year>2021</year><object-id pub-id-type="publisher-id">100286</object-id><pub-id pub-id-type="doi">10.1016/j.ynstr.2020.100286</pub-id><pub-id pub-id-type="pmcid">PMC7772817</pub-id><pub-id pub-id-type="pmid">33392367</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Touma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheung-Flynn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bull</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Ionescu</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Heinzmann</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Knapman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siebertz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Depping</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name></person-group><article-title>FK506 binding protein 5 shapes stress responsiveness: modulation of neuroendocrine reactivity and coping behavior</article-title><source>Biol. Psychiatry</source><volume>70</volume><issue>10</issue><year>2011</year><fpage>928</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.07.023</pub-id><pub-id pub-id-type="pmid">21907973</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Tozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sciaccaluga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Megaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ledonne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cardinale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Federici</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellingacci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paciotti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>E.</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Gardoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ghiglieri</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Leonibus</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>P.</given-names></name></person-group><article-title>Dopamine-dependent early synaptic and motor dysfunctions induced by alpha-synuclein in the nigrostriatal circuit</article-title><source>Brain</source><volume>144</volume><issue>11</issue><year>2021</year><fpage>3477</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1093/brain/awab242</pub-id><pub-id pub-id-type="pmid">34297092</pub-id><pub-id pub-id-type="pmcid">PMC8677552</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Tozzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carballedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wetterling</surname><given-names>F.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>H.</given-names></name><name name-style="western"><surname>O'Keane</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fahey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meaney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frodl</surname><given-names>T.</given-names></name></person-group><article-title>Single-nucleotide polymorphism of the FKBP5 gene and childhood maltreatment as predictors of structural changes in brain areas involved in emotional processing in depression</article-title><source>Neuropsychopharmacology</source><volume>41</volume><issue>2</issue><year>2016</year><fpage>487</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1038/npp.2015.170</pub-id><pub-id pub-id-type="pmid">26076833</pub-id><pub-id pub-id-type="pmcid">PMC5130124</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Tozzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Booij</surname><given-names>L.</given-names></name><name name-style="western"><surname>Doolin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nemoda</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Szyf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pomares</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Chiarella</surname><given-names>J.</given-names></name><name name-style="western"><surname>O'Keane</surname><given-names>V.</given-names></name><name name-style="western"><surname>Frodl</surname><given-names>T.</given-names></name></person-group><article-title>Epigenetic changes of FKBP5 as a link connecting genetic and environmental risk factors with structural and functional brain changes in major depression</article-title><source>Neuropsychopharmacology</source><volume>43</volume><issue>5</issue><year>2018</year><fpage>1138</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1038/npp.2017.290</pub-id><pub-id pub-id-type="pmid">29182159</pub-id><pub-id pub-id-type="pmcid">PMC5854813</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Tufano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cesaro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pacelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M.F.</given-names></name></person-group><article-title>FKBP51 affects TNF-related apoptosis inducing ligand response in Melanoma</article-title><source>Front. Cell Dev. Biol.</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">718947</object-id><pub-id pub-id-type="doi">10.3389/fcell.2021.718947</pub-id><pub-id pub-id-type="pmcid">PMC8473884</pub-id><pub-id pub-id-type="pmid">34589486</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Tyrka</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Ridout</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Parade</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Paquette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marsit</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Seifer</surname><given-names>R.</given-names></name></person-group><article-title>Childhood maltreatment and methylation of FK506 binding protein 5 gene (FKBP5)</article-title><source>Dev. Psychopathol.</source><volume>27</volume><issue>4 Pt 2</issue><year>2015</year><fpage>1637</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1017/S0954579415000991</pub-id><pub-id pub-id-type="pmid">26535949</pub-id><pub-id pub-id-type="pmcid">PMC4870720</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>van Doeselaar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abromeit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>T.</given-names></name><name name-style="western"><surname>Menegaz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ballmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rehawi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huettl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bordes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harbich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rammes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Czisch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knauer-Arloth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name></person-group><article-title>FKBP51 in glutamatergic forebrain neurons promotes early life stress inoculation in female mice</article-title><source>Nat. Commun.</source><volume>16</volume><issue>1</issue><year>2025</year><fpage>2529</fpage><pub-id pub-id-type="doi">10.1038/s41467-025-57952-x</pub-id><pub-id pub-id-type="pmid">40087272</pub-id><pub-id pub-id-type="pmcid">PMC11912546</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>van Doeselaar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bordes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stolwijk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kovarova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brix</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deussing</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Czisch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name></person-group><article-title>Sex-specific and opposed effects of FKBP51 in glutamatergic and GABAergic neurons: implications for stress susceptibility and resilience</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>120</volume><issue>23</issue><year>2023</year><object-id pub-id-type="publisher-id">e2300722120</object-id><pub-id pub-id-type="doi">10.1073/pnas.2300722120</pub-id><pub-id pub-id-type="pmcid">PMC10266018</pub-id><pub-id pub-id-type="pmid">37252963</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>van Zuiden</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geuze</surname><given-names>E.</given-names></name><name name-style="western"><surname>Willemen</surname><given-names>H.L.D.M.</given-names></name><name name-style="western"><surname>Vermetten</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amarouchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kavelaars</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heijnen</surname><given-names>C.J.</given-names></name></person-group><article-title>Glucocorticoid receptor pathway components predict posttraumatic stress disorder symptom development: a prospective study</article-title><source>Biol. Psychiatry</source><volume>71</volume><issue>4</issue><year>2012</year><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.10.026</pub-id><pub-id pub-id-type="pmid">22137507</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Verkhivker</surname><given-names>G.M.</given-names></name></person-group><article-title>Conformational dynamics and mechanisms of client protein integration into the Hsp90 chaperone controlled by allosteric interactions of regulatory switches: Perturbation-based network approach for mutational profiling of the Hsp90 binding and allostery</article-title><source>J. Phys. Chem. B</source><year>2022</year><pub-id pub-id-type="doi">10.1021/acs.jpcb.2c03464</pub-id><pub-id pub-id-type="pmid">35853093</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Vermeer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hendriks-Stegeman</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Buul-Offers</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>M.</given-names></name></person-group><article-title>Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability</article-title><source>J. Clin. Endocrinol. Metab.</source><volume>88</volume><issue>1</issue><year>2003</year><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-020354</pub-id><pub-id pub-id-type="pmid">12519866</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name></person-group><article-title>Excessive mitophagy for anxiety</article-title><source>Neuron</source><volume>109</volume><issue>23</issue><year>2021</year><fpage>3715</fpage><lpage>3716</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2021.11.007</pub-id><pub-id pub-id-type="pmid">34856130</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>Y.</given-names></name></person-group><article-title>Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: a systematic review and meta-analysis</article-title><source>J. Affect. Disord.</source><volume>225</volume><year>2018</year><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2017.08.066</pub-id><pub-id pub-id-type="pmid">28850857</pub-id><pub-id pub-id-type="pmcid">PMC5626653</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sudan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuede</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Poliani</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ellebedy</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Gilfillan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Brioschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M.</given-names></name></person-group><article-title>TREM2 drives microglia response to amyloid-beta via SYK-dependent and -independent pathways</article-title><source>Cell</source><volume>185</volume><issue>22</issue><year>2022</year><fpage>4153</fpage><lpage>4169.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.09.033</pub-id><pub-id pub-id-type="pmid">36306735</pub-id><pub-id pub-id-type="pmcid">PMC9625082</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5</article-title><source>Brain Behav. Immun.</source><volume>111</volume><year>2023</year><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2023.05.008</pub-id><pub-id pub-id-type="pmid">37196785</pub-id></element-citation></ref><ref id="bib171"><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name></person-group><article-title>Ketamine alleviates PTSD-like effect and improves hippocampal synaptic plasticity via regulation of GSK-3beta/GR signaling of rats</article-title><source>J. Psychiatr. Res.</source><volume>178</volume><year>2024</year><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2024.08.019</pub-id><pub-id pub-id-type="pmid">39167905</pub-id></element-citation></ref><ref id="bib172"><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harpaz-Rotem</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Southwick</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Krystal</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Gelernter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pietrzak</surname><given-names>R.H.</given-names></name></person-group><article-title>FKBP5 polymorphisms, childhood abuse, and PTSD symptoms: results from the national health and resilience in veterans study</article-title><source>Psychoneuroendocrinology</source><volume>69</volume><year>2016</year><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2016.04.001</pub-id><pub-id pub-id-type="pmid">27078785</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Wedel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hahnefeld</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Namendorf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Geisslinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sisignano</surname><given-names>M.</given-names></name></person-group><article-title>SAFit2 ameliorates paclitaxel-induced neuropathic pain by reducing spinal gliosis and elevating pro-resolving lipid mediators</article-title><source>J. Neuroinflammation</source><volume>20</volume><issue>1</issue><year>2023</year><fpage>149</fpage><pub-id pub-id-type="doi">10.1186/s12974-023-02835-5</pub-id><pub-id pub-id-type="pmid">37355700</pub-id><pub-id pub-id-type="pmcid">PMC10290418</pub-id></element-citation></ref><ref id="bib174"><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Wedel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mathoor</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rauh</surname><given-names>O.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ciotu</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Fuhrmann</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weigert</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Bruin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geisslinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sisignano</surname><given-names>M.</given-names></name></person-group><article-title>SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain</article-title><source>J. Neuroinflammation</source><volume>19</volume><issue>1</issue><year>2022</year><fpage>254</fpage><pub-id pub-id-type="doi">10.1186/s12974-022-02615-7</pub-id><pub-id pub-id-type="pmid">36217203</pub-id><pub-id pub-id-type="pmcid">PMC9552419</pub-id></element-citation></ref><ref id="bib175"><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name></person-group><article-title>Altered immune response is associated with sex difference in vulnerability to Alzheimer's disease in human prefrontal cortex</article-title><source>Brain Pathol.</source><volume>35</volume><issue>3</issue><year>2025</year><object-id pub-id-type="publisher-id">e13318</object-id><pub-id pub-id-type="doi">10.1111/bpa.13318</pub-id><pub-id pub-id-type="pmcid">PMC11961208</pub-id><pub-id pub-id-type="pmid">39497354</pub-id></element-citation></ref><ref id="bib176"><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Whittle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rakesh</surname><given-names>D.</given-names></name></person-group><article-title>Environmental and neurodevelopmental contributors to youth mental illness</article-title><source>Neuropsychopharmacology</source><volume>50</volume><issue>1</issue><year>2024</year><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/s41386-024-01926-y</pub-id><pub-id pub-id-type="pmid">39030435</pub-id><pub-id pub-id-type="pmcid">PMC11526094</pub-id></element-citation></ref><ref id="bib177"><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Wiechmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czamara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arloth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kodel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beintner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Menke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Provencal</surname><given-names>N.</given-names></name></person-group><article-title>Identification of dynamic glucocorticoid-induced methylation changes at the FKBP5 locus</article-title><source>Clin. Epigenet.</source><volume>11</volume><issue>1</issue><year>2019</year><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s13148-019-0682-5</pub-id><pub-id pub-id-type="pmcid">PMC6533766</pub-id><pub-id pub-id-type="pmid">31122292</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Graves</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Evans-Molina</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T.</given-names></name></person-group><article-title>Sex-specific impact of Fkbp5 on hippocampal response to acute alcohol injection: involvement in alterations of metabolism-related pathways</article-title><source>Cells</source><volume>13</volume><issue>1</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/cells13010089</pub-id><pub-id pub-id-type="pmcid">PMC10778370</pub-id><pub-id pub-id-type="pmid">38201293</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Harwood</surname><given-names>A.J.</given-names></name></person-group><article-title>Lithium therapy and signal transduction</article-title><source>Trends Pharmacol. Sci.</source><volume>21</volume><issue>2</issue><year>2000</year><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/s0165-6147(99)01428-5</pub-id><pub-id pub-id-type="pmid">10664610</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Wittchen</surname><given-names>H.U.</given-names></name><name name-style="western"><surname>Jacobi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gustavsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jonsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Olesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allgulander</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>J.</given-names></name><name name-style="western"><surname>Faravelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jennum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lieb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maercker</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Os</surname><given-names>J.</given-names></name><name name-style="western"><surname>Preisig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salvador-Carulla</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Steinhausen</surname><given-names>H.C.</given-names></name></person-group><article-title>The size and burden of mental disorders and other disorders of the brain in Europe 2010</article-title><source>Eur. Neuropsychopharmacol.</source><volume>21</volume><issue>9</issue><year>2011</year><fpage>655</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2011.07.018</pub-id><pub-id pub-id-type="pmid">21896369</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Wochnik</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Ruegg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name></person-group><article-title>FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells</article-title><source>J. Biol. Chem.</source><volume>280</volume><issue>6</issue><year>2005</year><fpage>4609</fpage><lpage>4616</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407498200</pub-id><pub-id pub-id-type="pmid">15591061</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Engler</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Friese</surname><given-names>M.A.</given-names></name></person-group><article-title>The neuropathobiology of multiple sclerosis</article-title><source>Nat. Rev. Neurosci.</source><volume>25</volume><issue>7</issue><year>2024</year><fpage>493</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1038/s41583-024-00823-z</pub-id><pub-id pub-id-type="pmid">38789516</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="other" id="sref183"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Depressive disorder (depression)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/depression" id="intref0010">https://www.who.int/news-room/fact-sheets/detail/depression</ext-link><year>2023</year></element-citation></ref><ref id="bib184"><element-citation publication-type="other" id="sref184"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Anxiety disorders</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders" id="intref0015">https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders</ext-link><year>2023</year></element-citation></ref><ref id="bib185"><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.</given-names></name></person-group><article-title>Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>2</volume><issue>1</issue><year>2012</year><object-id pub-id-type="publisher-id">a006346</object-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006346</pub-id><pub-id pub-id-type="pmcid">PMC3253025</pub-id><pub-id pub-id-type="pmid">22315714</pub-id></element-citation></ref><ref id="bib186"><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tripoli</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Czerniewski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ballabio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cirrito</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Diwan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name></person-group><article-title>Neuronal-targeted TFEB accelerates lysosomal degradation of APP, reducing abeta generation and amyloid plaque pathogenesis</article-title><source>J. Neurosci.</source><volume>35</volume><issue>35</issue><year>2015</year><fpage>12137</fpage><lpage>12151</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0705-15.2015</pub-id><pub-id pub-id-type="pmid">26338325</pub-id><pub-id pub-id-type="pmcid">PMC4556784</pub-id></element-citation></ref><ref id="bib187"><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name></person-group><article-title>Nicotine alleviates chronic stress-induced anxiety and depressive-like behavior and hippocampal neuropathology via regulating autophagy signaling</article-title><source>Neurochem. Int.</source><volume>114</volume><year>2018</year><fpage>58</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2018.01.004</pub-id><pub-id pub-id-type="pmid">29339018</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name></person-group><article-title>Transcriptional signal and cell specificity of genes related to cortical structural differences of post-traumatic stress disorder</article-title><source>J. Psychiatr. Res.</source><volume>160</volume><year>2023</year><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.02.002</pub-id><pub-id pub-id-type="pmid">36773345</pub-id></element-citation></ref><ref id="bib189"><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kranzler</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Poling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Anton</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Farrer</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gelernter</surname><given-names>J.</given-names></name></person-group><article-title>Interaction of FKBP5 with childhood adversity on risk for post-traumatic stress disorder</article-title><source>Neuropsychopharmacology</source><volume>35</volume><issue>8</issue><year>2010</year><fpage>1684</fpage><lpage>1692</lpage><pub-id pub-id-type="doi">10.1038/npp.2010.37</pub-id><pub-id pub-id-type="pmid">20393453</pub-id><pub-id pub-id-type="pmcid">PMC2946626</pub-id></element-citation></ref><ref id="bib190"><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kurihara</surname><given-names>H.</given-names></name></person-group><article-title>Gender differences in CMS and the effects of antidepressant venlafaxine in rats</article-title><source>Neurochem. Int.</source><volume>63</volume><issue>6</issue><year>2013</year><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2013.09.019</pub-id><pub-id pub-id-type="pmid">24090637</pub-id></element-citation></ref><ref id="bib191"><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bierer</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Flory</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Lehrner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Makotkine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Desarnaud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hammamieh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yehuda</surname><given-names>R.</given-names></name></person-group><article-title>Longitudinal genome-wide methylation study of PTSD treatment using prolonged exposure and hydrocortisone</article-title><source>Transl. Psychiatry</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>398</fpage><pub-id pub-id-type="doi">10.1038/s41398-021-01513-5</pub-id><pub-id pub-id-type="pmid">34282125</pub-id><pub-id pub-id-type="pmcid">PMC8289875</pub-id></element-citation></ref><ref id="bib192"><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Yehuda</surname><given-names>R.</given-names></name></person-group><article-title>Post-traumatic stress disorder</article-title><source>N. Engl. J. Med.</source><volume>346</volume><issue>2</issue><year>2002</year><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1056/NEJMra012941</pub-id><pub-id pub-id-type="pmid">11784878</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Yehuda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Golier</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sarapas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schmeidler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Buxbaum</surname><given-names>J.D.</given-names></name></person-group><article-title>Gene expression patterns associated with posttraumatic stress disorder following exposure to the world trade center attacks</article-title><source>Biol. Psychiatry</source><volume>66</volume><issue>7</issue><year>2009</year><fpage>708</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2009.02.034</pub-id><pub-id pub-id-type="pmid">19393990</pub-id></element-citation></ref><ref id="bib194"><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Selemon</surname><given-names>L.D.</given-names></name></person-group><article-title>BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls</article-title><source>Neurobiol. Stress</source><volume>2</volume><year>2015</year><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.ynstr.2015.07.002</pub-id><pub-id pub-id-type="pmid">26844242</pub-id><pub-id pub-id-type="pmcid">PMC4721476</pub-id></element-citation></ref><ref id="bib195"><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name></person-group><article-title>Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson's disease</article-title><source>J. Pharm. Anal.</source><volume>11</volume><issue>2</issue><year>2021</year><fpage>220</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.06.002</pub-id><pub-id pub-id-type="pmid">34012698</pub-id><pub-id pub-id-type="pmcid">PMC8116202</pub-id></element-citation></ref><ref id="bib196"><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name></person-group><article-title>FKBP5 exacerbates impairments in cerebral Ischemic stroke by inducing autophagy via the AKT/FOXO3 pathway</article-title><source>Front. Cell. Neurosci.</source><volume>14</volume><year>2020</year><fpage>193</fpage><pub-id pub-id-type="doi">10.3389/fncel.2020.00193</pub-id><pub-id pub-id-type="pmid">32760250</pub-id><pub-id pub-id-type="pmcid">PMC7374263</pub-id></element-citation></ref><ref id="bib197"><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name></person-group><article-title>Stress-related cognitive style is related to volumetric change of the hippocampus and FK506 binding protein 5 polymorphism in post-traumatic stress disorder</article-title><source>Psychol. Med.</source><volume>52</volume><issue>7</issue><year>2022</year><fpage>1243</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1017/S0033291720002949</pub-id><pub-id pub-id-type="pmid">32892762</pub-id></element-citation></ref><ref id="bib198"><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Zaba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirmeier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ionescu</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Wollweber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Buell</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Gall-Kleebach</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Holsboer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Putz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hohne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ising</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>U.</given-names></name></person-group><article-title>Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients</article-title><source>Psychoneuroendocrinology</source><volume>55</volume><year>2015</year><fpage>102</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.02.005</pub-id><pub-id pub-id-type="pmid">25745955</pub-id></element-citation></ref><ref id="bib199"><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Zannas</surname><given-names>A.S.</given-names></name></person-group><article-title>Molecular integrators of stress and aging: the example of FKBP5</article-title><source>Acta Neuropathol.</source><volume>145</volume><issue>6</issue><year>2023</year><fpage>713</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1007/s00401-023-02572-2</pub-id><pub-id pub-id-type="pmid">37020089</pub-id></element-citation></ref><ref id="bib200"><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Zannas</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Baumert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiechmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pape</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Arloth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kodel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roitman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haehle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Emeny</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Iurato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carrillo-Roa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lahti</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raikkonen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Waldenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lucae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gieger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hausch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Ressler</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Muller-Myhsok</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ladwig</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Rein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-kappaB-driven inflammation and cardiovascular risk</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume><issue>23</issue><year>2019</year><fpage>11370</fpage><lpage>11379</lpage><pub-id pub-id-type="doi">10.1073/pnas.1816847116</pub-id><pub-id pub-id-type="pmid">31113877</pub-id><pub-id pub-id-type="pmcid">PMC6561294</pub-id></element-citation></ref><ref id="bib201"><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Zannas</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Wiechmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gassen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Binder</surname><given-names>E.B.</given-names></name></person-group><article-title>Gene-stress-Epigenetic regulation of FKBP5: clinical and translational implications</article-title><source>Neuropsychopharmacology</source><volume>41</volume><issue>1</issue><year>2016</year><fpage>261</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/npp.2015.235</pub-id><pub-id pub-id-type="pmid">26250598</pub-id><pub-id pub-id-type="pmcid">PMC4677131</pub-id></element-citation></ref><ref id="bib202"><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name></person-group><article-title>Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer</article-title><source>Front. Pharmacol.</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1191129</object-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1191129</pub-id><pub-id pub-id-type="pmcid">PMC10244677</pub-id><pub-id pub-id-type="pmid">37292153</pub-id></element-citation></ref><ref id="bib203"><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name></person-group><article-title>Interaction between glucocorticoid receptors and FKBP5 in regulating neurotransmission of the hippocampus</article-title><source>Neuroscience</source><volume>483</volume><year>2022</year><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2021.12.020</pub-id><pub-id pub-id-type="pmid">34923037</pub-id></element-citation></ref><ref id="bib204"><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.J.</given-names></name></person-group><article-title>TFEB participates in the abeta-induced pathogenesis of Alzheimer's disease by regulating the autophagy-lysosome pathway</article-title><source>DNA Cell Biol.</source><volume>34</volume><issue>11</issue><year>2015</year><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1089/dna.2014.2738</pub-id><pub-id pub-id-type="pmid">26368054</pub-id></element-citation></ref><ref id="bib205"><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>M.</given-names></name></person-group><article-title>Xiaoyaosan alleviates chronic psychological stress-induced TH17/Treg imbalance via modulation of the FKBP5/NF-kappaB axis</article-title><source>J. Ethnopharmacol.</source><volume>352</volume><year>2025</year><object-id pub-id-type="publisher-id">120184</object-id><pub-id pub-id-type="doi">10.1016/j.jep.2025.120184</pub-id><pub-id pub-id-type="pmid">40550295</pub-id></element-citation></ref><ref id="bib206"><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Darling</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dickey</surname><given-names>C.A.</given-names></name></person-group><article-title>MicroRNA-511 binds to FKBP5 mRNA, which encodes a chaperone protein, and regulates neuronal differentiation</article-title><source>J. Biol. Chem.</source><volume>291</volume><issue>34</issue><year>2016</year><fpage>17897</fpage><lpage>17906</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.727941</pub-id><pub-id pub-id-type="pmid">27334923</pub-id><pub-id pub-id-type="pmcid">PMC5016178</pub-id></element-citation></ref><ref id="bib207"><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>W.</given-names></name></person-group><article-title>MiR-182-5p: a novel biomarker in the treatment of depression in CSDS-induced mice</article-title><source>Int. J. Neuropsychopharmacol.</source><volume>27</volume><issue>1</issue><year>2024</year><pub-id pub-id-type="doi">10.1093/ijnp/pyad064</pub-id><pub-id pub-id-type="pmcid">PMC10799762</pub-id><pub-id pub-id-type="pmid">38038373</pub-id></element-citation></ref><ref id="bib208"><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name></person-group><article-title>Social determinants of health and gender differences in depression among adults: a cohort study</article-title><source>Psychiatry Res.</source><volume>329</volume><year>2023</year><object-id pub-id-type="publisher-id">115548</object-id><pub-id pub-id-type="doi">10.1016/j.psychres.2023.115548</pub-id><pub-id pub-id-type="pmid">37890404</pub-id></element-citation></ref><ref id="bib209"><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Young</surname><given-names>L.E.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name></person-group><article-title>Mitochondrial metabolism in major neurological diseases</article-title><source>Cells</source><volume>7</volume><issue>12</issue><year>2018</year><pub-id pub-id-type="doi">10.3390/cells7120229</pub-id><pub-id pub-id-type="pmcid">PMC6316877</pub-id><pub-id pub-id-type="pmid">30477120</pub-id></element-citation></ref><ref id="bib210"><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.Y.</given-names></name></person-group><article-title>Fluoxetine treatment reverses chronic stress-induced promotion on Fk506-binding protein 5 expression and multiple effects on glucocorticoid receptor phosphorylation in the paraventricular nucleus of mice</article-title><source>Pharmacol. Biochem. Behav.</source><volume>246</volume><year>2025</year><object-id pub-id-type="publisher-id">173916</object-id><pub-id pub-id-type="doi">10.1016/j.pbb.2024.173916</pub-id><pub-id pub-id-type="pmid">39615557</pub-id></element-citation></ref><ref id="bib211"><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.H.</given-names></name></person-group><article-title>Corynoxine B targets at HMGB1/2 to enhance autophagy for alpha-synuclein clearance in fly and rodent models of Parkinson's disease</article-title><source>Acta Pharm. Sin. B</source><volume>13</volume><issue>6</issue><year>2023</year><fpage>2701</fpage><lpage>2714</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.03.011</pub-id><pub-id pub-id-type="pmid">37425041</pub-id><pub-id pub-id-type="pmcid">PMC10326294</pub-id></element-citation></ref><ref id="bib212"><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Zysk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beretta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Naia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dakhel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pavenius</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brismar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lindskog</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ankarcrona</surname><given-names>M.</given-names></name><name name-style="western"><surname>Erlandsson</surname><given-names>A.</given-names></name></person-group><article-title>Amyloid-beta accumulation in human astrocytes induces mitochondrial disruption and changed energy metabolism</article-title><source>J. Neuroinflammation</source><volume>20</volume><issue>1</issue><year>2023</year><fpage>43</fpage><pub-id pub-id-type="doi">10.1186/s12974-023-02722-z</pub-id><pub-id pub-id-type="pmid">36803838</pub-id><pub-id pub-id-type="pmcid">PMC9940442</pub-id></element-citation></ref></ref-list><glossary id="glos0010"><title>Glossary</title><def-list id="glossec0010"><def-item id="g0010"><term>WHO</term><def><p>World Health Organization</p></def></def-item><def-item id="g0015"><term>PTSD</term><def><p>post-traumatic stress disorder</p></def></def-item><def-item id="g0020"><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item id="g0025"><term>AD</term><def><p>Alzheimer's disease</p></def></def-item><def-item id="g0030"><term>PD</term><def><p>Parkinson's disease</p></def></def-item><def-item id="g0035"><term>MS</term><def><p>Multiple sclerosis</p></def></def-item><def-item id="g0040"><term>FKBP51</term><def><p>FK506-binding protein 51</p></def></def-item><def-item id="g0045"><term>FKBP</term><def><p>FK506-binding protein</p></def></def-item><def-item id="g0050"><term>FK</term><def><p>FKBP-type structural domain</p></def></def-item><def-item id="g0055"><term>TPR</term><def><p>tetratricopeptide repeat</p></def></def-item><def-item id="g0060"><term>Hsp90</term><def><p>heat shock protein 90</p></def></def-item><def-item id="g0065"><term>GR</term><def><p>glucocorticoid receptor</p></def></def-item><def-item id="g0070"><term>GC</term><def><p>glucocorticoids</p></def></def-item><def-item id="g0075"><term>AR</term><def><p>androgen receptor</p></def></def-item><def-item id="g0080"><term>PR</term><def><p>progesterone receptor</p></def></def-item><def-item id="g0085"><term>AKT</term><def><p>protein kinase B</p></def></def-item><def-item id="g0090"><term>CBD</term><def><p>cannabidiol</p></def></def-item><def-item id="g0095"><term>FK</term><def><p>FKBP-type structural domain</p></def></def-item><def-item id="g0100"><term>GSK-3&#946;</term><def><p>glycogen synthase kinase-3&#946;</p></def></def-item><def-item id="g0105"><term>IKK&#945;</term><def><p>I&#954;B kinase &#945; subunit</p></def></def-item><def-item id="g0110"><term>PHLPP</term><def><p>PH domain and leucine-rich repeat sequence protein phosphatase</p></def></def-item><def-item id="g0115"><term>SR</term><def><p>steroid hormone receptor</p></def></def-item><def-item id="g0120"><term>SAFit1</term><def><p>selective inhibitor</p></def></def-item><def-item id="g0125"><term>SAFit2</term><def><p>selective inhibitor</p></def></def-item><def-item id="g0130"><term>HPA</term><def><p>hypothalamic-pituitary-adrenal</p></def></def-item><def-item id="g0135"><term>MDD</term><def><p>major depressive disorder</p></def></def-item><def-item id="g0140"><term>CTQ</term><def><p>Childhood Trauma Questionnaire</p></def></def-item><def-item id="g0145"><term>CMS</term><def><p>Chronic mild stress</p></def></def-item><def-item id="g0150"><term>ELA</term><def><p>early life adversity</p></def></def-item><def-item id="g0155"><term>SNPs</term><def><p>single nucleotide polymorphisms</p></def></def-item><def-item id="g0160"><term>GAD</term><def><p>generalized anxiety disorder</p></def></def-item><def-item id="g0165"><term>BNST</term><def><p>bed nucleus of the stria terminalis</p></def></def-item><def-item id="g0170"><term>SIRT1</term><def><p>sirtuin 1</p></def></def-item><def-item id="g0175"><term>CRF</term><def><p>corticotropin-releasing factor</p></def></def-item><def-item id="g0180"><term>Crabp1</term><def><p>cellular retinoic acid binding protein 1</p></def></def-item><def-item id="g0185"><term>BLA</term><def><p>basolateral amygdala</p></def></def-item><def-item id="g0190"><term>ELS</term><def><p>early-life stress</p></def></def-item><def-item id="g0195"><term>CeA</term><def><p>central amygdala</p></def></def-item><def-item id="g0200"><term>dHc</term><def><p>dorsal hippocampus</p></def></def-item><def-item id="g0205"><term>ovBNST</term><def><p>oval bed nucleus of the stria terminalis</p></def></def-item><def-item id="g0210"><term>GABA</term><def><p>&#947;-amino butyric acid</p></def></def-item><def-item id="g0215"><term>GAD65</term><def><p>Glutamic acid decarboxylase 65</p></def></def-item><def-item id="g0220"><term>dlPFC</term><def><p>dorsolateral prefrontal cortex</p></def></def-item><def-item id="g0225"><term>ENDs</term><def><p>endothelial cells</p></def></def-item><def-item id="g0230"><term>OLGs</term><def><p>oligodendrocytes</p></def></def-item><def-item id="g0235"><term>BA11</term><def><p>medial orbitofrontal cortex</p></def></def-item><def-item id="g0240"><term>PL</term><def><p>prelimbic cortex</p></def></def-item><def-item id="g0245"><term>IL</term><def><p>infralimbic cortex</p></def></def-item><def-item id="g0250"><term>mPFC</term><def><p>medial prefrontal cortex</p></def></def-item><def-item id="g0255"><term>SPS</term><def><p>single prolonged stress</p></def></def-item><def-item id="g0260"><term>PVN</term><def><p>paraventricular nucleus</p></def></def-item><def-item id="g0265"><term>PC</term><def><p>posterior cingulate</p></def></def-item><def-item id="g0270"><term>A&#946;</term><def><p>amyloid-&#946;</p></def></def-item><def-item id="g0275"><term>APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item id="g0280"><term>SA</term><def><p>secretory autophagy</p></def></def-item><def-item id="g0285"><term>SKA2</term><def><p>spindle and kinetochore associated complex subunit 2</p></def></def-item><def-item id="g0290"><term>mTOR</term><def><p>mammalian target of rapamycin</p></def></def-item><def-item id="g0295"><term>TFEB</term><def><p>transcription factor EB</p></def></def-item><def-item id="g0300"><term>DA</term><def><p>dopaminergic</p></def></def-item><def-item id="g0305"><term>PINK1</term><def><p>putative protein kinase 1</p></def></def-item><def-item id="g0310"><term>MPP+</term><def><p>1-methyl-4-phenylpyridine</p></def></def-item><def-item id="g0315"><term>IL-6</term><def><p>interleukin-6</p></def></def-item><def-item id="g0320"><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item id="g0325"><term>TNF-&#945;</term><def><p>tumor necrosis factor-&#945;</p></def></def-item><def-item id="g0330"><term>NF-&#954;B</term><def><p>nuclear factor &#954;B</p></def></def-item><def-item id="g0335"><term>CDK5</term><def><p>cyclin-dependent kinase 5</p></def></def-item><def-item id="g0340"><term>PP2A</term><def><p>protein phosphatase 2A</p></def></def-item><def-item id="g0345"><term>SYK</term><def><p>spleen tyrosine kinase</p></def></def-item><def-item id="g0350"><term>AMPK</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item id="g0355"><term>MTORC1</term><def><p>mechanistic target of rapamycin kinase complex 1</p></def></def-item><def-item id="g0360"><term>ULK1</term><def><p>unc-51 like autophagy activating kinase 1</p></def></def-item><def-item id="g0365"><term>I/R</term><def><p>ischemia and reperfusion</p></def></def-item><def-item id="g0370"><term>TCM</term><def><p>Traditional Chinese medicine</p></def></def-item><def-item id="g0375"><term>Sirt1</term><def><p>silent information regulator1</p></def></def-item></def-list></glossary><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0025">No data was used for the research described in the article.</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0320">Thanks to Figdraw for providing the drawing tools and the relevant materials. The drawing software is Figdraw. We would like to thank the Laboratory of Anesthesia and Critical Care Medicine in Colleges and Universities of Shandong Province, School of Anesthesiology, Shandong Second Medical University, for providing research support.</p></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492342</article-id><article-id pub-id-type="pmcid-ver">PMC12492342.1</article-id><article-id pub-id-type="pmcaid">12492342</article-id><article-id pub-id-type="pmcaiid">12492342</article-id><article-id pub-id-type="manuscript-id">NIHMS2111465</article-id><article-id pub-id-type="pmid">39724536</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000210225</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2111465</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2111465</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Blood-based biomarkers and risk of onset of Mild Cognitive Impairment over the short and long-term</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Soldan</surname><given-names initials="A">Anja</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pettigrew</surname><given-names initials="C">Corinne</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jiangxia</given-names></name><degrees>MS, MA</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Albert</surname><given-names initials="M">Marilyn</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><degrees>MD, PhD</degrees><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bittner</surname><given-names initials="T">Tobias</given-names></name><degrees>PhD</degrees><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moghekar</surname><given-names initials="A">Abhay</given-names></name><degrees>MBBS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><collab>the BIOCARD Study team</collab></contrib></contrib-group><aff id="A1"><label>1</label>Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD</aff><aff id="A2"><label>2</label>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</aff><aff id="A3"><label>3</label>Institue of Neuroscience and Physiology, University of Gothenburg, M&#246;lndal, Sweden</aff><aff id="A4"><label>4</label>Clinical Neurochemistry Lab, Sahlgrenska University Hospital, M&#246;lndal, Sweden</aff><aff id="A5"><label>5</label>Paris Brain Institute, ICM, Piti&#233;-Salp&#234;tri&#232;re Hospital, Sorbonne University, Paris, France</aff><aff id="A6"><label>6</label>F.Hoffmann-LaRoche AG, Basel, Switzerland</aff><aff id="A7"><label>7</label>Genentech Inc, South San Francisco, CA, USA</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1"><bold>Statistical Analyses:</bold> Jiangxia Wang, MS, MA, Johns Hopkins Bloomberg School of Public Health</p></fn><corresp id="CR1"><bold>Corresponding author:</bold> Anja Soldan, Ph.D., 550 North Broadway, Suite 415, Baltimore, MD 21205, Fax: (410-502-2189); <email>asoldan1@jhmi.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>12</month><year>2024</year></pub-date><volume>104</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">498220</issue-id><fpage>e210225</fpage><lpage>e210225</lpage><pub-history><event event-type="nihms-submitted"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 10:26:05.627"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2111465.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and Objectives:</title><p id="P2">Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer&#8217;s disease (AD) dementia. Much less is known about their ability to predict risk of Mild Cognitive Impairment (MCI), an earlier disease stage. The current study examined whether levels of blood biomarkers of amyloid (A&#946;<sub>42</sub>/A&#946;<sub>40</sub> ratio), tau (p-tau<sub>181</sub>), neurodegeneration (NfL), and glial activation and neuroinflammation (GFAP, YKL40, sTREM2) collected when participants were cognitively normal are associated with the time to onset of MCI.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">Cognitively unimpaired participants from the longitudinal observational BIOCARD Study provided blood plasma at their baseline evaluation (&#8216;baseline 1&#8217;). A second &#8216;baseline&#8217; specimen (collected using slighly different procedures) was evaluated for participants who were still cognitively normal ~7 years later. The plasma assays were based on the NeuroToolKit (cobas Elecsys assays, Roche Diagnostics). Cox regression models tested the association of biomarker levels with time to MCI symptom onset, separately for both baselines.</p></sec><sec id="S3"><title>Results:</title><p id="P4">Participants included 271 individuals at &#8216;baseline 1&#8217; (mean age=57.5y, 60.5% female, including 82 who progressed to MCI/dementia) and 202 individuals at &#8216;baseline 2&#8217; (mean age = 64.5y, 62.4% female, including 31 progressors). Mean clinical follow-up was 15.5 years for &#8216;baseline 1&#8217; and 9.9 years for &#8216;baseline 2&#8217;. For both baselines, lower plasma A&#946;<sub>42</sub>/A&#946;<sub>40</sub> ratio (both hazard ratios, <italic toggle="yes">HR</italic>s&#8804;0.69, <italic toggle="yes">95% CIs</italic> &#8804; 0.55&#8211;0.87, <italic toggle="yes">p</italic>&#8804;0.034), higher GFAP (<italic toggle="yes">HR</italic>s&#8805;1.83, <italic toggle="yes">CI</italic>s&#8805;1.28&#8211; 2.60, <italic toggle="yes">p</italic>&lt;0.002), and a higher ratio of p-tau<sub>181</sub>/(A&#946;<sub>42</sub>/A&#946;<sub>40</sub>) (<italic toggle="yes">HR</italic>s&#8805;1.64, <italic toggle="yes">CI</italic>s&#8805;1.25&#8211;2.13, <italic toggle="yes">p</italic>&#8804;0.001) were each associated with an earlier time to MCI symptom onset. For baseline 2, higher p-tau<sub>181</sub> (<italic toggle="yes">HR</italic>=2.07, <italic toggle="yes">CI</italic>=1.12&#8211;3.83, <italic toggle="yes">p</italic>=0.021) and higher NfL (<italic toggle="yes">HR</italic>=1.75, <italic toggle="yes">CI</italic>=0.99&#8211;3.10, <italic toggle="yes">p</italic>=0.05) were also associated with earlier MCI symptom onset for progression within 7 years. When combining biomarkers, neither GFAP nor NFL were associated with MCI symptom onset after accounting for AD-biomarker levels (e.g., p-tau<sub>181</sub>/(A&#946;<sub>42</sub>/A&#946;<sub>40</sub>)), which remained significant. YKL40 and sTREM2 were not associated with MCI onset.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P5">Results indicate that during preclinical AD, more abnormal blood biomarker levels of amyloid (A&#946;<sub>42</sub>/A&#946;<sub>40</sub>), p-tau<sub>181</sub>, neurodegeneration (NfL), and neuroinflammation (GFAP) individually are associated with progression from normal cognition to MCI, but the AD non-specific neurodegeneration and inflammation markers were not associated with symptom onset after accounting for amyloid and p-tau levels.</p></sec></abstract><kwd-group><title>Search terms</title><kwd>blood plasma</kwd><kwd>cognitive aging</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>MCI (mild cognitive impairment)</kwd><kwd>cohort studies</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuroimage Rep</journal-id><journal-id journal-id-type="iso-abbrev">Neuroimage Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4761</journal-id><journal-id journal-id-type="pmc-domain">nirp</journal-id><journal-title-group><journal-title>Neuroimage: Reports</journal-title></journal-title-group><issn pub-type="epub">2666-9560</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489762</article-id><article-id pub-id-type="pmcid-ver">PMC12489762.1</article-id><article-id pub-id-type="pmcaid">12489762</article-id><article-id pub-id-type="pmcaiid">12489762</article-id><article-id pub-id-type="pmid">41050949</article-id><article-id pub-id-type="doi">10.1016/j.ynirp.2025.100273</article-id><article-id pub-id-type="pii">S2666-9560(25)00041-8</article-id><article-id pub-id-type="publisher-id">100273</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Quantitative MRI-based decision model for early-stage parkinsonism diagnosis: a pilot feasibility study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Nunez-Gonzalez</surname><given-names initials="L">Laura</given-names></name><email>l.nunezgonzalez@erasmusmc.nl</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Dopper</surname><given-names initials="EGP">Elise G.P.</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>van der Eerden</surname><given-names initials="AW">Anke W.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Seada</surname><given-names initials="SA">Samy Abo</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Boon</surname><given-names initials="AJW">Agnita J.W.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Verbeek</surname><given-names initials="MM">Marcel M.</given-names></name><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Bloem</surname><given-names initials="BR">Bastiaan R.</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Anton Meijer</surname><given-names initials="FJ">Frederick Jan</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Hernandez-Tamames</surname><given-names initials="JA">Juan Antonio</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><aff id="aff1"><label>a</label>Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands</aff><aff id="aff2"><label>b</label>Department of Neurology, Erasmus MC, the Netherlands</aff><aff id="aff3"><label>c</label>Alzheimer Centre, Erasmus MC, Rotterdam, the Netherlands</aff><aff id="aff4"><label>d</label>Surgical Reality, Amsterdam, the Netherlands</aff><aff id="aff5"><label>e</label>Department of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands</aff><aff id="aff6"><label>f</label>Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands</aff><aff id="aff7"><label>g</label>Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands</aff><aff id="aff8"><label>h</label>Department of Imaging Physics, TU Delft, the Netherlands</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>l.nunezgonzalez@erasmusmc.nl</email></corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>6</month><year>2025</year></pub-date><volume>5</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">494580</issue-id><elocation-id>100273</elocation-id><history><date date-type="received"><day>18</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>6</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 17:25:22.027"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0015">Parkinsonism is a clinical syndrome defined as bradykinesia, combined with rest tremor, rigidity, or both (<xref rid="bib41" ref-type="bibr">Postuma et al., 2015</xref>). Parkinson's disease (PD) is the most common cause of parkinsonism and the fastest-growing neurodegenerative disorder worldwide with currently almost 12 million affected people worldwide (<xref rid="bib3" ref-type="bibr">Bloem et al., 2021</xref>; <xref rid="bib34" ref-type="bibr">Murray, 2024</xref>). Atypical parkinsonisms, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB), are collectively less prevalent than idiopathic PD. These disorders are classified as rare, with estimated prevalence rates ranging from 5 to 22 cases per 100,000 population depending on the specific subtype and diagnostic criteria used (<xref rid="bib25" ref-type="bibr">Lo, 2022</xref>). MSA and PSP are the most frequently encountered atypical forms. For example, MSA has a reported prevalence of about 3&#8211;5 per 100,000, while PSP may reach up to 6 per 100,000 in some studies. DLB, often overlapping with both PD and Alzheimer's disease, appears to be more common, with estimates around 0.4&#160;%&#8211;5&#160;% of the elderly population, depending on whether clinical or neuropathological criteria are used (<xref rid="bib37" ref-type="bibr">Nysetvold et al., 2024</xref>; <xref rid="bib48" ref-type="bibr">Sekiya et al., 2024</xref>; <xref rid="bib7" ref-type="bibr">Delpirou et al., 2024</xref>). Diagnosis is typically made based on clinical grounds, and several exclusion criteria as well as red flags have been defined that should urge the clinician to consider an atypical parkinsonian syndrome (<xref rid="bib41" ref-type="bibr">Postuma et al., 2015</xref>). For instance, in case of early severe autonomic failure or frequent falls, the diagnosis of MSA or PSP should be considered respectively (<xref rid="bib54" ref-type="bibr">Wenning et al., 2022</xref>; <xref rid="bib14" ref-type="bibr">H&#246;glinger et al., 2017</xref>). Atypical parkinsonism (AP) has a more aggressive disease course than PD, leading to earlier loss of independent functioning and shorter life spans. Moreover, dopamirgenic treatments are less effective when applied in persons with AP. Therefore, for appropriate guidance and treatment, a timely accurate diagnosis is crucial. However, AP diagnoses are frequently missed in the early stages with reported sensitivities for MSA and PSP below 65&#160;% (<xref rid="bib15" ref-type="bibr">Hughes et al., 2002</xref>; <xref rid="bib22" ref-type="bibr">Joutsa et al., 2014</xref>).</p><p id="p0020">The latest diagnostic criteria for MSA and PSP have incorporated MRI findings. Prominent midbrain atrophy is considered a supportive feature of PSP (<xref rid="bib14" ref-type="bibr">H&#246;glinger et al., 2017</xref>). Atrophy of the putamen, middle cerebellar peduncle, pons or cerebellum, a &#8220;hot-cross bun&#8221; sign, putaminal signal decrease on iron-sensitive images, and increased diffusivity of putamen or middle cerebellar peduncle are defined as MRI markers for clinically established MSA (<xref rid="bib54" ref-type="bibr">Wenning et al., 2022</xref>). However, these MRI characteristics often manifest only late in the disease course, thereby hampering their usefulness for early diagnostics. For MSA, adding the MRI markers to diagnostic criteria even seems to have reduced sensitivity without increasing specificity (<xref rid="bib20" ref-type="bibr">Jensen et al., 2024</xref>).</p><p id="p0025">Quantitative MRI techniques showed promising results in enhancing the diagnostic accuracy (<xref rid="bib13" ref-type="bibr">Heim et al., 2017</xref>; <xref rid="bib5" ref-type="bibr">Chougar et al., 2020</xref>; <xref rid="bib23" ref-type="bibr">Lehericy et al., 2017</xref>; <xref rid="bib43" ref-type="bibr">Pyatigorskaya et al., 2020a</xref>; <xref rid="bib1" ref-type="bibr">Bae et al., 2021</xref>), however, they have not been extensively tested in large-scale studies at an early-stage. The clinical adoption of advanced techniques like quantitative susceptibility mapping (QSM) and diffusion tensor imaging (DTI) is hindered by challenges in standardization (<xref rid="bib20" ref-type="bibr">Jensen et al., 2024</xref>), inconsistent performance, and implementation difficulties (<xref rid="bib53" ref-type="bibr">Wang et al., 2017</xref>).</p><p id="p0030">Although several quantitative MRI biomarkers have shown potential in differentiating PD from disorders such as MSA or PSP, no single MRI biomarker has reliably distinguished between them. A potential solution could involve combining multiple quantitative MRI biomarkers into a decision model (<xref rid="bib1" ref-type="bibr">Bae et al., 2021</xref>), as proposed in recent research (<xref rid="bib44" ref-type="bibr">Pyatigorskaya et al., 2020b</xref>; <xref rid="bib12" ref-type="bibr">He et al., 2021</xref>; <xref rid="bib21" ref-type="bibr">Jin et al., 2019</xref>; <xref rid="bib24" ref-type="bibr">Leng et al., 2022</xref>). Abo <xref rid="bib47" ref-type="bibr">Seada et al. (2023)</xref> proposed a decision tree made up of decision rules which uses atrophy measurements in and around the brainstem (<xref rid="bib38" ref-type="bibr">Oba et al., 2005</xref>; <xref rid="bib35" ref-type="bibr">Nicoletti et al., 2006</xref>; <xref rid="bib45" ref-type="bibr">Quattrone et al., 2008</xref>; <xref rid="bib28" ref-type="bibr">Massey et al., 2013</xref>) and of the third ventricle (<xref rid="bib46" ref-type="bibr">Quattrone et al., 2018</xref>), QSM markers (<xref rid="bib29" ref-type="bibr">Mazzucchi et al., 2019</xref>; <xref rid="bib49" ref-type="bibr">Sj&#246;str&#246;m et al., 2017</xref>), DTI markers (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>), and neuromelanin MRI of the substantia nigra (SN) and locus coeruleus (LC) (<xref rid="bib39" ref-type="bibr">Ohtsuka et al., 2014</xref>).</p><p id="p0035">In this work, we applied the proposed pipeline (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>) retrospectively to 73 patients with a final clinical diagnosis of PD, MSA or PSP to evaluate the performance and feasibility of MRI-biomarkers in differentiating between PD, MSA, and PSP at early disease stages. These patients were included when the clinical diagnosis was still uncertain.</p></sec><sec id="sec2"><label>2</label><title>Methods</title><sec id="sec2.1"><label>2.1</label><title>Population</title><p id="p0040">For this study, we used data that were originally prospectively acquired for a different research project (<xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>; <xref rid="bib51" ref-type="bibr">Van et al., 2018</xref>). Between 2010 and 2012 patients with parkinsonism but uncertainty about the clinical diagnosis (CUP) and with a disease duration &lt;3 years were included at Radboud University Medical Center - Radboudumc - (Nijmegen, the Netherlands) and underwent clinical evaluation and MRI. Patients were excluded if they already had a clinically probable syndrome, were younger than 18 years, had undergone prior brain surgery, or had another neurodegenerative disorder or unstable comorbidity. Further details on the inclusion and exclusion criteria can be found in (<xref rid="bib51" ref-type="bibr">Van et al., 2018</xref>). The probable diagnoses (used in this study to classify the patients) were obtained after clinical follow-up (3&#8211;12 years later).</p><p id="p0045">All patients provided written informed consent and the Institutional Medical Ethics Committee approved the use of the data for this study.</p></sec><sec id="sec2.2"><label>2.2</label><title>Clinical evaluation</title><p id="p0050">At the time of inclusion, all patients underwent a thorough neurological examination by a movement disorder specialist (<xref rid="bib51" ref-type="bibr">Van et al., 2018</xref>). Motor symptoms were rated according to the Movement Disorder Society Unified Parkinson's disease rating scale (MDS-UPDRS) and clinical disease severity was assessed with the Hoehn and Yahr scale (HY) (<xref rid="bib10" ref-type="bibr">Goetz et al., 2008</xref>). Cognitive screening was performed with the Mini-mental state examination (MMSE) (<xref rid="bib9" ref-type="bibr">Folstein et al., 1975</xref>).</p></sec><sec id="sec2.3"><label>2.3</label><title>Clinical follow-up</title><p id="p0055">All patients received clinical follow-up as standard clinical practice. For the current analyses, we used the data from all patients with an initial CUP diagnosis. However, by the time of the current analyses they had a final clinical diagnosis of PD, PSP, or MSA (either the Parkinsonian type (MSA-P), the cerebellar type (MSA-C) or unclassified MSA (MSA-u). Clinical diagnoses were made according to current clinical diagnostic criteria (<xref rid="bib41" ref-type="bibr">Postuma et al., 2015</xref>; <xref rid="bib54" ref-type="bibr">Wenning et al., 2022</xref>; <xref rid="bib14" ref-type="bibr">H&#246;glinger et al., 2017</xref>) by neurologists specialized in movement disorders. The average time between inclusion and final diagnosis (and its standard deviation) was 27 (13) months for PD, 23 (13) months for MSA and 35 (15) months for PSP. All the details per patient are included in <xref rid="appsec1" ref-type="sec">Supplementary Tables S1, S2 and S3</xref>.</p></sec><sec id="sec2.4"><label>2.4</label><title>MRI acquisition</title><p id="p0060">MRI scans were acquired on a 3T Siemens MRI scanner (Magnetom Trio; Siemens, Erlangen, Germany) in Radboudumc. The MRI protocol included a 3D high-resolution T1w-SPGR, a 3D multi-echo gradient-echo sequence for susceptibility-weighted image (SWI), and a Diffusion Tensor Image (DTI) sequence. The MRI scan parameters are described in <xref rid="tbl1" ref-type="table">Table 1</xref>. For further explanation of these parameters, see <xref rid="bib30" ref-type="bibr">Meijer et al. (2015)</xref>. All the MRI scans were performed shortly after the inclusion of the patients in the study.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>MRI scanning parameters&#8212;iPAT indicates integrated parallel acquisition technique.</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sequence</th><th colspan="1" rowspan="1"><bold>TR (ms)</bold></th><th colspan="1" rowspan="1"><bold>TE (ms)</bold></th><th colspan="1" rowspan="1"><bold>Flip</bold><break/><bold>Angle</bold></th><th colspan="1" rowspan="1"><bold>Voxel size (mm)</bold></th><th colspan="1" rowspan="1">IPAT<break/>Factor</th><th colspan="1" rowspan="1">Acquisition Time (min:sec)</th><th colspan="1" rowspan="1">Others</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">T1w</td><td align="char" colspan="1" rowspan="1">2300</td><td align="char" colspan="1" rowspan="1">4.7</td><td align="char" colspan="1" rowspan="1">12&#176;</td><td align="left" colspan="1" rowspan="1">1.0x1.0x1.0</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">5:47</td><td align="left" colspan="1" rowspan="1">TI&#160;=&#160;1100 ms</td></tr><tr><td align="left" colspan="1" rowspan="1">SWI</td><td align="char" colspan="1" rowspan="1">29</td><td align="char" colspan="1" rowspan="1">20.0</td><td align="char" colspan="1" rowspan="1">15&#176;</td><td align="left" colspan="1" rowspan="1">0.6x0.6x3.0</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">4:42</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">DTI</td><td align="char" colspan="1" rowspan="1">13000</td><td align="char" colspan="1" rowspan="1">102.0</td><td align="char" colspan="1" rowspan="1">90&#176;</td><td align="left" colspan="1" rowspan="1">2.0x2.0x2.0</td><td align="char" colspan="1" rowspan="1">2</td><td align="char" colspan="1" rowspan="1">7:24</td><td align="left" colspan="1" rowspan="1"># Directions&#160;=&#160;30<break/>Diffusion values: b&#160;=&#160;0 and b&#160;=&#160;1000</td></tr></tbody></table></table-wrap></p></sec><sec id="sec2.5"><label>2.5</label><title>MRI-based decision model</title><p id="p0065">We used the acquired MRI sequences following the guidelines in (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>) to obtain the biomarkers specified in <xref rid="tbl2" ref-type="table">Table 2</xref>.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Specific biomarkers obtained from the MR images:<sup>a</sup>Obtained from T1 weighted scan; <sup>b</sup>Obtained from diffusion tensor imaging (DTI); <sup>c</sup>Obtained from susceptibility-weighted image (SWI).</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Biomarker</th><th colspan="1" rowspan="1">Description</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">MRPI<sup><italic toggle="yes">a</italic></sup></td><td align="left" colspan="1" rowspan="1">Magnetic Resonance Parkinsonian Index: multiply pons-to-midbrain ratio with the ratio of the mean diameters of the middle cerebral peduncle (MCP) to the mean diameters of the superior cerebellar peduncles (SCP) (<xref rid="bib45" ref-type="bibr">Quattrone et al., 2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">MRPI2<sup><italic toggle="yes">a</italic></sup></td><td align="left" colspan="1" rowspan="1">Modification of the MRPI by multiplying it by the ratio of the third ventricle to the frontal horns (<xref rid="bib46" ref-type="bibr">Quattrone et al., 2018</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">T1 PM_ratio<sup><italic toggle="yes">a</italic></sup></td><td align="left" colspan="1" rowspan="1">Pons-to-midbrain ratio (<xref rid="bib33" ref-type="bibr">M&#246;ller et al., 2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">DTI FA SCP<sup><italic toggle="yes">b</italic></sup></td><td align="left" colspan="1" rowspan="1">Average fractional anisotropy in the superior cerebellar peduncles (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>; <xref rid="bib40" ref-type="bibr">Planetta et al., 2016</xref>; <xref rid="bib36" ref-type="bibr">Nicoletti et al., 2008</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">DTI FA CB<sup><italic toggle="yes">b</italic></sup></td><td align="left" colspan="1" rowspan="1">Average fractional anisotropy in the cerebellum (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">DTI FA MCP<sup><italic toggle="yes">b</italic></sup></td><td align="left" colspan="1" rowspan="1">Average fractional anisotropy in the middle cerebral peduncle (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>; <xref rid="bib55" ref-type="bibr">Worker et al., 2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">DTI FA PUT<sup><italic toggle="yes">b</italic></sup></td><td align="left" colspan="1" rowspan="1">Average fractional anisotropy in the putamen (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>; <xref rid="bib55" ref-type="bibr">Worker et al., 2014</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">SWI PUT<sup><italic toggle="yes">c</italic></sup></td><td align="left" colspan="1" rowspan="1">Average value of the SWI in the putamen normalized to the SWI mean in the white matter (<xref rid="bib29" ref-type="bibr">Mazzucchi et al., 2019</xref>; <xref rid="bib49" ref-type="bibr">Sj&#246;str&#246;m et al., 2017</xref>; <xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>; <xref rid="bib11" ref-type="bibr">Gupta et al., 2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">SWI STN<sup><italic toggle="yes">c</italic></sup></td><td align="left" colspan="1" rowspan="1">Average value of the SWI in the substantia nigra normalized to the SWI mean in the white matter (<xref rid="bib29" ref-type="bibr">Mazzucchi et al., 2019</xref>; <xref rid="bib49" ref-type="bibr">Sj&#246;str&#246;m et al., 2017</xref>; <xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>; <xref rid="bib11" ref-type="bibr">Gupta et al., 2010</xref>)</td></tr><tr><td align="left" colspan="1" rowspan="1">SWI RN<sup><italic toggle="yes">c</italic></sup></td><td align="left" colspan="1" rowspan="1">Average value of the SWI in the red nucleus normalized to the SWI mean in the white matter</td></tr></tbody></table></table-wrap></p><p id="p0070">Subsequently, we used the decision model proposed by Seada et al. (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>; <xref rid="bib29" ref-type="bibr">Mazzucchi et al., 2019</xref>; <xref rid="bib49" ref-type="bibr">Sj&#246;str&#246;m et al., 2017</xref>; <xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>; <xref rid="bib11" ref-type="bibr">Gupta et al., 2010</xref>) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) to classify all patients according to the MRI measures.<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Figure and caption from Seada et al. (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>): &#8220;Decision models for differentially diagnosis Parkinson's disease and other parkinsonisms. A shows a model where all biomarkers are considered in a single multi-class classification. The decision tree in B is made up of two binary classifications followed by one multi-class classification. The cut-off values are weighted combinations of individual decision rules. (&#8727;) indicates metrics that overlap between MSA and PSP patients, and thus rely on separating PSP patients in the second stage. CUP: clinically unclassifiable parkinsonism. PD: Parkinson's disease. MSA: multiple system atrophy. PSP: progressive supranuclear palsy. HC: healthy controls. DTI: diffusion tensor imaging. QSM quantitative susceptibility mapping. PUT: putamen. SCP: superior cerebellar peduncle. STN: subthalamic nucleus. RN: red nucleus. MCP: middle cerebellar peduncle. CB: cerebellum. SNpr: substantia nigra pars reticulata. SNpc: substantia nigra pars compacta.&#8221;</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0075">Since we used data acquired for a different study, some limitations urged us to apply the following deviations from the decision model.<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#9679;</label><p id="p0080">We disregarded rules 1 and 2 from the decision model since those are used to differentiate healthy individuals from patients. In practice, it is not as difficult to differentiate healthy individuals from those with CUP compared to the diagnostic challenge later in disease. Therefore, the 2D MT-weighted gradient-echo sequence that can be used to measure neuromelanine volumes was not included in the analyses.</p></list-item><list-item id="u0015"><label>&#9679;</label><p id="p0085">We had to disregard rule 8, which is used to differentiate MSA-C from MSA-P because of the small number of MSA-C patients included (n&#160;=&#160;2)</p></list-item><list-item id="u0020"><label>&#9679;</label><p id="p0090">Because we were unable to retrieve the information needed for QSM, rule 6 was limited to SWI. We considered these susceptibility-weighted images still useful because all the patients were scanned in the same system and with the same parameters, therefore it should be possible to detect differences in iron concentration due to the specific disease (areas with increased mineralization show less signal intensity in the SWI images (<xref rid="bib11" ref-type="bibr">Gupta et al., 2010</xref>)).</p></list-item></list></p><p id="p0095">We used HD-Bet (<xref rid="bib18" ref-type="bibr">Isensee et al., 2019</xref>), FreeSurfer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://surfer.nmr.mgh.harvard.edu" id="intref0010">http://surfer.nmr.mgh.harvard.edu</ext-link> version 7.3.2) recon-all, and brainstem subsegmentation (<xref rid="bib17" ref-type="bibr">Iglesias et al., 2015</xref>; <xref rid="bib4" ref-type="bibr">Bocchetta et al., 2020</xref>) to automatically segment the T1 weighted images and FSL (<xref rid="bib19" ref-type="bibr">Jenkinson et al., 2012</xref>) and RL-atlas (<xref rid="bib50" ref-type="bibr">Tyszka et al., 2022</xref>) to segment and register the DTI and SWI images. Deep gray matter segmentation for SWI uses UNet approaches from swi-cnn (<xref rid="bib2" ref-type="bibr">Beliveau et al., 2021</xref>). No manual correction was needed since the output obtained was visually inspected and it was satisfactory for all the subjects.</p><p id="p0100">These biomarkers can be used all at once (model I) or in different steps (model II) (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>) to classify the disease into PD, MSA, and PSP (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p></sec><sec id="sec2.6"><label>2.6</label><title>Statistical analyses</title><p id="p0105">All the analyses were performed using in-house scripts written in Python. Boxplots of the biomarkers were plotted and a one-way ANOVA was calculated to investigate significant differences between groups.</p><p id="p0110">Subsequently, Bayesian Inference based on the decision models I and II was used to estimate each patient's diagnosis as PD, MSA, or PSP. Subsequently, we could calculate each patient's probability of belonging to the PD, MSA, or PSP group based on the values of their biomarkers. The patient was then classified to the diagnosis with the highest probability. Since the groups' sizes were very different, to obtain a better estimation of the sensitivity, specificity, and accuracy of the methods, we re-ran the Bayesian Inference analysis using bootstrapping (<xref rid="bib56" ref-type="bibr">Zhu, 1997</xref>) by randomly sampling with replacement of 10 subjects from the MSA group and 10 patients from the PD group, besides the 10 subjects from the PSP group. This experiment was run 25000 times and the average and its 95&#160;% confidence interval (<xref rid="bib52" ref-type="bibr">Vangel, 1996</xref>) of the sensitivity, specificity, and accuracy (for both models) were calculated.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Population</title><p id="p0115">A total of 93 patients with an initial diagnosis of CUP were included. Of those, 73 patients had a final clinical diagnosis of PD (n&#160;=&#160;38), PSP (n&#160;=&#160;10), MSA-P (n&#160;=&#160;13), MSA-C (n&#160;=&#160;2) or MSA-u (n&#160;=&#160;10), and thus were included in the imaging analyses. The remaining 20 patients had different clinical diagnoses during follow-up, such as vascular parkinsonism or Lewy body dementia, or they still had uncertain clinical diagnoses by the time of current analyses. Therefore, they were excluded. Demographic and clinical data are summarized in <xref rid="tbl3" ref-type="table">Table 3</xref>.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Mean (and standard deviation) per diagnosis group of Age, Disease Duration (from first symptoms to MRI scan), MMSE score, HY stadium, UPDRS score, and duration of follow-up (from MRI scan to final clinical diagnosis). Number of Female/Male patients in each group is in the third column.</p></caption><alt-text id="alttext0045">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Age</th><th colspan="1" rowspan="1">Gender<break/>Female/Male</th><th colspan="1" rowspan="1">Disease Duration (months)</th><th colspan="1" rowspan="1">MMSE score</th><th colspan="1" rowspan="1">HY stadium</th><th colspan="1" rowspan="1">UPDRS score</th><th colspan="1" rowspan="1">Follow-up (months)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>PD (n=38)</bold></td><td align="char" colspan="1" rowspan="1">61.4 (9.5)</td><td align="char" colspan="1" rowspan="1">16/22</td><td align="char" colspan="1" rowspan="1">24.6 (15.0)</td><td align="char" colspan="1" rowspan="1">28.4 (12.8)</td><td align="char" colspan="1" rowspan="1">1.7 (0.9)</td><td align="char" colspan="1" rowspan="1">32.4 (17.6)</td><td align="char" colspan="1" rowspan="1">27.08 (13.32)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>MSA (n=25)</bold></td><td align="char" colspan="1" rowspan="1">64.2 (8.2)</td><td align="char" colspan="1" rowspan="1">9/16</td><td align="char" colspan="1" rowspan="1">24.3 (14.5)</td><td align="char" colspan="1" rowspan="1">28.3 (14.4)</td><td align="char" colspan="1" rowspan="1">2.4 (1.3)</td><td align="char" colspan="1" rowspan="1">42.5 (22.7)</td><td align="char" colspan="1" rowspan="1">23.07 (13.90)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>PSP (n=10)</bold></td><td align="char" colspan="1" rowspan="1">64.3 (5.25)</td><td align="char" colspan="1" rowspan="1">3/7</td><td align="char" colspan="1" rowspan="1">38.0 (18.9)</td><td align="char" colspan="1" rowspan="1">28.4 (13.8)</td><td align="char" colspan="1" rowspan="1">2.7 (1.4)</td><td align="char" colspan="1" rowspan="1">30.7 (19.5)</td><td align="char" colspan="1" rowspan="1">35.1 (15.77)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Shows the mean, the standard deviation, and the results of the one-way ANOVA analysis per biomarker. All biomarkers related to the atrophy or SWI showed differences in at least two of the patient's groups. Conversely, for the DTI biomarkers, we found no significant differences between groups.</p></caption><alt-text id="alttext0050">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">PD (n&#160;=&#160;38)</th><th colspan="1" rowspan="1">MSA (n&#160;=&#160;25)</th><th colspan="1" rowspan="1">PSP (n&#160;=&#160;10)</th><th colspan="1" rowspan="1">F-value</th><th colspan="1" rowspan="1">P-value</th><th colspan="1" rowspan="1">Significant differences</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>MRPI</bold></td><td align="left" colspan="1" rowspan="1">143.054 (36.019)</td><td align="char" colspan="1" rowspan="1">142.024 (48.005)</td><td align="char" colspan="1" rowspan="1">210.761 (56.858)</td><td align="char" colspan="1" rowspan="1">10.589</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;4</sup></td><td align="left" colspan="1" rowspan="1">PSP&gt;(PD &amp; MSA)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>MRPI2</bold></td><td align="left" colspan="1" rowspan="1">32.964 (13.7359</td><td align="char" colspan="1" rowspan="1">33.539 (16.816)</td><td align="char" colspan="1" rowspan="1">59.316 (25.985)</td><td align="char" colspan="1" rowspan="1">10.397</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;3</sup></td><td align="left" colspan="1" rowspan="1">PSP&gt;(PD &amp; MSA)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>T1 PM ratio</bold></td><td align="left" colspan="1" rowspan="1">3.414 (0.573)</td><td align="char" colspan="1" rowspan="1">3.421 (0.738)</td><td align="char" colspan="1" rowspan="1">4.753 (0.927)</td><td align="char" colspan="1" rowspan="1">16.396</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;6</sup></td><td align="left" colspan="1" rowspan="1">PSP&gt;(PD &amp; MSA)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>DTI FA SCP</bold></td><td align="left" colspan="1" rowspan="1">670.262 (51.586)</td><td align="char" colspan="1" rowspan="1">638.731 (107.831)</td><td align="char" colspan="1" rowspan="1">623.115 (71.839)</td><td align="char" colspan="1" rowspan="1">2.092</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>DTI FA CB</bold></td><td align="left" colspan="1" rowspan="1">490.666 (44.345)</td><td align="char" colspan="1" rowspan="1">476.603 (65.668)</td><td align="char" colspan="1" rowspan="1">482.678 (37.284)</td><td align="char" colspan="1" rowspan="1">0.562</td><td align="left" colspan="1" rowspan="1">0.57</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>DTI FA MCP</bold></td><td align="left" colspan="1" rowspan="1">518.756 (62.025)</td><td align="char" colspan="1" rowspan="1">484.072 (88.165)</td><td align="char" colspan="1" rowspan="1">529.740 (25.134)</td><td align="char" colspan="1" rowspan="1">2.450</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>DTI FA STN</bold></td><td align="left" colspan="1" rowspan="1">527.369 (94.702)</td><td align="char" colspan="1" rowspan="1">532.173 (72.043)</td><td align="char" colspan="1" rowspan="1">497.292 (93.808)</td><td align="char" colspan="1" rowspan="1">0.600</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>DTI FA PUT</bold></td><td align="left" colspan="1" rowspan="1">430.992 (49.452)</td><td align="char" colspan="1" rowspan="1">429.342 (49.454)</td><td align="char" colspan="1" rowspan="1">446.568 (38.18)</td><td align="char" colspan="1" rowspan="1">0.499</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>SWI PUT</bold></td><td align="left" colspan="1" rowspan="1">0.925 (0.083)</td><td align="char" colspan="1" rowspan="1">0.804 (0.118)</td><td align="char" colspan="1" rowspan="1">0.796 (0.168)</td><td align="char" colspan="1" rowspan="1">11.442</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;4</sup></td><td align="left" colspan="1" rowspan="1">PD &gt; MSA&#160;&gt;&#160;PSP</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>SWI STN</bold></td><td align="left" colspan="1" rowspan="1">0.941 (0.103)</td><td align="char" colspan="1" rowspan="1">0.842 (0.141)</td><td align="char" colspan="1" rowspan="1">0.698 (0.258)</td><td align="char" colspan="1" rowspan="1">12.055</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;4</sup></td><td align="left" colspan="1" rowspan="1">PD &gt; MSA&#160;&gt;&#160;PSP</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>SWI RN</bold></td><td align="left" colspan="1" rowspan="1">0.921 (0.049)</td><td align="char" colspan="1" rowspan="1">0.857 (0.111)</td><td align="char" colspan="1" rowspan="1">0.703 (0.256)</td><td align="char" colspan="1" rowspan="1">10.289</td><td align="left" colspan="1" rowspan="1">&lt;10<sup>&#8722;3</sup></td><td align="left" colspan="1" rowspan="1">PD &gt; MSA&#160;&gt;&#160;PSP</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec4"><label>4</label><title>MRI biomarkers analyses</title><p id="p0120">Based on the results of the ANOVA, we decided to exclude the DTI biomarkers from the decision model, since there were no significant group differences. Thus, we disregarded rules 4 and 7, and only used rules 3, 5, and 6 in our model.(see <xref rid="tbl4" ref-type="table">Table 4</xref>)</p><p id="p0125"><xref rid="fig2" ref-type="fig">Fig. 2</xref> shows the boxplots for the atrophy biomarkers related to rules 3 and 5. Values for patients with MSA or PD were distinct from those of patients with PSP (rule 3). However, the difference between MSAc patients and PD patients (rule 5) was less obvious. <xref rid="fig3" ref-type="fig">Fig. 3</xref> shows boxplots for the SWI MRI measures used for rule 6 comparing MSA patients versus PD patients. Although the ANOVA showed significant differences between the 3 groups, the boxplots show some overlap between the different patient groups.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Boxplots of the atrophy biomarkers (MRPI - left -, MRPI2 - middle -, T1 PM_ratio - right -) for Parkinson's disease (PD), multiple system atrophy (MSA) - cerebellar (MSAc), parkinsonian (MSAp) or unclassified (MSAu), progressive supranuclear palsy (PSP), clinically unclassifiable parkinsonism (CUP).</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Boxplots of the SWI biomarkers in the putamen (left), substantia nigra (middle) and red nucleus (right) for Parkinson's disease (PD), multiple system atrophy (MSA) - cerebellar (MSAc), parkinsonian (MSAp) or unclassified (MSAu), progressive supranuclear palsy (PSP), and clinically unclassifiable parkinsonism (CUP).</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec5"><label>5</label><title>Bayesian Inference</title><p id="p0130">Next, we used Bayesian Inference with the selected biomarking using models I and II to classify each patient as PD, MSA, or PSP. Of the total group, 43 (59&#160;%) and 41 (56&#160;%) patients were correctly classified into their final clinical diagnosis by model I and II respectively.</p><p id="p0135"><xref rid="tbl5" ref-type="table">Table 5</xref> shows the sensitivity, specificity, and accuracy of both models. These parameters are calculated per group, considering in each case the patients included in that group as &#8216;positives&#8217;, and the rest of the patients as &#8216;negatives&#8217;. Both models performed moderately accurately in classifying MSA and PD (accuracy higher than 0.60) and quite well in classifying PSP (accuracy higher than 0.85). Both models have high specificity for diagnosing MSA and PSP with lower sensitivity, while for PD sensitivity and specificity are both around 60&#160;%. Model I seems to perform slightly better than model II, additional details for model I are provided in the Supplementary data.</p><p id="p0140">Subsequently, we used bootstrapping with 25.000 iterations to calculate the average and 95&#160;% confidence intervals for sensitivity, specificity, and accuracy for both models, also shown in <xref rid="tbl5" ref-type="table">Table 5</xref>. The estimations reached a steady state around the 15000 iterations (<xref rid="appsec1" ref-type="sec">Supplementary Fig. S1</xref>).<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Sensitivity, specificity, and accuracy classifying Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) using the classification model I (multi-class with all the biomarkers at once) and the classification model II (two binary classifications, first to separate PSP from the rest and second to separate MSA from PD). Columns 2 to 4 report the results using simple Bayesian inference and columns 5 to 7 report the average (and its 95&#160;% confidence interval) calculated using 25000 iterations with bootstrapping. The sensitivity, specificity and accuracy are calculated per group, considering the specific group as &#8216;positives&#8217; and the other 2 groups together as &#8216;negatives&#8217;.</p></caption><alt-text id="alttext0055">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="3" rowspan="1">Bayesian Inference</th><th colspan="3" rowspan="1">Bayesian Inference with bootstrapping</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Model 1</italic></td><td align="left" colspan="1" rowspan="1">PD (n&#160;=&#160;38)</td><td align="left" colspan="1" rowspan="1">MSA (n&#160;=&#160;25)</td><td align="left" colspan="1" rowspan="1">PSP (n&#160;=&#160;10)</td><td align="left" colspan="1" rowspan="1">PD (n&#160;=&#160;38)</td><td align="left" colspan="1" rowspan="1">MSA (n&#160;=&#160;25)</td><td align="left" colspan="1" rowspan="1">PSP (n&#160;=&#160;10)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Sensitivity</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">0.492 (0.490&#8211;0.494)</td><td align="left" colspan="1" rowspan="1">0.520 (0.518&#8211;0.522)</td><td align="left" colspan="1" rowspan="1">0.615 (0.614&#8211;0.616)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Specificity</td><td align="left" colspan="1" rowspan="1">0.57</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">0.683 (0.682&#8211;0.684)</td><td align="left" colspan="1" rowspan="1">0.748 (0.747&#8211;0.749)</td><td align="left" colspan="1" rowspan="1">0.882 (0.881&#8211;0.883)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Accuracy</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">0.66</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.619 (0.618&#8211;0.620)</td><td align="left" colspan="1" rowspan="1">0.672 (0.671&#8211;0.673)</td><td align="left" colspan="1" rowspan="1">0.793 (0.792&#8211;0.794)</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Model 2</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Sensitivity</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">0.36</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">0.443 (0.441&#8211;0.445)</td><td align="left" colspan="1" rowspan="1">0.443 (0.441&#8211;0.445)</td><td align="left" colspan="1" rowspan="1">0.655 (0.655-, 0.656)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Specificity</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.755 (0.754&#8211;0.756)</td><td align="left" colspan="1" rowspan="1">0.724 (0.723-0.725)</td><td align="left" colspan="1" rowspan="1">0.826 (0.825,- 0.826)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Accuracy</td><td align="left" colspan="1" rowspan="1">0.64</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">0.673 (0.672-0.674)</td><td align="left" colspan="1" rowspan="1">0.630 (0.629-0.631)</td><td align="left" colspan="1" rowspan="1">0.769 (0.768-,0.769)</td></tr></tbody></table></table-wrap></p><sec id="sec5.1"><label>5.1</label><title>Outliers analysis</title><p id="p0145"><xref rid="fig4" ref-type="fig">Fig. 4</xref> shows the scatter plot of the three selected MR biomarkers for the three different diagnoses. We consider as outliers those patients who visually are far from other patients with the same diagnosis in at least one of the biomarkers. The plot shows four possible outliers circled in purple (outlier 1), with higher MRPI2 than the rest of MSA patients; orange (outlier 2), with higher MRPI2 than other PD patients; gray (outlier 3), with higher SWI PUT than other MSA patients with similar MRPI2 and T1 PM_ratio; and blue (outlier 4), with lower MRPI2 and T1 PM_ratio than other MSA patients.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Scatter plot of the T1 PM_ratio versus MRPI2 and scaled-colored according to the SWI values in the putamen with triangles for multiple system atrophy (MSA), stars for Parkinson's disease (PD), and spheres for progressive supranuclear palsy (PSP).</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0150">Three out of these four outliers (cases 1, 2, and 3) were misclassified using Bayesian Inference, as shown in <xref rid="tbl6" ref-type="table">Table 6</xref>. For the outlier 1 there is still some doubt about the clinical diagnosis between MSA and PSP, but MSA was clinically more likely and the model classifies this case as PSP. For the outliers 2 and 3 there is no doubt about the clinical diagnosis. For the outlier 4 the clinical diagnosis is MSA, which is also how the model classified this case, but there is some clinical doubt of possible PD diagnosis.<table-wrap position="float" id="tbl6" orientation="portrait"><label>Table 6</label><caption><p>Summary of the results of the Bayesian Inference classification for the outliers observed as outliers in the scatter plot (<xref rid="fig4" ref-type="fig">Fig. 4</xref>).</p></caption><alt-text id="alttext0060">Table 6</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Case</th><th colspan="1" rowspan="1">Final clinical<break/>Diagnosis</th><th colspan="1" rowspan="1">MSA (%)</th><th colspan="1" rowspan="1">PD (%)</th><th colspan="1" rowspan="1">PSP (%)</th><th colspan="1" rowspan="1">Predicted</th><th colspan="1" rowspan="1">Age</th><th colspan="1" rowspan="1">Gender</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Outlier 1</td><td align="left" colspan="1" rowspan="1">MSA</td><td align="char" colspan="1" rowspan="1">00.01</td><td align="char" colspan="1" rowspan="1">00.08</td><td align="char" colspan="1" rowspan="1">99.91</td><td align="left" colspan="1" rowspan="1">False</td><td align="char" colspan="1" rowspan="1">76</td><td align="left" colspan="1" rowspan="1">Male</td></tr><tr><td align="left" colspan="1" rowspan="1">Outlier 2</td><td align="left" colspan="1" rowspan="1">PD</td><td align="char" colspan="1" rowspan="1">01.36</td><td align="char" colspan="1" rowspan="1">00.44</td><td align="char" colspan="1" rowspan="1">98.20</td><td align="left" colspan="1" rowspan="1">False</td><td align="char" colspan="1" rowspan="1">79</td><td align="left" colspan="1" rowspan="1">Female</td></tr><tr><td align="left" colspan="1" rowspan="1">Outlier 3</td><td align="left" colspan="1" rowspan="1">MSA-C</td><td align="char" colspan="1" rowspan="1">35.25</td><td align="char" colspan="1" rowspan="1">52.15</td><td align="char" colspan="1" rowspan="1">12.60</td><td align="left" colspan="1" rowspan="1">False</td><td align="char" colspan="1" rowspan="1">58</td><td align="left" colspan="1" rowspan="1">Male</td></tr><tr><td align="left" colspan="1" rowspan="1">Outlier 4</td><td align="left" colspan="1" rowspan="1">MSA</td><td align="char" colspan="1" rowspan="1">58.94</td><td align="char" colspan="1" rowspan="1">01.80</td><td align="char" colspan="1" rowspan="1">39.27</td><td align="left" colspan="1" rowspan="1">True</td><td align="char" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">Female</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="sec6"><label>6</label><title>Discussion</title><p id="p0155">In this study, we applied a previously proposed (<xref rid="bib47" ref-type="bibr">Seada et al., 2023</xref>) decision model based on quantitative MRI biomarkers on an available data set to explore its potential. We automatize the process without human interaction, therefore, the classification was blind to patient's known follow up. The strength of this study was its innovative approach, namely by including people only with an uncertain diagnosis at the time of scanning. These baseline results were compared to a silver standard diagnosis that was obtained after follow-up, based on rate of progression, development of additional red flags, and the treatment response. This allowed us to ascertain the value of neuroimaging performed at a time when it was needed most, namely when the clinician had diagnostic uncertainty. The model correctly classified 59&#160;% of patients (43 out of 73) into their final clinical diagnosis of PD, MSA, or PSP that was obtained at follow-up. These results suggest potential for quantitative MRI in improving diagnostics in the earliest stages of the disease, at a time when clinicians need ancillary testing to reduce their clinical uncertainty. Being able to establish an accurate diagnosis earlier in the disease course is important for many reasons, in particular to offer affected individuals their actual diagnosis and, within margins, an estimate of their possible prognosis. A timely diagnosis is also helpful to raise early awareness for specific disease complications, such as nocturnal sudden death due to stridor in patients with MSA. And an early accurate diagnosis helps with including the right patients for the right trials.</p><p id="p0160">The 8-rules method was reduced to the three most useful rules for different reasons. First, the two initial rules are used to distinguish between healthy and non-healthy subjects. Healthy controls were not included in this study since this distinction is not so challenging in clinical practice. Secondly, we decided to discard the rules based on DTI (4 and 7) because ANOVA analyses showed no significant differences between PD, MSA, and PSP. Finally, we didn't include rule 8, which is focused on distinguishing between MSAp and MSAc, because the number of patients with MSAc was too low.</p><p id="p0165">The lack of differences between patient groups in DTI biomarkers contrasts previous findings in the literature (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>; <xref rid="bib55" ref-type="bibr">Worker et al., 2014</xref>). One reason for this could be that we only used fractional anisotropy, while previous studies indicate possible benefits from adding other DTI-related measurements, including diffusion anisotropy, radial diffusivity, longitudinal diffusivity, and mean diffusivity in different regions of interest) to improve classification (<xref rid="bib40" ref-type="bibr">Planetta et al., 2016</xref>; <xref rid="bib42" ref-type="bibr">Prodoehl et al., 2013</xref>) or DTI in combination with other measurements as apparent transverse relaxation (<xref rid="bib8" ref-type="bibr">Du et al., 2017</xref>). However, the results are inconsistent (<xref rid="bib32" ref-type="bibr">Min et al., 2018</xref>). Also, the segmentation of the peduncles is very challenging since they are tiny structures and a relatively thick slice-thickness (5&#160;mm) can hinder a correct segmentation. In future studies, it could be useful to increase the resolution and to include more DTI-biomarkers and evaluate if the combination of them helps to improve the classifications.</p><p id="p0170">We used two different models: model I performs one single multi-classification with all the biomarkers available, whereas model II uses a two-step classification where patients are first classified as PSP or no PSP and then the latter group is further classified as PD or MSA. Our results show a slightly better performance of model I. In this case, it could be because there are differences in atrophy between PD and MSA, therefore, using them as a single group to compare with PSP makes the differences less obvious than separately comparing PSP vs PD and PSP vs MSA (<xref rid="bib45" ref-type="bibr">Quattrone et al., 2008</xref>; <xref rid="bib33" ref-type="bibr">M&#246;ller et al., 2017</xref>; <xref rid="bib26" ref-type="bibr">Mangesius et al., 2018</xref>). The estimations showed good specificity but lower sensitivity for classification and better accuracy for PSP than the rest. One explanation for this is the fact that patterns of atrophy are most distinct for PSP (<xref rid="bib45" ref-type="bibr">Quattrone et al., 2008</xref>, <xref rid="bib46" ref-type="bibr">2018</xref>; <xref rid="bib33" ref-type="bibr">M&#246;ller et al., 2017</xref>; <xref rid="bib27" ref-type="bibr">Mangesius et al., 2020</xref>), while atrophy measurements for PD and MSA greatly overlap and thus it is harder to differentiate from each other. Moreover, due to the low number of patients with MSA-C we had to lump all MSA cases together for the analyses, which could have led to lower accuracy. For instance, atrophy was reported to distinguish PD from MSAc (<xref rid="bib33" ref-type="bibr">M&#246;ller et al., 2017</xref>). Finally, rule 6 is supposed to use QSM-based iron concentrations to differentiate between MSA and PD (<xref rid="bib29" ref-type="bibr">Mazzucchi et al., 2019</xref>; <xref rid="bib49" ref-type="bibr">Sj&#246;str&#246;m et al., 2017</xref>) but here we used non-quantitative SWI which could be less robust and hamper a proper classification (<xref rid="bib43" ref-type="bibr">Pyatigorskaya et al., 2020a</xref>). Iron concentration (either using SWI or QSM) has been reported as a helpful biomarker (<xref rid="bib43" ref-type="bibr">Pyatigorskaya et al., 2020a</xref>; <xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>, <xref rid="bib31" ref-type="bibr">2016</xref>; <xref rid="bib11" ref-type="bibr">Gupta et al., 2010</xref>), specially evident in MASp patients (<xref rid="bib30" ref-type="bibr">Meijer et al., 2015</xref>; <xref rid="bib16" ref-type="bibr">Hwang et al., 2015</xref>). Some overlap can be noted between patients groups since these susceptibility changes of the lentiform nucleus can be seen in several disorders, and even as part of normal ageing. However, the combination of these susceptibility changes with putaminal atrophy is diagnostically specific for MSAp. This highlight the importance of an integrated assessment of imaging findings (<xref rid="bib6" ref-type="bibr">Chung et al., 2009</xref>) as we demonstrated here using SWI in combination with atrophy to classify PD, MSA, and PSP. We also hypothesize that the use of QSM instead of SWI would improve the accuracy and robustness of the method overall in differentiating between MSA and PD patients.</p><p id="p0175">The accuracy can also be limited by the simplicity of the classification model (Bayesian Inference), which could be improved by the use of DeepLearning models where more characteristics and properties could be considered to infer the actual diagnosis. However, to perform such an analysis much more patients than the current cohort are needed (at least 30 patients per group). The recruitment and assessment of more patients towards a more precise model is encouraged by the insights obtained in this pilot study.</p><p id="p0180">Regarding the four outliers that we depicted, 3 of them were incorrectly classified. Outliers 1 and 2 have diagnoses as MSA and PD respectively, but our classifier detects it as PSP. Both have higher MRPI2 than the MSA or PD group, which has been shown as characteristic in PSP patients (<xref rid="bib45" ref-type="bibr">Quattrone et al., 2008</xref>, <xref rid="bib46" ref-type="bibr">2018</xref>). In the follow-up, however, there are only doubts about the clinical diagnosis for the first case. Outlier 3 has a higher SWI in putamen than expected, which is associated with PD and it is how our model is classifying it. After reviewing the case by our specialist, it has the same diagnosis but follow-up would be recommended. The progression of the disease in these cases would be interesting feedback to further evaluate the performance of this model. The last case (oulier 4) is correctly classified. We pointed it as an outlier for having smaller values than the rest, but it can be also that it is not an actual outlier since the proportions are coherent (lower T1 PM_ratio with lower MRPI2 and lower SWI in the putamen), therefore the biomarkers are statistically similar to the rest of MSA patients (<xref rid="fig4" ref-type="fig">Fig. 4</xref>) and it is correctly classified.</p><p id="p0185">This study has two major strengths; one is the inclusion of biomarkers obtained from different types of images; and the other is that the MRI scans were acquired at an early stage of the disease at a time when the clinical diagnosis was uncertain. Most previous studies are based on patients with clear diagnoses and thus those conclusions may not be applicable to the early stages. Moreover, patients had clinical follow-ups, probably increasing the accuracy of the final clinical diagnosis. However, as stated before, even in the late stages of the disease there is a high rate of misdiagnoses (<xref rid="bib15" ref-type="bibr">Hughes et al., 2002</xref>; <xref rid="bib22" ref-type="bibr">Joutsa et al., 2014</xref>). It is possible that misclassified patients, such as outliers 1&#8211;3, actually have a different pathological diagnosis. Thus, a study with pathological confirmation of diagnoses through autopsy would be ideal, but it would be even more difficult to recruit sufficient numbers for adequate analyses.</p></sec><sec id="sec7"><label>7</label><title>Conclusion</title><p id="p0190">In summary, we applied a quantitative MRI-based decision model to a cohort of patients with PD, MSA, and PSP who had undergone MRI in the early stage of the disease when clinical diagnosis was uncertain. We showed that a combination of atrophy and SWI biomarkers can correctly classify 59&#160;% of patients into their final clinical diagnosis. These results are very promising and urge further studies with a higher number of patients per diagnosis and additional MR biomarkers to optimize and validate the decision model.</p></sec><sec id="sec8"><title>Code Availability</title><p id="p0195">The scripts used in this study were customized to our systems and files to automatize the tools mentioned in the &#8216;Methods&#8217; section and facilitate our processing. However, it doesn't include any novelty. Hence the code is not disclosed publicly.</p></sec><sec id="sec9"><title>CRediT authorship contribution statement</title><p id="p0200"><bold>Laura Nunez-Gonzalez:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. <bold>Elise G.P. Dopper:</bold> Writing &#8211; review &amp; editing, Visualization, Resources, Methodology, Investigation. <bold>Anke W. van der Eerden:</bold> Writing &#8211; review &amp; editing, Visualization, Resources, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Samy Abo Seada:</bold> Writing &#8211; review &amp; editing, Visualization, Validation, Software, Methodology, Investigation, Funding acquisition, Conceptualization. <bold>Agnita J.W. Boon:</bold> Writing &#8211; review &amp; editing, Visualization, Methodology, Conceptualization. <bold>Marcel M. Verbeek:</bold> Writing &#8211; review &amp; editing, Validation, Supervision, Resources, Investigation, Funding acquisition, Data curation. <bold>Bastiaan R. Bloem:</bold> Writing &#8211; review &amp; editing, Validation, Supervision, Resources, Investigation, Funding acquisition, Data curation. <bold>Frederick Jan Anton Meijer:</bold> Writing &#8211; review &amp; editing, Visualization, Validation, Resources, Methodology, Investigation, Data curation, Conceptualization. <bold>Juan Antonio Hernandez-Tamames:</bold> Writing &#8211; review &amp; editing, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of Competing interest</title><p id="p0205">Prof. Bloem serves as the co-Editor in Chief for the Journal of Parkinson's disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received fees from serving on the scientific advisory board for the Critical Path Institute, Gyenno Science, MedRhythms, UCB, Kyowa Kirin and Zambon (paid to the Institute), has received fees for speaking at conferences from AbbVie, Bial, Biogen, GE Healthcare, Oruen, Roche, UCB and Zambon (paid to the Institute), and has received research support from <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005614</institution-id><institution>Biogen</institution></institution-wrap></funding-source>, <funding-source id="gs14">Cure Parkinson's</funding-source>, <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009862</institution-id><institution>Davis Phinney Foundation</institution></institution-wrap></funding-source>, <funding-source id="gs15">Edmond J. Safra Foundation</funding-source>, <funding-source id="gs16">Fred Foundation</funding-source>, <funding-source id="gs17">Gatsby Foundation</funding-source>, <funding-source id="gs18">Hersenstichting Nederland</funding-source>, <funding-source id="gs19">Horizon 2020</funding-source>, <funding-source id="gs20">IRLAB Therapeutics</funding-source>, <funding-source id="gs21">Maag Lever Darm Stichting</funding-source>, <funding-source id="gs22">Michael J Fox Foundation</funding-source>, <funding-source id="gs23">Ministry of Agriculture</funding-source>, <funding-source id="gs24">Ministry of Economic Affairs &amp; Climate Policy</funding-source>, <funding-source id="gs25">Ministry of Health</funding-source>, <funding-source id="gs26">Welfare and Sport</funding-source>, <funding-source id="gs27">Netherlands Organization for Scientific Research</funding-source> (ZonMw), <funding-source id="gs28">Not Impossible</funding-source>, <funding-source id="gs29">Parkinson Vereniging</funding-source>, <funding-source id="gs30">Parkinson's Foundation</funding-source>, <funding-source id="gs31">Parkinson's UK</funding-source>, <funding-source id="gs32">Stichting Alkemade-Keuls</funding-source>, <funding-source id="gs33">Stichting Parkinson NL</funding-source>, <funding-source id="gs34">Stichting Woelse Waard</funding-source>, <funding-source id="gs35">Health Holland/Topsector Life Sciences and Health</funding-source>, <funding-source id="gs36">UCB</funding-source>, <funding-source id="gs37">Verily Life Sciences, Roche and Zambon</funding-source>.</p><p id="p0210">The other authors don't declare any conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Imaging the substantia nigra in Parkinson disease and other parkinsonian syndromes</article-title><source>Radiology</source><volume>300</volume><year>2021</year><fpage>260</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1148/radiol.2021203341</pub-id><pub-id pub-id-type="pmid">34100679</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Beliveau</surname><given-names>V.</given-names></name><name name-style="western"><surname>N&#248;rgaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Birkl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Seppi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scherfler</surname><given-names>C.</given-names></name></person-group><article-title>Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging</article-title><source>Hum. Brain Mapp.</source><volume>42</volume><year>2021</year><fpage>4809</fpage><lpage>4822</lpage><pub-id pub-id-type="doi">10.1002/hbm.25604</pub-id><pub-id pub-id-type="pmid">34322940</pub-id><pub-id pub-id-type="pmcid">PMC8449109</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>C.</given-names></name></person-group><article-title>Parkinson's disease</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Bocchetta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chelban</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jabbari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Automated brainstem segmentation detects differential involvement in atypical parkinsonian syndromes</article-title><source>J. Mod. Dynam.</source><volume>13</volume><year>2020</year><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.14802/jmd.19030</pub-id><pub-id pub-id-type="pmcid">PMC6987532</pub-id><pub-id pub-id-type="pmid">31552724</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Chougar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pyatigorskaya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Degos</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grabli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leh&#233;ricy</surname><given-names>S.</given-names></name></person-group><article-title>The role of magnetic resonance imaging for the diagnosis of atypical parkinsonism</article-title><source>Front. Neurol.</source><volume>11</volume><year>2020</year><fpage>665</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00665</pub-id><pub-id pub-id-type="pmid">32765399</pub-id><pub-id pub-id-type="pmcid">PMC7380089</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Eun</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Usefulness of diffusion-weighted MRI for differentiation between Parkinson's disease and Parkinson variant of multiple system atrophy</article-title><source>J. Mod. Dynam.</source><volume>2</volume><year>2009</year><fpage>64</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.14802/jmd.09017</pub-id><pub-id pub-id-type="pmcid">PMC4027714</pub-id><pub-id pub-id-type="pmid">24868359</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Delpirou Nouh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>K.</given-names></name></person-group><article-title>Diagnosis and management of progressive corticobasal syndrome</article-title><source>Curr. Treat. Options Neurol.</source><volume>26</volume><year>2024</year><fpage>319</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1007/s11940-024-00797-4</pub-id><pub-id pub-id-type="pmid">39886562</pub-id><pub-id pub-id-type="pmcid">PMC11781596</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kanekar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Combined diffusion tensor imaging and apparent transverse relaxation rate differentiate Parkinson disease and atypical parkinsonism</article-title><source>AJNR Am J Neuroradiol</source><volume>38</volume><year>2017</year><fpage>966</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A5136</pub-id><pub-id pub-id-type="pmid">28364007</pub-id><pub-id pub-id-type="pmcid">PMC5433885</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>P.R.</given-names></name></person-group><article-title>Mini-mental state</article-title><source>J. Psychiatr. Res.</source><volume>12</volume><year>1975</year><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Goetz</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Shaftman</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Stebbins</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Fahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martinez&#8208;Martin</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Movement disorder society&#8208;sponsored revision of the unified Parkinson's disease rating scale (MDS&#8208;UPDRS): scale presentation and clinimetric testing results</article-title><source>Mov. Disord.</source><volume>23</volume><year>2008</year><fpage>2129</fpage><lpage>2170</lpage><pub-id pub-id-type="doi">10.1002/mds.22340</pub-id><pub-id pub-id-type="pmid">19025984</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kesavadas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sarma</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Kishore</surname><given-names>A.</given-names></name></person-group><article-title>Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism</article-title><source>Neuroradiology</source><volume>52</volume><year>2010</year><fpage>1087</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1007/s00234-010-0677-6</pub-id><pub-id pub-id-type="pmid">20358367</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghassaban</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jokar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease</article-title><source>Neuroimage</source><volume>230</volume><year>2021</year><object-id pub-id-type="publisher-id">117810</object-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.117810</pub-id><pub-id pub-id-type="pmid">33524572</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Heim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krismer</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Marzi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seppi</surname><given-names>K.</given-names></name></person-group><article-title>Magnetic resonance imaging for the diagnosis of Parkinson's disease</article-title><source>J. Neural Transm.</source><volume>124</volume><year>2017</year><fpage>915</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1007/s00702-017-1717-8</pub-id><pub-id pub-id-type="pmid">28378231</pub-id><pub-id pub-id-type="pmcid">PMC5514207</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;glinger</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>Respondek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stamelou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kurz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Josephs</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP</article-title><source>Mov. Disord.</source><volume>32</volume><year>2017</year><fpage>853</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1002/mds.26987</pub-id><pub-id pub-id-type="pmid">28467028</pub-id><pub-id pub-id-type="pmcid">PMC5516529</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ben&#8208;Shlomo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A.J.</given-names></name></person-group><article-title>The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service</article-title><source>Brain</source><volume>125</volume><year>2002</year><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1093/brain/awf080</pub-id><pub-id pub-id-type="pmid">11912118</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Differentiation of parkinsonism-predominant multiple system atrophy from idiopathic Parkinson disease using 3T susceptibility-weighted MR imaging, focusing on putaminal change and lesion asymmetry</article-title><source>AJNR Am J Neuroradiol</source><volume>36</volume><year>2015</year><fpage>2227</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A4442</pub-id><pub-id pub-id-type="pmid">26338919</pub-id><pub-id pub-id-type="pmcid">PMC7964268</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Iglesias</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Van Leemput</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Casillas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dutt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schuff</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Bayesian segmentation of brainstem structures in MRI</article-title><source>Neuroimage</source><volume>113</volume><year>2015</year><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.02.065</pub-id><pub-id pub-id-type="pmid">25776214</pub-id><pub-id pub-id-type="pmcid">PMC4434226</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Isensee</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pflueger</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brugnara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonekamp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neuberger</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Automated brain extraction of multisequence MRI using artificial neural networks</article-title><source>Hum. Brain Mapp.</source><volume>40</volume><year>2019</year><fpage>4952</fpage><lpage>4964</lpage><pub-id pub-id-type="doi">10.1002/hbm.24750</pub-id><pub-id pub-id-type="pmid">31403237</pub-id><pub-id pub-id-type="pmcid">PMC6865732</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Jenkinson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>T.E.J.</given-names></name><name name-style="western"><surname>Woolrich</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name></person-group><article-title>Fsl</article-title><source>Neuroimage</source><volume>62</volume><year>2012</year><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.09.015</pub-id><pub-id pub-id-type="pmid">21979382</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ruf</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Compta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Porcel</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Troakes</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Impact of magnetic resonance imaging markers on the diagnostic performance of the international Parkinson and movement disorder society multiple system atrophy criteria</article-title><source>Mov. Disord.</source><year>2024</year><object-id pub-id-type="publisher-id">29879</object-id><pub-id pub-id-type="doi">10.1002/mds.29879</pub-id><pub-id pub-id-type="pmcid">PMC12403858</pub-id><pub-id pub-id-type="pmid">38847384</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Combined Visualization of Nigrosome-1 and Neuromelanin in the Substantia Nigra Using 3T MRI for the Differential Diagnosis of Essential Tremor and de novo Parkinson's Disease</article-title><source>Front. Neurol.</source><volume>10</volume><year>2019</year><fpage>100</fpage><pub-id pub-id-type="doi">10.3389/fneur.2019.00100</pub-id><pub-id pub-id-type="pmid">30809189</pub-id><pub-id pub-id-type="pmcid">PMC6379476</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Joutsa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gardberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>R&#246;ytt&#228;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaasinen</surname><given-names>V.</given-names></name></person-group><article-title>Diagnostic accuracy of parkinsonism syndromes by general neurologists</article-title><source>Park. Relat. Disord.</source><volume>20</volume><year>2014</year><fpage>840</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.04.019</pub-id><pub-id pub-id-type="pmid">24816002</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Lehericy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vaillancourt</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Seppi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Monchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rektorova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Antonini</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The role of high&#8208;field magnetic resonance imaging in parkinsonian disorders: pushing the boundaries forward</article-title><source>Mov. Disord.</source><volume>32</volume><year>2017</year><fpage>510</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1002/mds.26968</pub-id><pub-id pub-id-type="pmid">28370449</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="book" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><part-title>Stratified Parkinsonism classification based on multi-modality MRI</part-title><year>2022</year></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>R.Y.</given-names></name></person-group><article-title>Epidemiology of atypical parkinsonian syndromes</article-title><source>Tzu Chi Med. J.</source><volume>34</volume><year>2022</year><fpage>169</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.4103/tcmj.tcmj_218_20</pub-id><pub-id pub-id-type="pmid">35465274</pub-id><pub-id pub-id-type="pmcid">PMC9020244</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Mangesius</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hussl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krismer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mahlknecht</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tagwercher</surname><given-names>S.</given-names></name><etal/></person-group><article-title>MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP</article-title><source>Park. Relat. Disord.</source><volume>46</volume><year>2018</year><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.10.020</pub-id><pub-id pub-id-type="pmid">29126761</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Mangesius</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mariotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pereverzyev</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lerchner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers</article-title><source>Park. Relat. Disord.</source><volume>77</volume><year>2020</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.05.033</pub-id><pub-id pub-id-type="pmid">32622301</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Massey</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Paviour</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy</article-title><source>Neurology</source><volume>80</volume><year>2013</year><fpage>1856</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318292a2d2</pub-id><pub-id pub-id-type="pmid">23616165</pub-id><pub-id pub-id-type="pmcid">PMC3908351</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Mazzucchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frosini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Costagli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Prete</surname><given-names>E.</given-names></name><name name-style="western"><surname>Donatelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cecchi</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Quantitative susceptibility mapping in atypical Parkinsonisms</article-title><source>Neuroimage: Clinical</source><volume>24</volume><year>2019</year><object-id pub-id-type="publisher-id">101999</object-id><pub-id pub-id-type="doi">10.1016/j.nicl.2019.101999</pub-id><pub-id pub-id-type="pmcid">PMC6812245</pub-id><pub-id pub-id-type="pmid">31539801</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>F.J.A.</given-names></name><name name-style="western"><surname>Van Rumund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fasen</surname><given-names>B.A.C.M.</given-names></name><name name-style="western"><surname>Titulaer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Susceptibility-weighted imaging improves the diagnostic accuracy of 3T brain MRI in the work-up of parkinsonism</article-title><source>AJNR Am J Neuroradiol</source><volume>36</volume><year>2015</year><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A4140</pub-id><pub-id pub-id-type="pmid">25339647</pub-id><pub-id pub-id-type="pmcid">PMC8013057</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>F.J.A.</given-names></name><name name-style="western"><surname>Steens</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Van Rumund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Cappellen Van Walsum</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>K&#252;sters</surname><given-names>B.</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>R.A.J.</given-names></name><etal/></person-group><article-title>Nigrosome-1 on susceptibility weighted imaging to differentiate Parkinson's disease from atypical parkinsonism: an in vivo and ex vivo pilot study</article-title><source>Pol. J. Radiol.</source><volume>81</volume><year>2016</year><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.12659/PJR.897090</pub-id><pub-id pub-id-type="pmid">27559425</pub-id><pub-id pub-id-type="pmcid">PMC4975367</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Jahng</surname><given-names>G.-H.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>W.-J.</given-names></name></person-group><article-title>Inter-vendor and inter-session reliability of diffusion tensor imaging: implications for multicenter clinical imaging studies</article-title><source>Korean J. Radiol.</source><volume>19</volume><year>2018</year><fpage>777</fpage><pub-id pub-id-type="doi">10.3348/kjr.2018.19.4.777</pub-id><pub-id pub-id-type="pmid">29962884</pub-id><pub-id pub-id-type="pmcid">PMC6005957</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>M&#246;ller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kassubek</surname><given-names>J.</given-names></name><name name-style="western"><surname>S&#252;dmeyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hilker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hattingen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Manual MRI morphometry in Parkinsonian syndromes</article-title><source>Mov. Disord.</source><volume>32</volume><year>2017</year><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1002/mds.26921</pub-id><pub-id pub-id-type="pmid">28150443</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>C.J.L.</given-names></name></person-group><article-title>Findings from the global burden of disease study 2021</article-title><source>Lancet</source><volume>403</volume><year>2024</year><fpage>2259</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)00769-4</pub-id><pub-id pub-id-type="pmid">38762327</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Condino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Auteri</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>P.</given-names></name><etal/></person-group><article-title>MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from Parkinson disease</article-title><source>Radiology</source><volume>239</volume><year>2006</year><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1148/radiol.2393050459</pub-id><pub-id pub-id-type="pmid">16714464</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tonon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lodi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Condino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Manners</surname><given-names>D.</given-names></name><name name-style="western"><surname>Malucelli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease</article-title><source>Mov. Disord.</source><volume>23</volume><year>2008</year><fpage>2370</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1002/mds.22279</pub-id><pub-id pub-id-type="pmid">18816803</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Nysetvold</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Cogell</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Fryk</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pace</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Progressive Supranuclear palsy (PSP) disease progression, management, and healthcare resource utilization: a retrospective observational study in the US and Canada</article-title><source>Orphanet J. Rare Dis.</source><volume>19</volume><year>2024</year><fpage>215</fpage><pub-id pub-id-type="doi">10.1186/s13023-024-03168-z</pub-id><pub-id pub-id-type="pmid">38778404</pub-id><pub-id pub-id-type="pmcid">PMC11112758</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Oba</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yagishita</surname><given-names>A.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barkovich</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kutomi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>New and reliable MRI diagnosis for progressive supranuclear palsy</article-title><source>Neurology</source><volume>64</volume><year>2005</year><fpage>2050</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000165960.04422.D0</pub-id><pub-id pub-id-type="pmid">15985570</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Ohtsuka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Konno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging</article-title><source>Park. Relat. Disord.</source><volume>20</volume><year>2014</year><fpage>755</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.04.005</pub-id><pub-id pub-id-type="pmid">24768616</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Planetta</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ofori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pasternak</surname><given-names>O.</given-names></name><name name-style="western"><surname>Burciu</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>P.</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Free-water imaging in Parkinson's disease and atypical parkinsonism</article-title><source>Brain</source><volume>139</volume><year>2016</year><fpage>495</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1093/brain/awv361</pub-id><pub-id pub-id-type="pmid">26705348</pub-id><pub-id pub-id-type="pmcid">PMC5790142</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Postuma</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poewe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Olanow</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>W.</given-names></name><etal/></person-group><article-title>MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD Clinical Diagnostic Criteria</article-title><source>Mov. Disord.</source><volume>30</volume><year>2015</year><fpage>1591</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1002/mds.26424</pub-id><pub-id pub-id-type="pmid">26474316</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Prodoehl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Planetta</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Tangonan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor</article-title><source>Mov. Disord.</source><volume>28</volume><year>2013</year><fpage>1816</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1002/mds.25491</pub-id><pub-id pub-id-type="pmid">23674400</pub-id><pub-id pub-id-type="pmcid">PMC3748146</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Pyatigorskaya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sanz-Mor&#232;re</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Gaurav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Biondetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valabregue</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Iron imaging as a diagnostic tool for Parkinson's disease: a systematic review and meta-analysis</article-title><source>Front. Neurol.</source><volume>11</volume><year>2020</year><fpage>366</fpage><pub-id pub-id-type="doi">10.3389/fneur.2020.00366</pub-id><pub-id pub-id-type="pmid">32547468</pub-id><pub-id pub-id-type="pmcid">PMC7270360</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Pyatigorskaya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yahia&#8208;Cherif</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gaurav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ewenczyk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Valabregue</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Multimodal magnetic resonance imaging quantification of brain changes in progressive supranuclear palsy</article-title><source>Mov. Disord.</source><volume>35</volume><year>2020</year><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1002/mds.27877</pub-id><pub-id pub-id-type="pmid">31710146</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Quattrone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicoletti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Messina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fera</surname><given-names>F.</given-names></name><name name-style="western"><surname>Condino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>P.</given-names></name><etal/></person-group><article-title>MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy</article-title><source>Radiology</source><volume>246</volume><year>2008</year><fpage>214</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1148/radiol.2453061703</pub-id><pub-id pub-id-type="pmid">17991785</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Quattrone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nigro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quattrone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vescio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arabia</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease</article-title><source>Park. Relat. Disord.</source><volume>54</volume><year>2018</year><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2018.07.016</pub-id><pub-id pub-id-type="pmid">30068492</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Seada</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Van Der Eerden</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>Hernandez-Tamames</surname><given-names>J.A.</given-names></name></person-group><article-title>Quantitative MRI protocol and decision model for a &#8216;one stop shop&#8217; early-stage Parkinsonism diagnosis: study design</article-title><source>Neuroimage: Clinical</source><volume>39</volume><year>2023</year><object-id pub-id-type="publisher-id">103506</object-id><pub-id pub-id-type="doi">10.1016/j.nicl.2023.103506</pub-id><pub-id pub-id-type="pmcid">PMC10500558</pub-id><pub-id pub-id-type="pmid">37696098</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Sekiya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tipton</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Kawazoe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Current landscape of clinical diagnosis in multiple system atrophy: a 15-year analysis from 2008 to 2022</article-title><source>Neurology</source><volume>103</volume><year>2024</year><object-id pub-id-type="publisher-id">e210021</object-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000210021</pub-id><pub-id pub-id-type="pmid">39531604</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;str&#246;m</surname><given-names>H.</given-names></name><name name-style="western"><surname>Granberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Westman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>P.</given-names></name></person-group><article-title>Quantitative susceptibility mapping differentiates between parkinsonian disorders</article-title><source>Park. Relat. Disord.</source><volume>44</volume><year>2017</year><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.08.029</pub-id><pub-id pub-id-type="pmid">28886909</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="other" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Tyszka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pauli</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nili</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>M.</given-names></name></person-group><article-title>Reinforcement learning atlas</article-title><pub-id pub-id-type="doi">10.17605/OSF.IO/JKZWP</pub-id><year>2022</year></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Van Rumund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Esselink</surname><given-names>R.A.J.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>F.J.A.</given-names></name><name name-style="western"><surname>Verbeek</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bloem</surname><given-names>B.R.</given-names></name></person-group><article-title>Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism</article-title><source>BMC Neurol.</source><volume>18</volume><year>2018</year><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12883-018-1072-x</pub-id><pub-id pub-id-type="pmid">29764386</pub-id><pub-id pub-id-type="pmcid">PMC5954463</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="book" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Vangel</surname><given-names>M.G.</given-names></name></person-group><series>Confidence Intervals for a Normal Coefficient of Variation</series><volume>vol. 7</volume><year>1996</year></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Spincemaille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dimov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care</article-title><source>Magn. Reson. Imaging</source><volume>46</volume><year>2017</year><fpage>951</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1002/jmri.25693</pub-id><pub-id pub-id-type="pmcid">PMC5592126</pub-id><pub-id pub-id-type="pmid">28295954</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Wenning</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Stankovic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vignatelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fanciulli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calandra&#8208;Buonaura</surname><given-names>G.</given-names></name><name name-style="western"><surname>Seppi</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The movement disorder society criteria for the diagnosis of multiple system atrophy</article-title><source>Mov. Disord.</source><volume>37</volume><year>2022</year><fpage>1131</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1002/mds.29005</pub-id><pub-id pub-id-type="pmid">35445419</pub-id><pub-id pub-id-type="pmcid">PMC9321158</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Worker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blain</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jarosz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.C.R.</given-names></name><etal/></person-group><article-title>Diffusion tensor imaging of Parkinson's disease, multiple system atrophy and progressive supranuclear palsy: a tract-based spatial statistics study</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e112638</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112638</pub-id><pub-id pub-id-type="pmcid">PMC4236070</pub-id><pub-id pub-id-type="pmid">25405990</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Making bootstrap statistical inferences: a tutorial</article-title><source>Res. Q. Exerc. Sport</source><volume>68</volume><year>1997</year><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1080/02701367.1997.10608865</pub-id><pub-id pub-id-type="pmid">9094762</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0220">The following is the Supplementary data to this article.<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.doc" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0010">The data that has been used is confidential.</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0215">This project was financed by <funding-source id="gs12">Parkinson Vereniging</funding-source> (Netherlands) (<award-id award-type="grant" rid="gs12">Project number P2021-15</award-id>).</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0225">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ynirp.2025.100273" id="intref0015">https://doi.org/10.1016/j.ynirp.2025.100273</ext-link>.</p><p id="p0230">The data acquisition was supported by the <funding-source id="gs13">Stichting Parkinson Fonds and the Van Alkemade-Keuls Fonds</funding-source>. These non-corporate funding organizations have no role in study design or conduct of the study, data collection, data analysis and interpretation or manuscript preparation.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain Commun</journal-id><journal-id journal-id-type="iso-abbrev">Brain Commun</journal-id><journal-id journal-id-type="pmc-domain-id">3915</journal-id><journal-id journal-id-type="pmc-domain">braincomms</journal-id><journal-id journal-id-type="publisher-id">braincomms</journal-id><journal-title-group><journal-title>Brain Communications</journal-title></journal-title-group><issn pub-type="epub">2632-1297</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507090</article-id><article-id pub-id-type="pmcid-ver">PMC12507090.1</article-id><article-id pub-id-type="pmcaid">12507090</article-id><article-id pub-id-type="pmcaiid">12507090</article-id><article-id pub-id-type="doi">10.1093/braincomms/fcaf324</article-id><article-id pub-id-type="publisher-id">fcaf324</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Report</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00310</subject><subject>AcademicSubjects/SCI01870</subject></subj-group></article-categories><title-group><article-title>Uncovering &#945;-synuclein and tau burden in Alzheimer&#8217;s and Lewy body diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Quintin</surname><given-names initials="S">Stephan</given-names></name><aff>
<institution>Department of Neuroscience, College of Medicine, University of Florida</institution>, <addr-line>BMS J489/CTRND, 1275 Center Drive, Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paterno</surname><given-names initials="G">Giavanna</given-names></name><aff>
<institution>Department of Neuroscience, College of Medicine, University of Florida</institution>, <addr-line>BMS J489/CTRND, 1275 Center Drive, Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lloyd</surname><given-names initials="GM">Grace M</given-names></name><aff>
<institution>Department of Neuroscience, College of Medicine, University of Florida</institution>, <addr-line>BMS J489/CTRND, 1275 Center Drive, Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Prokop</surname><given-names initials="S">Stefan</given-names></name><aff>
<institution>Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Department of Pathology, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Norman Fixel Institute for Neurological Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Giasson</surname><given-names initials="BI">Benoit I</given-names></name><aff>
<institution>Department of Neuroscience, College of Medicine, University of Florida</institution>, <addr-line>BMS J489/CTRND, 1275 Center Drive, Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for Translational Research in Neurodegenerative Diseases, College of Medicine, University of Florida</institution>, <addr-line>Gainesville, FL 32610</addr-line>, <country country="US">USA</country></aff><xref rid="fcaf324-cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="fcaf324-cor1">Correspondence to: Benoit Giasson Department of Neuroscience College of Medicine University of Florida, BMS J489/CTRND 1275 Center Drive, Gainesville, FL 32610, USA E-mail: <email>bgiasson@ufl.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-09-02"><day>02</day><month>9</month><year>2025</year></pub-date><volume>7</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">495905</issue-id><elocation-id>fcaf324</elocation-id><history><date date-type="received"><day>15</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date><date date-type="corrected-typeset"><day>08</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcaf324.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf324.pdf"/><abstract><title>Abstract</title><p>Neurodegenerative diseases are classified based on their histopathological hallmarks alongside their clinical manifestations. Alzheimer&#8217;s disease and Lewy body disease, which includes Parkinson&#8217;s disease, are traditionally referred to as tauopathy and synucleinopathy, respectively. However, much like how Alzheimer&#8217;s disease can present with Parkinsonian features and Parkinson&#8217;s disease with cognitive impairment, there is considerable overlap in their underlying pathology. In this study, we applied antibodies specific for disease-related, post-translationally modified epitopes in &#945;-synuclein and tau to post-mortem brain tissue from 16 Alzheimer&#8217;s disease and 9 Lewy body disease cases with a focus on the substantia nigra and the locus coeruleus. We demonstrate the presence of inclusion pathology comprised of carboxy-terminally truncated &#945;-synuclein in the substantia nigra and locus coeruleus of Alzheimer&#8217;s disease cases that is not revealed with standard post-mortem screening. These findings suggest that &#945;-synuclein pathology in Alzheimer&#8217;s disease can be significantly underestimated. Additionally, we observed abundant tau pathology in the substantia nigra of Alzheimer&#8217;s disease cases at levels often exceeding those seen in Lewy body disease, despite the absence of a movement disorder diagnosis in Alzheimer&#8217;s disease cases. Furthermore, the connection between regional tau pathology and associated clinical impairment may be region-dependent, where some tau pathology may be, at least temporally, innocuous.</p></abstract><abstract abstract-type="teaser"><p>Quintin <italic toggle="yes">et al</italic>. reveal abundant carboxy-truncated &#945;-synuclein, undetected by conventional antibodies, together with tau pathology in the substantia nigra and locus coeruleus of Alzheimer&#8217;s disease brains, often greater than in Lewy body disease cases, highlighting an overlooked pathological overlap in these neurodegenerative diseases.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="anchor" id="fcaf324-fcaf324_ga" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf324_ga.jpg"/></fig>
</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>Lewy body disease</kwd><kwd>post-translational modifications</kwd><kwd>&#945;-synuclein</kwd><kwd>tau</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>National Institute of Neurological Disorders and Stroke</institution><institution-id institution-id-type="DOI">10.13039/100000065</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Charlotte and Howard Zimmerman Rising Star Professorship</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Norman Fixel Institute</institution></institution-wrap></funding-source><award-id>RF1NS129567</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>University of Florida Neuromedicine Brain and Tissue Bank</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>McKnight Brain Institute</institution><institution-id institution-id-type="DOI">10.13039/100031369</institution-id></institution-wrap></funding-source><award-id>P30AG066506</award-id></award-group></funding-group><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="fcaf324-s1"><title>Introduction</title><p>Alzheimer&#8217;s disease and Lewy body disease are the two most common neurodegenerative disorders, each characterized and defined by hallmark CNS pathological proteinaceous inclusions with distinct neuropathological distribution and progression. Insights from post-mortem pathological studies have shaped the current paradigm of neurodegenerative diseases, positing that aberrant protein aggregation and propagation can be central drivers of progressive physiological dysfunction and clinical decline.</p><p>Alzheimer&#8217;s disease is characterized by hyperphosphorylated tau aggregates accumulating as neurofibrillary tangles (NFTs) with concomitant amyloid-&#946; plaques; however, in many cases, co-occurring &#945;-synuclein pathology in the form of Lewy body (LB) pathology can be present.<sup><xref rid="fcaf324-B1" ref-type="bibr">1</xref>,<xref rid="fcaf324-B2" ref-type="bibr">2</xref></sup> Similarly, in Parkinson&#8217;s disease and other Lewy body diseases including dementia with Lewy bodies (DLB), defined by &#945;-synuclein inclusions, tau pathology can also be present.<sup><xref rid="fcaf324-B3" ref-type="bibr">3</xref></sup> A recent study shed light on the potential importance of NFTs in the midbrain, where these inclusions correlated more strongly with movement disorder than LBs, challenging the current dogma of &#945;-synuclein as a primary pathogenic mediator in PD.<sup><xref rid="fcaf324-B4" ref-type="bibr">4</xref></sup></p><p>Tau and &#945;-synuclein undergo extensive post-translational modifications that influence their conformation and immunohistochemical detection, complicating the accurate assessment of pathological findings but possibly revealing underlying pathogenesis.<sup><xref rid="fcaf324-B5" ref-type="bibr">5</xref>,<xref rid="fcaf324-B6" ref-type="bibr">6</xref></sup> To this end, we apply unique tau and &#945;-synuclein antibodies to investigate pathology in the locus coeruleus (LC) and substantia nigra (SN), two regions critically affected in Alzheimer&#8217;s disease and Lewy body disease.<sup><xref rid="fcaf324-B7" ref-type="bibr">7</xref>,<xref rid="fcaf324-B8" ref-type="bibr">8</xref></sup> The LC, an early site of neurodegeneration and accumulation of proteinaceous inclusions in Alzheimer&#8217;s disease and Lewy body disease,<sup><xref rid="fcaf324-B9" ref-type="bibr">9</xref></sup> has been proposed as a nidus for pathological spread through its extensive projections to the brainstem, midbrain and cortex.<sup><xref rid="fcaf324-B10" ref-type="bibr">10-12</xref></sup> In Alzheimer&#8217;s disease and Lewy body disease, LC degeneration and tau burden are linked to cognitive decline.<sup><xref rid="fcaf324-B8" ref-type="bibr">8</xref>,<xref rid="fcaf324-B13" ref-type="bibr">13</xref></sup> While more commonly associated with Lewy body disease, neurodegeneration of the SN is also common in Alzheimer&#8217;s disease, with almost a quarter of patients developing Parkinsonian features; however, the contribution of tau or &#945;-synuclein pathology to this occurrence is not resolved.<sup><xref rid="fcaf324-B14" ref-type="bibr">14</xref></sup></p><p>The present study investigated the prevalence and distribution of &#945;-synuclein and tau pathology in the LC and SN across Alzheimer&#8217;s disease, Lewy body disease, primary age-related tauopathy (PART) and control cases. Using a unique set of antibodies, we performed immunohistochemistry (IHC) analyses for the detection of &#945;-synuclein and tau inclusions. Our findings show an unprecedented prevalence of aggregated &#945;-synuclein in the SN of Alzheimer&#8217;s disease cases and regional tau pathology of surprising comparative abundance between Alzheimer&#8217;s disease and Lewy body disease cases, challenging the specificity of these pathological markers to their canonically associated diseases.</p></sec><sec sec-type="materials|methods" id="fcaf324-s2"><title>Materials and methods</title><sec id="fcaf324-s2.1"><title>Haematoxylin and eosin staining</title><p>Formalin-fixed paraffin-embedded human brain tissue was obtained from the University of Florida Neuromedicine Brain and Tissue Bank (UF HBTB) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Sections were deparaffinized in xylenes and rehydrated in a descending series of ethanol solutions (100, 100, 90, 70%) followed by water. Slides were incubated in haematoxylin and then washed in tap water. Slides were then incubated in 90% ethanol for 1&#8197;min, followed by Eosin Y-solution 0.5% alcoholic (Sigma-Aldrich, St. Louis, MO, USA) with 0.2% glacial acetic acid, followed by washes in several exchanges of 100% ethanol, xylenes and coverslipped.</p></sec><sec id="fcaf324-s2.2"><title>Immunohistochemistry</title><p>For IHC, paraffin-embedded human brain sections were processed following previously published protocols for each antibody, as outlined in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>.</p></sec><sec id="fcaf324-s2.3"><title>Independent clinicopathologic diagnosis of study cases</title><p>Post-mortem diagnoses of Lewy body disease and Alzheimer&#8217;s disease neuropathological change and other changes were made according to current guidelines and criteria proposed by the National Institute of Aging-Alzheimer&#8217;s Association,<sup><xref rid="fcaf324-B15" ref-type="bibr">15</xref></sup> the Dementia with Lewy Bodies Consortium.<sup><xref rid="fcaf324-B16" ref-type="bibr">16</xref></sup></p></sec><sec id="fcaf324-s2.4"><title>Analysis of immunohistochemical staining</title><p>For analysis of staining and capturing representative images, slides were scanned on an Aperio AT2 scanner (Leica Biosystems) at 40 &#215; magnification. Slide images were analysed using the QuPath platform (Version 0.5.1), running Windows 10. Regions of interest (ROI), including the SN and the LC, were identified on haematoxylin and Eosin (H&amp;E)-stained images and annotated on IHC-stained images accordingly. A manual analysis of staining was done for each case and ROI to determine whether pathology was present for which an assignment of positive or negative was given. Positivity in an ROI was defined by the presence of one or more inclusions, including globular or thread-like morphological features (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). Following the exclusion of tissue and stain artefacts, the &#8216;Pixel Classifier&#8217; tool was used to detect and quantify stained pathology. The percentage of annotated ROI covered by pathological staining was determined as (positive pixel count / pixel count of ROI) &#215; 100. Thresholds for positive staining were created under the following general settings: &#8216;resolution&#8217;, full (0.25&#8197;um/px); &#8216;channel&#8217;, DAB; &#8216;prefilter&#8217;, Gaussian. Thresholds for DAB positivity and staining vectors for DAB were adjusted on an image-by-image basis to ensure no false positive staining (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>).</p></sec><sec id="fcaf324-s2.5"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 10 software (GraphPad Software). Spearman&#8217;s ranked correlation was performed for all correlative analyses, and the Kruskal&#8211;Wallis test was used for group comparisons of quantified staining.</p></sec></sec><sec sec-type="results" id="fcaf324-s3"><title>Results</title><sec id="fcaf324-s3.1"><title>Clinical and neuropathologic characteristics of study groups</title><p>For the comparative assessment of pathology, we included 16 Alzheimer&#8217;s disease cases, 9 Lewy body disease cases, 6 PART cases and 8 control cases with prior clinical and neuropathological diagnoses (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Due to limited tissue availability, staining for the SN was not available for two Lewy body disease cases, and one control case, while the LC was unavailable for one Alzheimer&#8217;s disease case.</p><p>As expected, concomitant brain neuropathologies were present in some Alzheimer&#8217;s disease, Lewy body disease and PART cases.<sup><xref rid="fcaf324-B2" ref-type="bibr">2</xref></sup> The secondary neuropathological profiles observed in this study align with previous findings.<sup><xref rid="fcaf324-B2" ref-type="bibr">2</xref></sup> However, none of the Alzheimer&#8217;s disease cases selected for the current study exhibited previously identified Lewy body pathology.</p></sec><sec id="fcaf324-s3.2"><title>Prevalence of &#945;-synuclein and tau pathology in the locus coeruleus and substantia nigra</title><p>Haematoxylin and eosin (H&amp;E) staining was performed on all cases to identify regions of interest, which were annotated accordingly (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). IHC was conducted using &#945;-synuclein antibodies: 2G5 (specific to carboxy-terminal truncation at residue 103), 94-3A10 (targeting C-terminal residues 130&#8211;140) and 3H11 (targeting residues 43&#8211;62) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>). Tau IHC was performed using the AT8 antibody for tau phosphorylated at Ser202 and Thr205 (p-tau) and the conformational tau antibody 2F12 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>). Importantly, antibody AT8 has been commonly used in spatial and temporal studies of human tau pathology.<sup><xref rid="fcaf324-B17" ref-type="bibr">17</xref>,<xref rid="fcaf324-B18" ref-type="bibr">18</xref></sup> Antibodies 2G5, 3H11 and 2F12 target less conventional epitopes that can reveal novel pathological features.</p><p>Pathology was classified as positive or negative based on antibody staining (<xref rid="fcaf324-T1" ref-type="table">Table 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). All Lewy body disease cases presented with &#945;-synuclein inclusions positive for 2G5, 3H11 and 94-3A10 in the LC and SN (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1</xref>; Table 1, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). Unexpectedly, all but one Alzheimer&#8217;s disease case was positive for 2G5 pathology in the LC and the SN (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1</xref>, Table 1, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). However, only one Alzheimer&#8217;s disease case (AD-16) displayed positivity for all three &#945;-synuclein antibodies in both regions.</p><fig position="float" id="fcaf324-F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>
<bold>&#945;-Synuclein pathological inclusions in the locus coeruleus and substantia nigra of Alzheimer&#8217;s disease and Lewy body disease cases.</bold> (<bold>A</bold>) Representative images of 2G5, 94-3A10 and 3H11 immunostaining in the LC of Lewy body disease and Alzheimer&#8217;s disease cases. (<bold>B</bold>) Quantification of 2G5 inclusion pathology in the LC of Alzheimer&#8217;s disease (<italic toggle="yes">N</italic> = 15), Lewy body disease (<italic toggle="yes">N</italic> = 9), PART (<italic toggle="yes">N</italic> = 6) and control cases (<italic toggle="yes">N</italic> = 8). (<bold>C</bold>) Quantification of 94-3A10 inclusion pathology in the LC of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>D</bold>) Quantification of 3H11 inclusion pathology in the LC of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>E</bold>) Representative images of 2G5, 94-3A10 and 3H11 immunostaining in the SN of Lewy body disease and Alzheimer&#8217;s disease cases. (<bold>F</bold>) Quantification of 2G5 inclusion pathology in the SN of Alzheimer&#8217;s disease (<italic toggle="yes">N</italic> = 16), Lewy body disease (<italic toggle="yes">N</italic> = 7), PART (<italic toggle="yes">N</italic> = 6) and control cases (<italic toggle="yes">N</italic> = 7). (<bold>G</bold>) Quantification of 94-3A10 inclusion pathology in the SN of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>H</bold>) Quantification of 3H11 inclusion pathology in the SN of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. Arrows indicate inclusions. Arrowheads depict neuromelanin-laden neurons. Large image scale bar = 100&#8197;&#181;m, inset scale bar = 10&#8197;&#181;m. On graphed quantifications, data point shape indicates whether a case is positive or negative for a said pathology as determined during manual examination, with circles indicating positive cases and &#215;&#8217;s indicating negative cases. Kruskal&#8211;Wallis test was used for group comparisons. Error bars = SEM. <sup>&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.05; <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.01, <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf324f1.jpg"/></fig><table-wrap position="float" id="fcaf324-T1" orientation="portrait"><label>Table 1</label><caption><p>Fraction of cases with positive staining in ROI per disease group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">2G5 (&#945;-synuclein)</th><th align="center" colspan="2" rowspan="1">94-3A10 (&#945;-synuclein)</th><th align="center" colspan="2" rowspan="1">3H11 (&#945;-synuclein)</th><th align="center" colspan="2" rowspan="1">AT8 (tau)</th><th align="center" colspan="2" rowspan="1">2F12 (tau)</th></tr><tr><td align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">LC</th><th align="center" rowspan="1" colspan="1">SN</th><th align="center" rowspan="1" colspan="1">LC</th><th align="center" rowspan="1" colspan="1">SN</th><th align="center" rowspan="1" colspan="1">LC</th><th align="center" rowspan="1" colspan="1">SN</th><th align="center" rowspan="1" colspan="1">LC</th><th align="center" rowspan="1" colspan="1">SN</th><th align="center" rowspan="1" colspan="1">LC</th><th align="center" rowspan="1" colspan="1">SN</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Alzheimer&#8217;s disease</bold>
</td><td rowspan="1" colspan="1">14/15</td><td rowspan="1" colspan="1">15/16</td><td rowspan="1" colspan="1">1/15</td><td rowspan="1" colspan="1">1/16</td><td rowspan="1" colspan="1">1/15</td><td rowspan="1" colspan="1">1/16</td><td rowspan="1" colspan="1">15/15</td><td rowspan="1" colspan="1">16/16</td><td rowspan="1" colspan="1">15/15</td><td rowspan="1" colspan="1">16/16</td></tr><tr><td rowspan="1" colspan="1">
<bold>Lewy body disease</bold>
</td><td rowspan="1" colspan="1">9/9</td><td rowspan="1" colspan="1">7/7</td><td rowspan="1" colspan="1">9/9</td><td rowspan="1" colspan="1">7/7</td><td rowspan="1" colspan="1">9/9</td><td rowspan="1" colspan="1">7/7</td><td rowspan="1" colspan="1">9/9</td><td rowspan="1" colspan="1">7/7</td><td rowspan="1" colspan="1">9/9</td><td rowspan="1" colspan="1">6/7</td></tr><tr><td rowspan="1" colspan="1">
<bold>PART</bold>
</td><td rowspan="1" colspan="1">2/6</td><td rowspan="1" colspan="1">1/6</td><td rowspan="1" colspan="1">2/6</td><td rowspan="1" colspan="1">1/6</td><td rowspan="1" colspan="1">2/6</td><td rowspan="1" colspan="1">1/6</td><td rowspan="1" colspan="1">5/6</td><td rowspan="1" colspan="1">1/6</td><td rowspan="1" colspan="1">5/6</td><td rowspan="1" colspan="1">3/6</td></tr><tr><td rowspan="1" colspan="1">
<bold>Control</bold>
</td><td rowspan="1" colspan="1">0/8</td><td rowspan="1" colspan="1">0/7</td><td rowspan="1" colspan="1">0/8</td><td rowspan="1" colspan="1">0/7</td><td rowspan="1" colspan="1">0/8</td><td rowspan="1" colspan="1">0/7</td><td rowspan="1" colspan="1">6/8</td><td rowspan="1" colspan="1">3/7</td><td rowspan="1" colspan="1">6/8</td><td rowspan="1" colspan="1">1/7</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>LC, locus coeruleus; SN, substantia nigra; PART, primary age-related tauopathy.</p></fn></table-wrap-foot></table-wrap><p>Two PART cases (PART-1 and PART-2) exhibited &#945;-synuclein pathology in the LC and SN (<xref rid="fcaf324-T1" ref-type="table">Table 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 4</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). These cases showed positivity for all three &#945;-synuclein antibodies in the LC, but their SN staining patterns differed: PART-1 was positive for 2G5 but negative for 94-3A10 and 3H11, while PART-2 was positive for 94-3A10 and 3H11 but negative for 2G5 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>). In contrast, no control cases showed &#945;-synuclein positivity in either brain region (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>).</p><p>Tau pathology (AT8 and 2F12 positivity) was observed across all Alzheimer&#8217;s disease cases in the LC and SN regions (<xref rid="fcaf324-F2" ref-type="fig">Fig. 2</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). Similarly, all Lewy body disease cases exhibited AT8 and 2F12 positivity, except for LBD-1, which lacked positive 2F12 staining in the SN (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). Among PART and control cases, AT8- and 2F12-positive staining in the LC was more frequent than in the SN (<xref rid="fcaf324-F2" ref-type="fig">Fig. 2</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>).</p><fig position="float" id="fcaf324-F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>
<bold>Tau pathology immunoreactivity in the locus coeruleus and substantia nigra of Alzheimer&#8217;s disease, Lewy body disease, primary age-related tauopathy and control cases.</bold> (<bold>A</bold>) Representative images of AT8 and 2F12 staining in the LC of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>B</bold>) Quantification of AT8 inclusion pathology in the LC of Alzheimer&#8217;s disease (<italic toggle="yes">N</italic> = 15), Lewy body disease (<italic toggle="yes">N</italic> = 9), PART (<italic toggle="yes">N</italic> = 6) and control cases (<italic toggle="yes">N</italic> = 8). (<bold>C</bold>) Quantification of 2F12 inclusion pathology in the LC of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>D</bold>) Representative images of AT8 and 2F12 staining in the SN of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. (<bold>E</bold>) Quantification of AT8 inclusion pathology in the SN of Alzheimer&#8217;s disease (<italic toggle="yes">N</italic> = 16), Lewy body disease (<italic toggle="yes">N</italic> = 7), PART (<italic toggle="yes">N</italic> = 6) and control cases (<italic toggle="yes">N</italic> = 7). (<bold>F</bold>) Quantification of 2F12 inclusion pathology in the SN of Alzheimer&#8217;s disease, Lewy body disease, PART and control cases. Arrows indicate inclusions, and arrowheads indicate neuromelanin-rich neurons. Scale bar = 100&#8197;&#181;m. On graphed quantifications, data point shape indicates whether a case is positive or negative for a said pathology as determined during manual examination, with circles indicating positive cases and &#215;&#8217;s indicated negative cases. Kruskal&#8211;Wallis test was used for group comparisons. Error bars = SEM. <sup>&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.05; <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.01, <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.001, <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &#8804; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf324f2.jpg"/></fig></sec><sec id="fcaf324-s3.3"><title>Quantitative analysis of &#945;-synuclein staining in the locus coeruleus and substantia nigra</title><p>Qupath tissue analysis software was used to quantify and highlight pathology within an annotated region of interest (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 1</xref>). Percent positivity was calculated as the positive pixel count divided by the pixel count of the region of interest multiplied by 100. To ensure accuracy, positive pixel thresholds were set for each case to minimize false positive detection (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 2</xref>).</p><p>Lewy body disease cases exhibited diverse Lewy pathology with characteristic globular and thread-like &#945;-synuclein inclusions across the LC and SN (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1A</xref> and <xref rid="fcaf324-F1" ref-type="fig">E</xref>). 2G5-positive inclusions in Alzheimer&#8217;s disease cases were morphologically similar to those in Lewy body disease cases (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1A</xref> and <xref rid="fcaf324-F1" ref-type="fig">E</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. 3</xref>). As expected, most Lewy body disease cases had higher 2G5, 94-3A10 and 3H11 positivity in the LC than that of Alzheimer&#8217;s disease cases (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1B&#8211;D</xref>). PART cases also had relatively lower pathology in the LC than most Lewy body disease cases. While this observation remained true for 94-3A10 and 3H11 staining in the SN of positive Alzheimer&#8217;s disease and PART cases (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1G</xref> and <xref rid="fcaf324-F1" ref-type="fig">H</xref>), 2G5 per cent positivity in the SN of Alzheimer&#8217;s disease cases was in a similar range to that of Lewy body disease cases, with one Alzheimer&#8217;s disease case exceeding that of any Lewy body disease case (<xref rid="fcaf324-F1" ref-type="fig">Fig. 1F</xref>).</p></sec><sec id="fcaf324-s3.4"><title>Quantitative assessment of tau staining in the locus coeruleus and substantia nigra</title><p>In the present study, quantitative analysis of AT8 and 2F12 in Alzheimer&#8217;s disease and Lewy body disease cases revealed abundant positivity in both regions, with Alzheimer&#8217;s disease cases often surpassing that of Lewy body disease cases (<xref rid="fcaf324-F2" ref-type="fig">Fig. 2</xref>). Surprisingly, some PART cases exhibited a lower tau burden than control cases, with inclusions so sparse that quantified positivity rarely exceeded background levels of negative cases (<xref rid="fcaf324-F2" ref-type="fig">Fig. 2B, C, E, F</xref>).</p></sec><sec id="fcaf324-s3.5"><title>Correlation analysis of &#945;-synuclein and tau staining</title><p>Spearman&#8217;s ranked correlation analysis of 2G5, AT8 and 2F12 staining in the LC and SN of Alzheimer&#8217;s disease cases revealed significant interregional correlations for AT8 staining, with LC AT8 positively correlating with SN AT8 and 2F12 (<xref rid="fcaf324-F3" ref-type="fig">Fig. 3A</xref>). Within regions, the strongest correlation was in the SN between 2G5, AT8 and 2F12. In the LC, only AT8 and 2F12 were significantly correlated (<xref rid="fcaf324-F3" ref-type="fig">Fig. 3A</xref>).</p><fig position="float" id="fcaf324-F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>
<bold>Correlation and relative intensity of &#945;-synuclein and tau pathologies in the LC and SN of Lewy body disease and Alzheimer&#8217;s disease cases.</bold> (<bold>A</bold>) Correlation matrix of Spearman&#8217;s rank-based correlation analysis of 2G5, AT8 and 2F12 inclusion pathology in the LC (<italic toggle="yes">n</italic> = 15) and SN (<italic toggle="yes">n</italic> = 16) of Alzheimer&#8217;s disease cases with correlation coefficients displayed. (<bold>B</bold>) Correlogram of Spearman&#8217;s rank-based correlation analysis of 2G5, 94-3A10, AT8 and 2F12 inclusion pathology in the LC (<italic toggle="yes">n</italic> = 9) and SN (<italic toggle="yes">n</italic> = 7) of Lewy body disease cases with correlation coefficients displayed. Correlation analysis performed using quantified pathology (area covered) as detected by respective antibodies on stained sections. *<italic toggle="yes">P</italic>&#8804; 0.05; **<italic toggle="yes">P</italic> &#8804; 0.01; ***<italic toggle="yes">P</italic> &#8804; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcaf324f3.jpg"/></fig><p>Among Lewy body disease cases, AT8 staining in the LC and SN was positively correlated, as was LC 2F12 with SN AT8. However, LC AT8 and 2F12 staining was inversely correlated with SN 2G5 (<xref rid="fcaf324-F3" ref-type="fig">Fig. 3B</xref>). 2G5 and 94-3A10 staining were positively correlated in the LC but inversely correlated in the SN. Unlike that of Alzheimer&#8217;s disease cases, 2G5 staining was inversely correlated with AT8 and 2F12 staining in the SN of Lewy body disease cases (<xref rid="fcaf324-F3" ref-type="fig">Fig. 3B</xref>).</p></sec></sec><sec sec-type="discussion" id="fcaf324-s4"><title>Discussion</title><p>The present report brings new data that challenge the prominent dogmatic views of tau and &#945;-synuclein pathology and their isolated roles in neurodegeneration. We assessed the LC, an early region to accumulate tau and &#945;-synuclein inclusion pathology in Alzheimer&#8217;s disease and Lewy body disease, respectively.<sup><xref rid="fcaf324-B9" ref-type="bibr">9</xref>,<xref rid="fcaf324-B10" ref-type="bibr">10</xref></sup> We also assess the SN, which is primarily associated with neurodegeneration in Lewy body disease. Our data demonstrates the prominence of pathological inclusions comprised of carboxy-terminally cleaved &#945;-synuclein in SN and LC of Alzheimer&#8217;s disease cases. The presence of LBs in Alzheimer&#8217;s disease cases has been associated with more severe cognitive decline than that of &#8216;pure&#8217; Alzheimer&#8217;s disease cases; however, LBs in primary Alzheimer&#8217;s disease are largely restricted to the amygdala rather than the SN or LC.<sup><xref rid="fcaf324-B19" ref-type="bibr">19</xref>,<xref rid="fcaf324-B20" ref-type="bibr">20</xref></sup> Findings here show that LB may be more ubiquitous in Alzheimer&#8217;s disease, but the clinical implications of these highly cleaved &#945;-synuclein inclusions are unclear. Nevertheless, a high prevalence and the broader association between &#945;-synuclein pathology and neurodegenerative disease bring into question whether it has a more prominent role in Alzheimer&#8217;s disease.<sup><xref rid="fcaf324-B21" ref-type="bibr">21</xref></sup></p><p>The extent to which &#945;-synuclein pathology in Lewy body disease corresponds to neurodegeneration remains a contentious presumption, with some studies implicating tau rather than &#945;-synuclein as a disease correlate.<sup><xref rid="fcaf324-B22" ref-type="bibr">22</xref></sup> The present study shows that SN and LC tau pathology are less specific to neurodegenerative disease than &#945;-synuclein pathology. We show that Alzheimer&#8217;s disease cases, without clinical histories of parkinsonism, have abundant tau and carboxy-truncated &#945;-synuclein pathology in the LC and SN, with tau pathology often superseding that of Lewy body disease patients. In addition to newly revealed &#945;-synuclein pathology, these data bring into question the pathogenic implications of tau pathology in these regions. One might expect that abundant tau pathology in the SN of Alzheimer&#8217;s disease cases would correspond to Parkinsonism, but our additional findings of tau pathology in PART and control cases also support the notion that some tau inclusions could be, at least temporarily, benign&#8212;a concept that was previously proposed.<sup><xref rid="fcaf324-B23" ref-type="bibr">23</xref>,<xref rid="fcaf324-B24" ref-type="bibr">24</xref></sup> Others have also recently reported tau pathology in the SN of Alzheimer&#8217;s disease patients without overt motor disorders and conversely movement disorder in Alzheimer&#8217;s disease patients without &#945;-synuclein pathology.<sup><xref rid="fcaf324-B25" ref-type="bibr">25</xref></sup> Further investigation is needed to clarify the relationship of SN tau pathology to neurodegeneration and clinical outcomes in each disease context.</p><p>Our findings further demonstrate the histopathological overlap between Alzheimer&#8217;s disease and Lewy body disease and highlight the potential insufficiency of the terms tauopathy and synucleinopathies as categorical descriptors of the most prominent neurodegenerative diseases. However, a broader survey of carboxy-terminally truncated &#945;-synuclein pathology is needed to make definitive statements about the prevalence of such pathology. The present study is limited in scope regarding the number of cases included and the degree of sampling from each region of interest. While post-mortem IHC remains the gold standard for detecting these pathologies, it provides only a static snapshot of pathology, limiting insights into the temporal dynamics between co-occurring pathologies, neurodegeneration and clinical symptoms. Furthermore, the fidelity of histological findings depends on the sensitivity and specificity of the tools employed, introducing potential tool-dependent biases in studies attempting to survey the prevalence of pathologies. By employing PTM-specific antibodies, this study provides compelling evidence for an underappreciated prevalence of some forms of &#945;-synuclein pathology in Alzheimer&#8217;s disease and highlights the need for a reassessment of SN tau pathology in neurodegenerative diseases.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>fcaf324_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="fcaf324_supplementary_data.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec id="fcaf324-s5"><title>Supplementary material</title><p>Supplementary material is available at <italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">Brain Communications</xref></italic> online.</p></sec><sec id="fcaf324-s6"><title>Funding</title><p>S.Q., G.P. and G.M.L were supported by the T32NS082168 training grant from the National Institute of Neurological Disorders and Stroke. S.P. is supported by the Charlotte and Howard Zimmerman Rising Star Professorship at the Norman Fixel Institute for Neurological diseases. This work was supported by grant RF1NS129567 from the National Institute of Neurological Disorders and Stroke. The University of Florida Neuromedicine Human Brain and Tissue Bank is supported by the McKnight Brain Institute, the Center for Translational Research in Neurodegenerative Diseases at the University of Florida, and the National Institute on Aging (P30AG066506).</p></sec><sec sec-type="COI-statement" id="fcaf324-s7"><title>Competing interests</title><p>The authors report no competing interests.</p></sec><sec sec-type="data-availability" id="fcaf324-s8"><title>Data availability</title><p>The datasets used and analysed from the current study are available from the corresponding author upon reasonable request.</p></sec><ref-list id="ref1"><title>References</title><ref id="fcaf324-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deture</surname> &#160;<given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name></person-group>. <article-title>The neuropathological diagnosis of Alzheimer&#8217;s disease</article-title>. <source>Mol Neurodegener</source>. <year>2019</year>;<volume>14</volume>(<issue>1</issue>):<fpage>32</fpage>.<pub-id pub-id-type="pmid">31375134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmcid">PMC6679484</pub-id></mixed-citation></ref><ref id="fcaf324-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robinson</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname> &#160;<given-names>SX</given-names></string-name>, <string-name name-style="western"><surname>Baer</surname> &#160;<given-names>DR</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated</article-title>. <source>Brain</source>. <year>2023</year>;<volume>146</volume>(<issue>6</issue>):<fpage>2557</fpage>&#8211;<lpage>2569</lpage>.<pub-id pub-id-type="pmid">36864661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad059</pub-id><pub-id pub-id-type="pmcid">PMC10232273</pub-id></mixed-citation></ref><ref id="fcaf324-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname> &#160;<given-names>D</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Tau pathology in Parkinson&#8217;s disease</article-title>. <source>Front Neurol</source>. <year>2018</year>;<volume>9</volume>:<fpage>609</fpage>.<pub-id pub-id-type="pmid">30333786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2018.00809</pub-id><pub-id pub-id-type="pmcid">PMC6176019</pub-id></mixed-citation></ref><ref id="fcaf324-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chu</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hirst</surname> &#160;<given-names>WD</given-names></string-name>, <string-name name-style="western"><surname>Federoff</surname> &#160;<given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Harms</surname> &#160;<given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Stoessl</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Kordower</surname> &#160;<given-names>JH</given-names></string-name></person-group>. <article-title>Nigrostriatal tau pathology in parkinsonism and Parkinson&#8217;s disease</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>2</issue>):<fpage>444</fpage>&#8211;<lpage>457</lpage>.<pub-id pub-id-type="pmid">38006313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad388</pub-id><pub-id pub-id-type="pmcid">PMC10834249</pub-id></mixed-citation></ref><ref id="fcaf324-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sorrentino</surname> &#160;<given-names>ZA</given-names></string-name>, <string-name name-style="western"><surname>Giasson</surname> &#160;<given-names>BI</given-names></string-name></person-group>. <article-title>The emerging role of &#945;-synuclein truncation in aggregation and disease</article-title>. <source>J Biol Chem</source>. <year>2020</year>;<volume>295</volume>(<issue>30</issue>):<fpage>10224</fpage>&#8211;<lpage>10244</lpage>.<pub-id pub-id-type="pmid">32424039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.REV120.011743</pub-id><pub-id pub-id-type="pmcid">PMC7383394</pub-id></mixed-citation></ref><ref id="fcaf324-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Prokop</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giasson</surname> &#160;<given-names>BI</given-names></string-name></person-group>. <article-title>Don't phos over tau: Recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer&#8217;s disease and other tauopathies</article-title>. <source>Mol Neurodegener</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>37</fpage>.<pub-id pub-id-type="pmid">34090488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00460-5</pub-id><pub-id pub-id-type="pmcid">PMC8180161</pub-id></mixed-citation></ref><ref id="fcaf324-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manca</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>De Marco</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Soininen</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ruffini</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Venneri</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Changes in neurotransmitter-related functional connectivity along the Alzheimer&#8217;s disease continuum</article-title>. <source>Brain Commun</source>. <year>2025</year>;<volume>7</volume>(<issue>1</issue>):<fpage>jcaf008</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaf008</pub-id><pub-id pub-id-type="pmcid">PMC11840171</pub-id><pub-id pub-id-type="pmid">39980737</pub-id></mixed-citation></ref><ref id="fcaf324-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prasuhn</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Prasuhn</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fellbrich</surname> &#160;<given-names>A</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Association of locus Coeruleus and substantia nigra pathology with cognitive and motor functions in patients with Parkinson disease</article-title>. <source>Neurology</source>. <year>2021</year>;<volume>97</volume>(<issue>10</issue>):<fpage>e1007</fpage>&#8211;<lpage>E1016</lpage>.<pub-id pub-id-type="pmid">34187859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012444</pub-id></mixed-citation></ref><ref id="fcaf324-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zarow</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lyness</surname> &#160;<given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Mortimer</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Chui</surname> &#160;<given-names>HC</given-names></string-name></person-group>. <article-title>Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases</article-title>. <source>Arch Neurol</source>. <year>2003</year>;<volume>60</volume>(<issue>3</issue>):<fpage>337</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">12633144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.60.3.337</pub-id></mixed-citation></ref><ref id="fcaf324-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braak</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Thal</surname> &#160;<given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Ghebremedhin</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Del Tredici</surname> &#160;<given-names>K</given-names></string-name></person-group>. <article-title>Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years</article-title>. <source>J Neuropathol Exp Neurol.</source> &#160;<year>2011</year>;<volume>70</volume>(<issue>11</issue>):<fpage>960</fpage>&#8211;<lpage>969</lpage>.<pub-id pub-id-type="pmid">22002422</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/NEN.0b013e318232a379</pub-id></mixed-citation></ref><ref id="fcaf324-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Del Tredici</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>R&#252;b</surname> &#160;<given-names>U</given-names></string-name>, <string-name name-style="western"><surname>De Vos</surname> &#160;<given-names>RAI</given-names></string-name>, <string-name name-style="western"><surname>Bohl</surname> &#160;<given-names>JRE</given-names></string-name>, <string-name name-style="western"><surname>Braak</surname> &#160;<given-names>H</given-names></string-name></person-group>. <article-title>Where does Parkinson disease pathology begin in the brain?</article-title> &#160;<source>J Neuropathol Exp Neurol</source>. <year>2002</year>;<volume>61</volume>(<issue>5</issue>):<fpage>413</fpage>&#8211;<lpage>426</lpage>.<pub-id pub-id-type="pmid">12030260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnen/61.5.413</pub-id></mixed-citation></ref><ref id="fcaf324-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Grudzien</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Weintraub</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bigio</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mash</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Mesulam</surname> &#160;<given-names>MM</given-names></string-name></person-group>. <article-title>Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer&#8217;s disease</article-title>. <source>Neurobiol Aging</source>. <year>2007</year>;<volume>28</volume>(<issue>3</issue>):<fpage>327</fpage>&#8211;<lpage>335</lpage>.<pub-id pub-id-type="pmid">16574280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.02.007</pub-id></mixed-citation></ref><ref id="fcaf324-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>May&#224;</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Iranzo</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gaig</surname> &#160;<given-names>C</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: A case series</article-title>. <source>Lancet Neurol</source>. <year>2024</year>;<volume>23</volume>:<fpage>1238</fpage>&#8211;<lpage>1251</lpage>.<pub-id pub-id-type="pmid">39577924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00402-2</pub-id></mixed-citation></ref><ref id="fcaf324-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chui</surname> &#160;<given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Ramirez-Gomez</surname> &#160;<given-names>L</given-names></string-name></person-group>. <article-title>Clinical and imaging features of mixed Alzheimer and vascular pathologies</article-title>. <source>Alzheimer&#8217;s Res Ther</source>. <year>2015</year>;<volume>7</volume>(<issue>1</issue>):<fpage>21</fpage>.<pub-id pub-id-type="pmid">25722748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-015-0104-7</pub-id><pub-id pub-id-type="pmcid">PMC4342006</pub-id></mixed-citation></ref><ref id="fcaf324-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hyman</surname> &#160;<given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Phelps</surname> &#160;<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname> &#160;<given-names>TG</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>National Institute on Aging-Alzheimer&#8217;s Association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease</article-title>. <source>Alzheimer&#8217;s Dement</source>. <year>2012</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="pmid">22265587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.10.007</pub-id><pub-id pub-id-type="pmcid">PMC3266529</pub-id></mixed-citation></ref><ref id="fcaf324-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKeith</surname> &#160;<given-names>IG</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname> &#160;<given-names>J</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>(<issue>12</issue>):<fpage>1863</fpage>&#8211;<lpage>1872</lpage>.<pub-id pub-id-type="pmid">16237129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000187889.17253.b1</pub-id></mixed-citation></ref><ref id="fcaf324-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moloney</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname> &#160;<given-names>VJ</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname> &#160;<given-names>ME</given-names></string-name></person-group>. <article-title>Visualization of neurofibrillary tangle maturity in Alzheimer&#8217;s disease: A clinicopathologic perspective for biomarker research</article-title>. <source>Alzheimer&#8217;s Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1554</fpage>&#8211;<lpage>1574</lpage>.<pub-id pub-id-type="pmid">33797838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12321</pub-id><pub-id pub-id-type="pmcid">PMC8478697</pub-id></mixed-citation></ref><ref id="fcaf324-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Braak</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Alafuzoff</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Arzberger</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kretzschmar</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tredici</surname> &#160;<given-names>K</given-names></string-name></person-group>. <article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title>. <source>Acta Neuropathol</source>. <year>2006</year>;<volume>112</volume>(<issue>4</issue>):<fpage>389</fpage>&#8211;<lpage>404</lpage>.<pub-id pub-id-type="pmid">16906426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-006-0127-z</pub-id><pub-id pub-id-type="pmcid">PMC3906709</pub-id></mixed-citation></ref><ref id="fcaf324-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chung</surname> &#160;<given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Babulal</surname> &#160;<given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Monsell</surname> &#160;<given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname> &#160;<given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname> &#160;<given-names>JC</given-names></string-name></person-group>. <article-title>Clinical features of Alzheimer disease with and without Lewy bodies</article-title>. <source>JAMA Neurol</source>. <year>2015</year>;<volume>72</volume>(<issue>7</issue>):<fpage>789</fpage>&#8211;<lpage>796</lpage>.<pub-id pub-id-type="pmid">25985321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.0606</pub-id><pub-id pub-id-type="pmcid">PMC4501861</pub-id></mixed-citation></ref><ref id="fcaf324-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Uchikado</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname> &#160;<given-names>WL</given-names></string-name>, <string-name name-style="western"><surname>Delucia</surname> &#160;<given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name></person-group>. <article-title>Alzheimer disease with amygdala Lewy bodies: A distinct form of &#945;-synucleinopathy</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2006</year>;<volume>65</volume>(<issue>7</issue>):<fpage>685</fpage>&#8211;<lpage>697</lpage>.<pub-id pub-id-type="pmid">16825955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.jnen.0000225908.90052.07</pub-id><pub-id pub-id-type="pmcid">PMC5706655</pub-id></mixed-citation></ref><ref id="fcaf324-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calabresi</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mechelli</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Natale</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Volpicelli-Daley</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Di Lazzaro</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ghiglieri</surname> &#160;<given-names>V</given-names></string-name></person-group>. <article-title>Alpha-synuclein in Parkinson&#8217;s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction</article-title>. <source>Cell Death Dis</source>. <year>2023</year>;<volume>14</volume>(<issue>3</issue>):<fpage>176</fpage>.<pub-id pub-id-type="pmid">36859484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-023-05672-9</pub-id><pub-id pub-id-type="pmcid">PMC9977911</pub-id></mixed-citation></ref><ref id="fcaf324-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Espay</surname> &#160;<given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname> &#160;<given-names>AJ</given-names></string-name></person-group>. <article-title>Are we entering the &#8220;tau-lemaic&#8221; era of Parkinson&#8217;s disease?</article-title> &#160;<source>Brain</source>. <year>2024</year>;<volume>147</volume>(<issue>2</issue>):<fpage>330</fpage>&#8211;<lpage>332</lpage>.<pub-id pub-id-type="pmid">38190424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awae002</pub-id></mixed-citation></ref><ref id="fcaf324-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cowan</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Mudher</surname> &#160;<given-names>A</given-names></string-name></person-group>. <article-title>Are tau aggregates toxic or protective in tauopathies?</article-title> &#160;<source>Front Neurol</source>. <year>2013</year>;<volume>4</volume>:<fpage>114</fpage>.<pub-id pub-id-type="pmid">23964266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2013.00114</pub-id><pub-id pub-id-type="pmcid">PMC3741634</pub-id></mixed-citation></ref><ref id="fcaf324-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuchibhotla</surname> &#160;<given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>Wegmann</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kopeikina</surname> &#160;<given-names>KJ</given-names></string-name>, <etal>et al</etal></person-group> &#160;<article-title>Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>(<issue>1</issue>):<fpage>510</fpage>&#8211;<lpage>514</lpage>.<pub-id pub-id-type="pmid">24368848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1318807111</pub-id><pub-id pub-id-type="pmcid">PMC3890777</pub-id></mixed-citation></ref><ref id="fcaf324-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ono</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sekiya</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Maier</surname> &#160;<given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Koga</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dickson</surname> &#160;<given-names>DW</given-names></string-name></person-group>. <article-title>Parkinsonism in Alzheimer&#8217;s disease without Lewy bodies in association with nigral neuron loss&#8239;: A data-driven clinicopathologic study</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<fpage>e14628</fpage>.<pub-id pub-id-type="pmid">40042515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14628</pub-id><pub-id pub-id-type="pmcid">PMC11881629</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12490740</article-id><article-id pub-id-type="pmcid-ver">PMC12490740.1</article-id><article-id pub-id-type="pmcaid">12490740</article-id><article-id pub-id-type="pmcaiid">12490740</article-id><article-id pub-id-type="pmid">41050002</article-id><article-id pub-id-type="doi">10.7759/cureus.91484</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject></subj-group><subj-group><subject>Radiology</subject></subj-group><subj-group><subject>Physical Medicine &amp; Rehabilitation</subject></subj-group></article-categories><title-group><article-title>Top 100 Most-Cited Studies on MRI and Neuroplasticity in Stroke: A Scoping Review and Bibliometric Analysis of Citation Trends</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Manrique-Gutierrez</surname><given-names initials="G">Gabriel</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Roldan-Valadez</surname><given-names initials="E">Ernesto</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ternovoy</surname><given-names initials="SK">Sergey K</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramirez-Nava</surname><given-names initials="AG">Ana G</given-names></name><xref rid="aff-4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Montes-Ugaldo</surname><given-names initials="A">Aldo</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quinza&#241;os-Fresnedo</surname><given-names initials="J">Jimena</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Program of Combined Studies in Medicine (PECEM) Faculty of Medicine, National Autonomous University of Mexico (UNAM), Mexico City, MEX </aff><aff id="aff-2">
<label>2</label>
Division of Research, Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra" (INR), Mexico City, MEX </aff><aff id="aff-3">
<label>3</label>
Department of Radiology, I.M. Sechenov First Moscow State Medical University, Moscow, RUS </aff><aff id="aff-4">
<label>4</label>
Division of Neurological Rehabilitation, Instituto Nacional de Rehabilitaci&#243;n &#8220;Luis Guillermo Ibarra Ibarra&#8221;, Mexico City, MEX </aff><aff id="aff-5">
<label>5</label>
Division of Neurological Rehabilitation, Instituto Nacional de Rehabilitacion &#8220;Luis Guillermo Ibarra Ibarra&#8221;, Mexico City, MEX </aff><author-notes><corresp id="cor1">
Ernesto Roldan-Valadez <email>ernest.roldan@usa.net</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">495976</issue-id><elocation-id>e91484</elocation-id><history><date date-type="accepted"><day>2</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, Manrique-Gutierrez et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Manrique-Gutierrez et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0017-00000091484.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cureus.com/articles/405204-top-100-most-cited-studies-on-mri-and-neuroplasticity-in-stroke-a-scoping-review-and-bibliometric-analysis-of-citation-trends">This article is available from https://cureus.com/articles/405204-top-100-most-cited-studies-on-mri-and-neuroplasticity-in-stroke-a-scoping-review-and-bibliometric-analysis-of-citation-trends</self-uri><abstract><p>Stroke is a leading cause of long-term disability worldwide. Magnetic resonance imaging (MRI) has become central to understanding neuroplasticity-the brain&#8217;s capacity to reorganize after injury-by providing insights into structural and functional changes during recovery. Despite its importance, the intellectual and conceptual foundations of MRI-based neuroplasticity research in stroke remain underexplored.</p><p>We conducted a bibliometric analysis of publications indexed in Scopus from January 2004 to December 2024. Eligible studies were original articles and reviews assessing neuroplasticity in stroke using MRI modalities. Citation Classics were defined as &#8805;100 citations. Performance indicators (citations, citation rate per year, active years, authorship, article type) were compared using Mann-Whitney U and Chi-square tests. Science mapping was performed with Biblioshiny&#160;(K-Synth Srl, Naples, Italy) and VOSviewer (Centre for Science and Technology Studies, Leiden University, Leiden, The Netherlands) to identify intellectual, conceptual, and collaborative structures.</p><p>From 854 initial records, 100 most-cited articles were included (59-1,274 citations). Citation Classics (n = 62) had significantly higher mean citation counts and rates per year than non-Classics (p &lt; 0.0001). Reviews predominated among Classics, while original research was more frequent in non-Classics. High-impact journals (<italic toggle="yes">Brain</italic>, <italic toggle="yes">Stroke</italic>, <italic toggle="yes">Neurorehabilitation and Neural Repair</italic>, and <italic toggle="yes">NeuroImage</italic>) accounted for the most influential articles, with strong correlations between journal metrics and citation performance. Leading institutions were Harvard Medical School, University of Cambridge, and University of California, Irvine, while the United States, Germany, and the United Kingdom dominated global contributions. Emerging countries, including China and Japan, showed increasing participation. Science mapping revealed clusters on motor recovery, cortical reorganization, language rehabilitation, and emerging areas such as connectomics and machine learning.</p><p>This study provides a comprehensive overview of MRI-based neuroplasticity research in stroke, identifying seminal works, leading contributors, and evolving research themes. While citation activity has declined in recent years, advances in connectomics, multi-modal imaging, and computational approaches offer promising directions. Expanding global collaborations and addressing underrepresented regions will be critical for inclusive progress. MRI remains central to bridging mechanistic insights with clinical applications, guiding innovation in personalized stroke rehabilitation.</p></abstract><kwd-group kwd-group-type="author"><kwd>bibliometric analysis&#65292;visual analysis</kwd><kwd>cortical reorganization</kwd><kwd>diffusion tensor imaging (dti)</kwd><kwd>functional magnetic resonance imaging (fmri)</kwd><kwd>human connectomics</kwd><kwd>intrinsic brain networks</kwd><kwd>motor recovery</kwd><kwd>mri magnetic resonance imaging</kwd><kwd>neuroplasticity</kwd><kwd>post-stroke recovery</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Stroke is an acute vascular condition that produces neurological deficits&#160;[<xref rid="REF1" ref-type="bibr">1</xref>]. Traditionally, it was considered a localized disease affecting only the infarcted region&#160;[<xref rid="REF2" ref-type="bibr">2</xref>]. Advances in neuroanatomy and physiology, however, have shown that focal lesions disrupt activity in distant areas, including the non-affected hemisphere, through a phenomenon known as connectional diaschisis&#160;[<xref rid="REF3" ref-type="bibr">3</xref>]. Stroke remains one of the leading causes of long-term disability worldwide, imposing a substantial burden on patients, caregivers, and healthcare systems&#160;[<xref rid="REF4" ref-type="bibr">4</xref>-<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Recovery after stroke is mediated by multiple factors. Spontaneous recovery predominates during the first three to six months, while rehabilitation is essential in both acute and chronic stages to consolidate functional gains&#160;[<xref rid="REF7" ref-type="bibr">7</xref>-<xref rid="REF9" ref-type="bibr">9</xref>]. A critical substrate for these processes is&#160;neuroplasticity, defined as the brain&#8217;s ability to reorganize and form new connections after injury. Neuroplasticity reflects the nervous system&#8217;s intrinsic capacity to adapt to environmental changes, experiences, and external stimuli, enabling compensatory mechanisms in the presence of structural damage&#160;[<xref rid="REF7" ref-type="bibr">7</xref>,<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF11" ref-type="bibr">11</xref>]. After a stroke, several biological processes, including neurogenesis, synaptogenesis, neuronal reorganization, and compensatory pathways, contribute to recovery&#160;[<xref rid="REF12" ref-type="bibr">12</xref>-<xref rid="REF15" ref-type="bibr">15</xref>].</p><p>To study these mechanisms, a range of non-invasive techniques has been used. Electroencephalography (EEG), magnetoencephalography (MEG), positron emission tomography (PET), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS) are widely applied to assess brain activity, metabolism, and cortical excitability&#160;[<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF8" ref-type="bibr">8</xref>,<xref rid="REF16" ref-type="bibr">16</xref>]. Among these,&#160;magnetic resonance imaging (MRI)&#160;has emerged as a cornerstone tool for evaluating neuroplasticity.</p><p>MRI provides high-resolution structural and functional information, making it uniquely suited to investigate neural reorganization after stroke. Submodalities such as diffusion-weighted imaging (DWI) and diffusion tensor imaging (DTI) allow visualization of white matter tracts&#160;[<xref rid="REF17" ref-type="bibr">17</xref>], assessment of fiber orientation, and mapping of structural connectivity. Functional MRI (fMRI) measures hemodynamic responses to neural activity, enabling both task-based and resting-state network mapping&#160;[<xref rid="REF18" ref-type="bibr">18</xref>].&#160;Magnetic resonance spectroscopy (MRS) provides metabolic insights by quantifying biochemical changes associated with cerebral ischemia&#160;[<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF10" ref-type="bibr">10</xref>,<xref rid="REF16" ref-type="bibr">16</xref>,<xref rid="REF19" ref-type="bibr">19</xref>]. Together, these techniques establish MRI as a versatile platform for exploring brain plasticity.</p><p>Bibliometric analysis, defined as the quantitative study of publications and citations to identify influential research and emerging trends, offers a systematic way to assess the intellectual development of this field. Unlike traditional literature reviews, bibliometric studies enable both performance analysis, focusing on output and citation metrics, and science mapping, which identifies conceptual linkages and collaborative networks [<xref rid="REF20" ref-type="bibr">20</xref>-<xref rid="REF22" ref-type="bibr">22</xref>].</p><p>In this study, we applied a bibliometric approach to evaluate two decades (2004-2024) of MRI-based research on neuroplasticity in stroke. By integrating performance analysis with science mapping, we aimed to capture not only publication and citation trends but also the intellectual, conceptual, and collaborative structures shaping this area. This scoping approach provides a comprehensive overview of how MRI has informed understanding of post-stroke neuroplasticity, offering neurologists, rehabilitation specialists, and imaging researchers curated access to seminal contributions, thematic clusters, and future research priorities.</p></sec><sec sec-type="review"><title>Review</title><p>Methods</p><p>Search Methodology and Data Sources</p><p>A comprehensive literature search was conducted in Scopus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.scopus.com/home.uri" ext-link-type="uri">https://www.scopus.com/home.uri</ext-link>) on October 18, 2024. The timeframe was restricted to publications between January 2004 and December 2024. Impact Factor (IF) values and quartile classifications (Q1-Q4) were retrieved from Clarivate Analytics&#8217; Journal Citation Reports (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jcr.clarivate.com/jcr" ext-link-type="uri">https://jcr.clarivate.com/jcr</ext-link>). The search strategy was organized into four domains: MRI modalities, neuroplasticity, stroke, and exclusions (Table <xref rid="TAB1" ref-type="table">1</xref>).</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>Comprehensive Scopus Search Strategy for MRI-Based Neuroplasticity Research in Stroke. </title><p>The search algorithm was structured into four domains (MRI modalities, neuroplasticity, stroke, and exclusions), with grouped keywords and Boolean operators tailored to capture the breadth of the field. This approach ensured inclusion of diverse MRI submodalities (e.g., fMRI, DTI, MRS) and their applications in neuroplasticity assessments among stroke patients, while systematically excluding irrelevant or non-human studies. The detailed strategy enhances transparency and replicability of the bibliometric analysis.</p><p>fMRI: functional MRI; DTI: diffusion tensor imaging; MRS: magnetic resonance spectroscopy</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Primary Focus and Context</td><td rowspan="1" colspan="1">Explanation</td><td rowspan="1" colspan="1">Scopus Search Algorithm</td><td rowspan="1" colspan="1">Boolean Connector</td></tr><tr><td rowspan="1" colspan="1">MRI Techniques and Modalities</td><td rowspan="1" colspan="1">Keywords related to MRI neuroimaging modalities used to assess neuroplasticity in stroke patients.</td><td rowspan="1" colspan="1">(&#8220;MRI&#8221; OR &#8220;Magnetic Resonance Imaging&#8221; OR &#8220;Structural MRI&#8221; OR &#8220;Structural Magnetic Resonance Imaging&#8221; OR &#8220;dMRI&#8221; OR &#8220;Diffusion Magnetic Resonance Imaging&#8221; OR &#8220;DW-MRI&#8221; OR &#8220;Diffusion-Weighted Magnetic Resonance Imaging&#8221; OR &#8220;DWI&#8221; OR &#8220;Diffusion-Weighted Imaging&#8221; OR &#8220;DTI&#8221; OR &#8220;Diffusion Tensor Imaging&#8221; OR &#8220;DTI&#160;Tractography&#8221; OR &#8220;fMRI&#8221; OR &#8220;Functional Magnetic Resonance Imaging&#8221; OR &#8220;t-fMRI&#8221; OR &#8220;tfMRI&#8221; OR &#8220;Task Based fMRI&#8221; OR &#8220;rs-fMRI&#8221; OR &#8220;rsfMRI&#8221; OR &#8220;Resting State fMRI&#8221; OR &#8220;MRS&#8221; OR &#8220;Magnetic Resonance Spectroscopy&#8221;)</td><td rowspan="1" colspan="1">AND</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Application (Neuroplasticity)</td><td rowspan="1" colspan="1">Keywords related to the assessment of neuroplasticity in stroke.</td><td rowspan="1" colspan="1">(&#8220;Neuroplasticity&#8221; OR &#8220;Neuronal Plasticity&#8221; OR &#8220;Neural Plasticity&#8221; OR &#8220;Brain Plasticity&#8221; OR &#8220;Brain Reorganization&#8221; OR &#8220;Brain Restructuring&#8221;)</td><td rowspan="1" colspan="1">AND</td></tr><tr><td rowspan="1" colspan="1">Target Area (Stroke)</td><td rowspan="1" colspan="1">Keywords related to stroke and cerebrovascular accident.</td><td rowspan="1" colspan="1">(&#8220;Stroke&#8221; OR &#8220;Ischemic Stroke&#8221; OR &#8220;Brain Ischemia&#8221; OR &#8220;Brain Infarct&#8221; OR &#8220;Hemorrhagic Stroke&#8221; OR &#8220;Brain Hemorrhage&#8221; OR &#8220;Brain Vascular Accident&#8221;)</td><td rowspan="1" colspan="1">AND</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Exclusion Criteria</td><td rowspan="1" colspan="1">Keywords to exclude studies unrelated to neuroplasticity in stroke.</td><td rowspan="1" colspan="1">(&#8220;Traumatic Brain Injury&#8221; OR &#8220;Acquired Brain Injury&#8221; OR &#8220;Concussion&#8221; OR &#8220;Anoxic Ischemic Encephalopathy&#8221; OR &#8220;Spinal Cord Injury&#8221; OR &#8220;Chronic Pain&#8221; OR &#8220;Neurodegenerative Disorders&#8221; OR &#8220;Dementia&#8221; OR &#8220;Mild Cognitive Impairment&#8221; OR &#8220;Alzheimer&#8221; OR &#8220;Perinatal Stroke&#8221; OR &#8220;Cerebral Palsy&#8221; OR &#8220;Depression&#8221; OR &#8220;Schizophrenia&#8221;)</td><td rowspan="1" colspan="1">AND NOT</td></tr><tr><td colspan="4" rowspan="1">Complete Scopus Search Algorithm</td></tr><tr style="background-color:#ccc"><td colspan="4" rowspan="1">( TITLE-ABS-KEY ( (&#160;"MRI"&#160;OR&#160;"Magnetic Resonance Imaging"&#160;OR&#160;"Structural MRI"&#160;OR&#160;"Structural Magnetic Resonance Imaging"&#160;OR&#160;"dMRI"&#160;OR&#160;"Diffusion Magnetic Resonance Imaging"&#160;OR&#160;"DW-MRI"&#160;OR&#160;"Diffusion-Weighted Magentic Resonance Imaging"&#160;OR&#160;"DWI"&#160;OR&#160;"Diffusion Weighted Imaging"&#160;OR&#160;"DTI"&#160;OR&#160;"Diffusion Tensor Imaging"&#160;OR&#160;"DTI Tractography"&#160;OR&#160;"fMRI"&#160;OR&#160;"Functional Magnetic Resonance Imaging"&#160;OR&#160;"t-fMRI"&#160;OR&#160;"tfMRI"&#160;OR&#160;"Task Based fMRI"&#160;OR&#160;"rs-fMRI"&#160;OR&#160;"rsfMRI"&#160;OR&#160;"Resting State fMRI"&#160;OR&#160;"MRS"&#160;OR&#160;"Magnetic Resonance Spectroscopy"&#160;) ) AND TITLE-ABS-KEY ( (&#160;"Neuroplasticity"&#160;OR&#160;"Neuronal Plasticity"&#160;OR&#160;"Neural Plasticity"&#160;OR&#160;"Brain Plasticity"&#160;OR&#160;"Brain Reorganization"&#160;OR&#160;"Brain Restructuring"&#160;) ) AND TITLE-ABS-KEY ( (&#160;"Stroke"&#160;OR&#160;"Ischemic Stroke"&#160;OR&#160;"Brain Ischemia"&#160;OR&#160;"Brain Infarct"&#160;OR&#160;"Hemorrhagic Stroke"&#160;OR&#160;"Brain Hemorrhage"&#160;OR&#160;"Brain Vascular Accident"&#160;) ) AND NOT TITLE-ABS-KEY ( (&#160;"Traumatic Brain Injury"&#160;OR&#160;"Acquired Brain Injury"&#160;OR&#160;"Concussion"&#160;OR&#160;"Anoxic Ischemic Encephalopathy"&#160;OR&#160;"Spinal Cord Injury"&#160;OR&#160;"Chronic Pain"&#160;OR&#160;"Neurodegenerative Disorders"&#160;OR&#160;"Dementia"&#160;OR&#160;"Mild Cognitive Impairment"&#160;OR&#160;"Alzheimer"&#160;OR&#160;"Perinatal Stroke"&#160;OR&#160;"Cerebral Palsy"&#160;OR&#160;"Depression"&#160;OR&#160;"Schizophrenia"&#160;) ) ) AND PUBYEAR &gt;&#160;2003&#160;AND PUBYEAR</td></tr></tbody></table></table-wrap><p>Inclusion and Exclusion Criteria</p><p>Eligible studies were original research articles or reviews evaluating neuroplasticity in stroke survivors using MRI modalities. Exclusion criteria were: studies involving animal models or conditions other than stroke; non-peer-reviewed outputs (e.g., conference proceedings, editorials, short surveys, letters, book chapters); and publications not written in English.</p><p>Screening and Selection Process</p><p>The search initially identified 854 records. After removing duplicates, titles and abstracts were screened independently by two reviewers (G.M.G. and E.R.V.) to assess compliance with eligibility criteria. Disagreements were resolved by consensus. Following full-text review, the 100 most-cited articles were retained for analysis. This bibliometric study was not registered in PROSPERO, as it does not synthesize clinical outcomes, but it followed the PRISMA-ScR (Scoping Review) guidelines&#160;[<xref rid="REF20" ref-type="bibr">20</xref>]&#160;to ensure methodological transparency and replicability, the selection pathway is illustrated in&#160;Figure <xref rid="FIG1" ref-type="fig">1</xref>&#160;(PRISMA flow diagram).</p><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>Workflow of the Bibliometric Analysis. </title><p>Stepwise methodology for identifying the top 100 most-cited articles on MRI-based neuroplasticity in stroke. The PRISMA-style diagram illustrates database retrieval (854 records), application of inclusion/exclusion criteria, and final selection for analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i01.jpg"/></fig><p>Definition of Bibliometric Analysis</p><p>Bibliometric analysis (BA) is a&#160;quantitative approach&#160;to evaluating authorship patterns, journal impact, and publication influence within a research field&#160;[<xref rid="REF21" ref-type="bibr">21</xref>,<xref rid="REF22" ref-type="bibr">22</xref>]. By analyzing citation data, BA identifies seminal studies, research trends, institutions, and collaborative networks.</p><p>Identification of Citation Classics</p><p>Following Garfield&#8217;s original definition&#160;[<xref rid="REF23" ref-type="bibr">23</xref>], articles with &#8805;100 citations were classified as&#160;Citation Classics. Articles with&#160;&lt;100 citations&#160;were categorized as&#160;Non-Classics.</p><p>Bibliometric Analysis Techniques</p><p>Two complementary approaches were applied&#160;[<xref rid="REF21" ref-type="bibr">21</xref>]:&#160;(1) Performance analysis quantified research output through the following indicators: total publications (TP), number of active years of publication (NAY), articles per active year (APY), number of contributing authors (NCA), and classification as sole-authored (SA) or co-authored (CA). (2) Science mapping explored intellectual structures, conceptual linkages, and collaborative networks through co-citation, keyword co-occurrence, and co-authorship analysis.</p><p>Statistical Analysis</p><p>Comparisons between Citation Classics and non-Classics were performed using:&#160;Chi-squared test (&#967;&#178;) for categorical variables; and&#160;Mann-Whitney U test for nonparametric continuous variables.</p><p>For each group, means, standard deviations (SD), and 95% confidence intervals (CIs) were calculated. Journal bibliometric metrics (Impact Factor (IF), CiteScore, SCImago Journal Rank (SJR), and Source Normalized Impact per Paper (SNIP)) were summarized with medians, quartiles, and interquartile ranges (IQRs). Associations between bibliometric measures and citation performance were assessed with Spearman&#8217;s&#160;&#961;, and scatterplots were generated for visualization.&#160;Statistical significance was set at p &lt; 0.05&#160;[<xref rid="REF24" ref-type="bibr">24</xref>,<xref rid="REF25" ref-type="bibr">25</xref>].</p><p>Software:&#160;Data handling was performed with Microsoft Excel v.16.67 (Microsoft Corporation, Redmond, WA, USA). Statistical analyses were conducted in R v.4.4.1 (The R Foundation, Vienna, Austria). The Biblioshiny package (K-Synth Srl, Naples, Italy) [<xref rid="REF26" ref-type="bibr">26</xref>]&#160;was used for performance analysis. VOSviewer v.1.6.20 (Centre for Science and Technology Studies, Leiden University, Leiden, The Netherlands)&#160;[<xref rid="REF27" ref-type="bibr">27</xref>]&#160;generated science mapping visualizations. Thresholds were defined as follows: &#8805;10 citations per author, &#8805;2 documents for institutions, countries, or journals, and &#8805;5 keyword co-occurrences.</p><p>Results</p><p>Performance Analysis</p><p>Retrieval and Selection of Articles:<italic toggle="yes">&#160;</italic>The Scopus search yielded 854 records related to MRI-based neuroplasticity research in stroke. Restricting the timeframe to 2004-2024 reduced this to 804 records. Exclusion of conference papers, books, editorials, short surveys, letters, and non-human studies left 750 records.&#160;Limiting to English-language publications yielded 715 records. After duplicate removal and manual screening, 648 articles remained. From these, the 100 most-cited articles were retained for analysis&#160;(Table <xref rid="TAB2" ref-type="table">2</xref>). The selection workflow is depicted in&#160;Figure <xref rid="FIG1" ref-type="fig">1</xref>&#160;(PRISMA flow diagram).</p><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Top 100 Most-Cited Articles on MRI-Based Neuroplasticity Research in Stroke. </title><p>This table presents the 100 most-cited articles published between 2004 and 2024 that used magnetic resonance imaging (MRI) to evaluate neuroplasticity in stroke. Articles are ranked by citation count and include key bibliometric details (authors, year of publication, journal, and total citations). These studies represent seminal contributions that have shaped the intellectual and clinical understanding of stroke recovery and brain reorganization.</p><p>BCI: brain-computer interface; fMRI: functional MRI; rTMS: repetitive TMS; tDCS: transcranial direct current stimulation; TMS: transcranial magnetic stimulation; VR: virtual reality</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ranking</td><td rowspan="1" colspan="1">Title</td><td rowspan="1" colspan="1">1st Author</td><td rowspan="1" colspan="1">Journal</td><td rowspan="1" colspan="1">Publication Year</td><td rowspan="1" colspan="1">Times Cited</td><td rowspan="1" colspan="1">Average Citation per Year</td></tr><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">The plastic human brain cortex [<xref rid="REF8" ref-type="bibr">8</xref>]</td><td rowspan="1" colspan="1">Pascual-Leone A.</td><td rowspan="1" colspan="1">Annual Review of Neuroscience</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">1274</td><td rowspan="1" colspan="1">64</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Dynamics of language reorganization after stroke [<xref rid="REF28" ref-type="bibr">28</xref>]</td><td rowspan="1" colspan="1">Saur D.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">876</td><td rowspan="1" colspan="1">46</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Cognitive motor processes: The role of motor imagery in the study of motor representations [<xref rid="REF29" ref-type="bibr">29</xref>]</td><td rowspan="1" colspan="1">Munzert J.</td><td rowspan="1" colspan="1">Brain Research Reviews</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">587</td><td rowspan="1" colspan="1">37</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Motor imagery: A backdoor to the motor system after stroke? [<xref rid="REF30" ref-type="bibr">30</xref>]</td><td rowspan="1" colspan="1">Sharma N.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">583</td><td rowspan="1" colspan="1">31</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">Dynamic functional reorganization of the motor execution network after stroke [<xref rid="REF14" ref-type="bibr">14</xref>]</td><td rowspan="1" colspan="1">Wang L.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">527</td><td rowspan="1" colspan="1">35</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Robot-based hand motor therapy after stroke [<xref rid="REF31" ref-type="bibr">31</xref>]</td><td rowspan="1" colspan="1">Takahashi C.D.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">518</td><td rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Reorganization of the human ipsilesional premotor cortex after stroke [<xref rid="REF32" ref-type="bibr">32</xref>]</td><td rowspan="1" colspan="1">Fridman E.A.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">385</td><td rowspan="1" colspan="1">18</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Motor system activation after subcortical stroke depends on corticospinal system integrity [<xref rid="REF33" ref-type="bibr">33</xref>]</td><td rowspan="1" colspan="1">Ward N.S.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">357</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Virtual reality-induced cortical reorganization and associated locomotor recovery in chronic stroke: An experimenter-blind randomized study [<xref rid="REF34" ref-type="bibr">34</xref>]</td><td rowspan="1" colspan="1">You S.H.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">351</td><td rowspan="1" colspan="1">18</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Renewal of the neurophysiology of language: Functional neuroimaging [<xref rid="REF35" ref-type="bibr">35</xref>]</td><td rowspan="1" colspan="1">D&#233;monet J.-F.</td><td rowspan="1" colspan="1">Physiological Reviews</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">347</td><td rowspan="1" colspan="1">17</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Remodeling the brain: plastic structural brain changes produced by different motor therapies after stroke [<xref rid="REF36" ref-type="bibr">36</xref>]</td><td rowspan="1" colspan="1">Gauthier L.V.</td><td rowspan="1" colspan="1">Stroke; a journal of cerebral circulation</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">328</td><td rowspan="1" colspan="1">19</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Motor rehabilitation and brain plasticity after hemiparetic stroke [<xref rid="REF37" ref-type="bibr">37</xref>]</td><td rowspan="1" colspan="1">Schaechter J.D.</td><td rowspan="1" colspan="1">Progress in Neurobiology</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">325</td><td rowspan="1" colspan="1">15</td></tr><tr><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Motor recovery and cortical reorganization after mirror therapy in chronic stroke patients: A phase II randomized controlled trial [<xref rid="REF38" ref-type="bibr">38</xref>]</td><td rowspan="1" colspan="1">Michielsen M.E.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">297</td><td rowspan="1" colspan="1">21</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Ankle dorsiflexion as an fMRI paradigm to assay motor control for walking during rehabilitation [<xref rid="REF39" ref-type="bibr">39</xref>]</td><td rowspan="1" colspan="1">Dobkin B.H.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">258</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Functionally Specific Reorganization in Human Premotor Cortex [<xref rid="REF40" ref-type="bibr">40</xref>]</td><td rowspan="1" colspan="1">O'Shea J.</td><td rowspan="1" colspan="1">Neuron</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">255</td><td rowspan="1" colspan="1">14</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Sleep-dependent motor memory plasticity in the human brain [<xref rid="REF41" ref-type="bibr">41</xref>]</td><td rowspan="1" colspan="1">Walker M.P.</td><td rowspan="1" colspan="1">Neuroscience</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">237</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">Treadmill exercise activates subcortical neural networks and improves walking after stroke: A randomized controlled trial [<xref rid="REF42" ref-type="bibr">42</xref>]</td><td rowspan="1" colspan="1">Luft A.R.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">229</td><td rowspan="1" colspan="1">13</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">Motor imagery after stroke: Relating outcome to motor network connectivity [<xref rid="REF43" ref-type="bibr">43</xref>]</td><td rowspan="1" colspan="1">Sharma N.</td><td rowspan="1" colspan="1">Annals of Neurology</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">224</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Are networks for residual language function and recovery consistent across aphasic patients? [<xref rid="REF44" ref-type="bibr">44</xref>]</td><td rowspan="1" colspan="1">Turkeltaub P.E.</td><td rowspan="1" colspan="1">Neurology</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">223</td><td rowspan="1" colspan="1">16</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">Resting state changes in functional connectivity correlate with movement recovery for BCI and robot-Assisted upper-extremity training after stroke [<xref rid="REF45" ref-type="bibr">45</xref>]</td><td rowspan="1" colspan="1">V&#225;rkuti B.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">217</td><td rowspan="1" colspan="1">18</td></tr><tr><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Non-invasive mapping of corticofugal fibres from multiple motor areas - Relevance to stroke recovery [<xref rid="REF46" ref-type="bibr">46</xref>]</td><td rowspan="1" colspan="1">Newton J.M.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">214</td><td rowspan="1" colspan="1">11</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Recovery from stroke: Current concepts and future perspectives [<xref rid="REF7" ref-type="bibr">7</xref>]</td><td rowspan="1" colspan="1">Grefkes C.</td><td rowspan="1" colspan="1">Neurological Research and Practice</td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">209</td><td rowspan="1" colspan="1">42</td></tr><tr><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">Motor cortex stimulation for the enhancement of recovery from stroke: A prospective, multicenter safety study [<xref rid="REF47" ref-type="bibr">47</xref>]</td><td rowspan="1" colspan="1">Brown J.A.</td><td rowspan="1" colspan="1">Neurosurgery</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">197</td><td rowspan="1" colspan="1">10</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Extent of bilateral neuronal network reorganization and functional recovery in relation to stroke severity [<xref rid="REF48" ref-type="bibr">48</xref>]</td><td rowspan="1" colspan="1">van Meer M.P.A.</td><td rowspan="1" colspan="1">Journal of Neuroscience</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">188</td><td rowspan="1" colspan="1">14</td></tr><tr><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Efficient neuroplasticity induction in chronic stroke patients by an associative brain-computer interface [<xref rid="REF49" ref-type="bibr">49</xref>]</td><td rowspan="1" colspan="1">Mrachacz-Kersting N.</td><td rowspan="1" colspan="1">Journal of Neurophysiology</td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">184</td><td rowspan="1" colspan="1">20</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Combination of brain-computer interface training and goal-directed physical therapy in chronic stroke: A case report [<xref rid="REF50" ref-type="bibr">50</xref>]</td><td rowspan="1" colspan="1">Broetz D.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">183</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">Cortical plasticity following motor skill learning during mental practice in stroke [<xref rid="REF51" ref-type="bibr">51</xref>]</td><td rowspan="1" colspan="1">Page S.J.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">10</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">Training and exercise to drive poststroke recovery [<xref rid="REF52" ref-type="bibr">52</xref>]</td><td rowspan="1" colspan="1">Dobkin B.H.</td><td rowspan="1" colspan="1">Nature Clinical Practice Neurology</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">158</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">Chronic stroke recovery after combined BCI training and physiotherapy: A case report [<xref rid="REF53" ref-type="bibr">53</xref>]</td><td rowspan="1" colspan="1">Caria A.</td><td rowspan="1" colspan="1">Psychophysiology</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">11</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Movement-dependent stroke recovery: A systematic review and meta-analysis of TMS and fMRI evidence [<xref rid="REF54" ref-type="bibr">54</xref>]</td><td rowspan="1" colspan="1">Richards L.G.</td><td rowspan="1" colspan="1">Neuropsychologia</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">Left hemisphere plasticity and aphasia recovery [<xref rid="REF55" ref-type="bibr">55</xref>]</td><td rowspan="1" colspan="1">Fridriksson J.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">12</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Neuroplasticity of language networks in aphasia: Advances, updates, and future challenges [<xref rid="REF56" ref-type="bibr">56</xref>]</td><td rowspan="1" colspan="1">Kiran S.</td><td rowspan="1" colspan="1">Frontiers in Neurology</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">Adult Visual Cortical Plasticity [<xref rid="REF57" ref-type="bibr">57</xref>]</td><td rowspan="1" colspan="1">Gilbert C.</td><td rowspan="1" colspan="1">Neuron</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">153</td><td rowspan="1" colspan="1">12</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">Functional MRI follow-up study of language processes in healthy subjects and during recovery in a case of aphasia [<xref rid="REF58" ref-type="bibr">58</xref>]</td><td rowspan="1" colspan="1">Fernandez B.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Functional reorganization of the cerebral motor system after stroke [<xref rid="REF59" ref-type="bibr">59</xref>]</td><td rowspan="1" colspan="1">Ward N.S.</td><td rowspan="1" colspan="1">Current Opinion in Neurology</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">Bilateral and unilateral arm training improve motor function through differing neuroplastic mechanisms: A single-blinded randomized controlled trial [<xref rid="REF60" ref-type="bibr">60</xref>]</td><td rowspan="1" colspan="1">Whitall J.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">Neuroplasticity and brain repair after stroke [<xref rid="REF61" ref-type="bibr">61</xref>]</td><td rowspan="1" colspan="1">Cramer S.C.</td><td rowspan="1" colspan="1">Current Opinion in Neurology</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">9</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Structural and functional plasticity in the somatosensory cortex of chronic stroke patients [<xref rid="REF62" ref-type="bibr">62</xref>]</td><td rowspan="1" colspan="1">Schaechter J.D.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">147</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">The right hemisphere is not unitary in its role in aphasia recovery [<xref rid="REF63" ref-type="bibr">63</xref>]</td><td rowspan="1" colspan="1">Turkeltaub P.E.</td><td rowspan="1" colspan="1">Cortex</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">11</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">Integrated technology for evaluation of brain function and neural plasticity [<xref rid="REF64" ref-type="bibr">64</xref>]</td><td rowspan="1" colspan="1">Rossini P.M.</td><td rowspan="1" colspan="1">Physical Medicine and Rehabilitation Clinics of North America</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">Two different reorganization patterns after rehabilitative therapy: An exploratory study with fMRI and TMS [<xref rid="REF65" ref-type="bibr">65</xref>]</td><td rowspan="1" colspan="1">Hamzei F.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">Predicting behavioural response to TDCS in chronic motor stroke [<xref rid="REF66" ref-type="bibr">66</xref>]</td><td rowspan="1" colspan="1">O'Shea J.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">137</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">Structural changes induced by daily music listening in the recovering brain after middle cerebral artery stroke: A voxel-based morphometry study [<xref rid="REF67" ref-type="bibr">67</xref>]</td><td rowspan="1" colspan="1">S&#228;rk&#228;m&#246; T.</td><td rowspan="1" colspan="1">Frontiers in Human Neuroscience</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">135</td><td rowspan="1" colspan="1">12</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">Brain networks and their relevance for stroke rehabilitation [<xref rid="REF2" ref-type="bibr">2</xref>]</td><td rowspan="1" colspan="1">Guggisberg A.G.</td><td rowspan="1" colspan="1">Clinical Neurophysiology</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">22</td></tr><tr><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">Impact of alertness training on spatial neglect: A behavioural and fMRI study [<xref rid="REF68" ref-type="bibr">68</xref>]</td><td rowspan="1" colspan="1">Thimm M.</td><td rowspan="1" colspan="1">Neuropsychologia</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">Stem cell therapy: A clinical trial of stroke [<xref rid="REF69" ref-type="bibr">69</xref>]</td><td rowspan="1" colspan="1">Bhasin A.</td><td rowspan="1" colspan="1">Clinical Neurology and Neurosurgery</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">10</td></tr><tr><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">Functional plasticity induced by mirror training: The mirror as the element connecting both hands to one hemisphere [<xref rid="REF70" ref-type="bibr">70</xref>]</td><td rowspan="1" colspan="1">Hamzei F.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">122</td><td rowspan="1" colspan="1">9</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Leap Motion-based virtual reality training for improving motor functional recovery of upper limbs and neural reorganization in subacute stroke patients [<xref rid="REF71" ref-type="bibr">71</xref>]</td><td rowspan="1" colspan="1">Wang Z.-R.</td><td rowspan="1" colspan="1">Neural Regeneration Research</td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">15</td></tr><tr><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">Comparison of finger tracking versus simple movement training via telerehabilitation to alter hand function and cortical reorganization after stroke [<xref rid="REF72" ref-type="bibr">72</xref>]</td><td rowspan="1" colspan="1">Carey J.R.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">118</td><td rowspan="1" colspan="1">7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">Activity in preserved left hemisphere regions predicts anomia severity in aphasia [<xref rid="REF73" ref-type="bibr">73</xref>]</td><td rowspan="1" colspan="1">Fridriksson J.</td><td rowspan="1" colspan="1">Cerebral Cortex</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">Efficacy and brain imaging correlates of an immersive motor imagery BCI-driven VR system for upper limb motor rehabilitation: A clinical case report [<xref rid="REF74" ref-type="bibr">74</xref>]</td><td rowspan="1" colspan="1">Vourvopoulos A.</td><td rowspan="1" colspan="1">Frontiers in Human Neuroscience</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">20</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">Effects of high- and low-frequency repetitive transcranial magnetic stimulation on motor recovery in early stroke patients: Evidence from a randomized controlled trial with clinical, neurophysiological and functional imaging assessments [<xref rid="REF75" ref-type="bibr">75</xref>]</td><td rowspan="1" colspan="1">Du J.</td><td rowspan="1" colspan="1">NeuroImage: Clinical</td><td rowspan="1" colspan="1">2019</td><td rowspan="1" colspan="1">116</td><td rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">Induction of neuroplasticity and recovery in post-stroke aphasia by non-invasive brain stimulation [<xref rid="REF76" ref-type="bibr">76</xref>]</td><td rowspan="1" colspan="1">Shah P.P.</td><td rowspan="1" colspan="1">Frontiers in Human Neuroscience</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">113</td><td rowspan="1" colspan="1">9</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">Neuroimaging experimental studies on brain plasticity in recovery from stroke [<xref rid="REF77" ref-type="bibr">77</xref>]</td><td rowspan="1" colspan="1">Rossini P.M.</td><td rowspan="1" colspan="1">Europa Medicophysica</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">111</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial [<xref rid="REF78" ref-type="bibr">78</xref>]</td><td rowspan="1" colspan="1">Jaillard A.</td><td rowspan="1" colspan="1">Translational Stroke Research</td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">110</td><td rowspan="1" colspan="1">22</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">Functional connectivity in relation to motor performance and recovery after stroke [<xref rid="REF79" ref-type="bibr">79</xref>]</td><td rowspan="1" colspan="1">Westlake K.P.</td><td rowspan="1" colspan="1">Frontiers in Systems Neuroscience</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">108</td><td rowspan="1" colspan="1">8</td></tr><tr><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">Enduring representational plasticity after somatosensory stimulation [<xref rid="REF80" ref-type="bibr">80</xref>]</td><td rowspan="1" colspan="1">Wu C.W.-H.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">Shaping Early Reorganization of Neural Networks Promotes Motor Function after Stroke [<xref rid="REF81" ref-type="bibr">81</xref>]</td><td rowspan="1" colspan="1">Volz L.J.</td><td rowspan="1" colspan="1">Cerebral Cortex</td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage [<xref rid="REF82" ref-type="bibr">82</xref>]</td><td rowspan="1" colspan="1">Karki K.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">Neuroplasticity and constraint-induced movement therapy [<xref rid="REF83" ref-type="bibr">83</xref>]</td><td rowspan="1" colspan="1">Mark V.W.</td><td rowspan="1" colspan="1">Europa Medicophysica</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">102</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">Enhanced cortical activation in the contralesional hemisphere of chronic stroke patients in response to motor skill challenge [<xref rid="REF84" ref-type="bibr">84</xref>]</td><td rowspan="1" colspan="1">Schaechter J.D.</td><td rowspan="1" colspan="1">Cerebral Cortex</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">101</td><td rowspan="1" colspan="1">6</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">A macroscopic view of microstructure: Using diffusion-weighted images to infer damage, repair, and plasticity of white matter [<xref rid="REF85" ref-type="bibr">85</xref>]</td><td rowspan="1" colspan="1">Concha L.</td><td rowspan="1" colspan="1">Neuroscience</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">Motor cortex excitability and connectivity in chronic stroke: a multimodal model of functional reorganization [<xref rid="REF86" ref-type="bibr">86</xref>]</td><td rowspan="1" colspan="1">Volz L.J.</td><td rowspan="1" colspan="1">Brain Structure and Function</td><td rowspan="1" colspan="1">2015</td><td rowspan="1" colspan="1">96</td><td rowspan="1" colspan="1">10</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">Neuroplastic changes following rehabilitative training correlate with regional electrical field induced with tDCS [<xref rid="REF87" ref-type="bibr">87</xref>]</td><td rowspan="1" colspan="1">Halko M.A.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">95</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Diffusion tensor imaging and fiber tractography in acute stroke [<xref rid="REF88" ref-type="bibr">88</xref>]</td><td rowspan="1" colspan="1">Mukherjee P.</td><td rowspan="1" colspan="1">Neuroimaging Clinics of North America</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">A review of transcranial magnetic stimulation and multimodal neuroimaging to characterize post-stroke neuroplasticity [<xref rid="REF89" ref-type="bibr">89</xref>]</td><td rowspan="1" colspan="1">Auriat A.M.</td><td rowspan="1" colspan="1">Frontiers in Neurology</td><td rowspan="1" colspan="1">2015</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">Neural plasticity and treatment-induced recovery of sentence processing in agrammatism [<xref rid="REF90" ref-type="bibr">90</xref>]</td><td rowspan="1" colspan="1">Thompson . C.K.</td><td rowspan="1" colspan="1">Neuropsychologia</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">6</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">Functional MRI correlates of lower limb function in stroke victims with gait impairment [<xref rid="REF91" ref-type="bibr">91</xref>]</td><td rowspan="1" colspan="1">Enzinger C.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">Neural recruitment associated with anomia treatment in aphasia [<xref rid="REF92" ref-type="bibr">92</xref>]</td><td rowspan="1" colspan="1">Fridriksson J.</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">Enhanced Interhemispheric Functional Connectivity Compensates for Anatomical Connection Damages in Subcortical Stroke [<xref rid="REF93" ref-type="bibr">93</xref>]</td><td rowspan="1" colspan="1">Liu J.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2015</td><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">Neuroimaging and recovery of language in aphasia [<xref rid="REF94" ref-type="bibr">94</xref>]</td><td rowspan="1" colspan="1">Thompson C.K.</td><td rowspan="1" colspan="1">Current Neurology and Neuroscience Reports</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">Music supported therapy promotes motor plasticity in individuals with chronic stroke [<xref rid="REF95" ref-type="bibr">95</xref>]</td><td rowspan="1" colspan="1">Ripoll&#233;s P.</td><td rowspan="1" colspan="1">Brain Imaging and Behavior</td><td rowspan="1" colspan="1">2016</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">9</td></tr><tr><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">Functional MRI and Diffusion Tensor Imaging of Brain Reorganization After Experimental Stroke [<xref rid="REF96" ref-type="bibr">96</xref>]</td><td rowspan="1" colspan="1">Dijkhuizen R.M.</td><td rowspan="1" colspan="1">Translational Stroke Research</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">6</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">Post-lesional cerebral reorganisation: Evidence from functional neuroimaging and transcranial magnetic stimulation [<xref rid="REF97" ref-type="bibr">97</xref>]</td><td rowspan="1" colspan="1">B&#252;tefisch C.M.</td><td rowspan="1" colspan="1">Journal of Physiology Paris</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">Lesion-induced and training-induced brain reorganization [<xref rid="REF98" ref-type="bibr">98</xref>]</td><td rowspan="1" colspan="1">Liepert J.</td><td rowspan="1" colspan="1">Restorative Neurology and Neuroscience</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">Cortical reorganization - Effects of intensive therapy: Results from prospective functional imaging studies [<xref rid="REF99" ref-type="bibr">99</xref>]</td><td rowspan="1" colspan="1">Nelles G.</td><td rowspan="1" colspan="1">Restorative Neurology and Neuroscience</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">Evolution of fMRI activation in the perilesional primary motor cortex and cerebellum with rehabilitation training-related motor gains after stroke: A pilot study [<xref rid="REF100" ref-type="bibr">100</xref>]</td><td rowspan="1" colspan="1">Dong Y.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">Structural damage and functional reorganization in Ipsilesional M1 in well-recovered patients with subcortical stroke [<xref rid="REF101" ref-type="bibr">101</xref>]</td><td rowspan="1" colspan="1">Zhang J.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">Therapy-induced neuroplasticity in chronic aphasia [<xref rid="REF102" ref-type="bibr">102</xref>]</td><td rowspan="1" colspan="1">Marcotte K.</td><td rowspan="1" colspan="1">Neuropsychologia</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">6</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">Human adult cortical reorganization and consequent visual distortion [<xref rid="REF103" ref-type="bibr">103</xref>]</td><td rowspan="1" colspan="1">Dilks D.D.</td><td rowspan="1" colspan="1">Journal of Neuroscience</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">Neural correlates of proprioceptive integration in the contralesional hemisphere of very impaired patients shortly after a subcortical stroke: An fMRI study [<xref rid="REF104" ref-type="bibr">104</xref>]</td><td rowspan="1" colspan="1">Dechaumont-Palacin S.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">Structural plasticity in adulthood with motor learning and stroke rehabilitation [<xref rid="REF105" ref-type="bibr">105</xref>]</td><td rowspan="1" colspan="1">Sampaio-Baptista C.</td><td rowspan="1" colspan="1">Annual Review of Neuroscience</td><td rowspan="1" colspan="1">2018</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">11</td></tr><tr><td rowspan="1" colspan="1">83</td><td rowspan="1" colspan="1">Mechanism of Kinect-based virtual reality training for motor functional recovery of upper limbs after subacute stroke [<xref rid="REF106" ref-type="bibr">106</xref>]</td><td rowspan="1" colspan="1">Bao X.</td><td rowspan="1" colspan="1">Neural Regeneration Research</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">6</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">84</td><td rowspan="1" colspan="1">Changes in white matter integrity follow excitatory rTMS treatment of post-stroke aphasia [<xref rid="REF107" ref-type="bibr">107</xref>]</td><td rowspan="1" colspan="1">Allendorfer J.B.</td><td rowspan="1" colspan="1">Restorative Neurology and Neuroscience</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">Reorganization of syntactic processing following left-hemisphere brain damage: Does right-hemisphere activity preserve function? [<xref rid="REF108" ref-type="bibr">108</xref>]</td><td rowspan="1" colspan="1">Tyler L.K.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">86</td><td rowspan="1" colspan="1">Functional magnetic resonance imaging study on dysphagia after unilateral hemispheric stroke: A preliminary study [<xref rid="REF109" ref-type="bibr">109</xref>]</td><td rowspan="1" colspan="1">Li S.</td><td rowspan="1" colspan="1">Journal of Neurology, Neurosurgery and Psychiatry</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">Acute ischaemic stroke alters the brain's preference for distinct dynamic connectivity states [<xref rid="REF110" ref-type="bibr">110</xref>]</td><td rowspan="1" colspan="1">Bonkhoff A.K.</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">14</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">Functional neuroimaging in stroke recovery and neurorehabilitation: Conceptual issues and perspectives [<xref rid="REF111" ref-type="bibr">111</xref>]</td><td rowspan="1" colspan="1">Carey L.M.</td><td rowspan="1" colspan="1">International Journal of Stroke</td><td rowspan="1" colspan="1">2007</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">89</td><td rowspan="1" colspan="1">Cortical Reorganization Following Modified Constraint-Induced Movement Therapy: A Study of 4 Patients With Chronic Stroke [<xref rid="REF112" ref-type="bibr">112</xref>]</td><td rowspan="1" colspan="1">Szaflarski J.P.</td><td rowspan="1" colspan="1">Archives of Physical Medicine and Rehabilitation</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">3</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">A paradox: After stroke, the non-lesioned lower limb motor cortex may be maladaptive [<xref rid="REF113" ref-type="bibr">113</xref>]</td><td rowspan="1" colspan="1">Madhavan S.</td><td rowspan="1" colspan="1">European Journal of Neuroscience</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">Activity in the peri-infarct rim in relation to recovery from stroke [<xref rid="REF114" ref-type="bibr">114</xref>]</td><td rowspan="1" colspan="1">Cramer S.C.</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">3</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">A review of diffusion tensor imaging studies on motor recovery mechanisms in stroke patients [<xref rid="REF115" ref-type="bibr">115</xref>]</td><td rowspan="1" colspan="1">Jang S.H.</td><td rowspan="1" colspan="1">NeuroRehabilitation</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">93</td><td rowspan="1" colspan="1">When right is all that is left: Plasticity of right-hemisphere tracts in a young aphasic patient [<xref rid="REF116" ref-type="bibr">116</xref>]</td><td rowspan="1" colspan="1">Zipse L.</td><td rowspan="1" colspan="1">Annals of the New York Academy of Sciences</td><td rowspan="1" colspan="1">2012</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">fMRI analysis of ankle movement tracking training in subject with stroke [<xref rid="REF117" ref-type="bibr">117</xref>]</td><td rowspan="1" colspan="1">Carey J.R.</td><td rowspan="1" colspan="1">Experimental Brain Research</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">95</td><td rowspan="1" colspan="1">Effects of Virtual Reality Intervention on Neural Plasticity in Stroke Rehabilitation: A Systematic Review [<xref rid="REF118" ref-type="bibr">118</xref>]</td><td rowspan="1" colspan="1">Hao J.</td><td rowspan="1" colspan="1">Archives of Physical Medicine and Rehabilitation</td><td rowspan="1" colspan="1">2022</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">20</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">96</td><td rowspan="1" colspan="1">The neural correlates of semantic feature analysis in chronic aphasia: Discordant patterns according to the etiology [<xref rid="REF119" ref-type="bibr">119</xref>]</td><td rowspan="1" colspan="1">Marcotte K.</td><td rowspan="1" colspan="1">Seminars in Speech and Language</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">Effects of home-based telerehabilitation in patients with stroke: A randomized controlled trial [<xref rid="REF120" ref-type="bibr">120</xref>]</td><td rowspan="1" colspan="1">Chen J.</td><td rowspan="1" colspan="1">Neurology</td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">12</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">98</td><td rowspan="1" colspan="1">Functional MRI of swallowing: From neurophysiology to neuroplasticity [<xref rid="REF121" ref-type="bibr">121</xref>]</td><td rowspan="1" colspan="1">Malandraki G.A.</td><td rowspan="1" colspan="1">Head and Neck</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">Neuroplasticity in Post-Stroke Aphasia: A Systematic Review and Meta-Analysis of Functional Imaging Studies of Reorganization of Language Processing [<xref rid="REF122" ref-type="bibr">122</xref>]</td><td rowspan="1" colspan="1">Wilson S.M.</td><td rowspan="1" colspan="1">Neurobiology of Language</td><td rowspan="1" colspan="1">2020</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">12</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">100</td><td rowspan="1" colspan="1">Brain activity associated with stimulation therapy of the visual borderzone in hemianopic stroke patients [<xref rid="REF123" ref-type="bibr">123</xref>]</td><td rowspan="1" colspan="1">Marshall R.S.</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">2008</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><p>Yearly Publications and Citations:&#160;Annual publication output showed fluctuations, with a peak of 13 articles in 2006 (Figure <xref rid="FIG2" ref-type="fig">2A</xref>). After 2012, output declined, stabilizing at fewer than five publications per year after 2014. The overall mean publication rate across the two decades was 5.5 articles per year.</p><fig position="anchor" fig-type="figure" id="FIG2" orientation="portrait"><label>Figure 2</label><caption><title>Yearly Trends in Publications and Citations (2004&#8211;2024). </title><p>(A) Annual publication counts, peaking in 2006 with 13 articles, followed by a gradual decline. (B) Annual citation counts, peaking in 2006 with 3,042 citations, reflecting the enduring impact of seminal studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i02.jpg"/></fig><p>Citation activity followed a similar trajectory, peaking at 3,042 citations in 2006 (Figure <xref rid="FIG2" ref-type="fig">2B</xref>). Despite subsequent declines, modest rebounds in 2019 and 2020 reflected the enduring influence of foundational works. On average, the dataset accumulated 967 citations per year, underscoring the sustained relevance of seminal MRI studies in stroke neuroplasticity.</p><p>Citation Classics vs. Non-Classics:&#160;Of the 100 analyzed articles, 62 qualified as Citation Classics (&#8805;100 citations) and 38 as Non-Classics (&lt;100 citations). Citation Classics accrued a higher mean citation count (234.1 &#177; 198.4; 95% CI, 184.9-283.3) compared with Non-Classics (75.9 &#177; 12.4; 95% CI, 71.8-80.0; p &lt; 0.0001). Similarly, the average citation rate per year was significantly higher among Classics (15.7 &#177; 10.9; 95% CI, 13.0-18.4) than Non-Classics (6.4 &#177; 3.6; 95% CI, 5.3-7.5; p &lt; 0.0001) (Table <xref rid="TAB3" ref-type="table">3</xref>).</p><table-wrap position="float" id="TAB3" orientation="portrait"><label>Table 3</label><caption><title>Comparison of Citation Classics and Non-classics Based on Continuous Performance Metrics. </title><p>This table compares continuous performance variables (citations, citations per year, years active, and number of authors) between Citation Classics (&#8805;100 citations) and Non-classics (&lt;100 citations). Statistical comparisons were performed with the Mann&#8211;Whitney U test. Values for &#8220;All articles&#8221; are descriptive summaries of the entire dataset and were not included in statistical testing. A p-value &lt; 0.05 was considered statistically significant.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Performance variables
</td><td rowspan="1" colspan="1">
All articles Mean (SD) [95% CI]
</td><td rowspan="1" colspan="1">
Citation Classic (N = 62) Mean (SD) [95% CI]
</td><td rowspan="1" colspan="1">
Non-classic (N = 38) Mean (SD) [95% CI]
</td><td rowspan="1" colspan="1">
p-value
</td></tr><tr><td rowspan="1" colspan="1">
Citations
</td><td rowspan="1" colspan="1">
174.0 (174.0) [140.1&#8211;207.9]
</td><td rowspan="1" colspan="1">
234.1 (198.4) [184.0&#8211;284.2]
</td><td rowspan="1" colspan="1">
75.9 (12.4) [71.8&#8211;80.0]
</td><td rowspan="1" colspan="1">
&lt; 0.0001*
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Average citation per year
</td><td rowspan="1" colspan="1">
12.2 (9.9) [10.2&#8211;14.2]
</td><td rowspan="1" colspan="1">
15.7 (10.9) [13.0&#8211;18.4]
</td><td rowspan="1" colspan="1">
6.4 (3.6) [5.2&#8211;7.6]
</td><td rowspan="1" colspan="1">
&lt; 0.0001*
</td></tr><tr><td rowspan="1" colspan="1">
Years active
</td><td rowspan="1" colspan="1">
14.8 (4.7) [13.8&#8211;15.8]
</td><td rowspan="1" colspan="1">
15.3 (4.6) [14.1&#8211;16.5]
</td><td rowspan="1" colspan="1">
14.0 (4.9) [12.4&#8211;15.6]
</td><td rowspan="1" colspan="1">
0.162
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Number of authors
</td><td rowspan="1" colspan="1">
5.9 (5.1) [4.9&#8211;6.9]
</td><td rowspan="1" colspan="1">
6.3 (5.9) [4.8&#8211;7.8]
</td><td rowspan="1" colspan="1">
5.3 (3.4) [4.2&#8211;6.4]
</td><td rowspan="1" colspan="1">
0.295
</td></tr></tbody></table></table-wrap><p>No significant difference was found in years active (15.3 &#177; 4.6 vs. 14.0 &#177; 4.9; p = 0.162) or number of authors per article (6.3 &#177; 5.9 vs. 5.3 &#177; 3.4; p = 0.295).</p><p>Authorship patterns revealed that 93% of all publications were co-authored, with no significant difference between groups (p = 0.279). In terms of article type, original research comprised 73% of the dataset and reviews 27%, with no significant variation between groups (p = 0.904) (Table <xref rid="TAB4" ref-type="table">4</xref>).</p><table-wrap position="float" id="TAB4" orientation="portrait"><label>Table 4</label><caption><title>Comparison of Citation Classics and Non-classics Based on Categorical Performance Variables. </title><p>This table compares categorical variables (type of authorship and article type) between Citation Classics (&#8805;100 citations) and Non-classics (&lt;100 citations). Statistical comparison performed with the Chi-squared test (&#967;&#178; test). A p-value &lt; 0.05 was considered statistically significant. Values for &#8220;All articles&#8221; are descriptive summaries of the entire dataset and were not included in statistical testing.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Performance variables
</td><td rowspan="1" colspan="1">
All articles N (%) [95% CI]
</td><td rowspan="1" colspan="1">
Citation Classic N (%) [95% CI]
</td><td rowspan="1" colspan="1">
Non-classic N (%) [95% CI]
</td><td rowspan="1" colspan="1">
p-value
</td></tr><tr><td rowspan="1" colspan="1">
Authorship
</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Co-authored publications
</td><td rowspan="1" colspan="1">
93 (93.0%) [86.1&#8211;97.1]
</td><td rowspan="1" colspan="1">
59 (63.4%) [50.9&#8211;74.7]
</td><td rowspan="1" colspan="1">
34 (36.6%) [25.3&#8211;49.1]
</td><td rowspan="1" colspan="1">
0.279
</td></tr><tr><td rowspan="1" colspan="1">
Sole-authored publications
</td><td rowspan="1" colspan="1">
7 (7.0%) [2.9&#8211;13.9]
</td><td rowspan="1" colspan="1">
3 (42.9%) [9.9&#8211;81.6]
</td><td rowspan="1" colspan="1">
4 (57.1%) [18.4&#8211;90.1]
</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Type of article
</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">
Original
</td><td rowspan="1" colspan="1">
73 (73.0%) [63.3&#8211;81.4]
</td><td rowspan="1" colspan="1">
45 (61.6%) [48.7&#8211;73.3]
</td><td rowspan="1" colspan="1">
28 (38.4%) [26.7&#8211;51.3]
</td><td rowspan="1" colspan="1">
0.904
</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Review
</td><td rowspan="1" colspan="1">
27 (27.0%) [18.6&#8211;36.7]
</td><td rowspan="1" colspan="1">
17 (63.0%) [42.4&#8211;80.6]
</td><td rowspan="1" colspan="1">
10 (37.0%) [19.4&#8211;57.6]
</td><td rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap><p>Temporal distribution showed a concentration of Classics in 2006 (nine publications), coinciding with landmark fMRI and DTI studies on cortical reorganization. Non-Classics contributed more steadily but with lower overall impact.</p><p>Figure <xref rid="FIG3" ref-type="fig">3A</xref>&#160;illustrates the yearly distribution of Citation Classics and Non-Classics in terms of the number of articles. The data reveal a peak in Citation Classics in 2006, with nine publications, marking a period of heightened research activity. In contrast, Non-Classics demonstrated a steady but lower contribution across the years, reflecting their limited impact compared to highly cited works. The trends suggest that seminal publications from earlier years continue to dominate the field.</p><fig position="anchor" fig-type="figure" id="FIG3" orientation="portrait"><label>Figure 3</label><caption><title>Temporal Distribution of Citation Classics, Non-Classics, Review Articles, and Original Articles among the Top 100 Most-Cited Studies on MRI-Based Neuroplasticity in Stroke (2004&#8211;2022). </title><p>(A) Distribution of Citation Classics (&#8805;100 citations; orange bars) versus Non-Classics (&lt;100 citations; green bars). The upper panel displays the number of articles published per year, while the lower panel shows their annual citation totals. Citation Classics peaked in 2006 with 9 publications and 2,740 citations, followed by 8 publications in 2008. In contrast, Non-Classics maintained a relatively consistent but lower annual output. Dashed trend lines in both panels represent LOESS (Locally Estimated Scatterplot Smoothing) regression curves, illustrating a general decline in both publication frequency and citation volume for Citation Classics over time, with a mild resurgence in 2020. (B) Comparison of Original Articles (yellow bars) and Review Articles (orange bars). The upper panel presents annual publication counts, showing a peak in original articles in 2006 (11 articles) and review articles in 2005 and 2007 (4 articles each). The lower panel depicts annual citation counts, where original articles reached a peak of 2,357 citations in 2006 and sustained higher citation levels through 2012. Review articles exhibited lower overall citation volumes but demonstrated steadier citation rates over time. LOESS regression curves reveal a long-term decline in citations for original research, with a flatter citation trajectory for review articles, suggesting their continued influence in the field.</p><p>Together, these trends highlight the temporal dynamics of article type and citation performance, underscoring the early dominance of original research in driving citation impact, alongside the persistent relevance of review articles and the waning of hyper-cited classics in recent years.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i03.jpg"/></fig><p>Figure <xref rid="FIG3" ref-type="fig">3B</xref>&#160;provides further insights into citation trends, highlighting a pronounced citation peak in 2006, coinciding with the highest number of Citation Classics published. While the citation count for Non-Classics remained consistently low throughout the years, Citation Classics exhibited significant variability, reflecting the disproportionate influence of certain high-impact articles. The declining citation rates for Citation Classics after 2010 may indicate a natural lifecycle of citation accumulation as the field evolves.</p><p>Journals and Bibliometric Profiles:&#160;Highly cited articles were concentrated in a small group of high-impact journals (Table <xref rid="TAB5" ref-type="table">5</xref>).</p><table-wrap position="float" id="TAB5" orientation="portrait"><label>Table 5</label><caption><title>Journals Publishing the Top 100 Most-Cited Articles on MRI-Based Neuroplasticity in Stroke (2004&#8211;2024). </title><p>This table ranks journals that published the most influential articles on MRI applications in stroke-related neuroplasticity research. Data include the total number of articles, distribution by article type (original vs. review), total citation counts, percentage share of citations across the top 100 articles, and average annual citation rate. High-impact neuroscience and neuroimaging journals such as <italic toggle="yes">Brain</italic>, <italic toggle="yes">Stroke</italic>, and <italic toggle="yes">Neurorehabilitation and Neural Repair </italic>dominate the ranking, reflecting their central role in disseminating foundational and translational research. The inclusion of both general neuroscience outlets (e.g., <italic toggle="yes">Neuron</italic>, <italic toggle="yes">Annual Review of Neuroscience</italic>) and specialized clinical journals (e.g., <italic toggle="yes">Neurorehabilitation and Neural Repair</italic>, <italic toggle="yes">Archives of Physical Medicine and Rehabilitation</italic>) highlights the interdisciplinary nature of MRI-based neuroplasticity research in stroke recovery.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Rank</td><td rowspan="2" colspan="1">Journal</td><td colspan="3" rowspan="1">Articles</td><td colspan="3" rowspan="1">Citations</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">Original</td><td rowspan="1" colspan="1">Review</td><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">Average/year</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Brain</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3514</td><td rowspan="1" colspan="1">20.2%</td><td rowspan="1" colspan="1">20.7</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Stroke</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1744</td><td rowspan="1" colspan="1">10.0%</td><td rowspan="1" colspan="1">11.1</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">Neurorehabilitation and Neural Repair</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1403</td><td rowspan="1" colspan="1">8.1%</td><td rowspan="1" colspan="1">10.7</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Annual Review of Neuroscience</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1349</td><td rowspan="1" colspan="1">7.8%</td><td rowspan="1" colspan="1">37.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">NeuroImage</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">982</td><td rowspan="1" colspan="1">5.6%</td><td rowspan="1" colspan="1">8.6</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Brain Research Reviews</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">587</td><td rowspan="1" colspan="1">3.4%</td><td rowspan="1" colspan="1">37.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Neuropsychologia</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">450</td><td rowspan="1" colspan="1">2.6%</td><td rowspan="1" colspan="1">7.0</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Neuron</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">408</td><td rowspan="1" colspan="1">2.3%</td><td rowspan="1" colspan="1">13.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Frontiers in Human Neuroscience</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">365</td><td rowspan="1" colspan="1">2.1%</td><td rowspan="1" colspan="1">13.7</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Physiological Reviews</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">347</td><td rowspan="1" colspan="1">2.0%</td><td rowspan="1" colspan="1">17.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Neuroscience</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">334</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">10.5</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Stroke; a journal of cerebral circulation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">328</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">19.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Cerebral Cortex</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">325</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">8.7</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Progress in Neurobiology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">325</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">15.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Current Opinion in Neurology</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">8.0</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Neurology</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">282</td><td rowspan="1" colspan="1">1.6%</td><td rowspan="1" colspan="1">14.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">Journal of Neuroscience</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">264</td><td rowspan="1" colspan="1">1.5%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">Frontiers in Neurology</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">250</td><td rowspan="1" colspan="1">1.4%</td><td rowspan="1" colspan="1">17.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Restorative Neurology and Neuroscience</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">227</td><td rowspan="1" colspan="1">1.3%</td><td rowspan="1" colspan="1">4.3</td></tr><tr><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">Annals of Neurology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">224</td><td rowspan="1" colspan="1">1.3%</td><td rowspan="1" colspan="1">14.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Europa Medicophysica</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">213</td><td rowspan="1" colspan="1">1.2%</td><td rowspan="1" colspan="1">5.5</td></tr><tr><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Neurological Research and Practice</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">209</td><td rowspan="1" colspan="1">1.2%</td><td rowspan="1" colspan="1">42.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">Neurosurgery</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">197</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">10.0</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Neural Regeneration Research</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">193</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">10.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Translational Stroke Research</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">193</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">14.0</td></tr><tr><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Journal of Neurophysiology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">184</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">20.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">Nature Clinical Practice Neurology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">158</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">Psychophysiology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">11.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">Cortex</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">11.0</td></tr><tr><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Physical Medicine and Rehabilitation Clinics of North America</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">7.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">Clinical Neurophysiology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">22.0</td></tr><tr><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Archives of Physical Medicine and Rehabilitation</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">11.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">Clinical Neurology and Neurosurgery</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">10.0</td></tr><tr><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">NeuroImage: Clinical</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">116</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">19.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Frontiers in Systems Neuroscience</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">108</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">8.0</td></tr><tr><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">Brain Structure and Function</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">96</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">10.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">Neuroimaging Clinics of North America</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">5.0</td></tr><tr><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">Current Neurology and Neuroscience Reports</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">Brain Imaging and Behavior</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">Journal of Physiology Paris</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">Journal of Neurology, Neurosurgery and Psychiatry</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">European Journal of Neuroscience</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">International Journal of Stroke</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">Annals of the New York Academy of Sciences</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">NeuroRehabilitation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">Experimental Brain Research</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">3.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">Seminars in Speech and Language</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Head and Neck</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">Neurobiology of Language</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">12.0</td></tr></tbody></table></table-wrap><p><italic toggle="yes">Brain </italic>published 10 articles (3,514 citations; 20.2% of total). <italic toggle="yes">Stroke </italic>published nine articles (1,744 citations; 10%). <italic toggle="yes">Neurorehabilitation and Neural Repair</italic> contributed nine articles (1,403 citations; 8.1%). Review journals such as <italic toggle="yes">Annual Review of Neuroscience</italic> and <italic toggle="yes">Brain Research Reviews</italic> also ranked highly, with annual citation rates of 37.5 and 37.0, respectively. Among original research outlets, <italic toggle="yes">NeuroImage </italic>contributed seven studies (982 citations; 5.6%), reflecting its emphasis on advanced MRI techniques.</p><p>Correlation analyses demonstrated strong associations between journal bibliometric indices and citation performance: IF and CiteScore (r = 0.98), SNIP (r = 0.97), and SJR (r = 0.92) (Figure <xref rid="FIG4" ref-type="fig">4</xref>).&#160;</p><fig position="anchor" fig-type="figure" id="FIG4" orientation="portrait"><label>Figure 4</label><caption><title>Correlation of Journal Bibliometric Metrics with Citation Performance. </title><p>This figure illustrates the pairwise Spearman correlation coefficients among five major journal-level bibliometric metrics: Impact Factor (IF), CiteScore, Scimago Journal Rank (SJR), Source Normalized Impact per Paper (SNIP), and Quartile Ranking. The upper triangular matrix shows numerical correlation coefficients, while the lower triangular panels present scatterplots with locally smoothed regression lines. Notably, the strongest observed correlations include IF vs. CiteScore (r&#8239;=&#8239;0.98), IF vs. SNIP (r&#8239;=&#8239;0.97), and CiteScore vs. SNIP (r&#8239;=&#8239;0.98), indicating tight alignment between these metrics in reflecting journal performance. Moderate associations were observed between SJR and SNIP (r&#8239;=&#8239;0.90), and between all metrics and Quartile Rankings (r&#8239;&#8776;&#8239;0.44&#8211;0.49). These results suggest that the journals contributing most frequently to the highly cited literature in this field tend to occupy top positions across multiple evaluation systems. The high interdependence among these indicators underscores their collective value in assessing journal prestige and influence within the domain of neuroimaging and stroke research.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i04.jpg"/></fig><p>Most journals belonged to Q1 categories, underscoring the dominance of neuroscience and neurology outlets (Table <xref rid="TAB6" ref-type="table">6</xref>).</p><table-wrap position="float" id="TAB6" orientation="portrait"><label>Table 6</label><caption><title>Bibliometric Indicators of Journals Publishing the Top 100 Most-Cited Articles on MRI-Based Neuroplasticity in Stroke. </title><p>This table summarizes the distribution of journal impact metrics for the sources represented in the study. Reported values include median, 25th percentile, 75th percentile, and interquartile range (IQR) for Impact Factor (IF), CiteScore, SCImago Journal Rank (SJR), and Source Normalized Impact per Paper (SNIP). Quartile classifications (Q1&#8211;Q4) are also shown, highlighting that most influential publications were concentrated in Q1 journals. These data reflect the strong representation of high-impact neuroscience and neuroimaging journals in disseminating foundational and translational research on stroke neuroplasticity.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Metric</td><td rowspan="1" colspan="1">Median</td><td rowspan="1" colspan="1">25th percentile</td><td rowspan="1" colspan="1">75th percentile</td><td rowspan="1" colspan="1">IQR</td></tr><tr><td rowspan="1" colspan="1">Impact Factor (IF)</td><td rowspan="1" colspan="1">3.60</td><td rowspan="1" colspan="1">2.40</td><td rowspan="1" colspan="1">5.63</td><td rowspan="1" colspan="1">3.23</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CiteScore</td><td rowspan="1" colspan="1">7.30</td><td rowspan="1" colspan="1">5.53</td><td rowspan="1" colspan="1">11.98</td><td rowspan="1" colspan="1">6.45</td></tr><tr><td rowspan="1" colspan="1">SJR</td><td rowspan="1" colspan="1">1.31</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">2.19</td><td rowspan="1" colspan="1">1.22</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">SNIP</td><td rowspan="1" colspan="1">1.27</td><td rowspan="1" colspan="1">0.88</td><td rowspan="1" colspan="1">1.78</td><td rowspan="1" colspan="1">0.90</td></tr><tr><td rowspan="1" colspan="1">Quartile</td><td rowspan="1" colspan="1">Q1</td><td rowspan="1" colspan="1">Q2</td><td rowspan="1" colspan="1">Q4</td><td rowspan="1" colspan="1">Q4-Q2</td></tr></tbody></table></table-wrap><p>Institutional Contributions:&#160;Leading institutions were responsible for a disproportionate share of highly cited work (Table <xref rid="TAB7" ref-type="table">7</xref>).</p><table-wrap position="float" id="TAB7" orientation="portrait"><label>Table 7</label><caption><title>Leading Institutions Contributing to MRI-Based Neuroplasticity Research in Stroke.</title><p>This table ranks the top institutions publishing the most-cited articles on MRI-based neuroplasticity in stroke. For each institution, the number of articles, total citations, percentage of overall citations, and average citations per year are presented. The data highlight the leadership of high-income countries (e.g., Harvard Medical School, University of Cambridge, University of Freiburg, NIH, UC Irvine, King&#8217;s College London) while also showing emerging contributions from Asian and Latin American institutions (e.g., Beijing Normal University, Tianjin Medical University, National Autonomous University of Mexico (UNAM)). These findings emphasize both the concentration of research within well-resourced centers and the gradual expansion of global participation.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Rank</td><td rowspan="2" colspan="1">Institution</td><td rowspan="2" colspan="1">Articles</td><td colspan="3" rowspan="1">Citations</td></tr><tr><td rowspan="1" colspan="1">N</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">Average per year</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">Harvard Medical School</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1854</td><td rowspan="1" colspan="1">10.7%</td><td rowspan="1" colspan="1">19.4</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">University of Cambridge</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">877</td><td rowspan="1" colspan="1">5.0%</td><td rowspan="1" colspan="1">16.7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">University of Freiburg</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">876</td><td rowspan="1" colspan="1">5.0%</td><td rowspan="1" colspan="1">46.0</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">National Institute of Neurological Disorders and Stroke, NIH</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">817</td><td rowspan="1" colspan="1">4.7%</td><td rowspan="1" colspan="1">12.7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">University of T&#252;bingen</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">785</td><td rowspan="1" colspan="1">4.5%</td><td rowspan="1" colspan="1">13.5</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">University of California, Irvine</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">733</td><td rowspan="1" colspan="1">4.2%</td><td rowspan="1" colspan="1">14.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">University of California, Los Angeles</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">707</td><td rowspan="1" colspan="1">4.1%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">University of Giessen</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">587</td><td rowspan="1" colspan="1">3.4%</td><td rowspan="1" colspan="1">37.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Beijing Normal University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">527</td><td rowspan="1" colspan="1">3.0%</td><td rowspan="1" colspan="1">35.0</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">University College London</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">507</td><td rowspan="1" colspan="1">2.9%</td><td rowspan="1" colspan="1">13.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">University of Oxford</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">467</td><td rowspan="1" colspan="1">2.7%</td><td rowspan="1" colspan="1">12.3</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">University of Alabama</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">430</td><td rowspan="1" colspan="1">2.5%</td><td rowspan="1" colspan="1">12.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">French National Institute of Health and Medical Research</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">422</td><td rowspan="1" colspan="1">2.4%</td><td rowspan="1" colspan="1">10.5</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">University of South Carolina</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">364</td><td rowspan="1" colspan="1">2.1%</td><td rowspan="1" colspan="1">8.3</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">King's College London</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">352</td><td rowspan="1" colspan="1">2.0%</td><td rowspan="1" colspan="1">21.0</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Hampton University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">351</td><td rowspan="1" colspan="1">2.0%</td><td rowspan="1" colspan="1">18.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">University of Pennsylvania</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">336</td><td rowspan="1" colspan="1">1.9%</td><td rowspan="1" colspan="1">12.5</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">University of Cincinnati</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">300</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">6.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Erasmus University Medical Center</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">297</td><td rowspan="1" colspan="1">1.7%</td><td rowspan="1" colspan="1">21.0</td></tr><tr><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">Research Centre J&#252;lich</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">277</td><td rowspan="1" colspan="1">1.6%</td><td rowspan="1" colspan="1">28.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">University Medical Center Utrecht</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">271</td><td rowspan="1" colspan="1">1.6%</td><td rowspan="1" colspan="1">10.0</td></tr><tr><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">Universit&#224; Campus Bio-Medico</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">249</td><td rowspan="1" colspan="1">1.4%</td><td rowspan="1" colspan="1">6.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">University of California, San Francisco</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">202</td><td rowspan="1" colspan="1">1.2%</td><td rowspan="1" colspan="1">6.5</td></tr><tr><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Wayne State University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">197</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">10.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Aalborg University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">184</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">20.0</td></tr><tr><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Northwestern University</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">179</td><td rowspan="1" colspan="1">1.0%</td><td rowspan="1" colspan="1">5.5</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">University of Minnesota</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">179</td><td rowspan="1" colspan="1">1.0%</td><td rowspan="1" colspan="1">5.0</td></tr><tr><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">University of Cologne</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">173</td><td rowspan="1" colspan="1">1.0%</td><td rowspan="1" colspan="1">8.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">Tianjin Medical University</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">167</td><td rowspan="1" colspan="1">1.0%</td><td rowspan="1" colspan="1">8.0</td></tr><tr><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">Boston University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">26.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">University of Florida</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">156</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">The Rockefeller University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">153</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">12.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">Universit&#233; de Bordeaux</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">152</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">7.0</td></tr><tr><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">University of Maryland</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">150</td><td rowspan="1" colspan="1">0.9%</td><td rowspan="1" colspan="1">11.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Georgetown University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">11.0</td></tr><tr><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">University Medical Center Hamburg Eppendorf</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">138</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">7.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">Institut Universitaire de G&#233;riatrie de Montr&#233;al</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">5.0</td></tr><tr><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">University of Helsinki</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">135</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">12.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">University Hospital Geneva</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">22.0</td></tr><tr><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">University Hospital RWTH Aachen</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">126</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">7.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">All India Institute of Medical Sciences</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">10.0</td></tr><tr><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">University Clinic of Jena</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">122</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">9.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">Capital Medical University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">15.0</td></tr><tr><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">University of Southern California</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">117</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">20.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">Nanjing University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">116</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">19.0</td></tr><tr><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">Universit&#233; Grenoble Alpes</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">110</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">22.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">Henry Ford Hospital</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">7.0</td></tr><tr><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Universidad Nacional Aut&#243;noma de M&#233;xico</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">97</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">9.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">Max Planck Institute for Neurological Research</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">96</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">10.0</td></tr><tr><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">University of British Columbia</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">9.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">Medical University of Graz</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">5.0</td></tr><tr><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">University of Barcelona</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">85</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">9.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">University Hospital of D&#252;sseldorf</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">University Medical Center Hamburg-Eppendorf</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">Essen University Hospital</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">Massachusetts Institute of Technology</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">Sun Yat-sen University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">6.0</td></tr><tr><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">Sichuan University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">Rehabilitation Institute of Chicago</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">Beth Israel Deaconess Medical Center</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">Yeungnam University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">University of Nebraska Medical Center</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">20.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">Columbia University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">4.0</td></tr><tr><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">Fudan University</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">12.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Vanderbilt University Medical Center</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">12.0</td></tr></tbody></table></table-wrap><p>Harvard Medical School produced five articles (1,854 citations; 10.7%). The University of Cambridge contributed three articles (877 citations). University of Freiburg achieved 876 citations with a single paper, yielding the highest per-year average (46.0). Prominent U.S. centers included the National Institute of Neurological Disorders and Stroke (NINDS) (817 citations) and UC Irvine (733 citations). European leaders included T&#252;bingen, UCL, and Oxford. Beijing Normal University represented emerging Asian participation with one article (527 citations; 35/year).</p><p>These findings reflect both resource concentration in high-income countries and growing engagement from non-Western institutions.</p><p>Country-Level Contributions:&#160;Geographic analysis confirmed the dominance of the United States, contributing 46 articles and 8,010 citations (46%). Germany ranked second with 17 articles (3,417 citations; 19.6%), followed by the UK with nine articles (2,203 citations; 12.7%) (Table <xref rid="TAB8" ref-type="table">8</xref>,&#160;Figure <xref rid="FIG5" ref-type="fig">5</xref>).</p><table-wrap position="float" id="TAB8" orientation="portrait"><label>Table 8</label><caption><title>Geographic Distribution of Top-Cited Articles in MRI-Based Neuroplasticity Research in Stroke. </title><p>This table summarizes the country-level contributions to the top 100 most-cited articles, reporting the number of publications, total citations, percentage of global citations, and average citations per year. The United States led with 46 articles and 46% of all citations, followed by Germany, the United Kingdom, and China. European countries such as France and the Netherlands also had strong citation performance, while emerging contributors&#8212;including China, India, Mexico, and South Korea&#8212;reflect growing international participation. High average yearly citation rates in smaller contributors such as Denmark and Switzerland highlight the impact of select influential studies.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Ranking</td><td rowspan="2" colspan="1">Country</td><td rowspan="2" colspan="1">Articles</td><td rowspan="1" colspan="1">&#160;</td><td colspan="3" rowspan="1">Citations</td></tr><tr><td colspan="2" rowspan="1">Number</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">Average per year</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">United States</td><td rowspan="1" colspan="1">46</td><td colspan="2" rowspan="1">8010</td><td rowspan="1" colspan="1">46.0%</td><td rowspan="1" colspan="1">11.1</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">Germany</td><td rowspan="1" colspan="1">17</td><td colspan="2" rowspan="1">3417</td><td rowspan="1" colspan="1">19.6%</td><td rowspan="1" colspan="1">14.9</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">United Kingdom</td><td rowspan="1" colspan="1">9</td><td colspan="2" rowspan="1">2203</td><td rowspan="1" colspan="1">12.7%</td><td rowspan="1" colspan="1">14.9</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">China</td><td rowspan="1" colspan="1">8</td><td colspan="2" rowspan="1">1130</td><td rowspan="1" colspan="1">6.5%</td><td rowspan="1" colspan="1">13.4</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">France</td><td rowspan="1" colspan="1">4</td><td colspan="2" rowspan="1">684</td><td rowspan="1" colspan="1">3.9%</td><td rowspan="1" colspan="1">12.5</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">Netherlands</td><td rowspan="1" colspan="1">3</td><td colspan="2" rowspan="1">568</td><td rowspan="1" colspan="1">3.3%</td><td rowspan="1" colspan="1">13.7</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">Italy</td><td rowspan="1" colspan="1">2</td><td colspan="2" rowspan="1">249</td><td rowspan="1" colspan="1">1.4%</td><td rowspan="1" colspan="1">6.5</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">Canada</td><td rowspan="1" colspan="1">3</td><td colspan="2" rowspan="1">230</td><td rowspan="1" colspan="1">1.3%</td><td rowspan="1" colspan="1">6.3</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">Denmark</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">184</td><td rowspan="1" colspan="1">1.1%</td><td rowspan="1" colspan="1">20.0</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Finland</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">135</td><td rowspan="1" colspan="1">0.8%</td><td rowspan="1" colspan="1">12.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Switzerland</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">130</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">22.0</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">India</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">124</td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">10.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">Mexico</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">97</td><td rowspan="1" colspan="1">0.6%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">Austria</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">92</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Spain</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">85</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">9.0</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">South Korea</td><td rowspan="1" colspan="1">1</td><td colspan="2" rowspan="1">62</td><td rowspan="1" colspan="1">0.4%</td><td rowspan="1" colspan="1">4.0</td></tr></tbody></table></table-wrap><fig position="anchor" fig-type="figure" id="FIG5" orientation="portrait"><label>Figure 5</label><caption><title>Geographic Distribution of Publications and Citations (2004&#8211;2024). </title><p>(A) Global citation map showing the United States as the leading contributor (46% of total citations, n = 8,010). (B) Publications by country, with Germany (17 articles, 3,417 citations) and the United Kingdom (9 articles, 2,203 citations) as major contributors. Emerging outputs from China and Japan highlight growing international engagement.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i05.jpg"/></fig><p>China ranked fourth with eight publications (1,130 citations; 6.5%), reflecting rapid expansion in neuroimaging research. Other notable contributors included France, the Netherlands, and Canada.</p><p>Smaller nations made high-impact contributions: Denmark (20 citations/year) and Switzerland (22/year) produced single but influential papers.&#160;Emerging economies such as India, Mexico, and South Korea showed modest output but promising average citations (~9-10 per year).</p><p>Cross-country bibliographic coupling indicated strong collaborations among the U.S., UK, and Germany, but limited representation from Latin America and Africa.</p><p>Science Mapping</p><p>Intellectual Structure of the Field:&#160;The intellectual structure of MRI-based research on stroke neuroplasticity was visualized through co-citation and bibliographic coupling networks (Figure <xref rid="FIG6" ref-type="fig">6A</xref>-<xref rid="FIG6" ref-type="fig">6D</xref>).</p><fig position="anchor" fig-type="figure" id="FIG6" orientation="portrait"><label>Figure 6</label><caption><title>Science Mapping of MRI-Based Neuroplasticity Research. </title><p>(A) Author co-citation network (207 authors, &#8805;5 co-citations) clustering around Cohen L.G., Friston K.J., and Pascual-Leone A. (B) Country-level co-authorship network (25 countries), with the U.S., Germany, and the U.K. as central hubs. (C) Institutional co-authorship network (120 institutions), highlighting Harvard Medical School, University of California, and University of Freiburg. (D) Source journal co-citation map showing five clusters; key sources include <italic toggle="yes">Brain</italic>, <italic toggle="yes">Stroke</italic>, and <italic toggle="yes">Neurorehabilitation and Neural Repair</italic>. (E) Keyword co-occurrence map (112 terms, &#8805;5 occurrences) identifying clusters on motor recovery, cortical reorganization, language/aphasia, and neurophysiology. (F) Author-level co-authorship network (56 authors), led by Cramer, Szaflarski, and Hamilton, emphasizing collaborations in motor rehabilitation and cortical reorganization.&#160;</p><p>Visualization notes:&#160;Node size = frequency (occurrences or citations); node color = cluster membership from co-occurrence or co-citation analysis; line thickness = strength of the relationship (e.g., collaboration intensity, citation link, or keyword co-appearance). Collectively, these features depict the structural and intellectual landscape of the field.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i06.jpg"/></fig><p>Author co-citation network&#160;(Figure <xref rid="FIG6" ref-type="fig">6A</xref>) - Central nodes included Cohen L.G., Pascual-Leone A., and Friston K.J., whose foundational contributions span brain plasticity, neurorehabilitation, and advanced modeling. Other frequently co-cited authors such as Rothwell J.C., Rossini P.M., and Taub E. formed interconnected clusters emphasizing cortical stimulation, fMRI-based recovery, and rehabilitation theory. Authors including Grefkes C., Hallett M., and Weiller C. highlighted integration of MRI with clinical neurorehabilitation.</p><p>Country-level bibliographic coupling&#160;(Figure <xref rid="FIG6" ref-type="fig">6B</xref>) - The United States dominated output and collaborations, followed by Germany, the UK, and China. Strong cross-links also involved France, Italy, and Canada. Emerging clusters in Japan, Spain, and India underscored rising international participation.</p><p>Institutional network&#160;(Figure <xref rid="FIG6" ref-type="fig">6C</xref>) - Harvard Medical School and UC Irvine emerged as hubs, with additional key contributions from King&#8217;s College London and the Massachusetts General Hospital/Massachusetts Institute of Technology (MGH/MIT) Athinoula A. Martinos Center. These institutions exemplify the importance of multidisciplinary environments combining neurology, radiology, and neuroscience.</p><p>Journal co-citation map&#160;(Figure <xref rid="FIG6" ref-type="fig">6D</xref>) - Core journals included <italic toggle="yes">Brain</italic>, <italic toggle="yes">Stroke</italic>, <italic toggle="yes">NeuroImage</italic>, and <italic toggle="yes">Neurorehabilitation and Neural Repair</italic>. Strong co-citation ties were observed between <italic toggle="yes">Brain </italic>and <italic toggle="yes">Stroke</italic>, and between <italic toggle="yes">NeuroImage </italic>and <italic toggle="yes">Neuropsychologia</italic>. Additional influential outlets included <italic toggle="yes">Neuron</italic>, <italic toggle="yes">Cerebral Cortex</italic>, <italic toggle="yes">Annual Review of Neuroscience</italic>, and <italic toggle="yes">Neurology</italic>.</p><p>Conceptual Structure and Research Themes:&#160;Keyword co-occurrence analysis revealed distinct thematic clusters (Figure <xref rid="FIG6" ref-type="fig">6E</xref>):</p><p>Motor recovery and rehabilitation - Central terms included &#8220;neuroplasticity,&#8221; &#8220;stroke,&#8221; &#8220;motor performance,&#8221; and &#8220;recovery of function,&#8221; linked with &#8220;gait rehabilitation,&#8221; &#8220;mirror therapy,&#8221; &#8220;robotics,&#8221; and &#8220;muscle training.&#8221;</p><p>Cortical reorganization and imaging - Anchored by &#8220;cerebral cortex,&#8221; &#8220;functional neuroimaging,&#8221; and &#8220;image processing,&#8221; this cluster linked imaging findings with outcomes such as pyramidal tract integrity, oxygenation, and innervation.</p><p>Language and aphasia - Terms included &#8220;aphasia,&#8221; &#8220;semantics,&#8221; &#8220;white matter,&#8221; and &#8220;hippocampus,&#8221; with related concepts such as &#8220;anomia&#8221; and &#8220;language testing.&#8221;</p><p>Neurophysiology and recovery mechanisms - A smaller cluster that captured concepts such as &#8220;motor evoked potentials,&#8221; &#8220;reaction time,&#8221; and &#8220;grip strength,&#8221; reflecting integration of neuroimaging with physiological measures.</p><p>These clusters collectively illustrate the integration of structural, functional, and behavioral dimensions in MRI-based stroke neuroplasticity research.</p><p>Collaboration Networks:&#160;Author-level co-authorship networks (Figure <xref rid="FIG6" ref-type="fig">6F</xref>) highlighted the collaborative nature of the field.</p><p>The largest cluster was led by Steven C. Cramer, with extensive collaborations on imaging-based stroke recovery.</p><p>Jerzy P. Szaflarski represented another hub, bridging groups focused on motor recovery, functional connectivity, and cognitive outcomes.</p><p>A smaller but cohesive cluster led by Roy H. Hamilton and Catherine Norise emphasized non-invasive brain stimulation and cognitive rehabilitation, supported by contributions from Coslett H. Branch.</p><p>Another subgroup led by Page Stephen J. and Kissela Brett M. focused on motor recovery and neuroimaging, connecting closely with Szaflarski&#8217;s cluster.</p><p>Overall, the collaboration landscape displayed a hierarchical yet interconnected structure, with Cramer, Szaflarski, and Hamilton serving as pivotal figures. Smaller clusters complemented these hubs, reflecting both breadth and specialization across institutions and research foci.</p><p>Discussion</p><p>Overview of Performance Trends</p><p>The retrieval and selection of the top 100 most-cited articles underscore the pivotal role of MRI in advancing the understanding of neuroplasticity after stroke. This bibliometric focus highlights not only methodological rigor but also the intellectual and clinical influence of MRI-based investigations over the last two decades. Identifying highly cited works provides a framework for recognizing research trends, leading authors, and key institutions, while also guiding future studies toward emerging imaging modalities and multidisciplinary approaches in neurorehabilitation.</p><p>Publication and Citation Patterns</p><p>Annual publication and citation trends revealed distinct phases in the evolution of MRI-based neuroplasticity research. The surge in 2006 reflected a turning point marked by fMRI mapping of motor recovery and DTI assessment of white matter integrity&#160;[<xref rid="REF33" ref-type="bibr">33</xref>,<xref rid="REF62" ref-type="bibr">62</xref>,<xref rid="REF65" ref-type="bibr">65</xref>]. These seminal contributions established MRI as a cornerstone of stroke rehabilitation research. Between 2004 and 2012, steady productivity sustained advances in cortical reorganization and recovery mechanisms&#160;[<xref rid="REF36" ref-type="bibr">36</xref>,<xref rid="REF38" ref-type="bibr">38</xref>,<xref rid="REF51" ref-type="bibr">51</xref>]. After 2012, declines in both publications and citations suggested a shift toward newer imaging techniques and rehabilitation strategies, though landmark works from the mid-2000s continued to dominate. Citation rebounds in 2019-2020 underscored the enduring impact of studies on functional connectivity and advanced MRI-based monitoring of neuroplastic changes&#160;[<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF75" ref-type="bibr">75</xref>,<xref rid="REF78" ref-type="bibr">78</xref>,<xref rid="REF124" ref-type="bibr">124</xref>]. These dynamics confirm the lasting influence of early contributions while highlighting opportunities for innovation through connectomics, multi-modal imaging, and longitudinal approaches.</p><p>Citation Classics vs. Non-Classics</p><p>Comparisons between Citation Classics (&#8805;100 citations) and non-Classics showed that Classics achieved higher citation rates per year, underscoring their sustained relevance. Reviews were more common among Classics, synthesizing evidence on fMRI, DTI, and resting-state functional connectivity&#160;[<xref rid="REF29" ref-type="bibr">29</xref>,<xref rid="REF35" ref-type="bibr">35</xref>,<xref rid="REF37" ref-type="bibr">37</xref>]. In contrast, Citation Classics often represented original studies showcasing detailed clinical or technical applications&#160;[<xref rid="REF45" ref-type="bibr">45</xref>,<xref rid="REF63" ref-type="bibr">63</xref>,<xref rid="REF66" ref-type="bibr">66</xref>,<xref rid="REF71" ref-type="bibr">71</xref>]. The peak period of Classics around 2006 corresponded to landmark studies on perilesional cortical recruitment and hemispheric activation shifts&#160;[<xref rid="REF70" ref-type="bibr">70</xref>,<xref rid="REF100" ref-type="bibr">100</xref>,<xref rid="REF112" ref-type="bibr">112</xref>]. Their subsequent decline likely reflects thematic saturation and the difficulty of producing equally influential work. Future high-impact contributions may arise from combining MRI with complementary modalities such as EEG and MEG, integrating neuromodulation approaches like TMS and tDCS, and applying machine learning to predictive rehabilitation models.</p><p>Journals and Dissemination Platforms</p><p>The analysis reinforced the dominance of a small number of high-impact journals.&#160;<italic toggle="yes">NeuroImage</italic>,&#160;<italic toggle="yes">Brain</italic>, and <italic toggle="yes">Stroke </italic>accounted for the majority of influential publications, particularly those advancing fMRI and DTI&#160;[<xref rid="REF14" ref-type="bibr">14</xref>,<xref rid="REF46" ref-type="bibr">46</xref>,<xref rid="REF48" ref-type="bibr">48</xref>]. Specialized outlets, including&#160;<italic toggle="yes">Neurorehabilitation and Neural Repair&#160;</italic>and&#160;<italic toggle="yes">Archives of Physical Medicine and Rehabilitation</italic>, emphasized translational studies on therapies, telerehabilitation, and training interventions&#160;[<xref rid="REF60" ref-type="bibr">60</xref>,<xref rid="REF72" ref-type="bibr">72</xref>,<xref rid="REF112" ref-type="bibr">112</xref>]. Correlations between journal bibliometric metrics and citation performance highlighted the visibility advantage of top-ranked journals. While broad-scope journals ensured wide dissemination, selective outlets such as&#160;<italic toggle="yes">Cerebral Cortex&#160;</italic>and&#160;<italic toggle="yes">Restorative Neurology and Neuroscience&#160;</italic>maintained strong citation averages despite smaller publication volumes. Highly cited works addressed cortical reorganization, functional recovery, and structural integrity&#160;[<xref rid="REF34" ref-type="bibr">34</xref>,<xref rid="REF71" ref-type="bibr">71</xref>,<xref rid="REF85" ref-type="bibr">85</xref>], while more recent themes - connectomics, multimodal imaging, and network plasticity - signal evolving directions for impactful dissemination&#160;[<xref rid="REF56" ref-type="bibr">56</xref>,<xref rid="REF81" ref-type="bibr">81</xref>,<xref rid="REF107" ref-type="bibr">107</xref>].&#160;</p><p>Institutional and Geographic Contributions</p><p>Institutions such as UC Irvine, Harvard Medical School, and King&#8217;s College London consistently drove highly cited research, supported by infrastructure and interdisciplinary collaborations. UC Irvine contributed extensively to fMRI and DTI studies of cortical reorganization, while Harvard advanced resting-state connectivity research through the MGH/MIT Athinoula A. Martinos Center. King&#8217;s College London focused on white matter integrity and structural plasticity. European centers such as Oxford and T&#252;bingen added expertise in cognitive recovery and non-invasive stimulation.</p><p>At the national level, the United States dominated both output and citations, followed by the UK and Germany. China, Japan, and Canada showed increasing productivity, with Chinese teams integrating multimodal MRI and machine learning, and Japanese groups emphasizing cerebral reorganization and rehabilitation outcomes. Strong bibliographic coupling revealed extensive collaborations among the US, UK, and Germany, but limited participation of Latin America and Africa. Expanding collaborative networks in these regions remains essential to reducing disparities and ensuring global applicability of findings.</p><p>Science Mapping and Intellectual Structure</p><p>Science mapping revealed an interconnected research landscape shaped by leading institutions and authors. Harvard, UC Irvine, and King&#8217;s College London emerged as intellectual hubs, advancing fMRI, resting-state connectivity, and white matter integrity studies. Influential figures such as Pascual-Leone, with seminal work on non-invasive brain stimulation&#160;[<xref rid="REF125" ref-type="bibr">125</xref>-<xref rid="REF128" ref-type="bibr">128</xref>], and Friston, through dynamic causal modeling&#160;[<xref rid="REF129" ref-type="bibr">129</xref>-<xref rid="REF132" ref-type="bibr">132</xref>], established frameworks that integrated neuroimaging with neurophysiological insights. Core journals, including&#160;<italic toggle="yes">Brain</italic>,&#160;<italic toggle="yes">Stroke</italic>, and&#160;<italic toggle="yes">NeuroImage</italic>,<italic toggle="yes">&#160;</italic>served as key platforms consolidating progress and visibility.</p><p>Conceptual Clusters and Emerging Areas</p><p>Keyword mapping highlighted clusters centered on neuroplasticity, motor recovery, and structural connectivity, reaffirming the importance of fMRI and DTI in stroke rehabilitation. Emerging themes included connectomics and neurochemical imaging with MRS, reflecting a transition toward large-scale brain network mapping and biochemical profiling&#160;[<xref rid="REF2" ref-type="bibr">2</xref>,<xref rid="REF89" ref-type="bibr">89</xref>]. Translational priorities were evident in clusters on language recovery, robotic rehabilitation, and task-based neuroplasticity&#160;[<xref rid="REF45" ref-type="bibr">45</xref>,<xref rid="REF49" ref-type="bibr">49</xref>,<xref rid="REF76" ref-type="bibr">76</xref>,<xref rid="REF101" ref-type="bibr">101</xref>,<xref rid="REF122" ref-type="bibr">122</xref>], underscoring the effort to bridge imaging insights with clinical outcomes.</p><p>Collaboration Networks</p><p>Collaboration patterns showed highly interconnected structures. Steven C. Cramer emerged as a central figure in motor recovery and imaging-based rehabilitation&#160;[<xref rid="REF61" ref-type="bibr">61</xref>,<xref rid="REF133" ref-type="bibr">133</xref>], while Jerzy Szaflarski bridged domains of functional connectivity and cognitive recovery&#160;[<xref rid="REF112" ref-type="bibr">112</xref>]. Roy H. Hamilton and collaborators contributed significantly to non-invasive brain stimulation&#160;[<xref rid="REF134" ref-type="bibr">134</xref>]. Strong cross-national collaborations were evident among the US, UK, and Germany, though Latin America and Africa remained underrepresented. Multinational teams increasingly addressed novel technologies such as brain-computer interfaces, virtual reality, and integrative rehabilitation strategies&#160;[<xref rid="REF42" ref-type="bibr">42</xref>,<xref rid="REF49" ref-type="bibr">49</xref>,<xref rid="REF106" ref-type="bibr">106</xref>,<xref rid="REF110" ref-type="bibr">110</xref>].</p><p>International collaborations were strongly associated with higher citation impact, reflecting the synergistic benefits of shared expertise, access to advanced imaging infrastructure, and broader dissemination across multiple networks. However, the underrepresentation of Asia, Africa, and South America likely reflects both resource disparities in neuroimaging availability and database indexing biases that favor North American and European outputs. Strengthening global partnerships and expanding indexing inclusivity will be essential for broadening the scope and clinical applicability of MRI-based neuroplasticity research.</p><p>Evolution of Neuroplasticity Research</p><p>Between 2010-2015, research focused on motor recovery and cortical reorganization, establishing neuroplasticity as a foundation of rehabilitation science. From 2016-2020, multimodal imaging and brain stimulation gained prominence, reflecting interest in combining MRI with neuromodulatory and neurophysiological methods. Since 2021, connectomics and machine learning have risen rapidly, signaling a paradigm shift toward computational neuroscience and predictive modeling.</p><p>Citation trajectories (Figure <xref rid="FIG7" ref-type="fig">7</xref>) showed successive waves of influence: early dominance of functional connectivity, followed by multimodal integration, and most recently, computational approaches. Connectomics and machine learning studies have achieved the highest recent citation rates, while functional connectivity and imaging biomarkers remain enduring anchors.</p><fig position="anchor" fig-type="figure" id="FIG7" orientation="portrait"><label>Figure 7</label><caption><title>Evolution of Research Trends and Citation Impact.</title><p>This heatmap illustrates the annual distribution of citation-weighted publications across ten major research domains in neuroplasticity from 2010 to 2020. The x-axis categorizes research trends&#8212;Brain Stimulation, Connectomics, Functional Connectivity, Imaging Biomarkers, Language Recovery, Machine Learning, Motor Recovery, Multi-Modal Imaging, Neuroplasticity Mechanisms, and Stroke Rehabilitation&#8212;while the y-axis denotes publication year. Color intensity reflects the number of articles and their associated citation impact, with warmer tones (yellow) indicating higher activity. Thematic analysis reveals a notable rise in Connectomics and Machine Learning after 2019, suggesting a growing integration of computational modeling and network science into neuroplasticity research. Motor Recovery exhibited consistent representation, peaking in 2020 with 300 citations, while Imaging Biomarkers showed a sharp increase in 2016 (250 citations). Established topics such as Neuroplasticity Mechanisms and Brain Stimulation maintained intermittent yet impactful contributions throughout the decade. This visualization underscores evolving research priorities and the shifting focus toward interdisciplinary, data-driven approaches in stroke recovery and neurorehabilitation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000091484-i07.jpg"/></fig><p>Recent Advances and Translational Innovations</p><p>Recent progress includes improved diagnostic tools, collaborative research, and therapeutic innovation. High-resolution fMRI and PET now enable earlier identification of dysfunctional networks&#160;[<xref rid="REF135" ref-type="bibr">135</xref>], while machine learning augments prognostic modeling&#160;[<xref rid="REF136" ref-type="bibr">136</xref>]. International collaborations have facilitated VR-based telerehabilitation&#160;[<xref rid="REF137" ref-type="bibr">137</xref>], expanding access and engagement. Therapeutic advances include non-invasive brain stimulation (TMS, tDCS), robotic-assisted therapy, and immersive VR platforms&#160;[<xref rid="REF138" ref-type="bibr">138</xref>-<xref rid="REF140" ref-type="bibr">140</xref>], each enhancing recovery and real-world skill transfer. These advances demonstrate how neuroplasticity research continues to shape clinical practice.</p><p>Limitations</p><p>This study has several limitations. Reliance on citation counts privileges older, highly cited works and may underrepresent recent but high-quality contributions. Although citation rates per year were reported to mitigate age-related bias, field-weighted metrics were not applied. The top-100 cutoff may also exclude niche but relevant studies, such as those on connectomics or longitudinal designs. Exclusive reliance on Scopus and restriction to English-language publications introduce database and language bias, while the absence of dual independent screening and reliance on a single primary reviewer raise the possibility of selection bias. Finally, the dominance of high-income countries highlights disparities in global access to imaging, and the study did not evaluate methodological rigor or clinical applicability, limiting interpretability for direct patient outcomes.</p><p>Future directions</p><p>The intellectual and collaborative structures in this field reflect strong foundations and promising new directions. Advances in connectomics and multimodal imaging offer opportunities to uncover novel biomarkers, while qualitative assessments of study design and translational outcomes will improve clinical relevance. Expanding global collaboration, especially with underrepresented regions, remains critical for equitable progress. By combining historical insights with emerging computational tools, MRI-based neuroplasticity research is well-positioned to drive innovation in personalized rehabilitation and long-term recovery after stroke.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This bibliometric analysis offers a comprehensive overview of the intellectual landscape, key concepts, and collaborative networks that have shaped MRI-based neuroplasticity research in stroke. By examining the 100 most-cited articles, the study highlights the central role of fMRI and DTI in elucidating cortical reorganization, structural connectivity, and motor recovery mechanisms. Contributions from leading institutions such as Harvard Medical School and the University of California, Irvine underscore the importance of interdisciplinary collaboration and methodological innovation in advancing the field.</p><p>The findings also reveal the concentration of influential research in high-impact journals, including <italic toggle="yes">Brain</italic>, <italic toggle="yes">Stroke</italic>, and <italic toggle="yes">NeuroImage</italic>,<italic toggle="yes">&#160;</italic>which serve as primary platforms for disseminating both foundational and translational advances. Prominent authors such as Steven C. Cramer and Jerzy Szaflarski exemplify the collaborative networks that have accelerated clinical translation and sustained academic influence.</p><p>Although overall publication and citation activity have declined in recent years, the rapid growth of connectomics, multimodal imaging, and machine learning approaches signals a promising revitalization of the field. Expanding international collaborations, particularly with underrepresented regions, will be essential for ensuring inclusivity and global applicability of findings.</p><p>In conclusion, MRI continues to serve as a cornerstone in stroke neuroplasticity research, bridging mechanistic insights with clinical applications. Future progress will depend on integrating advanced imaging modalities, fostering multidisciplinary networks, and prioritizing translational outcomes to enhance rehabilitation strategies and ultimately improve patient care.</p></sec></body><back><ack><p>Correspondence should be addressed to Jimena Quinza&#241;os-Fresnedo at jimenaquinzanos@gmail.com and Ernesto Roldan-Valadez at ernest.roldan@usa.net.
| Authors' Contributions: Gabriel Manrique-Guti&#233;rrez, Ernesto Roldan-Valadez, and Jimena Quinza&#241;os-Fresnedo participated in the conception of the study and provided supervision throughout the project. Gabriel Manrique-Guti&#233;rrez and Ernesto Roldan-Valadez engaged in the methodology design, data acquisition, data analysis and interpretation, designing and developing tables and figures. All listed authors - Gabriel Manrique-Guti&#233;rrez, Ernesto Roldan-Valadez, Jimena Quinza&#241;os-Fresnedo, Sergey K. Ternovoy, Ana G. Ramirez-Nava, and Aldo Montes-Ugaldo - contributed to the following tasks: drafting the original manuscript, reviewing and editing the manuscript, and providing critical feedback to shape the research.
| Declaration of Generative AI and AI-assisted technologies in the Writing Process: During the preparation of this work, the author(s) used Grammarly software (Grammarly Inc., San Francisco, United States) to correct grammar and style. After using this tool/service, the author(s) reviewed and edited the content as needed and assume(s) full responsibility for the content of the publication.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#160; Ernesto Roldan-Valadez, Gabriel Manrique-Gutierrez, Sergey K. Ternovoy, Ana G. Ramirez-Nava, Aldo Montes-Ugaldo, Jimena Quinza&#241;os-Fresnedo</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#160; Ernesto Roldan-Valadez, Gabriel Manrique-Gutierrez, Sergey K. Ternovoy, Ana G. Ramirez-Nava, Aldo Montes-Ugaldo, Jimena Quinza&#241;os-Fresnedo</p><p><bold>Drafting of the manuscript:</bold>&#160; Ernesto Roldan-Valadez, Gabriel Manrique-Gutierrez, Sergey K. Ternovoy, Ana G. Ramirez-Nava, Aldo Montes-Ugaldo, Jimena Quinza&#241;os-Fresnedo</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#160; Ernesto Roldan-Valadez, Gabriel Manrique-Gutierrez, Sergey K. Ternovoy, Ana G. Ramirez-Nava, Aldo Montes-Ugaldo, Jimena Quinza&#241;os-Fresnedo</p><p><bold>Supervision:</bold>&#160; Ernesto Roldan-Valadez, Gabriel Manrique-Gutierrez, Sergey K. Ternovoy, Ana G. Ramirez-Nava, Aldo Montes-Ugaldo, Jimena Quinza&#241;os-Fresnedo</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Stroke: causes and clinical features</article-title><source>Medicine (Abingdon)</source><person-group><name name-style="western"><surname>Murphy</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Werring</surname><given-names>DJ</given-names></name></person-group><fpage>561</fpage><lpage>566</lpage><volume>48</volume><year>2020</year><pub-id pub-id-type="pmid">32837228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mpmed.2020.06.002</pub-id><pub-id pub-id-type="pmcid">PMC7409792</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Brain networks and their relevance for stroke rehabilitation</article-title><source>Clin Neurophysiol</source><person-group><name name-style="western"><surname>Guggisberg</surname><given-names>AG</given-names></name><name name-style="western"><surname>Koch</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>FC</given-names></name><name name-style="western"><surname>Buetefisch</surname><given-names>CM</given-names></name></person-group><fpage>1098</fpage><lpage>1124</lpage><volume>130</volume><year>2019</year><pub-id pub-id-type="pmid">31082786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2019.04.004</pub-id><pub-id pub-id-type="pmcid">PMC6603430</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Diaschisis: past, present, future</article-title><source>Brain</source><person-group><name name-style="western"><surname>Carrera</surname><given-names>E</given-names></name><name name-style="western"><surname>Tononi</surname><given-names>G</given-names></name></person-group><fpage>2408</fpage><lpage>2422</lpage><volume>137</volume><year>2014</year><pub-id pub-id-type="pmid">24871646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awu101</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Global burden of stroke</article-title><source>Semin Neurol</source><person-group><name name-style="western"><surname>Katan</surname><given-names>M</given-names></name><name name-style="western"><surname>Luft</surname><given-names>A</given-names></name></person-group><fpage>208</fpage><lpage>211</lpage><volume>38</volume><year>2018</year><pub-id pub-id-type="pmid">29791947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0038-1649503</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Pathophysiology and treatment of stroke: present status and future perspectives</article-title><source>Int J Mol Sci</source><person-group><name name-style="western"><surname>Kuriakose</surname><given-names>D</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name></person-group><volume>21</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21207609</pub-id><pub-id pub-id-type="pmcid">PMC7589849</pub-id><pub-id pub-id-type="pmid">33076218</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Neurol</source><fpage>795</fpage><lpage>820</lpage><volume>20</volume><year>2021</year><pub-id pub-id-type="pmid">34487721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00252-0</pub-id><pub-id pub-id-type="pmcid">PMC8443449</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Recovery from stroke: current concepts and future perspectives</article-title><source>Neurol Res Pract</source><person-group><name name-style="western"><surname>Grefkes</surname><given-names>C</given-names></name><name name-style="western"><surname>Fink</surname><given-names>GR</given-names></name></person-group><fpage>17</fpage><volume>2</volume><year>2020</year><pub-id pub-id-type="pmid">33324923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s42466-020-00060-6</pub-id><pub-id pub-id-type="pmcid">PMC7650109</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>The plastic human brain cortex</article-title><source>Annu Rev Neurosci</source><person-group><name name-style="western"><surname>Pascual-Leone</surname><given-names>A</given-names></name><name name-style="western"><surname>Amedi</surname><given-names>A</given-names></name><name name-style="western"><surname>Fregni</surname><given-names>F</given-names></name><name name-style="western"><surname>Merabet</surname><given-names>LB</given-names></name></person-group><fpage>377</fpage><lpage>401</lpage><volume>28</volume><year>2005</year><pub-id pub-id-type="pmid">16022601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.neuro.27.070203.144216</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Stroke recovery is a journey: prediction and potentials of motor recovery after a stroke from a practical perspective</article-title><source>Life (Basel)</source><person-group><name name-style="western"><surname>Li</surname><given-names>S</given-names></name></person-group><volume>13</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life13102061</pub-id><pub-id pub-id-type="pmcid">PMC10608684</pub-id><pub-id pub-id-type="pmid">37895442</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>The impact of studying brain plasticity</article-title><source>Front Cell Neurosci</source><person-group><name name-style="western"><surname>Mateos-Aparicio</surname><given-names>P</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Moreno</surname><given-names>A</given-names></name></person-group><fpage>66</fpage><volume>13</volume><year>2019</year><pub-id pub-id-type="pmid">30873009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2019.00066</pub-id><pub-id pub-id-type="pmcid">PMC6400842</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Brain plasticity and rehabilitation in stroke patients</article-title><source>J Nippon Med Sch</source><person-group><name name-style="western"><surname>Hara</surname><given-names>Y</given-names></name></person-group><fpage>4</fpage><lpage>13</lpage><volume>82</volume><year>2015</year><pub-id pub-id-type="pmid">25797869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1272/jnms.82.4</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Principles of neurorehabilitation after stroke based on motor learning and brain plasticity mechanisms</article-title><source>Front Syst Neurosci</source><person-group><name name-style="western"><surname>Maier</surname><given-names>M</given-names></name><name name-style="western"><surname>Ballester</surname><given-names>BR</given-names></name><name name-style="western"><surname>Verschure</surname><given-names>PF</given-names></name></person-group><fpage>74</fpage><volume>13</volume><year>2019</year><pub-id pub-id-type="pmid">31920570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnsys.2019.00074</pub-id><pub-id pub-id-type="pmcid">PMC6928101</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Connectivity measures are robust biomarkers of cortical function and plasticity after stroke</article-title><source>Brain</source><person-group><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Quinlan</surname><given-names>EB</given-names></name><name name-style="western"><surname>Dodakian</surname><given-names>L</given-names></name><etal/></person-group><fpage>2359</fpage><lpage>2369</lpage><volume>138</volume><year>2015</year><pub-id pub-id-type="pmid">26070983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awv156</pub-id><pub-id pub-id-type="pmcid">PMC4840951</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Dynamic functional reorganization of the motor execution network after stroke</article-title><source>Brain</source><person-group><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><fpage>1224</fpage><lpage>1238</lpage><volume>133</volume><year>2010</year><pub-id pub-id-type="pmid">20354002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awq043</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Neuroimaging of motor recovery after ischemic stroke - functional reorganization of motor network</article-title><source>Neuroimage Clin</source><person-group><name name-style="western"><surname>Yu</surname><given-names>P</given-names></name><name name-style="western"><surname>Dong</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L</given-names></name></person-group><fpage>103636</fpage><volume>43</volume><year>2024</year><pub-id pub-id-type="pmid">38950504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2024.103636</pub-id><pub-id pub-id-type="pmcid">PMC11267109</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Exploring the frontiers of neuroimaging: a review of recent advances in understanding brain functioning and disorders</article-title><source>Life (Basel)</source><person-group><name name-style="western"><surname>Yen</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>MC</given-names></name></person-group><volume>13</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life13071472</pub-id><pub-id pub-id-type="pmcid">PMC10381462</pub-id><pub-id pub-id-type="pmid">37511847</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Diffusion tensor imaging-derived measures of fractional anisotropy across the pyramidal tract are influenced by the cerebral hemisphere but not by gender in young healthy volunteers: a split-plot factorial analysis of variance</article-title><source>Chin Med J (Engl)</source><person-group><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name><name name-style="western"><surname>Rios-Piedra</surname><given-names>E</given-names></name><name name-style="western"><surname>Favila</surname><given-names>R</given-names></name><name name-style="western"><surname>Alcauter</surname><given-names>S</given-names></name><name name-style="western"><surname>Rios</surname><given-names>C</given-names></name></person-group><fpage>2180</fpage><lpage>2187</lpage><volume>125</volume><year>2012</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/22884150/">https://pubmed.ncbi.nlm.nih.gov/22884150/</uri><pub-id pub-id-type="pmid">22884150</pub-id></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Diagnostic performance of PWI/DWI MRI parameters in discriminating hyperacute versus acute ischaemic stroke: finding the best thresholds</article-title><source>Clin Radiol</source><person-group><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name><name name-style="western"><surname>Gonzalez-Gutierrez</surname><given-names>O</given-names></name><name name-style="western"><surname>Martinez-Lopez</surname><given-names>M</given-names></name></person-group><fpage>250</fpage><lpage>257</lpage><volume>67</volume><year>2012</year><pub-id pub-id-type="pmid">22018803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crad.2011.08.020</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Secondary MRI-findings, volumetric and spectroscopic measurements in mesial temporal sclerosis: a multivariate discriminant analysis</article-title><source>Swiss Med Wkly</source><person-group><name name-style="western"><surname>Lopez-Acevedo</surname><given-names>ML</given-names></name><name name-style="western"><surname>Martinez-Lopez</surname><given-names>M</given-names></name><name name-style="western"><surname>Favila</surname><given-names>R</given-names></name><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name></person-group><fpage>0</fpage><volume>142</volume><year>2012</year><pub-id pub-id-type="pmid">22688826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4414/smw.2012.13549</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation</article-title><source>Ann Intern Med</source><person-group><name name-style="western"><surname>Tricco</surname><given-names>AC</given-names></name><name name-style="western"><surname>Lillie</surname><given-names>E</given-names></name><name name-style="western"><surname>Zarin</surname><given-names>W</given-names></name><etal/></person-group><fpage>467</fpage><lpage>473</lpage><volume>169</volume><year>2018</year><pub-id pub-id-type="pmid">30178033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-0850</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Bibliometric analysis for medical research</article-title><source>Indian J Psychol Med</source><person-group><name name-style="western"><surname>Manoj Kumar</surname><given-names>L</given-names></name><name name-style="western"><surname>George</surname><given-names>RJ</given-names></name><name name-style="western"><surname>P S</surname><given-names>A</given-names></name></person-group><fpage>277</fpage><lpage>282</lpage><volume>45</volume><year>2023</year><pub-id pub-id-type="pmid">37152388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/02537176221103617</pub-id><pub-id pub-id-type="pmcid">PMC10159556</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>How to conduct a bibliometric analysis: an overview and guidelines</article-title><source>J Bus Res</source><person-group><name name-style="western"><surname>Donthu</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>D</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>N</given-names></name><name name-style="western"><surname>Lim</surname><given-names>WM</given-names></name></person-group><fpage>285</fpage><lpage>296</lpage><volume>133</volume><year>2021</year></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>100 citation classics from the Journal of the American Medical Association</article-title><source>JAMA</source><person-group><name name-style="western"><surname>Garfield</surname><given-names>E</given-names></name></person-group><fpage>52</fpage><lpage>59</lpage><volume>257</volume><year>1987</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/3537352/">https://pubmed.ncbi.nlm.nih.gov/3537352/</uri><pub-id pub-id-type="pmid">3537352</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics</article-title><source>Ir J Med Sci</source><person-group><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name><name name-style="western"><surname>Salazar-Ruiz</surname><given-names>SY</given-names></name><name name-style="western"><surname>Ibarra-Contreras</surname><given-names>R</given-names></name><name name-style="western"><surname>Rios</surname><given-names>C</given-names></name></person-group><fpage>939</fpage><lpage>951</lpage><volume>188</volume><year>2019</year><pub-id pub-id-type="pmid">30511320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11845-018-1936-5</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Impact factor correlations with Scimago Journal Rank, Source Normalized Impact per Paper, Eigenfactor Score, and the CiteScore in radiology, nuclear medicine &amp; medical imaging journals</article-title><source>Radiol Med</source><person-group><name name-style="western"><surname>Villase&#241;or-Almaraz</surname><given-names>M</given-names></name><name name-style="western"><surname>Islas-Serrano</surname><given-names>J</given-names></name><name name-style="western"><surname>Murata</surname><given-names>C</given-names></name><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name></person-group><fpage>495</fpage><lpage>504</lpage><volume>124</volume><year>2019</year><pub-id pub-id-type="pmid">30725395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11547-019-00996-z</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>bibliometrix: an R-tool for comprehensive science mapping analysis</article-title><source>J Informetrics</source><person-group><name name-style="western"><surname>Aria</surname><given-names>M</given-names></name><name name-style="western"><surname>Cuccurullo</surname><given-names>C</given-names></name></person-group><fpage>959</fpage><lpage>975</lpage><volume>11</volume><year>2017</year></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Software survey: VOSviewer, a computer program for bibliometric mapping</article-title><source>Scientometrics</source><person-group><name name-style="western"><surname>van Eck</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Waltman</surname><given-names>L</given-names></name></person-group><fpage>523</fpage><lpage>538</lpage><volume>84</volume><year>2010</year><pub-id pub-id-type="pmid">20585380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11192-009-0146-3</pub-id><pub-id pub-id-type="pmcid">PMC2883932</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Dynamics of language reorganization after stroke</article-title><source>Brain</source><person-group><name name-style="western"><surname>Saur</surname><given-names>D</given-names></name><name name-style="western"><surname>Lange</surname><given-names>R</given-names></name><name name-style="western"><surname>Baumgaertner</surname><given-names>A</given-names></name><name name-style="western"><surname>Schraknepper</surname><given-names>V</given-names></name><name name-style="western"><surname>Willmes</surname><given-names>K</given-names></name><name name-style="western"><surname>Rijntjes</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>C</given-names></name></person-group><fpage>1371</fpage><lpage>1384</lpage><volume>129</volume><year>2006</year><pub-id pub-id-type="pmid">16638796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl090</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>Cognitive motor processes: the role of motor imagery in the study of motor representations</article-title><source>Brain Res Rev</source><person-group><name name-style="western"><surname>Munzert</surname><given-names>J</given-names></name><name name-style="western"><surname>Lorey</surname><given-names>B</given-names></name><name name-style="western"><surname>Zentgraf</surname><given-names>K</given-names></name></person-group><fpage>306</fpage><lpage>326</lpage><volume>60</volume><year>2009</year><pub-id pub-id-type="pmid">19167426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresrev.2008.12.024</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Motor imagery: a backdoor to the motor system after stroke?</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name><name name-style="western"><surname>Pomeroy</surname><given-names>VM</given-names></name><name name-style="western"><surname>Baron</surname><given-names>JC</given-names></name></person-group><fpage>1941</fpage><lpage>1952</lpage><volume>37</volume><year>2006</year><pub-id pub-id-type="pmid">16741183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000226902.43357.fc</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>Robot-based hand motor therapy after stroke</article-title><source>Brain</source><person-group><name name-style="western"><surname>Takahashi</surname><given-names>CD</given-names></name><name name-style="western"><surname>Der-Yeghiaian</surname><given-names>L</given-names></name><name name-style="western"><surname>Le</surname><given-names>V</given-names></name><name name-style="western"><surname>Motiwala</surname><given-names>RR</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name></person-group><fpage>425</fpage><lpage>437</lpage><volume>131</volume><year>2008</year><pub-id pub-id-type="pmid">18156154</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm311</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Reorganization of the human ipsilesional premotor cortex after stroke</article-title><source>Brain</source><person-group><name name-style="western"><surname>Fridman</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hanakawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M</given-names></name><name name-style="western"><surname>Hummel</surname><given-names>F</given-names></name><name name-style="western"><surname>Leiguarda</surname><given-names>RC</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>LG</given-names></name></person-group><fpage>747</fpage><lpage>758</lpage><volume>127</volume><year>2004</year><pub-id pub-id-type="pmid">14749291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh082</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Motor system activation after subcortical stroke depends on corticospinal system integrity</article-title><source>Brain</source><person-group><name name-style="western"><surname>Ward</surname><given-names>NS</given-names></name><name name-style="western"><surname>Newton</surname><given-names>JM</given-names></name><name name-style="western"><surname>Swayne</surname><given-names>OB</given-names></name><etal/></person-group><fpage>809</fpage><lpage>819</lpage><volume>129</volume><year>2006</year><pub-id pub-id-type="pmid">16421171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl002</pub-id><pub-id pub-id-type="pmcid">PMC3717515</pub-id></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>Virtual reality-induced cortical reorganization and associated locomotor recovery in chronic stroke: an experimenter-blind randomized study</article-title><source>Stroke</source><person-group><name name-style="western"><surname>You</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name><etal/></person-group><fpage>1166</fpage><lpage>1171</lpage><volume>36</volume><year>2005</year><pub-id pub-id-type="pmid">15890990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000162715.43417.91</pub-id></element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>Renewal of the neurophysiology of language: functional neuroimaging</article-title><source>Physiol Rev</source><person-group><name name-style="western"><surname>D&#233;monet</surname><given-names>JF</given-names></name><name name-style="western"><surname>Thierry</surname><given-names>G</given-names></name><name name-style="western"><surname>Cardebat</surname><given-names>D</given-names></name></person-group><fpage>49</fpage><lpage>95</lpage><volume>85</volume><year>2005</year><pub-id pub-id-type="pmid">15618478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00049.2003</pub-id></element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Remodeling the brain: plastic structural brain changes produced by different motor therapies after stroke</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Gauthier</surname><given-names>LV</given-names></name><name name-style="western"><surname>Taub</surname><given-names>E</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>C</given-names></name><name name-style="western"><surname>Ortmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Mark</surname><given-names>VW</given-names></name><name name-style="western"><surname>Uswatte</surname><given-names>G</given-names></name></person-group><fpage>1520</fpage><lpage>1525</lpage><volume>39</volume><year>2008</year><pub-id pub-id-type="pmid">18323492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.502229</pub-id><pub-id pub-id-type="pmcid">PMC2574634</pub-id></element-citation></ref><ref id="REF37"><label>37</label><element-citation publication-type="journal"><article-title>Motor rehabilitation and brain plasticity after hemiparetic stroke</article-title><source>Prog Neurobiol</source><person-group><name name-style="western"><surname>Schaechter</surname><given-names>JD</given-names></name></person-group><fpage>61</fpage><lpage>72</lpage><volume>73</volume><year>2004</year><pub-id pub-id-type="pmid">15193779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2004.04.001</pub-id></element-citation></ref><ref id="REF38"><label>38</label><element-citation publication-type="journal"><article-title>Motor recovery and cortical reorganization after mirror therapy in chronic stroke patients: a phase II randomized controlled trial</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Michielsen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Selles</surname><given-names>RW</given-names></name><name name-style="western"><surname>van der Geest</surname><given-names>JN</given-names></name><etal/></person-group><fpage>223</fpage><lpage>233</lpage><volume>25</volume><year>2011</year><pub-id pub-id-type="pmid">21051765</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968310385127</pub-id></element-citation></ref><ref id="REF39"><label>39</label><element-citation publication-type="journal"><article-title>Ankle dorsiflexion as an fMRI paradigm to assay motor control for walking during rehabilitation</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Dobkin</surname><given-names>BH</given-names></name><name name-style="western"><surname>Firestine</surname><given-names>A</given-names></name><name name-style="western"><surname>West</surname><given-names>M</given-names></name><name name-style="western"><surname>Saremi</surname><given-names>K</given-names></name><name name-style="western"><surname>Woods</surname><given-names>R</given-names></name></person-group><fpage>370</fpage><lpage>381</lpage><volume>23</volume><year>2004</year><pub-id pub-id-type="pmid">15325385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2004.06.008</pub-id><pub-id pub-id-type="pmcid">PMC4164211</pub-id></element-citation></ref><ref id="REF40"><label>40</label><element-citation publication-type="journal"><article-title>Functionally specific reorganization in human premotor cortex</article-title><source>Neuron</source><person-group><name name-style="western"><surname>O'Shea</surname><given-names>J</given-names></name><name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name><name name-style="western"><surname>Trief</surname><given-names>D</given-names></name><name name-style="western"><surname>G&#246;bel</surname><given-names>S</given-names></name><name name-style="western"><surname>Rushworth</surname><given-names>MF</given-names></name></person-group><fpage>479</fpage><lpage>490</lpage><volume>54</volume><year>2007</year><pub-id pub-id-type="pmid">17481399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2007.04.021</pub-id></element-citation></ref><ref id="REF41"><label>41</label><element-citation publication-type="journal"><article-title>Sleep-dependent motor memory plasticity in the human brain</article-title><source>Neuroscience</source><person-group><name name-style="western"><surname>Walker</surname><given-names>MP</given-names></name><name name-style="western"><surname>Stickgold</surname><given-names>R</given-names></name><name name-style="western"><surname>Alsop</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaab</surname><given-names>N</given-names></name><name name-style="western"><surname>Schlaug</surname><given-names>G</given-names></name></person-group><fpage>911</fpage><lpage>917</lpage><volume>133</volume><year>2005</year><pub-id pub-id-type="pmid">15964485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2005.04.007</pub-id></element-citation></ref><ref id="REF42"><label>42</label><element-citation publication-type="journal"><article-title>Treadmill exercise activates subcortical neural networks and improves walking after stroke: a randomized controlled trial</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Luft</surname><given-names>AR</given-names></name><name name-style="western"><surname>Macko</surname><given-names>RF</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>LW</given-names></name><etal/></person-group><fpage>3341</fpage><lpage>3350</lpage><volume>39</volume><year>2008</year><pub-id pub-id-type="pmid">18757284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.108.527531</pub-id><pub-id pub-id-type="pmcid">PMC2929142</pub-id></element-citation></ref><ref id="REF43"><label>43</label><element-citation publication-type="journal"><article-title>Motor imagery after stroke: relating outcome to motor network connectivity</article-title><source>Ann Neurol</source><person-group><name name-style="western"><surname>Sharma</surname><given-names>N</given-names></name><name name-style="western"><surname>Baron</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>JB</given-names></name></person-group><fpage>604</fpage><lpage>616</lpage><volume>66</volume><year>2009</year><pub-id pub-id-type="pmid">19938103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.21810</pub-id><pub-id pub-id-type="pmcid">PMC3791355</pub-id></element-citation></ref><ref id="REF44"><label>44</label><element-citation publication-type="journal"><article-title>Are networks for residual language function and recovery consistent across aphasic patients?</article-title><source>Neurology</source><person-group><name name-style="western"><surname>Turkeltaub</surname><given-names>PE</given-names></name><name name-style="western"><surname>Messing</surname><given-names>S</given-names></name><name name-style="western"><surname>Norise</surname><given-names>C</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>RH</given-names></name></person-group><fpage>1726</fpage><lpage>1734</lpage><volume>76</volume><year>2011</year><pub-id pub-id-type="pmid">21576689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31821a44c1</pub-id><pub-id pub-id-type="pmcid">PMC3100133</pub-id></element-citation></ref><ref id="REF45"><label>45</label><element-citation publication-type="journal"><article-title>Resting state changes in functional connectivity correlate with movement recovery for BCI and robot-assisted upper-extremity training after stroke</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>V&#225;rkuti</surname><given-names>B</given-names></name><name name-style="western"><surname>Guan</surname><given-names>C</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><etal/></person-group><fpage>53</fpage><lpage>62</lpage><volume>27</volume><year>2013</year><pub-id pub-id-type="pmid">22645108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968312445910</pub-id></element-citation></ref><ref id="REF46"><label>46</label><element-citation publication-type="journal"><article-title>Non-invasive mapping of corticofugal fibres from multiple motor areas--relevance to stroke recovery</article-title><source>Brain</source><person-group><name name-style="western"><surname>Newton</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ward</surname><given-names>NS</given-names></name><name name-style="western"><surname>Parker</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Deichmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>DC</given-names></name><name name-style="western"><surname>Friston</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Frackowiak</surname><given-names>RS</given-names></name></person-group><fpage>1844</fpage><lpage>1858</lpage><volume>129</volume><year>2006</year><pub-id pub-id-type="pmid">16702192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl106</pub-id><pub-id pub-id-type="pmcid">PMC3718077</pub-id></element-citation></ref><ref id="REF47"><label>47</label><element-citation publication-type="journal"><article-title>Motor cortex stimulation for the enhancement of recovery from stroke: a prospective, multicenter safety study</article-title><source>Neurosurgery</source><person-group><name name-style="western"><surname>Brown</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lutsep</surname><given-names>HL</given-names></name><name name-style="western"><surname>Weinand</surname><given-names>M</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name></person-group><fpage>464</fpage><lpage>473</lpage><volume>58</volume><year>2006</year><pub-id pub-id-type="pmid">16528186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1227/01.NEU.0000197100.63931.04</pub-id></element-citation></ref><ref id="REF48"><label>48</label><element-citation publication-type="journal"><article-title>Extent of bilateral neuronal network reorganization and functional recovery in relation to stroke severity</article-title><source>J Neurosci</source><person-group><name name-style="western"><surname>van Meer</surname><given-names>MP</given-names></name><name name-style="western"><surname>Otte</surname><given-names>WM</given-names></name><name name-style="western"><surname>van der Marel</surname><given-names>K</given-names></name><etal/></person-group><fpage>4495</fpage><lpage>4507</lpage><volume>32</volume><year>2012</year><pub-id pub-id-type="pmid">22457497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.3662-11.2012</pub-id><pub-id pub-id-type="pmcid">PMC6622065</pub-id></element-citation></ref><ref id="REF49"><label>49</label><element-citation publication-type="journal"><article-title>Efficient neuroplasticity induction in chronic stroke patients by an associative brain-computer interface</article-title><source>J Neurophysiol</source><person-group><name name-style="western"><surname>Mrachacz-Kersting</surname><given-names>N</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>AJ</given-names></name><etal/></person-group><fpage>1410</fpage><lpage>1421</lpage><volume>115</volume><year>2016</year><pub-id pub-id-type="pmid">26719088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00918.2015</pub-id><pub-id pub-id-type="pmcid">PMC4808132</pub-id></element-citation></ref><ref id="REF50"><label>50</label><element-citation publication-type="journal"><article-title>Combination of brain-computer interface training and goal-directed physical therapy in chronic stroke: a case report</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Broetz</surname><given-names>D</given-names></name><name name-style="western"><surname>Braun</surname><given-names>C</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Soekadar</surname><given-names>SR</given-names></name><name name-style="western"><surname>Caria</surname><given-names>A</given-names></name><name name-style="western"><surname>Birbaumer</surname><given-names>N</given-names></name></person-group><fpage>674</fpage><lpage>679</lpage><volume>24</volume><year>2010</year><pub-id pub-id-type="pmid">20519741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968310368683</pub-id></element-citation></ref><ref id="REF51"><label>51</label><element-citation publication-type="journal"><article-title>Cortical plasticity following motor skill learning during mental practice in stroke</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Page</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Szaflarski</surname><given-names>JP</given-names></name><name name-style="western"><surname>Eliassen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name></person-group><fpage>382</fpage><lpage>388</lpage><volume>23</volume><year>2009</year><pub-id pub-id-type="pmid">19155350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968308326427</pub-id><pub-id pub-id-type="pmcid">PMC3258452</pub-id></element-citation></ref><ref id="REF52"><label>52</label><element-citation publication-type="journal"><article-title>Training and exercise to drive poststroke recovery</article-title><source>Nat Clin Pract Neurol</source><person-group><name name-style="western"><surname>Dobkin</surname><given-names>BH</given-names></name></person-group><fpage>76</fpage><lpage>85</lpage><volume>4</volume><year>2008</year><pub-id pub-id-type="pmid">18256679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncpneuro0709</pub-id><pub-id pub-id-type="pmcid">PMC4099052</pub-id></element-citation></ref><ref id="REF53"><label>53</label><element-citation publication-type="journal"><article-title>Chronic stroke recovery after combined BCI training and physiotherapy: a case report</article-title><source>Psychophysiology</source><person-group><name name-style="western"><surname>Caria</surname><given-names>A</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C</given-names></name><name name-style="western"><surname>Br&#246;tz</surname><given-names>D</given-names></name><etal/></person-group><fpage>578</fpage><lpage>582</lpage><volume>48</volume><year>2011</year><pub-id pub-id-type="pmid">20718931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1469-8986.2010.01117.x</pub-id></element-citation></ref><ref id="REF54"><label>54</label><element-citation publication-type="journal"><article-title>Movement-dependent stroke recovery: a systematic review and meta-analysis of TMS and fMRI evidence</article-title><source>Neuropsychologia</source><person-group><name name-style="western"><surname>Richards</surname><given-names>LG</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>KC</given-names></name><name name-style="western"><surname>Woodbury</surname><given-names>ML</given-names></name><name name-style="western"><surname>Senesac</surname><given-names>C</given-names></name><name name-style="western"><surname>Cauraugh</surname><given-names>JH</given-names></name></person-group><fpage>3</fpage><lpage>11</lpage><volume>46</volume><year>2008</year><pub-id pub-id-type="pmid">17904594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2007.08.013</pub-id><pub-id pub-id-type="pmcid">PMC2248459</pub-id></element-citation></ref><ref id="REF55"><label>55</label><element-citation publication-type="journal"><article-title>Left hemisphere plasticity and aphasia recovery</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Fridriksson</surname><given-names>J</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>JD</given-names></name><name name-style="western"><surname>Fillmore</surname><given-names>P</given-names></name><name name-style="western"><surname>Cai</surname><given-names>B</given-names></name></person-group><fpage>854</fpage><lpage>863</lpage><volume>60</volume><year>2012</year><pub-id pub-id-type="pmid">22227052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.12.057</pub-id><pub-id pub-id-type="pmcid">PMC3313653</pub-id></element-citation></ref><ref id="REF56"><label>56</label><element-citation publication-type="journal"><article-title>Neuroplasticity of language networks in aphasia: advances, updates, and future challenges</article-title><source>Front Neurol</source><person-group><name name-style="western"><surname>Kiran</surname><given-names>S</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>CK</given-names></name></person-group><fpage>295</fpage><volume>10</volume><year>2019</year><pub-id pub-id-type="pmid">31001187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2019.00295</pub-id><pub-id pub-id-type="pmcid">PMC6454116</pub-id></element-citation></ref><ref id="REF57"><label>57</label><element-citation publication-type="journal"><article-title>Adult visual cortical plasticity</article-title><source>Neuron</source><person-group><name name-style="western"><surname>Gilbert</surname><given-names>CD</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name></person-group><fpage>250</fpage><lpage>264</lpage><volume>75</volume><year>2012</year><pub-id pub-id-type="pmid">22841310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2012.06.030</pub-id><pub-id pub-id-type="pmcid">PMC3408614</pub-id></element-citation></ref><ref id="REF58"><label>58</label><element-citation publication-type="journal"><article-title>Functional MRI follow-up study of language processes in healthy subjects and during recovery in a case of aphasia</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Fernandez</surname><given-names>B</given-names></name><name name-style="western"><surname>Cardebat</surname><given-names>D</given-names></name><name name-style="western"><surname>Demonet</surname><given-names>JF</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>PA</given-names></name><name name-style="western"><surname>Mazaux</surname><given-names>JM</given-names></name><name name-style="western"><surname>Barat</surname><given-names>M</given-names></name><name name-style="western"><surname>Allard</surname><given-names>M</given-names></name></person-group><fpage>2171</fpage><lpage>2176</lpage><volume>35</volume><year>2004</year><pub-id pub-id-type="pmid">15297629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000139323.76769.b0</pub-id></element-citation></ref><ref id="REF59"><label>59</label><element-citation publication-type="journal"><article-title>Functional reorganization of the cerebral motor system after stroke</article-title><source>Curr Opin Neurol</source><person-group><name name-style="western"><surname>Ward</surname><given-names>NS</given-names></name></person-group><fpage>725</fpage><lpage>730</lpage><volume>17</volume><year>2004</year><pub-id pub-id-type="pmid">15542982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00019052-200412000-00013</pub-id></element-citation></ref><ref id="REF60"><label>60</label><element-citation publication-type="journal"><article-title>Bilateral and unilateral arm training improve motor function through differing neuroplastic mechanisms: a single-blinded randomized controlled trial</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Whitall</surname><given-names>J</given-names></name><name name-style="western"><surname>Waller</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sorkin</surname><given-names>JD</given-names></name><etal/></person-group><fpage>118</fpage><lpage>129</lpage><volume>25</volume><year>2011</year><pub-id pub-id-type="pmid">20930212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968310380685</pub-id><pub-id pub-id-type="pmcid">PMC3548606</pub-id></element-citation></ref><ref id="REF61"><label>61</label><element-citation publication-type="journal"><article-title>Neuroplasticity and brain repair after stroke</article-title><source>Curr Opin Neurol</source><person-group><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name><name name-style="western"><surname>Riley</surname><given-names>JD</given-names></name></person-group><fpage>76</fpage><lpage>82</lpage><volume>21</volume><year>2008</year><pub-id pub-id-type="pmid">18180655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WCO.0b013e3282f36cb6</pub-id></element-citation></ref><ref id="REF62"><label>62</label><element-citation publication-type="journal"><article-title>Structural and functional plasticity in the somatosensory cortex of chronic stroke patients</article-title><source>Brain</source><person-group><name name-style="western"><surname>Schaechter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Moore</surname><given-names>CI</given-names></name><name name-style="western"><surname>Connell</surname><given-names>BD</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>BR</given-names></name><name name-style="western"><surname>Dijkhuizen</surname><given-names>RM</given-names></name></person-group><fpage>2722</fpage><lpage>2733</lpage><volume>129</volume><year>2006</year><pub-id pub-id-type="pmid">16921177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awl214</pub-id></element-citation></ref><ref id="REF63"><label>63</label><element-citation publication-type="journal"><article-title>The right hemisphere is not unitary in its role in aphasia recovery</article-title><source>Cortex</source><person-group><name name-style="western"><surname>Turkeltaub</surname><given-names>PE</given-names></name><name name-style="western"><surname>Coslett</surname><given-names>HB</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>AL</given-names></name><name name-style="western"><surname>Faseyitan</surname><given-names>O</given-names></name><name name-style="western"><surname>Benson</surname><given-names>J</given-names></name><name name-style="western"><surname>Norise</surname><given-names>C</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>RH</given-names></name></person-group><fpage>1179</fpage><lpage>1186</lpage><volume>48</volume><year>2012</year><pub-id pub-id-type="pmid">21794852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cortex.2011.06.010</pub-id><pub-id pub-id-type="pmcid">PMC3221765</pub-id></element-citation></ref><ref id="REF64"><label>64</label><element-citation publication-type="journal"><article-title>Integrated technology for evaluation of brain function and neural plasticity</article-title><source>Phys Med Rehabil Clin N Am</source><person-group><name name-style="western"><surname>Rossini</surname><given-names>PM</given-names></name><name name-style="western"><surname>Dal Forno</surname><given-names>G</given-names></name></person-group><fpage>263</fpage><lpage>306</lpage><volume>15</volume><year>2004</year><pub-id pub-id-type="pmid">15029909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1047-9651(03)00124-4</pub-id></element-citation></ref><ref id="REF65"><label>65</label><element-citation publication-type="journal"><article-title>Two different reorganization patterns after rehabilitative therapy: an exploratory study with fMRI and TMS</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Hamzei</surname><given-names>F</given-names></name><name name-style="western"><surname>Liepert</surname><given-names>J</given-names></name><name name-style="western"><surname>Dettmers</surname><given-names>C</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>C</given-names></name><name name-style="western"><surname>Rijntjes</surname><given-names>M</given-names></name></person-group><fpage>710</fpage><lpage>720</lpage><volume>31</volume><year>2006</year><pub-id pub-id-type="pmid">16516499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2005.12.035</pub-id></element-citation></ref><ref id="REF66"><label>66</label><element-citation publication-type="journal"><article-title>Predicting behavioural response to TDCS in chronic motor stroke</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>O'Shea</surname><given-names>J</given-names></name><name name-style="western"><surname>Boudrias</surname><given-names>MH</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Bachtiar</surname><given-names>V</given-names></name><name name-style="western"><surname>Kischka</surname><given-names>U</given-names></name><name name-style="western"><surname>Blicher</surname><given-names>JU</given-names></name><name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name></person-group><fpage>924</fpage><lpage>933</lpage><volume>85 Pt 3</volume><year>2014</year><pub-id pub-id-type="pmid">23727528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2013.05.096</pub-id><pub-id pub-id-type="pmcid">PMC3899017</pub-id></element-citation></ref><ref id="REF67"><label>67</label><element-citation publication-type="journal"><article-title>Structural changes induced by daily music listening in the recovering brain after middle cerebral artery stroke: a voxel-based morphometry study</article-title><source>Front Hum Neurosci</source><person-group><name name-style="western"><surname>S&#228;rk&#228;m&#246;</surname><given-names>T</given-names></name><name name-style="western"><surname>Ripoll&#233;s</surname><given-names>P</given-names></name><name name-style="western"><surname>Veps&#228;l&#228;inen</surname><given-names>H</given-names></name><etal/></person-group><fpage>245</fpage><volume>8</volume><year>2014</year><pub-id pub-id-type="pmid">24860466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2014.00245</pub-id><pub-id pub-id-type="pmcid">PMC4029020</pub-id></element-citation></ref><ref id="REF68"><label>68</label><element-citation publication-type="journal"><article-title>Impact of alertness training on spatial neglect: a behavioural and fMRI study</article-title><source>Neuropsychologia</source><person-group><name name-style="western"><surname>Thimm</surname><given-names>M</given-names></name><name name-style="western"><surname>Fink</surname><given-names>GR</given-names></name><name name-style="western"><surname>K&#252;st</surname><given-names>J</given-names></name><name name-style="western"><surname>Karbe</surname><given-names>H</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>W</given-names></name></person-group><fpage>1230</fpage><lpage>1246</lpage><volume>44</volume><year>2006</year><pub-id pub-id-type="pmid">16280140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2005.09.008</pub-id></element-citation></ref><ref id="REF69"><label>69</label><element-citation publication-type="journal"><article-title>Stem cell therapy: a clinical trial of stroke</article-title><source>Clin Neurol Neurosurg</source><person-group><name name-style="western"><surname>Bhasin</surname><given-names>A</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>MV</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>R</given-names></name><name name-style="western"><surname>Kumaran</surname><given-names>SS</given-names></name><name name-style="western"><surname>Bose</surname><given-names>S</given-names></name></person-group><fpage>1003</fpage><lpage>1008</lpage><volume>115</volume><year>2013</year><pub-id pub-id-type="pmid">23183251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2012.10.015</pub-id></element-citation></ref><ref id="REF70"><label>70</label><element-citation publication-type="journal"><article-title>Functional plasticity induced by mirror training: the mirror as the element connecting both hands to one hemisphere</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Hamzei</surname><given-names>F</given-names></name><name name-style="western"><surname>L&#228;ppchen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Glauche</surname><given-names>V</given-names></name><name name-style="western"><surname>Mader</surname><given-names>I</given-names></name><name name-style="western"><surname>Rijntjes</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>C</given-names></name></person-group><fpage>484</fpage><lpage>496</lpage><volume>26</volume><year>2012</year><pub-id pub-id-type="pmid">22247501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968311427917</pub-id></element-citation></ref><ref id="REF71"><label>71</label><element-citation publication-type="journal"><article-title>Leap Motion-based virtual reality training for improving motor functional recovery of upper limbs and neural reorganization in subacute stroke patients</article-title><source>Neural Regen Res</source><person-group><name name-style="western"><surname>Wang</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><name name-style="western"><surname>Mei</surname><given-names>LP</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name></person-group><fpage>1823</fpage><lpage>1831</lpage><volume>12</volume><year>2017</year><pub-id pub-id-type="pmid">29239328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/1673-5374.219043</pub-id><pub-id pub-id-type="pmcid">PMC5745836</pub-id></element-citation></ref><ref id="REF72"><label>72</label><element-citation publication-type="journal"><article-title>Comparison of finger tracking versus simple movement training via telerehabilitation to alter hand function and cortical reorganization after stroke</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Carey</surname><given-names>JR</given-names></name><name name-style="western"><surname>Durfee</surname><given-names>WK</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>E</given-names></name><name name-style="western"><surname>Nagpal</surname><given-names>A</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>SA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>SM</given-names></name></person-group><fpage>216</fpage><lpage>232</lpage><volume>21</volume><year>2007</year><pub-id pub-id-type="pmid">17351083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968306292381</pub-id></element-citation></ref><ref id="REF73"><label>73</label><element-citation publication-type="journal"><article-title>Activity in preserved left hemisphere regions predicts anomia severity in aphasia</article-title><source>Cereb Cortex</source><person-group><name name-style="western"><surname>Fridriksson</surname><given-names>J</given-names></name><name name-style="western"><surname>Bonilha</surname><given-names>L</given-names></name><name name-style="western"><surname>Baker</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moser</surname><given-names>D</given-names></name><name name-style="western"><surname>Rorden</surname><given-names>C</given-names></name></person-group><fpage>1013</fpage><lpage>1019</lpage><volume>20</volume><year>2010</year><pub-id pub-id-type="pmid">19687294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhp160</pub-id><pub-id pub-id-type="pmcid">PMC2852500</pub-id></element-citation></ref><ref id="REF74"><label>74</label><element-citation publication-type="journal"><article-title>Efficacy and brain imaging correlates of an immersive motor imagery BCI-driven VR system for upper limb motor rehabilitation: a clinical case report</article-title><source>Front Hum Neurosci</source><person-group><name name-style="western"><surname>Vourvopoulos</surname><given-names>A</given-names></name><name name-style="western"><surname>Jorge</surname><given-names>C</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>R</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>P</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>JC</given-names></name><name name-style="western"><surname>Berm&#250;dez I Badia</surname><given-names>S</given-names></name></person-group><fpage>244</fpage><volume>13</volume><year>2019</year><pub-id pub-id-type="pmid">31354460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2019.00244</pub-id><pub-id pub-id-type="pmcid">PMC6637378</pub-id></element-citation></ref><ref id="REF75"><label>75</label><element-citation publication-type="journal"><article-title>Effects of high- and low-frequency repetitive transcranial magnetic stimulation on motor recovery in early stroke patients: evidence from a randomized controlled trial with clinical, neurophysiological and functional imaging assessments</article-title><source>Neuroimage Clin</source><person-group><name name-style="western"><surname>Du</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><fpage>101620</fpage><volume>21</volume><year>2019</year><pub-id pub-id-type="pmid">30527907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2018.101620</pub-id><pub-id pub-id-type="pmcid">PMC6411653</pub-id></element-citation></ref><ref id="REF76"><label>76</label><element-citation publication-type="journal"><article-title>Induction of neuroplasticity and recovery in post-stroke aphasia by non-invasive brain stimulation</article-title><source>Front Hum Neurosci</source><person-group><name name-style="western"><surname>Shah</surname><given-names>PP</given-names></name><name name-style="western"><surname>Szaflarski</surname><given-names>JP</given-names></name><name name-style="western"><surname>Allendorfer</surname><given-names>J</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>RH</given-names></name></person-group><fpage>888</fpage><volume>7</volume><year>2013</year><pub-id pub-id-type="pmid">24399952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2013.00888</pub-id><pub-id pub-id-type="pmcid">PMC3870921</pub-id></element-citation></ref><ref id="REF77"><label>77</label><element-citation publication-type="journal"><article-title>Neuroimaging experimental studies on brain plasticity in recovery from stroke</article-title><source>Eura Medicophys</source><person-group><name name-style="western"><surname>Rossini</surname><given-names>PM</given-names></name><name name-style="western"><surname>Altamura</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferreri</surname><given-names>F</given-names></name><etal/></person-group><fpage>241</fpage><lpage>254</lpage><volume>43</volume><year>2007</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17589415/">https://pubmed.ncbi.nlm.nih.gov/17589415/</uri><pub-id pub-id-type="pmid">17589415</pub-id></element-citation></ref><ref id="REF78"><label>78</label><element-citation publication-type="journal"><article-title>Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial</article-title><source>Transl Stroke Res</source><person-group><name name-style="western"><surname>Jaillard</surname><given-names>A</given-names></name><name name-style="western"><surname>Hommel</surname><given-names>M</given-names></name><name name-style="western"><surname>Moisan</surname><given-names>A</given-names></name><etal/></person-group><fpage>910</fpage><lpage>923</lpage><volume>11</volume><year>2020</year><pub-id pub-id-type="pmid">32462427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12975-020-00787-z</pub-id></element-citation></ref><ref id="REF79"><label>79</label><element-citation publication-type="journal"><article-title>Functional connectivity in relation to motor performance and recovery after stroke</article-title><source>Front Syst Neurosci</source><person-group><name name-style="western"><surname>Westlake</surname><given-names>KP</given-names></name><name name-style="western"><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><fpage>8</fpage><volume>5</volume><year>2011</year><pub-id pub-id-type="pmid">21441991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnsys.2011.00008</pub-id><pub-id pub-id-type="pmcid">PMC3060711</pub-id></element-citation></ref><ref id="REF80"><label>80</label><element-citation publication-type="journal"><article-title>Enduring representational plasticity after somatosensory stimulation</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Wu</surname><given-names>CW</given-names></name><name name-style="western"><surname>van Gelderen</surname><given-names>P</given-names></name><name name-style="western"><surname>Hanakawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Yaseen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>LG</given-names></name></person-group><fpage>872</fpage><lpage>884</lpage><volume>27</volume><year>2005</year><pub-id pub-id-type="pmid">16084740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2005.05.055</pub-id></element-citation></ref><ref id="REF81"><label>81</label><element-citation publication-type="journal"><article-title>Shaping early reorganization of neural networks promotes motor function after stroke</article-title><source>Cereb Cortex</source><person-group><name name-style="western"><surname>Volz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Rehme</surname><given-names>AK</given-names></name><name name-style="western"><surname>Michely</surname><given-names>J</given-names></name><name name-style="western"><surname>Nettekoven</surname><given-names>C</given-names></name><name name-style="western"><surname>Eickhoff</surname><given-names>SB</given-names></name><name name-style="western"><surname>Fink</surname><given-names>GR</given-names></name><name name-style="western"><surname>Grefkes</surname><given-names>C</given-names></name></person-group><fpage>2882</fpage><lpage>2894</lpage><volume>26</volume><year>2016</year><pub-id pub-id-type="pmid">26980614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhw034</pub-id><pub-id pub-id-type="pmcid">PMC4869817</pub-id></element-citation></ref><ref id="REF82"><label>82</label><element-citation publication-type="journal"><article-title>Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Karki</surname><given-names>K</given-names></name><name name-style="western"><surname>Knight</surname><given-names>RA</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><fpage>3384</fpage><lpage>3389</lpage><volume>40</volume><year>2009</year><pub-id pub-id-type="pmid">19644071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.108.544395</pub-id><pub-id pub-id-type="pmcid">PMC2758425</pub-id></element-citation></ref><ref id="REF83"><label>83</label><element-citation publication-type="journal"><article-title>Neuroplasticity and constraint-induced movement therapy</article-title><source>Eura Medicophys</source><person-group><name name-style="western"><surname>Mark</surname><given-names>VW</given-names></name><name name-style="western"><surname>Taub</surname><given-names>E</given-names></name><name name-style="western"><surname>Morris</surname><given-names>DM</given-names></name></person-group><fpage>269</fpage><lpage>284</lpage><volume>42</volume><year>2006</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/17039225/">https://pubmed.ncbi.nlm.nih.gov/17039225/</uri><pub-id pub-id-type="pmid">17039225</pub-id></element-citation></ref><ref id="REF84"><label>84</label><element-citation publication-type="journal"><article-title>Enhanced cortical activation in the contralesional hemisphere of chronic stroke patients in response to motor skill challenge</article-title><source>Cereb Cortex</source><person-group><name name-style="western"><surname>Schaechter</surname><given-names>JD</given-names></name><name name-style="western"><surname>Perdue</surname><given-names>KL</given-names></name></person-group><fpage>638</fpage><lpage>647</lpage><volume>18</volume><year>2008</year><pub-id pub-id-type="pmid">17602141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhm096</pub-id></element-citation></ref><ref id="REF85"><label>85</label><element-citation publication-type="journal"><article-title>A macroscopic view of microstructure: using diffusion-weighted images to infer damage, repair, and plasticity of white matter</article-title><source>Neuroscience</source><person-group><name name-style="western"><surname>Concha</surname><given-names>L</given-names></name></person-group><fpage>14</fpage><lpage>28</lpage><volume>276</volume><year>2014</year><pub-id pub-id-type="pmid">24051366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2013.09.004</pub-id></element-citation></ref><ref id="REF86"><label>86</label><element-citation publication-type="journal"><article-title>Motor cortex excitability and connectivity in chronic stroke: a multimodal model of functional reorganization</article-title><source>Brain Struct Funct</source><person-group><name name-style="western"><surname>Volz</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Sarfeld</surname><given-names>AS</given-names></name><name name-style="western"><surname>Diekhoff</surname><given-names>S</given-names></name><etal/></person-group><fpage>1093</fpage><lpage>1107</lpage><volume>220</volume><year>2015</year><pub-id pub-id-type="pmid">24415059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00429-013-0702-8</pub-id></element-citation></ref><ref id="REF87"><label>87</label><element-citation publication-type="journal"><article-title>Neuroplastic changes following rehabilitative training correlate with regional electrical field induced with tDCS</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Halko</surname><given-names>MA</given-names></name><name name-style="western"><surname>Datta</surname><given-names>A</given-names></name><name name-style="western"><surname>Plow</surname><given-names>EB</given-names></name><name name-style="western"><surname>Scaturro</surname><given-names>J</given-names></name><name name-style="western"><surname>Bikson</surname><given-names>M</given-names></name><name name-style="western"><surname>Merabet</surname><given-names>LB</given-names></name></person-group><fpage>885</fpage><lpage>891</lpage><volume>57</volume><year>2011</year><pub-id pub-id-type="pmid">21620985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.05.026</pub-id><pub-id pub-id-type="pmcid">PMC3167218</pub-id></element-citation></ref><ref id="REF88"><label>88</label><element-citation publication-type="journal"><article-title>Diffusion tensor imaging and fiber tractography in acute stroke</article-title><source>Neuroimaging Clin N Am</source><person-group><name name-style="western"><surname>Mukherjee</surname><given-names>P</given-names></name></person-group><fpage>655</fpage><lpage>0</lpage><page-range>655-65, xii</page-range><volume>15</volume><year>2005</year><pub-id pub-id-type="pmid">16360595</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nic.2005.08.010</pub-id></element-citation></ref><ref id="REF89"><label>89</label><element-citation publication-type="journal"><article-title>A review of transcranial magnetic stimulation and multimodal neuroimaging to characterize post-stroke neuroplasticity</article-title><source>Front Neurol</source><person-group><name name-style="western"><surname>Auriat</surname><given-names>AM</given-names></name><name name-style="western"><surname>Neva</surname><given-names>JL</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>JK</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>LA</given-names></name></person-group><fpage>226</fpage><volume>6</volume><year>2015</year><pub-id pub-id-type="pmid">26579069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2015.00226</pub-id><pub-id pub-id-type="pmcid">PMC4625082</pub-id></element-citation></ref><ref id="REF90"><label>90</label><element-citation publication-type="journal"><article-title>Neural plasticity and treatment-induced recovery of sentence processing in agrammatism</article-title><source>Neuropsychologia</source><person-group><name name-style="western"><surname>Thompson</surname><given-names>CK</given-names></name><name name-style="western"><surname>den Ouden</surname><given-names>DB</given-names></name><name name-style="western"><surname>Bonakdarpour</surname><given-names>B</given-names></name><name name-style="western"><surname>Garibaldi</surname><given-names>K</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>TB</given-names></name></person-group><fpage>3211</fpage><lpage>3227</lpage><volume>48</volume><year>2010</year><pub-id pub-id-type="pmid">20603138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2010.06.036</pub-id><pub-id pub-id-type="pmcid">PMC3164559</pub-id></element-citation></ref><ref id="REF91"><label>91</label><element-citation publication-type="journal"><article-title>Functional MRI correlates of lower limb function in stroke victims with gait impairment</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Enzinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name><name name-style="western"><surname>Dawes</surname><given-names>H</given-names></name><etal/></person-group><fpage>1507</fpage><lpage>1513</lpage><volume>39</volume><year>2008</year><pub-id pub-id-type="pmid">18340092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.501999</pub-id><pub-id pub-id-type="pmcid">PMC7610857</pub-id></element-citation></ref><ref id="REF92"><label>92</label><element-citation publication-type="journal"><article-title>Neural recruitment associated with anomia treatment in aphasia</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Fridriksson</surname><given-names>J</given-names></name><name name-style="western"><surname>Morrow-Odom</surname><given-names>L</given-names></name><name name-style="western"><surname>Moser</surname><given-names>D</given-names></name><name name-style="western"><surname>Fridriksson</surname><given-names>A</given-names></name><name name-style="western"><surname>Baylis</surname><given-names>G</given-names></name></person-group><fpage>1403</fpage><lpage>1412</lpage><volume>32</volume><year>2006</year><pub-id pub-id-type="pmid">16766207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.04.194</pub-id></element-citation></ref><ref id="REF93"><label>93</label><element-citation publication-type="journal"><article-title>Enhanced interhemispheric functional connectivity compensates for anatomical connection damages in subcortical stroke</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name></person-group><fpage>1045</fpage><lpage>1051</lpage><volume>46</volume><year>2015</year><pub-id pub-id-type="pmid">25721013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.114.007044</pub-id></element-citation></ref><ref id="REF94"><label>94</label><element-citation publication-type="journal"><article-title>Neuroimaging and recovery of language in aphasia</article-title><source>Curr Neurol Neurosci Rep</source><person-group><name name-style="western"><surname>Thompson</surname><given-names>CK</given-names></name><name name-style="western"><surname>den Ouden</surname><given-names>DB</given-names></name></person-group><fpage>475</fpage><lpage>483</lpage><volume>8</volume><year>2008</year><pub-id pub-id-type="pmid">18957184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-008-0076-0</pub-id><pub-id pub-id-type="pmcid">PMC3079407</pub-id></element-citation></ref><ref id="REF95"><label>95</label><element-citation publication-type="journal"><article-title>Music supported therapy promotes motor plasticity in individuals with chronic stroke</article-title><source>Brain Imaging Behav</source><person-group><name name-style="western"><surname>Ripoll&#233;s</surname><given-names>P</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>N</given-names></name><name name-style="western"><surname>Grau-S&#225;nchez</surname><given-names>J</given-names></name><etal/></person-group><fpage>1289</fpage><lpage>1307</lpage><volume>10</volume><year>2016</year><pub-id pub-id-type="pmid">26707190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11682-015-9498-x</pub-id></element-citation></ref><ref id="REF96"><label>96</label><element-citation publication-type="journal"><article-title>Functional MRI and diffusion tensor imaging of brain reorganization after experimental stroke</article-title><source>Transl Stroke Res</source><person-group><name name-style="western"><surname>Dijkhuizen</surname><given-names>RM</given-names></name><name name-style="western"><surname>van der Marel</surname><given-names>K</given-names></name><name name-style="western"><surname>Otte</surname><given-names>WM</given-names></name><name name-style="western"><surname>Hoff</surname><given-names>EI</given-names></name><name name-style="western"><surname>van der Zijden</surname><given-names>JP</given-names></name><name name-style="western"><surname>van der Toorn</surname><given-names>A</given-names></name><name name-style="western"><surname>van Meer</surname><given-names>MP</given-names></name></person-group><fpage>36</fpage><lpage>43</lpage><volume>3</volume><year>2012</year><pub-id pub-id-type="pmid">22408692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12975-011-0143-8</pub-id><pub-id pub-id-type="pmcid">PMC3284658</pub-id></element-citation></ref><ref id="REF97"><label>97</label><element-citation publication-type="journal"><article-title>Post-lesional cerebral reorganisation: evidence from functional neuroimaging and transcranial magnetic stimulation</article-title><source>J Physiol Paris</source><person-group><name name-style="western"><surname>B&#252;tefisch</surname><given-names>CM</given-names></name><name name-style="western"><surname>Kleiser</surname><given-names>R</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>RJ</given-names></name></person-group><fpage>437</fpage><lpage>454</lpage><volume>99</volume><year>2006</year><pub-id pub-id-type="pmid">16723211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jphysparis.2006.03.001</pub-id></element-citation></ref><ref id="REF98"><label>98</label><element-citation publication-type="journal"><article-title>Lesion-induced and training-induced brain reorganization</article-title><source>Restor Neurol Neurosci</source><person-group><name name-style="western"><surname>Liepert</surname><given-names>J</given-names></name><name name-style="western"><surname>Hamzei</surname><given-names>F</given-names></name><name name-style="western"><surname>Weiller</surname><given-names>C</given-names></name></person-group><fpage>269</fpage><lpage>277</lpage><volume>22</volume><year>2004</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/15502271/">https://pubmed.ncbi.nlm.nih.gov/15502271/</uri><pub-id pub-id-type="pmid">15502271</pub-id></element-citation></ref><ref id="REF99"><label>99</label><element-citation publication-type="journal"><article-title>Cortical reorganization--effects of intensive therapy</article-title><source>Restor Neurol Neurosci</source><person-group><name name-style="western"><surname>Nelles</surname><given-names>G</given-names></name></person-group><fpage>239</fpage><lpage>244</lpage><volume>22</volume><year>2004</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/15502268/">https://pubmed.ncbi.nlm.nih.gov/15502268/</uri><pub-id pub-id-type="pmid">15502268</pub-id></element-citation></ref><ref id="REF100"><label>100</label><element-citation publication-type="journal"><article-title>Evolution of FMRI activation in the perilesional primary motor cortex and cerebellum with rehabilitation training-related motor gains after stroke: a pilot study</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Winstein</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Albistegui-DuBois</surname><given-names>R</given-names></name><name name-style="western"><surname>Dobkin</surname><given-names>BH</given-names></name></person-group><fpage>412</fpage><lpage>428</lpage><volume>21</volume><year>2007</year><pub-id pub-id-type="pmid">17369516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968306298598</pub-id><pub-id pub-id-type="pmcid">PMC4067098</pub-id></element-citation></ref><ref id="REF101"><label>101</label><element-citation publication-type="journal"><article-title>Structural damage and functional reorganization in ipsilesional m1 in well-recovered patients with subcortical stroke</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Shi</surname><given-names>FD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name></person-group><fpage>788</fpage><lpage>793</lpage><volume>45</volume><year>2014</year><pub-id pub-id-type="pmid">24496396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.113.003425</pub-id></element-citation></ref><ref id="REF102"><label>102</label><element-citation publication-type="journal"><article-title>Therapy-induced neuroplasticity in chronic aphasia</article-title><source>Neuropsychologia</source><person-group><name name-style="western"><surname>Marcotte</surname><given-names>K</given-names></name><name name-style="western"><surname>Adrover-Roig</surname><given-names>D</given-names></name><name name-style="western"><surname>Damien</surname><given-names>B</given-names></name><name name-style="western"><surname>de Pr&#233;aumont</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#233;n&#233;reux</surname><given-names>S</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>M</given-names></name><name name-style="western"><surname>Ansaldo</surname><given-names>AI</given-names></name></person-group><fpage>1776</fpage><lpage>1786</lpage><volume>50</volume><year>2012</year><pub-id pub-id-type="pmid">22564481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2012.04.001</pub-id></element-citation></ref><ref id="REF103"><label>103</label><element-citation publication-type="journal"><article-title>Human adult cortical reorganization and consequent visual distortion</article-title><source>J Neurosci</source><person-group><name name-style="western"><surname>Dilks</surname><given-names>DD</given-names></name><name name-style="western"><surname>Serences</surname><given-names>JT</given-names></name><name name-style="western"><surname>Rosenau</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Yantis</surname><given-names>S</given-names></name><name name-style="western"><surname>McCloskey</surname><given-names>M</given-names></name></person-group><fpage>9585</fpage><lpage>9594</lpage><volume>27</volume><year>2007</year><pub-id pub-id-type="pmid">17804619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2650-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC2695877</pub-id></element-citation></ref><ref id="REF104"><label>104</label><element-citation publication-type="journal"><article-title>Neural correlates of proprioceptive integration in the contralesional hemisphere of very impaired patients shortly after a subcortical stroke: an FMRI study</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Dechaumont-Palacin</surname><given-names>S</given-names></name><name name-style="western"><surname>Marque</surname><given-names>P</given-names></name><name name-style="western"><surname>De Boissezon</surname><given-names>X</given-names></name><etal/></person-group><fpage>154</fpage><lpage>165</lpage><volume>22</volume><year>2008</year><pub-id pub-id-type="pmid">17916656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968307307118</pub-id></element-citation></ref><ref id="REF105"><label>105</label><element-citation publication-type="journal"><article-title>Structural plasticity in adulthood with motor learning and stroke rehabilitation</article-title><source>Annu Rev Neurosci</source><person-group><name name-style="western"><surname>Sampaio-Baptista</surname><given-names>C</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Johansen-Berg</surname><given-names>H</given-names></name></person-group><fpage>25</fpage><lpage>40</lpage><volume>41</volume><year>2018</year><pub-id pub-id-type="pmid">29490196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-neuro-080317-062015</pub-id></element-citation></ref><ref id="REF106"><label>106</label><element-citation publication-type="journal"><article-title>Mechanism of Kinect-based virtual reality training for motor functional recovery of upper limbs after subacute stroke</article-title><source>Neural Regen Res</source><person-group><name name-style="western"><surname>Bao</surname><given-names>X</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><etal/></person-group><fpage>2904</fpage><lpage>2913</lpage><volume>8</volume><year>2013</year><pub-id pub-id-type="pmid">25206611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3969/j.issn.1673-5374.2013.31.003</pub-id><pub-id pub-id-type="pmcid">PMC4146174</pub-id></element-citation></ref><ref id="REF107"><label>107</label><element-citation publication-type="journal"><article-title>Changes in white matter integrity follow excitatory rTMS treatment of post-stroke aphasia</article-title><source>Restor Neurol Neurosci</source><person-group><name name-style="western"><surname>Allendorfer</surname><given-names>JB</given-names></name><name name-style="western"><surname>Storrs</surname><given-names>JM</given-names></name><name name-style="western"><surname>Szaflarski</surname><given-names>JP</given-names></name></person-group><fpage>103</fpage><lpage>113</lpage><volume>30</volume><year>2012</year><pub-id pub-id-type="pmid">22233802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/RNN-2011-0627</pub-id><pub-id pub-id-type="pmcid">PMC3316910</pub-id></element-citation></ref><ref id="REF108"><label>108</label><element-citation publication-type="journal"><article-title>Reorganization of syntactic processing following left-hemisphere brain damage: does right-hemisphere activity preserve function?</article-title><source>Brain</source><person-group><name name-style="western"><surname>Tyler</surname><given-names>LK</given-names></name><name name-style="western"><surname>Wright</surname><given-names>P</given-names></name><name name-style="western"><surname>Randall</surname><given-names>B</given-names></name><name name-style="western"><surname>Marslen-Wilson</surname><given-names>WD</given-names></name><name name-style="western"><surname>Stamatakis</surname><given-names>EA</given-names></name></person-group><fpage>3396</fpage><lpage>3408</lpage><volume>133</volume><year>2010</year><pub-id pub-id-type="pmid">20870779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awq262</pub-id><pub-id pub-id-type="pmcid">PMC2965424</pub-id></element-citation></ref><ref id="REF109"><label>109</label><element-citation publication-type="journal"><article-title>Functional magnetic resonance imaging study on dysphagia after unilateral hemispheric stroke: a preliminary study</article-title><source>J Neurol Neurosurg Psychiatry</source><person-group><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B</given-names></name><etal/></person-group><fpage>1320</fpage><lpage>1329</lpage><volume>80</volume><year>2009</year><pub-id pub-id-type="pmid">19515639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.2009.176214</pub-id></element-citation></ref><ref id="REF110"><label>110</label><element-citation publication-type="journal"><article-title>Acute ischaemic stroke alters the brain's preference for distinct dynamic connectivity states</article-title><source>Brain</source><person-group><name name-style="western"><surname>Bonkhoff</surname><given-names>AK</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>FA</given-names></name><name name-style="western"><surname>Gazula</surname><given-names>H</given-names></name><etal/></person-group><fpage>1525</fpage><lpage>1540</lpage><volume>143</volume><year>2020</year><pub-id pub-id-type="pmid">32357220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa101</pub-id><pub-id pub-id-type="pmcid">PMC7241954</pub-id></element-citation></ref><ref id="REF111"><label>111</label><element-citation publication-type="journal"><article-title>Functional neuroimaging in stroke recovery and neurorehabilitation: conceptual issues and perspectives</article-title><source>Int J Stroke</source><person-group><name name-style="western"><surname>Carey</surname><given-names>LM</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>RJ</given-names></name></person-group><fpage>245</fpage><lpage>264</lpage><volume>2</volume><year>2007</year><pub-id pub-id-type="pmid">18705925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1747-4949.2007.00164.x</pub-id></element-citation></ref><ref id="REF112"><label>112</label><element-citation publication-type="journal"><article-title>Cortical reorganization following modified constraint-induced movement therapy: a study of 4 patients with chronic stroke</article-title><source>Arch Phys Med Rehabil</source><person-group><name name-style="western"><surname>Szaflarski</surname><given-names>JP</given-names></name><name name-style="western"><surname>Page</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kissela</surname><given-names>BM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Levine</surname><given-names>P</given-names></name><name name-style="western"><surname>Strakowski</surname><given-names>SM</given-names></name></person-group><fpage>1052</fpage><lpage>1058</lpage><volume>87</volume><year>2006</year><pub-id pub-id-type="pmid">16876549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apmr.2006.04.018</pub-id></element-citation></ref><ref id="REF113"><label>113</label><element-citation publication-type="journal"><article-title>A paradox: after stroke, the non-lesioned lower limb motor cortex may be maladaptive</article-title><source>Eur J Neurosci</source><person-group><name name-style="western"><surname>Madhavan</surname><given-names>S</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>LM</given-names></name><name name-style="western"><surname>Stinear</surname><given-names>JW</given-names></name></person-group><fpage>1032</fpage><lpage>1039</lpage><volume>32</volume><year>2010</year><pub-id pub-id-type="pmid">20722719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1460-9568.2010.07364.x</pub-id><pub-id pub-id-type="pmcid">PMC2943014</pub-id></element-citation></ref><ref id="REF114"><label>114</label><element-citation publication-type="journal"><article-title>Activity in the peri-infarct rim in relation to recovery from stroke</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name><name name-style="western"><surname>Juranek</surname><given-names>J</given-names></name><name name-style="western"><surname>Crafton</surname><given-names>KR</given-names></name><name name-style="western"><surname>Le</surname><given-names>V</given-names></name></person-group><fpage>111</fpage><lpage>115</lpage><volume>37</volume><year>2006</year><pub-id pub-id-type="pmid">16306462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000195135.70379.1f</pub-id></element-citation></ref><ref id="REF115"><label>115</label><element-citation publication-type="journal"><article-title>A review of diffusion tensor imaging studies on motor recovery mechanisms in stroke patients</article-title><source>NeuroRehabilitation</source><person-group><name name-style="western"><surname>Jang</surname><given-names>SH</given-names></name></person-group><fpage>345</fpage><lpage>352</lpage><volume>28</volume><year>2011</year><pub-id pub-id-type="pmid">21725167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/NRE-2011-0662</pub-id></element-citation></ref><ref id="REF116"><label>116</label><element-citation publication-type="journal"><article-title>When right is all that is left: plasticity of right-hemisphere tracts in a young aphasic patient</article-title><source>Ann N Y Acad Sci</source><person-group><name name-style="western"><surname>Zipse</surname><given-names>L</given-names></name><name name-style="western"><surname>Norton</surname><given-names>A</given-names></name><name name-style="western"><surname>Marchina</surname><given-names>S</given-names></name><name name-style="western"><surname>Schlaug</surname><given-names>G</given-names></name></person-group><fpage>237</fpage><lpage>245</lpage><volume>1252</volume><year>2012</year><pub-id pub-id-type="pmid">22524365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-6632.2012.06454.x</pub-id><pub-id pub-id-type="pmcid">PMC3589758</pub-id></element-citation></ref><ref id="REF117"><label>117</label><element-citation publication-type="journal"><article-title>fMRI analysis of ankle movement tracking training in subject with stroke</article-title><source>Exp Brain Res</source><person-group><name name-style="western"><surname>Carey</surname><given-names>JR</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kimberley</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>SM</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Ugurbil</surname><given-names>K</given-names></name></person-group><fpage>281</fpage><lpage>290</lpage><volume>154</volume><year>2004</year><pub-id pub-id-type="pmid">14578998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00221-003-1662-7</pub-id></element-citation></ref><ref id="REF118"><label>118</label><element-citation publication-type="journal"><article-title>Effects of virtual reality intervention on neural plasticity in stroke rehabilitation: a systematic review</article-title><source>Arch Phys Med Rehabil</source><person-group><name name-style="western"><surname>Hao</surname><given-names>J</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Harp</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Siu</surname><given-names>KC</given-names></name></person-group><fpage>523</fpage><lpage>541</lpage><volume>103</volume><year>2022</year><pub-id pub-id-type="pmid">34352269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apmr.2021.06.024</pub-id></element-citation></ref><ref id="REF119"><label>119</label><element-citation publication-type="journal"><article-title>The neural correlates of semantic feature analysis in chronic aphasia: discordant patterns according to the etiology</article-title><source>Semin Speech Lang</source><person-group><name name-style="western"><surname>Marcotte</surname><given-names>K</given-names></name><name name-style="western"><surname>Ansaldo</surname><given-names>AI</given-names></name></person-group><fpage>52</fpage><lpage>63</lpage><volume>31</volume><year>2010</year><pub-id pub-id-type="pmid">20221954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0029-1244953</pub-id></element-citation></ref><ref id="REF120"><label>120</label><element-citation publication-type="journal"><article-title>Effects of home-based telerehabilitation in patients with stroke: a randomized controlled trial</article-title><source>Neurology</source><person-group><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><fpage>0</fpage><lpage>30</lpage><volume>95</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000010821</pub-id><pub-id pub-id-type="pmid">32999058</pub-id></element-citation></ref><ref id="REF121"><label>121</label><element-citation publication-type="journal"><article-title>Functional MRI of swallowing: from neurophysiology to neuroplasticity</article-title><source>Head Neck</source><person-group><name name-style="western"><surname>Malandraki</surname><given-names>GA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>J</given-names></name></person-group><fpage>0</fpage><lpage>20</lpage><volume>33 Suppl 1</volume><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.21903</pub-id><pub-id pub-id-type="pmcid">PMC3747973</pub-id><pub-id pub-id-type="pmid">21901779</pub-id></element-citation></ref><ref id="REF122"><label>122</label><element-citation publication-type="journal"><article-title>Neuroplasticity in post-stroke aphasia: a systematic review and meta-analysis of functional imaging studies of reorganization of language processing</article-title><source>Neurobiol Lang (Camb)</source><person-group><name name-style="western"><surname>Wilson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Schneck</surname><given-names>SM</given-names></name></person-group><fpage>22</fpage><lpage>82</lpage><volume>2</volume><year>2021</year><pub-id pub-id-type="pmid">33884373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/nol_a_00025</pub-id><pub-id pub-id-type="pmcid">PMC8057712</pub-id></element-citation></ref><ref id="REF123"><label>123</label><element-citation publication-type="journal"><article-title>Brain activity associated with stimulation therapy of the visual borderzone in hemianopic stroke patients</article-title><source>Neurorehabil Neural Repair</source><person-group><name name-style="western"><surname>Marshall</surname><given-names>RS</given-names></name><name name-style="western"><surname>Ferrera</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>A</given-names></name><etal/></person-group><fpage>136</fpage><lpage>144</lpage><volume>22</volume><year>2008</year><pub-id pub-id-type="pmid">17698955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1545968307305522</pub-id></element-citation></ref><ref id="REF124"><label>124</label><element-citation publication-type="journal"><article-title>Functional MRI evince the safety and efficacy of umbilical cord blood cells therapy in patients with schizophrenia</article-title><source>Schizophr Res</source><person-group><name name-style="western"><surname>Ternovoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Ustyuzhanin</surname><given-names>D</given-names></name><name name-style="western"><surname>Morozova</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shariya</surname><given-names>M</given-names></name><name name-style="western"><surname>Roldan-Valadez</surname><given-names>E</given-names></name><name name-style="western"><surname>Smirnov</surname><given-names>V</given-names></name></person-group><fpage>175</fpage><lpage>177</lpage><volume>224</volume><year>2020</year><pub-id pub-id-type="pmid">33046337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.schres.2020.09.028</pub-id></element-citation></ref><ref id="REF125"><label>125</label><element-citation publication-type="journal"><article-title>Technology insight: noninvasive brain stimulation in neurology-perspectives on the therapeutic potential of rTMS and tDCS</article-title><source>Nat Clin Pract Neurol</source><person-group><name name-style="western"><surname>Fregni</surname><given-names>F</given-names></name><name name-style="western"><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><fpage>383</fpage><lpage>393</lpage><volume>3</volume><year>2007</year><pub-id pub-id-type="pmid">17611487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncpneuro0530</pub-id></element-citation></ref><ref id="REF126"><label>126</label><element-citation publication-type="journal"><article-title>Hand motor recovery after stroke: tuning the orchestra to improve hand motor function</article-title><source>Cogn Behav Neurol</source><person-group><name name-style="western"><surname>Fregni</surname><given-names>F</given-names></name><name name-style="western"><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><fpage>21</fpage><lpage>33</lpage><volume>19</volume><year>2006</year><pub-id pub-id-type="pmid">16633016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00146965-200603000-00003</pub-id></element-citation></ref><ref id="REF127"><label>127</label><element-citation publication-type="journal"><article-title>Transcranial magnetic stimulation coregistered with MRI: a comparison of a guided versus blind stimulation technique and its effect on evoked compound muscle action potentials</article-title><source>Clin Neurophysiol</source><person-group><name name-style="western"><surname>Gugino</surname><given-names>LD</given-names></name><name name-style="western"><surname>Romero</surname><given-names>JR</given-names></name><name name-style="western"><surname>Aglio</surname><given-names>L</given-names></name><etal/></person-group><fpage>1781</fpage><lpage>1792</lpage><volume>112</volume><year>2001</year><pub-id pub-id-type="pmid">11595135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1388-2457(01)00633-2</pub-id><pub-id pub-id-type="pmcid">PMC2845153</pub-id></element-citation></ref><ref id="REF128"><label>128</label><element-citation publication-type="journal"><article-title>Longitudinal changes of resting-state functional connectivity during motor recovery after stroke</article-title><source>Stroke</source><person-group><name name-style="western"><surname>Park</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>WH</given-names></name><name name-style="western"><surname>Ohn</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>ST</given-names></name><name name-style="western"><surname>Bang</surname><given-names>OY</given-names></name><name name-style="western"><surname>Pascual-Leone</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YH</given-names></name></person-group><fpage>1357</fpage><lpage>1362</lpage><volume>42</volume><year>2011</year><pub-id pub-id-type="pmid">21441147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.110.596155</pub-id><pub-id pub-id-type="pmcid">PMC3589816</pub-id></element-citation></ref><ref id="REF129"><label>129</label><element-citation publication-type="journal"><article-title>Functional and effective connectivity: a review</article-title><source>Brain Connect</source><person-group><name name-style="western"><surname>Friston</surname><given-names>KJ</given-names></name></person-group><fpage>13</fpage><lpage>36</lpage><volume>1</volume><year>2011</year><pub-id pub-id-type="pmid">22432952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/brain.2011.0008</pub-id></element-citation></ref><ref id="REF130"><label>130</label><element-citation publication-type="journal"><article-title>Multivariate autoregressive modeling of fMRI time series</article-title><source>Neuroimage</source><person-group><name name-style="western"><surname>Harrison</surname><given-names>L</given-names></name><name name-style="western"><surname>Penny</surname><given-names>WD</given-names></name><name name-style="western"><surname>Friston</surname><given-names>K</given-names></name></person-group><fpage>1477</fpage><lpage>1491</lpage><volume>19</volume><year>2003</year><pub-id pub-id-type="pmid">12948704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1053-8119(03)00160-5</pub-id></element-citation></ref><ref id="REF131"><label>131</label><element-citation publication-type="journal"><article-title>Dynamic diaschisis: anatomically remote and context-sensitive human brain lesions</article-title><source>J Cogn Neurosci</source><person-group><name name-style="western"><surname>Price</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Warburton</surname><given-names>EA</given-names></name><name name-style="western"><surname>Moore</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Frackowiak</surname><given-names>RS</given-names></name><name name-style="western"><surname>Friston</surname><given-names>KJ</given-names></name></person-group><fpage>419</fpage><lpage>429</lpage><volume>13</volume><year>2001</year><pub-id pub-id-type="pmid">11388916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/08989290152001853</pub-id></element-citation></ref><ref id="REF132"><label>132</label><element-citation publication-type="journal"><article-title>Analyzing effective connectivity with functional magnetic resonance imaging</article-title><source>Wiley Interdiscip Rev Cogn Sci</source><person-group><name name-style="western"><surname>Stephan</surname><given-names>KE</given-names></name><name name-style="western"><surname>Friston</surname><given-names>KJ</given-names></name></person-group><fpage>446</fpage><lpage>459</lpage><volume>1</volume><year>2010</year><pub-id pub-id-type="pmid">21209846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wcs.58</pub-id><pub-id pub-id-type="pmcid">PMC3013343</pub-id></element-citation></ref><ref id="REF133"><label>133</label><element-citation publication-type="journal"><article-title>Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery</article-title><source>Ann Neurol</source><person-group><name name-style="western"><surname>Cramer</surname><given-names>SC</given-names></name></person-group><fpage>272</fpage><lpage>287</lpage><volume>63</volume><year>2008</year><pub-id pub-id-type="pmid">18383072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.21393</pub-id></element-citation></ref><ref id="REF134"><label>134</label><element-citation publication-type="journal"><article-title>Stimulating conversation: enhancement of elicited propositional speech in a patient with chronic non-fluent aphasia following transcranial magnetic stimulation</article-title><source>Brain Lang</source><person-group><name name-style="western"><surname>Hamilton</surname><given-names>RH</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>L</given-names></name><name name-style="western"><surname>Benson</surname><given-names>J</given-names></name><etal/></person-group><fpage>45</fpage><lpage>50</lpage><volume>113</volume><year>2010</year><pub-id pub-id-type="pmid">20159655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bandl.2010.01.001</pub-id><pub-id pub-id-type="pmcid">PMC2909623</pub-id></element-citation></ref><ref id="REF135"><label>135</label><element-citation publication-type="journal"><article-title>Exploring the transformative influence of neuroplasticity on stroke rehabilitation: a narrative review of current evidence</article-title><source>Ann Med Surg (Lond)</source><person-group><name name-style="western"><surname>Aderinto</surname><given-names>N</given-names></name><name name-style="western"><surname>AbdulBasit</surname><given-names>MO</given-names></name><name name-style="western"><surname>Olatunji</surname><given-names>G</given-names></name><name name-style="western"><surname>Adejumo</surname><given-names>T</given-names></name></person-group><fpage>4425</fpage><lpage>4432</lpage><volume>85</volume><year>2023</year><pub-id pub-id-type="pmid">37663728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MS9.0000000000001137</pub-id><pub-id pub-id-type="pmcid">PMC10473303</pub-id></element-citation></ref><ref id="REF136"><label>136</label><element-citation publication-type="journal"><article-title>Towards data-driven stroke rehabilitation via wearable sensors and deep learning</article-title><source>Proc Mach Learn Res</source><person-group><name name-style="western"><surname>Kaku</surname><given-names>A</given-names></name><name name-style="western"><surname>Parnandi</surname><given-names>A</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>A</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>N</given-names></name><name name-style="western"><surname>Schambra</surname><given-names>H</given-names></name><name name-style="western"><surname>Fernandez-Granda</surname><given-names>C</given-names></name></person-group><fpage>143</fpage><lpage>171</lpage><volume>126</volume><year>2020</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/34337420/">https://pubmed.ncbi.nlm.nih.gov/34337420/</uri><pub-id pub-id-type="pmid">34337420</pub-id><pub-id pub-id-type="pmcid">PMC8320306</pub-id></element-citation></ref><ref id="REF137"><label>137</label><element-citation publication-type="journal"><article-title>The future of telerehabilitation: embracing virtual reality and augmented reality innovations</article-title><source>Pan Afr Med J</source><person-group><name name-style="western"><surname>Naqvi</surname><given-names>WM</given-names></name><name name-style="western"><surname>Naqvi</surname><given-names>IW</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>GV</given-names></name><name name-style="western"><surname>Vardhan</surname><given-names>VD</given-names></name></person-group><fpage>157</fpage><volume>47</volume><year>2024</year><pub-id pub-id-type="pmid">38974699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11604/pamj.2024.47.157.42956</pub-id><pub-id pub-id-type="pmcid">PMC11226757</pub-id></element-citation></ref><ref id="REF138"><label>138</label><element-citation publication-type="journal"><article-title>Innovations in stroke recovery and rehabilitation</article-title><source>Phys Med Rehabil Clin N Am</source><person-group><name name-style="western"><surname>Stilling</surname><given-names>J</given-names></name><name name-style="western"><surname>Stein</surname><given-names>J</given-names></name></person-group><fpage>0</fpage><volume>35</volume><year>2024</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pmr.2023.07.003</pub-id><pub-id pub-id-type="pmid">38514232</pub-id></element-citation></ref><ref id="REF139"><label>139</label><element-citation publication-type="journal"><article-title>Effectiveness of robotics in stroke rehabilitation to accelerate upper extremity function: systematic review</article-title><source>Occup Ther Int</source><person-group><name name-style="western"><surname>Carrillo</surname><given-names>C</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>D</given-names></name><name name-style="western"><surname>Horn</surname><given-names>K</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>M</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>C</given-names></name><name name-style="western"><surname>Hilton</surname><given-names>C</given-names></name><name name-style="western"><surname>Mani</surname><given-names>K</given-names></name></person-group><fpage>7991765</fpage><volume>2023</volume><year>2023</year><pub-id pub-id-type="pmid">37927581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/7991765</pub-id><pub-id pub-id-type="pmcid">PMC10624545</pub-id></element-citation></ref><ref id="REF140"><label>140</label><element-citation publication-type="journal"><article-title>Virtual and augmented reality in post-stroke rehabilitation: a narrative review</article-title><source>Cureus</source><person-group><name name-style="western"><surname>Khokale</surname><given-names>R</given-names></name><name name-style="western"><surname>S Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><etal/></person-group><fpage>0</fpage><volume>15</volume><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.37559</pub-id><pub-id pub-id-type="pmcid">PMC10183111</pub-id><pub-id pub-id-type="pmid">37193429</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of Alzheimer's disease : JAD</journal-title></journal-title-group><issn pub-type="ppub">1387-2877</issn><issn pub-type="epub">1875-8908</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507122</article-id><article-id pub-id-type="pmcid-ver">PMC12507122.1</article-id><article-id pub-id-type="pmcaid">12507122</article-id><article-id pub-id-type="pmcaiid">12507122</article-id><article-id pub-id-type="manuscript-id">NIHMS2115278</article-id><article-id pub-id-type="pmid">40702821</article-id><article-id pub-id-type="doi">10.1177/13872877251361934</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2115278</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2115278</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Associations between blood-based neurodegenerative biomarkers and cognitive functioning and decline in India</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nichols</surname><given-names initials="E">Emma</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="J">Jinkook</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gross</surname><given-names initials="AL">Alden L.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anwar</surname><given-names initials="M">Masroor</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gupta</surname><given-names initials="A">Abhishek</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Crimmins</surname><given-names initials="EM">Eileen M.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thyagarajan</surname><given-names initials="B">Bharat</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dey</surname><given-names initials="S">Sharmistha</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1"><label>1.</label>Center for Economic and Social Research, University of Southern California, 635 Downey Way, VPD, Los Angeles, CA 90089</aff><aff id="A2"><label>2.</label>Leonard Davis School of Gerontology, Andrus Gerontology Center, University of Southern California, Los Angeles, 3715 McClintock Ave, Los Angeles, CA 90089</aff><aff id="A3"><label>3.</label>Department of Economics, University of Southern California, 3620 South Vermont Avenue, Kaprelian (KAP) Hall, Los Angeles, CA 90089-0253</aff><aff id="A4"><label>4.</label>Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument St., Baltimore, MD 21231a</aff><aff id="A5"><label>5.</label>Department of Biophysics, All India Institute of Medical Sciences, H696+4QF, New, AIIMS Campus, Ansari Nagar East, New Delhi, Delhi 110029, India</aff><aff id="A6"><label>6.</label>Department of Laboratory Medicine and Pathology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455</aff><author-notes><fn fn-type="other" id="FN1"><label>*</label><p id="P1">denotes co-senior authorship</p></fn><fn fn-type="con" id="FN2"><p id="P2"><bold>Author contributions:</bold> Emma Nichols (Conceptualization; Methodology; Formal Analysis; Writing &#8211; Original draft preparation), Jinkook Lee (Conceptualization; Supervision; Funding acquisition; Writing &#8211; Review &amp; Editing), Alden L. Gross (Conceptualization; Investigation; Writing &#8211; Review &amp; Editing), Masroor Anwar (Investigation; Data Curation; Writing &#8211; Review &amp; Editing), Abhishek Gupta (Investigation; Data Curation; Writing &#8211; Review &amp; Editing), Eileen M. Crimmins (Conceptualization; Validation; Project administration; Writing &#8211; Review &amp; Editing), Bharat Thyagarajan (Conceptualization; Validation; Project administration; Writing &#8211; Review &amp; Editing), Sharmistha Dey (Conceptualization; Validation; Funding acquisition; Project administration; Writing &#8211; Review &amp; Editing)</p></fn><corresp id="CR1">Corresponding author: Emma Nichols, <email>emmanich@usc.edu</email> address: Center for Economic and Social Research, University of Southern California, 635 Downey Way, VPD 305, Los Angeles, CA, USA 90089</corresp><fn fn-type="COI-statement" id="FN3"><p id="P45"><bold>Conflicts:</bold> No conflicts.</p></fn><fn fn-type="COI-statement" id="FN6"><p id="P48"><underline>Declaration of competing interests:</underline> The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>7</month><year>2025</year></pub-date><volume>107</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">498505</issue-id><fpage>233</fpage><lpage>245</lpage><pub-history><event event-type="nihms-submitted"><date><day>05</day><month>10</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2115278.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P3">Mounting evidence supports the use of blood-based neurodegenerative biomarkers as a low-cost, minimally invasive tool for studying Alzheimer&#8217;s disease and other dementias, but existing data largely come from clinical samples or high-income settings. Despite emphasis in the literature on the importance of understanding the utility of neurodegenerative biomarkers in diverse populations, published analyses are limited.</p></sec><sec id="S2"><title>Objective:</title><p id="P4">To assess the utility of neurodegenerative biomarkers in India by quantifying associations between biomarkers and cognitive outcomes in a nationally representative cohort study.</p></sec><sec id="S3"><title>Methods:</title><p id="P5">We quantified associations between five neurodegenerative blood biomarkers (&#946;-amyloid 42/40 [A&#946;42/40], total tau, phosphorylated Tau181 [pTau-181], glial fibrillary acidic protein [GFAP], neurofilament light [NfL]) and cross-sectional and longitudinal cognitive outcomes using nationally-representative data from the Longitudinal Aging Study in India&#8211;Diagnostic Assessment of Dementia (N=4,096).</p></sec><sec id="S4"><title>Results:</title><p id="P6">We observed associations between biomarkers and cross-sectional cognitive functioning (A&#946;42/40, GFAP, and NfL) and longitudinal cognitive change (pTau-181 and NfL). NfL had the strongest associations; each SD increase in log NfL was associated with 0.007 (95% CI 0.000 to 0.014) SD unit/year worse cognitive decline, equivalent to about 35% of the mean longitudinal decline in the sample. We saw little evidence of effect modification by demographic variables or APOE-&#949;4 status.</p></sec><sec id="S5"><title>Conclusions:</title><p id="P7">Neurodegenerative biomarkers were associated with cross-sectional and longitudinal outcomes as well as mortality, though there was variation in outcome-specific findings across biomarkers. Findings generally support the use of neurodegenerative biomarkers in India. Future research in India should leverage these biomarkers to address a range of research topics, including heterogeneity in dementia phenotypes.</p></sec></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>dementia</kwd><kwd>blood-based biomarkers</kwd><kwd>neurodegeneration</kwd><kwd>amyloid</kwd><kwd>tau</kwd><kwd>neurofilament light</kwd><kwd>glial fibrillary acidic protein</kwd><kwd>cognition</kwd><kwd>cognitive decline</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther Nucleic Acids</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther Nucleic Acids</journal-id><journal-id journal-id-type="pmc-domain-id">1821</journal-id><journal-id journal-id-type="pmc-domain">mtna</journal-id><journal-title-group><journal-title>Molecular Therapy. Nucleic Acids</journal-title></journal-title-group><issn pub-type="epub">2162-2531</issn><publisher><publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489819</article-id><article-id pub-id-type="pmcid-ver">PMC12489819.1</article-id><article-id pub-id-type="pmcaid">12489819</article-id><article-id pub-id-type="pmcaiid">12489819</article-id><article-id pub-id-type="pmid">41049089</article-id><article-id pub-id-type="doi">10.1016/j.omtn.2025.102710</article-id><article-id pub-id-type="pii">S2162-2531(25)00264-1</article-id><article-id pub-id-type="publisher-id">102710</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Caron</surname><given-names initials="NS">Nicholas S.</given-names></name><email>ncaron@cmmt.ubc.ca</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Fan</surname><given-names initials="J">Jianjia</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Ma</surname><given-names initials="D">Da</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="fn1" ref-type="fn">9</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Yung</surname><given-names initials="A">Andrew</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Ko</surname><given-names initials="S">Seunghyun</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Bale</surname><given-names initials="K">Kirsten</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Anderson</surname><given-names initials="C">Christine</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Kozlowski</surname><given-names initials="P">Piotr</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Pouladi</surname><given-names initials="MA">Mahmoud A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Wellington</surname><given-names initials="CL">Cheryl L.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Hayden</surname><given-names initials="MR">Michael R.</given-names></name><email>mrh@cmmt.ubc.ca</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>1</label>Centre for Molecular Medicine and Therapeutics, Vancouver, BC V5Z 4H4, Canada</aff><aff id="aff2"><label>2</label>BC Children&#8217;s Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada</aff><aff id="aff3"><label>3</label>Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada</aff><aff id="aff4"><label>4</label>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada</aff><aff id="aff5"><label>5</label>School of Engineering Science, Simon Fraser University, Burnaby, BC V5A 1S6, Canada</aff><aff id="aff6"><label>6</label>UBC MRI Research Centre, Department of Radiology, University of British Columbia, Vancouver, BC V6T 2B5, Canada</aff><aff id="aff7"><label>7</label>Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada</aff><aff id="aff8"><label>8</label>Edwin S.H Leong Centre for Healthy Aging, University of British Columbia, Vancouver, BC V6T 1Z3, Canada</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author: Nicholas S. Caron, Centre for Molecular Medicine and Therapeutics, Vancouver, BC V5Z 4H4, Canada. <email>ncaron@cmmt.ubc.ca</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author: Michael R. Hayden, Centre for Molecular Medicine and Therapeutics, Vancouver, BC V5Z 4H4, Canada. <email>mrh@cmmt.ubc.ca</email></corresp><fn id="fn1"><label>9</label><p id="ntpara0010">Present address: Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA</p></fn></author-notes><pub-date pub-type="collection"><day>09</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>9</month><year>2025</year></pub-date><volume>36</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">497114</issue-id><elocation-id>102710</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Therapies targeting mutant huntingtin (mHTT) reduction in the brain hold promise as disease-modifying treatments for Huntington disease (HD), necessitating biomarkers that accurately reflect treatment response. We evaluated candidate molecular and imaging biomarkers after mHTT reduction in YAC128 HD mice, with equal numbers of males and females per group. At 6 months of age, YAC128 mice received unilateral intracerebroventricular injections of saline or mHTT-lowering antisense oligonucleotide (HTT ASO). Plasma neurofilament light chain (NEFL) and glial fibrillary acidic protein (GFAP) were measured longitudinally from 6 to 12 months. Structural MRI was performed at 6, 9, and 12 months. At study endpoint, we quantified mHTT target engagement in the brain and performed striatal RNA sequencing. Treatment with HTT ASO produced a sustained reduction of mHTT levels throughout the brain for up to 6 months, significantly slowed plasma NEFL increases, and moderately attenuated GFAP elevation. Although mHTT levels inversely correlated with gray and white matter volumes, treatment did not significantly stabilize regional brain atrophy, highlighting an association between mHTT load and neuroanatomical integrity. HTT ASO also partially reversed striatal transcriptome dysregulation and restored oligodendrocyte-specific gene expression. Plasma NEFL, but not brain imaging, emerges as a sensitive and dynamic response biomarker for mHTT-lowering therapies.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fx1.jpg"/></fig></abstract><abstract abstract-type="teaser" id="abs0020"><p>Caron and colleagues evaluated molecular and imaging biomarkers in response to brain mHTT reduction in YAC128 Huntington disease mice. HTT ASO treatment slowed plasma NEFL increases and corrected striatal oligodendrocyte transcriptional dysregulation. Plasma NEFL emerged as a sensitive response biomarker, whereas imaging did not reflect treatment effects.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>MT: Oligonucleotides: Therapies and Applications</kwd><kwd>Huntington disease</kwd><kwd>huntingtin lowering</kwd><kwd>antisense oligonucleotide</kwd><kwd>response biomarker</kwd><kwd>neurofilament light chain</kwd><kwd>glial fibrillary acidic protein</kwd><kwd>plasma</kwd><kwd>magnetic resonance imaging</kwd><kwd>RNA sequencing</kwd><kwd>oligodendrocytes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Huntington disease (HD) is a progressive neurodegenerative disorder with no approved disease-modifying therapies. A key challenge in clinical trials for HD is identifying biomarkers of treatment response that reliably reflect the efficacy of candidate therapies. Both molecular biomarkers, such as neurofilament light chain (NEFL) and glial fibrillary acidic protein (GFAP), and imaging biomarkers, including structural magnetic resonance imaging (MRI), have been used to monitor disease progression in HD.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> However, the sensitivity of these measures to therapeutic intervention remains incompletely understood. Here, we evaluate objective molecular and imaging measures in response to lowering levels of mutant huntingtin (mHTT) in the brains of YAC128 HD mice, focusing on plasma biomarkers, structural brain integrity, and transcriptomic changes in the striatum. Our findings provide insights into the differential sensitivity of molecular and imaging biomarkers to therapeutic intervention and highlight key considerations for evaluating treatment response in HD.</p><p id="p0015">HD is caused by a polymorphic C-A-G repeat expansion in the <italic toggle="yes">HTT</italic> gene that codes for an elongated polyglutamine tract in the HTT protein.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Polyglutamine-expanded mHTT is a primary driver of pathogenesis, disrupting transcriptional regulation, neurotrophic factor transport, stress response, and energy metabolism.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Over time, these pathogenic cascades cause both cell-autonomous and cell-non-autonomous dysfunction, leading to progressive neurodegeneration, primarily in the caudate and putamen, with additional involvement of the cortex and other subcortical regions.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref></p><p id="p0020">Therapeutic strategies that lower mHTT levels in the brain show strong potential as disease-modifying treatments for HD. Preclinical studies have demonstrated that reducing mHTT can ameliorate behavioral, neuropathological, and molecular phenotypes across diverse HD mouse models.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Approaches to lower HTT can be either non-selective, reducing both wild-type HTT (wtHTT) and mHTT, or allele-selective, targeting only the mutant allele through the expanded CAG tract<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> or linked polymorphisms.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Given the essential roles of wtHTT in development and maintaining neuronal health&#8212;where constitutive knockout of <italic toggle="yes">Htt</italic> in mice is embryonic lethal<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and conditional inactivation of <italic toggle="yes">Htt</italic> in adulthood leads to progressive neuropathology<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref>&#8212;allele-selective approaches that preserve wtHTT functions may offer a safer therapeutic profile. Among these approaches, antisense oligonucleotides (ASOs) that target the <italic toggle="yes">HTT</italic> transcript and promote its degradation are currently under investigation in clinical trials.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref></p><p id="p0025">Clinical assessments based on standardized rating scales are used as primary endpoints in clinical trials for HD.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> However, it remains unknown whether motor or functional readouts will be sufficiently robust to measure improvements in response to treatment in symptomatic patients over time intervals typical of clinical trials.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Imaging-based biomarkers for HD correlate with clinical measures of disease severity (reviewed in<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>) and have been adopted as exploratory efficacy endpoints in clinical trials. Structural MRI methods are sensitive enough to detect regional and whole-brain atrophy decades before predicted onset<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="bib58" ref-type="bibr"><sup>58</sup></xref><sup>,</sup><xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> and can accurately measure progressive regional gray and white matter changes in the brain associated with HD progression.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> However, regional brain atrophy progresses relatively slowly in HD, raising uncertainty about whether stabilization of brain volume reduction in response to therapeutic intervention would be sensitive or dynamic enough to detect over the short time intervals typical of clinical trials.</p><p id="p0030">Molecular biomarkers in accessible biological fluids hold promise for monitoring pathophysiological changes in the CNS associated with HD. NEFL, a neuron-specific intermediate filament protein, is a validated biomarker of neurodegeneration in HD<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> and other neurodegenerative disorders.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> In HD, cerebrospinal fluid (CSF) and blood NEFL concentrations increase with disease progression and correlate with clinical measures of motor and cognitive function, as well as imaging measures of brain atrophy.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> HD mouse models similarly show elevated NEFL concentrations in biofluids that track with phenotype severity.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref></p><p id="p0035">NEFL is being evaluated as an exploratory biomarker of treatment response in clinical trials for various neurological disorders, including HD.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> Decreases in CSF and serum NEFL concentrations have been observed in response to immunomodulation therapies that effectively reduce axonal damage in multiple sclerosis (MS).<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref><sup>,</sup><xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> In children with spinal muscular atrophy (SMA) type 1, treatment with nusinersen&#8212;an ASO that modulates the splicing of the <italic toggle="yes">SMN2</italic> gene&#8212;led to normalization of elevated CSF NEFL concentrations and significant improvements in motor function.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref><sup>,</sup><xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> Similarly, in amyotrophic lateral sclerosis, tofersen&#8212;an ASO targeting <italic toggle="yes">SOD1</italic>&#8212;decreased plasma NEFL levels without significant clinical improvements,<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> leading to the Food and Drug Administration (FDA)-accelerated approval based on the likelihood that NEFL reduction predicts future clinical benefit. Notably, our group recently demonstrated that plasma and CSF NEFL concentrations respond to mHTT lowering in the brain of an HD mouse model, with effects influenced by both the magnitude of mHTT and the timing of intervention.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> These findings support the continued investigation of NEFL as an exploratory biomarker of treatment response for HTT-lowering therapies in HD.</p><p id="p0040">GFAP, the major intermediate filament protein of astrocytes, is upregulated in response to diverse CNS insults, with elevated levels in plasma and CSF serving as a surrogate marker of astrocytic reactivity in Alzheimer disease,<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> MS,<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> and traumatic brain injury.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> In HD, immunoreactivity of GFAP in the brain increases with disease severity.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> Moreover, plasma and CSF GFAP concentrations are elevated in people with HD and correlate with clinical measures of disease severity.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> Importantly, plasma GFAP levels are strongly associated with plasma NEFL across stages of HD.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> GFAP has also been explored as a response biomarker in children with SMA type 1, where elevated CSF GFAP concentrations were found to decrease following treatment with nusinersen.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> In HD, GFAP is currently used as an exploratory measure of safety in clinical trials<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> but has yet to be evaluated as a response biomarker in preclinical and clinical studies.</p><p id="p0045">In this study, we evaluated molecular and imaging biomarkers in response to allele-selective lowering of mHTT in the brain. Specifically, we measured plasma NEFL and GFAP levels, regional brain volumes, as well as striatal gene expression in response to treatment with an ASO targeting human m<italic toggle="yes">HTT</italic>. We hypothesized that plasma biomarkers would provide a more sensitive and dynamic indication of therapeutic effect compared to structural brain changes. Studies were conducted in YAC128 transgenic mice, which express full-length human mHTT and recapitulate key features of HD, including motor and cognitive deficits, neuropathological changes, and striatal neuron loss.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref><sup>,</sup><xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib90" ref-type="bibr"><sup>90</sup></xref><sup>,</sup><xref rid="bib91" ref-type="bibr"><sup>91</sup></xref><sup>,</sup><xref rid="bib92" ref-type="bibr"><sup>92</sup></xref> These mice also exhibit age-dependent increases in CSF and plasma NEFL,<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> along with progressive, region-specific gray and white matter atrophy,<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref><sup>,</sup><xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> making them an ideal model for investigating the responsiveness of these markers.</p><p id="p0050">The gapmer ASO used in this study featured a fully phosphorothioate-modified backbone with locked nucleic acid (LNA) wing modifications and was designed to target intron 22 of the human <italic toggle="yes">HTT</italic> transcript (HTT ASO). This molecule was selected for its high potency and allele selectivity, as it exclusively targets human <italic toggle="yes">HTT</italic> without affecting endogenous mouse <italic toggle="yes">Htt.</italic><xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> In the YAC128 model, this enables selective reduction of mHTT while preserving <italic toggle="yes">Htt</italic> expression, thereby minimizing the potential confounding effects of wtHTT deficiency on molecular and imaging outcomes.</p><p id="p0055">We first validated elevated plasma NEFL in YAC128 mice<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref><sup>,</sup><xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> and characterized the natural history of plasma GFAP in cross-sectional samples collected from 2 to 12 months of age. We also confirmed regional brain atrophy in YAC128 mice at 8 months. To investigate biomarker response to mHTT lowering, we conducted a longitudinal intervention study in YAC128 mice treated with a HTT ASO or phosphate-buffered saline (PBS) vehicle beginning at 6 months. Plasma NEFL and GFAP, along with regional gray and white matter volumes, were measured over a 6-month interval in response to treatment. At study endpoint, we assessed mHTT, NEFL, and GFAP levels across brain regions and profiled striatal gene expression. This study was designed to model therapeutic intervention during early symptomatic stages of HD, prior to overt striatal neuron loss in YAC128 brains.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Overview of natural history and biomarker response study design</title><p id="p0060">To define the natural history of candidate plasma biomarkers, we first measured plasma NEFL and GFAP concentrations in cross-sectional cohorts of YAC128 mice and wild-type (WT) littermate controls aged 2 to 12 months using MesoScale Discovery (MSD) immunoassays. Regional brain atrophy in YAC128 was validated at 8 months using <italic toggle="yes">ex vivo</italic> structural MRI (see experimental timeline in <xref rid="fig1" ref-type="fig">Figure 1</xref>A).<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Overview of natural history and biomarker response study design</p><p>(A) Experimental timeline for the cross-sectional natural history study. (B) Experimental groups included in the longitudinal biomarker response study. (C) Schematic illustration of the ICV injection procedure used in longitudinal biomarker response study. (D) Experimental timeline for the longitudinal biomarker response study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0065">We next evaluated longitudinal biomarker dynamics and therapeutic response to HTT ASO treatment. Thirty mice (<italic toggle="yes">n</italic> = 10 per group, balanced for sex) were included (<xref rid="fig1" ref-type="fig">Figure 1</xref>B): naive WT controls (untreated), YAC128 mice receiving PBS, and YAC128 mice treated with 50 &#956;g of HTT ASO via unilateral intracerebroventricular (ICV) injection at 6 months of age (<xref rid="fig1" ref-type="fig">Figure 1</xref>C). Plasma samples were collected monthly from 6 to 12 months to monitor NEFL and GFAP levels. In parallel, longitudinal <italic toggle="yes">in vivo</italic> structural MRI was conducted using a 7T preclinical scanner at baseline (pre-treatment), as well as at 3- and 6-month post-treatment intervals.</p><p id="p0070">At the 12-month endpoint, brains were harvested and dissected into the striatum, cortex, hippocampus, and cerebellum for molecular analyses. Protein levels of mHTT, NEFL, and GFAP were quantified in all regions by immunoblotting, while myelin-associated markers CLDN11 and PLP1 were measured in the striatum. Bulk RNA sequencing (RNA-seq) was performed on striatal tissue to assess transcriptomic changes (see experimental timeline in <xref rid="fig1" ref-type="fig">Figure 1</xref>D).</p></sec><sec id="sec2.2"><title>Plasma NEFL and GFAP concentrations are elevated in YAC128 mice compared to WT littermate controls</title><p id="p0075">To evaluate the natural history of NEFL and GFAP in plasma from YAC128 mice, cross-sectional plasma samples were collected from YAC128 and WT littermate control mice at bi-monthly intervals from 2 to 12 months of age to measure NEFL and GFAP concentrations. A significant interaction between age and genotype was observed with plasma NEFL (<xref rid="fig2" ref-type="fig">Figure 2</xref>A; two-way ANOVA: age <italic toggle="yes">p</italic> &lt; 0.0001, genotype <italic toggle="yes">p</italic> &lt; 0.0001, interaction <italic toggle="yes">p</italic> &lt; 0.0001; <xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>A: natural log transformed values; two-way ANOVA: age <italic toggle="yes">p</italic> &lt; 0.0001, genotype <italic toggle="yes">p</italic> &lt; 0.0001, interaction <italic toggle="yes">p</italic> &lt; 0.0001), with concentrations significantly elevated in YAC128 compared to WT mice by 8 months of age (<xref rid="fig2" ref-type="fig">Figure 2</xref>A; 8&#8211;12 months: <italic toggle="yes">p</italic> &lt; 0.0001). We also observed a significant interaction between age and genotype for plasma GFAP (<xref rid="fig2" ref-type="fig">Figure 2</xref>B; two-way ANOVA: age <italic toggle="yes">p</italic> &lt; 0.0001, genotype <italic toggle="yes">p</italic> &lt; 0.0001, interaction <italic toggle="yes">p</italic> &lt; 0.0001; <xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>B: natural log transformed values. Two-way ANOVA: age <italic toggle="yes">p</italic> &lt; 0.0001, genotype <italic toggle="yes">p</italic> = 0.0002, interaction <italic toggle="yes">p</italic> = 0.0002), with significantly elevated GFAP concentrations in YAC128 mice emerging at 10 months of age (<xref rid="fig2" ref-type="fig">Figure 2</xref>B; 10 months: <italic toggle="yes">p</italic> = 0.0002; 12 months: <italic toggle="yes">p</italic> &lt; 0.0001). Receiver operating characteristic (ROC) curve analysis demonstrated that NEFL (<xref rid="fig2" ref-type="fig">Figure 2</xref>C) reliably discriminated between genotypes at 8 (AUC = 0.85, <italic toggle="yes">p</italic> = 0.016), 10 (AUC = 1, <italic toggle="yes">p</italic> = 0.004), and 12 months of age (AUC = 1, <italic toggle="yes">p</italic> = 0.004), whereas GFAP (<xref rid="fig2" ref-type="fig">Figure 2</xref>D) significantly predicted genotype at 10 (AUC = 0.94, <italic toggle="yes">p</italic> = 0.010) and 12 months of age (AUC = 1, <italic toggle="yes">p</italic> = 0.004). A strong positive correlation was observed between plasma NEFL and GFAP concentrations in both WT (<xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>C; r = 0.76, <italic toggle="yes">p</italic> &lt; 0.0001) and YAC128 mice (r = 0.86, <italic toggle="yes">p</italic> &lt; 0.0001) from 2 to 12 months of age.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Elevated plasma NEFL and GFAP concentrations as well as regional brain atrophy in YAC128 mice</p><p>Cross-sectional plasma concentrations of (A) NEFL (WT: <italic toggle="yes">n</italic> = 8; YAC128: <italic toggle="yes">n</italic> = 8) and (B) GFAP (WT: <italic toggle="yes">n</italic> = 8; YAC128: <italic toggle="yes">n</italic> = 8) over the natural history of disease in YAC128 mice. Two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons test was used to compare genotype effects across ages (&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001). Boxes show the interquartile range (IQR), whiskers extend from the minimum to maximum value, and horizontal lines show the median. ROC curves showing the classification performance of plasma (C) NEFL and (D) GFAP for discriminating between YAC128 and WT mice from 6 to 12 months of age. The <italic toggle="yes">y</italic> axis represents sensitivity (%), and the <italic toggle="yes">x</italic> axis represents 100 - specificity (%). AUC values are indicated, with statistically significant AUC values shown in bold. The diagonal reference line denotes an AUC of 50% (no discriminative ability). Regional brain volumes normalized to either (E) whole-brain (WB) volume or (F) cerebellar (CBL) volume in YAC128 mice (<italic toggle="yes">n</italic> = 4) compared to WT mice (<italic toggle="yes">n</italic> = 4) at 8 months of age as measured using <italic toggle="yes">ex vivo</italic> structural MRI. Multiple t tests controlling for FDR were used to compare genotype effects across brain regions. Mean volume differences (after normalization to either whole-brain or cerebellum volumes) are plotted. Regional brain volumes found to be significantly changed in YAC128 mice compared to WT after adjusting for FDR are colored in pink.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec2.3"><title>Regional gray and white matter atrophy in YAC128 mice</title><p id="p0080">To validate previously reported regional atrophy in YAC128 mice<italic toggle="yes">,</italic> we performed <italic toggle="yes">ex vivo</italic> structural MRI at 8 months of age and compared gray and white matter brain volumes across 20 distinct brain regions between YAC128 and WT mice. Raw volumes of the striatum (multiple t tests controlling for false discovery rate [FDR]; <italic toggle="yes">q</italic> = 0.004), fimbria (<italic toggle="yes">q</italic> = 0.004), globus pallidus (<italic toggle="yes">q</italic> = 0.004), thalamus (<italic toggle="yes">q</italic> = 0.021), internal capsule (<italic toggle="yes">q</italic> = 0.021), hippocampus (<italic toggle="yes">q</italic> = 0.024), and cortex (<italic toggle="yes">q</italic> = 0.044) were significantly reduced in YAC128 compared to WT mice at this age (<xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref>). When normalized to whole-brain volume, significant reductions remained evident in the striatum (<italic toggle="yes">q</italic> = 0.018), fimbria (<italic toggle="yes">q</italic> = 0.018), globus pallidus (<italic toggle="yes">q</italic> = 0.018), and internal capsule (<italic toggle="yes">q</italic> = 0.036), alongside relative increases of the central gray matter (<italic toggle="yes">q</italic> = 0.041) and the hypothalamus (<italic toggle="yes">q</italic> = 0.041; <xref rid="fig2" ref-type="fig">Figure 2</xref>E). Notably, raw whole-brain volume itself was reduced by 7.38% in YAC128 mice, consistent with widespread atrophy.</p><p id="p0085">To adjust for this global volume reduction, we additionally normalized regional volumes to cerebellar volume, a structure that is relatively spared in both YAC128 mice at this age<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> and in persons with HD.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> This approach revealed robust reductions in the striatum (<italic toggle="yes">q</italic> = 0.001), fimbria (<italic toggle="yes">q</italic> = 0.002), globus pallidus (<italic toggle="yes">q</italic> = 0.002), thalamus (<italic toggle="yes">q</italic> = 0.007), internal capsule (<italic toggle="yes">q</italic> = 0.008), hippocampus (<italic toggle="yes">q</italic> = 0.008), and cortex (<italic toggle="yes">q</italic> = 0.007), as well as the amygdala (<italic toggle="yes">q</italic> = 0.022), anterior commissure (<italic toggle="yes">q</italic> = 0.037), and ventricles (<italic toggle="yes">q</italic> = 0.007) in YAC128 mice (<xref rid="fig2" ref-type="fig">Figure 2</xref>F).</p></sec><sec id="sec2.4"><title>Sustained lowering of mHTT throughout the brain of YAC128 mice at the 6-month treatment interval</title><p id="p0090">Levels of mHTT in the brain were measured in YAC128 mice at 12 months of age following a single unilateral ICV injection with either PBS or 50 &#956;g HTT ASO at 6 months of age. A significant interaction between treatment condition and brain region was observed on mHTT levels (two-way ANOVA: treatment <italic toggle="yes">p</italic> &lt; 0.0001, brain region <italic toggle="yes">p</italic> = 0.023, interaction <italic toggle="yes">p</italic> = 0.023), with sustained reductions of 19.4% in the cortex (<italic toggle="yes">p</italic> &lt; 0.0001), 21.5% in the striatum (<italic toggle="yes">p</italic> &lt; 0.0001), 21.5% in the hippocampus (<italic toggle="yes">p</italic> &lt; 0.0001), and 36.3% in the cerebellum (<italic toggle="yes">p</italic> &lt; 0.0001) following HTT ASO treatment at the 6-month interval (12 months of age; <xref rid="fig3" ref-type="fig">Figures 3</xref>A and 3B).<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Sustained lowering of mHTT throughout the brain of YAC128 mice at the 6-month treatment interval</p><p>Representative (A) immunoblots and (B) boxplots of relative soluble mHTT levels in the cortex, striatum, hippocampus, and cerebellum from YAC128 mice at the 6-month interval (12 months of age) following treatment with either PBS (<italic toggle="yes">n</italic> = 10) or 50 &#956;g HTT ASO (<italic toggle="yes">n</italic> = 9) initiated at 6 months of age. mHTT levels were normalized to calnexin and presented relative to PBS levels for each respective brain region. Two-way ANOVA with &#352;&#237;d&#225;k&#8217;s multiple comparisons test was used to compare treatment effects across brain regions (&#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001). Boxplots of relative soluble mHTT levels in the (C) cortex (CTX), (D) striatum (STR), (E) hippocampus (HIP), and (F) cerebellum (CBL) of YAC128 mice at different intervals following treatment with PBS (<italic toggle="yes">N</italic> = 4) or 50 &#956;g HTT ASO (<italic toggle="yes">n</italic> = 4 at each time point). mHTT levels were normalized to calnexin and presented relative to PBS levels at the 5-month interval for each respective brain region. One-way ANOVA with Tukey&#8217;s multiple comparisons test was used to compare treatment effects across time points (&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001). Boxes show the IQR, whiskers extend from the minimum to maximum value, horizontal lines show the median, and crosses show the mean.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0095">In a separate cohort of YAC128 mice, we also performed a time course analysis of mHTT target engagement in the brain at 1-, 3-, and 5-month intervals following ICV delivery of either PBS or HTT ASO initiated at 6 months of age. We measured a significant reduction of soluble mHTT with HTT ASO treatment in the cortex (<xref rid="fig3" ref-type="fig">Figure 3</xref>C; one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001; 1- and 3-month interval: <italic toggle="yes">p</italic> &lt; 0.0001, 5-month interval: <italic toggle="yes">p</italic> = 0.0005), striatum (<xref rid="fig3" ref-type="fig">Figure 3</xref>D; one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001; 1- and 3-month interval: <italic toggle="yes">p</italic> &lt; 0.0001, 5-month interval: <italic toggle="yes">p</italic> = 0.006), hippocampus (<xref rid="fig3" ref-type="fig">Figure 3</xref>E; one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001; 1- and 3-month interval: <italic toggle="yes">p</italic> &lt; 0.0001, 5-month interval: <italic toggle="yes">p</italic> = 0.003), and cerebellum (<xref rid="fig3" ref-type="fig">Figure 3</xref>F; one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001; 1-, 3-, and 5-month interval: <italic toggle="yes">p</italic> &lt; 0.0001) at each of the three time points assessed, with the largest magnitude of mHTT lowering observed at the 1-month time point.</p></sec><sec id="sec2.5"><title>NEFL and GFAP levels are elevated in the striatum of YAC128 mice</title><p id="p0100">Levels of NEFL and GFAP were measured in the cortex and striatum of naive WT mice and YAC128 mice treated with either PBS or HTT ASO at the 6-month interval (12 months of age). In the cortex, no differences in NEFL or GFAP levels were observed across groups (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>A; NEFL: one-way ANOVA: <italic toggle="yes">p</italic> = 0.665; GFAP: one-way ANOVA: <italic toggle="yes">p</italic> = 0.164). In the striatum, NEFL and GFAP levels were significantly increased by 2.9- and 2.4-fold, respectively, in PBS-treated YAC128 mice compared to naive WT mice at 12 months of age (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>B; NEFL: one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001; GFAP: one-way ANOVA: <italic toggle="yes">p</italic> &lt; 0.0001). Notably, treatment with HTT ASO led to a modest, though non-significant, 7.8% reduction in striatal NEFL levels, while striatal GFAP remained relatively unchanged (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>B).</p></sec><sec id="sec2.6"><title>Plasma NEFL increase is attenuated in response to mHTT lowering in the brain</title><p id="p0105">Plasma NEFL and GFAP concentrations were measured in response to mHTT lowering in the brain over a 6-month treatment interval. Longitudinal plasma samples were collected from naive WT mice as well as YAC128 mice treated with either PBS or HTT ASO at baseline, prior to intervention (6 months of age), and at monthly intervals up to 12 months of age.</p><p id="p0110">A significant interaction between genotype and age on plasma NEFL levels was observed in PBS-treated YAC128 mice compared to WT mice (mixed-effects model: genotype <italic toggle="yes">p</italic> &lt; 0.0001, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> &lt; 0.0001), with NEFL concentrations in YAC128 mice being significantly elevated starting from the 1-month interval (7 months of age; <xref rid="fig4" ref-type="fig">Figure 4</xref>A; 1- to 6-month interval: <italic toggle="yes">p</italic> &lt; 0.0001). We also measured a significant interaction between treatment and treatment interval in YAC128 mice administered either PBS or HTT ASO (<xref rid="fig4" ref-type="fig">Figure 4</xref>A; mixed-effects model: treatment <italic toggle="yes">p</italic> = 0.002, interval <italic toggle="yes">p</italic> &lt; 0.0001, treatment &#215; interval <italic toggle="yes">p</italic> = 0.029). Notably, plasma NEFL concentrations were significantly decreased in response to HTT ASO treatment at the 4-month (<italic toggle="yes">p</italic> = 0.007) and 5-month intervals (<italic toggle="yes">p</italic> = 0.016).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Plasma NEFL increase is attenuated in response to mHTT lowering in the brain</p><p>Longitudinal plasma concentrations of (A) NEFL and (B) GFAP over a 6-month interval in WT naive (<italic toggle="yes">n</italic> = 10) and YAC128 mice treated with either PBS (<italic toggle="yes">n</italic> = 10) or HTT ASO (<italic toggle="yes">n</italic> = 10). Percent change from baseline of longitudinal plasma (C) NEFL and (D) GFAP concentrations over a 6-month interval in response to treatment with either PBS or HTT ASO initiated at 6 months of age. Mixed-effects models with &#352;&#237;d&#225;k&#8217;s multiple comparisons test were used to compare longitudinal effects across genotypes (YAC128 PBS vs. WT naive: &#8727;&#8727;<italic toggle="yes">p</italic> = 0.004, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001) and treatment conditions (YAC128 HTT ASO vs. YAC128 PBS: <sup>#</sup><italic toggle="yes">p</italic> = 0.016, <sup>##</sup><italic toggle="yes">p</italic> = 0.007). Solid lines indicate the mean, and shaded bands denote 95% CI for each condition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0115">A significant interaction between genotype and age on plasma GFAP was measured in PBS-treated YAC128 mice compared to naive WT mice (Mixed-effects model: genotype <italic toggle="yes">p</italic> &lt; 0.0001, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype x age <italic toggle="yes">p</italic> &lt; 0.0001), with GFAP concentrations significantly elevated in YAC128 mice starting from the 3-month interval (9 months of age; <xref rid="fig4" ref-type="fig">Figure 4</xref>B; 3-month interval: <italic toggle="yes">p</italic> = 0.004, 4- to 6-month interval: <italic toggle="yes">p</italic> &lt; 0.0001). However, no significant effect of HTT ASO treatment on plasma GFAP concentrations was detected at any interval (mixed-effects model: treatment <italic toggle="yes">p</italic> = 0.235, interval <italic toggle="yes">p</italic> &lt; 0.0001, treatment &#215; interval <italic toggle="yes">p</italic> = 0.536).</p><p id="p0120">No significant effect of HTT ASO treatment was observed on the mean percent change from baseline for either NEFL (<xref rid="fig4" ref-type="fig">Figure 4</xref>C; mixed-effects model: treatment <italic toggle="yes">p</italic> = 0.280, interval <italic toggle="yes">p</italic> &lt; 0.0001, treatment &#215; interval <italic toggle="yes">p</italic> = 0.137) or GFAP concentrations compared to PBS over the 6-month treatment interval (<xref rid="fig4" ref-type="fig">Figure 4</xref>D; mixed-effects model: treatment <italic toggle="yes">p</italic> = 0.330, interval <italic toggle="yes">p</italic> &lt; 0.0001, treatment &#215; interval <italic toggle="yes">p</italic> = 0.714).</p><p id="p0125">Moderate positive correlations were observed between brain mHTT levels and either plasma NEFL (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>A; r = 0.33, <italic toggle="yes">p</italic> = 0.177) or GFAP (<xref rid="mmc1" ref-type="supplementary-material">Figure S4</xref>B; Pearson&#8217;s correlation: r = 0.31, <italic toggle="yes">p</italic> = 0.217) at the 6-month post-treatment interval (12 months of age) in YAC128 mice that received either PBS or HTT ASO. Importantly, a strong correlation between plasma NEFL and GFAP was found in YAC128 mice treated with either PBS (r = 0.86, <italic toggle="yes">p</italic> &lt; 0.0001) or HTT ASO (r = 0.80, <italic toggle="yes">p</italic> &lt; 0.0001) over the 6-month interval (<xref rid="mmc1" ref-type="supplementary-material">Figure S5</xref>).</p></sec><sec id="sec2.7"><title>Regional and whole-brain atrophy is not stabilized in response to mHTT lowering in the brain</title><p id="p0130">Regional and whole-brain volumes were assessed in response to mHTT lowering in the brain over a 6-month treatment period. Longitudinal structural MRI was performed on naive WT mice and YAC128 mice treated with either PBS or HTT ASO at baseline, prior to intervention (6 months of age), as well as at 3- and 6-month intervals (9 and 12 months of age, respectively). Volumetric analysis was performed on gray matter structures (<xref rid="fig5" ref-type="fig">Figures 5</xref>A&#8211;5D), white matter structures (<xref rid="fig6" ref-type="fig">Figures 6</xref>A&#8211;6C), and the whole brain over a 6-month interval. Regional and whole-brain volumes were normalized to cerebellar volume, which increased with age in all groups but showed no significant difference between WT and PBS-treated YAC128 mice over the 6-month interval (<xref rid="mmc1" ref-type="supplementary-material">Figure S6</xref>; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.105, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.197).<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Regional gray matter atrophy is not rescued in response to mHTT lowering in the brain of YAC128 mice</p><p>(A&#8211;F) Representative MRI coronal (top panels) and sagittal (bottom panels) images of the (A) striatum, (B) cortex, (C) hippocampus, and (D) thalamus in WT mice at 12 months of age. Longitudinal volumes of the (E) striatum, (F) cortex, (G) hippocampus, and (H) thalamus normalized to cerebellum volume over a 6-month interval in WT naive (<italic toggle="yes">n</italic> = 10) and YAC128 mice treated with either PBS (<italic toggle="yes">n</italic> = 10) or HTT ASO (<italic toggle="yes">n</italic> = 10). Percent volume change from baseline of the (I) striatum, (J) cortex, (K) hippocampus, and (L) thalamus over a 6-month interval in response to treatment with either PBS or HTT ASO initiated at 6 months of age. Mixed-effects models with &#352;&#237;d&#225;k&#8217;s multiple comparisons test were used to compare longitudinal effects across genotypes (YAC128 PBS vs. WT naive: &#8727;<italic toggle="yes">p</italic> &lt; 0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001, &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001) and treatment conditions (YAC128 HTT ASO vs. YAC128 PBS). Solid lines indicate the mean, and shaded bands denote 95% CI for each condition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig><fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>White matter atrophy is not rescued in response to mHTT lowering in the brain of YAC128 mice</p><p>(A&#8211;C) Representative MRI coronal (top panels) and sagittal (bottom panels) images of the (A) fimbria, (B) internal capsule, and (C) corpus callosum in WT mice 12 months of age. Longitudinal volumes of the (D) fimbria, (E) internal capsule, and (F) corpus callosum normalized to cerebellum volume over a 6-month interval in WT naive (<italic toggle="yes">n</italic> = 10) and YAC128 mice treated with either PBS (<italic toggle="yes">n</italic> = 10) or HTT ASO (<italic toggle="yes">n</italic> = 10). Percent volume change from baseline of the (G) fimbria, (H) internal capsule, and (I) corpus callosum in YAC128 mice over a 6-month interval in response to treatment with either PBS or 50 &#956;g HTT ASO initiated at 6 months of age. Mixed-effects models with &#352;&#237;d&#225;k&#8217;s multiple comparisons test were used to compare longitudinal effects across genotypes (YAC128 PBS vs. WT naive: &#8727;<italic toggle="yes">p</italic> = 0.013, &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01) and treatment conditions (YAC128 HTT ASO vs. YAC128 PBS). Solid lines indicate the mean, and shaded bands denote 95% CI for each condition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0135">We observed significant regional volume loss in PBS-treated YAC128 mice compared to WT mice at baseline, as well as at the 3- and 6-month intervals, in both the striatum (<xref rid="fig5" ref-type="fig">Figure 5</xref>E; mixed-effects model: genotype <italic toggle="yes">p</italic> &lt; 0.0001, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.057. Baseline: <italic toggle="yes">p</italic> = 0.001, 3- and 6-month interval: <italic toggle="yes">p</italic> &lt; 0.0001) and cortex (<xref rid="fig5" ref-type="fig">Figure 5</xref>F; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.011, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.339. Baseline: <italic toggle="yes">p</italic> = 0.022, 3-month interval: <italic toggle="yes">p</italic> = 0.033, 6-month interval: <italic toggle="yes">p</italic> = 0.0009). At the 3- and 6-month time points, PBS-treated YAC128 mice exhibited significant atrophy in the hippocampus (<xref rid="fig5" ref-type="fig">Figure 5</xref>G; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.0009, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.045; 3-month interval: <italic toggle="yes">p</italic> = 0.0006, 6-month interval: <italic toggle="yes">p</italic> = 0.0008), thalamus (<xref rid="fig5" ref-type="fig">Figure 5</xref>H; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.0008, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.018; 3-month interval: <italic toggle="yes">p</italic> = 0.0013, 6-month interval: <italic toggle="yes">p</italic> = 0.0001), and fimbria (<xref rid="fig6" ref-type="fig">Figure 6</xref>D; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.0005, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.178; 3-month interval: <italic toggle="yes">p</italic> = 0.008, 6-month interval: <italic toggle="yes">p</italic> = 0.001). In contrast, significant volume loss in the internal capsule (<xref rid="fig6" ref-type="fig">Figure 6</xref>E; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.005, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.335; 3-month interval: <italic toggle="yes">p</italic> = 0.013) and corpus callosum (<xref rid="fig6" ref-type="fig">Figure 6</xref>F; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.004, age <italic toggle="yes">p</italic> = 0.233, genotype &#215; age <italic toggle="yes">p</italic> = 0.067; 3-month interval: &#8727;&#8727;<italic toggle="yes">p</italic> = 0.001, 6-month interval <italic toggle="yes">p</italic> = 0.058) was observed only at the 3-month interval. Additionally, whole-brain volumes were significantly decreased in PBS-treated YAC128 mice at all three time points from 6 to 12 months of age (<xref rid="mmc1" ref-type="supplementary-material">Figure S7</xref>A; mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.0002, age <italic toggle="yes">p</italic> = 0.0003, genotype &#215; age <italic toggle="yes">p</italic> = 0.115. Baseline: &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> = 0.0004, 3-month interval: &#8727;&#8727;<italic toggle="yes">p</italic> = 0.006, 6-month interval: &#8727;&#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.0001).</p><p id="p0140">No significant volumetric differences were observed between PBS- and HTT-ASO-treated YAC128 mice in any gray (<xref rid="fig5" ref-type="fig">Figures 5</xref>E&#8211;5H) or white matter structures (<xref rid="fig6" ref-type="fig">Figures 6</xref>D&#8211;6F), nor in the whole brain (<xref rid="mmc1" ref-type="supplementary-material">Figure S7</xref>A), over the 6-month treatment interval. However, modest, though non-significant, trends toward slowed atrophy were observed with HTT ASO treatment in the striatum, cortex, hippocampus, thalamus, fimbria, internal capsule, and whole brain between the 3- and 6-month intervals (9&#8211;12 months of age).</p><p id="p0145">The volumes of the amygdala (mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.258, age <italic toggle="yes">p</italic> = 0.002, genotype &#215; age <italic toggle="yes">p</italic> = 0.207) and anterior commissure (mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.072, age <italic toggle="yes">p</italic> = 0.0002, genotype &#215; age <italic toggle="yes">p</italic> = 0.341) did not differ significantly between PBS-treated YAC128 and naive WT mice from 6 to 12 months of age, despite significant atrophy observed in these regions by <italic toggle="yes">ex vivo</italic> structural MRI in YAC128 mice at 8 months of age (<xref rid="fig2" ref-type="fig">Figure 2</xref>F). In contrast, a genotypic effect on globus pallidus volume was noted (mixed-effects model: genotype <italic toggle="yes">p</italic> = 0.004, age <italic toggle="yes">p</italic> &lt; 0.0001, genotype &#215; age <italic toggle="yes">p</italic> = 0.896), although volumes were not significantly reduced in YAC128 mice at any time point.</p><p id="p0150">Additionally, no significant effect of HTT ASO treatment was measured on the mean percent change from baseline in either gray (<xref rid="fig5" ref-type="fig">Figures 5</xref>I&#8211;5L), white matter (<xref rid="fig6" ref-type="fig">Figures 6</xref>G&#8211;6I), or whole-brain volumes (<xref rid="mmc1" ref-type="supplementary-material">Figure S7</xref>B) compared to PBS treatment over the 6-month treatment interval.</p></sec><sec id="sec2.8"><title>Brain mHTT levels are inversely correlated with whole-brain volume and the volumes of selected gray and white matter structures</title><p id="p0155">The relationship between mHTT levels in the brain and normalized regional and whole-brain volumes was evaluated at the 6-month interval (12 months of age) in YAC128 mice treated with either PBS or HTT ASO. A strong inverse correlation was observed between mHTT levels in the brain of treated YAC128 mice and whole-brain volumes at the 6-month treatment time point (<xref rid="fig7" ref-type="fig">Figure 7</xref>A; r = &#8722;0.43, <italic toggle="yes">p</italic> = 0.073). Among gray matter structures, significant inverse correlations were noted with the volumes of the striatum (<xref rid="fig7" ref-type="fig">Figure 7</xref>B; r = &#8722;0.57, <italic toggle="yes">p</italic> = 0.014), cortex (<xref rid="fig7" ref-type="fig">Figure 7</xref>C; r = &#8722;0.47, <italic toggle="yes">p</italic> = 0.048), and thalamus (<xref rid="fig7" ref-type="fig">Figure 7</xref>D; r = &#8722;0.58, <italic toggle="yes">p</italic> = 0.013). Additionally, mHTT levels exhibited a strong inverse correlation with fimbrial volume (<xref rid="fig7" ref-type="fig">Figure 7</xref>E; r = &#8722;0.51, <italic toggle="yes">p</italic> = 0.032) and a moderate inverse correlation with the internal capsule (<xref rid="fig7" ref-type="fig">Figure 7</xref>F; r = &#8722;0.39, <italic toggle="yes">p</italic> = 0.110).<fig id="fig7" position="float" orientation="portrait"><label>Figure 7</label><caption><p>Brain mHTT levels are inversely correlated with whole-brain volume and the volumes of selected gray and white matter structures</p><p>Scatterplots showing the associations between relative soluble mHTT levels in the brain (average of all brain regions) and cerebellum normalized volumes of the (A) whole brain (WB), (B) striatum (STR), (C) cortex (CTX), (D) thalamus (THL), (E) fimbria (FIM), and (F) internal capsule (IC) at the 6-month interval (12 months of age) in YAC128 mice treated with either PBS (<italic toggle="yes">n</italic> = 9) or HTT ASO (<italic toggle="yes">n</italic> = 9). Pearson&#8217;s correlation analysis was performed to evaluate the strength and direction of relationships between variables. Correlation coefficients (r) and corresponding nominal <italic toggle="yes">p</italic> values are shown, with statistically significant <italic toggle="yes">p</italic> values shown in bold. Regression lines are shown in black, with dotted lines indicating the 95% CI bands.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p></sec><sec id="sec2.9"><title>Plasma NEFL concentrations are not associated with regional or whole-brain volumes in response to mHTT lowering in the brain</title><p id="p0160">We evaluated the relationship between plasma NEFL concentrations and normalized regional and whole-brain volumes in YAC128 mice treated with either PBS or HTT ASO at both the 3- and 6-month intervals (9 and 12 months of age). At the 3-month post-treatment time point, plasma NEFL concentrations showed weak associations with gray (<xref rid="mmc1" ref-type="supplementary-material">Figures S8</xref>A&#8211;S8D; striatum: r = &#8722;0.11, <italic toggle="yes">p</italic> = 0.655; cortex: r = &#8722;0.21, <italic toggle="yes">p</italic> = 0.381; hippocampus: r = &#8722;0.29, <italic toggle="yes">p</italic> = 0.230; thalamus: r = &#8722;0.25, <italic toggle="yes">p</italic> = 0.310) and white matter volumes (<xref rid="mmc1" ref-type="supplementary-material">Figures S9</xref>A&#8211;S9C; fimbria: r = &#8722;0.03, <italic toggle="yes">p</italic> = 0.901; internal capsule: r = 0.05, <italic toggle="yes">p</italic> = 0.830; corpus callosum: r = 0.004, <italic toggle="yes">p</italic> = 0.989), as well as whole-brain volumes (<xref rid="mmc1" ref-type="supplementary-material">Figure S9</xref>D; r = &#8722;0.21, <italic toggle="yes">p</italic> = 0.901). At the 6-month interval, moderate inverse correlations were observed between plasma NEFL concentrations and volumes of the cortex (<xref rid="mmc1" ref-type="supplementary-material">Figure S10</xref>; r = &#8722;0.33, <italic toggle="yes">p</italic> = 0.178) and fimbria (<xref rid="mmc1" ref-type="supplementary-material">Figure S11</xref>; r = &#8722;0.35, <italic toggle="yes">p</italic> = 0.152), while other structures showed weak associations (striatum: r = 0.23, <italic toggle="yes">p</italic> = 0.352; hippocampus: r = 0.14, <italic toggle="yes">p</italic> = 0.568; thalamus: r = &#8722;0.13, <italic toggle="yes">p</italic> = 0.606; internal capsule: r = 0.04, <italic toggle="yes">p</italic> = 0.862; corpus callosum: r = 0.24, <italic toggle="yes">p</italic> = 0.331).</p></sec><sec id="sec2.10"><title>Plasma GFAP concentrations are inversely correlated with gray matter and whole-brain volumes in response to mHTT lowering in the brain</title><p id="p0165">We also evaluated the association between plasma GFAP concentrations and normalized regional and whole-brain volumes from treated YAC128 mice at both the 3- and 6-month intervals (9 and 12 months of age). In contrast to plasma NEFL, we observed strong negative correlations between plasma GFAP and volumes of the striatum (<xref rid="mmc1" ref-type="supplementary-material">Figure S12</xref>; r = &#8722;0.47, <italic toggle="yes">p</italic> = 0.043), cortex (r = &#8722;0.44, <italic toggle="yes">p</italic> = 0.057), and thalamus (r = &#8722;0.51, <italic toggle="yes">p</italic> = 0.025), as well as whole-brain volumes (<xref rid="mmc1" ref-type="supplementary-material">Figure S13</xref>; r = &#8722;0.59, <italic toggle="yes">p</italic> = 0.008) at the 3-month interval. Additionally, strong inverse correlations between plasma GFAP and both cortical volume (<xref rid="mmc1" ref-type="supplementary-material">Figure S14</xref>; r = &#8722;0.47, <italic toggle="yes">p</italic> = 0.049) and whole-brain volume (<xref rid="mmc1" ref-type="supplementary-material">Figure S15</xref>; r = &#8722;0.46, <italic toggle="yes">p</italic> = 0.055) persisted at the 6-month post-treatment time point.</p></sec><sec id="sec2.11"><title>Dysregulated striatal oligodendrocyte gene expression is reversed in response to mHTT lowering in the brain</title><p id="p0170">Striatal gene expression was measured using bulk RNA-seq in naive WT mice and YAC128 treated with either PBS or HTT ASO at the 6-month interval. We identified a total of 1127 DE genes in the striatum of PBS-treated YAC128 compared to WT mice, with 710 genes downregulated and 417 upregulated (FDR &lt;0.1; <xref rid="fig8" ref-type="fig">Figure 8</xref>A; <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). Enrichment analysis of downregulated and upregulated striatal differentially expressed genes (DEGs) (FDR &lt;0.1) revealed strong enrichment with CAG-length dependent DEGs from the HD knock-in CAG allelic series mice at 10 months of age (downregulated: adjusted <italic toggle="yes">p</italic> = 3.93 &#215; 10<sup>&#8722;198</sup>, upregulated: adjusted <italic toggle="yes">p</italic> = 1.57 &#215; 10<sup>&#8722;90</sup>), including genes downregulated in the striatum of Q140 mice (adjusted <italic toggle="yes">p =</italic> 3.57 &#215; 10<sup>&#8722;213</sup>) and upregulated in striatum of Q175 mice (adjusted <italic toggle="yes">p</italic> = 4.95 x 10<sup>&#8722;125</sup>) (<xref rid="mmc1" ref-type="supplementary-material">Figures S16</xref>A and S16B).<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> Additionally, we observed significant enrichment of DEGs among <italic toggle="yes">HTT</italic> CAG length-dependent genes in striatal medium spiny neurons (MSNs) of both the direct (downregulated: adjusted <italic toggle="yes">p</italic> = 8.01 &#215; 10<sup>&#8722;80</sup>; upregulated: adjusted <italic toggle="yes">p</italic> = 2.65 &#215; 10<sup>&#8722;60</sup>) and indirect pathways (downregulated: adjusted <italic toggle="yes">p</italic> = 2.54 &#215; 10<sup>&#8722;52</sup>; upregulated: adjusted <italic toggle="yes">p</italic> = 1.15 &#215; 10<sup>&#8722;29</sup>) (<xref rid="mmc1" ref-type="supplementary-material">Figures S16</xref>A and S16B).<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Furthermore, downregulated striatal DEGs were significantly enriched in <italic toggle="yes">HTT</italic> CAG length-dependent co-expression modules, including the M2 module (adjusted <italic toggle="yes">p</italic> = 2.95 &#215; 10<sup>&#8722;109</sup>), which includes genes involved in neuronal function and synaptic transmission, and the M11 module (adjusted <italic toggle="yes">p</italic> = 3.75 &#215; 10<sup>&#8722;81</sup>), enriched for genes related to cellular energy production and bioenergetic homeostasis&#8212;both of which are downregulated with increasing CAG length (<xref rid="mmc1" ref-type="supplementary-material">Figure S16</xref>A).<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> Additionally, upregulated YAC128 striatal DEGs were also enriched in the M20 module (adjusted <italic toggle="yes">p</italic> = 3.82 &#215; 10<sup>&#8722;49</sup>), which consists of genes associated with immune response, inflammation, and glial activation and is upregulated with increasing CAG repeat length (<xref rid="mmc1" ref-type="supplementary-material">Figure S16</xref>B).<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref><fig id="fig8" position="float" orientation="portrait"><label>Figure 8</label><caption><p>Dysregulated striatal oligodendrocyte gene expression is reversed in response to mHTT lowering in the brain</p><p>(A) Volcano plot showing DEGs in the striatum of PBS-treated YAC128 mice (<italic toggle="yes">n</italic> = 6) compared to WT mice (<italic toggle="yes">n</italic> = 6) at the 6-month interval (12 months of age). The fold change of DEGs (log<sub>2</sub> transformed) are plotted versus adjusted <italic toggle="yes">p</italic> values (&#8722;log<sub>10</sub> transformed). DEGs significantly downregulated compared to WT are shown in blue, while those significantly upregulated are shown in red (FDR &lt;0.1). The total number of DEGs that are downregulated (left) or upregulated (right) is indicated. The top 10 most significantly down- and upregulated DEGs are annotated. <italic toggle="yes">Msantd1</italic> was the most significantly upregulated gene (&#8722;log<sub>10</sub>(adjusted <italic toggle="yes">p</italic> value) = 136.77) and exhibited the greatest fold change (log<sub>2</sub>(fold change) = 3.587); however, it was excluded from the plot as it fell outside the range of most other genes. Horizontal dotted line indicates the significance threshold. The top 100 downregulated and upregulated striatal DEGs for this comparison are available in <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>. (B) Balloon plot depicting selected GO biological process terms significantly enriched for DEGs that are downregulated (blue) or upregulated (red) (FDR &lt;0.1) in PBS-treated YAC128 mice compared to WT mice at the 6-month interval. The <italic toggle="yes">x</italic> axis represents the &#8211;log<sub>10</sub>(<italic toggle="yes">p</italic> value) of enrichment after multiple testing correction. Balloon color reflects the degree of overlap between DEGs and the corresponding GO term, while balloon size represents the total number of genes associated with the GO term. (C) Scatterplot (left) illustrating the transcriptome-wide association of Z-statistics between YAC128 (PBS) vs. WT (naive) and YAC128 (PBS) vs. YAC128 (HTT ASO) comparisons. Pearson&#8217;s correlation analysis was performed to evaluate the strength and direction of relationships between variables. The reversal correlation coefficient (r) and corresponding nominal <italic toggle="yes">p</italic> value are shown. Dashed gray lines indicate approximate FDR = 0.1 thresholds, while the regression line is shown in black. Genes fully rescued by HTT ASO treatment are highlighted in green, partially rescued in blue, exacerbated in orange, and minimally changed in gray. The top five fully rescued upregulated and downregulated genes are annotated. Vertical bar plot (right) depicting the number of genes from the HD signature (PBS-treated YAC128 vs. WT); 1,127 genes from (A) categorized based on their response to HTT ASO treatment at the 6-month interval. Genes are classified as fully rescued (green), partially rescued (blue), exacerbated (orange), or minimal change (gray). (D) Balloon plot showing selected terms from the HDSigDB gene sets significantly enriched for DEGs that are upregulated in HTT-ASO-treated compared to PBS-treated YAC128 mice. The top 100 downregulated and upregulated striatal DEGs for this comparison is available in <xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>. The <italic toggle="yes">x</italic> axis represents the &#8722;log<sub>10</sub>(<italic toggle="yes">p</italic> value) of enrichment after Benjamini-Hochberg correction. Balloon color indicates the odds ratio, while balloon size corresponds to the combined score. (E) Hierarchical clustering of cell types and bullseye plot outputs from CSEA, illustrating the overlap of transcripts enriched and/or specific to certain cell types with nominally significant DEGs (<italic toggle="yes">p</italic> &lt; 0.05) upregulated in HTT-ASO-treated compared to PBS-treated YAC128 mice. Hexagon colors indicate Benjamini-Hochberg corrected <italic toggle="yes">p</italic> values, ranging from yellow (adjusted <italic toggle="yes">p</italic> = 0.1) to burgundy (adjusted <italic toggle="yes">p</italic> = 0). (F) Heatmaps displaying Z-statistics for the top 20 DEGs enriched in MSNs (left) and oligodendrocytes (right) across groups. Color scale ranges from red (positive Z-statistics) to blue (negative Z-statistics). (G, H) Representative immunoblots and relative quantification of (G) PLP1 (one-way ANOVA: <italic toggle="yes">p</italic> = 0.051; unpaired t test: <italic toggle="yes">p</italic> = 0.052 HTT ASO vs. PBS) and (H) CLDN11 (one-way ANOVA: <italic toggle="yes">p</italic> = 0.066; unpaired t test: <sup>#</sup><italic toggle="yes">p</italic> = 0.043 HTT ASO vs. PBS) levels in the striatum of naive WT mice (<italic toggle="yes">N</italic> = 6) or YAC128 mice treated with either PBS (<italic toggle="yes">N</italic> = 8) or HTT ASO (<italic toggle="yes">N</italic> = 8). PLP1 and CLDN11 levels were normalized to actin and are presented relative to levels measured in WT naive controls for each respective protein. Boxes show the IQR, whiskers extend from the minimum to maximum value, horizontal lines show the median, and crosses show the mean.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p><p id="p0175">Functional enrichment analysis of striatal DEGs (FDR &lt;0.1) from PBS-treated YAC128 compared to WT mice revealed that downregulated genes in the striatum of YAC128 mice were associated with biological processes related to neuron differentiation (adjusted <italic toggle="yes">p</italic> = 6.02 &#215; 10<sup>&#8722;25</sup>), synapse organization (adjusted <italic toggle="yes">p</italic> = 2.38 &#215; 10<sup>&#8722;10</sup>), and axon ensheathment (adjusted <italic toggle="yes">p</italic> = 2.84 &#215; 10<sup>&#8722;8</sup>), whereas upregulated genes were enriched in processes involving cell-to-cell adhesion (adjusted <italic toggle="yes">p</italic> = 3.04 &#215; 10<sup>&#8722;15</sup>), axonogenesis (adjusted <italic toggle="yes">p</italic> = 1.22 &#215; 10<sup>&#8722;8</sup>), and chemical synaptic transmission (adjusted <italic toggle="yes">p</italic> = 2.08 &#215; 10<sup>&#8722;6</sup>) (<xref rid="fig8" ref-type="fig">Figure 8</xref>B). Cell-type-specific enrichment analysis (CSEA) performed on significantly differentially expressed (DE) striatal genes in the YAC128 striatum revealed that downregulated genes showed significant overlap with transcripts specific to DRD2+ (adjusted <italic toggle="yes">p</italic> = 8.399 &#215; 10<sup>&#8722;8</sup>) and DRD1+ MSNs (adjusted <italic toggle="yes">p</italic> = 1.077 &#215; 10<sup>&#8722;4</sup>), CNP+ mature oligodendrocytes (adjusted <italic toggle="yes">p</italic> = 1.167 &#215; 10<sup>&#8722;9</sup>), ALDH1L1+ astrocytes (adjusted <italic toggle="yes">p</italic> = 1.167 &#215; 10<sup>&#8722;9</sup>), and layer 5 COLGALT2+ cortical neurons (adjusted <italic toggle="yes">p</italic> = 0.003) (<xref rid="mmc1" ref-type="supplementary-material">Figure S16</xref>C), while upregulated genes showed significant overlap with transcripts enriched in layer 5b (COLGALT2+, adjusted <italic toggle="yes">p</italic> = 0.002) and layer 6 NTSR1+ cortical neurons (adjusted <italic toggle="yes">p</italic> = 0.012) (<xref rid="mmc1" ref-type="supplementary-material">Figure S16</xref>D).</p><p id="p0180">We observed a significant positive transcriptome-wide correlation of Z-statistics for DEGs between PBS-treated YAC128 vs. WT and PBS-treated vs. HTT-ASO-treated YAC128 mice at 12 months of age (6-month interval; <xref rid="fig8" ref-type="fig">Figure 8</xref>C, left panel). The strong concordance between upregulated and downregulated genes in the striatum of HTT-ASO-treated YAC128 mice and those in WT mice suggests that HTT ASO treatment broadly shifts transcriptome-wide gene expression in YAC128 mice toward WT profiles. Moreover, among the 1,127 DE striatal genes in PBS-treated YAC128 mice (HD signature), 39 exhibited full reversal, 808 showed partial reversal, 1 was exacerbated, and 202 displayed minimal change (<xref rid="fig8" ref-type="fig">Figure 8</xref>C, right panel).</p><p id="p0185">Although no striatal gene expression changes reached significance following FDR correction (FDR &lt;0.1) in HTT-ASO-treated YAC128 mice at the 6-month time point, we identified 105 downregulated and 148 upregulated genes that were nominally significant (<italic toggle="yes">p</italic> &lt; 0.05) in response to treatment (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>). Enrichment analysis of DE striatal genes upregulated with HTT ASO treatment (<italic toggle="yes">p</italic> &lt; 0.05) using HD-associated gene sets revealed significant enrichment for genes downregulated in oligodendrocytes of zQ175DN knock-in mice compared to WT mice (adjusted <italic toggle="yes">p</italic> = 9.49 &#215; 10<sup>&#8722;12</sup>).<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Notably, DEGs upregulated with HTT ASO treatment showed strong enrichment for oligodendrocyte-specific gene markers (adjusted <italic toggle="yes">p</italic> = 1.10 &#215; 10<sup>&#8722;11</sup>),<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib100" ref-type="bibr"><sup>100</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> as well as genes upregulated in the corpus callosum of BACHD mice where mHTT was selectively inactivated in the NG2+ oligodendrocyte progenitor cell population (BN mice) compared to BACHD mice (adjusted <italic toggle="yes">p</italic> = 3.25 &#215; 10<sup>&#8722;11</sup>) (<xref rid="fig8" ref-type="fig">Figure 8</xref>D).<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Striatal DEGs downregulated in HTT-ASO-treated compared to PBS-treated YAC128 mice were significantly enriched only for markers expressed in PVALB+ and TACR3+ GABAergic neurons (adjusted <italic toggle="yes">p</italic> = 0.012).<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref></p><p id="p0190">Among the 148 upregulated striatal DEGs in HTT-ASO-treated YAC128 mice, we observed a significant overlap with genes specific to CNP+ mature oligodendrocytes (adjusted <italic toggle="yes">p</italic> = 6.876 &#215; 10<sup>&#8722;8</sup>), with enrichment also observed in PDGFRA+ oligodendrocyte precursor cells (adjusted <italic toggle="yes">p</italic> = 0.054) and ALDH1L1+ astrocytes (adjusted <italic toggle="yes">p</italic> = 0.061) (<xref rid="fig8" ref-type="fig">Figure 8</xref>E). In contrast, no significant cell-type-specific enrichment was observed for downregulated striatal genes from HTT-ASO-treated YAC128 mice.</p><p id="p0195">A comparison of Z-statistics for DE MSN- and oligodendrocyte-enriched genes between PBS-treated YAC128 vs. WT and PBS-treated vs. HTT-ASO-treated YAC128 mice revealed that HTT ASO treatment had minimal impact on MSN gene expression (<xref rid="fig8" ref-type="fig">Figure 8</xref>F, left panel) but partially restored downregulated oligodendrocyte striatal gene expression observed in YAC128 mice toward WT levels (<xref rid="fig8" ref-type="fig">Figure 8</xref>F, right panel).</p><p id="p0200">Finally, given the reversal of oligodendrocyte gene expression following HTT ASO treatment, we assessed the levels of two essential proteins for oligodendrocyte structure and function, PLP1 and CLD11, in the striatum of all experimental groups (<xref rid="fig8" ref-type="fig">Figure 8</xref>G). We observed a strong trend toward increased PLP1 levels (<xref rid="fig8" ref-type="fig">Figure 8</xref>H; one-way ANOVA: <italic toggle="yes">p</italic> = 0.051; unpaired t test: <italic toggle="yes">p</italic> = 0.052 HTT ASO vs. PBS) and a significant increase in CLDN11 levels (<xref rid="fig8" ref-type="fig">Figure 8</xref>I; one-way ANOVA: <italic toggle="yes">p</italic> = 0.066; unpaired t test: <italic toggle="yes">p</italic> = 0.043 HTT ASO vs. PBS) in HTT-ASO-treated compared to PBS-treated YAC128 mice.</p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0205">In this study, we examined the longitudinal responsiveness of objective molecular and imaging outcome measures to a candidate disease-modifying treatment in YAC128 mice. This is the first preclinical study to directly evaluate and compare plasma NEFL and GFAP, along with regional gray and white matter volumes, as response biomarkers for mHTT-lowering therapies in HD. A longitudinal study design was used to assess treatment response, as it allows for measurements within the same animal, reducing the sample size required and enabling the detection of subtle, time-dependent changes that may not be evident in cross-sectional analyses.</p><p id="p0210">NEFL, a validated biomarker of neurodegeneration, increases in both CSF and blood as HD progresses, with levels strongly correlating with clinical and imaging outcome measures.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Similarly, GFAP, a marker of astrogliosis, is also increased in biofluids from people with HD, though its correlation with clinical outcomes is weaker than that of NEFL.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> Elevated CSF and plasma NEFL concentrations are among the earliest pathogenic changes in HD, appearing decades before predicted symptom onset in premanifest individuals<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> and increasing through early (total functional capacity [TFC] = 11&#8211;13) and moderate (TFC = 7&#8211;10) stages before plateauing in more advanced disease (TFC &lt;6).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> In contrast, plasma and CSF GFAP levels are not elevated in premanifest HD mutation carriers compared to healthy controls but show a significant increase during moderate HD.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref></p><p id="p0215">We characterized the natural history of NEFL and GFAP in cross-sectional plasma samples from YAC128 and WT littermate control mice, measured at 2-month intervals from 2 to 12 months of age. Consistent with our previous findings,<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> plasma NEFL levels increased with age in both genotypes, with significantly higher concentrations observed in YAC128 mice compared to WT mice from 8 to 12 months of age. This timing of elevated plasma NEFL coincides with the reported loss of striatal neurons in YAC128 mice starting at 9 months of age.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> In contrast, plasma GFAP concentrations were significantly elevated in YAC128 mice only from 10 to 12 months of age. Interestingly, increased numbers of GFAP-positive reactive astrocytes have been reported in the striatum of postmortem HD brain,<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref> indicating that astrocyte degeneration and loss are not characteristics of the disease. This observation raises important questions about the mechanisms underlying the release of GFAP from reactive astrocytes, leading to elevated levels in biofluids. We postulate that increased astrocytic reactivity, along with endothelial cell dysfunction and compromised blood-brain barrier integrity associated with disease,<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref><sup>,</sup><xref rid="bib106" ref-type="bibr"><sup>106</sup></xref> may contribute to the elevated release of GFAP into the blood. To our knowledge, this is the first report demonstrating elevated GFAP concentrations in a biofluid from an HD mouse model. Importantly, these findings suggest that the YAC128 mice accurately model changes in molecular biomarkers observed in people with HD.</p><p id="p0220">Repeated longitudinal sampling of plasma from the same mice, conducted monthly from 6 to 12 months of age, provided greater resolution than cross-sectional sampling, revealing distinct patterns in biomarker dynamics. Plasma NEFL concentrations were significantly elevated in YAC128 compared to WT mice starting from 7 months, whereas plasma GFAP levels rose later, becoming significantly elevated at 9 months. However, from 9 months onward, the rate of increase and absolute magnitude of plasma GFAP concentrations surpassed those of NEFL, suggesting a pronounced rise in astrogliosis during this more advanced stage of disease in YAC128 mice.</p><p id="p0225">Astrocytes play a critical role in neuronal function by regulating synaptic communication, maintaining ion homeostasis, forming the neurovascular unit, and supporting overall neuronal health and activity.<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> In HD, astrocytes exhibit impairments in cholesterol metabolism, calcium signaling, ion homeostasis, and neurotransmitter clearance, all of which contribute to neuronal dysfunction.<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref><sup>,</sup><xref rid="bib109" ref-type="bibr"><sup>109</sup></xref> However, it remains unclear whether the delayed elevation of GFAP in plasma reflects cell-autonomous mHTT-associated toxicity in astrocytes, emerging later in the disease course, or cell-non-autonomous effects in response to signals from neuroinflammatory microglia and degenerating neurons. We propose that pro-inflammatory cytokines released from activated microglia and degenerating neurons during disease progression drive the activation of A1 reactive astrocytes,<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> leading to elevated GFAP expression and increased release into CSF and plasma. This activation may establish a feedback loop in which A1 reactive astrocytes further exacerbate neuronal dysfunction and degeneration, resulting in increased NEFL release to biofluids.</p><p id="p0230">We employed automated atlas-based segmentation to achieve accurate volumetric measurements across multiple mouse brain structures. Most preclinical studies in HD have relied on manually delineated regions of interest (ROIs) to derive brain structure volumes (reviewed in<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref>). However, manual segmentation is labor-intensive, time-consuming, and prone to human error, which introduces inter-rater inconsistency and inter-subject variability. These limitations can compromise the robustness and statistical power needed to accurately detect longitudinal volume changes. Comparatively, automatic segmentation utilizes non-rigid registration and template-based ROIs, enhancing statistical accuracy through multi-label fusion. This method has demonstrated high reliability and accuracy in human neuroimaging studies<xref rid="bib112" ref-type="bibr"><sup>112</sup></xref> and mouse studies across various strains and disease models,<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref><sup>,</sup><xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib115" ref-type="bibr"><sup>115</sup></xref> including the Q175FDN model of HD.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib116" ref-type="bibr"><sup>116</sup></xref> Additionally, studies have employed voxel-based morphometry to identify localized morphological differences in tissue structure.<xref rid="bib117" ref-type="bibr"><sup>117</sup></xref> While voxel-based morphometry relies on accurate tissue segmentation to derive probabilistic brain tissue maps for different strains and disease models, its results still rely on brain structural parcellation to derive ROI-based structural deformation data.</p><p id="p0235">We performed high-resolution <italic toggle="yes">ex vivo</italic> T2-weighted structural MRI on YAC128 compared to WT mice at 8 months of age to validate previously reported regional gray and white matter atrophy in this mouse model of HD.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref><sup>,</sup><xref rid="bib94" ref-type="bibr"><sup>94</sup></xref><sup>,</sup><xref rid="bib118" ref-type="bibr"><sup>118</sup></xref> In line with MRI findings from other preclinical studies in YAC128 mice<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref><sup>,</sup><xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> and observational studies in people with HD,<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> we measured significant reductions in striatal (25.15%) and cortical (12.84%) volumes, alongside atrophy in multiple subcortical gray matter structures, including the thalamus (21.30%), globus pallidus (51.65%), hippocampus (25.09%), and amygdala (19.40%). Volumetric analysis also revealed pronounced atrophy in white matter structures, including the anterior commissure (24.73%), fimbria (31.32%), and internal capsule (59%), as well as a trend toward significant volume reduction in the corpus callosum (15.06%). In addition to these regional changes, we also observed significant whole-brain atrophy in YAC128 mice at this time point.</p><p id="p0240"><italic toggle="yes">Ex vivo</italic> imaging of fixed brains eliminates motion artifacts and allows for prolonged scanning times, which can improve signal-to-noise ratio and image quality, even when nominal resolution is comparable to <italic toggle="yes">in vivo</italic> scans. The use of fixed tissue also enables more accurate image registration across subjects, enhancing statistical power to detect subtle volume changes.<xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib115" ref-type="bibr"><sup>115</sup></xref><sup>,</sup><xref rid="bib119" ref-type="bibr"><sup>119</sup></xref> However, perfusion and fixation procedures can induce morphological alterations in certain brain structures,<xref rid="bib120" ref-type="bibr"><sup>120</sup></xref> potentially biasing volumetric analyses. To address this, <italic toggle="yes">in vivo</italic> imaging was performed to assess longitudinal trajectories of brain volumes across genotypes and in response to mHTT lowering. Importantly, <italic toggle="yes">ex vivo</italic> and <italic toggle="yes">in vivo</italic> datasets were analyzed separately to avoid confounding from fixation-induced tissue shrinkage in <italic toggle="yes">ex vivo</italic> scans; only <italic toggle="yes">in vivo</italic> data were used for longitudinal statistical comparisons between experimental groups. This ensured that dynamic changes in brain volumes could be accurately measured over time, without confounding effects from fixation artifacts.</p><p id="p0245">Longitudinal MRI imaging was performed at 6, 9, and 12 months of age, offering resolution into the dynamics of regional gray and white matter atrophy in the YAC128 mouse model of HD, both prior to and during active neurodegeneration. A previous longitudinal structural MRI study in YAC128 using a 9.4T scanner found significant differences in the mean rate of change (mm<sup>3</sup>/month) of the striatum, prefrontal cortex, hippocampus, and globus pallidus between 3 and 12 months of age.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> As expected, we found that the striatum was one of the earliest gray matter structures to exhibit volume loss, with progressive atrophy detected in YAC128 compared to WT mice from 6 (7.14%) to 12 months of age (11.65%). Interestingly, evidence from an <italic toggle="yes">ex vivo</italic> structural MRI study suggests that striatal volume reduction may begin as early as 3 months of age in YAC128 mice.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> We also observed progressive cortical atrophy in YAC128 mice, with volume loss of 4.19% at 6 months of age and increasing to 6.79% by 12 months, representing what we believe to be the earliest reported volume loss in this structure. By 9 months of age, significant atrophy was evident not only in the striatum, cortex, hippocampus (7.62%), and thalamus (5.76%) but also in key white matter structures, including the corpus callosum (14.12%), fimbria (10.21%), and internal capsule (18.37%). Progressive white matter atrophy is a hallmark feature of HD, reflecting widespread disruptions in axonal integrity and neuronal connectivity that typically precede motor symptom onset.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib121" ref-type="bibr"><sup>121</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> The observed volume loss in these regions underscores white matter abnormalities in YAC128 mice, characterized by microstructural deficits, thinner myelin sheaths, and reduced expression of myelin-related genes.<xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib124" ref-type="bibr"><sup>124</sup></xref> Notably, this pattern of concurrent gray and white matter atrophy mirrors the neurodegenerative changes observed in people with HD,<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> underscoring the translational relevance of this model.</p><p id="p0250">We and others have previously demonstrated that ICV administration of ASOs targeting <italic toggle="yes">HTT</italic> in transgenic mouse models of HD results in mHTT lowering throughout the brain.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib95" ref-type="bibr"><sup>95</sup></xref><sup>,</sup><xref rid="bib125" ref-type="bibr"><sup>125</sup></xref><sup>,</sup><xref rid="bib126" ref-type="bibr"><sup>126</sup></xref> Building on this, we recently showed that ICV injection with 50 &#956;g of an HTT ASO led to sustained reduction of mHTT in the brains of YAC128 mice for up to 6 months.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> Here, we observed that treatment with the same HTT ASO, initiated at 6 months of age in YAC128 mice, resulted in 75%&#8211;90% mHTT lowering in the cortex, striatum, and hippocampus at the 1-month interval, 40%&#8211;60% lowering at the 3-month interval, and approximately 20% lowering at the 6-month interval. Interestingly, while the magnitude of mHTT lowering in the cerebellum was smaller at the 1-month interval (&#8764;72%), the reduction was more sustained, with approximately 36% mHTT lowering observed at the 6-month interval. Based on this level of target engagement in the brain, we evaluated the response of plasma NEFL and GFAP, along with regional gray and white matter atrophy, over a 6-month interval in YAC128 mice.</p><p id="p0255">NEFL and GFAP concentrations in longitudinal plasma samples were measured to assess their sensitivity and dynamic changes in response to mHTT lowering in the brains of YAC128 mice. We have previously shown that mHTT lowering with 50 &#956;g HTT ASO slowed the rate of plasma NEFL increase when initiated at 8 months of age, prior to overt neuronal loss, and stabilized elevated plasma NEFL concentrations below baseline levels when initiated at 12 months of age, following significant neuronal loss.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> Gapmer ASOs, such as the <italic toggle="yes">HTT</italic>-targeting ASO used in this study, exhibit broad uptake and target engagement across brain cell types, including diverse neuronal subtypes, astrocytes, and oligodendrocytes.<xref rid="bib127" ref-type="bibr"><sup>127</sup></xref> Based on this, we hypothesized that a therapeutic response to mHTT lowering initiated at 6 months&#8212;modeling early-stage disease intervention&#8212;would lead to a decrease of elevated plasma NEFL and GFAP concentrations. Such reductions could indicate neuroprotection and reduced astrogliosis in the brain, driven by mHTT lowering in these cell types. Mixed-effect modeling revealed that mHTT lowering at this age attenuated the rate of plasma NEFL increase over the 6-month period, with significant reductions of 115.80 pg/mL (23.21%) at the 4-month interval (10 months of age) and 106.6 pg/mL (20.57%) at the 5-month interval (11 months of age), suggesting that axonal damage is particularly responsive to mHTT reduction. In contrast, HTT ASO treatment did not significantly slow the elevation of plasma GFAP but resulted in a substantial, though non-significant, reduction of 526 pg/mL (16.94%) at the 6-month interval. Notably, strong inverse correlations were observed between plasma GFAP levels and striatal, cortical, thalamic, and whole-brain volumes at the 3-month interval, as well as cortical and whole-brain volumes at the 6-month interval. These findings highlight the relationship between astrocytic pathology and neuroanatomical changes in the brain, further emphasizing the potential of GFAP as a biomarker for disease progression. The differential effect of HTT ASO intervention on plasma markers suggests that neurons may be more sensitive to mHTT lowering than astrocytes. Notably, mHTT load within neurons is higher than in astrocytes,<xref rid="bib128" ref-type="bibr"><sup>128</sup></xref><sup>,</sup><xref rid="bib129" ref-type="bibr"><sup>129</sup></xref> which has been linked to the greater dysfunction observed in neurons compared to astrocytes in HD. Furthermore, neuron-specific mHTT lowering in HD mice has been shown to elicit a more profound impact on HD phenotypes than astrocyte-specific mHTT lowering.<xref rid="bib130" ref-type="bibr"><sup>130</sup></xref> This suggests that a greater magnitude of mHTT lowering or longer ASO treatment duration may be required to elicit a more robust response of plasma GFAP levels.</p><p id="p0260">Longitudinal regional gray and white matter volumes were measured to assess whether neuroimaging outcomes could serve as sensitive measures in response to mHTT lowering in the brains of YAC128 mice. Given that brain regions undergoing atrophy in HD are unlikely to regain volume, we hypothesized that a therapeutic response to mHTT lowering would be reflected as either a reduced rate of atrophy or stabilization of volume over time. Mixed-effect model analysis of YAC128 regional brain volumes revealed no significant stabilization or slowing of gray and white matter atrophy in response to HTT ASO treatment over a 6-month interval. Despite the widespread reduction of mHTT throughout the brain and slowing of plasma NEFL increase&#8212;potentially indicative of improved neuronal health&#8212;treatment with HTT ASO in YAC128 mice led to modest, though non-significant, slowing of volume loss in the cortex (0.05%), hippocampus (1.46%), thalamus (1.43%), fimbria (3.67%), and internal capsule (9.16%) at the 6-month time point (12 months of age). Interestingly, the more pronounced slowing of atrophy seen in the fimbria and internal capsule suggests that white matter structures may be more sensitive to mHTT lowering compared to gray matter structures. We also observed strong inverse correlations between mHTT levels in the brain and the volumes of the striatum (r = &#8722;0.57), cortex (r = &#8722;0.47), thalamus (r = &#8722;0.58), fimbria (r = &#8722;0.51), and internal capsule (r = &#8722;0.39), highlighting a relationship between mHTT load and neuroanatomical integrity. These findings suggest that greater mHTT lowering in the brain may be associated with improved volume preservation. However, the absence of significant volumetric stabilization in gray or white matter structures following HTT ASO treatment suggests that initiating intervention after the onset of overt atrophy and neurodegenerative processes may limit the therapeutic potential of mHTT lowering. Thus, earlier treatment initiation and duration may be necessary to detect therapeutic effects on brain volumes.</p><p id="p0265">We performed bulk RNA-seq on striata from all groups to validate transcriptional dysregulation in YAC128 mice and assess the potential of HTT ASO treatment to reverse transcriptional profiles. Any observed correction in transcript expression with HTT ASO treatment could serve as an early indicator of restored cellular processes disrupted in HD, potentially signaling a therapeutic benefit. In people with HD, gene expression analysis has revealed widespread transcriptional dysregulation, particularly in brain regions such as the caudate and putamen, where neurodegeneration is most pronounced.<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib132" ref-type="bibr"><sup>132</sup></xref> These studies highlight widespread changes in the expression of genes related to neuronal signaling and homeostasis, synaptic function, neurogenesis, and ion transport, providing molecular signatures of HD pathology.<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref> Similarly, in HD animal models, extensive dysregulation of neuronal and glial-enriched genes has been reported, often occurring before the onset of severe phenotypic abnormalities.<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref><sup>,</sup><xref rid="bib98" ref-type="bibr"><sup>98</sup></xref><sup>,</sup><xref rid="bib102" ref-type="bibr"><sup>102</sup></xref><sup>,</sup><xref rid="bib123" ref-type="bibr"><sup>123</sup></xref><sup>,</sup><xref rid="bib124" ref-type="bibr"><sup>124</sup></xref><sup>,</sup><xref rid="bib132" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib133" ref-type="bibr"><sup>133</sup></xref><sup>,</sup><xref rid="bib134" ref-type="bibr"><sup>134</sup></xref><sup>,</sup><xref rid="bib135" ref-type="bibr"><sup>135</sup></xref><sup>,</sup><xref rid="bib136" ref-type="bibr"><sup>136</sup></xref> Consistent with reported transcriptional dysregulation in the striatum of YAC128,<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref><sup>,</sup><xref rid="bib132" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib137" ref-type="bibr"><sup>137</sup></xref><sup>,</sup><xref rid="bib138" ref-type="bibr"><sup>138</sup></xref><sup>,</sup><xref rid="bib139" ref-type="bibr"><sup>139</sup></xref> we found more downregulated (710) than upregulated DEGs (417), including key MSN-enriched markers such as <italic toggle="yes">Actn2</italic>, <italic toggle="yes">Ddit4l</italic>, <italic toggle="yes">Penk</italic>, <italic toggle="yes">Drd2</italic>, <italic toggle="yes">Arpp21</italic>, <italic toggle="yes">Ppp1r1b</italic>, <italic toggle="yes">Cnr1</italic>, and <italic toggle="yes">Pde10a</italic>. These genes are similarly downregulated in the striatum of human HD brains,<xref rid="bib131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="bib132" ref-type="bibr"><sup>132</sup></xref><sup>,</sup><xref rid="bib140" ref-type="bibr"><sup>140</sup></xref><sup>,</sup><xref rid="bib141" ref-type="bibr"><sup>141</sup></xref><sup>,</sup><xref rid="bib142" ref-type="bibr"><sup>142</sup></xref> highlighting the conserved transcriptional disruptions underlying neuronal dysfunction in people with HD. Additionally, oligodendrocyte- and myelin-associated markers, including <italic toggle="yes">Mal</italic>, <italic toggle="yes">Plp1</italic>, <italic toggle="yes">Cldn11</italic>, <italic toggle="yes">Tspan2</italic>, and <italic toggle="yes">Mobp</italic>, were among the most significantly downregulated in the YAC128 striatum. This pattern of oligodendrocyte gene dysregulation aligns with findings from a mouse model of HD where mHTT was selectively expressed in oligodendrocytes.<xref rid="bib143" ref-type="bibr"><sup>143</sup></xref></p><p id="p0270">We evaluated the effect of HTT ASO treatment on striatal transcriptional dysregulation in YAC128 mice by assessing the transcriptome-wide correlation of Z-statistics for DEGs between PBS-treated YAC128 vs. WT and PBS-treated vs. HTT-ASO-treated YAC128 mice at the 6-month interval. The significant positive correlation (r = 0.32) observed suggests that HTT ASO treatment broadly shifts gene expression in YAC128 mice toward WT profiles. Among the 1,127 striatal DEGs identified in PBS-treated YAC128 mice, 39 exhibited full reversal and 808 showed partial reversal, indicating a partial but notable restoration of gene expression patterns.</p><p id="p0275">When examining the effect of HTT ASO on cell-type-specific gene expression, we observed a strong enrichment of treatment-upregulated striatal genes for oligodendrocyte-specific markers.<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref><sup>,</sup><xref rid="bib100" ref-type="bibr"><sup>100</sup></xref><sup>,</sup><xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> These genes overlapped significantly with those upregulated in the corpus callosum of mice with oligodendrocyte progenitor cell-specific m<italic toggle="yes">HTT</italic> inactivation, a manipulation that prevented myelin abnormalities and rescued behavioral deficits.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Notably, HTT ASO treatment reversed the expression of key oligodendrocyte and myelin-related genes, such as <italic toggle="yes">Mal</italic>, <italic toggle="yes">Il33 Cldn11</italic>, <italic toggle="yes">Mobp</italic>, <italic toggle="yes">Tspan2, and Plp1</italic>, with corresponding increases in CLDN11 and PLP1 protein levels.</p><p id="p0280">The partial restoration of oligodendrocyte-enriched gene and protein expression supports the hypothesis that mHTT contributes to glial transcriptional dysregulation in HD. However, since our analysis was performed on bulk striatal tissue, it remains unclear whether these transcriptomic changes reflect direct mHTT lowering in oligodendrocytes or a secondary response to improved neuronal health. A recent single-nucleus RNA-seq study revealed oligodendrocyte maturation deficits and arrested oligodendrocyte progenitor cell states&#8212;phenotypes that were partially reversed in response to intervention.<xref rid="bib144" ref-type="bibr"><sup>144</sup></xref> A separate study identified pronounced transcriptional dysregulation in oligodendrocytes from HD postmortem brains, including altered expression of genes involved in myelination and metabolic support.<xref rid="bib145" ref-type="bibr"><sup>145</sup></xref> Together, these findings reinforce the emerging view that oligodendrocyte dysfunction is an early and potentially reversible feature of HD pathogenesis. Further studies employing cell-type-specific transcriptomic and epigenetic profiling will be necessary to determine whether the observed normalization of oligodendrocyte markers with HTT ASO reflects a direct pharmacologic effect or an indirect consequence of improved neuronal integrity.</p><p id="p0285">Functionally, restoration of oligodendrocyte and myelin-related gene expression may promote remyelination of degenerating axons in the striatum, enhancing neural stability and contributing to the observed decrease in plasma NEFL levels. This effect may also explain why white matter structures, such as the fimbria and internal capsule, exhibited the most pronounced stabilization in response to treatment. Given the progressive white matter atrophy in HD,<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib121" ref-type="bibr"><sup>121</sup></xref><sup>,</sup><xref rid="bib122" ref-type="bibr"><sup>122</sup></xref> targeting oligodendrocyte-specific mechanisms may offer a promising therapeutic avenue for HD.</p><p id="p0290">Levels of NEFL and GFAP were quantified in the striatum and cortex across all experimental groups at the study endpoint. Notably, NEFL and GFAP protein levels were significantly elevated (&#8764;2.9x and 2.4x, respectively) in the striatum of YAC128 mice compared to WT, despite no significant changes in their transcript expression. This pronounced increase in the striatum, a primary site of neurodegeneration in HD, may reflect the release of NEFL and GFAP from dysfunctional and/or dying cells into the extracellular space, driven by axonal damage and astrogliosis. In contrast, cortical NEFL and GFAP levels were not significantly elevated, consistent with neurodegeneration being more localized to the striatum at this time point in YAC128 mice. In response to mHTT lowering, we observed a modest reduction of elevated NEFL levels within the striatum, which may partly account for the decreased NEFL levels detected in the plasma. This reduction of striatal NEFL may reflect axonal repair, potentially supported by the upregulation of oligodendrocyte and myelin-related genes.</p><p id="p0295">Preclinical studies in mouse models of HD offer an ideal platform for evaluating the efficacy of therapeutic candidates due to the uniformity of genetic background across experimental animals and the ability to tightly control environmental conditions. This level of standardization minimizes variability, allowing researchers to attribute observed effects more directly to the therapeutic intervention being tested. However, despite these benefits, HTT-ASO-mediated mHTT lowering in YAC128 mice, initiated at an early symptomatic stage, did not have a significant effect on slowing brain atrophy. Our findings highlight potential limitations of using neuroimaging measures as biomarkers of treatment response in clinical trials involving symptomatic individuals, where significant atrophy and striatal cell loss have already occurred. These trials are often conducted over relatively short durations (typically 2&#8211;3 years), which may further constrain the detection of treatment effects. Additionally, human studies face substantial inter-individual variability, including differences in <italic toggle="yes">HTT</italic> CAG repeat lengths, <italic toggle="yes">cis</italic>-/<italic toggle="yes">trans</italic>-modifiers, age-of-onset and progression rates, as well as environmental influences such as diet, lifestyle, and healthcare access. This variability, along with the inherent measurement variability of imaging techniques, can obscure small treatment effects, complicating data interpretation and reducing the reliability of neuroimaging as a response biomarker for therapeutic efficacy in heterogeneous patient populations.</p><p id="p0300">The absence of ventricular enlargement, plasma NEFL elevation, or histopathological evidence of neurotoxicity following HTT ASO treatment in YAC128 mice stands in contrast to clinical observations from the GENERATION HD1 and phase I/IIa tominersen trials, where intrathecal ASO delivery was associated with dose-dependent increases in ventricular volume and CSF NEFL, indicative of CNS stress or injury.<xref rid="bib146" ref-type="bibr"><sup>146</sup></xref><sup>,</sup><xref rid="bib147" ref-type="bibr"><sup>147</sup></xref></p><p id="p0305">In our study, plasma NEFL was significantly reduced following mHTT lowering, whereas in clinical trials, CSF NEFL increases have been observed. Such divergence may reflect species-specific differences, distinct ASO chemistries, route of administration, and the potential contribution of inflammation related to repeated lumbar dosing in humans. The YAC128 model, while recapitulating key features of HD pathogenesis, may not fully capture human-like vulnerability to ASO-induced toxicity. The less severe neurodegenerative phenotype in YAC128 mice compared to humans could mask subtle toxic effects that would be more evident in models with higher disease burden. Additionally, differences in ASO sequence, wing modifications, backbone chemistry, dosing regimen, and route of administration likely contribute to the divergent safety profiles observed. Species-specific factors may also play a role. Rodents exhibit distinct CSF clearance dynamics, ASO tissue distribution patterns, and innate immune responses compared to humans, all of which could influence ASO pharmacokinetics and toxicity profiles. For instance, ASO accumulation in non-target regions or cell types, a potential driver of ventricular enlargement and neuroinflammatory responses in humans, may be less pronounced in the murine CNS due to differences in blood-CSF barrier properties and ASO uptake mechanisms.</p><p id="p0310">Collectively, these findings underscore the complexity of translating preclinical ASO data to clinical outcomes. While the YAC128 model provides a controlled platform to study pharmacodynamic effects of mHTT lowering, it may not fully predict human-specific safety liabilities. Nonetheless, our data contribute important mechanistic insights and highlight the need for further investigation into optimizing ASO design, dosing strategies, and delivery methods that minimize toxicity while preserving therapeutic efficacy.</p><p id="p0315">This study has several limitations that should be considered when interpreting the findings. The transient effects of ASO-mediated mHTT lowering create challenges for evaluating its therapeutic efficacy <italic toggle="yes">in vivo</italic>. Following ASO administration, mHTT levels decline to their lowest point within days to weeks and gradually return to baseline over weeks to months.<xref rid="bib126" ref-type="bibr"><sup>126</sup></xref><sup>,</sup><xref rid="bib127" ref-type="bibr"><sup>127</sup></xref> The duration of action of ASOs in the CNS is influenced by their pharmacokinetic properties, particularly their degradation and clearance from the brain. In this study, mHTT levels were lowest at 1 month but progressively increased over the 2&#8211;6 month interval, suggesting that repeated dosing may be required to achieve sustained suppression. Although a single ICV injection of 50 &#956;g of <italic toggle="yes">HTT</italic>-targeted ASO resulted in a 20%&#8211;40% mHTT reduction across brain regions at the 6-month treatment interval, this degree of target engagement was insufficient to fully halt neurodegenerative processes. The modest preservation of regional brain volumes indicates that a greater and more sustained reduction of brain mHTT levels may be necessary for robust structural rescue. Preclinical evidence suggests that maintaining approximately 50% mHTT lowering may be required to mitigate neurodegeneration and stabilize brain volume loss in HD rodent models.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Based on these findings, clinical trials are targeting similar reductions in the striatum, and other subcortical structures, using various HTT lowering modalities. Future preclinical studies should explore repeated ASO dosing schedules and optimize intervention timing, dosing, and delivery methods to achieve more durable mHTT lowering and clarify the sustained effects on molecular and imaging biomarkers of neurodegeneration in HD. These efforts will help establish the target engagement threshold necessary for optimal therapeutic outcomes.</p><p id="p0320">Our study employed a single ICV injection strategy to minimize confounds associated with repeated surgical interventions. Both NEFL and GFAP are established markers of CNS injury that can increase in response to mechanical trauma. Repeated injections could have artificially elevated these markers, complicating interpretation of pharmacodynamic effects. Given the longitudinal MRI component of our study, repeated injections could also introduce localized tissue damage, potentially affecting the accuracy of regional brain volume measurements. While a single-dose approach may have limited the observed structural rescue, it enabled assessment of mHTT-lowering effects while minimizing procedural artifacts.</p><p id="p0325">The <italic toggle="yes">HTT</italic>-targeted ASO used in this study does not address all pathogenic mHTT species, which may limit its neuroprotective potential. Specifically, the HTT ASO binds a sequence in intron 22 of human <italic toggle="yes">HTT</italic> and does not target the <italic toggle="yes">HTT1a</italic> transcript, which produces toxic mHTT exon 1 protein<xref rid="bib148" ref-type="bibr"><sup>148</sup></xref> that can accumulate even when the full-length m<italic toggle="yes">HTT</italic> transcript is degraded. Directly targeting exon 1 may enhance therapeutic outcomes by reducing the production of these toxic mHTT species. Therefore, an efficacious therapy for HD may need to address exon 1-related toxicity in addition to selectively lowering full-length mHTT.</p><p id="p0330">Although the study included equal numbers of male and female animals, sex was not included as a covariate in analyses of plasma NEFL, GFAP, or structural MRI due to the small sample size, which limited statistical power to detect sex-specific effects. Future work with larger cohorts is needed to evaluate potential sex differences in these measures in the YAC128 mouse model.</p><p id="p0335">Finally, selecting appropriate normalization methods for volumetric analysis in preclinical mouse studies remains challenging. While whole-brain volume has been used previously for normalization,<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> we opted against this approach because the observed genotypic differences could confound regional comparisons. Cerebellar volume was employed for normalization due to its relative stability between genotypes from 6 to 12 months of age and its relative preservation in adult-onset HD. A more robust approach would be to estimate total intracranial volume (TIV), commonly used in clinical MRI studies, which involves tissue classification techniques that apply expectation-maximization algorithms to estimate voxel-wise probabilities for gray matter, white matter, CSF, and non-brain tissues, summing these to calculate TIV.<xref rid="bib149" ref-type="bibr"><sup>149</sup></xref><sup>,</sup><xref rid="bib150" ref-type="bibr"><sup>150</sup></xref> However, accurate tissue probability maps for mouse brain MRI are not currently available, limiting this approach.</p><p id="p0340">In this study, we present evidence that HTT-ASO-mediated mHTT lowering in the brains of YAC128 mice yields selective benefits when treatment is initiated at an age modeling an early symptomatic stage of HD. While mHTT reduction significantly attenuated the increase of plasma NEFL levels, its effect on GFAP over a 6-month interval was more moderate. Additionally, this intervention restored oligodendrocyte-specific gene expression and partially reversed the transcriptome-wide dysregulation in the striatum. In contrast, HTT ASO treatment did not significantly slow regional or whole-brain atrophy. However, at study endpoint, mHTT levels in the brain were inversely correlated with volumes of gray and white matter structures, highlighting a relationship between mHTT load and neuroanatomical integrity. These findings suggest that while molecular markers such as plasma NEFL&#8212;and to a lesser extent, GFAP&#8212;are responsive to mHTT reduction in the brain, volumetric changes detectable by imaging appear less sensitive to stabilization, particularly when treatment is initiated after the onset of regional atrophy, which occurs early in the disease. Overall, our results indicate that NEFL could serve as a sensitive and dynamic response biomarker for assessing the efficacy of mHTT-lowering therapies. Additionally, they suggest that earlier intervention may be necessary to preserve regional gray and white matter volumes in HD.</p></sec><sec id="sec4"><title>Materials and methods</title><sec id="sec4.1"><title>Mice</title><p id="p0345">Experiments were performed using YAC128 and WT littermate control mice. Equal numbers of male and female mice were used for each experiment. Animals were maintained under a 12-h light:dark cycle in a clean barrier facility and given <italic toggle="yes">ad libitum</italic> access to food and water. Experiments were performed with the approval of the Animal Care Committee at the University of British Columbia (A20-0107 and A24-0071). The number of animals used for each experiment (<italic toggle="yes">n</italic>) is presented in the figure legends.</p></sec><sec id="sec4.2"><title>HTT ASO design</title><p id="p0350">A chimeric gapmer ASO with a fully phosphorothioate-modified backbone and five locked-nucleic acid modifications at each wing targeting intron 22 of the human <italic toggle="yes">HTT</italic> transcript was synthesized by Qiagen (Qiagen, Hilden, Germany) as previously described.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref></p></sec><sec id="sec4.3"><title>ICV injections</title><p id="p0355">Unilateral ICV injections were performed as previously described.<xref rid="bib125" ref-type="bibr"><sup>125</sup></xref> Briefly, mice were anesthetized with isoflurane and secured into a stereotaxic frame (Stoelting, Wood Dale, IL). The scalp was prepared as described above. A Hamilton syringe with a 26-gauge (G) needle, point style 2, (Hamilton, Reno, NV) was loaded with 10 &#956;L of sterile Dulbecco PBS or 50 &#956;g HTT ASO diluted in PBS (5 &#956;g/&#956;L) and was punched through the skull at &#8722;1 mm lateral, +0.3 mm anterior, and &#8722;3.0 mm ventral to the bregma. Both PBS and HTT ASO were delivered to the right lateral ventricle as a bolus injection. The needle was left in place for 2 min after injection and withdrawn slowly to limit backflow.</p></sec><sec id="sec4.4"><title>Blood collection</title><p id="p0360">Terminal blood collection was performed via cardiac puncture where whole blood was drawn from the right ventricle using a 23-G needle and distributed into prechilled EDTA-coated tubes (Sarstedt, N&#252;mbrecht, Germany, catalog # 41.1395.105) on ice. Repeated blood sampling from the same animal was performed via the lateral saphenous vein where whole blood was drawn using EDTA-coated capillary blood collection tubes (Sarstedt, N&#252;mbrecht, Germany, catalog # 16.444.100) and placed on ice. Whole blood was then centrifuged at 4,000 relative centrifugal force (RCF) for 10 min at 4&#176;C, and plasma was carefully removed using a pipette, separated into aliquots, flash frozen in liquid nitrogen, and stored at &#8722;80&#176;C until use.</p></sec><sec id="sec4.5"><title>Plasma NEFL and GFAP measurements</title><p id="p0365">Levels of murine GFAP in plasma samples from YAC128 and WT mice were quantified by a customized immunoassay using a pair of rabbit antibodies against mouse GFAP (Abcam, Cambridge, UK, catalog # ab244094) with the MSD platform as previously published.<xref rid="bib151" ref-type="bibr"><sup>151</sup></xref> Plasma was diluted four times with PBS containing 1% bovine serum albumin (Sigma Aldrich, cat. # A7906). The assay&#8217;s lower limit of detection (LLOD) threshold was determined for each run as 2.5 SD above the mean blank signal. Samples below the LLOD were excluded in statistical analyses. Levels of murine NEFL in plasma were measured by the MSD Neurofilament-light assay kit (MSD, Rockland, MD, catalog #K1517XR-2) following manufacturer&#8217;s instruction. Murine plasma was diluted six times with MSD Diluent 12 for the NEFL assay. No samples in this study were below LLOD at this dilution.</p><p id="p0370">A comparison of NEFL measurements in matched plasma samples from YAC128 mice was performed using the commercially available SIMOA NF-Light kit (Quanterix, Lexington, MA, catalog # 103186) on the SIMOA HD-1 analyzer (Quanterix, Lexington, MA) and the NEFL MSD assay (<xref rid="mmc1" ref-type="supplementary-material">Figure S17</xref>). We measured a strong correlation between NEFL concentrations measured using both assays (r = 0.91, <italic toggle="yes">p</italic> &lt; 0.0001) with an inter-assay coefficient of variation of 12.96%.</p></sec><sec id="sec4.6"><title>Tissue collection and processing</title><p id="p0375">Mice allotted for <italic toggle="yes">ex vivo</italic> MRI were terminally anesthetized using Avertin (tribromoethanol), then transcardially perfused with PBS for 4 min followed by 4% paraformaldehyde (PFA) in PBS for 3 min. Whole brains were removed and post-fixed in 4% PFA for 24 h at 4&#176;C, washed 1&#215; with PBS, and stored in PBS until imaging.</p><p id="p0380">Mice allotted for molecular and biochemical analyses were terminally anesthetized using Avertin and sacrificed by cervical dislocation according to UBC Animal Care Committee guidelines. Brains were then removed and placed on ice for 1 min to increase tissue rigidity, then microdissected into different regions (striatum, cortex, hippocampus, and cerebellum). Samples were then flash frozen in liquid N<sub>2</sub> and stored at &#8722;80&#176;C until use.</p></sec><sec id="sec4.7"><title>MRI acquisition</title><p id="p0385">For <italic toggle="yes">ex vivo</italic> and <italic toggle="yes">in vivo</italic> imaging experiments, mice were induced at 4% isoflurane and maintained between 1% and 1.5% in medical air at 1.5 L/min flow. A small animal monitoring system (SAII Instruments, Stony Brook, NY, USA) was employed to monitor respiration (80&#8211;100 breaths/min) and rectal temperature (36.5&#176;C&#8211;37.5&#176;C), using airflow heater with adjustable power. Imaging was performed on a 7 Tesla preclinical MRI scanner (Bruker Biospin, Ettlingen, Germany) using a quadrature volume coil for transmission and a quadrature surface coil for reception. Rapid acquisition with relaxation enhancement (RARE) localizer scans in the axial, coronal, and sagittal orientations were acquired to guide slice prescription.</p><p id="p0390">For <italic toggle="yes">ex vivo</italic> scans of fixed brains, regional brain volumes were evaluated by acquiring sagittal T2-weighted 3D RARE anatomical images with an isotropic resolution of 160 &#956;m in 1 h 38 min (repetition time/echo time [TR/TE] = 2,500/40 ms, number of averages [NA] = 1, RARE factor = 4, matrix = 128 &#215; 84 &#215; 112, field of view [FOV] = 20.48 &#215; 13.44 &#215; 17.92 mm, bandwidth = 50 kHz).</p><p id="p0395">For <italic toggle="yes">in vivo</italic> longitudinal scans, regional brain volumes were evaluated by acquiring sagittal T2-weighted 3D RARE anatomical images with an isotropic resolution of 165 &#956;m in 1 h 20 min 40 s (TR/TE = 2,200/40 ms, NA = 1, RARE factor = 4, matrix = 128 &#215; 80 &#215; 110, FOV = 21.12 &#215; 13.53 &#215; 18.15 mm, bandwidth = 50 kHz).</p></sec><sec id="sec4.8"><title>Automated mouse brain structural parcellation and volumetric analysis</title><p id="p0400">To derive an accurate and efficient structural parcellation, we utilized the open-source multi-atlas brain structure parcellation framework&#8212;Multi Atlas Segmentation and Morphometric Analysis Toolkit (MASMAT)<xref rid="bib113" ref-type="bibr"><sup>113</sup></xref><sup>,</sup><xref rid="bib114" ref-type="bibr"><sup>114</sup></xref><sup>,</sup><xref rid="bib152" ref-type="bibr"><sup>152</sup></xref> along with an <italic toggle="yes">in vivo</italic> multi-template mouse brain atlas database.<xref rid="bib153" ref-type="bibr"><sup>153</sup></xref> In the automated parcellation process, each template brain MRI image in the atlas was parallelly registered/aligned to the target image of interest, first globally using a symmetric affine registration with a block-matching algorithm,<xref rid="bib154" ref-type="bibr"><sup>154</sup></xref><sup>,</sup><xref rid="bib155" ref-type="bibr"><sup>155</sup></xref> followed with a non-rigid registration to further align local brain structural displacement using a symmetric cubic B-spline parametrization based on a stationary velocity field.<xref rid="bib156" ref-type="bibr"><sup>156</sup></xref><sup>,</sup><xref rid="bib157" ref-type="bibr"><sup>157</sup></xref><sup>,</sup><xref rid="bib158" ref-type="bibr"><sup>158</sup></xref> The brain structure labels from the original template brain image were then transformed into the target image space with the deformation field during the registration process. Finally, multiple candidates of the brain structural labels were fused according to the ranking calculated based on the local image feature similarity measurements.<xref rid="bib159" ref-type="bibr"><sup>159</sup></xref> Volumes of each brain structure were then extracted from the derived brain structural parcellations. A comparison of raw regional volumes and cerebellum-normalized volumes was conducted on the <italic toggle="yes">ex vivo</italic> dataset to assess the impact of normalization between genotypes and account for whole-brain atrophy in the YAC128 mouse model. Gray and white matter volumes normalized to cerebellar volumes are presented.</p></sec><sec id="sec4.9"><title>Quantitative immunoblotting</title><p id="p0405">Brain tissues were lysed through mechanical dissociation and triturated in lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 40 mM &#946;-glycerophosphate, 10 mM NaF) containing protease inhibitors (1 mM Roche Complete mini EDTA free, 1 nM NaVan, 1 mM PMSF, and 5 &#956;M zVAD). Lysates were incubated on ice and vortexed every 5 min for 20 min. Lysates were centrifuged for 15 min at 18,000 RCF at 4&#176;C, and the supernatant was collected. Total protein was quantified using the DC protein assay (Bio-Rad, Hercules, CA, catalog # 5000113 and 5000114). Samples containing 50 &#956;g total protein were prepared using NuPAGE LDS Sample Buffer (Invitrogen, Waltham, MA, catalog # NP0007) containing 50 mM dithiothreitol and denatured at 70&#176;C for 10 min.</p><p id="p0410">For quantitation of mHTT levels in different brain regions, HTT alleles were resolved as previously described.<xref rid="bib160" ref-type="bibr"><sup>160</sup></xref></p><p id="p0415">For quantitation of NEFL and GFAP levels in different brain regions, lysates were resolved using 4%&#8211;12% Bis-Tris gels (Invitrogen, Waltham, MA, catalog # NP0323) in MES SDS running buffer (Invitrogen, Waltham, MA, catalog # NP0002) at 100 V until loading dye front was &#8764;1 cm from the bottom of the gel. Gels were transferred for 2 h onto a 0.2-&#956;m nitrocellulose membrane at 18 V in transfer buffer (Invitrogen, Waltham, MA, catalog # NP0061). Membranes were blocked with 5% skim milk in PBS-T for 30 min at room temperature, followed by 4 &#215; 5 min washes with PBS-T. Blots were probed with rabbit anti-NEFL (C28E10) (1:1,000, Cell Signaling Technology, Danvers, MA, catalog # 2837) and mouse anti-GFAP (GA5) (1:1,000, Cell Signaling Technology, Danvers, MA, catalog # 3670) diluted in 5% BSA in PBS-T with 0.01% NaN<sub>3</sub> overnight at 4&#176;C. Membranes were then washed in PBS-T for 3 &#215; 10 min and incubated with IRDye 800CW goat anti-rabbit (1:5,000, LI-COR Biosciences, Lincoln, NE, catalog # 926-3221) and Alexa Fluor 680 goat anti-mouse (1:5,000, Invitrogen, Waltham, MA, catalog # A21058) secondary antibodies diluted in 5% skim milk in PBS-T for 1 h, protected from light. Blots were washed 4 &#215; 5 min with PBS-T and imaged using the LI-COR Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). Following imaging, the membranes were stripped using ReBlot Plus Strong Antibody Stripping Solution (Millipore, Burlington, MA, catalog # 2504) for 15 min at room temperature. Successful stripping was confirmed by re-imaging the blots using the LI-COR system. Blots were then washed with PBS-T and blocked with 5% skim milk in PBS-T as described above, then probed with mouse anti-actin (clone 4) (1:5,000, Sigma-Aldrich, Burlington, MA, catalog # MAB1501R) diluted in 5% BSA in PBS-T with 0.01% NaN<sub>3</sub> overnight at 4&#176;C. Membranes were then washed with PBS-T and incubated with IR dye 800CW goat anti-mouse (1:5,000, Rockland Immunochemicals, Philadelphia, PA, catalog # 610-131-007) secondary antibody for 1 h. Finally, membranes were washed with PBS-T and imaged using the LI-COR system. Densitometry on NEFL, GFAP, and actin bands was performed using the LI-COR Image Studio Lite software, and background-subtracted NEFL and GFAP intensities were normalized to actin loading control and then to levels in WT mice on the same membrane.</p><p id="p0420">For quantitation of CLDN11 and PLP1 in the striatum, lysates were resolved using 4%&#8211;12% Bis-Tris gels and transferred, blocked, and washed as described above. Blots were probed with rabbit anti-CLDN11 (E7E9U) (1:1,000, Cell Signaling Technology, Danvers, MA, catalog # 38062) and mouse anti-actin (clone 4) (1:5,000, Sigma-Aldrich, Burlington, MA, catalog # MAB1501R) diluted in 5% BSA in PBS-T with 0.01% NaN<sub>3</sub> overnight at 4&#176;C. Membranes were then washed with PBS-T and incubated with IRDye 800CW goat anti-rabbit (1:5,000, LI-COR Biosciences, Lincoln, NE, catalog # 926-3221) and Alexa Fluor 680 goat anti-mouse (1:5,000, Invitrogen, Waltham, MA, catalog # A21058) secondary antibodies. Finally, membranes were washed with PBS-T and imaged using the LI-COR system. Membranes were stripped as described above and probed with rabbit anti-PLP1 (E9V1N) (1:1,000, Cell Signaling Technology, Danvers, MA, catalog # 28702). Blots were then washed with PBS-T, incubated with Alexa Fluor 680 goat anti-rabbit (1:5,000, Invitrogen, Waltham, MA, catalog # A21076) secondary antibody for 1 h and scanned using the LI-COR system. Densitometry on CLDN11, PLP1, and actin bands was performed using the LI-COR Image Studio Lite software, and background-subtracted CLDN11 and PLP1 intensities were normalized to actin loading control and then to levels in WT mice on the same membrane.</p></sec><sec id="sec4.10"><title>RNA extraction and bulk RNA-seq</title><p id="p0425">One frozen striatal hemisphere was lysed using MP Biomedicals Lysing Matrix D tubes (Thermo Fisher Scientific, Waltham, MA, catalog # MP116913500) and the FastPrep FP120 Cell Disrupter (Thermo Electron, Waltham, MA). Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany, catalog # 74106) according to the manufacturer&#8217;s protocol. RNA concentrations and integrity were measured using the Agilent 4200 TapeStation. Samples were prepped following the standard protocol for the Illumina Stranded mRNA prep (Illumina, San Diego, CA). Sequencing was performed on the Illumina NextSeq2000 with Paired-End 59 bp &#215; 59 bp reads at a minimum read depth of 30 million reads per sample. Sequencing data were demultiplexed using Illumina&#8217;s BCL Convert, and the resulting read sequences were aligned to the <italic toggle="yes">Mus musculus</italic> (mm10) reference genome and quantified using the DRAGEN RNA application (Illumina, San Diego, CA). Transcript per million (TPM) values were used as input into DESeq2,<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref> which converted TPM to estimated counts and normalized them using the default median-of-ratios method. Normalized counts were then used for downstream statistical analyses.</p></sec><sec id="sec4.11"><title>Statistical analysis</title><p id="p0430">Statistical analyses were performed, and graphs were generated using GraphPad Prism version 10.2 (GraphPad). Statistical tests used are described in the text and figure legends.</p><p id="p0435">Cross-sectional plasma concentrations of NEFL and GFAP from the natural history cohort were assessed for normality using the Shapiro-Wilk test and found to be non-normally distributed. A natural log transformation normalized the distributions. Both untransformed and log-transformed values are presented. Statistical analysis was performed using two-way ANOVA with &#352;&#237;d&#225;k&#8217;s post hoc test to compare individual means and correct for multiple comparisons. Boxplots and whisker plots were used to show distribution and skewness of data. Boxes show the interquartile range (IQR), whiskers extend from minimum to maximum values, horizontal lines show the median, and crosses show the mean.</p><p id="p0440">The classification performance of plasma NEFL and GFAP for discriminating between genotypes from 6 to 12 months of age was evaluated using ROC curves. Corresponding AUC values and <italic toggle="yes">p</italic> values are shown.</p><p id="p0445">The analysis of <italic toggle="yes">ex vivo</italic> brain volumes was performed by multiple t tests where the two-stage step-up method of Benjamini, Krieger, and Yekutieli was used to control for FDR with an adjusted <italic toggle="yes">p</italic> value (<italic toggle="yes">q</italic>) = 5%.</p><p id="p0450">Levels of mHTT, NEFL, GFAP, CLDN11, and PLP1 in the brain were analyzed by either one-way or two-way ANOVA, followed by either Tukey&#8217;s or &#352;&#237;d&#225;k&#8217;s post hoc test, respectively, to compare individual means and correct for multiple comparisons.</p><p id="p0455">Residuals from the mixed-effects models fitted to longitudinal plasma NEFL and GFAP concentrations were assessed for normality using the Shapiro-Wilk test and found to be sufficiently normally distributed. Statistical analyses were performed separately to evaluate the effects of genotype and treatment, using mixed-effects models with restricted maximum likelihood estimation. Each model included subject-level random effects to account for repeated measures across time points and a fixed interaction term between genotype or treatment and time point. &#352;&#237;d&#225;k&#8217;s post hoc test was used to compare individual means and correct for multiple comparisons. Solid lines denote the mean, and shaded bands denote 95% confidence interval (CI) for each condition.</p><p id="p0460">Normalized regional brain volumes, measured at multiple time points, were analyzed using mixed-effects models with restricted maximum likelihood estimation. Statistical analyses were performed separately to evaluate the effects of genotype and treatment. Each model included subject-level random effects to account for repeated measures over time and fixed interaction terms between genotype or treatment and time point. &#352;&#237;d&#225;k&#8217;s post hoc test was used to compare individual means and correct for multiple comparisons. Solid lines represent group means, and shaded bands indicate 95% CI for each condition.</p><p id="p0465">Changes from baseline in plasma NEFL and GFAP concentrations and regional brain volumes were analyzed to assess treatment effects only. Mixed-effects models (restricted maximum likelihood method) were applied, followed by &#352;&#237;d&#225;k&#8217;s post hoc test to compare individual means and correct for multiple comparisons. Solid lines denote the mean, and shaded bands denote 95% CI for each condition.</p><p id="p0470">Pearson&#8217;s correlation analysis was used to assess relationships between mHTT levels, molecular markers, and/or imaging measures. Correlation coefficients (r) ranging from &#177;0.40 to &#177;1 were considered strong associations, &#177;0.30 to &#177;0.39 as moderate, and &#177;0.10 to &#177;0.29 as weak. Correlations with <italic toggle="yes">p</italic> &lt; 0.05 were considered statistically significant.</p><p id="p0475">Differential expression analysis of RNA-seq data was performed using DESeq2.<xref rid="bib161" ref-type="bibr"><sup>161</sup></xref> DEGs with adjusted <italic toggle="yes">p</italic> values &lt;0.1, determined using the Benjamini-Hochberg procedure to control for FDR, were considered significant in the PBS-treated YAC128 vs. untreated WT comparison. Nominally significant DEGs with <italic toggle="yes">p</italic> &lt; 0.05 from the HTT ASO- vs. PBS-treated YAC128 mice were considered significant. Volcano plots display log<sub>2</sub> fold change and &#8722;log<sub>10</sub> adjusted <italic toggle="yes">p</italic> values. Gene set enrichment analysis (GSEA) for functional annotations (gene ontology [GO] terms) of striatal DEGs from the PBS-treated YAC128 vs. WT comparison was performed using g:GOSt through the web-based interface, g:Profiler (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://biit.cs.ut.ee/gprofiler" id="intref0010">https://biit.cs.ut.ee/gprofiler</ext-link>).<xref rid="bib162" ref-type="bibr"><sup>162</sup></xref><sup>,</sup><xref rid="bib163" ref-type="bibr"><sup>163</sup></xref> Biological process GO terms with term sizes greater than 2,000 were filtered out. Balloon plots display statistically enriched GO terms, &#8722;log<sub>10</sub>(adjusted <italic toggle="yes">p</italic> values), the overlap with striatal DEGs, and term sizes. CSEA was performed using the web-based tool, CSEA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://doughertytools.wustl.edu/CSEAtool.html" id="intref0015">http://doughertytools.wustl.edu/CSEAtool.html</ext-link>).<xref rid="bib164" ref-type="bibr"><sup>164</sup></xref><sup>,</sup><xref rid="bib165" ref-type="bibr"><sup>165</sup></xref> Hierarchical clustering of cell types and CSEA bullseye plot outputs show the overlap of transcripts enriched or specific to certain cell types with candidate striatal DEGs, with Benjamini-Hochberg corrected <italic toggle="yes">p</italic> values indicated by color. In each cell type, hexagon sizes represent the number of enriched and/or specific transcripts, with size scaling from the least specific (outer hexagon) to the most specific (center hexagon) based on enrichment stringency thresholds. GSEA using the HDsigDB gene set library was performed on striatal DEGs from the PBS-treated vs. WT and HTT ASO vs. PBS-treated YAC128 comparisons using the Enrichr web-based tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://maayanlab.cloud/Enrichr/" id="intref0020">https://maayanlab.cloud/Enrichr/</ext-link>).<xref rid="bib166" ref-type="bibr"><sup>166</sup></xref><sup>,</sup><xref rid="bib167" ref-type="bibr"><sup>167</sup></xref> Balloon plots show ranked enrichment of striatal DEGs with HDsigDB HD reference gene sets, &#8722;log<sub>10</sub>(adjusted <italic toggle="yes">p</italic> values), odds ratios (derived from rank-based analysis of Fisher&#8217;s exact test across multiple random gene sets, computing a mean rank, standard deviation, and <italic toggle="yes">Z</italic> score to quantify deviation from expected rank), and combined scores (log of the Fisher&#8217;s exact test <italic toggle="yes">p</italic> value multiplied by the <italic toggle="yes">Z</italic> score of rank deviations). Transcriptome-wide reversal effect of HTT ASO treatment was evaluated by correlating the Z-statistics from the YAC128 (PBS) vs. WT and YAC128 (PBS) vs. YAC128 (HTT ASO) comparisons.<xref rid="bib136" ref-type="bibr"><sup>136</sup></xref><sup>,</sup><xref rid="bib168" ref-type="bibr"><sup>168</sup></xref> Z-statistics were calculated using the following formula: (1) <inline-formula><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mi>Z</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="italic">log</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.25em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="italic">log</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>f</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula></p><p id="p0480">Scatterplots illustrate the relationship between Z-statistics, highlighting genes that were significantly fully reversed, partially reversed, exacerbated, or showed minimal changes relative to the HD signature (PBS-treated YAC128 vs. WT). Fully reversed genes were significantly DE in PBS-treated YAC128 mice versus WT and significantly changed in the same direction following HTT ASO treatment. Partially reversed genes were also significantly DE in YAC128 vs. WT and changed in the same direction with HTT ASO treatment but not significantly. Exacerbated genes were significantly DE in YAC128 vs. WT and significantly changed in the opposite direction after HTT ASO treatment. Minimally changed genes were significantly DE in YAC128 vs. WT and changed in the opposite direction following treatment but not significantly. A positive Z-statistic correlation indicates that HTT ASO treatment shifts transcriptome-wide gene expression in YAC128 mice toward WT profiles. Heatmaps display Z-statistics for DEGs enriched in MSNs and oligodendrocytes across groups.</p></sec></sec><sec sec-type="data-availability" id="sec5"><title>Data availability</title><p id="p0485">The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.</p></sec><sec id="sec6"><title>Acknowledgments</title><p id="p0490">Support for N.S.C. provided by the Huntington&#8217;s Disease Society of America Berman/Topper HD Career Development Fellowship and Human Biology Project Fellowship. M.A.P. is supported by the BC Children&#8217;s <funding-source id="gs1">Health Research Institute Investigator</funding-source> Grant Award and a Scholar Award from <funding-source id="gs2">Michael Smith Health Research</funding-source> BC. Project operational support for N.S.C. and M.R.H. is provided by a Bev Hartig Huntington&#8217;s <funding-source id="gs3">Disease Foundation</funding-source> grant. Funding sources were not involved in the design of experiments, collection and measurement of samples, or analysis and interpretation of the data presented herein. The authors would like to thank Mark Wang for mouse husbandry, Qingwen Xia for animal genotyping, and Tara Stach and Bernie Zhao for their technical support with RNA-seq experiments. The graphical abstract was created using BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://biorender.com/ec2lcxc" id="intref0025">https://BioRender.com/ec2lcxc</ext-link>).</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0495">N.S.C. and M.R.H. designed the study; N.S.C., J.F., A.Y., K.B., S.K., and C.A. performed research; N.S.C., D.M., and M.A.P. analyzed data; N.S.C. drafted the manuscript; N.S.C., J.F., A.Y., D.M., K.B., S.K., C.A., P.K., M.A.P., C.L.W., and M.R.H. reviewed and edited the manuscript. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="sec8"><title>Declaration of interests</title><p id="p0500">N.S.C. is an employee of Incisive Genetics, Inc. M.R.H. is the Chief Executive Officer of Prilenia Therapeutics and serves on the public boards of Ionis Pharmaceuticals, Oxford Biomedica, AbCellera, and 89bio.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.C.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Langbehn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>E.J.</given-names></name></person-group><article-title>Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis</article-title><source>Lancet Neurol.</source><volume>16</volume><year>2017</year><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30124-2</pub-id><pub-id pub-id-type="pmid">28601473</pub-id><pub-id pub-id-type="pmcid">PMC5507767</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Wijeratne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>De Vita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Czech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schobel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><etal/></person-group><article-title>Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease</article-title><source>Sci. Transl. Med.</source><volume>10</volume><year>2018</year><object-id pub-id-type="publisher-id">eaat7108</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aat7108</pub-id><pub-id pub-id-type="pmid">30209243</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Neurofilament light protein in blood predicts regional atrophy in Huntington disease</article-title><source>Neurology</source><volume>90</volume><year>2018</year><fpage>e717</fpage><lpage>e723</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000005005</pub-id><pub-id pub-id-type="pmid">29367444</pub-id><pub-id pub-id-type="pmcid">PMC5818166</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Tortelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Wijeratne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Arridge</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Vita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ghazaleh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Houghton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Furby</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease</article-title><source>Sci. Transl. Med.</source><volume>12</volume><year>2020</year><object-id pub-id-type="publisher-id">eabc2888</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abc2888</pub-id><pub-id pub-id-type="pmcid">PMC7611886</pub-id><pub-id pub-id-type="pmid">33328328</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alpaugh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Chouinard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cicchetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>A.L.</given-names></name></person-group><article-title>Plasma GFAP and its association with disease severity in Huntington's disease</article-title><source>J. Neurol.</source><volume>271</volume><year>2024</year><fpage>2108</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1007/s00415-023-12109-y</pub-id><pub-id pub-id-type="pmid">37979092</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Burgunder</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>Z.</given-names></name></person-group><article-title>Evaluation of Blood Glial Fibrillary Acidic Protein as a Potential Marker in Huntington's Disease</article-title><source>Front. Neurol.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">779890</object-id><pub-id pub-id-type="doi">10.3389/fneur.2021.779890</pub-id><pub-id pub-id-type="pmcid">PMC8639701</pub-id><pub-id pub-id-type="pmid">34867769</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Langbehn</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Craufurd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kennard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><etal/></person-group><article-title>Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data</article-title><source>Lancet Neurol.</source><volume>8</volume><year>2009</year><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70170-X</pub-id><pub-id pub-id-type="pmid">19646924</pub-id><pub-id pub-id-type="pmcid">PMC3725974</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Reilmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.C.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Craufurd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data</article-title><source>Lancet Neurol.</source><volume>11</volume><year>2012</year><fpage>42</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70263-0</pub-id><pub-id pub-id-type="pmid">22137354</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.</given-names></name><name name-style="western"><surname>Landwehrmeyer</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis</article-title><source>Lancet Neurol.</source><volume>10</volume><year>2011</year><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(10)70276-3</pub-id><pub-id pub-id-type="pmid">21130037</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Borowsky</surname><given-names>B.</given-names></name><name name-style="western"><surname>Landwehrmeyer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data</article-title><source>Lancet Neurol.</source><volume>12</volume><year>2013</year><fpage>637</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70088-7</pub-id><pub-id pub-id-type="pmid">23664844</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Duyao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Srinidhi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>P.S.</given-names></name></person-group><article-title>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes</article-title><source>Cell</source><volume>72</volume><year>1993</year><fpage>971</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">8458085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(93)90585-e</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Antonini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leenders</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Spiegel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vontobel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weigell-Weber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanchez-Pernaute</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Y&#233;benez</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Boesiger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weindl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>R.P.</given-names></name></person-group><article-title>Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease</article-title><source>Brain</source><volume>119</volume><issue>Pt 6</issue><year>1996</year><fpage>2085</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1093/brain/119.6.2085</pub-id><pub-id pub-id-type="pmid">9010012</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Grafton</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Mazziotta</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Pahl</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>St George-Hyslop</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gusella</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>M.E.</given-names></name></person-group><article-title>Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease</article-title><source>Arch. Neurol.</source><volume>49</volume><year>1992</year><fpage>1161</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1001/archneur.1992.00530350075022</pub-id><pub-id pub-id-type="pmid">1444883</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Weydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Torrence</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Libby</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Satterfield</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Lazarowski</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Bammler</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration</article-title><source>Cell Metab.</source><volume>4</volume><year>2006</year><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2006.10.004</pub-id><pub-id pub-id-type="pmid">17055784</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Borovecki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Parkhurst</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Tanese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Krainc</surname><given-names>D.</given-names></name></person-group><article-title>Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration</article-title><source>Cell</source><volume>127</volume><year>2006</year><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.015</pub-id><pub-id pub-id-type="pmid">17018277</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Zuccato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ciammola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rigamonti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Goffredo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>L.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Friedlander</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Silani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease</article-title><source>Science</source><volume>293</volume><year>2001</year><fpage>493</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1126/science.1059581</pub-id><pub-id pub-id-type="pmid">11408619</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Dunah</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Standaert</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Hersch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mouradian</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Tanese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Krainc</surname><given-names>D.</given-names></name></person-group><article-title>Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease</article-title><source>Science</source><volume>296</volume><year>2002</year><fpage>2238</fpage><lpage>2243</lpage><pub-id pub-id-type="doi">10.1126/science.1072613</pub-id><pub-id pub-id-type="pmid">11988536</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Charrin</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Borrell-Pag&#232;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dompierre</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rangone</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cordeli&#232;res</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>De Mey</surname><given-names>J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Lessmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Humbert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saudou</surname><given-names>F.</given-names></name></person-group><article-title>Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules</article-title><source>Cell</source><volume>118</volume><year>2004</year><fpage>127</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2004.06.018</pub-id><pub-id pub-id-type="pmid">15242649</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Liot</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zala</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mottet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Piel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saudou</surname><given-names>F.</given-names></name></person-group><article-title>Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites</article-title><source>J. Neurosci.</source><volume>33</volume><year>2013</year><fpage>6298</fpage><lpage>6309</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2033-12.2013</pub-id><pub-id pub-id-type="pmid">23575829</pub-id><pub-id pub-id-type="pmcid">PMC6619069</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Zala</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rangone</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liot</surname><given-names>G.</given-names></name><name name-style="western"><surname>Humbert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saudou</surname><given-names>F.</given-names></name></person-group><article-title>Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons</article-title><source>Hum. Mol. Genet.</source><volume>17</volume><year>2008</year><fpage>3837</fpage><lpage>3846</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn281</pub-id><pub-id pub-id-type="pmid">18772195</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Munsie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atwal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Bamburg</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Truant</surname><given-names>R.</given-names></name></person-group><article-title>Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease</article-title><source>Hum. Mol. Genet.</source><volume>20</volume><year>2011</year><fpage>1937</fpage><lpage>1951</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr075</pub-id><pub-id pub-id-type="pmid">21355047</pub-id><pub-id pub-id-type="pmcid">PMC3080606</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Nath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munsie</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Truant</surname><given-names>R.</given-names></name></person-group><article-title>A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease</article-title><source>Hum. Mol. Genet.</source><volume>24</volume><year>2015</year><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu460</pub-id><pub-id pub-id-type="pmid">25205111</pub-id><pub-id pub-id-type="pmcid">PMC4275073</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Atwal</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinchev</surname><given-names>D.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Epand</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Truant</surname><given-names>R.</given-names></name></person-group><article-title>Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity</article-title><source>Hum. Mol. Genet.</source><volume>16</volume><year>2007</year><fpage>2600</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm217</pub-id><pub-id pub-id-type="pmid">17704510</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Albin</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Penney</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>A.</given-names></name></person-group><article-title>Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study</article-title><source>J. Chem. Neuroanat.</source><volume>27</volume><year>2004</year><fpage>143</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2004.02.005</pub-id><pub-id pub-id-type="pmid">15183201</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dragunow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.</given-names></name></person-group><article-title>The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease</article-title><source>Neuroscience</source><volume>97</volume><year>2000</year><fpage>505</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(00)00008-7</pub-id><pub-id pub-id-type="pmid">10828533</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Hedreen</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Peyser</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>C.A.</given-names></name></person-group><article-title>Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease</article-title><source>Neurosci. Lett.</source><volume>133</volume><year>1991</year><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(91)90583-f</pub-id><pub-id pub-id-type="pmid">1840078</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Singh-Bains</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Tippett</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hogg</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Synek</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Roxburgh</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Waldvogel</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.M.</given-names></name></person-group><article-title>Globus pallidus degeneration and clinicopathological features of Huntington disease</article-title><source>Ann. Neurol.</source><volume>80</volume><year>2016</year><fpage>185</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1002/ana.24694</pub-id><pub-id pub-id-type="pmid">27255697</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>DiFiglia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sena-Esteves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chase</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sapp</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sass</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Rajeev</surname><given-names>K.G.</given-names></name><etal/></person-group><article-title>Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>104</volume><year>2007</year><fpage>17204</fpage><lpage>17209</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708285104</pub-id><pub-id pub-id-type="pmid">17940007</pub-id><pub-id pub-id-type="pmcid">PMC2040405</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Drouet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hassig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>N.</given-names></name><name name-style="western"><surname>Auregan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bonvento</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brouillet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luthi-Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hantraye</surname><given-names>P.</given-names></name><name name-style="western"><surname>D&#233;glon</surname><given-names>N.</given-names></name></person-group><article-title>Sustained effects of nonallele-specific Huntingtin silencing</article-title><source>Ann. Neurol.</source><volume>65</volume><year>2009</year><fpage>276</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1002/ana.21569</pub-id><pub-id pub-id-type="pmid">19334076</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Boudreau</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B.L.</given-names></name></person-group><article-title>Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice</article-title><source>Mol. Ther.</source><volume>17</volume><year>2009</year><fpage>1053</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1038/mt.2009.17</pub-id><pub-id pub-id-type="pmid">19240687</pub-id><pub-id pub-id-type="pmcid">PMC2835182</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Kordasiewicz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Stanek</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wancewicz</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>C.</given-names></name><name name-style="western"><surname>McAlonis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Pytel</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Artates</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shihabuddin</surname><given-names>L.S.</given-names></name><etal/></person-group><article-title>Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis</article-title><source>Neuron</source><volume>74</volume><year>2012</year><fpage>1031</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.05.009</pub-id><pub-id pub-id-type="pmid">22726834</pub-id><pub-id pub-id-type="pmcid">PMC3383626</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Stanek</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sardi</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Mastis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Treleaven</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Taksir</surname><given-names>T.</given-names></name><name name-style="western"><surname>Misra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shihabuddin</surname><given-names>L.S.</given-names></name></person-group><article-title>Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease</article-title><source>Hum. Gene Ther.</source><volume>25</volume><year>2014</year><fpage>461</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1089/hum.2013.200</pub-id><pub-id pub-id-type="pmid">24484067</pub-id><pub-id pub-id-type="pmcid">PMC4028091</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Stanek</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sardi</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shihabuddin</surname><given-names>L.S.</given-names></name></person-group><article-title>Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease</article-title><source>J. Huntingtons Dis.</source><volume>2</volume><year>2013</year><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.3233/JHD-130057</pub-id><pub-id pub-id-type="pmid">25063516</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Harper</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Staber</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Eliason</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kotin</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>B.L.</given-names></name></person-group><article-title>RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume><year>2005</year><fpage>5820</fpage><lpage>5825</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501507102</pub-id><pub-id pub-id-type="pmid">15811941</pub-id><pub-id pub-id-type="pmcid">PMC556303</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Datson</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Barriga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kourkouta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weij</surname><given-names>R.</given-names></name><name name-style="western"><surname>van de Giessen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulders</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kontkanen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lehtim&#228;ki</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Deutekom</surname><given-names>J.C.T.</given-names></name></person-group><article-title>The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><object-id pub-id-type="publisher-id">e0171127</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0171127</pub-id><pub-id pub-id-type="pmcid">PMC5300196</pub-id><pub-id pub-id-type="pmid">28182673</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Lebron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Denovan-Wright</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Nash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>R.J.</given-names></name></person-group><article-title>Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice</article-title><source>Mol. Ther.</source><volume>12</volume><year>2005</year><fpage>618</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2005.05.006</pub-id><pub-id pub-id-type="pmid">16019264</pub-id><pub-id pub-id-type="pmcid">PMC2656966</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Cengio</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Black</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>van Deventer</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease</article-title><source>Nucleic Acids Res.</source><volume>48</volume><year>2020</year><fpage>36</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz976</pub-id><pub-id pub-id-type="pmid">31745548</pub-id><pub-id pub-id-type="pmcid">PMC7145682</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Kordasiewicz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Langbehn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Skotte</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease</article-title><source>Sci. Transl. Med.</source><volume>10</volume><year>2018</year><object-id pub-id-type="publisher-id">eaar3959</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aar3959</pub-id><pub-id pub-id-type="pmid">30282695</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Zeitler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Froelich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marlen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shivak</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pearl</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paschon</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease</article-title><source>Nat. Med.</source><volume>25</volume><year>2019</year><fpage>1131</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0478-3</pub-id><pub-id pub-id-type="pmid">31263285</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Thomson</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Stam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brouwers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fodale</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bresciani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mostafavi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petkau</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>A.</given-names></name><etal/></person-group><article-title>AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model</article-title><source>Brain</source><volume>146</volume><year>2023</year><fpage>2298</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1093/brain/awac458</pub-id><pub-id pub-id-type="pmid">36508327</pub-id><pub-id pub-id-type="pmcid">PMC10232253</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Evers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Pepers</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>van Deutekom</surname><given-names>J.C.T.</given-names></name><name name-style="western"><surname>Mulders</surname><given-names>S.A.M.</given-names></name><name name-style="western"><surname>den Dunnen</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Aartsma-Rus</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Ommen</surname><given-names>G.J.B.</given-names></name><name name-style="western"><surname>van Roon-Mom</surname><given-names>W.M.C.</given-names></name></person-group><article-title>Targeting several CAG expansion diseases by a single antisense oligonucleotide</article-title><source>PLoS One</source><volume>6</volume><year>2011</year><object-id pub-id-type="publisher-id">e24308</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024308</pub-id><pub-id pub-id-type="pmcid">PMC3164722</pub-id><pub-id pub-id-type="pmid">21909428</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Fiszer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mykowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krzyzosiak</surname><given-names>W.J.</given-names></name></person-group><article-title>Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats</article-title><source>Nucleic Acids Res.</source><volume>39</volume><year>2011</year><fpage>5578</fpage><lpage>5585</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr156</pub-id><pub-id pub-id-type="pmid">21427085</pub-id><pub-id pub-id-type="pmcid">PMC3141264</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Kay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Agostinho</surname><given-names>L.d.A.</given-names></name><name name-style="western"><surname>Findlay-Black</surname><given-names>H.</given-names></name><name name-style="western"><surname>Casal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sumathipala</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dissanayake</surname><given-names>V.H.W.</given-names></name><name name-style="western"><surname>Cornejo-Olivas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baine</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease</article-title><source>Am. J. Hum. Genet.</source><volume>105</volume><year>2019</year><fpage>1112</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2019.10.011</pub-id><pub-id pub-id-type="pmid">31708117</pub-id><pub-id pub-id-type="pmcid">PMC6904807</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Kay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Skotte</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Warby</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Griguoli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry</article-title><source>Mol. Ther.</source><volume>23</volume><year>2015</year><fpage>1759</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.128</pub-id><pub-id pub-id-type="pmid">26201449</pub-id><pub-id pub-id-type="pmcid">PMC4817952</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Warby</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Greenlee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Skotte</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Freier</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin</article-title><source>Mol. Ther.</source><volume>19</volume><year>2011</year><fpage>2178</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.201</pub-id><pub-id pub-id-type="pmid">21971427</pub-id><pub-id pub-id-type="pmcid">PMC3242664</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Duyao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Persichetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vonsattel</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gusella</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Joyner</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Inactivation of the mouse Huntington's disease gene homolog Hdh</article-title><source>Science</source><volume>269</volume><year>1995</year><fpage>407</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1126/science.7618107</pub-id><pub-id pub-id-type="pmid">7618107</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Zeitlin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Papaioannou</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Efstratiadis</surname><given-names>A.</given-names></name></person-group><article-title>Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue</article-title><source>Nat. Genet.</source><volume>11</volume><year>1995</year><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/ng1095-155</pub-id><pub-id pub-id-type="pmid">7550343</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Nasir</surname><given-names>J.</given-names></name><name name-style="western"><surname>Floresco</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>O'Kusky</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Diewert</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zeisler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marth</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes</article-title><source>Cell</source><volume>81</volume><year>1995</year><fpage>811</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90542-1</pub-id><pub-id pub-id-type="pmid">7774020</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Dietrich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Alli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dragatsis</surname><given-names>I.</given-names></name></person-group><article-title>Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis</article-title><source>PLoS Genet.</source><volume>13</volume><year>2017</year><object-id pub-id-type="publisher-id">e1006846</object-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006846</pub-id><pub-id pub-id-type="pmcid">PMC5536499</pub-id><pub-id pub-id-type="pmid">28715425</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Bragg</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Grindeland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cantle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Howland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>J.B.</given-names></name></person-group><article-title>Global huntingtin knockout in adult mice leads to fatal neurodegeneration that spares the pancreas</article-title><source>Life Sci. Alliance</source><volume>7</volume><year>2024</year><object-id pub-id-type="publisher-id">e202402571</object-id><pub-id pub-id-type="doi">10.26508/lsa.202402571</pub-id><pub-id pub-id-type="pmcid">PMC11272958</pub-id><pub-id pub-id-type="pmid">39054288</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="other" id="sref51"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington&#8217;s Disease (GENERATION HD2). Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05686551">NCT05686551</ext-link></article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05686551" id="intref0010a">https://clinicaltrials.gov/study/NCT05686551</ext-link></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="other" id="sref52"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington&#8217;s Disease (SELECT-HD). Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05032196">NCT05032196</ext-link></article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05032196" id="intref0010b">https://clinicaltrials.gov/study/NCT05032196</ext-link></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Huntington</surname><given-names>H.S.G.</given-names></name></person-group><article-title>Unified Huntington's disease rating scale: reliability and consistency</article-title><source>Movement disorders</source><volume>11</volume><year>1996</year><fpage>136</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1002/mds.870110204</pub-id><pub-id pub-id-type="pmid">8684382</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Schobel</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Auinger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khwaja</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Trundell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cudkowicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hersch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Motor, cognitive, and functional declines contribute to a single progressive factor in early HD</article-title><source>Neurology</source><volume>89</volume><year>2017</year><fpage>2495</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004743</pub-id><pub-id pub-id-type="pmid">29142089</pub-id><pub-id pub-id-type="pmcid">PMC5729794</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Kinnunen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Pustina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gantman</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Joules</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mullin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Georgiou-Karistianis</surname><given-names>N.</given-names></name></person-group><article-title>Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review</article-title><source>Front. Neurol.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">712555</object-id><pub-id pub-id-type="doi">10.3389/fneur.2021.712555</pub-id><pub-id pub-id-type="pmcid">PMC8490802</pub-id><pub-id pub-id-type="pmid">34621236</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Paulsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Langbehn</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Aylward</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Nance</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guttman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beglinger</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Detection of Huntington's disease decades before diagnosis: the Predict-HD study</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>79</volume><year>2008</year><fpage>874</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.128728</pub-id><pub-id pub-id-type="pmid">18096682</pub-id><pub-id pub-id-type="pmcid">PMC2569211</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Paulsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Erwin</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Westervelt</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Aylward</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study</article-title><source>Lancet Neurol.</source><volume>13</volume><year>2014</year><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70238-8</pub-id><pub-id pub-id-type="pmid">25453459</pub-id><pub-id pub-id-type="pmcid">PMC4373455</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Wijeratne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Garbarino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>D.C.</given-names></name></person-group><article-title>Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease</article-title><source>Neurol. Genet.</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">e617</object-id><pub-id pub-id-type="doi">10.1212/NXG.0000000000000617</pub-id><pub-id pub-id-type="pmcid">PMC8515202</pub-id><pub-id pub-id-type="pmid">34660889</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Scahill</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Zeun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Osborne-Crowley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A.</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis</article-title><source>Lancet Neurol.</source><volume>19</volume><year>2020</year><fpage>502</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30143-5</pub-id><pub-id pub-id-type="pmid">32470422</pub-id><pub-id pub-id-type="pmcid">PMC7254065</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Coarelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Darios</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dorgham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Adanyeguh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brice</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mochel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name></person-group><article-title>Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia</article-title><source>Neurobiol. Dis.</source><volume>153</volume><year>2021</year><object-id pub-id-type="publisher-id">105311</object-id><pub-id pub-id-type="doi">10.1016/j.nbd.2021.105311</pub-id><pub-id pub-id-type="pmid">33636389</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Olsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wahlgren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroksmark</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rostasy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tulinius</surname><given-names>M.</given-names></name></person-group><article-title>NFL is a marker of treatment response in children with SMA treated with nusinersen</article-title><source>J. Neurol.</source><volume>266</volume><year>2019</year><fpage>2129</fpage><lpage>2136</lpage><pub-id pub-id-type="doi">10.1007/s00415-019-09389-8</pub-id><pub-id pub-id-type="pmid">31123861</pub-id><pub-id pub-id-type="pmcid">PMC6687695</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Gaiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>L.</given-names></name><name name-style="western"><surname>Querin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Puthenparampil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruggero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Toffanin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cagnin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Briani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pegoraro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sorar&#249;</surname><given-names>G.</given-names></name></person-group><article-title>Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease</article-title><source>JAMA Neurol.</source><volume>74</volume><year>2017</year><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.5398</pub-id><pub-id pub-id-type="pmid">28264096</pub-id><pub-id pub-id-type="pmcid">PMC5822207</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Poesen</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Schaepdryver</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stubendorff</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gille</surname><given-names>B.</given-names></name><name name-style="western"><surname>Muckova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wendler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ringer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Rhode</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease</article-title><source>Neurology</source><volume>88</volume><year>2017</year><fpage>2302</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004029</pub-id><pub-id pub-id-type="pmid">28500227</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Chieh</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>M.J.</given-names></name></person-group><article-title>Blood NfL: A biomarker for disease severity and progression in Parkinson disease</article-title><source>Neurology</source><volume>93</volume><year>2019</year><fpage>e1104</fpage><lpage>e1111</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000008088</pub-id><pub-id pub-id-type="pmid">31420461</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Mollenhauer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dakna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>N.</given-names></name><name name-style="western"><surname>Galasko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Foroud</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schade</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gera</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression</article-title><source>Mov. Disord.</source><volume>35</volume><year>2020</year><fpage>1999</fpage><lpage>2008</lpage><pub-id pub-id-type="doi">10.1002/mds.28206</pub-id><pub-id pub-id-type="pmid">32798333</pub-id><pub-id pub-id-type="pmcid">PMC8017468</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Andreasson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name></person-group><article-title>Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease</article-title><source>JAMA Neurol.</source><volume>74</volume><year>2017</year><fpage>557</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.6117</pub-id><pub-id pub-id-type="pmid">28346578</pub-id><pub-id pub-id-type="pmcid">PMC5822204</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Preische</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Apel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuhle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Barro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gr&#228;ber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuder-Buletta</surname><given-names>E.</given-names></name><name name-style="western"><surname>LaFougere</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laske</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease</article-title><source>Nat. Med.</source><volume>25</volume><year>2019</year><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0304-3</pub-id><pub-id pub-id-type="pmid">30664784</pub-id><pub-id pub-id-type="pmcid">PMC6367005</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Soylu-Kucharz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sandelius</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Sj&#246;gren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bj&#246;rkqvist</surname><given-names>M.</given-names></name></person-group><article-title>Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><object-id pub-id-type="publisher-id">14114</object-id><pub-id pub-id-type="doi">10.1038/s41598-017-14179-1</pub-id><pub-id pub-id-type="pmcid">PMC5658344</pub-id><pub-id pub-id-type="pmid">29074982</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Banos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yanick</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aly</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.E.P.</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Findlay Black</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease</article-title><source>J. Neurosci.</source><volume>41</volume><year>2021</year><fpage>780</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1865-20.2020</pub-id><pub-id pub-id-type="pmid">33310753</pub-id><pub-id pub-id-type="pmcid">PMC7842749</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Bondulich</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ca&#241;ibano-Pico</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nita</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>G.P.</given-names></name></person-group><article-title>Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease</article-title><source>Brain Commun.</source><volume>6</volume><year>2024</year><object-id pub-id-type="publisher-id">fcae030</object-id><pub-id pub-id-type="doi">10.1093/braincomms/fcae030</pub-id><pub-id pub-id-type="pmcid">PMC10873584</pub-id><pub-id pub-id-type="pmid">38370446</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="other" id="sref71"><person-group person-group-type="author"><collab>ClinicalTrials.gov</collab></person-group><article-title>A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington&#8217;s Disease. Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04120493">NCT04120493</ext-link></article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT04120493" id="intref0010c">https://clinicaltrials.gov/study/NCT04120493</ext-link></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="other" id="sref72"><person-group person-group-type="author"><collab>Clinicaltrials.gov.</collab></person-group><article-title>A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington&#8217;s Disease. Identifier <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05243017">NCT05243017</ext-link></article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT05243017" id="intref0010e">https://clinicaltrials.gov/study/NCT05243017</ext-link></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Axelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malmestr&#246;m</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gunnarsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sundstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>A.</given-names></name></person-group><article-title>Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis</article-title><source>Mult. Scler.</source><volume>20</volume><year>2014</year><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1177/1352458513490544</pub-id><pub-id pub-id-type="pmid">23702432</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Gunnarsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malmestr&#246;m</surname><given-names>C.</given-names></name><name name-style="western"><surname>Axelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sundstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dahle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vrethem</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piehl</surname><given-names>F.</given-names></name><name name-style="western"><surname>Norgren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab</article-title><source>Ann. Neurol.</source><volume>69</volume><year>2011</year><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1002/ana.22247</pub-id><pub-id pub-id-type="pmid">21280078</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Novakova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sundstr&#246;m</surname><given-names>P.</given-names></name><name name-style="western"><surname>Axelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khademi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gunnarsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malmestr&#246;m</surname><given-names>C.</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Piehl</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Monitoring disease activity in multiple sclerosis using serum neurofilament light protein</article-title><source>Neurology</source><volume>89</volume><year>2017</year><fpage>2230</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004683</pub-id><pub-id pub-id-type="pmid">29079686</pub-id><pub-id pub-id-type="pmcid">PMC5705244</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Kuhle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Disanto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lorscheider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stites</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dahlke</surname><given-names>F.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shrinivasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radue</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L.</given-names></name></person-group><article-title>Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis</article-title><source>Neurology</source><volume>84</volume><year>2015</year><fpage>1639</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001491</pub-id><pub-id pub-id-type="pmid">25809304</pub-id><pub-id pub-id-type="pmcid">PMC4409586</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Novakova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Axelsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khademi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Malmestr&#246;m</surname><given-names>C.</given-names></name><name name-style="western"><surname>Piehl</surname><given-names>F.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lycke</surname><given-names>J.</given-names></name></person-group><article-title>Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis</article-title><source>Mult. Scler.</source><volume>23</volume><year>2017</year><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1177/1352458516639384</pub-id><pub-id pub-id-type="pmid">27003946</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Romme Christensen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ratzer</surname><given-names>R.</given-names></name><name name-style="western"><surname>B&#246;rnsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lyksborg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garde</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dyrby</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Siebner</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Sellebjerg</surname><given-names>F.</given-names></name></person-group><article-title>Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial</article-title><source>Neurology</source><volume>82</volume><year>2014</year><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000361</pub-id><pub-id pub-id-type="pmid">24682973</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guenther</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wurster</surname><given-names>C.D.</given-names></name></person-group><article-title>Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><volume>90</volume><year>2019</year><fpage>1068</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2018-320033</pub-id><pub-id pub-id-type="pmid">30630960</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Cudkowicz</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Genge</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Sobue</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bucelli</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Chi&#242;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS</article-title><source>N. Engl. J. Med.</source><volume>387</volume><year>2022</year><fpage>1099</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2204705</pub-id><pub-id pub-id-type="pmid">36129998</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lemari&#233;</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Bone</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Aly</surname><given-names>A.E.E.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Casal</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hawellek</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice</article-title><source>Transl. Neurodegener.</source><volume>13</volume><year>2024</year><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s40035-024-00443-8</pub-id><pub-id pub-id-type="pmid">39380076</pub-id><pub-id pub-id-type="pmcid">PMC11460072</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Benedet</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Mil&#224;-Alom&#224;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vrillon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Lussier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Karikari</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Hourregue</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cognat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dumurgier</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum</article-title><source>JAMA Neurol.</source><volume>78</volume><year>2021</year><fpage>1471</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.3671</pub-id><pub-id pub-id-type="pmid">34661615</pub-id><pub-id pub-id-type="pmcid">PMC8524356</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Azzolini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gilio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pavone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Iezzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dolcetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buttari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Musella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandolesi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guadalupi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis</article-title><source>Biomolecules</source><volume>12</volume><year>2022</year><object-id pub-id-type="publisher-id">222</object-id><pub-id pub-id-type="doi">10.3390/biom12020222</pub-id><pub-id pub-id-type="pmcid">PMC8961656</pub-id><pub-id pub-id-type="pmid">35204724</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Tabor</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Penner</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Galarneau</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Josafatow</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghodsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Smirl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Plasma Biomarkers of Traumatic Brain Injury in Adolescents With Sport-Related Concussion</article-title><source>JAMA Netw. Open</source><volume>7</volume><year>2024</year><object-id pub-id-type="publisher-id">e2431959</object-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.31959</pub-id><pub-id pub-id-type="pmcid">PMC11378000</pub-id><pub-id pub-id-type="pmid">39235809</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Faideau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cormier</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auregan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>N.</given-names></name><name name-style="western"><surname>Guillermier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brouillet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hantraye</surname><given-names>P.</given-names></name><etal/></person-group><article-title>In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects</article-title><source>Hum. Mol. Genet.</source><volume>19</volume><year>2010</year><fpage>3053</fpage><lpage>3067</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq212</pub-id><pub-id pub-id-type="pmid">20494921</pub-id><pub-id pub-id-type="pmcid">PMC2901144</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>A.Y.S.</given-names></name><name name-style="western"><surname>Tippett</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>M.E.V.</given-names></name><name name-style="western"><surname>Park</surname><given-names>T.I.H.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.M.</given-names></name><name name-style="western"><surname>Dragunow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh-Bains</surname><given-names>M.K.</given-names></name></person-group><article-title>Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortex</article-title><source>Neurobiol. Dis.</source><volume>198</volume><year>2024</year><object-id pub-id-type="publisher-id">106554</object-id><pub-id pub-id-type="doi">10.1016/j.nbd.2024.106554</pub-id><pub-id pub-id-type="pmid">38844243</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Korpela</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sundblom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Constantinescu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Svenningsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Paucar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Niemel&#228;</surname><given-names>V.</given-names></name></person-group><article-title>Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease</article-title><source>J. Neurol. Sci.</source><volume>459</volume><year>2024</year><object-id pub-id-type="publisher-id">122979</object-id><pub-id pub-id-type="doi">10.1016/j.jns.2024.122979</pub-id><pub-id pub-id-type="pmid">38569376</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Slow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>van Raamsdonk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bissada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.Z.</given-names></name><etal/></person-group><article-title>Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease</article-title><source>Hum. Mol. Genet.</source><volume>12</volume><year>2003</year><fpage>1555</fpage><lpage>1567</lpage><pub-id pub-id-type="pmid">12812983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddg169</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Van Raamsdonk</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Slow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease</article-title><source>J. Neurosci.</source><volume>25</volume><year>2005</year><fpage>4169</fpage><lpage>4180</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0590-05.2005</pub-id><pub-id pub-id-type="pmid">15843620</pub-id><pub-id pub-id-type="pmcid">PMC6724951</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Pouladi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Stanek</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Franciosi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Butland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shihabuddin</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice</article-title><source>Hum. Mol. Genet.</source><volume>21</volume><year>2012</year><fpage>2219</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds037</pub-id><pub-id pub-id-type="pmid">22328089</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>S.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>G.</given-names></name><name name-style="western"><surname>Janghra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dunnett</surname><given-names>S.B.</given-names></name></person-group><article-title>Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice</article-title><source>Brain Res. Bull.</source><volume>88</volume><year>2012</year><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2010.05.005</pub-id><pub-id pub-id-type="pmid">20460143</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Van Raamsdonk</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name></person-group><article-title>Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease</article-title><source>BMC Neurosci.</source><volume>7</volume><year>2006</year><fpage>80</fpage><pub-id pub-id-type="doi">10.1186/1471-2202-7-80</pub-id><pub-id pub-id-type="pmid">17147801</pub-id><pub-id pub-id-type="pmcid">PMC1762017</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Franciosi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Spreeuw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bissada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Henkelman</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease</article-title><source>Neurobiol. Dis.</source><volume>43</volume><year>2011</year><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2011.03.018</pub-id><pub-id pub-id-type="pmid">21458571</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Petrella</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Castelhano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>La&#231;o</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rego</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Castelo-Branco</surname><given-names>M.</given-names></name></person-group><article-title>A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes</article-title><source>Hum. Mol. Genet.</source><volume>27</volume><year>2018</year><fpage>2125</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy119</pub-id><pub-id pub-id-type="pmid">29668904</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Banos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aly</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Black</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice</article-title><source>Neurobiol. Dis.</source><volume>166</volume><year>2022</year><object-id pub-id-type="publisher-id">105652</object-id><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105652</pub-id><pub-id pub-id-type="pmcid">PMC8901112</pub-id><pub-id pub-id-type="pmid">35143966</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Younes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Hinkle</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phatak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Looi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Longitudinal imaging highlights preferential basal ganglia circuit atrophy in Huntington's disease</article-title><source>Brain Commun.</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">fcad214</object-id><pub-id pub-id-type="doi">10.1093/braincomms/fcad214</pub-id><pub-id pub-id-type="pmcid">PMC10516592</pub-id><pub-id pub-id-type="pmid">37744022</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cantle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chatzopoulou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al-Ramahi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>El-Zein</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice</article-title><source>Nat. Neurosci.</source><volume>19</volume><year>2016</year><fpage>623</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1038/nn.4256</pub-id><pub-id pub-id-type="pmid">26900923</pub-id><pub-id pub-id-type="pmcid">PMC5984042</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fenster</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Mohammadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davila-Velderrain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Therrien</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novis</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation</article-title><source>Neuron</source><volume>107</volume><year>2020</year><fpage>891</fpage><lpage>908.e8</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2020.06.021</pub-id><pub-id pub-id-type="pmid">32681824</pub-id><pub-id pub-id-type="pmcid">PMC7486278</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Lein</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Hawrylycz</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ayres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bensinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boe</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Boguski</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brockway</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Genome-wide atlas of gene expression in the adult mouse brain</article-title><source>Nature</source><volume>445</volume><year>2007</year><fpage>168</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nature05453</pub-id><pub-id pub-id-type="pmid">17151600</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hauberg</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Fullard</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kozlenkov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keenan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hurd</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Dracheva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casaccia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roussos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>Brain Cell Type Specific Gene Expression and Co-expression Network Architectures</article-title><source>Sci. Rep.</source><volume>8</volume><year>2018</year><fpage>8868</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-27293-5</pub-id><pub-id pub-id-type="pmid">29892006</pub-id><pub-id pub-id-type="pmcid">PMC5995803</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Doyle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Dougherty</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Heiman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bupp</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Doughty</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Application of a translational profiling approach for the comparative analysis of CNS cell types</article-title><source>Cell</source><volume>135</volume><year>2008</year><fpage>749</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.029</pub-id><pub-id pub-id-type="pmid">19013282</pub-id><pub-id pub-id-type="pmcid">PMC2763427</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Ferrari Bardile</surname><given-names>C.</given-names></name><name name-style="western"><surname>Garcia-Miralles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Rayan</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Harmston</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rondelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>R.T.Y.</given-names></name><name name-style="western"><surname>Waltl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>116</volume><year>2019</year><fpage>9622</fpage><lpage>9627</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818042116</pub-id><pub-id pub-id-type="pmid">31015293</pub-id><pub-id pub-id-type="pmcid">PMC6511031</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Tasic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Jarsky</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Dolbeare</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Adult mouse cortical cell taxonomy revealed by single cell transcriptomics</article-title><source>Nat. Neurosci.</source><volume>19</volume><year>2016</year><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nn.4216</pub-id><pub-id pub-id-type="pmid">26727548</pub-id><pub-id pub-id-type="pmcid">PMC4985242</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Vonsattel</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>E.P.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Neuropathological classification of Huntington's disease</article-title><source>J. Neuropathol. Exp. Neurol.</source><volume>44</volume><year>1985</year><fpage>559</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1097/00005072-198511000-00003</pub-id><pub-id pub-id-type="pmid">2932539</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Drouin-Ouellet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sawiak</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Cisbani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lagac&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuan</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Saint-Pierre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dury</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Alata</surname><given-names>W.</given-names></name><name name-style="western"><surname>St-Amour</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology</article-title><source>Ann. Neurol.</source><volume>78</volume><year>2015</year><fpage>160</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1002/ana.24406</pub-id><pub-id pub-id-type="pmid">25866151</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reyes-Ortiz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kedaigle</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gipson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vatine</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Stocksdale</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casale</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits</article-title><source>Cell Rep.</source><volume>19</volume><year>2017</year><fpage>1365</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.021</pub-id><pub-id pub-id-type="pmid">28514657</pub-id><pub-id pub-id-type="pmcid">PMC5646270</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Palpagama</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Waldvogel</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.M.</given-names></name><name name-style="western"><surname>Kwakowsky</surname><given-names>A.</given-names></name></person-group><article-title>The Role of Microglia and Astrocytes in Huntington's Disease</article-title><source>Front. Mol. Neurosci.</source><volume>12</volume><year>2019</year><fpage>258</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2019.00258</pub-id><pub-id pub-id-type="pmid">31708741</pub-id><pub-id pub-id-type="pmcid">PMC6824292</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Faas</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Nwaobi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haustein</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mody</surname><given-names>I.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sofroniew</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Khakh</surname><given-names>B.S.</given-names></name></person-group><article-title>Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice</article-title><source>Nat. Neurosci.</source><volume>17</volume><year>2014</year><fpage>694</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1038/nn.3691</pub-id><pub-id pub-id-type="pmid">24686787</pub-id><pub-id pub-id-type="pmcid">PMC4064471</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diaz-Castro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Looger</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Khakh</surname><given-names>B.S.</given-names></name></person-group><article-title>Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice</article-title><source>J. Neurosci.</source><volume>36</volume><year>2016</year><fpage>3453</fpage><lpage>3470</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3693-15.2016</pub-id><pub-id pub-id-type="pmid">27013675</pub-id><pub-id pub-id-type="pmcid">PMC4804005</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Bohlen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>M&#252;nch</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title><source>Nature</source><volume>541</volume><year>2017</year><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nature21029</pub-id><pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Hanrahan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Locke</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Cahill</surname><given-names>L.S.</given-names></name></person-group><article-title>Magnetic Resonance Imaging to Detect Structural Brain Changes in Huntington's Disease: A Review of Data from Mouse Models</article-title><source>J. Huntingtons Dis.</source><volume>13</volume><year>2024</year><fpage>279</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.3233/JHD-240045</pub-id><pub-id pub-id-type="pmid">39213087</pub-id><pub-id pub-id-type="pmcid">PMC11494634</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Doshi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Erus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Resnick</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Gur</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Gur</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Satterthwaite</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Furth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davatzikos</surname><given-names>C.</given-names></name></person-group><article-title>MUSE: MUlti-atlas region Segmentation utilizing Ensembles of registration algorithms and parameters, and locally optimal atlas selection</article-title><source>Neuroimage</source><volume>127</volume><year>2016</year><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.11.073</pub-id><pub-id pub-id-type="pmid">26679328</pub-id><pub-id pub-id-type="pmcid">PMC4806537</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zuluaga</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Siow</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Substantially thinner internal granular layer and reduced molecular layer surface in the cerebellar cortex of the Tc1 mouse model of down syndrome - a comprehensive morphometric analysis with active staining contrast-enhanced MRI</article-title><source>Neuroimage</source><volume>223</volume><year>2020</year><object-id pub-id-type="publisher-id">117271</object-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117271</pub-id><pub-id pub-id-type="pmcid">PMC8417772</pub-id><pub-id pub-id-type="pmid">32835824</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>O.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Study the Longitudinal in vivo and Cross-Sectional ex vivo Brain Volume Difference for Disease Progression and Treatment Effect on Mouse Model of Tauopathy Using Automated MRI Structural Parcellation</article-title><source>Front. Neurosci.</source><volume>13</volume><year>2019</year><fpage>11</fpage><pub-id pub-id-type="doi">10.3389/fnins.2019.00011</pub-id><pub-id pub-id-type="pmid">30733665</pub-id><pub-id pub-id-type="pmcid">PMC6354066</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>O.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>N.</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy</article-title><source>Front. Neuroinform.</source><volume>11</volume><year>2017</year><fpage>20</fpage><pub-id pub-id-type="doi">10.3389/fninf.2017.00020</pub-id><pub-id pub-id-type="pmid">28408879</pub-id><pub-id pub-id-type="pmcid">PMC5374887</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Smith-Dijak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sepers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Felczak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Waltl</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes</article-title><source>Hum. Mol. Genet.</source><volume>25</volume><year>2016</year><fpage>3654</fpage><lpage>3675</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw212</pub-id><pub-id pub-id-type="pmid">27378694</pub-id><pub-id pub-id-type="pmcid">PMC5216613</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>O'Callaghan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cleary</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>F.K.</given-names></name><etal/></person-group><article-title>Fully-Automated muMRI Morphometric Phenotyping of the Tc1 Mouse Model of Down Syndrome</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><object-id pub-id-type="publisher-id">e0162974</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0162974</pub-id><pub-id pub-id-type="pmcid">PMC5033246</pub-id><pub-id pub-id-type="pmid">27658297</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Lerch</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Spring</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertram</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Henkelman</surname><given-names>R.M.</given-names></name></person-group><article-title>Automated deformation analysis in the YAC128 Huntington disease mouse model</article-title><source>Neuroimage</source><volume>39</volume><year>2008</year><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.08.033</pub-id><pub-id pub-id-type="pmid">17942324</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Lerch</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gazdzinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Germann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sled</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Henkelman</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Nieman</surname><given-names>B.J.</given-names></name></person-group><article-title>Wanted dead or alive? The tradeoff between in-vivo versus ex-vivo MR brain imaging in the mouse</article-title><source>Front. Neuroinform.</source><volume>6</volume><year>2012</year><fpage>6</fpage><pub-id pub-id-type="doi">10.3389/fninf.2012.00006</pub-id><pub-id pub-id-type="pmid">22470335</pub-id><pub-id pub-id-type="pmcid">PMC3311228</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Lavenex</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lavenex</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>D.G.</given-names></name></person-group><article-title>Postmortem changes in the neuroanatomical characteristics of the primate brain: hippocampal formation</article-title><source>J. Comp. Neurol.</source><volume>512</volume><year>2009</year><fpage>27</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1002/cne.21906</pub-id><pub-id pub-id-type="pmid">18972553</pub-id><pub-id pub-id-type="pmcid">PMC2673533</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Paulsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Magnotta</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Mikos</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Penziner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Nopoulos</surname><given-names>P.C.</given-names></name></person-group><article-title>Brain structure in preclinical Huntington's disease</article-title><source>Biol. Psychiatry</source><volume>59</volume><year>2006</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.06.003</pub-id><pub-id pub-id-type="pmid">16112655</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Rosas</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Tuch</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Hevelone</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Zaleta</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Vangel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hersch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Salat</surname><given-names>D.H.</given-names></name></person-group><article-title>Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures</article-title><source>Mov. Disord.</source><volume>21</volume><year>2006</year><fpage>1317</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1002/mds.20979</pub-id><pub-id pub-id-type="pmid">16755582</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>R.T.Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu-Taeger</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>To</surname><given-names>X.V.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Novati</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease</article-title><source>Hum. Mol. Genet.</source><volume>25</volume><year>2016</year><fpage>2621</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddw122</pub-id><pub-id pub-id-type="pmid">27126634</pub-id><pub-id pub-id-type="pmcid">PMC5181633</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Miralles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yusof</surname><given-names>N.A.B.M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Radulescu</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Sidik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Belinson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zach</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Pouladi</surname><given-names>M.A.</given-names></name></person-group><article-title>Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease</article-title><source>Mol. Neurobiol.</source><volume>56</volume><year>2019</year><fpage>4464</fpage><lpage>4478</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1393-1</pub-id><pub-id pub-id-type="pmid">30334188</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Aly</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Black</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.D.O.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Casal</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease</article-title><source>J Control Release</source><volume>367</volume><year>2024</year><fpage>27</fpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2024.01.011</pub-id><pub-id pub-id-type="pmid">38215984</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Southwell</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Skotte</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Kordasiewicz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Watt</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Villanueva</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Petoukhov</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vaid</surname><given-names>K.</given-names></name><etal/></person-group><article-title>In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides</article-title><source>Mol. Ther.</source><volume>22</volume><year>2014</year><fpage>2093</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1038/mt.2014.153</pub-id><pub-id pub-id-type="pmid">25101598</pub-id><pub-id pub-id-type="pmcid">PMC4429695</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Mortberg</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gentile</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Nadaf</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Vanderburg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubinsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Slamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N.</given-names></name><etal/></person-group><article-title>A single-cell map of antisense oligonucleotide activity in the brain</article-title><source>Nucleic Acids Res.</source><volume>51</volume><year>2023</year><fpage>7109</fpage><lpage>7124</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad371</pub-id><pub-id pub-id-type="pmid">37188501</pub-id><pub-id pub-id-type="pmcid">PMC10415122</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Castro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gangwani</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Coppola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khakh</surname><given-names>B.S.</given-names></name></person-group><article-title>Astrocyte molecular signatures in Huntington's disease</article-title><source>Sci. Transl. Med.</source><volume>11</volume><year>2019</year><object-id pub-id-type="publisher-id">eaaw8546</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw8546</pub-id><pub-id pub-id-type="pmid">31619545</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Landwehrmeyer</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Dure</surname><given-names>L.S.</given-names><suffix>4th</suffix></name><name name-style="western"><surname>Ge</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aizawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Duyao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals</article-title><source>Ann. Neurol.</source><volume>37</volume><year>1995</year><fpage>218</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1002/ana.410370213</pub-id><pub-id pub-id-type="pmid">7847863</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Gangwani</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jami-Alahmadi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wohlschlegel</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Khakh</surname><given-names>B.S.</given-names></name></person-group><article-title>Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors</article-title><source>Cell Rep.</source><volume>42</volume><year>2023</year><object-id pub-id-type="publisher-id">111953</object-id><pub-id pub-id-type="doi">10.1016/j.celrep.2022.111953</pub-id><pub-id pub-id-type="pmcid">PMC9898160</pub-id><pub-id pub-id-type="pmid">36640336</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Hodges</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Aragaki</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sengstag</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Elliston</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hartog</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Thu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Regional and cellular gene expression changes in human Huntington's disease brain</article-title><source>Hum. Mol. Genet.</source><volume>15</volume><year>2006</year><fpage>965</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddl013</pub-id><pub-id pub-id-type="pmid">16467349</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Kuhn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Sengstag</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kooperberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Becanovic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pouladi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sathasivam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>J.H.J.</given-names></name><etal/></person-group><article-title>Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage</article-title><source>Hum. Mol. Genet.</source><volume>16</volume><year>2007</year><fpage>1845</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm133</pub-id><pub-id pub-id-type="pmid">17519223</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Valenza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leoni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Brilli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease</article-title><source>J. Neurosci.</source><volume>31</volume><year>2011</year><fpage>9544</fpage><lpage>9553</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1291-11.2011</pub-id><pub-id pub-id-type="pmid">21715619</pub-id><pub-id pub-id-type="pmcid">PMC3132810</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Marchionini</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Ambesi-Impiombato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kerker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mushlin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramboz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model</article-title><source>JCI Insight</source><volume>7</volume><year>2022</year><object-id pub-id-type="publisher-id">e161769</object-id><pub-id pub-id-type="doi">10.1172/jci.insight.161769</pub-id><pub-id pub-id-type="pmcid">PMC9714791</pub-id><pub-id pub-id-type="pmid">36278490</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Luthi-Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Strand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Solano</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hollingsworth</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Spektor</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Penney</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Schilling</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Decreased expression of striatal signaling genes in a mouse model of Huntington's disease</article-title><source>Hum. Mol. Genet.</source><volume>9</volume><year>2000</year><fpage>1259</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.9.1259</pub-id><pub-id pub-id-type="pmid">10814708</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ba&#241;ez-Coronel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice</article-title><source>Neuron</source><volume>110</volume><year>2022</year><fpage>1173</fpage><lpage>1192.e7</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2022.01.006</pub-id><pub-id pub-id-type="pmid">35114102</pub-id><pub-id pub-id-type="pmcid">PMC9462388</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Becanovic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pouladi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pavlidis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luthi-Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name></person-group><article-title>Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis</article-title><source>Hum. Mol. Genet.</source><volume>19</volume><year>2010</year><fpage>1438</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq018</pub-id><pub-id pub-id-type="pmid">20089533</pub-id><pub-id pub-id-type="pmcid">PMC2846159</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Mazarei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Becanovic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Luthi-Carter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name></person-group><article-title>Expression analysis of novel striatal-enriched genes in Huntington disease</article-title><source>Hum. Mol. Genet.</source><volume>19</volume><year>2010</year><fpage>609</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddp527</pub-id><pub-id pub-id-type="pmid">19934114</pub-id><pub-id pub-id-type="pmcid">PMC2807369</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Hebb</surname><given-names>A.L.O.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Denovan-Wright</surname><given-names>E.M.</given-names></name></person-group><article-title>Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms</article-title><source>Neuroscience</source><volume>123</volume><year>2004</year><fpage>967</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2003.11.009</pub-id><pub-id pub-id-type="pmid">14751289</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Richfield</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Maguire-Zeiss</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Voorn</surname><given-names>P.</given-names></name></person-group><article-title>Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients</article-title><source>Ann. Neurol.</source><volume>37</volume><year>1995</year><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1002/ana.410370309</pub-id><pub-id pub-id-type="pmid">7695232</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Augood</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Emson</surname><given-names>P.C.</given-names></name></person-group><article-title>Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease</article-title><source>Ann. Neurol.</source><volume>42</volume><year>1997</year><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1002/ana.410420213</pub-id><pub-id pub-id-type="pmid">9266732</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Augood</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Love</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Emson</surname><given-names>P.C.</given-names></name></person-group><article-title>Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study</article-title><source>Neuroscience</source><volume>72</volume><year>1996</year><fpage>1023</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(95)00595-1</pub-id><pub-id pub-id-type="pmid">8735227</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaertig</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes</article-title><source>Neuron</source><volume>85</volume><year>2015</year><fpage>1212</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.02.026</pub-id><pub-id pub-id-type="pmid">25789755</pub-id><pub-id pub-id-type="pmcid">PMC4366619</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Al-Dalahmah</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Reidling</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dansu</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Casaccia</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Huntington disease oligodendrocyte maturation deficits revealed by single-nucleus RNAseq are rescued by thiamine-biotin supplementation</article-title><source>Nat. Commun.</source><volume>13</volume><year>2022</year><fpage>7791</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-35388-x</pub-id><pub-id pub-id-type="pmid">36543778</pub-id><pub-id pub-id-type="pmcid">PMC9772349</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Bostrand</surname><given-names>S.M.K.</given-names></name><name name-style="western"><surname>Seeker</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bestard-Cuche</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kazakou</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Jakel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kenkhuis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>de Bot</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>van Roon-Mom</surname><given-names>W.M.C.</given-names></name><name name-style="western"><surname>Priller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.</given-names></name></person-group><article-title>Mapping the glial transcriptome in Huntington's disease using snRNAseq: selective disruption of glial signatures across brain regions</article-title><source>Acta Neuropathol Commun</source><volume>12</volume><year>2024</year><fpage>165</fpage><pub-id pub-id-type="doi">10.1186/s40478-024-01871-3</pub-id><pub-id pub-id-type="pmid">39428482</pub-id><pub-id pub-id-type="pmcid">PMC11492505</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Tabrizi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Landwehrmeyer</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Saft</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Craufurd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Priller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rickards</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Targeting Huntingtin Expression in Patients with Huntington's Disease</article-title><source>N. Engl. J. Med.</source><volume>380</volume><year>2019</year><fpage>2307</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1900907</pub-id><pub-id pub-id-type="pmid">31059641</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>McColgan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thobhani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schobel</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Nicotra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Palermo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trundell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schlegel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sanwald Ducray</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Tominersen in Adults with Manifest Huntington's Disease</article-title><source>N. Engl. J. Med.</source><volume>389</volume><year>2023</year><fpage>2203</fpage><lpage>2205</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2300400</pub-id><pub-id pub-id-type="pmid">38055260</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Sathasivam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Neueder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gipson</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Landles</surname><given-names>C.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Bondulich</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Faull</surname><given-names>R.L.M.</given-names></name><name name-style="western"><surname>Roos</surname><given-names>R.A.C.</given-names></name><name name-style="western"><surname>Howland</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>110</volume><year>2013</year><fpage>2366</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1073/pnas.1221891110</pub-id><pub-id pub-id-type="pmid">23341618</pub-id><pub-id pub-id-type="pmcid">PMC3568346</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Lemieux</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mackinnon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.S.N.</given-names></name></person-group><article-title>Automatic segmentation of the brain and intracranial cerebrospinal fluid in T1-weighted volume MRI scans of the head, and its application to serial cerebral and intracranial volumetry</article-title><source>Magn. Reson. Med.</source><volume>49</volume><year>2003</year><fpage>872</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1002/mrm.10436</pub-id><pub-id pub-id-type="pmid">12704770</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Acer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ba&#351;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ertekin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Usanmaz</surname><given-names>M.</given-names></name></person-group><article-title>Comparison of three methods for the estimation of total intracranial volume: stereologic, planimetric, and anthropometric approaches</article-title><source>Ann. Plast. Surg.</source><volume>58</volume><year>2007</year><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1097/01.sap.0000250653.77090.97</pub-id><pub-id pub-id-type="pmid">17197941</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Button</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Barron</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stukas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury</article-title><source>Alzheimers Res. Ther.</source><volume>13</volume><year>2021</year><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s13195-021-00793-9</pub-id><pub-id pub-id-type="pmid">33678186</pub-id><pub-id pub-id-type="pmcid">PMC7938597</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tybulewicz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lythgoe</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name></person-group><article-title>Automatic structural parcellation of mouse brain MRI using multi-atlas label fusion</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e86576</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0086576</pub-id><pub-id pub-id-type="pmcid">PMC3903537</pub-id><pub-id pub-id-type="pmid">24475148</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hof</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blackband</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benveniste</surname><given-names>H.</given-names></name></person-group><article-title>Vivo 3D Digital Atlas Database of the Adult C57BL/6J Mouse Brain by Magnetic Resonance Microscopy</article-title><source>Front. Neuroanat.</source><volume>2</volume><year>2008</year><fpage>1</fpage><pub-id pub-id-type="doi">10.3389/neuro.05.001.2008</pub-id><pub-id pub-id-type="pmid">18958199</pub-id><pub-id pub-id-type="pmcid">PMC2525925</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winston</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name></person-group><article-title>Global image registration using a symmetric block-matching approach</article-title><source>J. Med. Imaging</source><volume>1</volume><year>2014</year><object-id pub-id-type="publisher-id">024003</object-id><pub-id pub-id-type="doi">10.1117/1.JMI.1.2.024003</pub-id><pub-id pub-id-type="pmcid">PMC4478989</pub-id><pub-id pub-id-type="pmid">26158035</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="book" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ayache</surname><given-names>N.</given-names></name></person-group><part-title>Block Matching: A General Framework to Improve Robustness of Rigid Registration of Medical Images</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Delp</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>DiGoia</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jaramaz</surname><given-names>B.</given-names></name></person-group><source>Medical Image Computing and Computer-Assisted Intervention &#8211; MICCAI 2000</source><year>2000</year><publisher-name>Springer Berlin Heidelberg</publisher-name></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="book" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name></person-group><part-title>Inverse-Consistent Symmetric Free Form Deformation</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Dawant</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>D.</given-names></name></person-group><source>Biomedical Image Registration</source><year>2012</year><publisher-name>Springer</publisher-name></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="book" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ridgway</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Ashburner</surname><given-names>J.</given-names></name></person-group><part-title>Parametric non-rigid registration using a stationary velocity field</part-title><source>2012 IEEE Workshop on Mathematical Methods in Biomedical Image Analysis</source><year>2012</year></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Rueckert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Hawkes</surname><given-names>D.J.</given-names></name></person-group><article-title>Nonrigid registration using free-form deformations: application to breast MR images</article-title><source>IEEE Trans. Med. Imaging</source><volume>18</volume><year>1999</year><fpage>712</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1109/42.796284</pub-id><pub-id pub-id-type="pmid">10534053</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Jorge Cardoso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Modat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keihaninejad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cash</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Ourselin</surname><given-names>S.</given-names></name></person-group><article-title>STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation</article-title><source>Med. Image Anal.</source><volume>17</volume><year>2013</year><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.media.2013.02.006</pub-id><pub-id pub-id-type="pmid">23510558</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Black</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lemari&#233;</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Doty</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>M.R.</given-names></name></person-group><article-title>Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting</article-title><source>J. Huntingtons Dis.</source><volume>10</volume><year>2021</year><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.3233/JHD-200463</pub-id><pub-id pub-id-type="pmid">34092649</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Love</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><volume>15</volume><year>2014</year><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Reimand</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kull</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vilo</surname><given-names>J.</given-names></name></person-group><article-title>g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments</article-title><source>Nucleic Acids Res.</source><volume>35</volume><year>2007</year><fpage>W193</fpage><lpage>W200</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm226</pub-id><pub-id pub-id-type="pmid">17478515</pub-id><pub-id pub-id-type="pmcid">PMC1933153</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Kolberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Raudvere</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kuzmin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vilo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>H.</given-names></name></person-group><article-title>g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)</article-title><source>Nucleic Acids Res.</source><volume>51</volume><year>2023</year><fpage>W207</fpage><lpage>W212</lpage><pub-id pub-id-type="doi">10.1093/nar/gkad347</pub-id><pub-id pub-id-type="pmid">37144459</pub-id><pub-id pub-id-type="pmcid">PMC10320099</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Dougherty</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heintz</surname><given-names>N.</given-names></name></person-group><article-title>Analytical approaches to RNA profiling data for the identification of genes enriched in specific cells</article-title><source>Nucleic Acids Res.</source><volume>38</volume><year>2010</year><fpage>4218</fpage><lpage>4230</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq130</pub-id><pub-id pub-id-type="pmid">20308160</pub-id><pub-id pub-id-type="pmcid">PMC2910036</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Nehorai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dougherty</surname><given-names>J.D.</given-names></name></person-group><article-title>Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders</article-title><source>J. Neurosci.</source><volume>34</volume><year>2014</year><fpage>1420</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4488-13.2014</pub-id><pub-id pub-id-type="pmid">24453331</pub-id><pub-id pub-id-type="pmcid">PMC3898298</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meirelles</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Ma'ayan</surname><given-names>A.</given-names></name></person-group><article-title>Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool</article-title><source>BMC Bioinf.</source><volume>14</volume><year>2013</year><fpage>128</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-14-128</pub-id><pub-id pub-id-type="pmcid">PMC3637064</pub-id><pub-id pub-id-type="pmid">23586463</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Kuleshov</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Rouillard</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Koplev</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Jagodnik</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lachmann</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Res.</source><volume>44</volume><year>2016</year><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id><pub-id pub-id-type="pmcid">PMC4987924</pub-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Langfelder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Plascencia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dionisio</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice</article-title><source>Cell</source><volume>188</volume><year>2025</year><fpage>1524</fpage><lpage>1544.e22</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2025.01.031</pub-id><pub-id pub-id-type="pmid">39938516</pub-id><pub-id pub-id-type="pmcid">PMC11972609</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0510">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Document S1. Figures S1&#8211;S17 and Tables S1 and S2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Document S2. Article plus supplemental information</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p0505">Supplemental information can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.omtn.2025.102710" id="intref0030">https://doi.org/10.1016/j.omtn.2025.102710</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurol</journal-id><journal-id journal-id-type="iso-abbrev">J Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Journal of Neurology</journal-title></journal-title-group><issn pub-type="ppub">0340-5354</issn><issn pub-type="epub">1432-1459</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491116</article-id><article-id pub-id-type="pmcid-ver">PMC12491116.1</article-id><article-id pub-id-type="pmcaid">12491116</article-id><article-id pub-id-type="pmcaiid">12491116</article-id><article-id pub-id-type="pmid">41037094</article-id><article-id pub-id-type="doi">10.1007/s00415-025-13412-6</article-id><article-id pub-id-type="publisher-id">13412</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Communication</subject></subj-group></article-categories><title-group><article-title>Altered gut microbiota mediates the association between APOE genotype and amyloid-&#946; accumulation in middle-aged adults</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wadop</surname><given-names initials="YN">Yannick N.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bernal</surname><given-names initials="R">Rebecca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Njamnshi</surname><given-names initials="WY">Wepnyu Y.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Satizabal</surname><given-names initials="CL">Claudia L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beiser</surname><given-names initials="A">Alexa</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruiz</surname><given-names initials="A">Agustin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Njamnshi</surname><given-names initials="AK">Alfred K.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vasan</surname><given-names initials="RS">Ramachandran S.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seshadri</surname><given-names initials="S">Sudha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Himali</surname><given-names initials="JJ">Jayandra Jung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8161-1553</contrib-id><name name-style="western"><surname>Fongang</surname><given-names initials="B">Bernard</given-names></name><address><email>fongang@uthscsa.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff22">22</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6dcw23</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution>Glenn Biggs Institute for Alzheimer&#8217;s and Neurodegenerative Diseases, </institution><institution>University of Texas Health Science Center at San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff2"><label>2</label>Brain Research Africa Initiative (BRAIN), P. O. Box 25625, Yaound&#233;, Cameroon </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/022zbs961</institution-id><institution-id institution-id-type="GRID">grid.412661.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2173 8504</institution-id><institution>Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, </institution><institution>The University of Yaound&#233; I, </institution></institution-wrap>P. O. Box 1364, Yaound&#233;, Cameroon </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bgfrg80</institution-id><institution-id institution-id-type="GRID">grid.415857.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0668 6654</institution-id><institution>Ministry of Public Health, </institution><institution>Division of Health Operations Research, </institution></institution-wrap>P. O. Box 1937, Yaound&#233;, Cameroon </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6dcw23</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution>Department of Population Health Sciences, </institution><institution>University of Texas Health Science Center at San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/031grv205</institution-id><institution-id institution-id-type="GRID">grid.510954.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 3861</institution-id><institution>Framingham Heart Study, </institution></institution-wrap>Framingham, MA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Department of Neurology, </institution><institution>Boston University Chobanian and Avedisian School of Medicine, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Department of Biostatistics, </institution><institution>Boston University School of Public Health, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cwbxa29</institution-id><institution-id institution-id-type="GRID">grid.468222.8</institution-id><institution>Department of Microbiology, Immunology and Molecular Genetics. Long School of Medicine, </institution><institution>University of Texas Health Science Center, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00tse2b39</institution-id><institution-id institution-id-type="GRID">grid.410675.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 2325 3084</institution-id><institution>ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zca7903</institution-id><institution-id institution-id-type="GRID">grid.418264.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 4012</institution-id><institution>Network Center for Biomedical Research in Neurodegenerative Diseases, </institution><institution>CIBERNED, National Institute of Health Carlos III, </institution></institution-wrap>Madrid, Spain </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rx1ga86</institution-id><institution-id institution-id-type="GRID">grid.460723.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 4688</institution-id><institution>Department of Neurology, </institution><institution>Central Hospital Yaound&#233;, </institution></institution-wrap>P. O. Box 25625, Yaound&#233;, Cameroon </aff><aff id="Aff13"><label>13</label>Brain Research Africa Initiative (BRAIN), 1226 Geneva, Switzerland </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010b9wj87</institution-id><institution-id institution-id-type="GRID">grid.239424.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2183 6745</institution-id><institution>Department of Medicine, Section of Cardiovascular Medicine, </institution><institution>Boston Medical Center, Boston University School of Medicine, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Department of Medicine, Section of Preventive Medicine and Epidemiology, </institution><institution>Boston University School of Medicine, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Department of Epidemiology, </institution><institution>Boston University School of Public Health, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05qwgg493</institution-id><institution-id institution-id-type="GRID">grid.189504.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7558</institution-id><institution>Boston University&#8217;s Center for Computing and Data Sciences, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kd65564</institution-id><institution-id institution-id-type="GRID">grid.215352.2</institution-id><institution-id institution-id-type="ISNI">0000000121845633</institution-id><institution>The University of Texas School of Public Health in San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cwbxa29</institution-id><institution-id institution-id-type="GRID">grid.468222.8</institution-id><institution>The Long School of Medicine, </institution><institution>University of Texas Health Science Center, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6dcw23</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution>Department of Neurology, </institution><institution>University of Texas Health Science Center at San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6dcw23</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution>Graduate School of Biomedical Sciences, </institution><institution>University of Texas Health Science Center at San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f6dcw23</institution-id><institution-id institution-id-type="GRID">grid.267309.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0629 5880</institution-id><institution>Department of Biochemistry and Structural Biology, </institution><institution>University of Texas Health Science Center at San Antonio, </institution></institution-wrap>San Antonio, TX USA </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>272</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">498222</issue-id><elocation-id>670</elocation-id><history><date date-type="received"><day>4</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 14:25:37.640"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="415_2025_Article_13412.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" vol="6" elocation-id="2025.07.27.667048" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12324374"><article-title>
Altered Gut Microbiota Mediates the Association between APOE Genotype and Amyloid-&#946; Accumulation in Middle-Aged Adults
</article-title><date><day>31</day><month>7</month><year>2025</year></date><elocation-id>2025.07.27.667048</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC12324374</pub-id><pub-id pub-id-type="pmid">40766561</pub-id></related-article><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 allele is the strongest genetic risk factor for Alzheimer&#8217;s disease, yet the mechanisms linking <italic toggle="yes">APOE</italic> to amyloid-&#946; (A&#946;) pathology remain incompletely understood. Emerging evidence suggests that the gut microbiome may modulate neurodegeneration; however, its role as a mediator in the APOE&#8211;A&#946; relationship remains unclear.</p></sec><sec><title>Objective</title><p id="Par2">Evaluate whether specific microbial taxa mediate APOE-related effects on brain A&#946; burden in a population-based study.</p></sec><sec><title>Methods</title><p id="Par3">This study involved 227 participants from the Framingham Heart Study with stool 16S rRNA sequencing and carbon-11 Pittsburgh Compound-B imaging for A&#946; collected at the third examination (2016&#8211;2019). Associations between gut microbiota and global/regional A&#946; deposition were assessed using multivariable models. We stratified participants by APOE &#949;4 status and conducted mediation analysis to evaluate whether specific taxa mediated APOE-related effects on A&#946;. Microbial functional potential was inferred to examine enrichment of metabolic pathways.</p></sec><sec><title>Results</title><p id="Par4">Higher A&#946; burden was significantly associated with the depletion of protective genera (e.g., <italic toggle="yes">Faecalibacterium, Ruminococcus, Butyricicoccus</italic>) and the enrichment of pro-inflammatory taxa (e.g., <italic toggle="yes">Alistipes</italic>, <italic toggle="yes">Bacteroides</italic>) and <italic toggle="yes">Barnesiella</italic>. These associations were more pronounced in <italic toggle="yes">APOE</italic> &#949;4 carriers, who exhibited a broader spectrum of microbial dysbiosis. Mediation analysis showed that <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic> collectively mediated&#8201;~&#8201;0.3&#8211;0.4% of the effect of <italic toggle="yes">APOE</italic> &#949;4 on global A&#946; burden. Functional profiling revealed a reduced abundance of microbial genes involved in key metabolic pathways among individuals with higher A&#946; levels.</p></sec><sec><title>Conclusion</title><p id="Par5">Gut microbiome composition mediates the deleterious effect of <italic toggle="yes">APOE</italic> &#949;4 on cerebral amyloid deposition, suggesting that microbiome-targeted interventions may mitigate <italic toggle="yes">APOE</italic>-related risk.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gut microbiome</kwd><kwd>APOE genotype</kwd><kwd>Amyloid-&#946;</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Mediating role</kwd><kwd>Metabolic pathway</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>AG059421</award-id><award-id>AG054076</award-id><award-id>AG049607</award-id><award-id>AG033090</award-id><award-id>AG066524</award-id><award-id>P30 AG066546</award-id><award-id>5P30AG059305-03</award-id><award-id>RF1 AG061729A1</award-id><award-id>5U01AG052409-04</award-id><award-id>UG3AG090675)</award-id><award-id>NINDS (NS017950</award-id><award-id>UF1NS125513</award-id><award-id>K01NS126489</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>South Texas Alzheimer&#8217;s Disease Research Center</institution></funding-source><award-id>P30AG066546</award-id><principal-award-recipient><name name-style="western"><surname>Fongang</surname><given-names>Bernard</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Alzheimer&#8217;s disease (AD) is neuropathologically characterized by the accumulation of extracellular amyloid-&#946; (A&#946;) plaques and intraneuronal tau neurofibrillary tangles in the brain parenchyma [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. These proteinopathies begin to accumulate years, if not decades, before the onset of clinical symptoms, as evidenced by positron emission tomography (PET) imaging in cognitively unimpaired individuals. While the pathogenic cascade of AD is multifactorial, emerging research implicates the gut microbiome as an important contributor to neurodegenerative processes [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The gut microbiota is intimately involved in numerous aspects of human physiology, and perturbations in the microbiome have been linked to metabolic and inflammatory diseases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. In the context of brain health, accumulating evidence suggests that shifts in gut microbiome composition are associated with neuroinflammation and the development of neurodegenerative diseases [<xref ref-type="bibr" rid="CR9">9</xref>]. This gut and brain connection is mediated through a bidirectional communication network known as the gut&#8211;brain axis [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. Through neural, endocrine, and immune pathways, gut microbes can influence brain physiology and pathology [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par7">Although gut microbiome cannot predict the status of AD pathology, cross-sectional studies support a link between altered gut microbiota and AD pathology in human and animal models [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. AD patients have been reported to exhibit gut microbiome profiles enriched in pro-inflammatory taxa and depleted in beneficial commensals relative to cognitively normal controls [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Notably, taxa, such as <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Ruminococcus</italic>, and <italic toggle="yes">Barnesiella</italic> (typically regarded as anti-inflammatory or short-chain fatty acid producers), are reduced in AD, whereas certain pro-inflammatory genera are increased [<xref ref-type="bibr" rid="CR21">21</xref>]. These microbial changes correlate with elevated peripheral inflammatory markers in individuals with amyloid pathology, suggesting that the gut microbiota may modulate AD risk via immune-inflammatory mechanisms. In support of this idea, it was shown that cognitively impaired individuals with brain amyloidosis had higher abundances of pro-inflammatory gut bacteria (and lower anti-inflammatory bacteria), accompanied by increased inflammatory markers [<xref ref-type="bibr" rid="CR24">24</xref>]. Conversely, interventions that modulate the microbiome can impact amyloid pathology. In transgenic AD mouse models, exercise or probiotic supplementation has been shown to attenuate amyloid accumulation and reduce neuroinflammation [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par8">While the connections between the gut microbiome and AD pathology are increasingly recognized, the influence of host genetic factors on this gut&#8211;brain axis is only beginning to be explored [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The strongest genetic risk factor for both early-onset and late-onset AD is the apolipoprotein E (<italic toggle="yes">APOE</italic>) gene polymorphism [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The <italic toggle="yes">APOE</italic> gene has three common protein isoforms (&#949;2, &#949;3, &#949;4), yielding six possible genotypes in humans [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The &#949;4 allele is associated with a dose-dependent increase in AD risk: carrying one &#949;4 allele confers an estimated&#8201;~&#8201;threefold increased risk of developing AD (compared to the common &#949;3/&#949;3 genotype), and two &#949;4 alleles lead to even greater risk and earlier onset [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref>]. In contrast, the &#949;2 allele is relatively protective against AD [<xref ref-type="bibr" rid="CR37">37</xref>]. <italic toggle="yes">APOE</italic> encodes the apolipoprotein E, a lipid-transport protein that plays a major role in lipid metabolism in both the periphery and the brain [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. <italic toggle="yes">APOE</italic> is a key carrier of cholesterol and other lipids, and in the brain, it helps clear A&#946; peptides from the interstitial fluid [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The isoform-specific effects of APOE on AD are complex; <italic toggle="yes">APOE &#949;4</italic> is thought to be less effective at A&#946; clearance and to promote neuroinflammatory and synaptotoxic pathways [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. However, the precise mechanisms by which <italic toggle="yes">APOE4</italic> accelerates AD pathogenesis are still under intense investigation.</p><p id="Par9">Importantly, host genetics can also shape the gut microbiome. Recent research indicates that <italic toggle="yes">APOE</italic> genotype is associated with specific gut microbiome profiles [<xref ref-type="bibr" rid="CR9">9</xref>]. For example, one study reported that humans carrying the <italic toggle="yes">APOE &#949;4</italic> allele (and <italic toggle="yes">APOE</italic>-targeted replacement mice) exhibited differences in gut microbial communities, including changes in <italic toggle="yes">Lachnospiraceae</italic>, <italic toggle="yes">Ruminococcaceae</italic>, and several SCFA-producing genera [<xref ref-type="bibr" rid="CR9">9</xref>]. These findings suggest that APOE4 may predispose individuals to a pro-AD gut-microbiome composition (low anti-inflammatory microbes, high pro-inflammatory microbes), which could, in turn, exacerbate amyloid accumulation and neurodegeneration. This three-way interplay between host genotype, gut microbiota, and amyloid pathology has not been directly examined in humans to date.</p><p id="Par10">Here, we address this gap by leveraging data from the Framingham Heart Study (FHS) to investigate whether the gut microbiome mediates the relationship between <italic toggle="yes">APOE</italic> genotype and brain A&#946; burden. We hypothesized that <italic toggle="yes">APOE &#949;4 carriers would exhibit a gut microbiome signature associated with higher amyloid burden</italic>, particularly characterized by a reduction in anti-inflammatory bacteria. We performed 16S rRNA gene sequencing on stool samples from 227 cognitively normal to mildly impaired adults who also underwent A&#946; PET imaging to explore the role of the gut microbiome as a potential modulator of genetic risk for AD.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par11">This study utilized data from the Framingham Heart Study (FHS), a multi-generational longitudinal cohort initiated in 1948, to investigate risk factors for cardiovascular disease [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In recent years, the FHS has expanded to include studies on brain aging [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Starting in 2015, members of the FHS Third Generation cohort were invited to participate in an amyloid imaging sub-study. Key eligibility criteria for the PET sub-study included: (1) age&#8201;&#8805;&#8201;30&#160;years at the time of the third examination visit (2016&#8211;2019) and (2) absence of major neurological conditions (including clinical dementia, stroke, or multiple sclerosis). A total of 227 participants provided stool samples and underwent A&#946; PET scanning approximately around the time of their third examination (2016&#8211;2019). All participants gave written informed consent, and the study protocol was approved by the Institutional Review Boards of Boston University Medical Center and Massachusetts General Hospital.</p></sec><sec id="Sec4"><title>Gut microbiome collection and analysis</title><p id="Par12">Participants provided a single stool sample, which was collected and processed following standardized FHS protocols [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Stool specimens were immediately frozen at &#8722;80&#160;&#176;C after collection and stored until batch analysis. Microbial DNA was extracted using the Qiagen PowerSoil DNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer&#8217;s guidelines. The V4 hypervariable region of the 16S rRNA gene was amplified by polymerase chain reaction and sequenced on the Illumina MiSeq platform to generate paired-end reads (2&#8201;&#215;&#8201;250&#160;bp). Quality control and amplicon sequence variant (ASV) inference were performed using the DADA2 pipeline [<xref ref-type="bibr" rid="CR47">47</xref>], yielding high-resolution bacterial sequence features. The taxonomic assignment of each ASV was performed against the SILVA 16S rRNA database (version 132). For downstream analyses, we agglomerated ASVs at various taxonomic levels (phylum, family, and genus) and focused primarily on genus-level relative abundances. Rare taxa with extremely low counts were filtered out to reduce noise. We calculated &#945;-diversity (within-sample diversity) metrics, such as the Shannon index, and &#946;-diversity (between-sample differences) using Bray&#8211;Curtis distances. Although our primary analyses focused on specific taxa abundances rather than global diversity measures, we also employed these metrics.</p></sec><sec id="Sec5"><title>A&#946; PET imaging and quantification</title><p id="Par13">Participants underwent carbon-11 Pittsburgh Compound-B PET scans to measure cerebral amyloid-&#946; deposition, performed at the Massachusetts General Hospital PET facility. Imaging was conducted on&#160;HR&#8201;+&#8201;or GE Discovery MI PET scanners using standardized protocols as previously described [<xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref>]. In brief, each participant received a 10&#8211;15&#160;mCi bolus injection of [^11C]PiB, followed by dynamic PET acquisition over 60&#160;min (four 5-min frames, 50&#8211;70&#160;min post-injection, were used for analysis). T1-weighted volumetric brain MRI scans (acquired within a year of the PET scan) were used for co-registration and definition of regions of interest. PET images were motion-corrected, spatially co-registered to each individual&#8217;s MRI, and normalized to a common space. A cerebellar gray matter reference region was used to calculate standardized uptake value ratios (SUVR) for cortical target regions [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In addition, a global A&#946; composite measure was computed by averaging PiB SUVR across a set of frontal, parietal, temporal, and retrosplenial cortical regions (often termed the FLR composite) [<xref ref-type="bibr" rid="CR54">54</xref>]. This global PiB SUVR served as our primary outcome for &#8220;<italic toggle="yes">overall</italic>&#8221; amyloid burden [<xref ref-type="bibr" rid="CR54">54</xref>]. This global PiB SUVR served as our primary outcome for &#8220;<italic toggle="yes">overall</italic>&#8221; amyloid burden. Regional SUVR values were analyzed as secondary outcomes to explore region-specific relationships. Twelve regions were examined based on their known vulnerability to early amyloid accumulation and their susceptibility to early AD pathology (including the precuneus, inferior temporal cortex, frontal pole, accumbens area, amygdala, cingulate, insula cortex, hippocampus, entorhinal cortex, parahippocampal cortex, temporal pole, cerebellum white matter, and cerebral white matter) [<xref ref-type="bibr" rid="CR54">54</xref>&#8211;<xref ref-type="bibr" rid="CR56">56</xref>]. A global PiB SUVR of 1.10 is commonly considered an abnormal threshold for amyloid positivity; in our sample, the median global SUVR was around 1.06, with&#8201;~&#8201;23% of participants exceeding 1.10 (reflecting a mix of amyloid-positive and -negative individuals, as expected for this age range).</p></sec><sec id="Sec6"><title>APOE genotyping</title><p id="Par14">DNA was isolated from whole blood samples collected at FHS exams using a standard salting-out procedure [<xref ref-type="bibr" rid="CR57">57</xref>]. <italic toggle="yes">APOE</italic> genotyping was performed as described by Lahoz et al<italic toggle="yes">.</italic> [<xref ref-type="bibr" rid="CR58">58</xref>]. The region of the <italic toggle="yes">APOE</italic> gene encompassing the two polymorphic sites (codons 112 and 158) was amplified by PCR [<xref ref-type="bibr" rid="CR59">59</xref>]. The PCR product was then digested with the restriction enzyme HhaI, which yields characteristic fragment patterns for the &#949;2, &#949;3, and &#949;4 alleles. Fragment separation was done on an 8% polyacrylamide gel and visualized under UV light after ethidium bromide staining. From the band patterns, we determined each participant&#8217;s APOE genotype (&#949;2/&#949;2, &#949;2/&#949;3, &#949;3/&#949;3, etc.). For quality control, known <italic toggle="yes">APOE</italic> control samples were run in parallel, and a random 5% subset of samples was re-genotyped with 100% concordance.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par15">All statistical analyses were conducted using R (v4.2.3) [<xref ref-type="bibr" rid="CR60">60</xref>]. Our overarching analytic approach was to identify associations between gut microbial features and A&#946; burden, assess how these associations differ by APOE genotype, and test for mediation by microbial features in the APOE&#8211;A&#946; relationship. Based on prior literature and directed acyclic graph considerations, we included the following covariates in all models: age, age squared, sex, BMI, PET scanner type (HR&#8201;+&#8201;vs. Discovery), and the time interval (in weeks) between stool collection and the PET scan. These factors were chosen to account for potential confounding of microbiome&#8211;A&#946; relationships (e.g., age and sex influence both gut microbiome and amyloid burden; BMI relates to systemic metabolism; different PET cameras have different signal characteristics; and the stool-to-PET time interval could introduce measurement noise).</p></sec><sec id="Sec8"><title>Association of gut microbiome with A&#946;</title><p id="Par16">To identify specific bacteria associated with amyloid burden, we performed a multivariable linear regression through MaAsLin2 (Multivariate Association with Linear Models) R package [<xref ref-type="bibr" rid="CR61">61</xref>]. MaAsLin2 was run at the genus level (and repeated for phylum and family levels for completeness). We set a couple of parameters in MaAsLin2 function such as: (i) cumulative sum scaling (CSS) normalization to raw count data to account for varying sequencing depth across samples, (ii) a negative binomial regression model for association testing (suitable for overdispersed count or relative abundance data), (iii) minimum abundance and prevalence thresholds to filter out very rare taxa (features present in at least 10% of samples and relative abundance&#8201;&gt;&#8201;&#8201;=&#8201;0.001 were required), and (iv) no additional transformation of the normalized data (setting transform&#8201;=&#8201;&#8220;NONE&#8221;). Each model tested the association between a given taxon&#8217;s abundance (predictor of interest) and the global A&#946; PET SUVR (outcome), including the covariates listed above. In formula form, for each genus<disp-formula id="Equa"><alternatives><tex-math id="d33e840">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$A\beta \_global\sim Taxon Abundance+Age+Ag{e}^{2}+Sex+BMI+PET\_Camera+T\_\left\{Stool-PET\right\}.$$\end{document}</tex-math><mml:math id="d33e845" display="block"><mml:mrow><mml:mi>A</mml:mi><mml:mi>&#946;</mml:mi><mml:mi>_</mml:mi><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mo>&#8764;</mml:mo><mml:mi>T</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mi>A</mml:mi><mml:mi>g</mml:mi><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>x</mml:mi><mml:mo>+</mml:mo><mml:mi>B</mml:mi><mml:mi>M</mml:mi><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mi>P</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi><mml:mi>_</mml:mi><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>_</mml:mi><mml:mfenced close="}" open="{"><mml:mi>S</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo>-</mml:mo><mml:mi>P</mml:mi><mml:mi>E</mml:mi><mml:mi>T</mml:mi></mml:mfenced><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="415_2025_13412_Article_Equa.gif"/></alternatives></disp-formula></p><p id="Par17">We also ran analogous models for each regional <italic toggle="yes">A&#946;_SUVR</italic> in place of the <italic toggle="yes">A&#946;_global</italic> term to see if certain brain regions drove the global associations. Multiple-testing correction: given the number of taxa tested, we applied the Benjamini&#8211;Hochberg false discovery rate (FDR) correction to the <italic toggle="yes">p</italic> values from these models. Associations with FDR-adjusted <italic toggle="yes">p</italic> (<italic toggle="yes">q</italic> value)&#8201;&lt;&#8201;0.05 were deemed statistically significant.</p></sec><sec id="Sec9"><title>Sensitivity analyses by <italic toggle="yes">APOE</italic> genotype</title><p id="Par18">We conducted a stratified analysis to examine whether gut&#8211;A&#946; associations differ in <italic toggle="yes">APOE</italic> &#949;4 carriers vs. non-carriers. Essentially, we repeated the MaAsLin2 modeling described above in two subsets: (1) participants with no <italic toggle="yes">APOE</italic> &#949;4 allele (i.e., &#949;2/&#949;2, &#949;2/&#949;3, or &#949;3/&#949;3 genotypes), and (2) participants with at least one <italic toggle="yes">APOE</italic> &#949;4 allele (&#949;2/&#949;4, &#949;3/&#949;4, or &#949;4/&#949;4). This stratification was motivated by prior reports that <italic toggle="yes">APOE</italic> &#949;4 carriers may have a distinct microbiome profile and by our interest in whether the microbiome-amyloid link is present even in individuals without a genetic risk. We hypothesized that even <italic toggle="yes">APOE</italic> &#949;4 non-carriers would show an association between low SCFA-producer abundance and high A&#946; (indicating a general gut-A&#946; phenomenon), whereas <italic toggle="yes">APOE</italic> &#949;4 carriers might show the same pattern, perhaps even more strongly (if <italic toggle="yes">APOE</italic> &#949;4 exacerbates gut dysbiosis in concert with amyloid). In these subgroup analyses, we used the same modeling approach and covariates.</p></sec><sec id="Sec10"><title>Mediation analysis</title><p id="Par19">To formally test whether the gut microbiome mediates the relationship between <italic toggle="yes">APOE</italic> genotype and amyloid burden, we performed a causal mediation analysis using the mediation package in R [<xref ref-type="bibr" rid="CR62">62</xref>]. We focused on <italic toggle="yes">APOE</italic> &#949;4 carrier status (yes/no) as the exposure (X) and global A&#946; PET SUVR as the outcome (Y). We considered each candidate taxon that showed significant associations with A&#946; in the earlier analyses as a potential mediator (M). For each such taxon, we set up two regression models:<list list-type="bullet"><list-item><p id="Par20"><italic toggle="yes">Mediator model</italic>: Taxon&#8201;~&#8201;APOE &#949;4&#8201;+&#8201;age&#8201;+&#8201;age<sup>2</sup>&#8201;+&#8201;sex&#8201;+&#8201;BMI</p></list-item><list-item><p id="Par21"><italic toggle="yes">Outcome model</italic>: A&#946;&#8201;~&#8201;APOE &#949;4&#8201;+&#8201;M&#8201;+&#8201;age&#8201;+&#8201;age<sup>2</sup>&#8201;+&#8201;sex&#8201;+&#8201;BMI</p></list-item></list></p><p id="Par22">All models were either linear or generalized linear, as appropriate (taxon abundances were modeled using negative binomial or an appropriate transformation). We then used the mediate function of the R package &#8220;<italic toggle="yes">mediation</italic>&#8221; [<xref ref-type="bibr" rid="CR62">62</xref>] to estimate the &#8220;<italic toggle="yes">indirect effect&#8221;</italic> of <italic toggle="yes">APOE</italic> &#949;4 on A&#946; through the taxon (i.e., the mediation effect), as well as the direct effect not through the taxon. We employed nonparametric bootstrap resampling (1000 simulations) to compute confidence intervals for the mediated effect. An indirect (mediated) effect was considered statistically significant if the bootstrap <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. We included multiple taxa in parallel only qualitatively (since formal multiple-mediator models are complex); instead, we tested each mediator separately. In reporting results, we focus on taxa that met the significance threshold for mediation.</p><p id="Par23">All statistical tests were two-tailed, with an alpha level of 0.05 for significance (or FDR q&#8201;&lt;&#8201;0.05 for multiple comparisons, as noted). Analyses were primarily descriptive/exploratory given the novelty of this area; thus, we also report trends (p&#8201;&lt;&#8201;0.05) that align with hypotheses for completeness. Data analysis scripts and code for reproducing the results will be made available in a public repository upon publication.</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Participant characteristics and amyloid burden</title><p id="Par24">Relevant demographic and clinical characteristics of the studied cohort are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The mean age was 56.5&#8201;&#177;&#8201;8.3&#160;years (range 32&#8211;73), and 58% were female. By design, all participants were free of clinical dementia, and overall had low comorbidity burdens (e.g., 8.8% with a history of diabetes, 3.1% with cardiovascular disease). <italic toggle="yes">APOE</italic> genotyping was successfully performed for 219 of the 227 participants (96.5%); the distribution of <italic toggle="yes">APOE</italic> genotypes in our sample was: 0.5% &#949;2/&#949;2, 10.9% &#949;2/&#949;3, 62.6% &#949;3/&#949;3, 3.2% &#949;2/&#949;4, 21.0% &#949;3/&#949;4, and 1.8% &#949;4/&#949;4. For analytical purposes, we classified individuals as <italic toggle="yes">APOE</italic> &#949;4 carriers (those with at least one &#949;4 allele; n&#8201;=&#8201;57, 26%) or non-carriers (those with no &#949;4 allele; n&#8201;=&#8201;162, 74%), consistent with common practice in stratifying <italic toggle="yes">APOE</italic>-related risk groups.
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline characteristics of the study participants stratified by APOE &#949;4 status and summary of global/regional A&#946;-PET values</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">Overall (<italic toggle="yes">N</italic>&#8201;=&#8201;227)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, years</td><td align="left" colspan="1" rowspan="1">56.5&#8201;&#177;&#8201;8.3</td></tr><tr><td align="left" colspan="1" rowspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">131 (58)</td></tr><tr><td align="left" colspan="2" rowspan="1">Camera, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Discovery GE-smooth</td><td align="left" colspan="1" rowspan="1">66 (29)</td></tr><tr><td align="left" colspan="1" rowspan="1">HR&#8201;+&#8201;</td><td align="left" colspan="1" rowspan="1">161 (71)</td></tr><tr><td align="left" colspan="1" rowspan="1">Time interval between stool collection and PET amyloid scans, weeks, median [Q1, Q3]</td><td align="left" colspan="1" rowspan="1">110.0 [47.9, 239.6]</td></tr><tr><td align="left" colspan="2" rowspan="1">Cardiovascular risk factors</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Triglycerides, mg/dL</td><td align="left" colspan="1" rowspan="1">112.6&#8201;&#177;&#8201;77.2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Systolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">120&#8201;&#177;&#8201;13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Diastolic blood pressure, mmHg</td><td align="left" colspan="1" rowspan="1">76&#8201;&#177;&#8201;8</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Total cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">189.7&#8201;&#177;&#8201;34.5</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;HDL cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">61.4&#8201;&#177;&#8201;19.1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Treatment for hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">58 (25.55)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Stage I hypertension, n (%)</td><td align="left" colspan="1" rowspan="1">70 (30.84)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Prevalent of cardiovascular disease, n (%)</td><td align="left" colspan="1" rowspan="1">7 (3.08)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Current smoking, n (%)</td><td align="left" colspan="1" rowspan="1">9 (3.96)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;History of diabetes, n (%)</td><td align="left" colspan="1" rowspan="1">20 (8.81)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Body mass index, kg/m<sup>2</sup>, median [Q1, Q3]</td><td align="left" colspan="1" rowspan="1">27.5 [24.4, 30.6]</td></tr><tr><td align="left" colspan="2" rowspan="1">Global and regional A&#946;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Global A&#946;-PET</td><td align="left" colspan="1" rowspan="1">1.08&#8201;&#177;&#8201;0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the accumbens area</td><td align="left" colspan="1" rowspan="1">1.09&#8201;&#177;&#8201;0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the amygdala</td><td align="left" colspan="1" rowspan="1">1.11&#8201;&#177;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the cerebellum white matter</td><td align="left" colspan="1" rowspan="1">1.42&#8201;&#177;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the cerebral white matter</td><td align="left" colspan="1" rowspan="1">1.36&#8201;&#177;&#8201;0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the entorhinal cortex</td><td align="left" colspan="1" rowspan="1">0.97&#8201;&#177;&#8201;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the frontal pole</td><td align="left" colspan="1" rowspan="1">0.78&#8201;&#177;&#8201;0.18</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the hippocampus</td><td align="left" colspan="1" rowspan="1">1.13&#8201;&#177;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the inferior temporal cortex</td><td align="left" colspan="1" rowspan="1">1.03&#8201;&#177;&#8201;0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the insula cortex</td><td align="left" colspan="1" rowspan="1">1.13&#8201;&#177;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the parahippocampal cortex</td><td align="left" colspan="1" rowspan="1">1.01&#8201;&#177;&#8201;0.08</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the precuneus cortex</td><td align="left" colspan="1" rowspan="1">1.17&#8201;&#177;&#8201;0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;A&#946;-PET in the temporal pole</td><td align="left" colspan="1" rowspan="1">0.87&#8201;&#177;&#8201;0.07</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">APOE</italic>, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic>&#8201;=&#8201;219</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;2/&#949;2</td><td align="left" colspan="1" rowspan="1">1 (0.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;2/&#949;3</td><td align="left" colspan="1" rowspan="1">24 (10.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;3/&#949;3</td><td align="left" colspan="1" rowspan="1">137 (62.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;2/&#949;4</td><td align="left" colspan="1" rowspan="1">7 (3.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;3/&#949;4</td><td align="left" colspan="1" rowspan="1">46 (21.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;&#949;4/&#949;4</td><td align="left" colspan="1" rowspan="1">4 (1.8)</td></tr></tbody></table></table-wrap></p><p id="Par25">The global A&#946; PET SUVR ranged from&#8201;~&#8201;0.9 to 1.3 (mean&#8201;&#177;&#8201;SD &#8776; 1.08&#8201;&#177;&#8201;0.09) [<xref ref-type="bibr" rid="CR49">49</xref>]. Approximately 23% of participants had high A&#946; burden (above a typical positivity cut-off of&#8201;~&#8201;1.10 SUVR), consistent with the age range and inclusion of preclinical AD cases. Regional A&#946; PET values demonstrated the expected pattern of amyloid accumulation: highest retention in frontal and cingulate regions (e.g., frontal pole SUVR 0.78&#8201;&#177;&#8201;0.18; precuneus 1.17&#8201;&#177;&#8201;0.13; cingulate included in composite) and relatively lower in medial temporal regions (entorhinal cortex 0.97&#8201;&#177;&#8201;0.07) and the hippocampus (1.13&#8201;&#177;&#8201;0.08) which often have delayed amyloid involvement. Notably, white matter regions (cerebral and cerebellar white matter) showed higher PiB uptake (as they are used for off-target binding references). These values align with established regional patterns of amyloid deposition [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par26">Out of 219 genotyped individuals, 26% carried at least one <italic toggle="yes">APOE</italic> &#949;4 allele. By definition, <italic toggle="yes">APOE</italic> &#949;4 carriers are at elevated risk for AD; accordingly, they had slightly higher mean global A&#946; (1.11&#8201;&#177;&#8201;0.10) than non-carriers (1.07&#8201;&#177;&#8201;0.08), and a greater proportion of amyloid-positive cases (though many &#949;4 carriers were still amyloid-negative, given their middle age). <italic toggle="yes">APOE</italic> &#949;2 carriers (including &#949;2/&#949;2 and &#949;2/&#949;3) tended to have lower A&#946; levels, though numbers were small.</p><p id="Par27">Microbiome sequencing and processing were performed as described above. The relative abundance of the predominant genera in the stool samples, ranked from lowest to highest burden of global A&#946;, is shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. The minimum read was 13,549. Across all samples, we found a median sequencing depth of 67,389 (interquartile, 50,348&#8211;77,626) paired-end reads. A total of&#8201;~&#8201;5,118 ASVs, agglomerated into 14 phyla, 70 families, and more than 140 genera, were shared across depths. The predominant genera were <italic toggle="yes">Pseudobutyrivibrio</italic>, <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Prevotella</italic>, <italic toggle="yes">Cytophaga</italic>, <italic toggle="yes">Ruminococcus</italic>, and <italic toggle="yes">Alistipes</italic>. The processed data were used to assess the link between gut microbiome composition and A&#946; burden in the brain.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Taxonomic profiling from stool samples of FHS subjects. Stacked plot showing the microbiome profiles of predominant taxa in the stool samples of FHS individuals ordered from lowest to highest global A&#946; burden at the genus level</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Gut microbiome composition and global A&#946; burden (full sample analysis)</title><p id="Par28">We first examined the association between gut bacterial genera and global brain A&#946; burden in the full sample (N&#8201;=&#8201;227). Multivariable MaAsLin2 regression identified a set of microbial taxa significantly associated with global A&#946; PET, after adjusting for covariates and correcting for multiple tests. Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> summarizes the significant associations at the genus level with global A&#946; (and shows associations with regional A&#946; for those genera). Table <xref rid="Tab2" ref-type="table">2</xref> provides a full listing of all tested genera and their regression coefficients.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Heatmap of multivariable associations between gut microbiome (genera) and amyloid-&#946; PET burden in the full sample<italic toggle="yes">.</italic> Genera with BH-adjusted p&#8201;&lt;&#8201;0.05 are shown. Warmer colors (green) indicate a positive association (higher abundance with higher A&#946;), and cooler colors (blue) indicate a negative association (lower abundance with higher A&#946;). The first column is global A&#946;, followed by columns for regional A&#946; measures (Accumbens, Amygdala, etc.). Notably, SCFA-producing genera (<italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Pseudobutyrivibrio</italic>, <italic toggle="yes">Slackia</italic>) show negative associations (blue), while <italic toggle="yes">Alistipes</italic>, <italic toggle="yes">Bacteroides</italic>, and <italic toggle="yes">Barnesiella</italic> show positive (green)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig2_HTML.jpg"/></fig><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>List of bacteria that showed association with global A&#946; at the phylum (green), family (red), and genus (orange) levels. Multivariable association between global A&#946; and gut microbial diversity using the model described in the Methods section</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Bacteria</th><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">q</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Firmicutes</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.426</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td align="left" colspan="1" rowspan="1">1.804E-230</td><td align="left" colspan="1" rowspan="1">1.598E-228</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bacteroidetes</italic></td><td align="left" colspan="1" rowspan="1">0.378</td><td char="." align="char" colspan="1" rowspan="1">0.012</td><td align="left" colspan="1" rowspan="1">2.089E-221</td><td align="left" colspan="1" rowspan="1">1.789E-219</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Actinobacteria</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.319</td><td char="." align="char" colspan="1" rowspan="1">0.418</td><td align="left" colspan="1" rowspan="1">0.0016</td><td align="left" colspan="1" rowspan="1">0.0096</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Lachnospiraceae</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.426</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td align="left" colspan="1" rowspan="1">1.804E-230</td><td align="left" colspan="1" rowspan="1">1.598E-228</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Ruminococcaceae</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.248</td><td char="." align="char" colspan="1" rowspan="1">0.008</td><td align="left" colspan="1" rowspan="1">1.4565E-205</td><td align="left" colspan="1" rowspan="1">1.134E-203</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Rikenellaceae</italic></td><td align="left" colspan="1" rowspan="1">0.071</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">6.903E-132</td><td align="left" colspan="1" rowspan="1">2.463E-130</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Barnesiellaceae</italic></td><td align="left" colspan="1" rowspan="1">0.178</td><td char="." align="char" colspan="1" rowspan="1">0.009</td><td align="left" colspan="1" rowspan="1">5.682E-82</td><td align="left" colspan="1" rowspan="1">1.404E-80</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bacteroidaceae</italic></td><td align="left" colspan="1" rowspan="1">0.101</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">3.662E-11</td><td align="left" colspan="1" rowspan="1">3.290E-10</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Coriobacteriaceae</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.319</td><td char="." align="char" colspan="1" rowspan="1">0.418</td><td align="left" colspan="1" rowspan="1">0.0016</td><td align="left" colspan="1" rowspan="1">0.0096</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bifidobacteriaceae</italic></td><td align="left" colspan="1" rowspan="1">0.065</td><td char="." align="char" colspan="1" rowspan="1">0.024</td><td align="left" colspan="1" rowspan="1">0.0056</td><td align="left" colspan="1" rowspan="1">0.0314</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Pseudobutyrivibrio</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.426</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td align="left" colspan="1" rowspan="1">1.804E-230</td><td align="left" colspan="1" rowspan="1">1.598E-228</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Ruminococcus</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.248</td><td char="." align="char" colspan="1" rowspan="1">0.008</td><td align="left" colspan="1" rowspan="1">1.456E-205</td><td align="left" colspan="1" rowspan="1">1.134E-203</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Alistipes</italic></td><td align="left" colspan="1" rowspan="1">0.071</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1">6.904E-132</td><td align="left" colspan="1" rowspan="1">2.463E-130</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Barnesiella</italic></td><td align="left" colspan="1" rowspan="1">0.178</td><td char="." align="char" colspan="1" rowspan="1">0.009</td><td align="left" colspan="1" rowspan="1">5.682E-82</td><td align="left" colspan="1" rowspan="1">1.404E-80</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Faecalibacterium</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.352</td><td char="." align="char" colspan="1" rowspan="1">0.025</td><td align="left" colspan="1" rowspan="1">7.616E-45</td><td align="left" colspan="1" rowspan="1">1.304E-43</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Butyricicoccus</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.269</td><td char="." align="char" colspan="1" rowspan="1">0.024</td><td align="left" colspan="1" rowspan="1">9.231E-29</td><td align="left" colspan="1" rowspan="1">1.216E-27</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bacteroides</italic></td><td align="left" colspan="1" rowspan="1">0.101</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">3.663E-11</td><td align="left" colspan="1" rowspan="1">3.290E-10</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Slackia</italic></td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.319</td><td char="." align="char" colspan="1" rowspan="1">0.418</td><td align="left" colspan="1" rowspan="1">0.0016</td><td align="left" colspan="1" rowspan="1">0.0096</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Bifidobacterium</italic></td><td align="left" colspan="1" rowspan="1">0.065</td><td char="." align="char" colspan="1" rowspan="1">0.024</td><td align="left" colspan="1" rowspan="1">0.00568</td><td align="left" colspan="1" rowspan="1">0.031</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="6" rowspan="1">Gut microbiome diversity analysis</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Chao1</td><td align="left" colspan="1" rowspan="1">&#8722;5.520E-05</td><td char="." align="char" colspan="1" rowspan="1">9.480E-05</td><td align="left" colspan="1" rowspan="1">0.5610</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;ACE</td><td align="left" colspan="1" rowspan="1">&#8722;6.258E-05</td><td char="." align="char" colspan="1" rowspan="1">9.754E-05</td><td align="left" colspan="1" rowspan="1">0.5218</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Observed</td><td align="left" colspan="1" rowspan="1">&#8722;5.704E-05</td><td char="." align="char" colspan="1" rowspan="1">9.854E-05</td><td align="left" colspan="1" rowspan="1">0.5633</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Shannon</td><td align="left" colspan="1" rowspan="1">&#8722;7.866E-03</td><td char="." align="char" colspan="1" rowspan="1">1.007E-02</td><td align="left" colspan="1" rowspan="1">0.4355</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Pielou</td><td align="left" colspan="1" rowspan="1">&#8722;7.452E-02</td><td char="." align="char" colspan="1" rowspan="1">7.412E-02</td><td align="left" colspan="1" rowspan="1">0.3158</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Simpson</td><td align="left" colspan="1" rowspan="1">&#8722;9.704E-02</td><td char="." align="char" colspan="1" rowspan="1">9.690E-02</td><td align="left" colspan="1" rowspan="1">0.3177</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">227</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SE</italic> standard error, <italic toggle="yes">p</italic> nominal p value, <italic toggle="yes">q</italic> Benjamini&#8211;Hochberg adjusted p value (q value), <italic toggle="yes">N</italic> sample size</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Key findings (global A&#946; associations)</title><p id="Par29">Higher global A&#946; was associated with a lower relative abundance of several protective genera. In particular, genera in the family <italic toggle="yes">Ruminococcaceae</italic> were prominently implicated: <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Butyricicoccus</italic>, and <italic toggle="yes">Ruminococcus</italic> all showed significant negative associations with global A&#946; (&#946; [95%CI] &#8776; &#8722;0.35 [&#8722;0.40, &#8722;0.30], &#8722;0.27 [&#8722;0.32, &#8722;0.22]), &#8722;0.25 [&#8722;0.27, &#8722;0.23], respectively, all <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001). Indicating that a standard deviation unit (1-SDU) greater abundance of <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Butyricicoccus</italic>, and <italic toggle="yes">Ruminococcus</italic> was associated with a 0.35, 0.27, and 0.25 lower global A&#946; burden (by SDU), respectively (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). These bacteria are known to harbor anti-inflammatory properties in the gut and can produce SCFAs. Similarly, <italic toggle="yes">Pseudobutyrivibrio</italic> belonging to family <italic toggle="yes">Lachnospiraceae</italic> (another protective bacterium) was significantly reduced in those with higher A&#946; levels (&#8722;0.42 [&#8722;0.44, &#8722;0.39]), suggesting a 0.42 lower global A&#946; burden for an SDU increase in the abundance of <italic toggle="yes">Pseudobutyrivibrio</italic>). Another genus, <italic toggle="yes">Slackia</italic> (a member of the family <italic toggle="yes">Coriobacteriaceae</italic> that produces acetate), was also less abundant, with a greater A&#946; (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, blue cells indicating a negative correlation). The associations were strong, indicating an extremely robust relationship. These results suggest a pattern of SCFA depletion in the gut microbiomes of individuals with elevated brain amyloid. In these models, &#946; coefficients indicate the difference in the A&#946; burden measures (by SDU) associated with a 1-SDU higher or lower abundance of a specific bacterium.</p><p id="Par30">Conversely, higher global A&#946; was associated with an increased abundance of certain genera often considered opportunistic or pro-inflammatory. Notably, <italic toggle="yes">Alistipes</italic> (order <italic toggle="yes">Bacteroidales</italic>) and <italic toggle="yes">Bacteroides</italic> (family <italic toggle="yes">Bacteroidaceae</italic>) were positively associated with A&#946; burden (&#946; &#8776; 0.07, 0.10, <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.01). Both genera are Gram-negative and can produce endotoxins (lipopolysaccharides); <italic toggle="yes">Alistipes,</italic> in particular, has been linked to pro-inflammatory states. Additionally, <italic toggle="yes">Barnesiella</italic> (family <italic toggle="yes">Barnesiellaceae</italic>) was more abundant in those with higher A&#946; (<italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.001). Interestingly, <italic toggle="yes">Barnesiella</italic> is typically considered to have beneficial effects on gut health (e.g., it can protect against <italic toggle="yes">C. difficile</italic> infection), but in our data, it positively correlated with the amyloid burden. Finally, <italic toggle="yes">Bifidobacterium</italic> (a genus often considered beneficial and probiotic) showed a modest positive association with A&#946; (&#946; (SE) &#8776;&#8201;+&#8201;0.07 [0.02, 0.12], <italic toggle="yes">q</italic>&#8201;=&#8201;0.03). The <italic toggle="yes">Bifidobacterium</italic> finding was somewhat unexpected, as we anticipated it to be lower in high-A&#946; individuals; we revisit this in subgroup analyses. In summary, the global A&#946; burden was associated with a gut bacterial profile indicative of dysbiosis, characterized by a reduction in SCFA-producing, anti-inflammatory microbes and an enrichment of bacteria that could contribute to inflammation or thrive in inflammatory environments.</p><p id="Par31">At higher taxonomic levels, we observed analogous patterns (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). For instance, the family <italic toggle="yes">Ruminococcaceae</italic> (which includes <italic toggle="yes">Faecalibacterium</italic> and <italic toggle="yes">Ruminococcus</italic>) was found to be lower in participants with high-A&#946; globally, and the family <italic toggle="yes">Lachnospiraceae</italic> (which includes <italic toggle="yes">Butyricicoccus</italic> and <italic toggle="yes">Pseudobutyrivibrio</italic>) was also decreased, although the <italic toggle="yes">Lachnospiraceae</italic> family overall did not reach significance after correction. <italic toggle="yes">Coriobacteriaceae</italic> (family of <italic toggle="yes">Slackia</italic>) was negatively associated with A&#946;. On the other hand, the families <italic toggle="yes">Bacteroidaceae</italic>, <italic toggle="yes">Barnesiellaceae</italic>, and <italic toggle="yes">Rikenellaceae</italic> (the latter includes <italic toggle="yes">Alistipes</italic>) were positively associated with A&#946; (all <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.05). At the broad phylum level, we noted a trend that high-A&#946; subjects had a higher <italic toggle="yes">Bacteroidetes</italic>:<italic toggle="yes">Firmicutes</italic> ratio compared to low-A&#946; subjects. Phylum <italic toggle="yes">Bacteroidetes</italic> was relatively increased with greater A&#946;, whereas phylum <italic toggle="yes">Firmicutes</italic> (which encompasses most SCFA producers) was reduced (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). There was also an apparent lower proportion of <italic toggle="yes">Actinobacteria</italic> (which includes <italic toggle="yes">Bifidobacteria</italic>) in high-A&#946; individuals, although the <italic toggle="yes">Bifidobacterium</italic> genus itself was slightly higher, as noted (suggesting other <italic toggle="yes">Actinobacteria</italic> genera were lower). These broad patterns align with a pro-inflammatory microbiome state in individuals with higher amyloid levels.</p><p id="Par32">In addition, to evaluate whether gut microbiota diversity is associated with A&#946; loads, we conducted a multivariable linear regression analysis after controlling for the covariates indicated in the methods section. We found that the Shannon index (&#946; &#8776; &#8722;0.008, <italic toggle="yes">p</italic>&#8201;=&#8201;0.43) and Pielou evenness (&#946; &#8776; &#8722;0.074, <italic toggle="yes">p</italic>&#8201;=&#8201;0.31) showed negative relationships that were not statistically significant with A&#946; burden (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>); supporting the evidence that there is no significant difference in gut microbial diversity in individuals with higher A&#946; vs. lower A&#946; levels on average.</p></sec><sec id="Sec15"><title>Regional A&#946; associations mirror global trends</title><p id="Par33">To understand whether the global A&#946;&#8211;microbiome associations were driven by particular brain regions, we examined associations with regional A&#946; PET measures. We found that, in general, the same genera associated with global A&#946; were also associated with A&#946; in multiple individual regions (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> shows a heatmap across regions for each genus). For example, <italic toggle="yes">Ruminococcus</italic> was negatively associated not only with global A&#946; but also with A&#946; in the entorhinal cortex, amygdala, frontal pole, insular cortex, and temporal pole (all <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.01). This suggests that amyloid in those specific regions may be more susceptible to changes in gut microbial composition. <italic toggle="yes">Faecalibacterium</italic>&#8217;s negative association with global A&#946; was also observed with A&#946; in the nucleus accumbens area and precuneus, two regions known to show early amyloid deposition. <italic toggle="yes">Butyricicoccus</italic> was inversely associated with A&#946; in most regions, except for a few (the entorhinal, temporal pole, and frontal pole did not reach significance for <italic toggle="yes">Butyricicoccus</italic>, although the directions were consistent). <italic toggle="yes">Pseudobutyrivibrio</italic> showed a remarkably consistent negative association with A&#946; across many regions (particularly entorhinal, amygdala, and temporal pole). <italic toggle="yes">Slackia</italic> was negatively associated with A&#946; in the precuneus, insula, and temporal pole as well. On the &#8220;increased&#8221; side, <italic toggle="yes">Bacteroides</italic>&#8217; positive link with global A&#946; was reflected in its association with A&#946; in a broad set of regions: hippocampus, inferior temporal, amygdala, accumbens, frontal pole, parahippocampal, and temporal pole (all <italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.05). <italic toggle="yes">Barnesiella</italic>&#8217;s positive association was consistent across most regions, except for a few, where it was not significant (in the accumbens, frontal pole, amygdala, or cerebellar white matter). In sum, regional amyloid measures generally reinforced the global findings, indicating that the gut microbiome correlations are not driven by a single anomalous brain region but rather reflect a whole-brain amyloid load effect. Regions known to accumulate amyloid early (like precuneus, frontal cortex, and temporal cortex) showed particularly strong microbiome ties. To assess the degree of correlation between A&#946; loads in different brain regions and global A&#946;, we performed a Spearman correlation analysis. All the regional A&#946; burdens and global A&#946; exhibited significant positive correlation with correlation coefficients ranging between 0.24 and 0.75.</p><p id="Par34">These results bolster our confidence that the microbiome-A&#946; relationships are biologically meaningful. The consistency across brain regions and the coherence of the bacteria involved (mostly SCFA producers and a few prominent <italic toggle="yes">Bacteroidetes</italic> genera) suggest a scenario in which a higher brain amyloid burden is associated with deficient gut microbial production of beneficial metabolites and a relative overrepresentation of potentially pro-inflammatory microbes. This set the stage for exploring whether the <italic toggle="yes">APOE</italic> genotype influences these associations.</p></sec><sec id="Sec16"><title><italic toggle="yes">APOE</italic> genotype modifies the gut&#8211;A&#946; association patterns</title><p id="Par35">We next performed stratified analyses to determine how the presence or absence of the <italic toggle="yes">APOE &#949;4</italic> allele might alter the relationship between gut microbiome and amyloid burden. We separated participants into <italic toggle="yes">APOE</italic> &#949;4 non-carriers (N&#8201;=&#8201;162, with no &#949;4 allele) and <italic toggle="yes">APOE</italic> &#949;4 carriers (N&#8201;=&#8201;57, with at least one &#949;4 allele). While the limited sample size in the carrier group cautions against over-interpretation, several interesting patterns emerged.</p></sec><sec id="Sec17"><title>Gut microbiome and A&#946; in <italic toggle="yes">APOE</italic> &#949;4 non-carriers</title><p id="Par36">Even among individuals without <italic toggle="yes">APOE</italic> &#949;4, we observed that higher A&#946; levels were associated with a microbiome profile characterized by reduced SCFA-producing bacteria, a pattern similar to that observed in the full sample. Specifically, <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Ruminococcus</italic>, and <italic toggle="yes">Pseudobutyrivibrio</italic> were all significantly negatively associated with global A&#946; in APOE &#949;4 non-carriers (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). This suggests that the link between A&#946; deposition and depletion of these beneficial gut bacteria is a general phenomenon, not solely driven by <italic toggle="yes">APOE</italic> &#949;4. Additionally, in <italic toggle="yes">APOE</italic> &#949;4 non-carriers, <italic toggle="yes">Barnesiella</italic> and <italic toggle="yes">Bacteroides</italic> remained positively associated with global A&#946; (mirroring the full sample).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p><bold>A</bold> Gut microbiome&#8211;A&#946; associations in APOE &#949;4 non-carriers. Heatmap similar to Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, but for the subset of participants with no &#949;4 allele. The pattern is largely similar to the full sample (e.g., low <italic toggle="yes">Faecalibacterium</italic> with high A&#946;). <italic toggle="yes">Prevotella</italic> appears as an additional negatively associated genus in this subgroup. <bold>B</bold>
<italic toggle="yes">Gut microbiome&#8211;A&#946; associations in APOE &#949;4 carriers.</italic> Heatmap for participants with&#8201;&#8805;&#8201;1 &#949;4 allele. A broader array of associations is seen: in addition to those in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, <italic toggle="yes">Barnesiella</italic> and <italic toggle="yes">Clostridium</italic> are now negatively associated (blue) with A&#946;, and several additional genera (bottom rows) are positively associated (green). This indicates a more pronounced dysbiosis in APOE4 carriers with high A&#946;</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig3_HTML.jpg"/></fig></p><p id="Par37">However, there were a few notable differences in the non-carrier group relative to the full cohort. In <italic toggle="yes">APOE</italic> &#949;4 non-carriers, <italic toggle="yes">Bifidobacterium</italic> showed a negative association with A&#946; (opposite to the slight positive trend seen in the full sample). That is, non-carriers with high A&#946; had lower <italic toggle="yes">Bifidobacterium</italic> abundance, which aligns with expectations, since <italic toggle="yes">Bifidobacterium</italic> is generally beneficial. This discrepancy suggests that the small positive association we saw earlier for <italic toggle="yes">Bifidobacterium</italic> might have been driven by the <italic toggle="yes">APOE</italic> &#949;4 carrier subset. Indeed, we will see that in <italic toggle="yes">APOE</italic> &#949;4 carriers, <italic toggle="yes">Bifidobacterium</italic> was not significantly associated with A&#946; (and possibly trended positive, diluting the overall effect). Also, in <italic toggle="yes">APOE</italic> &#949;4 non-carriers, <italic toggle="yes">Prevotella</italic> (genus in family <italic toggle="yes">Prevotellaceae</italic>) emerged as significantly negatively associated with global A&#946; (<italic toggle="yes">q</italic>&#8201;&lt;&#8201;0.05), whereas in the full sample, <italic toggle="yes">Prevotella</italic> had shown no significant relationship. <italic toggle="yes">Prevotella</italic> is a fiber-degrading bacterium that can produce propionate; a lower <italic toggle="yes">Prevotella</italic> in high-A&#946; non-carriers could indicate another SCFA-related deficit. Meanwhile, <italic toggle="yes">Alistipes</italic> and <italic toggle="yes">Slackia</italic> were not significantly associated with A&#946; in non-carriers (though directions were consistent with the full sample). At the family level, the patterns for <italic toggle="yes">Ruminococcaceae</italic>, <italic toggle="yes">Lachnospiraceae</italic>, <italic toggle="yes">Coriobacteriaceae</italic>, <italic toggle="yes">Barnesiellaceae</italic>, and <italic toggle="yes">Bacteroidaceae</italic> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A) in non-carriers were largely the same as in the full cohort.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p><bold>A</bold> Gut microbiome&#8211;A&#946; associations in APOE &#949;4 non-carriers. Findings close to those reported in the full sample. <bold>B</bold> Gut microbiome&#8211;A&#946; associations in APOE &#949;4 carriers. Heatmap for participants with&#8201;&#8805;&#8201;1 &#949;4 allele. A broader array of associations is seen</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig4_HTML.jpg"/></fig></p><p id="Par38">In summary, <italic toggle="yes">APOE</italic> &#949;4 non-carriers exhibited the same core gut&#8211;A&#946; associations: lower levels of anti-inflammatory bacteria, higher <italic toggle="yes">levels of Bacteroides/Barnesiella, and</italic> higher A&#946;. They also showed that <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Prevotella</italic> (both generally health-associated genera) were inversely linked to A&#946; in this subgroup, a signal that might have been masked in the combined analysis. This consistency in non-carriers underscores that the gut microbiome&#8217;s relationship with amyloid is not contingent on <italic toggle="yes">APOE</italic> &#949;4 status; even without the high-risk allele, having a more &#8220;dysbiotic&#8221; microbiome correlates with greater amyloid deposition.</p></sec><sec id="Sec18"><title>Gut microbiome and A&#946; in APOE &#949;4 carriers</title><p id="Par39">We then assessed the associations in <italic toggle="yes">APOE</italic> &#949;4 carriers, who constitute the higher-risk group for AD. Notably, <italic toggle="yes">APOE</italic> &#949;4 carriers exhibited a more extensive array of significant microbiome associations with A&#946;, both in the direction observed in non-carriers and with some additional taxa not previously identified (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). This suggests that carrying an <italic toggle="yes">APOE</italic> &#949;4 allele may exacerbate the gut microbial changes associated with amyloid accumulation.</p><p id="Par40">In <italic toggle="yes">APOE</italic> &#949;4 carriers, greater global A&#946; was strongly associated with a lower abundance of SCFA-producing genera, including <italic toggle="yes">Faecalibacterium</italic> and <italic toggle="yes">Ruminococcus</italic> (again), but also lower <italic toggle="yes">Barnesiella</italic> and lower <italic toggle="yes">Clostridium</italic>. The finding that <italic toggle="yes">Barnesiella</italic> was decreased with high A&#946; in <italic toggle="yes">APOE</italic> &#949;4 carriers is especially noteworthy, because, in non-carriers (and overall), <italic toggle="yes">Barnesiella</italic> tended to increase with A&#946;. This indicates a potential genotype interaction: <italic toggle="yes">APOE</italic> &#949;4 carriers with high A&#946; levels lose <italic toggle="yes">Barnesiella</italic> (a generally beneficial commensal), whereas non-carriers with high A&#946; levels do not show this loss. <italic toggle="yes">Clostridium</italic> (sensu stricto, a core anaerobic genus with many butyrate-producing species) was also significantly lower in high-A&#946; <italic toggle="yes">APOE</italic> &#949;4 carriers but not significant in non-carriers. Additionally, <italic toggle="yes">Succinispira</italic> (a lesser-known genus that ferments succinate) was identified as reduced in high-A&#946; <italic toggle="yes">APOE</italic> &#949;4 carriers.</p><p id="Par41">On the other hand, APOE &#949;4 carriers with higher A&#946; showed increases in certain genera that were not as evident in non-carriers. <italic toggle="yes">Alistipes</italic> and <italic toggle="yes">Pseudobutyrivibrio</italic> remained positively associated with A&#946; (as before), and new associations emerged: <italic toggle="yes">Cytophaga</italic>, <italic toggle="yes">Anaerosinus</italic>, <italic toggle="yes">Catenibacterium</italic>, and <italic toggle="yes">Victivallis</italic> were all significantly more abundant with greater A&#946; in <italic toggle="yes">APOE</italic> &#949;4 carriers (these genera did not reach significance in non-carriers). Many of these are relatively uncommon gut genera; for instance, <italic toggle="yes">Catenibacterium</italic> and <italic toggle="yes">Anaerosinus</italic> are anaerobes whose roles are not well characterized, and <italic toggle="yes">Victivallis</italic> is a member of the phylum <italic toggle="yes">Lentisphaerae</italic>. Their increase might indicate a wider dysbiosis under <italic toggle="yes">APOE</italic> &#949;4 conditions, or perhaps these taxa fill niches when protective taxa dwindle.</p><p id="Par42">Moreover, at the family level, <italic toggle="yes">APOE</italic> &#949;4 carriers exhibited broader alterations: families <italic toggle="yes">Ruminococcaceae</italic>, <italic toggle="yes">Barnesiellaceae</italic>, <italic toggle="yes">Christensenellaceae</italic>, <italic toggle="yes">Peptostreptococcaceae</italic>, and <italic toggle="yes">Veillonellaceae</italic> were all significantly lower in abundance, with higher A&#946; levels (all <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Notably, <italic toggle="yes">Christensenellaceae</italic> is a family often associated with a healthy gut and metabolic benefits; its reduction in high-A&#946; <italic toggle="yes">APOE</italic> &#949;4 carriers is consistent with our narrative of protective taxa depletion. On the other hand, families, such as <italic toggle="yes">Rikenellaceae</italic>, <italic toggle="yes">Marinilabiliaceae</italic>, <italic toggle="yes">Erysipelotrichaceae</italic>, <italic toggle="yes">Lachnospiraceae</italic>, <italic toggle="yes">Bacillaceae</italic>, and <italic toggle="yes">Victivallaceae</italic>, exhibited higher abundance and greater A&#946; levels in <italic toggle="yes">APOE</italic> &#949;4 carriers (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>B). Several of these contain pro-inflammatory or less beneficial members. For example, <italic toggle="yes">Erysipelotrichaceae</italic> increases have been linked to metabolic syndrome and inflammation.</p><p id="Par43">In essence, <italic toggle="yes">APOE</italic> &#949;4 carriers displayed a more pronounced &#8220;<italic toggle="yes">amyloid-associated dysbiosis</italic>&#8221; than non-carriers. The same beneficial bacteria (<italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Ruminococcus</italic>, etc.) were depleted, but additionally, <italic toggle="yes">APOE</italic> &#949;4 carriers lost other beneficial taxa (<italic toggle="yes">Barnesiella</italic>, <italic toggle="yes">Christensenellaceae</italic>, etc.) and experienced a bloom of various minor genera. This suggests an interaction where <italic toggle="yes">APOE</italic> &#949;4 status might exacerbate gut microbial responses to (or drivers of) amyloid accumulation. It is intriguing that <italic toggle="yes">Barnesiella</italic> transitions from a positive association in non-carriers to a negative one in carriers, possibly indicating that <italic toggle="yes">APOE</italic> &#949;4 carriers cannot maintain <italic toggle="yes">Barnesiella</italic> in the face of mounting amyloid or inflammation, whereas non-carriers can (hence, non-carriers paradoxically showed an increase in <italic toggle="yes">Barnesiella</italic> with A&#946;, perhaps as a compensatory response). The lower <italic toggle="yes">Christensenellaceae</italic> in <italic toggle="yes">APOE</italic> &#949;4 carriers with high A&#946; is also of interest, given <italic toggle="yes">Christensenellaceae&#8217;s</italic> links to low inflammation and healthy metabolism have been previously reported.</p><p id="Par44">Taken together, our stratified analyses indicate that the gut microbiome&#8211;amyloid relationship exists irrespective of <italic toggle="yes">APOE</italic> genotype, but is broadened and intensified in <italic toggle="yes">APOE</italic> &#949;4 carriers. Even <italic toggle="yes">APOE</italic> &#949;2/&#949;3 individuals exhibit the core pattern of anti-inflammatory taxa loss with amyloid, whereas <italic toggle="yes">APOE</italic> &#949;4 carriers show this pattern, along with additional dysbiotic shifts. This raises the possibility that the <italic toggle="yes">APOE</italic> &#949;4 genotype may be associated with gut dysbiosis, which could promote AD pathology. To further investigate causality, we next examined whether the gut microbiome might mediate the effect of <italic toggle="yes">APOE</italic> &#949;4 on amyloid burden.</p></sec><sec id="Sec19"><title>Mediating role of the gut microbiome in APOE &#949;4-related A&#946; burden</title><p id="Par45">Finally, we conducted mediation analyses to determine whether certain gut bacteria significantly mediate the association between <italic toggle="yes">APOE</italic> &#949;4 carrier status and A&#946; burden. In our data, carrying an <italic toggle="yes">APOE</italic> &#949;4 allele was associated with higher amyloid burden (linear model &#946;&#8201;=&#8201;0.055, SE&#8201;=&#8201;0.013, <italic toggle="yes">p</italic>&#8201;=&#8201;5.6&#8201;&#215;&#8201;10<sup>&#8211;5</sup> after adjusting for age, sex, and BMI). This confirms the known deleterious effect of <italic toggle="yes">APOE</italic> &#949;4 on amyloid accumulation in our cohort. We then examined whether this effect might be transmitted via changes in the gut microbiome.</p><p id="Par46">Out of the set of candidates mediating taxa (those showing significant A&#946; associations in both <italic toggle="yes">APOE</italic> strata), we identified two gut microbial taxa that exhibited a significant indirect mediation effect: the genera <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, and <italic toggle="yes">Clostridium</italic>, as well as the family <italic toggle="yes">Christensenellaceae</italic> (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). These bacteria mediated a portion of 0.07%, 0.13%, 0.06%, and 0.11% of the <italic toggle="yes">APOE</italic> &#949;4&#8217;s effect on A&#946; (each with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), respectively. In both cases, the mediation followed a plausible biological direction: <italic toggle="yes">APOE</italic> &#949;4 carriers tended to have a lower abundance of <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic> (path a: genotype&#8201;&#8594;&#8201;microbiome), and lower levels of these microbes were in turn associated with higher A&#946; (path b: microbiome&#8201;&#8594;&#8201;amyloid), yielding a significant indirect effect of <italic toggle="yes">APOE</italic> &#949;4 via these microbes. In other words, part of the reason <italic toggle="yes">APOE</italic> &#949;4 carriers have more amyloid may be that <italic toggle="yes">APOE</italic> &#949;4 leads to a deficiency of these taxa, specifically SCFA-producing, inflammation-modulating bacteria. The reduction of these beneficial microbes could contribute to a pro-amyloid environment. The mediation analysis quantifies this: we estimated that a significant fraction of <italic toggle="yes">APOE</italic> &#949;4&#8217;s effect (on the order of 0.3&#8211;0.4%) on A&#946; burden was mediated by <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium,</italic> and <italic toggle="yes">Christensenellaceae</italic>, though these estimates have wide confidence intervals. While the mediating pathways exist (since indirect effect is statistically significant), the effects (strength of the indirect effect) appeared quite modest. One possible explanation is that each bacterium might account for a small portion of the link between <italic toggle="yes">APOE</italic> &#949;4 and amyloid-beta burden.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Mediation analysis of gut microbiome in the APOE&#8211;A&#946; relationship. <bold>A</bold> Indirect effect estimates for candidate mediating taxa. <italic toggle="yes">Ruminococcus</italic> and <italic toggle="yes">Christensenellaceae</italic> show significant mediation (indirect effect <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), meaning that they carry part of the APOE &#949;4&#8201;&#8594;&#8201;A&#946; effect. <bold>B&#8211;E</bold> Example mediation plots for <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic>, illustrating that APOE4 status is associated with lower abundance of these taxa, which in turn is associated with higher A&#946;. (* &#8211; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, ** &#8211; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, *** &#8211; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 for mediation effect). <bold>F</bold> Mediation plot for gut bacteria score, demonstrating the linear combination effect of <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Christensenellaceae</italic>, <italic toggle="yes">Butyricicoccus</italic>, and <italic toggle="yes">Clostridium</italic> in the association between APOE4 and A&#946; burden</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig5_HTML.jpg"/></fig></p><p id="Par47">The majority of tested bacteria showed non-significant mediation effects, and notably, most of those effects were negative in sign. A negative indirect effect here would mean that <italic toggle="yes">APOE</italic> &#949;4 decreases the bacterium, which in turn increases A&#946; (in the same direction as we observed for protective bacteria). Therefore, while not individually significant, the consistent negative direction across many SCFA producers suggests a general mediating trend: <italic toggle="yes">APOE</italic> &#949;4 likely drives a broad reduction in beneficial gut microbes, collectively contributing to higher amyloid levels, even if only a couple reach statistical significance individually. Hypothesizing that bacteria may act in concert and have a combined effect on A&#946; deposition, we sought to establish a model that encompasses all key bacteria related to A&#946; in our cohort. We built a gut bacteria score based on a linear combination of bacteria demonstrating <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 for the indirect effect. These bacteria include <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic>. Then, the model was constructed as follows: <inline-formula id="IEq1"><alternatives><tex-math id="d33e2615">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$gut bacteria score=\sum_{i=1}^{5}{\beta }_{i}*{bacteria}_{i}$$\end{document}</tex-math><mml:math id="d33e2620"><mml:mrow><mml:mi>g</mml:mi><mml:mi>u</mml:mi><mml:mi>t</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mo>&#8721;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>5</mml:mn></mml:msubsup><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="italic">bacteria</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="415_2025_13412_Article_IEq1.gif"/></alternatives></inline-formula>. The results also revealed the mediating role of gut microbiome, supporting the hypothesis that a colony of bacteria may act together in the association between <italic toggle="yes">APOE</italic> genotype and A&#946; burden (indirect effect&#8201;=&#8201;&#8722;0.006, 0.14% of <italic toggle="yes">APOE</italic>&#8217;s effect mediated by this gut bacteria score, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>F).</p></sec><sec id="Sec20"><title>Predicted functional profile of gut microbiome in relation to A&#946;</title><p id="Par48">Given that our microbiome data are based on 16S profiles, we utilized predictive metagenomic tools (PICRUSt2 via the ggpicrust R framework [<xref ref-type="bibr" rid="CR65">65</xref>]) to infer the functional capacity of the gut microbiome, specifically regarding SCFA metabolism. We identified KEGG orthologs (KOs) in microbial genomes that are involved in the synthesis of SCFAs and tested which of these predicted functions were associated with global A&#946; levels.</p><p id="Par49">From&#8201;~&#8201;10,473 KOs predicted by PICRUSt, we curated a list of 299 KOs that are functionally annotated as related to SCFA synthesis (covering pathways for acetate, propionate, butyrate, succinate, lactate, pyruvate fermentation, etc.). We then ran MaAsLin2 regression for each KO (similar to the taxon models) to determine if KO abundance was associated with global A&#946;, while adjusting for the same covariates. Results were visualized in a volcano plot (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref> and Table&#160;<xref rid="Tab3" ref-type="table">3</xref>) and summarized by pathway (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Volcano plot of associations between predicted microbial gene functions (KEGG orthologs) and global A&#946;. Each point is a KO (SCFA-related KOs in color). The x-axis is the regression coefficient (effect of high A&#946; on KO abundance), and the y-axis is &#8211;log10(<italic toggle="yes">p</italic> value). KOs to the left (negative direction) are lower in high-A&#946; individuals. Nine SCFA-related KOs (red diamonds) surpass the significance threshold (dashed line corresponds to FDR q&#8201;=&#8201;0.05), all with negative coefficients, meaning that they are significantly depleted with greater A&#946;. No SCFA-related KO appears on the right side as significantly increased. This suggests a targeted loss of SCFA production genes in the high-amyloid microbiome</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig6_HTML.jpg"/></fig><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>List of KEGG orthologues that showed significant association with global A&#946; burden</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">Description</th><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">q</italic></th><th align="left" colspan="1" rowspan="1">N</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">K18336</td><td align="left" colspan="1" rowspan="1">2,4-diketo-3-deoxy-L-fuconate hydrolase</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;1.347</td><td align="left" colspan="1" rowspan="1">0.284</td><td align="left" colspan="1" rowspan="1">2.038E-06</td><td align="left" colspan="1" rowspan="1">0.000419</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K01908">K01908</ext-link></td><td align="left" colspan="1" rowspan="1">propionyl-CoA synthetase (prpE)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.649</td><td align="left" colspan="1" rowspan="1">0.153</td><td align="left" colspan="1" rowspan="1">2.199E-05</td><td align="left" colspan="1" rowspan="1">0.003167</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K01578">K01578</ext-link></td><td align="left" colspan="1" rowspan="1">malonyl-CoA decarboxylase (MLYCD)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.726</td><td align="left" colspan="1" rowspan="1">0.206</td><td align="left" colspan="1" rowspan="1">0.00042</td><td align="left" colspan="1" rowspan="1">0.026402</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K00242">K00242</ext-link></td><td align="left" colspan="1" rowspan="1">succinate dehydrogenase subunit D (sdhD)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.442</td><td align="left" colspan="1" rowspan="1">0.129</td><td align="left" colspan="1" rowspan="1">0.00059</td><td align="left" colspan="1" rowspan="1">0.034114</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">K10764</td><td align="left" colspan="1" rowspan="1">homoserine O-acetyltransferase (metZ)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.509</td><td align="left" colspan="1" rowspan="1">0.152</td><td align="left" colspan="1" rowspan="1">0.00082</td><td align="left" colspan="1" rowspan="1">0.036576</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K00163">K00163</ext-link></td><td align="left" colspan="1" rowspan="1">alanine transaminase (avtA)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.363</td><td align="left" colspan="1" rowspan="1">0.116</td><td align="left" colspan="1" rowspan="1">0.00169</td><td align="left" colspan="1" rowspan="1">0.040186</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K00835">K00835</ext-link></td><td align="left" colspan="1" rowspan="1">pyruvate dehydrogenase E1 component (aceE)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.673</td><td align="left" colspan="1" rowspan="1">0.119</td><td align="left" colspan="1" rowspan="1">0.00168</td><td align="left" colspan="1" rowspan="1">0.042186</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="K01631">K01631</ext-link></td><td align="left" colspan="1" rowspan="1">3-dehydrogalactonate aldolase (dgoA)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.521</td><td align="left" colspan="1" rowspan="1">0.118</td><td align="left" colspan="1" rowspan="1">0.00173</td><td align="left" colspan="1" rowspan="1">0.045186</td><td align="left" colspan="1" rowspan="1">227</td></tr><tr><td align="left" colspan="1" rowspan="1">K06718</td><td align="left" colspan="1" rowspan="1">ectoine synthase (ectA)</td><td align="left" colspan="1" rowspan="1">&#8722;&#160;0.892</td><td align="left" colspan="1" rowspan="1">0.130</td><td align="left" colspan="1" rowspan="1">0.00262</td><td align="left" colspan="1" rowspan="1">0.048180</td><td align="left" colspan="1" rowspan="1">227</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SE</italic> standard error, <italic toggle="yes">p</italic> nominal p-value, <italic toggle="yes">q</italic> Benjamini&#8211;Hochberg adjusted p value (q value), <italic toggle="yes">N</italic> sample size</p></table-wrap-foot></table-wrap><fig id="Fig7" position="float" orientation="portrait"><label>Fig.&#160;7</label><caption><p>Predicted functional potential of gut microbiome related to SCFA metabolism. Bar charts showing the distribution of 299 SCFA-related KEGG orthologs (KOs) across major metabolic pathways (acetate, butyrate, propionate, succinate, etc.). Highlighted in red are pathways where multiple KOs were significantly less abundant in high-A&#946; individuals. For example, several enzymes in the pyruvate&#8201;&#8594;&#8201;acetyl-CoA&#8201;&#8594;&#8201;butyrate pathway and in the propionate fermentation pathway were under-represented with higher A&#946;, indicating a systemic reduction in SCFA biosynthetic capacity</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="415_2025_13412_Fig7_HTML.jpg"/></fig></p><p id="Par50">We found nine SCFA-related microbial genes (KOs) that were significantly less abundant in individuals with higher global A&#946; burden (BH-adjusted <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 for each; no KO was higher with high A&#946; after FDR correction). These nine KOs correspond to enzymes in various metabolic pathways, largely consistent with reduced SCFA production potential in high-A&#946; microbiomes.</p><p id="Par51">All these KOs were significantly under-represented in the gut microbiomes of participants with higher A&#946; (with effect sizes indicating&#8201;~&#8201;20&#8211;30% lower abundance per unit increase in A&#946; SUVR, on average). No SCFA-related KO was found at higher levels in high-A&#946; individuals, suggesting a global functional deficit in SCFA production capacity. Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref> (volcano plot) highlights these nine KOs among the many tested (with most KOs showing no association, as expected under null). Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref> provides a more intuitive overview: it shows the distribution of all SCFA-related KOs across major SCFA pathways (pyruvate to acetate, succinate to propionate, etc.), illustrating that the pathways for pyruvate/acetyl-CoA conversion, propionate biosynthesis, and succinate utilization had multiple KOs significantly depleted with high A&#946;.</p><p id="Par52">In practical terms, these functional predictions align with our taxonomic findings. For instance, the reduction in <italic toggle="yes">Ruminococcaceae</italic> and <italic toggle="yes">Lachnospiraceae</italic> (butyrate producers) in high-A&#946; subjects is reflected by lower gene abundance in pyruvate to butyrate conversion (e.g., pyruvate dehydrogenase, which feeds acetyl-CoA for butyrate synthesis, was lower). Similarly, lower <italic toggle="yes">Prevotellaceae</italic> and other propionate producers correspond with lower propionyl-CoA synthetase. Although these predictions need validation with shotgun metagenomics or metabolite profiling, they provide supporting evidence that microbial metabolic functions related to SCFA production are suppressed in individuals with greater amyloid burden.</p><p id="Par53">To sum up, the functional inference suggests that the gut microbiomes of high-amyloid individuals are not only taxonomically shifted but also functionally impaired in producing neuroprotective metabolites, such as butyrate and propionate. This could result in lower circulating SCFA levels reaching the brain, potentially weakening beneficial effects such as maintenance of the blood&#8211;brain barrier and suppression of neuroinflammation. It strengthens the case that SCFA depletion is a mechanism by which gut dysbiosis might influence AD pathology.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par54">Our study reveals a new connection between host genetic variation (specifically, <italic toggle="yes">APOE</italic> genotype) and the gut microbiome, which is associated with A&#946; deposits&#8212;a key feature of Alzheimer&#8217;s disease. Using a well-phenotyped cohort from the Framingham Heart Study, we found that individuals with higher brain amyloid-&#946; levels have a distinct gut microbiome, characterized by a deficiency in bacteria that provide protective benefits and are known to produce short-chain fatty acids (SCFAs). This microbiome profile is also associated with the <italic toggle="yes">APOE</italic> genotype. To our knowledge, only a handful of human studies have shown a direct link between <italic toggle="yes">APOE</italic> status, the gut microbiome, and brain amyloid deposition. These findings shed light on the gut&#8211;brain axis as a potential mediator of genetic risk for AD and suggest that modulating the gut microbiota could be a novel avenue for mitigating <italic toggle="yes">APOE</italic>-related AD risk.</p><p id="Par55">We found that higher global A&#946; load was associated with a decrease in SCFA-producing gut bacteria, most notably members of the <italic toggle="yes">Ruminococcaceae</italic> family (<italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Faecalibacterium</italic>) and some <italic toggle="yes">Lachnospiraceae</italic> (e.g., <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Pseudobutyrivibrio</italic>). Many of these genera play a major role in protecting the colon. This microbiome signature, which can be viewed as a loss of &#8220;good&#8221; commensals, is important, because SCFA-producing bacteria are key microbes with anti-inflammatory and neuroprotective effects. The loss of protective taxa we observe in high-amyloid individuals is consistent with a pro-inflammatory gut environment. Indeed, depletion of <italic toggle="yes">Ruminococcaceae</italic> has been causally linked to inflammatory responses in prior studies [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. For example, <italic toggle="yes">Faecalibacterium prausnitzii</italic> (a <italic toggle="yes">Ruminococcaceae</italic> member) is known to produce butyrate and anti-inflammatory molecules; its absence can lead to gut inflammation [<xref ref-type="bibr" rid="CR68">68</xref>&#8211;<xref ref-type="bibr" rid="CR70">70</xref>]. Our findings align with the growing evidence that gut dysbiosis, characterized by deficits in protective microbes, can contribute to systemic inflammation, which may, in turn, affect the brain [<xref ref-type="bibr" rid="CR71">71</xref>&#8211;<xref ref-type="bibr" rid="CR73">73</xref>]. The concurrent reduction of <italic toggle="yes">Lachnospiraceae</italic> (reflected by lower <italic toggle="yes">Pseudobutyrivibrio</italic>) and increase in <italic toggle="yes">Bacteroides</italic> and <italic toggle="yes">Barnesiella</italic> we observed fit the pattern of a dysbiotic microbiota in AD, as reported in prior studies [<xref ref-type="bibr" rid="CR74">74</xref>&#8211;<xref ref-type="bibr" rid="CR76">76</xref>]. In fact, <italic toggle="yes">Bacteroides</italic> genus includes species that produce endotoxins and have been linked to neuroinflammation; its relative overgrowth may further exacerbate inflammatory tone.</p><p id="Par56">Crucially, when we stratified by <italic toggle="yes">APOE</italic> genotype, we found that even <italic toggle="yes">APOE</italic> &#949;4 non-carriers (who have lower genetic AD risk) showed the core gut-amyloid relationship: higher A&#946; linked to lower SCFA bacteria. This suggests that the gut microbiome&#8217;s association with amyloid is a general phenomenon not entirely dependent on <italic toggle="yes">APOE</italic>. However, in <italic toggle="yes">APOE</italic> &#949;4 carriers, the gut&#8211;A&#946; associations were <italic toggle="yes">more extensive</italic>, with an even greater loss of beneficial microbes (e.g., <italic toggle="yes">Clostridium</italic>, <italic toggle="yes">Barnesiella</italic>, and <italic toggle="yes">Christensenellaceae</italic> were significantly implicated only in &#949;4 carriers). Notably, we observed in &#949;4 carriers that <italic toggle="yes">Barnesiella</italic> and <italic toggle="yes">Clostridium</italic> were depleted with high A&#946;, whereas in non-carriers, <italic toggle="yes">Barnesiella</italic> was not depleted. This aligns with a recent study by Tran et al<italic toggle="yes">.,</italic> which reported that <italic toggle="yes">APOE</italic> &#949;4 carriers (both humans and mice) had reduced levels of certain SCFA-producing taxa compared to non-carriers [<xref ref-type="bibr" rid="CR9">9</xref>]. Our data extend this by showing that <italic toggle="yes">APOE</italic> &#949;4 carriers with a heavy amyloid burden exhibit the most pronounced gut dysbiosis, suggesting that <italic toggle="yes">APOE</italic> &#949;4 and amyloid pathology may synergistically disrupt the microbiome. This supports the hypothesis that these SCFA-producing bacteria may contribute to the protective effect observed in <italic toggle="yes">APOE</italic> &#949;2 and <italic toggle="yes">APOE</italic> &#949;3 genotypes. In other words, <italic toggle="yes">APOE</italic> &#949;2/&#949;3 individuals might maintain a healthier microbiome (richer in taxa having anti-inflammatory properties), which could help limit amyloid or its consequences, whereas <italic toggle="yes">APOE</italic> &#949;4 individuals may lack this microbiome-mediated protection.</p><p id="Par57">Our mediation analysis further strengthens the argument that the gut microbiome is not just correlated with, but potentially causally involved in, the <italic toggle="yes">APOE</italic>&#8211;amyloid link. We identified <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic> as significant mediators of the <italic toggle="yes">APOE</italic> &#949;4 effect on A&#946; burden. These taxa are known for beneficial roles: <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, and <italic toggle="yes">Clostridium</italic> include fiber fermenters that produce SCFAs, and <italic toggle="yes">Christensenellaceae</italic> are associated with low inflammation and healthy metabolic profiles. The mediation suggests that <italic toggle="yes">APOE</italic> &#949;4&#8217;s association with higher brain amyloid burden is partly <italic toggle="yes">through</italic> its effect on lowering these microbes. To put it another way, if we could somehow restore <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Christensenellaceae</italic> in <italic toggle="yes">APOE</italic> &#949;4 carriers, we might attenuate some of <italic toggle="yes">APOE</italic> &#949;4&#8217;s pro-amyloid impact. This dovetails with literature highlighting the importance of protective microbes in maintaining the integrity of the blood&#8211;brain barrier (BBB) and regulating neuroinflammation [<xref ref-type="bibr" rid="CR77">77</xref>]. Anti-inflammatory bacteria, such as those producing SCFAs, can promote tight junction expression and reduce peripheral inflammation, thereby helping to protect the brain [<xref ref-type="bibr" rid="CR77">77</xref>]. Thus, the proposed mechanism linking <italic toggle="yes">APOE</italic> &#949;4 to amyloid accumulation likely involves SCFA-related pathways: <italic toggle="yes">APOE</italic> &#949;4 leads to a less favorable gut microbiome (perhaps due to <italic toggle="yes">APOE</italic> &#949;4-driven immunometabolic differences in the host gut environment), this microbiome produces fewer SCFAs, and the lack of SCFAs leads to a weakened BBB and more systemic inflammation, facilitating A&#946; deposition and aggregation in the brain. Our findings provide empirical support for this mechanistic (often observed in mice [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]) model in humans.</p><p id="Par58">The predictive functional analysis of the microbiome corroborated these ideas by showing a decrease in genes related to SCFA biosynthesis in high-amyloid individuals. Functions for producing acetate, butyrate, and propionate were all significantly down-represented. This adds a layer of evidence that it is not just the names of bacteria that differ&#8212;the metabolic output of the microbiome is likely altered in a way that could impact the host. Lower abundance of key microbial enzymes like pyruvate dehydrogenase and propionyl-CoA synthetase in the gut suggests that less SCFA is being made available. SCFAs have been shown to modulate microglial activation and astrocyte function in the brain; deficiency in SCFAs might tilt microglia toward a pro-inflammatory, less amyloid-clearing phenotype [<xref ref-type="bibr" rid="CR78">78</xref>]. Therefore, our results integrate well with the emerging paradigm that microbial metabolites are crucial intermediaries in the gut&#8211;brain axis influencing AD [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par59">From a broader perspective, our study highlights a few important points for the field of AD research and neurogastroenterology:<list list-type="bullet"><list-item><p id="Par60"><italic toggle="yes">Host&#8211;microbiome interactions in AD</italic>: we provide evidence that host genotype (<italic toggle="yes">APOE</italic>) and gut microbes interact to influence disease-related pathology. This underscores that AD risk is not purely intrinsic to the brain or genes; it may be modulated by potentially modifiable factors, such as the microbiome. <italic toggle="yes">APOE</italic> &#949;4 has long been seen as a &#8220;non-modifiable&#8221; risk factor, but if part of <italic toggle="yes">APOE</italic> &#949;4&#8217;s effect is microbiome-mediated, it opens the door to modifying the downstream consequences of <italic toggle="yes">APOE</italic> &#949;4 via diet, probiotics, or other microbiota-directed interventions.</p></list-item><list-item><p id="Par61"><italic toggle="yes">Consistency with previous literature</italic>: our findings of reduced <italic toggle="yes">Faecalibacterium</italic> and <italic toggle="yes">Ruminococcaceae</italic> in association with AD biomarkers align with prior human studies, which have shown that these taxa are reduced in AD patients and in amyloid-positive cognitively impaired individuals [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. We also saw increased <italic toggle="yes">Alistipes</italic> and <italic toggle="yes">Bacteroides</italic> with amyloid, which has been reported (e.g., <italic toggle="yes">Cattaneo </italic>et al<italic toggle="yes">.</italic> found that pro-inflammatory genera including some <italic toggle="yes">Bacteroidetes</italic> were higher with brain amyloid) [<xref ref-type="bibr" rid="CR24">24</xref>]. The uniqueness here is linking it specifically to <italic toggle="yes">APOE</italic> groups and mediation.</p></list-item><list-item><p id="Par62"><italic toggle="yes">limitations</italic>: we acknowledge several limitations. First, the cross-sectional design precludes definitive causal conclusions. While mediation analysis and biological plausibility suggest a causal chain, longitudinal studies are needed to confirm that microbiome changes precede and contribute to amyloid accumulation (there is some evidence from mouse models and one study in humans that gut changes can precede amyloid [<xref ref-type="bibr" rid="CR81">81</xref>]. Second, our study design cannot demonstrate whether modifying gut microbiome might directly change the burden of A&#946; in the brain in an individual. Third, our microbiome data are based on 16S rRNA gene sequencing, which has limited taxonomic resolution and only infers function. Future studies should employ metagenomic shotgun sequencing and metabolomic profiling to directly measure microbial enzymes and metabolites (such as SCFAs and lipopolysaccharide) in <italic toggle="yes">APOE</italic>-stratified groups. Fourth, the cohort, while large for a PET study (n&#8201;=&#8201;227), is relatively healthy and mostly middle-aged; as such, results may differ in older, more clinically impaired populations. The generalizability to other ethnic groups or to those with advanced AD remains to be tested. Nonetheless, the FHS sample is community-dwelling and not enriched for AD, which is a strength in observing preclinical changes. Fifth, dietary factors and medication use were not extensively accounted for in this study; diet and medication have a strong influence on the microbiome and could confound the associations. However, one advantage is that all participants are from the same study site with similar regional diets, and we adjusted for BMI, which partially captures diet/lifestyle.</p></list-item></list></p><p id="Par63">Despite these limitations, our study has several strengths, including the relatively large sample with both high-quality microbiome and PET imaging data, the use of robust statistical tools with multiple comparison correction, and replication of known microbiome&#8211;AD associations, which adds credibility to our novel findings about <italic toggle="yes">APOE</italic> interactions.</p></sec><sec id="Sec22"><title>Conclusion</title><p id="Par64">This work provides compelling evidence of a link between <italic toggle="yes">APOE</italic> genotype, gut microbiome composition, and cerebral amyloid-&#946; deposition. We discovered that <italic toggle="yes">APOE</italic> &#949;4-associated risk for AD may be partly mediated by perturbations in the gut microbiota, notably a deficiency in SCFA-producing bacteria that correlates with greater amyloid burden. These findings underscore a previously unappreciated connection between a major genetic risk factor for AD and modifiable microbial and metabolic pathways. The gut microbiome thus emerges as a key player in the complex network connecting <italic toggle="yes">APOE</italic> genotype to AD neuropathology.</p><p id="Par65">Our results emphasize a possible role for gut-derived metabolites (like SCFAs) in protecting against amyloid-beta accumulation and suggest that <italic toggle="yes">APOE</italic> &#949;4 disrupts this protective link. This opens avenues for novel interventions: targeting gut bacteria that produce neuroprotective metabolites could potentially buffer the impact of <italic toggle="yes">APOE</italic> &#949;4 on the brain. Future studies should prioritize longitudinal designs and metagenomic analyses to validate these mediating relationships and to explore causality. If confirmed, manipulating the gut microbiome (through diet, probiotics, or fecal microbiota transplantation) may become a viable strategy for AD prevention, particularly in high-risk individuals. In conclusion, our study reveals a new facet of the gut&#8211;brain axis in Alzheimer&#8217;s disease, highlighting the gut microbiota as a potential therapeutic target at the intersection of genetics and neurodegeneration.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank Dr. Ramnik Xavier from the Broad Institute of MIT and Harvard, and the Center for Microbiome Informatics and Therapeutics (Massachusetts Institute of Technology, Cambridge, MA, USA) for providing access to the FHS microbiome data. The authors also thank Drs. Stanley Y Shaw, Charles De Carli, Keith Johnson, and Georges El Fakhri from the Broad Institute of MIT and Harvard.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>B.F. conceived the study. J.J.H., C.L.S., S.S., R.S.V., and A.B. provided access to the data. Y.N.W. performed all statistical analyses. Y.N.W. and B.F. wrote the manuscript. All authors discussed the results, provided feedback during the writing process, and commented on the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded in part by the UT Health San Antonio Center for Biomedical Neuroscience (CBN) and Grants from the NIA (<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG059421">AG059421</ext-link></underline>,&#160;<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG054076">AG054076</ext-link></underline>,&#160;<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG049607">AG049607</ext-link></underline>,&#160;<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG033090">AG033090</ext-link></underline>,&#160;<underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AG066524">AG066524</ext-link></underline>, P30 AG066546, 5P30AG059305-03, RF1 AG061729A1, 5U01AG052409-04, UG3AG090675) and NINDS (NS017950, UF1NS125513, K01NS126489). In addition, Drs. Fongang, Seshadri, Satizabal, and Himali are partially supported by the South Texas Alzheimer&#8217;s Disease Research Center (P30AG066546). Drs. Seshadri and Himali receive support from The Bill and Rebecca Reed Endowment for Precision Therapies and Palliative Care. Dr. Himali is supported by an endowment from the William Castella family as William Castella Distinguished University Chair for Alzheimer&#8217;s Disease Research, and Dr. Seshadri by an endowment from the Barker Foundation as the Robert R Barker Distinguished University Professor of Neurology, Psychiatry and Cellular and Integrative Physiology.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data supporting the findings of this study are publicly accessible through dbGap (Study ID: phs000007.v32.p13,&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v32.p13">https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v32.p13</ext-link>).</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par66">The authors declare no competing interests.</p><p id="Par67">
<bold>Ethical approval and patient consent.</bold>
</p><p id="Par68">This study was approved by the Institutional Review Boards of Boston University Medical Center and Massachusetts General Hospital. Written informed consent was obtained from participants.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X-Q</given-names></name><name name-style="western"><surname>Mobley</surname><given-names>WC</given-names></name></person-group><article-title>Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A&#946; and tau species</article-title><source>Front Neurosci</source><year>2019</year><volume>13</volume><fpage>659</fpage><pub-id pub-id-type="doi">10.3389/fnins.2019.00659</pub-id><pub-id pub-id-type="pmid">31293377</pub-id><pub-id pub-id-type="pmcid">PMC6598402</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Chen X-Q, Mobley WC (2019) Alzheimer disease pathogenesis: insights from molecular and cellular biology studies of oligomeric A&#946; and tau species. Front Neurosci 13:659<pub-id pub-id-type="pmid">31293377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2019.00659</pub-id><pub-id pub-id-type="pmcid">PMC6598402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><article-title>Neuropathology of the Alzheimer&#8217;s continuum: an update</article-title><source>Free neuropathology</source><year>2020</year><pub-id pub-id-type="doi">10.17879/freeneuropathology-2020-3050</pub-id><pub-id pub-id-type="pmid">37283686</pub-id><pub-id pub-id-type="pmcid">PMC10209886</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jellinger KA (2020) Neuropathology of the Alzheimer&#8217;s continuum: an update. Free neuropathology. 10.17879/freeneuropathology-2020-3050<pub-id pub-id-type="pmid">37283686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17879/freeneuropathology-2020-3050</pub-id><pub-id pub-id-type="pmcid">PMC10209886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogels</surname><given-names>T</given-names></name></person-group><article-title>Propagation of tau pathology: integrating insights from postmortem and in vivo studies</article-title><source>Biol Psychiatry</source><year>2020</year><volume>87</volume><issue>9</issue><fpage>808</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2019.09.019</pub-id><pub-id pub-id-type="pmid">31735253</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Vogels T (2020) Propagation of tau pathology: integrating insights from postmortem and in vivo studies. Biol Psychiatry 87(9):808&#8211;818<pub-id pub-id-type="pmid">31735253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2019.09.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><etal/></person-group><article-title>Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><issue>11</issue><fpage>2381</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02049-x</pub-id><pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ossenkoppele R et al (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 28(11):2381&#8211;2387<pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02049-x</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afzaal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human gut microbiota in health and disease: unveiling the relationship</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>999001</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.999001</pub-id><pub-id pub-id-type="pmid">36225386</pub-id><pub-id pub-id-type="pmcid">PMC9549250</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Afzaal M et al (2022) Human gut microbiota in health and disease: unveiling the relationship. Front Microbiol 13:999001<pub-id pub-id-type="pmid">36225386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2022.999001</pub-id><pub-id pub-id-type="pmcid">PMC9549250</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekirov</surname><given-names>I</given-names></name></person-group><article-title>Gut microbiota in health and disease</article-title><source>Physiol Rev</source><year>2010</year><pub-id pub-id-type="doi">10.1152/physrev.00045.2009</pub-id><pub-id pub-id-type="pmid">20664075</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sekirov I (2010) Gut microbiota in health and disease. Physiol Rev. 10.1152/physrev.00045.2009<pub-id pub-id-type="pmid">20664075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00045.2009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>O</given-names></name></person-group><article-title>Gut microbiota in human metabolic health and disease</article-title><source>Nat Rev Microbiol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0433-9</pub-id><pub-id pub-id-type="pmid">32887946</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Fan Y, Pedersen O (2021) Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 19(1):55&#8211;71<pub-id pub-id-type="pmid">32887946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-0433-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boulang&#233;</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Impact of the gut microbiota on inflammation, obesity, and metabolic disease</article-title><source>Genome Med</source><year>2016</year><volume>8</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s13073-016-0303-2</pub-id><pub-id pub-id-type="pmid">27098727</pub-id><pub-id pub-id-type="pmcid">PMC4839080</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Boulang&#233; CL et al (2016) Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 8:1&#8211;12<pub-id pub-id-type="pmid">27098727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-016-0303-2</pub-id><pub-id pub-id-type="pmcid">PMC4839080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>TT</given-names></name><etal/></person-group><article-title>APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer&#8217;s disease pathophysiology</article-title><source>FASEB J</source><year>2019</year><volume>33</volume><issue>7</issue><fpage>8221</fpage><pub-id pub-id-type="doi">10.1096/fj.201900071R</pub-id><pub-id pub-id-type="pmid">30958695</pub-id><pub-id pub-id-type="pmcid">PMC6593891</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tran TT et al (2019) APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer&#8217;s disease pathophysiology. FASEB J 33(7):8221<pub-id pub-id-type="pmid">30958695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1096/fj.201900071R</pub-id><pub-id pub-id-type="pmcid">PMC6593891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">LH, M., S. HL, and M. SK, The gut microbiota-brain axis in behaviour and brain disorders. Nature reviews. Microbiology, 2021. <bold>19</bold>(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-00460-0</pub-id><pub-id pub-id-type="pmid">33093662</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">HX, W. and W. YP, Gut Microbiota-brain Axis. Chinese medical journal, 2016. <bold>129</bold>(19).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0366-6999.190667</pub-id><pub-id pub-id-type="pmcid">PMC5040025</pub-id><pub-id pub-id-type="pmid">27647198</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">AI, P., et al., Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical therapeutics, 2015. <bold>37</bold>(5).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2015.04.002</pub-id><pub-id pub-id-type="pmcid">PMC4458706</pub-id><pub-id pub-id-type="pmid">26046241</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhammad</surname><given-names>JA</given-names></name></person-group><article-title>Poor cognition is associated with increased abundance of <italic toggle="yes">Alistipes</italic> and decreased abundance of <italic toggle="yes">Clostridium</italic> genera in the gut</article-title><source>Alzheimers Dement</source><year>2023</year><volume>19</volume><fpage>e076520</fpage><pub-id pub-id-type="doi">10.1002/alz.076520</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Muhammad JA (2023) Poor cognition is associated with increased abundance of <italic toggle="yes">Alistipes</italic> and decreased abundance of <italic toggle="yes">Clostridium</italic> genera in the gut. Alzheimers Dement 19:e076520</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Askarova</surname><given-names>S</given-names></name><etal/></person-group><article-title>The links between the gut microbiome, aging, modern lifestyle and Alzheimer&#8217;s disease</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00104</pub-id><pub-id pub-id-type="pmid">32257964</pub-id><pub-id pub-id-type="pmcid">PMC7093326</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Askarova S et al (2020) The links between the gut microbiome, aging, modern lifestyle and Alzheimer&#8217;s disease. Front Cell Infect Microbiol 10:104<pub-id pub-id-type="pmid">32257964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00104</pub-id><pub-id pub-id-type="pmcid">PMC7093326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huttenhower</surname><given-names>C</given-names></name><etal/></person-group><article-title>Structure, function and diversity of the healthy human microbiome</article-title><source>Nature</source><year>2012</year><volume>486</volume><issue>7402</issue><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/nature11234</pub-id><pub-id pub-id-type="pmid">22699609</pub-id><pub-id pub-id-type="pmcid">PMC3564958</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Huttenhower C et al (2012) Structure, function and diversity of the healthy human microbiome. Nature 486(7402):207&#8211;214<pub-id pub-id-type="pmid">22699609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11234</pub-id><pub-id pub-id-type="pmcid">PMC3564958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Structure, function and diversity of the healthy human microbiome. Nature, 2012. <bold>486</bold>(7402): 207&#8211;14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11234</pub-id><pub-id pub-id-type="pmcid">PMC3564958</pub-id><pub-id pub-id-type="pmid">22699609</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowalski</surname><given-names>K</given-names></name><name name-style="western"><surname>Mulak</surname><given-names>A</given-names></name></person-group><article-title>Brain-gut-microbiota axis in Alzheimer&#8217;s disease</article-title><source>J Neurogastroenterol Motil</source><year>2019</year><volume>25</volume><issue>1</issue><fpage>48</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.5056/jnm18087</pub-id><pub-id pub-id-type="pmid">30646475</pub-id><pub-id pub-id-type="pmcid">PMC6326209</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Kowalski K, Mulak A (2019) Brain-gut-microbiota axis in Alzheimer&#8217;s disease. J Neurogastroenterol Motil 25(1):48&#8211;60<pub-id pub-id-type="pmid">30646475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5056/jnm18087</pub-id><pub-id pub-id-type="pmcid">PMC6326209</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Investigating the biological and clinical significance of human dysbioses</article-title><source>Trends Microbiol</source><year>2011</year><volume>19</volume><issue>9</issue><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2011.06.005</pub-id><pub-id pub-id-type="pmid">21775143</pub-id><pub-id pub-id-type="pmcid">PMC3164499</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Frank DN et al (2011) Investigating the biological and clinical significance of human dysbioses. Trends Microbiol 19(9):427&#8211;434<pub-id pub-id-type="pmid">21775143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2011.06.005</pub-id><pub-id pub-id-type="pmcid">PMC3164499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>AW</given-names></name><name name-style="western"><surname>Lawley</surname><given-names>TD</given-names></name></person-group><article-title>Therapeutic modulation of intestinal dysbiosis</article-title><source>Pharmacol Res</source><year>2013</year><volume>69</volume><issue>1</issue><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2012.09.008</pub-id><pub-id pub-id-type="pmid">23017673</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Walker AW, Lawley TD (2013) Therapeutic modulation of intestinal dysbiosis. Pharmacol Res 69(1):75&#8211;86<pub-id pub-id-type="pmid">23017673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2012.09.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name></person-group><article-title>The gut microbiome in neurological disorders</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><issue>2</issue><fpage>179</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30356-4</pub-id><pub-id pub-id-type="pmid">31753762</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Cryan JF (2020) The gut microbiome in neurological disorders. Lancet Neurol 19(2):179&#8211;194<pub-id pub-id-type="pmid">31753762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(19)30356-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattaneo</surname><given-names>A</given-names></name></person-group><article-title>Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly</article-title><source>Neurobiol Aging</source><year>2017</year><volume>49</volume><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.08.019</pub-id><pub-id pub-id-type="pmid">27776263</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cattaneo A (2017) Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 49:60&#8211;68<pub-id pub-id-type="pmid">27776263</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2016.08.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>D</given-names></name></person-group><article-title>Exercise and probiotics attenuate the development of Alzheimer&#8217;s disease in transgenic mice: role of microbiome</article-title><source>Exp Gerontol</source><year>2019</year><volume>115</volume><fpage>122</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2018.12.005</pub-id><pub-id pub-id-type="pmid">30529024</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Abraham D (2019) Exercise and probiotics attenuate the development of Alzheimer&#8217;s disease in transgenic mice: role of microbiome. Exp Gerontol 115:122&#8211;131<pub-id pub-id-type="pmid">30529024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exger.2018.12.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonfili</surname><given-names>L</given-names></name><etal/></person-group><article-title>Microbiota modulation counteracts Alzheimer&#8217;s disease progression influencing neuronal proteolysis and gut hormones plasma levels</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>2426</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-02587-2</pub-id><pub-id pub-id-type="pmid">28546539</pub-id><pub-id pub-id-type="pmcid">PMC5445077</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bonfili L et al (2017) Microbiota modulation counteracts Alzheimer&#8217;s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep 7(1):2426<pub-id pub-id-type="pmid">28546539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-02587-2</pub-id><pub-id pub-id-type="pmcid">PMC5445077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marizzoni</surname><given-names>M</given-names></name></person-group><article-title>Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><year>2020</year><volume>78</volume><issue>2</issue><fpage>683</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.3233/JAD-200306</pub-id><pub-id pub-id-type="pmid">33074224</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Marizzoni M (2020) Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer&#8217;s disease. J Alzheimers Dis 78(2):683&#8211;697<pub-id pub-id-type="pmid">33074224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Towards understanding brain-gut-microbiome connections in Alzheimer&#8217;s disease</article-title><source>BMC Syst Biol</source><year>2016</year><volume>10</volume><issue>3</issue><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12918-016-0307-y</pub-id><pub-id pub-id-type="pmcid">PMC5009560</pub-id><pub-id pub-id-type="pmid">27585440</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Xu R, Wang Q (2016) Towards understanding brain-gut-microbiome connections in Alzheimer&#8217;s disease. BMC Syst Biol 10(3):277&#8211;285<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12918-016-0307-y</pub-id><pub-id pub-id-type="pmcid">PMC5009560</pub-id><pub-id pub-id-type="pmid">27585440</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>K</given-names></name></person-group><article-title>The host genetics affects gut microbiome diversity in Chinese depressed patients</article-title><source>Front Genet</source><year>2022</year><volume>13</volume><fpage>976814</fpage><pub-id pub-id-type="doi">10.3389/fgene.2022.976814</pub-id><pub-id pub-id-type="pmid">36699448</pub-id><pub-id pub-id-type="pmcid">PMC9868868</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Han K (2022) The host genetics affects gut microbiome diversity in Chinese depressed patients. Front Genet 13:976814<pub-id pub-id-type="pmid">36699448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2022.976814</pub-id><pub-id pub-id-type="pmcid">PMC9868868</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>W</given-names></name><etal/></person-group><article-title>Role of the gut&#8211;brain axis in the shared genetic etiology between gastrointestinal tract diseases and psychiatric disorders: a genome-wide pleiotropic analysis</article-title><source>JAMA Psychiatr</source><year>2023</year><volume>80</volume><issue>4</issue><fpage>360</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.4974</pub-id><pub-id pub-id-type="pmcid">PMC9909581</pub-id><pub-id pub-id-type="pmid">36753304</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gong W et al (2023) Role of the gut&#8211;brain axis in the shared genetic etiology between gastrointestinal tract diseases and psychiatric disorders: a genome-wide pleiotropic analysis. JAMA Psychiatr 80(4):360&#8211;370<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2022.4974</pub-id><pub-id pub-id-type="pmcid">PMC9909581</pub-id><pub-id pub-id-type="pmid">36753304</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pontifex</surname><given-names>M</given-names></name><name name-style="western"><surname>Vauzour</surname><given-names>D</given-names></name><name name-style="western"><surname>Minihane</surname><given-names>A-M</given-names></name></person-group><article-title>The effect of APOE genotype on Alzheimer&#8217;s disease risk is influenced by sex and docosahexaenoic acid status</article-title><source>Neurobiol Aging</source><year>2018</year><volume>69</volume><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.05.017</pub-id><pub-id pub-id-type="pmid">29909178</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Pontifex M, Vauzour D, Minihane A-M (2018) The effect of APOE genotype on Alzheimer&#8217;s disease risk is influenced by sex and docosahexaenoic acid status. Neurobiol Aging 69:209&#8211;220<pub-id pub-id-type="pmid">29909178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2018.05.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Calle</surname><given-names>R</given-names></name><etal/></person-group><article-title>APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer&#8217;s disease pathology and brain diseases</article-title><source>Mol Neurodegener</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/s13024-022-00566-4</pub-id><pub-id pub-id-type="pmid">36153580</pub-id><pub-id pub-id-type="pmcid">PMC9509584</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Fern&#225;ndez-Calle R et al (2022) APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer&#8217;s disease pathology and brain diseases. Mol Neurodegener 17(1):62<pub-id pub-id-type="pmid">36153580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-022-00566-4</pub-id><pub-id pub-id-type="pmcid">PMC9509584</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>KL</given-names></name></person-group><article-title>Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: a review</article-title><source>Atherosclerosis</source><year>2016</year><volume>255</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.10.037</pub-id><pub-id pub-id-type="pmid">28340945</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Rasmussen KL (2016) Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: a review. Atherosclerosis 255:145&#8211;155<pub-id pub-id-type="pmid">28340945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2016.10.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huebbe</surname><given-names>P</given-names></name><name name-style="western"><surname>Rimbach</surname><given-names>G</given-names></name></person-group><article-title>Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors</article-title><source>Ageing Res Rev</source><year>2017</year><volume>37</volume><fpage>146</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2017.06.002</pub-id><pub-id pub-id-type="pmid">28647612</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Huebbe P, Rimbach G (2017) Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors. Ageing Res Rev 37:146&#8211;161<pub-id pub-id-type="pmid">28647612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2017.06.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Misiak</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Apo E4 alleles and impaired olfaction as predictors of Alzheimer&#8217;s disease</article-title><source>Clin Exp Psychol</source><year>2017</year><volume>3</volume><issue>4</issue><fpage>169</fpage><pub-id pub-id-type="doi">10.4172/2471-2701.1000169</pub-id><pub-id pub-id-type="pmid">29423459</pub-id><pub-id pub-id-type="pmcid">PMC5800509</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Misiak MM et al (2017) Apo E4 alleles and impaired olfaction as predictors of Alzheimer&#8217;s disease. Clin Exp Psychol 3(4):169<pub-id pub-id-type="pmid">29423459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4172/2471-2701.1000169</pub-id><pub-id pub-id-type="pmcid">PMC5800509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><etal/></person-group><article-title>Apolipoprotein E genotype e2: neuroprotection and its limits</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>919712</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.919712</pub-id><pub-id pub-id-type="pmid">35912085</pub-id><pub-id pub-id-type="pmcid">PMC9329577</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kim H et al (2022) Apolipoprotein E genotype e2: neuroprotection and its limits. Front Aging Neurosci 14:919712<pub-id pub-id-type="pmid">35912085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.919712</pub-id><pub-id pub-id-type="pmcid">PMC9329577</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotze</surname><given-names>M</given-names></name><etal/></person-group><article-title>Apolipoprotein E &#949;-4 as a genetic determinant of Alzheimer&#8217;s disease heterogeneity</article-title><source>Degener Neurol Neuromuscul Dis</source><year>2015</year><pub-id pub-id-type="doi">10.2147/DNND.S41721</pub-id><pub-id pub-id-type="pmid">32669910</pub-id><pub-id pub-id-type="pmcid">PMC7337157</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kotze M et al (2015) Apolipoprotein E &#949;-4 as a genetic determinant of Alzheimer&#8217;s disease heterogeneity. Degener Neurol Neuromuscul Dis. 10.2147/DNND.S41721<pub-id pub-id-type="pmid">32669910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DNND.S41721</pub-id><pub-id pub-id-type="pmcid">PMC7337157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Safieh</surname><given-names>M</given-names></name><name name-style="western"><surname>Korczyn</surname><given-names>AD</given-names></name><name name-style="western"><surname>Michaelson</surname><given-names>DM</given-names></name></person-group><article-title>ApoE4: an emerging therapeutic target for Alzheimer&#8217;s disease</article-title><source>BMC Med</source><year>2019</year><volume>17</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1186/s12916-019-1299-4</pub-id><pub-id pub-id-type="pmid">30890171</pub-id><pub-id pub-id-type="pmcid">PMC6425600</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Safieh M, Korczyn AD, Michaelson DM (2019) ApoE4: an emerging therapeutic target for Alzheimer&#8217;s disease. BMC Med 17:1&#8211;17<pub-id pub-id-type="pmid">30890171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-019-1299-4</pub-id><pub-id pub-id-type="pmcid">PMC6425600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bales</surname><given-names>K</given-names></name><etal/></person-group><article-title>Apolipoprotein E, amyloid, and Alzheimer disease</article-title><source>Mol Interv</source><year>2002</year><volume>2</volume><issue>6</issue><fpage>363</fpage><pub-id pub-id-type="doi">10.1124/mi.2.6.363</pub-id><pub-id pub-id-type="pmid">14993413</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Bales K et al (2002) Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv 2(6):363<pub-id pub-id-type="pmid">14993413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/mi.2.6.363</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies</article-title><source>Nat Rev Neurol</source><year>2019</year><volume>15</volume><issue>9</issue><fpage>501</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/s41582-019-0228-7</pub-id><pub-id pub-id-type="pmid">31367008</pub-id><pub-id pub-id-type="pmcid">PMC7055192</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Yamazaki Y et al (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15(9):501&#8211;518<pub-id pub-id-type="pmid">31367008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-019-0228-7</pub-id><pub-id pub-id-type="pmcid">PMC7055192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginsberg</surname><given-names>HN</given-names></name><etal/></person-group><article-title>Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies&#8212;a consensus statement from the European Atherosclerosis Society</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>47</issue><fpage>4791</fpage><lpage>4806</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab551</pub-id><pub-id pub-id-type="pmid">34472586</pub-id><pub-id pub-id-type="pmcid">PMC8670783</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ginsberg HN et al (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies&#8212;a consensus statement from the European Atherosclerosis Society. Eur Heart J 42(47):4791&#8211;4806<pub-id pub-id-type="pmid">34472586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehab551</pub-id><pub-id pub-id-type="pmcid">PMC8670783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chait</surname><given-names>A</given-names></name><etal/></person-group><article-title>Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease</article-title><source>Diabetes</source><year>2020</year><volume>69</volume><issue>4</issue><fpage>508</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.2337/dbi19-0007</pub-id><pub-id pub-id-type="pmid">32198194</pub-id><pub-id pub-id-type="pmcid">PMC7085249</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Chait A et al (2020) Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 69(4):508&#8211;516<pub-id pub-id-type="pmid">32198194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dbi19-0007</pub-id><pub-id pub-id-type="pmcid">PMC7085249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>MA</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>B</given-names></name><name name-style="western"><surname>Plourde</surname><given-names>M</given-names></name></person-group><article-title>APOE and Alzheimer&#8217;s disease: from lipid transport to physiopathology and therapeutics</article-title><source>Front Neurosci</source><year>2021</year><volume>15</volume><fpage>630502</fpage><pub-id pub-id-type="doi">10.3389/fnins.2021.630502</pub-id><pub-id pub-id-type="pmid">33679311</pub-id><pub-id pub-id-type="pmcid">PMC7925634</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Husain MA, Laurent B, Plourde M (2021) APOE and Alzheimer&#8217;s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci 15:630502<pub-id pub-id-type="pmid">33679311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.630502</pub-id><pub-id pub-id-type="pmcid">PMC7925634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzioras</surname><given-names>M</given-names></name><etal/></person-group><article-title>Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer&#8217;s disease</article-title><source>Neuropathol Appl Neurobiol</source><year>2019</year><volume>45</volume><issue>4</issue><fpage>327</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1111/nan.12529</pub-id><pub-id pub-id-type="pmid">30394574</pub-id><pub-id pub-id-type="pmcid">PMC6563457</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Tzioras M et al (2019) Invited review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer&#8217;s disease. Neuropathol Appl Neurobiol 45(4):327&#8211;346<pub-id pub-id-type="pmid">30394574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nan.12529</pub-id><pub-id pub-id-type="pmcid">PMC6563457</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raulin</surname><given-names>A-C</given-names></name></person-group><article-title>ApoE in Alzheimer&#8217;s disease: pathophysiology and therapeutic strategies</article-title><source>Mol Neurodegener</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s13024-022-00574-4</pub-id><pub-id pub-id-type="pmid">36348357</pub-id><pub-id pub-id-type="pmcid">PMC9644639</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Raulin A-C (2022) ApoE in Alzheimer&#8217;s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72<pub-id pub-id-type="pmid">36348357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-022-00574-4</pub-id><pub-id pub-id-type="pmcid">PMC9644639</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fongang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cerebral small vessel disease burden is associated with decreased abundance of gut <italic toggle="yes">Barnesiella intestinihominis</italic> bacterium in the Framingham Heart Study</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>13622</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-40872-5</pub-id><pub-id pub-id-type="pmid">37604954</pub-id><pub-id pub-id-type="pmcid">PMC10442369</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Fongang B et al (2023) Cerebral small vessel disease burden is associated with decreased abundance of gut <italic toggle="yes">Barnesiella intestinihominis</italic> bacterium in the Framingham Heart Study. Sci Rep 13(1):13622<pub-id pub-id-type="pmid">37604954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-40872-5</pub-id><pub-id pub-id-type="pmcid">PMC10442369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>C</given-names></name><etal/></person-group><article-title>70-year legacy of the Framingham Heart Study</article-title><source>Nat Rev Cardiol</source><year>2019</year><volume>16</volume><issue>11</issue><fpage>687</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/s41569-019-0202-5</pub-id><pub-id pub-id-type="pmid">31065045</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Andersson C et al (2019) 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol 16(11):687&#8211;698<pub-id pub-id-type="pmid">31065045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-019-0202-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study</article-title><source>BMC Med Genet</source><year>2007</year><volume>8</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/1471-2350-8-S1-S15</pub-id><pub-id pub-id-type="pmid">17903297</pub-id><pub-id pub-id-type="pmcid">PMC1995608</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Seshadri S et al (2007) Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study. BMC Med Genet 8:1&#8211;14<pub-id pub-id-type="pmid">17903297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2350-8-S1-S15</pub-id><pub-id pub-id-type="pmcid">PMC1995608</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging</article-title><source>Neurology</source><year>2015</year><volume>85</volume><issue>19</issue><fpage>1712</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002100</pub-id><pub-id pub-id-type="pmid">26453643</pub-id><pub-id pub-id-type="pmcid">PMC4653114</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Knopman DS et al (2015) Spectrum of cognition short of dementia: Framingham Heart Study and Mayo Clinic Study of Aging. Neurology 85(19):1712&#8211;1721<pub-id pub-id-type="pmid">26453643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000002100</pub-id><pub-id pub-id-type="pmcid">PMC4653114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okoro</surname><given-names>PC</given-names></name><etal/></person-group><article-title>A two-cohort study on the association between the gut microbiota and bone density, microarchitecture, and strength</article-title><source>Front Endocrinol</source><year>2023</year><volume>14</volume><fpage>1237727</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1237727</pub-id><pub-id pub-id-type="pmcid">PMC10551180</pub-id><pub-id pub-id-type="pmid">37810879</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Okoro PC et al (2023) A two-cohort study on the association between the gut microbiota and bone density, microarchitecture, and strength. Front Endocrinol 14:1237727<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1237727</pub-id><pub-id pub-id-type="pmcid">PMC10551180</pub-id><pub-id pub-id-type="pmid">37810879</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease</article-title><source>Genome Med</source><year>2021</year><volume>13</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s13073-020-00808-4</pub-id><pub-id pub-id-type="pmid">34915914</pub-id><pub-id pub-id-type="pmcid">PMC8680346</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Walker RL et al (2021) Population study of the gut microbiome: associations with diet, lifestyle, and cardiometabolic disease. Genome Med 13:1&#8211;16<pub-id pub-id-type="pmid">34915914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-021-01007-5</pub-id><pub-id pub-id-type="pmcid">PMC8680346</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>MM</given-names></name></person-group><article-title>Association of midlife depressive symptoms with regional amyloid-&#946; and tau in the Framingham Heart Study</article-title><source>J Alzheimers Dis</source><year>2021</year><volume>82</volume><issue>1</issue><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.3233/JAD-210232</pub-id><pub-id pub-id-type="pmid">34024836</pub-id><pub-id pub-id-type="pmcid">PMC8900661</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Gonzales MM (2021) Association of midlife depressive symptoms with regional amyloid-&#946; and tau in the Framingham Heart Study. J Alzheimers Dis 82(1):249&#8211;260<pub-id pub-id-type="pmid">34024836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210232</pub-id><pub-id pub-id-type="pmcid">PMC8900661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatchel</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: a pilot study</article-title><source>J Alzheimers Dis</source><year>2017</year><volume>59</volume><issue>3</issue><fpage>975</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.3233/JAD-170001</pub-id><pub-id pub-id-type="pmid">28697559</pub-id><pub-id pub-id-type="pmcid">PMC5577564</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Gatchel JR et al (2017) Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: a pilot study. J Alzheimers Dis 59(3):975&#8211;985<pub-id pub-id-type="pmid">28697559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-170001</pub-id><pub-id pub-id-type="pmcid">PMC5577564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costoya-S&#225;nchez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-&#946; positivity</article-title><source>JAMA Neurol</source><year>2023</year><volume>80</volume><issue>10</issue><fpage>1051</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2023.2560</pub-id><pub-id pub-id-type="pmid">37578787</pub-id><pub-id pub-id-type="pmcid">PMC10425864</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Costoya-S&#225;nchez A et al (2023) Increased medial temporal tau positron emission tomography uptake in the absence of amyloid-&#946; positivity. JAMA Neurol 80(10):1051&#8211;1061<pub-id pub-id-type="pmid">37578787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.2560</pub-id><pub-id pub-id-type="pmcid">PMC10425864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>RF</given-names></name></person-group><article-title>Menopause status moderates sex differences in tau burden: a Framingham PET study</article-title><source>Ann Neurol</source><year>2022</year><volume>92</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/ana.26382</pub-id><pub-id pub-id-type="pmid">35471588</pub-id><pub-id pub-id-type="pmcid">PMC9233144</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Buckley RF (2022) Menopause status moderates sex differences in tau burden: a Framingham PET study. Ann Neurol 92(1):11&#8211;22<pub-id pub-id-type="pmid">35471588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26382</pub-id><pub-id pub-id-type="pmcid">PMC9233144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>RS</given-names></name><etal/></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><issue>3</issue><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Desikan RS et al (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31(3):968&#8211;980<pub-id pub-id-type="pmid">16530430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2006.01.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanseeuw</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>PET staging of amyloidosis using striatum</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>10</issue><fpage>1281</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.04.011</pub-id><pub-id pub-id-type="pmid">29792874</pub-id><pub-id pub-id-type="pmcid">PMC6219621</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hanseeuw BJ et al (2018) PET staging of amyloidosis using striatum. Alzheimers Dement 14(10):1281&#8211;1292<pub-id pub-id-type="pmid">29792874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.04.011</pub-id><pub-id pub-id-type="pmcid">PMC6219621</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlassenko</surname><given-names>AG</given-names></name><name name-style="western"><surname>Benzinger</surname><given-names>TL</given-names></name><name name-style="western"><surname>Morris</surname><given-names>JC</given-names></name></person-group><article-title>PET amyloid-beta imaging in preclinical Alzheimer&#8217;s disease</article-title><source>Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease</source><year>2012</year><volume>1822</volume><issue>3</issue><fpage>370</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2011.11.005</pub-id><pub-id pub-id-type="pmid">22108203</pub-id><pub-id pub-id-type="pmcid">PMC3264790</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Vlassenko AG, Benzinger TL, Morris JC (2012) PET amyloid-beta imaging in preclinical Alzheimer&#8217;s disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1822(3):370&#8211;379<pub-id pub-id-type="pmid">22108203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2011.11.005</pub-id><pub-id pub-id-type="pmcid">PMC3264790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Tau positron emission tomographic imaging in aging and early Alzheimer disease</article-title><source>Ann Neurol</source><year>2016</year><volume>79</volume><issue>1</issue><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1002/ana.24546</pub-id><pub-id pub-id-type="pmid">26505746</pub-id><pub-id pub-id-type="pmcid">PMC4738026</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Johnson KA et al (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79(1):110&#8211;119<pub-id pub-id-type="pmid">26505746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24546</pub-id><pub-id pub-id-type="pmcid">PMC4738026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MWer</surname><given-names>S</given-names></name><name name-style="western"><surname>Dykes</surname><given-names>D</given-names></name><name name-style="western"><surname>Polesky</surname><given-names>H</given-names></name></person-group><article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title><source>Nucleic Acids Res</source><year>1988</year><volume>16</volume><issue>3</issue><fpage>1215</fpage><pub-id pub-id-type="doi">10.1093/nar/16.3.1215</pub-id><pub-id pub-id-type="pmid">3344216</pub-id><pub-id pub-id-type="pmcid">PMC334765</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">MWer S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215<pub-id pub-id-type="pmid">3344216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/16.3.1215</pub-id><pub-id pub-id-type="pmcid">PMC334765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahoz</surname><given-names>C</given-names></name><etal/></person-group><article-title>Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study</article-title><source>Atherosclerosis</source><year>2001</year><volume>154</volume><issue>3</issue><fpage>529</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(00)00570-0</pub-id><pub-id pub-id-type="pmid">11257253</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Lahoz C et al (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154(3):529&#8211;537<pub-id pub-id-type="pmid">11257253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0021-9150(00)00570-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hixson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Vernier</surname><given-names>D</given-names></name></person-group><article-title>Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI</article-title><source>J Lipid Res</source><year>1990</year><volume>31</volume><issue>3</issue><fpage>545</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)43176-1</pub-id><pub-id pub-id-type="pmid">2341813</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Hixson JE, Vernier D (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31(3):545&#8211;548<pub-id pub-id-type="pmid">2341813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Rizzo, M.L., Statistical computing with R. 2019: Chapman and Hall/CRC</mixed-citation></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multivariable association discovery in population-scale meta-omics studies</article-title><source>PLoS Comput Biol</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>e1009442</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1009442</pub-id><pub-id pub-id-type="pmid">34784344</pub-id><pub-id pub-id-type="pmcid">PMC8714082</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Mallick H et al (2021) Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol 17(11):e1009442<pub-id pub-id-type="pmid">34784344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pcbi.1009442</pub-id><pub-id pub-id-type="pmcid">PMC8714082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tingley</surname><given-names>D</given-names></name></person-group><article-title>Mediation: R package for causal mediation analysis</article-title><source>J Stat Softw</source><year>2014</year><volume>59</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.18637/jss.v059.i05</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Tingley D (2014) Mediation: R package for causal mediation analysis. J Stat Softw 59:126917999
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grothe</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>In vivo staging of regional amyloid deposition</article-title><source>Neurology</source><year>2017</year><volume>89</volume><issue>20</issue><fpage>2031</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004643</pub-id><pub-id pub-id-type="pmid">29046362</pub-id><pub-id pub-id-type="pmcid">PMC5711511</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Grothe MJ et al (2017) In vivo staging of regional amyloid deposition. Neurology 89(20):2031&#8211;2038<pub-id pub-id-type="pmid">29046362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000004643</pub-id><pub-id pub-id-type="pmcid">PMC5711511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeil</surname><given-names>J</given-names></name><etal/></person-group><article-title>Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer&#8217;s disease</article-title><source>Neurobiol Aging</source><year>2021</year><volume>106</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.06.014</pub-id><pub-id pub-id-type="pmid">34284259</pub-id><pub-id pub-id-type="pmcid">PMC8461082</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Pfeil J et al (2021) Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer&#8217;s disease. Neurobiol Aging 106:119&#8211;129<pub-id pub-id-type="pmid">34284259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.06.014</pub-id><pub-id pub-id-type="pmcid">PMC8461082</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><etal/></person-group><article-title>ggpicrust2: an R package for PICRUSt2 predicted functional profile analysis and visualization</article-title><source>Bioinformatics</source><year>2023</year><volume>39</volume><issue>8</issue><fpage>btad470</fpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btad470</pub-id><pub-id pub-id-type="pmid">37527009</pub-id><pub-id pub-id-type="pmcid">PMC10425198</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Yang C et al (2023) ggpicrust2: an R package for PICRUSt2 predicted functional profile analysis and visualization. Bioinformatics 39(8):btad470<pub-id pub-id-type="pmid">37527009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btad470</pub-id><pub-id pub-id-type="pmcid">PMC10425198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Beneficial effect of butyrate-producing <italic toggle="yes">Lachnospiraceae</italic> on stress-induced visceral hypersensitivity in rats</article-title><source>J Gastroenterol Hepatol</source><year>2019</year><volume>34</volume><issue>8</issue><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1111/jgh.14536</pub-id><pub-id pub-id-type="pmid">30402954</pub-id><pub-id pub-id-type="pmcid">PMC7379616</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Zhang J (2019) Beneficial effect of butyrate-producing <italic toggle="yes">Lachnospiraceae</italic> on stress-induced visceral hypersensitivity in rats. J Gastroenterol Hepatol 34(8):1368&#8211;1376<pub-id pub-id-type="pmid">30402954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.14536</pub-id><pub-id pub-id-type="pmcid">PMC7379616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Repulsive guidance molecule b deficiency induces gut microbiota dysbiosis and increases the susceptibility to intestinal inflammation in mice</article-title><source>Front Microbiol</source><year>2021</year><volume>12</volume><fpage>648915</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2021.648915</pub-id><pub-id pub-id-type="pmid">33995306</pub-id><pub-id pub-id-type="pmcid">PMC8113641</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Shi Y et al (2021) Repulsive guidance molecule b deficiency induces gut microbiota dysbiosis and increases the susceptibility to intestinal inflammation in mice. Front Microbiol 12:648915<pub-id pub-id-type="pmid">33995306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2021.648915</pub-id><pub-id pub-id-type="pmcid">PMC8113641</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitkin</surname><given-names>S</given-names></name><name name-style="western"><surname>Pokrotnieks</surname><given-names>J</given-names></name></person-group><article-title>Clinical potential of anti-inflammatory effects of <italic toggle="yes">Faecalibacterium prausnitzii</italic> and butyrate in inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2019</year><volume>25</volume><issue>4</issue><fpage>e40</fpage><lpage>e41</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy258</pub-id><pub-id pub-id-type="pmid">30085080</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Sitkin S, Pokrotnieks J (2019) Clinical potential of anti-inflammatory effects of <italic toggle="yes">Faecalibacterium prausnitzii</italic> and butyrate in inflammatory bowel disease. Inflamm Bowel Dis 25(4):e40&#8211;e41<pub-id pub-id-type="pmid">30085080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izy258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miquel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii</article-title><source>MBio</source><year>2015</year><volume>6</volume><issue>2</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1128/mBio.00300-15</pub-id><pub-id pub-id-type="pmcid">PMC4453580</pub-id><pub-id pub-id-type="pmid">25900655</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Miquel S et al (2015) Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio 6(2):10<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00300-15</pub-id><pub-id pub-id-type="pmcid">PMC4453580</pub-id><pub-id pub-id-type="pmid">25900655</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miquel</surname><given-names>S</given-names></name></person-group><article-title><italic toggle="yes">Faecalibacterium prausnitzii</italic> and human intestinal health</article-title><source>Curr Opin Microbiol</source><year>2013</year><volume>16</volume><issue>3</issue><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2013.06.003</pub-id><pub-id pub-id-type="pmid">23831042</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Miquel S (2013) <italic toggle="yes">Faecalibacterium prausnitzii</italic> and human intestinal health. Curr Opin Microbiol 16(3):255&#8211;261<pub-id pub-id-type="pmid">23831042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mib.2013.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morais</surname><given-names>LH</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>HL</given-names><suffix>IV</suffix></name><name name-style="western"><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group><article-title>The gut microbiota&#8211;brain axis in behaviour and brain disorders</article-title><source>Nat Rev Microbiol</source><year>2021</year><volume>19</volume><issue>4</issue><fpage>241</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00460-0</pub-id><pub-id pub-id-type="pmid">33093662</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Morais LH, Schreiber HL IV, Mazmanian SK (2021) The gut microbiota&#8211;brain axis in behaviour and brain disorders. Nat Rev Microbiol 19(4):241&#8211;255<pub-id pub-id-type="pmid">33093662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-00460-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>796288</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.796288</pub-id><pub-id pub-id-type="pmid">35464431</pub-id><pub-id pub-id-type="pmcid">PMC9021448</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Mou Y et al (2022) Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging. Front Immunol 13:796288<pub-id pub-id-type="pmid">35464431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.796288</pub-id><pub-id pub-id-type="pmcid">PMC9021448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>YP</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Frozza</surname><given-names>RL</given-names></name></person-group><article-title>The role of short-chain fatty acids from gut microbiota in gut&#8211;brain communication</article-title><source>Front Endocrinol</source><year>2020</year><volume>11</volume><fpage>508738</fpage><pub-id pub-id-type="doi">10.3389/fendo.2020.00025</pub-id><pub-id pub-id-type="pmcid">PMC7005631</pub-id><pub-id pub-id-type="pmid">32082260</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Silva YP, Bernardi A, Frozza RL (2020) The role of short-chain fatty acids from gut microbiota in gut&#8211;brain communication. Front Endocrinol 11:508738<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2020.00025</pub-id><pub-id pub-id-type="pmcid">PMC7005631</pub-id><pub-id pub-id-type="pmid">32082260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verhaar</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Gut microbiota composition is related to AD pathology</article-title><source>Front Immunol</source><year>2022</year><volume>12</volume><fpage>794519</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.794519</pub-id><pub-id pub-id-type="pmid">35173707</pub-id><pub-id pub-id-type="pmcid">PMC8843078</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Verhaar BJ et al (2022) Gut microbiota composition is related to AD pathology. Front Immunol 12:794519<pub-id pub-id-type="pmid">35173707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.794519</pub-id><pub-id pub-id-type="pmcid">PMC8843078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Gut microbiome alterations in preclinical Alzheimer&#8217;s disease</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>11</issue><fpage>e0278276</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0278276</pub-id><pub-id pub-id-type="pmid">36445883</pub-id><pub-id pub-id-type="pmcid">PMC9707757</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Jung JH et al (2022) Gut microbiome alterations in preclinical Alzheimer&#8217;s disease. PLoS ONE 17(11):e0278276<pub-id pub-id-type="pmid">36445883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0278276</pub-id><pub-id pub-id-type="pmcid">PMC9707757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jemimah</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gut microbiome dysbiosis in Alzheimer&#8217;s disease and mild cognitive impairment: a systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><issue>5</issue><fpage>e0285346</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0285346</pub-id><pub-id pub-id-type="pmid">37224131</pub-id><pub-id pub-id-type="pmcid">PMC10208513</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Jemimah S et al (2023) Gut microbiome dysbiosis in Alzheimer&#8217;s disease and mild cognitive impairment: a systematic review and meta-analysis. PLoS ONE 18(5):e0285346<pub-id pub-id-type="pmid">37224131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0285346</pub-id><pub-id pub-id-type="pmcid">PMC10208513</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoyles</surname><given-names>L</given-names></name><etal/></person-group><article-title>Regulation of blood&#8211;brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide</article-title><source>Microbiome</source><year>2021</year><volume>9</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1186/s40168-021-01181-z</pub-id><pub-id pub-id-type="pmid">34836554</pub-id><pub-id pub-id-type="pmcid">PMC8626999</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Hoyles L et al (2021) Regulation of blood&#8211;brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide. Microbiome 9:1&#8211;21<pub-id pub-id-type="pmid">34836554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40168-021-01181-z</pub-id><pub-id pub-id-type="pmcid">PMC8626999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>X-H</given-names></name></person-group><article-title>Mechanisms of short-chain fatty acids derived from gut microbiota in Alzheimer&#8217;s disease</article-title><source>Aging Dis</source><year>2022</year><volume>13</volume><issue>4</issue><fpage>1252</fpage><pub-id pub-id-type="doi">10.14336/AD.2021.1215</pub-id><pub-id pub-id-type="pmid">35855330</pub-id><pub-id pub-id-type="pmcid">PMC9286902</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Qian X-H (2022) Mechanisms of short-chain fatty acids derived from gut microbiota in Alzheimer&#8217;s disease. Aging Dis 13(4):1252<pub-id pub-id-type="pmid">35855330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14336/AD.2021.1215</pub-id><pub-id pub-id-type="pmcid">PMC9286902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gut microbiota and dysbiosis in Alzheimer&#8217;s disease: implications for pathogenesis and treatment</article-title><source>Mol Neurobiol</source><year>2020</year><volume>57</volume><fpage>5026</fpage><lpage>5043</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02073-3</pub-id><pub-id pub-id-type="pmid">32829453</pub-id><pub-id pub-id-type="pmcid">PMC7541367</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Liu S et al (2020) Gut microbiota and dysbiosis in Alzheimer&#8217;s disease: implications for pathogenesis and treatment. Mol Neurobiol 57:5026&#8211;5043<pub-id pub-id-type="pmid">32829453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-020-02073-3</pub-id><pub-id pub-id-type="pmcid">PMC7541367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intestinal microflora changes in patients with mild Alzheimer&#8217;s disease in a Chinese cohort</article-title><source>J Alzheimers Dis</source><year>2022</year><volume>88</volume><issue>2</issue><fpage>563</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.3233/JAD-220076</pub-id><pub-id pub-id-type="pmid">35662119</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Wang Y et al (2022) Intestinal microflora changes in patients with mild Alzheimer&#8217;s disease in a Chinese cohort. J Alzheimers Dis 88(2):563&#8211;575<pub-id pub-id-type="pmid">35662119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbiome alterations precede cerebral amyloidosis and microglial pathology in a mouse model of Alzheimer&#8217;s disease</article-title><source>Biomed Res Int</source><year>2020</year><volume>2020</volume><issue>1</issue><fpage>8456596</fpage><pub-id pub-id-type="doi">10.1155/2020/8456596</pub-id><pub-id pub-id-type="pmid">32596386</pub-id><pub-id pub-id-type="pmcid">PMC7273394</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Chen Y et al (2020) Gut microbiome alterations precede cerebral amyloidosis and microglial pathology in a mouse model of Alzheimer&#8217;s disease. Biomed Res Int 2020(1):8456596<pub-id pub-id-type="pmid">32596386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/8456596</pub-id><pub-id pub-id-type="pmcid">PMC7273394</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pharmacol Exp Ther</journal-id><journal-id journal-id-type="iso-abbrev">J Pharmacol Exp Ther</journal-id><journal-id journal-id-type="pmc-domain-id">828</journal-id><journal-id journal-id-type="pmc-domain">jpet</journal-id><journal-title-group><journal-title>The Journal of Pharmacology and Experimental Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0022-3565</issn><issn pub-type="epub">1521-0103</issn><publisher><publisher-name>American Society for Pharmacology and Experimental Therapeutics</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12489360</article-id><article-id pub-id-type="pmcid-ver">PMC12489360.1</article-id><article-id pub-id-type="pmcaid">12489360</article-id><article-id pub-id-type="pmcaiid">12489360</article-id><article-id pub-id-type="pmid">40674941</article-id><article-id pub-id-type="doi">10.1016/j.jpet.2025.103639</article-id><article-id pub-id-type="pii">S0022-3565(25)39852-6</article-id><article-id pub-id-type="publisher-id">103639</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Minireview</subject></subj-group></article-categories><title-group><article-title>Alzheimer disease: Amyloid peptide controversies and challenges of anti-A<italic toggle="yes">&#946;</italic> immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Almohmadi</surname><given-names initials="NH">Najlaa Hamed</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Al-Kuraishy</surname><given-names initials="HM">Hayder M.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Albuhadily</surname><given-names initials="AK">Ali K.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Al-Gareeb</surname><given-names initials="AI">Ali I.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Abdelaziz</surname><given-names initials="AM">Ahmed M.</given-names></name><email>ahmed.abdelaziz@su.edu.eg</email><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor2" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Alexiou</surname><given-names initials="A">Athanasios</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Papadakis</surname><given-names initials="M">Marios</given-names></name><email>drmariospapadakis@gmail.com</email><xref rid="aff7" ref-type="aff">7</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>El-Saber Batiha</surname><given-names initials="G">Gaber</given-names></name><email>dr_gaber_batiha@vetmed.dmu.edu.eg</email><xref rid="aff8" ref-type="aff">8</xref><xref rid="cor3" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>1</label>Clinical Nutrition Department, College of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia</aff><aff id="aff2"><label>2</label>Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq</aff><aff id="aff3"><label>3</label>Jabir ibn Hayyan Medical University, Najaf, Iraq</aff><aff id="aff4"><label>4</label>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University &#8211; Arish Branch, Arish, Egypt</aff><aff id="aff5"><label>5</label>University Centre for Research &amp; Development, Chandigarh University, Mohali, India</aff><aff id="aff6"><label>6</label>Department of Research &amp; Development, Funogen, Athens, Greece</aff><aff id="aff7"><label>7</label>University Hospital Witten-Herdecke, University of Witten, Herdecke, Wuppertal, Germany</aff><aff id="aff8"><label>8</label>Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label><bold>Address correspondence to:</bold> Prof. Marios Papadakis, University Hospital Witten-Herdecke, University of Witten, Herdecke, Heusnerstrasse 40, Wuppertal 42283, Germany. <email>drmariospapadakis@gmail.com</email></corresp><corresp id="cor2"><label>&#8727;</label>Dr Ahmed M. Abdelaziz, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University &#8211; Arish Branch, Arish, 45511, Egypt. <email>ahmed.abdelaziz@su.edu.eg</email></corresp><corresp id="cor3"><label>&#8727;</label>Prof. Gaber El-Saber Batiha, Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt. <email>dr_gaber_batiha@vetmed.dmu.edu.eg</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>392</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">498166</issue-id><elocation-id>103639</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-03 11:25:16.713"><day>03</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><p>Alzheimer disease (AD) is a progressive neurodegenerative disease marked by the accumulation of extracellular <italic toggle="yes">&#946;</italic>-amyloid (A<italic toggle="yes">&#946;</italic>) plaques and intracellular neurofibrillary tangles containing tau protein. Given the relentless deterioration in AD, strategies to slow its progression often focus on inhibiting A<italic toggle="yes">&#946;</italic> production or aggregation. However, numerous clinical trials targeting A<italic toggle="yes">&#946;</italic> in later disease stages have shown limited success in reversing cognitive decline, potentially due to intervening too late in the disease course. Emerging evidence suggests that addressing A<italic toggle="yes">&#946;</italic> pathology during the earliest phases of AD, before the occurrence of neuronal damage, may be beneficial for preserving cognitive function. Thus, therapeutic approaches aimed at reducing A<italic toggle="yes">&#946;</italic> levels, such as anti-A<italic toggle="yes">&#946;</italic> antibodies, are likely to yield greater benefits when implemented early in the disease trajectory. Such evidence underscores the rationale for prioritizing early-stage interventions in AD drug development. However, disrupting the physiological role of A<italic toggle="yes">&#946;</italic>, which plays a role in normal brain function, might inadvertently worsen clinical outcomes, highlighting the need for nuanced therapeutic strategies. Therefore, this review aims to explore the dual aspects of A<italic toggle="yes">&#946;</italic> biology: its natural role in the brain and the potential of anti-A<italic toggle="yes">&#946;</italic> immunotherapy, particularly targeting amyloid plaques, as a promising avenue for modifying AD progression when timed appropriately.</p></sec><sec><title>Significance Statement</title><p>This review highlights that <italic toggle="yes">&#946;</italic>-amyloid (A<italic toggle="yes">&#946;</italic>) has a dual role in both supporting synaptic plasticity and memory via nicotinic receptor activation and driving Alzheimer disease neuropathology, emphasizing that early-stage A<italic toggle="yes">&#946;</italic>-targeted immunotherapy may prevent cognitive decline while preserving the neuroprotective functions of A<italic toggle="yes">&#946;</italic>, thereby refining therapeutic strategies and advancing understanding of the complex role of A<italic toggle="yes">&#946;</italic> in neural health and disease.</p></sec></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Alzheimer disease</kwd><kwd>Anti-A<italic toggle="yes">&#946;</italic> immunotherapy</kwd><kwd><italic toggle="yes">&#946;</italic>-amyloid</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0030">A<italic toggle="yes">&#946;</italic></term><def><p><italic toggle="yes">&#946;</italic>-amyloid</p></def></def-item><def-item><term id="kwrd0040">AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term id="kwrd0050">APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item><term id="kwrd0060">ARIA-E</term><def><p>amyloid-related imaging abnormality</p></def></def-item><def-item><term id="kwrd0070">BACE</term><def><p><italic toggle="yes">&#946;</italic>-secretase</p></def></def-item><def-item><term id="kwrd0080">CSF</term><def><p>cerebrospinal fluid</p></def></def-item><def-item><term id="kwrd0090">LTP</term><def><p>long-term potentiation</p></def></def-item><def-item><term id="kwrd0100">NFT</term><def><p>neurofibrillary tangle</p></def></def-item><def-item><term id="kwrd0110">NMDA</term><def><p>N-methyl-<sc>d</sc>-aspartate</p></def></def-item><def-item><term id="kwrd0120">oA<italic toggle="yes">&#946;</italic></term><def><p>oligomeric <italic toggle="yes">&#946;</italic>-amyloid</p></def></def-item><def-item><term id="kwrd0130">sAPP<italic toggle="yes">&#945;</italic></term><def><p>soluble amyloid precursor protein <italic toggle="yes">&#945;</italic></p></def></def-item></def-list></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Alzheimer disease (AD) is defined by the presence of extracellular <italic toggle="yes">&#946;</italic>-amyloid (A<italic toggle="yes">&#946;</italic>) plaques and intracellular tau protein-containing neurofibrillary tangles (NFTs).<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> Characterized by cognitive decline and memory loss, AD is the most prevalent neurodegenerative disease of the brain and the most common form of dementia.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The primary biological concept of AD pertains to the appearance of synaptic dysfunction and the deterioration of synaptic homeostasis resulting from an imbalance in the formation of A<italic toggle="yes">&#946;</italic> and NFTs, as well as the clearance of these misfolded proteins.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> AD is regarded as a medical care challenge as more than 40 million people suffer from dementia worldwide, and this number has been proposed to double every 20 years until 2050.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> The lengthening of the human lifespan will lead to increasing numbers of patients with dementia correlated with aging.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> A recent study showed that the number of people with dementia may increase from 57.4 million in 2019 to 152.8 million in 2050 and that it is more common in women than men.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Therefore, public health efforts are recommended to control modifiable risk factors that are associated with the development and progression of dementia and AD.</p><p id="p0015">AD neuropathology is related to the progressive accumulation of A<italic toggle="yes">&#946;</italic> and NFTs. A<italic toggle="yes">&#946;</italic> peptides, mainly A<italic toggle="yes">&#946;</italic><sub>38</sub>, A<italic toggle="yes">&#946;</italic><sub>40</sub> and A<italic toggle="yes">&#946;</italic><sub>42</sub>, which are the most common types, are generated from amyloid precursor protein (APP) after sequential cleavage by <italic toggle="yes">&#947;</italic>-secretase and <italic toggle="yes">&#946;</italic>-secretase (BACE1).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> However, cleavage of APP by <italic toggle="yes">&#945;</italic>-secretase via the non-amyloidogenic pathway generates soluble amyloid precursor protein <italic toggle="yes">&#945;</italic> (sAPP<italic toggle="yes">&#945;</italic>), which improves synaptic plasticity.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Normally, in young subjects, APP is processed mainly through the non-amyloidogenic pathway to generate the neuroprotective sAPP<italic toggle="yes">&#945;</italic>. However, in AD and aging, APP processing is shifted toward the amyloidogenic pathway to produce insoluble A<italic toggle="yes">&#946;</italic>.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The neuroprotective potential of sAPP<italic toggle="yes">&#945;</italic> is related to the regulation of the brain neurogenic microenvironment and neurogenesis, which are implicated in memory deficits and cognitive impairment in AD and dementia.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> In addition, sAPP<italic toggle="yes">&#945;</italic> promotes cell survival, neurite outgrowth, and synaptogenesis.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Accordingly, the amyloid hypothesis was suggested to be mainly involved in AD neuropathology by initiating neurotoxicity and associated excitotoxicity, inflammation, and oxidative stress<xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Amyloid precursor protein (APP) processing in Alzheimer disease (AD). APP processing pathways and their implications in AD pathology. The non-amyloidogenic pathway, mediated by <italic toggle="yes">&#945;</italic>-secretase, generates soluble amyloid precursor protein <italic toggle="yes">&#945;</italic> (sAPP<italic toggle="yes">&#945;</italic>), which promotes synaptic plasticity and growth. In contrast, the amyloidogenic pathway involves <italic toggle="yes">&#946;</italic>-secretase (BACE1) cleavage of APP into <italic toggle="yes">&#946;</italic>-APP and <italic toggle="yes">&#946;</italic>-APP-C99, leading to amyloid beta (A<italic toggle="yes">&#946;</italic>) production. A<italic toggle="yes">&#946;</italic> accumulation triggers cerebrovascular damage, microglial and astrocyte activation, neurotoxicity, and synaptic loss. Subsequent A<italic toggle="yes">&#946;</italic>-driven pathologies include hyperphosphorylated Tau and neurofibrillary tangles (NFTs), hallmark features of AD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0020">However, tauopathy in AD is considered a prime pathology because targeting A<italic toggle="yes">&#946;</italic> fails to produce significant amelioration of cognitive decline and AD neuropathology.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Tau protein has an important function in the regulation of axonal transport. However, mutant tau protein triggers hyperphosphorylation of tau protein and the development of NFTs.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Progressive accumulation of NFTs is correlated with cognitive impairment in patients with AD.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Of interest, hyperphosphorylated tau protein is regarded as a downstream event of A<italic toggle="yes">&#946;</italic> accumulation, as both progress in parallel in AD.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> It has been shown that A<italic toggle="yes">&#946;</italic> facilitates the aggregation of tau protein in neuritic plaques through activation of glycogen synthase kinase 3 beta, which promotes the formation of hyperphosphorylated tau protein.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> In addition, A<italic toggle="yes">&#946;</italic> triggers tau protein hyperphosphorylation and aggregation by activating mitogen-activated protein kinase.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Interestingly, A<italic toggle="yes">&#946;</italic> neurotoxicity is mediated by hyperphosphorylated tau protein.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> The results reported here indicate a mutual association between A<italic toggle="yes">&#946;</italic> and hyperphosphorylated tau protein in the etiology of AD and the neurodegeneration of cholinergic neurons.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Therefore, acetylcholinesterase inhibitors such as rivastigmine, galantamine, and donepezil have been approved for the management of cognitive impairment in patients with AD.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Acetylcholinesterase inhibitors were proposed as treatments according to the cholinergic hypothesis, which suggests that deteriorations of learning, attention, and memory are correlated with loss of cholinergic neurons in the neocortex, basal forebrain, and limbic system.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> However, this therapeutic strategy cannot prevent the progression of AD neuropathology. Therefore, it is reasonable to suggest that inhibition of A<italic toggle="yes">&#946;</italic> processing in AD may stop the progression of the disease. However, since 1984, a large number of clinical trials targeting A<italic toggle="yes">&#946;</italic> have failed to mitigate cognitive impairment in patients with AD.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> Remarkably, there are no significant effects on cognitive function from use of anti-A<italic toggle="yes">&#946;</italic> antibodies in the many clinical trials conducted from 2012 to 2017 in patients with AD. This inconsequential effect might be due to not using anti-A<italic toggle="yes">&#946;</italic> antibodies in the late stage of AD. However, a phase 3 clinical trial conducted in 2023 illustrated that use of the anti-A<italic toggle="yes">&#946;</italic> monoclonal antibodies aducanumab and lecanemab improves cognitive function in patients with AD.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> In 2025, a systematic review and meta-analysis of clinical trials concerning the efficacy of anti-A<italic toggle="yes">&#946;</italic> monoclonal antibodies illustrated that donanemab is more effective and has a safety profile comparable to that of aducanumab and lecanemab.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Thus, targeting A<italic toggle="yes">&#946;</italic> in the early stage of AD is more effective in preventing the deterioration of cognitive function.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> In clinical trials, tau protein and A<italic toggle="yes">&#946;</italic> could the prime targets in preventing the development and progression of AD.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> However, inhibition of A<italic toggle="yes">&#946;</italic> that is normally present may adversely affect cognitive function and the clinical course of AD.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Consequently, this review aims to discuss the normal physiological function of A<italic toggle="yes">&#946;</italic> in the brain and how targeting A<italic toggle="yes">&#946;</italic> with anti-A<italic toggle="yes">&#946;</italic> immunotherapy may be effective in treating AD.</p></sec><sec id="sec2"><label>2</label><title>The protective role of A<italic toggle="yes">&#946;</italic> in AD</title><p id="p0025">A<italic toggle="yes">&#946;</italic> in the brain is primarily produced by neurons and astrocytes and is normally found in a soluble form.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> A<italic toggle="yes">&#946;</italic> is eliminated from brain extracellular space through the cerebrospinal fluid (CSF) into the systemic circulation where it is metabolized by the liver and excreted by the kidney and gastrointestinal tract.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> In healthy humans, the most common A<italic toggle="yes">&#946;</italic> isoforms present in the CSF are A<italic toggle="yes">&#946;</italic><sub>40</sub> and A<italic toggle="yes">&#946;</italic><sub>42</sub>.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Soluble A<italic toggle="yes">&#946;</italic> can bind other A<italic toggle="yes">&#946;</italic> proteins to form insoluble oligomers and plaques, causing progressive neurodegeneration and the development of AD.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></p><p id="p0030">Mounting evidence suggests that soluble A<italic toggle="yes">&#946;</italic> in the brain is essential for memory function by regulating hippocampal synaptic plasticity and long-term potentiation (LTP) by activating the nicotinic acetylcholine receptors.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Administration of anti-rodent A<italic toggle="yes">&#946;</italic> antibody and against APP inhibits LTP, and this effect was reversed by administration of human A<italic toggle="yes">&#946;</italic><sub>42</sub>.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Normally, A<italic toggle="yes">&#946;</italic> is released from presynaptic neurons together with neurotransmitters into the synaptic cleft. In addition, through modulation of presynaptic receptors, A<italic toggle="yes">&#946;</italic> increases the release of excitatory neurotransmitters such as acetylcholine.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> However, in AD, presynaptic failure develops due to alteration of APP binding to the presynaptic receptors.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Therefore, A<italic toggle="yes">&#946;</italic> improves LTP by increasing the release of acetylcholine and activation of postsynaptic neurons. Supporting to this claim, Morley et al<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> found that direct administration of A<italic toggle="yes">&#946;</italic> into the hippocampus enhanced the memory task in mice by increasing the release of acetylcholine. However, this effect is concentration dependent; a low (picomolar) concentration of A<italic toggle="yes">&#946;</italic> stimulates <italic toggle="yes">&#945;</italic>7-nicotinic acetylcholine receptors and LTP, whereas a higher (nanomolar) concentration of A<italic toggle="yes">&#946;</italic> inhibits this receptor and impairs memory.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> In addition, a low (picomolar) concentration of A<italic toggle="yes">&#946;</italic> stimulates the N-methyl-<sc>d</sc>-aspartate (NMDA) receptor and improves LTP, whereas a higher (nanomolar) concentration of A<italic toggle="yes">&#946;</italic> had an inhibitory effect on NMDA-mediated LTP.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Consistently, depletion of endogenous A<italic toggle="yes">&#946;</italic> impairs memory consolidation and LTP in rodents.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Interestingly, the effect of A<italic toggle="yes">&#946;</italic> on memory function and LTP is time-dependent. Exposure of hippocampal neurons to the physiological concentration of A<italic toggle="yes">&#946;</italic> for minutes improves synaptic plasticity, whereas prolonged exposure to A<italic toggle="yes">&#946;</italic> attenuates hippocampal synaptic plasticity.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Consequently, transgenic mice overexpressing APP and A<italic toggle="yes">&#946;</italic> early in life exhibit impaired plasticity in multiple cortical regions.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> It has been reported that use of bapineuzumab triggers neuronal dysfunction independent of A<italic toggle="yes">&#946;</italic> clearance in transgenic mice.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Notably, antibodies targeting A<italic toggle="yes">&#946;</italic> in the brain proved ineffective at synaptic repair in mice but provoked cortical hyperexcitability.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Conversely, administration of anti-A<italic toggle="yes">&#946;</italic> immunotherapy to transgenic mice attenuated neuronal hyperexcitability and epileptiform discharges.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Of note, APP/A<italic toggle="yes">&#946;</italic> can trigger neuronal hyperexcitability and the development of seizures in early-onset AD<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>; hence, targeting of APP/A<italic toggle="yes">&#946;</italic> by anti-A<italic toggle="yes">&#946;</italic> immunotherapy may be beneficial in preventing associated seizures in AD. However, knockout of BACE1 or APP increases seizure susceptibility in mice.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Compared to wild-type mice, <italic toggle="yes">BACE1</italic> null mice exhibited increased susceptibility to kainic acid-induced seizures resulting from altered and hyperactive neuronal voltage-gated Na<sup>+</sup> channels.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> These preclinical findings indicated that A<italic toggle="yes">&#946;</italic> has a neuroprotective effect, and deletion of A<italic toggle="yes">&#946;</italic> may deteriorate synaptic plasticity, neuronal function, and cognition. Notably, many of the adverse outcomes of A<italic toggle="yes">&#946;</italic>-targeting approaches are derived from studies in non-AD models. Depletion of endogenous A<italic toggle="yes">&#946;</italic> deteriorates the cognitive function, according to many animal model studies<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref> (<xref rid="tbl1" ref-type="table">Table 1</xref>).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Detrimental effects of targeting the A<italic toggle="yes">&#946;</italic> pathway in non-AD models</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Experimental Models</th><th colspan="1" rowspan="1">Findings</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>A<italic toggle="yes">&#946;</italic> Immunodepletion In Mouse Model</bold></td><td colspan="1" rowspan="1">Accumulation Of Iron In Choroid Plexus And Brain Micro-bleeding</td><td colspan="1" rowspan="1">Joseph-Mathurin et al<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></td></tr><tr><td colspan="1" rowspan="1">A<italic toggle="yes">&#946;</italic> immunodepletion, <italic toggle="yes">&#947;</italic>-secretase inhibitor, and BACE1 inhibitor in SH-SY5Y cells or cortical neurons</td><td colspan="1" rowspan="1">Decreased the cell viability that was prevented by administration of human A<italic toggle="yes">&#946;</italic><sub>40</sub></td><td colspan="1" rowspan="1">Plant et al<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></td></tr><tr><td colspan="1" rowspan="1">A<italic toggle="yes">&#946;</italic> immunodepletion in rats</td><td colspan="1" rowspan="1">Impairment of memory function that was prevented by administration of human A<italic toggle="yes">&#946;</italic><sub>42</sub></td><td colspan="1" rowspan="1">Garcia-Osta and Alberi<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">BACE1</italic> knockout in mice</td><td colspan="1" rowspan="1">Impairment of memory and development of seizures</td><td colspan="1" rowspan="1">Joseph-Mathurin et al<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">BACE1</italic> and <italic toggle="yes">BACE2</italic> double knockout in mice</td><td colspan="1" rowspan="1">Hyperactive behavior and increased mortality</td><td colspan="1" rowspan="1">Dominguez et al<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic> knockdown in mice</td><td colspan="1" rowspan="1">Inhibits hippocampal LTP and memory impairment</td><td colspan="1" rowspan="1">Rolland et al<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>; Ricciarelli et al<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APP</italic> or <italic toggle="yes">BACE1</italic> knockdown in mice</td><td colspan="1" rowspan="1">Acute mortality</td><td colspan="1" rowspan="1">Koike et al<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Secretase inhibition in mice</td><td colspan="1" rowspan="1">Impairment of locomotor activity</td><td colspan="1" rowspan="1">Pajoohesh-Ganji et al<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></td></tr></tbody></table></table-wrap></p><p id="p0035">In clinical settings, many clinical trials have reported that depletion of A<italic toggle="yes">&#946;</italic> in the brain is associated with cognitive impairment and other cognitive adverse events due to the development of synaptic dysfunction. Use of the anti-A<italic toggle="yes">&#946;</italic> antibodies bapineuzumab and CAD106 was associated with the development of seizures and acute psychosis.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> Compared to the other therapies, lecanemab exhibited the most promise in reducing A<italic toggle="yes">&#946;</italic> in the brain and slowing cognitive decline. Additional research is warranted, highlighting the requirement of AD therapeutic research to alter the trajectory of AD and deliver reliable treatment.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> In addition, use of the <italic toggle="yes">&#947;</italic>-secretase inhibitor avagacestat reduced the psychomotor performance.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> However, patients with AD that received avagacestat had higher rate of brain atrophy and clinical progression to dementia,<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and this may explain the failure of avagacestat in the improvement of cognitive impairment. A phase 2 placebo-controlled clinical trial showed that avagacestat was safe and well-tolerated at 25 mg and 50 mg, but was not tolerated at doses of 100 mg and 125 mg.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> Similarly, use of the <italic toggle="yes">&#947;</italic>-secretase inhibitor semagacestate reduced cognitive function; this adverse effect continued for 32 weeks after discontinuing the drug.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> A phase 3 placebo-controlled clinical trial determined that semagacestate was not tolerated and did not mitigate cognitive impairment. In addition, higher doses of semagacestate worsen cognitive function and increase risk of infections and cancers.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> The negative and undesirable effects of anti-A<italic toggle="yes">&#946;</italic> immunotherapies highlight that depletion of A<italic toggle="yes">&#946;</italic> in the brain is linked with the development of cognitive impairment due to synaptic failure and dysfunction<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> (<xref rid="tbl2" ref-type="table">Table 2</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Adverse effects of anti-A<italic toggle="yes">&#946;</italic> agents in patients with Alzheimer disease</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Anti-A<italic toggle="yes">&#946;</italic> Agents</th><th colspan="1" rowspan="1">Findings</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Bapineuzumab and CAD106</td><td colspan="1" rowspan="1">Seizures and acute psychosis</td><td colspan="1" rowspan="1">Chhabra et al<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Avagacestat</td><td colspan="1" rowspan="1">The <italic toggle="yes">&#947;</italic>-secretase inhibitor avagacestat leads to the impairment of psychomotor performance, brain atrophy, and dementia</td><td colspan="1" rowspan="1">Chhabra et al<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Semagacestate</td><td colspan="1" rowspan="1">The <italic toggle="yes">&#947;</italic>-secretase inhibitor semagacestate reduced cognitive function and increased the risk of infections and cancers</td><td colspan="1" rowspan="1">Doody et al<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec3"><label>3</label><title>Detrimental effects of A<italic toggle="yes">&#946;</italic> in AD</title><p id="p0040">AD pathogenesis is strongly linked to A<italic toggle="yes">&#946;</italic>, especially its soluble oligomeric forms, which contribute to neurodegeneration through diverse pathways.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> A<italic toggle="yes">&#946;</italic> oligomers, transient soluble aggregates of A<italic toggle="yes">&#946;</italic> peptides, are increasingly recognized as the primary neurotoxic agents in AD, surpassing the harm caused by inert monomers or fibrillar plaques.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Their neurotoxicity stems from unstable, <italic toggle="yes">&#946;</italic>-sheet-rich structures that interact with neuronal membranes and receptors, directly impairing synaptic signaling.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> Oligomer formation depends on A<italic toggle="yes">&#946;</italic> concentration and is influenced by genetic factors such as <italic toggle="yes">APP</italic> mutation, aging, and deficient clearance mechanisms, which promote the transition from monomers to low- (dimers/trimers) and high-molecular-weight oligomers.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> These A<italic toggle="yes">&#946;</italic> oligomers impair synaptic health by attaching to neuronal membranes via triggering the internalization of NMDA and AMPA receptors, disrupting LTP, and promoting oxidative stress and mitochondrial dysfunction, ultimately causing synaptic spine degeneration.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Accumulation of A<italic toggle="yes">&#946;</italic> aggregates, resulting from overproduction or defective clearance, forms toxic fibrils and plaques that spread the pathology and induce tau hyperphosphorylation, hastening neuronal death.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><sup>,</sup><xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> Elevated oligomer levels in the CSF and postmortem brain tissue of patients with AD correlate with cognitive deficits and synaptic degeneration, underscoring their clinical relevance.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Beyond neurons, oligomers activate microglia and astrocytes, initiating chronic neuroinflammation marked by the release of inflammatory cytokines such as IL-1<italic toggle="yes">&#946;</italic>, TNF-<italic toggle="yes">&#945;</italic>, and reactive oxygen species, which worsen neuronal injury.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> Additionally, A<italic toggle="yes">&#946;</italic> deposits in cerebral blood vessels disrupt the blood-brain barrier and reduce cerebral blood flow, further compromising brain function.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> Current therapies, including conformation-specific antibodies like lecanemab and aducanumab, aim to neutralize oligomers or inhibit their assembly, reflecting their importance as therapeutic targets.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> However, selectively targeting toxic oligomers without interfering with the physiological roles of A<italic toggle="yes">&#946;</italic> remains challenging, requiring further research into its structural diversity and disease-associated conformations.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></p></sec><sec id="sec4"><label>4</label><title>Targeting of the A<italic toggle="yes">&#946;</italic> pathway in AD</title><p id="p0045">According to the amyloid hypothesis, inhibition of <italic toggle="yes">&#947;</italic>- and <italic toggle="yes">&#946;</italic>-secretases, activation of <italic toggle="yes">&#945;</italic>-secretase, and immunotherapy against aggregated A<italic toggle="yes">&#946;</italic> could a possible therapeutic strategy in the management of AD.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> In this context, anti-A<italic toggle="yes">&#946;</italic> immunotherapy is discussed below.</p><sec id="sec4.1"><label>4.1</label><title>Passive immunization</title><p id="p0050">Passive immunization involves passive administration of antibodies directed against brain A<italic toggle="yes">&#946;</italic>, resulting in an immune response without a T cell-mediated response and the release of proinflammatory cytokines.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> Targeting monomeric species has not resulted in robust clinical efficacy, whereas targeting A<italic toggle="yes">&#946;</italic> in the form of oligomers, protofibrils, and plaques has shown evidence of slowing clinical decline.<xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref> Findings from a preclinical study revealed that passive immunization mitigated cognitive deficits even before the amyloid plaques are fully eliminated.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> However, humanized monoclonal antibodies solanezumab and bapineuzumab failed to improve cognitive impairment in patients with mild-to-moderate AD.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> A double-blind, randomized, placebo-controlled, phase 3 trial involving patients with mild-to-moderate AD, with one group of 1121 carriers of the apolipoprotein E (<italic toggle="yes">APOE</italic>) <italic toggle="yes">&#949;</italic>4 allele and the other with 1331 noncarriers showed that bapineuzumab did not improve clinical outcomes in AD patients despite treatment differences in biomarkers observed in <italic toggle="yes">APOE &#949;</italic>4 carriers.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. In 2 phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), 1012 and 1040 mild-to-moderate AD patients, respectively, received intravenous 400 mg solanezumab every 4 weeks for 18 months and showed no improvement.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> Although bapineuzumab reduced CSF cerebral amyloid plaques and phosphorylated tau protein levels, hallmarks of AD neuropathology, it did not improve cognitive function.<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> Recently, many studies have shown that humanized monoclonal anti-A<italic toggle="yes">&#946;</italic> antibodies including aducanumab and lecanemab improve cognitive functions in patients with AD.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> A recent systematic review and meta-analysis illustrated that bapineuzumab was safe in patients with AD, but it increased risk of vasogenic edema.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> A literature survey found that bapineuzumab is effective in improving cognitive function and daily activities but is associated with serious adverse effects such as headache, vomiting, delirium, convulsion, hypertension, and the development of neoplasms.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> A clinical trial showed that solanezumab did not improve cognitive impairment in patients with AD compared with placebo over a period of 240 weeks.<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> In addition, A<italic toggle="yes">&#946;</italic>-related imaging abnormalities (ARIAs) with edema occurred in &lt;1% of patients treated with anti-A<italic toggle="yes">&#946;</italic> antibodies, but it occurred in 29.2% of the participants in the solanezumab group compared to 32.8% of the placebo group.<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> However, Holdridge et al<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> found that low-dose solanezumab attenuates the progression of AD neuropathology in patients with mild dementia. Pooled analyses suggest a high probability that low-dose solanezumab has at least some effect on slowing the clinical progression of AD with mild dementia. Across cognitive and functional outcome measures, estimates from disease progression model analyses range from 15% to 30% slowing of cognitive decline with low-dose solanezumab in AD with mild dementia.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> Therefore, use of solanezumab in early but not late AD may be effective against cognitive impairment.</p><p id="p0055">Over 2 decades of gantenerumab development in the context of scientific discoveries has occurred in the broader AD field. Key findings from the field were incorporated into the gantenerumab phase 3 program, including confirmed amyloid positivity as an entry criterion, an enriched clinical trial population to ensure measurable clinical decline, data-driven exposure-response models to inform a safe and efficacious dosing regimen, and the use of several blood-based biomarkers. Subcutaneous formulation for more pragmatic implementation was prioritized as a key feature from the beginning of the gantenerumab development program. It has been suggested that gantenerumab is effective in treating cognitive impairment in patients with AD.<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> A meta-analysis and systematic review of clinical trials regarding the therapeutic efficacy of gantenerumab showed that gantenerumab has negative impacts on the cognitive outcomes in patients with AD.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Gantenerumab increases the incidence of ARIA with hemosiderosis.<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> Gantenerumab exhibits stronger binding to A<italic toggle="yes">&#946;</italic> fibrils than A<italic toggle="yes">&#946;</italic> protofibrils,<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> and this may explain a wide range of adverse events that are associated with the use of gantenerumab. A recent meta-analysis of phase 3 trial results of high-dose gantenerumab in prodromal and mild AD illustrated that gantenerumab had negative impacts on cognitive function in early AD.<xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> However, these clinical trials had several limitations such as assessment of original data and analysis sensitivity was not considered, which limits the clinical effects of gantenerumab.</p><p id="p0060">Moreover, the humanized monoclonal antibody crenezumab was previously evaluated in patients with mild AD. However, the results were contradictory due to heterogeneity of clinical trials.<xref rid="bib76" ref-type="bibr">76</xref>, <xref rid="bib77" ref-type="bibr">77</xref>, <xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref> Crenezumab at dose of 120 mg/kg was safe and well-tolerated by patients with mild-to-moderate AD.<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> A phase 2 clinical trial conducted in 2018 revealed that a high dose of crenezumab was effective in patients with mild AD.<xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> In 2019, Sink et al<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> found that crenezumab in a phase 3 clinical trial was effective even at high doses in the management of mild AD. Oligomeric forms of A<italic toggle="yes">&#946;</italic> protein (oA<italic toggle="yes">&#946;</italic>) are supposed to be predominantly responsible for neurotoxicity in AD, but it is not known whether anti-A<italic toggle="yes">&#946;</italic> antibodies are capable of lowering oA<italic toggle="yes">&#946;</italic> levels in humans. Interestingly, crenezumab has the ability to reduce CSF oA<italic toggle="yes">&#946;</italic>, a biomarker of anti-A<italic toggle="yes">&#946;</italic> agents.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> Among patients receiving crenezumab, 89% receiving subcutaneous and 86% receiving intravenous doses had lower levels of oA<italic toggle="yes">&#946;</italic> at week 69 compared with baseline. The difference in the proportion of patients with decreasing levels was significant for both treatment arms. No systematic alteration was detected in the placebo group, and equivalent portions exhibited negative and positive changes.<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> Conversely, 2 phase 3 randomized, placebo-controlled clinical trials disclosed that crenezumab did not mitigate the clinical impairment in patients with early AD.<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> Compared with previous trials, no new safety signals were identified, and ARIAs with edema were rare, mild, and transient.<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> However, a phase 3 clinical trial was terminated due to futility for the use of crenezumab in AD.<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref></p><p id="p0065">The humanized monoclonal antibody ponezumab, which mainly targets A<italic toggle="yes">&#946;</italic><sub>34-41</sub>, has been developed for the management of AD.<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> A randomized, placebo-controlled clinical trial of the use of ponezumab in multiple doses over a period of 18 months compared to placebo in AD patients illustrated that ponezumab was safe and well-tolerated but had low CSF penetration and little effect on cognitive function in patients with mild-to-moderate AD.<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> Therefore, ponezumab is ineffective in the management of mild-to-moderate AD. Leurent et al<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> revealed that ponezumab was ineffective in reducing cerebral amyloid angiopathy in patients with AD. During a phase 2 trial, the development of ponezumab was ceased as the results did not indicate clinical benefits or modifications in CSF biomarkers as the primary end point, although it was found to be safe and well-tolerated.<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref> Consequently, additional development of ponezumab has been obsolete. These findings indicate the lack of efficacy of ponezumab in the management of AD.</p><p id="p0070">Furthermore, lecanemab has a higher affinity for the soluble and large A<italic toggle="yes">&#946;</italic> protofibrils, but its efficacy was low in patients with mild AD.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> Data from phase 2 clinical trials have proposed the opportunity for a good efficacy signal and practicable risk of ARIAs.<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref> A systematic review and meta-analysis of clinical trials revealed that donanemab had limited therapeutic efficacy in treating mild-to-moderate AD.<xref rid="bib86" ref-type="bibr"><sup>86</sup></xref> A human antibody solution, gammagard, derived from healthy volunteers was evaluated in treating AD in humans. This immunoglobulin has an immunomodulatory effect by inducing A<italic toggle="yes">&#946;</italic> phagocytosis by microglia.<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> A pilot study illustrated that gammagard can stabilize cognitive function in patients with AD. However, reports from the Octagams phase 2 clinical trial found no clinical efficacy for reducing AD progression.<xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> Finally, 3 studies evaluating aducanumab in phase 2 clinical trials illustrated that use of aducanumab in patients with early AD was associated with ARIAs with edema in 35.2% of patients.<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref></p><p id="p0075">Therefore, antibodies directed to the C-terminal of the central region of A<italic toggle="yes">&#946;</italic>, such as crenezumab, solanezumab, and ponezumab, have insignificant effects on the clearance of amyloid plaques or slowing of AD progression.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref> However, antibodies directed to the N-terminal region of A<italic toggle="yes">&#946;</italic>, such as donanemab, lecanemab, and aducanumab, have some efficacy in clearance of amyloid plaques or slowing of AD progression according to many clinical trials. However, antibodies directed to the epitopes of N-terminal and central regions of A<italic toggle="yes">&#946;</italic>, such as gantenerumab, failed to clear of amyloid plaques in AD patients.<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref></p><p id="p0080">These outcomes highlight that passive immunization in AD is neither categorically effective nor ineffective. There is robust evidence that certain anti-A<italic toggle="yes">&#946;</italic> antibodies can achieve their biological target of plaque removal and confer a statistically significant, albeit modest, slowing of clinical decline in patients with early symptomatic AD. The finding represents a major scientific advancement and provides the first clear evidence of disease modification. However, this effectiveness is tempered by significant limitations: the benefit is modest, restricted to early stages, and is accompanied by ARIAs, and long-term outcomes are uncertain. Previous failures of other antibodies underscore the complexity. Therefore, while passive immunization has moved from purely ineffective to showing conditional effectiveness for a specific patient group, it is not a panacea. Its role is evolving, requiring careful patient selection, risk management, and further research to optimize benefits and understand long-term implications. The evidence base supports its potential as a valuable tool, but one with significant caveats<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>, <xref rid="bib80" ref-type="bibr">80</xref><sup>,</sup><xref rid="bib82" ref-type="bibr">82</xref>, <xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref><sup>,</sup><xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> (<xref rid="tbl3" ref-type="table">Table 3</xref>). Further studies are recommended to detect the clinical efficacy of passive immunization in AD.<table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Passive immunization and role of anti-A<italic toggle="yes">&#946;</italic> immunotherapy in AD</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Anti-A<italic toggle="yes">&#946;</italic> Igs</th><th colspan="1" rowspan="1">Findings</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Bapineuzumab</td><td colspan="1" rowspan="1">Did not improve clinical outcomes in patients with AD</td><td colspan="1" rowspan="1">Chhabra et al<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Solanezumab</td><td colspan="1" rowspan="1">Did not improve clinical outcomes in patients with AD</td><td colspan="1" rowspan="1">Chhabra et al<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Aducanumab and lecanemab</td><td colspan="1" rowspan="1">Improved cognitive function in patients with AD</td><td colspan="1" rowspan="1">Jeremic et al<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>, Jeong et al<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Gantenerumab</td><td colspan="1" rowspan="1">Effective in treating cognitive impairment in patients with AD, but it is associated with ARIA-H and other serious adverse effects.</td><td colspan="1" rowspan="1">Doody et al<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Crenezumab</td><td colspan="1" rowspan="1">Has controversial effects on cognitive function in patients with AD</td><td colspan="1" rowspan="1">Bateman et al<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref>; Asnaghi et al<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref>; Sink et al<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref>; Melo et al<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref>; Ostrowitzki et al<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Ponezumab</td><td colspan="1" rowspan="1">Safe and well-tolerated but has low CSF penetration and little effect on the cognitive function in patients with mild-to-moderate AD</td><td colspan="1" rowspan="1">Landen et al<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref>; Leurent et al<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref>; Vaz and Silvestre<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Lecanemab</td><td colspan="1" rowspan="1">Low efficacy in patients with mild AD</td><td colspan="1" rowspan="1">Vitek et al<xref rid="bib85" ref-type="bibr"><sup>85</sup></xref></td></tr><tr><td colspan="1" rowspan="1">Gammagard</td><td colspan="1" rowspan="1">Human antibody solution derived from healthy volunteers that has an immunomodulatory effect by inducing A<italic toggle="yes">&#946;</italic> phagocytosis by microglia; improves cognitive function in patients with AD</td><td colspan="1" rowspan="1">Puli et al<xref rid="bib90" ref-type="bibr"><sup>90</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>ARIA-H, amyloid-related imaging abnormalities with hemosiderosis.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4.2"><label>4.2</label><title>Active immunization</title><p id="p0085">Active immunotherapy has been extensively studied in A<italic toggle="yes">&#946;</italic>-targeted therapy due to its safety and promising antibody response.<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> Active immunotherapy against amyloid plaques is more effective in the early stages of AD neuropathology, highlighting the importance of early diagnosis of AD.<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> Antiamyloid immunotherapy has promising therapeutic efficacy against AD neuropathology before the onset of symptomatic disease. For example, a DNA A<italic toggle="yes">&#946;</italic><sub>42</sub> trimer vaccine may delay the progression of AD.<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref> Active immunization and active immunotherapy antibodies have been suggested to play a critical role in the management of AD.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref> Preclinical studies have indicated that immunization against neurotoxic A<italic toggle="yes">&#946;</italic> in mice is also beneficial against human AD.<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> The first clinical trial considering the role of active immunization against AD was performed in 2000 using an A<italic toggle="yes">&#946;</italic><sub>1-42</sub> vaccine (AN1792).<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> In 2005, AN1792 was evaluated in a clinical trial of 80 patients with AD; the result was a weak effect of this vaccine on the amelioration of cognitive function in AD patients.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> In a phase 2 clinical trial, Pride et al<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> revealed that 50% of patients with AD developed immune response and antibody production. However, 6% of patients with AD developed meningoencephalitis in response to AN1792 vaccine due an exaggerated T cell response.<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> A previous study published by <italic toggle="yes">JAMA</italic> in 2007 illustrated that immunization with AN1792 resulted in significant reduction of amyloid deposits in AD brains.<xref rid="bib98" ref-type="bibr"><sup>98</sup></xref> Brain histopathology of patients with AD treated with AN1792 revealed moth-eaten amyloid plaques due to activation of microglia for clearance of A<italic toggle="yes">&#946;</italic>.<xref rid="bib99" ref-type="bibr"><sup>99</sup></xref> Despite of the great effects of antiamyloid vaccines on the brain amyloid pathology, the enhancement effects of antiamyloid vaccines on cognitive function are limited.<xref rid="bib100" ref-type="bibr"><sup>100</sup></xref> However, postmortem examination of brains that received A<italic toggle="yes">&#946;</italic> immunization showed histopathological changes similar to that present in AD, characterized by increasing expression of proteins involved in DNA methylation.<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> In a postmortem study, 16 patients with AD who received AN1792 were compared to 65 patients with AD with systemic infection, 70 patients with AD without infection, and 48 healthy controls. The results showed that DNA methylation genes were upregulated in patients with AD who received AN1792 and in those with systemic infection.<xref rid="bib101" ref-type="bibr"><sup>101</sup></xref> This study proposed that the AN1792 vaccine may exacerbate AD neuropathology.</p><p id="p0090">CAD106 is a second-generation vaccine that has completed the phase 2 clinical trial; it reduced A<italic toggle="yes">&#946;</italic> by 75% without severe adverse events.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> CAD106 triggered strong immune response against A<italic toggle="yes">&#946;</italic> by increasing of IgG in a dose-dependent manner in patients with AD.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Despite the development of ARIAs in 6 patients, none were symptomatic.<xref rid="bib102" ref-type="bibr"><sup>102</sup></xref> Therefore, CAD106 is safe and well-tolerated and effective in patients with AD. A recent clinical trial on 65 patients with AD positive for ApoE4 with/without amyloid deposition received intramuscular CAD106 450 <italic toggle="yes">&#956;</italic>g (<italic toggle="yes">n</italic> = 42) or placebo (<italic toggle="yes">n</italic> = 23) followed for 24 months showed that CAD106 increased IgG and reduced amyloid deposits as measured by positron emission tomography compared to placebo.<xref rid="bib103" ref-type="bibr"><sup>103</sup></xref> A systematic review and meta-analysis of 16 randomized and nonrandomized clinical trials illustrated that A<italic toggle="yes">&#946;</italic> vaccines in phase 1 and phase 2 clinical trials are safe and well-tolerated and have a promising immune response and efficacy against AD neuropathology.<xref rid="bib104" ref-type="bibr"><sup>104</sup></xref> However, phase 3 clinical trials are recommended to determine the therapeutic efficacy and safety of A<italic toggle="yes">&#946;</italic> vaccines in patients with AD.</p><p id="p0095">ACC-001 is an A<italic toggle="yes">&#946;</italic> vaccine known as vanutide cridificar that has a potent immunotherapeutic effect against brain amyloid deposits. It has completed phase 2 clinical trials, although it was discontinued by the pharmaceutical company.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> ACC-001 has an acceptable safety profile but has little clinical benefit in patients with AD.<xref rid="bib105" ref-type="bibr"><sup>105</sup></xref> In addition, a clinical trial found that ACC-001 can efficiently reduce amyloid deposits in patients with AD.<xref rid="bib106" ref-type="bibr"><sup>106</sup></xref> Moreover, ACI-24, which is A<italic toggle="yes">&#946;</italic><sub>1-15</sub> tetra-palmitoylated peptide, may be effective for the treatment of AD. Preclinical findings showed that immunization of monkeys and mice with ACI-24 increased the IgG response, which identified the neurotoxic A<italic toggle="yes">&#946;</italic>-including oligomers and truncated pyroglutamate oligomers.<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> ACI-24 may have a plaque reduction effect in AD and Down syndrome-related AD.<xref rid="bib107" ref-type="bibr"><sup>107</sup></xref> Rudan et al<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref> found that ACI-24 has beneficial effects on plaque neuropathology and microglial phenotype in an AD mouse model. ACI-24 activates microglia activity, which is impaired in AD, leading to elimination of amyloid plaques in amyloidosis mouse model.<xref rid="bib108" ref-type="bibr"><sup>108</sup></xref> Furthermore, AF205 and MER5101 vaccines are in preclinical stages and under laboratory investigation.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="bib109" ref-type="bibr"><sup>109</sup></xref> Finally, the AD02 vaccine has the ability to reduce amyloid plaques.<xref rid="bib110" ref-type="bibr"><sup>110</sup></xref> As a vaccination antigen, AD02 can trigger an antibody immune response against A<italic toggle="yes">&#946;</italic> without any effect on APP and sAPP<italic toggle="yes">&#945;</italic>. AD02 reduced amyloid burden and improved the cognitive function in mice.<xref rid="bib111" ref-type="bibr"><sup>111</sup></xref> Thus, AD02 may be a future promising therapy in human AD.</p><p id="p0100">Taken together, both passive and active amyloid immunotherapies have potential effects on brain amyloid deposits (<xref rid="fig2" ref-type="fig">Fig. 2</xref>), but there are controversial results regarding their safety and clinical efficacy in AD. Therefore, additional studies are recommended to address this concern.<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The mechanism of passive and active immunization in Alzheimer disease (AD). Active immunotherapy involves administering an <italic toggle="yes">&#946;</italic>-amyloid (A<italic toggle="yes">&#946;</italic>) fragment to stimulate B cells, leading to the production of endogenous antibodies against A<italic toggle="yes">&#946;</italic>. These antibodies bind to soluble A<italic toggle="yes">&#946;</italic>, preventing its aggregation into plaques and reducing AD neuropathology. Passive immunotherapy employs direct administration of monoclonal antibodies targeting A<italic toggle="yes">&#946;</italic>, which similarly neutralize A<italic toggle="yes">&#946;</italic> and inhibit plaque formation. Both strategies aim to mitigate A<italic toggle="yes">&#946;</italic>-driven pathology, including amyloid plaque deposition, thereby alleviating disease progression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec></sec><sec id="sec5"><label>5</label><title>Limitations and future perspectives</title><p id="p0105">The limitations of anti-A<italic toggle="yes">&#946;</italic> immunotherapy for AD include reliance on preclinical models that inadequately replicate human AD complexity and heterogeneity in clinical trials. In addition, patient cohorts, intervention timing often during late-stage neurodegeneration, the dual physiological and pathological roles of A<italic toggle="yes">&#946;</italic> complicating therapeutic depletion, and adverse effects such as ARIAs and cognitive decline are worsening. Additionally, the narrow focus on A<italic toggle="yes">&#946;</italic> overlooks tau pathology, neuroinflammation, and metabolic dysfunction. Future efforts should prioritize early intervention guided by biomarkers such as CSF A<italic toggle="yes">&#946;</italic><sub>42</sub>, tau positron emission tomography in preclinical AD, combination therapies targeting A<italic toggle="yes">&#946;</italic>, tau, and neuroinflammation, and personalized approaches leveraging <italic toggle="yes">APOE</italic> genotyping to mitigate risks. Advancements in drug delivery systems, next-generation antibodies selective for toxic A<italic toggle="yes">&#946;</italic> conformations, and longitudinal real-world studies are critical to optimize safety and efficacy. Integrating nonpharmacological strategies, such as lifestyle interventions with immunotherapy, may enhance cognitive resilience, while revisiting the physiological functions of A<italic toggle="yes">&#946;</italic> could refine therapies to spare synaptic benefits. Overcoming these challenges demands a paradigm shift toward multifactorial, biomarker-guided strategies that balance amyloid modulation with broader AD pathomechanisms.</p></sec><sec id="sec6"><label>6</label><title>Conclusions</title><p id="p0110">AD is defined by the presence of extracellular A<italic toggle="yes">&#946;</italic> plaques and intracellular NFTs. Therefore, it is sensible to inhibit A<italic toggle="yes">&#946;</italic> processing in AD to halt the progression of the disease. Nevertheless, a large number of clinical trials since 1984 that targeted A<italic toggle="yes">&#946;</italic> failed to mitigate cognitive impairment in AD patients. Targeting of A<italic toggle="yes">&#946;</italic> in the early stage of AD is more successful in preventing the deterioration of cognitive function. In clinical trials, A<italic toggle="yes">&#946;</italic> could be the prime target in preventing the development and progression of AD. However, inhibition of normally present A<italic toggle="yes">&#946;</italic> may adversely affect cognitive function and the clinical course of AD.</p><p id="p0115">Mounting evidence suggests that brain soluble A<italic toggle="yes">&#946;</italic> is essential for memory function by regulating hippocampal synaptic plasticity and LTP through activation of nicotinic acetylcholine receptors. A<italic toggle="yes">&#946;</italic> has a neuroprotective effect, and deletion of A<italic toggle="yes">&#946;</italic> may worsen the neuronal function activity and cognitive function. The negative and undesirable effects of anti-A<italic toggle="yes">&#946;</italic> immunotherapies highlights that depletion of brain A<italic toggle="yes">&#946;</italic> is linked with the development of cognitive impairment due to synaptic failure and dysfunction. These outcomes suggest that immunization against A<italic toggle="yes">&#946;</italic> in treating AD may be ineffective and associated with adverse events. Further studies are recommended to detect the clinical efficacy of passive immunization in AD. Active immunotherapy has been extensively studied in A<italic toggle="yes">&#946;</italic>-targeted therapy due to safety and a promising antibody response. Anti-A<italic toggle="yes">&#946;</italic> immunotherapy has a promising therapeutic efficacy against development of AD neuropathology before the onset of symptomatic disease. Collectively, both passive and active amyloid immunotherapies have controversial effects regarding their safety and clinical efficacy in AD. Therefore, additional studies are recommended.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflict of interest</title><p id="p0120">The authors declare no conflicts of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Alsayegh</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>A potential link between visceral obesity and risk of Alzheimer&#8217;s disease</article-title><source>Neurochem Res</source><volume>48</volume><issue>3</issue><year>2023</year><fpage>745</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1007/S11064-022-03817-4</pub-id><pub-id pub-id-type="pmid">36409447</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G.E.</given-names></name></person-group><article-title>Benzodiazepines in Alzheimer&#8217;s disease: beneficial or detrimental effects</article-title><source>Inflammopharmacology</source><volume>31</volume><issue>1</issue><year>2023</year><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">36418599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10787-022-01099-4</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jabir</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Albuhadily</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Rafeeq</surname><given-names>M.F.</given-names></name></person-group><article-title>The link between metabolic syndrome and Alzheimer disease: a mutual relationship and long rigorous investigation</article-title><source>Ageing Res Rev</source><volume>91</volume><year>2023</year><object-id pub-id-type="publisher-id">102084</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.102084</pub-id><pub-id pub-id-type="pmid">37802319</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G.E.S.</given-names></name></person-group><article-title>Long-term use of metformin and Alzheimer&#8217;s disease: beneficial or detrimental effects</article-title><source>Inflammopharmacology</source><volume>31</volume><issue>3</issue><year>2023</year><fpage>1107</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1007/s10787-023-01163-7</pub-id><pub-id pub-id-type="pmid">36849855</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Sulaiman</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>H.A.</given-names></name><etal/></person-group><article-title>Beyond amyloid plaque, targeting <italic toggle="yes">&#945;</italic>-synuclein in Alzheimer disease: the battle continues</article-title><source>Ageing Res Rev</source><volume>105</volume><year>2025</year><object-id pub-id-type="publisher-id">102684</object-id><pub-id pub-id-type="doi">10.1016/J.ARR.2025.102684</pub-id><pub-id pub-id-type="pmid">39914501</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Alsayegh</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Insights on benzodiazepines&#8217; potential in Alzheimer&#8217;s disease</article-title><source>Life Sci</source><volume>320</volume><year>2023</year><object-id pub-id-type="publisher-id">121532</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2023.121532</pub-id><pub-id pub-id-type="pmid">36858314</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><etal/></person-group><article-title>The probable role of tissue plasminogen activator/neuroserpin axis in Alzheimer&#8217;s disease: a new perspective</article-title><source>Acta Neurol Belg</source><volume>124</volume><issue>2</issue><year>2024</year><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">37917293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13760-023-02403-x</pub-id><pub-id pub-id-type="pmcid">PMC10965687</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pubmed" xlink:href="40021594"/></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>AlAnazi</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Alexiou</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Primary hypothyroidism and Alzheimer&#8217;s Disease: a tale of two</article-title><source>Cell Mol Neurobiol</source><volume>43</volume><issue>7</issue><year>2023</year><fpage>3405</fpage><lpage>3416</lpage><pub-id pub-id-type="pmid">37540395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-023-01392-y</pub-id><pub-id pub-id-type="pmcid">PMC10477255</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bryce</surname><given-names>R.</given-names></name><name name-style="western"><surname>Albanese</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wimo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ferri</surname><given-names>C.P.</given-names></name></person-group><article-title>The global prevalence of dementia: a systematic review and metaanalysis</article-title><source>Alzheimers Dement</source><volume>9</volume><issue>1</issue><year>2013</year><fpage>63</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">23305823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2012.11.007</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><article-title>GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title><source>Lancet Public Health</source><volume>7</volume><issue>2</issue><year>2022</year><fpage>e105</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(21)00249-8</pub-id><pub-id pub-id-type="pmid">34998485</pub-id><pub-id pub-id-type="pmcid">PMC8810394</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Jabir</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><etal/></person-group><article-title>Evaluation and targeting of amyloid precursor protein (APP)/amyloid beta (A<italic toggle="yes">&#946;</italic>) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel</article-title><source>Ageing Res Rev</source><volume>92</volume><year>2023</year><object-id pub-id-type="publisher-id">102119</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2023.102119</pub-id><pub-id pub-id-type="pmid">37931848</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Dar</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Glazner</surname><given-names>G.W.</given-names></name></person-group><article-title>Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP<italic toggle="yes">&#945;</italic>)</article-title><source>Cell Mol Life Sci</source><volume>77</volume><issue>12</issue><year>2020</year><fpage>2315</fpage><lpage>2330</lpage><pub-id pub-id-type="pmid">31960113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-019-03404-x</pub-id><pub-id pub-id-type="pmcid">PMC11105086</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Alsubaie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><etal/></person-group><article-title>Statins use in Alzheimer disease: bane or boon from frantic search and narrative review</article-title><source>Brain Sci</source><volume>12</volume><issue>10</issue><year>2022</year><fpage>1290</fpage><pub-id pub-id-type="doi">10.3390/BRAINSCI12101290</pub-id><pub-id pub-id-type="pmid">36291224</pub-id><pub-id pub-id-type="pmcid">PMC9599431</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Abdulhadi</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hussien</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Al-Niemi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name></person-group><article-title>Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review</article-title><source>Brain Circ</source><volume>6</volume><issue>2</issue><year>2020</year><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">33033776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/bc.bc_42_19</pub-id><pub-id pub-id-type="pmcid">PMC7511915</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Muralidar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ambi</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Sekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thirumalai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Palaniappan</surname><given-names>B.</given-names></name></person-group><article-title>Role of tau protein in Alzheimer&#8217;s disease: the prime pathological player</article-title><source>Int J Biol Macromol</source><volume>163</volume><year>2020</year><fpage>1599</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">32784025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2020.07.327</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Wegmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group><article-title>A current view on Tau protein phosphorylation in Alzheimer&#8217;s disease</article-title><source>Curr Opin Neurobiol</source><volume>69</volume><year>2021</year><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">33892381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2021.03.003</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.B.</given-names></name><etal/></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><volume>388</volume><issue>10043</issue><year>2016</year><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">26921134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)01124-1</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Interaction between A<italic toggle="yes">&#946;</italic> and Tau in the Pathogenesis of Alzheimer&#8217;s Disease</article-title><source>Int J Biol Sci</source><volume>17</volume><issue>9</issue><year>2021</year><fpage>2181</fpage><lpage>2192</lpage><pub-id pub-id-type="doi">10.7150/IJBS.57078</pub-id><pub-id pub-id-type="pmid">34239348</pub-id><pub-id pub-id-type="pmcid">PMC8241728</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>F.F.</given-names></name></person-group><article-title>Role of cholinergic signaling in Alzheimer&#8217;s disease</article-title><source>Molecules</source><volume>27</volume><issue>6</issue><year>2022</year><fpage>1816</fpage><pub-id pub-id-type="pmid">35335180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27061816</pub-id><pub-id pub-id-type="pmcid">PMC8949236</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Marucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buccioni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ben</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Lambertucci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Volpini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amenta</surname><given-names>F.</given-names></name></person-group><article-title>Efficacy of acetylcholinesterase inhibitors in Alzheimer&#8217;s disease</article-title><source>Neuropharmacology</source><volume>190</volume><year>2021</year><object-id pub-id-type="publisher-id">108352</object-id><pub-id pub-id-type="doi">10.1016/J.NEUROPHARM.2020.108352</pub-id><pub-id pub-id-type="pmid">33035532</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mesulam</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cuello</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>The cholinergic system in the pathophysiology and treatment of Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>141</volume><issue>7</issue><year>2018</year><fpage>1917</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">29850777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy132</pub-id><pub-id pub-id-type="pmcid">PMC6022632</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Mangialasche</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Clinical trials and late-stage drug development for Alzheimer&#8217;s disease: an appraisal from 1984 to 2014</article-title><source>J Intern Med</source><volume>275</volume><issue>3</issue><year>2014</year><fpage>251</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/joim.12191</pub-id><pub-id pub-id-type="pmid">24605808</pub-id><pub-id pub-id-type="pmcid">PMC3956752</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Jeremic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Navarro-L&#243;pez</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Jim&#233;nez-D&#237;az</surname><given-names>L.</given-names></name></person-group><article-title>Efficacy and safety of anti-amyloid-<italic toggle="yes">&#946;</italic> monoclonal antibodies in current Alzheimer&#8217;s disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis</article-title><source>Ageing Res Rev</source><volume>90</volume><year>2023</year><object-id pub-id-type="publisher-id">102012</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2023.102012</pub-id><pub-id pub-id-type="pmid">37423541</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Jeremic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Navarro-Lopez</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Jimenez-Diaz</surname><given-names>L.</given-names></name></person-group><article-title>Clinical benefits and risks of antiamyloid antibodies in sporadic Alzheimer disease: systematic review and network meta-analysis with a web application</article-title><source>J Med Internet Res</source><volume>27</volume><year>2025</year><object-id pub-id-type="publisher-id">e68454</object-id><pub-id pub-id-type="doi">10.2196/68454</pub-id><pub-id pub-id-type="pmcid">PMC12012406</pub-id><pub-id pub-id-type="pmid">40194268</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Incidence of amyloid-related imaging abnormalities in phase III clinical trials of anti-amyloid-<italic toggle="yes">&#946;</italic> immunotherapy: an updated meta-analysis</article-title><source>Neurology</source><volume>104</volume><issue>8</issue><year>2025</year><object-id pub-id-type="publisher-id">e68454</object-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000213483</pub-id><pub-id pub-id-type="pmid">40112274</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.J.</given-names></name></person-group><article-title>Early intervention in Alzheimer&#8217;s disease: how early is early enough?</article-title><source>Neurosci Bull</source><volume>36</volume><issue>2</issue><year>2020</year><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">31494835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12264-019-00429-x</pub-id><pub-id pub-id-type="pmcid">PMC6977799</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.M.</given-names></name></person-group><article-title>The role of astrocytes in amyloid production and Alzheimer&#8217;s disease</article-title><source>Open Biol</source><volume>7</volume><issue>12</issue><year>2017</year><object-id pub-id-type="publisher-id">170228</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rsob.170228</pub-id><pub-id pub-id-type="pmcid">PMC5746550</pub-id><pub-id pub-id-type="pmid">29237809</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sul</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name></person-group><article-title>Cerebrospinal fluid <italic toggle="yes">&#946;</italic>-amyloid<sub>1-42</sub> levels in the differential diagnosis of Alzheimer&#8217;s disease&#8212;systematic review and meta-analysis</article-title><source>PLoS One</source><volume>10</volume><issue>2</issue><year>2015</year><object-id pub-id-type="publisher-id">e0116802</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0116802</pub-id><pub-id pub-id-type="pmcid">PMC4339391</pub-id><pub-id pub-id-type="pmid">25710596</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name></person-group><article-title>A review of application of A<italic toggle="yes">&#946;</italic><sub>42/40</sub> ratio in diagnosis and prognosis of Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><volume>90</volume><issue>2</issue><year>2022</year><fpage>495</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">36155521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-220673</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Puzzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Privitera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fa&#8217;</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Endogenous amyloid-<italic toggle="yes">&#946;</italic> is necessary for hippocampal synaptic plasticity and memory</article-title><source>Ann Neurol</source><volume>69</volume><issue>5</issue><year>2011</year><fpage>819</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">21472769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22313</pub-id><pub-id pub-id-type="pmcid">PMC4071456</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Rolland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jacquier-Sarlin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of A<italic toggle="yes">&#946;</italic> oligomers on neuronal APP triggers a vicious cycle leading to the propagation of synaptic plasticity alterations to healthy neurons</article-title><source>J Neurosci</source><volume>40</volume><issue>27</issue><year>2020</year><fpage>5161</fpage><lpage>5176</lpage><pub-id pub-id-type="pmid">32444385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2501-19.2020</pub-id><pub-id pub-id-type="pmcid">PMC7329309</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Barthet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mulle</surname><given-names>C.</given-names></name></person-group><article-title>Presynaptic failure in Alzheimer&#8217;s disease</article-title><source>Prog Neurobiol</source><volume>194</volume><year>2020</year><object-id pub-id-type="publisher-id">101801</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2020.101801</pub-id><pub-id pub-id-type="pmid">32428558</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Morley</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Farr</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>A physiological role for amyloid-<italic toggle="yes">&#946;</italic> protein: enhancement of learning and memory</article-title><source>J Alzheimers Dis</source><volume>19</volume><issue>2</issue><year>2010</year><fpage>441</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1230</pub-id><pub-id pub-id-type="pmid">19749407</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Ricciarelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fedele</surname><given-names>E.</given-names></name></person-group><article-title>The amyloid cascade hypothesis in Alzheimer&#8217;s disease: it&#8217;s time to change our mind</article-title><source>Curr Neuropharmacol</source><volume>15</volume><issue>6</issue><year>2017</year><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.2174/1570159X15666170116143743</pub-id><pub-id pub-id-type="pmid">28093977</pub-id><pub-id pub-id-type="pmcid">PMC5652035</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Lipton</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Oligomeric A<italic toggle="yes">&#946;</italic>-induced synaptic dysfunction in Alzheimer&#8217;s disease</article-title><source>Mol Neurodegener</source><volume>9</volume><year>2014</year><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-9-48</pub-id><pub-id pub-id-type="pmid">25394486</pub-id><pub-id pub-id-type="pmcid">PMC4237769</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Early impairment of cortical circuit plasticity and connectivity in the 5XFAD Alzheimer&#8217;s disease mouse model</article-title><source>Transl Psychiatry</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>371</fpage><pub-id pub-id-type="pmid">36075886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-02132-4</pub-id><pub-id pub-id-type="pmcid">PMC9458752</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Koppensteiner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Trinchese</surname><given-names>F.</given-names></name><name name-style="western"><surname>F&#224;</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric A<italic toggle="yes">&#946;</italic>42: an early index of Alzheimer&#8217;s disease</article-title><source>Sci Rep</source><volume>6</volume><year>2016</year><object-id pub-id-type="publisher-id">32553</object-id><pub-id pub-id-type="doi">10.1038/srep32553</pub-id><pub-id pub-id-type="pmcid">PMC5007504</pub-id><pub-id pub-id-type="pmid">27581852</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Busche</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Grienberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Decreased amyloid-<italic toggle="yes">&#946;</italic> and increased neuronal hyperactivity by immunotherapy in Alzheimer&#8217;s models</article-title><source>Nat Neurosci</source><volume>18</volume><issue>12</issue><year>2015</year><fpage>1725</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1038/nn.4163</pub-id><pub-id pub-id-type="pmid">26551546</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Kazim</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>K.</given-names></name></person-group><article-title>Early-onset network hyperexcitability in presymptomatic Alzheimer&#8217;s disease transgenic mice is suppressed by passive immunization with anti-human APP/A<italic toggle="yes">&#946;</italic> antibody and by mGluR5 blockade</article-title><source>Front Aging Neurosci</source><volume>9</volume><year>2017</year><fpage>71</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2017.00071</pub-id><pub-id pub-id-type="pmid">28392767</pub-id><pub-id pub-id-type="pmcid">PMC5364175</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><etal/></person-group><article-title>BACE1 deficiency causes altered neuronal activity and neurodegeneration</article-title><source>J Neurosci</source><volume>30</volume><year>2010</year><fpage>8819</fpage><lpage>8829</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1334-10.2010</pub-id><pub-id pub-id-type="pmid">20592204</pub-id><pub-id pub-id-type="pmcid">PMC2902368</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Joseph-Mathurin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dorieux</surname><given-names>O.</given-names></name><name name-style="western"><surname>Trouche</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds</article-title><source>Neurobiol Aging</source><volume>34</volume><issue>11</issue><year>2013</year><fpage>2613</fpage><lpage>2622</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.05.013</pub-id><pub-id pub-id-type="pmid">23796662</pub-id><pub-id pub-id-type="pmcid">PMC4107237</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Plant</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Peers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>H.A.</given-names></name></person-group><article-title>The production of amyloid <italic toggle="yes">&#946;</italic> peptide is a critical requirement for the viability of central neurons</article-title><source>J Neurosci</source><volume>23</volume><issue>13</issue><year>2003</year><fpage>5531</fpage><lpage>5535</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-13-05531.2003</pub-id><pub-id pub-id-type="pmid">12843253</pub-id><pub-id pub-id-type="pmcid">PMC6741264</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Osta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alberini</surname><given-names>C.M.</given-names></name></person-group><article-title>Amyloid beta mediates memory formation</article-title><source>Learn Mem</source><volume>16</volume><issue>4</issue><year>2009</year><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1101/lm.1310209</pub-id><pub-id pub-id-type="pmid">19318468</pub-id><pub-id pub-id-type="pmcid">PMC2661754</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tournoy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Phenotypic and biochemical analysis of BACE1- and BACE2-deficient mice</article-title><source>J Biol Chem</source><volume>280</volume><issue>35</issue><year>2005</year><fpage>30797</fpage><lpage>30806</lpage><pub-id pub-id-type="doi">10.1074/jbc.M505249200</pub-id><pub-id pub-id-type="pmid">15987683</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Koike</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>J.</given-names></name><etal/></person-group><article-title>APP knockout mice experience acute mortality as the result of ischemia</article-title><source>PLoS One</source><volume>7</volume><issue>8</issue><year>2012</year><object-id pub-id-type="publisher-id">e42665</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0042665</pub-id><pub-id pub-id-type="pmcid">PMC3415410</pub-id><pub-id pub-id-type="pmid">22912719</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Pajoohesh-Ganji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pal-Ghosh</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Inhibition of amyloid precursor protein secretases reduces recovery after spinal cord injury</article-title><source>Brain Res</source><volume>1560</volume><year>2014</year><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/J.BRAINRES.2014.02.049</pub-id><pub-id pub-id-type="pmid">24630972</pub-id><pub-id pub-id-type="pmcid">PMC4129635</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Chhabra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Solanki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saravanabawan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Venkiteswaran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nimmathota</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Modi</surname><given-names>N.M.</given-names></name></person-group><article-title>A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer&#8217;s disease</article-title><source>Expert Opin Biol Ther</source><volume>24</volume><issue>11</issue><year>2024</year><fpage>1261</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1080/14712598.2024.2416947</pub-id><pub-id pub-id-type="pmid">39432414</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Coric</surname><given-names>V.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial</article-title><source>JAMA Neurol</source><volume>72</volume><issue>11</issue><year>2015</year><fpage>1324</fpage><lpage>1333</lpage><pub-id pub-id-type="doi">10.1001/JAMANEUROL.2015.0607</pub-id><pub-id pub-id-type="pmid">26414022</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Coric</surname><given-names>V.</given-names></name><name name-style="western"><surname>Van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and tolerability of the &#947;-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease</article-title><source>Arch Neurol</source><volume>69</volume><issue>11</issue><year>2012</year><fpage>1430</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1001/ARCHNEUROL.2012.2194</pub-id><pub-id pub-id-type="pmid">22892585</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Doody</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A phase 3 trial of semagacestat for treatment of Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>369</volume><issue>4</issue><year>2013</year><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1210951</pub-id><pub-id pub-id-type="pmid">23883379</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>H.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease and the <italic toggle="yes">&#946;</italic>-amyloid peptide</article-title><source>J Alzheimers Dis</source><volume>19</volume><issue>1</issue><year>2010</year><fpage>311</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-1221</pub-id><pub-id pub-id-type="pmid">20061647</pub-id><pub-id pub-id-type="pmcid">PMC2813509</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The amyloid-<italic toggle="yes">&#946;</italic> pathway in Alzheimer&#8217;s disease</article-title><source>Mol Psychiatry</source><volume>26</volume><issue>10</issue><year>2021</year><fpage>5481</fpage><lpage>5503</lpage><pub-id pub-id-type="doi">10.1038/S41380-021-01249-0</pub-id><pub-id pub-id-type="pmid">34456336</pub-id><pub-id pub-id-type="pmcid">PMC8758495</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Viola</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>W.L.</given-names></name></person-group><article-title>Amyloid <italic toggle="yes">&#946;</italic> oligomers in Alzheimer&#8217;s disease pathogenesis, treatment, and diagnosis</article-title><source>Acta Neuropathol</source><volume>129</volume><issue>2</issue><year>2015</year><fpage>183</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1007/S00401-015-1386-3</pub-id><pub-id pub-id-type="pmid">25604547</pub-id><pub-id pub-id-type="pmcid">PMC4390393</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>L.</given-names></name></person-group><article-title>The role of amyloid oligomers in neurodegenerative pathologies</article-title><source>Int J Biol Macromol</source><volume>181</volume><year>2021</year><fpage>582</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/J.IJBIOMAC.2021.03.113</pub-id><pub-id pub-id-type="pmid">33766600</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Role of A<italic toggle="yes">&#946;</italic> in Alzheimer&#8217;s-related synaptic dysfunction</article-title><source>Front Cell Dev Biol</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">964075</object-id><pub-id pub-id-type="doi">10.3389/FCELL.2022.964075</pub-id><pub-id pub-id-type="pmcid">PMC9459380</pub-id><pub-id pub-id-type="pmid">36092715</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Won</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>M.</given-names></name></person-group><article-title>Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer&#8217;s disease: a comprehensive review of the characteristics and therapeutic strategies</article-title><source>Transl Neurodegener</source><volume>14</volume><issue>1</issue><year>2025</year><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/S40035-025-00479-4</pub-id><pub-id pub-id-type="pmid">40133924</pub-id><pub-id pub-id-type="pmcid">PMC11938702</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Valiukas</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tangalakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Feehan</surname><given-names>J.</given-names></name></person-group><article-title>Microglial activation states and their implications for Alzheimer&#8217;s disease</article-title><source>J Prev Alzheimers Dis</source><volume>12</volume><issue>1</issue><year>2025</year><object-id pub-id-type="publisher-id">100013</object-id><pub-id pub-id-type="doi">10.1016/J.TJPAD.2024.100013</pub-id><pub-id pub-id-type="pmcid">PMC12184064</pub-id><pub-id pub-id-type="pmid">39800461</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Gireud-Goss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Urayama</surname><given-names>A.</given-names></name></person-group><article-title>Cerebral amyloid angiopathy and blood-brain barrier dysfunction</article-title><source>Neuroscientist</source><volume>27</volume><issue>6</issue><year>2020</year><fpage>668</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1177/1073858420954811</pub-id><pub-id pub-id-type="pmid">33238806</pub-id><pub-id pub-id-type="pmcid">PMC9853919</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Fantini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chahinian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yahi</surname><given-names>N.</given-names></name></person-group><article-title>Progress toward Alzheimer&#8217;s disease treatment: leveraging the Achilles&#8217; heel of A<italic toggle="yes">&#946;</italic> oligomers?</article-title><source>Protein Sci</source><volume>29</volume><issue>8</issue><year>2020</year><fpage>1748</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1002/PRO.3906</pub-id><pub-id pub-id-type="pmid">32567070</pub-id><pub-id pub-id-type="pmcid">PMC7380673</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Azargoonjahromi</surname><given-names>A.</given-names></name></person-group><article-title>The duality of amyloid-<italic toggle="yes">&#946;</italic>: its role in normal and Alzheimer&#8217;s disease states</article-title><source>Mol Brain</source><volume>17</volume><issue>1</issue><year>2024</year><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/S13041-024-01118-1</pub-id><pub-id pub-id-type="pmid">39020435</pub-id><pub-id pub-id-type="pmcid">PMC11256416</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Folch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ettcheto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petrov</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Review of the advances in treatment for Alzheimer disease: strategies for combating <italic toggle="yes">&#946;</italic>-amyloid protein</article-title><source>Neurologia (Engl Ed)</source><volume>33</volume><issue>1</issue><year>2018</year><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">25976937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nrl.2015.03.012</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Solfrizzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Logroscino</surname><given-names>G.</given-names></name></person-group><article-title>Amyloid-directed monoclonal antibodies for the treatment of Alzheimer&#8217;s disease: the point of no return?</article-title><source>Expert Opin Biol Ther</source><volume>14</volume><issue>10</issue><year>2014</year><fpage>1465</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">24981190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2014.935332</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Panza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Solfrizzi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Tortelli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santamato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Logroscino</surname><given-names>G.</given-names></name></person-group><article-title>Amyloid-based immunotherapy for Alzheimer&#8217;s disease in the time of prevention trials: the way forward</article-title><source>Expert Rev Clin Immunol</source><volume>10</volume><issue>3</issue><year>2014</year><fpage>405</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">24490853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/1744666X.2014.883921</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><etal/></person-group><article-title>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>370</volume><issue>4</issue><year>2014</year><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1304839</pub-id><pub-id pub-id-type="pmid">24450891</pub-id><pub-id pub-id-type="pmcid">PMC4159618</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Doody</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Farlow</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>370</volume><issue>4</issue><year>2014</year><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1312889</pub-id><pub-id pub-id-type="pmid">24450890</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.D.</given-names></name></person-group><article-title>Passive immunotherapy for Alzheimer&#8217;s disease: challenges &amp; future directions</article-title><source>J Transl Med</source><volume>22</volume><issue>1</issue><year>2024</year><fpage>430</fpage><pub-id pub-id-type="doi">10.1186/S12967-024-05248-X</pub-id><pub-id pub-id-type="pmid">38715084</pub-id><pub-id pub-id-type="pmcid">PMC11075320</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Tayeb</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Price</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Tarazi</surname><given-names>F.I.</given-names></name></person-group><article-title>Bapineuzumab and solanezumab for Alzheimer&#8217;s disease: is the &#8216;amyloid cascade hypothesis&#8217; still alive?</article-title><source>Expert Opin Biol Ther</source><volume>13</volume><issue>7</issue><year>2013</year><fpage>1075</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">23574434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2013.789856</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Safety analysis of bapineuzumab in the treatment of mild to moderate Alzheimer&#8217;s disease: a systematic review and meta-analysis</article-title><source>Comb Chem High Throughput Screen</source><volume>27</volume><issue>1</issue><year>2024</year><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">37076966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1386207326666230419095813</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>W.</given-names></name></person-group><article-title>Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-&#224;-vis placebo in mild or moderate Alzheimer&#8217;s disease</article-title><source>Front Neurol</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1147757</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2023.1147757</pub-id><pub-id pub-id-type="pmcid">PMC10050585</pub-id><pub-id pub-id-type="pmid">37006475</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Donohue</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Trial of solanezumab in preclinical Alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><volume>389</volume><issue>12</issue><year>2023</year><fpage>1096</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1056/NEJMOA2305032</pub-id><pub-id pub-id-type="pmid">37458272</pub-id><pub-id pub-id-type="pmcid">PMC10559996</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Holdridge</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Yaari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hoban</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name></person-group><article-title>Targeting amyloid <italic toggle="yes">&#946;</italic> in Alzheimer&#8217;s disease: meta-analysis of low-dose solanezumab in Alzheimer&#8217;s disease with mild dementia studies</article-title><source>Alzheimers Dement</source><volume>19</volume><issue>10</issue><year>2023</year><fpage>4619</fpage><lpage>4628</lpage><pub-id pub-id-type="pmid">36946603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13031</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schobel</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>14</volume><issue>1</issue><year>2022</year><fpage>178</fpage><pub-id pub-id-type="pmid">36447240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01110-8</pub-id><pub-id pub-id-type="pmcid">PMC9707418</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Sobral</surname><given-names>M.V.S.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>O.R.</given-names></name><etal/></person-group><article-title>Efficacy and safety of gantenerumab in the treatment of Alzheimer&#8217;s disease: A meta-analysis of randomized controlled trials</article-title><source>Arch Gerontol Geriatr Plus</source><volume>1</volume><issue>2</issue><year>2024</year><object-id pub-id-type="publisher-id">100016</object-id><pub-id pub-id-type="doi">10.1016/J.AGGP.2024.100016</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>S&#246;derberg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Johannesson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Lecanemab, aducanumab, and gantenerumab&#8212;binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer&#8217;s disease</article-title><source>Neurotherapeutics</source><volume>20</volume><issue>1</issue><year>2023</year><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">36253511</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13311-022-01308-6</pub-id><pub-id pub-id-type="pmcid">PMC10119362</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Teipel</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Temp</surname><given-names>A.G.M.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>M.W.</given-names></name></person-group><article-title>Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement (N Y)</source><volume>10</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e12454</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/trc2.12454</pub-id><pub-id pub-id-type="pmcid">PMC10883242</pub-id><pub-id pub-id-type="pmid">38389855</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Asnaghi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rabbia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ostrowitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.</given-names></name></person-group><article-title>Long-term safety and tolerability of escalating doses of crenezumab in patients with mild-to-moderate Alzheimer&#8217;s disease (P6.083)</article-title><source>Neurology</source><volume>88</volume><issue>16 suppl</issue><year>2017</year><object-id pub-id-type="publisher-id">P6.083</object-id><pub-id pub-id-type="doi">10.1212/wnl.88.16_supplement.p6.083</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease</article-title><source>Neurology</source><volume>90</volume><issue>21</issue><year>2018</year><fpage>e1889</fpage><lpage>e1897</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000005550</pub-id><pub-id pub-id-type="pmid">29695589</pub-id><pub-id pub-id-type="pmcid">PMC5962917</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Sink</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ostrowitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Millar</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer&#8217;s disease (CREAD) (P4.1-002)</article-title><source>Neurology</source><volume>92</volume><issue>15 suppl</issue><year>2019</year><object-id pub-id-type="publisher-id">P4.1-002</object-id><pub-id pub-id-type="doi">10.1212/wnl.92.15_supplement.p4.1-002</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Melo</surname><given-names>V.S.D.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>I.A.</given-names></name></person-group><article-title>Anti-amyloid-<italic toggle="yes">&#946;</italic> monoclonal antibodies as promising disease-modifying therapies in Alzheimer&#8217;s disease: a focus on aducanumab, lecanemab, crenezumab, gantenerumab and solanezumab</article-title><source>Eur Psychiatry</source><volume>66</volume><issue>supp1</issue><year>2023</year><object-id pub-id-type="publisher-id">S297</object-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Ostrowitzki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bittner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sink</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials</article-title><source>JAMA Neurol</source><volume>79</volume><issue>11</issue><year>2022</year><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2022.2909</pub-id><pub-id pub-id-type="pmid">36121669</pub-id><pub-id pub-id-type="pmcid">PMC9486635</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ostaszewski</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Target engagement in an Alzheimer trial: Crenezumab lowers amyloid <italic toggle="yes">&#946;</italic> oligomers in cerebrospinal fluid</article-title><source>Ann Neurol</source><volume>86</volume><issue>2</issue><year>2019</year><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">31168802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.25513</pub-id><pub-id pub-id-type="pmcid">PMC6771589</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Landen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Billing</surname><given-names>C.B.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Multiple-dose ponezumab for mild-to-moderate Alzheimer&#8217;s disease: Safety and efficacy</article-title><source>Alzheimer Dement (N Y)</source><volume>3</volume><issue>3</issue><year>2017</year><fpage>339</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2017.04.003</pub-id><pub-id pub-id-type="pmcid">PMC5651443</pub-id><pub-id pub-id-type="pmid">29067341</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Leurent</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Immunotherapy with ponezumab for probable cerebral amyloid angiopathy</article-title><source>Ann Clin Transl Neurol</source><volume>6</volume><issue>4</issue><year>2019</year><fpage>795</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1002/acn3.761</pub-id><pub-id pub-id-type="pmid">31020004</pub-id><pub-id pub-id-type="pmcid">PMC6469253</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Vaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silvestre</surname><given-names>S.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: recent treatment strategies</article-title><source>Eur J Pharmacol</source><volume>887</volume><year>2020</year><object-id pub-id-type="publisher-id">173554</object-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173554</pub-id><pub-id pub-id-type="pmid">32941929</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Vitek</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Decourt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.N.</given-names></name></person-group><article-title>Lecanemab (BAN2401): an anti&#8211;beta-amyloid monoclonal antibody for the treatment of Alzheimer disease</article-title><source>Expert Opin Investig Drugs</source><volume>32</volume><issue>2</issue><year>2023</year><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1080/13543784.2023.2178414</pub-id><pub-id pub-id-type="pmcid">PMC10275297</pub-id><pub-id pub-id-type="pmid">36749830</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Rashad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasool</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaheryar</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Donanemab for Alzheimer&#8217;s disease: a systematic review of clinical trials</article-title><source>Healthcare (Basel)</source><volume>11</volume><issue>1</issue><year>2022</year><fpage>32</fpage><pub-id pub-id-type="pmid">36611492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/healthcare11010032</pub-id><pub-id pub-id-type="pmcid">PMC9818878</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>D.A.</given-names></name></person-group><article-title>Intravenous immunoglobulin and Alzheimer&#8217;s disease: what now?</article-title><source>J Neuroinflammation</source><volume>10</volume><year>2013</year><fpage>70</fpage><pub-id pub-id-type="pmid">23735288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-10-70</pub-id><pub-id pub-id-type="pmcid">PMC3720252</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chalkias</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease</article-title><source>JAMA Neurol</source><volume>79</volume><issue>1</issue><year>2022</year><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">34807243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.4161</pub-id><pub-id pub-id-type="pmcid">PMC8609465</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Development of amyloid beta-directed antibodies against Alzheimer&#8217;s disease: twists and turns</article-title><source>Drug Discov Ther</source><volume>17</volume><issue>6</issue><year>2023</year><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">38220210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5582/ddt.2023.01215</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Puli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pomeshchik</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Olas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Malm</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koistinaho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanila</surname><given-names>H.</given-names></name></person-group><article-title>Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer&#8217;s disease</article-title><source>J Neuroinflammation</source><volume>9</volume><year>2012</year><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-9-105</pub-id><pub-id pub-id-type="pmid">22642812</pub-id><pub-id pub-id-type="pmcid">PMC3416679</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Andreasen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>J.M.</given-names></name></person-group><article-title>Active immunotherapy options for Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><volume>6</volume><issue>1</issue><year>2014</year><fpage>7</fpage><pub-id pub-id-type="pmid">24476230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/alzrt237</pub-id><pub-id pub-id-type="pmcid">PMC3979042</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Lambracht-Washington</surname><given-names>D.</given-names></name></person-group><article-title>Active immunotherapy to prevent Alzheimer disease&#8212;a DNA amyloid <italic toggle="yes">&#946;</italic> 1-42 trimer vaccine</article-title><source>JAMA Neurol</source><volume>77</volume><issue>3</issue><year>2020</year><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">31816028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.4182</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Alshamrani</surname><given-names>M.</given-names></name></person-group><article-title>Recent trends in active and passive immunotherapies of Alzheimer&#8217;s disease</article-title><source>Antibodies</source><volume>12</volume><issue>2</issue><year>2023</year><fpage>41</fpage><pub-id pub-id-type="pmid">37366656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib12020041</pub-id><pub-id pub-id-type="pmcid">PMC10295010</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Go&#241;i</surname><given-names>F.</given-names></name></person-group><article-title>Immunotherapy for Alzheimer&#8217;s disease</article-title><source>Biochem Pharmacol</source><volume>88</volume><issue>4</issue><year>2014</year><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2013.12.020</pub-id><pub-id pub-id-type="pmid">24412277</pub-id><pub-id pub-id-type="pmcid">PMC3972315</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B.</given-names></name></person-group><article-title>Immunological and anti-chaperone therapeutic approaches for Alzheimer disease</article-title><source>Brain Pathol</source><volume>15</volume><issue>1</issue><year>2005</year><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2005.tb00102.x</pub-id><pub-id pub-id-type="pmid">15779239</pub-id><pub-id pub-id-type="pmcid">PMC8095760</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Bayer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Evaluation of the safety and immunogenicity of synthetic A<italic toggle="yes">&#946;</italic>42 (AN1792) in patients with AD</article-title><source>Neurology</source><volume>64</volume><issue>1</issue><year>2005</year><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000148604.77591.67</pub-id><pub-id pub-id-type="pmid">15642910</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Pride</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seubert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grundman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name></person-group><article-title>Progress in the active immunotherapeutic approach to Alzheimer&#8217;s disease: clinical investigations into AN1792-associated meningoencephalitis</article-title><source>Neurodegener. Dis</source><volume>5</volume><issue>3-4</issue><year>2008</year><fpage>194</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1159/000113700</pub-id><pub-id pub-id-type="pmid">18322388</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Bombois</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maurage</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Gompel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Absence of <italic toggle="yes">&#946;</italic>-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia</article-title><source>Arch Neurol</source><volume>64</volume><issue>4</issue><year>2007</year><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.4.583</pub-id><pub-id pub-id-type="pmid">17420322</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A<italic toggle="yes">&#946;</italic> species removal after A<italic toggle="yes">&#946;</italic><sub>42</sub> immunization</article-title><source>J Neuropathol Exp Neurol</source><volume>65</volume><issue>11</issue><year>2006</year><fpage>1040</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000240466.10758.ce</pub-id><pub-id pub-id-type="pmid">17086100</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Gilman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Black</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Clinical effects of A<italic toggle="yes">&#946;</italic> immunization (AN1792) in patients with AD in an interrupted trial</article-title><source>Neurology</source><volume>64</volume><issue>9</issue><year>2005</year><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000159740.16984.3C</pub-id><pub-id pub-id-type="pmid">15883316</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>MacBean</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Boche</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lunnon</surname><given-names>K.</given-names></name></person-group><article-title>An integrated systems-level analysis of the molecular changes resulting from systemic inflammation and amyloid-beta immunisation in Alzheimer&#8217;s disease</article-title><source>Alzheimer Dement (N Y)</source><volume>18</volume><issue>S3</issue><year>2022</year><object-id pub-id-type="publisher-id">e060320</object-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Vandenberghe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Active A<italic toggle="yes">&#946;</italic> immunotherapy CAD106 in Alzheimer&#8217;s disease: a phase 2b study</article-title><source>Alzheimer Dement (N Y)</source><volume>3</volume><issue>1</issue><year>2017</year><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2016.12.003</pub-id><pub-id pub-id-type="pmcid">PMC5651373</pub-id><pub-id pub-id-type="pmid">29067316</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Riviere</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Langbaum</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired <italic toggle="yes">APOE</italic> &#949;4 homozygotes</article-title><source>Alzheimer Dement</source><volume>20</volume><issue>3</issue><year>2024</year><fpage>1839</fpage><lpage>1850</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13532</pub-id><pub-id pub-id-type="pmcid">PMC10984441</pub-id><pub-id pub-id-type="pmid">38145469</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bogati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name></person-group><article-title>Attempts to develop vaccines against Alzheimer&#8217;s disease: a systematic review of ongoing and completed vaccination trials in humans</article-title><source>Cureus</source><volume>15</volume><issue>6</issue><year>2023</year><object-id pub-id-type="publisher-id">e40138</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.40138</pub-id><pub-id pub-id-type="pmcid">PMC10329479</pub-id><pub-id pub-id-type="pmid">37425610</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Pasquier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sadowsky</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer&#8217;s disease</article-title><source>J Alzheimers Dis</source><volume>51</volume><issue>4</issue><year>2016</year><fpage>1131</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">26967206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150376</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Ketter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Di</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A randomized, double-blind, phase 2 study of the effects of the vaccine vanutide cridificar with QS-21 adjuvant on immunogenicity, safety and amyloid imaging in patients with mild to moderate Alzheimer&#8217;s disease</article-title><source>J Prev Alzheimers Dis</source><volume>3</volume><issue>4</issue><year>2016</year><fpage>192</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">29199321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2016.118</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Fiorini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vukicevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carpintero</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Optimized ACI-24, an amyloid beta (Abeta) vaccine that safely drives immunity to oligomers and pyroglutamate Abeta, key pathological species of Alzheimer&#8217;s disease (AD)</article-title><source>Alzheimers Dement (N Y)</source><volume>18</volume><issue>S10</issue><year>2022</year><object-id pub-id-type="publisher-id">e065688</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac022</pub-id><pub-id pub-id-type="pmcid">PMC9037369</pub-id><pub-id pub-id-type="pmid">35479516</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Rudan Njavro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vukicevic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fiorini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Beneficial effect of ACI-24 vaccination on A<italic toggle="yes">&#946;</italic> plaque pathology and microglial phenotypes in an amyloidosis mouse model</article-title><source>Cells</source><volume>12</volume><issue>1</issue><year>2022</year><fpage>79</fpage><pub-id pub-id-type="doi">10.3390/CELLS12010079</pub-id><pub-id pub-id-type="pmid">36611872</pub-id><pub-id pub-id-type="pmcid">PMC9818422</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="book" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Dhas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><etal/></person-group><part-title>Intranasal gene therapy for the treatment of neurological disorders</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Pardeshi</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Souto</surname><given-names>E.B.</given-names></name></person-group><source>Direct Nose-to-Brain Drug Delivery</source><year>2021</year><publisher-name>Academic Press</publisher-name><fpage>351</fpage><lpage>387</lpage></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Schneeberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otava</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zauner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mattner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>W.</given-names></name></person-group><article-title>Development of AFFITOPE vaccines for Alzheimer&#8217;s disease (AD) &#8212; from concept to clinical testing</article-title><source>J Nutr Health Aging</source><volume>13</volume><issue>3</issue><year>2009</year><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/S12603-009-0070-5</pub-id><pub-id pub-id-type="pmid">19262965</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Mandler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santic</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Tailoring the antibody response to aggregated A<italic toggle="yes">&#946;</italic> using novel Alzheimer-vaccines</article-title><source>PLoS One</source><volume>10</volume><issue>1</issue><year>2015</year><object-id pub-id-type="publisher-id">e0115237</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0115237</pub-id><pub-id pub-id-type="pmcid">PMC4303436</pub-id><pub-id pub-id-type="pmid">25611858</pub-id></element-citation></ref></ref-list><ack id="ack0010"><sec id="sec7"><title>Financial support</title><p id="p0125">Open Access funding enabled and organized by project DEAL. This work was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100024068</institution-id><institution>University of Witten-Herdecke</institution></institution-wrap></funding-source>, Germany.</p></sec><sec sec-type="data-availability" id="sec8"><title>Data availability</title><p id="p0130">There are no datasets presented in this paper.</p></sec><sec id="sec9"><title>CRediT authorship contribution statement</title><p id="p0135"><bold>Najlaa Hamed Almohmadi:</bold> Investigation, Writing &#8211; review and editing. <bold>Hayder M. Al-Kuraishy:</bold> Conceptualization, Investigation, Data curation, Formal analysis, Writing &#8211; original draft. <bold>Ali K. Albuhadily:</bold> Data curation, Formal analysis, Writing &#8211; review and editing. <bold>Ali I. Al-Gareeb:</bold> Conceptualization, Resources, Data curation, Formal analysis, Writing &#8211; original draft. <bold>Ahmed M. Abdelaziz:</bold> Writing &#8211; review and editing, Data curation, Formal analysis. <bold>Athanasios Alexiou:</bold> Administration, Writing &#8211; review and editing, Data curation, Formal analysis, Visualization. <bold>Marios Papadakis:</bold> Funding, Acquisition. <bold>Gaber El-Saber Batiha:</bold> Conceptualization, Investigation, Data curation, Formal analysis, Writing &#8211; original draft, Visualization.</p></sec></ack></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Pharm Sin B</journal-id><journal-id journal-id-type="iso-abbrev">Acta Pharm Sin B</journal-id><journal-id journal-id-type="pmc-domain-id">2814</journal-id><journal-id journal-id-type="pmc-domain">apsb</journal-id><journal-title-group><journal-title>Acta Pharmaceutica Sinica. B</journal-title></journal-title-group><issn pub-type="ppub">2211-3835</issn><issn pub-type="epub">2211-3843</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491705</article-id><article-id pub-id-type="pmcid-ver">PMC12491705.1</article-id><article-id pub-id-type="pmcaid">12491705</article-id><article-id pub-id-type="pmcaiid">12491705</article-id><article-id pub-id-type="pmid">41049748</article-id><article-id pub-id-type="doi">10.1016/j.apsb.2025.01.027</article-id><article-id pub-id-type="pii">S2211-3835(25)00034-6</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Tools</subject></subj-group></article-categories><title-group><article-title>AI-powered model for accurate prediction of MCI-to-AD progression</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Abdelhameed</surname><given-names initials="A">Ahmed</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Feng</surname><given-names initials="J">Jingna</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Hu</surname><given-names initials="X">Xinyue</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Li</surname><given-names initials="F">Fang</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Lundin</surname><given-names initials="S">Sori</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Schulz</surname><given-names initials="PE">Paul E.</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Tao</surname><given-names initials="C">Cui</given-names></name><email>Tao.Cui@Mayo.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="aff1"><label>a</label>Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, FL 32224, USA</aff><aff id="aff2"><label>b</label>McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA</aff><aff id="aff3"><label>c</label>McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>Tao.Cui@Mayo.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">498229</issue-id><fpage>4427</fpage><lpage>4437</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>29</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Alzheimer&#8217;s disease (AD) remains a formidable challenge in modern healthcare, necessitating innovative approaches for its early detection and intervention. This study aimed to enhance the identification of individuals with mild cognitive impairment (MCI) at risk of developing AD. Leveraging advances in computational power and the extensive availability of healthcare data, we explored the potential of deep learning models for early prediction using medical claims data. We employed a bidirectional gated recurrent unit (BiGRU) deep learning model for predictive modeling of MCI progression across various prediction intervals, extending up to five years post-initial MCI diagnosis. The performance of the BiGRU model was rigorously compared with several machine-learning model baselines to evaluate its efficacy. Using a robust cross-validation methodology, the BiGRU emerged as the top-performing model, achieving an Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of 0.833 (95% CI: 0.822, 0.843), an Area Under the Precision-Recall Curve (AUC-PR) of 0.856 (95% CI: 0.845, 0.867), and an F1-Score of 0.71 (95% CI: 0.694, 0.724) for a five-year prediction interval. The results indicate that BiGRU, utilizing longitudinal claims data, reliably predicts MCI-to-AD progression over a lengthy interval following the initial MCI diagnosis, offering clinicians a valuable tool for targeted risk identification and stratification.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p>This study explores the potential of deep learning models in predicting the progression from MCI to AD using longitudinal claims data, promising advance clinical practice by enabling more proactive and personalized patient care.<fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>BiGRU</kwd><kwd>Predictive modeling</kwd><kwd>Machine learning</kwd><kwd>Longitudinal claim data</kwd><kwd>Risk stratification</kwd><kwd>Electronic health records</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Alzheimer&#8217;s disease (AD) is the most common degenerative neurological disorder, characterized by a spectrum of symptoms ranging from short-term memory lapses to loss of bodily function and eventual death<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. Presently, AD afflicts approximately 6.7 million Americans aged 65 and older. With an aging population and increasing life spans, the incidence and prevalence of AD are predicted to rise substantially over the next several decades. In the absence of significant medical and technological breakthroughs to prevent, arrest, or cure AD, estimates suggest that the affected population could increase to 13.8 million by the year 2060<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>. The progression of AD unfolds from subtle brain changes to significant alterations that lead to memory impairments and eventual physical incapacitation in affected individuals. The disease trajectory is delineated into three broad stages: preclinical AD, mild cognitive impairment (MCI) attributable to AD, and dementia ascribable to AD, also termed Alzheimer&#8217;s dementia. The latter category is further subdivided into mild, moderate, and severe stages<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>.</p><p id="p0015">MCI identifies individuals who do not manifest dementia but exhibit cognitive abnormalities, such as performing below average on memory tasks while sustaining their activities of daily living (ADLs). The progression of MCI to AD dementia may or may not occur, a transition influenced by a variety of risk factors<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref>. Identifying patients clinically diagnosed with MCI who are at heightened risk of developing AD is critical for effective risk stratification and early intervention, particularly when newly developed medications prove efficacious.</p><p id="p0020">Existing studies offer diverse approaches to predict the likelihood of MCI progressing to AD and to identify the significant risk factors for this progression. Various methods have utilized distinct data modalities, including neuroimaging data such as magnetic resonance imaging (MRI)<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, positron emission tomography (PET)<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>, magnetoencephalography (MEG)<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>, as well as combinations of these modalities<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref>. Although these imaging techniques have proven invaluable, their limited availability and substantial cost have prompted researchers to investigate more accessible alternatives.</p><p id="p0025">Recent years have seen significant advancements in PET imaging and fluid biomarkers. PET tracers like <sup>18</sup>F-FDG assess glucose metabolism, while amyloid tracers such as <sup>18</sup>F-Florbetapir and tau-specific tracers like <sup>18</sup>F-Flortaucipir provide insights into amyloid plaques and tau tangles, respectively<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>. Similarly, while cerebrospinal fluid (CSF) biomarkers were traditionally used to confirm AD in later stages<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref>, blood-based biomarkers now present less invasive alternatives for early detection<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref>. However, these specialized tests remain inaccessible to many patients in routine clinical practice. Despite the availability of biomarkers in neuroimaging and fluid data, detecting progression from MCI to AD in clinical practice remains challenging. To address this issue, some studies have tried to integrate neuroimaging datasets with other patient data, such as demographics and genetics<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref>.</p><p id="p0030">More advanced models have recently employed machine learning, particularly deep learning-based techniques, to study the progression of AD by leveraging the extensive information stored in electronic health records (EHRs). These EHRs encompass a wealth of data, including, but not limited to, patient demographics, diagnoses, medications, procedures, laboratory measurements, and clinical notes. For example, Fouladvand et al.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> utilized patient EHR data such as demographics and clinical notes, along with patient-provided information, to predict the progression from cognitively unimpaired (CU) to MCI using the long short-term memory (LSTM) deep learning model. Similarly, Gao et al.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> combined a subset of patient EHR data with genetic data and traditional risk factors and applied machine learning techniques for AD prediction.</p><p id="p0035">In clinical settings, the completeness of EHR and biomarker data exhibits significant variability across patients, attributable to factors such as differing care pathways, the frequency of clinical visits, and access to specialized testing. While some patients may possess comprehensive data including neuroimaging and biomarker measurements, many others have only basic clinical records and claims data. This inconsistency in data availability can impede the broad applicability of predictive models in real-world settings. Furthermore, it&#8217;s imperative to acknowledge the temporal dimension of the data as a crucial factor in ensuring accurate risk prediction.</p><p id="p0040">Despite these challenges, there has been a scarcity of research focused on utilizing EHRs to predict the complex progression from MCI to AD. For instance, Mao et al.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> utilized unstructured clinical notes from EHRs to develop a deep learning framework based on the pre-trained Bidirectional Encoder Representations from Transformers (BERT) model, with the aim of predicting the likelihood of disease progression from MCI to AD. Recent advancements in artificial intelligence, including Large Language Models (LLMs) and foundation models, have further expanded the potential of EHR analysis. These models have demonstrated promising capabilities in processing EHR and claims data, particularly in tasks involving unstructured clinical text and complex medical knowledge representation<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>. While such models open new avenues for healthcare data analysis, sequence-based deep learning approaches remain especially adept at structured temporal prediction tasks, such as forecasting disease progression, particularly when dealing with longitudinal claims data<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref>.</p><p id="p0045">The primary objective of this study is to develop a deep learning framework for predicting the progression from MCI to AD. Our approach is distinctive, as it does not rely on imaging or biomarker data but instead exclusively utilizes claims data, which is routinely available for all patients. This distinction is pivotal, as many patients do not undergo brain scans or blood tests, thereby allowing our model to encompass a broader population. The framework leverages retrospective longitudinal claim data spanning a five-year period prior to the initial diagnosis of MCI (index date). We evaluate the model&#8217;s predictive accuracy across multiple time horizons: one, two, three, and five years from the index date. This approach is innovative in its ability to predict both short-term and long-term progression of MCI to AD using a comprehensive set of readily available clinical variables including, age, gender, diagnoses, medications, and procedures.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>Study cohort</title><p id="p0050">In this study, we used Optum&#8217;s de-identified Clinformatics&#174; Data Mart Database, which is a database of administrative health claims for members of large commercial and Medicare Advantage health plans. We identified a cohort of 80,931 patients who received their initial MCI diagnosis between January 2007 and March 2020, all of whom were at least 40 years old. Employing Clinformatics&#174;, we conducted comprehensive queries on claim records to extract patient information, including diagnoses, procedures, medications, and demographics both prior to and following the initial MCI diagnosis.</p><p id="p0055">The MCI diagnosis was defined using the International Classification of Diseases, Ninth Revision (ICD-9) code 331.83, and Tenth Revision (ICD-10) code G31.84<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>. As illustrated in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, 16 patients were excluded due to a lack of gender information. Additionally, 785 patients were removed from the study after being deemed ineligible due to the absence of any records before their MCI diagnosis.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Study cohort construction.</p></caption><alt-text id="alttext0020">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0060">For the remaining cohort, patients were classified into case and control groups. Those patients whose MCI progressed to AD were identified using ICD-9 code 331.0 and ICD-10 codes G30.&#8727;<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>, forming the case group. The control group consisted of MCI patients who did not receive an AD diagnosis during their entire follow-up period. To ensure reliable classification, control patients were required to have a minimum follow-up duration that matched or exceeded the prediction window being analyzed (<italic toggle="yes">i.e.</italic>, at least one year of follow-up for the one-year prediction model, two years for the two-year model, and so on). This criterion ensures adequate observation time to confirm non-conversion status within each prediction timeframe.</p></sec><sec id="sec2.2"><label>2.2</label><title>Observation period and prediction window</title><p id="p0065">In the final patient cohort, we designated the index date as the date of the first MCI diagnosis for both cases and controls. Our analysis encompassed all accessible patient information within the five-year observation window preceding the first MCI diagnosis. Although not all patients had a full five years of observation data prior to their MCI diagnosis, we utilized all available data within this window, acknowledging variations in observation periods among patients. This observation window constituted the dataset for our AD risk prediction task. For cases, we pinpointed the date of the first AD diagnosis after the index date as the event date, as illustrated in the timeline in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Patient timeline for the prediction task.</p></caption><alt-text id="alttext0025">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0070">The predictive modeling of MCI-to-AD progression was assessed across four distinct prediction windows, spanning one, two, three, and five years, all commencing the day following the index date. For each prediction window analysis, we included only those control patients whose follow-up duration met or exceeded the respective prediction window length. This methodology ensured consistency in our control group definition across different prediction timeframe, while also ensuring sufficient observation time to validate non-conversion status.</p></sec><sec id="sec2.3"><label>2.3</label><title>Claims data preprocessing and code mapping</title><p id="p0075">The utilization of large-scale patient claims data holds significant potential for the prediction of MCI-to-AD progression. These datasets contain comprehensive patient information, including vital variables such as demographics, diagnoses, treatments, and procedures. However, medical claim records pose challenges in model development and prediction accuracy due to their large number of variables, data sparsity, and irregular nature.</p><p id="p0080">In the data-driven approach followed in this study, we preprocessed the patient data before employing it as input features in our prediction models. Demographic data, such as age, was categorized into age groups. We included all diagnostic ICD-9 and ICD-10 codes present in the patient records and removed entries containing invalid ICD diagnosis codes, which included incorrectly formatted codes, typographical errors, and codes unrecognized within the ICD system. Additionally, we converted incorrectly labeled ICD-10 diagnosis codes back to their original ICD-9 labels, and <italic toggle="yes">vice versa</italic>. To mitigate the sparsity of the features, we consolidated equivalent ICD-9 and ICD-10 diagnosis codes and mapped them to a reduced set of &#8220;phecodes&#8221; using the Phenome-wide association studies (PheWAS) method, which analyzes many phenotypes and groups similar diagnoses under unique codes<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref>. This method reduced the total number of diagnosis codes from 46,434 to 1854.</p><p id="p0085">A similar approach was applied to procedure codes, encompassing their various types: ICD-9-CM, ICD-10-PCS, Healthcare Common Procedure Coding System (HCPCS) Level I [also known as Current Procedural Terminology (CPT) codes and maintained by the American Medical Association (AMA)], and HCPCS Level II procedure codes [maintained by the Centers for Medicare &amp; Medicaid Services (CMS)]. We first removed patient records with invalid procedure codes and corrected mislabeled procedure codes. Then, employing the Agency for Healthcare Research and Quality (AHRQ)&#8217;s Clinical Classification Software (CCS), we mapped procedure codes into their equivalent single-level procedure categories. Using this method, we reduced the total number of procedure codes from 11,067 to 236. For medications, identified in claim records using National Drug Codes (NDC), we mapped all codes to their corresponding generic medication names, resulting in 2916 unique identifiers.</p></sec><sec id="sec2.4"><label>2.4</label><title>Deep learning model</title><p id="p0090">In this study, we employed the Bidirectional Gated Recurrent Unit (GRU) model<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> as our deep learning architecture. A Bidirectional GRU, or BiGRU, is a sequence-processing model consisting of two GRUs. The first GRU processes the input sequence in one direction, while the second processes it in the opposite direction. The outputs from both units are combined and used for prediction after processing the entire input sequence. BiGRUs are particularly effective for extracting meaningful representations from sequential data during training because they consider temporal dependencies by processing information bidirectionally, incorporating both preceding and succeeding elements of the input sequence.</p><p id="p0095">We aggregated medical concepts (diagnoses, medications, and procedures) for all patients in 15-day intervals throughout the five-year observation window preceding the MCI index date. This aggregated information served as the input sequence for our proposed deep learning model. Consequently, at each aggregation point, we transformed each patient record into a feature vector containing the aggregated medical concepts, along with demographic details, such as gender and age group.</p><p id="p0100">As depicted in <xref rid="fig3" ref-type="fig">Fig. 3</xref>, we implemented this BiGRU architecture through multiple neural network layers. The model processes these 15-day interval inputs (shown as X<sub>t1</sub> to X<sub>tn</sub> at the bottom of the figure) through an embedding layer, transforming them into dense vector representations (E<sub>t1</sub> to E<sub>tn</sub>) that capture relationships between different medical concepts.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Deep learning model architecture.</p></caption><alt-text id="alttext0030">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0105">The core of the architecture consists of two stacked BiGRU layers, marked as &#8220;1st BiGRU Layer&#8221; and &#8220;2nd BiGRU Layer&#8221; in the figure. Each BiGRU layer contains paired GRU units&#8212;forward GRUs (shown in blue) processing the sequence from left to right, and backward GRUs (shown in green) processing from right to left. At each timestep, the outputs from forward and backward GRUs are merged via concatenation operations (depicted by &#8853; nodes), enabling the model to capture bidirectional temporal patterns in the patient&#8217;s medical history.</p><p id="p0110">Unlike traditional machine learning approaches that compress temporal data into a single multi-hot encoded vector aggregated from the five-year observation window, our architecture preserves the temporal sequence of medical events. The model culminates in a final concatenation operation (shown by the topmost &#8853; node) that combines the terminal hidden states of the second BiGRU layer&#8217;s forward and backward paths. This concatenated representation then passes through a sigmoid function to output the probability of MCI-to-AD progression prediction.</p><p id="p0115">For our prediction task, we evaluated the performance of the BiGRU against several established baseline models: Light Gradient Boosting Machine (LGBM), Random Forest (RF), Extreme Gradient Boosting (XGBoost), and traditional Logistic Regression (LR). To ensure a fair comparison, we applied consistent data preprocessing across all baseline models. For these models, we aggregated all medical concepts throughout the five-year observation window prior to the MCI index date, counting each unique medical concept only once, regardless of its frequency in the claim records. Subsequently, we constructed each patient&#8217;s input feature vector by converting these aggregated medical concepts into a multi-hot encoding representation. This method transforms the temporal sequence of medical events into a fixed-length feature vector, where each dimension represents the presence (1) or absence (0) of a specific medical concept during the observation period. While this representation simplifies the complex temporal patterns in the data, it provides a standardized input format for our baseline models. This standardization allows us to effectively evaluate the advantages of our proposed BiGRU&#8217;s sequential learning approach against these conventional machine learning techniques.</p></sec><sec id="sec2.5"><label>2.5</label><title>Data selection and training</title><p id="p0120">In each prediction scenario, the patient cohort was randomly divided into two subsets: 80% formed the training set, and 20% constituted the test set. Within each subset, we ensured a balanced distribution of positive cases (MCI-to-AD converters) and negative controls (non-converters) to mitigate bias in model training and evaluation. The test set was reserved exclusively for the final performance assessment of all models.</p><p id="p0125">To optimize model performance, we implemented a robust cross-validation strategy on the training set. The training process involved two main phases. Initially, we utilized a stratified five-fold cross-validation method for hyperparameter tuning and internal validation. As depicted in <xref rid="fig4" ref-type="fig">Fig. 4</xref>, this phase included five iterations, during which the training set was repeatedly split into training folds (80%) and a validation fold (20%). Each iteration featured, the rotation of the validation fold through different segments of the data. The hyperparameters were optimized using the Optuna automatic optimization software<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> (see <xref rid="appsec1" ref-type="sec">Supporting Information Table S1</xref> for detailed hyperparameter settings across all prediction scenarios).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Data selection for the training and testing in all prediction scenarios.</p></caption><alt-text id="alttext0035">Figure 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0130">Upon determining the most effective model configuration through cross-validation and hyperparameter optimization, we advanced to the second phase. The optimal model was then retrained on the entirely of the training set, representing 80% of the original dataset.</p><p id="p0135">This comprehensive training and evaluation framework, as illustrated in <xref rid="fig4" ref-type="fig">Fig. 4</xref>, ensured robust model development. It effectively prevented data leakage and provided unbiased performance estimates, thereby enhancing the reliability of the results.</p></sec><sec id="sec2.6"><label>2.6</label><title>Model evaluation</title><p id="p0140">We conducted a comprehensive evaluation by comparing the performance of our BiGRU model against several established baseline machine learning models: Light Gradient Boosting Machine (LGBM), Extreme Gradient Boosting (XGBoost), Logistic Regression (LR), and Random Forest (RF). The models were assessed using three key performance metrics: the area under the receiver operating curve (AUC-ROC), the area under the precision-recall curve (AUC-PR), and the F1 score.</p><p id="p0145">The AUC-ROC statistic assesses a model&#8217;s classification performance by depicting the trade-off between the true positive rate (sensitivity) and the false positive rate (1-specificity) across various threshold settings. A higher AUC-ROC score denotes enhanced discrimination capability between cases and controls. The AUC-PR serves as a critical performance indicator, particularly valuable for assessing classification effectiveness in datasets with class imbalances. It represents the trade-off between precision (positive predictive value) and recall (sensitivity) across different classification thresholds. A higher AUC-PR score reflects better model performance, with a score of 1 signifying an ideal precision-recall trade-off. The F1 score provides a single value performance metric by calculating the harmonic mean of precision and recall, offering a balanced assessment of the model&#8217;s precision-recall trade-off, and is defined as Eq. <xref rid="fd1" ref-type="disp-formula">(1)</xref>:<disp-formula id="fd1"><label>(1)</label><mml:math id="M1" altimg="si1.svg" alttext="Equation 1."><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">=</mml:mo><mml:mn>2</mml:mn><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mfrac><mml:mrow><mml:mtext>Precision</mml:mtext><mml:mo linebreak="badbreak">&#215;</mml:mo><mml:mtext>Recall</mml:mtext></mml:mrow><mml:mrow><mml:mtext>Precision</mml:mtext><mml:mo linebreak="badbreak">+</mml:mo><mml:mtext>Recall</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p id="p0150">For a consistent comparison across all models, including BiGRU and the baseline machine learning models, we calculated these metrics using a classification threshold of 0.5. To ensure robust evaluation, we employed bootstrapped performance assessment on the held-out test set to generate confidence intervals for our performance metrics. This comprehensive evaluation framework allowed us to rigorously compare the predictive capabilities of our proposed BiGRU architecture against established machine learning approaches.</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Patient characteristics</title><p id="p0155">The baseline characteristics of the total study cohort are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. Among patients diagnosed with MCI who progressed to AD (case-patients), females comprised 62.58% (<italic toggle="yes">n</italic> = 7811) and males 37.42% (<italic toggle="yes">n</italic> = 4670). In the control group (patients diagnosed with MCI who did not progress to AD), females represented 56.24% (<italic toggle="yes">n</italic> = 38,052) and males 43.76% (<italic toggle="yes">n</italic> = 29,605).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Cohort demographic and clinical characteristics of patients.</p></caption><alt-text id="alttext0050">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Case (<italic toggle="yes">n</italic> = 12,481)</th><th colspan="1" rowspan="1">Control (<italic toggle="yes">n</italic> = 67,657)</th><th colspan="1" rowspan="1">Overall (<italic toggle="yes">n</italic> = 80,138)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Age (mean)</td><td colspan="1" rowspan="1">MCI mean (SD): 78.49 (6.60)</td><td rowspan="2" colspan="1">MCI mean (SD): 74.48 (10.33)</td><td rowspan="2" colspan="1">MCI mean: 75.11</td><td align="char" rowspan="2" colspan="1">&lt;0.0001<xref rid="tbl1fna" ref-type="table-fn">a</xref></td></tr><tr><td colspan="1" rowspan="1">AD mean (SD): 80.61 (6.65)</td></tr><tr><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">7811 (62.58%)</td><td colspan="1" rowspan="1">38,052 (56.24%)</td><td colspan="1" rowspan="1">45,863 (57.2%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td></tr><tr><td colspan="1" rowspan="1">Obesity</td><td colspan="1" rowspan="1">2687 (21.53%)</td><td colspan="1" rowspan="1">21,313 (31.50%)</td><td colspan="1" rowspan="1">24,000 (29.95%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">Smoking</td><td colspan="1" rowspan="1">4883 (39.12%)</td><td colspan="1" rowspan="1">28,232 (41.73%)</td><td colspan="1" rowspan="1">33,115 (41.32%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">Type 2 diabetes mellitus</td><td colspan="1" rowspan="1">4078 (32.67%)</td><td colspan="1" rowspan="1">23,711 (35.04%)</td><td colspan="1" rowspan="1">27,789 (34.68%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1">10,312 (82.62%)</td><td colspan="1" rowspan="1">27,118 (77.78%)</td><td colspan="1" rowspan="1">52,629 (78.54%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">Anxiety</td><td colspan="1" rowspan="1">3525 (28.24%)</td><td colspan="1" rowspan="1">16,869 (24.93%)</td><td colspan="1" rowspan="1">20,394 (25.45%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td colspan="1" rowspan="1">Depression</td><td colspan="1" rowspan="1">4991 (39.99%)</td><td colspan="1" rowspan="1">21,931 (32.42%)</td><td colspan="1" rowspan="1">26,922 (33.59%)</td><td align="char" colspan="1" rowspan="1">&lt;0.0001</td></tr><tr><td rowspan="2" colspan="1">Conversion time (MCI to AD)</td><td colspan="1" rowspan="1">Mean: 776.8 days</td><td rowspan="2" colspan="1"/><td rowspan="2" colspan="1"/><td rowspan="2" colspan="1"/></tr><tr><td colspan="1" rowspan="1">Median: 586 days</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0020">Age <italic toggle="yes">P</italic>-value is calculated with the Kruskal test.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0025">Categorical parameters' <italic toggle="yes">P</italic>-value is calculated with the Chi&#8211;Square test.</p></fn></table-wrap-foot></table-wrap></p><p id="p0160">The mean age of case patients at MCI diagnosis was 78.49 years (SD: 6.60), and their average age at the AD diagnosis was 80.61 years (SD: 6:65). For control patients, the mean age at the MCI diagnosis was 74.48 years (SD: 10.33). The average time from initial MCI diagnosis to AD conversion was 776.8 days (median: 586 days).</p><p id="p0165">Regarding comorbidities, obesity was present in 21.53% (<italic toggle="yes">n</italic> = 2687) of case patients compared to 31.50% (<italic toggle="yes">n</italic> = 21,313) of control patients. Case patients showed different comorbidity patterns compared to controls: hypertension was notably high in both groups but more prevalent in case patients (82.62% <italic toggle="yes">vs</italic> 77.78%), depression (39.99% <italic toggle="yes">vs</italic> 32.42%), and anxiety (28.24% <italic toggle="yes">vs</italic> 24.93%) were more common in case patients. Type 2 diabetes mellitus was observed in 32.67% of case patients compared to 35.04% of controls, while smoking rates were lower in case patients at 39.12% (<italic toggle="yes">n</italic> = 4883) compared to 41.73% (<italic toggle="yes">n</italic> = 28,232) in controls. All these differences were statistically significant (<italic toggle="yes">P</italic> &lt; 0.0001).</p><p id="p0170">The number of patients belonging to both the case and control groups varied across the four prediction intervals of our testing scenarios. The patient counts for each testing scenario are shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p>Patient count for each prediction interval.</p></caption><alt-text id="alttext0040">Figure 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0175">We adopted a methodology analogous to that described in<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> for selecting control patients based on their last claim record. As illustrated in <xref rid="fig6" ref-type="fig">Fig. 6</xref>, we established specific criteria for including control patients based on the timeline of their claim records. Panel (a) displays a valid control patient, where the last claim record extends beyond the prediction window (<italic toggle="yes">X</italic> years) following the MCI diagnosis. In contrast, panel (b) demonstrates scenario where a patient is excluded from the control group because their last claim record falls within the prediction window. This exclusion criterion is essential as it ensures that the follow-up data is complete; without it, we cannot definitively determine whether these patients progressed to AD within the prediction window. This methodology guarantees that all included control patients have adequate follow-up time to confirm their non-conversion status for at least <italic toggle="yes">X</italic> years following their initial MCI diagnosis.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p>Control patient inclusion and exclusion criteria.</p></caption><alt-text id="alttext0045">Figure 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec><sec id="sec3.2"><label>3.2</label><title>Prediction performance comparison across models</title><p id="p0180"><xref rid="tbl2" ref-type="table">Table 2</xref> presents the prediction performance metrics of our BiGRU deep learning model alongside four baseline machine learning models: LGBM, XGBoost, LR, and RF. Performance was assessed across four prediction scenarios using the testing set.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Comparison of model performance between the bidirectional gated recurrent units (BiGRU) deep learning model and baseline machine learning models (LGBM, XGBoost, LR, RF) using the area under the receiver operating characteristic curve (AUC-ROC), the area under the precision-recall curve (AUC-PR), and the F1-Score.</p></caption><alt-text id="alttext0055">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Performance measure</th><th colspan="4" rowspan="1">Prediction scenarios<hr/></th></tr><tr><th colspan="1" rowspan="1">1&#8211;365 days (1-year)</th><th colspan="1" rowspan="1">1&#8211;730 days (2-years)</th><th colspan="1" rowspan="1">1&#8211;1095 days (3-years)</th><th colspan="1" rowspan="1">1&#8211;1825 days (5-years)</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">BiGRU</td></tr><tr><td colspan="1" rowspan="1">AUC-ROC</td><td colspan="1" rowspan="1">0.679 (0.662,0.695)</td><td colspan="1" rowspan="1">0.690 (0.674, 0.702)</td><td colspan="1" rowspan="1">0.751 (0.741,0.763)</td><td colspan="1" rowspan="1">0.833 (0.822,0.843)</td></tr><tr><td colspan="1" rowspan="1">AUC-PR</td><td colspan="1" rowspan="1">0.122 (0.112,0.136)</td><td colspan="1" rowspan="1">0.274 (0.251,0.295)</td><td colspan="1" rowspan="1">0.554 (0.533,0.575)</td><td colspan="1" rowspan="1">0.856 (0.845,0.867)</td></tr><tr><td colspan="1" rowspan="1">F1 (Binary)</td><td colspan="1" rowspan="1">0.182 (0.169,0.191)</td><td colspan="1" rowspan="1">0.326 (0.309,0.341)</td><td colspan="1" rowspan="1">0.492 (0.473,0.510)</td><td colspan="1" rowspan="1">0.71 (0.694,0.724)</td></tr><tr><td colspan="5" rowspan="1">LGBM</td></tr><tr><td colspan="1" rowspan="1">AUC-ROC</td><td colspan="1" rowspan="1">0.694 (0.678,0.709)</td><td colspan="1" rowspan="1">0.692 (0.679,0.707)</td><td colspan="1" rowspan="1">0.736 (0.721,0.749)</td><td colspan="1" rowspan="1">0.818 (0.806,0.830)</td></tr><tr><td colspan="1" rowspan="1">AUC-PR</td><td colspan="1" rowspan="1">0.131 (0.119,0.145)</td><td colspan="1" rowspan="1">0.272 (0.252,0.295)</td><td colspan="1" rowspan="1">0.495 (0.473,0.521)</td><td colspan="1" rowspan="1">0.838 (0.824,0.851)</td></tr><tr><td colspan="1" rowspan="1">F1 (Binary)</td><td colspan="1" rowspan="1">0.195 (0.186,0.215)</td><td colspan="1" rowspan="1">0.327 (0.316,0.349)</td><td colspan="1" rowspan="1">0.481 (0.465,0.499)</td><td colspan="1" rowspan="1">0.716 (0.701,0.731)</td></tr><tr><td colspan="5" rowspan="1">XGBoost</td></tr><tr><td colspan="1" rowspan="1">AUC-ROC</td><td colspan="1" rowspan="1">0.676 (0.659,0.693)</td><td colspan="1" rowspan="1">0.698 (0.684,0.711)</td><td colspan="1" rowspan="1">0.731 (0.718, 0.745)</td><td colspan="1" rowspan="1">0.818 (0.807,0.823)</td></tr><tr><td colspan="1" rowspan="1">AUC-PR</td><td colspan="1" rowspan="1">0.127 (0.115,0.143)</td><td colspan="1" rowspan="1">0.295 (0.276,0.311)</td><td colspan="1" rowspan="1">0.493 (0.469,0.517)</td><td colspan="1" rowspan="1">0.838 (0.825,0.849)</td></tr><tr><td colspan="1" rowspan="1">F1 (Binary)</td><td colspan="1" rowspan="1">0.188 (0.176,0.201)</td><td colspan="1" rowspan="1">0.334 (0.320,0.349)</td><td colspan="1" rowspan="1">0.484 (0.468,0.501)</td><td colspan="1" rowspan="1">0.718 (0.704,0.732)</td></tr><tr><td colspan="5" rowspan="1">LR</td></tr><tr><td colspan="1" rowspan="1">AUC-ROC</td><td colspan="1" rowspan="1">0.676 (0.659, 0.692)</td><td colspan="1" rowspan="1">0.695 (0.682,0.709)</td><td colspan="1" rowspan="1">0.729 (0.717,0.741)</td><td colspan="1" rowspan="1">0.816 (0.804,0.828)</td></tr><tr><td colspan="1" rowspan="1">AUC-PR</td><td colspan="1" rowspan="1">0.123 (0.111,0.138)</td><td colspan="1" rowspan="1">0.268 (0.251,0.288)</td><td colspan="1" rowspan="1">0.486 (0.463,0.509)</td><td colspan="1" rowspan="1">0.836 (0.823,0.849)</td></tr><tr><td colspan="1" rowspan="1">F1 (Binary)</td><td colspan="1" rowspan="1">0.191 (0.178,0.205)</td><td colspan="1" rowspan="1">0.340 (0.325,0.356)</td><td colspan="1" rowspan="1">0.479 (0.461, 0.494)</td><td colspan="1" rowspan="1">0.711 (0.695, 0.727)</td></tr><tr><td colspan="5" rowspan="1">RF</td></tr><tr><td colspan="1" rowspan="1">AUC-ROC</td><td colspan="1" rowspan="1">0.662 (0.645,0.678)</td><td colspan="1" rowspan="1">0.681 (0.667,0.695)</td><td colspan="1" rowspan="1">0.714 (0.701,0.727)</td><td colspan="1" rowspan="1">0.801 (0.790,0.813)</td></tr><tr><td colspan="1" rowspan="1">AUC-PR</td><td colspan="1" rowspan="1">0.117 (0.107,0.130)</td><td colspan="1" rowspan="1">0.271 (0.252,0.292)</td><td colspan="1" rowspan="1">0.463 (0.435,0.485)</td><td colspan="1" rowspan="1">0.821 (0.806,0.834)</td></tr><tr><td colspan="1" rowspan="1">F1 (Binary)</td><td colspan="1" rowspan="1">0.186 (0.173,0.199)</td><td colspan="1" rowspan="1">0.328 (0.311,0.343)</td><td colspan="1" rowspan="1">0.464 (0.447,0.482)</td><td colspan="1" rowspan="1">0.693 (0.678,0.708)</td></tr></tbody></table></table-wrap></p><p id="p0185">A comparative analysis of the AUC-ROC, AUC-PR, and the F1-Score values reveals distinct performance patterns across different prediction windows. Notably, the BiGRU model exhibited higher performance for longer prediction intervals, particularly in the 3- and 5-year scenarios. For the 5-year prediction window, BiGRU achieved an AUC-ROC of 0.833 (95% CI: 0.822&#8211;0.843), surpassing LGBM at 0.818 (95% CI: 0.806&#8211;0.830), XGBoost at 0.818 (95% CI: 0.807&#8211;0.823), LR at 0.816 (95% CI: 0.804&#8211;0.828), and RF at 0.801 (95% CI: 0.790&#8211;0.813). In this scenario, the BiGRU model also attained an AUC-PR of 0.856 (95% CI: 0.845&#8211;0.867) and an F1-Score of 0.71 (95% CI: 0.694&#8211;0.724), marking the best overall performance.</p><p id="p0190">For the 2-year prediction window, all models showed comparable performance levels. However, in the shorter 1-year interval, the baseline models, particularly LGBM with an AUC-ROC of 0.694 (95% CI: 0.678&#8211;0.709), exceeded the performance of the BiGRU model, which posted an AUC-ROC of 0.679 (95% CI: 0.662&#8211;0.695). This pattern suggests that while traditional machine learning approaches may suffice for short-term predictions, the BiGRU&#8217;s capacity to integrate temporal patterns proves more advantageous for predicting for longer-term progression prediction.</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0195">This research systematically investigated the application of sequence-based deep learning in predicting the progression from MCI to AD, focusing on the Bidirectional Gated Recurrent Unit (BiGRU) architecture while comparing its performance against multiple baseline machine learning models. The study leveraged patient data gathered before the initial MCI diagnosis and involved the analysis of over 80,000 patients diagnosed with MCI. The effectiveness of the models in forecasting both short-term and long-term progression from MCI to AD was evaluated across different prediction windows of one, two, three, and five years. This predictive capability was enhanced by utilizing extensive patient claims data, which provided comprehensive information including demographics, diagnoses, medications, and procedures.</p><p id="p0200">The clinical significance of this research is underscored by current progression patterns and treatment options. Notably, the conversion rate from MCI to AD over five years varies from 30% to 50%, depending on the studied cohort<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref>, indicating that a significant portion of MCI patients do not progress to AD during this period. With the advent of disease-modifying therapies (DMTs), which are most effective in the earliest stages of MCI and AD, early prediction of progression risk has become crucial. However, given that DMTs can entail significant side effects, clinicians may prefer to reserve these treatments for patients most likely to progress. This research addresses this clinical need by developing a deep learning approach that can predict MCI-to-AD progression across different time windows, thus aiding clinicians in more informed discussions with their patients regarding individual risk-benefit ratios when considering DMT initiation.</p><p id="p0205">It is important to highlight that predicting MCI-to-AD progression presents notably challenging endeavors compared to identifying initial Alzheimer&#8217;s disease and associated dementias. MCI patients often share similar diagnoses and medications, complicating the distinction between those who will progress to AD and those who will not. In contrast, distinguishing patients who have never experienced any stage of AD from those who have is generally more straightforward, as the clinical differences are well-defined.</p><p id="p0210">Our study sourced its data from Clinformatics&#174;, ensuring a comprehensive representation that extends beyond the confines of a single hospital or member hospitals. Despite this broad scope, accurately forecasting the progression from MCI to AD remains challenging due to the multitude of variables within the claims data. Furthermore, the sparsity, irregularity, and temporality of the data impede the seamless creation of models, adding complexity to the prediction process.</p><p id="p0215">To address these complexities, advanced analytics techniques, including machine learning (ML) algorithms, prove invaluable in analyzing these claims data. These algorithms can handle nonlinear data and unveil hidden correlations between clinical variables and desired outcomes. Deep learning algorithms, particularly effective with large datasets, eliminate the need for extensive feature selection expertise. The temporal nature of medical claim data encodes valuable information that can be particularly well-captured through deep learning sequence modeling techniques. Our findings showed that sequence-based models' ability to process sequential information bidirectionally made them suitable for capturing temporal patterns in claims data. While other architectures like vanilla RNNs or different LSTM variants could potentially offer additional insights, our focus was on establishing the effectiveness of sequence-based deep learning approaches versus traditional ML methods that rely on engineered features. We chose BiGRU over LSTM as it offers simpler and computationally less intensive architecture with fewer parameters.</p><p id="p0220">Our model contributes to the field by addressing both short-term and long-term progression from MCI to AD. Using longitudinal patient claim records before MCI diagnosis, which include demographic and clinical information, our study demonstrates that deep learning models can effectively predict MCI-to-AD progression with promising accuracy. Through the analysis of our patient data, we confirmed previously established high-risk factors for AD, including age, gender, hypertension, anxiety, and depression. Notably, one study<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> suggests that mood disorders not only serve as potential risk factors for AD but may also manifest as presenting symptoms of the disease, a correlation that aligns seamlessly with our research outcomes.</p><p id="p0225">The robustness of this study is emphasized by its reliance on a sizable and diverse patient cohort, which ensures a comprehensive representation of individuals transitioning from MCI to AD. The BiGRU model employed leverages all accessible patient data as predictors for the progression from MCI to AD. This approach obviates the need for expert-driven feature selection and thereby streamlining the analytical process. Additionally, the model&#8217;s ability to handle temporal sequences of varying lengths is particularly valuable in healthcare settings where patient visit patterns can be irregular. Noteworthy is the model&#8217;s capacity to forecast the short-term progression from MCI to AD and its effectiveness over an extended period, providing valuable insights into the long-term trajectory of the disease, with performance notably improving in longer prediction windows.</p><p id="p0230">Another distinctive advantage of this study is the utilization of claims data, a universally available resource for virtually every patient. The model&#8217;s versatility extends beyond the confines of a single hospital, demonstrating applicability across various healthcare institutions rather than being restricted to a specific facility or group of member hospitals. The model efficiently processes raw claims data, incorporating a diverse range of predictors including demographics, diagnoses, medications, and procedures. This approach provides a comprehensive view of patient health status without the need for extensive data preprocessing.</p><p id="p0235">In contrast, with the limited availability of recorded images and the potential challenges associated with obtaining genetic information, which may not be as widespread unless necessary for specific medical requirements. The study&#8217;s reliance on this widely accessible claims data enhances its practicality and generalizability in real-world healthcare settings.</p><p id="p0240">It is important, however, to recognize certain limitations to this analysis. The accuracy of diagnoses, medications, or procedural codes may be influenced by the complexities of billing practices and clinic workflows, introducing a potential source of imprecision. Misclassification of these codes could introduce bias into our results. Additionally, claims data lack information about important factors such as lifestyle, socioeconomic status, and other social determinants of health that might influence disease progression. The potential impact of missing data or incomplete follow-up in claims databases presents another limitation. Moreover, since our predictive model is based on historical data, future alterations in clinical practices and treatments could affect disease progression patterns.</p><p id="p0245">Another limitation stems from inherent class imbalance in our dataset, where the number of patients who progress from MCI to AD is considerably smaller than those who do not progress. To address this issue, we implemented a class weighting strategy during model training to mitigate its impact. Although this adjustment has improved model performance, the underlying issue of data imbalance remains and warrants further investigation.</p><p id="p0250">Despite recognizing the importance of evaluating our model&#8217;s generalizability across diverse datasets, external validation was not conducted due to limited accessibility to such data. To mitigate this constraint, our study design incorporated two tiers of internal validation, to provide a robust assessment. Because the model relies on standard coded variables, it can be readily adapted to comparable datasets, potentially validated without retraining. This adaptability highlights a practical avenue for future research and validation efforts, ensuring that similar coding structures can facilitate the assessment and enhancement of the model&#8217;s predictive reliability.</p><p id="p0255">Additionally, while our study utilized a proprietary claims dataset which may affect result reproducibility, we have made our complete implementation publicly available through a GitHub repository, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/Tao-AI-group/MCI-to-AD-Progression-Model" id="PC_linkt8Nqr2sz99">https://github.com/Tao-AI-group/MCI-to-AD-Progression-Model</ext-link>, with comprehensive documentation. This ensures that researchers can apply our methodology to any EHR or claims dataset, fostering reproducibility and wider applicability of our approach.</p></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p id="p0260">This study explores the potential of deep learning models in predicting the progression from MCI to AD using longitudinal claims data. Our results demonstrate that the BiGRU model can effectively predict progression risk, particularly over longer intervals following initial MCI diagnosis. By leveraging comprehensive patient data without the necessity for expert-driven feature selection, the model provides a pragmatic approach to risk assessment. This could assist clinicians in identifying patients at elevated risk for AD progression, potentially facilitating more informed decisions about monitoring and intervention strategies. The findings underscore that machine learning approaches, when applied to readily available healthcare data, can contribute to early detection strategies in neurocognitive disorders. While further validation is needed, this research provides a foundation for developing automated tools that can augment existing clinical assessment methods. Future research could explore the integration of such predictive models into clinical workflows, potentially enhancing the timeliness and efficiency of AD risk assessment in clinical practice. This integration promises to advance clinical practice by enabling more proactive and personalized patient care.</p></sec><sec id="sec6"><title>Author contributions</title><p id="p0265">Cui Tao and Ahmed Abdelhameed designed the study; Ahmed Abdelhameed prepared and analyzed the data with the help of Jingna Feng, Xinyue Hu, and Sori Lundin. Ahmed Abdelhameed designed the models and generated the results and the figures. Fang Li helped with the design of the machine learning model; Paul Schulz reviewed and evaluated the clinical findings of the study. Cui Tao provided institutional support and guided the data analysis; All authors discussed the results and read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflicts of interest</title><p id="p0270">The authors declare no conflicts of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>T.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cline</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merikle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martenyi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Estimating Alzheimer&#8217;s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia</article-title><source>Curr Alzheimer Res</source><volume>15</volume><year>2018</year><fpage>777</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">29357799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1567205015666180119092427</pub-id><pub-id pub-id-type="pmcid">PMC6156780</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><article-title>Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><volume>19</volume><year>2023</year><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">36918389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Toward defining the preclinical stages of Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><volume>7</volume><year>2011</year><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">21514248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type="pmcid">PMC3220946</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N.C.</given-names></name><etal/></person-group><article-title>The diagnosis of mild cognitive impairment due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><volume>7</volume><year>2011</year><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">21514249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.008</pub-id><pub-id pub-id-type="pmcid">PMC3312027</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>McKhann</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Chertkow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Kawas</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>The diagnosis of dementia due to Alzheimer&#8217;s disease: recommendations from the National Institute on Aging-Alzheimer&#8217;s Association workgroups on diagnostic guidelines for Alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><volume>7</volume><year>2011</year><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">21514250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type="pmcid">PMC3312024</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Monfared</surname><given-names>A.A.T.</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease: epidemiology and clinical progression</article-title><source>Neurol Ther</source><volume>11</volume><year>2022</year><fpage>553</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">35286590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-022-00338-8</pub-id><pub-id pub-id-type="pmcid">PMC9095793</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Abrol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhattarai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fedorov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Plis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V.</given-names></name></person-group><article-title>Deep residual learning for neuroimaging: an application to predict progression to Alzheimer&#8217;s disease</article-title><source>J Neurosci Methods</source><volume>339</volume><year>2020</year><object-id pub-id-type="publisher-id">108701</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneumeth.2020.108701</pub-id><pub-id pub-id-type="pmcid">PMC7297044</pub-id><pub-id pub-id-type="pmid">32275915</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Predicting the progression of mild cognitive impairment to Alzheimer&#8217;s disease by longitudinal magnetic resonance imaging-based dictionary learning</article-title><source>Clin Neurophysiol</source><volume>131</volume><year>2020</year><fpage>2429</fpage><lpage>2439</lpage><pub-id pub-id-type="pmid">32829290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2020.07.016</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ngetich</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Predicting MCI to AD conversation using integrated SMRI and RS-FMRI: machine learning and graph theory approach</article-title><source>Front Aging Neurosci</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">688926</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.688926</pub-id><pub-id pub-id-type="pmcid">PMC8375594</pub-id><pub-id pub-id-type="pmid">34421570</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Cabral</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morgado</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Silveira</surname><given-names>M.</given-names></name></person-group><article-title>Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages</article-title><source>Comput Biol Med</source><volume>58</volume><year>2015</year><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">25625698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2015.01.003</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnestic mild cognitive impairment to Alzheimer disease</article-title><source>Medicine</source><volume>98</volume><year>2019</year><object-id pub-id-type="publisher-id">e16604</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000016604</pub-id><pub-id pub-id-type="pmcid">PMC6709245</pub-id><pub-id pub-id-type="pmid">31348306</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Pusil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimitriadis</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pereda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maest&#250;</surname><given-names>F.</given-names></name></person-group><article-title>Aberrant MEG multi-frequency phase temporal synchronization predicts conversion from mild cognitive impairment-to-Alzheimer&#8217;s disease</article-title><source>Neuroimage Clin</source><volume>24</volume><year>2019</year><object-id pub-id-type="publisher-id">101972</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2019.101972</pub-id><pub-id pub-id-type="pmcid">PMC6745514</pub-id><pub-id pub-id-type="pmid">31522127</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Garces</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maestu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Pantazis</surname><given-names>D.</given-names></name></person-group><article-title>A Graph Gaussian embedding method for predicting Alzheimer&#8217;s disease progression with MEG brain networks</article-title><source>IEEE Trans Biomed Eng</source><volume>68</volume><year>2021</year><fpage>1579</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">33400645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TBME.2021.3049199</pub-id><pub-id pub-id-type="pmcid">PMC8162933</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Grueso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Viejo-Sobera</surname><given-names>R.</given-names></name></person-group><article-title>Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer&#8217;s disease dementia: a systematic review</article-title><source>Alzheimers Res Ther</source><volume>13</volume><year>2021</year><fpage>162</fpage><pub-id pub-id-type="pmid">34583745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-021-00900-w</pub-id><pub-id pub-id-type="pmcid">PMC8480074</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Burkett</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>V.J.</given-names></name></person-group><article-title>Evaluation of neurodegenerative disorders with Amyloid-<italic toggle="yes">&#946;</italic>, Tau, and dopaminergic PET imaging: interpretation pitfalls</article-title><source>J Nucl Med</source><volume>65</volume><year>2024</year><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">38664015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.123.266463</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Bouwman</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Engelborghs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ikeuchi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Clinical application of CSF biomarkers for Alzheimer&#8217;s disease: from rationale to ratios</article-title><source>Alzheimers Dement (Amst)</source><volume>14</volume><year>2022</year><object-id pub-id-type="publisher-id">e12314</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12314</pub-id><pub-id pub-id-type="pmcid">PMC9044123</pub-id><pub-id pub-id-type="pmid">35496374</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tideman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Blood biomarkers to detect Alzheimer disease in primary care and secondary care</article-title><source>JAMA</source><volume>332</volume><year>2024</year><fpage>1245</fpage><pub-id pub-id-type="pmid">39068545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2024.13855</pub-id><pub-id pub-id-type="pmcid">PMC11284636</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Spasov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Passamonti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duggento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li&#242;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Toschi</surname><given-names>N.</given-names></name></person-group><article-title>A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><volume>189</volume><year>2019</year><fpage>276</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">30654174</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2019.01.031</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Fouladvand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Vassilaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sauver</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>S.</given-names></name></person-group><article-title>Deep learning prediction of mild cognitive impairment using electronic health records</article-title><source>Proc (IEEE Int Conf Bioinforma Biomed</source><volume>2019</volume><year>2019</year><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/bibm47256.2019.8982955</pub-id><pub-id pub-id-type="pmcid">PMC7665163</pub-id><pub-id pub-id-type="pmid">33194303</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Chiariglione</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Nuytemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E.R.</given-names></name></person-group><article-title>Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer&#8217;s disease prediction</article-title><source>Alzheimers Dement</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">e063653</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-27551-1</pub-id><pub-id pub-id-type="pmcid">PMC9829871</pub-id><pub-id pub-id-type="pmid">36624143</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adekkanattu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J.</given-names></name><etal/></person-group><article-title>AD-BERT: using pre-trained language model to predict the progression from mild cognitive impairment to Alzheimer&#8217;s disease</article-title><source>J Biomed Inform</source><volume>144</volume><year>2023</year><object-id pub-id-type="publisher-id">104442</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2023.104442</pub-id><pub-id pub-id-type="pmcid">PMC11131134</pub-id><pub-id pub-id-type="pmid">37429512</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>PourNejatian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Parisien</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A large language model for electronic health records</article-title><source>NPJ Digit Med</source><volume>5</volume><year>2022</year><fpage>194</fpage><pub-id pub-id-type="pmid">36572766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-022-00742-2</pub-id><pub-id pub-id-type="pmcid">PMC9792464</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xian</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Large language models in biomedical and health informatics: a review with bibliometric analysis</article-title><source>arXivOrg</source><year>2024</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://arxiv.org/abs/2403.16303" id="intref0015">https://arxiv.org/abs/2403.16303</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s41666-024-00171-8</pub-id><pub-id pub-id-type="pmcid">PMC11499577</pub-id><pub-id pub-id-type="pmid">39463859</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Novoa-Laurentiev</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plasaek</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Enhancing early detection of cognitive decline in the elderly: a comparative study utilizing large language models in clinical notes</article-title><source>medRxiv</source><year>2024</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1101/2024.04.03.24305298</pub-id><pub-id pub-id-type="pmcid">PMC11663780</pub-id><pub-id pub-id-type="pmid">39396423</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>M.E.H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Deep learning for temporal data representation in electronic health records: a systematic review of challenges and methodologies</article-title><source>J Biomed Inform</source><volume>126</volume><year>2021</year><object-id pub-id-type="publisher-id">103980</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbi.2021.103980</pub-id><pub-id pub-id-type="pmid">34974189</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>W.Q.</given-names></name><name name-style="western"><surname>Bastarache</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Marlo</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Osterman</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Gamazon</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><object-id pub-id-type="publisher-id">e0175508</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0175508</pub-id><pub-id pub-id-type="pmcid">PMC5501393</pub-id><pub-id pub-id-type="pmid">28686612</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Varley</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Mapping ICD-10 and ICD-10-CM codes to Phecodes: workflow development and initial evaluation</article-title><source>JMIR Med Inform</source><volume>7</volume><year>2019</year><object-id pub-id-type="publisher-id">e14325</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/14325</pub-id><pub-id pub-id-type="pmcid">PMC6911227</pub-id><pub-id pub-id-type="pmid">31553307</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Bahdanau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y.</given-names></name></person-group><article-title>Neural machine translation by jointly learning to align and translate</article-title><source>arXivOrg</source><year>2014</year><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://arxiv.org/abs/1409.0473" id="intref0020">https://arxiv.org/abs/1409.0473</ext-link></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="book" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Akiba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yanase</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koyama</surname><given-names>M.</given-names></name></person-group><part-title>Optuna</part-title><source>Proceedings of the 25th ACM SIGKDD international Conference on knowledge discovery; data mining</source><year>2019</year><comment>Available from: </comment><pub-id pub-id-type="doi">10.1145/3292500.3330701</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Liss</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Assun&#231;&#227;o</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Atri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geldmacher</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Candela</surname><given-names>S.F.</given-names></name><etal/></person-group><article-title>Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer&#8217;s disease (MCI and dementia) in primary care: a review and synthesis</article-title><source>J Intern Med</source><volume>290</volume><year>2021</year><fpage>310</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">33458891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.13244</pub-id><pub-id pub-id-type="pmcid">PMC8359937</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Mendez</surname><given-names>M.F.</given-names></name></person-group><article-title>Degenerative dementias: alterations of emotions and mood disorders</article-title><source>Handb Clin Neurol</source><volume>183</volume><year>2021</year><fpage>261</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">34389121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-822290-4.00012-8</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supporting information</title><p id="p0280">The following is the Supporting Information to this article:<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Multimedia component 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0275">The study was partially funded by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source> (NIH/NIA) [grant numbers <award-id award-type="grant" rid="gs1">R01AG084236</award-id>, <award-id award-type="grant" rid="gs1">R01AG083039</award-id>, <award-id award-type="grant" rid="gs1">RF1AG072799</award-id> and <award-id award-type="grant" rid="gs1">R56AG074604</award-id>, USA].</p></ack><fn-group><fn id="d36e422"><p id="ntpara0010">This article is part of a special issue entitled: AI, computational and systems biology-guided translational research in Alzheimer's disease published in Acta Pharmaceutica Sinica B.</p></fn><fn id="d36e425"><p id="ntpara0015">Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.</p></fn><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0285">Supporting information to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.apsb.2025.01.027" id="intref0010">https://doi.org/10.1016/j.apsb.2025.01.027</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="fsn371044" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Food Sci Nutr</journal-id><journal-id journal-id-type="iso-abbrev">Food Sci Nutr</journal-id><journal-id journal-id-type="pmc-domain-id">2357</journal-id><journal-id journal-id-type="pmc-domain">fsn</journal-id><journal-id journal-id-type="publisher-id">FSN3</journal-id><journal-title-group><journal-title>Food Science &amp; Nutrition</journal-title></journal-title-group><issn pub-type="epub">2048-7177</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12491657</article-id><article-id pub-id-type="pmcid-ver">PMC12491657.1</article-id><article-id pub-id-type="pmcaid">12491657</article-id><article-id pub-id-type="pmcaiid">12491657</article-id><article-id pub-id-type="pmid">41049418</article-id><article-id pub-id-type="doi">10.1002/fsn3.71044</article-id><article-id pub-id-type="publisher-id">FSN371044</article-id><article-id pub-id-type="other">FSN3-2025-04-1169.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Hepatoprotective Properties of <italic toggle="no">Opuntia ficus indica</italic> Cladodes Against NiSO<sub>4</sub>&#8208;Induced Oxidative Stress and Liver Damage</article-title></title-group><contrib-group><contrib id="fsn371044-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Razzak</surname><given-names initials="S">Sara</given-names></name><xref rid="fsn371044-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>sara.razzak@uit.ac.ma</email></address></contrib><contrib id="fsn371044-cr-0002" contrib-type="author"><name name-style="western"><surname>Aouji</surname><given-names initials="M">Marouane</given-names></name><xref rid="fsn371044-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="fsn371044-cr-0003" contrib-type="author"><name name-style="western"><surname>El Assri</surname><given-names initials="S">Soufiane</given-names></name><xref rid="fsn371044-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="fsn371044-cr-0004" contrib-type="author"><name name-style="western"><surname>Sabri</surname><given-names initials="C">Chaima</given-names></name><xref rid="fsn371044-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="fsn371044-cr-0005" contrib-type="author"><name name-style="western"><surname>Ittorahou</surname><given-names initials="A">Abdessamad</given-names></name><xref rid="fsn371044-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="fsn371044-cr-0006" contrib-type="author"><name name-style="western"><surname>Ibouzinedine</surname><given-names initials="L">Laila</given-names></name><xref rid="fsn371044-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="fsn371044-cr-0007" contrib-type="author"><name name-style="western"><surname>Bouallegue</surname><given-names initials="A">Amir</given-names></name><xref rid="fsn371044-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="fsn371044-cr-0008" contrib-type="author"><name name-style="western"><surname>Alyami</surname><given-names initials="EM">Esmael M.</given-names></name><xref rid="fsn371044-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="fsn371044-cr-0009" contrib-type="author"><name name-style="western"><surname>Almehizia</surname><given-names initials="AA">Abdulrahman A.</given-names></name><xref rid="fsn371044-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="fsn371044-cr-0010" contrib-type="author"><name name-style="western"><surname>Khalouki</surname><given-names initials="F">Farid</given-names></name><xref rid="fsn371044-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="fsn371044-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Dabiellil</surname><given-names initials="F">Fakhreldeen</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-9583-2150</contrib-id><xref rid="fsn371044-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><address><email>researcherzem@gmail.com</email></address></contrib><contrib id="fsn371044-cr-0012" contrib-type="author"><name name-style="western"><surname>Bourhia</surname><given-names initials="M">Mohammed</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3707-8461</contrib-id><xref rid="fsn371044-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="fsn371044-cr-0013" contrib-type="author"><name name-style="western"><surname>Haloui</surname><given-names initials="A">Anass</given-names></name><xref rid="fsn371044-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="fsn371044-cr-0014" contrib-type="author"><name name-style="western"><surname>Taboz</surname><given-names initials="Y">Youness</given-names></name><xref rid="fsn371044-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="fsn371044-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Natural Resources and Sustainable Development Laboratory, Research Unit in Nutrition, Metabolism and Physiology, Department of Biology, Faculty of Sciences</named-content>
<institution>Ibn Tofail University</institution>
<city>Kenitra</city>
<country country="MA">Morocco</country>
</aff><aff id="fsn371044-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Biochemistry Laboratory, Central Laboratory Service Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda</named-content>
<institution>Mohammed First University</institution>
<city>Oujda</city>
<country country="MA">Morocco</country>
</aff><aff id="fsn371044-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Biology and Health Laboratory, Faculty of Sciences</named-content>
<institution>Ibn Tofail University</institution>
<city>Kenitra</city>
<country country="MA">Morocco</country>
</aff><aff id="fsn371044-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Food Oral Processing, School of Food Science and Biotechnology</named-content>
<institution>Zhejiang Gongshang University</institution>
<city>Hangzhou</city>
<country country="CN">China</country>
</aff><aff id="fsn371044-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Biology, College of Science</named-content>
<institution>King Khalid University</institution>
<city>Abha</city>
<country country="SA">Saudi Arabia</country>
</aff><aff id="fsn371044-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Chemistry, College of Pharmacy</named-content>
<institution>King Saud University</institution>
<city>Riyadh</city>
<country country="SA">Saudi Arabia</country>
</aff><aff id="fsn371044-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Biology Department, FSTE</named-content>
<institution>Moulay Ismail University of Meknes</institution>
<city>Errachidia</city>
<country country="MA">Morocco</country>
</aff><aff id="fsn371044-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>University of Bahr el Ghazal</institution>
<city>Wau</city>
<country country="SS">South Sudan</country>
</aff><aff id="fsn371044-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Biotechnology and Natural Resources Valorization, Faculty of Sciences</named-content>
<institution>Ibn Zohr University</institution>
<city>Agadir</city>
<country country="MA">Morocco</country>
</aff><aff id="fsn371044-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Pathological Anatomy, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy of Oujda</named-content>
<institution>Mohammed First University</institution>
<city>Oujda</city>
<country country="MA">Morocco</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Sara Razzak (<email>sara.razzak@uit.ac.ma</email>)<break/>
Fakhreldeen Dabiellil (<email>researcherzem@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>13</volume><issue seq="680">10</issue><issue-id pub-id-type="pmc-issue-id">497558</issue-id><issue-id pub-id-type="doi">10.1002/fsn3.v13.10</issue-id><elocation-id>e71044</elocation-id><history><date date-type="rev-recd"><day>21</day><month>8</month><year>2025</year></date><date date-type="received"><day>21</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-06 15:25:14.893"><day>06</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Food Science &amp; Nutrition</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="FSN3-13-e71044.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:FSN3-13-e71044.pdf"/><abstract><title>ABSTRACT</title><p>The <italic toggle="no">Opuntia</italic> genus exhibits several mechanisms that support liver function. Due to its richness in phenolic compounds, our study highlights the hepatoprotective potential of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Opuntia ficus&#8208;indica</italic>
</styled-content> cladode juice in mitigating nickel&#8208;induced liver injury. The polyphenol content was determined using spectrophotometric analysis and HPLC&#8208;MS. Experimental hepatotoxicity was induced by intraperitoneal (i.p.) injection of NiSO<sub>4</sub>. To assess the hepatoprotective effects of cladode juice, various analyses were performed to evaluate its impact on enzymatic activity, serum biomarkers, oxidative stress markers, and liver tissue structure. Quantification of phenolic compounds confirmed the presence of total polyphenols and flavonoids. Chromatographic analysis identified p&#8208;coumaric acid, piscidic acid, isorhamnetin&#8208;3&#8208;O&#8208;neohesperoside, and ellagic acid as the major phenolic constituents. Cladode juice exhibited a hepatoprotective effect in rats intoxicated with nickel sulfate (NiSO<sub>4</sub>), as evidenced by the modulation of plasma hepatic biomarkers, restoration of oxidative stress marker levels, and a marked reduction in hepatic lesions observed through histological analysis. Molecular docking studies of the four identified polyphenolic compounds with alanine transaminase revealed a higher binding affinity for ellagic acid, followed by p&#8208;coumaric acid. These beneficial effects are attributed to the plant's diverse bioactive compounds, highlighting their potential to mitigate oxidative damage and support liver function.</p></abstract><abstract abstract-type="graphical"><p>Our study suggests that <italic toggle="no">Opuntia ficus indica</italic> cladode juice exhibits hepatoprotective properties, mitigating liver damage induced by nickel exposure. The polyphenol content was determined using spectrophotometric analysis and HPLC&#8208;MS. Experimental hepatotoxicity was induced by intraperitoneal (i.p.) injection of NiSO<sub>4</sub>.<boxed-text position="anchor" content-type="graphic" id="fsn371044-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="FSN3-13-e71044-g004.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="fsn371044-kwd-0001">cladode juice</kwd><kwd id="fsn371044-kwd-0002">hepatic biomarkers</kwd><kwd id="fsn371044-kwd-0003">hepatoprotective</kwd><kwd id="fsn371044-kwd-0004">histological analysis</kwd><kwd id="fsn371044-kwd-0005">molecular docking</kwd><kwd id="fsn371044-kwd-0006">NiSO<sub>4</sub></kwd><kwd id="fsn371044-kwd-0007">oxidative stress</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Deanship of Scientific Research, King Khalid University (RGP2/534/45 ) and the Ongoing Research Funding program, King Saud University (ORF&#8208;2025&#8208;852).</institution><institution-id institution-id-type="doi">10.13039/501100023674</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="6"/><table-count count="6"/><page-count count="17"/><word-count count="12200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:03.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="fsn371044-cit-1001"><string-name name-style="western"><surname>Razzak</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Aouji</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>El Assri</surname></string-name>, et al. <year>2025</year>. &#8220;<article-title>Hepatoprotective Properties of <italic toggle="no">Opuntia ficus indica</italic> Cladodes Against NiSO<sub>4</sub>&#8208;Induced Oxidative Stress and Liver Damage</article-title>.&#8221; <source>Food Science &amp; Nutrition</source><volume>13</volume>, no. <issue>10</issue>: <elocation-id>e71044</elocation-id>. <pub-id pub-id-type="doi">10.1002/fsn3.71044</pub-id>.</mixed-citation>
</p><fn-group id="fsn371044-ntgp-0001"><fn fn-type="funding" id="fsn371044-note-0001"><p>
<bold>Funding:</bold> This work is funded by the Deanship of Scientific Research and Graduate Studies at King Khalid University through the Large Research Project under grant number RGP2/534/45, and King Saud University, Riyadh, Saudi Arabia, through the Ongoing Research Funding program (ORF&#8208;2025&#8208;852).</p></fn></fn-group></notes></front><body id="fsn371044-body-0001"><sec id="fsn371044-sec-0001"><label>1</label><title>Introduction</title><p>Heavy metal pollution is a global problem that threatens human and animal health and also the environment. Human activities, including industry, agriculture, and transport, release heavy metals into the air, water, and soil (Brown and Margolis&#160;<xref rid="fsn371044-bib-0018" ref-type="bibr">2012</xref>). Unlike heavy metals, there are light metals such as nickel (Ni), which can become toxic if present at high levels (Iyaka&#160;<xref rid="fsn371044-bib-0042" ref-type="bibr">2011</xref>). The 24th most prevalent element in the crust of the planet is nickel (Ni), accounting for 3% of its composition, second only to iron, oxygen, magnesium, and silicon. Nickel metals and their alloys are widely used in the food industry, particularly as catalysts and pigments, in chemical and metallurgical applications. Nickel is recognized as a valuable micronutrient for specific plant species (Liu et&#160;al.&#160;<xref rid="fsn371044-bib-0054" ref-type="bibr">2011</xref>) and a crucial trace element for the human body (Cao et&#160;al.&#160;<xref rid="fsn371044-bib-0020" ref-type="bibr">2016</xref>); nonetheless, excessive concentrations can have adverse effects. The exposure to high levels of nickel has been associated with the development of cancer and various health complications such as fatigue, headaches, dermatitis, vertigo, cardiovascular issues, and respiratory disorders (Pasha et&#160;al.&#160;<xref rid="fsn371044-bib-0064" ref-type="bibr">2010</xref>). Commercially important nickel salts include nickel chloride, nickel sulphate, nickel nitrate, nickel carbonate, nickel hydroxide, nickel acetate, and nickel oxide (Cempel and Nikel&#160;<xref rid="fsn371044-bib-0022" ref-type="bibr">2006</xref>). Nickel is a metal that can accumulate in the body, particularly in the bones, liver, and kidneys. This bioaccumulation can have negative health consequences, based on the dosage and duration of contact. Nickel is an immunotoxic and carcinogenic agent that can damage the immune system and cause disease (Genchi et&#160;al.&#160;<xref rid="fsn371044-bib-0038" ref-type="bibr">2020</xref>). However, excessive consumption may lead to oxidative stress, resulting in an overproduction of harmful free radicals. This can damage cellular structures and impair liver function, potentially resulting in severe liver toxicity (Meng et&#160;al.&#160;<xref rid="fsn371044-bib-0058" ref-type="bibr">2018</xref>).</p><p>The liver is the organ most sensitive to nickel toxicity, whether of environmental or occupational origin. Because nickel disrupts the metabolism of ascorbate&#8208;cholesterol and changes the activity of various enzymes, it can cause significant damage to the liver and kidneys (Derbal et&#160;al.&#160;<xref rid="fsn371044-bib-0029" ref-type="bibr">2022</xref>). The production of reactive oxygen species (ROS) and a rise in lipid peroxidation (LPO) at the cellular level are two negative consequences of nickel's action in the body. Nickel accumulation is responsible for increased production of ROS and increased LPO (Guo et&#160;al.&#160;<xref rid="fsn371044-bib-0039" ref-type="bibr">2019</xref>). The exposure to nickel has been correlated with alterations in the functionality of various antioxidant enzymes, which encompass catalase (CAT), reduced glutathione (GSH), glutathione peroxidase (GPX), and glutathione S&#8208;transferase (GST). These enzymes assume a critical function in the detoxification of reactive oxygen species (ROS) and the safeguarding of cellular integrity against damage (Sidhu et&#160;al.&#160;<xref rid="fsn371044-bib-0078" ref-type="bibr">2004</xref>). Moreover, oxidative stress, a condition arising from a lack of balance in the middle of antioxidant defenses and reactive oxygen species, is implicated throughout the initiation and development of liver damage (Li et&#160;al.&#160;<xref rid="fsn371044-bib-0052" ref-type="bibr">2015</xref>). Due to its significant role in liver injury, antioxidants have been thoroughly investigated for their possible help in treating and preventing liver disorders, both acute and chronic (Adak&#160;<xref rid="fsn371044-bib-0002" ref-type="bibr">2018</xref>). For this reason, numerous studies have demonstrated the positive effects of antioxidants, especially in the prevention and treatment of liver injury. Aggressive antioxidant therapy is thought to enhance liver injury outcomes. Furthermore, using synthetic medications to treat liver illness may not be effective or may result in major side effects (Touiss et&#160;al.&#160;<xref rid="fsn371044-bib-0085" ref-type="bibr">2021</xref>).</p><p>The hepatoprotective potential pertains to the ability of specific compounds to mitigate hepatic injury, safeguarding this vital organ engaged in numerous biochemical pathways. Multiple investigations have substantiated the efficacy of various agents in preserving liver integrity (Sharukh et&#160;al.&#160;<xref rid="fsn371044-bib-0076" ref-type="bibr">2023</xref>).</p><p>The genus <italic toggle="yes">Opuntia</italic> provides a variety of mechanisms and benefits for liver function. Antioxidant action is a notable mechanism exhibited by several species within this genus (Chen et&#160;al.&#160;<xref rid="fsn371044-bib-0027" ref-type="bibr">2021</xref>). The liver&#8208;protective properties of cactus cladodes, particularly those from <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Opuntia atropes</italic>
</styled-content> and <italic toggle="yes">Opuntia ficus indica</italic>, are linked to their abundant phytochemical profile, including flavonoids and dietary fibers, which exhibit notable antioxidative potential. Investigations indicate that cactus cladode extracts can mitigate hepatic damage induced by toxins such as lithium carbonate and high&#8208;fat diets, leading to reductions in hepatic lipid and triacylglycerol content by up to 73.1% in models used in experiments (Ben Saad et&#160;al.&#160;<xref rid="fsn371044-bib-0009" ref-type="bibr">2016</xref>; Duarte&#8208;Medina et&#160;al.&#160;<xref rid="fsn371044-bib-0032" ref-type="bibr">2024</xref>). <italic toggle="yes">Opuntia ficus indica</italic> (<italic toggle="yes">OFI</italic>), a cactus of the Cactaceae family, has fruits and cladodes that are rich in essential nutrients, including minerals, vitamins, and antioxidants. Traditional medicine uses it to treat illnesses through these health benefits. The researchers have confirmed their efficiency in the treatment of multiple diseases thanks to these anti&#8208;ulcerogenic, antioxidant, anti&#8208;cancer, and hepatoprotective properties (Brahmi et&#160;al.&#160;<xref rid="fsn371044-bib-0017" ref-type="bibr">2011</xref>). Cladode juice's phenolic components, namely certain flavonoids and proanthocyanidins, along with beta&#8208;carotene (provitamin A), vitamins C and E, and glutathione, have been linked to a reduction in blood glucose and cholesterol levels when consumed regularly (Hfaiedh et&#160;al.&#160;<xref rid="fsn371044-bib-0041" ref-type="bibr">2008</xref>). Furthermore, recent studies have substantiated the elevated concentration of some substances that are bioactive in cladodes, including phenolic compounds, phytosterols, betalains, carotenoids, and essential fatty acids, particularly linoleic and palmitic acids. This biochemical composition underscores their potential therapeutic and nutritional significance (Razzak, Aouji, Sabri, et&#160;al.&#160;<xref rid="fsn371044-bib-0069" ref-type="bibr">2024</xref>). Additionally, their rich nutritional profile, encompassing polysaccharides, vitamins, and minerals, further highlights their value in health and disease prevention (Razzak, Aouji, Zirari, et&#160;al.&#160;<xref rid="fsn371044-bib-0070" ref-type="bibr">2024</xref>).</p><p>Advanced computer&#8208;assisted drug discovery technologies have advanced to allow the detection of drugs derived from phytochemical compounds present in various medicinal plants. In computer science, predictive models are essential for directing the methodological selection of technical and medical research. Additionally, they have been applied to the in silico prediction of toxicological, pharmacokinetic, and pharmacological performance (Loza&#8208;Mej&#237;a et&#160;al.&#160;<xref rid="fsn371044-bib-0055" ref-type="bibr">2018</xref>). Currently, molecular docking represents an efficient and economical approach for the development and evaluation of pharmaceutical products. By using this technique, information on how pharmaceuticals interact with receptors is generated, which can be used to predict how drug candidates would align with their target protein (Lee and Kim&#160;<xref rid="fsn371044-bib-0050" ref-type="bibr">2019</xref>). In addition, this method promotes systematic exploration by positioning a molecule non&#8208;covalently on the docking site of a target macromolecule, which leads to a specific association with the active sites of each ligand (Bharathi et&#160;al.&#160;<xref rid="fsn371044-bib-0011" ref-type="bibr">2014</xref>).</p><p>The main objective of this study was to evaluate the hepatoprotective capacity of phenolic compounds in cladode juice in laboratory animals. Using a rat model of NiSO<sub>4</sub>&#8208;induced acute liver injury, we investigated the therapeutic properties of cladode juice extract from <italic toggle="yes">Opuntia ficus indica</italic> (<italic toggle="yes">OFI</italic>) and explored the mechanisms underlying its hepatoprotective efficacy. A molecular docking study involving alanine aminotransferase was also carried out to deepen the understanding of the mode of action of these molecules.</p></sec><sec sec-type="materials-and-methods" id="fsn371044-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="fsn371044-sec-0003"><label>2.1</label><title>Cladodes Juice Preparation</title><p>Mature cladodes of the <italic toggle="yes">Opuntia ficus indica</italic> species were harvested in the commune of Oulad Boubker (Morocco). After the spines had been cleaned, the cladodes were cut into small pieces and mixed with a volume of distilled water (50%) using a Moulinex. The juice obtained was then filtered to remove the hard fibers and homogenized using a high&#8208;speed blender (CAT Unidrive 1000 D).</p></sec><sec id="fsn371044-sec-0004"><label>2.2</label><title>Analysis of Phenolic Compounds</title><sec id="fsn371044-sec-0005"><label>2.2.1</label><title>Determination of Total Phenolic Content (TPC)</title><p>The Folin&#8211;Ciocalteu method, as described by Singleton et&#160;al.&#160;(<xref rid="fsn371044-bib-0079" ref-type="bibr">1999</xref>), was used to determine the phenolic compound content in cladode extracts. Specifically, 0.5&#8201;mL of the sample extract was mixed with 2.5&#8201;mL of Folin&#8211;Ciocalteu reagent, which had been previously diluted tenfold with distilled water. Upon interaction with phenolic compounds, this reagent produces a blue coloration, the intensity of which is directly proportional to the phenolic concentration. After an 8&#8208;min incubation period, 2&#8201;mL of a 7.5% sodium bicarbonate solution was added, followed by a 15&#8208;min incubation in the absence of light. The absorbance was then measured at 765&#8201;nm, and the total phenolic content was quantified. Micrograms of gallic acid per milliliter of juice (mg GAE&#8201;mL<sup>&#8722;1</sup>) were used to express the results. Three duplicates of the experiment were conducted.</p></sec><sec id="fsn371044-sec-0006"><label>2.2.2</label><title>Determination of Total Flavonoid Content (<styled-content style="fixed-case" toggle="no">TFC</styled-content>)</title><p>The total flavonoid content of cladodes was determined by colorimetric analysis following the protocol described by Djeridane et&#160;al.&#160;(<xref rid="fsn371044-bib-0030" ref-type="bibr">2006</xref>). A reaction mixture consisting of 1&#8201;mL of extract and 1&#8201;mL of a 2% methanolic solution of aluminum chloride (AlCl<sub>3</sub>) was incubated for 15&#8201;min at room temperature. The absorbance was then measured using a spectrophotometer set at 430&#8201;nm. The reference blank for this analysis consisted of methanol combined with AlCl<sub>3</sub>. Flavonoid concentrations in the extracts were determined using a quercetin calibration curve, and the findings were reported as mg QE&#8201;mL<sup>&#8722;1</sup>, or quercetin equivalent per milliliter of juice.</p></sec><sec id="fsn371044-sec-0007"><label>2.2.3</label><title>Identification of Polyphenols by <styled-content style="fixed-case" toggle="no">HPLC</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">MS</styled-content>
</title><p>Polyphenol Separation: A C18 column (5&#8201;&#956;m, 250&#8201;&#215;&#8201;4.6&#8201;mm) kept at 30&#176;C was used to examine the material. Detection of UV/DAD was done between 200 and 600&#8201;nm. Phase A and Phase B mobile phases are 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. The injection volume was 10&#8201;&#956;L, and the applied flow rate was 0.8&#8201;mL/min. 0&#8211;5&#8201;min at 15% A; 5&#8211;20&#8201;min at 15%&#8211;25% A; 20&#8211;30&#8201;min at 25%&#8211;35% A; 30&#8211;40&#8201;min at 35%&#8211;50% A; 40&#8211;50&#8201;min at 80% A; and 50&#8211;55&#8201;min at 15%. A was the gradient elution schedules. The following crucial characteristics were present in the system, which had a heated electrospray ionization (ESI) source and ran in either negative or positive ESI mode (&#177;4.0&#8201;kV) (Shang et&#160;al. <xref rid="fsn371044-bib-0095" ref-type="bibr">2022</xref>).
<list list-type="simple" id="fsn371044-list-0001"><list-item id="fsn371044-li-0001"><label>&#8211;</label><p>The flow rate of auxiliary gas is measured at 10 arbitrary units (arb) (Shang et&#160;al. <xref rid="fsn371044-bib-0095" ref-type="bibr">2022</xref>); the flow rate of sheath gas is quantified at 35 arb.</p></list-item><list-item id="fsn371044-li-0002"><label>&#8211;</label><p>The temperature of the capillary is maintained at 325&#176;C; the temperature of the auxiliary gas heater is set at 350&#176;C.</p></list-item><list-item id="fsn371044-li-0003"><label>&#8211;</label><p>The collision energies employed in a stepped and normalized fashion are quantified at 20, 40, and 60&#8201;eV (eV).</p></list-item><list-item id="fsn371044-li-0004"><label>&#8211;</label><p>The analytical procedure is conducted in full&#8208;scan mass spectrometry mode with a resolution of 70,000 full width at half maximum (FWHM).</p></list-item><list-item id="fsn371044-li-0005"><label>&#8211;</label><p>The scanning range is established from m/z 10,0 to 100,000.</p></list-item></list>
</p></sec></sec><sec id="fsn371044-sec-0008"><label>2.3</label><title>Animals</title><p>Twenty female albino Wistar rats with an initial weight of 205&#8201;&#177;&#8201;22&#8201;g were bred at the Faculty of Science, Ibn Tofail University, Kenitra 14000, Morocco. The rats were maintained on a 12&#8208;h light/12&#8208;h dark cycle and at a room temperature of 21&#176;C&#8201;&#177;&#8201;2&#176;C. Access to water and food was free throughout the study. All experimental procedures were conducted following approval by the Institutional Ethics Committee for the Care and Use of Laboratory Animals at the Faculty of Sciences, ensuring full compliance with established animal welfare regulations.</p></sec><sec id="fsn371044-sec-0009"><label>2.4</label><title>Experimental Procedure</title><p>Rats were divided into four groups consisting of five animals in each group and treated for 40&#8201;days as follows: Control group: normal control rats, receiving distilled water (10&#8201;mL&#8201;kg<sup>&#8722;1</sup>) daily for 30&#8201;days and injected with physiological saline (0.9% NaCl) at a dose of 4&#8201;mL&#8201;kg<sup>&#8722;1</sup> on days 31 to 40. Ni group: intoxicated control rats receiving distilled water (10&#8201;mL&#8201;kg<sup>&#8722;1</sup>) daily for 30&#8201;days and injected with NiSO<sub>4</sub> at a dose of 4&#8201;mL&#8201;kg<sup>&#8722;1</sup> on days 31 to 40. CJ group: rats receiving cladode juice (10&#8201;mL&#8201;kg<sup>&#8722;1</sup>) daily for 30&#8201;days and injected with physiological saline (0.9% NaCl) at a dose of 4&#8201;mL&#8201;kg<sup>&#8722;1</sup> on days 31 to 40. CJ&#8201;+&#8201;NiSO<sub>4</sub> group: rats receiving cladode juice (10&#8201;mL&#8201;kg<sup>&#8722;1</sup>) daily for 30&#8201;days and injected with NiSO<sub>4</sub> at a dose of 4&#8201;mL&#8201;kg<sup>&#8722;1</sup> on days 31 to 40. The study by Hfaiedh et&#160;al.&#160;(<xref rid="fsn371044-bib-0041" ref-type="bibr">2008</xref>) was used as the basis for the nickel dose and experimental protocol in this study, with some modifications.</p></sec><sec id="fsn371044-sec-0010"><label>2.5</label><title>Serum Collection and Tissue Homogenate Preparation</title><p>Before each administration, the rats' body weight is recorded. After 24&#8201;h following the last NiSO<sub>4</sub> injection, the rats are anesthetized with Pentobarbital. Heparin&#8208;containing tubes are filled with blood drawn from the abdominal aorta. After centrifuging the samples for 10&#8201;min at 3000&#8201;rpm, the plasma is extracted and kept at &#8722;20&#176;C for serum marker tests. After the liver is taken out, it is cleaned with physiological saline (NaCl, 0.9%), weighed, and 1&#8201;g of liver tissue is mixed with 5&#8201;mL of PBS (pH&#8201;7.4) in a Potter tube at 0 degrees Celsius (on ice). After that, the homogenate is centrifuged for 15&#8201;min at 14,500&#8201;rpm. The supernatant is stored at &#8722;20&#176;C for oxidative stress assays. The remaining liver tissue is fixed in 10% formalin for histological analysis.</p><p>The following formula was used to calculate the liver index (Su et&#160;al.&#160;<xref rid="fsn371044-bib-0083" ref-type="bibr">2014</xref>):<disp-formula id="fsn371044-disp-0001"><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Liver index</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mo>%</mml:mo></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>liver weight</mml:mtext><mml:mo>/</mml:mo><mml:mtext>body weight</mml:mtext></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p></sec><sec id="fsn371044-sec-0011"><label>2.6</label><title>Analytical Methods</title><sec id="fsn371044-sec-0012"><label>2.6.1</label><title>Serum Marker Assays</title><p>All Serum marker enzyme experiments aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), glucose, total protein, total and direct bilirubin (TB and DB) were conducted in triplicate for each specimen using the ROCHE COBAS INTEGRA 400 Plus autoanalyzer with the utilization of commercially available reagent kits.</p></sec><sec id="fsn371044-sec-0013"><label>2.6.2</label><title>Estimate of Lipid Peroxidation (<styled-content style="fixed-case" toggle="no">MDA</styled-content>)</title><p>By quantifying the production of malondialdehyde (MDA) in liver extracts, the level of lipid peroxidation (LPO) was indirectly assessed (Mihara and Uchiyama&#160;<xref rid="fsn371044-bib-0059" ref-type="bibr">1978</xref>). The concentration was expressed as nanomoles MDA/mg protein by measuring the absorbance of the complex formed at 535&#8201;nm.</p></sec><sec id="fsn371044-sec-0014"><label>2.6.3</label><title>Estimation of Glutathione Reduction (<styled-content style="fixed-case" toggle="no">GSH</styled-content>)</title><p>Hepatic glutathione (GSH) was measured by a colorimetric method known as the Ellman method. This method is based on the fact that glutathione reacts with 5,5&#8242;&#8208;dithio&#8208;bis(2&#8208;nitrobenzoate) (DTNB) to form a yellow complex. The amount of GSH is proportional to the intensity of the yellow color (Ellman&#160;<xref rid="fsn371044-bib-0034" ref-type="bibr">1959</xref>). Expressed as nmol GSH/mg protein, it is the total GSH content of the sample.</p></sec><sec id="fsn371044-sec-0015"><label>2.6.4</label><title>Glutathione Peroxidase Activity (<styled-content style="fixed-case" toggle="no">GSH</styled-content>&#8208;Px)</title><p>Glutathione peroxidase activity (GSH&#8208;Px) was measured according to the method of Floh&#233; and G&#252;nzler&#160;(<xref rid="fsn371044-bib-0037" ref-type="bibr">1984</xref>). GSH&#8208;Px activity was expressed as &#956;mol GSH/min/mg protein.</p></sec><sec id="fsn371044-sec-0016"><label>2.6.5</label><title>Catalase Activity (<styled-content style="fixed-case" toggle="no">CAT</styled-content>)</title><p>The breakdown of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to water (H<sub>2</sub>O) and oxygen (O<sub>2</sub>) in the presence of the catalase enzyme at a wavelength of 240&#8201;nm was used to measure catalase activity. According to Aebi&#160;(<xref rid="fsn371044-bib-0004" ref-type="bibr">1984</xref>), enzyme activity was measured as &#956;mol H<sub>2</sub>O<sub>2</sub> consumed/min/mg protein.</p></sec><sec id="fsn371044-sec-0017"><label>2.6.6</label><title>Superoxide Dismutase Activity (<styled-content style="fixed-case" toggle="no">SOD</styled-content>)</title><p>The inhibition of the reduction of nitro blue tetrazolium (NBT) is the principle of superoxide dismutase activity. Activity expressed in units/mg protein (Misra and Fridovich&#160;<xref rid="fsn371044-bib-0060" ref-type="bibr">1977</xref>).</p></sec></sec><sec id="fsn371044-sec-0018"><label>2.7</label><title>Histopathological Study</title><p>The histopathological study was conducted at the Department of Pathological Anatomy, Mohammed VI University Hospital, Oujda. Organs harvested post&#8208;mortem were weighed and preserved in a 10% formalin solution. Longitudinal sections were prepared using the paraffin embedding technique. Paraffin blocks were sectioned into 4&#8211;5&#8201;&#956;m thick slices using a microtome (Leica RM2235) and stained with hematoxylin and eosin according to standard histological procedures. Microscopic observations and image capture were performed using a light microscope (Leica Microsystems) equipped with a camera (Leica DMD108) (Hewitson and Darby&#160;<xref rid="fsn371044-bib-0040" ref-type="bibr">2010</xref>).</p></sec><sec id="fsn371044-sec-0019"><label>2.8</label><title>Molecular Docking</title><p>As shown by the HPLC&#8208;MS analysis, four molecules are present in the cladode of <italic toggle="yes">Opuntia ficus indica</italic> juice. The four ligands, namely ellagic acid, p&#8208;coumaric acid, isorhamnetin 3&#8208;o&#8208;neohesperoside, and piscidic acid, were extracted from the PubChem database, while the biomacromolecule Alanine aminotransferase (PDB ID: 3IHJ) was obtained in PDB format. The ligands have been formatted as PDB files to simplify molecular research via PYMOL. In addition, Discovery Studio was used to prepare the proteins extracted from the PDB base. The active site of the enzyme was used to anchor the ligand structures thanks to AutoDockTools. The analysis of interactions between the active site residues of the enzyme and ligand molecules was conducted using Discovery Studio software, including a 2D interaction study (Zirari et&#160;al.&#160;<xref rid="fsn371044-bib-0094" ref-type="bibr">2025</xref>).</p></sec><sec id="fsn371044-sec-0020"><label>2.9</label><title>Statistical Analysis</title><p>Data are expressed as mean&#8201;&#177;&#8201;SEM. Statistical significance between groups was assessed using one&#8208;way analysis of variance (ANOVA), followed by Tukey's post hoc test with a 95% confidence interval (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), using SPSS software (version 27; IBM Corp., Armonk, NY, USA).</p></sec></sec><sec sec-type="results" id="fsn371044-sec-0021"><label>3</label><title>Results</title><sec id="fsn371044-sec-0022"><label>3.1</label><title>Total Phenolic Concentration (<styled-content style="fixed-case" toggle="no">TPC</styled-content>) and Total Flavonoid Concentration (<styled-content style="fixed-case" toggle="no">TFC</styled-content>)</title><p>The assessment of bioactive constituents in <italic toggle="yes">Opuntia ficus indica</italic> cladode juice (CJ) extracted with different solvents was carried out using a colorimetric assay. The primary objective was to quantify phenolic compounds, as these organic molecules are largely responsible for the biological activities of the extract and contribute to mitigating oxidative damage induced by free radicals, which are implicated in various human pathologies. Phenolic compounds, abundantly distributed in the plant kingdom, exhibit noteworthy pharmacological properties (Kumari et&#160;al.&#160;<xref rid="fsn371044-bib-0045" ref-type="bibr">2017</xref>).</p><p>The findings from the quantification of total polyphenols and flavonoids revealed that all the cladode juices analyzed contained varying levels of these bioactive compounds.</p><p>The assessment of TPC using the Folin&#8211;Ciocalteu assay indicated that the average concentration in cladode juice, expressed in milligrams of gallic acid equivalent per milliliter, was 0.389&#8201;&#177;&#8201;0.04&#8201;mg GAE&#8201;mL<sup>&#8722;1</sup> (Table&#160;<xref rid="fsn371044-tbl-0001" ref-type="table">1</xref>). This concentration reflects a significant presence of phenolic constituents, known for their potential involvement in various biochemical and protective mechanisms. In comparison with previous studies, Boutakiout et&#160;al.&#160;(<xref rid="fsn371044-bib-0016" ref-type="bibr">2018</xref>) reported that the total polyphenol content in cladode juice could range from approximately 455.65 to 542.70&#8201;&#956;g GAE&#8201;mL<sup>&#8722;1</sup>. Similarly, Chahdoura et&#160;al.&#160;(<xref rid="fsn371044-bib-0023" ref-type="bibr">2024</xref>) documented a polyphenol concentration of 58.13&#8201;mg GAE&#8201;g<sup>&#8722;1</sup> of extract, while Moussaoui&#160;(<xref rid="fsn371044-bib-0061" ref-type="bibr">2020</xref>) recorded a total polyphenol content of 63.54&#8201;mg GAE&#8201;g<sup>&#8722;1</sup> dry matter. These reported values were higher than those obtained in the present study. It is important to emphasize that total polyphenol concentrations are influenced by various factors, including the harvesting location, different developmental stages of the plant, and its age (Santiago&#8208;Saenz et&#160;al.&#160;<xref rid="fsn371044-bib-0074" ref-type="bibr">2018</xref>).</p><table-wrap position="float" id="fsn371044-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Total phenolic content (TPC) and total flavonoid content (TFC) of cladode juice of <italic toggle="no">Opuntia ficus indica</italic>.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Cladode juice</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">TPC (mg AGE&#8201;mL<sup>&#8722;1</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">0.389&#8201;&#177;&#8201;0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TFC (mg QE&#8201;mL<sup>&#8722;1</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">0.187&#8201;&#177;&#8201;0.05</td></tr></tbody></table></table-wrap><p>Similarly, the quantification of TFC demonstrated that the mean content in the juice, expressed as milligrams of quercetin equivalent per milliliter, was 0.187&#8201;&#177;&#8201;0.05&#8201;mg QE&#8201;mL<sup>&#8722;1</sup>. The observed flavonoid levels underscore the presence of these secondary metabolites, which are recognized for their diverse bioactive properties, particularly in modulating oxidative stress and contributing to cellular defense systems. In comparison with other studies, Chahdoura et&#160;al.&#160;(<xref rid="fsn371044-bib-0023" ref-type="bibr">2024</xref>) reported that the total flavonoid content in cladodes reached 28.89&#8201;mg QE&#8201;g<sup>&#8722;1</sup> of extract. Similarly, Lahmidi et&#160;al.&#160;(<xref rid="fsn371044-bib-0048" ref-type="bibr">2023</xref>) documented values ranging from 3.77 to 7.55&#8201;mg QE&#8201;100<sup>&#8722;1</sup>&#8201;mL of cladode puree, while Moussaoui&#160;(<xref rid="fsn371044-bib-0061" ref-type="bibr">2020</xref>) recorded a total flavonoid concentration of 18.07&#8201;mg QE&#8201;g<sup>&#8722;1</sup> dry matter. Flavonoid levels fluctuate during cladode maturation, peaking at 1&#8201;year of growth before gradually declining (Lahmidi et&#160;al.&#160;<xref rid="fsn371044-bib-0048" ref-type="bibr">2023</xref>). Flavonoids, a class of phenolic compounds with exceptional antioxidant potential, are regarded as essential dietary components. They are widely recognized for their potent free radical&#8208;scavenging properties (Kumari et&#160;al.&#160;<xref rid="fsn371044-bib-0045" ref-type="bibr">2017</xref>), cardioprotective effects (Li et&#160;al.&#160;<xref rid="fsn371044-bib-0051" ref-type="bibr">2013</xref>), anti&#8208;inflammatory and hepatoprotective activities (Chen et&#160;al.&#160;<xref rid="fsn371044-bib-0026" ref-type="bibr">2014</xref>), as well as their antimicrobial action (Biharee et&#160;al.&#160;<xref rid="fsn371044-bib-0012" ref-type="bibr">2020</xref>). Despite their promising bioactivities, flavonoids exhibit limited bioavailability, which restricts their efficient utilization by the human body (Wang et&#160;al.&#160;<xref rid="fsn371044-bib-0089" ref-type="bibr">2018</xref>).</p></sec><sec id="fsn371044-sec-0023"><label>3.2</label><title>
<styled-content style="fixed-case" toggle="no">HPLC</styled-content>&#8208;<styled-content style="fixed-case" toggle="no">MS</styled-content> Characterization of Phenolic Compounds</title><p>The phenolic constituents of cladode juice were elucidated through the comparative analysis of their retention durations and mass spectrometry spectra against established data. Figure&#160;<xref rid="fsn371044-fig-0001" ref-type="fig">1</xref> presents the identification results of the various peaks observed in the HPLC&#8208;MS chromatogram. Based on the obtained data, four bioactive molecules were identified in the cladode juice: p&#8208;coumaric acid at 4.25&#8201;min, piscidic acid at 5.48&#8201;min, isorhamnetin&#8208;3&#8208;O&#8208;neohesperoside at 18.95&#8201;min, and ellagic acid at 605&#8201;min.</p><fig position="float" fig-type="FIGURE" id="fsn371044-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Chromatogram of polyphenols in <italic toggle="yes">Opuntia ficus indica</italic> cladode juice.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="FSN3-13-e71044-g002.jpg"/></fig><p>p&#8208;Coumaric acid, a phenolic compound belonging to the hydroxycinnamic acid family (Poleto et&#160;al.&#160;<xref rid="fsn371044-bib-0065" ref-type="bibr">2024</xref>), exhibits high antioxidant activity and plays a crucial role in mitigating diseases associated with oxidative stress. Studies have highlighted its ability to reduce oxidative stress (Chen et&#160;al.&#160;<xref rid="fsn371044-bib-0025" ref-type="bibr">2024</xref>). Research conducted on mice revealed that p&#8208;coumaric acid protects the liver from damage induced by potassium bromate by alleviating oxidative stress and inflammation (Nivetha et&#160;al.&#160;<xref rid="fsn371044-bib-0062" ref-type="bibr">2024</xref>).</p><p>Piscidic acid, a bioactive compound derived from the cladodes of <italic toggle="yes">OFI</italic>, exhibits significant pharmacological properties, particularly in cholesterol regulation and potential anticancer effects (Ressaissi et&#160;al.&#160;<xref rid="fsn371044-bib-0071" ref-type="bibr">2017</xref>). This compound demonstrated the ability to inhibit the formation of new blood and lymphatic vessels. Additionally, its antioxidant capacity, comparable to that of carnosic acid, enhances its protective effects on the body (Shibata et&#160;al.&#160;<xref rid="fsn371044-bib-0077" ref-type="bibr">2016</xref>).</p><p>Isorhamnetin&#8208;3&#8208;O&#8208;neohesperoside is a flavonoid glycoside with significant pharmacological properties, particularly in terms of antioxidant and anticancer activities (Du et&#160;al.&#160;<xref rid="fsn371044-bib-0031" ref-type="bibr">2016</xref>). It is distinguished by its strong antioxidant capacity. This flavonoid also plays a protective role against genetic damage induced by aflatoxin B1 and nifuroxazide (Bouhlel et&#160;al.&#160;<xref rid="fsn371044-bib-0015" ref-type="bibr">2010</xref>). Moreover, isorhamnetin itself has demonstrated notable anticancer and antifungal potential (Unver&#160;<xref rid="fsn371044-bib-0086" ref-type="bibr">2024</xref>; Li et&#160;al.&#160;<xref rid="fsn371044-bib-0053" ref-type="bibr">2022</xref>).</p><p>Administration of isorhamnetin has been shown to reduce lipid accumulation and triglyceride levels, decrease both serum and hepatic lipids, and improve liver lesions (La et&#160;al.&#160;<xref rid="fsn371044-bib-0047" ref-type="bibr">2024</xref>). Additionally, Yang et&#160;al.&#160;(<xref rid="fsn371044-bib-0092" ref-type="bibr">2024</xref>) observed that isorhamnetin reduces markers of liver damage and oxidative stress, including superoxide dismutase (SOD) and catalase (CAT).</p><p>Ellagic acid is a potent polyphenol found in fruits and vegetables, widely recognized for its antioxidant properties and ability to neutralize free radicals (Alfei and Zuccari&#160;<xref rid="fsn371044-bib-0006" ref-type="bibr">2024</xref>). However, its bioavailability is limited due to poor water solubility and rapid metabolism (Alfei and Zuccari&#160;<xref rid="fsn371044-bib-0007" ref-type="bibr">2025</xref>). It combats aging by reducing oxidative stress, inflammation, and mitochondrial dysfunction. Additionally, it can be metabolized into urolithin, which enhances its bioactivity (Sun&#160;<xref rid="fsn371044-bib-0084" ref-type="bibr">2024</xref>).</p></sec><sec id="fsn371044-sec-0024"><label>3.3</label><title>Effect on Body Weight and Liver Index</title><p>The effects of body weight gain and hepatic index in each experimental group are illustrated in Table&#160;<xref rid="fsn371044-tbl-0002" ref-type="table">2</xref>.</p><table-wrap position="float" id="fsn371044-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Effect of <italic toggle="no">Opuntia ficus indica</italic> cladode juice on growth parameters in NiSO<sub>4</sub>&#8208;intoxicated rats.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">T</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ni</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ&#8201;+&#8201;Ni</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight gain (g)</td><td align="center" valign="top" rowspan="1" colspan="1">36.00&#8201;&#177;&#8201;2.92</td><td align="center" valign="top" rowspan="1" colspan="1">35.60&#8201;&#177;&#8201;2.70<xref rid="fsn371044-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.20&#8201;&#177;&#8201;1.79***</td><td align="center" valign="top" rowspan="1" colspan="1">22.40&#8201;&#177;&#8201;2.30***</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver index (%)</td><td align="center" valign="top" rowspan="1" colspan="1">2.50&#8201;&#177;&#8201;0.27</td><td align="center" valign="top" rowspan="1" colspan="1">2.57&#8201;&#177;&#8201;0.09<xref rid="fsn371044-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.75&#8201;&#177;&#8201;0.05**</td><td align="center" valign="top" rowspan="1" colspan="1">3.07&#8201;&#177;&#8201;0.19*</td></tr></tbody></table><table-wrap-foot id="fsn371044-ntgp-0002"><fn id="fsn371044-note-0002"><p>
<italic toggle="yes">Note:</italic> Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values. T: normal control; JC: cladode juice; Ni: nickel sulphate; JC&#8201;+&#8201;Ni: cladode juice and nickel sulphate; JC group: comparison with T group; Ni group: comparison with T group; JC&#8201;+&#8201;Ni group: comparison with Ni group.</p></fn><fn id="fsn371044-note-0003"><label>
<sup>a</sup>
</label><p>Not significant.</p></fn><fn id="fsn371044-note-0004"><p>***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><p>The daily oral administration of CJ at a dosage of 10&#8201;mL&#8201;kg<sup>&#8722;1</sup> body weight for 30&#8201;days did not induce any discernible toxic effects in rats. Throughout the study, no mortality or significant clinical abnormalities were found in the group that received treatment, and the animals exhibited normal body weight progression, comparable to that of the control group. Assessments of body mass and hepatic indices revealed no signs of toxicity linked to CJ administration, further supporting the extract's safety profile.</p><p>Conversely, NiSO<sub>4</sub> injections led to a significant reduction in body weight and an increase in the hepatic index, highlighting its hepatotoxic effects. However, oral administration of CJ markedly mitigated these alterations. Intraperitoneal injection of NiSO<sub>4</sub> resulted in a pronounced decrease in weight gain (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and a significant rise in the hepatic index (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) compared to the control group. These variations indicate liver toxicity and metabolic disturbances.</p><p>However, daily administration of CJ for 30&#8201;days enhanced growth performance. Treatment with the cladode extract significantly reduced the hepatic index (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) and improved body weight gain (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) compared to the NiSO<sub>4</sub> group, suggesting a protective effect of cladodes against NiSO<sub>4</sub>&#8208;induced toxicity.</p><p>The tolerance of CJ, with no signs of toxicity or clinical symptoms, reinforces its potential as a natural hepatoprotective agent. Moreover, the improvement in body weight may reflect not only protection against muscle mass loss but also stimulation of anabolic processes, suggesting that CJ could aid in restoring normal metabolic functions disrupted by toxins such as NiSO<sub>4</sub>.</p><p>Several studies have demonstrated that the relative liver weight is a sensitive marker of hepatotoxicity in experimental models of liver injury induced by toxins such as nickel sulfate (NiSO<sub>4</sub>) (Adeyemi and Orekoya&#160;<xref rid="fsn371044-bib-0003" ref-type="bibr">2014</xref>; Faoziyat et&#160;al.&#160;<xref rid="fsn371044-bib-0035" ref-type="bibr">2014</xref>). In line with this, multiple authors have reported that nickel accumulation in the liver is associated with an increase in the hepatic index (Bouhalit and Kechrid&#160;<xref rid="fsn371044-bib-0014" ref-type="bibr">2018</xref>; Derbal et&#160;al.&#160;<xref rid="fsn371044-bib-0029" ref-type="bibr">2022</xref>), further supporting the link between NiSO<sub>4</sub> exposure and liver dysfunction. While NiSO<sub>4</sub> exhibits hepatotoxic effects, the cladodes of <italic toggle="yes">OFI</italic> have shown hepatoprotective properties in other toxicity models. Their mode of action, primarily through oxidative stress reduction, suggests a potential to mitigate nickel&#8208;induced liver damage (Brahmi et&#160;al.&#160;<xref rid="fsn371044-bib-0017" ref-type="bibr">2011</xref>; Makeen et&#160;al.&#160;<xref rid="fsn371044-bib-0056" ref-type="bibr">2019</xref>). Phenolic compounds in plants are widely recognized for their health benefits, primarily due to their antioxidant properties. Their hydroxyl groups and aromatic structure enable them to neutralize free radicals (Villa&#241;o et&#160;al.&#160;<xref rid="fsn371044-bib-0087" ref-type="bibr">2007</xref>). These effects result from the synergistic action of flavonoids, particularly quercetin, known as the most potent free radical scavenger (Stintzing and Carle&#160;<xref rid="fsn371044-bib-0082" ref-type="bibr">2005</xref>; Hfaiedh et&#160;al.&#160;<xref rid="fsn371044-bib-0041" ref-type="bibr">2008</xref>).</p></sec><sec id="fsn371044-sec-0025"><label>3.4</label><title>Effect on Enzymatic Biomarkers (<styled-content style="fixed-case" toggle="no">ALT</styled-content>, <styled-content style="fixed-case" toggle="no">AST</styled-content>, <styled-content style="fixed-case" toggle="no">ALP</styled-content>, and <styled-content style="fixed-case" toggle="no">GGT</styled-content>)</title><p>Table&#160;<xref rid="fsn371044-tbl-0003" ref-type="table">3</xref> illustrates the effect of <italic toggle="yes">Opuntia ficus indica</italic> cladode juice on the enzymatic activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma&#8208;glutamyl transferase (GGT).</p><table-wrap position="float" id="fsn371044-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Effect of <italic toggle="no">Opuntia ficus indica</italic> cladode juice on ALT, AST, ALP, and GGT enzyme activity in NiSO<sub>4</sub>&#8208;intoxicated rats.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ni</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ&#8201;+&#8201;Ni</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT U/L</td><td align="center" valign="top" rowspan="1" colspan="1">42.60&#8201;&#177;&#8201;0.86</td><td align="center" valign="top" rowspan="1" colspan="1">41.01&#8201;&#177;&#8201;0.43<xref rid="fsn371044-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">65.05&#8201;&#177;&#8201;2.61***</td><td align="center" valign="top" rowspan="1" colspan="1">49.96&#8201;&#177;&#8201;0.38**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST U/L</td><td align="center" valign="top" rowspan="1" colspan="1">99.02&#8201;&#177;&#8201;0.08</td><td align="center" valign="top" rowspan="1" colspan="1">96.04&#8201;&#177;&#8201;0.27<xref rid="fsn371044-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">137.94&#8201;&#177;&#8201;3.72***</td><td align="center" valign="top" rowspan="1" colspan="1">113.80&#8201;&#177;&#8201;0.60**</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALP U/L</td><td align="center" valign="top" rowspan="1" colspan="1">106.77&#8201;&#177;&#8201;2.49</td><td align="center" valign="top" rowspan="1" colspan="1">103.40&#8201;&#177;&#8201;2.73<xref rid="fsn371044-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">266.49&#8201;&#177;&#8201;2.62***</td><td align="center" valign="top" rowspan="1" colspan="1">220.86&#8201;&#177;&#8201;3.11***</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GGT U/L</td><td align="center" valign="top" rowspan="1" colspan="1">2.16&#8201;&#177;&#8201;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">1.93&#8201;&#177;&#8201;0.03<xref rid="fsn371044-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.62&#8201;&#177;&#8201;0.04***</td><td align="center" valign="top" rowspan="1" colspan="1">3.82&#8201;&#177;&#8201;0.04**</td></tr></tbody></table><table-wrap-foot id="fsn371044-ntgp-0003"><fn id="fsn371044-note-0005"><p>
<italic toggle="yes">Note:</italic> Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values. T: normal control; JC: cladode juice; Ni: nickel sulphate; JC&#8201;+&#8201;Ni: cladode juice and nickel sulphate; JC group: comparison with T group; Ni group: comparison with T group; JC&#8201;+&#8201;Ni group: comparison with Ni group.</p></fn><fn id="fsn371044-note-0006"><label>
<sup>a</sup>
</label><p>Not significant.</p></fn><fn id="fsn371044-note-0007"><p>***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><sec id="fsn371044-sec-0026"><label>3.4.1</label><title>Hepatocytolysis (<styled-content style="fixed-case" toggle="no">ALT</styled-content>, <styled-content style="fixed-case" toggle="no">AST</styled-content>)</title><p>The findings demonstrated that nickel exposure (Ni group) elicited a highly significant increase (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, both well&#8208;established biomarkers of hepatocellular injury. These elevations indicate nickel&#8208;induced hepatic impairment. Administration of cladode juice significantly attenuated (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) these ALT and AST elevations, highlighting its hepatoprotective potential.</p><p>The pronounced increase in transaminases (ALT, AST) in the Ni group suggests impaired hepatic function, corroborating findings from previous studies (Lee et&#160;al.&#160;<xref rid="fsn371044-bib-0049" ref-type="bibr">2007</xref>; Yang et&#160;al.&#160;<xref rid="fsn371044-bib-0091" ref-type="bibr">2011</xref>; Kuriakose et&#160;al.&#160;<xref rid="fsn371044-bib-0046" ref-type="bibr">2017</xref>).</p><p>Compared to the Ni group, cladode juice administration significantly mitigated these elevations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 for ALT and AST) in the JC&#8201;+&#8201;Ni group, indicating a beneficial effect on hepatic function. Moreover, cladode juice treatment in the JC group did not induce significant changes in the enzymatic markers assessed, suggesting that its protective effects are specific to nickel&#8208;induced toxicity.</p><p>For the diagnosis and ongoing management of liver disorders, the measurement of Hepatocytolysis markers like ALT and AST is essential (Bishnoi et&#160;al.&#160;<xref rid="fsn371044-bib-0013" ref-type="bibr">2024</xref>). Hepatic dysfunction can be accurately detected biochemically by elevated serum levels of AST and ALT, which are caused by damaged hepatocytes releasing more of these enzymes (Sharma and Shukla&#160;<xref rid="fsn371044-bib-0075" ref-type="bibr">2011</xref>; Kharchoufa et&#160;al.&#160;<xref rid="fsn371044-bib-0044" ref-type="bibr">2020</xref>).</p></sec><sec id="fsn371044-sec-0027"><label>3.4.2</label><title>Cholestasis (<styled-content style="fixed-case" toggle="no">ALP</styled-content>, <styled-content style="fixed-case" toggle="no">GGT</styled-content>)</title><p>However, alkaline phosphatase (ALP) and gamma&#8208;glutamyl transferase (GGT) activities, which are associated with cholestatic processes and bile duct dysfunction, were also significantly elevated in the Ni group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Such increases are commonly associated with obstruction or damage to the biliary tract, leading to impaired bile flow and accumulation of bile acids in the liver (Lee et&#160;al.&#160;<xref rid="fsn371044-bib-0049" ref-type="bibr">2007</xref>; Yang et&#160;al.&#160;<xref rid="fsn371044-bib-0091" ref-type="bibr">2011</xref>; Kuriakose et&#160;al.&#160;<xref rid="fsn371044-bib-0046" ref-type="bibr">2017</xref>).</p><p>In the JC&#8201;+&#8201;Ni group, the addition of cladode juice significantly reduced these increases (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 for ALP and <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 for GGT) compared to the Nickel (Ni) group, suggesting a beneficial impact on liver function.</p><p>Furthermore, the administration of cladode juice in the JC group did not elicit noteworthy alterations in the evaluated cholestasis biomarkers, indicating that its protective properties are particularly tailored to counteract nickel&#8208;induced toxicity.</p><p>The potent antioxidant activity of <italic toggle="yes">Opuntia ficus indica</italic> cladodes, attributed to their high content of bioactive phytochemicals such as polyphenols and flavonoids, may underlie their hepatoprotective properties (Slimane et&#160;al.&#160;<xref rid="fsn371044-bib-0080" ref-type="bibr">2024</xref>). These compounds enhance liver function and confer protection against hepatic injury through their antioxidative and anti&#8208;inflammatory mechanisms (Abbas et&#160;al.&#160;<xref rid="fsn371044-bib-0001" ref-type="bibr">2022</xref>).</p><p>Moreover, GGT levels fluctuate depending on the nature of liver disorders, with their elevation being a highly sensitive marker of hepatic impairment and a valuable tool in clinical investigations (Xing et&#160;al.&#160;<xref rid="fsn371044-bib-0090" ref-type="bibr">2022</xref>).</p></sec></sec><sec id="fsn371044-sec-0028"><label>3.5</label><title>Effect on Plasma Direct Bilirubin (<styled-content style="fixed-case" toggle="no">DB</styled-content>) and Total Bilirubin (<styled-content style="fixed-case" toggle="no">TB</styled-content>) Levels</title><p>To evaluate the NiSO<sub>4</sub> intoxication as well as the potential protective effect of the juice of <italic toggle="yes">Opuntia ficus indica</italic> cladodes (CJ), total (TB), direct (DB), and indirect bilirubin (IB&#8201;=&#8201;TB&#8211;DB) were measured. The results are indicated in Table&#160;<xref rid="fsn371044-tbl-0004" ref-type="table">4</xref>.</p><table-wrap position="float" id="fsn371044-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Effect of <italic toggle="no">Opuntia ficus indica</italic> cladode juice on TB and DB in NiSO<sub>4</sub>&#8208;intoxicated rats.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ni</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ&#8201;+&#8201;Ni</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">TB (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.03&#8201;&#177;&#8201;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">1.07&#8201;&#177;&#8201;0.02<xref rid="fsn371044-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.67&#8201;&#177;&#8201;0.13***</td><td align="center" valign="top" rowspan="1" colspan="1">2.49&#8201;&#177;&#8201;0.13*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DB (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">0.53&#8201;&#177;&#8201;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.46&#8201;&#177;&#8201;0.04<xref rid="fsn371044-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.89&#8201;&#177;&#8201;0.14***</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#8201;&#177;&#8201;0.03*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IB (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">0.51&#8201;&#177;&#8201;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#8201;&#177;&#8201;0.06<xref rid="fsn371044-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.86&#8201;&#177;&#8201;0.27***</td><td align="center" valign="top" rowspan="1" colspan="1">1.87&#8201;&#177;&#8201;0.10*</td></tr></tbody></table><table-wrap-foot id="fsn371044-ntgp-0004"><fn id="fsn371044-note-0008"><p>
<italic toggle="yes">Note:</italic> Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values. Ni control group versus normal control group; CJ&#8201;+&#8201;Ni versus Ni control group; CJ group versus normal control group.</p></fn><fn id="fsn371044-note-0009"><label>
<sup>a</sup>
</label><p>Not significant.</p></fn><fn id="fsn371044-note-0010"><p>***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><p>Exposure to NiSO<sub>4</sub> resulted in a highly significant increase in total bilirubin levels (3.67&#8201;&#177;&#8201;0.13&#8201;mg/L; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and direct bilirubin levels (0.89&#8201;&#177;&#8201;0.14&#8201;mg/L; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) compared to the control group (1.03&#8201;&#177;&#8201;0.01&#8201;mg/L and 0.53&#8201;&#177;&#8201;0.03&#8201;mg/L, respectively). The calculation of indirect bilirubin showed a clear increase (2.78&#8201;&#177;&#8201;0.27&#8201;mg/L against 0.50&#8201;&#177;&#8201;0.04&#8201;mg/L in the controls), suggesting a mixed liver injury which is characteristically described as &#8220;hepatocellular jaundice&#8221;. This type of jaundice occurs when the mechanisms of conjugation and bile excretion of bilirubin are both incapacitated, as in cases of toxic hepatitis.</p><p>The combined treatment with cladodes juice and NiSO<sub>4</sub> (CJ&#8201;+&#8201;Ni) made it possible to significantly reduce the levels of total bilirubin (2.49&#8201;&#177;&#8201;0.13&#8201;mg/L; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), direct bilirubin (0.62&#8201;&#177;&#8201;0.03&#8201;mg/L; <italic toggle="yes">p&#8201;&lt;</italic>&#8201;0.05), and indirect bilirubin (1.87&#8201;&#177;&#8201;0.16&#8201;mg/L), thus showing an improvement in liver function. The decrease in these levels indicates an improvement in liver damage and incomplete but recovering hepatobiliary function.</p><p>Moreover, the administration of cladode juice alone, without NiSO<sub>4</sub> exposure, did not lead to significant changes in total, direct, and indirect bilirubin concentrations compared to the healthy control group. The differences observed between the groups did not reach statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). This indicates that, in the absence of toxic stress induced by metals such as nickel, cladode juice does not appear to notably affect bilirubin levels and, therefore, does not disrupt its normal metabolism. These findings suggest that cladode juice has neither hepatotoxic effects nor an impact on bilirubin metabolism in healthy subjects, further supporting its safety when consumed alone.</p><p>The administration of NiSO<sub>4</sub> in rats leads to an elevation in serum bilirubin levels, indicating liver injury (Bouhalit and Kechrid&#160;<xref rid="fsn371044-bib-0014" ref-type="bibr">2018</xref>). Similarly, direct bilirubin levels have been positively correlated with the severity of hepatic dysfunction and other conditions related to oxidative stress (Song et&#160;al.&#160;<xref rid="fsn371044-bib-0081" ref-type="bibr">2022</xref>).</p><p>Furthermore, Okaiyeto et&#160;al.&#160;(<xref rid="fsn371044-bib-0063" ref-type="bibr">2018</xref>) reported that elevated serum bilirubin levels are indicative of increased erythrocyte degradation. Additionally, an increase in blood bilirubin levels may result from enhanced tissue destruction or bile duct obstruction (Sabiu et&#160;al.&#160;<xref rid="fsn371044-bib-0073" ref-type="bibr">2015</xref>).</p><p>The therapeutic properties of <italic toggle="yes">OFI</italic> cladodes in improving liver function highlight their potential as a natural remedy for supporting liver health and preventing the progression of metabolic disorders and diabetes&#8208;related complications (Jain et&#160;al.&#160;<xref rid="fsn371044-bib-0043" ref-type="bibr">2023</xref>). Their hepatoprotective effects are attributed to their anti&#8208;inflammatory and antioxidant properties. Several studies have confirmed their ability to reduce cytokines associated with liver damage, thereby helping to mitigate hepatic injury (Abbas et&#160;al.&#160;<xref rid="fsn371044-bib-0001" ref-type="bibr">2022</xref>; Mannaa and Abdel&#8208;Wahhab&#160;<xref rid="fsn371044-bib-0057" ref-type="bibr">2016</xref>).</p></sec><sec id="fsn371044-sec-0029"><label>3.6</label><title>Effect on Plasma Total Protein and Glucose Levels</title><p>The plasma concentrations of total proteins and glucose in treated and untreated animals are presented in Table&#160;<xref rid="fsn371044-tbl-0005" ref-type="table">5</xref>.</p><table-wrap position="float" id="fsn371044-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Effect of <italic toggle="no">Opuntia ficus indica</italic> cladode juice on plasma total protein and glucose levels in NiSO<sub>4</sub>&#8208;intoxicated rats.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ni</th><th align="center" valign="bottom" rowspan="1" colspan="1">CJ&#8201;+&#8201;Ni</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Glucose g/L</td><td align="center" valign="top" rowspan="1" colspan="1">1.37&#8201;&#177;&#8201;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">1.17&#8201;&#177;&#8201;0.11<xref rid="fsn371044-note-0012" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.72&#8201;&#177;&#8201;0.07***</td><td align="center" valign="top" rowspan="1" colspan="1">1.98&#8201;&#177;&#8201;0.06*</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T protein mg/L</td><td align="center" valign="top" rowspan="1" colspan="1">76.22&#8201;&#177;&#8201;0.43</td><td align="center" valign="top" rowspan="1" colspan="1">79.86&#8201;&#177;&#8201;0.43<xref rid="fsn371044-note-0012" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">55.75&#8201;&#177;&#8201;0.17***</td><td align="center" valign="top" rowspan="1" colspan="1">69.11&#8201;&#177;&#8201;0.54*</td></tr></tbody></table><table-wrap-foot id="fsn371044-ntgp-0005"><fn id="fsn371044-note-0011"><p>
<italic toggle="yes">Note:</italic> Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values. Ni control group versus normal control group; CJ&#8201;+&#8201;Ni versus Ni control group; CJ group versus normal control group.</p></fn><fn id="fsn371044-note-0012"><label>
<sup>a</sup>
</label><p>Not significant.</p></fn><fn id="fsn371044-note-0013"><p>***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></fn></table-wrap-foot></table-wrap><p>Nickel sulfate (NiSO<sub>4</sub>) exposure induced a significant decline in plasma total protein concentrations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) while markedly elevating blood glucose levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) compared to the healthy control group. However, cladode juice administration over 30&#8201;days exerted a notable protective effect against these biochemical disturbances. This supplementation mitigated the reduction in total protein levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) and effectively restrained the rise in plasma glucose concentrations (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) observed in the JC&#8201;+&#8201;Ni group.</p><p>Furthermore, cladode juice administration alone (JC group) resulted in a non&#8208;significant decrease in glucose concentration and a non&#8208;significant increase in total protein concentration compared to the normal control group. The variations observed between these two groups did not reach statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), indicating the absence of a measurable effect of cladode juice on these parameters under normal conditions.</p><p>Additionally, in the absence of toxic stress, particularly that induced by nickel exposure, cladode juice does not disrupt the normal metabolism of these substances. These findings further support the notion that cladodes do not exert adverse metabolic effects under non&#8208;toxic conditions and exhibit beneficial modulatory properties, helping to maintain the balance of plasma parameters disrupted by NiSO<sub>4</sub> exposure. This highlights their safety when consumed under physiological conditions.</p><p>Studies have demonstrated that the consumption of <italic toggle="yes">OFI</italic> cladodes leads to a significant reduction in blood glucose levels in rats as well as in healthy individuals following a glucose tolerance test (Butterweck et&#160;al.&#160;<xref rid="fsn371044-bib-0019" ref-type="bibr">2010</xref>; Proeyen et&#160;al.&#160;<xref rid="fsn371044-bib-0067" ref-type="bibr">2012</xref>). Research by Avila&#8208;Nava et&#160;al.&#160;(<xref rid="fsn371044-bib-0008" ref-type="bibr">2014</xref>) highlighted a significant increase in plasma antioxidant capacity after the intake of <italic toggle="yes">OFI</italic> extracts, which are rich in phenolic compounds. These findings suggest a promising potential for mitigating oxidative stress and inflammation.</p><p>Dahdouh et&#160;al.&#160;(<xref rid="fsn371044-bib-0028" ref-type="bibr">2014</xref>) reported that exposure to NiSO<sub>4</sub> leads to a significant reduction in serum total protein and albumin levels, indicating liver dysfunction and impaired protein synthesis. Similarly, it has been associated with an increase in blood glucose concentrations, suggesting disruptions in glucose metabolism and a potential risk of insulin resistance (Bouhalit and Kechrid&#160;<xref rid="fsn371044-bib-0014" ref-type="bibr">2018</xref>).</p></sec><sec id="fsn371044-sec-0030"><label>3.7</label><title>Effect on <styled-content style="fixed-case" toggle="no">MDA</styled-content> and <styled-content style="fixed-case" toggle="no">SOD</styled-content> Activity in <styled-content style="fixed-case" toggle="no">NiSO4</styled-content>&#8208;Intoxicated Rats</title><p>The impact of the effect of OFI cladode juice on lipid peroxidation and SOD activity in treated experimental animals is presented in Figure&#160;<xref rid="fsn371044-fig-0002" ref-type="fig">2</xref>.</p><fig position="float" fig-type="FIGURE" id="fsn371044-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Effect of <italic toggle="yes">Opuntia ficus indica</italic> cladode juice on MDA levels (A) and SOD activity (B) in NiSO<sub>4</sub>&#8208;intoxicated rats. Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values; T: normal control; JC: cladode juice; Ni: nickel sulfate; JC&#8201;+&#8201;Ni: cladode juice and nickel sulfate. JC group: comparison with the T group; Ni group: comparison with the T group; JC&#8201;+&#8201;Ni group: comparison with the Ni group. ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; <sup>#</sup>Non&#8208;significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="FSN3-13-e71044-g003.jpg"/></fig><p>Intraperitoneal administration of nickel sulfate (NiSO<sub>4</sub>) in rats triggered pronounced oxidative stress, as evidenced by a significant elevation in hepatic malondialdehyde (MDA) levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), indicating heightened lipid peroxidation and membrane damage driven by reactive oxygen species (ROS). Concurrently, a marked decline in superoxide dismutase (SOD) activity (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) was observed, suggesting an inhibitory effect of NiSO<sub>4</sub> on this critical antioxidant enzyme.</p><p>Daily administration of <italic toggle="yes">OFI</italic> cladode juice for 30&#8201;days in NiSO<sub>4</sub>&#8208;exposed rats led to a significant reduction in MDA levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), reflecting an attenuation of lipid peroxidation due to the antioxidant properties of its bioactive compounds. Furthermore, pre&#8208;exposure supplementation conferred notable protection against oxidative stress, as evidenced by a significant increase in SOD activity (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in treated animals. These findings indicate that cladode juice, enriched with antioxidant and anti&#8208;inflammatory agents, exerts a prophylactic effect by preserving cellular redox homeostasis under nickel&#8208;induced oxidative insult.</p><p>Moreover, the administration of cladode juice alone in healthy rats led to a slight reduction in hepatic MDA levels, though this decrease did not reach statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), suggesting a mild antioxidant effect in the absence of exogenous oxidative stress. Similarly, no significant alteration in SOD activity was detected, indicating that cladode juice functions as an adaptive modulator, enhancing enzymatic response only under oxidative challenge, such as that induced by NiSO<sub>4</sub> exposure.</p><p>The observed benefits of cladode juice, though more pronounced under induced oxidative stress, may also contribute to maintaining hepatic redox balance in healthy individuals. Preliminary findings suggest that cladodes could enhance baseline antioxidant status by moderately reducing spontaneous lipid peroxidation (Besn&#233;&#8208;Eseverri et&#160;al.&#160;<xref rid="fsn371044-bib-0010" ref-type="bibr">2023</xref>). These effects may stem from the high concentration of phytochemicals such as flavonoids and polyphenols, known for their ability to scavenge reactive oxygen species (ROS) and prevent lipid membrane damage (Zeghbib et&#160;al.&#160;<xref rid="fsn371044-bib-0093" ref-type="bibr">2022</xref>; Ahmedah&#160;<xref rid="fsn371044-bib-0005" ref-type="bibr">2023</xref>).</p></sec><sec id="fsn371044-sec-0031"><label>3.8</label><title>Effect on <styled-content style="fixed-case" toggle="no">GSH</styled-content>, <styled-content style="fixed-case" toggle="no">GSH</styled-content>&#8208;Px and Catalase in <styled-content style="fixed-case" toggle="no">NiSO4</styled-content>&#8208;Intoxicated Rats</title><p>The impact of the juice effect of OFI cladodes on the levels of reduced glutathione (GSH), glutathione peroxidase (GSH&#8208;Px), and catalase (CAT) activity in treated experimental animals is shown in Figure&#160;<xref rid="fsn371044-fig-0003" ref-type="fig">3</xref>.</p><fig position="float" fig-type="FIGURE" id="fsn371044-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Effect of <italic toggle="yes">Opuntia ficus indica</italic> cladode juice on GSH (A) and GSH&#8208;Px (B) levels, and catalase activity (C) in NiSO<sub>4</sub>&#8208;intoxicated rats. Mean&#8201;&#177;&#8201;SEM (<italic toggle="yes">n</italic>&#8201;=&#8201;5) is used to express values; T: normal control; JC: cladode juice; Ni: nickel sulfate; JC&#8201;+&#8201;Ni: cladode juice and nickel sulfate. JC group: comparison with the T group; Ni group: comparison with the T group; JC&#8201;+&#8201;Ni group: comparison with the Ni group. ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05; <sup>#</sup>Non&#8208;significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="FSN3-13-e71044-g001.jpg"/></fig><p>Intraperitoneal injection of nickel sulfate (NiSO<sub>4</sub>) resulted in a highly significant decrease (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) in reduced glutathione (GSH), glutathione peroxidase (GSH&#8208;Px), and catalase (CAT) levels in exposed rats compared to the healthy control group. This reduction indicates significant oxidative stress, accompanied by an increase in reactive oxygen species (ROS) production, leading to redox imbalances and increased cellular damage. The decline in GSH reflects an impairment of the primary antioxidant defense system, while the decrease in GSH&#8208;Px and CAT further compromises the hepatic cells' ability to neutralize peroxides and mitigate NiSO<sub>4</sub>&#8208;induced oxidative stress. However, the preventive administration of <italic toggle="yes">OFI</italic> cladode juice for 30&#8201;days prior to NiSO<sub>4</sub> exposure exerted a notable protective effect by alleviating oxidative stress. Compared to untreated intoxicated rats, those receiving cladode juice exhibited significantly higher GSH, GSH&#8208;Px, and CAT levels (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 to <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), indicating a beneficial modulation of antioxidant defense mechanisms. The increase in CAT levels facilitated the decomposition of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) into water and oxygen, thereby reducing its toxic accumulation in hepatic cells. These findings suggest that the bioactive compounds present in <italic toggle="yes">OFI</italic> cladodes enhance the body's antioxidant system and mitigate the deleterious effects of NiSO<sub>4</sub>&#8208;induced oxidative stress, highlighting their protective potential against oxidative agents.</p><p>The exclusive administration of <italic toggle="yes">OFI</italic> cladode juice to rats, in the absence of NiSO<sub>4</sub> exposure, showed no signs of intoxication or notable physiological alterations compared to healthy control rats. Statistical analysis of reduced glutathione (GSH) levels revealed no significant difference (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05) between the group receiving cladode juice alone and the control group, suggesting the absence of toxic effects under normal physiological conditions. Similarly, although an increase in glutathione peroxidase (GSH&#8208;Px) levels was observed in treated rats compared to controls, this elevation did not reach statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05), indicating that cladode juice does not exert any harmful effects on cellular antioxidant systems. Conversely, in rats exposed to NiSO<sub>4</sub>, prior administration of cladode juice helped preserve GSH levels and mitigate oxidative stress, suggesting a potential protective role by enhancing intrinsic antioxidant defenses. Regarding catalase (CAT) activity, a slight but non&#8208;significant decrease (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) was observed in rats receiving cladode juice alone, without indicating any disruption of endogenous antioxidant defense mechanisms. These findings confirm the safety of <italic toggle="yes">OFI</italic> cladode juice and support its potential as a natural, risk&#8208;free supplement capable of modulating oxidative stress induced by toxic agents such as nickel sulfate.</p><p>The cladodes of <italic toggle="yes">OFI</italic> contain bioactive compounds, such as polyphenols and flavonoids, which play a key role in modulating antioxidant activity and reducing oxidative damage (&#270;ura&#269;kov&#225;&#160;<xref rid="fsn371044-bib-0033" ref-type="bibr">2010</xref>; Voronkova et&#160;al.&#160;<xref rid="fsn371044-bib-0088" ref-type="bibr">2018</xref>). Their consumption can stimulate glutathione peroxidase (GSH&#8208;Px) activity, thereby strengthening cellular antioxidant defenses and helping to mitigate oxidative stress resulting from an imbalance between free radicals and antioxidants. According to Chekkal et&#160;al.&#160;(<xref rid="fsn371044-bib-0024" ref-type="bibr">2019</xref>), young cactus cladodes exert a protective effect against oxidative stress induced by an unbalanced diet, as evidenced by increased GSH&#8208;Px activity and reduced lipid peroxidation. Furthermore, the antioxidant properties of <italic toggle="yes">OFI</italic> cladodes contribute to the preservation of catalase activity in hepatic cells, which is essential for counteracting peroxide accumulation (Rocchetti et&#160;al.&#160;<xref rid="fsn371044-bib-0072" ref-type="bibr">2018</xref>). Additionally, their anti&#8208;inflammatory effects support liver function by minimizing inflammation, a factor that can compromise catalase activity (Caroline et&#160;al.&#160;<xref rid="fsn371044-bib-0021" ref-type="bibr">2024</xref>).</p></sec><sec id="fsn371044-sec-0032"><label>3.9</label><title>Histological Study</title><p>Figure&#160;<xref rid="fsn371044-fig-0004" ref-type="fig">4</xref> illustrates the effect of cladode juice on the histological alterations in the liver of rats intoxicated with NiSO<sub>4</sub>.</p><fig position="float" fig-type="FIGURE" id="fsn371044-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Effect of <italic toggle="yes">OFI</italic> cladode juice on liver histological alterations in NiSO<sub>4</sub>&#8208;intoxicated rats. Histological sections of liver tissue (stained with hematoxylin&#8211;eosin) were examined in the normal control group (A), the group treated with cladode juice (B), the group exposed to nickel sulfate (NiSO<sub>4</sub>) (C), and the group receiving cladode juice + NiSO<sub>4</sub> (D). Observed features include normal sinusoidal dilation (yellow arrow), a portal structure (red arrow), hepatocytic trabeculae (blue arrow), portal inflammation (gray arrow), and interface hepatitis (green arrow).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="FSN3-13-e71044-g006.jpg"/></fig><p>Histological examination of liver sections reveals marked differences between control rats, NiSO<sub>4</sub>&#8208;exposed rats, and those pretreated with cladode juice (CJ). These observations provide deeper insights into the potential hepatoprotective effects of CJ against oxidative and inflammatory stress induced by nickel exposure, as well as the cellular responses and defense mechanisms involved.</p><p>In control rats (Figure&#160;<xref rid="fsn371044-fig-0004" ref-type="fig">4A</xref>), liver sections exhibit hepatic parenchyma with structurally normal characteristics. Hepatocyte trabeculae are regularly aligned, featuring rounded nuclei and showing no signs of lobular necrosis, indicative of hepatic integrity (blue arrow). The portal spaces contain well&#8208;organized portal structures embedded in connective tissue, with a few scattered lymphocytes (red arrow), likely ensuring minimal immune surveillance without triggering an inflammatory response. A mild sinusoidal dilation is observed (yellow arrow), which may be attributed to volumetric overload following increased water intake. These findings confirm the absence of cellular disturbances or functional impairments, providing a morphological reference for the liver under normal physiological conditions.</p><p>Administration of cladode juice (Figure&#160;<xref rid="fsn371044-fig-0004" ref-type="fig">4B</xref>) in the absence of NiSO<sub>4</sub> exposure did not induce any significant alterations in the hepatic parenchyma, suggesting that cladode juice does not interfere with hepatic homeostasis under non&#8208;stressed conditions. Hepatocyte trabeculae remain structurally intact (blue arrow), with no signs of dilation or necrosis, and the portal spaces retain their normal architecture without notable inflammation (red arrow). These findings confirm that cladode juice does not exert hepatotoxic effects on its own but may possess protective and anti&#8208;inflammatory properties in the presence of hepatic injury.</p><p>In rats exposed to NiSO<sub>4</sub>, histological examination reveals pronounced hepatic alterations (Figure&#160;<xref rid="fsn371044-fig-0004" ref-type="fig">4C</xref>). Hepatocyte trabeculae exhibit focal sinusoidal dilation, indicative of impaired microcirculation, a phenomenon commonly associated with oxidative stress. This dilation may result from fluid overload due to a nickel&#8208;induced metabolic imbalance, leading to the accumulation of reactive oxygen species in the liver. The portal spaces exhibit dense and chronic inflammatory infiltration (gray arrow), consisting predominantly of lymphocytes with a few polymorphonuclear neutrophils, contributing to mild to moderate interface hepatitis (green arrow). The pro&#8208;inflammatory properties of nickel within the hepatic parenchyma likely account for this portal inflammation and associated interface hepatitis. High&#8208;magnification imaging highlights the severity of the portal inflammatory infiltrate, predominantly composed of lymphocytes and scattered polymorphonuclear cells (gray arrow), nearly obstructing all portal structures, with only a single remaining portal arteriole (red arrow).</p><p>Rats pretreated for 30&#8201;days with cladode juice before NiSO<sub>4</sub> exposure exhibit significant protection against nickel&#8208;induced toxicity (Figure&#160;<xref rid="fsn371044-fig-0004" ref-type="fig">4D</xref>). Although mild sinusoidal dilation persists, indicating some degree of microvascular stress, inflammatory infiltration around the portal structures is markedly reduced. The portal space (red arrow) contains only a few scattered lymphocytes within the connective tissue (blue arrow), with no significant inflammatory density, suggesting a mitigation of the excessive immune response triggered by nickel exposure. Additionally, interface hepatitis is completely resolved, with a preserved hepatocyte limiting plate, indicating restoration of hepatocyte membrane integrity and reestablishment of normal trabecular organization.</p><p>The observed protective effects can be attributed to the antioxidant and anti&#8208;inflammatory properties of cladode juice, which is rich in bioactive compounds. Previous studies on liver histology have documented nickel&#8208;induced alterations, such as sinusoidal dilation, vacuolization, and hepatocytes exhibiting deformed nuclei (Rao et&#160;al.&#160;<xref rid="fsn371044-bib-0068" ref-type="bibr">2009</xref>; Fatmi et&#160;al.&#160;<xref rid="fsn371044-bib-0036" ref-type="bibr">2018</xref>). Furthermore, oxidative stress plays a crucial role in hepatic dysfunction and contributes to the progression of chronic liver diseases (Li et&#160;al.&#160;<xref rid="fsn371044-bib-0052" ref-type="bibr">2015</xref>). Given their significant involvement in liver failure, antioxidants have been extensively investigated for their potential in preventing and managing both acute and chronic hepatic disorders (Adak&#160;<xref rid="fsn371044-bib-0002" ref-type="bibr">2018</xref>). Consequently, numerous studies have demonstrated the beneficial effects of antioxidants, particularly in the prophylaxis and treatment of liver injuries. The prevailing hypothesis suggests that intensive antioxidant intervention may enhance recovery outcomes in cases of hepatic damage (Touiss et&#160;al.&#160;<xref rid="fsn371044-bib-0085" ref-type="bibr">2021</xref>).</p></sec><sec id="fsn371044-sec-0033"><label>3.10</label><title>Docking Molecular</title><p>To achieve our goal, we tested four bioactive compounds against alanine aminotransferase. Molecular docking analysis of these compounds revealed that all of them exhibited highly negative binding energy values. The molecular docking results for the four identified molecules with the target protein are presented in Table&#160;<xref rid="fsn371044-tbl-0006" ref-type="table">6</xref> and Figure&#160;<xref rid="fsn371044-fig-0005" ref-type="fig">5</xref>.</p><table-wrap position="float" id="fsn371044-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Interaction scores between bioactive compounds and target protein.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Ligands</th><th align="center" valign="bottom" rowspan="1" colspan="1">Be (Kcal/mol)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ic (&#956;M)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Ellagic acid</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;5.74</td><td align="center" valign="top" rowspan="1" colspan="1">61.97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">p&#8208;coumaric acid</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;6.35</td><td align="center" valign="top" rowspan="1" colspan="1">22.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Isorhamnetin3&#8208;o&#8208;neohesperoside</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;2.77</td><td align="center" valign="top" rowspan="1" colspan="1">9.36&#8201;mM</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Piscidic acid</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;4.18</td><td align="center" valign="top" rowspan="1" colspan="1">867.87</td></tr></tbody></table></table-wrap><fig position="float" fig-type="FIGURE" id="fsn371044-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Molecular docking of ellagic acid (A), <italic toggle="yes">p</italic>&#8208;coumaric acid (B), isorhamnetin 3&#8208;O&#8208;neohesperoside (C), and piscidic acid (D) with the target protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="FSN3-13-e71044-g005.jpg"/></fig><p>The table shows that p&#8208;coumaric acid with a binding energy of &#8722;6.35&#8201;Kcal/mol has a stronger interaction than ellagic acid with &#8722;5.74&#8201;Kcal/mol. Thus, Isorhamnetin 3&#8208;o&#8208;neohesperoside with an Ic of 9.36&#8201;mM is less effective than p&#8208;coumaric acid with an Ic of 22.27&#8201;&#956;M. Due to its high binding affinity and low inhibitory concentration, p&#8208;coumaric acid appears to be the most promising candidate for therapeutic applications.</p><p>The results of the molecular docking study showed that the Ellagic acid compound had five hydrogen bond interactions with the protein residues Val A:306, Tyr A:106, Asp A:304, and Phe A:313. In addition, the compound p&#8208;coumaric acid exhibited an interaction at a hydrogen bond with the protein residue Arg A:494, as well as two pi&#8208;alkyl bonds with the protein residues Val A:507 and Met A:495. The Piscidic acid exhibited a four&#8208;hydrogen bond interaction with the protein residues Ser A:304, Asn A:271, Tyr A:440, and Arg A:494. Isorhamnetin3&#8208;o&#8208;neohesperoside had four hydrogen bonds with the protein residues Tyr A:216, Leu A:218, Tyr A:62, and Val A:64.</p><p>After analyzing the molecular docking results of the four compounds, we found that they successfully interacted with and correlated to the binding sites of the selected protein. This strong interaction suggests that these compounds have a high affinity for the target protein, potentially influencing its biological activity. Given their binding properties, it can be inferred that these compounds may exhibit significant antioxidant activity, which could contribute to their potential therapeutic benefits.</p><p>It is widely known that bioactive compounds that contain a phenolic ring and a hydroxyl group have superior antioxidant activity (Pripdeevech et&#160;al.&#160;<xref rid="fsn371044-bib-0066" ref-type="bibr">2025</xref>). Nevertheless, the results of this molecular anchoring research suggest opportunities for the use of cladodes juice as effective antioxidants by reducing oxidative stress.</p></sec></sec><sec sec-type="conclusions" id="fsn371044-sec-0034"><label>4</label><title>Conclusion</title><p>This study highlights the hepatoprotective properties of the polyphenols found in <italic toggle="yes">Opuntia ficus indica</italic> cladode juice. Analyses revealed a significant level of phenolic compounds, particularly polyphenols and flavonoids, that contribute to the protective effect on liver function. Assessment of hepatic enzymatic biomarkers and oxidative stress provided significant results, supporting both the safety of the cladode juice and its potential as a protective agent against NiSO<sub>4</sub>&#8208;induced liver damage. Furthermore, histopathological examinations revealed distinct differences between groups, confirming the protective role of the juice against nickel&#8208;induced hepatic lesions. Molecular docking analysis of the four polyphenolic compounds present in the juice demonstrated their interaction with and alignment to the binding sites of target protein, suggesting that these compounds possess notable antioxidant properties.</p></sec><sec id="fsn371044-sec-0040"><title>Author Contributions</title><p>Conceptualization, original draft writing, reviewing, and editing: Sara Razzak, Marouane Aouji, Soufiane El Assri, Chaimae Sabri, Abdulrahman A. Almehizia. Formal analysis, investigations, funding acquisition, reviewing, and editing: Abdessamad Ittorahou, Laila Ibouzinedine, Amir Bouallegue, Esmael M. Alyami. Resources, data validation, data curation, and supervision: Farid Khalouki, Fakhreldeen Dabiellil, Mohammed Bourhia, Anass Haloui, Youness Taboz.</p></sec><sec sec-type="COI-statement" id="fsn371044-sec-0036"><title>Disclosure</title><p>ARRIVE Guidelines: The experimentation was conducted in accordance with applicable laws, and ARRIVE guidelines.</p></sec><sec id="fsn371044-sec-0035"><title>Ethics Statement</title><p>All experimental procedures were performed in strict accordance with current ethical standards and were approved by the Academic Ethics Committee for Animal Experiments.</p></sec><sec sec-type="conclusions" id="fsn371044-sec-0037"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="fsn371044-sec-0038"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="fsn371044-sec-0039"><title>Acknowledgments</title><p>The authors extend their appreciation to the Deanship of Scientific Research and Graduate Studies at King Khalid University for funding this work through the Large Research Project under grant number RGP2/534/45. The authors are also grateful to King Saud University, Riyadh, Saudi Arabia, for funding this work through the Ongoing Research Funding program (ORF&#8208;2025&#8208;852).</p></ack><sec sec-type="data-availability" id="fsn371044-sec-0042"><title>Data Availability Statement</title><p>All data generated or analyzed during this study is included in this published article.</p></sec><ref-list content-type="cited-references" id="fsn371044-bibl-0001"><title>References</title><ref id="fsn371044-bib-0001"><mixed-citation publication-type="journal" id="fsn371044-cit-0001"><string-name name-style="western"><surname>Abbas</surname>, <given-names>E. Y.</given-names></string-name>, <string-name name-style="western"><given-names>M. I.</given-names><surname>Ezzat</surname></string-name>, <string-name name-style="western"><given-names>H. M.</given-names><surname>El Hefnawy</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Abdel&#8208;Sattar</surname></string-name>. <year>2022</year>. &#8220;<article-title>An Overview and Update on the Chemical Composition and Potential Health Benefits of <italic toggle="yes">Opuntia ficus&#8208;indica</italic> (L.) Miller</article-title>.&#8221; <source>Journal of Food Biochemistry</source><volume>46</volume>, no. <issue>11</issue>: <elocation-id>e14310</elocation-id>. <pub-id pub-id-type="doi">10.1111/jfbc.14310</pub-id>.<pub-id pub-id-type="pmid">35780308</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0002"><mixed-citation publication-type="journal" id="fsn371044-cit-0002"><string-name name-style="western"><surname>Adak</surname>, <given-names>M.</given-names></string-name><year>2018</year>. &#8220;<article-title>Protective Role of Antioxidants in Alcoholic Liver Disease</article-title>.&#8221; <source>Med Phoenix</source><volume>3</volume>, no. <issue>1</issue>: <fpage>75</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.3126/medphoenix.v3i1.20767</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0003"><mixed-citation publication-type="journal" id="fsn371044-cit-0003"><string-name name-style="western"><surname>Adeyemi</surname>, <given-names>O. S.</given-names></string-name>, and <string-name name-style="western"><given-names>B. T.</given-names><surname>Orekoya</surname></string-name>. <year>2014</year>. &#8220;<article-title>Lipid Profile and Oxidative Stress Markers in Wistar Rats Following Oral and Repeated Exposure to Fijk Herbal Mixture</article-title>.&#8221; <source>Journal of Toxicology</source><volume>2014</volume>: <fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1155/2014/876035</pub-id>.<pub-id pub-id-type="pmcid">PMC4217246</pub-id><pub-id pub-id-type="pmid">25386188</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0004"><mixed-citation publication-type="journal" id="fsn371044-cit-0004"><string-name name-style="western"><surname>Aebi</surname>, <given-names>H.</given-names></string-name><year>1984</year>. &#8220;<article-title>Catalase In&#160;Vitro</article-title>.&#8221; <source>Methods in Enzymology</source><volume>105</volume>: <fpage>121</fpage>&#8211;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1016/s0076-6879(84)05016-3</pub-id>.<pub-id pub-id-type="pmid">6727660</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0005"><mixed-citation publication-type="journal" id="fsn371044-cit-0005"><string-name name-style="western"><surname>Ahmedah</surname>, <given-names>H. T.</given-names></string-name><year>2023</year>. &#8220;<article-title>
<italic toggle="yes">Opuntia ficus indica</italic> and Its Potential Effects on Cancer</article-title>.&#8221; <source>Journal of Contemporary Medical Sciences</source><volume>9</volume>, no. <issue>5</issue>: <fpage>321</fpage>&#8211;<lpage>327</lpage>. <pub-id pub-id-type="doi">10.22317/jcms.v9i5.1430</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0006"><mixed-citation publication-type="miscellaneous" id="fsn371044-cit-0006"><string-name name-style="western"><surname>Alfei</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Zuccari</surname></string-name>. <year>2024</year>. <article-title>&#8220;Ellagic Acid (EA): A Green Multi&#8208;Target Weapon Reducing Oxidative Stress and Inflammation Thus Preventing and Ameliorating Alzheimer Disease (AD) Condition</article-title>.&#8221; <pub-id pub-id-type="doi">10.20944/preprints202411.1130.v2</pub-id>.<pub-id pub-id-type="pmcid">PMC11766176</pub-id><pub-id pub-id-type="pmid">39859559</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0007"><mixed-citation publication-type="journal" id="fsn371044-cit-0007"><string-name name-style="western"><surname>Alfei</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Zuccari</surname></string-name>. <year>2025</year>. &#8220;<article-title>Ellagic Acid: A Green Multi&#8208;Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer's Disease</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>26</volume>, no. <issue>2</issue>: <elocation-id>844</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms26020844</pub-id>.<pub-id pub-id-type="pmid">39859559</pub-id><pub-id pub-id-type="pmcid">PMC11766176</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0008"><mixed-citation publication-type="journal" id="fsn371044-cit-0008"><string-name name-style="western"><surname>Avila&#8208;Nava</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Calder&#243;n&#8208;Oliver</surname></string-name>, <string-name name-style="western"><given-names>O. N.</given-names><surname>Medina&#8208;Campos</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Extract of Cactus (<italic toggle="yes">Opuntia ficus indica</italic>) Cladodes Scavenges Reactive Oxygen Species In&#160;Vitro and Enhances Plasma Antioxidant Capacity in Humans</article-title>.&#8221; <source>Journal of Functional Foods</source><volume>10</volume>: <fpage>13</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2014.05.009</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0009"><mixed-citation publication-type="journal" id="fsn371044-cit-0009"><string-name name-style="western"><surname>Ben Saad</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Dalel</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Rjeibi</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Phytochemical, Antioxidant and Protective Effect of Cactus Cladodes Extract Against Lithium&#8208;Induced Liver Injury in Rats</article-title>.&#8221; <source>Pharmaceutical Biology</source><volume>55</volume>, no. <issue>1</issue>: <fpage>516</fpage>&#8211;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1080/13880209.2016.1255976</pub-id>.<pub-id pub-id-type="pmcid">PMC6130665</pub-id><pub-id pub-id-type="pmid">27951739</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0010"><mixed-citation publication-type="journal" id="fsn371044-cit-0010"><string-name name-style="western"><surname>Besn&#233;&#8208;Eseverri</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Trepiana</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>G&#243;mez&#8208;Zorita</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Antunes&#8208;Ricardo</surname></string-name>, <string-name name-style="western"><given-names>M. P.</given-names><surname>Cano</surname></string-name>, and <string-name name-style="western"><given-names>M. P.</given-names><surname>Portillo</surname></string-name>. <year>2023</year>. &#8220;<article-title>Beneficial Effects of <italic toggle="yes">Opuntia</italic> Spp. on Liver Health</article-title>.&#8221; <source>Antioxidants</source><volume>12</volume>, no. <issue>6</issue>: <elocation-id>1174</elocation-id>. <pub-id pub-id-type="doi">10.3390/antiox12061174</pub-id>.<pub-id pub-id-type="pmid">37371904</pub-id><pub-id pub-id-type="pmcid">PMC10294873</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0011"><mixed-citation publication-type="journal" id="fsn371044-cit-0011"><string-name name-style="western"><surname>Bharathi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>S. M.</given-names><surname>Roopan</surname></string-name>, <string-name name-style="western"><given-names>C. S.</given-names><surname>Vasavi</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Munusami</surname></string-name>, <string-name name-style="western"><given-names>G. A.</given-names><surname>Gayathri</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Gayathri</surname></string-name>. <year>2014</year>. &#8220;<article-title>In Silico Molecular Docking And In&#160;Vitro Antidiabetic Studies of Dihydropyrimido[4,5&#8208;a] Acridin&#8208;2&#8208;Amines</article-title>.&#8221; <source>BioMed Research International</source><volume>2014</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2014/971569</pub-id>.<pub-id pub-id-type="pmcid">PMC4060768</pub-id><pub-id pub-id-type="pmid">24991576</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0012"><mixed-citation publication-type="journal" id="fsn371044-cit-0012"><string-name name-style="western"><surname>Biharee</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sharma</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Kumar</surname></string-name>, and <string-name name-style="western"><given-names>V.</given-names><surname>Jaitak</surname></string-name>. <year>2020</year>. &#8220;<article-title>Antimicrobial Flavonoids as a Potential Substitute for Overcoming Antimicrobial Resistance</article-title>.&#8221; <source>Fitoterapia</source><volume>146</volume>: <elocation-id>104720</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fitote.2020.104720</pub-id>.<pub-id pub-id-type="pmid">32910994</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0013"><mixed-citation publication-type="journal" id="fsn371044-cit-0013"><string-name name-style="western"><surname>Bishnoi</surname>, <given-names>S. K.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Dariya</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mathur</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Estimation of Serum Enzymes (AST, ALT, GGT and ALP) Level in Goat (<italic toggle="yes">Capra hircus</italic>) in Various Hepatic Lesions</article-title>.&#8221; <source>International Journal of Advanced Biochemistry Research</source><volume>8</volume>, no. <issue>1</issue>: <fpage>625</fpage>&#8211;<lpage>627</lpage>. <pub-id pub-id-type="doi">10.33545/26174693.2024.v8.i1i.459</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0014"><mixed-citation publication-type="journal" id="fsn371044-cit-0014"><string-name name-style="western"><surname>Bouhalit</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Kechrid</surname></string-name>. <year>2018</year>. &#8220;<article-title>Protective Effect of Silymarin Extracted From <italic toggle="yes">Silybum marianum</italic> Seeds Upon Nickel&#8208;Induced Hepatotoxicity in Albino Wistar Rats</article-title>.&#8221; <source>Annals of Microbiology and Immunology</source><volume>1</volume>, no. <issue>1</issue>: <fpage>1005</fpage>.</mixed-citation></ref><ref id="fsn371044-bib-0015"><mixed-citation publication-type="journal" id="fsn371044-cit-0015"><string-name name-style="western"><surname>Bouhlel</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Limem</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Skandrani</surname></string-name>, et&#160;al. <year>2010</year>. &#8220;<article-title>Assessment of Isorhamnetin 3&#8208;O&#8208;Neohesperidoside From <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Acacia salicina</italic>
</styled-content>: Protective Effects Toward Oxidation Damage and Genotoxicity Induced by Aflatoxin B1 and Nifuroxazide</article-title>.&#8221; <source>Journal of Applied Toxicology</source><volume>30</volume>, no. <issue>6</issue>: <fpage>551</fpage>&#8211;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1002/jat.1525</pub-id>.<pub-id pub-id-type="pmid">20809543</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0016"><mixed-citation publication-type="journal" id="fsn371044-cit-0016"><string-name name-style="western"><surname>Boutakiout</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Elothmani</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Hanine</surname></string-name>, et&#160;al. <year>2018</year>. &#8220;<article-title>Effects of Different Harvesting Seasons on Antioxidant Activity and Phenolic Content of Prickly Pear Cladode Juice</article-title>.&#8221; <source>Journal of the Saudi Society of Agricultural Sciences</source><volume>17</volume>, no. <issue>4</issue>: <fpage>471</fpage>&#8211;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.jssas.2016.11.005</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0017"><mixed-citation publication-type="journal" id="fsn371044-cit-0017"><string-name name-style="western"><surname>Brahmi</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Bouaziz</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ayed</surname></string-name>, <string-name name-style="western"><given-names>H. B.</given-names><surname>Mansour</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zourgui</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Bacha</surname></string-name>. <year>2011</year>. &#8220;<article-title>Chemopreventive Effect of Cactus <italic toggle="yes">Opuntia ficus indica</italic> on Oxidative Stress and Genotoxicity of Aflatoxin B1</article-title>.&#8221; <source>Nutrition &amp; Metabolism</source><volume>8</volume>, no. <issue>1</issue>: <fpage>73</fpage>. <pub-id pub-id-type="doi">10.1186/1743-7075-8-73</pub-id>.<pub-id pub-id-type="pmid">22008149</pub-id><pub-id pub-id-type="pmcid">PMC3214131</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0018"><mixed-citation publication-type="journal" id="fsn371044-cit-0018"><string-name name-style="western"><surname>Brown</surname>, <given-names>M. J.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Margolis</surname></string-name>. <year>2012</year>. &#8220;<article-title>Lead in Drinking Water and Human Blood Lead Levels in the United States</article-title>.&#8221; <source>MMWR Supplements</source><volume>61</volume>, no. <issue>4</issue>: <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22874873</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0019"><mixed-citation publication-type="journal" id="fsn371044-cit-0019"><string-name name-style="western"><surname>Butterweck</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Semlin</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Feistel</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Pischel</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Bauer</surname></string-name>, and <string-name name-style="western"><given-names>E. J.</given-names><surname>Verspohl</surname></string-name>. <year>2010</year>. &#8220;<article-title>Comparative Evaluation of Two Different <italic toggle="yes">Opuntia ficus indica</italic> Extracts for Blood Sugar Lowering Effects in Rats</article-title>.&#8221; <source>Phytotherapy Research</source><volume>25</volume>: <fpage>370</fpage>&#8211;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.3271</pub-id>.<pub-id pub-id-type="pmid">20687136</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0020"><mixed-citation publication-type="journal" id="fsn371044-cit-0020"><string-name name-style="western"><surname>Cao</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mou</surname></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Cao</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>Nickel in Milled Rice (<italic toggle="yes">Oryza sativa</italic> L.) From the Three Main Rice&#8208;Producing Regions in China</article-title>.&#8221; <source>Food Additives and Contaminants Part B</source><volume>10</volume>, no. <issue>1</issue>: <fpage>69</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1080/19393210.2016.1250822</pub-id>.<pub-id pub-id-type="pmid">27782776</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0021"><mixed-citation publication-type="journal" id="fsn371044-cit-0021"><string-name name-style="western"><surname>Caroline</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Fabr&#237;cia</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Dantas</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Exploring the Potential Hepatoprotective Properties of Cactus (Cactaceae) in Liver Health and Disease Management: A Brief Review</article-title>.&#8221; <source>Liver</source><volume>4</volume>, no. <issue>2</issue>: <fpage>287</fpage>&#8211;<lpage>313</lpage>. <pub-id pub-id-type="doi">10.3390/livers4020021</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0022"><mixed-citation publication-type="journal" id="fsn371044-cit-0022"><string-name name-style="western"><surname>Cempel</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Nikel</surname></string-name>. <year>2006</year>. &#8220;<article-title>Nickel: A Review of Its Sources and Environmental Toxicology</article-title>.&#8221; <source>Polish Journal of Environmental Studies</source><volume>15</volume>, no. <issue>3</issue>: <fpage>375</fpage>&#8211;<lpage>382</lpage>.</mixed-citation></ref><ref id="fsn371044-bib-0023"><mixed-citation publication-type="journal" id="fsn371044-cit-0023"><string-name name-style="western"><surname>Chahdoura</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Ben Hsouna</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Boujbiha</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Phytochemical Characterization and Biological Activities Evaluation of Opuntia Sp. Cladode</article-title>.&#8221; <source>South African Journal of Botany</source><volume>168</volume>: <fpage>246</fpage>&#8211;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2024.03.024</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0024"><mixed-citation publication-type="journal" id="fsn371044-cit-0024"><string-name name-style="western"><surname>Chekkal</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Harrat</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Affane</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Bensalah</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Louala</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Lamri&#8208;Senhadji</surname></string-name>. <year>2019</year>. &#8220;<article-title>Cactus Young Cladodes Improves Unbalanced Glycemic Control, Dyslipidemia, Prooxidant/Antioxidant Stress Biomarkers and Stimulate Lecithin&#8208;Cholesterol Acyltransferase and Paraoxonase Activities in Young Rats After Cafeteria Diet Exposure</article-title>.&#8221; <source>Nutrition &amp; Food Science</source><volume>50</volume>, no. <issue>2</issue>: <fpage>288</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1108/nfs-01-2019-0025</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0025"><mixed-citation publication-type="journal" id="fsn371044-cit-0025"><string-name name-style="western"><surname>Chen</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Mao</surname></string-name>. <year>2024</year>. &#8220;<article-title>P&#8208;Coumaric Acid: Advances in Pharmacological Research Based on Oxidative Stress</article-title>.&#8221; <source>Current Topics in Medicinal Chemistry</source><volume>24</volume>, no. <issue>5</issue>: <fpage>416</fpage>&#8211;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.2174/0115680266276823231230183519</pub-id>.<pub-id pub-id-type="pmid">38279744</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0026"><mixed-citation publication-type="journal" id="fsn371044-cit-0026"><string-name name-style="western"><surname>Chen</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Z.&#8208;Z.</given-names><surname>Jiang</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>Anti&#8208;Inflammatory and Hepatoprotective Effects of Total Flavonoid C&#8208;Glycosides From Abrus Mollis Extracts</article-title>.&#8221; <source>Chinese Journal of Natural Medicines</source><volume>12</volume>, no. <issue>8</issue>: <fpage>590</fpage>&#8211;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1016/s1875-5364(14)60090-x</pub-id>.<pub-id pub-id-type="pmid">25156284</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0027"><mixed-citation publication-type="journal" id="fsn371044-cit-0027"><string-name name-style="western"><surname>Chen</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Shen</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>The Water&#8208;Soluble Non&#8208;Starch Polysaccharides From Natural Resources Against Excessive Oxidative Stress: A Potential Health&#8208;Promoting Effect and Its Mechanisms</article-title>.&#8221; <source>International Journal of Biological Macromolecules</source><volume>171</volume>: <fpage>320</fpage>&#8211;<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.01.022</pub-id>.<pub-id pub-id-type="pmid">33421468</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0028"><mixed-citation publication-type="journal" id="fsn371044-cit-0028"><string-name name-style="western"><surname>Dahdouh</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><given-names>M.&#8208;R.</given-names><surname>Djabar</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Kechrid</surname></string-name>. <year>2014</year>. &#8220;<article-title>Vitamins C and E Combination Potentially Prevented Oxidative Stress Mediated Liver Injury in Nickel Intoxicated Mice</article-title>.&#8221; <source>Global Veterinaria</source><volume>13</volume>, no. <issue>6</issue>: <fpage>938</fpage>&#8211;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.5829/idosi.gv.2014.13.06.86257</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0029"><mixed-citation publication-type="journal" id="fsn371044-cit-0029"><string-name name-style="western"><surname>Derbal</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Triki</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Zine</surname></string-name>. <year>2022</year>. &#8220;<article-title>Hepatoprotective Role of Garlic (<italic toggle="yes">Allium sativum</italic>) on Nickel&#8208;Induced Liver Injury in Albino Wistar Rats</article-title>.&#8221; <source>Synth&#232;se: Revue des Sciences et De La Technologie</source><volume>28</volume>, no. <issue>1</issue>: <fpage>37</fpage>&#8211;<lpage>45</lpage>.</mixed-citation></ref><ref id="fsn371044-bib-0030"><mixed-citation publication-type="journal" id="fsn371044-cit-0030"><string-name name-style="western"><surname>Djeridane</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yousfi</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Nadjemi</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Vidal</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Lesgards</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Stocker</surname></string-name>. <year>2006</year>. &#8220;<article-title>Screening of Some Algerian Medicinal Plants for the Phenolic Compounds and Their Antioxidant Activity</article-title>.&#8221; <source>European Food Research and Technology</source><volume>224</volume>, no. <issue>6</issue>: <fpage>801</fpage>&#8211;<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1007/s00217-006-0361-6</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0031"><mixed-citation publication-type="journal" id="fsn371044-cit-0031"><string-name name-style="western"><surname>Du</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zhao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Tao</surname></string-name>, et&#160;al. <year>2016</year>. &#8220;<article-title>The Metabolic Profiling of Isorhamnetin&#8208;3&#8208;O&#8208;Neohesperidoside Produced by Human Intestinal Flora Employing UPLC&#8208;Q&#8208;TOF/MS</article-title>.&#8221; <source>Journal of Chromatographic Science</source><volume>55</volume>, no. <issue>3</issue>: <fpage>243</fpage>&#8211;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1093/chromsci/bmw176</pub-id>.<pub-id pub-id-type="pmid">27881493</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0032"><mixed-citation publication-type="journal" id="fsn371044-cit-0032"><string-name name-style="western"><surname>Duarte&#8208;Medina</surname>, <given-names>D. J.</given-names></string-name>, <string-name name-style="western"><given-names>H. E.</given-names><surname>Mart&#237;nez&#8208;Flores</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Tranquilino&#8208;Rodr&#237;guez</surname></string-name>, and <string-name name-style="western"><given-names>J. P.</given-names><surname>Secundino</surname></string-name>. <year>2024</year>. &#8220;<article-title>Hypolipidemic&#8208;Hepatoprotective Effect of a Cookie Added With <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Opuntia Atropes</italic>
</styled-content> Cladodes and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Opuntia Joconostle</italic>
</styled-content> Fruits in a Rat Model</article-title>.&#8221; <source>Future Foods</source><volume>9</volume>: <elocation-id>100306</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fufo.2024.100306</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0033"><mixed-citation publication-type="journal" id="fsn371044-cit-0033"><string-name name-style="western"><surname>&#270;ura&#269;kov&#225;</surname>, <given-names>Z.</given-names></string-name><year>2010</year>. &#8220;<article-title>Some Current Insights Into Oxidative Stress</article-title>.&#8221; <source>Physiological Research</source><volume>59</volume>, no. <issue>4</issue>: <fpage>459</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.33549/physiolres.931844</pub-id>.<pub-id pub-id-type="pmid">19929132</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0034"><mixed-citation publication-type="journal" id="fsn371044-cit-0034"><string-name name-style="western"><surname>Ellman</surname>, <given-names>G. L.</given-names></string-name><year>1959</year>. &#8220;<article-title>Tissue Sulfhydryl Groups</article-title>.&#8221; <source>Archives of Biochemistry and Biophysics</source><volume>82</volume>, no. <issue>1</issue>: <fpage>70</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/0003-9861(59)90090-6</pub-id>.<pub-id pub-id-type="pmid">13650640</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0035"><mixed-citation publication-type="journal" id="fsn371044-cit-0035"><string-name name-style="western"><surname>Faoziyat</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><given-names>A. E.&#8208;I. M.</given-names><surname>Amina</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Adeyemo</surname></string-name>, et&#160;al. <year>2014</year>. &#8220;<article-title>
<italic toggle="yes">Aspergillus</italic>&#8208;Fermented <italic toggle="yes">Jatropha curcas</italic> Seed Cake: Proximate Composition and Effects on Biochemical Indices in Wistar Rats</article-title>.&#8221; <source>Biological Letters</source><volume>51</volume>, no. <issue>1</issue>: <fpage>37</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1515/biolet-2015-0004</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0036"><mixed-citation publication-type="journal" id="fsn371044-cit-0036"><string-name name-style="western"><surname>Fatmi</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Bellik</surname></string-name>, and <string-name name-style="western"><given-names>Z.</given-names><surname>Kechrid</surname></string-name>. <year>2018</year>. &#8220;<article-title>Protective Effect of <italic toggle="yes">Artimisia herba alba</italic> Aqueous Extract Upon Nickel Induced Hepatotoxicity in Albino Wistar Rats</article-title>.&#8221; <source>Austin Journal of Pharmacology and Therapeutics</source><volume>6</volume>, no. <issue>2</issue>: <fpage>1106</fpage>&#8211;<lpage>1112</lpage>.</mixed-citation></ref><ref id="fsn371044-bib-0037"><mixed-citation publication-type="journal" id="fsn371044-cit-0037"><string-name name-style="western"><surname>Floh&#233;</surname>, <given-names>L.</given-names></string-name>, and <string-name name-style="western"><given-names>W. A.</given-names><surname>G&#252;nzler</surname></string-name>. <year>1984</year>. &#8220;<article-title>[12] Assays of Glutathione Peroxidase</article-title>.&#8221; <source>Methods in Enzymology</source><volume>105</volume>: <fpage>114</fpage>&#8211;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/s0076-6879(84)05015-1</pub-id>.<pub-id pub-id-type="pmid">6727659</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0038"><mixed-citation publication-type="journal" id="fsn371044-cit-0038"><string-name name-style="western"><surname>Genchi</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Carocci</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Lauria</surname></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Sinicropi</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Catalano</surname></string-name>. <year>2020</year>. &#8220;<article-title>Nickel: Human Health and Environmental Toxicology</article-title>.&#8221; <source>International Journal of Environmental Research and Public Health</source><volume>17</volume>, no. <issue>3</issue>: <elocation-id>679</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijerph17030679</pub-id>.<pub-id pub-id-type="pmid">31973020</pub-id><pub-id pub-id-type="pmcid">PMC7037090</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0039"><mixed-citation publication-type="journal" id="fsn371044-cit-0039"><string-name name-style="western"><surname>Guo</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wu</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Nickel Carcinogenesis Mechanism: DNA Damage</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>20</volume>, no. <issue>19</issue>: <elocation-id>4690</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms20194690</pub-id>.<pub-id pub-id-type="pmid">31546657</pub-id><pub-id pub-id-type="pmcid">PMC6802009</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0040"><mixed-citation publication-type="book" id="fsn371044-cit-0040"><string-name name-style="western"><surname>Hewitson</surname>, <given-names>T. D.</given-names></string-name>, and <string-name name-style="western"><given-names>I. A.</given-names><surname>Darby</surname></string-name>. <year>2010</year>. <source>Histology Protocols: Methods in Molecular Biology</source>, <fpage>299</fpage>. <publisher-name>Humana Press</publisher-name>.</mixed-citation></ref><ref id="fsn371044-bib-0041"><mixed-citation publication-type="journal" id="fsn371044-cit-0041"><string-name name-style="western"><surname>Hfaiedh</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Allagui</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Hfaiedh</surname></string-name>, <string-name name-style="western"><given-names>A. E.</given-names><surname>Feki</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Zourgui</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Croute</surname></string-name>. <year>2008</year>. &#8220;<article-title>Protective Effect of Cactus (<italic toggle="yes">Opuntia ficus indica</italic>) Cladode Extract Upon Nickel&#8208;Induced Toxicity in Rats</article-title>.&#8221; <source>Food and Chemical Toxicology</source><volume>46</volume>, no. <issue>12</issue>: <fpage>3759</fpage>&#8211;<lpage>3763</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2008.09.059</pub-id>.<pub-id pub-id-type="pmid">18950672</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0042"><mixed-citation publication-type="journal" id="fsn371044-cit-0042"><string-name name-style="western"><surname>Iyaka</surname>, <given-names>Y. A.</given-names></string-name><year>2011</year>. &#8220;<article-title>Nickel in Soils: A Review of Its Distribution and Impacts</article-title>.&#8221; <source>Scientific Research and Essays</source><volume>6</volume>, no. <issue>33</issue>: <fpage>6774</fpage>&#8211;<lpage>6777</lpage>. <pub-id pub-id-type="doi">10.5897/srex11.035</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0043"><mixed-citation publication-type="journal" id="fsn371044-cit-0043"><string-name name-style="western"><surname>Jain</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Singla</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Kumar</surname></string-name>. <year>2023</year>. &#8220;<article-title>Anti&#8208;Diabetic Potential of Natural Plant Sources: An Assessment of Awareness and Consumption Among Diabetics</article-title>.&#8221; <source>Indian Journal of Nutrition and Dietetics</source><volume>60</volume>, no. <issue>4</issue>: <fpage>520</fpage>&#8211;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.21048/ijnd.2023.60.4.33855</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0044"><mixed-citation publication-type="journal" id="fsn371044-cit-0044"><string-name name-style="western"><surname>Kharchoufa</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bouhrim</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Bencheikh</surname></string-name>, et&#160;al. <year>2020</year>. &#8220;<article-title>Acute and Subacute Toxicity Studies of the Aqueous Extract From Haloxylon Scoparium Pomel (<italic toggle="yes">Hammada scoparia</italic> (Pomel)) by Oral Administration in Rodents</article-title>.&#8221; <source>BioMed Research International</source><volume>2020</volume>: <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2020/4020647</pub-id>.<pub-id pub-id-type="pmcid">PMC7582073</pub-id><pub-id pub-id-type="pmid">33123573</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0045"><mixed-citation publication-type="journal" id="fsn371044-cit-0045"><string-name name-style="western"><surname>Kumari</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>A. K.</given-names><surname>Parida</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Rangani</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Panda</surname></string-name>. <year>2017</year>. &#8220;<article-title>Antioxidant Activities, Metabolic Profiling, Proximate Analysis, Mineral Nutrient Composition of Salvadora Persica Fruit Unravel a Potential Functional Food and a Natural Source of Pharmaceuticals</article-title>.&#8221; <source>Frontiers in Pharmacology</source><volume>08</volume>: <fpage>08</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00061</pub-id>.<pub-id pub-id-type="pmcid">PMC5306401</pub-id><pub-id pub-id-type="pmid">28261096</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0046"><mixed-citation publication-type="journal" id="fsn371044-cit-0046"><string-name name-style="western"><surname>Kuriakose</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Lal Raisa</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Vysakh</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Eldhose</surname></string-name>, and <string-name name-style="western"><given-names>M. S.</given-names><surname>Latha</surname></string-name>. <year>2017</year>. &#8220;<article-title>
<italic toggle="yes">Terminalia bellirica</italic> (Gaertn.) Roxb. Fruit Mitigates CCl<sub>4</sub> Induced Oxidative Stress and Hepatotoxicity in Rats</article-title>.&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>93</volume>: <fpage>327</fpage>&#8211;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.06.080</pub-id>.<pub-id pub-id-type="pmid">28651233</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0047"><mixed-citation publication-type="journal" id="fsn371044-cit-0047"><string-name name-style="western"><surname>La</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>Z.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Dong</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Isorhamnetin in Quinoa Whole&#8208;Grain Flavonoids Intervenes in Non&#8208;Alcoholic Fatty Liver Disease by Modulating Bile Acid Metabolism Through Regulation of FXR Expression</article-title>.&#8221; <source>Food</source><volume>13</volume>, no. <issue>19</issue>: <elocation-id>3076</elocation-id>. <pub-id pub-id-type="doi">10.3390/foods13193076</pub-id>.<pub-id pub-id-type="pmcid">PMC11475887</pub-id><pub-id pub-id-type="pmid">39410111</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0048"><mixed-citation publication-type="journal" id="fsn371044-cit-0048"><string-name name-style="western"><surname>Lahmidi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Bakali</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Harrak</surname></string-name>. <year>2023</year>. &#8220;<article-title>Physical and Physicochemical Characteristics, Bioactive Compounds, and Antioxidant Activity of Cladodes From Erect Prickly Pear <italic toggle="yes">Opuntia stricta</italic> (Haw.) Haw</article-title>.&#8221; <source>Journal of Food Quality</source><volume>2023</volume>: <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2023/3028552</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0049"><mixed-citation publication-type="journal" id="fsn371044-cit-0049"><string-name name-style="western"><surname>Lee</surname>, <given-names>C.&#8208;P.</given-names></string-name>, <string-name name-style="western"><given-names>P.&#8208;H.</given-names><surname>Shih</surname></string-name>, <string-name name-style="western"><given-names>C.&#8208;L.</given-names><surname>Hsu</surname></string-name>, and <string-name name-style="western"><given-names>G.&#8208;C.</given-names><surname>Yen</surname></string-name>. <year>2007</year>. &#8220;<article-title>Hepatoprotection of Tea Seed Oil (<italic toggle="yes">Camellia oleifera</italic> Abel.) Against CCl<sub>4</sub>&#8208;Induced Oxidative Damage in Rats</article-title>.&#8221; <source>Food and Chemical Toxicology</source><volume>45</volume>, no. <issue>6</issue>: <fpage>888</fpage>&#8211;<lpage>895</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2006.11.007</pub-id>.<pub-id pub-id-type="pmid">17188414</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0050"><mixed-citation publication-type="journal" id="fsn371044-cit-0050"><string-name name-style="western"><surname>Lee</surname>, <given-names>K.</given-names></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Kim</surname></string-name>. <year>2019</year>. &#8220;<article-title>In&#8208;Silico Molecular Binding Prediction for Human Drug Targets Using Deep Neural Multi&#8208;Task Learning</article-title>.&#8221; <source>Genes</source><volume>10</volume>, no. <issue>11</issue>: <elocation-id>906</elocation-id>. <pub-id pub-id-type="doi">10.3390/genes10110906</pub-id>.<pub-id pub-id-type="pmid">31703452</pub-id><pub-id pub-id-type="pmcid">PMC6896155</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0051"><mixed-citation publication-type="journal" id="fsn371044-cit-0051"><string-name name-style="western"><surname>Li</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Lang</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Ling</surname></string-name>. <year>2013</year>. &#8220;<article-title>Estimated Daily Flavonoid and Stilbene Intake From Fruits, Vegetables, and Nuts and Associations With Lipid Profiles in Chinese Adults</article-title>.&#8221; <source>Journal of the Academy of Nutrition and Dietetics</source><volume>113</volume>, no. <issue>6</issue>: <fpage>786</fpage>&#8211;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1016/j.jand.2013.01.018</pub-id>.<pub-id pub-id-type="pmid">23522824</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0052"><mixed-citation publication-type="journal" id="fsn371044-cit-0052"><string-name name-style="western"><surname>Li</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>H.&#8208;Y.</given-names><surname>Tan</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Wang</surname></string-name>, et&#160;al. <year>2015</year>. &#8220;<article-title>The Role of Oxidative Stress and Antioxidants in Liver Diseases</article-title>.&#8221; <source>International Journal of Molecular Sciences</source><volume>16</volume>, no. <issue>11</issue>: <fpage>26087</fpage>&#8211;<lpage>26124</lpage>. <pub-id pub-id-type="doi">10.3390/ijms161125942</pub-id>.<pub-id pub-id-type="pmid">26540040</pub-id><pub-id pub-id-type="pmcid">PMC4661801</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0053"><mixed-citation publication-type="journal" id="fsn371044-cit-0053"><string-name name-style="western"><surname>Li</surname>, <given-names>W.&#8208;Q.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Wu</surname></string-name>, et&#160;al. <year>2022</year>. &#8220;<article-title>Isorhamnetin: A Novel Natural Product Beneficial for Cardiovascular Disease</article-title>.&#8221; <source>Current Pharmaceutical Design</source><volume>28</volume>, no. <issue>31</issue>: <fpage>2569</fpage>&#8211;<lpage>2582</lpage>. <pub-id pub-id-type="doi">10.2174/1381612828666220829113132</pub-id>.<pub-id pub-id-type="pmid">36043710</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0054"><mixed-citation publication-type="journal" id="fsn371044-cit-0054"><string-name name-style="western"><surname>Liu</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><given-names>X.&#8208;H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Tran</surname></string-name>, <string-name name-style="western"><given-names>D.&#8208;Q.</given-names><surname>Wang</surname></string-name>, and <string-name name-style="western"><given-names>Y.&#8208;N.</given-names><surname>Zhu</surname></string-name>. <year>2011</year>. &#8220;<article-title>Heavy Metal Contamination and Risk Assessment in Water, Paddy Soil, and Rice Around an Electroplating Plant</article-title>.&#8221; <source>Environmental Science and Pollution Research</source><volume>18</volume>, no. <issue>9</issue>: <fpage>1623</fpage>&#8211;<lpage>1632</lpage>. <pub-id pub-id-type="doi">10.1007/s11356-011-0523-3</pub-id>.<pub-id pub-id-type="pmid">21611830</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0055"><mixed-citation publication-type="journal" id="fsn371044-cit-0055"><string-name name-style="western"><surname>Loza&#8208;Mej&#237;a</surname>, <given-names>M. A.</given-names></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Salazar</surname></string-name>, and <string-name name-style="western"><given-names>J. F.</given-names><surname>S&#225;nchez&#8208;Tejeda</surname></string-name>. <year>2018</year>. &#8220;<article-title>In Silico Studies on Compounds Derived From Calceolaria: Phenylethanoid Glycosides as Potential Multitarget Inhibitors for the Development of Pesticides</article-title>.&#8221; <source>Biomolecules</source><volume>8</volume>, no. <issue>4</issue>: <elocation-id>121</elocation-id>. <pub-id pub-id-type="doi">10.3390/biom8040121</pub-id>.<pub-id pub-id-type="pmid">30360548</pub-id><pub-id pub-id-type="pmcid">PMC6322355</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0056"><mixed-citation publication-type="journal" id="fsn371044-cit-0056"><string-name name-style="western"><surname>Makeen</surname>, <given-names>H. A.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ncibi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mohan</surname></string-name>, et&#160;al. <year>2019</year>. &#8220;<article-title>Cytoprotective Effect of Cactus Cladode (<italic toggle="yes">Opuntia ficus indica</italic>) Against Chlorpyrifos Induced Reactive Oxygen Species in Rat Hepatocytes: Involvement of Heat Shock Protein 70 and CYP1A1/2 Proteins</article-title>.&#8221; <source>Pharmacognosy Magazine</source><volume>15</volume>, no. <issue>62</issue>: <fpage>47</fpage>. <pub-id pub-id-type="doi">10.4103/pm.pm_484_18</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0057"><mixed-citation publication-type="journal" id="fsn371044-cit-0057"><string-name name-style="western"><surname>Mannaa</surname>, <given-names>F. A.</given-names></string-name>, and <string-name name-style="western"><given-names>K. G.</given-names><surname>Abdel&#8208;Wahhab</surname></string-name>. <year>2016</year>. &#8220;<article-title>Physiological Potential of Cytokines and Liver Damages</article-title>.&#8221; <source>Hepatoma Research</source><volume>2</volume>, no. <issue>6</issue>: <fpage>131</fpage>. <pub-id pub-id-type="doi">10.20517/2394-5079.2015.58</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0058"><mixed-citation publication-type="journal" id="fsn371044-cit-0058"><string-name name-style="western"><surname>Meng</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>R.&#8208;Y.</given-names><surname>Gan</surname></string-name>, and <string-name name-style="western"><given-names>H.&#8208;B.</given-names><surname>Li</surname></string-name>. <year>2018</year>. &#8220;<article-title>Natural Products for Prevention and Treatment of Chemical&#8208;Induced Liver Injuries</article-title>.&#8221; <source>Comprehensive Reviews in Food Science and Food Safety</source><volume>17</volume>, no. <issue>2</issue>: <fpage>472</fpage>&#8211;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1111/1541-4337.12335</pub-id>.<pub-id pub-id-type="pmid">33350084</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0059"><mixed-citation publication-type="journal" id="fsn371044-cit-0059"><string-name name-style="western"><surname>Mihara</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Uchiyama</surname></string-name>. <year>1978</year>. &#8220;<article-title>Determination of Malonaldehyde Precursor in Tissues by Thiobarbituric Acid Test</article-title>.&#8221; <source>Analytical Biochemistry</source><volume>86</volume>, no. <issue>1</issue>: <fpage>271</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1016/0003-2697(78)90342-1</pub-id>.<pub-id pub-id-type="pmid">655387</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0060"><mixed-citation publication-type="journal" id="fsn371044-cit-0060"><string-name name-style="western"><surname>Misra</surname>, <given-names>H. P.</given-names></string-name>, and <string-name name-style="western"><given-names>I.</given-names><surname>Fridovich</surname></string-name>. <year>1977</year>. &#8220;<article-title>Superoxide Dismutase: &#8220;Positive&#8221; Spectrophotometric Assays</article-title>.&#8221; <source>Analytical Biochemistry</source><volume>79</volume>, no. <issue>1&#8211;2</issue>: <fpage>553</fpage>&#8211;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1016/0003-2697(77)90429-8</pub-id>.<pub-id pub-id-type="pmid">17332</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0061"><mixed-citation publication-type="miscellaneous" id="fsn371044-cit-0061"><string-name name-style="western"><surname>Moussaoui</surname>, <given-names>B.</given-names></string-name><year>2020</year>. <article-title>&#8220;Propri&#233;t&#233;s biologiques d'extraits des pads d'<italic toggle="yes">Opuntia ficus indica</italic> (L).&#8221; Th&#232;se de Doctorat, Universite Abdelhamid Ibn Badis Mostaganem. Alg&#233;rie</article-title>.</mixed-citation></ref><ref id="fsn371044-bib-0062"><mixed-citation publication-type="journal" id="fsn371044-cit-0062"><string-name name-style="western"><surname>Nivetha</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>K. R. T.</given-names><surname>Asha</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Srinivasan</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Murali</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Kanagalakshmi</surname></string-name>. <year>2024</year>. &#8220;<article-title>P&#8208;Coumaric Acid Pronounced Protective Effect Against Potassium Bromate&#8208;Induced Hepatic Damage in Swiss Albino Mice</article-title>.&#8221; <source>Cell Biochemistry and Function</source><volume>42</volume>, no. <issue>4</issue>: <elocation-id>e4076</elocation-id>. <pub-id pub-id-type="doi">10.1002/cbf.4076</pub-id>.<pub-id pub-id-type="pmid">38895919</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0063"><mixed-citation publication-type="journal" id="fsn371044-cit-0063"><string-name name-style="western"><surname>Okaiyeto</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Nwodo</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Mabinya</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Okoh</surname></string-name>. <year>2018</year>. &#8220;<article-title>A Review on Some Medicinal Plants With Hepatoprotective Effects</article-title>.&#8221; <source>Pharmacognosy Reviews</source><volume>12</volume>, no. <issue>24</issue>: <fpage>186</fpage>. <pub-id pub-id-type="doi">10.4103/phrev.phrev_52_17</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0064"><mixed-citation publication-type="journal" id="fsn371044-cit-0064"><string-name name-style="western"><surname>Pasha</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western"><given-names>S. A.</given-names><surname>Malik</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Shaheen</surname></string-name>, and <string-name name-style="western"><given-names>M. H.</given-names><surname>Shah</surname></string-name>. <year>2010</year>. &#8220;<article-title>Investigation of Trace Metals in the Blood Plasma and Scalp Hair of Gastrointestinal Cancer Patients in Comparison With Controls</article-title>.&#8221; <source>Clinica Chimica Acta</source><volume>411</volume>, no. <issue>7&#8211;8</issue>: <fpage>531</fpage>&#8211;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2010.01.010</pub-id>.<pub-id pub-id-type="pmid">20083098</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0065"><mixed-citation publication-type="journal" id="fsn371044-cit-0065"><string-name name-style="western"><surname>Poleto</surname>, <given-names>K. H.</given-names></string-name>, <string-name name-style="western"><given-names>D. E.</given-names><surname>Janner</surname></string-name>, <string-name name-style="western"><given-names>M. M. M.</given-names><surname>Dahleh</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>P&#8208;Coumaric Acid Potential in Restoring Neuromotor Function and Oxidative Balance Through the Parkin Pathway in a Parkinson Disease&#8208;Like Model in <italic toggle="yes">Drosophila melanogaster</italic>
</article-title>.&#8221; <source>Food and Chemical Toxicology</source><volume>193</volume>: <elocation-id>115002</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.fct.2024.115002</pub-id>.<pub-id pub-id-type="pmid">39276910</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0066"><mixed-citation publication-type="journal" id="fsn371044-cit-0066"><string-name name-style="western"><surname>Pripdeevech</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Chumpolsri</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Suttiarporn</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Wongpornchai</surname></string-name>. <year>2025</year>. &#8220;<article-title>The Chemical Composition and Antioxidant Activities of Basil From Thailand Using Retention Indices and Comprehensive Two&#8208;Dimensional Gas Chromatography</article-title>.&#8221; <source>Journal of the Serbian Chemical Society</source><volume>75</volume>, no. <issue>11</issue>: <fpage>1503</fpage>&#8211;<lpage>1513</lpage>. <pub-id pub-id-type="doi">10.2298/JSC100203125P</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0067"><mixed-citation publication-type="journal" id="fsn371044-cit-0067"><string-name name-style="western"><surname>Proeyen</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ramaekers</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Pischel</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Hespel</surname></string-name>. <year>2012</year>. &#8220;<article-title>
<italic toggle="yes">Opuntia ficus indica</italic> Ingestion Stimulates Peripheral Disposal of Oral Glucose Before and After Exercise in Healthy Men</article-title>.&#8221; <source>International Journal of Sport Nutrition and Exercise Metabolism</source><volume>22</volume>, no. <issue>4</issue>: <fpage>284</fpage>&#8211;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1123/ijsnem.22.4.284</pub-id>.<pub-id pub-id-type="pmid">22805855</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0068"><mixed-citation publication-type="journal" id="fsn371044-cit-0068"><string-name name-style="western"><surname>Rao</surname>, <given-names>M. V.</given-names></string-name>, <string-name name-style="western"><given-names>S. L.</given-names><surname>Chawla</surname></string-name>, and <string-name name-style="western"><given-names>S. R.</given-names><surname>Sharma</surname></string-name>. <year>2009</year>. &#8220;<article-title>Protective Role of Vitamin E on Nickel and/or Chromium Induced Oxidative Stress in the Mouse Ovary</article-title>.&#8221; <source>Food and Chemical Toxicology</source><volume>47</volume>, no. <issue>6</issue>: <fpage>1368</fpage>&#8211;<lpage>1371</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2009.03.018</pub-id>.<pub-id pub-id-type="pmid">19306907</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0069"><mixed-citation publication-type="journal" id="fsn371044-cit-0069"><string-name name-style="western"><surname>Razzak</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Aouji</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Sabri</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Benchehida</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Taibi</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Taboz</surname></string-name>. <year>2024</year>. &#8220;<article-title>Effect of Solvent Polarity of Phytochemical Analysis of Different Moroccan Sites of <italic toggle="yes">Opuntia ficus&#8208;indica</italic> (L.) Mill. Pads</article-title>.&#8221; <source>International Journal of Secondary Metabolite</source><volume>11</volume>, no. <issue>1</issue>: <fpage>93</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.21448/ijsm.1354740</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0070"><mixed-citation publication-type="journal" id="fsn371044-cit-0070"><string-name name-style="western"><surname>Razzak</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Aouji</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Zirari</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Nutritional Composition, Functional and Chemical Characterization of Moroccan <italic toggle="yes">Opuntia ficus&#8208;indica</italic> Cladode Powder</article-title>.&#8221; <source>International Journal of Food Properties</source><volume>27</volume>, no. <issue>1</issue>: <fpage>1167</fpage>&#8211;<lpage>1179</lpage>. <pub-id pub-id-type="doi">10.1080/10942912.2024.2382877</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0071"><mixed-citation publication-type="journal" id="fsn371044-cit-0071"><string-name name-style="western"><surname>Ressaissi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Attia</surname></string-name>, <string-name name-style="western"><given-names>P. L.</given-names><surname>Fal&#233;</surname></string-name>, et&#160;al. <year>2017</year>. &#8220;<article-title>Isorhamnetin Derivatives and Piscidic Acid for Hypercholesterolemia: Cholesterol Permeability, HMG&#8208;CoA Reductase Inhibition, and Docking Studies</article-title>.&#8221; <source>Archives of Pharmacal Research</source><volume>40</volume>, no. <issue>11</issue>: <fpage>1278</fpage>&#8211;<lpage>1286</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-017-0959-1</pub-id>.<pub-id pub-id-type="pmid">28936788</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0072"><mixed-citation publication-type="journal" id="fsn371044-cit-0072"><string-name name-style="western"><surname>Rocchetti</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Pellizzoni</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Montesano</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Lucini</surname></string-name>. <year>2018</year>. &#8220;<article-title>Italian <italic toggle="yes">Opuntia ficus indica</italic> Cladodes as Rich Source of Bioactive Compounds With Health&#8208;Promoting Properties</article-title>.&#8221; <source>Food</source><volume>7</volume>, no. <issue>2</issue>: <elocation-id>24</elocation-id>. <pub-id pub-id-type="doi">10.3390/foods7020024</pub-id>.<pub-id pub-id-type="pmcid">PMC5848128</pub-id><pub-id pub-id-type="pmid">29463028</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0073"><mixed-citation publication-type="journal" id="fsn371044-cit-0073"><string-name name-style="western"><surname>Sabiu</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>T. O.</given-names><surname>Sunmonu</surname></string-name>, <string-name name-style="western"><given-names>E. O.</given-names><surname>Ajani</surname></string-name>, and <string-name name-style="western"><given-names>T. O.</given-names><surname>Ajiboye</surname></string-name>. <year>2015</year>. &#8220;<article-title>Combined Administration of Silymarin and Vitamin C Stalls Acetaminophen&#8208;Mediated Hepatic Oxidative Insults in Wistar Rats</article-title>.&#8221; <source>Revista Brasileira de Farmacognosia</source><volume>25</volume>, no. <issue>1</issue>: <fpage>29</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjp.2014.11.012</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0074"><mixed-citation publication-type="journal" id="fsn371044-cit-0074"><string-name name-style="western"><surname>Santiago&#8208;Saenz</surname>, <given-names>Y. O.</given-names></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Hern&#225;ndez&#8208;Fuentes</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Monroy&#8208;Torres</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Cari&#241;o&#8208;Cort&#233;s</surname></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Jim&#233;nez&#8208;Alvarado</surname></string-name>. <year>2018</year>. &#8220;<article-title>Physicochemical, Nutritional and Antioxidant Characterization of Three Vegetables (<italic toggle="yes">Amaranthus hybridus</italic> L., <italic toggle="yes">Chenopodium berlandieri</italic> L., <italic toggle="yes">Portulaca oleracea</italic> L.) as Potential Sources of Phytochemicals and Bioactive Compounds</article-title>.&#8221; <source>Journal of Food Measurement and Characterization</source><volume>12</volume>, no. <issue>4</issue>: <fpage>2855</fpage>&#8211;<lpage>2864</lpage>. <pub-id pub-id-type="doi">10.1007/s11694-018-9900-7</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0095"><mixed-citation publication-type="journal" id="fsn371044-cit-0095"><string-name name-style="western"><surname>Shang</surname>, <given-names>Y.&#8208;F.</given-names></string-name>, <string-name name-style="western"><given-names>T.&#8208;H.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Thakur</surname></string-name>, <string-name name-style="western"><given-names>J.&#8208;G.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Leonardo</surname></string-name>, and <string-name name-style="western"><given-names>Z.&#8208;J.</given-names><surname>Wei</surname></string-name>. <year>2022</year>. &#8220;<article-title>HPLC&#8208;MS/MS Targeting Analysis of Phenolics Metabolism and Antioxidant Activity of Extractions from <italic toggle="yes">Lycium barbarum</italic> and Its Meal Using Different Methods</article-title>.&#8221; <source>Food Science and Technology</source><volume>42</volume>. <pub-id pub-id-type="doi">10.1590/fst.71022</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0075"><mixed-citation publication-type="journal" id="fsn371044-cit-0075"><string-name name-style="western"><surname>Sharma</surname>, <given-names>N.</given-names></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Shukla</surname></string-name>. <year>2011</year>. &#8220;<article-title>Hepatoprotective Potential of Aqueous Extract of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Butea monosperma</italic>
</styled-content> Against CCl4 Induced Damage in Rats</article-title>.&#8221; <source>Experimental and Toxicologic Pathology</source><volume>63</volume>, no. <issue>7&#8211;8</issue>: <fpage>671</fpage>&#8211;<lpage>676</lpage>. <pub-id pub-id-type="doi">10.1016/j.etp.2010.05.009</pub-id>.<pub-id pub-id-type="pmid">20561774</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0076"><mixed-citation publication-type="journal" id="fsn371044-cit-0076"><string-name name-style="western"><surname>Sharukh</surname>, <given-names>A. K.</given-names></string-name>, <string-name name-style="western"><given-names>A. S.</given-names><surname>Shekh</surname></string-name>, and <string-name name-style="western"><given-names>A. C.</given-names><surname>Pathan</surname></string-name>. <year>2023</year>. &#8220;<article-title>Hepatoprotective Activity of Polyherbal Extract</article-title>.&#8221; <source>International Journal of Advanced Research in Science, Communication and Technology</source><volume>71</volume>, no. <issue>4</issue>: <fpage>308</fpage>&#8211;<lpage>319</lpage>. <pub-id pub-id-type="doi">10.48175/ijarsct-13652</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0077"><mixed-citation publication-type="journal" id="fsn371044-cit-0077"><string-name name-style="western"><surname>Shibata</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Yatagai</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Tateishi</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Matsubara</surname></string-name>. <year>2016</year>. &#8220;<article-title>Inhibitory Effects of Pisiferic Acid on Angiogenesis and Lymphangiogenesis</article-title>.&#8221; <source>Planta Medica International Open</source><volume>3</volume>, no. <issue>02</issue>: <fpage>e31</fpage>&#8211;<lpage>e34</lpage>. <pub-id pub-id-type="doi">10.1055/s-0042-107801</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0078"><mixed-citation publication-type="journal" id="fsn371044-cit-0078"><string-name name-style="western"><surname>Sidhu</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Garg</surname></string-name>, and <string-name name-style="western"><given-names>D. K.</given-names><surname>Dhawan</surname></string-name>. <year>2004</year>. &#8220;<article-title>Protective Role of Zinc in Nickel Induced Hepatotoxicity in Rats</article-title>.&#8221; <source>Chemico&#8208;Biological Interactions</source><volume>150</volume>, no. <issue>2</issue>: <fpage>199</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2004.09.012</pub-id>.<pub-id pub-id-type="pmid">15535990</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0079"><mixed-citation publication-type="journal" id="fsn371044-cit-0079"><string-name name-style="western"><surname>Singleton</surname>, <given-names>V. L.</given-names></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Orthofer</surname></string-name>, and <string-name name-style="western"><given-names>R. M.</given-names><surname>Lamuela&#8208;Ravent&#243;s</surname></string-name>. <year>1999</year>. &#8220;<article-title>Analysis of Total Phenols and Other Oxidation Substrates and Antioxidants by Means of Folin&#8208;Ciocalteu Reagent</article-title>.&#8221; <source>Oxidants and Antioxidants Part A</source><volume>299</volume>: <fpage>152</fpage>&#8211;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/s0076-6879(99)99017-1</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0080"><mixed-citation publication-type="journal" id="fsn371044-cit-0080"><string-name name-style="western"><surname>Slimane</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Boumediene</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Cruz</surname></string-name>, et&#160;al. <year>2024</year>. &#8220;<article-title>Phytochemical Characterization and Evaluation of the Biological Activities of <italic toggle="yes">Opuntia ficus indica</italic> L</article-title>.&#8221; <source>Preprint</source><volume>2024</volume>. <pub-id pub-id-type="doi">10.20944/preprints202402.0362.v1</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0081"><mixed-citation publication-type="journal" id="fsn371044-cit-0081"><string-name name-style="western"><surname>Song</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Zhang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Zhou</surname></string-name>, and <string-name name-style="western"><given-names>X.</given-names><surname>Wu</surname></string-name>. <year>2022</year>. &#8220;<article-title>Is Bilirubin Associated With the Severity of Ischemic Stroke? A Dose Response Meta&#8208;Analysis</article-title>.&#8221; <source>Journal of Clinical Medicine</source><volume>11</volume>, no. <issue>12</issue>: <elocation-id>3262</elocation-id>. <pub-id pub-id-type="doi">10.3390/jcm11123262</pub-id>.<pub-id pub-id-type="pmid">35743332</pub-id><pub-id pub-id-type="pmcid">PMC9224549</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0082"><mixed-citation publication-type="journal" id="fsn371044-cit-0082"><string-name name-style="western"><surname>Stintzing</surname>, <given-names>F. C.</given-names></string-name>, and <string-name name-style="western"><given-names>R.</given-names><surname>Carle</surname></string-name>. <year>2005</year>. &#8220;<article-title>Cactus Stems (<italic toggle="yes">Opuntia</italic> Spp.): A Review on Their Chemistry, Technology, and Uses</article-title>.&#8221; <source>Molecular Nutrition &amp; Food Research</source><volume>49</volume>, no. <issue>2</issue>: <fpage>175</fpage>&#8211;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200400071</pub-id>.<pub-id pub-id-type="pmid">15729672</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0083"><mixed-citation publication-type="journal" id="fsn371044-cit-0083"><string-name name-style="western"><surname>Su</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wei</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Chen</surname></string-name>, and <string-name name-style="western"><given-names>W.</given-names><surname>Wu</surname></string-name>. <year>2014</year>. &#8220;<article-title>Potential Protection of Vitamin C Against Liver&#8208;Lesioned Mice</article-title>.&#8221; <source>International Immunopharmacology</source><volume>22</volume>, no. <issue>2</issue>: <fpage>492</fpage>&#8211;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2014.07.034</pub-id>.<pub-id pub-id-type="pmid">25116224</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0084"><mixed-citation publication-type="journal" id="fsn371044-cit-0084"><string-name name-style="western"><surname>Sun</surname>, <given-names>J.</given-names></string-name><year>2024</year>. &#8220;<article-title>The Effect of Ellagic Acid on Anti&#8208;Aging</article-title>.&#8221; <source>MedScien</source><volume>1</volume>, no. <issue>7</issue>. <pub-id pub-id-type="doi">10.61173/8nysn657</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0085"><mixed-citation publication-type="journal" id="fsn371044-cit-0085"><string-name name-style="western"><surname>Touiss</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Ouahhoud</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Harnafi</surname></string-name>, et&#160;al. <year>2021</year>. &#8220;<article-title>Toxicological Evaluation and Hepatoprotective Efficacy of Rosmarinic Acid&#8208;Rich Extract From <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Ocimum basilicum</italic>
</styled-content> L</article-title>.&#8221; <source>Evidence&#8208;Based Complementary and Alternative Medicine</source><volume>2021</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2021/6676998</pub-id>.<pub-id pub-id-type="pmcid">PMC7870305</pub-id><pub-id pub-id-type="pmid">33603821</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0086"><mixed-citation publication-type="journal" id="fsn371044-cit-0086"><string-name name-style="western"><surname>Unver</surname>, <given-names>T.</given-names></string-name><year>2024</year>. &#8220;<article-title>Isorhamnetin as a Promising Natural Bioactive Flavonoid: In&#160;Vitro Assessment of Its Antifungal Property</article-title>.&#8221; <source>International Journal of Agriculture, Environment and Food Sciences</source><volume>8</volume>, no. <issue>1</issue>: <fpage>54</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.31015/jaefs.2024.1.6</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0087"><mixed-citation publication-type="journal" id="fsn371044-cit-0087"><string-name name-style="western"><surname>Villa&#241;o</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><given-names>M. S.</given-names><surname>Fern&#225;ndez&#8208;Pach&#243;n</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Moy&#225;</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Troncoso</surname></string-name>, and <string-name name-style="western"><given-names>M. C.</given-names><surname>Garc&#237;a&#8208;Parrilla</surname></string-name>. <year>2007</year>. &#8220;<article-title>Radical Scavenging Ability of Polyphenolic Compounds Towards DPPH Free Radical</article-title>.&#8221; <source>Talanta</source><volume>71</volume>, no. <issue>1</issue>: <fpage>230</fpage>&#8211;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1016/j.talanta.2006.03.050</pub-id>.<pub-id pub-id-type="pmid">19071293</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0088"><mixed-citation publication-type="journal" id="fsn371044-cit-0088"><string-name name-style="western"><surname>Voronkova</surname>, <given-names>Y. S.</given-names></string-name>, <string-name name-style="western"><given-names>O. S.</given-names><surname>Voronkova</surname></string-name>, <string-name name-style="western"><given-names>V. A.</given-names><surname>Gorban</surname></string-name>, and <string-name name-style="western"><given-names>K. K.</given-names><surname>Holoborodko</surname></string-name>. <year>2018</year>. &#8220;<article-title>Oxidative Stress, Reactive Oxygen Species, Antioxidants: A Review</article-title>.&#8221; <source>Ecology and Noospherology</source><volume>29</volume>, no. <issue>1</issue>: <fpage>52</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.15421/031809</pub-id>.</mixed-citation></ref><ref id="fsn371044-bib-0089"><mixed-citation publication-type="journal" id="fsn371044-cit-0089"><string-name name-style="western"><surname>Wang</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><given-names>Q.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Bi</surname></string-name>. <year>2018</year>. &#8220;<article-title>Bioactive Flavonoids in Medicinal Plants: Structure, Activity and Biological Fate</article-title>.&#8221; <source>Asian Journal of Pharmaceutical Sciences</source><volume>13</volume>, no. <issue>1</issue>: <fpage>12</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajps.2017.08.004</pub-id>.<pub-id pub-id-type="pmid">32104374</pub-id><pub-id pub-id-type="pmcid">PMC7032191</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0090"><mixed-citation publication-type="journal" id="fsn371044-cit-0090"><string-name name-style="western"><surname>Xing</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gao</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Han</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Mei</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Zhao</surname></string-name>. <year>2022</year>. &#8220;<article-title>Characteristics of Peripheral Blood Gamma&#8208;Glutamyl Transferase in Different Liver Diseases</article-title>.&#8221; <source>Medicine</source><volume>101</volume>, no. <issue>1</issue>: <elocation-id>e28443</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000028443</pub-id>.<pub-id pub-id-type="pmid">35029891</pub-id><pub-id pub-id-type="pmcid">PMC8735790</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0091"><mixed-citation publication-type="journal" id="fsn371044-cit-0091"><string-name name-style="western"><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Ye</surname></string-name>, and <string-name name-style="western"><given-names>H.</given-names><surname>Li</surname></string-name>. <year>2011</year>. &#8220;<article-title>Hepatoprotective Effects of Polyprenols From <italic toggle="yes">Ginkgo biloba</italic> L. Leaves on CCl<sub>4</sub>&#8208;Induced Hepatotoxicity in Rats</article-title>.&#8221; <source>Fitoterapia</source><volume>82</volume>, no. <issue>6</issue>: <fpage>834</fpage>&#8211;<lpage>840</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2011.04.009</pub-id>.<pub-id pub-id-type="pmid">21596107</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0092"><mixed-citation publication-type="journal" id="fsn371044-cit-0092"><string-name name-style="western"><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Shen</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Dong</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Li</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Liu</surname></string-name>. <year>2024</year>. &#8220;<article-title>Effects of Isorhamnetin on Liver Injury in Heat Stroke&#8208;Affected Rats Under Dry&#8208;Heat Environments via Oxidative Stress and Inflammatory Response</article-title>.&#8221; <source>Scientific Reports</source><volume>14</volume>, no. <issue>1</issue>: <elocation-id>7476</elocation-id>. <pub-id pub-id-type="doi">10.1038/s41598-024-57852-y</pub-id>.<pub-id pub-id-type="pmid">38553498</pub-id><pub-id pub-id-type="pmcid">PMC10980765</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0093"><mixed-citation publication-type="journal" id="fsn371044-cit-0093"><string-name name-style="western"><surname>Zeghbib</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Boudjouan</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Vasconcelos</surname></string-name>, and <string-name name-style="western"><given-names>G.</given-names><surname>Lopes</surname></string-name>. <year>2022</year>. &#8220;<article-title>Phenolic Compounds' Occurrence in Opuntia Species and Their Role in the Inflammatory Process: A Review</article-title>.&#8221; <source>Molecules</source><volume>27</volume>, no. <issue>15</issue>: <elocation-id>4763</elocation-id>. <pub-id pub-id-type="doi">10.3390/molecules27154763</pub-id>.<pub-id pub-id-type="pmid">35897933</pub-id><pub-id pub-id-type="pmcid">PMC9330797</pub-id></mixed-citation></ref><ref id="fsn371044-bib-0094"><mixed-citation publication-type="journal" id="fsn371044-cit-0094"><string-name name-style="western"><surname>Zirari</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Aouji</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Baghdad</surname></string-name>, et&#160;al. <year>2025</year>. &#8220;<article-title>In&#8208;Depth Study of the Nutritional Composition, Phytochemicals, Antioxidant Activity, Molecular Docking Interactions, and Toxicological Evaluation of <italic toggle="yes">Abies marocana</italic> Trab. Woody Biomass</article-title>.&#8221; <source>Frontiers in Sustainable Food Systems</source><volume>8</volume>: <elocation-id>1525572</elocation-id>. <pub-id pub-id-type="doi">10.3389/fsufs.2024.1525572</pub-id>.</mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Aging</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Aging</journal-id><journal-id journal-id-type="pmc-domain-id">3724</journal-id><journal-id journal-id-type="pmc-domain">jmaging</journal-id><journal-id journal-id-type="publisher-id">aging</journal-id><journal-title-group><journal-title>JMIR Aging</journal-title></journal-title-group><issn pub-type="epub">2561-7605</issn><publisher><publisher-name>JMIR Publications Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12507341</article-id><article-id pub-id-type="pmcid-ver">PMC12507341.1</article-id><article-id pub-id-type="pmcaid">12507341</article-id><article-id pub-id-type="pmcaiid">12507341</article-id><article-id pub-id-type="doi">10.2196/76981</article-id><article-id pub-id-type="publisher-id">76981</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="primary-section"><subject>Geroinformatics and Electronic Clinical Information/Decision Making in Geriatrics</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Artificial Intelligence</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>AI Language Models in Health Care</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Reviews in Medical Informatics</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Digital Mental Health Interventions, e-Mental Health and Cyberpsychology</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Neurotechnology in Clinical Studies</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Comparative Diagnostic Accuracy of AI-Assisted Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Versus Structural Magnetic Resonance Imaging in Alzheimer Disease: Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-6994-5802</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="B">Bingbing</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-3401-4426</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="T">Tailiang</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-8115-8481</contrib-id><name name-style="western"><surname>Ma</surname><given-names initials="R">Rongrong</given-names></name><degrees>MSc</degrees><xref rid="aff2" ref-type="aff">2</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-4206-601X</contrib-id><name name-style="western"><surname>Huo</surname><given-names initials="X">Xiaochuan</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8439-4593</contrib-id><name name-style="western"><surname>Xiong</surname><given-names initials="X">Xiaoxiao</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-2551-7457</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="M">Minjie</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-8361-7961</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuran</given-names></name><degrees>MSc</degrees><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-5708-6430</contrib-id><name name-style="western"><surname>Liu</surname><given-names initials="L">Liu</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-0981-0136</contrib-id><name name-style="western"><surname>Zhuang</surname><given-names initials="Z">Zhijiang</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0012-9835</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="B">Bin</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0618-4934</contrib-id><name name-style="western"><surname>Shou</surname><given-names initials="J">Jixin</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Department of Neurosurgery</institution>, <institution>Fifth Affiliated Hospital of Zhengzhou University</institution>, <addr-line>No. 3 Kangfu-qian Street</addr-line>, <addr-line content-type="city">Zhengzhou</addr-line>, <addr-line>450052</addr-line>, <country>China</country>, <phone>86 17630927442</phone></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Anesthesiology and Perioperative Medicine, Xuchang Central Hospital</institution>, <institution>Henan University of Science and Technology</institution>, <addr-line content-type="city">Xuchang</addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Neurology</institution>, <institution>Fifth Affiliated Hospital of Zhengzhou University</institution>, <addr-line content-type="city">Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff4"><label>4</label><institution content-type="department">The Fifth Clinical Medical College, Henan Medical College</institution>, <institution>Zhengzhou University</institution>, <addr-line content-type="city">Zhengzhou</addr-line>, <country>China</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine</institution>, <institution>Tsinghua University</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>O'Connell</surname><given-names initials="M">Megan</given-names></name></contrib></contrib-group><author-notes><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>these authors contributed equally</p></fn><corresp id="cor1">Tailiang Zhao, PhD, Department of Neurosurgery, Fifth Affiliated Hospital of Zhengzhou University, No. 3 Kangfu-qian Street, Zhengzhou, 450052, China, <phone>86 17630927442</phone>; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tailiang1996@163.com">tailiang1996@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>8</day><month>10</month><year>2025</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">480159</issue-id><elocation-id>e76981</elocation-id><history><date date-type="received"><day>05</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>03</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-09 00:25:43.637"><day>09</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Bingbing Wang, Tailiang Zhao, Rongrong Ma, Xiaochuan Huo, Xiaoxiao Xiong, Minjie Wu, Yuran Wang, Liu Liu, Zhijiang Zhuang, Bin Wang, Jixin Shou. Originally published in JMIR Aging (https://aging.jmir.org)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Aging, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://aging.jmir.org">https://aging.jmir.org</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="aging-v8-e76981.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="aging-v8-e76981.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>Neuroimaging is crucial in the diagnosis of Alzheimer disease (AD). In recent years, artificial intelligence (AI)&#8211;based neuroimaging technology has rapidly developed, providing new methods for accurate diagnosis of AD, but its performance differences still need to be systematically evaluated.</p></sec><sec><title>Objective</title><p>This study aims to conduct a systematic review and meta-analysis comparing the diagnostic performance of AI-assisted fluorine-18 fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) and structural magnetic resonance imaging (sMRI) for AD.</p></sec><sec><title>Methods</title><p>Databases including Web of Science, PubMed, and Embase were searched from inception to January 2025 to identify original studies that developed or validated AI models for AD diagnosis using <sup>18</sup>F-FDG PET or sMRI. Methodological quality was assessed using the TRIPOD-AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis&#8211;Artificial Intelligence) checklist. A bivariate mixed-effects model was employed to calculate pooled sensitivity, specificity, and summary receiver operating characteristic curve area (SROC-AUC).</p></sec><sec><title>Results</title><p>A total of 38 studies were included, with 28 moderate-to-high-quality studies analyzed. Pooled SROC-AUC values were 0.94 (95% CI 0.92&#8208;0.96) for sMRI and 0.96 (95% CI 0.94&#8208;0.98) for <sup>18</sup>F-FDG PET, demonstrating statistically significant intermodal differences (<italic toggle="yes">P</italic>=.02). Subgroup analyses revealed that for machine learning, pooled SROC-AUCs were 0.89 (95% CI 0.86&#8208;0.92) for sMRI and 0.95 (95% CI 0.92&#8208;0.96) for <sup>18</sup>F-FDG PET, while for deep learning, these values were 0.96 (95% CI 0.94&#8208;0.97) and 0.97 (95% CI 0.96&#8208;0.99), respectively. Meta-regression identified heterogeneity arising from study quality stratification, algorithm types, and validation strategies.</p></sec><sec><title>Conclusions</title><p>Both AI-assisted <sup>18</sup>F-FDG PET and sMRI exhibit high diagnostic accuracy in AD, with <sup>18</sup>F-FDG PET demonstrating superior overall diagnostic performance compared to sMRI.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><title>Keywords</title><kwd><sup>18</sup>F-FDG PET</kwd><kwd>Alzheimer disease</kwd><kwd>artificial intelligence</kwd><kwd>deep learning</kwd><kwd>machine learning</kwd><kwd>Preferred Reporting Items for Systematic Reviews and Meta-Analyses</kwd><kwd>PRISMA</kwd><kwd>sMRI</kwd><kwd>structural magnetic resonance imaging</kwd><kwd>systematic review</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by insidious onset, cognitive decline, and memory impairment. In the United States, approximately 6.7 million adults aged &#8805;65 years are affected by AD, while China faces an even greater burden, with over 13 million cases [<xref rid="R1" ref-type="bibr">1</xref><xref rid="R2" ref-type="bibr">2</xref>]. The prolonged disease course and high comorbidity rates have established AD as one of the most fatal and economically burdensome conditions of the 21st century [<xref rid="R3" ref-type="bibr">3-5</xref>]. Accurate diagnosis of AD is critical for therapeutic decision-making and prognostic evaluation, particularly in the context of global population aging and increasing demands for precise patient stratification in clinical trials [<xref rid="R6" ref-type="bibr">6</xref><xref rid="R7" ref-type="bibr">7</xref>].</p><p>Neuroimaging modalities, including fluorine-18 fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) and structural magnetic resonance imaging (sMRI), have become cornerstone technologies in AD diagnostic frameworks (eg, National Institute on Aging-Alzheimer's Association criteria) because of their noninvasive nature and quantitative capabilities [<xref rid="R8" ref-type="bibr">8-10</xref>]. Recent advancements in artificial intelligence (AI) have revolutionized medical image analysis: machine learning (ML) enables data-driven predictive modeling beyond traditional rule-based programming, while deep learning (DL), an advanced ML paradigm, employs multilayer neural networks to extract high-level features from complex datasets, demonstrating transformative potential in neuroimaging [<xref rid="R11" ref-type="bibr">11-14</xref>]. Despite extensive research on AI-assisted sMRI or <sup>18</sup>F-FDG PET for AD diagnosis, two critical challenges hinder evaluation of model generalizability: (1) substantial heterogeneity in algorithm designs and validation frameworks, and (2) significant variability in the quality of individual studies [<xref rid="R15" ref-type="bibr">15</xref>]. Furthermore, no high-quality meta-analysis has comprehensively compared the diagnostic performance of these two imaging modalities.</p><p>This systematic review and meta-analysis addresses three critical objectives: (1) quantitative evaluation of diagnostic accuracy metrics for AI-assisted <sup>18</sup>F-FDG PET and sMRI based on moderate-to-high-quality evidence; (2) direct comparison of diagnostic performance between modalities; and (3) investigation of confounding factors, including study quality (moderate-to-high vs low), algorithm types (ML vs DL), and validation strategies (internal vs external), through meta-regression. The findings are anticipated to inform evidence-based optimization of AD diagnostic pathways.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Overview</title><p>This study adhered to the PRISMA-DTA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy) guidelines and was prospectively registered on PROSPERO (ID: CRD42023449927) to ensure transparency and minimize reporting bias [<xref rid="R16" ref-type="bibr">16</xref><xref rid="R17" ref-type="bibr">17</xref>]. Two reviewers independently conducted all stages of the review process, including title and abstract screening, full-text evaluation, data extraction, adherence assessment to reporting guidelines, and risk-of-bias evaluation. Discrepancies were resolved through group consensus.</p></sec><sec id="s2-2"><title>Literature Search Strategy</title><p>Two investigators (TLZ and BW) systematically searched PubMed, Web of Science, and Embase from inception to January 2025 using a combination of Medical Subject Headings (MeSH) terms and free-text keywords. Additional searches were performed on clinical trial registries and OpenGrey to identify unpublished clinical trials and gray literature. Search terms encompassed four domains: (1) disease terminology (Alzheimer disease, AD, Alzheimer Syndrome); (2) imaging modalities (<sup>18</sup>F-FDG PET, sMRI); (3) AI methodologies (ML, DL); and (4) diagnostic metrics (sensitivity, specificity, summary receiver operating characteristic curve area [SROC-AUC]). Reference lists of included studies were manually screened to identify additional relevant publications. The specific search strategies are provided in Table S1 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>.</p></sec><sec id="s2-3"><title>Literature Inclusion and Exclusion Criteria</title><p>The inclusion criteria were as follows: (1) human studies developing or validating AI models using <sup>18</sup>F-FDG PET or sMRI to differentiate AD from normal controls; (2) AD diagnosis based on National Institute on Aging-Alzheimer's Association or International Working Group for New Research Criteria for Alzheimer&#8217;s Disease criteria; (3) availability of diagnostic performance metrics (eg, true positives, false positives, true negatives, false negatives) or explicit reporting of sensitivity and specificity; and (4) full-text availability in English. The exclusion criteria were as follows: (1) case reports, reviews, letters, or conference abstracts; (2) studies lacking sufficient diagnostic performance data; and (3) duplicate publications reporting on the same cohort without novel analyses.</p></sec><sec id="s2-4"><title>Literature Screening and Data Extraction</title><p>Two reviewers (TZ and BW) independently performed title and abstract and full-text screening, followed by cross-verification to ensure accuracy. Two additional investigators (RM and XH) extracted data using predefined forms, including study characteristics (first author, publication year), model specifications (algorithm type, validation strategies), and diagnostic performance metrics (2&#215;2 contingency tables, sensitivity, specificity). Extracted data were cross-checked for completeness and precision.</p></sec><sec id="s2-5"><title>Quality Assessment of Included Studies</title><p>The methodological quality of included studies was evaluated using an adapted TRIPOD-AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis&#8211;Artificial Intelligence) checklist (Table S2 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>) by two independent reviewers (RM and XH) [<xref rid="R18" ref-type="bibr">18</xref>]. The instrument assessed four domains: (1) data quality (sample diversity, adequacy, preprocessing standardization), (2) model development (feature extraction rationale, algorithm selection, hyperparameter optimization), (3) validation methods (cross-validation rigor, external validation), and (4) clinical applicability (interpretability, net clinical benefit). Each of the nine items was scored 0&#8208;2 (0=unsatisfied; 1=partially satisfied; 2=fully satisfied), with total scores categorized as high quality (&#8805;16), moderate quality (10-15), or low quality (&#8804;9). Disagreements were resolved through discussion.</p></sec><sec id="s2-6"><title>Data Analysis</title><p>Diagnostic performance metrics were calculated using a bivariate mixed-effects model. SROC-AUC served as the primary outcome due to its threshold independence. Diagnostic accuracy was classified per National Institutes of Health criteria as high (AUC&#8805;0.90), moderate (0.70&#8208;0.89), or low (AUC&lt;0.70) [<xref rid="R19" ref-type="bibr">19</xref>].</p></sec><sec id="s2-7"><title>Heterogeneity Assessment and Publication Bias Evaluation</title><p>Heterogeneity was quantified using Cochran <italic toggle="yes">Q</italic> test (significance defined at the .05 level) and <italic toggle="yes">I</italic><sup>2</sup> statistics (25%: low; 50%: moderate; 75%: high heterogeneity) [<xref rid="R20" ref-type="bibr">20</xref>]. Threshold effects were assessed using Spearman correlation between logit-transformed sensitivity and 1&#8211;specificity. Sensitivity analyses evaluated outlier influence by iteratively excluding individual studies. Univariable meta-regression analyses were conducted to assess the influence of potential confounding factors, including study quality (moderate to high vs low quality), algorithm type (ML vs DL), and validation strategy (internal vs external validation). Statistical significance of modifiers of the pooled effect size was defined at the .05 level after adjustment via the Holm-Bonferroni method. Publication bias was assessed via funnel plot asymmetry and Egger test, with significance defined at the .05 level. All analyses were conducted in Stata 16.0 using the MIDAS commands.</p><p>As this study focused on diagnostic accuracy, we employed the bivariate random-effects model via the MIDAS command in Stata to jointly synthesize sensitivity and specificity. This approach accounts for both within- and between-study variability, as well as the inherent correlation between sensitivity and specificity. In such models, conventional heterogeneity measures like <italic toggle="yes">I</italic>&#178;, although still reported for completeness, may not fully capture the joint variability of test performance measures. Therefore, to better understand heterogeneity, we additionally performed meta-regression and calculated joint likelihood ratio tests to explore potential effect modifiers. These methods align with recommended practices in diagnostic test accuracy meta-analyses [<xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">22</xref>].</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Literature Screening Process and Results</title><p>Initial searches identified 876 PubMed records (n=89 involving <sup>18</sup>F-FDG PET; n=787 sMRI), 932 Embase records (n=111 <sup>18</sup>F-FDG PET; n=821 sMRI), and 2610 Web of Science records (n=230 <sup>18</sup>F-FDG PET; n=2380 sMRI), supplemented by 3 additional studies. After deduplication in EndNote 20, 2 reviewers independently screened titles and abstracts using the Population, Intervention, Comparison, Outcome, Study Design (PICOS) criteria, followed by full-text evaluation against predefined inclusion/exclusion criteria. This rigorous process yielded 38 studies for systematic review and meta-analysis [<xref rid="R23" ref-type="bibr">23-60</xref>]. The literature screening process and results are shown in <xref rid="F1" ref-type="fig">Figure 1</xref>.</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><title>PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flow diagram.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aging-v8-e76981-g001.jpg"/></fig></sec><sec id="s3-2"><title>Characteristics of Included Studies</title><p><xref rid="T1" ref-type="table">Table 1</xref> and Table S3 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref> detail the characteristics of the included studies. Imaging modalities comprised sMRI (n=15, 39%), <sup>18</sup>F-FDG PET (n=15, 39%), and combined sMRI/<sup>18</sup>F-FDG PET (n=8, 22%). Data sources predominantly relied on open-access databases (n=29, 76%), with 28 (97%) from the Alzheimer&#8217;s Disease Neuroimaging Initiative database and 1 (3%) from the Open Access Series of Imaging Studies database. Four studies (11%) used institutional data, while 5 (13%) combined Alzheimer&#8217;s Disease Neuroimaging Initiative database with local datasets. Algorithmically, 26 studies (68%) employed ML, predominantly support vector machines (17/26, 65%), whereas 12 (32%) utilized DL, primarily convolutional neural networks (9/12, 75%). Internal validation was implemented in 33 studies (87%), with 10-fold cross-validation in 16 (48%); only 5 studies (13%) incorporated external validation.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><title> Characteristics of all included studies (n=38).</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Studies</th><th colspan="7" valign="bottom" rowspan="1">Model development and internal validation</th><th colspan="2" valign="bottom" rowspan="1">Model external validation</th></tr><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Definition</th><th valign="bottom" rowspan="1" colspan="1">Modality</th><th valign="bottom" rowspan="1" colspan="1">Data source</th><th valign="bottom" rowspan="1" colspan="1">Algorithm used</th><th valign="bottom" rowspan="1" colspan="1">Training/validation (ratio)</th><th valign="bottom" rowspan="1" colspan="1">Testing</th><th valign="bottom" rowspan="1" colspan="1">Type of internal validation</th><th valign="bottom" rowspan="1" colspan="1">Data source</th><th valign="bottom" rowspan="1" colspan="1">Definition</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">Zhang et al [<xref rid="R23" ref-type="bibr">23</xref>], 2011</td><td align="left" valign="top" rowspan="1" colspan="1">AD<xref rid="T1_FN1" ref-type="table-fn"><sup>a</sup></xref>: 51; NC<xref rid="T1_FN13" ref-type="table-fn"><sup>b</sup></xref>: 52</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI<xref rid="T1_FN18" ref-type="table-fn"><sup>c</sup></xref>; PET<xref rid="T1_FN23" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">ADNI<xref rid="T1_FN21" ref-type="table-fn"><sup>e</sup></xref> database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM<xref rid="T1_FN20" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR<xref rid="T1_FN14" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV<xref rid="T1_FN4" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Yun et al [<xref rid="R24" ref-type="bibr">24</xref>], 2015</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 71; NC: 85</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">LDA<xref rid="T1_FN9" ref-type="table-fn"><sup>i</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV<xref rid="T1_FN10" ref-type="table-fn"><sup>j</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Westman et al [<xref rid="R25" ref-type="bibr">25</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 96; NC: 111</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">OPLS<xref rid="T1_FN15" ref-type="table-fn"><sup>k</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">7-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Vemuri et al [<xref rid="R26" ref-type="bibr">26</xref>], 2008</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 190; NC: 190</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">Mayo Clinic</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">280</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">4-fold CV; hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Suk et al [<xref rid="R27" ref-type="bibr">27</xref>], 2014</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 93; NC: 101</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">DBM<xref rid="T1_FN5" ref-type="table-fn"><sup>l</sup></xref>; SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Sayeed et al [<xref rid="R28" ref-type="bibr">28</xref>], 2002</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 18; NC: 10</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">Hammersmith Hospital</td><td align="left" valign="top" rowspan="1" colspan="1">DFA<xref rid="T1_FN6" ref-type="table-fn"><sup>m</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Pan et al [<xref rid="R29" ref-type="bibr">29</xref>], 2019</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 247; NC: 246</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Padilla et al [<xref rid="R30" ref-type="bibr">30</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 53; NC: 52</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ni et al [<xref rid="R31" ref-type="bibr">31</xref>], 2021</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 638; NC: 629</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">CNN<xref rid="T1_FN3" ref-type="table-fn"><sup>n</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">1000</td><td align="left" valign="top" rowspan="1" colspan="1">267</td><td align="left" valign="top" rowspan="1" colspan="1">Hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Magnin et al [<xref rid="R32" ref-type="bibr">32</xref>], 2009</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 16; NC: 22</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">Piti&#233;-Salp&#233;triere Hospital</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">Bootstrap resampling</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Lu et al [<xref rid="R33" ref-type="bibr">33</xref>], 2018</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 226; NC: 304</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">MDNN<xref rid="T1_FN12" ref-type="table-fn"><sup>o</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Liu et al [<xref rid="R34" ref-type="bibr">34</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 198; NC: 229</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SRC<xref rid="T1_FN19" ref-type="table-fn"><sup>p</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Liu et al [<xref rid="R35" ref-type="bibr">35</xref>], 2018</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 93; NC: 100</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">2D-CNN</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Li et al [<xref rid="R36" ref-type="bibr">36</xref>], 2015</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 44; NC: 45</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database; TUM database</td><td align="left" valign="top" rowspan="1" colspan="1">GMM<xref rid="T1_FN8" ref-type="table-fn"><sup>q</sup></xref>; SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Lerch et al [<xref rid="R37" ref-type="bibr">37</xref>], 2008</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 19; NC: 17</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">Ludwig Maximilian University of Munich</td><td align="left" valign="top" rowspan="1" colspan="1">QDA<xref rid="T1_FN16" ref-type="table-fn"><sup>r</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Kim et al [<xref rid="R38" ref-type="bibr">38</xref>], 2020</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 141; NC: 348</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">CNN</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Severance dataset</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 80; NC: 72</td></tr><tr><td valign="top" rowspan="1" colspan="1">Kim et al [<xref rid="R39" ref-type="bibr">39</xref>], 2020</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 139; NC: 347</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">BEGAN<xref rid="T1_FN2" ref-type="table-fn"><sup>s</sup></xref>; SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Severance dataset</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 73; NC: 68</td></tr><tr><td valign="top" rowspan="1" colspan="1">Katako et al [<xref rid="R40" ref-type="bibr">40</xref>], 2018</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 94; NC: 111</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ismail et al [<xref rid="R41" ref-type="bibr">41</xref>], 2023</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 511; NC: 535</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">MultiAz-Net; SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ill&#225;n et al [<xref rid="R42" ref-type="bibr">42</xref>], 2011</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 95; NC: 97</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hinrichs et al [<xref rid="R43" ref-type="bibr">43</xref>], 2009</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 89; NC: 94</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">LPboosting<xref rid="T1_FN11" ref-type="table-fn"><sup>t</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Leave-many-out CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Gray et al [<xref rid="R44" ref-type="bibr">44</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 50; NC: 54</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">Monte Carlo CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Gray et al [<xref rid="R45" ref-type="bibr">45</xref>], 2013</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 37; NC: 35</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">RF<xref rid="T1_FN17" ref-type="table-fn"><sup>u</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">Monte Carlo CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Feng et al [<xref rid="R46" ref-type="bibr">46</xref>], 2019</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 93; NC: 100</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">FSBi-LSTM<xref rid="T1_FN7" ref-type="table-fn"><sup>v</sup></xref>; 3D-CNN</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Cuingnet et al [<xref rid="R47" ref-type="bibr">47</xref>], 2011</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 137; NC: 162</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">50%</td><td align="left" valign="top" rowspan="1" colspan="1">Hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Chen et al [<xref rid="R48" ref-type="bibr">48</xref>], 2022</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 326; NC: 413</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI-1 database; ADNI-2 database</td><td align="left" valign="top" rowspan="1" colspan="1">2D-CNN; 3D-CNN</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI-1 database; ADNI-2 database</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 326; NC: 413</td></tr><tr><td valign="top" rowspan="1" colspan="1">Song et al [<xref rid="R49" ref-type="bibr">49</xref>], 2021</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 95; NC: 126</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI; PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">3D-CNN</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Li et al [<xref rid="R50" ref-type="bibr">50</xref>], 2019</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 130; NC: 162</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">70%</td><td align="left" valign="top" rowspan="1" colspan="1">30%</td><td align="left" valign="top" rowspan="1" colspan="1">Monte Carlo CV</td><td align="left" valign="top" rowspan="1" colspan="1">Huashan database</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 22; NC: 22</td></tr><tr><td valign="top" rowspan="1" colspan="1">Ahila et al [<xref rid="R51" ref-type="bibr">51</xref>], 2022</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 220; NC: 635</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">2D-CNN</td><td align="left" valign="top" rowspan="1" colspan="1">90%</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1">Hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Toussaint et al [<xref rid="R52" ref-type="bibr">52</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 80; NC: 80</td><td align="left" valign="top" rowspan="1" colspan="1">PET</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Tong et al [<xref rid="R53" ref-type="bibr">53</xref>], 2014</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 198; NC: 231</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">LOOCV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Min et al [<xref rid="R54" ref-type="bibr">54</xref>], 2014</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 97; NC: 128</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Jin et al [<xref rid="R55" ref-type="bibr">55</xref>], 2020</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 488; NC: 536</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">In-house database; ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">3D attention network</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV; leave center out CV</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database; in-house database</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 488; NC: 536</td></tr><tr><td valign="top" rowspan="1" colspan="1">Cho et al [<xref rid="R56" ref-type="bibr">56</xref>], 2012</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 128; NC: 160</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">LDA</td><td align="left" valign="top" rowspan="1" colspan="1">142</td><td align="left" valign="top" rowspan="1" colspan="1">146</td><td align="left" valign="top" rowspan="1" colspan="1">Hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Chincarini et al [<xref rid="R57" ref-type="bibr">57</xref>], 2011</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 144; NC: 189</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">RF; SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">20-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Beheshti et al [<xref rid="R58" ref-type="bibr">58</xref>], 2017</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 92; NC: 94</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Anandh et al [<xref rid="R59" ref-type="bibr">59</xref>], 2016</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 30; NC: 55</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">OASIS<xref rid="T1_FN22" ref-type="table-fn"><sup>w</sup></xref> database</td><td align="left" valign="top" rowspan="1" colspan="1">SVM</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td valign="top" rowspan="1" colspan="1">Amoroso et al [<xref rid="R60" ref-type="bibr">60</xref>], 2018</td><td align="left" valign="top" rowspan="1" colspan="1">AD: 86; NC: 81</td><td align="left" valign="top" rowspan="1" colspan="1">sMRI</td><td align="left" valign="top" rowspan="1" colspan="1">ADNI database</td><td align="left" valign="top" rowspan="1" colspan="1">RF</td><td align="left" valign="top" rowspan="1" colspan="1">67</td><td align="left" valign="top" rowspan="1" colspan="1">100</td><td align="left" valign="top" rowspan="1" colspan="1">10-fold CV; hold-out</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1" fn-type="other"><label>a</label><p>AD: Alzheimer disease.</p></fn><fn id="T1_FN13" fn-type="other"><label>b</label><p>NC: normal cognitive.</p></fn><fn id="T1_FN18" fn-type="other"><label>c</label><p>sMRI: structural magnetic resonance imaging.</p></fn><fn id="T1_FN23" fn-type="other"><label>d</label><p>PET: positron emission tomography. </p></fn><fn id="T1_FN21" fn-type="other"><label>e</label><p>ADNI: Alzheimer&#8217;s Disease Neuroimaging Initiative<named-content content-type="">.</named-content></p></fn><fn id="T1_FN20" fn-type="other"><label>f</label><p>SVM: support vector machine.</p></fn><fn id="T1_FN14" fn-type="other"><label>g</label><p>NR: no report.</p></fn><fn id="T1_FN4" fn-type="other"><label>h</label><p>CV: cross-validation.</p></fn><fn id="T1_FN9" fn-type="other"><label>i</label><p>LDA: linear discriminant analysis.</p></fn><fn id="T1_FN10" fn-type="other"><label>j</label><p>LOOCV: leave-one-out cross-validation.</p></fn><fn id="T1_FN15" fn-type="other"><label>k</label><p>OPLS: orthogonal partial least squares.</p></fn><fn id="T1_FN5" fn-type="other"><label>l</label><p>DBM: deep Boltzmann machine.</p></fn><fn id="T1_FN6" fn-type="other"><label>m</label><p>DFA: discriminant function analysis.</p></fn><fn id="T1_FN3" fn-type="other"><label>n</label><p>CNN: convolutional neural network.</p></fn><fn id="T1_FN12" fn-type="other"><label>o</label><p>MDNN: multiscale deep neural network.</p></fn><fn id="T1_FN19" fn-type="other"><label>p</label><p>SRC: sparse representation&#8211;based classifier.</p></fn><fn id="T1_FN8" fn-type="other"><label>q</label><p>GMM: Gaussian mixture model.</p></fn><fn id="T1_FN16" fn-type="other"><label>r</label><p>QDA: quadratic discriminant analysis.</p></fn><fn id="T1_FN2" fn-type="other"><label>s</label><p>BEGAN: boundary equilibrium generative adversarial network.</p></fn><fn id="T1_FN11" fn-type="other"><label>t</label><p>LP: linear program.</p></fn><fn id="T1_FN17" fn-type="other"><label>u</label><p>RF: random forest.</p></fn><fn id="T1_FN7" fn-type="other"><label>v</label><p>FSBi-LSTM: fully stacked bidirectional long short-term memory.</p></fn><fn id="T1_FN22" fn-type="other"><label>w</label><p>OASIS: Open Access Series of Imaging Studies.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Quality Assessment Results of Included Studies</title><p>Nine (24%) studies were high quality, characterized by adequate sample sizes, rigorous validation (eg, multicenter external validation), and standardized reporting. Moderate-quality studies (n=19, 50%) met basic methodological standards (eg, cross-validation) but had limitations such as single-center data or insufficient clinical correlation analyses. Ten (26%) studies were low quality due to small sample sizes (&lt;100 cases) and inadequate validation strategies, compromising external validity. The results of quality assessments for each study are detailed in Table S4 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>.</p></sec><sec id="s3-4"><title>Data Analysis Results</title><sec id="s3-4-1"><title>Overall Diagnostic Performance</title><p>Analysis of 29 sMRI-related contingency tables demonstrated a pooled sensitivity of 88% (95% CI 86%-89%), a specificity of 92% (95% CI 90%-93%), and an SROC-AUC of 0.94 (95% CI 0.92-0.96). Subgroup analyses stratified by algorithm type revealed that ML (19 tables) achieved a sensitivity of 86% (95% CI 85%-88%), a specificity of 91% (95% CI 88%-93%), and an SROC-AUC of 0.88 (95% CI 0.85-0.90), while DL (10 tables) showed improved performance with a sensitivity of 88% (95% CI 86%-91%), a specificity of 92% (95% CI 90%-94%), and an SROC-AUC of 0.96 (95% CI 0.94-0.97). Stratification by study quality indicated that moderate-to-high-quality studies (24 tables) yielded a sensitivity of 87% (95% CI 85%-89%), a specificity of 91% (95% CI 89%-93%), and an SROC-AUC of 0.94 (95% CI 0.92-0.96), whereas low-quality studies (5 tables) reported elevated metrics with a sensitivity of 91% (95% CI 87%-94%), a specificity of 95% (95% CI 92%-97%), and an SROC-AUC of 0.98 (95% CI 0.96-0.99). Validation strategy&#8211;based analysis showed that internal validation (25 tables) achieved a sensitivity of 88% (95% CI 86%-90%), a specificity of 92% (95% CI 90%-94%), and an SROC-AUC of 0.95 (95% CI 0.92-0.96), while external validation (4 tables) demonstrated marginally lower performance with a sensitivity of 85% (95% CI 81%-89%), a specificity of 91% (95% CI 85%-94%), and an SROC-AUC of 0.93 (95% CI 0.90-0.95).</p><p>For <sup>18</sup>F-FDG PET (27 tables), pooled estimates demonstrated a sensitivity of 90% (95% CI 88%-92%), a specificity of 93% (95% CI 91%-94%), and an SROC-AUC of 0.96 (95% CI 0.94-0.98). Subgroup analyses stratified by algorithm type revealed that ML (15 tables) achieved a sensitivity of 89% (95% CI 86%-90%), a specificity of 91% (95% CI 88%-93%), and an SROC-AUC of 0.94 (95% CI 0.91-0.96), while DL (12 tables) exhibited superior performance with a sensitivity of 91% (95% CI 89%-93%), a specificity of 94% (95% CI 93%-96%), and an SROC-AUC of 0.98 (95% CI 0.96-0.99). Moderate-to-high-quality studies (21 tables) demonstrated a sensitivity of 90% (95% CI 88%-92%), a specificity of 93% (95% CI 91%-94%), and an SROC-AUC of 0.96 (95% CI 0.94-0.98), whereas low-quality studies (6 tables) showed comparable metrics with a sensitivity of 91% (95% CI 86%-94%), a specificity of 93% (95% CI 87%-96%), and an SROC-AUC of 0.96 (95% CI 0.94-0.98). Internal validation (24 tables) yielded a sensitivity of 90% (95% CI 89%-92%), a specificity of 93% (95% CI 91%-94%), and an SROC-AUC of 0.96 (95% CI 0.94%-0.97%), while external validation data (3 tables) were insufficient for SROC-AUC calculation but reported a sensitivity of 87% (95% CI 81%-93%) and a specificity of 95% (95% CI 91%-97%). The data analysis results are shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><title>Summary estimates and meta-regression of pooled performance of all studies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" colspan="2" rowspan="1">Main and subordinate directory<break/></th><th valign="bottom" rowspan="1" colspan="1">Tables, n</th><th valign="bottom" rowspan="1" colspan="1">Sensitivity (%; 95% CI)</th><th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup>
</th><th valign="bottom" rowspan="1" colspan="1">Specificity (%; 95% CI)</th><th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup>
</th><th valign="bottom" rowspan="1" colspan="1">Joint <italic toggle="yes">P</italic> value</th><th valign="bottom" rowspan="1" colspan="1">AUC<xref rid="T2_FN8" ref-type="table-fn"><sup>a</sup></xref> (95% CI)</th></tr></thead><tbody><tr><td colspan="9" valign="top" rowspan="1">sMRI<xref rid="T2_FN4" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td valign="top" colspan="2" rowspan="1">&#8195;Overall</td><td align="left" valign="top" rowspan="1" colspan="1">29</td><td align="left" valign="top" rowspan="1" colspan="1">88 (86-89)</td><td align="left" valign="top" rowspan="1" colspan="1">55.32</td><td align="left" valign="top" rowspan="1" colspan="1">92 (90-93)</td><td align="left" valign="top" rowspan="1" colspan="1">74.08</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;<xref rid="T2_FN6" ref-type="table-fn"><sup>j</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.92-0.96)</td></tr><tr><td colspan="7" valign="top" rowspan="1">&#8195;Study quality</td><td align="left" valign="top" rowspan="1" colspan="1">.02</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Medium-to-high quality</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">87 (85-89)</td><td align="left" valign="top" rowspan="1" colspan="1">57.99</td><td align="left" valign="top" rowspan="1" colspan="1">91 (89-93)</td><td align="left" valign="top" rowspan="1" colspan="1">75.94</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.92-0.96)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Low quality</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">91 (87-94)</td><td align="left" valign="top" rowspan="1" colspan="1">10.2</td><td align="left" valign="top" rowspan="1" colspan="1">95 (92-97)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.96-0.99)</td></tr><tr><td colspan="7" valign="top" rowspan="1">&#8195;Algorithm type</td><td align="left" valign="top" rowspan="1" colspan="1">.40</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;ML<xref rid="T2_FN3" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">86 (85-88)</td><td align="left" valign="top" rowspan="1" colspan="1">21.23</td><td align="left" valign="top" rowspan="1" colspan="1">91 (88-93)</td><td align="left" valign="top" rowspan="1" colspan="1">73.82</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.88 (0.85-0.90)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;DL<xref rid="T2_FN2" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">88 (86-91)</td><td align="left" valign="top" rowspan="1" colspan="1">76.56</td><td align="left" valign="top" rowspan="1" colspan="1">92 (90-94)</td><td align="left" valign="top" rowspan="1" colspan="1">76.53</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.94-0.97)</td></tr><tr><td colspan="7" valign="top" rowspan="1">&#8195;Validation strategy</td><td align="left" valign="top" rowspan="1" colspan="1">.33</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Internal validation</td><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">88 (86-90)</td><td align="left" valign="top" rowspan="1" colspan="1">46.38</td><td align="left" valign="top" rowspan="1" colspan="1">92 (90-94)</td><td align="left" valign="top" rowspan="1" colspan="1">71.65</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.95 (0.92-0.96)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;External validation</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">85 (81-89)</td><td align="left" valign="top" rowspan="1" colspan="1">72.26</td><td align="left" valign="top" rowspan="1" colspan="1">91 (85-94)</td><td align="left" valign="top" rowspan="1" colspan="1">83.65</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.90-0.95)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;SVM<xref rid="T2_FN5" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">87 (85-90)</td><td align="left" valign="top" rowspan="1" colspan="1">17.47</td><td align="left" valign="top" rowspan="1" colspan="1">93 (90-95)</td><td align="left" valign="top" rowspan="1" colspan="1">57.65</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.93 (0.90-0.95)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;CNN<xref rid="T2_FN1" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="left" valign="top" rowspan="1" colspan="1">88 (85-91)</td><td align="left" valign="top" rowspan="1" colspan="1">78.19</td><td align="left" valign="top" rowspan="1" colspan="1">92 (90-94)</td><td align="left" valign="top" rowspan="1" colspan="1">77.55</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.93-0.97)</td></tr><tr><td colspan="9" valign="top" rowspan="1"><sup>18</sup>F-FDG PET<xref rid="T2_FN7" ref-type="table-fn"><sup>k</sup></xref></td></tr><tr><td valign="top" colspan="2" rowspan="1"><break/>&#8195;Overall</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">90 (88-92)</td><td align="left" valign="top" rowspan="1" colspan="1">42.04</td><td align="left" valign="top" rowspan="1" colspan="1">93 (91-94)</td><td align="left" valign="top" rowspan="1" colspan="1">61.49</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.94-0.98)</td></tr><tr><td colspan="7" valign="top" rowspan="1">&#8195;Study quality</td><td align="left" valign="top" rowspan="1" colspan="1">.96</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Medium-to-high quality</td><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="left" valign="top" rowspan="1" colspan="1">90 (88-92)</td><td align="left" valign="top" rowspan="1" colspan="1">44.58</td><td align="left" valign="top" rowspan="1" colspan="1">93 (91-94)</td><td align="left" valign="top" rowspan="1" colspan="1">58.52</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.94-0.98)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Low quality</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">91 (86-94)</td><td align="left" valign="top" rowspan="1" colspan="1">42.73</td><td align="left" valign="top" rowspan="1" colspan="1">93 (87-96)</td><td align="left" valign="top" rowspan="1" colspan="1">72.3</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.94-0.98)</td></tr><tr><td colspan="7" valign="top" rowspan="1">&#8195;Algorithm type</td><td align="left" valign="top" rowspan="1" colspan="1">.01</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;ML</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">89 (86-90)</td><td align="left" valign="top" rowspan="1" colspan="1">1.61</td><td align="left" valign="top" rowspan="1" colspan="1">91 (88-93)</td><td align="left" valign="top" rowspan="1" colspan="1">45.64</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.91-0.96)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;DL</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">91 (89-93)</td><td align="left" valign="top" rowspan="1" colspan="1">55.23</td><td align="left" valign="top" rowspan="1" colspan="1">94 (93-96)</td><td align="left" valign="top" rowspan="1" colspan="1">45.92</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.98 (0.96-0.99)</td></tr><tr><td colspan="6" valign="top" rowspan="1">&#8195;Validation strategy</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.26</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;Internal validation</td><td align="left" valign="top" rowspan="1" colspan="1">24</td><td align="left" valign="top" rowspan="1" colspan="1">90 (89-92)</td><td align="left" valign="top" rowspan="1" colspan="1">34.61</td><td align="left" valign="top" rowspan="1" colspan="1">93 (91-94)</td><td align="left" valign="top" rowspan="1" colspan="1">64.9</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.94-0.97)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;External validation</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">87 (81-93)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">95 (91-99)</td><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;SVM</td><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="left" valign="top" rowspan="1" colspan="1">90 (87-92)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">92 (89-94)</td><td align="left" valign="top" rowspan="1" colspan="1">37.5</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.92-0.96)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;CNN</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">91 (88-94)</td><td align="left" valign="top" rowspan="1" colspan="1">69.76</td><td align="left" valign="top" rowspan="1" colspan="1">93 (92-95)</td><td align="left" valign="top" rowspan="1" colspan="1">34.63</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.97 (0.95-0.98)</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN8" fn-type="other"><label>a</label><p>AUC: area under the receiver operating characteristic curve.</p></fn><fn id="T2_FN4" fn-type="other"><label>b</label><p>sMRI: structural magnetic resonance imaging.</p></fn><fn id="T2_FN6" fn-type="other"><label>c</label><p>Not applicable.</p></fn><fn id="T2_FN3" fn-type="other"><label>d</label><p>ML: machine learning.</p></fn><fn id="T2_FN2" fn-type="other"><label>e</label><p>DL: deep learning.</p></fn><fn id="T2_FN5" fn-type="other"><label>f</label><p>SVM: support vector machine.</p></fn><fn id="T2_FN1" fn-type="other"><label>g</label><p>CNN: convolutional neural network.</p></fn><fn id="T2_FN7" fn-type="other"><label>h</label><p>18F-FDG PET: fluorine-18 fluorodeoxyglucose positron emission tomograph.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4-2"><title>Moderate-to-High-Quality Study Subgroup Analysis</title><p>For sMRI, pooled sensitivity, specificity, and SROC-AUC were 87% (95% CI 85%&#8208;89%), 91% (95% CI 89%&#8208;93%), and 0.94 (95% CI 0.92&#8208;0.96), respectively (see <xref rid="F2" ref-type="fig">Figures2 </xref><xref rid="F3" ref-type="fig"> 3</xref>). Stratification by algorithm type indicated that ML models achieved 86% (95% CI 84%&#8208;88%) sensitivity, 89% (95% CI 86%&#8208;92%) specificity, and an SROC-AUC of 0.89 (95% CI 0.86&#8208;0.92), while DL models demonstrated 88% (95% CI 86%&#8208;91%) sensitivity, 92% (95% CI 90%&#8208;94%) specificity, and an SROC-AUC of 0.96 (95% CI 0.94&#8208;0.97).</p><p>For <sup>18</sup>F-FDG PET, pooled sensitivity, specificity, and SROC-AUC were 90% (95% CI 88%&#8208;92%), 93% (95% CI 91%&#8208;94%), and 0.96 (95% CI 0.94&#8208;0.98), respectively (see <xref rid="F4" ref-type="fig">Figures4 </xref><xref rid="F5" ref-type="fig"> 5</xref>). Subgroup analyses revealed ML models achieved 89% (95% CI 86&#8208;91%) sensitivity, 91% (95% CI 87%&#8208;93%) specificity, and an SROC-AUC of 0.95 (95% CI 0.92&#8208;0.96), whereas DL models outperformed with 91% (95% CI 89%&#8208;93%) sensitivity, 94% (95% CI 93%&#8208;96%) specificity, and SROC-AUC 0.97 (95% CI 0.96&#8208;0.99). The data analysis results are also shown in <xref rid="T3" ref-type="table">Table 3</xref>.</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><title>The pooled sensitivities and specificities based on moderate-to-high-quality studies for structural magnetic resonance imaging [<xref rid="R60" ref-type="bibr">23-27</xref><xref rid="R57" ref-type="bibr">34</xref><xref rid="R55" ref-type="bibr">41</xref><xref rid="R53" ref-type="bibr">43</xref><xref rid="R49" ref-type="bibr">45-49</xref><xref rid="R48" ref-type="bibr">53</xref><xref rid="R47" ref-type="bibr">55</xref><xref rid="R46" ref-type="bibr">57</xref><xref rid="R45" ref-type="bibr">60</xref><xref rid="R43" ref-type="bibr">undefined</xref><xref rid="R41" ref-type="bibr">undefined</xref><xref rid="R34" ref-type="bibr">undefined</xref><xref rid="R27" ref-type="bibr">undefined</xref><xref rid="R26" ref-type="bibr">undefined</xref><xref rid="R25" ref-type="bibr">undefined</xref><xref rid="R24" ref-type="bibr">undefined</xref><xref rid="R23" ref-type="bibr">undefined</xref>].</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aging-v8-e76981-g002.jpg"/></fig><fig position="float" id="F3" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><title>Summary receiver operating characteristic (SROC) based on moderate-to-high-quality studies curves for structural magnetic resonance imaging. AUC: area under the receiver operating characteristic curve area; SENS: sensitivity; SPEC: specificity.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aging-v8-e76981-g003.jpg"/></fig><fig position="float" id="F4" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><title>The pooled sensitivities and specificities based on moderate-to-high-quality studies for fluorine-18 fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) [<xref rid="R50" ref-type="bibr">23</xref><xref rid="R49" ref-type="bibr">24</xref><xref rid="R46" ref-type="bibr">27</xref><xref rid="R45" ref-type="bibr">29</xref><xref rid="R45" ref-type="bibr">31</xref><xref rid="R44" ref-type="bibr">33</xref><xref rid="R43" ref-type="bibr">35</xref><xref rid="R42" ref-type="bibr">38</xref><xref rid="R41" ref-type="bibr">39</xref><xref rid="R39" ref-type="bibr">41-45</xref><xref rid="R38" ref-type="bibr">45</xref><xref rid="R35" ref-type="bibr">46</xref><xref rid="R33" ref-type="bibr">49</xref><xref rid="R31" ref-type="bibr">50</xref><xref rid="R29" ref-type="bibr">undefined</xref><xref rid="R27" ref-type="bibr">undefined</xref><xref rid="R24" ref-type="bibr">undefined</xref><xref rid="R23" ref-type="bibr">undefined</xref>].</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aging-v8-e76981-g004.jpg"/></fig><fig position="float" id="F5" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><title>Summary receiver operating characteristic (SROC) based on moderate-to-high-quality studies curves for fluorine-18 fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET). AUC: area under the receiver operating characteristic curve area; SENS: sensitivity; SPEC: specificity.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="aging-v8-e76981-g005.jpg"/></fig><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><title>Summary estimates and meta-regression of pooled performance of moderate-to-high-quality studies.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" colspan="2" rowspan="1">Main and subordinate directory<break/></th><th valign="bottom" rowspan="1" colspan="1">Tables, n</th><th valign="bottom" rowspan="1" colspan="1">Sensitivity (%; 95% CI)</th><th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup>
</th><th valign="bottom" rowspan="1" colspan="1">Specificity (%; 95% CI)</th><th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup>
</th><th valign="bottom" rowspan="1" colspan="1">Joint <italic toggle="yes">P</italic> value</th><th valign="bottom" rowspan="1" colspan="1">AUC<xref rid="T3_FN5" ref-type="table-fn"><sup>a</sup></xref> (95% CI)</th></tr></thead><tbody><tr><td colspan="7" valign="top" rowspan="1">Overall</td><td valign="top" rowspan="1" colspan="1">.02</td><td valign="top" rowspan="1" colspan="1"/></tr><tr><td valign="top" colspan="2" rowspan="1">&#8195;sMRI<xref rid="T3_FN2" ref-type="table-fn"><sup>b</sup></xref><break/></td><td valign="top" align="char" rowspan="1" colspan="1">24</td><td valign="top" align="char" rowspan="1" colspan="1">87 (85-97)</td><td valign="top" align="char" rowspan="1" colspan="1">57.99</td><td valign="top" align="char" rowspan="1" colspan="1">91 (89-93)</td><td valign="top" align="char" rowspan="1" colspan="1">75.94</td><td valign="top" align="char" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.94 (0.92-0.96)</td></tr><tr><td valign="top" colspan="2" rowspan="1">&#8195;<sup>18</sup>F-FDG PET<xref rid="T3_FN6" ref-type="table-fn"><sup>c</sup></xref><break/></td><td valign="top" align="char" rowspan="1" colspan="1">21</td><td valign="top" align="char" rowspan="1" colspan="1">90 (88-92)</td><td valign="top" align="char" rowspan="1" colspan="1">44.58</td><td valign="top" align="char" rowspan="1" colspan="1">93 (91-94)</td><td valign="top" align="char" rowspan="1" colspan="1">58.52</td><td valign="top" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.96 (0.94-0.98)</td></tr><tr><td colspan="9" valign="top" rowspan="1">&#8195;ML<xref rid="T3_FN3" ref-type="table-fn"><sup>d</sup></xref></td></tr><tr><td valign="top" colspan="2" rowspan="1">&#8195;&#8195;sMRI</td><td valign="top" align="char" rowspan="1" colspan="1">14</td><td valign="top" align="char" rowspan="1" colspan="1">86 (84-88)</td><td valign="top" align="char" rowspan="1" colspan="1">3.72</td><td valign="top" align="char" rowspan="1" colspan="1">89 (86-92)</td><td valign="top" align="char" rowspan="1" colspan="1">75.58</td><td valign="top" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.89 (0.86-0.92)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;<sup>18</sup>F-FDG PET</td><td valign="top" align="char" rowspan="1" colspan="1">10</td><td valign="top" align="char" rowspan="1" colspan="1">89 (86-91)</td><td valign="top" align="char" rowspan="1" colspan="1">16.51</td><td valign="top" align="char" rowspan="1" colspan="1">91 (87-93)</td><td valign="top" align="char" rowspan="1" colspan="1">53.95</td><td valign="top" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.95 (0.92-0.96)</td></tr><tr><td colspan="9" valign="top" rowspan="1">&#8195;DL<xref rid="T3_FN4" ref-type="table-fn"><sup>e</sup></xref></td></tr><tr><td valign="top" colspan="2" rowspan="1">&#8195;&#8195;sMRI</td><td valign="top" align="char" rowspan="1" colspan="1">10</td><td valign="top" align="char" rowspan="1" colspan="1">88 (86-91)</td><td valign="top" align="char" rowspan="1" colspan="1">76.56</td><td valign="top" align="char" rowspan="1" colspan="1">92 (90-94)</td><td valign="top" align="char" rowspan="1" colspan="1">76.53</td><td valign="top" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.96 (0.94-0.97)</td></tr><tr><td colspan="2" valign="top" rowspan="1">&#8195;&#8195;<sup>18</sup>F-FDG PET</td><td valign="top" align="char" rowspan="1" colspan="1">11</td><td valign="top" align="char" rowspan="1" colspan="1">91 (89-93)</td><td valign="top" align="char" rowspan="1" colspan="1">54.59</td><td valign="top" align="char" rowspan="1" colspan="1">94 (93-95)</td><td valign="top" align="char" rowspan="1" colspan="1">36.23</td><td valign="top" rowspan="1" colspan="1"/><td valign="top" align="char" rowspan="1" colspan="1">0.97 (0.96-0.99)</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN5" fn-type="other"><label>a</label><p>AUC: area under the receiver operating characteristic curve.</p></fn><fn id="T3_FN2" fn-type="other"><label>b</label><p>sMRI: structural magnetic resonance imaging.</p></fn><fn id="T3_FN6" fn-type="other"><label>c</label><p>18F-FDG PET: fluorine-18 fluorodeoxyglucose positron emission tomography.</p></fn><fn id="T3_FN3" fn-type="other"><label>d</label><p>ML: machine learning.</p></fn><fn id="T3_FN4" fn-type="other"><label>e</label><p>DL: deep learning.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3-5"><title>Exploration of Statistical Heterogeneity Sources</title><sec id="s3-5-1"><title>Full Study Cohort</title><p>For sMRI contingency tables, sensitivity exhibited moderate heterogeneity (<italic toggle="yes">I</italic>&#178;=55.32%), while specificity showed high heterogeneity (<italic toggle="yes">I</italic>&#178;=74.08%). Threshold effect testing revealed no significant threshold effect (<italic toggle="yes">r</italic>=&#8722;0.101, <italic toggle="yes">P</italic>=.60). Subgroup analyses identified study quality stratification (<italic toggle="yes">P</italic>=.02) as a source of heterogeneity, with moderate-to-high-quality studies demonstrating lower sensitivity (87% vs 91%) and specificity (91% vs 95%) compared to low-quality studies. Algorithm type (<italic toggle="yes">P</italic>=.40) and validation strategy (<italic toggle="yes">P</italic>=.33) were not significant contributors.</p><p>For <sup>18</sup>F-FDG PET analyses, sensitivity and specificity displayed moderate (<italic toggle="yes">I</italic>&#178;=42.04%) and high heterogeneity (<italic toggle="yes">I</italic>&#178;=61.49%), respectively, with no threshold effect (<italic toggle="yes">r</italic>=&#8722;0.087, <italic toggle="yes">P</italic>=.67). Algorithm type (<italic toggle="yes">P</italic>=.01) significantly influenced heterogeneity, as ML models demonstrated lower sensitivity (89% vs 91%) and specificity (91% vs 94%) than DL. Study quality (<italic toggle="yes">P</italic>=.96) and validation strategy (<italic toggle="yes">P</italic>=.26) showed no significant impact. The data analysis results are also shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p></sec><sec id="s3-5-2"><title>Moderate-to-High-Quality Study Subgroups</title><p>For sMRI-based models, ML implementations demonstrated minimal sensitivity heterogeneity (<italic toggle="yes">I</italic>&#178;=3.72%) but high specificity heterogeneity (<italic toggle="yes">I</italic>&#178;=75.58%). Exclusion of studies using traditional ensemble algorithms (random forest, boosting) reduced specificity heterogeneity to moderate (<italic toggle="yes">I</italic>&#178;=45.47%), revealing that ensemble methods achieved higher sensitivity (89% vs 87%) but significantly lower specificity (79% vs 93%) compared to nonensemble ML models (<italic toggle="yes">P</italic>&lt;.001). In contrast, DL-based sMRI models exhibited high heterogeneity for both sensitivity (<italic toggle="yes">I</italic>&#178;=76.56%) and specificity (<italic toggle="yes">I</italic>&#178;=76.53%). Removing external validation data mitigated heterogeneity to moderate (<italic toggle="yes">I</italic>&#178;=54.36%) and low levels (<italic toggle="yes">I</italic>&#178;=38.60%), respectively, with external validation studies showing significantly reduced sensitivity (85% vs 90%) and specificity (91% vs 93%) compared to internal validation (<italic toggle="yes">P</italic>&lt;.001).</p><p>For <sup>18</sup>F-FDG PET-based models, ML implementations showed low sensitivity heterogeneity (<italic toggle="yes">I</italic>&#178;=16.51%) and moderate specificity heterogeneity (<italic toggle="yes">I</italic>&#178;=53.95%). DL models exhibited moderate sensitivity heterogeneity (<italic toggle="yes">I</italic>&#178;=54.59%) and low specificity heterogeneity (<italic toggle="yes">I</italic>&#178;=36.23%). The data analysis results also are shown in <xref rid="T3" ref-type="table">Table 3</xref> and Table S5 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>.</p></sec></sec><sec id="s3-6"><title>Publication Bias Test</title><p>Funnel plot analysis of the full study cohort revealed no significant publication bias for sMRI (<italic toggle="yes">P</italic>=.69), whereas the <sup>18</sup>F-FDG PET subgroup exhibited significant bias (<italic toggle="yes">P</italic>&lt;.001). In the moderate-to-high-quality cohort, both sMRI (<italic toggle="yes">P</italic>=.03) and <sup>18</sup>F-FDG PET (<italic toggle="yes">P</italic>=.01) demonstrated publication bias. However, subgroup analyses showed no significant bias for sMRI+ML (<italic toggle="yes">P</italic>=.06), sMRI+DL (<italic toggle="yes">P</italic>=.89), <sup>18</sup>F-FDG PET+ML (<italic toggle="yes">P</italic>=.08), or <sup>18</sup>F-FDG PET+DL (<italic toggle="yes">P</italic>=.28).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This meta-analysis confirms that AI-enhanced sMRI and <sup>18</sup>F-FDG PET achieve high diagnostic accuracy for AD, with pooled SROC-AUCs of 0.94 and 0.96, respectively, outperforming conventional visual assessments [<xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref>]. <sup>18</sup>F-FDG PET demonstrated superior overall performance (<italic toggle="yes">P</italic>=.02), likely attributable to its sensitivity to AD-specific metabolic abnormalities. Notably, ML amplified PET&#8217;s diagnostic advantage (SROC-AUC: 0.95 vs 0.89), while DL narrowed the gap (SROC-AUC: 0.97 vs 0.96), highlighting DL&#8217;s capacity to extract complex metabolic features and mitigate structural imaging limitations [<xref rid="R63" ref-type="bibr">63</xref>].</p><p>Subgroup analyses identified three key determinants of heterogeneity and performance variation. First, methodological quality significantly influenced sMRI models: moderate-to-high-quality studies reported lower sensitivity (87% vs 91%) and specificity (91% vs 95%) compared to low-quality studies (<italic toggle="yes">P</italic>=.02), suggesting inflated performance in the latter due to small sample sizes, single-center data, or nonstandardized preprocessing. Adherence to TRIPOD-AI guidelines and transparent reporting of preprocessing workflows are critical for future studies [<xref rid="R18" ref-type="bibr">18</xref>]. Second, algorithm type drove technical divergence in PET models: DL outperformed ML (sensitivity: 91% vs 89%; specificity: 94% vs 91%; <italic toggle="yes">P</italic>=.01) through end-to-end feature learning. However, ML&#8217;s interpretability better aligns with clinical demands for transparency, whereas DL&#8217;s reliance on large annotated datasets and computing resources limits its deployment in resource-constrained regions [<xref rid="R64" ref-type="bibr">64</xref>]. Third, validation strategies exposed generalizability limitations: external validation of sMRI+DL models showed reduced sensitivity (85% vs 90%) and specificity (91% vs 93%) compared to internal validation (<italic toggle="yes">P</italic>&lt;.001).</p><p>The reduced diagnostic accuracy observed in externally validated models may stem from (1) data distribution shift&#8212;differences in feature distributions, class balance, and temporal trends between training and external datasets; (2) overfitting&#8212;models may have overfitted to training-specific noise or spurious patterns, limiting generalization; and (3) implementation and annotation inconsistencies&#8212;variations in data preprocessing, feature scaling, and labeling protocols across datasets [<xref rid="R65" ref-type="bibr">65</xref>].</p></sec><sec id="s4-2"><title>Future Directions and Study Limitations</title><p>This study has two methodological constraints: potential selection bias from English-only inclusion and possible overestimation by prioritizing optimal contingency tables. Future research should focus on enhancing evidence robustness through multinational, multiethnic cohorts; improving transparency via open-source preprocessing codes, findable, accessible, interoperable, and reusable-compliant data sharing, and independent validation; and balancing performance and interpretability via explainable DL frameworks to meet clinical ethical standards [<xref rid="R66" ref-type="bibr">66</xref>].</p><p>We also acknowledge the risk of publication bias, as studies with positive results are more likely to be published, particularly in AI-related research where rapid progress and selective reporting may skew the literature. Additionally, language and geographic biases may exist since only English-language articles were included and most studies originated from a limited number of regions (eg, China, the United States, and Europe). This may limit the generalizability of our findings to underrepresented regions.</p><p>Despite <sup>18</sup>F-FDG PET&#8217;s higher accuracy, its radiation exposure and cost hinder widespread screening [<xref rid="R67" ref-type="bibr">67</xref>]. Conversely, sMRI&#8217;s cost-effectiveness and noninvasiveness position it as a first-line screening tool, with PET reserved for confirmatory testing in complex cases&#8212;a tiered diagnostic strategy. The 2023 Responsible AI for Social and Ethical Healthcare consensus implementation priorities, including transparent cost-benefit frameworks cross-modal standardization, and dynamic performance monitoring [<xref rid="R68" ref-type="bibr">68</xref>].</p></sec><sec id="s4-3"><title>Comparison With Existing Reviews</title><p>Although previous reviews have explored the diagnostic accuracy of AI in AD, studies involving meta-analyses remain scarce [<xref rid="R69" ref-type="bibr">69-71</xref>]. Conducting such meta-analyses faces significant challenges, particularly due to substantial methodological heterogeneity across studies. This heterogeneity manifests in multiple dimensions, including variations in neuroimaging modalities, disparities in model validation strategies, and differences in algorithm types&#8212;all of which influence AD diagnostic performance and complicate the synthesis of evidence.</p><p>Borchert et al [<xref rid="R70" ref-type="bibr">70</xref>] conducted a comprehensive systematic review of 255 neuroimaging studies utilizing AI for dementia diagnosis and prognosis. Their findings demonstrated that discriminative models, particularly DL approaches, outperformed algorithmic classifiers in distinguishing AD patients from healthy controls. However, they emphasized critical methodological limitations, with conclusions primarily relying on qualitative synthesis rather than quantitative evidence.</p><p>In a systematic review and meta-analysis by Sun et al [<xref rid="R71" ref-type="bibr">71</xref>], the diagnostic accuracy of DL models based on <sup>18</sup>F-FDG PET for AD was investigated. While the study reported excellent diagnostic performance, notable heterogeneity was observed during meta-analysis, raising concerns about the reliability of the findings. Furthermore, the study focused exclusively on DL, overlooking the widespread application of traditional ML methods in current clinical research for AD diagnostic modeling.</p><p>In contrast, our meta-analysis incorporates a broader range of studies, rigorously controls methodological heterogeneity through stringent quality assessment and detailed subgroup analyses, and systematically evaluates the diagnostic accuracy of both ML and DL in AD. By emphasizing methodological rigor and the importance of external validation in AI-assisted neuroimaging for AD diagnosis, this study addresses critical gaps in the existing literature.</p><p>Although our subgroup comparisons between ML and DL models provide a useful overview of broad methodological trends, it must be noted that algorithm complexity, training data size, and model optimization procedures vary considerably within each group. The observed performance differences may, therefore, reflect not only model class but also differences in dataset size, feature representation, and implementation quality. Future studies should aim to compare individual algorithms under standardized conditions.</p></sec><sec id="s4-4"><title>Conclusions</title><p>In conclusion, AI can effectively support the diagnosis of AD using sMRI and <sup>18</sup>F-FDG PET imaging. Among these approaches, combining PET imaging with DL techniques yields the highest diagnostic accuracy. These findings suggest that a future direction lies in integrating precision neuroimaging with AI tools. To bring such systems into routine clinical use&#8212;helping doctors detect AD earlier, personalize treatment, and improve patient outcomes&#8212;future studies should focus on repeated validation with high-quality clinical datasets and the development of standardized implementation protocols.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supplementary material</title><supplementary-material id="SAP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.2196/76981</object-id><label>Multimedia Appendix 1</label><caption><title>Detailed database search process, characteristics of included studies, quality assessment results, and subgroup analysis findings.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aging-v8-e76981-s001.docx" xlink:title="DOCX File, 59 KB" id="d67e2522" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SCHL1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.2196/76981</object-id><label>Checklist 1</label><caption><title>PRISMA 2020 checklist.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aging-v8-e76981-s002.pdf" xlink:title="PDF File, 101 KB" id="d67e2529" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>This research was funded by the Henan Province Medical Science and Technology Public Relations Plan Joint Construction Project (LHGJ20230402).</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflicts of Interest:</bold> None declared.</p></fn></fn-group><notes><def-list><title>Abbreviations</title><def-item><term><sup>18</sup>FDG-PET</term><def><p>fluorine-18 fluorodeoxyglucose positron emission tomography</p></def></def-item><def-item><term>AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term>AI</term><def><p>artificial intelligence</p></def></def-item><def-item><term>DL</term><def><p>deep learning</p></def></def-item><def-item><term>MeSH</term><def><p>Medical Subject Headings</p></def></def-item><def-item><term>ML</term><def><p>machine learning</p></def></def-item><def-item><term>PICOS</term><def><p>Population, Intervention, Comparison, Outcome, Study Design</p></def></def-item><def-item><term>PRISMA-DTA</term><def><p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy</p></def></def-item><def-item><term>sMRI</term><def><p>structural magnetic resonance imaging</p></def></def-item><def-item><term>SROC-AUC</term><def><p>summary receiver operating characteristic curve area</p></def></def-item><def-item><term>TRIPOD-AI</term><def><p>Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis&#8211;Artificial Intelligence</p></def></def-item></def-list></notes><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><article-title>2023 Alzheimer&#8217;s disease facts and figures</article-title><source>Alzheimers Dement</source><month>Apr</month><year>2023</year><volume>19</volume><issue>4</issue><fpage>1598</fpage><lpage>1695</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>R</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The China Alzheimer Report 2022</article-title><source>Gen Psychiatr</source><year>2022</year><volume>35</volume><issue>1</issue><elocation-id>e100751</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1136/gpsych-2022-100751</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35372787</pub-id><pub-id pub-id-type="pmcid">PMC8919463</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>J</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The cost of Alzheimer&#8217;s disease in China and re-estimation of costs worldwide</article-title><source>Alzheimers Dement</source><month>Apr</month><year>2018</year><volume>14</volume><issue>4</issue><fpage>483</fpage><lpage>491</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.jalz.2017.12.006</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">29433981</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>MMB</given-names></name><etal>et al</etal></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><month>07</month><day>30</day><year>2016</year><volume>388</volume><issue>10043</issue><fpage>505</fpage><lpage>517</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01124-1</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">26921134</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickett</surname><given-names>AC</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>D</given-names></name><name name-style="western"><surname>White</surname><given-names>LA</given-names></name><etal>et al</etal></person-group><article-title>The CareVirtue digital journal for family and friend caregivers of people living with Alzheimer disease and related dementias: exploratory topic modeling and user engagement study</article-title><source>JMIR Aging</source><month>Dec</month><day>24</day><year>2024</year><volume>7</volume><elocation-id>e67992</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.2196/67992</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">39719081</pub-id><pub-id pub-id-type="pmcid">PMC11707446</pub-id></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cahill</surname><given-names>S</given-names></name></person-group><article-title>WHO&#8217;s global action plan on the public health response to dementia: some challenges and opportunities</article-title><source>Aging Ment Health</source><month>Feb</month><year>2020</year><volume>24</volume><issue>2</issue><fpage>197</fpage><lpage>199</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1080/13607863.2018.1544213</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30600688</pub-id></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Recent advancements in the early diagnosis and treatment of Alzheimer&#8217;s disease</article-title><source>Adv Therap</source><month>Nov</month><year>2023</year><volume>6</volume><issue>11</issue><comment>URL</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/toc/23663987/6/11" ext-link-type="uri">https://onlinelibrary.wiley.com/toc/23663987/6/11</ext-link><comment>doi</comment><pub-id pub-id-type="doi">10.1002/adtp.202300181</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">36818419</pub-id><pub-id pub-id-type="pmcid">PMC9937035</pub-id></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>NIA&#8208;AA Research Framework: toward a biological definition of Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><month>Apr</month><year>2018</year><volume>14</volume><issue>4</issue><fpage>535</fpage><lpage>562</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><etal>et al</etal></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer&#8217;s disease: Alzheimer&#8217;s Association Workgroup</article-title><source>Alzheimer&#8217;s &amp; Dementia</source><month>Aug</month><year>2024</year><volume>20</volume><issue>8</issue><fpage>5143</fpage><lpage>5169</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/alz.13859</pub-id></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>By</surname><given-names>S</given-names></name><name name-style="western"><surname>Kahl</surname><given-names>A</given-names></name><name name-style="western"><surname>Cogswell</surname><given-names>PM</given-names></name></person-group><article-title>Alzheimer&#8217;s disease clinical trials: what have we learned from magnetic resonance imaging</article-title><source>J Magn Reson Imaging</source><month>Feb</month><year>2025</year><volume>61</volume><issue>2</issue><fpage>579</fpage><lpage>594</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/jmri.29462</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">39031716</pub-id></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>RYL</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>C</given-names></name><name name-style="western"><surname>Curran</surname><given-names>TA</given-names></name><etal>et al</etal></person-group><article-title>Artificial intelligence in fracture detection: a systematic review and meta-analysis</article-title><source>Radiology</source><month>07</month><year>2022</year><volume>304</volume><issue>1</issue><fpage>50</fpage><lpage>62</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1148/radiol.211785</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35348381</pub-id><pub-id pub-id-type="pmcid">PMC9270679</pub-id></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>L</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson&#8217;s disease: a systematic review and meta-analysis</article-title><source>NPJ Digit Med</source><month>01</month><day>22</day><year>2024</year><volume>7</volume><issue>1</issue><fpage>17</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41746-024-01012-z</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">38253738</pub-id><pub-id pub-id-type="pmcid">PMC10803804</pub-id></element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Malekar</surname><given-names>M</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>High-throughput phenotyping of the symptoms of Alzheimer disease and related dementias using large language models: cross-sectional study</article-title><source>JMIR AI</source><month>Jun</month><day>3</day><year>2025</year><volume>4</volume><elocation-id>e66926</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.2196/66926</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">40460418</pub-id><pub-id pub-id-type="pmcid">PMC12174885</pub-id></element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosco</surname><given-names>C</given-names></name><name name-style="western"><surname>Shojaei</surname><given-names>F</given-names></name><name name-style="western"><surname>Theisz</surname><given-names>AA</given-names></name><etal>et al</etal></person-group><article-title>Testing 3 modalities (voice assistant, chatbot, and mobile app) to assist older African American and Black adults in seeking information on Alzheimer disease and related dementias: wizard of Oz usability study</article-title><source>JMIR Form Res</source><month>Dec</month><day>9</day><year>2024</year><volume>8</volume><elocation-id>e60650</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.2196/60650</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">39653372</pub-id><pub-id pub-id-type="pmcid">PMC11667134</pub-id></element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudroff</surname><given-names>T</given-names></name><name name-style="western"><surname>Rainio</surname><given-names>O</given-names></name><name name-style="western"><surname>Kl&#233;n</surname><given-names>R</given-names></name></person-group><article-title>AI for the prediction of early stages of Alzheimer&#8217;s disease from neuroimaging biomarkers&#8212;a narrative review of a growing field</article-title><source>Neurol Sci</source><month>Nov</month><year>2024</year><volume>45</volume><issue>11</issue><fpage>5117</fpage><lpage>5127</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s10072-024-07649-8</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">38866971</pub-id></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>D</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R</given-names></name></person-group><article-title>Power analysis for random-effects meta-analysis</article-title><source>Res Synth Methods</source><month>Sep</month><year>2017</year><volume>8</volume><issue>3</issue><fpage>290</fpage><lpage>302</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/jrsm.1240</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">28378395</pub-id><pub-id pub-id-type="pmcid">PMC5590730</pub-id></element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McInnes</surname><given-names>MDF</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Thombs</surname><given-names>BD</given-names></name><etal>et al</etal></person-group><article-title>Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement</article-title><source>JAMA</source><month>01</month><day>23</day><year>2018</year><volume>319</volume><issue>4</issue><fpage>388</fpage><lpage>396</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1001/jama.2017.19163</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">29362800</pub-id></element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><article-title>TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods</article-title><source>BMJ</source><month>Apr</month><year>2024</year><elocation-id>q902</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1136/bmj.q902</pub-id><pub-id pub-id-type="pmid">38636956</pub-id><pub-id pub-id-type="pmcid">PMC11025451</pub-id></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Matchar</surname><given-names>DB</given-names></name><name name-style="western"><surname>Bass</surname><given-names>EB</given-names></name></person-group><article-title>Chapter 7: grading a body of evidence on diagnostic tests</article-title><source>J Gen Intern Med</source><month>Jun</month><year>2012</year><volume>27 Suppl 1</volume><issue>Suppl 1</issue><fpage>S47</fpage><lpage>55</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s11606-012-2021-9</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22648675</pub-id><pub-id pub-id-type="pmcid">PMC3364356</pub-id></element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruppar</surname><given-names>T</given-names></name></person-group><article-title>Meta-analysis: how to quantify and explain heterogeneity?</article-title><source>Eur J Cardiovasc Nurs</source><month>Oct</month><year>2020</year><volume>19</volume><issue>7</issue><fpage>646</fpage><lpage>652</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1177/1474515120944014</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32757621</pub-id></element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rutter</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gatsonis</surname><given-names>CA</given-names></name></person-group><article-title>A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations</article-title><source>Stat Med</source><month>Oct</month><day>15</day><year>2001</year><volume>20</volume><issue>19</issue><fpage>2865</fpage><lpage>2884</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/sim.942</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">11568945</pub-id></element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitsma</surname><given-names>JB</given-names></name><name name-style="western"><surname>Glas</surname><given-names>AS</given-names></name><name name-style="western"><surname>Rutjes</surname><given-names>AWS</given-names></name><name name-style="western"><surname>Scholten</surname><given-names>RJPM</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Zwinderman</surname><given-names>AH</given-names></name></person-group><article-title>Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews</article-title><source>J Clin Epidemiol</source><month>Oct</month><year>2005</year><volume>58</volume><issue>10</issue><fpage>982</fpage><lpage>990</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.jclinepi.2005.02.022</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">16168343</pub-id></element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><article-title>Multimodal classification of Alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>Neuroimage</source><month>Apr</month><day>1</day><year>2011</year><volume>55</volume><issue>3</issue><fpage>856</fpage><lpage>867</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.01.008</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">21236349</pub-id><pub-id pub-id-type="pmcid">PMC3057360</pub-id></element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></person-group><article-title>Multimodal discrimination of Alzheimer&#8217;s disease based on regional cortical atrophy and hypometabolism</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>6</issue><elocation-id>e0129250</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1371/journal.pone.0129250</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">26061669</pub-id><pub-id pub-id-type="pmcid">PMC4463854</pub-id></element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westman</surname><given-names>E</given-names></name><name name-style="western"><surname>Muehlboeck</surname><given-names>JS</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>A</given-names></name></person-group><article-title>Combining MRI and CSF measures for classification of Alzheimer&#8217;s disease and prediction of mild cognitive impairment conversion</article-title><source>Neuroimage</source><month>Aug</month><day>1</day><year>2012</year><volume>62</volume><issue>1</issue><fpage>229</fpage><lpage>238</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.04.056</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22580170</pub-id></element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Gunter</surname><given-names>JL</given-names></name><name name-style="western"><surname>Senjem</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Alzheimer&#8217;s disease diagnosis in individual subjects using structural MR images: validation studies</article-title><source>Neuroimage</source><month>Feb</month><day>1</day><year>2008</year><volume>39</volume><issue>3</issue><fpage>1186</fpage><lpage>1197</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.09.073</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">18054253</pub-id><pub-id pub-id-type="pmcid">PMC2390889</pub-id></element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suk</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SW</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><article-title>Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis</article-title><source>Neuroimage</source><month>Nov</month><day>1</day><year>2014</year><volume>101</volume><fpage>569</fpage><lpage>582</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.06.077</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">25042445</pub-id><pub-id pub-id-type="pmcid">PMC4165842</pub-id></element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayeed</surname><given-names>A</given-names></name><name name-style="western"><surname>Petrou</surname><given-names>M</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>N</given-names></name><name name-style="western"><surname>Kadyrov</surname><given-names>A</given-names></name><name name-style="western"><surname>Spinks</surname><given-names>T</given-names></name></person-group><article-title>Diagnostic features of Alzheimer&#8217;s disease extracted from PET sinograms</article-title><source>Phys Med Biol</source><month>01</month><day>7</day><year>2002</year><volume>47</volume><issue>1</issue><fpage>137</fpage><lpage>148</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1088/0031-9155/47/1/310</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">11814222</pub-id></element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>X</given-names></name><name name-style="western"><surname>Adel</surname><given-names>M</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Multiscale spatial gradient features for <sup>18</sup>F-FDG PET image-guided diagnosis of Alzheimer&#8217;s disease</article-title><source>Comput Methods Programs Biomed</source><month>Oct</month><year>2019</year><volume>180</volume><fpage>105027</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.cmpb.2019.105027</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31430595</pub-id></element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padilla</surname><given-names>P</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#243;rriz</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>NMF-SVM based CAD tool applied to functional brain images for the diagnosis of Alzheimer&#8217;s disease</article-title><source>IEEE Trans Med Imaging</source><month>Feb</month><year>2012</year><volume>31</volume><issue>2</issue><fpage>207</fpage><lpage>216</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1109/TMI.2011.2167628</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">21914569</pub-id></element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>YC</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>FP</given-names></name><name name-style="western"><surname>Pai</surname><given-names>MC</given-names></name><etal>et al</etal></person-group><article-title>Detection of Alzheimer&#8217;s disease using ECD SPECT images by transfer learning from FDG PET</article-title><source>Ann Nucl Med</source><month>Aug</month><year>2021</year><volume>35</volume><issue>8</issue><fpage>889</fpage><lpage>899</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s12149-021-01626-3</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34076857</pub-id></element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magnin</surname><given-names>B</given-names></name><name name-style="western"><surname>Mesrob</surname><given-names>L</given-names></name><name name-style="western"><surname>Kinkingn&#233;hun</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Support vector machine-based classification of Alzheimer&#8217;s disease from whole-brain anatomical MRI</article-title><source>Neuroradiology</source><month>Feb</month><year>2009</year><volume>51</volume><issue>2</issue><fpage>73</fpage><lpage>83</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00234-008-0463-x</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">18846369</pub-id></element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Popuri</surname><given-names>K</given-names></name><name name-style="western"><surname>Ding</surname><given-names>GW</given-names></name><name name-style="western"><surname>Balachandar</surname><given-names>R</given-names></name><name name-style="western"><surname>Beg</surname><given-names>MF</given-names></name></person-group><article-title>Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer&#8217;s disease</article-title><source>Med Image Anal</source><month>05</month><year>2018</year><volume>46</volume><fpage>26</fpage><lpage>34</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.media.2018.02.002</pub-id><pub-id pub-id-type="pmid">29502031</pub-id></element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>MH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>DQ</given-names></name><name name-style="western"><surname>Shen</surname><given-names>DG</given-names></name></person-group><article-title>Ensemble sparse classification of Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><month>Apr</month><year>2012</year><volume>60</volume><issue>2</issue><fpage>1106</fpage><lpage>1116</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.055</pub-id><pub-id pub-id-type="pmid">22270352</pub-id><pub-id pub-id-type="pmcid">PMC3303950</pub-id></element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab></person-group><article-title>Classification of Alzheimer&#8217;s disease by combination of convolutional and recurrent neural networks using FDG-PET images</article-title><source>Front Neuroinform</source><year>2018</year><volume>12</volume><fpage>35</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fninf.2018.00035</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">29970996</pub-id><pub-id pub-id-type="pmcid">PMC6018166</pub-id></element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Perneczky</surname><given-names>R</given-names></name><name name-style="western"><surname>Yakushev</surname><given-names>I</given-names></name><etal>et al</etal></person-group><article-title>Gaussian mixture models and model selection for [18F] fluorodeoxyglucose positron emission tomography classification in Alzheimer&#8217;s disease</article-title><source>PLoS ONE</source><month>Apr</month><year>2015</year><volume>10</volume><issue>4</issue><elocation-id>e0122731</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1371/journal.pone.0122731</pub-id><pub-id pub-id-type="pmid">25919662</pub-id><pub-id pub-id-type="pmcid">PMC4412726</pub-id></element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lerch</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pruessner</surname><given-names>J</given-names></name><name name-style="western"><surname>Zijdenbos</surname><given-names>AP</given-names></name><etal>et al</etal></person-group><article-title>Automated cortical thickness measurements from MRI can accurately separate Alzheimer&#8217;s patients from normal elderly controls</article-title><source>Neurobiol Aging</source><month>01</month><year>2008</year><volume>29</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.09.013</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">17097767</pub-id></element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HE</given-names></name><name name-style="western"><surname>Oh</surname><given-names>K</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Yun</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>SK</given-names></name></person-group><article-title>Multi-slice representational learning of convolutional neural network for Alzheimer&#8217;s disease classification using positron emission tomography</article-title><source>Biomed Eng Online</source><month>Sep</month><day>7</day><year>2020</year><volume>19</volume><issue>1</issue><fpage>70</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1186/s12938-020-00813-z</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32894137</pub-id><pub-id pub-id-type="pmcid">PMC7487538</pub-id></element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HE</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>KT</given-names></name><name name-style="western"><surname>Yun</surname><given-names>M</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>SK</given-names></name></person-group><article-title>Slice-selective learning for Alzheimer&#8217;s disease classification using a generative adversarial network: a feasibility study of external validation</article-title><source>Eur J Nucl Med Mol Imaging</source><month>Aug</month><year>2020</year><volume>47</volume><issue>9</issue><fpage>2197</fpage><lpage>2206</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00259-019-04676-y</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31980910</pub-id></element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katako</surname><given-names>A</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>P</given-names></name><name name-style="western"><surname>Goertzen</surname><given-names>AL</given-names></name><etal>et al</etal></person-group><article-title>Machine learning identified an Alzheimer&#8217;s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson&#8217;s disease dementia</article-title><source>Sci Rep</source><month>Sep</month><day>5</day><year>2018</year><volume>8</volume><issue>1</issue><elocation-id>13236</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41598-018-31653-6</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30185806</pub-id><pub-id pub-id-type="pmcid">PMC6125295</pub-id></element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>WN</given-names></name><name name-style="western"><surname>P. P.</surname><given-names>FR</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MAS</given-names></name></person-group><article-title>A meta-heuristic multi-objective optimization method for Alzheimer&#8217;s disease detection based on multi-modal data</article-title><source>Mathematics</source><month>Feb</month><year>2023</year><volume>11</volume><issue>4</issue><fpage>957</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.3390/math11040957</pub-id></element-citation></ref><ref id="R42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ill&#225;n</surname><given-names>IA</given-names></name><name name-style="western"><surname>G&#243;rriz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>18F-FDG PET imaging analysis for computer aided Alzheimer&#8217;s diagnosis</article-title><source>Inf Sci (Ny)</source><month>Feb</month><year>2011</year><volume>181</volume><issue>4</issue><fpage>903</fpage><lpage>916</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.ins.2010.10.027</pub-id></element-citation></ref><ref id="R43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinrichs</surname><given-names>C</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset</article-title><source>Neuroimage</source><month>Oct</month><day>15</day><year>2009</year><volume>48</volume><issue>1</issue><fpage>138</fpage><lpage>149</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.05.056</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">19481161</pub-id><pub-id pub-id-type="pmcid">PMC2773131</pub-id></element-citation></ref><ref id="R44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>KR</given-names></name><name name-style="western"><surname>Wolz</surname><given-names>R</given-names></name><name name-style="western"><surname>Heckemann</surname><given-names>RA</given-names></name><etal>et al</etal></person-group><article-title>Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><month>Mar</month><year>2012</year><volume>60</volume><issue>1</issue><fpage>221</fpage><lpage>229</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.12.071</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22236449</pub-id><pub-id pub-id-type="pmcid">PMC3303084</pub-id></element-citation></ref><ref id="R45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>KR</given-names></name><name name-style="western"><surname>Aljabar</surname><given-names>P</given-names></name><name name-style="western"><surname>Heckemann</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hammers</surname><given-names>A</given-names></name><name name-style="western"><surname>Rueckert</surname><given-names>D</given-names></name></person-group><article-title>Random forest-based similarity measures for multi-modal classification of Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><month>01</month><day>15</day><year>2013</year><volume>65</volume><fpage>167</fpage><lpage>175</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.09.065</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">23041336</pub-id><pub-id pub-id-type="pmcid">PMC3516432</pub-id></element-citation></ref><ref id="R46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>C</given-names></name><name name-style="western"><surname>Elazab</surname><given-names>A</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Deep learning framework for Alzheimer&#8217;s disease diagnosis via 3D-CNN and FSBi-LSTM</article-title><source>IEEE Access</source><year>2019</year><volume>7</volume><fpage>63605</fpage><lpage>63618</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1109/ACCESS.2019.2913847</pub-id></element-citation></ref><ref id="R47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuingnet</surname><given-names>R</given-names></name><name name-style="western"><surname>Gerardin</surname><given-names>E</given-names></name><name name-style="western"><surname>Tessieras</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Automatic classification of patients with Alzheimer&#8217;s disease from structural MRI: a comparison of ten methods using the ADNI database</article-title><source>Neuroimage</source><month>05</month><day>15</day><year>2011</year><volume>56</volume><issue>2</issue><fpage>766</fpage><lpage>781</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.06.013</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">20542124</pub-id></element-citation></ref><ref id="R48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>HZ</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name></person-group><article-title>Alzheimer&#8217;s disease diagnosis with brain structural MRI using multiview-slice attention and 3D convolution neural network</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><elocation-id>871706</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fnagi.2022.871706</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35557839</pub-id><pub-id pub-id-type="pmcid">PMC9088013</pub-id></element-citation></ref><ref id="R49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name><name name-style="western"><surname>Shen</surname><given-names>P</given-names></name></person-group><article-title>An effective multimodal image fusion method using MRI and PET for Alzheimer&#8217;s disease diagnosis</article-title><source>Front Digit Health</source><year>2021</year><volume>3</volume><elocation-id>637386</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fdgth.2021.637386</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34713109</pub-id><pub-id pub-id-type="pmcid">PMC8521941</pub-id></element-citation></ref><ref id="R50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>C</given-names></name></person-group><article-title>Radiomics: a novel feature extraction method for brain neuron degeneration disease using <sup>18</sup>F-FDG PET imaging and its implementation for Alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>Ther Adv Neurol Disord</source><year>2019</year><volume>12</volume><elocation-id>1756286419838682</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1177/1756286419838682</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30956687</pub-id><pub-id pub-id-type="pmcid">PMC6444412</pub-id></element-citation></ref><ref id="R51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>A</surname><given-names>A</given-names></name><name name-style="western"><surname>M</surname><given-names>P</given-names></name><name name-style="western"><surname>Hamdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bourouis</surname><given-names>S</given-names></name><name name-style="western"><surname>Rastislav</surname><given-names>K</given-names></name><name name-style="western"><surname>Mohmed</surname><given-names>F</given-names></name></person-group><article-title>Evaluation of neuro images for the diagnosis of Alzheimer&#8217;s disease using deep learning neural network</article-title><source>Front Public Health</source><year>2022</year><volume>10</volume><elocation-id>834032</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fpubh.2022.834032</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35198526</pub-id><pub-id pub-id-type="pmcid">PMC8860231</pub-id></element-citation></ref><ref id="R52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toussaint</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Perlbarg</surname><given-names>V</given-names></name><name name-style="western"><surname>Bellec</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer&#8217;s disease using conjoint univariate and independent component analyses</article-title><source>Neuroimage</source><month>Nov</month><day>1</day><year>2012</year><volume>63</volume><issue>2</issue><fpage>936</fpage><lpage>946</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.03.091</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22510256</pub-id></element-citation></ref><ref id="R53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wolz</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Multiple instance learning for classification of dementia in brain MRI</article-title><source>Med Image Anal</source><month>07</month><year>2014</year><volume>18</volume><issue>5</issue><fpage>808</fpage><lpage>818</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.media.2014.04.006</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">24858570</pub-id></element-citation></ref><ref id="R54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><article-title>Multi-atlas based representations for Alzheimer&#8217;s disease diagnosis</article-title><source>Hum Brain Mapp</source><month>Oct</month><year>2014</year><volume>35</volume><issue>10</issue><fpage>5052</fpage><lpage>5070</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/hbm.22531</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">24753060</pub-id><pub-id pub-id-type="pmcid">PMC4169318</pub-id></element-citation></ref><ref id="R55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Generalizable, reproducible, and neuroscientifically interpretable imaging biomarkers for Alzheimer&#8217;s disease</article-title><source>Adv Sci (Weinh)</source><month>07</month><year>2020</year><volume>7</volume><issue>14</issue><elocation-id>2000675</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1002/advs.202000675</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32714766</pub-id><pub-id pub-id-type="pmcid">PMC7375255</pub-id></element-citation></ref><ref id="R56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Seong</surname><given-names>JK</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SY</given-names></name></person-group><article-title>Individual subject classification for Alzheimer&#8217;s disease based on incremental learning using a spatial frequency representation of cortical thickness data</article-title><source>Neuroimage</source><month>Feb</month><day>1</day><year>2012</year><volume>59</volume><issue>3</issue><fpage>2217</fpage><lpage>2230</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.09.085</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22008371</pub-id><pub-id pub-id-type="pmcid">PMC5849264</pub-id></element-citation></ref><ref id="R57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chincarini</surname><given-names>A</given-names></name><name name-style="western"><surname>Bosco</surname><given-names>P</given-names></name><name name-style="western"><surname>Calvini</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer&#8217;s disease</article-title><source>Neuroimage</source><month>Sep</month><day>15</day><year>2011</year><volume>58</volume><issue>2</issue><fpage>469</fpage><lpage>480</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.05.083</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">21718788</pub-id></element-citation></ref><ref id="R58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beheshti</surname><given-names>I</given-names></name><name name-style="western"><surname>Demirel</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>H</given-names></name></person-group><article-title>Classification of Alzheimer&#8217;s disease and prediction of mild cognitive impairment-to-Alzheimer&#8217;s conversion from structural magnetic resource imaging using feature ranking and a genetic algorithm</article-title><source>Comput Biol Med</source><month>Apr</month><day>1</day><year>2017</year><volume>83</volume><issue>109-19</issue><fpage>109</fpage><lpage>119</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.compbiomed.2017.02.011</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">28260614</pub-id></element-citation></ref><ref id="R59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anandh</surname><given-names>KR</given-names></name><name name-style="western"><surname>Sujatha</surname><given-names>CM</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>S</given-names></name></person-group><article-title>A method to differentiate mild cognitive impairment and Alzheimer in MR images using eigen value descriptors</article-title><source>J Med Syst</source><month>01</month><year>2016</year><volume>40</volume><issue>1</issue><fpage>26547845</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s10916-015-0396-y</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">26547845</pub-id></element-citation></ref><ref id="R60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amoroso</surname><given-names>N</given-names></name><name name-style="western"><surname>La Rocca</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Multiplex networks for early diagnosis of Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2018</year><volume>10</volume><elocation-id>365</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fnagi.2018.00365</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30487745</pub-id><pub-id pub-id-type="pmcid">PMC6247675</pub-id></element-citation></ref><ref id="R61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamane</surname><given-names>T</given-names></name><name name-style="western"><surname>Ikari</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation</article-title><source>AJNR Am J Neuroradiol</source><month>Feb</month><year>2014</year><volume>35</volume><issue>2</issue><fpage>244</fpage><lpage>249</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.3174/ajnr.A3665</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">23907243</pub-id><pub-id pub-id-type="pmcid">PMC7965770</pub-id></element-citation></ref><ref id="R62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harper</surname><given-names>L</given-names></name><name name-style="western"><surname>Fumagalli</surname><given-names>GG</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases</article-title><source>Brain (Bacau)</source><month>Apr</month><year>2016</year><volume>139</volume><issue>Pt 4</issue><fpage>1211</fpage><lpage>1225</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1093/brain/aww005</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">26936938</pub-id><pub-id pub-id-type="pmcid">PMC4806219</pub-id></element-citation></ref><ref id="R63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loddo</surname><given-names>A</given-names></name><name name-style="western"><surname>Buttau</surname><given-names>S</given-names></name><name name-style="western"><surname>Di Ruberto</surname><given-names>C</given-names></name></person-group><article-title>Deep learning based pipelines for Alzheimer&#8217;s disease diagnosis: a comparative study and a novel deep-ensemble method</article-title><source>Comput Biol Med</source><month>Feb</month><year>2022</year><volume>141</volume><fpage>105032</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.105032</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34838263</pub-id></element-citation></ref><ref id="R64"><label>64.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Pawar</surname><given-names>U</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>D</given-names></name><name name-style="western"><surname>Rea</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Reilly</surname><given-names>R</given-names></name></person-group><article-title>Explainable AI in healthcare</article-title><comment>Presented at</comment><conf-name>2020 International Conference on Cyber Situational Awareness, Data Analytics and Assessment (CyberSA)</conf-name><conf-date>Jun 15-19, 2020</conf-date><conf-loc>Dublin, Ireland</conf-loc><comment>doi</comment><pub-id pub-id-type="doi">10.1109/CyberSA49311.2020.9139655</pub-id></element-citation></ref><ref id="R65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkenbihl</surname><given-names>C</given-names></name><name name-style="western"><surname>Emon</surname><given-names>MA</given-names></name><name name-style="western"><surname>Vrooman</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia - lessons for translation into clinical practice</article-title><source>EPMA J</source><month>Sep</month><year>2020</year><volume>11</volume><issue>3</issue><fpage>367</fpage><lpage>376</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s13167-020-00216-z</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32843907</pub-id><pub-id pub-id-type="pmcid">PMC7429672</pub-id></element-citation></ref><ref id="R66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barredo Arrieta</surname><given-names>A</given-names></name><name name-style="western"><surname>D&#237;az-Rodr&#237;guez</surname><given-names>N</given-names></name><name name-style="western"><surname>Del Ser</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI</article-title><source>Information Fusion</source><month>Jun</month><year>2020</year><volume>58</volume><fpage>82</fpage><lpage>115</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.inffus.2019.12.012</pub-id></element-citation></ref><ref id="R67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayerhoefer</surname><given-names>ME</given-names></name><name name-style="western"><surname>Prosch</surname><given-names>H</given-names></name><name name-style="western"><surname>Beer</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations</article-title><source>Eur J Nucl Med Mol Imaging</source><month>01</month><year>2020</year><volume>47</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00259-019-04452-y</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31410538</pub-id><pub-id pub-id-type="pmcid">PMC6885019</pub-id></element-citation></ref><ref id="R68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>CB</given-names></name><name name-style="western"><surname>Adams</surname><given-names>L</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>To do no harm - and the most good - with AI in health care</article-title><source>Nat Med</source><month>Mar</month><year>2024</year><volume>30</volume><issue>3</issue><fpage>623</fpage><lpage>627</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41591-024-02853-7</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">38388841</pub-id></element-citation></ref><ref id="R69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frizzell</surname><given-names>TO</given-names></name><name name-style="western"><surname>Glashutter</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CC</given-names></name><etal>et al</etal></person-group><article-title>Artificial intelligence in brain MRI analysis of Alzheimer&#8217;s disease over the past 12 years: A systematic review</article-title><source>Ageing Res Rev</source><month>05</month><year>2022</year><volume>77</volume><fpage>101614</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.arr.2022.101614</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35358720</pub-id></element-citation></ref><ref id="R70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borchert</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>T</given-names></name><name name-style="western"><surname>Badhwar</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review</article-title><source>Alzheimers Dement</source><month>Dec</month><year>2023</year><volume>19</volume><issue>12</issue><fpage>5885</fpage><lpage>5904</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/alz.13412</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">37563912</pub-id></element-citation></ref><ref id="R71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic performance of deep learning-assisted [<sup>18</sup>F]FDG PET imaging for Alzheimer&#8217;s disease: a systematic review and meta-analysis</article-title><source>Eur J Nucl Med Mol Imaging</source><month>Aug</month><year>2025</year><volume>52</volume><issue>10</issue><fpage>3600</fpage><lpage>3612</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00259-025-07228-9</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">40159544</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70447" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12492072</article-id><article-id pub-id-type="pmcid-ver">PMC12492072.1</article-id><article-id pub-id-type="pmcaid">12492072</article-id><article-id pub-id-type="pmcaiid">12492072</article-id><article-id pub-id-type="pmid">41041908</article-id><article-id pub-id-type="doi">10.1002/alz.70447</article-id><article-id pub-id-type="publisher-id">ALZ70447</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease risk</article-title><alt-title alt-title-type="left-running-head">VAQU&#201;&#8208;ALC&#193;ZAR <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70447-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Vaqu&#233;&#8208;Alc&#225;zar</surname><given-names initials="L">L&#237;dia</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70447-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>LVaque@santpau.cat</email></address></contrib><contrib id="alz70447-cr-0002" contrib-type="author"><name name-style="western"><surname>Videla</surname><given-names initials="L">Laura</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70447-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70447-cr-0003" contrib-type="author"><name name-style="western"><surname>Benejam</surname><given-names initials="B">Bessy</given-names></name><xref rid="alz70447-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70447-cr-0004" contrib-type="author"><name name-style="western"><surname>Del Hoyo Soriano</surname><given-names initials="L">Laura</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0005" contrib-type="author"><name name-style="western"><surname>Barroeta</surname><given-names initials="I">Isabel</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0006" contrib-type="author"><name name-style="western"><surname>Fernandez</surname><given-names initials="S">Susana</given-names></name><xref rid="alz70447-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70447-cr-0007" contrib-type="author"><name name-style="western"><surname>Rodr&#237;guez&#8208;Baz</surname><given-names initials="&#xCD;">&#205;&#241;igo</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0008" contrib-type="author"><name name-style="western"><surname>Arriola&#8208;Infante</surname><given-names initials="JE">Jos&#233; Enrique</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0009" contrib-type="author"><name name-style="western"><surname>Arranz</surname><given-names initials="J">Javier</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70447-cr-0010" contrib-type="author"><name name-style="western"><surname>Maure Blesa</surname><given-names initials="L">Luc&#237;a</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70447-cr-0011" contrib-type="author"><name name-style="western"><surname>Sanjuan&#8208;Hern&#225;ndez</surname><given-names initials="A">Aida</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0012" contrib-type="author"><name name-style="western"><surname>Morcillo&#8208;Nieto</surname><given-names initials="AO">Alejandra O.</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0013" contrib-type="author"><name name-style="western"><surname>Bejanin</surname><given-names initials="A">Alexandre</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0014" contrib-type="author"><name name-style="western"><surname>Arenaza&#8208;Urquijo</surname><given-names initials="EM">Eider M.</given-names></name><xref rid="alz70447-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="alz70447-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70447-cr-0015" contrib-type="author"><name name-style="western"><surname>Lle&#243;</surname><given-names initials="A">Alberto</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70447-cr-0016" contrib-type="author"><name name-style="western"><surname>Bartr&#233;s&#8208;Faz</surname><given-names initials="D">David</given-names></name><xref rid="alz70447-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70447-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70447-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70447-cr-0017" contrib-type="author"><name name-style="western"><surname>Carmona&#8208;Iragui</surname><given-names initials="M">Maria</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70447-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70447-cr-0018" contrib-type="author"><name name-style="western"><surname>Fortea</surname><given-names initials="J">Juan</given-names></name><xref rid="alz70447-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70447-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70447-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="alz70447-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Sant Pau Memory Unit</named-content>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<named-content content-type="organisation-division">Hospital de la Santa Creu i Sant Pau</named-content>
<named-content content-type="organisation-division">Biomedical Research Institute Sant Pau</named-content>
<institution>Universitat Aut&#242;noma de Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Faculty of Medicine and Health Sciences</named-content>
<named-content content-type="organisation-division">Institute of Neurosciences</named-content>
<institution>University of Barcelona</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Institut d'Investigacions Biom&#232;diques August Pi i Sunyer (IDIBAPS)</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED)</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Barcelona Down Medical Center</named-content>
<institution>Fundaci&#243; Catalana de S&#237;ndrome de Down</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Barcelona Institute for Global Health (ISGlobal)</named-content>
<institution>Environment and Health Over the Lifecourse Program</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Pompeu Fabra University</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="alz70447-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>Guttmann Brain Health Institute, Institut Guttmann, Institut Universitari de Neurorehabilitaci&#243; adscrit a la Universitat Aut&#242;noma de Barcelona</institution>
<city>Badalona</city>
<country country="ES">Spain</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>L&#237;dia Vaqu&#233;&#8208;Alc&#225;zar, Sant Pau Memory Unit &#8208; Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Aut&#242;noma de Barcelona, Institut de Recerca Sant Pau, Sant Quint&#237; 77&#8208;79, 08041, Barcelona, Spain.<break/> Email: <email>LVaque@santpau.cat</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="90">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70447</elocation-id><history><date date-type="rev-recd"><day>27</day><month>5</month><year>2025</year></date><date date-type="received"><day>13</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-04 13:25:42.290"><day>04</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70447.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70447.pdf"/><abstract><title>Abstract</title><sec id="alz70447-sec-0010"><title>INTRODUCTION</title><p>Down syndrome (DS) is the leading cause of intellectual disability (ID) and a genetic form of Alzheimer's disease (AD). We wanted to assess whether generational changes have induced (1) milder ID with greater independence and (2) delayed AD diagnosis.</p></sec><sec id="alz70447-sec-0020"><title>METHODS</title><p>We analyzed 681 asymptomatic DS to test generational effects on ID, functionality, and cognition. In 353 DS individuals with AD, we compared clinical diagnosis age by ID using analysis of variance. In addition, dementia diagnosis age was examined through a published meta&#8208;analysis.</p></sec><sec id="alz70447-sec-0030"><title>RESULTS</title><p>Our results indicate a generational shift toward a higher proportion of individuals with mild/moderate ID, greater intelligence, and autonomy. However, it was not paralleled by an ID&#8208;related delay in the age at AD onset in our cohort, or by generational delays reported over the past 35 years.</p></sec><sec id="alz70447-sec-0040"><title>DISCUSSION</title><p>The findings highlight notable generational improvements in DS, but no effects on the age at AD dementia diagnosis.</p></sec><sec id="alz70447-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70447-list-0001"><list-item><p>A generational effect has reduced the severity of intellectual disability in Down syndrome (DS).</p></list-item><list-item><p>Individuals with DS have increased autonomy and improved intellectual milestones.</p></list-item><list-item><p>The enriched environment has not delayed the age at Alzheimer's disease (AD) dementia in DS.</p></list-item><list-item><p>Further studies should confirm if cognitive reserve might delay AD in DS.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70447-kwd-0001">Alzheimer's disease (AD)</kwd><kwd id="alz70447-kwd-0002">Down syndrome (DS)</kwd><kwd id="alz70447-kwd-0003">functionality</kwd><kwd id="alz70447-kwd-0004">intellectual disability (ID)</kwd><kwd id="alz70447-kwd-0005">intelligence</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Instituto de Salud Carlos III</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source><award-id>CD23/00235</award-id><award-id>CM22/00052</award-id><award-id>CM22/00219</award-id><award-id>CM23/00291</award-id><award-id>CP20/00038</award-id><award-id>CP24/00112</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>European Union</institution><institution-id institution-id-type="doi">10.13039/501100000780</institution-id></institution-wrap></funding-source><award-id>PI18/00335</award-id><award-id>PI22/00785</award-id><award-id>PI22/00307</award-id><award-id>PI14/1561</award-id><award-id>PI20/01330</award-id><award-id>PI20/01473</award-id><award-id>PI23/01786</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Fundaci&#243;n Tatiana P&#233;rez de Guzm&#225;n el Bueno</institution><institution-id institution-id-type="doi">10.13039/501100010805</institution-id></institution-wrap></funding-source><award-id>IIBSP&#8208;DOW&#8208;2020&#8208;151</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Global Brain Health Institute</institution><institution-id institution-id-type="doi">10.13039/100015442</institution-id></institution-wrap></funding-source><award-id>GBHI_ALZ&#8208;18&#8208;543740</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>ICREA Academia</institution></institution-wrap></funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Fondation J&#233;r&#244;me Lejeune</institution><institution-id institution-id-type="doi">10.13039/100007353</institution-id></institution-wrap></funding-source><award-id>2326 &#8208; GRT&#8208;2024A</award-id><award-id>#1913Cycle2019B</award-id></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>BrightFocus Foundation</institution><institution-id institution-id-type="doi">10.13039/100006312</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Horizon 2020 Framework Programme</institution><institution-id institution-id-type="doi">10.13039/100010661</institution-id></institution-wrap></funding-source><award-id>H2020&#8208;SC1&#8208;BHC&#8208;2018&#8208;2020/GA 965422</award-id></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>Alzheimer's Association</institution><institution-id institution-id-type="doi">10.13039/100000957</institution-id></institution-wrap></funding-source><award-id>AARG&#8208;22&#8208;923680</award-id><award-id>AARG&#8208;22&#8208;973966</award-id></award-group><award-group id="funding-0010"><funding-source><institution-wrap><institution>Foundation for the National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000009</institution-id></institution-wrap></funding-source><award-id>1R01AG056850&#8208;01A1</award-id><award-id>3RF1AG056850&#8208;01S1</award-id><award-id>AG056850</award-id><award-id>R21AG056974</award-id><award-id>and R01AG061566</award-id></award-group><award-group id="funding-0011"><funding-source><institution-wrap><institution>Generalitat de Catalunya</institution><institution-id institution-id-type="doi">10.13039/501100002809</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0012"><funding-source><institution-wrap><institution>Life Molecular Imaging (LMI)</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="11"/><word-count count="7185"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:03.10.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70447-cite-0001"><string-name name-style="western"><surname>Vaqu&#233;&#8208;Alc&#225;zar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Videla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Benejam</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Generational effects in Down syndrome: Enriched environment enhances functionality without reducing Alzheimer's disease risk</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70447</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70447</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70447-sec-0060"><label>1</label><title>BACKGROUND</title><p>Down syndrome (DS) affects &#8776;6 million people worldwide.<xref rid="alz70447-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> It is the most common genetic cause of intellectual disability (ID), resulting from an extra copy of chromosome 21.<xref rid="alz70447-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> The full trisomy is present in more than 95% of cases, with this genetic imbalance<xref rid="alz70447-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> being the primary cause of neurodevelopmental alterations. Despite ID being the most prevalent phenotype of DS,<xref rid="alz70447-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> its degree and manifestation vary among individuals with the trisomy. Advancements in health care have significantly increased the life expectancy of individuals with DS, now averaging around 60 years.<xref rid="alz70447-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> As a result, addressing the challenges of aging in this population, particularly Alzheimer's disease (AD), has become increasingly urgent, being the proximate cause of death in 70%&#8211;80% of these individuals.<xref rid="alz70447-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The triplication of chromosome 21, which results in an extra copy of the <italic toggle="yes">amyloid precursor protein</italic> (<italic toggle="yes">APP</italic>) gene,<xref rid="alz70447-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> is both sufficient and necessary to cause AD pathology in DS,<xref rid="alz70447-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> leading individuals with DS to have a&#160;&gt;90% lifetime risk of AD.<xref rid="alz70447-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> The natural history of DS&#8208;associated AD (DSAD) follows a sequence of events (both biomarker alteration and clinical changes) that begins over two decades before the onset of dementia, mirroring the order observed in autosomal dominant AD (ADAD).<xref rid="alz70447-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70447-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70447-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The age at symptom onset is as predictable in DS as in ADAD<xref rid="alz70447-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> and, on average, 20&#8211;30 years younger than in sporadic late&#8208;onset AD (LOAD). However, there remains considerable variability<xref rid="alz70447-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> in the age at onset of dementia diagnosis. Protective or risk factors could partially contribute to this variability but remain largely unexplored in this population.</p><p>The theoretical construct of &#8220;cognitive reserve&#8221; (CR) provides a framework for investigating the gap between pathological changes and clinical manifestations, and the significant heterogeneity increases in cognitive profiles that emerge across the lifespan. CR is defined as a &#8220;resilience&#8221; mechanism that allows a successful adaptation of cognitive resources to compensate for brain damage, resulting in a better&#8208;than&#8208;expected cognitive level given a degree of pathology. Within the broader concept of resilience, &#8220;brain reserve&#8221; captures the neurobiological status of the brain (i.e., its characteristics measured at any given time).<xref rid="alz70447-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Complementing this, &#8220;resistance&#8221; denotes biological or environmental factors that slow or diminish the accumulation of AD pathology (i.e., modulation of amyloid beta or tau accumulation) in the presence of the disease.<xref rid="alz70447-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70447-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70447-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>Thus, both &#8220;resistance&#8221; and &#8220;resilience&#8221; have been associated with high cognitive performance, reduced cognitive decline, and lower dementia risk in later life.<xref rid="alz70447-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70447-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> CR is typically measured through potential proxies, including educational attainment, estimated premorbid intelligence, occupational complexity, and engagement in cognitive&#8208;intellectual activities.<xref rid="alz70447-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> According to the Lancet Commission, extensive epidemiological evidence supports the association between various protective lifetime exposures and a reduced incidence of age&#8208;related dementia.<xref rid="alz70447-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70447-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>There is growing interest in understanding how CR influences brain and cognitive development across the lifespan.<xref rid="alz70447-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Notably, in 2023, a working group was established under the umbrella of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) to advance research on &#8220;resistance&#8221; and &#8220;resilience&#8221; to DSAD, culminating in a consensus publication.<xref rid="alz70447-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> However, the study of protective factors in terms of their impact on a developmental disorder like DS and their effect on AD development in this population remains largely underexplored.<xref rid="alz70447-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> In this context, it is well known that in recent decades, individuals with DS have experienced improvements in access to and quality of stimulating cognitive and social activities, driven by increased employment opportunities<xref rid="alz70447-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and greater investment in community support resources.<xref rid="alz70447-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Moreover, concurrent advances in medical care (i.e., earlier detection and surgical correction of congenital heart defects<xref rid="alz70447-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>) expanded early intervention and parent&#8208;mediated therapies and inclusive education policies.<xref rid="alz70447-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Therefore, we hypothesize that this enriched environment has contributed to generational improvements, resulting in individuals from more recent birth exhibiting lower ID levels and better cognitive profiles. In addition, we propose that ID, as a proxy for CR analogous to premorbid intelligence quotient (IQ), may influence the age at symptom onset of AD in DS. Our primary objectives are to (1) examine whether an enriched environment has led to generational improvements in ID levels and (2) investigate whether ID might influence the clinical onset of AD. We also studied generational changes in the age at AD dementia diagnosis in the literature in the last 35 years.</p></sec><sec id="alz70447-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70447-sec-0080"><label>2.1</label><title>Study design</title><p>This study included a subset of participants from the longitudinal, prospective cohort of adults with DS recruited through the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) in Barcelona, Spain, which began in 2014.<xref rid="alz70447-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The DABNI cohort integrates a population&#8208;based health plan designed for screening neurological complications in the DS population (notably AD). In this cohort, participants are referred for semiannual or annual visits. Inclusion criteria were (1) having DS (including all levels of ID) and (2) age &#8805;18 years.</p><p>To address our first aim&#8212;assessing the generational effect&#8212;we analyzed the initial visits of DS individuals without AD symptoms. For the second objective&#8212;trying to detect an effect on AD clinical manifestation&#8212;we used the first visit with an AD dementia diagnosis for each patient, based on all diagnoses during the 10&#8208;year DABNI study. It is important to note that we excluded all those visits in which participants had an uncertain diagnosis or non&#8211;AD&#8208;related neurocognitive disorder (i.e., a medical, pharmacological, or psychiatric condition interfering with cognition and/or activities of daily living, but no suspicion of AD). Figure <xref rid="alz70447-supinfo-0001" ref-type="">S1</xref> shows the sample flowchart.</p><p>The study was approved by the Sant Pau Research Ethics Committees, following the standards for medical research in humans recommended by the Declaration of Helsinki. All participants or their legally authorized representatives provided written informed consent before enrollment.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70447-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70447-list-0002"><list-item><p>
<bold>Systematic review</bold>: In recent decades, individuals with Down syndrome (DS) have gained access to enhanced cognitive and social opportunities, including increased employment and community support resources, enriching their life experiences. A literature search was conducted using PubMed, and the extent to which these generational improvements reduce the degree of intellectual disability (ID) and increase autonomy in individuals with DS remains unknown.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We corroborated a generational effect in individuals with DS with major changes in the degree of ID, the independence in activities of daily living, and the intelligence quotient but not the penetrance of symptomatic Alzheimer's disease (AD) diagnosis.</p></list-item><list-item><p>
<bold>Future directions</bold>: Longitudinal studies including biomarkers are needed to better understand the putative resilience and resistance mechanisms against AD in DS, assessing the interplay of biological, cognitive, and environmental factors, leading to a significant advancement in primary prevention strategies.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70447-sec-0100"><label>2.2</label><title>Clinical assessment</title><p>The study procedures included medical/neurological and neuropsychological visits. The medical visit consists of a structured anamnesis with the patient and his caregiver, performed by expert neurologists, including The Cambridge Examination for Mental Disorders of Older People with Down Syndrome and Others with Intellectual Disabilities (CAMDEX&#8208;DS) interview,<xref rid="alz70447-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70447-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> a physical examination, and the collection of demographic data, and clinical and neurological history. The data collected from the informant's structured interview, encompassing questions about intellectual milestones achieved and daily life activities, were utilized to assess the intellectual profile and functional level in the present study. In addition, variables such as type of school, occupation, and bilingualism were analyzed as proxies for CR.</p><p>The ID level was categorized as mild, moderate, severe, or profound, based on caregivers&#8217; reports of the individuals&#8217; best&#8208;ever level of functioning&#160;across the&#160;conceptual, social, and practical domains, following criteria outlined in the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</italic> (DSM&#8208;5).<xref rid="alz70447-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> This classification was informed&#160;by&#160;clinician judgment&#160;through&#160;caregiver interview. The score of the Kaufman Brief Intelligence Test (KBIT) Spanish version,<xref rid="alz70447-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> which was evaluated in the first neuropsychological visit, provided additional insight into cognitive functioning, particularly in the&#160;conceptual domain, and served as a proxy for&#160;premorbid cognitive level&#160;in our clinical context (for further details regarding ID level assessment see ref. [<xref rid="alz70447-bib-0028" ref-type="bibr">28</xref>]). In addition, in our analyses, KBIT measures were analyzed through two subscales: vocabulary and matrices. The vocabulary evaluates verbal intelligence and the breadth of word knowledge, assessing language comprehension, lexical knowledge, and verbal expression abilities. In contrast, the matrix reasoning subscale assesses nonverbal problem&#8208;solving and abstract reasoning, evaluating skills such as pattern recognition, logical reasoning, and the ability to understand relationships between shapes and designs without relying on language. Together these subscales provide a balanced overview of an individual's verbal and non&#8208;verbal cognitive strengths.</p><p>The clinical classification along the AD continuum was first performed independently by the neurologist and neuropsychologist followed by a consensus meeting to determine the final diagnosis. Global cognition was assessed, using a Spanish version of the Cambridge Cognitive Examination for Older Adults with Down syndrome (CAMCOG&#8208;DS) Spanish version, which is an adapted cognitive battery.<xref rid="alz70447-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Thus, at each visit, the participants were clinically classified into three groups along the AD continuum: (1) asymptomatic: no clinical or neuropsychological suspicion of symptomatic AD (absence of cognitive impairment beyond the ID or functional decline compared to previous functioning); (2) prodromal AD: suspicion of AD&#8208;related cognitive impairment, but symptoms did not fulfill criteria for dementia (no additional functional impairment); and (3) AD dementia: full&#8208;blown AD dementia (evidence of cognitive impairment that interfered with everyday activities beyond the basal functioning).</p></sec><sec id="alz70447-sec-0110"><label>2.3</label><title>Statistical analyses</title><p>All statistical analyses were performed with R version 4.3.3 (R foundation for statistical computing). To assess the descriptive statistics for the baseline data, we performed analyses of variance (ANOVAs) for numerical variables and chi&#8208;square test (&#967;<sup>2</sup>) for categorical variables. Density plots were created as a visual tool to display frequency differences across birth years in relation to ID level, intellectual milestone acquisition, and the maximum level of autonomous functionality reached. In addition, a stacked bar chart was used to represent the distribution of ID levels by decades of birth. To test the association between decade of birth and ID, &#967;<sup>2</sup> test was conducted. To investigate the relationship between the birth year and subscales of the KBIT raw scores, locally estimated scatterplot smoothing (LOESS) curves&#8212;with a tricubic weight function and a span parameter of 0.75&#8212;and linear models were conducted. ANOVA was conducted to compare the age at AD clinical diagnosis across the four ID levels. Finally, we created a LOESS plot to illustrate the relationship between the mean age at symptom onset of DSAD and the publication year of the studies included in a previous meta&#8208;analysis conducted by our group.<xref rid="alz70447-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> All statistical analyses were performed using two&#8208;sided tests with a level of significance at <italic toggle="yes">p</italic>&#160;&lt;&#160;&#8201;0.05.</p></sec></sec><sec id="alz70447-sec-0120"><label>3</label><title>RESULTS</title><sec id="alz70447-sec-0130"><label>3.1</label><title>Population</title><p>A total of 1002 participants with DS were included in our study (see Tables&#160;<xref rid="alz70447-tbl-0001" ref-type="table">1</xref> and <xref rid="alz70447-supinfo-0001" ref-type="">S1</xref> for further details regarding comorbidities in our sample). For the first aim, a cross&#8208;sectional subset was selected, consisting of the first visit of 681 individuals with DS who showed no clinical symptoms of AD (excluding prodromal AD and AD dementia diagnosis; see Table&#160;<xref rid="alz70447-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="alz70447-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Study participants.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">
<p>Asymptomatic</p>
<p>
<italic toggle="yes">N</italic>&#160;=&#160;681</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Prodromal AD</p>
<p>
<italic toggle="yes">N</italic>&#160;=&#160;105</p>
</th><th align="left" rowspan="1" colspan="1">
<p>AD dementia</p>
<p>
<italic toggle="yes">N</italic>&#160;=&#160;216</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8208;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>AGE</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&lt; 0.001<xref rid="alz70447-tbl1-note-0004" ref-type="table-fn">
<sup>***</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD), years</td><td align="left" rowspan="1" colspan="1">37.5 (10.3)</td><td align="left" rowspan="1" colspan="1">50.9 (5.02)</td><td align="left" rowspan="1" colspan="1">53.5 (5.77)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SEX</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.519</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">307 (45.1%)</td><td align="left" rowspan="1" colspan="1">52 (49.5%)</td><td align="left" rowspan="1" colspan="1">105 (48.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ID</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&lt; 0.001<xref rid="alz70447-tbl1-note-0004" ref-type="table-fn">
<sup>***</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">172 (25.3%)</td><td align="left" rowspan="1" colspan="1">14 (13.3%)</td><td align="left" rowspan="1" colspan="1">15 (6.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">317 (46.5%)</td><td align="left" rowspan="1" colspan="1">61 (58.1%)</td><td align="left" rowspan="1" colspan="1">124 (57.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Severe, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">126 (18.5%)</td><td align="left" rowspan="1" colspan="1">24 (22.9%)</td><td align="left" rowspan="1" colspan="1">65 (30.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Profound, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">66 (9.7%)</td><td align="left" rowspan="1" colspan="1">6 (5.7%)</td><td align="left" rowspan="1" colspan="1">12 (5.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">APOE</italic>
</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" rowspan="1" colspan="1">&#949;4 Carriers, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">76 (10.3%)</td><td align="left" rowspan="1" colspan="1">21 (16.2%)</td><td align="left" rowspan="1" colspan="1">31 (16.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Progressors</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">to prodromal AD, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">95 (14%)</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">to AD dementia, <italic toggle="yes">n</italic> (%)</td><td align="left" rowspan="1" colspan="1">65 (9.5%)</td><td align="left" rowspan="1" colspan="1">72 (68.6%)</td><td align="left" rowspan="1" colspan="1">&#8211;</td><td align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Visits</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&lt; 0.001<xref rid="alz70447-tbl1-note-0004" ref-type="table-fn">
<sup>***</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean (SD)</td><td align="left" rowspan="1" colspan="1">5.10 (3.59)</td><td align="left" rowspan="1" colspan="1">7.01 (4.89)</td><td align="left" rowspan="1" colspan="1">5.14 (4.14)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="alz70447-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Continuous data are mean (SD) and categorical data are <italic toggle="yes">n</italic> (%).</p></fn><fn id="alz70447-tbl1-note-0002"><p>Abbreviations: AD, Alzheimer's disease; <italic toggle="yes">APOE</italic>, apolipoprotein E; ID, intellectual disability; SD, standard deviation.</p></fn><fn id="alz70447-tbl1-note-0003"><p>Statistical differences with asterisks denoting significance thresholds:</p></fn><fn id="alz70447-tbl1-note-0004"><p>
<sup>***</sup>(<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001)</p></fn><fn id="alz70447-tbl1-note-0005"><p>
<sup>**</sup>(<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01)</p></fn><fn id="alz70447-tbl1-note-0006"><p>
<sup>*</sup>(<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05)</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>This sample of DS asymptomatic for AD (see Tables&#160;<xref rid="alz70447-tbl-0001" ref-type="table">1</xref> and <xref rid="alz70447-supinfo-0001" ref-type="">S2</xref>) had a mean age of 37.47&#160;&#177;&#160;10.31 years and an approximately equal distribution of sexes (45.08% female, 54.92% male). The participants were divided into ID groups with the following distribution: 25.25% mild (<italic toggle="yes">N</italic>&#160;=&#160;172), 46.55% moderate (<italic toggle="yes">N</italic>&#160;=&#160;317), 18.50% severe (<italic toggle="yes">N</italic>&#160;=&#160;126), and 9.70% profound (<italic toggle="yes">N</italic>&#160;=&#160;66). Regarding age, there were significant differences across ID levels (<italic toggle="yes">t</italic>&#160;=&#160;45.289, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), with mild ID individuals being younger (mean age: 35.18&#160;&#177;&#160;9.61 years) and the severe ID group being older (mean age: 40.55&#160;&#177;&#160;11.13 years). In addition, the distribution of sex varied (&#967;<sup>2</sup>&#160;=&#160;16.579, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), driven by an imbalance in the profound ID group, where males comprised 74.2%. The proportion of apolipoprotein E (<italic toggle="yes">APOE</italic>) &#949;4 carriers and non&#8208;carriers was equal across groups (<italic toggle="yes">p</italic>&#160;=&#160;0.376).</p><p>The sample for the second aim comprised a subset of 353 DS patients with a clinical diagnosis of AD dementia. This group included the participants diagnosed with AD dementia at their first visit (<italic toggle="yes">N</italic>&#160;=&#160;216), as well as asymptomatic individuals (<italic toggle="yes">N</italic>&#160;=&#160;65) and those with prodromal AD (<italic toggle="yes">N</italic>&#160;=&#160;72) who progressed during follow&#8208;up visits (see Tables&#160;<xref rid="alz70447-tbl-0001" ref-type="table">1</xref> and <xref rid="alz70447-supinfo-0001" ref-type="">S3</xref> and Figure <xref rid="alz70447-supinfo-0001" ref-type="">S1</xref> for further details).</p></sec><sec id="alz70447-sec-0140"><label>3.2</label><title>Generational effect on ID level</title><p>We first performed a smooth density plot showing the distribution of the four degrees of ID along the birth year (from 1952 to 1996), which evidenced an increase in the proportion of individuals with mild or moderate ID and a decrease in those with profound or severe levels of ID (Figure&#160;<xref rid="alz70447-fig-0001" ref-type="fig">1A</xref>). To further explore this finding, we divided the sample by decade of birth (1950s&#8211;2000s) and analyzed the percentage of subjects in each ID level. The results showed a marked generational (decade of birth) effect on the distribution of IDs (&#967;<sup>2</sup>&#160;=&#160;45.041, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001; Figure&#160;<xref rid="alz70447-fig-0001" ref-type="fig">1B</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70447-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Generational effect on ID level and KBIT scores. Upper panel: plots showing the percentage distribution of the four degrees of ID (mild, moderate, severe, and profound) (A) along the birth year (from 1955 to 1995) with a smoothed density plot and (B) by decades of birth (from the 1950s to 1990s) using a stacked bar chart. Lower panel: plots illustrate the association between KBIT (C) vocabulary and (D) matrices scores by birth year across ID levels (mild, moderate, severe). Individual data points are colored by ID groups, whereas a LOESS smoothing curve (black line) highlights the overall trend, with confidence intervals shaded in gray. Subsample of <italic toggle="yes">N</italic>&#160;=&#160;455 asymptomatic DS, split by ID level: mild (<italic toggle="yes">N</italic>&#160;=&#160;147), moderate (<italic toggle="yes">N</italic>&#160;=&#160;239), and severe (<italic toggle="yes">N</italic>&#160;=&#160;69). Raw scores are displayed for KBIT vocabulary and matrices. DS, Down syndrome; ID, intellectual disability; KBIT, Kaufman Brief Intelligence Test; LOESS, locally estimated scatterplot smoothing.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70447-g002.jpg"/></fig><p>Moreover, since KBIT scores were used to categorize asymptomatic individuals across different ID levels, the relationship between this variable and the year of birth in the sample was examined. After excluding participants with outlier values or a floor effect (i.e., those in the profound ID group), a total of 455 participants were included in the regression analysis (see Figure <xref rid="alz70447-supinfo-0001" ref-type="">S1</xref> and Table <xref rid="alz70447-supinfo-0001" ref-type="">S4</xref>). The results revealed a significant positive relationship between the year of birth and both the verbal (KBIT vocabulary: <italic toggle="yes">t</italic>&#160;=&#160;4.513, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001; Figure&#160;<xref rid="alz70447-fig-0001" ref-type="fig">1C</xref>) and non&#8208;verbal (KBIT matrices: <italic toggle="yes">t</italic>&#160;=&#160;7.636, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001; Figure&#160;<xref rid="alz70447-fig-0001" ref-type="fig">1D</xref>) subscales, indicating that later years of birth were associated with higher KBIT scores.</p><p>Of note, the aforementioned generational trend for ID levels reversed in those born after the year 2000, but we did not see this effect in the KBIT measures.</p></sec><sec id="alz70447-sec-0150"><label>3.3</label><title>Generational effect on schooling, occupation, and bilingualism</title><p>Furthermore, a generational shift was observed in the variables commonly used as proxies for CR, which may themselves contribute to the generational effect assessed. Regarding the type of school attended, our data revealed that in later birth cohorts, the previously significant percentage of non&#8208;schooling (nearly 50% in those born in 1950) dropped to zero after 1980, whereas there was a notable increase in the rate of individuals with DS who attended regular classrooms, either partially or fully (Figure&#160;<xref rid="alz70447-fig-0002" ref-type="fig">2A</xref>). Furthermore, we confirmed changes in occupational status across different birth years, observing, as expected, a higher proportion of students among younger cohorts, alongside a notable decrease in unemployment rates across generations (Figure&#160;<xref rid="alz70447-fig-0002" ref-type="fig">2B</xref>). Finally, the number of individuals with DS in our cohort who were bilingual also showed an increase over time (Figure&#160;<xref rid="alz70447-fig-0002" ref-type="fig">2C</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70447-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Generational effect on schooling, occupation, and bilingualism. The density plots show (A) the type of school, (B) the job status (unemployed, adapted, or regular job, and student), and (C) being or not bilingual as a function of the birth year. Data reported by their caregivers. Plots are based on complete&#8208;case data for the specific variables displayed (missing participants &#8776;10%). NE, non&#8208;educated; OS, ordinary school; SE, special education; SE&#8208;OS, special education in ordinary school.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70447-g001.jpg"/></fig></sec><sec id="alz70447-sec-0160"><label>3.4</label><title>A higher proportion of individuals acquired intellectual milestones and developed day&#8208;to&#8208;day function</title><p>Similarly, a greater proportion of individuals achieved intellectual milestones, including calculation, language, literacy, writing, reading, and comprehension (Figure&#160;<xref rid="alz70447-fig-0003" ref-type="fig">3A&#8211;F</xref>). In addition, a higher percentage of individuals developed daily living skills autonomously as a function of their birth year (Figure&#160;<xref rid="alz70447-fig-0003" ref-type="fig">3G&#8211;L</xref>). As with the ID levels, the aforementioned generational trend partially reversed in those born after the year 2000.</p><fig position="float" fig-type="FIGURE" id="alz70447-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Generational effect on intellectual milestone acquisition and day&#8208;to&#8208;day function autonomy. Smooth density plots display in the upper panel (A)&#8211;(F) the distribution of the acquisition, partial acquisition, or not, of intellectual abilities. In the lower panel, (G)&#8211;(L) the plots show if the individuals were capable, partially capable, or not capable of carrying out these tasks autonomously. The darker color represents the percentage of individuals who have never acquired this ability, the medium shade indicates those who have partially acquired it, and the lighter color shows the percentage who have achieved this intellectual milestone or have been able to do a day&#8208;to&#8208;day function autonomously at some point in their lives (at their highest functioning level reported by their caregivers). The categorization for intellectual abilities was based on the Spanish version of CAMDEX&#8208;DS. Plots are based on complete&#8208;case data for the specific variables displayed (missing participants&#160;&lt;5%). Cambridge Examination for Mental Disorders of Older People with Down Syndrome and Others with Intellectual Disabilities.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70447-g004.jpg"/></fig><p>In addition, we conducted two extra analyses. On the one hand, we divided the sample by sex, operating under the hypothesis that the caregivers could potentially exhibit varying degrees of protectiveness or autonomy limitations based on the DS individual's sex. However, we observed that the trend mirrored that of the overall sample (see Figures <xref rid="alz70447-supinfo-0001" ref-type="">S2&#8211;S5</xref>). On the other hand, we explored how individuals&#8217; birth year and ID level together shape the generational effect on the acquisition of intellectual and functional abilities. All groups showed clear positive cohort gains in both intellectual milestones and daily living activities, consistent with what would be expected based on their level of ID (see Figures <xref rid="alz70447-supinfo-0001" ref-type="">S6&#8211;S8</xref>).</p></sec><sec id="alz70447-sec-0170"><label>3.5</label><title>The age of AD clinical onset in DS is not influenced by ID and has remained stable over decades</title><p>The group comparison on the age at AD dementia diagnosis (<italic toggle="yes">N</italic>&#160;=&#160;353; see Table <xref rid="alz70447-supinfo-0001" ref-type="">S3</xref> for subsample characteristics) did not identify significant differences across ID levels (<italic toggle="yes">p</italic>&#160;=&#160;0.851; Figure&#160;<xref rid="alz70447-fig-0004" ref-type="fig">4A</xref>). The same analysis performed for the prodromal AD age at diagnosis by ID level was displayed in the supporting information (Figure <xref rid="alz70447-supinfo-0001" ref-type="">S9</xref>). Additionally, in a supplementary analysis we found that <italic toggle="yes">APOE</italic> status did not influence the age at clinical onset of either prodromal AD or AD dementia when its interaction with ID level was examined (see Figure <xref rid="alz70447-supinfo-0001" ref-type="">S10</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70447-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Age at AD clinical onset in DS by ID and over decades. (A) Boxplot of mean age on clinical diagnosis for AD dementia (<italic toggle="yes">N</italic>&#160;=&#160;353) by ID level: mild (<italic toggle="yes">N</italic>&#160;=&#160;34), moderate (<italic toggle="yes">N</italic>&#160;=&#160;196), severe (<italic toggle="yes">N</italic>&#160;=&#160;100), and profound (<italic toggle="yes">N</italic>&#160;=&#160;23). Jittered points display individual data within each group. The dashed line shows the estimated age at onset for AD dementia (53.8 years). (B) Scatterplot depicting the relationship between the mean age at onset of AD in DS and the publication year of the 44 studies. Point size and color reflect the number of individuals in each study. The LOESS curve (in red) shows the trend over time, with a dashed line at 53.8 years representing the pooled mean age with the confidence interval shaded in grey. See Iulita et&#160;al.<xref rid="alz70447-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> for further details. AD, Alzheimer's disease; ID, intellectual disability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70447-g003.jpg"/></fig><p>Finally, to broaden our analysis beyond data from our cohort, we explored the relationship between the mean age at onset of AD in DS and the year of study publication across 44 articles (<italic toggle="yes">N</italic>&#160;=&#160;2,695 individuals) included in a meta&#8208;analysis by Iulita et&#160;al.<xref rid="alz70447-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The resulting plot reveals a flat association, suggesting an absence of a generational effect when considering published data from the past three decades (Figure&#160;<xref rid="alz70447-fig-0004" ref-type="fig">4B</xref>).</p></sec></sec><sec id="alz70447-sec-0180"><label>4</label><title>DISCUSSION</title><p>The present study provides evidence for a dramatically changing scenario of enhancement in the lives of individuals with DS in the last decades. We observed marked improvements in ID levels and independence in activities of daily living as a function of birth year, but no clear impact on the age at AD dementia diagnosis over the last 35 years.</p><p>The degree of ID associated with DS is inherently unique to each individual. However, our findings highlight a significant generational shift in the distribution of ID severity, showing an increased proportion of individuals being diagnosed with mild or moderate ID and a corresponding decrease in those with profound or severe ID. This is further supported by concurrent increases in KBIT scores and a higher proportion of individuals in later birth years achieving key intellectual milestones and developing daily living skills autonomously. Of interest, this trend peaked among individuals born in 1990 for ID and intellectual profile, but importantly, not for KBIT scores. Our interpretation is that the youngest individuals in our study may not have yet reached their full level of functional independence, which could lead us to underestimate their ID. Furthermore, these results could be biased by the modest sample size in the more recent decades. The decoupling of the aforementioned trends and the KBIT scores (that do not reverse) make less plausible the <italic toggle="yes">&#8220;Reversal Flynn Effect&#8221;</italic>
<xref rid="alz70447-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> observed in the general population. In addition, we cannot rule out the possibility that generations born since the 1990s are highly digitized, with screen time potentially displacing other cognitively and socially enriching activities.</p><p>In addition, the drastic decline in non&#8208;schooling rates and the increase in attendance in regular classrooms for those born after 1980, reflect broader societal changes in inclusion and access to education for individuals with DS. It is worth noting that adapted education programs in Spain are particularly successful, and that although these results are broadly comparable across high&#8208;income countries, significant differences might still exist between nations, even among developed ones. These changes were paralleled by increases in the number of bilingual people. Bilingualism might help to compensate for the development of AD neuropathology, delaying the emergence of clinical symptoms up to 4&#8211;5 years in the general population.<xref rid="alz70447-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Overall, although plasticity mechanisms are limited in individuals with DS, contributing to their characteristic cognitive deficits,<xref rid="alz70447-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="alz70447-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70447-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> our findings suggested that they are benefiting from environmental enrichment. This provides grounds for optimism regarding the effectiveness of interventions aimed at enhancing cognitive function and fostering social and leisure activities. Moreover, it reinforces the necessity of increasing access to education and employment opportunities for adults with DS, as they still do not participate to the same degree as the general population.<xref rid="alz70447-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p><p>Notably, our exploratory analysis of sex differences did not reveal significant deviations from the overall generational trends. The findings showed that the percentage of men with profound ID was higher in the older generations, but the proportion of mild/moderate cases was progressively aligning with that observed in women over the decades. Overall, the observed advantages appeared to apply equally to both sexes, suggesting that the fact that, historically, women have had less access to CR contributors, potentially explaining their increased risk of AD,<xref rid="alz70447-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> is not reflected in the DS population. Our results examining the joint effects of birth year and ID revealed that generational gains were uniform. However, interpreting subgroup effects by ID level requires caution, since lower&#8208;severity individuals inherently attain more education, enter more complex occupations, and exhibit higher baseline functioning. Disentangling true enrichment effects from preexisting cognitive capacity will therefore require alternative reserve markers (e.g., neurobiological measures of resilience) to clarify the causal pathways linking environmental enrichment, ID level, and intellectual&#8208;functional outcomes.</p><p>The findings from our second aim revealed that the age at dementia diagnosis was consistent across ID levels, which contrasts with theoretical expectations suggesting that greater functionality and intellectual abilities (e.g., individuals with mild ID) might delay the clinical manifestation of AD symptoms.<xref rid="alz70447-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> However, aligned with our findings, a recent publication based on a cross&#8208;sectional study involving a large multicenter DS sample found no differences in the average age of individuals with prodromal AD or AD dementia by ID.<xref rid="alz70447-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Nonetheless, a previous study assessing the effect of leisure activities (i.e., CR proxy) in DS<xref rid="alz70447-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> and employment complexity<xref rid="alz70447-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> on dementia symptoms, showed protective effects on AD&#8208;related cognitive decline. It is worth noting that the studies comparing AD progression by premorbid ID level in DS have also shown mixed results,<xref rid="alz70447-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70447-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70447-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70447-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> but predominantly showed no differences by ID levels. In the general population, a strong association between higher intelligence and a reduced risk of AD symptoms has been repeatedly reported (e.g., ref. [<xref rid="alz70447-bib-0041" ref-type="bibr">41</xref>]). Furthermore, higher educational levels and greater occupational complexity&#8212;variables where we have detected a generational effect&#8212;have been linked to increased resilience against AD&#8208;related pathology in LOAD (e.g., ref. [<xref rid="alz70447-bib-0042" ref-type="bibr">42</xref>]). Parallel findings in autosomal dominant AD exist, demonstrating that each additional year of education delays the onset of cognitive decline,<xref rid="alz70447-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> or that greater CR slows the rate of longitudinal deterioration in mutation carriers.<xref rid="alz70447-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> In support of these human observations, APP/PS1 transgenic mouse studies have revealed that environmental enrichment not only reduces cerebral amyloid beta accumulation and boosts neurogenesis but also enhances cognitive performance,<xref rid="alz70447-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> suggesting that enrichment&#8208;driven reserve mechanisms may postpone clinical dementia onset in DSAD. Besides, in our supplementary analysis of <italic toggle="yes">APOE</italic> status, &#949;4 carriers showed no overall effect on age at prodromal or AD dementia onset across ID levels. However, sensitivity analyses restricted to mild and moderate ID individuals indicated an earlier onset in carriers.<xref rid="alz70447-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> This finding underscored the need for cautious interpretation and further investigation in larger, well&#8208;characterized samples, to examine the gene&#8211;environment interaction, and in which it should also be possible to test the demonstrated gene&#8211;dose effect of <italic toggle="yes">APOE</italic> in the euploid population.<xref rid="alz70447-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</p><p>Aligned with our lack of results on the effects of ID level and clinical AD onset, we observed no changes in the age at dementia diagnosis reported in the last 35 years across studies, including more than 2500 individuals from population&#8208;based or convenience cohorts and epidemiological registers or clinical records.</p><p>The present work also has some limitations that lay the groundwork for future research based on the findings obtained. First, although this study utilized a well&#8208;characterized large cohort, the generational effect studied is closely linked to cultural differences and socioeconomic status. Therefore, future research should replicate these findings in other cohorts accounting for the disparities between high&#8208; and low&#8208;income countries, which is particularly important given that around 80% of people with disabilities live in low&#8208; and middle&#8208;income countries.<xref rid="alz70447-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> Furthermore, studies involving ethnically diverse populations are needed, and it is important to highlight that culture&#8208;dependent factors such as parental authority/permissiveness in determining daily life activities that can be done autonomously also contribute to the difficulty of comparing populations. In this regard, population&#8208;based studies are essential to establish consensus across centers for objectively determining ID categorization.<xref rid="alz70447-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Second, because we are investigating a potential generational effect, it is possible that not enough time has passed to observe clear impacts on AD manifestation. This fact might also explain the lack of significant findings in the meta&#8208;analysis. The sample included a relatively small number of individuals with severe ID and even fewer with profound ID levels. In addition, these individuals are particularly challenging to evaluate, and establishing a clinical diagnosis of AD in these highly disabled subgroups poses a significant limitation in accurately determining their clinical onset. In this light, incorporating biomarker information would enhance risk stratification for individuals and allow for the testing of resilience mechanisms using robust methodological approaches aligned with the &#8220;Reserve and Resilience&#8221; framework.<xref rid="alz70447-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In addition, the approach used to evaluate premorbid IQ has limitations, such as floor effects, which could be improved using ID populations as norms, or biases stemming from the weight of the verbal component in final scores. Furthermore, future studies should consider incorporating standardized adaptive behavior scales (i.e., the Vineland Adaptive Behavior Scales or the Adaptive Behavior Assessment System<xref rid="alz70447-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>), and additional measures such as the KBIT Riddles subtest, to capture potential generational effects in other cognitive domains (i.e., executive functioning). Shifting the focus to other CR proxies that can be enhanced along the lifespan (e.g., physical activity<xref rid="alz70447-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70447-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>) or to other social dimensions (e.g., quality care, social support<xref rid="alz70447-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>), may offer a more comprehensive approach to capturing these potential resilience mechanisms. Finally, it may be advantageous to explore the design of multidomain lifestyle interventions to assess the impact of modifiable factors, as the Finnish Institute for Health and Welfare (FINGER) Project<xref rid="alz70447-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> in the general population.</p><p>In conclusion, the significant changes identified in the degree of ID, autonomous functionality, and intellectual profile have important implications for the well&#8208;being and quality of life of individuals with DS and their caregivers. These findings may influence health, education, policy, and intervention strategies. Further studies are needed to better characterize the effects of sociodemographic and environmental factors (e.g., lifestyles) and to assess the potential influence of modifiable risk and protective factors in adults with DS to delay symptomatic AD. Such research will be crucial in improving the prediction and understanding of variability in responses to interventions.</p></sec><sec sec-type="COI-statement" id="alz70447-sec-0200"><title>CONFLICT OF INTEREST STATEMENT</title><p>A.L. has served as a consultant or on advisory boards for Fujirebio&#8208;Europe, Roche, Biogen, Grifols, Novartis, Eisai, Lilly, and Nutricia, outside the submitted work. J.F. reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zamb&#243;n, Spanish Neurological Society, T21 Research Society, Lumind foundation, J&#233;r&#244;me&#8208;Lejeune Foundation, Alzheimer's Association, National Institutes of Health (USA), and Instituto de Salud Carlos III. M.C.I. reports receiving personal fees for service on the advisory boards and speaker honoraria or educational activities from Esteve, Lilly, Neuraxpharm, Adium, and Roche diagnostics. J.A. reported receiving personal fees for service on speaker honoraria or educational activities from Lilly, Esteve, Fujirebio&#8208;Europe, and Roche diagnostics. A.L. and J.F. report holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). No other competing interests were reported. Author disclosures are available in the <xref rid="alz70447-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70447-sec-0210"><title>CONSENT STATEMENT</title><p>All participants and/or their legally authorized representatives provided written informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70447-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70447-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70447-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70447-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70447-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70447-sec-0190"><title>ACKNOWLEDGMENTS</title><p>The authors thank all the participants with Down syndrome and their families and/or caregivers for their support and dedication to this research. They also acknowledge Fundaci&#243; Catalana S&#237;ndrome de Down (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://fcsd.org/" ext-link-type="uri">https://fcsd.org/</ext-link>) for global support and the members of the Alzheimer Down Unit and the Memory Unit from Hospital de la Santa Creu i Sant Pau for their daily work and dedication; and Cecilia Mota and Cristina Pastor and for administrative support. This study was funded by the Fondo de Investigaciones Sanitario, Instituto de Salud Carlos III and co&#8208;funded by the European Union (PI18/00335 and PI22/00785 to M.C.I., PI22/00307 to A.B., PI14/1561, PI20/01330 to A.L., PI20/01473 and PI23/01786 to J.F.), the CIBERNED Program 1, the National Institutes of Health (NIH; 1R01AG056850&#8208;01A1; 3RF1AG056850&#8208;01S1; AG056850, R21AG056974, and R01AG061566 to J.F.), the Departament de Salut de la Generalitat de Catalunya, Fundaci&#243;n Tatiana P&#233;rez de Guzm&#225;n el Bueno (IIBSP&#8208;DOW&#8208;2020&#8208;151 to J.F.), the European Union's Horizon 2020, &#8220;MES&#8208;CoBraD&#8221; (H2020&#8208;SC1&#8208;BHC&#8208;2018&#8208;2020 / GA 965422 to J.F.), Brightfocus, and Life Molecular Imaging (LMI) to J.F. L.V.A. was supported by Instituto de Salud Carlos III through the Sara Borrell Postdoctoral Fellowship &#8220;CD23/00235.&#8221; M.C.I. acknowledges support from the Alzheimer's Association (AARG&#8208;22&#8208;973966) and Global Brain Health Institute (GBHI_ALZ&#8208;18&#8208;543740), the J&#233;r&#244;me Lejeune Foundation (#1913 Cycle 2019B), and the Societat Catalana de Neurologia (Premi Beca Fundaci&#243; SCN 2020). I.R.B. was supported by Instituto de Salud Carlos III through the R&#237;o Hortega Fellowship &#8220;CM22/00052&#8221; and co&#8208;funded by the European Union. J.E.A.I. was supported by Instituto de Salud Carlos III through the R&#237;o Hortega Fellowship &#8220;CM22/00219&#8221; and co&#8208;funded by the European Union. L.M.B. was supported by Instituto de Salud Carlos III through the R&#237;o Hortega Fellowship &#8220;CM23/00291&#8221; and co&#8208;funded by the European Union. A.B. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant &#8220;CP20/00038&#8221; and co&#8208;funded by the European Union and the Alzheimer's Association &#8220;AARG&#8208;22&#8208;923680&#8221;. L.D.H.S. acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant &#8220;CP24/00112&#8221; and co&#8208;funded by the European Union and the J&#233;r&#244;me Lejeune Foundation (2326 &#8208; GRT&#8208;2024A).&#160;D.B.F. was supported by funds of the ICREA Academia program (2019 and 2024). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit for publication.</p></ack><ref-list id="alz70447-bibl-0001"><title>REFERENCES</title><ref id="alz70447-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70447-cite-0002"><string-name name-style="western"><surname>Ballard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mobley</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>A</given-names></string-name>. <article-title>Dementia in Down's syndrome</article-title>. <source>Lancet Neurol</source>. <year>2016</year>;<volume>15</volume>:<fpage>622</fpage>&#8208;<lpage>636</lpage>.<pub-id pub-id-type="pmid">27302127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(16)00063-6</pub-id></mixed-citation></ref><ref id="alz70447-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70447-cite-0003"><string-name name-style="western"><surname>Bull</surname><given-names>MJ</given-names></string-name>. <article-title>Down syndrome</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>2344</fpage>&#8208;<lpage>2352</lpage>.<pub-id pub-id-type="pmid">32521135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1706537</pub-id></mixed-citation></ref><ref id="alz70447-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70447-cite-0004"><string-name name-style="western"><surname>Antonarakis</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Skotko</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Rafii</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>Down syndrome</article-title>. <source>Nat Rev Dis Primers</source>. <year>2020</year>;<volume>6</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">32029743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-019-0143-7</pub-id><pub-id pub-id-type="pmcid">PMC8428796</pub-id></mixed-citation></ref><ref id="alz70447-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70447-cite-0005"><string-name name-style="western"><surname>Lott</surname><given-names>IT</given-names></string-name>, <string-name name-style="western"><surname>Dierssen</surname><given-names>M</given-names></string-name>. <article-title>Cognitive deficits and associated neurological complications in individuals with Down's syndrome</article-title>. <source>Lancet Neurol</source>. <year>2010</year>;<volume>9</volume>:<fpage>623</fpage>&#8208;<lpage>633</lpage>.<pub-id pub-id-type="pmid">20494326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(10)70112-5</pub-id></mixed-citation></ref><ref id="alz70447-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70447-cite-0006"><string-name name-style="western"><surname>Mccarron</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mccallion</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mulryan</surname><given-names>N</given-names></string-name>. <article-title>A prospective 14&#8208;year longitudinal follow&#8208;up of dementia in persons with Down syndrome</article-title>. <source>J Intellect Disabil Res</source>. <year>2014</year>;<volume>58</volume>:<fpage>61</fpage>&#8208;<lpage>70</lpage>.<pub-id pub-id-type="pmid">23902161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jir.12074</pub-id></mixed-citation></ref><ref id="alz70447-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70447-cite-0007"><string-name name-style="western"><surname>Iulita</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Garz&#243;n Chavez</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Klitgaard Christensen</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Association of Alzheimer disease with life expectancy in people with Down syndrome</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>5</issue>):<elocation-id>e2212910</elocation-id>.<pub-id pub-id-type="pmid">35604690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.12910</pub-id><pub-id pub-id-type="pmcid">PMC9127560</pub-id></mixed-citation></ref><ref id="alz70447-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70447-cite-0008"><string-name name-style="western"><surname>Fortea</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zaman</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Hartley</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Rafii</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Head</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Carmona&#8208;Iragui</surname><given-names>M</given-names></string-name>. <article-title>Alzheimer's disease associated with Down syndrome: a genetic form of dementia</article-title>. <source>Lancet Neurol</source>. <year>2021</year>;<volume>20</volume>:<fpage>930</fpage>&#8208;<lpage>942</lpage>.<pub-id pub-id-type="pmid">34687637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00245-3</pub-id><pub-id pub-id-type="pmcid">PMC9387748</pub-id></mixed-citation></ref><ref id="alz70447-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70447-cite-0009"><string-name name-style="western"><surname>McCarron</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McCallion</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Reilly</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Dunne</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Carroll</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mulryan</surname><given-names>N</given-names></string-name>. <article-title>A prospective 20&#8208;year longitudinal follow&#8208;up of dementia in persons with Down syndrome</article-title>. <source>J Intellect Disabil Res</source>. <year>2017</year>;<volume>61</volume>:<fpage>843</fpage>&#8208;<lpage>852</lpage>.<pub-id pub-id-type="pmid">28664561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jir.12390</pub-id></mixed-citation></ref><ref id="alz70447-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70447-cite-0010"><string-name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Benzinger</surname><given-names>TLS</given-names></string-name>, et&#160;al. <article-title>Clinical and biomarker changes in dominantly inherited Alzheimer's disease</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>795</fpage>&#8208;<lpage>804</lpage>.<pub-id pub-id-type="pmid">22784036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1202753</pub-id><pub-id pub-id-type="pmcid">PMC3474597</pub-id></mixed-citation></ref><ref id="alz70447-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70447-cite-0011"><string-name name-style="western"><surname>Fortea</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vilaplana</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Carmona&#8208;Iragui</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross&#8208;sectional study</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1988</fpage>&#8208;<lpage>1997</lpage>.<pub-id pub-id-type="pmid">32593336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30689-9</pub-id><pub-id pub-id-type="pmcid">PMC7322523</pub-id></mixed-citation></ref><ref id="alz70447-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70447-cite-0012"><string-name name-style="western"><surname>Davidson</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Prasher</surname><given-names>VP</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>DMA</given-names></string-name>. <article-title>The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome</article-title>. <source>Acta Neuropathol Commun</source>. <year>2018</year>;<volume>6</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">29973279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0559-4</pub-id><pub-id pub-id-type="pmcid">PMC6030772</pub-id></mixed-citation></ref><ref id="alz70447-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70447-cite-0013"><string-name name-style="western"><surname>Arenaza&#8208;Urquijo</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></string-name>. <article-title>Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies</article-title>. <source>Neurology</source>. <year>2018</year>;<volume>90</volume>:<fpage>695</fpage>&#8208;<lpage>703</lpage>.<pub-id pub-id-type="pmid">29592885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000005303</pub-id><pub-id pub-id-type="pmcid">PMC5894932</pub-id></mixed-citation></ref><ref id="alz70447-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70447-cite-0014"><string-name name-style="western"><surname>Stern</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Cabeza</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pascual&#8208;Leone</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rapp</surname><given-names>PR</given-names></string-name>. <article-title>A framework for concepts of reserve and resilience in aging</article-title>. <source>Neurobiol Aging</source>. <year>2023</year>;<volume>124</volume>:<fpage>100</fpage>&#8208;<lpage>103</lpage>.<pub-id pub-id-type="pmid">36653245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2022.10.015</pub-id><pub-id pub-id-type="pmcid">PMC10424718</pub-id></mixed-citation></ref><ref id="alz70447-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70447-cite-0015"><string-name name-style="western"><surname>Stern</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Arenaza&#8208;Urquijo</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Bartr&#233;s&#8208;Faz</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>16</volume>:<fpage>1305</fpage>&#8208;<lpage>1311</lpage>.<pub-id pub-id-type="pmid">30222945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.07.219</pub-id><pub-id pub-id-type="pmcid">PMC6417987</pub-id></mixed-citation></ref><ref id="alz70447-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70447-cite-0016"><string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sommerlad</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Orgeta</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Dementia prevention, intervention, and care</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>:<fpage>2673</fpage>&#8208;<lpage>2734</lpage>.<pub-id pub-id-type="pmid">28735855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)31363-6</pub-id></mixed-citation></ref><ref id="alz70447-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70447-cite-0017"><string-name name-style="western"><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission</article-title>. <source>Lancet</source>. <year>2024</year>;<volume>404</volume>:<fpage>572</fpage>&#8208;<lpage>628</lpage>.<pub-id pub-id-type="pmid">39096926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)01296-0</pub-id></mixed-citation></ref><ref id="alz70447-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70447-cite-0018"><string-name name-style="western"><surname>Kremen</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Beck</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Elman</surname><given-names>JA</given-names></string-name>, et&#160;al. <article-title>Influence of young adult cognitive ability and additional education on later&#8208;life cognition</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2019</year>;<volume>116</volume>:<fpage>2021</fpage>&#8208;<lpage>2026</lpage>.<pub-id pub-id-type="pmid">30670647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1811537116</pub-id><pub-id pub-id-type="pmcid">PMC6369818</pub-id></mixed-citation></ref><ref id="alz70447-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70447-cite-0019"><string-name name-style="western"><surname>Boyle</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Koops</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Ances</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Resistance and resilience to Alzheimer's disease in Down syndrome</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>4</issue>):<elocation-id>e70151</elocation-id>.<pub-id pub-id-type="pmid">40289889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70151</pub-id><pub-id pub-id-type="pmcid">PMC12035553</pub-id></mixed-citation></ref><ref id="alz70447-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70447-cite-0020"><string-name name-style="western"><surname>Fortea</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vaqu&#233;&#8208;Alc&#225;zar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pegueroles</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Reply to: challenges to identifying risk versus protective factors in Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>(<issue>11</issue>):<fpage>3096</fpage>&#8208;<lpage>3097</lpage>.<pub-id pub-id-type="pmid">39025967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03159-4</pub-id></mixed-citation></ref><ref id="alz70447-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70447-cite-0021"><string-name name-style="western"><surname>Kumin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schoenbrodt</surname><given-names>L</given-names></string-name>. <article-title>Employment in adults with Down syndrome in the United States: results from a National Survey</article-title>. <source>J Appl Res Intellect Disabil</source>. <year>2016</year>;<volume>29</volume>:<fpage>330</fpage>&#8208;<lpage>345</lpage>.<pub-id pub-id-type="pmid">25847188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jar.12182</pub-id></mixed-citation></ref><ref id="alz70447-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70447-cite-0022"><string-name name-style="western"><surname>Rasmussen</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Whitehead</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Collier</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Fr&#237;as</surname><given-names>JL</given-names></string-name>. <article-title>Setting a public health research agenda for Down syndrome: summary of a meeting sponsored by the Centers for Disease Control and Prevention and the National Down Syndrome Society</article-title>. <source>Am J Med Genet A</source>. <year>2008</year>;<volume>146A</volume>:<fpage>2998</fpage>&#8208;<lpage>3010</lpage>.<pub-id pub-id-type="pmid">19006076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajmg.a.32581</pub-id></mixed-citation></ref><ref id="alz70447-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70447-cite-0023"><string-name name-style="western"><surname>O'Toole</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Gibbon</surname><given-names>FE</given-names></string-name>, <string-name name-style="western"><surname>van Bysterveldt</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>NJ</given-names></string-name>. <article-title>Parent&#8208;mediated interventions for promoting communication and language development in young children with Down syndrome</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2018</year>;<volume>10</volume>(<issue>10</issue>):<elocation-id>CD012089</elocation-id>.<pub-id pub-id-type="pmid">30321454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD012089.pub2</pub-id><pub-id pub-id-type="pmcid">PMC6516877</pub-id></mixed-citation></ref><ref id="alz70447-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70447-cite-0024"><string-name name-style="western"><surname>Bunt</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Bunt</surname><given-names>SK</given-names></string-name>. <article-title>Care of infants and children with Down syndrome: role of the family physician</article-title>. <source>Am Fam Physician</source>. <year>2025</year>;<volume>111</volume>(<issue>3</issue>):<fpage>236</fpage>&#8208;<lpage>244</lpage>.<pub-id pub-id-type="pmid">40106290</pub-id></mixed-citation></ref><ref id="alz70447-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70447-cite-0025"><string-name name-style="western"><surname>Esteba&#8208;Castillo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dalmau&#8208;Bueno</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ribas&#8208;Vidal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vil&#224;&#8208;Alsina</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Novell&#8208;Alsina</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a&#8208;Alba</surname><given-names>J</given-names></string-name>. <article-title>[Adaptation and validation of CAMDEX&#8208;DS (Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and others with intellectual disabilities) in Spanish population with intellectual disabilities]</article-title>. <source>Rev Neurol</source>. <year>2013</year>;<volume>57</volume>(<issue>8</issue>):<fpage>337</fpage>&#8208;<lpage>346</lpage>.<pub-id pub-id-type="pmid">24081888</pub-id></mixed-citation></ref><ref id="alz70447-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70447-cite-0026"><string-name name-style="western"><surname>Videla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Benejam</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Pegueroles</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Longitudinal clinical and cognitive changes along the Alzheimer disease continuum in Down syndrome</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>:<elocation-id>E2225573</elocation-id>.<pub-id pub-id-type="pmid">35930282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2022.25573</pub-id><pub-id pub-id-type="pmcid">PMC9356319</pub-id></mixed-citation></ref><ref id="alz70447-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70447-cite-0027"><string-name name-style="western"><surname>Regier</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Kuhl</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></string-name>. <article-title>The DSM&#8208;5: classification and criteria changes</article-title>. <source>World Psychiatry</source>. <year>2013</year>;<volume>12</volume>:<fpage>92</fpage>&#8208;<lpage>98</lpage>.<pub-id pub-id-type="pmid">23737408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wps.20050</pub-id><pub-id pub-id-type="pmcid">PMC3683251</pub-id></mixed-citation></ref><ref id="alz70447-bib-0027"><label>27</label><mixed-citation publication-type="book" id="alz70447-cite-0028"><string-name name-style="western"><surname>Kaufman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaufman</surname><given-names>N</given-names></string-name>. <source>KBIT2: Kaufmann Brief Intelligence Test</source>. <edition>3rd ed</edition>. <publisher-name>Pearson/PsychCorp</publisher-name>; <year>2004</year>.</mixed-citation></ref><ref id="alz70447-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70447-cite-0029"><string-name name-style="western"><surname>Soriano</surname><given-names>LDH</given-names></string-name>, <string-name name-style="western"><surname>Sandk&#252;hler</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Videla</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Discrepancies in assessing intellectual disability levels in adults with Down syndrome: implications for Dementia diagnosis</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>6</issue>):<elocation-id>e70307</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.70307</pub-id>. ACCEPTED.<pub-id pub-id-type="pmid">40528393</pub-id><pub-id pub-id-type="pmcid">PMC12173952</pub-id></mixed-citation></ref><ref id="alz70447-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70447-cite-0030"><string-name name-style="western"><surname>Benejam</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Videla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Vilaplana</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests</article-title>. <source>Alzheimers Dement</source>. <year>2020</year>;<volume>12</volume>:<elocation-id>e12047</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12047</pub-id><pub-id pub-id-type="pmcid">PMC7322242</pub-id><pub-id pub-id-type="pmid">32613076</pub-id></mixed-citation></ref><ref id="alz70447-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70447-cite-0031"><string-name name-style="western"><surname>Bratsberg</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rogeberg</surname><given-names>O</given-names></string-name>. <article-title>Flynn effect and its reversal are both environmentally caused</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2018</year>;<volume>115</volume>:<fpage>6674</fpage>&#8208;<lpage>6678</lpage>.<pub-id pub-id-type="pmid">29891660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1718793115</pub-id><pub-id pub-id-type="pmcid">PMC6042097</pub-id></mixed-citation></ref><ref id="alz70447-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70447-cite-0032"><string-name name-style="western"><surname>Mendez</surname><given-names>MF</given-names></string-name>. <article-title>Can speaking more than one language help prevent Alzheimer's disease?</article-title>. <source>J Alzheimers Dis</source>. <year>2023</year>;<volume>95</volume>:<fpage>363</fpage>&#8208;<lpage>377</lpage>.<pub-id pub-id-type="pmid">37545240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230285</pub-id></mixed-citation></ref><ref id="alz70447-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70447-cite-0033"><string-name name-style="western"><surname>Contestabile</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Benfenati</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gasparini</surname><given-names>L</given-names></string-name>. <article-title>Communication breaks&#8208;Down: from neurodevelopment defects to cognitive disabilities in Down syndrome</article-title>. <source>Prog Neurobiol</source>. <year>2010</year>;<volume>91</volume>:<fpage>1</fpage>&#8208;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20097253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2010.01.003</pub-id></mixed-citation></ref><ref id="alz70447-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70447-cite-0034"><string-name name-style="western"><surname>Guidi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ciani</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bonasoni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Santini</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bartesaghi</surname><given-names>R</given-names></string-name>. <article-title>Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome</article-title>. <source>Brain Pathol</source>. <year>2011</year>;<volume>21</volume>:<fpage>361</fpage>&#8208;<lpage>373</lpage>.<pub-id pub-id-type="pmid">21040072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1750-3639.2010.00459.x</pub-id><pub-id pub-id-type="pmcid">PMC8094247</pub-id></mixed-citation></ref><ref id="alz70447-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70447-cite-0035"><string-name name-style="western"><surname>Guidi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bonasoni</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ceccarelli</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome</article-title>. <source>Brain Pathol</source>. <year>2008</year>;<volume>18</volume>:<fpage>180</fpage>&#8208;<lpage>197</lpage>.<pub-id pub-id-type="pmid">18093248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1750-3639.2007.00113.x</pub-id><pub-id pub-id-type="pmcid">PMC8095525</pub-id></mixed-citation></ref><ref id="alz70447-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70447-cite-0036"><string-name name-style="western"><surname>Butterworth</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Winsor</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Kamau</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Migliore</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mahoehney</surname><given-names>D</given-names></string-name>. <article-title>The state of employment for people with IDD: implications for practice, policy, and equity</article-title>. <source>Intellect Dev Disabil</source>. <year>2024</year>;<volume>62</volume>:<fpage>225</fpage>&#8208;<lpage>240</lpage>.<pub-id pub-id-type="pmid">38802097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1352/1934-9556-62.3.225</pub-id></mixed-citation></ref><ref id="alz70447-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70447-cite-0037"><string-name name-style="western"><surname>Subramaniapillai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Almey</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Natasha Rajah</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Einstein</surname><given-names>G</given-names></string-name>. <article-title>Sex and gender differences in cognitive and brain reserve: implications for Alzheimer's disease in women</article-title>. <source>Front Neuroendocrinol</source>. <year>2021</year>;<volume>60</volume>:<elocation-id>100879</elocation-id>.<pub-id pub-id-type="pmid">33137359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yfrne.2020.100879</pub-id></mixed-citation></ref><ref id="alz70447-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70447-cite-0038"><string-name name-style="western"><surname>Hartley</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Fleming</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Schworer</surname><given-names>EK</given-names></string-name>, et&#160;al. <article-title>Timing of Alzheimer's disease by intellectual disability level in Down syndrome</article-title>. <source>J Alzheimers Dis</source>. <year>2023</year>;<volume>95</volume>:<fpage>213</fpage>&#8208;<lpage>225</lpage>.<pub-id pub-id-type="pmid">37482997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230200</pub-id><pub-id pub-id-type="pmcid">PMC10578224</pub-id></mixed-citation></ref><ref id="alz70447-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70447-cite-0039"><string-name name-style="western"><surname>Mihaila</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Handen</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Christian</surname><given-names>BT</given-names></string-name>, et&#160;al. <article-title>Leisure activity, brain &#946;&#8208;amyloid, and episodic memory in adults with Down syndrome</article-title>. <source>Dev Neurobiol</source>. <year>2019</year>;<volume>79</volume>:<fpage>738</fpage>&#8208;<lpage>749</lpage>.<pub-id pub-id-type="pmid">30912871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dneu.22677</pub-id><pub-id pub-id-type="pmcid">PMC7063586</pub-id></mixed-citation></ref><ref id="alz70447-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70447-cite-0040"><string-name name-style="western"><surname>Piro&#8208;Gambetti</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schworer</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Handen</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Glukhovskaya</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hartley</surname><given-names>SL</given-names></string-name>. <article-title>Does employment complexity promote healthy cognitive aging in Down syndrome?</article-title>. <source>J Intellect Disabil</source>. <year>2024</year>;<volume>28</volume>:<fpage>499</fpage>&#8208;<lpage>513</lpage>.<pub-id pub-id-type="pmid">37040598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17446295231169379</pub-id><pub-id pub-id-type="pmcid">PMC10564966</pub-id></mixed-citation></ref><ref id="alz70447-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70447-cite-0041"><string-name name-style="western"><surname>Hom</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kirby</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Ricks&#8208;Oddie</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Cognitive function during the prodromal stage of Alzheimer's disease in Down syndrome: comparing models</article-title>. <source>Brain Sci</source>. <year>2021</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1220</fpage>.<pub-id pub-id-type="pmid">34573242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci11091220</pub-id><pub-id pub-id-type="pmcid">PMC8471085</pub-id></mixed-citation></ref><ref id="alz70447-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70447-cite-0042"><string-name name-style="western"><surname>Anderson</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Howe</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Wade</surname><given-names>KH</given-names></string-name>, et&#160;al. <article-title>Education, intelligence and Alzheimer's disease: evidence from a multivariable two&#8208;sample Mendelian randomization study</article-title>. <source>Int J Epidemiol</source>. <year>2020</year>;<volume>49</volume>:<fpage>1163</fpage>&#8208;<lpage>1172</lpage>.<pub-id pub-id-type="pmid">32003800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyz280</pub-id><pub-id pub-id-type="pmcid">PMC7660137</pub-id></mixed-citation></ref><ref id="alz70447-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70447-cite-0043"><string-name name-style="western"><surname>Boots</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Almeida</surname><given-names>RP</given-names></string-name>, et&#160;al. <article-title>Occupational Complexity and cognitive reserve in a middle&#8208;aged cohort at risk for Alzheimer's disease</article-title>. <source>Arch Clin Neuropsychol</source>. <year>2015</year>;<volume>30</volume>:<fpage>634</fpage>&#8208;<lpage>642</lpage>.<pub-id pub-id-type="pmid">26156334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acv041</pub-id><pub-id pub-id-type="pmcid">PMC4605365</pub-id></mixed-citation></ref><ref id="alz70447-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70447-cite-0044"><string-name name-style="western"><surname>Aguirre&#8208;Acevedo</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Lopera</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Henao</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Cognitive decline in a Colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study</article-title>. <source>JAMA Neurol</source>. <year>2016</year>;<volume>73</volume>:<fpage>431</fpage>&#8208;<lpage>438</lpage>.<pub-id pub-id-type="pmid">26902171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.4851</pub-id><pub-id pub-id-type="pmcid">PMC5505685</pub-id></mixed-citation></ref><ref id="alz70447-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70447-cite-0045"><string-name name-style="western"><surname>Llibre&#8208;Guerra</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Renton</surname><given-names>AE</given-names></string-name>, et&#160;al. <article-title>Cognitive reserve influences symptom onset and longitudinal decline in dominantly inherited Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>20</volume>(Suppl <issue>3</issue>):<elocation-id>e086295</elocation-id>.</mixed-citation></ref><ref id="alz70447-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70447-cite-0046"><string-name name-style="western"><surname>Lazarov</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>YP</given-names></string-name>, et&#160;al. <article-title>Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice</article-title>. <source>Cell</source>. <year>2005</year>;<volume>120</volume>(<issue>5</issue>):<fpage>701</fpage>&#8208;<lpage>713</lpage>.<pub-id pub-id-type="pmid">15766532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2005.01.015</pub-id></mixed-citation></ref><ref id="alz70447-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70447-cite-0047"><string-name name-style="western"><surname>Bejanin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Iulita</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Vilaplana</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Association of Apolipoprotein E &#603;4 Allele with clinical and multimodal biomarker changes of Alzheimer disease in adults with Down syndrome</article-title>. <source>JAMA Neurol</source>. <year>2021</year>;<volume>78</volume>(<issue>8</issue>):<fpage>937</fpage>&#8208;<lpage>947</lpage>.<pub-id pub-id-type="pmid">34228042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2021.1893</pub-id><pub-id pub-id-type="pmcid">PMC8261691</pub-id></mixed-citation></ref><ref id="alz70447-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70447-cite-0048"><string-name name-style="western"><surname>Fortea</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pegueroles</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alcolea</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease [published correction appears in Nat Med</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>(<issue>7</issue>):<fpage>2093</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03127-y</pub-id><pub-id pub-id-type="pmid">38886628</pub-id></mixed-citation></ref><ref id="alz70447-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70447-cite-0049"><string-name name-style="western"><surname>Saran</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kuper</surname><given-names>H</given-names></string-name>. <article-title>Evidence and gap map of studies assessing the effectiveness of interventions for people with disabilities in low&#8208;and middle&#8208;income countries</article-title>. <source>Campbell Syst Rev</source>. <year>2020</year>;<volume>16</volume>:<elocation-id>e1070</elocation-id>.<pub-id pub-id-type="pmid">37131970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cl2.1070</pub-id><pub-id pub-id-type="pmcid">PMC8356326</pub-id></mixed-citation></ref><ref id="alz70447-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70447-cite-0050"><string-name name-style="western"><surname>Hamburg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lowe</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Startin</surname><given-names>CM</given-names></string-name>, et&#160;al. <article-title>Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review</article-title>. <source>J Neurodev Disord</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>20</fpage>.<pub-id pub-id-type="pmid">31470792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s11689-019-9279-8</pub-id><pub-id pub-id-type="pmcid">PMC6716931</pub-id></mixed-citation></ref><ref id="alz70447-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70447-cite-0051"><string-name name-style="western"><surname>Fleming</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Piro&#8208;Gambetti</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Patrick</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome</article-title>. <source>Neurobiol Aging</source>. <year>2021</year>;<volume>107</volume>:<fpage>118</fpage>&#8208;<lpage>127</lpage>.<pub-id pub-id-type="pmid">34428720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2021.07.016</pub-id><pub-id pub-id-type="pmcid">PMC8641014</pub-id></mixed-citation></ref><ref id="alz70447-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70447-cite-0052"><string-name name-style="western"><surname>Pape</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Baksh</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Startin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hamburg</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hithersay</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Strydom</surname><given-names>A</given-names></string-name>. <article-title>The association between physical activity and CAMDEX&#8208;ds changes prior to the onset of Alzheimer's disease in Down syndrome</article-title>. <source>J Clin Med</source>. <year>2021</year>;<volume>10</volume>(<issue>9</issue>):<fpage>1882</fpage>.<pub-id pub-id-type="pmid">33925348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10091882</pub-id><pub-id pub-id-type="pmcid">PMC8123639</pub-id></mixed-citation></ref><ref id="alz70447-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70447-cite-0053"><string-name name-style="western"><surname>Ding</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schmidt&#8208;Mende</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Modig</surname><given-names>K</given-names></string-name>. <article-title>Social factors, age, and health at time of dementia diagnosis</article-title>. <source>JAMA Netw Open</source>. <year>2025</year>;<volume>8</volume>(<issue>2</issue>):<elocation-id>e2461117</elocation-id>.<pub-id pub-id-type="pmid">39982724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2024.61117</pub-id><pub-id pub-id-type="pmcid">PMC11846011</pub-id></mixed-citation></ref><ref id="alz70447-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70447-cite-0054"><string-name name-style="western"><surname>Rosenberg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mangialasche</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ngandu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Solomon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></string-name>. <article-title>Multidomain interventions to prevent cognitive impairment, Alzheimer's disease, and dementia: from FINGER to world&#8208;wide FINGERS</article-title>. <source>J Prev Alzheimers Dis</source>. <year>2020</year>;<volume>7</volume>:<fpage>29</fpage>&#8208;<lpage>36</lpage>.<pub-id pub-id-type="pmid">32010923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2019.41</pub-id><pub-id pub-id-type="pmcid">PMC7222931</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>